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Prepared by and for policy-makers, leaders of public sector research establishments, 
technology transfer professionals, licensing executives, and scientists, this Handbook 
offers up-to-date information and strategies for utilizing the power of both intellectual 
property and the public domain.
Eschewing ideological debates and general proclamations, the authors always keep 
their eye on the practical side of IP management. The Handbook provides substantive 
discussions and analyses of the opportunities awaiting anyone in the field who wants 
to put intellectual property to work.
“This Handbook is timely. [It] is a valuable guide in helping to navigate the complex— 
but rewarding—world of an increasingly global innovation system.”
—From the Foreword of Norman Borlaug, Nobel Peace Prize Laureate
“[This] Handbook is an important step towards transnational networks … involving multiple 
partners in both North and South—donors and doers alike—who believe in the power of 
innovation to address the needs of the poor.”
—From the Foreword of Sir Gordon Conway, KCMG DL FRS, Chief Scientific Adviser, DFID UK
“At the dawn of the 21st 
century the world created 
an unprecedented wave of 
public–private partnerships. 
For such investments to 
bear fruit as public goods 
it is paramount to manage 
intellectual property with the 
public interest in mind. This 
Handbook provides expert 
guidance to do just that 
and will assist in developing 





“This Handbook—which really transcends the category of handbooks altogether— 
is a must read for anyone who deals with intellectual property.”
—Pramilla Senanayake, FRCOG, Chair, Global Forum for Health Research, MIHR, and the Concept Foundation
The companion Executive Guide distills the key points 
of each chapter into simple language and places them 
in the context of evolving best practices.
“For all who believe, as I believe, that developing countries can—and should—participate in 
and benefit from an interconnected world of innovation, this book is an indispensable guide.”
—Mahmoud F. Fathalla, Professor and former Dean, Medical School at Assiut University, Egypt, 
 and Chairperson of the WHO Advisory Committee on Health Research
“Intellectual property (IP) has become a much richer field of endeavor as it has moved from 
isolationism in the world of policy to a position of engagement …  [This Handbook] will serve 
as an invaluable resource in this challenging new environment.”
—From the Foreword of Francis Gurry, Deputy Director General, WIPO
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Technology and Product Licensing

ABSTRACT
After providing an overview of licensing in the field of 
biotechnology, the chapter carefully examines the key 
components of a license agreement, particularly in rela-
tion to the field’s unique concerns. The chapter raises a 
number of issues that licensors and licensees should con-
sider when negotiating patent license agreements. It of-
fers precise definitions of key terms, points out areas of 
the agreement that merit special attention (including the 
relative merits of exclusive and nonexclusive licensing), 
considers the difficult question of how to determine a 
patent’s value (especially when the patent is being used for 
screening purposes), and gives much-needed attention to 
the complexities of confidentiality agreements, especially 
those involving academic research institutions. To make 
negotiations easier and more realistic, the incentives for 
licensors and licensees are discussed, as are some of the 
finer points of development collaboration. In addition, 
the author offers some advice about how to define patent 
misuse, offering some helpful suggestions about what to 
do should things go bad. The goal of this chapter, how-
ever, is to ensure that agreements succeed.
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before commercial goals are even in sight. This 
is particularly true for inventions with important 
medical applications that involve a drug or a di-
agnostic that will travel an extraordinarily long 
road before being manufactured commercially 
and used clinically. Even for inventions that are 
not related to medicine, extraordinary amounts 
of money are likely to change hands long before 
commercial goals are reached, if they ever are. 
Often, patent licenses play a key role in the devel-
opment of biotech inventions.
Indeed, the likelihood of successfully com-
mercializing any medical application embodied 
in a patent is a battle against the odds. According 
to an article by Henry Grabowski, professor of 
economics at Duke University, less than 1% of 
compounds examined in preclinical studies makes 
it into human testing, and only 20% of the com-
pounds entering clinical trials survives and gains 
marketing approval.1 Thus, less than one-fourth 
of 1% of newly developed compounds makes it 
to market. Once the product achieves market-
ing approval the task does not get much easier. 
The product will face enormous pressures from 
competition and will have significant difficulties 
establishing an infrastructure to manufacture and 
commercialize the drug product.
This is not to say that a biotech patent license 
needs to address all of these issues in detail. That 
would be impossible. These issues are raised to 
CHAPTER 11.1
1.	 BioTeCh	liCenSing	oveRview
The issues raised in licensing patents are similar 
to those raised when prosecuting and enforcing 
biotech patents. In the case of licensing, however, 
the process is somewhat of an art, and the char-
acteristics of the biotech industry are the artist’s 
tools. No other industry requires so much time 
and so much money to market a product. Indeed, 
biotech patent applications typically are filed, and 
biotech patent licenses typically are executed, well 
Freeman JW. 2007. Licensing Biotechnology Inventions. In Intellectual Property Management in Health and Agricultural In-
novation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org.
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John W. Freeman, Principal, Fish & Richardson P.C., U.S.A.
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suggest some of the ways biotech patent licenses 
differ from patent licenses in other industries. 
Moreover, knowing that a biotech invention is 
unlikely to succeed should heighten the license 
drafter’s sensitivity to the kinds of reasons permit-
ted for terminating the agreement, as well as what 
the impact of that termination would be. Other 
industry characteristics that the license drafter 
should keep in mind include:
• long, costly lead times to market that can 
result in limited patent life remaining after 
commercialization
• process of discovery, proof, and develop-
ment into a product that requires a synergy 
of complex operations
• very high risks combined with high (often 
deferred) reward
2.	 Key	ComponenTS	of	The	liCenSe
Given the inherent complexities, in terms of busi-
ness and science, of biotech patent licensing, it 
is easy to forget that a biotech patent license is 
merely a contract. All of the basic principles of 
contract law apply. The license drafter must take a 
step back from business terms and scientific sub-
ject matter to consider how the document will 
stand up to questions of enforceability, breach, 
and so forth. 
A patent license, like other contracts, is en-
forceable in a legal action seeking either (a) dam-
ages for the aggrieved party in an amount cor-
responding to the benefit of the bargain that was 
breached; or (b) equitable (injunctive) relief giv-
ing the aggrieved party the benefit of its bargain. 
To withstand the scrutiny that a license will face, 
particularly if there is legal action for breach of 
contract or patent infringement, the licensing 
document should be precise and written in com-
plete, clear sentences without errors in grammar, 
use, or syntax that could make interpretation dif-
ficult. Above all, the license should use terminol-
ogy consistently (as is true for a patent claim) and 
avoid using different words for the same thing or 
using the same word to indicate different things.
Completeness and clarity are important 
goals, but some ambiguity is unavoidable. The 
parties need to use good judgment in tolerating 
ambiguities that cannot be resolved at the con-
tracting stage.
The license document governs the parties’ 
rights over a substantial period of time during 
which unforeseen events very likely will occur. 
The license cannot address explicitly all of the 
possibilities.  
During the negotiations, it is important to 
consider, along with their consequences, events 
that are unlikely to occur. However, attention 
to these unlikely events can easily consume a 
disproportionate amount of time and effort and 
can sidetrack progress toward agreement on core 
issues. Thus, care should be taken to devote an 
amount of attention that is proportional to the 
potential cost or benefit associated with such an 
unlikely event. Keep in mind that alternate ways 
of mitigating the risks may be equally appropri-
ate. For example, excessively negotiating over 
the division of risks and liabilities, and trying to 
structure the language of the agreement accord-
ingly, may be less efficient than agreeing on insur-
ance coverage to address those risks. This chapter 
will review some key components of the license to 
identify issues that recur during the negotiation 
and enforcement of biotech patent license rights.
2.1	 Background
The background section of a license agreement 
identifies the factual predicates (or basis) for the 
license, including the parties, the effective date, 
and the parties’ motivations and expectations. 
Definitions of critical terms may also appear in 
the background section.
Certain types of problems commonly arise 
when drafting this section. One type involves the 
identification of participants. Because corporate 
structure can be extremely fluid in the biotech 
industry—companies are acquired and spun off, 
and they frequently collaborate—and because 
small companies may have key personnel whose 
participation in product development is more im-
portant than the other assets of the licensee, care-
ful attention must be paid to the identification of 
the party who is obligated to perform under the 
contract. The parties would be wise to consider 
the following questions: 
• Does the obligation carry over to affiliates? 
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• Is the term affiliates defined in a way that 
meets expectations about who the other 
party should be? Does the term include a 
well-capitalized corporation that can be ex-
pected to survive other less well-capitalized 
affiliates? 
• Could a competitor be defined as party 
to the license through its affiliation with 
another company that is more directly in-
volved in your negotiation? (For example, 
does the definition of parties include com-
panies that could sell to your customers or 
to the customers of your affiliates?)
• Should the flow of confidential information 
be restricted to certain affiliates in the family? 
• Is a competitor company a shareholder in 
the licensor? 
• Does a competitor company have a right of 
refusal in the commercialization of certain 
technologies or in certain territories based 
on previous agreements?
Terms such as net sales, net profits, and li-
censed product will likely appear and need to be 
defined in the background section. The following 
list presents a few of those terms and some notes 
on how they are likely to be treated:
• Net Sales. Includes deductions from gross 
sales before figuring royalty. Typical exclu-
sions from net sales can include transporta-
tion costs, returns, bad debt, actual trade, 
quantity or cash discounts, broker’s/agent’s 
commissions, credits or allowances made or 
given on account of rejects or returns, and 
so on.
• Net Profits. Can be used instead of net 
sales but can be problematic as a basis for 
calculating royalty because profit figures 
can vary tremendously depending on ac-
counting practices.
• Licensed Product(s). Identifies the 
product(s) whose sales constitute the royal-
ty base. Include(s) any product covered by 
the licensed patents, or any product made 
by a method covered by the licensed pat-
ents. The scope of licensed products should 
be limited by field in accordance with the 
license grant.
• Licensed Patent. Usually includes particu-
lar patents identified by number. Problems 
may arise over patents issuing on applica-
tions that are continuations, divisionals, 
foreign counterparts, reissues, reexamina-
tions, and continuations-in-part of known 
patents. Another issue is whether the license 
covers all of the licensor’s patents that could 
ever be used in conjunction with the tech-
nology of the licensed patent. For example, 
the licensee may want to license “all patents 
covering a licensed product.” Such a defini-
tion is unclear, because the applicability of 
other licensor patents would depend en-
tirely on what embodiment(s) the licensee 
chose to practice. For an academic institu-
tion with wide-ranging patent positions in 
many fields, this type of open-ended license 
is likely to raise problems and should be 
avoided. An even worse definition would 
sweep in “all patents necessary to practice 
the licensed invention.” In addition to the 
problem of not knowing exactly what em-
bodiments the licensee will practice (and 
therefore not knowing which patents are 
being licensed), this definition is circular 
when combined with the standard defini-
tion of licensed products: products licensed 
are those covered by the licensed patents, 
and the licensed patents are those necessary 
to make, use, or sell the licensed product. 
Further, this definition is problematic be-
cause it implies a license to patents belong-
ing to third parties. Finally, a license to 
“improvements” can raise problems (see 
also sections 2.5 and 5. below). 
Seemingly innocuous definitions in the back-
ground section of the license agreement may de-
cide key issues, including the scope of the license 
and the nature of the parties.
2.2	 Grant
The grant section of a license establishes whether 
the license is exclusive to the licensee or whether 
others (including the licensor) may practice the in-
vention. The grant section establishes limitations 
on the grant, such as restrictions on the technical 
FREEMAN
994 | HANDBOOK OF BEST PRACTICES
or commercial fields or on the geographical areas 
within which the license may be practiced. The 
grant section may set out rights to sublicense or 
assign, or it may say that there are no such rights 
under the license.
The right to allow sublicensing or a prohibi-
tion on sublicensing should be explicit, as should 
be a right to assign or a prohibition on assigning. 
A party can retain some level of control on future 
events by using provisions allowing for the assign-
ment of the license only with the consent of that 
party. The licensor should be aware that with-
holding the right to sublicense or even to assign 
does not guarantee that the nature and character 
of the licensee will remain constant. In one case, 
a very large player in HIV diagnostics purchased 
controlling stock in a relatively minor player that 
had a license under a key patent from a third party 
licensor, with no right to assign or sublicense. The 
licensor’s intent in making the license personal to 
the minor company was to avoid competition 
from a large competitor. By purchasing control-
ling stock in the small licensee, the large com-
petitor frustrated the licensor’s purpose (Institut 
Pasteur v. Cambridge Biotech Corp.).2 
In certain cases, it may be desirable to allow 
an assignment of interests without consent when 
a significant change in control occurs (for exam-
ple, a merger or acquisition of a party) provided 
that the surviving entity assumes all of the obliga-
tions and benefits of the merged/acquired party. 
This can be advantageous to a corporate entity 
considering merger or spinout scenarios because 
it can simplify such transactions. This may be ac-
ceptable when a licensor is more concerned about 
income and less concerned about who is paying 
(and getting access to the license) and what future 
research/development interactions may arise with 
a partner. 
Biotech licenses frequently are limited to 
specific medical indications, treatment modali-
ties (for example, route of administration) or 
diagnostic formats (for example, screening ver-
sus confirmatory diagnosis). One reason for this 
might be that the technology is in a very early 
stage and substantial resources are needed to com-
mercialize the technology, even in one limited 
field. Many biotech inventions feature basic ideas 
or technologies that may be used for a number 
of different medical indications, and the licen-
sor may seek to increase its chances of success by 
establishing different licensees in different fields, 
particularly if no one licensee is likely to have 
the resources or interest to give top priority to all 
fields. Examples of such basic or platform tech-
nologies include viral constructs to deliver genes 
to a patient for gene therapy, diagnostic formats, 
and methods of screening.
Another reason the parties may prefer to ne-
gotiate a license with a limited field of use is to tai-
lor the field of use to the strength of the licensee. 
Even large pharmaceutical companies generally 
specialize to some degree in certain medical indi-
cations. One may have made a strategic decision 
to invest in cystic fibrosis therapies; another may 
favor clotting disorders. A company with ongo-
ing research projects related to both indications 
may decide to prove the technology in one area 
first before trying it in a second.
For these and many other good reasons, the 
licensor may want to license a number of compa-
nies exclusively, but in different fields. Some cau-
tions are appropriate. Some biotech patent claims 
define the invention functionally (for example, 
by molecular mechanism). While claim language 
that relies heavily on functional limitations should 
generally be avoided, if possible, or supplement-
ed with narrower claims that avoid descriptions 
of events at the molecular level (for reasons ex-
plained elsewhere in these materials), such func-
tional language does have a place in patent claims 
when there is no other way to broadly express the 
inventive contribution. That does not mean that 
similar functional expressions are suitable to de-
fine license fields. No matter how certain scientists 
are about the molecular mechanisms, nature has a 
way of foiling neat pigeonholes. Functional limi-
tations in patent claims can cause problems for 
patent claim interpretation and validity.3 When 
it comes to licensing, functional descriptions in 
fields of use can be the seeds of a major disaster, in 
effect granting the same rights to multiple licens-
ees, each of which was thought to have a distinct 
field. For example, it might seem safe to license 
a broad patent on administration of substance X 
exclusively in each of two fields (say, protection 
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of central nervous system neurons and relaxation 
of blood vessels) thought to be distinct when the 
two licenses were executed. Should the data indi-
cate that the substance helps glaucoma patients 
both by relaxing blood vessels to reduce intraocu-
lar pressure and by protecting the retinal ganglion 
from damage due to hypoxia, then which licensee 
is authorized to treat glaucoma may become a hot 
topic of dispute. The point is simply that fields 
of use typically should be defined according to 
medical indications so that licensees are less likely 
to trip over each other.
One problem with licenses limited to treat-
ing certain medical indications concerns so-called 
off-label uses. If the license is limited to a par-
ticular one of several uses of a patented drug, the 
licensee will want to consider procedures that can 
be put in place in the contract to prevent, or at 
least limit, the extent of overlapping sales by the 
products of other licensees. The licensee should 
also consider ways to avoid a possible charge of 
infringement if it allows its products to be sold 
for other uses. Even careful labeling of the drug 
for use in the licensed field does not ensure that 
doctors will not prescribe it for off-label uses, or 
that the product from the licensee will not be 
used outside the licensee’s field.
Licensors may also grant multiple exclusive 
licenses based on geographic territory. The ad-
vantages to the licensor include: having access 
to multiple research and development partners, 
(thus tapping additional expertise as well as ame-
liorating the risk of a single development partner), 
allowing the selection of a partner with particular 
sales/marketing expertise in that geographic area, 
and allowing the selection of a partner with regu-
latory agency experience in a particular territory. 
A note of caution about the decision to grant 
multiple licenses, whether exclusive in a field or 
nonexclusive: it is important to establish a finan-
cial incentive for at least one party to defend the 
patent. A licensor who is not prepared or able to 
spend the money and effort to defend its patent 
is well advised not to establish a nonexclusive li-
censing program. Nonexclusive licensees rarely, if 
ever, have an incentive to defend the patent, which 
leaves enforcement solely to the licensor. If the 
licensor lacks the resources, or will be unwilling 
to enforce the patent for some other reason, its 
licensing program may stall at the starting gate. 
Believing the patent will not be enforced, poten-
tial licensees may have no incentive to accept fair 
license terms.
Indeed, situations justifying nonexclusive li-
censes as a purposeful strategy from the outset (as 
opposed to a basis for settling legal actions) are 
rare. One such exceptional situation was a license 
to a family of the early patents on manipulating 
genetic material—Stanford University’s so-called 
Cohen/Boyer patents on gene splicing. Stanford 
sought to make this technology available through-
out the industry under nonexclusive licenses. This 
strategy was highly successful, in part because the 
license fee was fixed very low, but perhaps also 
because it was the first of its kind. Companies 
were willing to accept the first such license, but 
they soon drew the line and refused to spend 
money for nonexclusive licenses to later patents 
from other licensors, complaining that their frag-
ile commercial beginnings would be substantially 
jeopardized by the multiple royalty burdens im-
posed by licenses for such broad-based patents. 
Of course, when dealing with federally funded 
or co-owned inventions, political considerations 
may rule out exclusive licensing, even if exclusive 
licensing represents the best business strategy.
2.3	 Fixed	payments,	royalties,	or	both?
Nearly every license negotiation involves a trade-
off between risks taken for a large sum in the fu-
ture (for example, getting a percentage of sales) 
and the more-certain enjoyment of a smaller, up-
front sum. This choice is particularly significant 
in biotechnology, where both the upside poten-
tial and the risk are enormous. Licensees may 
wish to save the upside for themselves and not 
share it. On the other hand, they face substantial 
expenditures for commercializing the technology, 
and they may not want to add to their cash-flow 
burden in the near term, particularly in view of 
the low probability that a marketable product will 
result from the technology. From the licensor’s 
standpoint it may be hard to accept the idea that 
someone else stands to realize more from devel-
oping and commercializing an idea than those 
who originated it and obtained patents.
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Royalties are typically calculated as a percent-
age of a royalty base (such as net sales). Where 
the license is exclusive (and therefore the licen-
sor gives up the opportunity to commercialize 
the invention itself or through other parties) the 
agreement typically provides minimum annual 
royalties, or at least reversion to nonexclusivity if 
a minimum royalty is not paid in a given period 
of time. The problem with the latter provision is 
that the licensor can no longer grant an exclusive 
license to another party, so long as the original 
licensee retains any license rights. Thus, diligence 
provisions, coupled with a complete reversion 
right for failure to meet those provisions, are de-
sirable to ensure that a technology moves through 
the development stage, either with another part-
ner or alone.
In return for an exclusive license, the licensor 
should place contractual requirements to ensure 
that the licensee exerts sufficient efforts to com-
mercialize the invention. In addition to rather 
vague efforts requirements, such as “reasonable 
efforts” or similar language, the licensor should 
consider easily measurable requirements, such as 
minimum sales amounts or clinical achievement 
milestones. Conversely, if the licensor requires 
a minimum annual payment, the licensee may 
want to specify that the minimum annual fee is 
in lieu of best (or other) efforts, so the licensee 
retains the exclusive rights by paying the annual 
minimum fee, even if it sits on the technology 
and develops a competing product. 
Milestones at which additional fixed pay-
ments may be due from the licensee (for example, 
selection of a clinical candidate, initiation of a 
clinical trial, completion of a satisfactory clini-
cal trial, and filing of a nondisclosure agreement) 
provide a convenient middle ground for the risk/
reward trade-off. The licensee with commercial-
ization rights should be able to obtain additional 
financing at that milestone. Moreover, some of the 
risk of project failure at the clinical-trial stage is 
shifted to the licensor, justifying higher payments 
than would have been due at the license signing 
date. Other common milestones that indicate 
progress in accordance with the business plan 
and that are likely to bring funds to the licens-
ee include U.S. Food and Drug Administration 
(FDA) marketing approval, the execution of an 
agreement with a marketing partner or some oth-
er collaborator, the first commercial sale, and/or 
the creation of a joint venture.
A common licensee complaint in the biotech 
field is royalty stacking, which is the need to pay 
royalties to multiple parties for commercializing 
a single product. For instance, a pharmaceutical 
company that screens a combinatorial chemistry 
library for compounds that bind to and block a 
particular neuronal receptor might owe royalties to 
the various owners of patents covering the library, 
the general screening assay, the isolated receptor, 
a cDNA encoding the receptor, and an expressed 
sequence tag (EST) derived from the cDNA (if 
the EST patent claim is written in open-ended 
“comprising” language). Stanford University met 
with success in its Cohen/Boyer patent license 
program, in part because Stanford University was 
the first with a broad biotech patent. Afterward, 
biotech companies were heard increasingly to say 
that they would not pay multiple royalties for a 
single product.
One compromise on stacking is to permit an 
offset to royalties up to but not more than some 
percentage (say, .5%) of the nominal royalty, if 
the accumulated nominal royalties add up to 
more than a set percentage of sales. In effect, the 
licensor is funding one-half of the cost of obtain-
ing licenses under additional patents.
2.4	 Confidentiality
Depending on the extent to which the parties 
exchange confidential information and biologi-
cal materials, confidentiality provisions can be 
extremely important in the agreement. In some 
cases, patent protection may be narrowly limited 
to biological material that is not reproducible, 
and that alone is important confidential informa-
tion, at least until the patent issues.4 In such cases, 
the applicant may decide to abandon allowed but 
extremely narrow claims instead of making avail-
able the key biological deposits required for those 
claims to be issued.
Nucleic acid and amino acid sequence in-
formation is another type of confidential infor-
mation. With modern sequencing technologies, 
however, such information arguably becomes 
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nonconfidential when materials become available 
in a form pure enough to sequence easily.
In any confidentiality provision, it is impor-
tant to spell out how long each type of informa-
tion and materials remains confidential under the 
agreement, the disposition of written informa-
tion and materials when no longer needed, and 
ownership of inventions made when the recipient 
makes authorized use of the materials and infor-
mation internally.
One particularly important implication of 
confidentiality provisions is that they hinder a 
party’s freedom to look for another partner should 
the collaboration fail. Having been “contaminat-
ed” by the first partner’s confidential information, 
a licensor or licensee may be unattractive to future 
partners who are risk averse and do not want to 
have to deal with the possibility of a legal action 
for “misappropriation” of that information. 
One solution is to limit the time period of 
confidentiality and to provide (in a sort of pre-
nuptial agreement) an understanding that if cer-
tain milestones are not reached, the parties may 
collaborate with others on the same subject mat-
ter. Of course, such an understanding does not 
amount to a license under improvements that 
one or both parties may have made during the 
collaboration using confidential information. If 
the agreement does not specify who owns such 
improvements, there may need to be inordinate 
emphasis on murky and contentious ownership 
and inventorship issues related to improvements 
that are made after the license is executed. 
2.5	 Enforcement	against	infringers
As with payment terms, the decision about which 
party shoulders the burdens and realizes the ben-
efits from enforcing the licensed patent against 
infringers often involves allocating the risks and 
rewards of the overall success of the venture. The 
party standing to make the most money from 
the operation typically wants (and should have) 
the right to enforce the patent against infringers. 
Litigation strategy (particularly settlement) of 
expensive and protracted patent infringement ac-
tions should be guided by proper business incen-
tives and not by an entity on the financial sidelines 
of the litigation. For example, it is undesirable to 
have a licensee who can maintain unreasonable 
positions in patent enforcement litigation when 
the licensor is paying for the litigation, directly 
or indirectly (for example, with an offset to royal-
ties that is carried forward to future years when it 
exceeds current-year royalties due). To the extent 
that the license provides a total offset to royalties, 
the licensor is, in effect, partially financing litiga-
tion it doesn’t control, which is a very frustrating 
position to be in. Even deferral (as opposed to 
permanent offset) of guaranteed minimum roy-
alties increases the licensor’s risk, because if the 
patent is struck down or narrowed, those deferred 
royalties probably will never get paid. 
One solution is to allow the licensee commer-
cializing the invention to control litigation and to 
defer some portion (not all) of the royalties due 
each year, down to some minimum amount that 
is due no matter what legal expenses the licensee 
incurs. The offset ceases when the licensee’s legal 
expenses in a given royalty period fall below a cer-
tain level. A variation on this theme allows the 
licensee to deduct a certain percentage of legal 
expenses due in a given year. If the total royal-
ties owed in the year are less than the amount of 
that deduction, the question is whether any legal 
expenses from that year can be carried forward 
to reduce royalties in future years. While the fact 
patterns and license provisions vary tremendous-
ly, it is generally a good idea to set up the license 
so that the licensee will experience at least some 
significant nonrecoverable legal expenses and 
thus will have an appropriate economic incentive 
(litigation cost) to conduct and/or settle the liti-
gation efficiently. 
On the other side of the table, the licensor 
who wants to reduce or eliminate any risk of liti-
gation expense should understand that its valu-
able patent property is at risk. It may make sense 
for the licensor to at least partially fund and fully 
control the litigation, as a strategy for avoiding 
an inept defense of the patent by the licensee. 
This is particularly true if the patent represents 
an important asset for the licensor in the form of 
income from other sources, such as royalties from 
other licensees or increased licensor profits due to 
the licensor’s enhanced market position under the 
patent outside the licensee’s field. Moreover, to 
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give a licensee responsibility to fund and control 
litigation, with no offset or deferral of royalty pay-
ments, may deprive the licensee of the resources 
and incentive to defend the patent properly. 
One important incentive for the licensee is 
exclusivity under the patent, at least in one im-
portant field. In general, only an exclusive licens-
ee has a strong interest in maintaining the patent. 
A nonexclusive licensee is likely to face competi-
tion with or without the patent. Moreover, as far 
as the nonexclusive licensee is concerned, a roy-
alty is owed so long as the patent is valid, yet the 
validity of the patent does not give the licensee 
a significantly better market position. In some 
cases, the nonexclusive licensee may have a sub-
stantial incentive to invalidate the patent, so it is 
unwise to place such a licensee in control of pat-
ent enforcement. Indeed, nonexclusive licensees 
lack standing to enforce the licensed patent, so 
even if the parties want the nonexclusive licensee 
to enforce the patent, the infringement action 
will probably be brought in the licensor’s name 
(Ortho Pharmaceutical Corp. v. Genetics Institute).5 
Moreover, even when the licensee is the enforcing 
party, the licensor may be a necessary party under 
the Federal Rules of Civil Procedure, so the ac-
cused infringer can force the licensor to be joined 
in the action.
In sum, when negotiating the terms of pat-
ent enforcement, one should keep an eye on the 
business incentives that are created. Obviously, 
these questions depend on the context of a given 
license, such as the relative financial strength of 
the parties and their relative interest in maintain-
ing the patent.
2.6	 Term	and	termination
As with most licenses, the biotechnology license 
will often have a term that coincides with the pat-
ent term. Also, the right to premature termina-
tion for material breach typically includes a grace 
period for correcting the breach after notice. 
One common provision is that a bankruptcy 
filing by either party constitutes termination. It 
is unlikely, however, that courts will uphold such 
provisions when the licensee declares bankruptcy 
under chapter 11. This is because the license is 
viewed as an executory contract under 11 U.S.C. 
§ 365, with substantial performance remaining 
due on both sides (Institut Pasteur v. Cambridge 
Biotech Corp).6 Therefore, the trustee in bank-
ruptcy has the option to assume the rights and 
obligations under the license. 
3.	 inCenTiveS	foR	liCenSing
As with any contract negotiation, it is important 
to know how the deal will benefit both parties. 
Without knowing both parties’ incentives, it is 
difficult to negotiate effectively.
Biotech patent owners grant licenses for a 
number of reasons:
• to trade long-term risk and the possibil-
ity of substantial income for the certainty 
of a, perhaps more modest, short-term 
payoff
• to obtain development and marketing as-
sistance beyond the owner’s abilities
• to obtain clinical development for applica-
tions of academic discoveries
• to obtain funding for further research
• to exploit areas that would not be devel-
oped in-house by the patent owner
• to enhance reputation in a field by collabo-
rating with a well-known company
In granting licenses, the owner is exposed to 
several risks:
• adding a competitor if the product is in an 
area the licensor already exploits
• having to depend on the choice of the li-
censee to realize the value of the discovery 
(if the licensee fails, the opportunity may 
be lost)
• having to share profit in the long run if the 
invention succeeds
• losing control over information that could 
be kept secret if development were done 
in-house
The licensee takes a license for any of several 
reasons, such as:
• to ensure freedom to use a product line
• to obtain exclusivity for a product line
• to become current quickly without the cost 
of internal research
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• to gain access to technology from a leader
• to gain access to trained personnel
In exchange, of course, the licensee:
• adds to costs and reduces profit margin
• undertakes potential liabilities associ-
ated with long-term confidentiality 
agreements
• undertakes a long-term obligation to share 
internal financial information with the 
licensee
Understanding the balance of pros and cons 
in a given situation is critical for assessing how 
much the opposite party will be willing to pay 
and what other terms are critical for them. Not 
surprisingly, the balance the parties strike will be 
different in different licensing contexts.
4.	 DevelopmenT	CollABoRATion	
Usually a great deal of work with uncertain suc-
cess remains to be done between the time the 
license is signed and the date that the biotech 
product reaches the market. Unless that work is 
carried out entirely by the licensor or handed off 
entirely to another entity, collaboration will be 
necessary. The licensor has made the initial dis-
coveries and knows their nature and promise best. 
The licensee, however, generally is best equipped 
to develop those discoveries further to the point 
of marketability. The synergies achieved by com-
bining these disparate strengths are the rationale 
for the collaboration of licensee and licensor, at 
least in theory. Such collaborations, however, of-
ten raise additional licensing issues.
4.1	 Confidentiality	in	the	context		
of	collaboration
We have already discussed some of the confiden-
tiality issues raised in nearly all biotech-licensing 
situations. Where there is a genuine collabora-
tion, in which employees of each company share 
ideas and information, confidentiality provisions 
become even more important.
Confidentiality provisions in a collaborative 
license should address several points. First, they 
should forbid any use or disclosure of confidential 
information by the recipient for any purpose oth-
er than the furtherance of duties under the col-
laboration. Second, if each party brings existing 
expertise (and confidential information) to the 
collaboration, the agreement should be two way, 
with each party disclosing and receiving informa-
tion solely pursuant to confidentiality provisions. 
Third, it is important not to give either party an 
excuse to create a confidentiality obligation for 
information that was never intended to be con-
fidential. To avoid doing so, it helps to identify 
in the background section of the license agree-
ment the technical expertise of each party and the 
technical nature of each party’s expected contri-
bution. This information may also be helpful for 
sorting out inventorship.
While the following points apply generally to 
confidentiality agreements, they take on particu-
lar significance when the information at issue is 
disclosed as part of a long-term mutual exchange 
of information and skill. In effect, nonemployees 
are given the type of information and access to in-
formation usually reserved for employees. These 
long-term exchanges make the confidentiality is-
sues extremely important.
4.1.1 	 The	nature	of	confidential	information
Put simply, any information that gives a com-
mercial advantage over those not possessing the 
information can be a trade secret. The authors 
know of no meaningful distinctions between 
trade secret versus proprietary versus confidential 
information. Regardless of the label used, infor-
mation that is valuable and obtained as part of a 
confidential relationship is in theory protectable. 
The ability to recreate information by combining 
numerous public sources does not necessarily es-
tablish that the information was readily available 
to those outside the confidential relationship. 
The standard for considering information confi-
dential is not nearly so high as it is for nonobvi-
ousness, and analysis akin to a patent obviousness 
test has no place in determining whether some-
thing is confidential. Items of commercial value, 
such as customer and vendor lists, price lists, and 
selection of certain specific combinations of steps 
out of a large number of known alternative ways 
of approaching each step, may in some cases be 
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protected. Typical exceptions to confidentiality 
include information that has been
• published
• independently developed by the recipient 
of the information (sometimes limited to 
information developed before receipt of the 
confidential information)
• independently learned by the recipient 
from a third party not obligated to the dis-
closing party
• ordered to be disclosed by a judicial- or 
regulatory-body process (subject to no-
tice and best efforts to oppose such a 
process)
It makes sense to put the burden on the 
recipient of the information for invoking one 
of these exceptions. They should document 
the factual basis for the exception and notify 
the disclosing party before the recipient’s dis-
closure or use of the information. The key is 
to avoid letting these exceptions become after-




What is, or will be, the value of the lifetime of the 
information? Information that is about to be pub-
lished will be confidential for only a short time. 
On the other hand, biological materials that can-
not be duplicated may retain value indefinitely. 
It is important to be realistic about the length of 
time, so as not to provide a wide-open opportu-
nity for a dispute on this subject. 
Of course, there should be no obligation to 
maintain confidence for information that has 
been published or otherwise made public. This 
principle is easily stated, but not easily applied, 
because the typical fact pattern does not involve 
a wholesale publication of all information on a 
given topic. Instead, the information may dribble 
out over time in many publications, and a uni-
fied knowledge of the entire process, from start to 
finish, may continue to be valuable business in-
formation that is not generally available to com-
petitors or other members of the public without a 
great deal of work. 
4.1.3 	 Survival	of	obligation	
Parties may be bound to maintain confidence for 
at least some period after the collaboration ends 
(so long as the information still qualifies as con-
fidential information), and this obligation may 
affect the parties’ ability to work on the subject 
matter alone or with others. The confidentiality 
obligation therefore creates a disincentive to ter-
minate the collaboration because the parties’ free-
dom to develop the technology separately is in 
doubt. This doesn’t mean one has to avoid post-
collaboration confidentiality obligations. In fact, 
the client may want such obligations to protect its 
own information.
4.1.4 	 Recordkeeping	for	confidentiality
Often the agreement requires the disclosing 
party to label information as confidential, if that 
party wishes it to be treated as such. Because of 
the proof issues raised about the content of the 
information disclosed, information disclosed 
orally with no written record before or after the 
disclosure generally is not treated as confidential. 
In this situation, the one making oral disclo-
sures of confidential information has the burden 
of following up with a written disclosure. That 
procedure may seem unnecessarily cumbersome, 
but the alternative is to seek protection of orally 
disclosed information, which entails the burden 
of proving in detail the nature and full content 
of the information disclosed (along with the con-
fidentiality of that information). Thus, sound 
business practice dictates making a record of the 
disclosure. A requirement to put a legend on the 
written disclosures is useful, but it should not 
apply when the nature of the information and 
the context of the disclosure make clear that the 




Deciding who owns inventions is the hardest 
part of any collaboration negotiation. Without 
a contractual arrangement, ownership will de-
pend on inventorship. Inventorship decisions 
can be contentious, and the law can be difficult 
to apply to individual facts. Therefore, consider 
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avoiding the standard solution, for which each 
side owns its inventions and joint inventions 
are jointly owned. One option is to put owner-
ship of all inventions in the field of the collabo-
ration in a single party, with the other party 
having exclusivity in its field. Alternatively, 
ownership can be divided by field or geogra-
phy. The parties’ inability to agree on these is-
sues may indicate that they want to keep open 
their option to compete and that the collabo-
ration is not really a long-term arrangement. 
The inability to agree on ownership issues may 
reflect an inability to decide at an early stage 
about the relative sharing of risk and reward 
that is implicit in every license. A party may 
want to share in the ultimate success of the ven-
ture, even though the party’s near-term contri-
butions (capital plus IP plus commitment to 
use resources) are not commensurate with the 
other party’s contribution.
Finally, ownership of an invention at the time 
the invention was made can determine whether 
commonly owned patents or inventions are pri-
or art under 35 U.S.C. § 102(e), (f ) and (g) as 
those sections are applied through § 103. A well-
thought-out collaboration agreement should ad-
dress ownership in a way that will minimize or 
avoid serious prior-art problems arising from in-
ventions and patent applications that the parties 
bring to the collaboration. This issue had been 
quite a thorn in the side of biotech-patent license 
drafters for many years. Fortunately, however, 
with the passage of the Cooperative Research 
and Technology Enhancement (CREATE) Act 
in December 2004, the scope of common own-
ership was expanded. The existence of prior art 
under 35 U.S.C. § 102(e), (f ) and (g) does not 
preclude patentability where the related inven-
tions were made pursuant to a joint research 
agreement (in addition to the already existing 
safe harbors under 35 U.S.C. § 103[c]). New 
terms in the amendment, such as joint-research 
agreement, are certain to go through some inter-
pretive growing pains. Still, it is interesting to 
note that the CREATE Act was pushed in large 
part by the biotech industry. This change recog-




An exclusive license is presumed to prevent even 
the licensor from practicing the invention. If the 
licensor intends to practice the invention, even in 
a narrow field, the license must explicitly reserve 
or grant that right.
In the United States, each joint owner may 
practice the invention without authorization 
from the other owner(s), and the licensor/owner 
need not account to other owners (35 U.S.C. 
§ 262). In the absence of an agreement, there-
fore, joint owners can compete with each oth-
er. Indeed, a prospective licensee may force the 
owners to compete each other. Also, by defini-
tion, neither joint owner can unilaterally grant 
an exclusive license, because the other owner and 
the other owner’s licensees are free to practice the 
invention.
Japan and Europe also permit each owner to 
practice the invention, but the countries differ 
from the United States when it comes to licens-
ing. A licensee of a European or Japanese patent 
position must have authorization from all owners 
in order to practice the invention. If your busi-
ness plan calls for licensing overseas, and your co-
owner’s plan calls for practicing the invention on 
his or her own, you should obtain the co-owner’s 
agreement that you can license for both parties.
5.	 liCenSing	fRom	
ACADemiC	inSTiTuTionS
Academic institutions pose special licensing is-
sues. Part of the academic mission is to make 
worthwhile technology available to the public, 
particularly medical technology. Of course, mon-
ey helps to do that, but other factors are equally, 
if not more, important. The licensee’s stability, 
competence, incentive, and willingness to use its 
resources, technical expertise, and business skill 
to achieve this end are critical to the academic 
licensor’s goal of bringing the invention to the 
public. Another factor in achieving this goal is the 
relationship between the licensee and the investi-
gator. Cooperation between the parties increases 
the chances that the licensee will be able to de-
velop clinical applications of the invention. 
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Many academic research institutions depend 
heavily on federal government funding. In com-
parison, licensing revenue is relatively minor. 
Under the terms of most government research 
grants, the licensing of inventions made with 
grant funding is controlled to some degree by 
the government. The key tool for control is leg-
islation known as the Bayh-Dole Act.7 The terms 
of the research grant typically follow that legis-
lation, providing that the recipient of the grant 
(usually the academic institution as the grantee 
under the grant) must retain title, so that the gov-
ernment can regain title if certain conditions are 
not met. These conditions include a requirement 
that the academic institution or its licensee make 
reasonable progress toward commercialization of 
inventions resulting from funded research. Also, 
the government must have advance notice of the 
abandonment of patent applications in time to 
take over ownership and prosecution of those ap-
plications. In either case (failure to make progress 
or abandonment of the application), the govern-
ment may take over. The government also has a 
royalty free, paid-up license to practice the inven-
tion—for example, to use such medical inven-
tions as vaccines for military personnel.
In addition to the government’s residual 
rights, certain other provisions are generally es-
sential in an academic license. First and fore-
most, the inventors must retain the right to 
publish, although the licensee often is given the 
right to review manuscripts to identify potential 
inventions prior to submission or publication of 
the manuscript. In addition, the academic insti-
tution will require indemnification and insur-
ance covering legal actions (for example, work-
ers’ compensation, commercial general liability, 
umbrella liability, product liability, or personal 
injury) growing out of development activities, 
sometimes naming the licensor as an insured 
party. There should, however, be flexibility in 
the insurance requirements depending on local 
regulations and customary business practices in 
the territory. 
Many academic inventions are early stage 
and based on work that will be or has been pub-
lished. Thus, confidential information generally 
is not a long-term asset. In an academic context, 
the value of the license to the licensee lies in the 
patents, and the value of the patents depends on:
• the likelihood of getting broad coverage 
from early-stage patent applications that 
will dominate later improvements
• the likelihood of getting patents on narrow 
improvements after the original work has 
been published
• recognition that the licensee is free to use 
unpatented, published work without a 
license
• the licensee’s ability to obtain an option 
to license improvements under reasonable 
terms
6.	 pATenT	miSuSe
Patent misuse is a defense to patent infringement. 
In asserting this defense, the accused infringer 
takes the position that the patent owner has mis-
used its government-granted monopoly, thereby 
forfeiting the right to enforce that monopoly in 
a patent infringement action (C.R. Bard, Inc. v. 
M3 Systems, Inc.8). A body of case law has evolved 
to address the application of this doctrine to pat-
ent licensing practices, and in 1988, the Patent 
Misuse Reform Act9 was enacted to amend 35 
U.S.C. § 271 (d) regarding certain aspects of pat-
ent misuse. 
Unenforceability due to misuse does not 
call into question the inventor’s entitlement to 
a patent under the provisions of 35 U.S.C. It is 
distinguished from a defense of invalidity, which 
would require proof that the U.S. Patent and 
Trademark Office (PTO) was not empowered to 
grant the patent because the invention applica-
tion did not meet the statutory requirements for 
patentability.
Most often, resolution of misuse issues in-
volves a balancing of the inherent tension between 
patent law and antitrust law. To establish a claim 
of patent misuse, it must be shown that the pat-
ent owner misused its government-granted right, 
or in other words, used the patent to improperly 
extend its power in the marketplace. Patent-mis-
use analysis is acknowledged to be somewhat 
convoluted, due in part to its close interplay with 
antitrust analysis, which makes it susceptible to 
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contemporary societal/regulatory pressures at the 
moment of analysis, and also in that often such 
analyses are particularly fact specific, leading to 
narrowly applicable analyses. Historically, certain 
activities were considered per se patent misuse. 
Other activities, such as those governed by 35 
U.S.C. § 271(d), were evaluated under a “rule of 
reason” analysis similar to that in antitrust analy-
sis. (Virginia Panel Corp. v. MacPanel Co.10).
It is now abundantly clear that the mere existence 
of a patent right does not establish market power 
in the antitrust sense and that certain licensing 
provisions that were once thought to unfairly 
extend the patent monopoly do not constitute 
patent misuse, per se. Rather, the courts require 
a factual analysis (a rule of reason) of whether 
the patent owner possessed market power, and 
the patent is simply one factor in that analysis. 
The Supreme Court dealt with an allegation that 
a patentee misused its patent by tying sales of a 
patented printhead and ink container to sales of 
unpatented ink in Illinois Tool Works, Inc. et al. 
v. Independent Ink, Inc.11 The court held that a 
patent does not necessarily confer market power 
upon the patentee in every case involving a tying 
arrangement. The plaintiff seeking a finding of 
illegal tying and monopolization in violation of 
the Sherman Act must prove that the patentee 
has market power in the tying product.
The United States Court of Appeals for 
the Federal Circuit relied on the Illinois Tool 
Works decision when it recently held that vari-
ous Monsanto marketing practices for sales of 
seeds resistant to its Roundup® pesticide did 
not constitute patent misuse (Monsanto Co. v. 
Scruggs et al.12). The facts in that case involved a 
complex marketing scheme that included flex-
ibility to react to FDA approval of competitive 
products.
CSU, LLC, et al. v. Xerox Corporation13 
raised the basic issue of whether a refusal to li-
cense is anticompetitive activity under § 2 of the 
Sherman Act (15 U.S.C. § 2). CSU brought an 
antitrust action charging that Xerox had engaged 
in anticompetitive behavior when it tried to mo-
nopolize markets for sales and service of Xerox 
high-volume copiers and printers. Xerox counter-
claimed for patent infringement, and CSU raised 
a misuse defense. The Kansas District Court de-
nied Xerox’s motions for summary judgment, 
in part based on the conclusion that CSU may 
have a valid defense of misuse (In re Indep. Serv. 
Orgs. Antitrust Litig.14 and In re Indep. Serv. Orgs. 
Antitrust Litig.15). The Federal Circuit, however, 
ultimately supported the notion that although 
a patentee’s right to exclude is not without lim-
its, a unilateral refusal to sell or license a patent 
does not exceed the scope of the patent grant and 
does not rise to patent misuse (CSU LLC, et al. 
v. Xerox16).
A per se rule on whether refusal to license 
always (or never) amounts to misuse seems un-
likely. Such a rule would eviscerate the patent 
system and exceed judicial authority to compel 
patent owners to license in all situations. On the 
other hand, it seems artificial to ignore a patent 
owner’s licensing activities (or lack of them) when 
viewing the overall picture of monopolization. 
The practitioner is left to exercise judgment in the 
vast middle ground. 
One interesting aspect of the CSU case in-
volves the accused monopolist’s state of mind 
(“intent”). In concluding that it must take evi-
dence on the misuse issue, the Kansas District 
Court expressly declined to follow the Federal 
Circuit’s subjective intent standard for evaluating 
misuse. The Kansas District Court also refused 
to adopt a per se rule on the ground that refusal 
to license violates the Sherman Act. This trend 
away from per se rules has been going on for a 
long time (Eastman Kodak Co. v. Goodyear Tire & 
Rubber Co.17).
Another example of potential patent misuse 
is a license requiring royalty payments after ex-
piration of the patent of the licensed technology. 
Case law that has not been explicitly overruled 
holds that such license agreements are illegal and 
unenforceable and are per se misuse (Brulotte v. 
Thys Co.18; Scheiber v. Dolby Laboratories, Inc.19). 
Conditioning a license grant upon the payment 
of royalties on unpatented products has also been 
found to be a per se wrong (Zenith Radio Corp. 
v. Hazeltine Research, Inc.20). Another example is 
charging royalties twice (PSC v. Symbol Tech.21). 
This example was analyzed under a rule-of-rea-
son analysis. It is open to question whether any 
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such license arrangement will be misuse, per se 
(that is, without an analysis of market power).
A federal district court addressed the issue of 
whether a license requiring reach through royal-
ties to products (for example, drugs), discovered 
using patented screening tools, constitutes patent 
misuse in Bayer A.G. v. Housey Pharmaceuticals, 
Inc.,22 affirmed on other grounds,23 further pro-
ceedings on other grounds,24 affirmed by the 
Court of Appeals of the Federal Circuit.25 Bayer 
first alleged that misuse arose because the li-
cense contemplated royalties on products and 
activities not covered in the licensed patents by 
claims relating to screening. As Housey offered 
alternative compensation structures to licensees, 
for example, lum-sum payment, royalty based 
on discovered-product sales, or royalty based on 
licensee’s total R&D expenditure (the selection 
of which was explicitly stated in the agreement 
as the “most appropriate” and “convenient” ap-
proach), the district court found that Housey did 
not “condition” the license on products/activities 
outside the patent, and therefore there was no 
misuse. Bayer next alleged that misuse arose be-
cause the agreement imposed a requirement of 
royalty payments beyond the term of the patent, 
which was a per se misuse under Brulotte. The 
district court, also finding no misuse by Housey 
on this issue, held that collection of royalties af-
ter expiration of a patent was not per se misuse. 
The district court reasoned that a patentee can 
charge a royalty for practicing an invention prior 
to the expiration of the patent covering the in-
vention and that payment for such can be post-
poned beyond the expiration date of that patent. 
Whether the payment is for pre- versus post-pat-
ent expiration use appeared to be determinative 
to the district court. Thus, agreement language 
explicitly delineating that payment is “time-
shifted” for the convenience of the parties, and is 
not for post-patent expiration use, seems to be an 
important factor in this district court’s analysis of 
patent misuse. 
In sum, it remains risky for a patentee that 
has external (nonpatent) market power to engage 
in the above licensing practices, but it is likely 
that the rule-of-reason analysis will be required 
to find misuse.
7.	 SponSoReD	ReSeARCh
Sponsored research, for example, at an academic 
institution, should not be viewed as a typical col-
laboration but as a special case. The sponsor will 
nearly always want exclusivity over the fruits of 
the research, regardless of inventorship. Also, dis-
putes about confidential information may arise 
should the sponsor want to establish a competi-
tive advantage by maintaining confidence, at least 
until a patent application is filed, and maybe for 
some time thereafter. The researcher will want 
freedom to obtain future funding from others, 
given that current funding will be limited in 
amount and duration. If the researcher is an aca-
demic, he or she will want the freedom to publish 
without interference, though he or she may be 
willing to delay publication for a short period to 
give the sponsor an opportunity to prepare and 
file a patent application. In a highly competitive 
field, however, even a month can give another 
laboratory a chance to scoop the researcher in 
print. The researcher is unlikely to cede any con-
trol over the content of his or her publication, 
with the exception of information that originated 
with the sponsor.
The extent to which the issues discussed above 
will present serious problems for any given spon-
sored research arrangement depends on specific 
circumstances, particularly the extent and dura-
tion of the funding. A researcher whose entire 
operation is funded to a substantial extent by a 
single sponsor obviously will have fewer problems 
with such issues as the right to collaborate with 
other companies. Ideally, a sponsor desires a rep-
resentation and warrant from the researcher that 
no confidential information of a third party or 
proprietary material or process of a third party is 
utilized in the sponsored research. In reality, par-
ticularly with the multiple funding scenarios from 
both institutional and government sources, such 
representation and warrants cannot be made. 
Maintaining the confidentiality of sponsors’ 
confidential information can also be a challenge. 
Some institutions may not allow some of their 
researchers to be a party to confidentiality agree-
ments. In such instances, it is necessary to iden-
tify the specific researchers (in addition to the 
principal investigator) and what their exposure 
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to confidential information will likely be. 
Mechanisms for protecting information should 
be carefully considered. Representations and war-
rants that the materials will not be used other 
than as agreed and that the materials will specifi-
cally not be analyzed or reverse engineered, may 
also be appropriate.
One common problem when drafting a spon-
sored research agreement in an academic setting 
is the “mobility of funding” culture. Typically, a 
principal investigator has the freedom to move 
his or her operation, funding and all, to another 
institution. If the sponsor wants to remain with 
a particular investigator should the investigator 
move from one institution to another, the agree-
ment must be clear on this point. Otherwise, 
if the principal investigator moves, the sponsor 
could be left in the position of being obligated to 
fund other researchers at the original institution. 
One solution is to clearly state that the sponsor’s 
funding obligation terminates if certain named 
individuals (usually just the principal investiga-
tor and perhaps one or two others) cease em-
ployment. The sponsor then has the freedom to 
decide whether to continue funding the project 
elsewhere.
Another problem arises from the culture of 
authorship and even ownership of technology as 
discretionary privileges to be controlled by the 
principal investigator. It is common for a princi-
pal investigator to assume that he or she has the 
right to determine the inventorship and content 
of a patent application, just as he or she has the 
power to control content and authorship of jour-
nal publications. Obviously, these decisions must 
instead be controlled by inventorship law, patent 
prosecution strategy, and the sponsored research 
contract. For these reasons, the sponsor may want 
to control the prosecution of patent applications 
arising from the research.
A similar problem arises from multiple grants 
for a single laboratory. Investigators are used to 
deciding to some degree how grant funds will 
be allocated among a number of projects. Here 
again, the agreement should contain a carefully 
drafted statement of the work and the field of the 
research, coupled with clear entitlement to exclu-
sivity in the investigator’s work in the field.
8.	 liCenSing	ToolS	foR	DRug	
SCReening	AnD	DevelopmenT
Even biotech discoveries that are too fundamen-
tal to support a patent claiming a clinical thera-
peutic or diagnostic use may support a patent on 
screening. Driven by the rapid increase in knowl-
edge about molecular (including DNA) bases for 
diseases, coupled with automated equipment for 
synthesis, screening, and analysis, the interest in 
rational drug design and screening has explod-
ed. Indeed, licensing inventions featuring drug 
screening and development are all the rage.
8.1	 The	computer	software	component
The computer software developed in connection 
with rational drug design and screening can be 
protected by patent, copyright, and/or trade se-
cret. The particular form of protection will depend 
upon the ability to reverse engineer the software, 
and/or the effect upon the company of making 
the software public, as will happen in connection 
with patent protection. No matter what form(s) 
of protection are selected, the license agreement 
will include several elements that are unique to 
the software environment.
For example, various limitations upon the 
use of the software, and the availability of the 
software (in source code or object code form) 
need be addressed. Further, will the licensee, if 
he or she is able to obtain source code, be permit-
ted to modify and improve the software, and if 
so, which of the improvements, if any, will flow 
back to the licensor? Will the use of the software 
be limited to a particular database, CPU, physi-
cal location, number of users, simultaneous users, 
and/or application?
If the license is for object code only, will the 
licensee insist, as well he or she might, that the 
source code be placed in escrow in case computer 
software bugs develop that are not corrected by 
the licensor? (The nature of the escrow agree-
ment, and who shall hold the escrow, is typically 
the subject of yet another agreement.)
If software is provided, will it be subject to a 
maintenance agreement, that is, an agreement by 
which the licensor submits to providing improve-
ments, fixing problems if they develop in the 
software code, and in return receiving an annual 
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maintenance fee? If maintenance is provided but 
not taken by the licensee, will the licensor dis-
claim all responsibility for operation of the soft-
ware after a fixed period of time, for example, one 
year?
If the software being provided is experimen-
tal software and there is a software bug, the licen-
sor will likely limit his or her liability to either a 
return of any monies paid or to using reasonable 
efforts to correct the code. On the other hand, 
most academic institutions provide software code 
“as is,” without any obligation on the institution’s 
part to provide any further help. (As a result, 
there is often a consulting arrangement with the 
developer of the code to aid in fixing problems or 
improving the code, if improvements are allowed 
under the license agreement.)
One should also consider the distinction 
between providing the software code, the tech-
nology, and the license to develop similar func-
tionality under a patent license. With respect to 
the latter, no technology may be transferred at all, 
only the license to use the technology as covered 
by the patent claims. The provision of technol-
ogy invokes many of the elements noted above 
with regard to protecting the technology being 
transferred.
8.2	 Controlling	the	reagents	used	to	screen
The reagents used for screening typically are pro-
tectable trade secrets. For example, monoclonal 
antibodies, specific peptide fragments or DNA 
fragments, and cellular components that are used 
in a screen may not be publicly known or avail-
able. When licensing others to perform the screen, 
the agreement should be clear that the license is 
limited (for example, in time or in the number 
of compounds that can be screened) and that the 
materials are to be returned when that license has 
run out. At least, the license should provide (as 
do software licenses) that the reagents can only be 
used in limited ways (for example, on the prem-
ises in certain types of screen formats) and can 
be duplicated only to provide a secure backup in 
case the primary reagent is lost or damaged. The 
reagents (or their derivatives) should not be du-
plicated and used in additional screens at other 
sites or by other companies. In cases where the 
PTO is unlikely to grant broad protection, this 
type of contractual protection may be the only 
meaningful protection available. 
8.3	 Valuation	of	screening	patents
Assessing the value of screening patents poses 
special issues. Because screening patents specifi-
cally focus on research activities and do not cover 
commercial products or manufacturing process-
es, and, indeed, by their nature are practiced be-
fore any product is identified—much less ready 
to market—traditional valuation techniques 
(discounted stream of sales over time) may be 
inappropriate.
One way to evaluate screening patents is to 
estimate the amount of research expense saved 
by licensing the screen from outside rather than 
engaging in an in-house project. Another way is 
to consider the screen in view of its proportion 
to the total R&D budget or to the appropriate 
program or screening budget. As discussed below, 
however, other factors come into play.
8.3.1 	 Concerns	about	screening	preissuance
Since in the United States there can be no in-
fringement until the patent issues, screening 
preissuance cannot give rise to damages absent 
an issued patent having claims covering the 
screening.26 However, the American Inventors 
Protection Act27 provides provisional rights. If the 
application is published, a resulting patent will 
include the right to a reasonable royalty for the 
period between the date of publication and the 
date of grant, if: (1) notice of the published ap-
plication is provided, and (2) the patent claims 
are substantially identical to the claims of the 
published application. Given the ordinary course 
of at least two years pendency for biotech patent 
applications, the potential licensee should evalu-
ate the likely duration of its screening project to 
determine how long, if at all, screening will con-
tinue after patent issuance. 
8.3.2	 Damages	for	unlicensed	use
For screening that is likely to be conducted after 
issuance, the question remains of how much to 
pay for a license. Of course, the licensor would like 
to have a percentage of sales of drugs discovered 
CHAPTER 11.1
 HANDBOOK OF BEST PRACTICES  | 1007 
using the screen, but there is no reason to believe 
that measure is common in the industry, or that 
it would be used by a court in fixing “reason-
able” royalty damages for infringement. More 
typically, screening assays will produce a royalty 
based on the length and intensity of use and the 
noninfringing alternative screens available. Thus, 
a screen used occasionally to confirm results of a 
noninfringing screen would be compensated at a 
much lower rate than a screen so well accepted 
that it is effectively required to get approval for 
human clinical trials.
Finally, use of a screen to generate data for 
submission to the FDA may not constitute in-
fringement at all. It may be difficult for many 
reasons to obtain suitable value when licensing 
screening technologies. 
8.3.3 	 Compositions	used	for	screening	
In general, licenses of patents covering composi-
tions used for screening are subject to the same 
considerations as those discussed above. To take 
into account the situation in which the reagents 
may have some other, more valuable use, the li-
cense should restrict use of the reagents to screen-
ing (for example, as a field of use) and should ex-
plicitly exclude clinical uses.
9.	 ConCluSion
Licensing of biotech inventions requires special 
considerations and specialized license drafting 
with clear provisions that unambiguously detail 
the obligations of the licensors and licensees. In 
large part, this attention is needed because of the 
nature of biotech inventions and the risks and 
uncertainty that are integral to the biotech busi-
ness. For example, development of an invention 
into a product requires a synergy of complex op-
erations. Hence, the biotech invention may be 
unlikely to succeed, or may entail long, costly 
lead times to market, resulting in limited patent 
life remaining after commercialization. Such high 
risks are combined with high (often deferred) 
rewards. Therefore, licenses are structured to re-
flect this risk/reward reality of the biotech busi-
ness. Key considerations include: fees and royal-
ties, royalty stack ceilings, fields of use, setting 
milestones, mergers and acquisitions, exclusivity 
of licenses, patent maintenance, patent enforce-
ment, confidentiality, patent misuse, and issues 
relating to collaborations. Notwithstanding this 
rather daunting list of considerations, there are 
many incentives that drive successful licensing of 
biotech inventions. 
For the licensor, incentives include obtaining:
• development and marketing assistance be-
yond the owner’s abilities
• clinical development for applications of 
academic discoveries
• funding for further research 
• assistance in areas that would otherwise not 
be developed
For the licensee, incentives include: 
• ensuring freedom to use a product line 
• obtaining exclusivity for a product line 
• becoming current quickly without the cost 
of internal research
• gaining access to technology from a leader and 
accessing or developing trained personnel
Hence, by balancing the inherent risks and 
potential rewards, properly structured biotech li-
censes serve to coherently actualize the incentives 
of licensors and licensees, such that all parties 
are winners, and biotech R&D advances toward 
commercialization for the benefit of all. ■
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ABSTRACT
Though similar in many ways to other kinds of license 
agreements, agri-biotech licenses have some unique ele-
ments that require special attention. Considering first 
the similarities, this chapter looks closely at the typical 
boilerplate language that all license agreements share 
and outlines the basic structures and concerns of all such 
agreements. The chapter then turns to the singularities of 
agri-biotech licenses, focusing on such issues as multiple 
property types that often cover a single technology and/or 
product, freedom to operate issues that drive anti-royalty-
stacking provisions, philanthropic- and humanitarian use 
clauses, and stewardship obligations.
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used synonymously to describe this area of genetic 
engineering). Since the largest amount of genetic 
engineering activity in agriculture to date has in-
volved plants, the discussion focuses on plant-re-
lated technology. But many of the principles of 
intellectual and biological property-based man-
agement and licensing in plant-based agri-biotech 
apply equally to animals and microbes.
This chapter’s topic is license agreements. It 
explores the basic nature and purpose of a license 
agreement: the definition and transfer of certain 
property rights between two or more parties un-
der a specified sharing of rights and obligations 
between those parties. A license is distinguished 
from a “sale” in that ownership of the property 
does not transfer but remains with the original 
owner. In a license, the owner, called the licensor, 
transfers certain rights of possession and use (but 
not ownership) to the recipient of those rights (the 
licensee).
As in any area, the process of creating a license 
agreement in agri-biotech involves the precise def-
inition of the property of interest, an articulation 
of the exact rights of the licensor and licensee in 
the property after the agreement is signed, and the 
ongoing rights and obligations of each party. The 
elements of this process are defined below, and 
the attendant issues in agri-biotech licensing are 




“Agricultural biotechnology” is a relatively broad 
term that can include cell culture, fermentations, 
bioprocessing, breeding and animal husbandry, di-
agnostic methods and apparatus, and biocontrol of 
plant disease and pests. An important, challenging 
area of IP management and licensing in agricul-
tural biotechnology relates to the genetic engineer-
ing of plants and animals through applied nucleic 
acid chemistry and related technologies. These 
technologies include methods and materials for 
isolating functional pieces of DNA (for example, 
genes and promoters), creating genetic constructs 
(that is, functional packages of DNA sequences), 
and stably inserting genes into plants and animals. 
This chapter focuses on these issues (the terms 
agricultural biotechnology and agri-biotech will be 
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2.	 BACkgRound	ISSueS	In		
AgRI-BIoTeCh	lICenSIng
A decision about whether to license an agri-bio-
tech invention is typically based on a few impor-
tant background issues:
• the significant cost to create, develop, and 
commercialize agri-biotech products
• the critical role of government regulations 
in testing and commercializing products
• the importance of public perception and 
acceptance of agri-biotech products
• the necessity of using numerous, different 
(and often proprietary) technologies to cre-
ate agri-biotech products
This last issue leads to the following related 
problems:
• the “tragedy of the anticommons” problem, 
which creates different technology owners 
with respect to a single product
• the challenge of obtaining freedom to op-
erate (FTO) for agri-biotech technologies 
and products
• the royalty-stacking problem, in which each 
owner of a proprietary technology expects a 
significant royalty on sales
• the existence of multiple forms of property 
that can exist simultaneously in any one 
technology or product, namely:
- utility patents
- plant patents
- plant breeder’s rights (for example, plant 




- tangible biological property
• the unique attributes of the agricultural in-
dustry, that is:
- low profit margins
- commodity economics
- national food security issues
- humanitarian concerns over hunger and 
malnutrition
3.	 oveRvIew	of	AgRI-BIoTeCh	lICenSeS
The factors described above combine to con-
figure and constrain agri-biotech license terms 
and conditions. For example, the multifaceted 
aspects of possible property instruments in agri-
biotech require the type and scope of property 
rights contained in the license to be carefully 
described. Does the license include a patent and 
a plant variety protection certificate on a new 
plant variety? Does the license include limited 
rights of possession of tangible materials such as 
seeds, vegetative cuttings, or tissue cultures? 
Similarly, the precise nature of the rights 
granted to the licensee must be clearly stated. 
Is the grant limited to a nonexclusive, freedom 
to operate for testing only or an exclusive right 
to make, use, and sell? Does the grant include 
rights in improvements to the technology or 
product and to related future inventions (for 
example, does the right to make, use, and sell 
a transgenic plant include rights to all crosses 
made with that plant using traditional breeding 
techniques)? And does the grant of rights per-
mit ownership of further developments by the 
licensee? For example, does the grant of rights 
to a transgenic plant include the right to use 
individual components of the genetic construct 
(individually or in combination) in other con-
structs and “transgenic plant events” made by the 
licensee? Agri-biotech licenses should also define 
the precise rights of sublicensing granted to the 
licensee. For example, is sublicensing limited to 
specific transgenic events or to genetic compo-
nents? Finally, what is the geographical scope of 
these rights? Are certain rights granted in one 
country but not in another? Breeding rights, for 
example, could be limited to one country and 
sales to another.
The low profit margins typical of com-
modity agriculture naturally depress the royalty 
rates that a technology owner can expect. For 
similar reasons, the large up-front license fees 
more typical of pharmaceuticals are unlikely.
The flipside of rights is obligations, and 
several sections of the license will define the 
obligations of the licensee. The most obvi-
ous are the financial obligations. Licensee 
payments will be defined, which may include 
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license fees, royalty on product sales, mile-
stone payments, and IP expenses. Such ob-
ligations can be defined in many different 
structures, schedules, and unique terms. In 
agri-biotech licenses, milestones may include 
the achievement of successful field tests, regu-
latory approval, and first product sale. Other 
obligations of the licensee are likely to include 
adherence to applicable laws, assumption of 
business risk, and product quality assurance. 
The license may also include licensee obliga-
tions for mandatory sublicensing, diligence 
in commercial development, labeling require-
ments, trademark use, confidentiality, and 
requirements for certain philanthropic and 
humanitarian uses, especially in developing 
countries.
The license is also likely to contain obliga-
tions for the licensor. For example, the licensor 
may be obligated to provide a specified amount 
of biological material over a certain time period. 
Similarly, the licensor may be required to pro-
vide know-how, and/or access to proprietary 
data, documents, and related information. On 
occasion, licensors will be obligated to perform 
certain tests or laboratory work or to provide 
access to future inventions and improvements. 
Almost certainly, the licensor will be obligated 
to guarantee its ownership rights and perhaps 
also product performance, noninfringement of 
licensed IP, and so on.
Of course, the parties to the license will be 
obligated to adhere to a set of legal requirements 
that are standards of contracts, such as formal 
notifications, protocols for contract amendment, 
dispute resolution, use of names, and the delin-
eation of legal remedies and venues. Although 
each part of a contract has importance, one of 
these sections of legal boilerplate, warrants and 
representations, is especially critical. This lan-
guage exactly defines the commitments being 
made by the parties and must always be scruti-
nized carefully.
The important sections of an agri-biotech 
license are described in more detail below, and 
some of the implications unique to licensing in 




The preface sections, which precisely define the 
parties and provide background and context for 
the agreement, are not unique to agri-biotech li-
censes. Like any license, the WHEREAS clauses 
of an agri-biotech license provide a good back-
ground to the terms and conditions of the agree-
ment—when they are written well.
4.2 Definition	of	property	rights
It is particularly important in agri-biotech li-
censing to precisely define the property rights 
contained in and transferred by the agreement. 
Biological materials should be described pre-
cisely. For example, complete lists of named 
plant-breeding lines, cell type sand lines, plas-
mids, and the like should be attached to the 
agreement. All patents, patent applications, and 
plant protection certificates should be listed in 
an attachment that includes serial numbers and 
their applicable countries. It should also be clear 
what derivates of patents and applications are 
to be included in the grant of rights, including 
continuations, continuations-in-part, division-
als, and reexaminations. 
4.3 Grant	of	rights
This section of the license agreement precisely de-
fines the rights conveyed by the owner-licensor 
to the licensee. In agri-biotech, there will likely 
be a mix of such rights granted. For example, the 
licensee may receive an exclusive right to sell a 
specific line of transgenic plant but not to make 
variants of the line. The grant of commercial ex-
clusivity to a transgenic plant line will very likely 
not include the right to make, use, or sell any of 
the components of the genetic construct alone or 
in combination, but only as an inextricably linked 
part of the specific transgenic plant.
The grant of rights should also define any ter-
ritorial limitations. As with any IP, agri-biotech 
patents are country-specific. But in agri-biotech 
this might include limits on export from countries 
where the right to make and sell has been granted. 
In addition, licensors in agri-biotech will frequently 
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provide incentives for licensees to sublicense, es-
pecially when the sublicense will cover markets in 
which the licensee may not be strong or even have 
a presence. The grant of sublicensing rights and its 
scope, therefore, is often an important issue. 
It is particularly important in agri-biotech 
to define whether the licensee may use the tech-
nology to create new variants. For example, will 
the licensee have the right to make crosses of the 
exclusively licensed plant line with its own pro-
prietary germplasm? If so, will this affect other 
license terms, such as the royalty rate owed?
The grant of rights will define the nature of 
rights exclusivity and whether there are any time 
limits to the exclusivity. For example, some exclu-
sive licenses provide only an exclusive lead-time 
of five years or so, after which the license reverts. 
Nonexclusive licenses are common in agri-bio-
tech licensing, but sole, exclusive, and co-exclu-
sive licenses are also often granted.
Finally, agri-biotech licenses are relatively 
unique with regard to the scope of rights concept 
field-of-use. In agri-biotech licenses, field-of-use 
typically refers to a crop type that may be broadly 
or narrowly defined. For example, the grant of 
rights may broadly include the right to make, use, 
and sell all monocots and dicots created using the 
technology. Or, the field-of-use might grant only 
monocots, or only corn. The field-of-use grant 
is particularly prevalent in the licensing of agri-
biotech genetic construct components, such as 
genes, selectable markers, translation enhancers, 
or promoters. This is due to the technologies’ fre-
quently broad applicability.
4.4 Consideration
The consideration section of the agreement is one 
of the most familiar. It is common to all licenses, 
including agri-biotech. What did the license cost? 
How valuable is the license? These are standard is-
sues dealt with in the consideration. This section 
is designed to deal with the opportunity cost to the 
licensor and to account for the potential value, cost 
to develop, and market potential of the licensed 
rights. Agri-biotech licenses may provide for ex-
changes of germplasm and access to other technol-
ogy owned by the licensor. For example, the licens-
ee may provide the licensor of a genetic construct 
access to the licensee’s valuable germplasm for 
future transformations. As mentioned above, agri-
biotech licenses have typically lower license fees 
and are often characterized by milestone payments 
at critical commercial development stages.
4.5 Royalty	payments
Like most licenses, agri-biotech agreements con-
tain provisions for a royalty payment linked to 
sales volume. Frequently, this link is a percentage 
of net sales. Due to low profit margins in agricul-
ture, this percentage is almost always much less 
than 10%. In fact, royalties of between 1% and 
5% are common.
A relatively unique aspect of agri-biotech 
royalty rate setting is the important problem of 
royalty stacking. This problem arises when several 
different owners of intellectual or tangible prop-
erty components in an agri-biotech product all 
expect a reasonable royalty on each sale. All of 
the owners will then “stack” their royalty expecta-
tion on the sale of each product. While this may 
be relatively manageable for two or three separate 
stacked royalties, it is wholly unmanageable when 
there are several and/or when any one of the com-
ponent owners expects a royalty that is too large. 
For example, it is common for each of four or 
five different owners of different proprietary 
technical components to request half of the profit 
margin. Obviously, that kind of royalty stacking 
makes commercializing an agri-biotech product 
economically unfeasible. The royalty stacking 
provisions of agri-biotech licenses are designed to 
mitigate this problem. Although such provisions 
can be difficult to negotiate, when implemented 
they can provide a pro rata sharing protocol that 
self-adjusts as the technology-property-owner-
ship mosaic changes over time.
Other popular royalty mechanisms include 
fixed-fee payments based on some type of add-
ed-value calculation. For example, in the United 
States, royalty on the sale of transgenic corn 
with lepidopteran and/or herbicide resistance 
(that is, Bt corn or Roundup Ready® Corn) has 
been based on a fixed tech fee on each bag of 
seed. Rebates, trademark use, incentives, and 
other mechanisms act to modify the fixed-fee 
amount.
CHAPTER 11.2
 HANDBOOK OF BEST PRACTICES  | 1013 
4.6 Minimum	royalty	payment
Minimum royalty payment obligations are not 
unique to agri-biotech licensing. They are com-
mon in all exclusive licenses. In agri-biotech li-
censes, such payments are often linked to the 
scope of rights granted, particularly territory and 
field-of-use rights. For example, the licensor may 
use increased or decreased minimum payments as 
an incentive (or disincentive) for the licensee to 
pursue commercialization in certain crop types or 
countries.
4.7 Philanthropic	and	humanitarian	use
There is often pressure to establish philanthropic- 
or humanitarian-use provisions in agri-biotech 
licenses, particularly if the crops are important 
food staples (for example, rice or wheat) in de-
veloping countries. Such provisions are designed 
to establish clear boundaries between the com-
mercial sphere and uses that directly impact a 
country’s poor population. Although there are a 
variety of ways to define these boundaries, they 
are often based on the scale of production and the 
scope of commercial activity. Such definitions de-
pend on the crop, the country, and the particular 
socio-economic situation. For example, growing 
three avocado trees would very likely be defined 
as philanthropic use in Bangladesh. Growing 
twenty-five trees there may or may not be philan-
thropic; a plantation of 500 hectares would most 
certainly be considered commercial. However, if 
the production of these 500 hectares was used 
by a nonprofit organization to feed the poor, it 
would likely be considered philanthropic use. 
Carefully designing and implementing philan-
thropic-use boundaries is essential, as is ongoing 
monitoring for compliance. Philanthropic use 
should always be considered when staple crops 
in developing countries are involved. However, 
such provisions should not be used to disguise 
commercial-scale use.
Philanthropic- or humanitarian-use pro-
visions of a commercial agri-biotech license 
will often identify a third party responsible for 
implementing the noncommercial provisions. 
The license may also define certain protocols 
for the interaction of the commercial licensee 
and the philanthropic-use licensee. A separate 
philanthropic-use license will be in place between 
the technology owner and the noncommercial 
partner. Such licenses usually would contain 
royalty or other payment obligations. However, 
stringent obligations for controlling and moni-
toring the technology and products may be im-
posed on the licensee to ensure the achievement 
of philanthropic and commercial goals. Despite 
the licensor’s waiver of royalty payments for phil-
anthropic use, nominal fees may be required by 
the philanthropic licensees to support dissemi-
nation of the technology. Both commercial and 
philanthropic-use licenses must be designed to 
enhance—and not hinder—the respective pur-
poses of each agreement.
4.8 Stewardship	of	technology
The issue of stewardship arises frequently in agri-
biotech licensing. Although precise definitions 
vary, stewardship generally refers to the ongoing 
oversight and guidance of the commercial devel-
opment and dissemination of the new technology. 
It typically refers to the importance of maintain-
ing a licensor’s overall interests in sustaining the 
long-term use of transgenic crops. Stewardship 
clauses in agri-biotech licenses have been particu-
larly concerned with smooth regulatory approv-
als, good government relations, effective manage-
ment of public relations, and mitigation of the 
loss of product efficacy caused by inappropriate or 
less-than-optimal implementation. For example, 
stewardship clauses in an agri-biotech license will 
most certainly obligate the licensee to actions that 
will not harm regulatory approvals or relations be-
tween relevant government officials, the licensee, 
and/or the licensor. These clauses may also pre-
scribe rights and obligations of the licensor and 
licensee that are designed to allow the licensor to 
maintain effective control over public relations 
efforts. Finally, on the technical side, stewardship 
clauses have been used to avoid the development 
of pest resistance in transgenic crops by mandat-
ing certain crop management techniques, such as 
rotations, buffers, and pest reservoirs.
4.9 Enforcement	and	litigation	
Successful agri-biotech products have a history 
of significant patent-infringement litigation. For 
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example, large agri-biotech companies such as 
Monsanto, Syngenta, Bayer, and Pioneer Hi-Bred 
International Inc. (now a division of DuPont) 
have engaged in numerous, complex patent in-
fringement actions against each other and their 
sublicensees. Although litigation can be viewed 
as generally undesirable, it may be unavoidable. 
Therefore, agri-biotech licenses should contain 
enforcement and litigation provisions that are de-
signed with this eventuality in mind.
5.	 pRACTICAl	eXAmpleS
Cornell University’s long history of licensing its 
agricultural intellectual property (IP) began with 
veterinary vaccines. Cornell patented and licensed 
these animal vaccines in the early 1930s after estab-
lishing its patent and licensing subsidiary, Cornell 
Research Foundation (CRF). Years before this, 
Cornell had an informal technology transfer pro-
cess through which it delivered new crop varieties 
to New York farmers. Using this informal process, 
Cornell transferred new seed varieties to the com-
mercial sector (farmers) through the New York 
Seed Improvement Program (NYSIP), a function 
of the New York Agricultural Experiment Station 
within Cornell’s College of Agricultural and Life 
Sciences. Although not a licensing process per se, 
NYSIP provided farmers with Cornell-developed 
seed under a long-held tradition in which farmers 
paid a nominal fee to NYSIP in exchange for the 
seed. And, following a practice that characterizes 
Cornell’s IP technology transfer today, NYSIP 
transferred these seeds from the University to the 
private sector nonexclusively.
Nonexclusive licensing reflects Cornell’s 
public mission and its fundamental desire to see 
Cornell technology widely disseminated.
Given the long history of the NYSIP seed-
distribution program, it’s not surprising that after 
vet vaccines, the next significant effort of Cornell’s 
patenting and licensing in agriculture was a pro-
gram to transfer new varieties of tree, vine, and 
other fruits through nonexclusive licenses. In the 
early 1980s, Cornell began a program to patent 
and license new raspberry and strawberry variet-
ies. This activity was driven, in part, by the ar-
rival of a new generation of plant breeders who 
saw patents and licensing as an important part 
of the mission for plant breeding at a land-grant 
university. More-traditional breeders at Cornell, 
responsible for Cornell’s apples and other tree 
fruits, were resistant to the notion of such using 
intellectual property to control dissemination of 
new varieties. They preferred the traditional route 
of placing new-fruit varieties in the public do-
main, involving no intellectual property, no con-
trols over distribution, and no financial return to 
Cornell or its breeding program.
This traditional view of public domain releas-
es began to change with the release of Cornell’s 
“Jonagold” apple variety. Although this variety 
was a modest success in the United States (often 
labeled as other, more common apples), Jonagold 
was hugely popular throughout Europe. For many 
years, it was the most popular European apple. 
But, because Cornell had not sought protection 
for the variety, there was no intellectual property 
in place, and this marketplace popularity did not 
translate into financial benefit for Cornell. This 
fact, coupled with a decline in state and federal 
support for apple breeding, changed the tradi-
tional “public domain” mind-set among certain 
groups at Cornell once and for all.
Since the mid-to-late 1980s, Cornell has had 
a comprehensive program of patenting and do-
mestic licensing of apples, cherries, plums, grapes, 
apple rootstocks, raspberries, and strawberries. 
These licenses are nonexclusive, simple, two-page 
contracts that provide for a royalty to be paid to 
CRF on sales of plants. These licenses have no 
up-front fees or minimums. While these licenses 
have accomplished the goal of widespread use 
of Cornell varieties, they have also been a disap-
pointment because nonexclusive licensees provide 
little or no incentive to invest in developing the 
market for the licensed variety. So, sales volume 
per licensee stays small.
In one rare instance, Cornell decided to li-
cense a raspberry variety, “Watson,” exclusively, 
with significant license fees, minimum royalty 
payments, and higher royalty amounts per sale. 
The license proved to be a financial success for 
Cornell and its fruit-breeding program and one 
that catalyzed significant market development for 
Watson. But this exclusive license was a political 
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failure. Various political constituencies at Cornell, 
including farmers, nursery owners, state legisla-
tors, and others, protested this license. Thus, until 
recently, all domestic licenses for Cornell fruit va-
rieties have been nonexclusive. And, although the 
royalties gained from these nonexclusive licenses 
have provided significant support for Cornell’s 
fruit breeders, one wonders if Cornell fruit variet-
ies might have been even more successful in the 
market if exclusive licenses had been allowed to 
incentivize market development.
Despite this adherence to nonexclusive li-
censing in the crop sector, Cornell continued 
to license veterinary technology on an exclusive 
basis. This was in consideration of the large in-
vestment necessary by the licensee to bring the 
product to market, but also the lack of political 
resistance to exclusive licenses in the animal-
health area. These conditions likewise existed in 
the food-process and agricultural-device fields. 
Throughout the seventies, eighties, and nineties, 
Cornell patented and exclusively licensed several 
food-manufacturing processes including: egg pas-
teurization and vegetable blanching, as well as the 
supercritical CO2 fluid extruder. The latter was 
unique in that the licensed device required a roy-
alty payment on sales of food product made using 
the patented machine.
During this same period, a number of bio-
logical control technologies were patented and 
licensed, all exclusively. Two of these are notable 
because the technologies were commercialized 
through start-up companies. In both cases, CRF 
took an equity stake in the companies. One com-
pany, Bioworks, sells a patented fungal species for 
control of plant disease. Bioworks is privately held, 
and Cornell retains strong ties to this New York 
company. A second company, Eden Bioscience 
trades on NASDAQ and was responsible for one 
of the largest equity-liquidation events realized by 
Cornell for its patented inventions.
The policy decision to allow CRF to take eq-
uity in start-ups as part of a patent license was a 
watershed event. That decision, made in the late 
1980s, was driven by one of the first and most 
important inventions in plant biotechnology—
the “gene gun.” The gene gun, which is based 
on a biolistics process, was invented by Cornell 
professors, John Sanford and Edward Wolf. CRF 
patented the invention but was unsuccessful in 
licensing it to existing agriculture-related com-
panies. Sanford and Wolf founded a company, 
Biolistics, which was ultimately purchased by 
DuPont, that actively commercialized the device. 
CRF had founder’s equity in Biolistics and real-
ized significant benefits on the sale of the com-
pany to DuPont.
Although the Biolistics story was a technology 
transfer success in many respects, the early partici-
pants were not fully aware of certain implications 
of some of the intellectual property aspects of the 
license arrangements. In particular, Cornell failed 
to retain its own right to use the invention for re-
search and technology transfer purposes and also 
failed to carve out certain philanthropic or human-
itarian uses from the commercial license. This has 
presented problems for some who wish to use the 
technology without having to abide by constraints 
imposed by DuPont and its sublicensees. Cornell 
has been criticized for this lack of foresight and, 
perhaps, rightly so. However, at the time, few peo-
ple understood the full implications of licensing 
agri-biotechnologies that were largely unproven.
There was one, very positive outcome of the 
gene-gun experience. After the gene gun, every 
invention licensed by CRF was also made avail-
able for philanthropic and humanitarian purpos-
es. Furthermore, all licensing by CRF contained 
explicit conditions that would ensure diligent use 
of Cornell technologies for any and all crops and 
in any geographical region.
After the gene-gun experience, Cornell and 
CRF actively pursued a two-pronged approach 
in agri-biotech licensing: nonexclusive and ex-
clusive. Nonexclusive licensing is more common, 
and when exclusive licenses are granted, they con-
tain quite stringent requirements for diligent de-
velopment in all applications, as well as carve-outs 
for philanthropy and orphan crops. For example, 
the “harpin” technology was licensed to Eden 
Bioscience under two different sets of terms: one 
for topical applications of the harpin proteins (for 
plant-disease control and yield enhancement), 
and the other for transgenic expression of the 
harpin genes. This provided for two sets of dili-
gence requirements and financial terms. 
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A good example of Cornell’s nonexclusive li-
censing strategy in agri-biotechnology has been 
the licensing of the rice actin promoter. This pro-
moter, discovered in rice, has widespread utility in 
monocot crops. It has particular utility in trans-
genic corn and has been used in corn lines with 
stacked traits of herbicide and insect resistance. 
Use of the rice actin promoter in corn has stimu-
lated widespread interest in licensing. Cornell’s 
strategy of nonexclusive licensing has successfully 
disseminated the invention while providing rea-
sonable compensation to Cornell. However, the 
licensing effort has been complicated by the var-
ied business models of the various nonexclusive 
licensees. Although Cornell attempted to main-
tain a standard set of license terms, each succes-
sive licensee asked for variations that were tai-
lored to their particular business models. In order 
to maintain fairness to all licensees, this tailoring 
of license terms required Cornell to adjust the 
balance of rights and obligations. For example, 
significant adjustments have been required in the 
sublicense provisions. Of course, no sublicensing 
of the promoter, per se, was allowed. However, 
the extent to which sublicensees could develop 
new crosses has been a frequent area of license 
negotiations.
An aspect of the nonexclusive rice actin li-
censing strategy has been the development of a 
hybrid of paid-up and royalty-bearing licenses. 
The agri-biotechnology industry has demanded 
paid-up licenses. The industry’s complaint was 
that royalty on each sale was too much of an ac-
counting burden. But, such terms make it diffi-
cult for the licensor to realize a significant return; 
unless the paid-up amount is very, very large. So, 
Cornell developed a hybrid for which the licensee 
would not pay an ongoing royalty on each sale; 
rather, lump-sum payments (of a predetermined 
amount) are owed upon reaching certain defined 
milestones. For example, payments are owed on 
signing, first successful field trial, first regulatory 
approval, first sale, third anniversary of first sale, 
and so on.
Today, Cornell uses a variety of licensing 
strategies to accomplish the privacy goal of assur-
ing delivery of Cornell technology to the market-
place. This practice relies heavily on nonexclusive 
licenses, but exclusives are more readily accepted. 
Cornell continues to try new and innovative licens-
ing strategies to satisfy its multifaceted mission. 
6.	 ConCluSIon
Agri-biotech license agreements share many simi-
larities with other types of intellectual-property-
based technology licenses. Much of the standard, 
legal boilerplate will be similar to that of any other 
license technology agreement. However, there are 
unique aspects of agri-biotech that set its licenses 
apart. Those differences include:
• multiple property types often covering a 
single technology and/or product
• freedom-to-operate issues that drive anti-
royalty-stacking provisions
• philanthropic- and humanitarian-use clauses
• stewardship obligations.
Common themes, structures, and contract 
conventions are part of this technology domain, 
but the complex nature of agri-biotech and its 
industry requires each license agreement to be 
unique, with special, built-in mechanisms that fos-
ter the mutual agreement of licensor and licensee. 
Hopefully, this overview will take us a step closer 
to a greater understanding of both the common 
and the unique aspects of agri-biotech licensing. ■
RICHARD S. CAHOON, Executive Director, Cornell Center 
for Technology, Enterprise & Commercialization and Senior 
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ABSTRACT
Variety licensing is a tool for plant breeding companies 
and institutions to commercialize their varieties and to 
transfer technology to farmers efficiently. As the seed 
industry becomes increasingly privatized, interest in in-
licensing new varieties, both from national and interna-
tional sources, is likely to increase. Likewise, financial 
pressure on public sector breeding will increase the need 
for the targeted commercialization of varieties through 
out-licensing. As the seed sector becomes more transpar-
ent, the market should see more foreign investment from 
companies who wish to make their varieties available 
through licensing. That, in turn, should promote local 
seed production and variety testing. The licensee and the 
licensor should focus primarily on the practical content 
of the license agreement, specifically, exclusivity to plant 
material and territory, plant variety protection, variety tri-
als, national registration, royalty payment, and informa-
tion transfer. The purpose of this chapter is to provide 
guidance for prospective licensors and licensees in the 
practical issues of in- and out-licensing of varieties.
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of an agreement between the owner of the variet-
ies, or an authorized representative, and a legally 
eligible person who wishes to commercialize the 
variety.
As described by Louwaars,1 the first problem 
in seed policy development is the dual function of 
seeds. Seeds are a method of technology transfer, 
and each seed itself is a commercial commodity. 
These two functions are among the most impor-
tant issues to address in establishing long-term 
success in variety in- and out-licensing. The tech-
nology embedded in the seed of a new variety is 
easily transferred to farmers on a large scale and 
can be used instantly. In many countries, pub-
lic breeding has supplied varieties for use by seed 
producers and farmers at no cost. This free shar-
ing of varieties makes it difficult to give recogni-
tion, in terms of royalty payments, for the variety 
improvement work.
Further use of the technology—and its im-
provements—depend on the seed’s other func-
tion, that of a commercial commodity. The seed 
must be used in trade. Once the seed is circulat-
ing in the marketplace, a portion of the profits 
can be re-invested in further breeding and the de-
velopment of new technology and plant varieties. 
This is possible because the incentive, especially 
for the private seed business, for continued crop 
development lies in the possibility of getting a re-
turn on the investment.
CHAPTER 11.3
1. inTRoDuCTion
Variety licensing allows breeding companies 
or institutions to commercialize their products 
(plant varieties) and is also an efficient tool for 
technology transfer. New technology in a variety, 
represented by improved genetics and expressed 
mostly through improved agricultural perfor-
mance, can be transferred to farmers by licensing 
out seed production and distribution rights to 
seed companies. The variety license itself consists 
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The In- and Out-Licensing of Plant Varieties
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Development of the private seed sector will 
increase competition and could speed up efforts 
to reach a larger part of the farming community. 
Small- and medium-sized seed companies need 
to develop their product portfolios through in-
licensing of varieties (whereas public institutes 
could increase profitability by out-licensing their 
varieties). The privatization and increased trans-
parency of the seed sector could promote foreign 
investment from companies wishing to make 
their varieties available through licensing, which 
in turn would promote local seed production and 
variety testing.
Access to new varieties requires proper 
handling of intellectual property (IP). This 
can be accomplished through variety license 
agreements, which also provide a strategy for 
developing and introducing new varieties. A 
variety license agreement can be divided into 
two main parts: first, those clauses describing 
the key rights and obligations of the parties and 
the conditions that make the framework of the 
license—these clauses will set the standards for 
cooperation and outline what the parties wish 
to achieve—and second, “boilerplate” clauses 
that are not specific to the agreement but are 
legally relevant (for example, processes for deal-
ing with arbitration, relevant law, legality, as-
signability, warranty, and force majeure). The 
purpose of this chapter is to provide guidance 
for establishing the first part of a variety license, 




• evaluation of the licensed material
• protection of germplasm
• national registration and plant variety 
protection
• royalties
• effect of termination
• reporting to licensor
In this chapter, the words breeder and vari-
ety owner will be used interchangeably, to mean 
a breeding company, an individual plant breeder, 





In-licensing plant varieties can raise market share 
or offer competitive advantages by increasing 
the ability to meet customer demands. The most 
obvious reason for in-licensing varieties is to en-
hance or complete a company’s variety portfolio. 
This applies both to companies with their own 
breeding programs and to companies working 
exclusively with in-licensed varieties. Those spe-
cies for which a company has existing breeding 
programs—or other species that may be of in-
terest to the market—are potentially subject to 
in-licensing. Demand for certain products from 
farmers, the processing industry, or consumers 
could be met by a company obtaining a license 
from the variety owner to supply the market with 
seed of that variety. These parties may demand 
things such as a species not available on the exist-
ing market, varieties with improved agricultural 
characteristics, or improved nutritional value. 
In-licensing gives breeding and seed compa-
nies access to new technology (like hybrid vari-
eties); breeding companies may profit from this 
new technology without obtaining a license to 
use the hybrid system itself in variety develop-
ment. Another advantage, or, rather, side effect, is 
the possibility for breeders to compare their ma-
terial with that of their competitors in the early 
stages of variety development.
2.2 Out-licensing
The most common reason for a company to out-
license its varieties is to maximize the return on its 
investment by allowing others to produce and sell 
its varieties in markets that the company cannot 
reach. Small- or medium-sized breeding compa-
nies, for example, may not have the resources to 
establish their own sales organization either within 
their own country or in different countries. Thus 
the companies will use out-licensing to fully ex-
ploit the potential of their breeding program.
2.3 Plant	variety	protection
The importance of plant variety protection (PVP) 
legislation as a driving force for successful variety 
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licensing cannot be stressed enough. PVP confers 
IP rights, known as plant breeder’s rights (PBR), 
which provide an incentive to plant breeders for 
the development of new varieties of crops. This, 
in turn, fosters progress in sustainable agriculture 
and generally improves the economic circum-
stances of farmers and growers, since it gives them 
access to new and improved varieties. However, 
without the legal framework for acknowledging 
the ownership of the licensed varieties, the variety 
owner will have difficulty getting a return on in-
vestments made in variety development. Effective 
PVP legislation supports the interests of both the 
variety owner and the farmer. It will also facilitate 
the transfer of technology and provide incentives 
for further investments in the development of 
new plant varieties. In many countries, PVP leg-
islation is based on the International Union for 
the Protection of New Varieties of Plants (UPOV) 
Convention, which exists in three revised versions 
(adopted 1961, 1978, and 1991, respectively). 
Currently, 61 countries2 have ratified the UPOV 
Convention. This makes it the most widely ad-
opted form of a sui generis IP protection system 
developed specifically for plant varieties. The latest 
revision of the Convention has not been ratified by 
all member countries; however, all new members 
are required to ratify the Convention of 1991.
Major differences in the conventions will af-
fect the approach to licensing. These differences 
include the species and genera for which PVP 
provides IP protection, exemptions from PBR 
(that is, the plant breeder’s exemption and the 
farmer’s, or crop, exemption, also known as the 
“farmer’s privilege”), the period of protection, 
and the scope of protection under PBR. The lat-
est UPOV Convention strengthens the rights of 
the breeder: member states are obliged to provide 
protection to all botanical genera and species 
(Chapter II, Article 13(1–2)); the Convention 
also extends the duration of the breeder’s right 
by five years (Chapter V, Article 19(2)), and ex-
tends the scope of protection to include condi-
tioning for the purpose of propagation, export, 
import, and stocking (Chapter V, Article 14(1)). 
The farmer’s privilege is an optional exemption 
from the PBR (Chapter V, Article 15(2)). It may 
limit the farmer’s rights to use on-farm harvested 
material—obtained from a protected variety on 
the same farmer’s holdings—as propagating ma-
terial. This propagating material is commonly 
called farm-saved seed (FSS), and this exemption 
stems from the basic rights outlined in the 1961 
and 1978 UPOV conventions (though the ex-
emption is not optional in either and is not as 
clearly defined as in the 1991 version).
The PVP legislation of the UPOV members 
is well documented and should not pose any large 
problems for prospective licensors and licensees. 
An awareness of the differences will facilitate the 
development of the variety license agreement. 
On the other hand, it may prove more difficult to 
influence PVP legislation in nonmember coun-
tries, and licensors are strongly advised to gather 
as much information as possible about the PVP 
system in a new territory so that they can adapt 
their licensing strategy accordingly.
3. Key	iSSueS	in	vARieTy	liCenSing
When establishing a license agreement, whether 
for in- or out-licensing, it is important to discuss 
and agree upon those issues that will constitute 
the spirit of the agreement and set the foundation 
for good cooperation.
3.1 Exclusivity
The following section on exclusivity has been di-
vided into two parts. The first section discusses 
the rights granted under the license. The second 
defines the material for which an exclusive license 
is granted.
Nonexclusive licenses are rare, and experience 
has shown that breeders grant exclusive licenses 
more willingly than nonexclusive ones. Exclusive 
licenses are preferred because breeders believe that 
the mutual commitment will be stronger when 
working exclusively. A good variety provides a 
competitive advantage and will thus create rev-
enue for the company with the exclusive rights. 
It is in the best interest of both parties to make 
the variety as profitable as possible, and the com-
mitment resulting from exclusive rights is consid-
ered to lead to the best market coverage possible. 
Indeed, working on a nonexclusive basis is con-
sidered to have smaller market potential.
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The extent of exclusivity is defined by various 
factors (such as the territory for which crop or va-
riety exclusivity is granted) that will be discussed 
in greater detail later.
3.1.1  The	rights	granted
The exclusive rights granted to the licensee of-
ten correspond, either in part or in whole, to the 
rights that can be obtained through the plant 
breeder’s rights (PBR) protection for a variety. 
As defined in the UPOV Convention Act of 
19913, 4 (Chapter V, Article 14 (1)), the following 
actions shall require prior authorization from the 
breeder:
• production or reproduction (multiplication)
• conditioning for the purpose of 
propagation
• offering for sale
• selling or marketing
• exporting
• importing
• stocking for any of the purposes mentioned 
above
These provisions are recommended as a start-
ing point for discussions about what rights the 
licensee will be allowed to exercise. The most im-
portant factors in determining the type of license 
to grant include: former experience, seed produc-
tion and distribution infrastructure accessible to 
the licensee, type of species to be licensed, and 
plant variety protection.
There are two major types of licenses. The 
first type is the distribution license, which includes 
the rights to market and sell the licensed mate-
rial. The second is a production license, which in 
addition to these rights includes the rights to seed 
multiplication and production. For varieties that 
are easily and rapidly multiplied, such as those of 
species with small seeds and low sowing rates, the 
licensor may prefer to keep all or most of the seed 
production within its own control. This would 
limit the exclusive rights for a distribution license. 
For varieties of species with high sowing rates and 
low multiplication factors (for example, cereals), 
the transportation cost of the commercial seed to 
the licensee is likely to be high, and so a produc-
tion license is usually preferred.
Breeders can partially preserve variety pro-
tection by limiting access to seed for propagating 
purposes. If the licensor allows only for marketing 
and sales, the variety is better protected because 
the licensor will not have to leave out early gener-
ations of seed for multiplication from its internal 
control system. However, under certain circum-
stances, the final seed generation, or the commer-
cial seed, may be more expensive because the total 
seed costs increase if the seed has to be transported 
between countries or over long distances within 
the same country. Giving the licensee responsi-
bility for seed multiplication and production will 
decrease margins (actual sales revenue for the 
seed itself ) for the licensor because the income 
will then be based on royalties (revenues derived 
from licensed use, propagation, sales, and so on), 
as opposed to sales margins and royalties, that is, 
a more lucrative double revenue stream. Licensed 
production may, however, be advantageous for 
the licensor because risks in seed multiplication 
will be spread, as will the costs for handling the 
seed in the production chain. 
High transaction costs in the chain from the 
breeder to the farmer can present large problems 
since many factors influence these costs.5 High 
transaction costs result in expensive seed, which 
makes it difficult to realize sales on the market. 
This is especially true for countries using large 
amounts of farm-saved seed or for places that 
market predominantly public varieties; these 
countries have a hard time realizing sales because 
both of these seed categories are chosen for their 
low costs to farmers. Still, if the licensee has ac-
cess to the required seed production infrastruc-
ture (basically, farm capacity for growing, har-
vesting, processing, storing, and transporting 
seed), costs can be kept low when incorporating 
new varieties. This will increase the value of the 
seed for the licensee and promote local agricul-
tural business. Still, as stated earlier, contracting 
seed production to small-scale enterprises will 
spread the risks in seed production and lower 
transportation costs because the seed can be pro-
duced closer to the market.
The number of generations of seed the licens-
ee is allowed to multiply can also be a matter of 
discussion. Generally, the number of generations 
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is decided on a case-by-case basis rather than reg-
ulated through the license agreement. National 
legislation, as well as international rules and di-
rections (such as the OECD Seed Schemes,6, 7 as 
laid down by the Organisation for Economic Co-
operation and Development [OECD]8), should 
be consulted during licensing, since they regulate 
the number of generations that any seed may be 
reproduced. Because the reproduction system 
will influence the stability of a specific variety, the 
number of generations varies between cross-pol-
linated and self-pollinated species.
The rights of the licensee to hybrid varieties are 
most commonly restricted to marketing and sales 
of the commercial seed. Hybrid seed production 
is more expensive and considerably more complex 
than the production of line varieties. The owner 
control of the hybrid components may influence 
the possibilities for out-licensing the production 
of hybrid seed. Moreover, by keeping hybrid seed 
production within its own control, the licensor, to 
some degree, protects the hybrid components. In 
addition, in some jurisdictions (for example, the 
United States) inbred seed lines can be protected 
as trade secrets. Or, to be legally, technically ac-
curate, the “information” embedded in the seeds 
is protected as a trade secret. 
The licensor may wish to restrict the rights 
of the licensee to import seed from sources other 
than the licensor. It may also wish to similarly 
limit the export of seed from the defined terri-
tory. In contrast, the licensee may want to retain 
these rights, and it is not always possible to re-
strict seed import and export, since this may be 
prohibited by legislation. For example, accord-
ing to the [European] Community Plant Variety 
Rights (Chapter III, Article 13(2)),9, 10 authori-
zation of the holder is required for export from 
the European Community (EC) and format im-
port to the EC of a protected variety. Between 
EC member countries, the export and import of 
protected variety material can only be restricted if 
the material is for propagating purposes (that is, 
higher seed generations than certified seed).
3.1.2  Defining	the	licensed	material
The second part of exclusivity deals with the defini-
tion of the licensed material. The access to varieties 
a licensor is prepared to give a prospective licensee 
depends on such factors as earlier experience, mar-
ket penetration ability, the licensee’s existing vari-
ety portfolio, and ongoing cooperation with other 
breeders. The exact size of the material must also 
be determined on a case-by-case basis. Exclusivity 





The most common type of exclusivity at the 
beginning of a partnership is likely to be first 
right of refusal, or exclusivity based on single 
varieties provided by the licensor. The licensor 
provides a few varieties of its choice, or it may 
allow the licensee to choose its candidates among 
a number of varieties for commercialization. The 
licensor may freely dispose of the remaining va-
rieties through other marketing channels within 
the same territory. Exclusivity is maintained, 
for single varieties only, and the licensor has the 
opportunity to evaluate the licensee’s ability to 
commercialize the licensed variety. This can also 
be a strategic tool to distribute varieties among a 
number of licensees, in the hopes of stimulating 
competition and obtaining a larger total market 
share in a particular market.
Granting a licensee exclusive rights to the 
whole set of crops in a breeding program occurs 
rarely, but this differs based on the number of 
crops or species within which the licensor is ac-
tive. This kind of exclusive relationship between 
the breeder and the licensee is likely to result from 
strategic decisions concerning the long-term rela-
tionship between companies, a wish to strengthen 
connections with key partners or between moth-
er/daughter companies, and so forth.
The other type of exclusivity is to grant exclu-
sive rights to selected crops or species. In a coun-
try with limited participants in the seed business, 
participants will likely specialize in certain crops. 
In such cases it could be appropriate to grant ex-
clusivity to all material from a breeding program. 
In certain circumstances, exclusivity may 
limit the work of a company or public insti-
tute. The public sector or other external funding 
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source might support a company’s breeding pro-
gram in whole or in part. These funds may come 
with provisions restricting the breeder’s options 
to offer exclusivity in out-licensing. Public sector 
breeding may also be unable to grant exclusivity 
to selected licensees, because this may limit pub-
lic access to the varieties.
License agreements may regulate continued ac-
cess to new varieties from the same licensor. Where 
the license agreement is limited to a single variety, 
it is likely that continued access would require a re-
quest from either party and could be part of the 
written agreement. For collaboration based on 
more-extensive variety trials, it would be sensible to 
settle an appropriate number of new breeding lines 
or varieties to submit each year to the licensee, sub-
ject to availability and request from either party.
3.2 Territory
Territory defines the geographic area where the 
licensee has the right to exercise its exclusive 
rights. The territory is not necessarily restricted to 
a country; it could be a part of a country, one or 
more countries, continents, or even the world.
In variety licensing, however, the most com-
mon territory is that of a country. Depending on 
the market coverage capabilities of the licensee, it 
may also be suitable to instead define the territory 
as a group of countries or established unions, such 
as the European Union,11 the African Union,12 or 
the Mercosur.13 In places such as these, the com-
mon rules for PVP, seed trade, and other relevant 
areas are more harmonized. Such territories have 
a tendency to change over time, and so it is rec-
ommended that parties in a licensing agreement 
consider defining a union as its member countries 
when the agreement is signed.
Definition of the territory may be influenced 
by existing PVP legislation. As discussed above, 
not all countries are UPOV members, and even 
UPOV members differ in PVP legislation depend-
ing on which version of the UPOV Convention 
the country has ratified. Many countries, especial-
ly developing countries, are not UPOV members. 
This should be taken into consideration when de-
fining the territory and the rights that the licensee 




The aim for both parties when in- and out-licens-
ing varieties is to select varieties for marketing 
that show improved agricultural performance or 
have other desired characteristics. Apart from the 
market (end-user) demand, the value of a variety 
is largely ascribed to its adaptation to local grow-
ing conditions. Depending on the plant species, 
varieties can be transferred between geographic 
areas and climatic zones. Introducing new vari-
eties usually requires the local confirmation of 
agricultural performance, which is done for the 
purpose of national listing and/or marketing ad-
vantages. Either the public system of variety test-
ing or private trials can be used to introduce the 
new variety.
The trial strategy and the minimum require-
ments for assessing local adaptation should be 
discussed and settled in the agreement, includ-
ing any decisions about cost sharing. Commonly, 
the licensor will require the licensee to evaluate 
the value of the varieties at its own cost, with 
the aim of including them in the national list, 
recommended list, or any corresponding list of 
varieties officially registered for release in the ter-
ritory. These trials are often referred to as VCU 
(value for cultivation and use) trials. Of course, 
the trial strategy can also consider whether it 
is necessary to have a variety officially listed in 
the territory or not. For example, within the 
European Union, varieties included on a na-
tional list in one member state or in any of the 
European Free Trade Association (EFTA) coun-
tries can be marketed in any other member state 
without any prior demand of inclusion on an 
additional national variety list.
Plant variety protection has to be applied 
for separately from the local adaptation trials. All 
three versions of the UPOV Convention provide 
the legal means to provisionally protect the va-
riety from the date of filing an application un-
til the grant of PBR. This gives the applicant the 
right to enforce the provisional rights in case of 
breach during the evaluation period, whether in 
a private or an official trial network, provided an 
application for PBR has been filed. If no such sys-
tem for provisional protection exists, the licensor 
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may add clauses in the license agreement that will 
regulate the distribution conditions of the plant 
material for trials.
3.3.1  Private	trials
Private trials in this context are defined as all tri-
als that are not part of publicly performed trials. 
The trials can be conducted by the licensee or any 
other skilled partner equipped to perform them 
(for example, other seed or breeding enterprises, 
farmers’ cooperatives, universities, or agricultural 
extension service centers). In countries without 
an official trial system, the role of the private tri-
als can be significant.
Private trials are a potential tool for the li-
censee to test varieties and select the best candi-
dates for official trials. Some countries require a 
minimum number of station data for entering a 
variety into official trials. Collection of these data 
can occur either in one year from the number of 
stations required for the application, or on fewer 
stations over a period of two or more years.
Unfortunately, breeders, either through ne-
glect, procrastination, or possibly selfish moti-
vation, might abuse the private trial system by 
keeping varieties within the private trial system 
until they are too old for market introduction. 
This could either prevent competitors from in-
cluding the variety in their portfolio or prevent 
breeding companies from entering the market 
with that specific variety. In order to avoid this 
abuse, it is necessary to limit the number of years 
a variety can be tested in the private trial network 
before it will be included in national list trials. 
For annual crops, a maximum of two years or 
two growth cycles should be sufficient for evalu-
ation unless some unpredictable event occurs, in 
which case the period can be extended by one 
year or growth cycle.
3.3.2 Official	trials
Official variety trials, also referred to as nation-
al or recommended list trials, are carried out to 
evaluate the candidate variety’s value for cultiva-
tion and use. This incorporates the varieties’ agri-
cultural performance and quality characteristics. 
Varieties that show an improvement compared to 
standard control varieties qualify for inclusion in 
the national list, a register of varieties approved 
for release on the national market. A national list 
or register of varieties does not provide any PVP 
for the varieties included. Instead, it is a means of 
safeguarding the quality of the varieties released 
on the national market—they have been tested 
and proved valuable in cultivation and use, in 
comparison to the other varieties on the list.
The private sector can undertake VCU tri-
als in countries where the public sector does not 
perform such trials. It is possible also to establish 
private trial networks that will enable new variet-
ies to be independently evaluated.
3.4 Germplasm	protection
It is important for a breeder to obtain protec-
tion for finished varieties and those still in tri-
als. Due to the importance of protection, it is 
essential to include a section in the agreement 
outlining the handling and supervision of plant 
material before it has obtained plant breeder’s 
rights (PBR) protection. If the production and 
sale of a variety is initiated before PBR has been 
granted, there is a risk that the variety will not 
be eligible for protection. It is advisable to re-
strict the licensee’s distribution rights of the not-
yet-protected material to third parties and use 
of the germplasm to the licensee’s own breeding 
programs. This restriction could either be part of 





Plant variety protection (PVP) is important when 
granting access to new varieties. It provides pro-
tection of the proprietary rights of particular spe-
cies in a territory. There is no blueprint solution 
for implementing PVP laws because the policies 
between countries differ greatly. Europe and the 
United States, both members of UPOV, are good 
examples of public versus private responsibil-
ity systems. Both systems provide protection for 
plant varieties and a legal means of enforcement 
of the rights, and both seek to grant PBR based 
on trials, usually referred to as DUS trials, that 
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show that the variety is distinct, uniform, and 
stable, and have received a novelty declaration 
from the breeder. The European Union (E.U.) 
has harmonized PBR legislation, and European 
countries have generally adopted a system based 
on testing and registration that is fully controlled 
and performed by designated authorities. PBR 
can be applied for at the community plant variety 
office (CPVO) and will be valid throughout the 
entire union. The system in the United States is 
based on self-control. The plant variety protec-
tion office (PVPO) issues PBR certificates, and 
the applicant is responsible for carrying out the 
necessary trials and filing an application based on 
forms and guidelines from the PVPO.14 
The PBR legislation in the defined territory 
will determine two matters: the strategy chosen 
by the licensor and the licensee to protect li-
censed varieties and what action to take if there is 
a breach of rights of the protected varieties.
In the first case, the licensor and the licensee 
can jointly decide on the appropriate way to pro-
tect the licensed varieties, as well as when to apply 
for protection. In some countries, even though 
there is PBR legislation in place, it may prove dif-
ficult to enforce the rights. Critics argue that, in 
these cases, the PVP system is a way to finance 
and maintain the bureaucracy rather than protect 
IP. Others claim that using the system, despite 
enforcement difficulties, is a way to ensure its 
improvement. At any rate, the licensor and the li-
censee have to decide jointly on the best approach 
for protecting the varieties under the current cir-
cumstances. This strategy should be clearly stated 
in the agreement.
The use of hybrid technology can provide 
additional IP protection in plants. Although 
F2 seed harvested from hybrid varieties can be 
used as seed, the agronomic advantages from hy-
brid vigour and a homogenous crop cannot be 
maintained in the second seed generation. This 
provides a self-regulating kind of protection for 
hybrid varieties and increases profitability for 
the licensee and the licensor through repeated 
seed sales. It should be noted that national PVP 
legislations differ: some permit the use of farm-
saved seed of the F2 seed from hybrid varieties, 
others do not.
3.5.2  Official	registration	of	varieties
Many countries require that new varieties un-
dergo official trials following official registration 
of the approved varieties. Official registration of 
a variety results in its inclusion in a national list 
of recommended varieties approved for market 
release. As mentioned above, the official trial 
system is one method of maintaining quality 
control for a variety, since the listed varieties 
have been tested for their agricultural perfor-
mance and quality. Release decisions are based 
either on results from independent public trials, 
on testing data supplied by the breeder, or on 
both. The appropriate trial strategy for the of-
ficial registration should be jointly decided by 
the licensee and the licensor and included in the 
license agreement.
3.5.3  Responsibility	and	cost	sharing
In addition to decisions concerning PBR and of-
ficial registration strategies, the licensor and the 
licensee must agree upon who will be in charge 
of applying for and maintaining the PBR and na-
tional list entries. It is also important that neither 
party withdraw the PBR grant or the national 
list entry without obtaining a written confirma-
tion from the other about the decision. Even if 
the licensee wishes to stop marketing a variety, 
continued protection may be required for other 
purposes (for example, if the variety is used as a 
hybrid component, for marketing it through an-
other channel or to allow for continued collection 
of FSS royalties).
The application and maintenance of variet-
ies for protection or official listing has associ-
ated costs. If the licensee has exclusive rights to 
the varieties in the territory, the licensee usually 
carries the costs connected to variety protection 
and the national list (including trials for either 
purpose). However, if the licensee has nonexclu-
sive rights to the variety, the licensor will usually 
carry these costs. In the European Union, where 
it is possible to obtain either national PBR or 
Community PBR (valid within the entire union), 
the cost for maintaining national PBR protection 
is commonly absorbed by the licensee, whereas 
the licensor is responsible for the cost for com-
munity PBR.
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Costs for trials, such as marketing or demon-
stration trials, are commonly paid by the licensee. 
The licensor could make other contributions (for 
example, providing promotional material, field 
signs, technical support through information ma-
terial, or by attending field days, and supplying 
seed bags with the licensor’s logotype).
3.6 Royalties
For the rights to commercial exploitation of the 
plant varieties granted under the license agree-
ment, the licensee pays the licensor a royalty. A 
royalty can include not only the fee agreed to by 
the licensor and the licensee, but all fees connect-
ed with the use of the licensed varieties, such as 
fees for FSS and acreage fees.
The royalty should be at a level acceptable to 
the market. It must neither be so high that the farm-
ers cannot buy the seed, nor so low that the licensor 
will not find it profitable. It is common practice for 
the licensor and the licensee to split the collected 
royalty. The proportions of the royalty paid to each 
party are a matter of negotiation. The amount de-
pends on the structure of sharing costs related to 
trials, maintenance of national list entries, PBR, 
market support, and other factors. There is no blue-
print solution: for each variety license the royalty 
has to be negotiated separately. Nevertheless, a few 
royalty-calculation principles can be used on their 
own or in combination: fixed royalty rate, royalties 
connected to the seed price, minimum royalty rate, 
royalty intervals and sold quantities, and multipli-
cation acreage and end-point royalties.
3.6.1  Fixed	royalty	rate
Setting the royalty at a fixed rate is the most com-
mon remuneration system. It requires knowledge 
of the seed business in the territory and the farmers’ 
ability to pay for the seed. The fixed rate is indepen-
dent of the sales price and is calculated per weight 
unit of seed bags containing a specified quantity. 
One can also calculate a fixed royalty based on the 
units of a specified number of seeds. The latter sys-
tem is used, for example, for winter oilseed rape 
(Brassica napus) in Europe, where the seed is sold in 
units of 1.5 or 2 million germinating seeds (hybrid 
and line varieties, respectively, in Germany) and 2 
million seeds (hybrid varieties in France).
Royalties can also be settled centrally in ne-
gotiations between breeder and farmer represen-
tatives. This is done, for example, by GESLIVE15 
in Spain and SICASOV16 in France. The royalties 
are negotiated and fixed annually for each species 
and seed generation—they could potentially be 
settled for individual varieties.
3.6.2	 Royalty	connected	to	the	seed	price
A royalty level connected to the price of the seed 
will instantly change as seed prices increase or de-
crease. The rate may be calculated as a percent-
age of the net sales price to the farmer, and since 
the actual net sales prices may be difficult for the 
licensor to verify, trust between the licensee and 
the licensor is of great importance.
3.6.3 Minimum	royalty	rate
A minimum royalty rate paid annually is a less 
common form of royalty and must be com-
bined with some other royalty system. In this 
system, the royalty is calculated on one of the 
calculation principles described above, but a 
minimum royalty is added to it. For example, if 
the royalty is calculated on a fixed rate and the 
total royalty collected exceeds the minimum 
royalty, the royalty based on the fixed rate will 
be paid to the licensee. If the total royalty col-
lected is below the minimum rate, the mini-




Royalties can also be connected to the seed quan-
tities sold. The royalty rates per unit can be fixed 
at intervals of sold seed quantities. The licensee 
either pays the royalty rate for the highest interval 
achieved for all seed sold or for the royalty cor-
responding to each interval.
3.6.5 Multiplication	acreage	and		
end-point	royalties
There are royalty systems that are independent of 
the actual seed sales. If sales volumes are difficult 
to control, it might be more efficient to use a roy-
alty system calculated on the multiplication acre-
age with a fixed rate per surface unit.
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In countries or areas where much of the 
agricultural produce is not used on the farm, a 
so-called end-point royalty can be successfully im-
plemented. When the farmer delivers his or her 
produce, a royalty based on the delivered quantity 
will be charged, regardless of whether the farmer 
has purchased the seed or used his or her own. 
This royalty system can be based on variety, use of 
certified seed, or other criteria.
3.7 Effect	of	termination
Termination of the agreement will have both 
immediate and long-term effects on the licensee 
and the licensor. Controversy can be avoided by 
defining the consequences of termination on the 
licensed varieties and the remaining seed at ter-
mination. The varieties can be divided into three 
groups: 
1. Marketed varieties
2. Varieties to enter the market soon
3. Varieties in trials
The varieties of the second group usually in-
clude varieties in official trials and varieties that 
recently have been officially listed but are not yet 
marketed.
If the agreement is terminated for reasons that 
allow for immediate termination, the licensor is 
likely to require that all rights to all varieties be re-
scinded immediately and that any seed still in the 
licensee’s possession be retuned to the licensor.
If the agreement is terminated for other rea-
sons, the licensor may want to treat the three va-
riety groups differently. Usually, the agreement 
will continue for the lifetime of the varieties with 
regard to the varieties in groups (1) and (2), but 
will be terminated immediately with regard to the 
those in group (3). 
3.8 Reporting	to	licensor
It is recommended that the agreement specify the 
information that should be transferred between 
the parties (usually from the licensee to the licen-
sor) on a regular basis. This information could in-
clude anything relevant to the activities resulting 
from the license agreement, such as:
• marketing plans and sales targets for the 
season(s)
• sales reports and forecasts throughout the 
season
• royalty statements
• variety trialing plans
• variety trial results
• seed certification reports
• copies of documents connected to PBR and 
a national list, such as application forms 
and PBR certificates
Establishing such routines through the agree-
ment will facilitate establishment of a transparent 
communication and relationship and will help 
both parties achieve their goals and continue to 
improve cooperation.
4. ConCluSionS
The seed sector in many developing countries 
is moving toward decreased funding of pub-
lic sector breeding and increased privatization. 
This trend is leading to a decrease in new variet-
ies entering the market on the one side and an 
increased opportunity for introduction of new 
varieties on the other. Seed companies need to 
in-license varieties, while private sector breeders, 
national and international, may need to out-li-
cense their products. The financial pressure on 
public sector breeding makes it difficult to main-
tain development of improved varieties; thus, 
incomes could be generated through variety 
out-licensing. Privatization could further attract 
foreign seed companies by making their variet-
ies available for local production and sales. This 
would also provide local seed companies and, 
presumably, farmers with access to new technol-
ogy. The development of new varieties—as well 
as good geographic coverage of the private seed 
sector—requires that breeders and seed com-
panies get a return on their investment. This is 
achieved when farmers buy seed and a royalty 
is paid to the breeder. It is also important for a 
breeder to obtain proper protection for the IP 
of a new plant variety. Proper PVP legislation is 
also needed. Providing the legal framework for 
breeders to get a fair chance to profit from their 
breeding efforts will promote further incentives 
for investments in variety development.
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The discussions around PVP in this chapter 
have dealt exclusively with PVP based on the acts 
under the UPOV Convention. Granting PBR is 
the predominant system for IP protection of plant 
varieties; in most countries of the world where 
plant varieties are not patentable, it is the only 
system for such protection. The major difference 
between PBR and patent rights lies within the 
breeder’s exemption and the farmer’s privilege of 
the PBR, as there are no similar exceptions from 
the rights in the patent.
The license agreement is a written statement 
of what the licensor and the licensee wish to 
achieve together. The principal objectives of the 
license must be clearly stated; otherwise, they will 
never be achieved. This chapter has described the 
key elements of variety licensing and how to ap-
proach them. The conditions of the license agree-
ment should set out the framework and the stan-
dards for cooperation, but it is also important to 
recognize that a license agreement is not static. 
There are certain provisions to follow, but these 
provisions also need to be flexible. Changes in 
the market, seed legislation, and PVP laws should 
be reflected in the agreement, because it is partly 
built upon them.
The issues discussed in this chapter should 
make it possible for prospective licensors and li-
censees to focus on the part of a license agreement 
that will have the largest impact on its successful 
implementation. ■
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Licensing between companies of both traits and varieties 
is routine, and there is no reason that it should be any-
thing other than routine between companies and public 
sector institutions, as well. Some public entities struggle 
to gain experience in this area. This leads companies to 
shun negotiations and, even, discussions. Yet opportuni-
ties for the public sector to in-license traits (in the form 
of well-characterized and deregulated transgenic “events”) 
and varieties are vast and could lead to earlier access with 
respect to transgenic events (through backcrossing into 
local varieties) and to improved varieties for subsistence 
farmers. In order to improve the ability of the public sec-
tor to both in-license and out-license germplasm, a test 
version of a software program, the “Computer Generated 
Contract Template System” (CoGenCo), was developed. 
It aims to facilitate the exchange (or licensing) of com-
mercial varieties by “walking” potential licensors and li-
censees though a systematic list of questions and tested 
parameters. CoGenCo is a pragmatic way of increasing 
the licensing of both finished varieties and germplasm 
containing transgenes for backcrossing, and its flexibil-
ity would make it especially suited for use in developing 
countries. This chapter explains the concept behind the 
software’s test version and leads the reader through its use. 
The authors very much welcome comments and sugges-
tions about the software and look forward to collaborat-
ing with interested parties to further develop CoGenCo 
into a comprehensive and widely available system.
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groups disagree about how to transfer protected 
varieties and biotechnological inventions to devel-
oping countries. Yet everyone agrees that access to 
these inventions in developing countries should 
be improved and accelerated, either through do-
nations or “open-source” licensing or through a 
variety of other strategies. But too often this goal 
is made complicated by too much industry in-
crementalism, or by activist demagoguery. From 
a humanitarian perspective, such debates distract 
from the only focus that matters—the urgent 
need for farmers to access improved traits and 
varieties.
There is no reason that the licensing of germ-
plasm and traits, particularly to meet the needs 
of resource-poor farmers in developing coun-
tries, need be more difficult than out-licensing 
for routine business purposes. Any plant-breed-
ing company that does the latter—virtually all of 
them—considers out-licensing routine. Consider 
Holden’s Foundation Seeds, a company now 
owned by Monsanto, the sole revenue of which 
comes from the out-licensing of its foundation 
seeds. In terms of developing country licensing, 
however, most companies are reluctant to even 
enter into discussions, let alone negotiations, 
partly because many variables are unknown or 
little tested, and because few companies have any 
experience in this area. For these reasons, a small 
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project was undertaken to develop a test version 
of a software program, the Computer Generated 
Contract Template System (CoGenCo).
2.		whAT	iS	CogenCo?
CoGenCo was designed to contribute to facili-
tating the exchange (or licensing) of commercial 
varieties by “walking” potential licensors and li-
censees though a systematic list of questions and 
tested parameters. The word commercial here is 
used because the licensor transfers commercial 
varieties primarily for commercialization in de-
veloping countries (following appropriate back-
crossing, as necessary). Such commercialization 
may be in the form of donations, through na-
tional agricultural-research systems, or directly 
through seed companies.
CoGenCo is a concept proposed as a prag-
matic way of increasing licensing of proprietary 
and finished varieties that may or may not in-
corporate proprietary technologies. Essentially, 
CoGenCo facilitates the awarding of out-licenses 
to developing country institutions, including 
germplasm from the Consultative Group on 
International Agricultural Research (CGIAR). 
Under the legally binding terms of these license 
agreements, several entities in a given country 
could compete against one another on price in 
poor (developing) countries but would not be al-
lowed to compete against the patent holder in de-
veloped countries, where revenues and incentives 
for developing new varieties and new technolo-
gies would be undiminished. Under appropriate 
circumstances, the germplasm and/or traits could 
also be licensed royalty free. Such out-licensing 
separates these fundamentally different markets 
and promotes access to improved germplasm and 
technologies, all by reaffirming various statutory 
protections as indispensable for successful agri-
cultural research and development. 
The CoGenCo system, therefore, is aimed 
at establishing a certain international standard 
license. The more institutions use the CoGenCo 
template, the more the system becomes valu-
able. For this reason, we intend to make the 
CoGenCo system available for free once it is fully 
developed. 
3.		 The	TeST	veRSion
Based on discussions with several lawyers and li-
censing experts, we generated a basic license tem-
plate. First, we developed a set of key variables and 
agreed on different options to choose from within 
defined ranges. A software engineer translated the 
concept into a “workable” software version that 
would provide a feel for what a finished product 
would look like. We selected Microsoft® Access® 
as the backbone of the system because it provides 
flexibility and easily expands into a version that 
can be used via a Web interface. Users around 
the world would thus be able to access the system 
without having to invest in expensive database 
software.
The primary objective of this test version was 
to see how different types of potential users would 
use it. The software allows for certain parameters 
to be adjusted. For example, for “humanitarian” 
licensing, a royalty of 0% could be specified, 
whereas for larger farmers, a sliding-scale royalty 
rate could be chosen. Depending on the option 
preferred, a different set of follow-up options will 
arise, such as liabilities, payment terms, audit-
ing requirements, and so on. The software will 
be developed in such a way that individual users 
may customize the software. For example, they 
could include their own institutional standard 
language where appropriate. It could also eventu-
ally be downloadable from the online version of 
this Handbook.1
Figure 1 shows one of many screenshots that 
allow users to input various parameters and select 
from a range of options. For example, by selecting 
the tab License, the user is offered a screen that 
lists all the pertinent licensing details, including 
the territory (countries), and many more. The 
user basically walks through the different issues 
that should be considered in a license and is pro-
vided with one, two, or more options.
The software thus presents users with an in-
teractive decision tree, which allows for multiple 
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•	 material transfer/reach-through clauses
•	 farm income
•	 import/export matters
•	 cooperative farm issues
•	 sliding scale for royalties
•	 royalty stacking issues
•	 warranties
•	 liabilities
•	 third-party distribution issues
•	 farmer-seeds issues
For example, the software system will ask 
the user whether tangible material is being trans-
ferred under the license. If NO is selected, then 
the next options will be limited to IP licensing 
aspects (including patents and/or know-how 
and/or trademarks and/or copyrights). If YES is 
selected under tangible material, then a specific 
question arises as to the conditions of the trans-
fer, primarily in terms of possible reach-through 
clauses. To include reach-through clauses has cer-
tain advantages and disadvantages. If the user se-
lects YES, then he or she will be prompted with 
different language and issues to consider. Also, if 
the user selected YES, then later down the path, 
an alternative liability clause will be offered that 
is somewhat different from the scenario under 
which no material transfer takes place.
To illustrate, if the user clicks YES under ma-
terial transfer, he or she will be offered options 
such as these:
1. Is the licensor transferring the material with 
certain claims of ownership on new inven-
tions based on the transferred material?
 No, the licensor makes no claims on 
ownership of new inventions.
figure	1:	user	Interface	for	the	Specification	of	licensee,	
licensor,	and	license	details	
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  The software system will pro-
ceed to the next topic.
 Yes, the licensor does make some claim 
of ownership.
 The software system will offer 
some of the options illustrated 
below:
First, the user will be offered some text about 
reach-through clauses, their utility, and their ratio-
nale, and information about how common such 
clauses are under different conditions. Basically, 
licensors want to ensure that if the licensee makes 
an improvement, the licensor is not prevented 
from using/licensing the improved licensed tech-
nology and benefiting from the improvements. 
There are several levels of ownership a licen-
sor may wish to exercise. Which one is chosen 
depends on the commercialization strategies of 
the licensor, including the symmetry of negotia-
tions. Generally, three levels are typical (whether 
for commercial or humanitarian use). These will 
be listed, together with a blank field for the users 
to specify their own terms. For example:
Licensor gives the material, and if licensee 
improves the invention or invents something 
based on the transferred material, licensee will 
give licensor one of the following:
1. an exclusive license in all Fields of Use 
(crops or applications, that is, medical, 
agricultural, environmental, and so on, as 
defined above) in all territories (countries, 
group of countries, as defined above) and 
grant back a royalty-free nonexclusive li-
cense to licensee in Field of Use 
2. a royalty-free nonexclusive license and a 
right of first refusal to an exclusive license 
(in some/all Fields of Use and in some/all 
territories)
3. a first right of refusal to an exclusive license 
(in some/all Fields of Use and in some/all 
Territories).
4. other (specified by user)
Each such option will be linked to legal lan-
guage in plain English to be inserted into the li-
cense. For example, under 2. above, the following 
language would be inserted:
In consideration of Licensor’s contribution of 
Materials (defined above), Licensee grants to Licensor 
a paid-up, worldwide, nonexclusive license to make, 
have made, use, have used, import, export, sell and 
have sold products and processes developed from 
Materials and an option to obtain a fee-bearing, 
worldwide, exclusive license to make, have made … 
(terms to exercise option to be defined; software 
will prompt user with a new screen on the ways in 
which such options can be exercised; depending 
on which is selected, the legal language and clause 
will be amended accordingly).
For number 3. above, the clause could read:
In consideration of Licensor’s contribution 
of Materials (defined above), Licensee grants to 
Licensor an option, exercisable at any time up to 
two years after expiration or termination to obtain a 
royalty-bearing, worldwide, exclusive license with a 
right to grant sublicenses to Company affiliates and 
subsidiaries in the following Field of Use (defined 
where field of use refers to crops) in Territory (geo-
graphic region, limited or worldwide) or a combina-
tion thereof.
Other fields are diverse and include the type 
of licensee institution, the countries, or the type 
of license (Table 1).
As above, depending on which field is cho-
sen, other text in the database template will auto-
matically be inserted into the license agreement.
To generate the complete license in Microsoft® 
Word®, the user now presses the tab Submit at 
the bottom right corner. See Box 1 for an ex-
ample of the output ( see also the Appendix to 




CoGenCo has the potential to help public insti-
tutions license plant varieties and associated intel-
lectual property more easily than before. It offers 
a very flexible, pragmatic approach to drafting 
licensing agreements. A test version of CoGenCo 
and a preliminary user’s guide, together with the 
draft license, are available to interested parties. 
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It will require running Microsoft® Access® on 
a Windows XP or higher system. The authors 
very much welcome comments and suggestions 
about the software and look forward to collabo-
rating with interested parties to further develop 
CoGenCo into a comprehensive and widely 
available system. ■ 
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Exclusive license is a promise by the licensor not to practice under the licensed 
intellectual property and not to grant any further licenses.
Nonexclusive
Nonexclusive license ensures that the owner of the licensed intellectual 
property shall not sue the licensee with respect to acts done within the scope 
of the license. The licensor can grant several nonexclusive licenses to same 
intellectual property.
Coexclusive
Coexclusive license is otherwise similar to the exclusive license but the 
licensor retains rights to itself practice the intellectual property.
Table	1:	options	under	license	Type
John DoDDs, Founder, Dodds & Associates, 1707 N Street 
NW, Washington, DC, 20036, U.S.A. j.dodds@doddsasso-
ciates.com
Donna BoBroWicz, Technology Transfer Specialist, Loyola 
University Chicago, Stritch School of Medicine, 2160 S. 
First Avenue, Building 120, Room 400, Maywood, IL, 
60153 U.S.A. dbobrowicz@lumc. edu
1 See www.ipHandbook.org.
2 This means that the LICENSOR shall be the first party 
to which a worldwide exclusive license is offered. Only 
after the LICENSOR has refused from such a license 
may the LICENSEE offer the license to others.
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Box	1:	Sample	noncommercial	variety	licensing	Agreement
Effective day of month, insert year (hereafter, the EFFECTIVE DATE) full name of organization 
licensing out to the other, having a principal place of business at   address                             (hereafter 
LICENSOR) and full name of organization licensing in, having a principal place of business at 
address                                           (hereafter LICENSEE) agrees as follows:
I. PARTIES
LICENSOR being  
a) a not-for-profit organization with the objective to _____________
b) a not-for-profit company in business of_____________
c) a for-profit entity in business of _____________ 
and LICENSEE being 
a) a small farmer_____________ 
b) a farmer’s association_____________
c) a for-profit entity in business of _____________
d) a not-for-profit organization with the objective to _____________ 
have agreed to _______________(for example, commercialize and produce seeds of the variety 
CCC) 











license to the LICENSEE.







for purposes of (for example, seed production, distribution, sale, to have sold, etc.)
Underlined and bolded text means that these gaps will be filled in when completing the 
agreement using the software.
Italicized and bolded text means that these are one or more alternatives to be chosen 
depending on the parties, the circumstances, and so forth.
Bold indicates text that may not apply to given agreement.
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Box	1	(continued)
(Continued	on	next	page)
LICENSOR and LICENSEE are hereunder commonly referred to as PARTIES.
ARTICLE 1. DEFINITIONS
In this Agreement defined terms shall have the meanings set out below:
[optional] aFFiliate of a PARTY means any person or legal entity that is a general licensee of 
such PARTY in the field of this agreement and that has a contract with such PARTY entitling it to 
receive continuing technical services from the PARTY, but any such person shall be deemed to be 
an affiliate only so long as it has such a contract and continues to be such a licensee. 
commercial sales means the sales made by LICENSEE in the TERRITORY. 
cooPeratiVe means an enterprise or organization jointly owned or managed by those who use 
its facilities or services.
[optional] coUntrY means a country in which the LICENSEE makes EXPORT SALES. A list of 
COUNTRIES is attached as an integral part of this license agreement. Such list may be updated 
in writing by the parties from time to time by mutual agreement. 
[optional] eXPort sales means the sales made by the LICENSEE in COUNTRIES.
Farmers’ association means an organized body of farmers.
[optional] gross sales means income at invoice values received for goods and services over a 
given period of time.
[optional] inVention means the invention, which is the subject matter of patents, PVP or any 
other form of Intellectual Property Protection.
intellectUal ProPertY means the patents, copyrights, trademarks, design rights, data 
protection rights, plant variety rights and any other statutory rights for inventions, improvements, 
designs, and any other intellectual property rights in any territory of the world relating to the 
INVENTION.
KnoW-hoW means all information, data, results and know-how (including without limitation 
reports, notebooks, drawings, papers, documents, manuals and databases) but excluding 
MATERIAL. 
licenseD croP means the crop or crops listed in Appendix I, initially derived from the plant 
variety XXXX. 





KRATTIGER, DODDS & BOBROWICZ






material means all forms of living and nonliving biological material including without 
limitation, strains, clones, antiserum, plants, parts of plants, cultivars, germplasm, genetic 
material, gene constructs, and microorganisms. 
[optional] net sales means gross sales reduced by customer discounts, returns, freight out, and 
allowances
[optional] nonProFit corPoration means a corporation no part of the income of which is 
distributable to its members, directors, or officers. Corporation organized for other than profit-
making purposes. 
[optional] nonProFit organization means an organization for purposes other than 
generating profit, such as charitable, scientific, or literary organization.
[optional] Patents mean any and all patents (including but not limited to patents of 
implementation, improvement, or addition; utility model and appearance design patents; and 
inventors’ certificates; as well as divisions, reissues, continuations, renewals, and extensions of 
any of these), applications for patent, and letters of patent that may issue on such applications.
[optional] Unit oF ProDUct emBoDYing the inVention means kg of seeds of the VarietY or 
number of fruits of the VarietY.
ProDUcts emBoDYing the inVention means for example, fruit, seed or plant parts of the 
Plant VarietY. 
ProPrietarY germPlasm means Germplasm, which in the relevant TERRITORY or COUNTRIES 
is the subject of intellectual property protection owned or controlled by LICENSOR. 
ProDUction cost means combined cost of raw material and labor incurred in producing 
seeds.
[optional] PVP means Plant Variety Protection; the protection of varieties as a form of exclusive 
ownership and use rights determined based on distinctness, uniformity, and stability of the 
Plant Material. 
samPles means any samples or copies of the MATERIAL distributed to third parties for testing 
purposes.
small Farmer means a farmer 
a)  owning and operating a farm smaller than the area and growing the crop  on at least 
(percentage) % of the area  
b)  having yearly sell less than $amount 
[optional] sUBsiDiarY of a PARTY means any corporation over 50% of the voting stock of which 
is directly or indirectly owned or controlled by such a PARTY. 
technologY means the INVENTION, LICENSED KNOW-HOW, LICENSED MATERIAL, and 
INTELLECTUAL PROPERTY.
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Box	1	(continued)
(Continued	on	next	page)
territorY means the geographic territory of name of the territory (for example, Uganda).
[optional] VarietY means plant variety as described in relevant certificate of Plant Variety 
Protection.
VARIETY NAME means the name.
ARTICLE 2. LICENSE GRANT
LICENSOR grants to LICENSEE an
a)  exclusive/nonexclusive license to  produce and use PRODUCTS EMBODYING THE INVENTION 
worldwide/throughout the TERRITORY and offer to sell and sell worldwide/ throughout the 
TERRITORY/in the COUNTRIES  
and/or
b)  an exclusive/nonexclusive license to produce and use worldwide/throughout the TERRITORY 





a right to export the PRODUCTS EMBODYING THE INVENTION to the COUNTRIES. LICENSEE 
has
has not 
a right to sell the PRODUCTS EMBODYING THE INVENTION to a third party exporting or aiming 
to export. LICENSEE 
has
has not 
a right to sell the PRODUCTS EMBODYING THE INVENTION through any third party, including 
any FARMER’S ASSOCIATION. 
[optional] the license granted in this article is subject to a reserved nonexclusive license to 
the licensor to produce, use, sell, offer for sale and import the ProDUcts emBoDYing the 
inVention.
article 3. oBligations oF the Parties
[optional] 3.1. right to saVe seeDs
a)  There is no limit to how much seed LICENSEE may save
b)  LICENSEE may save enough seed to plant his/her own farm holding 
c)  LICENSEE has no right to save seeds
[optional] if a or b was selected from above then 3.1.1. right to sell saVeD seeDs 
a) The saved seeds may not be sold without permission of LICENSOR
b) LICENSEE may sell the saved seed 
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Box	1	(continued)
(Continued	on	next	page)
a) but only by VARIETY NAME
b) but only under the LICENSED TRADEMARK
When this agreement is terminated LICENSEE 
a) may not sell the saved seeds/ 
b) may sell the saved seeds 
a) but only by VARIETY NAME 
b) but only under the LICENSED TRADEMARK 
c) shall sell the seeds to the LICENSOR at the production cost
[optional] 3.1 right to giVe samPles
[optional] the licensor reserves a right to give samPles to 
a) any third party for (e.g. research, testing)  purposes/
b) to (e.g. research) institutes to  (e.g. research) purposes
3.3 RIGHT TO GRANT SUBLICENSES
a) LICENSEE has not a right to grant a sublicense to a third party/
b) LICENSEE has a right to grant a sublicense to a third party. LICENSEE has such a right only at 
such times, as it is not in material default with any of its obligations to LICENSOR under this 
agreement.  Any such sublicense should be in writing and shall be accepted in writing by any such 
third party.
The operations of such third party shall be deemed to be the operations of LICENSEE, and LICENSEE 
shall account therefore and be primarily responsible for the performance by such third party of all 
of its obligations hereunder.
LICENSEE shall notify LICENSOR promptly in writing of any such sublicense.
Any sublicense granted by the LICENSEE shall be deemed to terminate upon termination of this 
Agreement terminates.
3.4. ADVERTISING, MARKETING AND PROMOTION COSTS
LICENSEE shall bear all costs associated with the advertising, marketing, and promotion of 
MATERIAL and TECHNOGIY covered by this license. [optional] licensee shall make reasonable 
efforts to share with licensor details of such campaigns in advance of release. 
3.5.  goVernment anD regUlatorY aPProVals
LICENSEE shall be responsible for adhering to all laws and regulations and for obtaining and 
complying with all government and regulatory approvals, licenses, clearances and consents 
pertinent to or required to cover its activities under this agreement.
[optional]	3.5.	plAnT	vARieTy	pRoTeCTion
LICENSOR shall bear all the costs of seeking PLANT VARIETY PROTECTION in TERRITORY and/or 
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Box	1	(continued)
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COUNTRIES when it is mutually agreed that the potential markets justify such costs. 
3.6.  INDEPENDENT ENTITIES
Each PARTY is acting as an independent entity. Nothing in this Agreement shall be construed 
so as to constitute a partnership or joint venture of any kind between the PARTIES hereto. This 
document merely serves to license MATERIAL and TECHNOLOGY from LICENSOR TO LICENSEE.
article 4.  roYalties
4.1. RATE OF ROYALTIES
a) LICENSEE shall pay royalties to LICENSOR from COMMERCIAL SALES at the rate of number % 
of a) the gross sales/ b) net sales of the PRODUCT EMBODYING THE INVENTION and/or
b) LICENSEE shall pay royalties to LICENSOR from EXPORT SALES at the rate of number% of a) 
the gross sales/ b) net sales of the PRODUCT EMBODYING THE INVENTION and/or
c) LICENSEE shall pay royalties to the LICENSOR from COMMERCIAL SALES at the rate of US$ 
the amount per UNIT of a) PRODUCT EMBODYING THE INVENTION sold/ 2) PRODUCT 
EMBODYING THE INVENTION produced  
d) LICENSEE shall pay royalties to the LICENSOR from EXPORT SALES at the rate of US$ the 
amount per UNIT of 1) PRODUCT EMBODYING THE INVENTION sold/ 2) PRODUCT EMBODYIN 
THE INVENTION produced.
[optional] in case the royalties paid do not aggregate a minimum of the sum Us$ dollars for 
the year ending December 31, the year, and for each succeeding calendar year during the 
life of this agreement, licensee will pay to licensor, within thirty (30) days of the end 
of such year, the difference between the royalties actually paid under this agreement for 
such year and such minimum sum.
4.2. REPORTING 
a) LICENSEE agrees to a) report/ b) make written report to LICENSOR
i.) once a year
ii)  twice a year during the life of this Agreement stating in each such report the number and 
description of 
a.  net 
b.  gross sales of each PRODUCT EMBODYING THE INVENTION sold or otherwise disposed 
of during the preceding 
i.  12 months
ii.  6 months 
b)  LICENSEE agrees to report to LICENSOR once a year during the life of this Agreement the 
amount of UNITS of PRODUCTS EMBODYING THE INVENTION a) produced/b) sold.
LICENSEE agrees to make a written report to LICENSOR within thirty (30) days after the date of 
termination of this Agreement stating in such report the number and description 
a) of net/gross sales of each PRODUCT EMBODYING THE INVENTION sold or otherwise 
disposed 
b) amount of  UNITS of PRODUCTS EMBODYING THE INVENTION
c) amount of UNITS of PRODUCTS EMBODYING THE INVENTION produced 
and on which royalty is payable hereunder but that were not previously reported to 
LICENSOR.
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4.4. RECORD KEEPING 
 
LICENSEE agrees to keep records showing the sales or other dispositions of the PRODUCTS 
EMBODYING THE INVENTION  in sufficient details and further agrees to permit its books and 
record to be examined from time to time to the extent necessary to verify the reports provided 
above. Any costs of the examination of the books are due to the LICENSOR. 
4.5  TERMINATION OF OBLIGATION TO PAY ROYALTIES
The obligation to pay royalties shall terminate when this Agreement terminates.
[optional] article 5.  
the ProDUcts emBoDYing the inVention and aimed to commercial sales or eXPort 
sales shall be 
a) of high quality which is at least equal to comparable products produced and marketed by 
licensee and in conformity with a standard samPle approved by licensor/ 
b) of the quality of certified seeds/ 
c) shall have germination percentage of at least ___(%)
if the quality of such ProDUcts emBoDYing the inVention falls below such quality as 
previously approved by licensor, licensee shall use its best efforts to restore such a quality. 
in the event that licensee has not taken appropriate steps to restore such a quality within 
number days after notification by licensor, licensor shall have the right to terminate this 
agreement.
Before selling ProDUcts emBoDYing the inVention, licensee shall submit to licensor, at 
no cost to licensor and for approval as to quality, number sets of samples of the ProDUcts 
emBoDYing the inVention, which licensee intends to sell and one (1) complete set of all 
promotional and advertising material associated therewith.  Failure of licensor to approve 
such samples within number working days after receipt hereof will be deemed approval. if 
licensor should disapprove any samPle, it shall provide specific reasons for such disapproval. 
once such samPles have been approved by licensor, licensee shall not materially depart 
therefrom without licensor’s prior express written consent that shall not be unreasonably 
withheld. 
the licensee agrees to permit licensor or its representatives to inspect the facilities where 




[optional] article 6. inVentions
6.1. notiFication oF inVentions, imProVements, or DiscoVeries
if during the term of this agreement licensee generates any inVention, improvement, or 
discovery that improves the material or technologY, it shall notify licensor immediately 
and the Parties shall meet to discuss the ownership and patenting of the neW material, 
technologY, or inVention, and if appropriate the territorY and coUntries in which such 
patent protection should be sought. should such material, technologY, or inVention be 
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patentable licensor will be granted a royalty-free worldwide nonexclusive commercial license 
thereunder including the right to sublicense for all applications and a first option1 to negotiate 
worldwide exclusive access or all uses. 
6.2.  licensee’s rights to neW intellectUal ProPertY
in any event licensee shall retain royalty bearing nonexclusive licenses for use 
a) in the territorY 
b) in country 
of any such intellectual property generated by licensee arising during the term of this 
agreement. 
[optional] 6.3.  licensee’s oBligations 
licensee shall not make or permit to be made by any employee, appointee, agent contractor, or 
otherwise any publication or results, or data arising under or in connection with this agreement, 
nor disclose the existence or content of this agreement without the prior written consent of 
licensor. 
ARTiCle	7.		ConfiDenTiAl	infoRmATion
Any information provided under this Agreement to LICENSEE, which LICENSOR considers 
confidential, will be provided in a written or oral form or in the form of a sample. LICENSEE agrees 
that it will treat such information and material confidential and will not divulge or provide such 
information and material to any third party. LICENSEE further agrees that it will not make any 
use of such information or material except as required or authorized by LICENSOR.
ARTiCle	8.	TeRminATion	of	The	AgReemenT
[optional] In case royalties paid through December 31, year or any subsequent full calendar year 
do not equal or exceed minimum of  amount in letters dollars $amount in numbers. LICENSOR 
may at its option terminate this Agreement and the license granted to LICENSEE by thirty (30) 
days’ notice in writing to LICENSEE. Such termination shall not release LICENSEE from any liability 
or obligations to LICENSOR, which occurred on or prior to the date of such termination.
This Agreement may be terminated by either PARTY upon written notice to the other PARTY 
specifying a material breach by the other party of the provisions thereof. The nonbreaching 
PARTY may terminate this Agreement in the event the specified breach has not been cured 
within sixty (60) days after the written notice.
Unless earlier terminated, this agreement shall extend for number of years) years from the date 
of execution of this agreement. 
ARTiCle	9.	liABiliTieS
LICENSOR shall in no event be liable for damages, whether direct or otherwise, arising out of the 
use by LICENSEE or any third party of information or materials supplied hereunder. 
In no event shall LICENSOR be liable for lost or prospective profits or special or consequential 
damages, whether or not LICENSOR has been advised of the possibility of the damages, nor for 
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Box	1	(continued)
any claim by a third party against LICENSEE. 
LICENSOR warrants that it is the sole owner of the (describe the iP) and that it has the right to 
grant licenses. 
ARTiCle	10.	AppliCABle	lAw
This agreement shall be governed by and construed according to the laws of  country or state.
ARTiCle	11.	vAliDiTy
If any of the provisions of this Agreement are held to be invalid or unenforceable, the PARTIES 
will attempt to replace them with new provisions, which have the same force and effect and the 
remaining provisions shall not be affected.
ARTiCle	12.	DiSpuTe	ReSoluTion
In the event a dispute shall arise between the PARTIES to this Agreement, the PARTIES agree to 
participate in at least four (4) hours mediation in accordance with the mediation rules of ______
_________. The PARTIES agree to share equally the costs of the mediation. In case the PARTIES are 
unable to resolve the dispute in mediation they agree to submit the dispute to 
a) final and binding arbitration under the arbitration rules of ______, [optional] and the 
judgment upon the award rendered by the arbitrator(s) may be entered into any court 
having judgment thereof. The PARTIES agree to share equally the costs of the arbitration. 
b)  court decision 
IN WITNESS WHEREOF, the PARTIES hereto have caused this Agreement to be executed by their 
duly authorized representatives as of the dates below.
____________________________   _____________________
For       Date
________________________________  _______________________
For                                             Date
a  This means that the LICENSOR shall be the first party to which a worldwide exclusive license is offered. 
Only after the LICENSOR has refused from such a license may the LICENSEE offer the license to others.
ABSTRACT
Exploiting the overlap between intellectual property (IP) 
categories, especially between patents and trade secrets, 
is an important facet of IP management. Patents (which 
require full disclosure) and trade secrets (which are kept 
confidential) are not incompatible. On the contrary, they 
can complement one another: patents protect inventions 
and trade secrets protect collateral know-how. Using patent 
and trade-secret protection together in a synergistic man-
ner results in a potent exclusivity. Moreover, as licensing has 
become the preferred instrument for technology transfer, 
most technology licenses are hybrids, covering both pat-
ents and trade secrets. This situation has evolved because 
licenses that cover patents but do not allow access to col-
lateral know-how usually do not permit patented technol-
ogy to become commercialized. Despite the ease of obtain-
ing trade-secret protection—immediate efficacy and low 
cost—this type of IP protection is too often neglected.
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acquired by, or used by others without their 
consent in a manner contrary to honest com-
mercial practices so long as such information:
(a) is secret in the sense that it is not, as a body or 
in the precise configuration and assembly of its 
components, generally known among or read-
ily accessible to persons within the circles that 
normally deal with the kind of information 
in question;
(b) has commercial value because it is secret; and
(c) has been subject to reasonable steps under the 
circumstances, by the person lawfully in con-
trol of the information, to keep it secret.1
If national legislation is not already in com-
pliance, all WTO countries must adopt this trea-
ty provision. Although the provision eschews the 
actual term trade secret, it certainly refers to what 
are commonly known as trade secrets and follows 
the definition of the American Uniform Trade 
Secrets Act (UTSA) of 1985, cited below (section 
2). The language of the North American Free 
Trade Agreement (NAFTA), binding upon the 
Canada, Mexico, and the United States also con-
forms closely with the definitions in the UTSA.
2. Defining	TRADe	SeCReT
The UTSA, now in force in 45 U.S. states, defines 
trade secret as follows:
CHAPTER 11.5
1. inTRoDuCTion
The term trade secret refers to information that is 
maintained in secrecy and has commercial val-
ue. World Trade Organization (WTO) treaties 
(General Agreement on Trade and Tariffs [GATT] 
and the Agreement on Trade-Related Aspects of 
Intellectual Property Rights [TRIPS]), which have 
150 nation-signatories, protect trade secrets. The 
following is an excerpt, addressing the concept of 
trade secrets, from the TRIPS Agreement:
 Natural and legal persons shall have the pos-
sibility of preventing information lawfully 
within their control from being disclosed to, 
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 A trade secret is any information, includ-
ing a formula, pattern, compilation, device, 
method, technique, or process, that: (i) de-
rives independent economic value, actual or 
potential, from not being generally known to, 
and not being readily ascertainable by proper 
means by, other persons who can obtain eco-
nomic value from its disclosure or use, and (ii) 
is the subject of efforts that are reasonable un-
der the circumstances to maintain its secrecy.2
The most widely used definition, from 1929, 
of trade secret is found in the Restatement of 
Torts.3 It reads:
 A trade secret may consist of any formula, pat-
tern, device or compilation of information 
which is used in one’s business, and which gives 
him [or her] an opportunity to obtain an ad-
vantage over competitors who do not know or 
use it. It may be a formula for a chemical com-
pound, a process of manufacturing, treating or 
preserving materials, a pattern for a machine 
or other device, or a list of customers.4
In applying this 1929 definition to determine 
whether trade secrets exist, courts have relied on 
the following criteria:
• extent to which the information is known 
outside of the business
•  extent to which it is known by employees 
and others involved in the business
•  measures taken to guard the secrecy of the 
information
•  value of the information to the business 
and to competitors
• amount of effort or money expended in de-
veloping the information
•  ease or difficulty with which the informa-
tion could be properly acquired or dupli-
cated by others
The most recent and, in this author’s view, 
the broadest and best definition of trade secret 
is set forth in Restatement (Third) of Unfair 
Competition:5
 A trade secret is any information that can be 
used in the operation of a business or other 
enterprise and that is sufficiently valuable and 
secret to afford an actual or potential econom-
ic advantage over others.
This definition most likely will eventually 
replace the earlier definitions. As of 1996, the 
Economic Espionage Act (EEA), a federal crimi-
nal trade-secret statute, includes the following 
definition:
(A) The term trade secret means all forms and types 
of financial, business, scientific, technical, eco-
nomic, or engineering information, including 
patterns, plans, compilations, program de-
vices, formulas, designs, prototypes, methods, 
techniques, processes, procedures, programs, 
or codes, whether tangible or intangible, and 
whether or how stored, compiled, or memo-
rialized physically, electronically, graphically, 
photographically, or in writing if —
(B) the owner thereof has taken reasonable mea-
sures to keep such information secret; and the 
information derives independent economic 
value, actual or potential, from not being gen-
erally known to, and not being readily ascer-
tainable through proper means by, the public.
3.  whAT	iS	AnD	whAT	iS		
noT	A	TRADe	SeCReT
The definitions included above provide a fairly 
clear picture of what constitutes a trade secret. 
At the most basic level, a trade secret is simply 
information and knowledge. More specifically, it 
is any proprietary technical or business informa-
tion, often embodied in inventions, know-how, 
and show-how. The definitions roughly agree on 
three requirements that must be met for enforce-
able trade secrets to exist. The proprietary infor-
mation must be: 
1. secret, in the sense that it is not generally 
known in the trade
2. valuable to competitors that do not possess 
it
3. the subject of reasonable efforts to safe-
guard and maintain it in secrecy
There are critical limitations on trade secrets 
and pitfalls in trade-secret enforcement and liti-
gation. The requirement to maintain secrecy is a 
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frequent pitfall. Moreover, any information that 
is readily ascertainable, or is derived from the per-
sonal skills of employees, cannot be considered an 
enforceable trade secret.
Trade secret protection applies not just to 
manufacturing processes, early stage inventions, 
and subpatentable innovations, as is sometimes 
believed. Patentable inventions can be considered 
trade secrets; this was made clear in the Supreme 
Court decision in Kewanee Oil v. Bicron, which 
recognized trade secrets as perfectly viable alter-
natives to patents.6 In holding that state trade-
secret law is not preempted by the federal patent 
law, the court tellingly held:
 Certainly the patent policy of encouraging 
invention is not disturbed by the existence 
of another form of incentive to invention. In 
this respect, the two systems are not and never 
would be in conflict… . Trade secret law and 
patent law have coexisted in this country for 
over one hundred years. Each has its particu-
lar role to play, and the operation of one does 
not take away from the need for the other… . 
We conclude that the extension of trade-secret 
protection (even) to clearly patentable inven-
tions does not conflict with the patent policy 
of disclosure.
Since the essence of the patent system is the 
public disclosure of inventions, it is sometimes sug-
gested that keeping inventions secret is wrong. This 
is a serious misconception. The decision in Dunlop 
Holdings v. Ram Golf made clear that the public 
benefits from trade secrets. Trade secrets generally 
do not suppress economic activity, because em-
ployees, suppliers, licensees, and others are given 
access to the necessary information.7 Additionally, 
given the high incidence of employee mobility and 
inadvertent or deliberate leakage, many trade se-
crets dissipate within a few years. Possible reverse 
engineering and analysis of products are additional 
ways that trade secrets may dissipate or become 
compromised. In other words, trade secrets are se-
cret only in a limited legal sense. 
Contrary to conventional wisdom, trade-se-
cret protection can be used in conjunction with 
patents to protect the tremendous volume of as-
sociated know-how that exists for any patentable 
invention but that cannot be disclosed in a patent 
specification. 
It is useful, also, to specify the use of the terms 
know-how and trade secret. While the key require-
ment of a trade secret is secrecy, know-how does 
not necessarily require or imply secrecy, as can be 
seen from the following definitions:
• the knowledge and skill required to do 
something correctly.8 
• information that enables one to accomplish 
a particular task or to operate a particular 
device or process.9
• knowledge and experience of a technical, 
commercial, administrative, financial or 
other nature, which is practically applica-
ble in the operation of an enterprise or the 
practice of a profession.10
Know-how is not protectable as an IP right. 
Know-how acquires trade-secret status only if it is 
secret and has economic value and if measures are 
in place to secure its secrecy. Know-how is intel-
lectual property, however, and is protected if it 
qualifies as a trade secret. Since we do not speak 
of “invention and patent licenses,” it is likewise 
inappropriate to refer to “know-how and trade-
secret licenses.”
4. hiSToRy	of	TRADe	SeCReTS
Trade secret law is the oldest form of IP pro-
tection. In ancient Rome, trade secret laws es-
tablished legal consequences for a person who 
induced another’s employee (or slave) to divulge 
secrets relating to the master’s commercial af-
fairs. Trade secrecy was practiced extensively in 
Medieval European guilds. Modern trade-secret 
law, however, evolved in the early 19th centu-
ry, in England, in response to the growing ac-
cumulation of technology and know-how and 
the increased mobility of employees. In 1868, a 
Massachusetts court held, in Peabody v. Norfolk, 
that a secret manufacturing process was consid-
ered property, and was protectable against mis-
appropriation, and that a secrecy obligation for 
an employee outlasted the term of employment. 
The decision also held that a trade secret can be 
disclosed confidentially to others who need to 
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practice it, and that a recipient can be enjoined 
from using a misappropriated trade secret. Peabody 
v. Norfolk clearly anticipated the main features of 
our present trade-secret system, and by the end of 
the 19th century the principal aspects of contem-
porary law were well established. 11
5. impoRTAnCe	of	TRADe	SeCReTS
Trade secrets are the crown jewels of corporations. 
Indeed, trade secrets are now even more relevant 
than they were a few decades ago as a tool for 
protecting innovation, and the stakes involved in 
their protection are getting higher. Injunctions 
are now a greater threat in trade-secret misappro-
priation cases than only a decade ago, and dam-
age awards have been in the hundreds of millions 
of U.S. dollars in recent years. In a recent trial in 
Orlando, Florida, two businessmen were seeking 
US$1.4 billion in damages from the Walt Disney 
Company, accusing them of stealing trade secrets 
for use in a Walt Disney World sports complex. 
The jury awarded the businessmen US$240 mil-
lion.12 In another recent case, Cargill, Inc. was 
found to have misappropriated genetic-corn-
seed trade secrets belonging to then Pioneer Hi-
Bred International, Inc., and was forced to pay 
US$300 million. In another instance, Lexar won 
US$465.4 million in damages from Toshiba for 
misappropriation of controller technology that 
enabled a memory chip to communicate with its 
host device.13
Mark Halligan recently proclaimed, “Trade 
secrets are the IP of the new millennium and can 
no longer be treated as a stepchild.” James Pooley 
concurred, “Forget patents, trademarks and copy-
rights … trade secrets could be your company’s most 
important and valuable assets.”14 Henry Perritt15 
said trade secrets are “the oldest form of IP protec-
tion,” and that, “patent law was developed as a way 
of protecting trade secrets without requiring them 
to be kept secret and thereby discouraging wider use 
of useful information.” This interpretation makes 
patents a supplement to trade secrets, rather than 
the other way around.
In fact, according to a 2003 survey on strate-
gic IP management sponsored by the Intellectual 
Property Owners Association (IPO), patents are 
rarely viewed as an IP panacea, but rather as a 
supplement to other forms of IP protection.16 
Patents have limits, such as early publication, 
invent-around feasibility, and strict patentabil-
ity requirements. Survey respondents did rate 
proprietary technology highly as a key source of 
competitive advantage, and a large majority of 
respondents (88%) cited skills and knowledge as 
the most important intellectual assets. Trade se-
crets are therefore directly implicated in the pro-
tection of proprietary skills and knowledge.
Moreover, patents are only the tips of ice-
bergs in an ocean of trade secrets. Over 90% of all 
new technology is covered by trade secrets. And 
over 80% of all license and technology transfer 
agreements cover proprietary know-how (trade 
secrets) or are hybrid agreements covering both 
patents and trade secrets. Bob Sherwood, an in-
ternational IP consultant, calls trade secrets the 
“workhorse[s] of technology transfer.”
Finally, and very importantly, trade-secret 
protection operates without delay and without 
undue cost, while patents are territorial, expen-
sive to obtain, and can be acquired only in certain 
countries.
6. TRADe	SeCReT	ChARACTeRiSTiCS
From the above trade-secret definitions, we can 
understand the following salient characteristics 
of trade secrets and how they differ substantially 
from other types of IP rights.
For trade secrets, there is no subject matter 
or term limitation, registration or tangibility re-
quirement. Furthermore, there is no strict nov-
elty requirement, and trade-secret protection ob-
tains as long as the subject matter is not generally 
known or available.
What does matter is secrecy—that the infor-
mation is not known by outsiders. And main-
taining secrecy requires reasonable affirmative 
measures to safeguard it. Such measures might 
include:
• stipulating in writing a trade-secret policy 
• informing employees of the trade-secret 
policy
• having employees sign employment agree-
ments with confidentiality obligations
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• restricting access to trade-secrets (on a 
need-to-know basis)
• restricting public accessibility and escorting 
visitors
• locking gates and cabinets to sites that 
house trade secrets
• labeling trade-secret documents as propri-
etary and confidential
• screening the speeches and publications of 
employees
• using secrecy contracts in dealing with third 
parties
• conducting exit interviews with departing 
employees
It is important to consider that while suf-
ficient economic value or competitive advan-
tage is significant, the proper touchstone for a 
trade secret is not actual use but only value to 
the owner. This means that negative R&D re-
sults can give a competitive advantage (just as 
positive results can), in that the owner of the 
information has a greater knowledge of what 
are, and what are not, feasible and/or viable 
options for further commercialization. If com-
petitors become privy to what is not feasible, 
by sidestepping known blind alleys, their R&D 
activities can accelerate, and any strategic or 
competitive advantage originally held by the 
owner will diminish.
Finally, the misappropriation of trade secrets 
is actionable if the secrets were acquired improp-
erly, if a trade secret that was acquired improperly 
is either used or disclosed, or if an individual vio-
lates a duty to maintain confidentiality. A trade 
secret is acquired by improper means if it was ob-
tained through theft, bribery, misrepresentation, 
breach or inducement of a breach of a duty to 
maintain secrecy, or through espionage, includ-
ing electronic espionage. Remedies for misappro-
priation of trade secrets include actual and pu-
nitive damages, profits, reasonable royalties, and 
injunctions. The proper means of acquiring a trade 
secret (which do not support a claim for misap-
propriation) include independent discovery, re-
verse engineering, chemical analysis, or discovery 
from observing what has been allowed to enter 
the public domain. 
7. inTegRATion	of	ip	RighTS
Literature and presentations on IP strategies, IP 
valuation, and other IP topics almost always ad-
dress patents and patent portfolios. This focus 
on patents, however, overlooks the fact that legal 
protection of innovations of any kind, especially 
in high-tech fields, requires the use of more than 
one IP category. This overlap assures dual or mul-
tiple protections.
Jay Dratler, in his Intellectual Property Law: 
Commercial, Creative, and Industrial Property, 
was the first to “tie all the fields of IP together.” 
According to Dratler, IP rights, formerly frag-
mented by specialties, are now a “seamless web” 
due to progress in technology and commerce.17 
Six years later in 1997, the authors of Intellectual 
Property in the New Technological Age also stressed 
the need to “avoid the fragmented coverage … by 
approaching IP as a unified whole” and by concen-
trating on the “interaction between different types 
of IP rights.”18 Today, we have a unified theory of 
IP management, a single field of law with sub-
sets, and a significant overlap between IP fields. 
Several IP rights are available for the same IP or 
for different aspects of the same IP. Not taking 
advantage of the overlap misses opportunities, 
and, according to Dratler, amounts to a kind of 
“malpractice.”
Especially for high-tech products, trade-
marks and copyrights can supplement patents, 
trade secrets, and mask works (“blueprints” used 
in the R&D and production of semiconductor 
chips). One IP category, often patents, may be 
the “center of gravity” in certain instances. Other 
IP rights categories are then supplemental but 
equally valuable. The supplemental forms of IP 
may function to:
• cover additional subject matter 
•  strengthen exclusivity
• invoke additional remedies in litigation 
• provide a backup if a primary IP right be-
comes invalid, thus providing synergy and 
optimal legal protection
Dratler provides the following examples:
a) Multiple protection for a data processing 
system can involve:
• patented hardware and software
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• patented computer architecture on cir-
cuit designs
• trade-secret production processes
• copyrighted microcode
• copyrighted operating system
• copyrighted instruction manual
• semiconductor chips protected as mask 
works
• consoles or keyboards protected by de-
sign patents, or as trade dress under 
trademark principles
• trademark registration
b) Multiple protection for a diagnostic kit in-
volving monoclonal antibodies:
• product patent on the test kit
• process patent on the preparation of the 
antibodies
• trade secrecy for production know-how
• copyright for test kit’s instructions
• trademark
Even these examples are somewhat limited, 
because trade secrets can protect not only know-
how and processes, but also large amounts of col-
lateral data, information, and other know-how 
that are not found in patent specifications.
Other valuable examples:
c) Multiple protection of aesthetic designs:
• patent
• copyright for separable features
• trademark for nonfunctional features
• trade dress for overall appearance
• utility patent for functional features
• trade secrets for collateral and collateral 
know-how and data
d) Multiple protection for plants and plant 
parts:
• plant patents




To encapsulate the IP integration concept, 
numerous practitioners recommend to clients to 
do the following:
• exploit the overlap
• develop a fall-back position
• create a web of rights
• build an IP estate
• build a “wall”
• overprotect (multiple layers of IP rights 
protection)
• lay a “minefield”
The most important IP management and 
technology licensing strategy is to exploit the 
overlap between patents and trade secrets.
8. iniTiAl	pATenT/TRADe-SeCReT	
evAluATion
IP management always requires deciding during 
development between seeking patent protection 
and maintaining trade secrecy. The Initial Patent/
Trade Secret Evaluation Questionnaire (Box 1) can 
be used to facilitate the decision and to help deter-
mine the center of gravity (often patents for prod-
ucts and trade secrets for processes).20 To avoid the 
implications of the term invention and to cover the 
wide variety of innovations that may be addressed 
by this questionnaire, the term development is used 
generically.
The 11 questions are arranged by function, 
not importance, and roughly correspond to mar-
keting (questions 1–4), technical (questions 5–
8), and legal (questions 9–11) categories. Each 
question should be answered on a scale from 1 
to 10. The responses are then totaled. With the 
current number of questions, the total would 
range from 11 to 110. If the sum approaches the 
higher end of the scale (above 75), trade-secret 
protection would seem favorable; a sum at the 
lower end (below 45) would suggest that pat-
ent protection would be more advantageous. At 
times, values in the middle range (45–75) will 
result. Such a score suggests that it doesn’t re-
ally matter which approach is followed initially. 
For example, trade-secret protection might be 
appropriate for manufacturing-process tech-
nology, which competitors might find easier to 
re-create; patents make sense for products that 
can be analyzed or reverse engineered. However, 
there need be no prejudice about resorting to 
the other strategy to protect collateral aspects 
and improvements. 
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Box	1:	Initial	patent/Trade	Secret	evaluation	Questionnaire
1) is	the	development	likely	to	be	a	commercial	product	or	the	subject	of	licensing?	
1	 			2	 3	 4	 5	 6	 7	 8	 9	 10 
Likely               Unlikely
2) how	much	of	a	competitive	advantage	would	be	provided	if	the	company	maximized	
exclusivity?
 1	 			2	 3	 4	 5	 6	 7	 8	 9	 10 
Very Great              Very Little
3) how	much	of	a	competitive	disadvantage	would	it	be	if	a	competitor	obtained	exclusivity?
 1	 			2	 3	 4	 5	 6	 7	 8	 9	 10 
Very Great              Very Little
4) is	it	likely	the	commercial	significance	of	the	development	would	be	limited	in	time?
 1	 			2	 3	 4	 5	 6	 7	 8	 9	 10 
Yes-Limited                        No
5) is	it	likely	one	could	develop	alternatives	(“design	around”)?
 1	 			2	 3	 4	 5	 6	 7	 8	 9	 10 
Unlikely                  Likely
6) Can	the	nature	of	development	be	ascertained	from	commercial	product	(could	the	
product	be	“reverse	engineered”)?
 1	 			2	 3	 4	 5	 6	 7	 8	 9	 10 
Likely                                 Unlikely
7) would	disclosure	of	this	development	require	or	permit	access	to	other,	unprotectable	
information?
 1	 			2	 3	 4	 5	 6	 7	 8	 9	 10 
No                        Yes
8) is	it	likely	others	will	independently	arrive	at	the	same	development?
 1	 			2	 3	 4	 5	 6	 7	 8	 9	 10 
Likely                                                  Unlikely
9)	 if	a	patent	was	obtained,	what	are	the	chances	of	validity	being	upheld	by	a	court?
 1	 			2	 3	 4	 5	 6	 7	 8	 9	 10 
High                                       Low
10) is	it	likely	that	dissemination	of	the	development	from	within	the	company	would	be	
difficult	to	control?
 1	 			2	 3	 4	 5	 6	 7	 8	 9	 10 
Yes-Difficult                                        Not Difficult
11) would	it	be	difficult	to	determine	if	competitors	are	using	the	development?
 1	 			2	 3	 4	 5	 6	 7	 8	 9	 10 
Not Difficult             Difficult
Total Score ______
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To obtain the most-accurate results from the 
questionnaire, the following considerations for 
each question will be helpful in interpreting the 
survey responses.
Question 1. If the development is likely to 
be commercialized or licensed, patent protection 
would seem preferable to trade-secret protec-
tion. There might be some exceptions (such as 
the Coca-Cola® situation), but presumably these 
would be limited to situations where the nature 
of the product could not be easily ascertained by 
reverse engineering (see Question 6).
Note that Question 1 pertains to commercial-
ization of the development itself. Thus the mere 
use of a process to produce a commercial prod-
uct is not commercialization of the process (see 
Question 4, about commercial significance). The 
desirability of patenting the process itself would 
depend on the answers to Questions 2–11.
Question 2. Here the aim is to ascertain 
whether exclusivity on the development would 
be meaningful commercially. A development of 
marginal commercial importance might be better 
kept as a trade secret. One that provided a signifi-
cant commercial edge, however, probably should 
be patented.
Question 3. This addresses the opposite of 
the issue in Question 2, namely the defensive 
value of a patent publication. Hence, while the 
development may be of minimum commer-
cial advantage to the company, thereby favoring 
trade secrets, a patent (or publication) should be 
considered if a competitor’s exclusivity would be 
disadvantageous.
Question 4. This is a difficult question. Some 
writers have suggested that a product with a short 
commercial life favors a patenting approach, while 
a long life favors trade secrets. In this author’s 
view, life span is not a particularly useful crite-
rion since it depends on factors unrelated to the 
development itself. Estimating the future lifespan 
for a product under development may also be a 
highly subjective matter. In some circumstances 
this question might not have to be considered.
Question 5. The ability to design around an 
invention is a function of the nature of the patent 
protection. If a claim is easily avoided, its value 
is considerably reduced. The destructive effect of 
trade-secret protection by publication is therefore 
unchanged, and the relative value of the trade-
secret option is higher (because of the decreased 
value of patent protection).
Question 6. Counterbalancing Question five 
is the issue of whether, if the trade-secret route 
is chosen, a competitor will nevertheless be able 
to ascertain the nature of the development from 
the product. If competitors can reasonably easily 
ascertain the nature of the product, patent pro-
tection would be favored.
Question 7. The issue of disclosure is often 
overlooked. For example, the required disclosure 
of a culture collection-deposit number could pro-
vide competitors with access to the culture itself, 
and this access might greatly outweigh the value 
of patent protection. The impact of a disclosure 
of an unclaimed or intermediate process might 
also have a bearing on whether the final product 
should be patented.
Question 8. In many cases, evaluating 
whether others could arrive at the same develop-
ment independently could be extremely difficult. 
If, however, it is known that others are working 
in the field, it would seem quite possible that they 
could arrive at the same development and patent 
it first. Consequently, one might eventually be 
excluded from using the product if patent protec-
tion is not sought.
Question 9. Even though patent protection 
might be indicated for other reasons, this could 
be counterbalanced by the fact that any coverage 
eventually obtained would be weak. A weak pat-
ent, ignored by competitors and for which the 
company is unwilling to sue, is as good as no pat-
ent. In fact, it may be worse, since the opportu-
nity for trade-secret protection would have been 
irrevocably lost through publication.
Question 10. Ideally, the dissemination of 
information from within the company can be 
controlled. If not, however, a trade secret might 
be lost. If this risk exists, for example when nu-
merous employees, visitors, and suppliers have 
access to the development, patent protection is 
more attractive. The same question arises with 
scientific publications.
Question 11. This question is related to 
question nine but goes to the issue of inherent 
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enforceability rather than patent strength. If 
detecting infringement would be extremely dif-
ficult, the ultimate value of a patent would be 
reduced. Such reduced value must be weighed 
against the cost of the loss of trade-secret pro-
tection caused by patent publication. If the pat-
ent rights cannot be effectively enforced, then 
what ensues may become a de facto release of a 
trade secret. 
9. The	pATenT/TRADe	SeCReT	inTeRfACe
Trade secrets are the first line of defense, but they 
not only come before patents but can go with 
patents and even follow patents (see sections 11 
and 12, below). Moreover, as a practical matter, 
licenses under patents without access to associ-
ated or collateral know-how are often not enough 
for taking advantage of the patented technology 
commercially. This is because patents rarely dis-
close the ultimate scaled-up commercial embodi-
ments. Data and know-how, therefore, are im-
mensely important. In this regard, consider the 
following persuasive comments:
• In many cases, particularly in chemical tech-
nology, the know-how is the most important 
part of a technology transfer agreement.21
• Acquire not just the patents but the rights to 
the know-how. Access to experts and records, 
lab notebooks, and reports on pilot-scale op-
erations, including data on markets and po-
tential users of the technology are crucial.22
• It is common practice in industry to seek and 
obtain patents on that part of a technology 
that is amenable to patent protection, while 
maintaining related technological data and 
other information in confidence. Some regard 
a patent as little more than an advertisement 
for the sale of accompanying know-how.23
• [In technology licensing] related patent rights 
generally are mentioned late in the discussion 
and are perceived to have ‘insignificant’ value 
relative to the know-how.24
• Trade secrets are a component of almost ev-
ery technology license… [and] can increase 
the value of a license up to three to ten times 
the value of the deal if no trade secrets are 
involved.25
A very striking case about the importance 
of proprietary know-how comes from Brazil. 
Brazilian officials learned a quick and startling 
lesson when they decided, some years ago, to 
translate important patents that issued in devel-
oped countries into Portuguese for the benefit of 
Brazilian industry. They believed that this was all 
that was necessary to enable their industries to 
practice these foreign inventions without paying 
royalties for licenses. Needless to say, without 
access to the necessary know-how, this scheme 
was an utter failure. This oversight is somewhat 
surprising, since Brazil, following the amazing 
progress and successes of the Asian tigers, had 
years earlier begun a project of importing tech-
nology (including know-how) from developed 
countries to be adapted and improved for local 
needs. They expected that the cost of import-
ing the technology would be money well spent. 
And, in fact, importing the technologies led not 
only to exports of improved products, but also 
to exports of the resulting improved technology 
to developing countries in Africa, the Middle 
East, and the rest of Latin America. Such an im-
portation/exportation policy is termed reverse 
technology transfer.26 
To reiterate, patents and trade secrets are 
not mutually exclusive but actually highly 
complementary and mutually reinforcing. This 
is partly why the U.S. Supreme Court has rec-
ognized trade secrets as perfectly viable alter-
natives to patents: “The extension of trade-secret 
protection to clearly patentable inventions does 
not conflict with the patent policy of disclosure.”27 
Interestingly, in his concurring opinion in the 
Kewanee Oil28 decision, Justice Marshall was 
“persuaded” that “Congress, in enacting the patent 
laws, intended merely to offer inventors a limited 
monopoly [sic] in exchange for disclosure of their 
inventions [rather than] to exert pressure on inven-
tors to enter into this exchange by withdrawing any 
alternative possibility of legal protection for their 
inventions.” Thus, it is clear that patents and 
trade secrets can not only coexist but are also in 
harmony with each other. “[T]rade-secret/patent 
coexistence is well-established, and the two are in 
harmony because they serve different economic and 
ethical functions.”29
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In fact, patents and trade secrets are inextri-
cably intertwined, because the bulk of R&D data 
and results, and of associated collateral know-how 
for any commercially important innovation, can-
not, and need not, be included in a patent appli-
cation. Such information deserves, and requires, 
the protection that trade secrets can provide. In 
the past, and sometimes still today, if trade-secret 
maintenance is contemplated (for example, for a 
manufacturing process technology) the question 
is always phrased as a choice between patents and 
trade secrets. For example, titles of articles dis-
cussing the matter read, “Trade Secret vs. Patent 
Protection”; “To Patent or Not to Patent?”; “Trade 
Secret or Patent?”; and “To Patent or to Padlock?” 
This perspective imagines that patents and trade 
secrets are substantially different in terms of dura-
tion and scope of protection and have clearly per-
ceivable advantages and disadvantages. However, 
as this chapter has demonstrated, the perceived 
differences are illusory. The life of a patent is 
roughly 20 years from filing, and an average trade 
secret may last but a few years. Nor do they differ 
in regard to the scope of protection, since virtu-
ally everything produced with human ingenuity 
is potentially patentable. And while a patent pro-
tects against independent discovery and a trade 
secret does not, a patent can lead competitors to 
attempt to design or invent around it. A properly 
guarded and secured trade secret, however, may 
withstand attempts to crack it.
10. how	pATenTS	AnD	TRADe		
SeCReTS	ARe	ComplemenTARy
It is unnecessary and, in fact, shortsighted to 
choose one IP strategy over another. Indeed, the 
question is not so much whether to patent or to 
padlock, but rather what to patent and what to 
keep a trade secret. Of course, it may be best to 
both patent and padlock, thus integrating patents 
and trade secrets for the optimal, synergistic pro-
tection of innovation.
It is true that patents and trade secrets are 
opposed on the issue of disclosure. Information 
that is disclosed in a patent is no longer a trade 
secret. But patents and trade secrets are indeed 
complementary, especially under the following 
circumstances. In the critical R&D stage, be-
fore any patent applications are filed and before 
applications are published and patents issued, 
trade-secret law dovetails very nicely with patent 
law.30 If an invention has been fully described so 
as to enable a person skilled in the art to make 
and use it, and if the best mode for carrying out 
the invention, if available, has been disclosed (as 
is required in a patent application), all associated 
or collateral know-how not divulged can, and 
should, be retained as a trade secret. All of the 
massive R&D data—including data pertaining 
to better modes developed after filing, whether 
or not inventive—should also be maintained as 
trade secrets, if the data is not disclosed in sub-
sequent applications. Complementary patenting 
and padlocking is tantamount to having the best 
of both worlds, especially when technologies are 
complex and consist of many patentable inven-
tions and volumes of associated know-how.
11. BeST	moDe	AnD	enABlemenT	
RequiRemenTS
The conventional wisdom is that, because of best 
mode and enablement requirements, trade secret 
protection cannot coexist with patent protection. 
This, also, is a serious misconception. These re-
quirements apply only at the time of filing, only 
to the knowledge of the inventor(s), and only to the 
claimed invention.
Patent applications are filed early in the 
R&D stage to get the earliest possible filing or 
priority date. The patent claims tend to be nar-
row in order to achieve distance from prior art. 
Therefore, the specification normally describes 
rudimentary lab experiments or prototypes in 
only a few pages; the best mode for commercial 
manufacture and use are developed later. The best 
mode and the enablement requirements are thus 
no impediments to maintaining, as trade secrets, 
the mountains of collateral know-how developed 
after filing.
The recent decision in CFMT v. Yieldup 
International is particularly germane to this 
point: “Enablement does not require an inventor to 
meet lofty standards for success in the commercial 
marketplace. Title 35 does not require that a patent 
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disclosure enable one of ordinary skill in the art to 
make and use a perfected, commercially viable em-
bodiment absent a claim limitation to that effect … 
[T]his court gauges enablement at the date of the 
filing, not in light of later developments.”31 Such 
reasoning applies equally well to the best mode 
requirement.
In Peter Rosenberg’s opinion, “patents pro-
tect only a very small portion of the total technol-
ogy involved in the commercial exploitation of an 
invention … Considerable expenditure of time, 
effort, and capital is necessary to transform an (in-
ventive concept) into a marketable product.”32 In 
the process, he adds, valuable know-how is gen-
erated, which, even if inventive and protectable 
by patents, can be maintained as trade secrets. 
Rosenberg asserts that there is “nothing improper 
in patenting some inventions and keeping others 
trade secrets.” Likewise, Tom Arnold asserts that 
it is “flat wrong” to assume, as “many courts and 
even many patent lawyers seem prone” to do, that 
“because the patent statute requires a best mode 
disclosure, patents necessarily disclose or preempt 
all the trade secrets that are useful in the practice of 
the invention.”33
Gale Peterson also emphasizes that “the pat-
ent statute only requires a written description of the 
claimed invention and how to make and use the 
claimed invention.” He therefore advises that, 
since allowed claims on a patentable system usu-
ally cover much less than the entire scope of the 
system, the disclosure in the application be lim-
ited to that necessary to support the claims in a 
35 U.S.C. §112 sense (that is, having sufficient 
information to enable one to make and use the 
invention) and that every effort be taken to main-
tain the remainder of the system as a trade secret. 
In short, manufacturing-process details, even 
if available, are not a part of the statutorily required 
best mode and enablement disclosure of a patent, 
and it is in this process area where “best modes” for 
scale-up toward actual production very often lie.
12. exemplARy	TRADe	SeCReT	CASeS
Of course, it goes without saying that techni-
cal and commercial information and collateral 
know-how that can be protected with trade 
secrets cannot include information that is gen-
erally known, readily ascertainable, or consti-
tutes personal skill. But this exclusion still leaves 
masses of data and know-how that are protect-
able as trade secrets—and often also with addi-
tional improvement patents. For example, GE’s 
industrial-diamond-process technology is an ex-
cellent illustration of the synergistic integration 
of patents and trade secrets to secure invulner-
able exclusivity.
The artificial manufacture of diamonds for 
industrial uses was very big business for GE, and 
they had the best proprietary technology for mak-
ing these diamonds. GE patented much of its 
technology, and when the patents expired, much 
of the technology was in the technical literature 
and in the public domain. But GE also kept cer-
tain distinct inventions and developments secret. 
The Soviet Union and a Far East country were very 
interested in obtaining licenses to this technology, 
but GE refused to license to anyone. After get-
ting nowhere with GE, the Far East interests re-
sorted to industrial espionage. A trusted fast-track 
star performer at GE, a national of that country, 
was enticed with million dollar payments to spirit 
away GE’s precious trade secrets. The employee 
was eventually caught, tried and jailed.
Similarly, Wyeth has had an exclusive position 
on Premarin®, the high-selling hormone-therapy 
drug, since 1942. Their patents on the manu-
facturing process (starting with pregnant mares’ 
urine) expired decades ago, but the company also 
held closely guarded trade secrets. On behalf of a 
pharmaceutical company that had been trying to 
come out with a generic form of Premarin® for 15 
years, Natural Biologics stole the Wyeth trade se-
crets. Wyeth sued, prevailed, and got a sweeping 
injunction, as this was clearly an egregious case of 
trade-secret misappropriation.
These cases illustrate the value of trade se-
crets and, more importantly, the merits of marry-
ing patents with trade secrets. Indeed, these cases 
show that GE and Wyeth could have the best of 
both worlds, patenting their inventions and still 
keeping their competitive advantage by maintain-
ing production details in secrecy. Were GE’s or 
Wyeth’s policies to rely on trade secrets in this 
manner or was Coca Cola’s decision to keep its 
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formula a secret rather than to patent it, unwise 
and careless? Clearly not.
Other recent decisions, such as C&F Packing 
v. IBP and Pizza Hut and Celeritas Technologies v. 
Rockwell International, demonstrate that dual or 
multiple IP protection is not only possible but 
essential to exploit the IP overlap and provide a 
fallback.34
In the Pizza Hut case, for instance, Pizza Hut 
was made to pay US$10.9 million to C&F for 
misappropriation of trade secrets.35 After many 
years of research, C&F had developed a process 
for making and freezing a precooked sausage 
for pizza toppings that had the characteristics of 
freshly cooked sausage and surpassed other pre-
cooked products in price, appearance, and taste. 
C&F had obtained a patent on the equipment to 
make the sausage and also one on the process for 
making the sausage. C&F improved the process 
after submitting its patent applications and kept 
its new developments as trade secrets.
Pizza Hut agreed to buy C&F’s precooked 
sausage on the condition that C&F divulge its 
process to several other Pizza Hut suppliers, 
ostensibly to assure that backup suppliers were 
available to Pizza Hut. In exchange, Pizza Hut 
promised to purchase a large amount of pre-
cooked sausage from C&F. Accordingly, C&F 
disclosed the process to several Pizza Hut suppli-
ers and entered into confidentiality agreements 
with them. Subsequently, Pizza Hut’s other sup-
pliers learned how to duplicate C&F’s results. 
Pizza Hut then told C&F that it would not pur-
chase any more of their sausage without drastic 
price reductions.
One of Pizza Hut’s largest suppliers of meat 
products other than sausage was IBP. Pizza Hut 
furnished IBP with a specification and formula-
tion of the sausage toppings and IBP signed a con-
fidentiality agreement with Pizza Hut concerning 
this information. In addition, IBP hired a former 
supervisor in C&F’s sausage plant as its produc-
tion superintendent, but then fired this employee 
five months later, after it had implemented its 
sausage-making process and Pizza Hut was buy-
ing the precooked sausage from IBP.
C&F then brought suit against IBP and Pizza 
Hut for patent infringement and misappropriation 
of trade secrets, and the court found on summary 
judgment that the patents of C&F were invalid 
because the inventions had been on sale more 
than one year before the filing date. However, the 
court determined that C&F possessed valuable 
and enforceable trade secrets, which had indeed 
been misappropriated. What a great example of 
trades secrets serving as backup where patents fail 
to provide any protection! 
In certain instances, a patent is a weak instru-
ment indeed, given the many potential patent at-
trition factors, such as:
• doubtful patentability due to patent-de-
feating grounds
• narrow claims granted by a patent office
• the fact that “only about 5% of a large patent 
portfolio” has commercial value36
• the short life of a patent (average effective 
economic life is “only about five years”)37
• enforcement of patents is daunting and 
expensive
• limited nature or lack of coverage in some 
countries
13.  TRADe	SeCReTS	AnD	hyBRiD	liCenSeS
In trade-secret licensing practice, the threshold 
concern one encounters is the so-called black 
box dilemma. Two pieces of Anglo-Saxon wis-
dom describe it vividly. The trade-secret owner 
cannot “let the cat out of the bag,” and the po-
tential licensee will not want to “buy a pig in a 
poke.” In plainer words, unrestricted disclosure 
of a new invention or proprietary know-how 
would result in the certain loss of trade-secret 
rights. On the other side, the potential recipient 
is unlikely to acquire something sight unseen. 
Fortunately, there is a perfect way out of this 
quandary. It is a secrecy agreement, also called a 
nondisclosure agreement, a confidential disclo-
sure agreement, or a prenegotiation agreement. 
In negotiating and drafting such an agreement, 
the parties have different concerns that have to 
be addressed.
Trade secret owners will want to know:
• What mechanisms and procedures should 
be used to divulge the contents of the black 
box?
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• What restrictions should be placed on re-
cipients with respect to their use of the in-
formation in the black box, if they elect to 
use the information or if they decide not to 
use the information?
• How long and how thoroughly should re-
cipients be permitted to examine the con-
tents of the black box?
• How much should they charge for a peek 
into the black box?
On the other side, trade-secret recipients will 
want to know:
• What restrictions should they accept on use 
of the information if they want to license 
and use it?
• What restrictions should they accept on 
the future use of the information, if they 
do not want to license it?
• What if the information is already in the 
public domain?
• What if it turns out that they are already in 
possession of the information, or an impor-
tant part of it?
• How much should they pay for a look into 
the black box?
A written agreement is the safest way to 
preserve secrecy and the best way to arrange an 
agreement. It should have provisions that define 
the area of technology with precision, establish 
a confidential legal relationship between the par-
ties, furnish proprietary information for a specific 
purpose only, oblige the recipient to hold infor-
mation in confidence, and spell out exceptions 
to secrecy obligations. The last could include 
information already in the public domain, in-
formation that later becomes public knowledge 
other than through the fault of the recipient, in-
formation that is already known to the recipient 
or that later comes into the possession of the re-
cipient through a third party that has no secrecy 
obligation to the owner. Very importantly, the 
written agreement should limit the duration of 
the secrecy obligation.
Similar critical provisions should be incor-
porated into trade-secret licenses, technical assis-
tance agreements, and hybrid patent/trade-secret 
licenses. The provisions should accompany the 
typical operational clauses that spell out license 
grants, royalty payments, indemnities, warran-
ties, terms and termination conditions, and other 
miscellaneous matters.
While such hybrid agreements are very preva-
lent in the United States, they are quite problem-
atic, since it is a misuse of a patent or an antitrust 
violation to exact royalty payments after a patent 
ceases to be in force.38 This could happen, since 
the lives of trade secrets are potentially indefinite 
while patents have a finite lifetime. Hence, de-
pending on how a license agreement is drafted, 
in the United States it can become impossible to 
agree to spread royalty payments over a specified 
term that extends beyond the lives of patents or 
trade secrets that are embodied in such an agree-
ment. In an American hybrid licensing agree-
ment, the obligation to pay royalties thus ends, 
even though valuable trade secrets are still in play. 
But there are solutions to this predicament:
• separate patent and trade-secret 
agreements
• make initial lump-sum payment(s)
• clearly differentiate between patent and 
trade-secret rights
• separate allocation of royalties to each of 
the rights
• provide for appropriate decreases in the roy-
alty rate if patents terminate or are declared 
invalid or if applications do not issue
• reduce the royalty-payment period (for ex-
ample to 10 years)
• grant a royalty-free license to patents
• grant a trade-secret license but no patent 
license
The choice would depend largely on the rela-
tive role and value of patents and trade secrets in 
the given technology.
14. ConCluSion
Trade secrets are a viable mode of IP protection. 
They can be used instead of patents, but, more 
importantly, they can and should be used side-by-
side with patents, so that inventions volumes of 
collateral know-how can be protected. Far from 
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being irreconcilable, patents and trade secrets 
make for a happy marriage as equal partners: it 
is patents and trade secrets, not patents or trade 
secrets.
With patents and trade secrets it is clearly pos-
sible to cover additional subject matter, strengthen 
exclusivity, invoke different remedies in litigation, 
and have a backup when the first protection tool 
becomes invalid or unenforceable. Exploiting the 
overlap between patents and trade secrets for opti-
mal protection is a practical, profitable, and ratio-
nal IP management and licensing strategy.
License agreements have become the pre-
ferred instruments for technology transfer. 
Hybrid patent/trade-secret agreements are also 
prevalent, since patent disclosures generally cover 
only embryonic or early stage R&D results, which 
are insufficient for commercializing the patented 
technology, absent access to collateral proprietary 
know-how. This know-how, protectable as trade 
secrets, need not be included in patent applica-
tions and is usually developed after filing appli-
cations. Such hybrid agreements require clauses 
that not only maintain trade secrecy for the ben-
efit of the trade-secret owner, but also provide 
appropriate limitations for the protection of the 
trade-secret licensee. ■
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ABSTRACT
The principal forms of IP rights protection for plant va-
rieties are plant patents, plant variety protection patents 
(PVPs), and utility patents. However, trademarks can also 
provide long-lasting and significant protection for plant 
varieties. One advantage that trademarks have over the 
statutory forms of IP protection for plants (plant patents, 
PVPs, utility patents) is that trademarks can be protected 
indefinitely, as long as the product is marketed and the 
trademark enforced. The most important agreements deal-
ing with international trademark registration are the Madrid 
system and the Madrid Protocol (of which the United States 
is a signatory). Licensing of a trademark can either stand 
alone or be combined with another form of IP rights pro-
tection, such as with a hybrid PVP/trademark license.
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multinational companies develop brand names 
(which are usually trademarked names, such as 
Dole®, Del Monte®, and Chiquita®) and others 
commercialize varieties under recognizable trade-
marks (for example, plums using the Sun World 
Black Diamond® trademark and green and gold 
kiwifruit using the ZESPRI® trademark).
2.		whAT	iS	A	TRADemARK?
A trademark is any marking, sign, or designation 
that, during the course of trade, indicates a con-
nection between certain goods and services and 
the trademark owner. Trademarks identify goods 
and services, distinguish them from similar goods 
and services, and indicate their source or origin, 
thereby guiding and influencing consumers’ deci-
sions. A trademark guarantees that a certain good 
or service is of known and reliable quality, for ex-
ample, a bottle labeled with the Coca-Cola® logo 
indicates to the consumer that the bottle is filled 
with a specific cola drink. In many jurisdictions, 
trademarks can be registered at the local patent 
and trademark office. A registered trademark (or 
a very similar version of it) cannot be used by 
anyone else in association with goods or services, 
and the owner of the mark can bring proceedings 
for trademark infringement against anyone else 
who attempts to use the mark. However, owner-
ship of a registered trademark does not prevent 
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1.	 inTRoDuCTion	
The top ten global “brands”1 in 2006: Coca-
Cola®, Microsoft®, IBM®, GE®, Intel®, Nokia®, 
Toyota®, Disney®, McDonalds®, and Mercedes-
Benz®—with a collective estimated brand value 
of a staggering US$396 billion2—each rely on a 
successful branding strategy, an important part 
of which is a recognizable trademark. Successful 
product branding can create phenomenal intan-
gible value for companies. Intangible assets today 
have been estimated to account for at least 80% of 
the market value of publicly traded companies.3
The fresh-fruit-and-vegetable business sec-
tor, however, has not fully taken advantage of the 
value that can be created by a successful branding 
and trademark strategy. But that is changing, as 
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others from making or selling the same or a simi-
lar product under a clearly different mark. 
Trademarks can come in a variety of differ-
ent forms. Registrable trademarks often include 
distinctive, sometimes nonsense, words (for ex-
ample, Kodak). Registered trademarks can take 
other forms as well: numbers, number and word 
combinations, slogans, designs, images, colors, 
sounds, pictures, labels, smells, and three-dimen-
sional configurations (such as the triangular form 
of Toblerone® chocolates). 
In order to be protectable, trademarks must 
be reasonably distinctive. They are classified ac-
cording to their distinctiveness, from most pro-
tectable to nonprotectable:
1. Fanciful marks are the most distinctive and 
protectable. They are unique nonsense 
words. Examples include Clorox, Exxon, 
and Pepsi.
2. Arbitrary marks are real (not nonsense) 
words, but they have no readily apprehen-
sible connection with the goods or services 
with which they are associated. Examples 
include Apple (computers), Apple (records), 
Domino’s (pizza), and Sonic (restaurants). 
3. Suggestive marks suggest, but do not explic-
itly describe, a characteristic of the goods 
or services. For example, the name Holiday 
Inn and Suites suggests that it is a “holiday” 
to stay in this guest residence.
4. Descriptive marks refer to the purpose, func-
tion, quality, size, geographical origin, and 
so on, of a good or service. In order to qual-
ify as distinctive, and therefore protectable, 
consumers must be able to associate such 
marks with a particular good or service. For 
example, Fried Chicken as a descriptive mark 
would not qualify since it merely qualifies 
a chicken. Kentucky Fried Chicken, how-
ever, means more to consumers than simply 
“chicken, fried in a style that is popular in 
Kentucky”: it indicates a place where cus-
tomers can obtain a meal of known and pre-
dictable quality. 
5. Generic terms, such as soap, tomato, or car can-
not be registered as trademarks. Interestingly, 
and unfortunately for trademark owners, 
some trademarks have transformed from 
fanciful to generic over the years; exam-
ples include now-common words such as 
linoleum, aspirin, kerosene, and escalator. 




A trademark has no inherent value. It only gains 
value when the good or service with which it is 
associated is accepted by consumers, who then 
come to rely on the brand/trademark as an in-
dicator of consistent quality. In contrast, plant 
patents, plant variety protection, and utility 
patents on plants (together called plant variety 
rights or PVRs) have an immediate tradeable 
value that may or may not decline from the time 
of the patent grant to the time of the patent ex-
piration (Figure 1).
A significant advantage of a trademark over a 
PVR is that, unlike other forms of IP rights pro-
tection such as patents and copyrights, trademarks 
can be owned indefinitely, so long as they are used 
appropriately, are enforced, and their registration 
is kept current (through renewals). Trademarks 
are recognizable, and therefore valuable, even af-
ter the term of a patent or PVR has expired. The 
pharmaceutical industry owns a number of pow-
erful trademarks: Schering-Plough Corporation, 
maker of Claritin®, has managed to retain a sig-
nificant market share of this antihistamine even 
after the patent expired and generic equivalents 
entered the market.
Registering a trademark is usually an in-
expensive and straightforward process. Some 
money must be put into creating a distinctive, 
and therefore protectable, mark. When design-
ing a mark for use in global commerce, it is im-
portant to research the trademark registries of 
countries where the product is to be sold in or-
der to ensure that the mark, or something very 
similar to it, has not already been registered by 
another party. It is not a good idea to use dif-
ferent trademarks in different countries or to 
put the same trademark on different goods, as 
these practices can confuse consumers and will 
then reduce the mark’s value. Trademark owners 
should be aware that a nonsense word in one 
language might be a real word (and perhaps 
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one with a negative connotation) in another 
language; fanciful marks that essentially mean 
nothing in any language (such as Exxon) are 
usually safe. 
Trademarks are a “use it or lose it” commod-
ity. First, a trademark only has value if the good 
or service that it represents is of consistent quali-
ty and is continuously available; the marketplace 
can have a very short memory. Furthermore, and 
more seriously, a trademark can be invalidated if 
it is not used in a country for a continuous pe-
riod, usually three years in most countries. 
It costs considerably more to promote and 
develop consumer recognition of a trademark 
than it does to register the mark. The trademark 
owner will need to identify the target audience 
and develop promotional material tailored to that 
audience, a process that can become quite com-
plex if globally marketed products are involved. It 
may be worthwhile to delegate these tasks to an 
advertising company. 
The trademark owner must invest not only 
in establishing and maintaining a brand pres-
ence in the marketplace but also in protecting 
the trademark. The trademark owner will need to 
appoint IP managers to monitor the filing and li-
censing of trademarks, the policing of trademark 
use, and the prosecution of those who use regis-
tered trademarks illegally. 
4.	 uSing	TRADemARKS	CoRReCTly
A trademark will become generic if, because 
of uncontrolled use, it no longer indicates that 
goods or services come from a particular source. 
Once a trademark is generic, then it is free for 
all to use. Such “genericide” has been the fate of 
many famous trademarks such as cellophane and 
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thermos—words that are now part of the com-
mon lexicon. Though the trademarks Xerox® and 
Kleenex® are still protected, it has become com-
mon practice to substitute the phrase “Xerox ma-
chine” for a photocopier or Kleenex for a tissue, 
and the argument has been made that the trade-
mark names have already become generic. 
Trademark owners must try to ensure that 
marks are used correctly, especially within their 
own organizations. Trademarks are adjectives that 
qualify nouns, and should not be used as proper 
nouns or as verbs. For example, it is improper us-
age to say, “I’m going to xerox a couple of pages,” 
even if one is the trademark owner.
Finally, trademarks should always be used with 
the ® or ™ symbol. In the U.S., the ® symbol in-dicates federal registration of a trademark (which 
has significant legal connotation); the ™ symbol 
indicates a common law mark (which has far less 
legal significance). The ™ symbol is also used for 
a federally registered trademark between the filing 
and registration period. Trademarks should always 
be used to modify a generic noun, for example, Del 
Monte Gold ™ pineapple or Jazz™ apple. In order 
to avoid violating trademark laws, breeders and 
growers must refer to a plant variety using the va-
riety name and not the trademark. This can be a 
challenge, especially if the trademark is particularly 
catchy (which it should probably be in order to be 
successful!) or the variety name is alphanumeric. 
5. TRADemARKS	in	AgRiCulTuRe
Trademarks have helped create value for agri-
cultural products. One example is the Roundup 
Ready® trademark, which designates crops devel-
oped by Monsanto that contain transgenes that 
encode tolerance to the herbicide glyphosate. 
Trademarks have been used to emphasize 
distinctive and attractive attributes of plant vari-
eties (for example, Pink Lady® [apples], Superior 
Seedless®[grapes]) and Sun-Maid®[raisins])4 is a 
branding success story: its trademark has made an 
otherwise pedestrian agricultural product so at-
tractive to consumers that the owners of the mark 
license it for use in association with products that 
contain their raisins. 
It is important to note that plant variety 
names are not the same as plant variety trade-
marks. Traditional plant variety names range 
from descriptive to fanciful, and are often cho-
sen by the plant breeder. The only restriction 
on a plant variety name is that it cannot have 
been used before for a plant of the same species. 
Choosing a trademark, however, requires consid-
erably more care. First, the variety name cannot 
be trademarked: the variety name is considered 
“generic” because it is the name for all plants of 
a particular variety, whereas a trademark serves to 
identify the source (the grower, marketer, and so 
on) of a particular plant. Second, the trademark 
office often rejects geographic names, especially 
if a particular geographic name is associated with 
the crop in question (for example, “Valencia” for 
citrus, “Turkey” for figs). Colors associated with 
the particular crop are usually not acceptable as 
trademarks, either. Finally, it can be difficult to 
register a trademark if it is already being used to 
refer to a related good or service, even if the good 
or service is different.
In order to illustrate some of the complica-
tions that may arise when attempting to trade-
mark a product, let us take the example of the 
Shasta Gold® seedless mandarin, owned by the 
University of California. The U.S. trademark ex-
aminer objected to the use of a geographical name 
in the trademark, but the university argued that 
Shasta was not a region in California that is as-
sociated with citrus. The examiner objected to the 
use of a color in the trademark, but the university 
argued that Gold referred to the fruit’s quality, not 
its color. Having prevailed at the U.S. Patent and 
Trademark Office, the university was then chal-
lenged by the Shasta Beverage Company, which 
claimed that the existence of the Shasta Gold® 
mandarin would impact sales of its own Shasta® 
fruit-flavored sodas. Ultimately, the parties reached 
a compromise out of court. Had the university 
simply chosen to call the variety “Shasta Gold” 
(without trademarking it) in the relevant U.S. 
Plant Patent, there would have been no conflict.
Using a trademark to cover a whole category 
of produce is a particularly powerful strategy. 
Sun World5 uses its Amber Crest® trademark for 
various early peach varieties. These varieties are 
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all similar in appearance and taste, but ripen at 
different times. Individual varieties are protect-
ed with distinct names (for example, Supechsix, 
Supechnine), but the consumer knows them only 
by their trademark name, AmberCrest®. This 
strategy has allowed Sun World to develop new 
varieties of early peaches while still maintaining 
a consistent brand image. Another strategy is to 
develop secondary marks or qualifying names for 
individual products within a brand. An example 
of this is the trademarked Zespri® kiwifruit from 
New Zealand: the yellow-fleshed kiwi is called 
Zespri® GOLD and the original fruit is called 
Zespri® GREEN (Figure 2). Because the qualify-
ing names are common words, they cannot be 
trademarked.
Trademarks, if used judiciously, can add 
value to a single variety. The Pink Lady® apple is 
a good example. Whereas few consumers would 
recognize the variety name Cripp’s Pink, most 
are familiar with the trademarked name Pink 
Lady®.  Trademarks gain their value from con-
tinuous market presence and acceptance, so it 
may not make financial sense to create a trade-
mark for a seasonal variety.  Pink Lady® apples, 
however, are available year-round, so this trade-
mark has been very successful.
Recent changes in the structure of the retail 
market will affect the use of trademarks in the 
fresh produce industry. In developed countries, 
the supermarket business is becoming increasing-
ly consolidated, and these supermarkets are often 
expanding beyond their countries of origin. In 
order to keep up with the competition, supermar-
ket chains are seeking ways to distinguish them-
selves from their competitors, and focusing much 
of the effort on the stores’ produce sections
Large chains have the necessary marketing 
power to support trademarked produce, but the 
only produce varieties that are likely to provide 
a return on such an investment are those with 
unique consumer appeal: they might have an un-
usual or improved shape, color, texture, flavor, or 
other quality (such as seedlessness), or an atypical 
or extended market availability (such as with an 
early or late variety). 
The growing power of supermarket chains 
can also work to the disadvantage of the variety’s 
owner.  The retailer may choose to reject an own-
er’s mark in favor of its own. This is the situation 
in Australia, where two supermarket chains con-
trol about 80% of the fresh produce retail mar-
ket. Both chains are developing their own over-
arching produce brands, so they are unwilling to 
figure	2:	Zespri®	gold	kiwi
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decrease the potential value of their trademarks 
by stocking and marketing products that bear 
other trademarks. 
Because plant variety rights are not available 
(or particularly enforceable) in many countries, 
trademark protection is often stronger than, and 
can serve as a proxy for, variety rights protection. 
For example, the University of California was 
able to register the name Camarosa for a straw-
berry variety in certain countries where PVR was 
not available, and then licensed production of the 
Camarosa® strawberry. The central part of the 
license was the use of the trademark. Although 
third parties who were not licensed to commer-
cialize the Camarosa strawberry could still grow 
them in these countries where PVR was not avail-
able, they could not sell them under the protected 
name of Camarosa. However, as PVR protection 
compliant with the International Union for the 
Protection of New Varieties of Plants (UPOV) 
becomes more common in developing countries, 
and if multistate protection (as exemplified by 
the Community Plant Variety Office [CVPO] of 
the European Union [E.U.]) becomes available 
in other regions, using trademarks as a proxy for 
PVR may become obsolete.
6.	 inTeRnATionAl	TRADemARK	
pRoTeCTion
Under the Madrid system,6 which is administered 
by the World Intellectual Property Organization 
(WIPO), a trademark can be protected in several 
countries (members of the Madrid Union) if the 
owner files one application directly with his own 
national or regional trademark office. In contrast, 
PVR procedures are much more complicated: 
the variety owner must file for protection in ev-
ery country (with the exception of PVRs filed in 
E.U. countries, which are protected throughout 
the European Union). The Madrid system can 
reduce the amount of money a trademark owner 
must spend on both outside lawyers’ fees and fil-
ing fees.7 The United States is not a member of 
the Madrid Union but is a member of the similar 
Madrid Protocol, adopted in 2002 and imple-
mented in late 2003.8 
The Madrid system has helped, in some cir-
cumstances, to curb the problem of trademark pi-
racy and extortion, provided that the trademark 
owner makes use of the system and possibility to 
file for trademark protection in many countries at 
once. Consider the following scenario: a rogue en-
tity, seeing a product on the market in one coun-
try and recognizing that it might have commercial 
success in another country, registers the same or 
a very similar mark in the second country (most 
countries do not require that a registered mark 
ever be used). When the product owner wants to 
enter the market in the second country, the pirate 
then attempts to sell the plagiarized mark to him. 
Taking a trademark plagiarist to court costs time 
and money, and the pirate relies on the probability 
that the trademark owner will want to settle out 
of court rather than engage in formal proceedings. 
This scenario occurred in conjunction with one of 
the strawberry varieties owned by the University 
of California: in a foreign country, a pirate reg-
istered the name of one of the university’s straw-
berry varieties and then challenged its right to sell 
plant material in that country under the registered 
name. The ability to protect trademarks in several 
countries at once under the Madrid system gives 
product owners a useful tool for thwarting such 
schemes. 
7. liCenSing	iSSueS	
A license that addresses both PVR and trademark 
rights, as well as when and how these rights will 
expire, is called a hybrid license. Trademarks are 
perpetual if the trademarked product is continu-
ously marketed, but PVRs have a limited term. 
A licensee will naturally want to maintain his 
rights to use the trademark even after the PVR 
has expired and others are selling the same prod-
uct. The license agreement can therefore be struc-
tured so that any given right and its associated 
obligations are distinct from, and can expire (or 
be terminated) without compromising any other 
rights or obligations. Box 1 provides some sample 
language for a licensing agreement. In addition 
to granting rights and specifying product mark-
ing requirements, it is important that a hybrid 
licensing agreement define the amount and kind 
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of compensation to be paid for use of each right. 
For example, an agreement could specify a royalty 
for use of the PVR and a royalty for use of the 
trademark. In this case, after the PVR expired, the 
licensee would pay only the trademark royalty. 
Not all products may meet the quality standards 
required under the terms of the trademark license, 
so an agreement might permit the licensee to sell 
low-grade produce through other channels (for ex-
ample, nonexport-grade products might be sold to 
the processing industry or local markets) without 
using the trademark. For these off-grade sales, the 
licensor would only collect a royalty for use of the 
PVR. 
The licensing agreement must also cover 
forseeable contingencies. The quality of goods 
or services sold under trademark must be strict-
ly controlled. A license agreement must require, 
therefore, that the licensee use the trademark only 
in conjunction with the licensed plant variety, and 
only on products that meet a prescribed quality 
standard (such as size/count or grade, whichever 
is applicable). Once a licensee has created brand 
equity in its own mark, it may very well terminate 
the license agreement and sell the licensed variety 
or a very similar variety under that mark; such an 
act would obviously be illegal, but Madrid system 
or not, it can be time-consuming, costly, and logis-
tically difficult for a licensor to enforce its rights in 
many foreign countries. In order to avoid this kind 
of situation in the first place, the license can forbid 
the licensee to use any other trademark that could 
be confused with the licensed mark. Alternatively, 
a clause can be included in the license that requires 
any mark that was created and used by the licensee 
in association with the licensed product to revert 




Many future novel fruit products will likely 
come from the tropics, a region that includes 
many developing countries. The owners of 
such varieties may want to adopt a strategy that 
stimulates global demand for the product, while 
maximizing commercial returns for themselves. 
A global trademarking program that relies on 
consumer demand may be more feasible than a 
PVR strategy that relies on licensing for return 
on investment. 
The developer of new branded fruit products 
must remember the four critical aspects of any 
trademarking strategy:
1. Determine what is to be trademarked. 
The owner must clearly define the registered 
product, as well as the standards and brand 
values it wishes to develop. Developing 
countries with variable agricultural practic-
es may find it challenging to achieve prod-
uct consistency.
2. Register the trademark where it will be 
used. The owner must have a well-devel-
oped commercialization plan with separate 
strategies for each country in which the fruit 
might be sold. The owner may need to reg-
ister the trademark at the local patent and 
trademark office in every country or terri-
tory in which the product will be marketed.
3. Promptly register the trademark. 
Trademarks should be filed in the early 
stages of product conceptualization, before 
competitors can do so. 
4. Enforce the trademark. The owner will 
need to invest money to ensure that the 
trademark is used appropriately, and only 
by those with rights to do use it. Fruit pro-
ducers in developing countries may try to 
use a successful trademark (or a close copy) 
on their own products. Care must be taken 
to ensure that a trademark is not used so 
indiscriminately that it becomes a generic 
descriptor. 
9.	 ConCluSion
If chosen well and used effectively, a trademark 
can add substantial value to a plant variety. 
However, the time, effort, and up-front costs are 
significant, so a variety owner must be willing to 
make the needed investments. Moreover, an effec-
tive global trademark strategy especially requires 
the IP owner and its licensees to work together 
for mutual benefit. ■ 
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1.1 Subject to the limitations set forth in this Agreement and the reservation of rights set forth in 
Paragraph XX, Licensor hereby grants to Licensee under Trademark Rights:
1.1.1 the right to use the Trademark in association with the testing and marketing of 
Trademark Products;
1.1.2  the exclusive right to sublicense Propagators to use the Trademark in association with the Sale 
of Trademark Propagator Products;
1.1.3  the exclusive right to sublicense Growers to use the Trademark in association with the 
Sale of Fruit;
1.1.4 the exclusive right to sublicense Packers to use the Trademark in association with the 
Sale of Fruit; and
1.1.5 the exclusive right to sublicense Distributors to use the Trademark in association with 
the Sale of Fruit.
1.2 Licensee will use the Trademarks on all promotional materials produced that refer to Licensed 
Products. Licensee will use the Trademarks in a featured and prominent manner. Sublicenses will 
require Sublicensees (a) to use the Trademark in association with, and only with (i) Trademark 
Products Sold or offered for Sale, and (ii) any marketing or advertising describing Trademark 
Products; and (b) to use the Trademarks in a featured and prominent manner. With respect to 
Sublicensees’ Sale of Fruit, such Sublicenses will require Sublicensees to use the Trademarks 
with, and ONLY with, the highest grade of Fruit Sold or offered for Sale.
1.3 Neither Licensee, a Sublicensee, nor any entity which is an Affiliate, Joint Venture, or Related 
Party of a Licensee or a Sublicensee, will use any other trademark or name in association with 
Trademark Products that is confusingly similar to or, in Licensor’s judgment, suggestive of, the 
Trademarks. Licensee and all Sublicensees will not use the Trademarks except as permitted by 
this Agreement.
 If Licensee learns, either directly or upon notice from a Sublicensee, of any unauthorized use 
of the Trademarks or any colorable imitation thereof or any name or mark confusingly similar 
thereto, Licensee will immediately inform Licensor in writing of such unauthorized use in 
accordance with the provisions of Paragraph XYZ. Moreover, Sublicensor will require Sublicensees 
to notify Licensee (often through Sublicensor) of any unauthorized use of the Trademarks or 
any colorable imitation thereof or any name or mark confusingly similar thereto.
Product-marking clause: 
Licensee will require all its Packers and Distributors to attach to Fruit (where commercially 
practicable and consistent with normal industry practice) and its cartons, boxes, pallets, or 
containers, sold under the terms of this Agreement, a durable and legible label or tag specifying 
the correct name of the Licensed Cultivar and the corresponding Trademark, if applicable.
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have trademark-law practices. 
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An option to acquire rights in university intellectual prop-
erty (IP) may be encountered in several guises: as a stand-
alone agreement, as a clause within an agreement (for 
example, a sponsored research agreement or a material 
transfer agreement), or as a “pipeline,” or IP framework, 
agreement for a university spinout company. Although 
the grant of an option may often form quite a small part 
of a larger agreement, the grant can raise important issues 
in terms of an organization’s IP commercialization strat-
egy. This is especially true of pipeline agreements that are, 
effectively, a specialized form of option agreement. The 
purpose of this chapter is threefold: 
1.  to provide an introduction to options, and their 
uses, and including legal, practical, and negotiat-
ing issues 
2.  to provide suggested templates along with guide-
lines concerning completion of the templates
3. to consider and discuss some of issues that are prob-
lematic or of particular concern to universities.
The chapter attempts to provide information that 
is useful for both the beginner and the experienced 
research-contracts or technology transfer professional. 
The breadth of material covered may give the mistaken 
impression that university contracts are wrought with 
legal and commercial difficulties. Usually, this is not 
the case. But sometimes differences of expectation, 
practice, or legal culture can arise between parties ne-
gotiating an agreement, particularly in international 
transactions. 
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FOREWORD
This chapter  is based on one of a series of UNICO 
Practical Guides. Over recent years, the knowledge com-
mercialization profession has grown and matured, creating 
a huge wealth of knowledge, experience, and best practice 
relating to university commercialization contracts. The 
UNICO Practical Guides have been produced specifically 
to share this knowledge, experience, and best practice 
within the profession. They are practical guidebooks on 
university contracts designed primarily for use by peo-
ple both new and experienced in the profession that tap 
into the collective learning of colleagues and peers. The 
guides have been produced as a resource for knowledge 
commercialization professionals, primarily in the United 
Kingdom. The guides are not designed to replace or com-
pete with existing manuals or other guides, but to provide 
a new and, we at UNICO believe, vitally important set of 
support materials to those who deal with university com-
mercialization contracts on a daily basis. We hope that 
you find this document useful. (Kevin Cullen, University 
of Glasgow; Chair, UNICO).
1.		 inTRoDuCTion
1.1 What	is	an	option?
An option may be either an agreement or a clause 
within an agreement. Typically, an option gives 
one party to the agreement the right: 
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• to acquire a particular right (for example, a 
patent license) or asset (for example, a patent)
• to require another party to enter into an 
agreement (in a specified form) or to nego-
tiate the terms of a further agreement 
• to evaluate materials, products, or assets 
to determine whether to enter into further 
agreements (such as further research or li-
censing arrangements)
Usually, options are granted on an exclusive 
basis. Thus, where a university grants an op-
tion to acquire rights to a package of intellectual 
property, the option terms may require the uni-
versity not to license that intellectual property 
to anyone else during the option period. This 
may be implicit in the grant of an exclusive op-
tion, but sometimes the parties prefer to add a 
clause to the option that states explicitly that the 
university will not license anyone else while the 
option continues. Sometimes, wording may go 
further and prohibit the university from talking 
to anyone else about a possible license during the 
option term. This type of explicit wording (when 
it is used) is most often requested by the grantee 
of the option. 
The main types of agreement that an indi-
vidual working in technology transfer will come 
across, and about which an understanding of op-
tions is useful, include the following: 
• a stand-alone option agreement in which 
the main subject matter of the agreement is 
the granting of an option, such as an option 
to take a license to a specific patent applica-
tion, and which is not part of a larger con-
tract (See Box 1, at the end of this chapter, 
for a sample option agreement.) 
• an option and evaluation agreement, of-
ten referred to just as an evaluation agree-
ment, and commonplace in regard to com-
puter software (For example, under such 
an agreement one party provides an item 
of software for a second party to evaluate, 
over a defined period of time, to enable the 
second party to ascertain whether it wants 
to take a license to the software. The evalu-
ation period gives the second party an op-
tion to acquire such a license if it so wishes. 
See Box 2, at the end of this chapter, for a 
sample software evaluation agreement.) 
• a research collaboration/sponsorship agree-
ment, in which the collaborator/sponsor is 
sometimes given an option of acquiring rights 
in the intellectual property generated by the 
university under the research program 
• a license agreement, where in addition to the 
licensee obtaining a license to a university’s 
particular patents and know-how, there may 
be a provision for the licensee to acquire 
rights in improvements to the licensed tech-
nology (Such a provision is usually made by 
granting an option to such improvements 
and by including an appropriate definition 
of improvements in the agreement.) 
• pipeline agreements and rights of first 
refusal, which are similar to options, 
outlined separately, and in slightly more 
detail, below, along with a brief explana-
tion of how they differ from basic option 
agreements and clauses (See Box 3, at the 
end of this chapter, for a sample pipeline 
agreement.)
1.2 What	is	a	right	of	first	refusal?	
People sometimes use the terms option and 
right of first refusal loosely, and interchangeably, 
to refer to any kind of opportunity right. (See 
Box 4, at the end of this chapter, for examples 
of options, rights of first refusal, and similar 
provisions.)
The authors of this guide are not aware of 
any official definition of these terms. However, a 
right of first refusal is often understood as having 
the following, more precise meaning, and it is 
considered best practice to adopt this meaning. 
The key distinction between an option and 
a right of first refusal, involves who initiates the 
grant of rights. Typically, with an option, the party 
benefiting from the option (the grantee) is given 
a period of time in which to claim the prize—to 
notify the party granting the option (grantor) 
that it wishes to obtain the grant of rights (such 
as a license or an assignment). 
By contrast, if the grantee is given a right of 
first refusal, it cannot initiate the grant of rights. 
The grantor is in control of the process. If the 
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grantor wishes to grant the rights, it must notify 
the grantee and give the grantee an opportunity 
to accept, or refuse, those rights. 
Typically, right of first refusal clauses operate 
at one or both of the following stages: 
1. When the grantor first decides it is ready to 
grant the rights (or is about to start offering 
the rights to third parties), it must offer the 
rights to the grantee.
2. When the grantor is about to sign an agree-
ment with a third party, the grantor must 
give the grantee an opportunity to match 
the terms agreed upon with the third party. 
If the grantee accepts this opportunity, the 
grantor must grant the rights to the grantee 
on those terms, instead of granting them to 
the third party. 
Rights of first refusal are often encountered 
where the other party to an underlying agree-
ment (for example, a research agreement) is either 
sponsoring the research (financially or in kind) 
or providing materials. Indeed, many university 
research agreements and material transfer agree-
ments (MTAs) that originate from large pharma-
ceutical companies often incorporate a right of 
first refusal.
A right of first refusal can therefore cover the 
following situations: 
• If party A negotiates with party B over 
certain terms (for example, a license agree-
ment), then party A will give party C an 
opportunity to match those terms. 
• If party A creates intellectual property from 
a research program or produces something 
(such as a prototype), then before party A 
offers to license it or assign it (either gener-
ally or to a specific party, B) party C will 
be given a first opportunity to acquire the 
right or product. 
Depending on how rights of first refusal 
over intellectual property are drafted, they can 
present practical difficulties, particularly in the 
situation described in the second bulleted item, 
above. Negotiations over the grant of IP rights 
can take months to complete, and usually re-
quire a degree of confidence building with regard 
to the potential value of the technology and IP 
rights and to how the parties will work together 
under the agreement. A practical issue arises when 
one party in a negotiation must decide when to 
tell the other party that a third party has a right 
of first refusal over the same rights. If the second 
party is told at the outset, will it be willing to 
spend time and resources in negotiating terms? If 
the second party is told only when the third party 
exercises the right of first refusal, the second party 
may feel that it has been misled. 
Universities may therefore wish to resist 
granting rights of first refusal that operate imme-
diately prior to signing an agreement with a third 
party. Where it is commercially necessary to grant 
a right of first refusal, one solution the authors 
have found is to draft the right of first refusal 
so that it operates immediately before signing a 
nonbinding term sheet with the third party. The 
third party may be less likely to complain if it is 
trumped at this stage. 
Another variation on options and rights of 
first refusal is termed right of first opportunity. This 
expression is used less frequently than right of 
first refusal and probably its meaning is more in 
flux. Where the authors have encountered right 
of first opportunity, it has tended to mean a right 
of the grantee to make a proposal to the grantor 
at some defined point in time (for example, when 
the grantor decides to grant rights) but with the 
provision that the grantor has no obligation to 
accept the grantee’s proposal or negotiate exclu-
sively with the grantee. Sometimes this level of 
right is described as having a (nonexclusive) seat 
at the negotiating table. As with other types of 
options, the precise meaning and extent of any 
right of first opportunity, and the procedure to be 
followed when exercising it, should be clearly set 
out in an agreement. 
Sometimes one encounters heavyweight 
clauses that are a composite of both an option 
and a right of first refusal. For example, there may 
be an option to negotiate a further agreement, 
and if the parties cannot agree on terms, then the 
university can grant the rights elsewhere but must 
come back to the other party before entering into 
an agreement with terms that are no better for the 
university than those that the other party offered. 
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Any such clauses need to be carefully scrutinized 
to ensure that they are workable and do not prej-
udice discussions with the third party. 
1.3 What	is	a	pipeline	agreement?	
A pipeline agreement is normally encountered 
only in contracts involving the formation of a 
university spinout company. Under these cir-
cumstances, the university (or its technology 
transfer office) would have assigned or licensed 
certain intellectual property to the spinout. The 
intellectual property in question usually has its 
origins in the laboratory/department of the aca-
demics who created it. These academics usually 
end up being the founders of the new spinout 
company. 
A pipeline agreement is basically a sophis-
ticated form of option agreement, the purpose 
of which is to set out the rights the spinout has 
to future intellectual property generated in the 
founders department. Under such an agreement, 
the recipient of the option (the spinout company) 
is obtaining a “pipeline” to enable it to obtain 
rights in the intellectual property from the origi-
nating university department. 
A typical pipeline agreement is therefore nor-
mally entered into by three parties: 
1. The technology transfer company/office 
(TTO) of the academic organization 
2. The spinout company 
3. The original inventors/academics (often 
defined as the founders in company-forma-
tion agreements) involved in the creation 
of the invention or technology that has 
been assigned or licensed to the spinout 
company
A scenario that normally generates a pipeline 
agreement might include the following parts: 
• The founders or their laboratory identifies 
or creates further intellectual property re-
lated to an original invention or technol-
ogy, or, possibly, not related to the original 
invention or technology. 
• The further intellectual property is created 
within a limited time span (for example, 
one or three years from the date of the pipe-
line agreement).
• The spinout company gets an option to ob-
tain an assignment or license of the further 
intellectual property. 
Furthermore, pipeline agreements generally 
include: 
• a requirement for the founders to report 
regularly on their work and to identify any 
intellectual property that will be covered 
under the option 
• a clause allowing the company to identify 
intellectual property suitable to be covered 
under the option 
• clauses dealing with intellectual prop-
erty created during the term of the agree-
ment that may involve third-party rights 
or third-party funding, that incorporates 
third-party intellectual property (or tech-
nology), or that has been developed subject 
to third-party restrictions (for example, on 
assignment or licensing), or is subject to 
third-party licensing, assignment, or op-
tion requirements 
• provisions giving the university a license 
back to (or reservation of rights over) any 
IP or technology licensed to the company 
under the pipeline agreement (for example, 
for research and/or teaching or for “non-
commercial” use [setting out the parties’ 
understanding of noncommercial] or for 
use outside a defined field) 
• provisions imposing, on the company, an 
obligation to develop and commercially ex-
ploit the intellectual property and technol-
ogy assigned, or licensed, to it under the 
pipeline agreement 
• provisions stating which party is respon-
sible for obtaining IP protection and bear-
ing the costs of IP protection and when the 
protection should be sought and the costs 
borne 
The negotiation and drafting of a good op-
tion agreement, right of first refusal agreement, 
and especially pipeline agreement are substantial 
tasks, during which consideration must be given 
to many issues—legal issues as well as commercial 
ones.
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Options and similar agreements should never 
be taken lightly and should be clearly and com-
prehensively negotiated and drafted, in order to 




The practices described in this section are put 
forward for consideration as possible best prac-
tice (some of the practices, readers may feel, are 
ideal practice) with respect to the preparation of 
options. 
Policy. Have in place an institutional policy 
for the different types of options, covering such 
matters as: 
• whether to enter into them at all, and if so, 
which type is appropriate—that is, a basic 
option, a right of first refusal, or a pipeline 
• what “due diligence” should be carried out 
to ensure that obligations under an option 
do not conflict with obligations under other 
existing agreements and to ensure that the 
terms of each option do not conflict with, or 
prejudice, an IP commercialization strategy 
• use of questionnaires to be completed by 
the relevant researcher/department, to pro-
vide information relevant to the option 
and/or surrounding intellectual property 
• who has authority to sign the option for the 
institution 
Templates. Have in place templates for each 
type of option agreement ready for use in indi-
vidual transactions. 
Negotiation. Decide who has responsibility 
for negotiating the terms of options. Does that 
person have the required level of training and 
skill? Set out a procedure for referring difficult is-
sues to a more specialist advisor (for example, an 
in-house lawyer). 
Terms. Have in place clear “bottom lines” re-
garding terms that must, or cannot, be accepted 
in each type of option agreement. Possible key is-
sues might include: 
• law and jurisdiction (is it covered by rel-
evant insurance policies?) 
• duration of option 
• exactly how the option is exercised 
• clarification of what happens when the op-
tion is exercised (that is, there may be a 
need to enter into a further agreement) 
• whether warranties or indemnities can be 
accepted in the different types of options 
Monitoring. Implement procedures to mon-
itor obligations under option agreements, includ-
ing maintaining a database of options (and other 
agreements). 
3.	 CompleTing	A	TemplATe	AgReemenT
The following section provides a quick step-by-
step list of points to be noted when drafting/com-
pleting a standard option agreement, or option 
clause comprising part of a larger agreement. The 
assumption, for purposes of this text, is that the 
basic starting point is an agreement similar to, or 
the same as, the templates set out in Box 1, al-
though the comments below are generic enough 
to be of universal value. The issues referred to here 
have already been dealt with in the main text, but 
it seems appropriate to state them briefly again, 
so that one may have a one-shot view of the draft-
ing of suitable option wording. 
Signature Date. This is the date of the agree-
ment and is usually (unless otherwise agreed) the 
date on which the last person/party signs. It is not 
advisable to backdate the agreement by merely 
inserting an earlier date at the beginning of the 
agreement; if one wishes the agreement to cover 
periods prior to the date of the agreement, one 
should insert, in the definitions section, a sepa-
rate definition of a commencement date, effective 
date, that is, a date after which the rights and ob-
ligations under the agreement are effective. 
Parties. For a university: parties must be au-
thorized signatories. It is sometimes the case that 
senior members of an academic department may 
think they have authority to enter into legally 
binding agreements on behalf of the university, 
when they, in fact, do not. 
For U.K. companies: The full address of 
the company should appear (this may be a 
registered address or business address; it must 
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be stated which address is being provided). 
Consideration should be given to providing the 
company number.3  
For individuals: The home address should be 
provided (people move from one employer to an-
other, which can prove problematic if they need 
to be found to sign further documents or in the 
event of a dispute). 
The “Recitals,” or “Whereas” section. The 
section generally appears on the first page of the 
agreement, after the “Parties” section, but before 
the main body of the agreement (the part that 
usually commences with “It is agreed as follows” 
or similar language). Recitals are intended to give 
some background to the agreement, but, strictly 
speaking, they are not necessary. 
Definitions. This may or may not be a sepa-
rate clause in the agreement. Quite often defini-
tions are found throughout the document; the 
standard way of providing definitions is to follow 
a definition with its term, with initial caps and 
inside parenthesis. Thereafter, throughout the 
agreement, the phrase Effective Date would be 
used in place of the actual date. If a separate clause 
is used for definitions, the convention generally is 
to place the defined term in between quotation 
marks. For example:
1.4 “Contract Period” shall mean the period 
beginning on the Effective Date and ending on the 
[third] anniversary of the Effective Date, subject to 
any earlier or later termination in accordance with 
Clause 8; 
From a drafting, as well as a contractual in-
terpretation point of view, both versions are very 
efficient approaches. 
Obligations: The option agreement needs to 
set out clearly: 
• the intellectual property covered by the 
agreement, or if it is future intellectual 
property in a pipeline agreement, it needs 
to be properly ring-fenced by, for example, 
defining it as intellectual property in a par-
ticular field, generated by a specific research 
group, during a limited period 
• the duration period of the option 
• how the option can be exercised 
• what happens if it is not exercised 
• what happens to any materials/software 
transferred under the option agreement 
once agreement is terminated 
Jurisdiction: The law governing the agree-
ment should as far as possible be English law, 
while jurisdiction should be the “Non-Exclusive 




Although the detailed terms of option agreements 
vary, they often include provisions covering the 
following points: 
• a description of the general subject matter 
of the option 
• a detailed definition of “option intellectual 
property/pipeline intellectual property” 
(that may refer to existing intellectual prop-
erty or future intellectual property based on 
some existing intellectual property) 
• stating what the option is for, for example, 
to take an exclusive license or assignment
• in an evaluation agreement, obligations to 
use the intellectual property only for a de-
fined purpose
• the option exercise period (for example, 
“for a period of three months from the date 
of the agreement”; or “within one month 
of the Company being informed of new in-
tellectual property arising under a pipeline 
agreement”)
• the method of how the option is actually 
exercised 
• a statement of what happens after the exer-
cise of the option, for example, obligations 
of the parties: 
− to execute a formal assignment of spe-
cific patents 
− to enter into a detailed license agreement 
on pre-agreed terms, for example, those 
terms set out in a schedule accompany-
ing the option agreement
− to negotiate the terms of further agree-
ments, for example, a license agreement 
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or assignment, including any time limit 
for such negotiations and what would 
result if the parties are unable to reach 
agreement 
• payments clause setting out the option fee, 
including the reimbursement of any his-
toric patent costs 
• general confidentiality obligations
• various IP-related provisions, including 
ownership of intellectual property, any 
warranties that may be given, or a provi-
sion that no warranties are given relating to 
any information/IP provided for evaluation 
(that is, the material, information or IP li-
cense is provided as is) 
• in an evaluation agreement, or a research 
agreement containing option provisions, 
obligations to disclose the results of re-
search or evaluation 
• in a pipeline agreement, obligations to 
promptly inform the spinout company of 
arising intellectual property that may fall 
within the pipeline 




The terms that are often negotiated in option 
agreements include the following: 
• the extent of the intellectual property cov-
ered by the agreement, especially in pipe-
line situations, where the university needs 
to keep the pipeline narrow (defined by in-
ventors and research groups, field, sources 
of funding of the research, and so on), of-
ten against the wishes of the spinout com-
pany (and their investors) 
• the option fee 
• the duration of the option 
• the name of the party who has control over 
(and pays for) patenting during the option 
period 
• the detailed terms of the “further agree-
ment” (for example, license agreement) or, 
if these have not yet been agreed to at the 
time the option agreement is negotiated, 
the extent to which the parties are required 
to negotiate, in good faith, the terms of the 
further agreement, for example, the actual 
final license of the intellectual property and 
the consequences of failing to agree those 
terms (for example, whether the terms are 
settled by an expert and whether the grant-
ee receives a right of first refusal 
Sometimes, as a halfway point between items 
entering into a detailed license agreement and 
negotiating the terms of further agreements, cer-
tain key commercial terms of the future license 
or assignment are agreed to as part of the option 
agreement, for example, that there will be an ex-
clusive license, with royalty payments. However, 
certain provisions, such as the actual percentage 
figure for royalties, may be left for agreement at 
a later stage (with provisions for referral to an 
expert where the parties cannot agree). 
5.		 A	CheCKliST	of	opTion	pRoviSionS	
A checklist in Table 1 (see end of chapter) lists: 
• preliminary points that may need 
consideration
• the main clauses usually found in an option 
together with the main issues that should 
be addressed regarding each provision 
6.	 SpeCiAl	legAl	iSSueS	in	opTionS	
Note: the following comments are based on 
English law, and different considerations may ap-
ply in other jurisdictions, e.g. as to the enforce-
ability of obligations to negotiate in good faith. 
The enforcement of option agreements de-
pends on both (1) the terms of the agreement 
and (2) the effect of the underlying law relating to 
such matters as “agreements to agree” among oth-
ers. The manner in which an option agreement is 
drafted might have a similar effect as when par-
ties use and characterize documents as letters of 
intent or “heads of terms” in the course of ne-
gotiations—the document is not as much setting 
out all of the details of the overall transaction as it 
is anticipating future events (and perhaps further 
written agreements too) down the line. 
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Generally, where substantial and necessary 
terms of an option agreement are left open for 
future negotiations, a contract has not been cre-
ated. Ideally (from the point of view of legal 
enforcement) all the terms of the further agree-
ment (for example, license agreement) will be 
set out as a schedule to the option agreement, 
so that all the parties have to do when the op-
tion is exercised is sign the further agreement. 
However, the parties do not always wish to 
spend time negotiating detailed license terms at 
the time of negotiating the option agreement. 
An alternative is to specify that the parties will 
negotiate the detailed terms once the option is 
exercised. Unless carefully drafted (in particular, 
with a default mechanism stating what hap-
pens if the parties cannot reach agreement, for 
example, referring the terms for settlement by 
an independent expert), this may amount to an 
unenforceable agreement to agree. 
Where a party intends to create a legally 
binding option agreement, it should refrain from 
merely agreeing to “agree in the future,” even if 
future agreements will be necessary corollaries to 
the contract at issue. Instead, the parties should 
specifically describe the responsibilities and ob-
ligations of each party, clearly stating the consid-
eration for each party’s obligations. By avoiding 
the inclusion of uncertain terms requiring future 
negotiation, a party can help ensure that a bind-
ing contract has been formed. 
If certain commercial terms cannot be deter-
mined at the time of the execution of the option 
agreement, the parties should provide a method 
for determining the matter. For example, in rela-
tion to any options fees or other payments to be 
paid at a later date, the parties can agree upon a 
formula that permits the calculation of fees/prices 
in the future, or such fees/prices will be deter-
mined by a specified independent person, that is 
referred to an expert. These matters should not be 
left for the court to decide. 
7.	 DeTAileD	DiSCuSSion	of	
CommeRCiAl	iSSueS	in	opTionS	
Compared with other topics covered in the 
UNICO Practical Guides, there are relatively few 
detailed commercial issues to discuss, once the 
key drafting and negotiating issues have been 
resolved, that is, the scope and duration of the 
option and the procedure for exercising it. 
7.1 Option	for	license	or	option	for	
assignment?	
As has already been noted, there are many differ-
ent types of options and many different subject 
matters these options can address—for example, 
acquisition of shares, intellectual property, con-
tractual rights, and income streams. In the context 
of technology transfer activities, and where the 
subject matter of the option is intellectual prop-
erty, a key question is whether an option should 
give the grantee the ownership of the intellectual 
property (that is, by means of an assignment) or 
merely a license, with ownership remaining with 
the university. 
From the university’s perspective, the main 
advantage of retaining ownership (that is, licens-
ing rather than assigning) is the degree of control 
(or at least influence) that ownership gives. The 
main areas of control may be: 
• control over patenting (the licensee or as-
signee’s interests may not always coincide 
with those of the university) 
• control over development and commercial 
exploitation of the intellectual property 
• recovery of rights if the company becomes 
insolvent 
Diligence obligations can, of course, be in-
cluded in an assignment agreement. However, 
if the grantee obtains outright ownership of the 
intellectual property, regaining control of the in-
tellectual property may be more difficult (if the 
assignee is in breach of contract) than if only a 
license had been granted. A license can be ter-
minated; an obligation to assign back intellectual 
property may be more difficult to enforce. If the 
grantee owns the intellectual property and then 
sells it (for example, through the grantee’s liqui-
dator, as part of a winding-up process), the new 
owner may be able to avoid complying with the 
obligations under the assignment agreement (and 
this is an even greater risk if the new owner were 
not aware of these obligations). 
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In the case of pipeline agreements with 
spinout companies, the company’s investors 
may push hard for an assignment rather than a 
license of intellectual property (both in relation 
to the original package of intellectual property 
that is being acquired from the university and 
in relation to any further intellectual property 
that is acquired under a pipeline agreement). 
A few universities are becoming more resistant 
to such pressure and granting only a license, or, 
in some cases, granting only a license initially, 
but converting the license to an assignment once 
the company has generated a certain level of 
investment. 
7.2 Options	as	part	of	research	agreements	
Take the example of an agreement under which 
a company sponsors a program of research at a 
university. Such an agreement will usually in-
clude provisions that determine which of the 
parties would own the results of the research, 
including any resulting intellectual property. 
Sometimes, the agreement will specify that the 
results are owned by the university and that the 
sponsor is granted an option to acquire a li-
cense to develop and commercialize the results. 
Some of the “Lambert” agreements (agreement 
number 2, Clause 4.6) include such option 
terms.4
This approach—the grant of an option to 
acquire a license to commercialize results—is 
just one of a number of possible ways of “carv-
ing up” any intellectual property generated from 
a sponsored research program. The Lambert 
agreements offer some alternative ways of deal-
ing with this issue. Other possible approaches 
include: 
• sponsor owns all the results (solely or joint-
ly with the university) 
• sponsor has an automatic license to the results 
(either for all purposes, including commer-
cialization, or for research purposes only) 
• sponsor gets no automatic rights to, or op-
tion over, the results 
Other variations include granting rights in 
specific fields or territories. 
7.3 No	automatic	offer	of	license	or	
assignment:	the	U.S.	approach	
Although Lambert may assist U.K. universities 
in developing a more standardized approach to 
the question of intellectual property arising from 
research contracts, U.K. universities have not yet 
become as consistent in their approach as many 
U.S. universities are. Generally, in the United 
States, the policy of most universities is to only 
grant options to arising intellectual property that 
is generated under a research contract. 
Although exceptions may be made in certain 
(rare) circumstances, U.S. universities gener-
ally retain ownership of any intellectual property 
that arises from the results of its own research. 
However, they are willing to negotiate the grant 
of commercial rights to a sponsor through an ap-
propriate license, so that the sponsor may com-
mercialize the intellectual property. This approach 
has evolved for two reasons—first, universities feel 
the need to have a certain degree of control of the 
discoveries made in-house (no matter who fund-
ed the research), and second, the Bayh-Dole Act 
prohibits universities from transferring ownership 
of intellectual property to a company if federal 
funding has helped support the work—instead, 
the law encourages the transfer of technologies to 
industry through licensing. 
The Bayh-Dole Act was passed in 1980 in 
the United States, and the policy set down in 
the act encourages the utilization of inventions 
produced under U.S. federal funding. The policy 
promotes the participation of universities and 
small businesses in the development and com-
mercialization process. The policy permits ex-
clusive licensing with the transfer of an inven-
tion to the marketplace for the public good. The 
U.S. government enjoys royalty-free, nonexclu-
sive licenses to use such inventions for govern-
ment purposes (including for use by government 
contractors). 
Some licenses granted by U.S. universities 
must be nonexclusive either because federal re-
quirements demand it or because the research has 
had multiple sponsors. Under some circumstanc-
es, U.S. universities are willing to grant an exclu-
sive license to a company. However, care is taken 
to ensure that, first, the field of use specified in the 
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license is limited to the application of commer-
cial interest to the company (so that the univer-
sity researchers can continue to conduct research 
on other applications and develop other licensing 
possibilities), and second, the university will wish 
to ensure that the company is diligent in pursu-
ing commercialization opportunities (a diligence 
clause is normally inserted into license agreements 
to allow the university to terminate the license if 
the company does not take the promised steps to 
develop or market the product). 
In addition, licenses granted by U.S. univer-
sities normally obligate the company to pay or 
to reimburse the university for historic expenses 
associated with obtaining patents, as well as pay-
ing to the university licensing fees and/or royal-
ties on the sale of products. If the company and 
the university are unable to reach agreement, or 
the company does not wish to obtain a license, 
the university is then generally free to negotiate 
with other parties. 
In cases in which research is sponsored by a 
private company, a U.S. university might con-
sider granting the sponsor a free, nonexclusive, 
nontransferable, royalty-free license, for internal 
research purposes only, to intellectual property 
generated by academics under the agreement. In 
addition, the university could, in consideration 
for a fixed annual fee (or royalties), grant the 
company the option to a nonexclusive, nontrans-
ferable, royalty-free license without the right to 
sublicense for the company to make products us-
ing the intellectual property. 
A good example of the U.S. model is 
Massachusetts Institute of Technology (M.I.T.). 
In the majority of cases where M.I.T. research 
agreements involve a single sponsor, the sponsors 
accept M.I.T.’s standard IP clause, which gives 
the sponsor a number of options (including an 
option to an exclusive license) with regard to the 
licensing of patents and copyrightable materi-
als, including software. In situations in which a 
sponsor wants to negotiate particular “nonstan-
dard” IP provisions, M.I.T. is willing to enter 
into further negotiations. If an M.I.T. research 
agreement involves a consortium, the standard 
licensing options are limited to nonexclusive 
licenses.5 
In relation to software licensing, whether in-
tellectual property arises from sponsored research 
or not, companies are often willing to accept 
nonexclusive licenses. Also, because of the large 
number of patents involved in a typical electronic 
consumer product and because accounting for 
the use of each patent in such a product is oner-
ous, many companies do not like royalty-bearing 
licenses in such cases. Therefore, universities 
might consider offering royalty-free licenses but 
with an upfront fee—a good example of the 
use of such an approach is Stanford University’s 
EPIC (Engineering Portfolio of Inventions for 
Commercialization) Program, a subscription-
type system with standard fees.6 Such an approach 
should increase a university’s chances of licensing 
its software technologies. 
7.4  When	is	an	option	agreement	a	pipeline	
agreement?	
An agreement will generally be described as a 
pipeline agreement if the party wishing to obtain 
rights in the intellectual property is a university 
spinout company and the intellectual property 
that is the subject of the agreement is future 
intellectual property that may be generated by 
the university (normally developed in the spinout 
of the department of the founding academics, or 
founders). Most standard option agreements, on 
the other hand, quite often relate to a discrete, 
existing item of intellectual property that a party 
wishes to evaluate and, possibly, obtain a license 
to commercially exploit. 
Given that a pipeline agreement involves dif-
ferent pieces of (as yet unidentified) intellectual 
property, and also serves to set out the future re-
lationship of the spinout and the university (and/
or the university’s technology transfer office), the 
pipeline agreement is necessarily a more complex 
type of agreement than a straightforward option. 
Pipeline agreements usually grant an option 
to obtain an assignment or license of intellectual 
property. A pipeline agreement will usually in-
clude a definition of “pipeline IP” that will serve 
to define and limit the intellectual property that 
is to flow through the pipeline. Usually, a univer-
sity will wish to limit the pipeline flow to intellec-
tual property generated by the founders, or their 
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laboratory, during a defined period. The uni-
versity may wish to exclude from the definition 
any intellectual property that is subject to obli-
gations to third parties, for example, obligations 
to sponsors, or to that in which any third party 
owns rights (for example, joint inventions made 
with academics employed by other universities). 
The method by which new intellectual property 
is correctly identified as pipeline IP needs to be 
set out in detail—that is, provisions should be set 
out for the submission of regular reports, by the 
university/founders about their relevant research, 
to the spinout company, in order that the com-
pany may then choose to exercise its options. 
In addition, a pipeline agreement will address 
which of the parties is responsible for IP protec-
tion going forward, as well as certain diligence 
obligations on the company in relation to its com-
mercial exploitation of the intellectual property. 
7.5 Should	the	university	be	entering	into	a	
pipeline	agreement	at	all?	
In ascertaining whether it is really in the uni-
versity’s interest to grant a pipeline to a spinout 
company, various factors need to be taken into 
account. A fundamental point is whether the uni-
versity spinout in question is really the best com-
pany to commercialize the intellectual property 
coming out of the pipeline. Often, the assumption 
is made that a spinout is the automatic licensee 
for further developments made by the university 
in the same field as the intellectual property on 
which the spinout is based (and bearing in mind 
that the academic inventors of the new intellec-
tual property in question are also involved in the 
spinout and have a close relationship with the 
technology in question). However, this assump-
tion may not always be correct. Another compa-
ny may be better able to develop the new items of 
intellectual property, for example, because of its 
greater resources or because of its complementary 
product offerings. 
Another scenario where a spinout may not be 
the “licensee of choice” is one in that the university 
may decide to grant nonexclusive licenses—for ex-
ample, if several companies are possible infringers 
of the university intellectual property in question 
and may be interested in taking out a license. 
7.6 Scope,	duration,	and	procedure	for	exercise	
The option agreement should be clear in relation to: 
• the period of time during which the option 
can be exercised—the option agreement 
should clearly set out the relevant com-
mencement and termination dates for ex-
ercise of the option. Options sometimes 
have provisions covering several different 
periods: 
− the period during which the grantee can 
decide to exercise the option, for exam-
ple, during the period of a research pro-
gram and for a defined period after the 
final report is produced 
− if the grantee exercises the option, the 
period during which the parties are re-
quired to negotiate the terms of a further 
agreement, for example, a license agree-
ment (Sometimes, this period is vaguely 
specified, and there is merely an obliga-
tion on the parties to negotiate, with no 
clear cut-off point. From the university’s 
point of view this approach is highly 
undesirable.) 
− if the option incorporates a right of first 
refusal, the period of that right of first 
refusal (For example, the clause might 
provide that if the parties fail to agree the 
terms of the further agreement within a 
defined period, the university is free to 
license to a third party, but must offer 
to the grantee the terms offered to the 
third party. Sometimes this right of first 
refusal will only operate for a specified 
period of time, for example, a year af-
ter the collapse of negotiations with the 
grantee.)
• what the option is exactly for, for example, 
whether it is a right to negotiate something 
or a right to acquire something, specify-
ing exactly what the subject matter of the 
option is—a specific piece of technology 
or a specific patent, for example (Precise 
definitions on that subject are generally 
needed.) 
• consequences of any failure to agree to the 
terms of any further agreement (The two 
main alternatives are: (1) the option lapses 
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or (2) referral to an expert who will decide 
the terms of the further agreement.) 
7.7 Payments	
Sometimes, options are granted without charge. 
This usually happens in cases in which the grantee 
of the option is perceived to be in a sufficiently 
strong bargaining position to demand a period of 
exclusivity prior to deciding whether to acquire 
rights to the asset in question. 
In many situations, however, the university 
may take the view that the grant of an option has 
commercial value that should be recognized in an 
option fee. One possible argument for such a fee 
is that if an exclusive option is granted, the univer-
sity is prevented from pursuing its licensing activi-
ties with other companies during the option term. 
The fee could be either or both of the following: 
• a fee payable for the grant of the option (for 
example, payable on signature of an option 
agreement) 
• a fee payable on exercise of the option 
The amount that should be charged for the 
grant of an option is clearly a commercial, rather 
than a legal, issue. The authors have seen option 
fees of the order of tens of thousands of pounds, 
but much will depend on the technology, the 
market, the extent of rights granted, and so on. 
Usually, a university will wish to recover its in-
curred patent costs on exercise of the option, in 
addition to any option fee. Option fees should 
not be confused with initial payments under any 
further agreement (for example, a license agree-
ment). Various standard techniques have been 
applied for the valuation (and therefore pricing) 
of technology generally.7 
8.	 ADminiSTRATion	of	opTionS	
It is important to keep track of options—both 
during the review and negotiation period and 
once options agreements have been signed. This 
task is probably best administered centrally, for 
greater ease of checking existing options that 
may have already been signed with the same par-
ty, and any other agreements, for potential con-
flicts with the option under review. Once a party 
has decided to grant an option, then a number of 
administrative issues may need to be addressed. 
8.1	 Standard	operating	procedure	(SOP)	
It is extremely helpful to the person negotiating 
the option if his or her institution has an estab-
lished written policy, or written standard operat-
ing procedure (SOP) for dealing with options, 
that includes guidelines regarding particular 
clauses and issues. It is particularly helpful if 
written guidance exists for nonnegotiable pro-
visions as this enables the negotiator to take a 
more confident stance. The guidance should be 
updated regularly and honed in light of practical 
issues experienced by the negotiators on a daily 
basis. 
In addition to aiding the negotiator, having 
an SOP is also in the institution’s interest. By is-
suing clear guidelines (and emphasizing which 
clauses should be referred to more senior staff or 
legal advisers) the potential for errors or oversights 
is reduced. An SOP might usefully include: 
• checklist of provisions that should (or 
should not) be included
• guidance on when to refer particular issues 
to more senior staff
• reminders to enter certain details of a final-
ized option on the relevant database and to 
send a copy to appropriate academics
• list of authorized signatories and the rel-
evant procedures for holiday cover
• whether or not to have an option question-
naire for relevant academics to complete 
(Unlike Material Transfer Agreements, 
which may be quite complex and require a 
more structured approach in order to ensure 
that the university has not granted identical 
rights to rival sponsors or contaminated its 
own background, options tend to be more 
straightforward. In the author’s view, the 
essential information can probably be cap-
tured in an e-mail, with a follow-up tele-
phone conversation if necessary.)
8.2	 Getting	all	the	essential	information	
for	a	new	option	
The researcher or scientist requesting or receiv-
ing the option holds the essential information 
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that enables the negotiator to understand the rel-
evant issues and establish a position that will best 
protect the interests of the institution (and the 
academic). Even if the organization does not use 
a formal questionnaire and, instead, gathers in-
formation by e-mail/phone, having a note of the 
relevant questions on an SOP has the advantage 
that (1) the negotiator does not need to rely on 
memory for the appropriate questions to ask and 
(2) it saves time. 
8.3	 Deciding	which	information	
should	be	disclosed	
Where a suite of confidential information is con-
cerned, it may be safest to provide only some of 
the confidential information to the recipient and 
withhold the most valuable, sensitive, and con-
fidential parts of the information. Or, it may be 
prudent to disclose the most sensitive information 
at a later date, for example, when a further agree-
ment has been signed or when a patent applica-
tion has been filed. 
Other detailed issues and best practice sug-
gestions in relation to confidential disclosures of 
information are discussed in the UNICO Practical 
Guide: Confidentiality Agreements. 
8.4	 Appointing	a	coordinator	
It may be desirable to appoint someone, for ex-
ample, a senior secretary or contracts officer, to 
make sure that an option has been signed prior 
to disclosure and to oversee the disclosure and 
receipt of information under the option. Other 
duties could include: 
• monitoring any deadlines (for example, the 
expiry date of the option) 
• where appropriate, keeping a log of which 
employees have received the confidential 
information of an external party 
• noting any unusual provisions or deviation of 
an option from one’s own standard option 
• sending a copy of the signed option to 
the relevant academic together with a cov-
ering letter highlighting any particular 
obligations 
• recording details of the option in a con-
tracts database and filing the original in a 
safe (or designated area) 
8.5 Making	employees	and	others	aware	of	
their	obligations
It is good practice to ensure that employees are 
aware of their obligations with respect to options. 
In order to achieve this, all third-party confi-
dential information should be clearly identified, 
perhaps by labeling it clearly as confidential. Any 
employee who receives third-party information 
should be informed that the information must be 
kept confidential and not used except as permit-
ted under the option with the third party. In some 
cases it may be appropriate to provide a copy of 
that option to the employee. 
8.6	 Contracts	databases	
Many universities enter into large numbers of IP 
contracts, including options, with many different 
organizations. It can be difficult to keep track of 
whether, if the university wants to talk to a third 
party, there is already a option in place between 
them, and if so, whether it is in force and whether 
it covers the type of discussions that are contem-
plated. Maintaining a general contracts database 
(or even better, having a discrete database just for 
options) that includes brief details of the terms 
of each option, and searchable fields, can be of 
invaluable assistance. 
8.7 When	to	involve	the	lawyers	
Liability and indemnity provisions are probably 
the main areas where more-specialized legal ad-
vice is sought. It is also important to ensure that 
the procedures for exercising the option are un-
ambiguously worded and do not leave the op-
tion in limbo for a prolonged period of time. 
However, unfamiliar phrasing within any clause 
is often worth checking. Some institutions may 
have a set policy that requires a final legal review 
before signature before certain nonstandard op-
tions are passed. Whether or not this is the case, a 
legal review of a random selection of nonstandard 
options at regular intervals may be useful as part 
of a due diligence exercise. ■
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Kingdom, other areas (such as Scots contract law) dif-
fer significantly from that in England and Wales.  To 
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THIS AGREEMENT dated the ___ day of _____________ 2007 is between: 
University Technology Transfer Ltd a company incorporated in England and Wales whose 
registered office is at [ ] (“University Technology Transfer”) and 
[name of company] a [ U.S. corporation incorporated in the State of ] whose principal place of 
business is at [address] (the “Company”). 
WHEREAS 
A.  University Technology Transfer is responsible for the development and commercialization 
of certain technologies that have been developed at [University] (“University”). 
B.  Either University Technology Transfer or University has filed patent application number(s) 
[state number(s)] in [the United Kingdom] in respect of an invention made by a University 
employee [name], relating to [specify invention]. 
C.  The Company wishes to acquire an Option to obtain a license under the Patent Rights, 
[and is willing to fund work to establish a “proof of concept” for the said invention that, 
it is intended, will enable the specification and claims of the Patent Application to be 
improved,] and University Technology Transfer is willing to grant the Company such an 
Option in accordance with the provisions of this Agreement. 
IT IS AGREED as follows: 
1.	Definitions	




The Option described in Clause 2.1 
Option Fee 
The sum of [Currency]
Option Period 
The period of [90] days from the Commencement Date, subject to any earlier termination of the 
Option under Clause 2.4 
Patent Rights
The patent application(s) referred to in Recital B[, together with any continuations, continuations 
in part, extensions, reissues, divisions, and any patents, supplementary protection certificates 
and similar rights that [are based on or] derive priority from the foregoing]. 
2.	option 
2.1  In consideration of the Option Fee, University Technology Transfer hereby grants to the 
Company an exclusive Option (the “Option”), during the Option Period and subject to 
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Box	1	(continued)
right to sublicense) under the Patent Rights to develop, manufacture, have manufactured, 
market, use, and sell products [in the Field] (the “License Rights”). 
2.2  During the Option Period, University Technology Transfer and the Company shall negotiate 
in good faith the terms of a license agreement between them under which the Company 
would be granted the License Rights. [Any such license agreement would include, without 
limitation, terms based on the provisions of Schedule 2.] Upon agreement of the terms 
of the license agreement during the Option Period, the Parties shall forthwith execute a 
license agreement between them on such terms. 
2.3  If the Parties are unable to agree the terms of a license agreement during the Option 
Period, despite negotiating in good faith, the Option will lapse. 
2.4  During the Option Period, University Technology Transfer shall consult with the Company 
in relation to the filing and prosecution of patent applications in respect of the Patent 
Rights. The Company shall reimburse to University Technology Transfer all of University 
Technology Transfer’s costs and expenses in relation to the filing and prosecution of Patent 
Applications, including without limitation patent agents’ fees. If at any time during the 
continuation of this Agreement the Company notifies University Technology Transfer that 
it does not wish to reimburse University Technology Transfer’s costs in respect of any family 
of patent applications, the Option shall terminate in respect of such patent applications on 
the date of University Technology Transfer’s receipt of such notification, and the Company 
shall not have any responsibility for such patent costs arising after such date. 
2.5  [If the Option lapses and University Technology Transfer licenses any of the Patent Rights to 
a third party, University Technology Transfer shall seek to recover any patenting costs paid 
to it by the Company in respect of such Patent Rights from the third party and reimburse 
such recovered costs to the Company.] 
3.	payments 
3.1  In consideration of the Option, the Company shall pay to University Technology Transfer 
the Option Fee (plus taxes, if applicable) within [30] days of the date of this Agreement. 
3.2  During the continuation of the Option, the Company shall: 
3.2.1 reimburse to University Technology Transfer all of University Technology Transfer’s costs 
and expenses in relation to the drafting, filing and prosecution of the Patents, including 
without limitation patent agents’ fees[; and] 
3.2.2 [pay to University Technology Transfer the amounts described in the attached Schedule 
1, on the dates stated in Schedule 1, by way of funding for the work described in that 
Schedule.] 
3.3  For the avoidance of doubt, all intellectual property and other rights in the work referred 
to in Clause 3.2 above shall vest in University Technology Transfer, but if an agreement is 
reached pursuant to Clause 2.2, such intellectual property and rights shall be included in 
the license to the Company contemplated by Clause 2.2. 
3.4  All amounts stated or referred to in this Agreement are exclusive of VAT, and VAT will be 
charged by University Technology Transfer to the Company, in addition to such amounts, if 
applicable and at the appropriate rate. 
(Continued	on	next	page)
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Box	1	(continued)
4.	general	
4.1  This Agreement is made under English law and the parties submit to the exclusive 
jurisdiction of the English courts in respect of any dispute arising out of or relating to this 
Agreement. 
4.2  Any notice to be given under this Agreement shall be in writing and shall be sent by first 
class mail, or by fax (confirmed by first class mail) to the address of the relevant Party set 
out at the head of this Agreement, or to the relevant fax number set out below, or such 
other address or fax number as that Party may from time to time notify to the other Party 
in accordance with this Clause 4.2, and marked for the attention of the representatives of 
the parties set out below: 
4.2.1    University Technology Transfer’s representative for notices—[insert name] 
4.2.2   University Technology Transfer’s fax number—[insert number] 
4.2.3   Company’s representative for notices—[insert name] 
4.2.4   Company’s fax number—[insert number] 
4.3  Notices sent as above shall be deemed to have been received three working days after 
the day of posting (in the case of inland first-class mail), or on the next working day after 
transmission (in the case of fax messages, but only if a transmission report is generated by 
the sender’s fax machine recording a message from the recipient’s fax machine, confirming 
that the fax was sent to the number indicated above and confirming that all pages were 
successfully transmitted). 
AGREED by the Parties through their authorized signatories: 
For and on behalf of  For and on behalf of
University Technology Transfer Ltd  […]
Signed  Signed     
Print name  Print name     
Title  Title      
Date  Date      
[Schedule 1] 
[description of work to be done and amount and dates of payment]
[Schedule 2] 
[Key points to be incorporated in license agreement]
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Box	2:	Sample	Software	evaluation	Agreement
THIS AGREEMENT is made on _____________________________ 2007 by and between: 
(1) [ ] a company incorporated in [England and Wales] under company number [ ] whose registered 
office is at [ ] (the “Licensor”); and 
(2) [ ] a company incorporated in [England and Wales] under company number [ ] whose registered 
office is at [ ] (the “Licensee”). 
WHEREAS: 
A. The Licensor has developed the Software (as defined below). 
B. The Licensee is interested in evaluating the Software with a view to taking a Software License 
(as defined below) [on [advantageous][the] terms as annexed to this Agreement) and is willing 
to evaluate and test the Software at its own risk subject to the provisions of this Agreement. 
NOW IT IS AGREED as follows: 
1.	Definitions	
In this Agreement, the following words shall have the following meanings: 
1.1  “Documentation” shall have the meaning as described in the Software License. 
1.2  “Evaluation Fee” shall mean the fee to be paid by the Licensee to The Licensor as described 
in Schedule 1, Part B to this Agreement. 
1.3 “Evaluation Period” shall mean the period of time, commencing on the date of this 
Agreement, during which the Licensee is permitted to use, evaluate [and test] the Software 
as described in Schedule 1, Part C to this Agreement. 
1.4 “Site” shall mean [ ].”
1.5 “Software” shall mean the software to be licensed under this Agreement and potentially 
under the Software License as described in Schedule 1, Part A to this Agreement. 
1.6 “Software License” shall mean the software license annexed as Schedule 2 to this 
Agreement. 
2.	Software	license	
2.1  In consideration of the Licensee paying the Evaluation Fee to the Licensor, the Licensor 
hereby grants the Licensee the nonexclusive right to use the Software for the purpose of 
internal evaluation only during the Evaluation Period at the Site and in accordance with the 
(Continued	on	next	page)
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Box	2	(continued)
provisions of the Software License, except to the extent that such terms are varied by this 
Agreement. 
2.2 [The Licensee agrees and undertakes to use the Software and to undertake its [testing and] 
evaluation for the Licensor [without charge to the Licensor] for the Evaluation Period.] 
2.3  Within 30 days after the end of the Evaluation Period, unless the Licensee terminates this 
Agreement in accordance with Clause 2.4, the Licensee may enter into the Software License 
subject to the financial and other terms set out in the Software License. 
2.4	The Licensee may at any time during the Evaluation Period, and must at the end of the 
Evaluation Period if the Licensee decides not to enter into the Software License, uninstall 
the Software from its computer system and return to the Licensor all copies of the Software, 
together with all documentation for the Software and all other material containing 
information concerning the Software that has either been supplied to it or of which it has 
become aware, whereupon the Licensee’s obligations under this Agreement and under the 
Software License shall cease, other than those under Clause 4 of this Agreement and those 
in the Software License that are expressed to continue to subsist after its termination. 
2.5  [For the avoidance of doubt, Documentation will not be provided by the Licensor to the 
Licensee under this Agreement.] 
3.	licensee’s	obligations	
3.1  During the Evaluation Period the Licensee shall: 
(a)  install and keep the Software installed on its computer system in its offices and [permit the 
Licensor to] install upgrades to the Software as soon as they become available; 
(b)  provide for the Software to be used at the Site by at least [ ] of its employees, being employees 
who would normally use such a product; 
(c)  produce verbal [weekly] written reports on the Software’s performance (addressing quality, 
content, and functionality of the Software as well as its marketability), which reports shall 
also identify any errors, bugs, or shortcomings in the Software as well as the Licensee’s 
comments and observations as the Licensor may from time to time reasonably request; 
(d)  make those of its employees who are using the Software available for meetings and 
discussions with the Licensor from time to time; 
(e)  at the request of the Licensor from time to time provide, and will procure that its staff 
provide, free of charge, references and information as to their practical experience of using 
the Software to potential and actual licensees nominated by the Licensor; 
(f)  comply with the terms of the Software License (except in so far as varied by this Agreement) 
and with the terms as to confidentiality set out in Clause 4. 
4.			References	to	licensee’s	use	
The Licensor may state in any publicity and other promotional materials that the Licensee is a user 
of the Software during the existence of this Agreement.
(Continued	on	next	page)
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Box	2	(continued)
5.	Confidentiality	
5.1  During and after the Evaluation Period the Licensee shall treat the Software and all 
information concerning it that is either supplied to it or of which it becomes aware as 
confidential and accordingly shall not: 
(a)  disclose any such information to any third party; or 
(b)  disclose any such information to any employee who has not acknowledged in writing the 
confidentiality of such information; or 
(c)  use any such information other than for the purpose of its own internal use, testing and 
evaluation of the Software except to the extent that such information is or becomes public 
knowledge other than through any fault of the Licensor; and shall at the request of the 
Licensor and at its own cost take such proceedings as may be necessary to preserve the 
confidentiality of such information. 
6.	noncompetition (It is advisable to seek legal advice before including this clause) 
6.1  During the period of [ ] [months][years] from the commencement of the Evaluation 
Period the Licensee undertakes not supply to, and/or develop on behalf of any third party 
or develop or supply to any third party, any product that competes whether directly or 
indirectly with the Software. Any such product shall include any software that operates as 
a stand-alone product, or whether as part of, or integrated into, another software product, 
whether can only operate in conjunction with another product, whether another product 
is owned, licensed to or used by the Licensee. 
6.2  This obligation shall not restrict the Licensee from itself undertaking internal research 
and development work in respect of such competing product but the Licensee shall not 
undertake any marketing or promotional activities in respect of the same prior to expiry of 
such period. 
6.3  For the avoidance of doubt, the provisions of this Clause 6 shall survive the expiration of 
this Agreement and/or the Software License. 
7.	exclusion	of	warranty 
Notwithstanding any warranty to be given by the Licensor in the Software License, the Licensee 
acknowledges that during the Evaluation Period the Software will still be under development, 
will be for test and evaluation purposes only, is being provided at a fee less than that normally 
charged by The Licensor and accordingly is provided “AS IS” without any warranty of any kind and 
is being tested and evaluated by the Licensee at its own risk. 
8.	general 
8.1  The Licensee may not assign its rights and/or obligations under this Agreement. 
8.2  In the event that all or any part of the terms, conditions or provisions contained in this 
Agreement are determined by any competent authority to be invalid, unlawful, or 
unenforceable to any extent such term, condition or provision shall to that extent be 
severed from the remaining terms, conditions, and provisions that shall continue to be 
valid and enforceable to the fullest extent permitted. 
(Continued	on	next	page)
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8.3 This Agreement shall be governed by and construed in accordance with the laws of 
England and Wales to the [nonexclusive] jurisdiction of the courts of which the parties 
hereby submit. 
8.4  This agreement does not create any right enforceable by any person not a party to it. 
AGREED by the parties through their authorized signatories: 
For and on behalf of    For and on behalf of 
[……]      [……] 
Signed      Signed      
Print name     Print name      
Title      Title       
Date      Date       
Schedule 1 
A. Description of the Software: 
B. The Evaluation Fee: 
C. The Evaluation Period: 
Schedule 2 
The Software License 
Box	2	(continued)
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Box	3:	Sample	pipeline	Agreement
THIS AGREEMENT is made the ___ day of ________2007 by, between and among: 
1.  ABC LIMITED whose registered office is at [] (“the Company”); and 
2.  THE INDIVIDUALS DEFINED BELOW AS THE FOUNDERS (“the Founders”); and 
3.  UNIVERSITY TECHNOLOGY TRANSFER COMPANY LTD whose registered office is at [ ] 
(“Technology Transfer”) 
 WHEREAS: 
A.  Technology Transfer is responsible for the commercialization of Pipeline IPR (as defined 
below) generated within the University (as defined below). 
B.  The Research Group (as defined below) of the University carries out activities that 
include work in the Field (as defined below). 
C.  The Parties envisage that some of this work will be of commercial interest to the 
Company. 
D.  The Founders and Technology Transfer are prepared to grant the Company an opportunity 
to exploit Pipeline IPR generated in the course of the Research Group’s work in the Field 
on the terms of this Agreement. 
IT IS AGREED as follows: 
1.	Definitions	
In this Agreement, the following terms shall have the following meanings: 
1.1  “Affiliate” shall mean, in relation to a Party, any entity or person that controls, is controlled 
by, or is under common control with that Party. For the purposes of this definition, “control” 
shall mean direct or indirect beneficial ownership of 50% or more of the share capital, 
stock, or other participating interest carrying the right to vote or to distribution of profits 
of that entity or person, as the case may be; 
1.2  This “Agreement” shall mean this pipeline agreement together with all of its schedules, 
annexes, and amendments; 
1.3  “Candidate Technology” shall mean an invention, know-how or other IP rights that: 
(a)  are generated by the Research Group in the Research Work during the Option Exercise 
Period; 
(b)  are considered suitable and ready for commercialization and protection by the Company; 
and 
(c)  are identified by a Party in accordance with Clauses 2.1 to 2.3; 
1.4  “Contract Period” shall mean the period beginning on the Effective Date and ending on 
the [third] anniversary of the Effective Date, subject to any earlier or later termination in 
accordance with Clause 8; 
(Continued	on	next	page)
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Box	3	(continued)
1.5  “Department” shall mean the Department of [ ], that is within the Faculty of [ ] of the 
University; 
1.6  “Effective Date” shall mean [XXXX] [the date of this Agreement]; 
1.7  “Encumbered,” with respect to any Pipeline IPR, shall mean that Technology Transfer is not 
entitled to assign such Pipeline IPR to the Company free of all liens, encumbrances and 
Third-Party rights and obligations, and “Encumbrance” shall be interpreted accordingly. As 
examples, but without limitation, Pipeline IPR may be Encumbered if: 
(a)  it incorporates IP rights or materials that are owned wholly or partly by someone other 
than the University or Technology Transfer (for example, but without limitation, where 
a person who is not a University employee contributed to its development); or 
(b)  it was developed under an agreement with a Third Party on terms that restricted or 
prevented the University’s use or disclosure of such Pipeline IPR or vested rights in such 
Pipeline IPR in the Third Party or any other person; 
(c)  it was developed in the course of a project that was funded wholly or partly by an external 
funding body on terms that restricted the University’s ownership, use or disclosure of 
the results; or 
(d)  in cases falling outside (a) to (c) above, it is the subject of an option, license, agreement 
to assign, or other commercial arrangement with a Third Party; or negotiations for the 
grant of commercial rights to a Third Party are continuing; 
1.8  “Exclusive Commercial License” shall mean an exclusive, worldwide license to research, 
develop and commercialize products and services, with the right to grant sublicenses, 
subject to any limitations or reservations on such license stated in this Agreement; 
1.9  “Expert’s Decision” shall mean the procedure set out in Schedule 2; 
1.10 “Field” shall mean the field of low power circuits for use in chip designs for wireless 
communication applications; 
1.11  “Founders” shall mean Professor [ ] and [ ]; 
1.12 “Inventive Contribution” shall mean a contribution to an item of Pipeline IPR that, in the 
absence of this Agreement, would entitle the maker of the contribution, or his or her 
employer, to be an owner or joint owner of the Pipeline IPR as a matter of applicable IP 
law. In particular, it is understood that being named as a joint author of an academic paper 
that describes the research in which the Pipeline IPR was generated shall not, of itself, be 
evidence of an Inventive Contribution; 
1.13 “Major Territory” shall mean any of the following territories: [United States of America, 
Canada, United Kingdom, Germany, France, Italy or Japan]; 
1.14 “Net Sales Receipts” shall mean the amount of any payment (excluding Value Added Tax), 
and the value of any nonmonetary receipt, received by or due to Company or its Affiliate, 
in any transaction or series of linked transactions that involve the sale by the Company 
or its Affiliates of products that incorporate technology that is the subject of any Pipeline 
Patents or Pipeline Trade Secrets that are assigned or licensed to the Company pursuant to 
this Agreement (“Relevant Transaction”), and including any of the following: 
(a)  up-front, milestone (whether at the stage of development, marketing or otherwise), 
success, bonus, maintenance and periodic (including annual) payments, and minimum 
payments, received pursuant to any license or other transactions involving the Pipeline 
Patents or Pipeline Trade Secrets; 
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(b)  any receipt greater than actual incurred cost (“Incurred Costs”) in respect of the funding 
of research or development activities (“R&D Funding”) relating to the Pipeline Patents 
or Pipeline Trade Secrets; provided that Incurred Costs shall not include any costs that 
were incurred prior to the date of the agreement under which the R&D Funding was 
provided; 
(c)  any premium paid by the licensee (or its affiliate) for shares, options or other securities 
in the share capital of Company or its Affiliate over and above the fair market value of 
such shares, options or securities, pursuant to a Relevant Transaction (such fair market 
value to be determined on the assumption that Technology Transfer had not granted, 
nor agreed to grant, any rights to Company in respect of any Pipeline IPR); 
(d)  any loan, guarantee or other financial benefit made or given other than on normal 
market terms by the licensee (or its affiliate) pursuant to a Relevant Transaction; and any 
shares, options or other securities obtained from a third party pursuant to a Relevant 
Transaction; 
1.15  “Net Licensing Receipts” shall mean the amount of any payment (excluding Value Added 
Tax), and the value of any nonmonetary receipt, received by or due to Company or its Affiliate, 
in any transaction or series of linked transactions that involve the grant or assignment 
of any rights (including the grant of any option over such rights) of any Pipeline Patents 
or Pipeline Trade Secrets that are assigned or licensed to the Company pursuant to this 
Agreement (“Relevant Transaction”), and including any of the following: 
(a)  up-front, milestone (whether at the stage of development, marketing or otherwise), 
success, bonus, maintenance, and periodic (including annual) payments, and minimum 
payments, received pursuant to any license or other transactions involving the Pipeline 
Patents or Pipeline Trade Secrets; 
(b)  any receipt greater than actual incurred cost (“Incurred Costs”) in respect of the funding 
of research or development activities (“R&D Funding”) relating to the Pipeline Patents 
or Pipeline Trade Secrets; provided that Incurred Costs shall not include any costs that 
were incurred prior to the date of the agreement under which the R&D Funding was 
provided; 
(c)  where any license or sublicense is to be granted under cross-licensing arrangements, 
the value of any third-party license obtained under such arrangements; 
(d)  any premium paid by the licensee (or its affiliate) for shares, options, or other securities 
in the share capital of Company or its Affiliate over and above the fair market value of 
such shares, options, or securities, pursuant to a Relevant Transaction (such fair market 
value to be determined on the assumption that Technology Transfer had not granted, 
nor agreed to grant, any rights to Company in respect of any Pipeline IPR); 
(e)  any loan, guarantee or other financial benefit made or given other than on normal 
market terms by the licensee (or its affiliate) pursuant to a Relevant Transaction; and 
(f)  any shares, options, or other securities obtained from a third party pursuant to a Relevant 
Transaction; 
1.16 “Nondepartmental University Academic” shall mean a person who is employed by the 
University but is not part of the Research Group; 
1.17  “Option Exercise Period” has the meaning given in Clause 3.1; 
1.18  “Party” shall mean any of the Company, each Founder, and Technology Transfer, and “Parties” 
shall mean all of them; 
1.19 “Patent Rights” shall mean patents and patent applications, petty patents, utility models 
and certificates, improvement patents and models, certificates of addition, and all foreign 
counterparts thereof, including any continuations, continuations in part, extensions, 
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reissues, divisions, and including any patents, patent term extensions, supplementary 
protection certificates, and similar rights; 
1.20 “Pipeline Know-How” shall mean technical information that is generated by the University 
in the course of the Research Work and protected under the law of confidence, and that is 
not Pipeline Patents or Pipeline Trade Secrets but that [relates directly to] Pipeline Patents 
or Pipeline Trade Secrets; 
1.21  “Pipeline IPR” shall mean Pipeline Patents, Pipeline Trade Secrets, Pipeline Know-How, [and 
Pipeline Other Intellectual Property]; 
1.22  [“Pipeline Other Intellectual Property” shall mean all IP rights that are generated in 
the course of the Research Work by the University and are owned by the University or 
Technology Transfer, other than Pipeline Patents, Pipeline Trade Secrets, and Pipeline Know-
how; such IP rights may include, without limitation, copyright, database right, design rights 
(registered and unregistered), property rights in respect of physical materials (including 
biological samples), and similar rights existing in any country of the world;] 
1.23  “Pipeline Patents” shall mean all Patent Rights that are developed in the course of the 
Research Work and are owned by the University or Technology Transfer; 
1.24  “Pipeline Trade Secrets” shall mean inventions and discoveries made in the course of the 
Research Work that the University’s patent attorneys consider to be suitable to be the 
subject of patent applications and that, if such applications were made, would be Pipeline 
Patents, but that the Company elects to keep secret in accordance with the provisions of 
Clause 5; 
1.25  “Research Group” shall mean the Founders and their postdoctoral research assistants 
and postgraduate students when working under any of the Founders’ sole or joint, direct 
supervision in the Department in the Field; 
1.26 “Research Work” shall mean all research carried out in the Field by the Research Group 
during the Contract Period; but shall exclude (unless otherwise agreed under such separate 
agreements) work done under: 
(a)  any separate agreement(s) between (1) the Company and (2) the University and/or 
Technology Transfer (including without limitation research or consultancy agreements); 
or 
(b)  any private consultancy agreement between (1) the Company and (2) any employee of 
the University; 
1.27  “Selected Technology” shall have the meaning given in Clause 3.2;
1.28  “Software and Database Net Receipts” shall mean the amount of any payment (excluding 
Value Added Tax), and the value of any nonmonetary receipt, received by or due to Company 
or its Affiliate, in any transaction or series of linked transactions that involve the grant or 
assignment of any rights (including the grant of any option over such rights) of any of the 
Pipeline Other Intellectual Property that is assigned or licensed to the Company pursuant 
to this Agreement (“Relevant Transaction”), and including any of the following: 
(a)  up-front, milestone (whether at the stage of development, marketing or otherwise), 
success, bonus, maintenance and periodic (including annual) payments, and minimum 
payments, received pursuant to any license or other transactions involving the Pipeline 
Other Intellectual Property; 
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(b)  any receipt greater than actual incurred cost (“Incurred Costs”) in respect of the funding 
of research or development activities (“R&D Funding”) relating to the Pipeline Other 
Intellectual Property; provided that Incurred Costs shall not include any costs that 
were incurred prior to the date of the agreement under which the R&D Funding was 
provided; 
(c)  where any license or sublicense is to be granted under cross-licensing arrangements, 
the value of any third-party license obtained under such arrangements; 
(d)  any premium paid by the licensee (or its affiliate) for shares, options, or other securities 
in the share capital of Company or its Affiliate over and above the fair market value of 
such shares, options or securities, pursuant to a Relevant Transaction (such fair market 
value to be determined on the assumption that Technology Transfer had not granted, 
nor agreed to grant, any rights to Company in respect of any Pipeline IPR); 
(e)  any loan, guarantee, or other financial benefit made or given other than on normal 
market terms by the licensee (or its affiliate) pursuant to a Relevant Transaction; and 
(f)  any shares, options, or other securities obtained from a third party pursuant to a Relevant 
Transaction.
1.29 “Third Party” shall mean any party other than the Parties, the University, and their 
respective employees and agents; 
1.30 “Transferred Technology” has the meaning given in Clause 3.5; 
1.31  “Unencumbered” shall mean, with respect to any Pipeline IPR, that it is not Encumbered; 
and 
1.32  “University” shall mean [ ]; and every reference to a particular Clause or Schedule shall 
be a reference to that Clause or Schedule in or to this Agreement. 
2.	identification	of	Candidate	Technologies	
2.1	 Identified by Founders. Whenever the Founders identify any Candidate Technology, they 
shall promptly notify Technology Transfer and the Company in writing. 
2.2  Quarterly reviews. Without limiting the Founders obligations under Clause 2.1, every three 
months during the Contract Period, the Founders shall provide Technology Transfer and the 
Company with a written description of the current status of the Research Work in sufficient 
detail to enable any resulting inventions, know-how, or other IP rights to be identified. 
Using this written description, the Founders, in consultation with Technology Transfer 
and the Company, will identify any Candidate Technologies and will jointly prepare for the 
Company a report specifying these Candidate Technologies, and identifying whether they 
are Encumbered as described in Clause 2.4. 
2.3  Identified by Company. If the Company (other than pursuant to Clause 2.1 or 2.2) identifies 
a Candidate Technology that it wishes to attempt to protect or commercialize, it shall 
promptly notify the Founders and Technology Transfer in writing, and the Founders shall 
notify all employees or students of the University who made an inventive contribution to 
the Candidate Technology (“Inventors”) of the Company’s interest. 
2.4  Encumbered Technology. When a Candidate Technology is identified pursuant to Clauses 
2.1, 2.2, or 2.3, Technology Transfer shall promptly inform the Company whether or not the 
Candidate Technology is Encumbered. If the Candidate Technology is Encumbered, the 
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Company shall only be entitled to acquire rights in the Candidate Technology under this 
Agreement to the extent not in conflict with such Encumbrances. 
2.5  Other research contracts. For the avoidance of doubt, nothing in this Agreement shall prevent 
Technology Transfer or the University from entering into sponsored research contracts in 
the Field under which the Pipeline IPR arising from such contracts is Encumbered. 
2.6  [Record-keeping. The Founders shall ensure that all members of the Research Group shall 
maintain laboratory notebooks in a suitable form to provide evidence of inventions in 
accordance with patenting practice in the United States.] 
3.	grant	of	option	
3.1  Option Exercise Period. Where a Candidate Technology is first identified to or by the Company, 
the Parties shall for a period of three months beginning on the date of such identification 
(“the Option Exercise Period”) not discuss that Candidate Technology with any Third Parties 
(subject to Clause 5), nor grant any rights therein, unless and until either: (a) Technology 
Transfer notifies the Company that the Candidate Technology is Encumbered; or (b) the 
Company notifies Technology Transfer during the Option Exercise Period that it does not 
wish to exercise the Option. 
3.2  Exercise of Option. The Company shall have the Option, exercisable at any time before 
the termination of the Option Exercise Period, to require Technology Transfer by notice in 
writing to deal with the Candidate Technology in accordance with Clauses 3.4 and 3.5 (“the 
Option”). 
3.3  Expiry of Option. If the Option Exercise Period in respect of a Candidate Technology expires 
without Technology Transfer receiving notification that the Company wishes to exercise 
the Option, the Option in respect of that Candidate Technology shall lapse, and Technology 
Transfer shall be free to dispose of that Candidate Technology as it wishes. 
3.4  Assignment of Pipeline IPR to Technology Transfer. If the Company exercises the Option 
during the Option Exercise Period, the Candidate Technology shall be considered Selected 
Technology and the procedure described in Clauses 3.4.1 to 3.4.2 shall be followed. 
3.4.1  Where the Pipeline IPR in the Selected Technology vests automatically in the University, 
Technology Transfer shall procure that the University shall assign such Pipeline IPR to 
Technology Transfer. 
3.4.2 If the Selected Technology does not vest automatically in the University, the Founders 
and Technology Transfer shall use their reasonable endeavors to obtain an express 
assignment to Technology Transfer of the Selected Technology. 
3.5  License of Pipeline IPR to the Company. Subject to Technology Transfer successfully acquiring 
all Pipeline IPR in the Selected Technology (pursuant to Clauses 3.4.1 and 3.4.2), Technology 
Transfer shall then deal with the Selected Technology in accordance with Clauses 3.5.1 to 
3.5.2. Selected Technology that is licensed to the Company pursuant to Clauses 3.5.1 or 3.5.2 
is referred to in this Agreement as “Transferred Technology.” 
3.5.1 Generated solely within the Department. If the Selected Technology was generated 
solely by members of the Research Group, the Pipeline IPR therein shall be licensed to 
the Company on the terms set out in Schedule 1. 
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3.5.2  Generated jointly with Nondepartmental University Academics. If the Selected Technology 
was generated jointly by members of the Research Group and Nondepartmental 
University Academics, then: 
(a)  Noninventive. If Technology Transfer is advised that the contribution of the 
Nondepartmental University Academic(s) to the Selected Technology was not an 
Inventive Contribution, the Pipeline IPR therein shall be licensed to the Company on the 
terms set out in Schedule 1; but 
(b)  Inventive. If Technology Transfer is advised that the contribution of the Nondepartmental 
University Academic(s) to the Selected Technology was an Inventive Contribution then 
[Technology Transfer shall have no obligation to license such Selected Technology to the 
Company and the provisions of this Agreement shall lapse with respect to such Selected 
Technology][, subject always to the consent of those Nondepartmental University 
Academic(s), Technology Transfer shall negotiate in good faith with the Company during 
the Option Exercise Period for the grant to the Company of a license (at the discretion 
of Technology Transfer) of the Pipeline IPR in such Selected Technology on terms to be 
agreed, taking into account Technology Transfer’s policy of compensating all University 
researchers when Pipeline IPR that they have generated is commercially exploited]. 
3.6  License back. The Company hereby grants to Technology Transfer and the University a 
perpetual nonexclusive royalty-free license to use all Transferred Technology and Project 
IPR therein on the following terms: 
(a)  Technology Transfer and the University shall be entitled to use Pipeline Patents for the 
purposes of teaching and research, including use as enabling technology in research 
and development projects that are funded by Third Parties; and 
(b)  Technology Transfer and the University shall be entitled to use Pipeline Trade Secrets, 
Pipeline Know-How [and Pipeline Other Intellectual Property] in the Field for the 
purposes of teaching and research, including use as enabling technology in research and 
development projects (“Funded Research”) that are funded by Third Parties (“Funding 
Parties”), and Technology Transfer and the University shall have the right to license 
Pipeline Trade Secrets, Pipeline Know-How and Pipeline Other Intellectual Property to 
Funding Parties for use in connection with the development and commercial exploitation 
of the results of Funded Research. Nothing in this Agreement shall restrict the rights 
of Technology Transfer and the University to use, license, or otherwise exploit Pipeline 
Trade Secrets, Pipeline Know-How, and Pipeline Other Intellectual Property outside the 
Field. 
4.	payments	
4.1  Options and Equity. In consideration for the grant of Option rights under this Agreement, 
the Company shall: (a) allot and issue of [relevant shares equivalent to 10% of the Company’s 
equity as on the [Effective Date]] shares in the Company to Technology Transfer; (b) register 
Technology Transfer as the holder of the [relevant ] shares in the Company; and (c) prepare 
and deliver to Technology Transfer share certificates in respect of such shares. 
4.2  Licenses. In consideration for the execution of any licenses that are executed pursuant to 
Clause 3.5, the Company shall: 
(a)  upon executing any such license, pay to Technology Transfer the amount of any patenting 
costs that Technology Transfer incurred, prior to the date of execution, in respect of any 
Pipeline Patents or Pipeline Trade Secrets that are the subject of such license; and 
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(b)  pay to Technology Transfer the amounts and rates described in Schedule 1. 
4.3  Payment terms. All sums due under this Agreement: 
(a)  are exclusive of Value Added Tax that where applicable will be paid by the Company to 
Technology Transfer in addition; 
(b)  shall be paid directly into Technology Transfer’ bank account number [ ], sort code [ ] 
with [ ] Bank, [address] or such other account as Technology Transfer may specify from 
time to time; 
(c)  shall be paid in pounds sterling and, in the case of Net Sales Receipts, Net Licensing 
Receipts [or Software and Database Net Receipts] received by the Company in a currency 
other than pounds sterling, the income shall be calculated in the other currency and 
then converted into equivalent pounds sterling at the rate charged by the Company’s 
U.K. bankers for converting such other currency into sterling in the Company’s bank 
account on the last business day of the quarterly period with respect to which the 
payment is made; 
(d)  shall be made without deduction of corporation tax or other taxes charges or duties 
that may be imposed, except insofar as the Company is required to deduct the same to 
comply with applicable laws. Any and all taxes levied by a proper taxing authority required 
to be withheld by the Company on account of royalties or other payments accruing 
to Technology Transfer under this Agreement may be deducted from such payment 
provided that (a) such amount is paid for and on behalf of Technology Transfer to the 
appropriate tax authorities within the applicable payment period and (b) the Company 
furnishes Technology Transfer with official tax receipts or other appropriate evidence of 
payment issued by the appropriate tax authorities. The Parties shall cooperate and take 
all steps reasonably and lawfully available to them to avoid deducting such taxes and 
to obtain double taxation relief. 
4.4  Exchange controls, etc. If at any time during the continuation of this Agreement the Company 
is prohibited from making any of the payments required hereunder by a governmental 
authority in any country, then the Company will within the prescribed period for making 
the said payments in the appropriate manner use its reasonable endeavors to secure 
from the proper authority in the relevant country permission to make the said payments 
and will make them within 7 days of receiving such permission. If such permission is not 
received within 30 (thirty) days of the Company making a request for such permission 
then, at the Option of Technology Transfer, the Company shall deposit the payments due in 
the currency of the relevant country either into a bank account designated by Technology 
Transfer within such country, or such payments shall be made to an associated company of 
Technology Transfer designated by Technology Transfer and having offices in the relevant 
country designated by Technology Transfer. 
4.5  Statements. The Company shall send to Technology Transfer at the same time as each 
payment is made in accordance with Clause 4.2 a statement, where relevant, showing how 
any amounts paid have been calculated. 
4.6  Records. The Company shall keep at its normal place of business detailed and up-to-date 
records and accounts showing the amount of income received by it in respect of Net Sales 
Receipts, Net Licensing Receipts [and Software and Database Net Receipts], on a country-
by-country basis, and being sufficient to ascertain the payments due under this Agreement. 
The Company shall make such records and accounts available, on reasonable notice, for 
inspection during business hours by an independent chartered accountant nominated by 
Technology Transfer for the purpose of verifying the accuracy of any statement or report 
given by the Company to Technology Transfer under Clause 4.5, such inspection to take 
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place not more than once in any calendar year (other than re-inspection of accounts 
where errors have been found). The accountant shall be required to keep confidential all 
information learned during any such inspection, and to disclose to Technology Transfer only 
such details as may be necessary to report on the accuracy of the Company’s statement or 
report. Technology Transfer shall be responsible for the accountant’s charges unless there 
is an inaccuracy of more than 5% (five percent) in any royalty statement, in which case the 
Company shall pay his or her charges in respect of that particular inspection. The Company 
shall ensure that it has the same rights as those set out in this Clause 4.6 in respect of 
any Affiliate or licensee (including any agent or distributor appointed by the Company, 
its Affiliate or licensee) of the Company that is licensed any Pipeline IPR pursuant to this 
Agreement. 
5.	Confidentiality	and	publications	
5.1  General obligation. Subject to Clauses 5.3 to 5.5, each Party shall maintain in confidence any 
information or materials provided to it directly or indirectly by the other Party under, or in 
contemplation of, this Agreement and shall use the same only for the purpose of exercising 
rights under this Agreement. 
5.2  Exceptions. The obligations set out in Clause 5.1 shall not apply to any information or 
materials that the Party receiving the same (“Receiving Party”) can prove by written 
records: 
(a)  were already the Receiving Party’s property or lawfully in its possession prior to receiving 
it from the other Party; 
(b)  were already in the public domain when they were provided by the other Party; 
(c)  subsequently enter the public domain through no fault of the Receiving Party; 
(d)  are received from a Third Party who has the right to provide them to the Receiving Party 
without imposing obligations of confidentiality; 
(e)  that it has been advised by its information officer that it is required to disclose under 
the Freedom of Information Act 2000; or 
(f)  are required to be disclosed by an order of any court of competent jurisdiction or 
governmental authority PROVIDED that reasonable efforts shall be used by the 
Receiving Party to secure a protective order or equivalent over such information and 
PROVIDED further that the other Party shall be informed as soon as possible and be 
given an opportunity, if time permits, to make appropriate representations to such court 
or authority to attempt to secure that the information is kept confidential. 
5.3  Disclosure of Selected Technology during Option Period. The Founders, the University, and 
Technology Transfer shall use their reasonable endeavors to prevent the publication of any 
information relating to a Selected Technology during the Option Exercise Period for that 
Selected Technology. 
5.4  Postexpiry of Option Period. If the Company has not exercised the Option before the expiry 
of the Option Exercise Period, the University and the Inventors shall be free to publish 
information forming part of the Selected Technology in accordance with normal academic 
practice. 
5.5  Postexercise of Option. If the Company exercises the Option before the expiry of the Option 
Exercise Period then, following the exercise of the Option, the following provisions of this 
Clause 5.5 shall apply: 
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5.5.1  The Company acknowledges that the University is an academic research organization 
supported by charitable funds and that timely publication of research results is essential 
to the University. The University acknowledges that the Company is a commercial 
organization and that patent protection of inventions with commercial value is essential 
to the Company. 
5.5.2 To allow time for review of any proposed disclosure of information that may be 
patentable, the University shall provide to the Company: 
(a)  a copy of any manuscript that discloses any Transferred Technology at least 14 days 
prior to submission of the manuscript for publication; and 
(b)  a copy of any slides to be used in an oral presentation that would disclose any 
Transferred Technology at least 14 days prior to making such oral presentation. 
5.6  The Company shall review all material provided to it under Clause 5.5.2 promptly. If in the 
Company’s opinion the proposed disclosure does not include patentable subject matter, 
the Company shall notify the University and the University shall thereafter be free to make 
the disclosure. If in the Company’s opinion the proposed disclosure does include patentable 
subject matter and the Company anticipates that it may wish a patent application to be 
made, it will so inform the University within the said 14 day period, in which event the 
University shall delay such intended public disclosure for up to [30 days][three months][six 
months] to allow patent application(s) to be made, provided that the Parties shall seek to 
minimize any such delay. 
6.	Diligence 
6.1  The Company shall diligently proceed to develop and commercially exploit Transferred 
Technologies to the maximum extent worldwide, or as otherwise agreed between the 
Company and Technology Transfer. 
6.2  Without prejudice to the generality of the Company’s obligations under Clause 6.1, the 
Company shall provide at least annually, to Technology Transfer, an updated, written 
development plan, showing all past, current and projected activities taken or to be taken by 
the Company to commercialize the products based on Transferred Technologies worldwide. 
Technology Transfer’s receipt or approval of any such plan shall not be taken to waive or 
qualify the Company’s obligations under Clause 6.1. Technology Transfer shall hold all 
development plans submitted under this Clause 6.2 in confidence, and shall disclose the 
same only to its own employees and to employees of University on a need-to-know basis. 
6.3  If Technology Transfer considers at any time during the period of this Agreement that 
the Company has without legitimate reason failed to proceed diligently to develop and 
commercially exploit specific Transferred Technologies (the “Specific Technologies”), 
Technology Transfer shall notify the Company and the Parties shall use their best endeavors 
to resolve the situation amicably. If such a resolution is not reached within three months 
of Technology Transfer first notifying the Company, Technology Transfer shall be entitled to 
refer to an independent expert the following questions: 
(a)  whether the Company has acted diligently in its attempts to develop and commercially 
exploit the Specific Technologies; and if not 
(b)  what specific action the Company should have taken (“Specific Action”) in order to have 
acted diligently. 
6.4  The independent expert shall be appointed in accordance with the provisions of Schedule 
2 and his or her decision shall be final and binding on the Parties. 
(Continued	on	next	page)
ANDERSON & KEEVEY-KOTHARI
1100 | HANDBOOK OF BEST PRACTICES
Box	3	(continued)
6.5  If the expert determines that the Company has failed to comply with its obligations under 
this Clause 6, and if the Company fails to take the Specific Action within six months of the 
expert giving his or her decision in accordance with Schedule 2, the Company shall lose all 
rights in and to all such Specific Technologies. 
7.	patents	
7.1  [Following the identification of Candidate Technology in accordance with Clauses 2.1 to 2.3, 
Technology Transfer shall be responsible for making any initial patent applications, at its 
cost and discretion, in respect of such Candidate Technology.] 
7.2  Upon the Company exercising an Option under Clause 3.2 with respect to any Pipeline 
Patents or Pipeline Trade Secrets in respect of item of Candidate Technology, responsibility 
for (including paying the costs of) pursuing any Pipeline Patents shall be the responsibility 
of Technology Transfer. [Subject to any terms to the contrary agreed in any license granted 
to the Company following the exercise of the Options contained in Clause 3, Technology 
Transfer shall have the right, at its discretion, to discontinue patent prosecution or 
maintenance of any invention licensed to the Company.] It shall be the responsibility of 
[Technology Transfer][the Company], in consultation with [the Company][Technology 
Transfer], to prepare, file, and prosecute (at the Company’s sole expense) such patent 
applications. [The Company shall consult with Technology Transfer and keep Technology 
Transfer informed of all developments with respect to such patent applications, and on 
request shall promptly supply Technology Transfer with copies of any documents relating 
to the prosecution thereof.] 
7.3  If any of the Results are capable of being the subject of a patent application, Technology 
Transfer may file a patent application at its own discretion and expense or shall do so at the 
request and expense of the Company. 
7.4  Where Technology Transfer files or has filed a patent application at the request and expense 
of the Company, the Company shall give Technology Transfer at least three months’ written 
notice of the Company’s intention to cease payment of any costs and expenses incurred in 
connection with such filing. On receipt of the Company’s notice, Technology Transfer may 
either abandon that patent application or continue to prosecute that patent application 
but at Technology Transfer expense. 
8.	Term	and	Termination	
8.1  Term. This Agreement shall become effective upon the Effective Date and shall continue in 
force for the full duration of the Contract Period unless terminated earlier in accordance 
with the provisions of this Clause 8. 
8.2  Founders leaving. In the event that any one of the Founders ceases to be employed by the 
University, this Agreement shall continue in force but the definition of “the Founders” shall 
be automatically amended by removal of that Founder’s name. 
8.3  Founders joining. Any member of the academic or permanent research staff of the 
University who is active in the Field may become a Party to this Agreement such that this 
Agreement shall continue in force with the definition of “the Founders” amended to include 
such person, subject to the written agreement of that person, the Founders, the Company, 
(Continued	on	next	page)
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[,the University], and Technology Transfer. 
8.4 All Founders leaving. In the event that all the Founders cease to be employed at the 
University, this Agreement shall automatically terminate. 
8.5  Breach or insolvency. Without prejudice to any other right or remedy it may have, either 
Technology Transfer or the Company may terminate this Agreement at any time by notice 
in writing to the other of those two Parties (“Other Party”), such notice to take effect as 
specified in the notice: 
(a) if the Other Party is in breach of this Agreement and, in the case of a breach capable of 
remedy within 30 days, the breach is not remedied within 30 days of the Other Party 
receiving notice specifying the breach and requiring its remedy; or 
(b)  if the Other Party becomes insolvent, or if an order is made or a resolution is passed for 
the winding up of the Other Party (other than voluntarily for the purpose of solvent 
amalgamation or reconstruction), or if an administrator, administrative receiver or 
receiver is appointed in respect of the whole or any part of the Other Party’s assets 
or business, or if the Other Party makes any composition with its creditors or takes or 
suffers any similar or analogous action in consequence of debt. 
8.6  Consequences of termination. Termination of this Agreement by any Party for any reason 
shall not affect the rights and obligations of the Parties accrued prior to the effective date 
of termination of this Agreement. Upon any termination, all Options that have not been 
exercised prior to termination shall automatically lapse. No termination of this Agreement, 
however effected, shall affect the Parties’ rights and obligations under Clauses 3 to 7 with 
respect to Selected Technology in respect of which the Company has exercised an Option 
prior to termination. 
9.	general	
9.1  Nothing in this Agreement and no action taken by the Parties pursuant to this Agreement 
shall constitute or be deemed to constitute a partnership association, joint venture, or other 
cooperative entity between the Parties, and none of the Parties shall have any authority to 
bind the others in any way except as provided in this Agreement. 
9.2  It is acknowledged and agreed that this Agreement relates to results of experimental 
research the properties and safety of which may not have been established, and that, 
accordingly: 
(a)  any results, materials, information, Candidate Technology, Selected Technology, 
Transferred Technology, and Pipeline IPR provided under this Agreement (“Delivered 
Items”) are provided “as is” and without any express or implied warranties, 
representations or undertakings other than those set out in this agreement; and 
(b)  the Company shall indemnify and hold harmless the University and Technology 
Transfer, their Affiliates, and their respective officers, employees, consultants, agents, 
and representatives (“the Indemnitees”) against all Third-Party Claims that may be 
asserted against or suffered by any of the Indemnitees and that relate to the use of any 
Delivered Items, or the manufacture, distribution, sale, supply or use of any products 
or services that incorporate any Delivered Items, by or on behalf of the Company or its 
licensee or subsequently by any Third Party, including without limitation claims based 
on product liability laws. 
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9.3  None of the Parties shall without the prior written agreement of the other Parties assign or 
otherwise transfer the benefit and/or burden of this Agreement. 
9.4  Any agreement to change the terms of this Agreement in any way shall be valid only if the 
change is made in writing and approved by mutual agreement of authorized representatives 
of the Parties. 
9.5  Any notice or other communication to be given pursuant to or made under or in connection 
with the matters contemplated by this Agreement shall be in writing in the English language 
and shall be delivered by courier or sent by post using the addresses of the Parties set out 
above. 
9.6 This Agreement shall be governed by English Law and shall be subject to the exclusive 
jurisdiction of the English courts. 
IN WITNESS of which this Agreement has been executed as a Deed and delivered the date and 
year first above written. 
EXECUTED AS A DEED by [ABC] LIMITED acting by: 
 
Director      Director/Secretary     
EXECUTED AS A DEED by [UNIVERSITY TECHNOLOGY TRANSFER] LIMITED acting by: 
Director      Director/Secretary     
SIGNED AS A DEED by PROFESSOR [ ] 
      
in the presence of: 
      
Witness’s signature 
      
Name 
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Upon exercise of an Option in respect of a Pipeline Patent then, subject to the provisions of this 
Agreement, Technology Transfer hereby grants to the Company an Exclusive Commercial License 
under that Pipeline Patent in the Field. 
Upon the first receipt by the Company of Net Sales Receipts in respect of a Transferred Patent, 
the Company shall pay to Technology Transfer a royalty on Net Sales Receipts. Such royalty will 
be agreed between the Company and Technology Transfer at the time of receipt of such first Net 
Sales Receipts on normal arm’s-length commercial terms [and is anticipated to be between 4% 
to 8%].
Upon first receipt by the Company of Net Licensing Receipts from a license in respect of a 
Pipeline Patent pursuant to Clause 3.5 (the licensed Pipeline Patent being referred to below as a 
“Transferred Patent”), the Company shall pay to Technology Transfer a royalty on Net Licensing 
Receipts. Such royalty will be agreed at the time on normal arm’s-length commercial terms. 
2.	pipeline	Trade	Secrets	
Upon exercise of an Option in respect of a Pipeline Trade Secret then, subject to the provisions 
of this Agreement, Technology Transfer hereby grants to the Company an Exclusive Commercial 
License under that Pipeline Trade Secret in the Field. 
The Parties acknowledge that Pipeline Trade Secrets arise where the Company elects not to 
pursue a Pipeline Patent in respect of a Transferred Technology and instead elects to maintain 
the invention as a Pipeline Trade Secret. Accordingly, upon exercise of an Option in respect of a 
Pipeline Trade Secret, the Company shall pay to Technology Transfer the relevant amount that 
would have been due, under Section 1 of this Schedule, if a Pipeline Patent had been pursued. 
3.	pipeline	Know-how	
Upon exercise of an Option in respect of Pipeline Know-How then, subject to the provisions of 
this Agreement, Technology Transfer hereby grants to the Company an Exclusive Commercial 
License under that Pipeline Know-How in the Field. 
4.	pipeline	other	intellectual	property	
Upon exercise of an Option in respect of an item of Pipeline Other Intellectual Property then, 
subject to the provisions of this Agreement: 
(a)  Technology Transfer hereby grants to the Company an Exclusive Commercial License under 
ANDERSON & KEEVEY-KOTHARI
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the Pipeline Other Intellectual Property in the Field; and 
(b)  The Company shall pay to Technology Transfer, with respect to each such item of Pipeline 
Other Intellectual Property, either (and at the Company’s election made and notified to 
Technology Transfer on receipt of the first Software and Database Net Receipts): 
(i)  A one-time fee of [currency]X on receipt of first Software & Database Net Receipts with 
respect to that Pipeline Other Intellectual Property; or 
(ii)  A royalty of X% on all Software & Database Net Receipts received by the Company with 
respect to that Pipeline Other Intellectual Property. 
Schedule	2	
expert’s	Decision
1.  Any matter or dispute to be determined by an expert under this Agreement shall be referred 
to a person suitably qualified to determine that matter or dispute who shall be nominated 
jointly by the relevant Parties. Failing agreement between the Parties within 30 days of a 
written request by one Party to another seeking to initiate the expert’s decision procedure, 
either of the relevant Parties may request the president for the time being of the relevant 
Professional Institution to nominate the expert. 
2.  In all cases the terms of appointment of the expert by whomsoever appointed shall 
include: 
2.1  a commitment by the Parties to share equally the expert’s fee; 
2.2  a requirement on the expert to act fairly as between the Parties and according to the 
principles of natural justice; 
2.3  a requirement on the expert to hold professional indemnity insurance both then and for 
three years following the date of his or her determination; and 
2.4  a commitment by the Parties to supply to the expert all such assistance, documents, and 
information as he or she may require for the purpose of his or her determination. 
3.  The expert’s decision shall be final and binding on the Parties (save in the case of negligence 
or manifest error). 
4.  The Parties expressly acknowledge and agree that they do not intend the reference to 
the expert to constitute an arbitration within the scope of any arbitration legislation. The 
Expert’s Decision is not a quasi-judicial procedure, and the Parties shall have no right of 
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appeal against the Expert’s Decision provided always that this shall not be construed as 
waiving any rights the Parties might have against the expert for breaching his or her terms 
of appointment or otherwise being negligent. 
 Note: the following examples of rights of first refusal (“ROFRs”) have been included to illustrate the 
variety of ROFRs that are encountered. In general, universities should be cautious about giving any 
ROFR, and legal advice should generally be sought on the wording of the ROFR. 
example	1:	Simple,	pro-university	option	Clause.	
(a)  Subject to the provisions of this Clause [ ], the University grants to the Company an 
exclusive Option (the “Option”) to acquire an exclusive, worldwide license (with the right 
to sublicense) under the Arising Intellectual Property to develop, manufacture, have 
manufactured, market, use, and sell products in [the Field] (the “License Rights”). 
(b)  The Option shall be exercisable [at any time during the agreed period of the Research] [and] 
[up to three months following the University’s submission of the final Report]. The Option 
shall be exercised by the Company giving notice in writing to the University (“Notice of 
Exercise of Option”). 
(c)  On receipt of the Company’s Notice of Exercise of Option, the Parties shall negotiate in 
good faith, for a period of up to 90 days from the date of such receipt, the terms of a 
license agreement between them under which the Company would be granted the License 
Rights. [Any such license agreement would include, without limitation, terms based on the 
provisions of the attached Schedule [x]]. Upon agreement of the terms of such license, the 
Parties shall forthwith execute a license agreement between them on such terms. 
(d) [If the Parties fail to agree the terms of a license agreement within 90 days of the University’s 
receipt of the Company’s Notice of Exercise of Option, the Option will lapse.] 
example	2:	RofR	to	be	tacked	on	to	option	(fairly	brief).	
If LICENSEE and TTCO or UNIVERSITY, as the case may be, are unable to agree on the terms of a 
license agreement within 90 days of TTCO’s or UNIVERSITY’s (as applicable) receipt of LICENSEE’s 
Notice of Exercise of Option, despite negotiating in good faith, the Option will lapse; provided, 
that TTCO or UNIVERSITY, as the case may be, may not thereafter, without first offering such 
terms and conditions to LICENSEE, enter into an agreement with a THIRD PARTY on terms and 
conditions equal to or more favorable to such THIRD PARTY than the terms and conditions 
negotiated between TTCO or UNIVERSITY, as the case may be, and LICENSEE. 
example	3:	Strong	option	and	RofR	to	expand	field;	milder	option	to	expand	territory.	
1.1 Expansion of Field 
1.1.1  With respect to each Compound, Owner hereby grants to Licensee a first right to 
expand the then current Field for such Compound and all Licensed Products based 
on such Compound to include additional disease indications in humans and disease 
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Owner determines to pursue development and commercialization (whether directly 
or through an Affiliate or Sublicensee) of a Compound in the Territory in one or more 
additional disease indications in humans or in one or more disease indications in 
animals outside the then current Field. 
1.1.2 Within a reasonable period after such determination by Owner, Owner shall provide 
written notice to Licensee of proposed terms for such expansion of the Field in the 
Territory and disclose to Licensee all information that is within Owner’s control and 
reasonably related to such expansion of the Field. Within sixty (60) days of such written 
notice from Owner, Licensee shall provide written notice to Owner as to whether it is 
interested in such expansion of the Field. If Licensee is not interested in such expansion 
of the Field or if Licensee does not provide written notice within such sixty (60) day 
period, Owner shall be free to develop and commercialize (whether directly or through 
an Affiliate or Sublicensee) the Compound and all Licensed Products based on such 
Compound in such additional disease indications in the Territory. 
1.1.3 If Licensee provides written notice indicating its interest in such expansion of the Field 
within such sixty (60) day period, the Parties shall negotiate in good faith to reach 
agreement within one hundred twenty (120) days of the written notice from Licensee. 
1.1.4 If the Parties are unable to reach agreement within such one hundred twenty (120) 
day period (or any mutually agreed upon extension), then Owner shall be free to (i) 
submit the matter to arbitration for resolution pursuant to Section 14.8 or (ii) enter 
into an agreement with a third party during the subsequent twelve (12) month period 
(but not to develop or commercialize directly or through an Affiliate) to license rights 
to practice the Owner Patent Rights and use the Owner Know-How for such purpose 
in the Territory; provided, however, that Licensee is first given the right to enter into 
any proposed agreement reached by Owner with a third party on substantially the 
same financial terms and conditions as such proposed agreement reached by Owner 
(it being understood that Licensee shall have the right to substitute cash or Licensee 
equity for equity of the third party). 
1.2  Expansion of Territory. With respect to each Compound, in the event that Owner 
is approached by a potential Sublicensee that desires to pursue development and 
commercialization of such Compound or Owner determines to pursue development and 
commercialization of such Compound through a Sublicensee, in each case, in one or more 
countries outside the then-current Territory for such Compound, Owner shall promptly 
inform Licensee. As available, Owner will advise Licensee of the structure of the proposed 
license (for example, the field and countries that are the subject of the potential license) 
and Licensee will thereupon have the nonexclusive right to negotiate for such a license 
from Owner.
Example	4:	RofR	(very	brief).	
ABC agrees with XYZ that it will not sell or otherwise transfer all or any material part of its 
[•] business to any third party without first giving the XYZ the opportunity to purchase such 
business on terms identical to those offered to such third party. 
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example	5:	RofR	to	purchase	shares.	
Unless Seller otherwise agrees, Purchaser may not sell, assign, encumber, pledge, convey, grant, 
or otherwise transfer any of the Shares, or any interest therein (collectively and individually 
“Transfer”), except to an unaffiliated third-party bona fide purchaser of value, in which case Seller 
shall have a “Right of First Refusal” for any Shares, or any interest in any Shares, that Purchaser 
desires to Transfer to the third party. In the event Purchaser desires to Transfer some or all of the 
Shares, Purchaser shall provide a written notice (“Transfer Notice”) to Seller describing fully the 
proposed Transfer, including the number of Shares proposed to be Transferred, the proposed price 
for the Transfer, the proposed method of payment for the Shares, the name and address of the 
proposed transferee, and proof satisfactory to Seller that the proposed Transfer will not violate 
any applicable federal or state securities laws. The Transfer Notice shall be signed by both the 
Purchaser and proposed transferee and must constitute a binding commitment of both parties 
to the Transfer of the Shares. Seller shall have the right to purchase some or all of the Shares 
on the terms of the proposal described in the Transfer Notice (subject, however, to any change 
in such terms permitted under Subsection 2(b) below) by delivery of a notice of exercise of the 
Right of First Refusal within thirty (30) calendar days after the date Seller received the Transfer 
Notice. The Right of First Refusal shall be freely assignable, in whole or in part, by Seller at its sole 
discretion. 
example	6:	RofR	to	acquire	royalty	stream.
Transfer of other interests: If the Educational Institution, at any time on or after the Start Date 
[until April [ ], 2012], wishes to Transfer any other rights to any royalty stream it may own derived 
from intellectual property (the “Remaining Royalty Interests”), then the Educational Institution 
will give notice to SPONSOR of (i) its wish to Transfer such royalty stream, and (ii) the proposed 
consideration, payable by a named bona fide third party, for such royalty stream, and SPONSOR 
shall have ninety (90) days to offer to purchase such royalty stream. In the event SPONSOR does 
not offer to purchase such royalty stream, for equal or higher consideration than the said bona 
fide third-party offer, within ninety (90) days of such notice, the Educational Institution shall be 
free to sell such royalty stream to a third party for a consideration equal to or higher than that 
specified in the aforesaid notice. 
Box	4	(continued)
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Field-of-use licensing provides the licensor with greater 
control over the use of its intellectual property, while 
maximizing the use and value of the technology. In order 
to maximize the use of a given technology, managers will 
have some additional work to do as they identify, negoti-
ate with, and manage more than one licensee. Special 
issues related to multiple licensees in distinct or overlap-
ping fields will have to be handled with forethought and 
a balancing of interests. When is field-of-use licensing 
worth the extra effort? When more than one company 
is needed to fully develop a technology’s potential, when 
different licensees are needed to address different mar-
kets, or when field-of-use licensing has the potential to 
significantly increase the financial return from a technol-
ogy. In all of these situations, field-of-use licensing can 
produce better results for everyone involved.
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One company may not be able to develop all the 
possible uses of a technology because of its busi-
ness focus or limited resources. Having multiple 
licensees with different fields of use may help to 
ensure that many uses of a technology are devel-
oped, may speed different types of products to 
market, and may increase the return to the licen-
sor. Guidelines issued by agencies that fund inven-
tions can sometimes be honored, in part, through 
field-of-use licensing.1 It also can be used to focus 
company attention on humanitarian markets and 
ensure commercialization of products to serve the 
different needs of those markets (though this may 
be handled through territory limitations, rather 
than field of use). For any of these reasons, field-
of-use licensing can be valuable. On the other 
hand, a restriction on field of use imposed by a 
potential licensor can reduce the motivation of 
a potential licensee, so a balance must be struck 
between the needs and motivations of each party 
to the license.
Even if a licensor sees only one possible field 
of use for an invention, it makes sense to limit 
an exclusive licensee to that field. Technology 
changes so rapidly that a new use for the inven-
tion would have a very good chance of developing 
during the life of the patent. A licensor should 
CHAPTER 11.8
1.	 InTRoduCTIon
Innovative organizations can license a technology 
exclusively or nonexclusively without any limita-
tions on its commercial use. The licensee can use 
the technology to make soup, pharmaceuticals, or 
integrated circuits. Use is limited only by the ob-
ligations set out in the license agreement (and the 
current and future applications of the technology).
Often, however, value can be obtained from 
limiting the uses available to any single licensee. 
Shotwell SL. 2007. Field-of-Use Licensing. In Intellectual Property Management in Health and Agricultural Innovation: A 
Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Avail-
able online at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us 
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM 
Technology Transfer Practice Manual (Part IX: Chapter 4).
© 2007. SL Shotwell. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
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keep open the option of working with the best 
possible licensee for a new use, should one arise.
2.	 TeChnologIeS	ThAT	ARe	AppRopRIATe	
foR	fIeld-of-uSe	lICenSIng
A field-of-use license grants rights to the licensee 
to practice, not all uses of the licensed technol-
ogy, but only a subset of those uses. The scope of 
the license could be limited by a general field of 
use (for example, digital recording or therapeu-
tics) or a very specific field of use (for example, 
products for the treatment of human non-Hodg-
kin’s lymphoma). In any case, the licensee’s right 
to use the technology is limited in scope, leaving 
the licensor free to work with other companies 
on other uses.
Many types of technologies are appropriate 
for field-of-use licensing. In general, any technol-
ogy that has, or may come to have, multiple, dis-
tinct uses may warrant this approach. Examples 
are easily found in the electrical engineering, 
computer, chemical, and health care areas. In the 
biochemistry department of a university, for in-
stance, a new gene may be isolated and sequenced 
and its protein product expressed. This sounds 
like one technology, but it could easily lead to at 
least nine separate commercial uses:
1. Selling the protein product to the research 
reagent market
2. Making and selling antibodies directed 
against the protein to the research reagent 
market
3. Making and selling antibody-based diag-
nostic products
4. Making and selling DNA-based diagnostic 
products
5. Performing DNA-based diagnostic tests as 
a service
6. Making and selling the protein as a thera-
peutic product (this may be further focused 
by disease if the gene is involved in mul-
tiple disease states)
7. Using the gene and protein in-house for 
screening pharmaceutical drug candidates
8. Using the gene in gene therapy
9. Using the gene to develop a therapeutic 
based on antisense approaches
A company that sells to the research reagent 
market may not be in a position to make and 
sell therapeutic drugs (too much investment re-
quired). A company that develops therapeutics 
may not be interested in performing DNA-based 
diagnostic tests as a service (not enough return). 
A company that provides the DNA-based diag-
nostic service may not be capable of putting the 
protein on the research reagent market (no mar-
keting and sales staff). Yet, each of these products 
is useful, further develops the technology, and is a 
potential source of revenue for the licensor.
What approaches can a licensor take when 
presented with a technology that has many dis-
tinct uses? There are at least three options:
1. License it to one company with no limita-
tions, sit back, and hope that as the com-
pany maximizes its value from the license, 
all the markets will be served, and the licen-
sor’s returns also will be maximized 
2. License it to one company with the require-
ment that it develop all uses, either directly 
or through sublicensing, and work closely 
with that company to ensure that it meets 
its obligations
3. License it to multiple companies with field-
of-use licenses
This chapter is about the third option, a do-
it-yourself approach, which entails more work, 
provides more control, and has a higher probabil-
ity of maximizing the return for the licensor.
3.	 STRuCTuRIng	The	lICenSe	
AgReemenT	To	lImIT	The	fIeld	of	uSe
Some technologies clearly have multiple uses 
from the outset. For other technologies the po-
tential uses may not be so obvious, but it is worth 
planning for the possibility. In either case, a licen-
sor has several approaches available for drafting 
agreements for distinct fields of use.
First, however, some homework must be 
done: one must ascertain the possible fields of 
use. For example, the potential licensor could ask: 
Is the latest product from the organic chemistry 
department useful as a fertilizer? A food additive? 
A perfume ingredient? A pharmaceutical? If it is 
CHAPTER 11.8
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useful as a food additive, can it be used in liquid 
products? Dried soups? Animal feed? If it is use-
ful in animal feed, will it be useful in pet food? 
Livestock feed? Included as part of the normal 
market-evaluation process that most technology 
transfer professionals undertake, this exercise will 
yield essential information for developing the 
best field-of-use approach to take.
Once the possible fields of use are clearly de-
fined, the next step is to market the technology 
to companies serving one or more of the markets 
those fields represent. Given a willing licensee 
and agreement on the scope of the license, several 
approaches can be evaluated for limiting the field 
of use in the actual license agreement.
3.1	 The	grant	clause
The field of use can be limited in the grant clause 
by adding a phrase that delineates the field. The 
examples in this and the following two sections 
use various modifications to grant clauses from 
publicly available agreements to limit the field of 
use granted. (The original clauses and full agree-
ments can be found on the example licensor’s Web 
pages. Addresses can be found in endnotes.)
a. PHS hereby grants and Licensee accepts, 
subject to the terms and conditions of this 
Agreement, an exclusive license under the 
Licensed Patent Rights in the Licensed 
Territory to make and have made, to use 
and have used, to sell and have sold, to 
offer to sell, and to import any Licensed 
Products in the field of use of veterinary 
medicine and to practice and have prac-
ticed any Licensed Processes in the field of 
use of veterinary medicine.2 
 
The approach in example a works well if the 
term being used to describe the field of use has a 
commonly accepted meaning. If it does not, or if 
clarification is needed, an additional (for exam-
ple, exclusionary) sentence can be added to the 
grant, as in the following example:
b.  Subject to the terms and conditions of 
this Agreement, Stanford grants Licensee 
a license under Licensed Patent to pro-
vide DNA-based diagnostic services in the 
Licensed Territory for providing DNA-
based diagnostic services. This license spe-
cifically excludes the right to sell Licensed 
Product(s).3
In example b, there might be some ambigu-
ity about whether the field of use of “providing 
DNA-based diagnostic services” includes selling 
DNA-based diagnostic products that enable oth-
ers to carry out a diagnostic test. The additional 
sentence clarifies the limitation on the licens-
ee: the licensee cannot sell Licensed Products. 
Providing diagnostic services must therefore be 
limited to an activity in which the licensee itself 
uses the Licensed Products.
In these two examples, the underlined lan-
guage in the grant clause limits what otherwise 
would have been an unlimited license for any 
and all uses of the technology. Note that the lan-
guage can define what is included in the field, as 
well as what is excluded. This approach to limit-
ing the field of use in the grant can be taken with 
no other field-of-use-specific language in the li-
cense agreement, or in conjunction with related 
language in the Definitions section, as described 
below.
3.2	 Defining	the	field
Perhaps the most common approach to limiting 
the field of use in the license agreement is to es-
tablish Field or Licensed Field of Use as a defined 
term in the agreement. It then can be used to 
limit the field in the grant clause. This approach 
has the advantage of simplifying the grant clause, 
while allowing a full definition of the field else-
where. This is especially advantageous in a grant 
clause that is already lengthy or segmented, or for 
a field that cannot be expressed adequately in a 
few words. Examples of possible paired definition 
and grant clauses follow:
a.  Field of Use. shall mean the field of research 
reagent products. LICENSED FIELD OF 
USE specifically excludes the field of hu-
man diagnostic products.
OHSU hereby grants and Licensee ac-
cepts, subject to the terms and conditions 
of this Agreement, a nonexclusive license 
under the Licensed Patent Rights in the 
Licensed Territory to make and have made, 
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to use and have used, and to sell and have 
sold any Licensed Products and/or Licensed 
Processes in the Licensed Field of Use.4
b. FIELD shall mean the field of human vac-
cines and human therapeutics for Acquired 
Immune Deficiency Syndrome.
Dartmouth hereby grants to Company 
and its Subsidiaries an exclusive, royalty-bear-
ing license under Dartmouth Know-How 
and Dartmouth Patent Rights to make, have 
made, use, and/or sell Licensed Products in 
the Field in the Territory. Notwithstanding 
the foregoing, Dartmouth expressly reserves 
a nontransferable royalty-free right to use the 
Dartmouth Patent Rights and Dartmouth 
Know-How in the Field itself, including use 
by its faculty, staff and researchers, for educa-
tional and research purposes only. Company 
agrees during the period of exclusivity of this 
license in the United States that any Licensed 
Product produced for sale in the United 
States will be manufactured substantially in 
the United States.5  
An alternative construction would include 
a phrase in the Grant to limit the license, and 
then define that phrase in the Definitions. As 
an example:
c.  Human Cancer Therapeutics shall mean 
the treatment of human patients exhib-
iting malignant tumors, including but 
not limited to carcinomas, sarcomas and 
lymphomas.
Subject to the terms and conditions of 
this Agreement, Stanford grants Licensee a 
license under Licensed Patent in the field of 
Human Cancer Therapeutics. 
Example c has the advantage of being cus-
tom tailored, while examples a and b have the 
advantage of being model documents that can be 
revised more simply for a new technology. The 
only change needed to the model document dur-
ing drafting is in the Definitions; the Grant is 
designed to be used without modification and to 




A third general approach to limiting the field 
of use of a license involves limiting the grant of 
rights to specific patent claims, or to a specific 
family of related patent applications. A well-writ-
ten patent application will cover broad areas re-
lated to the technology. If the claims, however, 
fall into distinct groups, one could reference the 
claims necessary for the intended field of use or 
specifically exclude claims that cover uses not in-
tended for inclusion in the license. Here are some 
examples of grant language that could be used in 
this type of approach:
a. Where an issued patent exists and is all that 
is referenced in the Definitions section un-
der patent rights, the approach is straight-
forward. Determine the issued claims that 
are required for the field of use and refer-
ence them by number in the Grant. For 
example:
PHS hereby grants and Licensee ac-
cepts, subject to the terms and conditions of 
this Agreement, an exclusive license under 
claims 1 through 7 in the Licensed Patent 
Rights in the Licensed Territory to make 
and have made, to use and have used, to sell 
and have sold, to offer to sell, and to import 
any Licensed Products and to practice and 
have practiced any Licensed Processes. 
b. Another reasonably straightforward situa-
tion is where a distinct invention associated 
with the field of use is contained within 
one patent application within a family of 
related applications that otherwise covers 
broader uses of the technology outside of 
the intended field of use. In this situation, 
the patent application can be the basis of 
the definition of licensed patents, but care 
must be taken not to intermingle different 
uses of the technology between patent ap-
plications during prosecution. The grant 
language would be unchanged, and the 
definition of the patent rights to be licensed 
would be limited to the appropriate patent 
application, as in the following example:
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Licensed Patent Rights shall mean:
1) U.S. patent application (serial num-
ber) filed (filing date), the inventions 
claimed therein, and to the extent 
that the following contain one or 
more claims directed to the inven-
tions claimed in U.S. patent applica-
tion (serial number), all divisions and 
continuations of this application, all 
patents issuing from such application, 
divisions, and continuations, and any 
reissues, reexaminations, and exten-
sions of all such patents;
2) to the extent that the following con-
tain one or more claims directed to 
the invention or inventions claimed 
in U.S. patent application (serial 
number): i) continuations-in-part of 
a) above; ii) all divisions and con-
tinuations of these continuations-in-
part; iii) all patents issuing from such 
continuations-in-part, divisions, and 
continuations; and iv) any reissues, 
reexaminations, and extensions of all 
such patents;
3) to the extent that the following 
contain one or more claims direct-
ed to the invention or inventions 
claimed in U.S. patent application 
(serial number): all counterpart for-
eign applications and patents to a 
and b above.
 Licensed Patent Rights shall not include a, 
b, or c above to the extent that they contain 
one or more claims directed to new matter 
which is not the subject matter of a claim in 
U.S. patent application (serial number).
Note that this patent rights definition allows 
for the usual possibilities during prosecution (di-
visions, continuations, foreign counterparts); but 
where a normal descendant, a continuation-in-
part, may bring in new matter, the definition 
limits that case’s inclusion to claims related to 
the subject matter of the original patent applica-
tion. This provides some assurance that uses of 
the invention beyond the intended field of use 
will not be wrapped into the license during the 
process of attempting to get a patent to issue.
It should be noted that there are some draw-
backs associated with limiting the field of use 
solely by reference to a patent application still in 
prosecution. It is much cleaner to refer to an al-
ready issued claim (see section 3.3, paragraph a, 
above). The claims of a case still in prosecution 
can change through modification, deletion, or ad-
dition; in theory, they could change in ways that 
are not consistent with the intended field of use. 
Thus, when working with a patent application, as 
opposed to an issued patent, the approach out-
lined in this section can be combined with lan-
guage that specifically states the field of use (see 
3.2.a and 3.2.b, above). This “belt and suspend-
ers approach” ensures that the field of use will be 
clearly defined, while separating out the claims 
to that field in a separate patent application. The 
additional value of having one licensee’s claims in 
a separate patent property will become apparent 
in the following sections on “Reimbursing patent 




Several problems may be encountered if, instead 
of granting all rights associated with a technol-
ogy to a particular company, a licensor divides 
those rights by field among several companies. 
These problems, which are described in the fol-
lowing three sections, arise whether or not the 
field-of-use licenses are exclusive; in fact, some 
of the problems are the same as those that occur 
when licensing nonexclusively without limita-
tion as to field of use. The good news is that, 
with some planning, a licensor can minimize 
these problems.
4.1	 Overlap	of	rights	between	licenses
In the field-of-use licensing, the licensor works 
to clearly define the possible fields of use for a 
technology. While attempts can be made to dis-
tinguish fields as much as possible with currently 
available information, only hindsight can be 
crystal clear. The licensor and licensees should be 
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aware that overlap in fields might occur in the 
future. An overlap could be due to different inter-
pretations of the rights granted under licenses or 
to unexpected future technical developments.
Such overlap could have significant economic 
impact on a licensee. For example, it could render 
nonexclusive a market segment that the licensee 
expected to hold exclusively, which could re-
duce a licensee’s income stream in its field of use. 
While the economic interests under dispute affect 
the licensees, it is through the contract with the 
licensor that the situation can be resolved most 
effectively.
It is wise to lay the groundwork early on for 
resolving potential disputes related to this specific 
issue. A provision in each license that allows the 
licensor to resolve disputes may be acceptable. 
Alternatively, there could be a commitment to 
mediation, arbitration, alternative dispute reso-
lution, or some other means short of litigation.
Of course, the best course involves ongoing, 
constructive dialogue between the licensee and 
licensors, so that when problems arise, good com-
munication and strong relationships needed to 
encourage negotiated solutions will already exist. 
If all parties enter the relationship with awareness 
of the potential need for dispute resolution, and 
if they agree, before problems arise, on a balanced 
way to deal with a dispute, then such problems 
will be easier to manage if and when they arise.
A variation on this theme is the issue of 
cross-prescription or cross-marketing—when the 
licensee sells products for use under its field, but 
the products are usable by the purchaser outside 
that field, in a field licensed to another company. 
Again, advance planning can help head off seri-
ous problems. For example, in the area of thera-
peutics, it would be worthwhile to group together 
fields that will use the technology in the same de-
livery form, and then grant a license to one com-
pany for these fields. If a therapeutic can be used 
intravenously, at similar concentrations, to treat 
both cancer and heart disease, it may be wise to 
license both uses to one company. There are mul-
tiple benefits to all parties in such instances. One 
party can handle research, development, regulato-
ry approval, and sales more efficiently. Cross-pre-
scription will not be a problem because proceeds 
flow to the same licensee. In addition, the licensee 
can choose independently to work with another 
company through sublicensing to develop one or 
more of the uses, staying in closer control while 
accessing needed resources. Grouping related uses 
together in a larger field provides the licensee with 
a larger incentive to invest in the technology and 
reduces problems for the licensor.
4.2	 Maintaining	control	of	patent	prosecution
The interests of licensee and licensor do not al-
ways overlap during prosecution. This truism 
is amplified when a licensee has a limited field 
of use. The licensee may not be willing to sup-
port prosecution of certain claims or may seek to 
modify claim language to enhance the patent’s 
value to the licensee at the expense of other li-
censees or the licensor. For this and other reasons, 
it is recommended that the licensor retain control 
over patent prosecution, while seeking to fairly 
distribute costs over field-of-use licensees.
4.3	 Reimbursing	patent	expenses
As with any program involving multiple licensees 
for a technology, the field-of-use licensor must 
manage patent expenses creatively. With no single 
licensee committed to paying or reimbursing all 
costs, the licensor must choose another mecha-
nism to cover patent expenses. The possibilities 
include the following:
a. The licensor covers patent expenses up 
front, reimbursing them from the royalty 
stream. This model results in licenses that 
have no patent-reimbursement language.
b. If the field-of-use licenses have been struc-
tured to relate to distinct patent applica-
tions or patents, costs can be cleanly linked 
to a specific license, and patent-reimburse-
ment language as per a standard, exclusive 
license agreement will suffice.
c. The licensor prorates patent expenses over 
multiple licensees. This approach involves 
patent-reimbursement language in the li-
cense, with a variation on the standard 
theme. For example, “On March 1 of each 
year during the term of this Agreement, 
Licensor shall provide Licensee an invoice for 
Patent Expenses equal to the patent costs for 
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the prior calendar year divided by the num-
ber of licensees of Licensed Patents during that 
calendar year. Costs will be prorated for li-
censes that are effective for only a portion of 
said calendar year. Licensee shall pay this in-
voice within thirty days of receipt.”
d. In some situations, considerable patent 
expenses can accrue before a technology 
is successfully licensed. In this scenario, if 
costs are to be reimbursed by the licensees, 
language can be used to include future li-
censees in that reimbursement. A fixed sum 
of past patent expenses can be attached to 
each license, or the initial licensee(s) can 
reimburse all the costs to make the licen-
sor whole and then use those payments as 
credits as new licensees sign up. This last ap-
proach has the advantage of providing some 
incentive to licensees to have other compa-
nies also licensed under the technology.
4.4	 Handling	patent	infringement/
interference	issues
In field-of-use licensing, as with nonexclusive li-
censing, the lack of an all-inclusive license held 
by any one company reduces the licensee’s moti-
vation to protect the patent in an interference or 
infringement situation. The exclusive field-of-use 
licensee has more motivation than a straight non-
exclusive licensee, because it has some exclusivity 
and would possibly have significantly more com-
petition in the absence of a valid patent. Other 
parties (the other licensees), however, would also 
benefit from the patent being upheld, so that any 
one company may be unlikely to agree to bear the 
total cost of interference or litigation.
Again, there are clear advantages to designing 
the patent filing strategy for field-of-use licens-
ing. If a field-of-use licensee is the only licensee 
of a particular patent or application in a family 
of related patents on a technology, the standard 
arrangements made with an exclusive licensee still 
can be used, focusing on that particular case.
If the field-of-use licensing has been under-
taken in such a way that more than one licensee 
has an interest in a particular patent property, the 
simplest approach is for the licensor to carry in-
terference and infringement costs alone, recovering 
them through royalties or settlements. Using this 
approach, the licensor retains more control. The 
approach also places the risk and cost on the li-
censor, and thus should be taken only when the 
potential reward justifies the resources required. 
Financial and legal support for these events could 
be obtained from other sources within the licen-
sor’s organization, supplied from a set-aside cre-
ated at the beginning of the royalty stream, or 
covered by an insurance product carried by the 
licensee or licensor. Part of the planning process 
for field-of-use licensing (as for nonexclusive li-
censing), therefore, includes developing a strategy 
to manage the possibility of sizable future costs 
that might be borne solely by the licensor. 
Another approach to addressing possible 
infringement and interference actions would be 
to work out a mechanism to share the costs and 
management of these activities with one or more 
licensees. For example, a licensee could be allowed 
or required to take the lead in litigating infringe-
ment in its field of use. The net proceeds could be 
treated as net sales or profits, as appropriate, for 
earned royalty purposes. Alternatively, both par-
ties could share the costs and proceeds within the 
licensee’s field, or the licensor could take the lead 
in litigating infringement, retaining all proceeds. 
These suggestions are much the same as those a li-
censor would select from for any exclusive license. 
In this case, the licensed field of use limits the 
infringement or interference actions that would 
trigger licensee responsibility.
It should be noted that the existence of more 
than one exclusive licensee makes it more likely 
that a licensor will be drawn into litigation as the 
only party having standing to sue. The license can 
require that the licensee cover any licensor legal 
costs, but for licensors that do not want to be 
named as a party to a lawsuit, a single exclusive li-
censee with an undivided interest that is required 
by the license agreement to take the lead in litiga-
tion may still be preferable.
4.5 Diligence
Managing diligence by the licensee is one of 
the issues that become simpler with field-of-use 
licensing. For example, if one company has re-
sponsibility for developing products for less 
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developed countries, or for developing a human 
therapeutic, it is straightforward for the licensor 
to assess licensee performance. Having a field of 
use isolated from other fields removes the need 
to stage commercialization of products for mul-
tiple fields because of resource limitations for a 
single licensee with responsibility for more than 
one field.
5.	 ConCluSIonS
The guidance provided here is intended to help 
licensors maximize the reach of their innovations 
into multiple fields, whether those fields exist at 
the time of the license, or arise as the innovation 
develops. Sometimes one licensee can develop 
the full potential of a technology, but often it will 
take multiple partners, each with its own focus, 
resources and expertise, to fully realize that po-
tential. ■
SANDRA L. SHOTWELL, Managing Partner, Alta Biomedical 
Group LLC, 7505 S.E. 36th Avenue, Portland, OR, 97202, 
U.S.A. shotwell@altabiomedical.com
1 For example, the National Institutes of Health from 
time to time issues guidelines intended to ensure 
broad access to certain types of technologies, such as 
biomedical research tools, and suggests limitations 
on how such technologies should be licensed. (See, 
for example, Sharing Biomedical Research Resources: 
Principles and Guidelines for Recipients of NIH Re-
search Grants and Contracts at ott.od.nih.gov/policy/
rt_guide_final.html#20.) The approach some institu-
tions have taken to follow these guidelines has been 
to issue nonexclusive licenses for the research reagent 
market and exclusive licenses for therapeutics or other 
fields requiring significant investment. 
2 See model agreements at ott.od.nih.gov.
3 See sample documents at otl.stanford.edu/industry/
resources.html#documents.
4 See sample agreements at www.ohsu.edu/tech-
transfer/index.shtml.
5 See www.autm.net/aboutTT/aboutTT_policies.cfm or 
www.dartmouth.edu/%7Etto/standard.html.
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ABSTRACT
Virtually all products now developed using biotech-
nology, genetic engineering, and chemistry are techno-
logically complex, incorporating many different inputs. 
While this alone complicates R&D efforts, there is also 
the added complexity of potentially relevant intellec-
tual property (IP) rights held by third parties, attached 
to these inputs. For example, R&D for a new vaccine 
might have used numerous inputs with corresponding 
third-party proprietary rights attached: research tools, 
recombinant techniques, DNA sequences, transforma-
tion vectors, cell lines, adjuvants, and delivery devices. 
Hence, when the vaccine is ultimately ready for use, it 
will likely be subject to royalty obligations to many li-
censors. This dilemma of multiple royalty obligations 
is called royalty stacking. This occurs when various li-
censes combine to impose aggregate royalty obligations 
of 6%–20% (or greater). Royalty packing, a similar situ-
ation where multiple technologies are bundled together 
(for example, multiple vaccine packages), is sometimes 
imposed by the licensor or by best practices within an 
industry or health ministry. The resulting aggregate-roy-
alty problem is the same as with royalty stacking. There 
are several techniques to manage royalty stacking and 
packing: royalty ceilings, royalty floors, variable royalties, 
and royalty alternatives (lump-sum payments and patent 
pools). Royalty stacking and packing are serious licens-
ing issues that any organization involved in IP manage-
ment and technology transfer can, and must, proactively 
and preemptively plan for and manage.
1.	 inTRoDuCTion
Virtually all products developed using biotech-
nology and chemistry are protected by one or 
more tools of intellectual property (IP) rights, 
for example, patents, material transfer agree-
ments, and trade secrets. Royalty rates that li-
censees must pay on sales or use of these prod-
ucts can vary widely depending on how the 
products will be used, where they will be used, 
and the relative bargaining positions of the li-
censees and licensors at the time of drafting the 
license agreement for the product. In addition, 
most biotechnology products are made using one 
or more patented-research tools, each of which 
may have reach through royalty obligations; ob-
ligations to pay for sales of products made using 
the research tool, even though the patent holder 
does not have a patent on the product which is 
produced. This type of requirement should not 
be confused with patent misuse which may in-
clude a violation of antitrust laws.1 Those royal-
ties may be related to a product identified using 
a proprietary research tool and requiring the use 
of several different patented technologies owned 
by several different entities. 
One example of royalty stacking would occur 
under these circumstances: a potential vaccine is 
identified and tested using one or more propri-
etary research tools that have all been licensed by 
different companies; the vaccine is produced us-
ing recombinant techniques and employs propri-
etary DNA sequences; at the same time, the vec-
tors used for insertion and expression are owned 
by additional companies, while production of 
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the vaccine employs a proprietary cell line; the 
vaccine itself is packaged with one or more pro-
prietary adjuvants and is delivered to patients us-
ing a patented delivery method or device. When 
the vaccine is ultimately ready for use, it may be 
subject to royalty obligations to several different 
companies or licensors. The various licenses in-
volved may ultimately impose combined royalty 
obligations of 6%–20%, or more, of the selling 
price of the product. Further complicating mat-
ters is the need for separate reporting and ac-
counting to each of the licensors. Table 1 provides 
another example of royalty stacking involving a 
multiantigen vaccine with a proprietary adjuvant. 
This situation might require total royalties on the 
selling price of 8%, with separate reporting re-
quirements to four different entities.
Often, a burden of 8% versus 4%, for ex-
ample, can make the difference as to whether the 
vaccine is commercialized at all. Similar problems 
arise in agriculture where a genetically engineered 
crop might be made using proprietary varieties, 
proprietary vectors, proprietary gene sequences, 
and proprietary research tools, all owned by dif-
ferent companies. In one case, a published freedom 
to operate report2 indicated that Golden Rice,3 a 
line of rice genetically engineered at a university to 
have significant expression of pro-vitamin A, was 
covered by 45 patents or patent families and pat-
ent applications by more than 20 different own-
ers in the United States. Fortunately, for the 124 
million individuals severely afflicted with vitamin 
A deficiency (VAD) and the 500,000 cases of ir-
reversible blindness, it was possible to obtain roy-
alty-free licenses for use in developing countries, 
thanks to the strong support this project received 
from many companies. However, in the com-
mercial realm, potential royalty obligations for a 
particular product may be too high collectively 
to allow for development and commercial imple-
mentation of the product. The royalty stacking 
problem can often be compounded in agricultur-
al technologies. For example, a new vaccine for a 
pig disease will often need to be packaged along 
with vaccines for other pig diseases, if the vac-
cines must be administered at the same time.
Individuals that are charged with the man-
agement of IP in health and agriculture will need 
to deal with issues involving royalties and royalty 
stacking on almost every product or technology 
they encounter. This paper is intended to high-
light some of these issues, explain the competing 
interests, and provide commentary on practices 
that can be adopted. 
2.	 whAT	DoeS	The	RoyAlTy	Apply	To?	
2.1	 The	“royalty	basis”
Clearly, one of the goals of an IP license is to allow 
the licensor to receive a quantifiable sum of mon-
ey based on a licensee’s use of a proprietary tech-
nology, or sale of products made using or incor-
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should include a provision for basic reports that 
identify the sales on which royalties are due and 
that itemize any deductions (for example, docu-
mented returns of product, damaged product, 
and free samples) that have been agreed upon. 
The licensee should keep accurate records so that 
sales records can be audited and reports can be 
verified. The records should allow the licensor to 
confirm that it is receiving accurate royalty rev-
enue and that the licensee is complying with all 
milestones and other provisions of the license, 
such as the reporting of minimum sales figures.
Seemingly simple operations can be difficult 
in some licensing situations. Tallying up unit 
sales and multiplying the total by a percentage or 
price-per-unit royalty can become complicated 
when the licensee bundles a licensed product 
with other licensed products. A licensor may be-
lieve that its technology makes the product more 
valuable in combination with others, and that 
the licensor should be due a royalty on the sell-
ing price of the combination or collection product. 
Without a prior agreement on and consideration 
of such a product-combining approach, the li-
censee may risk patent infringement litigation. 
For an example, refer to Georgia-Pacific Corp. v. 
United States Plywood Corp. 318 F. Supp. 1116 
(S.D.N.Y., 1970). In this case, the court sought 
to provide royalties based on the value of the IP, 
rather than the resulting combination. (Court-
imposed royalty rates may be higher or lower 
than either party has agreed to in advance.) 
In cases involving a combination or collec-
tion product, the licensee may be of the opinion 
that the portion of the collection covered by pro-
prietary rights of the licensor constitutes only a 
small fraction of the value of the combination 
or collection product. Resolving the value of 
the proprietary product versus the value of the 
combination or collection product can be espe-
cially difficult if the proprietary product is not 
being, or has never been, sold separately by the 
time a dispute arises. One way of handling this 
type of problem is to add a valuation calculation 
methodology to the license agreement. However, 
it should be recognized that parties to a license 
agreement may be motivated to make the calcu-
lation work in their own favor, and disputes can 
arise on how calculations are made. To avoid this 
type of problem, the agreement may stipulate 
that the product be sold only as a single unit un-
less otherwise agreed to by the licensor. Still an-
other way to address the issue is to specify in the 
agreement that royalty will be calculated based 
on the sale price of the proprietary product if it 
is sold alone, or on the sale price of the combina-
tion or collection product if the product is sold 
as a combination or collection. 
Often, license agreements will specify that a 
licensed product is one that infringes valid claims 
of a licensed patent in a territory where the li-
censed product is made, sold, or used. This type of 
provision has the immediate effect of eliminating 
royalties on products manufactured and sold in 
areas where licensed patents do not exist. Further, 
this type of language can permit the licensee to 
refuse payment of royalties on the grounds that a 
valid patent does not exist in the territory where 
royalties are sought. From the licensee’s perspec-
tive, there will be a concern that the licensee will 
have competition from unlicensed competitors in 
territories where patents do not exist. However, 
from the licensor’s perspective, particularly in 
cases where an exclusive license is given and 
where data, information, and other know-how is 
provided in addition to rights under patents and 
patent applications, a licensee benefits from more 
than just the patent rights provided under the li-
cense and should be obligated to pay royalties on 
all sales of licensed products. 
This issue can be addressed by designing the 
license agreement to address both patents and 
know-how.4 Such agreements should include: 
(1) provisions that separate royalties from differ-
ent technologies (such as royalties from patented 
technologies and royalties from use of trade se-
crets); (2) provisions that eliminate royalties from 
patents that expire or are invalidated (see Brulotte 
v. Thys. 379 U.S. 29, 33 (1964) and Pitney-Bowes, 
Inc. v. Mestre 517 F. Supp. 52 (S.D. Fla. 1981), 
which represent the view that royalties should 
not be due on patents upon expiration or invali-
dation; (3) provisions that address when a trade 
secret becomes known or subject to a patent; 
and (4) a provision that the license to know-how 
and/or trade secrets continues after expiration 
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of a patent. Care must be taken to define what 
the obligations are for transferring know-how. 
For example, a university, private nonprofit, or 
governmental body would likely not want to be 
obligated to provide the same services implicated 
in a know-how license that commercial transac-
tion might involve (for example, the delivery of 
a working prototype or a provision for a certain 
number of hours of instruction time). 
Another way of avoiding the problems in-
volving royalties on products manufactured and 
sold in areas where licensed patents do not exist 
is to include a provision that the licensor receives 
reduced royalties in territories where patents do 
not exist or to provide for the payment of royal-
ties for a shortened term in territories where pat-
ents do not exist. It may be appropriate to set the 
royalty rate at zero in developing countries where 
no patent exists. 
With respect to tying the royalties to valid 
claims covering a product produced or sold by a 
licensee, the technology manager at a university 
or within a government agency in a developing 
country should recognize that such a requirement 
favors the licensee and that the licensee may be 
able to benefit, for very little money, from a pro-
prietary position on a technology (that is, prevent 
the licensor from licensing to others for a period 
of years) by commercializing a product which, 
according to the licensee, does not infringe the 
patent claims. Further, the licensee could take 
this position in any of several different countries 
or jurisdictions in the world (that is, challenge 
the validity of a patent in India while separately 
challenging the validity of a related patent in the 
United States). Such actions could force the licen-
sor to attempt to prove in court that the product 
being produced by the licensee indeed infringes 
the patent claims, or attempt to license the tech-
nology to another party (in which case the value 
of the technology would be likely to be less be-
cause the remaining patent term would be less, 
obviously, than the term of the original agreement 
with the licensor). Neither option is very helpful 
to a licensor who has had its technology tied up 
with a company that will ultimately not commer-
cialize the technology. The licensor could address 
this potential frustration by requiring the licensee 
to agree in advance that, regardless of any finding 
of patent infringement, royalties will be due on 
the product under development by the licensee. 
Further, the license agreement might define 
valid claim to include any claim in any patent 
that has not been adjudicated, by a court of com-
petent jurisdiction, to be invalid and from which 
no appeal has or can be taken. With this provi-
sion, the licensor might be able to collect royalties 
up until a final adjudication of patent invalidity. 
Of course, such a definition would not benefit 
the licensee in cases where prior art that is spot on 
is identified to the licensor.
2.2 Royalty	stacking
Royalty stacking occurs when multiple patents 
affect a single product and thus involve mul-
tiple licenses. As noted above, a biotechnology 
product may require separate licenses for use of 
such items as research tools, gene sequences, ex-
pression vectors, cell lines, and adjuvants. Thus, 
from the prospective of the company making 
the product, the multiple royalty demands must 
be “stacked” together to determine the total roy-
alty burden on producing the product. Because 
royalty stacking involves many IP holders, effi-
cient exploitation of a product subject to royalty 
stacking may be inhibited (that is, development 
can be delayed or discontinued completely) and 
the development of future products might be 
impeded.
2.3 Royalty	packing
Royalty packing occurs when there is a require-
ment to bundle one technology with other tech-
nologies. Such a requirement could be imposed 
by the licensor, but also could be imposed by best 
practices within an industry or by a health min-
istry. For example, a vaccine could be required 
to be administered simultaneously with one or 
more different vaccines that are proprietary to 
one or more different companies in order to re-
duce the cost of administration. In this situation, 
the royalties imposed on each of the proprietary 
products that are administered will be “packed” 
together. Royalty packing may result in the ag-
gregate cost of the several packed products being 
too high.
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3.	 TeChniqueS	To	mAnAge	RoyAlTy	
STACKing	AnD	pACKing	
A licensee may seek to impose a ceiling for roy-
alties in any agreements it makes with licensors. 
For example, the licensee might establish a ceil-
ing of 6% for combined royalties on product 
sales. In turn, if the stacked royalties exceeded 
6%, each of the licensors would be agreeing to 
have the royalties they are to be paid reduced on 
a pro rata basis, so that the total royalties due to 
the licensors would be 6%. In this situation, the 
licensee may be motivated to add more technol-
ogies to its product or process because its total 
royalties per unit are capped. To the contrary, 
the licensor may dispute the need to add the ad-
ditional technologies to the product and may be 
frustrated if its own share decreases much below 
the expected return. In many situations, licen-
sors take the position that their technology is the 
most important and that their share of the royal-
ties should not be depleted pro rata. These types 
of competing interests require the parties to have 
a good understanding of how and when reduc-
tions would apply when the agreement is made 
and good communications between the parties 
when new technologies are incorporated into a 
product that would affect the licensor’s expected 
royalty stream. Also, there may be a need to dif-
ferentiate some types of royalties from others. For 
example, some licensors may be willing to agree 
to a pro rata reduction in royalties when other 
proprietary technologies are used in the product 
to be commercialized. But the licensors may not 
be willing to agree to a reduction due to reach 
through licenses resulting from the licensee’s use 
of proprietary research tools. 
A licensor may seek to impose a floor below 
which its share of the royalties may not fall. For 
example, if additional technologies are required to 
exploit a product, a licensor might agree to have 
its royalties reduced on a pro rata basis, but not 
below a specified floor (for example, the license 
requires royalties of 5% but allows for reduction, 
if additional licenses are required, with the pro-
viso that in no event will the amount due be less 
than 2% per unit sold). The licensor may agree 
to a reduction to the floor only if a license from 
a third party with a dominant patent position 
to the licensor is required to effectively use the 
licensor’s technology. That is, a licensor may not 
agree to a reduction if additional technologies are 
desired by the licensee to make a better product, 
but not needed to use the invention—for exam-
ple, the license agreement might specify that if 
an additional license to practice the invention de-
scribed in the licensed patent(s) is required from 
a third party, the licensee may reduce its royalty 
payments by 50% (or by an amount equal to the 
amount that would have been due to the licensor, 
but in no event shall such reduction be more than 
50%). It is not unusual to have in the same license 
both a ceiling on stacked royalties and a hard floor 
below which royalty rates could not fall. The hard 
floor may need to take into account other deduc-
tions from royalty payments that are allowed by 
the license. For example, a deduction of patent 
costs may be allowed, but will be limited in any 
year by the hard floor in royalty payments.
Licensees and licensors might agree to have 
variable royalties that depended on, for example, 
the importance of the technology in relation to 
the creation of the product. The more important 
the role a proprietary technology plays in a prod-
uct, the higher the royalties, and vice versa (for 
example, the owner of proprietary antigen in a 
vaccine raised against the antigen would receive 
higher royalties than the owner of a proprietary 
expression system for expressing the antigen). In 
this situation, however, it is likely that licensors 
and licensees would disagree over the importance 
of the proprietary technology in relation to the 
product being developed.
Packing issues may be handled by requiring 
that the royalty be calculated based on the sale 
prices of the product if sold alone, or the sale 
price of the combination or collection product if 
the proprietary product is sold as a combination 
or collection. 
4.	 oTheR	mATTeRS
Not every arrangement requires revenues in the 
form of a royalty stream. For example, a lump- 
sum payment for use of a research tool may be an 
appropriate way to disseminate and exploit a pat-
ented technology. Some technologies may best be 
JONES, WHITHAM & HANDlER
1126 | HANDBOOK OF BEST PRACTICES
collected in patent pools which allow for free use 
of the technologies or use of the technologies at 
fixed prices. A patent pool can make the licensed 
technology more widely available for use in dif-
ferent markets (for example, different products 
could incorporate the technology), and, further, 
access to a number of other different but related 
technologies that would be useful to a universi-
ty or nonprofit organization might be available 
within the patent pool. Such arrangements may 
allow research and development using a variety 
of proprietary technologies without the need to 
negotiate licenses.
5.	 ConCluSionS
License agreements should clearly define when 
and how a licensor will be paid a royalty. An im-
portant part of any agreement is a clear definition 
of the product, such that both parties understand 
what royalties will be based on. Further, to avoid 
any disputes on royalty payments, the agreement 
should also clearly define when royalties are not 
due. Royalty stacking should be recognized and 
understood by those involved with managing IP 
in the health and agriculture fields, particularly 
when biotechnology products, services, and re-
search tools are involved. Providing agreements 
that allow commercialization of a product that 
embodies the proprietary technology of several 
different companies, and for which royalty pay-
ments are due to each of those companies, re-
quires recognition by the parties of the role each 
technology performs if royalty ceilings, floors, 
or other mechanisms to address stacking are to 
be adopted. Finally, alternatives to royalty-bear-
ing arrangements should be considered, includ-
ing the use of lump-sum payments and patent 
pools.5 ■
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In the past, it was possible for some countries to ignore 
IP (intellectual property) management while pursuing 
economic development and improved public health. 
Globalization, however, has brought the world closer and 
closer together, and with the advent of the Agreement 
on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS), no country can afford to be isolated from the 
global IP system. This chapter explains how develop-
ing countries can use this new system to their advantage 
through in-licensing technologies (that is, bringing tech-
nology into the public sector through patent license agree-
ments). Offering an overview of the usual requirements 
of a license agreement, the chapter also considers issues 
that are uniquely relevant to public-sector institutions in 
developing countries as they negotiate such licenses.
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censing technologies developed by public-sector 
research and development (R&D) institutions to 
the pharmaceutical industry (including the bio-
technology industry in general, which encom-
passes agricultural applications); and second, by 
in-licensing technologies from the pharmaceu-
tical industry. While the public sector wants to 
introduce affordable health products to the mar-
ketplace, the biotechnology industry is primarily 
interested in optimizing its investment returns. 
But compromises can be made. For example, IP 
developed by the biotechnology industry can 
be transferred to the public sector for further 
development.
In-licensing is a well-recognized strategy for 
transferring technologies from companies to the 
public sector. In-licensing allows many parties to 
manufacture products, thereby creating enough 
competition to bring down the costs of public 
health products (like drugs, diagnostics, vaccines 
and other biologicals) and crops in agriculture. IP 
licensing is often complex because the parties con-
cerned have conflicting objectives. Furthermore, 
the biotechnology industry, at least in developing 
countries, usually is not very eager to work with 
often-times inefficient and incompetent govern-
ment officials. In any case, all parties involved in 
IP licensing need: 
• the skill to negotiate a deal
• a strategy for negotiation
CHAPTER 11.10
1.	 inTRoDuCTion
Thanks to globalization, the rules governing 
intellectual property (IP) are changing rapidly. 
Many countries, such as India, that formerly 
stood outside the patent system have become 
fully compliant with the Agreement on Trade-
Related Aspects of Intellectual Property Rights 
(TRIPS). For developing nations with strong sci-
ence and technology bases, established pharma-
ceutical industries, and emerging biotechnology 
industries, adherence to TRIPS compliance and 
the ensuing changes have created both challeng-
es and opportunities. Developing countries can 
produce health products in two ways: first, by li-
Satyanarayana K. 2007. In-Licensing Strategies by Public-Sector Institutions in Developing Countries. In Intellectual Prop-
erty Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L 
Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. K Satyanarayana. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
noncommercial purposes is permitted and encouraged.
In-Licensing Strategies by Public-Sector Institutions 
in Developing Countries
KaniKaram satYanaraYana, Chief, IP Rights Unit, Indian Council of Medical Research, India
SATYANARAYANA
1128 | HANDBOOK OF BEST PRACTICES




IP transfer agreements must address a number 
of aspects: confidentiality, material transfer, de-
velopment (the licensee assumes all responsibility 
for further development), co-development (two 
parties collaborate on continued development), 
and distribution. 
Such agreements are at least two-way because 
more than one public-sector institution can be 
involved in developing a product. For example, 
if the Indian Council of Medical Research, New 
Delhi, (ICMR) were to in-license a technology 
for developing a vaccine from a private company, 
there could be at least three parties involved in 
the agreement: the ICMR, which is the licens-
ee and a public-sector institution; the licensor, 
which is a private company; and the Ministry of 
Health & Family Welfare, Government of India, 
which will fully or partly fund the project, con-
duct clinical trials, and make the vaccine avail-
able to the public. Usually, either the public-sec-
tor agency or the private company will provide 
the first draft of a negotiation agreement.1 It is 
important that all the parties, especially the li-
censee, clearly understand the basic philosophy 
behind the deal: to provide a product to people 
who would not have access to it without govern-
ment support. A good agreement is one that ben-
efits all parties.
Well-drafted agreements should allow gov-
ernment officials to negotiate quickly, get ap-
proval from the bureaucracy, as appropriate, and 
come to a consensus. Since it takes several years 
to bring a product from the laboratory bench to 
the patient’s bedside, mutual trust is very impor-
tant during the negotiations and implementation 
of the project, especially if some renegotiation is 
needed partway through. Court battles are messy, 
expensive, and generally unwelcome, especially if 
they involve a foreign party. 
Parties intending to enter a long-term 
working relationship with each other may 
either sign a series of agreements, one omnibus 
comprehensive agreement (with smaller spe-
cific agreements attached), or one broad, gen-
eral agreement with two or more related, but 
separate, specific agreements. The following 
sections describe the kinds of agreements that 
can be signed by two parties engaged in jointly 
developing a product. The appendices provide 
examples of agreements that might be used by 
public-sector organizations.
2.2	 Confidentiality	agreements	
The development of a proprietary health product 
usually involves the use of confidential informa-
tion: research data, sources of materials, methods 
of production, designs of specialized proprietary 
equipment, and other nonscientific business in-
formation. The involved parties should therefore 
enter into a confidentiality/nondisclosure agree-
ment. Such an agreement not only protects com-
mercially useful information but also indicates 
the value of that information. Such agreements 
allow all parties to exchange sensitive information 
confidently. 
2.3	 Materials	transfer	agreement	
A materials transfer agreement is drawn up when-
ever a potential licensee wants to evaluate a new 
product or process. The licensor should be will-
ing to provide samples or information but, natu-
rally, will want to assure that the other party does 
not misuse them (such as by passing on a por-
tion of a sample to some third party or using it to 
generate additional material for unlicensed use). 
The Center for the Management of Intellectual 
Property in Health Research and Development 
(MIHR) recommends that public sector re-
search organizations use the Uniform Biological 
Materials Transfer Agreement and the implement-
ing-letter format developed by the U.S. National 
Institutes of Health (NIH). The wording of the 
agreement is uniform for all IP transfers, with 
only the Implementing Letter specifically tailored 
to each transfer. 
2.4	 Co-development	through	collaboration
Even after acquiring new IP from a private com-
pany, it is not always possible or feasible for a 
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single public sector agency to carry out all stages 
of production and marketing. The agency may, 
for example, need to collaborate with other pub-
lic sector laboratories in order to complete prod-
uct evaluation (preclinical toxicity tests, clinical 
trials, and so on). Also, high-quality, good manu-
facturing practice (GMP) production facilities, 
which most public sector research organizations 
lack, are needed to develop products for the mar-
ket. The licensee can either pay other agencies to 
perform some of the tasks, or, preferably, form 
partnerships with them. Collaborating agencies 
may request a share of the IP rights or a portion 
of the revenue generated by product sales. It is 
possible that the final stages of product develop-
ment will require new IP. 
Requests for collaboration often take the 
form of open tenders. In the absence of estab-
lished procedures (since technology commercial-
ization by the public sector is still an emerging 
area), various means have been adopted by the 
public sector—primarily to “protect” the pub-
lic sector institution from the unlikely event of 
a commercial blunder—most government de-
partments resort to what is called a “committee 
approach” through which a group of officials, 
including tech transfer professionals, adminis-
trators, finance people, and so forth, work in a 
transparent manner to negotiate a deal. Public 
communication is important because the gov-
ernment that is funding the initiative will expect 
the deal to be performed with complete transpar-
ency. Furthermore, transparency reassures part-
ners and investors. 
2.5	 Technology	licensing	agreement	
Technology licensing agreements allow one par-
ty to use the proprietary materials or know-how 
of other parties. Standard technology licensing 
agreements clearly define the period of time for 
which the license is valid, the kind of license (ex-
clusive or nonexclusive), the territory in which 
the license is valid, the market in which the 
product will be released (public sector or open 
market), whether or not the product can be 
sublicensed, the amount of money to be paid 




A confidentiality agreement requires all informa-
tion to be carefully protected. Access to confiden-
tial information should be given only to the prov-
en trustworthy, as improper use of confidential 
material can seriously erode mutual confidence 
between partners and even lead to litigation. 
Scientists, especially those in the public sector, 
should be especially careful because they, in other 
contexts, discuss science openly. 
2.6.2	 	 Territorial	exclusivity
In a licensing agreement, the territory is the geo-
graphic region in which the licensee is permitted 
to sell the product. The territory could be part of a 
country, part of a subcontinent, several countries, 
or the whole world;2 or, alternately, territory can 
refer to a segment of the market in a single com-
pany like public sector or private sale. Sometimes, 
nonexclusive licenses are awarded to licensees in 
order to promote competition between them. Or 
an exclusive license may be granted to market an 
expensive product within a limited market—un-
less such market exclusivity is guaranteed, no one 
may be willing to manufacture it. Commissioning 
a professional agency to carry out market research 
in order to make sure that the product is correctly 
priced and appropriate for the intended terri-
tory is always advisable. (Commissioning such 
surveys is slowly becoming routine practice due 
to a lack of in-house expertise and the system of 
government regulations.) The guiding principle 
for deciding whether to grant exclusive licenses 
of nonexclusive licenses should be that while it is 
most important to bring new products to market 
at affordable prices. 
2.6.3	 	 Product	liability
Health-related products can lead to liabilities; 
especially susceptible products, such as vaccines, 
are tested on healthy volunteers. Often, compa-
nies are unwilling to market a product because of 
potential liabilities. The licensing agreement for 
a health-related technology must define the cases 
in which the investigators will, and will not, be 
held responsible (for example, such cases might 
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involve bad or inferior product, improper storage 
and use, administration of the wrong dosage) and 
the licensee must take out an appropriate amount 
of insurance before starting trials. The clinical tri-
al agreement should also describe how, and how 
much, an individual who is harmed by a health 
product should be compensated. 
2.6.4 	 Up-front	fees	and	royalties
Ultimately, marketability and price decide a 
product’s fate. The licensor must decide the kind 
and number of licenses, how much market access, 
and so on, it will grant. The parties must agree on 
how much money the licensor will receive both 
up front and via royalties. These decisions will be 
influenced by the amount of revenue the product 
is expected to generate. A committee of experts, 
administrators, and financial advisors usually ne-
gotiates on behalf of public-sector institutions. A 
balance must be struck between the desires of the 
licensee (to pay less up front and more through 
royalties) and those of the licensor (to receive 
as much money as possible at the beginning). 
Factors that affect the price of the license include 
the expected life of the product, the duration of 
IP rights, the existence of a competing product, 
purchasing capacity, and whether or not there is a 
committed market (in other words, governments 
offering purchase commitments), and so on. 
2.6.5  Arbitration
The licensing agreement must stipulate the terms 
of arbitration in case something goes wrong and 
there is disagreement between parties. Arbitration 
procedures can be relatively simple if the parties are 
in the same country. If governments are involved 
in such arbitration proceedings, such governments 
will often dictate the outcome. Arbitration be-
comes very complex when parties from different 
countries are involved, especially if the arbitration 
is conducted in a third country. Of course, all ef-
forts should be made to settle issues amicably. 
3.	 ConCluSionS	AnD	
ReCommenDATionS
In developing countries, it is important for the phar-
maceutical industry, in general, and the biotech-
nology industry, in particular, to develop products 
(drugs, diagnostics, and vaccines) with a potential 
global market. This reorientation from an exclusive 
concentration on markets in developed countries 
to a product development plan that includes de-
veloping countries can be achieved through part-
nerships between the public and private sectors in 
both developed and developing countries.
Most developing countries do not have the 
expertise to deal with complex IP licensing is-
sues. Public officials in developing countries of-
ten postpone making decisions in order to cover 
up their ignorance and lack of expertise, thereby 
discouraging private companies that might be in-
terested in collaboration with them. Professional 
help in all areas, from product valuation to draft-
ing IP agreements, would be useful. The follow-
ing drivers are needed for developing countries to 
optimize their success: 
• a business strategy that aims to balance the 
objectives of the public sector (to bring af-
fordable health products to market) with 
those of the private sector (making profits)
• a marketing strategy that prices products 
realistically, using up-to-date marketing 
information (any existing products, their 
price structure, potential customers, the 
size of the potential market in private and 
public sectors, and so on)
• the proper legal expertise is usually al-
ready locally available, as many legal firms 
in developing countries are familiar with 
basic licensing procedures. Marketing and 
scientific experts could assist in valuating 
patents 
Perhaps the ideal solution to the lack of know-
how in developing countries is two fold: first, the 
establishment of a national technology transfer 
office; and second, the development of core team 
of experts drawn from diverse disciplines devoted 
to helping to negotiate product in-licensing. ■
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1 Some argue that in general, the public sector 
organization should offer the first draft of a licensing 
agreement. (See for example, in this Handbook, chapter 
12.1 by RT Mahoney.) This approach is generally much 
easier than trying to work from a draft prepared by the 
private sector organization, because the draft needs to 
cover a number of topics of particular concern to public 
sector organizations, and these topics probably would 
not be addressed in a private sector organization’s 
draft.
2 In India, as perhaps in other poor countries, there 
are states, or equivalent entities, that are rich, and 
politically stable, with promising markets, while other 
states—often those with unstable governments—
have uncertain market potential. Currently, each state 
in India has its own drug regulator. These officials 
have varying expertise and, along with other factors, 
can determine the marketability of products in their 
states. Additionally, while a price can be the same over 
the entire country, each state has its own rates for sales 
tax and other taxes.

ABSTRACT
This chapter provides a road map for licensing profes-
sionals to identify the most common terms, contractual 
obligations, and other provisions that are likely to be 
encountered in crafting a license agreement. Emphasis 
is placed on agricultural technology licenses. Since most 
people engaged in deal making are involved in multiple 
deals at the same time, important aspects can be forgotten 
or overlooked at any time and for any deal. The checklist 
format allows the licensing practitioner to check off each 
item once it has been addressed to the parties’ satisfac-
tion. While expansive, it does not necessarily fit all con-
texts and is therefore intended to serve as a basis from 
which institutions and individuals can develop their own 
checklists.
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1. 	 inTRoDuCTion
A checklist to aid in negotiating a licensing 
agreement, much less to aid in actually preparing 
and writing the agreement itself, may sound like 
a simplistic tool to an experienced negotiator or 
contract attorney. After all, most people in such 
positions are well educated and used to dealing 
with multiple projects having many details in 
the scientific, legal, and business arenas, all at 
the same time. If they did not have the compe-
tence to deal with this type of work situation, 
they would not last long in the active, high-pres-
sure licensing environment. But it is precisely 
because of myriad details that a checklist can be 
life (or deal) saving for the working licensing of-
ficer or attorney. Since most people engaged in 
deal making are involved in multiple deals at the 
same time, important aspects can be forgotten 
or overlooked at any time and for any deal. One 
of the simplest ways to make sure that a crucial 
or costly mistake does not happen because of an 
oversight is to use a tool such as the checklist 
presented here. 
2.	 SpeCifiC	CheCKliST	SeCTionS
This section introduces and discusses for both li-
censors and licensees each element of the check-
list. If your work requires you to draft license 
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2.1	 Section 1	–	The	parties
Although seemingly self-evident, having all pertinent information about the parties in one place, such 
as their legal names, the negotiating party’s contact information, and the legal addresses is a time saver 
when the final agreement is being written. No more last-minute telephone calls or e-mails to get infor-
mation that should have been exchanged at the first meeting.
PARTIES:
1. Licensor’s Name: 
Address:  
Principal Office:   
 Incorporated In:      Short Title:  
 Contact Name:  
 Contact Title: 
 Contact Tel/Fax: 
 Contact E-mail: 
2. Licensee’s Name: 
 Address:
 Principal Office: 
 Incorporated In:      Short Title: 
 Contact Name: 
 Contact Title:
 Contact Tel/Fax: 
Contact E-mail:
2.2 Whereas	clauses
The following set of “whereas clauses” is offered as a guide for detailing the background of the license. 
Not all parties use whereas clauses; some prefer to make the background information a standard set 
of clauses that follow language specifying that “the following are terms of the Agreement” or similar 
language. Some use of background information in a contract is recommended because within a short 
period of time after the deal is done and the agreement signed, negotiators memories will fade and a 
short set of statements regarding the background of the deal may become invaluable should the con-
tract need to be interpreted by a court or an arbitrator.
agreements, download the checklist from the online version of this Handbook where it is given without 
the annotations.  
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DEFINITIONS:
All other appropriate terms should be listed and defined. Clear definitions will add great 
clarity to a license. Care should be taken to write definitions that, in general, stand alone 
and are not circular in construction. 
A good place to begin thinking about what to define is with a definition of the parties. If 
dealing with a company, is it the company and all its affiliates? All of its subsidiaries? Or 
only the parent company? Products/Processes licensed should be specifically defined as 
Licensed Products or Licensed Processes. If only certain types of inventions are covered, 
define the inventions here and refer to them as Inventions; include the patent number and/
or patent application number that is being licensed, and specify if Know-how is included.
2.3 Definitions
A simple contract will not need to have a section devoted to definitions, as the definitions can be pre-
sented when special terms are first encountered. A complex document should present all definitions 
in one section for ease of drafting and later interpreting the contract. General terms used throughout 
the contract should be placed in this section, as should technical terms that are used frequently. Either 
an alphabetical or a hierarchical order is recommended, the latter being used when a number of terms 
are closely related and having them near to each other would allow the reader to more easily navigate 
the agreement.
 Each license will have its own specific set of definitions, so a short list that includes only the 
most commonly used terms is presented here.
WHEREAS CLAUSES:
1.  Licensor owns/controls certain Intellectual Property/Tangible Property including inventions 
______, patents ______, applications ______, know-how ______, other _______ relating to 
________________
2.  Licensor represents that it has the right to grant a license to _________
3.  Licensee owns/controls certain Intellectual Property/Tangible Property including inventions 
______, patents ______, applications ______, know-how ______, other _________ relating 
to ________________
4.  Licensee represents ________________________________
5.  Licensee desires license relating to ___________ in order to ________________
(Continued	on	next	page)
BOBROWICZ
1136 | HANDBOOK OF BEST PRACTICES
2.4	 The	grant	sections
The following sections may seem to be overkill to the licensing professional. However, each and every 
section, if not handled with care and forethought, can result in a deal that is more than unsatisfactory 
to one or both parties.
2.4.1		 Rights	granted
The exact grant language should be specified. This includes which intellectual property rights the 
license is given under: patent right only or know-how right or both and exclusive right, coexclusive 
with the licensor, or nonexclusive. The section should also specify the term of the exclusivity and/or 
nonexclusivity, and whether such right is irrevocable; and if there is a right to grant sublicenses. Each 
organization will find that it tends to make deals in a certain way and may find that certain combina-
tions of grant language will be used repeatedly. In that case, this section may be easily amended to the 
specific organization’s needs.
1. RIGHTS GRANTED:
a) All substantial (statutory) rights to practice under the rights in specified Intellectual 
Property/Tangible Property (detail here) ________________;
b) and to make ____, have made_____, use_____, import_____, offer for sale____, and sell 
_____ products and processes;
c) Exclusive for ______ years and nonexclusive thereafter, or
d) Non-exclusive ______, to make (manufacture) ______, or
e) Exclusive _____ to have made for own use ______; or
f) Exclusive except as to Licensor ______, to use ______, to export ________, to make and sell 
in limited markets _______;
g) Irrevocable ______, to sell ______, have sold ________;
h) With right to grant sublicenses ______, to lease ______, rent ______.
2.4.2	 License	restrictions
This section deals with the field, territory, prior licensee’s rights, and the commercial rights retained by 
the licensor. Some of what is contained in this section appears under Section 1 (the parties), and may 
not be needed in all situations.
DEFINITIONS (continued)
Licensee, sales, net sales, profit, territory, field, patents, patent rights, intellectual property, 
and nonprofit are examples of other relatively common terms, and there are many more. 
Once defined, these terms will usually appear, throughout the rest of the contract, with the 
first letter capitalized or in all capitals.
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2. LICENSE RESTRICTIONS:
 Limited to the Field _________________________________________________________ 
Limited to Territory _________________________________________________________ 
Subject to prior Licensee (identify, if any) rights _________________________________ 
Subject to Licensor’s right to make ______, have made ______, use ______, have used 
_____, export _____, import _____, sell ______, have sold ______ (as many as applicable).
2.4.3	 Reservation	of	rights
This section is particularly important when the licensor is a nonprofit and must ensure that certain 
rights to use the intellectual property are reserved for academic, nonprofit research, or humanitarian 
uses in developing countries, or according to the terms of the Bayh-Dole Act (in the United States). 
Forgetting to include the needed reservation of rights in a license could make the license invalid and/or 
could lead to an expensive court fight to determine what rights are in fact owned by the licensor.
3. RESERVATION OF RIGHTS:
a) Licensor hereby reserves an irrevocable, nonexclusive right in the Technology (on behalf of 
itself and all other nonprofit/academic research institutions)
b) For Educational and Research uses_____, including uses in Sponsored Research ____ and 
nonprofit collaborations_____.
c) For Humanitarian Purposes_____, or 
d) For uses in Developing or Economically Disadvantaged countries_____ (specify countries)_
________,
e) For the U.S. government under the Bayh-Dole Act ______.
2.4.4	 Right	to	grant	sublicenses
The grant of a right to grant sublicenses to third parties also has a number of important choices that 
must be considered by parties when awarding this portion of the license. Sublicensees may be anyone 
or may be limited to, for example, only parties in privity with the licensee; only affiliates of the licensee; 
only a specified number of third parties; or only parties preapproved by the licensor. 
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4. LICENSEE MAY GRANT SUBLICENSES:
a) To any other party ____;
b) To limited number of parties _____;
c) To Affiliates of Licensee ____ only _____;
d)   To third parties preapproved by Licensor ____;
e)   To nominees of Licensor ____;
f) At specified consideration (indicate) ____________________;
g) Consideration to be shared with Licensor ________________;
h) Copies of sublicense to be furnished to Licensor ________;
i) Under other conditions _______________________________________
2.4.5	 Territory
The territory that is granted to the licensee under the license must be specifically identified.
5. TERRITORY:
a)  All countries ______ 
b) All countries except _______________________
c) Following country/countries_____________________________________
d)  That portion of a specific country comprising ___________________
2.4.6	 Term	of	the	agreement
The date the agreement begins, the effective date, should be noted, as well as the ending date of the 
agreement, by whatever method that is calculated. Some of the most common ways are listed below.
6. TERM OF AGREEMENT:
Effective Date is _______.
For ______ years/months/day (as agreed), until (specify date) _____; or
For the life of a specific patent or other intellectual property ________; or
Until some future event (specify) ______________________________
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2.5	 Improvements
This section deals with any improvements made and/or patented (by whom and paid for by whom) 
during the term of the license by either the licensor or licensee and what obligations are present in 
the deal as to whether or not to include future technology under the present license or to have future 
technology fall under the reservation of rights to the licensor.
7.  IMPROVEMENTS BY: 
LICENSOR: LICENSEE
Included ______ Included _______   
Not included ______ Not included _________   
Who will file _____________________________ Who will file _________________________ 
Who will pay costs _______ Who will pay costs _________ 
Assigned/licensed to Licensee ______. Assigned/licensed to Licensor_________
2.6	 Consideration
The consideration sections of the checklist is relatively involved, and can be cut back if equity is not 
part of the payment for the license. Royalty, milestone payments, type of currency, determining rate 
of exchange, and equity-ownership issues are listed here, as is the issue of minimum annual payments, 
particularly important in the case of an exclusive license.
8. CONSIDERATION FOR LICENSE:
Royalty free ___; or
Royalty, ____ per cent; of profits ______; of gross sales ______; of net sales ______; specific 
amount (specify) ______ per unit (specify) ______; other (specify) _________;
Single sum (license fee) of _________;
Milestones (what they are and amount owed) ________________________;
Payment is to be made in currency of which country ___________;
At the then current rate of exchange ___________________;
At the rate of _______(currency) for ________ (currency) 
If exchange rate decreases or increases by ____(specify a percentage) %  
the payments shall decrease or increase by like amount; or exchange rate shall be that 
published in __________________.
 Equity: Stock of Licensee (specify) _____________________________ 
 stock of existing company ______; new company ______ 
 value of the shares of stock shall be market value ____ at date of agreement _______ 
 book value ______ according to Schedule ____; stock shall have full voting rights   
 ______; nonvoting ______;
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2.7	 Reports	and	auditing	of	accounts
Royalties based on any measure tied to a product’s sales should be paid to the licensor accompanied by 
a report stating how the royalty was calculated. It should be decided how often and when these reports 
(and royalties) are due. Additionally, the right of the licensor to audit the books that generate these 
reports should be a part of the license.
11.    INSPECTION OF LICENSEE’S ACCOUNTS:
Not permitted ______
Permitted ______ 
at any time during business hours ______ 
at specified times ______ 
by Licensor’s authorized representatives ______ 
by Certified Public Accountants ______ 
Audit to be paid by Licensor unless underpayment is greater than ___%
10.    STATEMENTS OF EARNED ROYALTY:
Quarterly, within ______ days of end of quarter
Annually, within ______ days of end of year
Other periods, (specify) ____________________
In writing, and certified by __(official or auditing firm) ____
With names and addresses of sublicenses ______
With copies of sublicenses ______
Together with payment of royalty accrued ______
9. MINIMUM ANNUAL PAYMENT FOR LICENSE:
 
 Amount ______ per calendar year; per 12-month period ______
 Payable in advance ______
 Payable at end of calendar year ______; of 12-month period ______
 Credited against earned royalties, yes ______; no ______
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2.8	 Representations/warranties
Certain basic representations and warranties should be given by each party to the other, such as the 
ability to enter into this agreement, the validity of the intellectual property, and a standard warranty 
disclaimer. These and others are listed below.
12.    REPRESENTATIONS/WARRANTIES:
A. Validity of Licensed IP 
 Not admitted ______ 
 Admitted to Licensee ______
   If patents held invalid, then: 
  Licensee may terminate: 
   as to invalid claims ______ 
   entire agreement ______ 
B. Good title to Intellectual Property in _______ (specify countries)
C. Authority of Licensor to enter into the License _____ 
 Authority of Licensee to enter into the License _____
D. Standard warranty disclaimer, of fitness for particular purpose 
 Merchantability ______; Express or Implied ______.
2.9 Infringement
These sections deal with how past infringement by the licensee is handled; if the IP is infringed by third 
parties, how such infringement will be handled, and if there is a recovery for the infringement, how 
that will be divided between the licensor and licensee. Indemnification by the licensor of the licensee 
to practice under the IP rights is also covered.
13. INFRINGEMENT:
 A.  INFRINGEMENT OF LICENSED INTELLECTUAL PROPERTY/TANGIBLE PROPERTY
 Past infringement by Licensee 
  forgiven ______; not forgiven ______ 
  forgiven for payment of ______  
   If infringed by others: 
    Who will notify _______________ 
    Who will file suit ______________ 
    Who is in charge of suit ________ 
    Costs: borne by ______________ 
                divided ______________
(Continued	on	next	page)
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13. INFRINGEMENT (continnued)
B. INFRINGEMENT OF OTHER’S INTELLECTUAL PROPERTY/TANGIBLE PROPERTY
No indemnity by Licensor ______ 
Licensor indemnifies Licensee ______ 
Licensee indemnifies Licensor ______ 
 Who will notify _____________ 
 Who will defend _____________ 
 Who will pay costs __________ 
 Costs: borne by ____________ 
  divided _______________ 
C. RECOVERY AFTER DECREE
Retained by ______; Divided ______
Right to settle suit: 
 by Licensor ______; by Licensee ______ 
 by Licensor only with consent of Licensee ______ 
 by Licensee only with consent of Licensor ______
2.10 Diligence
Diligence covers the concept that the exclusive licensee will do all it can to operate under the license 
so that the licensor reaps a monetary benefit under the license. If this issue is not covered, then the 
exclusive licensee can sit on the technology and keep others from exploiting it and bringing money to 
the licensor.
14. DILIGENCE BY LICENSEE (Usually in absence of minimum royalty): 
 No obligation ______ 
 Licensee will use its best efforts to ______ 
 Licensee will use its reasonable best efforts ______ 
 Licensee agrees to: 
  produce ______ or sell ______ specified units _____ 
  produce ______ or sell ______ specified products ____ 
  invest specified amount ____________________ 
  satisfy demands of trade ______ 
  not to refuse reasonable request for sublicense ______
  Penalty for lack of diligence: 
  license converted to nonexclusive ______ 
  Licensor may nominate Licensees ______
 Licensor may terminate __ upon __ days’ notice in writing
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15. INTELLECTUAL AND TANGIBLE PROPERTY OF LICENSOR:
 Not included, except as described in patents or applications ______ 
Included for products (specify) _______________________ 
For term of agreement ______; for specified term ______ 
For territory of license ______; for other territory _______
A. NATURE OF INTELLECTUAL AND TANGIBLE PROPERTY 
i.  Invention records __Know-how, not confidential ___ 
ii.  Laboratory records ___Know-how, confidential ____ 
iii.  Research reports ___Employee to be bound ______ 
iv.  Development reports ______ 
v.  Laboratory notebooks ______ 
vi.  Construct components and design ______ 
vii.  Test field lay-out and design ______ 
viii.  Production specifications ______ 
ix.  Raw material specifications ______ 
x.  Quality controls ______; ISO 9000 procedures _______ 
xi.  Economic surveys ______ 
xii.  Market surveys ___; Producer lists __; Brokers ___ 
xiii.  Promotion methods ______ 
xiv.  Trade secrets ______ 
xv.  List of customers ______ 
xvi.  Drawings and photographs ______ 
xvii.  Models, tools and parts ______ 
xviii.  Germplasm ____________________ 
xix.  Other (specify) ____________________________
B.  PAYMENT FOR INTELLECTUAL AND TANGIBLE PROPERTY 
Included in royalty ______ 
Not included in royalty ______ 
Single payment of ________________________________ 
Stock in amount of _______________________________ 
Annual service fee of ______________________________ 
 for term of agreement _______________________ 
 for specified term __________________________ 
If Intellectual Property surrounding it is held invalid: 
 Know-how payment stops ______ 
 Know-how payment continues ______
2.11 IP	defined
Intellectual property (IP), and how it is paid for, must be defined in the agreement, whether it is only 
one patent or if it includes various reports and tangible materials.  This part of the checklist may be 
more relevant to for-profit licensors, but nonprofit licensors may also have more than just a patent (and 
its family) to include in the definition of IP. 
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16. INTELLECTUAL AND TANGIBLE PROPERTY OF LICENSEE:
Not included, except as described ______ 
Included for products (specify) ______________________ 
For term of agreement ______; for specified term ___ 
For Territory ______________________ 
Nature of Property included: _________________
2.12 	 Right	of	inspection;	technical	personnel
If the licensee has licensed seed that is being produced by the licensor and that will include the transfer 
of tangible material (the seed) to the licensee, the licensee may want to have the right to inspect the 
licensors research data and fields during the term of the license. Whether or not licensors personnel 
shall be used to transfer know-how or tangible materials to the licensee, and at what cost, is also an 
important item to note in the contract. 
17. RIGHT OF INSPECTION:
Licensee shall have the right to inspect Licensor’s: 
 Research laboratory ______ 
 Development laboratory ______ 
 Laboratory notebooks ______ 
 Test fields ______ 
 Production fields ______; Nurseries ______; Greenhouses _____
Number of visits permitted per year ______; Number of persons ______
Special conditions of visits _______________________________________
Licensor shall have reciprocal rights of inspection ___________________
18. TECHNICAL PERSONNEL: 
Licensor shall provide technical personnel to deliver Intellectual Property/Tangible Property 
(specify) _________: 
 At Licensor’s expense ______; At Licensee’s expense ______ 
 Not more than ______ persons for not more than ______ days 
 At a fee which shall be the salary, plus ______ per cent 
 Travel expenses ______; living expenses ______ 
 borne by Licensor ______; borne by Licensee ______
(Continued	on	next	page)
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TECHNICAL PERSONNEL: (continued)
Number and duration of stay of technical personnel determined by:
Licensor ______; Licensee ______; mutually ______
Ownership of reports made by technical personnel ________
2.13	 	 Remaining	sections
The remaining sections of the checklist are what may be identified as the “boilerplate sections” of the 
license, even though all of these terms are subject to negotiation. In any case, confidentiality terms, 
provisions for export control, the non-use of each party’s name by the other party, arbitration (or not), 
terms of breach that will cause termination of the contract and the ramifications thereof, force majeure, 
assignment, favored-nation clause, notices, integration, language, modifications, applicable law, and 
schedules should be standard items considered by every licensing professional. 
2.14	 	 Confidentiality
If a confidentiality, or nondisclosure, agreement has been entered into by the parties and will remain 
effective during the term of the license agreement, nothing else is needed. If this hasn’t been done, a 
section dealing with terms of confidentiality may be put into the license agreement. If the previously 
agreed-to confidentiality agreement is weak, now is the time to bolster it and to make sure that these 
terms in the license agreement take precedence over earlier agreements.
19. CONFIDENCE OF CONFIDENTIAL INFORMATION:
No obligation ______; Licensee obligated ______
Both parties obligated ______
Confidence maintained for specified time ____; Without limitation as to time ______; life of 
agreement ______
Until published by owner ______
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2.15	 	 Export	regulations;	use	of	party’s	name
Export regulations are important in deals where technology is exported from the United States. All 
exports must comply with U.S. export control laws and regulations, and in particular, those goods and 
IP that may have a military use. It is a topic outside of the scope of this chapter, but as an item on the 
checklist, it alerts the negotiator that this is a topic to be considered. Other countries may have laws 
dealing with the same topic or with issues or registering the final agreement with the government. 
Again, this is a memory jog for the negotiator.
In some cases, either one or all of the parties will not want its/their name used in connection with any 
licensed products advertised or sold, as it may suggest that the licensing institution is recommending 
these goods. If this is the case, this should be stated in the agreement. 
20. A. EXPORT CONTROL _______ 
 B. Government registration regulations _____
	
21. NON-USE OF NAMES
Licensor’s ______, with permission ______ 
Licensee’s ______, with permission ______
2.16	 	 Arbitration
In the case of a major disagreement about the terms of an agreement, parties may wish to take the issue 
to arbitration. Arbitration can be carried out in many different ways and it is easier to specify in the 
agreement the rules to be used for arbitration, before there is an issue to arbitrate.
22. ARBITRATION:
No right of arbitration ______ 
Parties will use their best efforts ______ 
Parties agree to arbitration by:
American Arbitration Association ______ 
By other body ______ 
By three persons, one selected by each party and a third by the selected persons  
______
Appeal from arbitration decision:
 Not permitted, decision final and binding ______
 Permitted _____________ to ____________
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2.17	 	 Termination
The termination section of an agreement can be quite complicated, or it can be very simple. I have 
seen agreements that have been hung up on determining what to do with the rights of the parties if a 
material breach were to occur. Thought should be given to this area, but beware of having it take over 
the negotiation. Areas to consider include the right of either party to end the agreement for no reason 
at all; the rights of the party that has performed when confronted with a party that refuses to perform; 
material breach issues; and length of notification of breaching activity and time given to the breaching 
party to cure the breach before losing rights and/or being charged penalties. Issues dealing with the 
natural expiration of the license should be considered, as well. What happens to the know-how (if any) 
upon the expiration of all patents? And what are the confidentiality provisions?
23. TERMINATION:
A. By Licensor:
If certain person incapacitated ___ (name) ___
If certain person terminated __ (name) __
At specified time ______
Upon breach after __ days written notice if not remedied within ____ days
Other ___________________________________
B. By Licensee:
At any time upon ______ days written notice
On any anniversary date ______
At a specified time ______
Only upon payment of penalty of __________ dollars
Upon breach after ___ days written notice if not remedied within __ days
Other ___________________________________





As to any specified patents or applications ______
Germplasm _________________
As to any specified country ______
Of exclusive license with right to continue as nonexclusive ______
Whenever any essential claim held invalid ______
Upon bankruptcy of either party ______
(Continued	on	next	page)
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As to any specified patents or applications ______
Germplasm _________________
As to any specified country ______
Of exclusive license with right to continue as nonexclusive ______
Whenever any essential claim held invalid ______
Upon bankruptcy of either party ______





As to any specified patents or applications ______
Germplasm _________________
As to any specified country ______
Of exclusive license with right to continue as nonexclusive ______
Whenever any essential claim held invalid ______
Upon bankruptcy of either party ______





As to any specified patents or applications ______
Germplasm _________________
As to any specified country ______
Of exclusive license with right to continue as nonexclusive ______
Whenever any essential claim held invalid ______
Upon bankruptcy of either party ______
2.18 		Force	majeure
This is the “it is out of my control” reason for not performing under the license. A hurricane has just 
wiped out your seed crops for the year, and you have no seeds to provide or to sell; your chemical plant 
just went up in flames. Things happen, and this fact of life should be considered in the contract. The 
key is to determine what is required after the force majeure occurs to get the licensed product out the 
door, or the goods to the licensee as quickly as possible. Technically a French term, it literally means 
“greater force.”
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24. FORCE MAJEURE:
Licensor has right ______
Licensee has right ______
Both parties have right ______
Nature of Force Majeure:
Natural events: fire, floods, lightning, windstorm, earthquake, subsidence of soil, etc. 
(specify) ______________
Accidents: fire, explosion, equipment failure, other ___________ 
Civil events: commotion, riot, war, strike, labor disturbances, labor shortages, raw 
material and equipment shortages ______
Governmental: government controls, rationing, court order ______
Any cause beyond control of party ______
Time after occurrence that the exclusive license becomes nonexclusive _____months
If there are fixed payments, are they excused during FM period ___?
2.19	 	 Assignment	provision
A license is considered to be personal to the licensor, especially in the case of an exclusive license. The 
licensor hand picks the licensee, for many reasons, and rejects others for many reasons. Additionally, an 
exclusive licensee may be interested in taking a license from a particular licensor, and not from another. 
In these cases, the right to assign a license may be forbidden, or at least greatly limited to “only with 
the permission of the nonassigning party.” Nonexclusive licenses tend to be more open to assignment, 
especially if there are many licensees. There may or may not be fees attached to the transfer, or assign-
ment, of a license.
25. ASSIGNMENT OF AGREEMENT AND LICENSE:
a) Not assignable by either party ______
b) Assignable by Licensor, without consent of Licensee __; only with consent __
c) Assignable by Licensee, without consent of Licensor; only with consent ___
d) By either party upon:
 Merger ______
 To successor  of portion of business involving: license___; or only entire business ___
 To any company of which a majority of stock is owned ______
 To any company of which a controlling interest is owned ______
 
Binding upon heirs, successors and assigns ______
Fee for assigning _______ How much? ________
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2.20		 Favored	nation
A licensee may demand that they pay the same royalty and/or fee as another licensee that pays the least 
for the same license. This can be limited, for example, to the same royalty rate, but not to up-front 
fees, or not take in consideration the worth that cross-licenses to IP bring to a deal. Generally, it is very 
tough to determine if one party has a better deal than another unless it is a straight money deal.
26. FAVORED NATION CLAUSE:
 
 Licensee guarantees performance (and amount of return) ______
 Licensor required to notify Licensee of similar license ______
 Licensee has option to take term of similar license ______
 License changed to terms of more-favorable license ______
 Licensee may terminate if not given cheaper license ______
2.21	 	 Notices;	integration;	language;	modifications;	law;	signatures
You will find that clauses that involve the following issues tend to be boilerplate clauses:
• Notices. the handling of any notices, payments, and so forth, that you must make or should 
receive
• Integration. a statement that this is the controlling document, no matter what else was said or 
signed previously, unless specifically stated in the license.
• Language: deals with languages used in writing the license (Will each translation of the license 
be acceptable? Or only the license written in one of the languages?) 
• Modifications: specifies whether amendments to the license are to be in writing (If oral chang-
es are OK for your deal, or for portions of it, specify it here.)
• Law: specifies which country’s laws will be applied to interpreting the license; what courts will 
hear a lawsuit; and in what country, specifically, lawsuit would be filed.
• Signature: recommended to type in the name and title of the signatory (Two years after sign-
ing, all parties to the deal may have changed, and many signatures may be illegible by then.)
27. NOTICES AND ADDRESSES:
 
 By registered mail ______
 By registered air mail (for foreign licenses) ______
 By overnight mail ______
 After ___ days if by FAX with confirming telephone call ___
 After ____ hours if by e-mail to ____specify_____
 Licensor’s legal address for notice: ___________________
 Licensee’s legal address for notice: ___________________
(Continued	on	next	page)
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28. INTEGRATION:
This instrument is the entire agreement between parties ______
This agreement supersedes all ______ prior agreements between the parties or the 
agreement dated _____________________
29. LANGUAGE (for agreement with foreign language licenses):
 The official language(s) shall be __specify language(s)____
 Copy in _____ language shall be official ______; unofficial __
30. MODIFICATIONS AND AMENDMENTS:
 This License can not be modified or amended ___________
 No modification effective unless written and signed by both parties __
31. APPLICABLE LAW:
 
 To be read, construed, understood and adjudicated according to the laws of _______ in  




 Witnessed by ______ witness(es)
 For Corporations:
  By officer ______
  Title shown ______
2.22  Schedules
This is the place to give very specific listings of items covered in the license, background documents, 
and research project outlines and specific procedures. It can be easier to modify a schedule than the 
whole contract, should the need for changes arise. A few types of schedules are listed.
BOBROWICZ
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33. SCHEDULES:
A.  PATENT LIST (Give inventor, number, issue date, official title)
B.  PATENT APPLICATIONS (Give inventor, number, filing date, official title) 
C.  DESCRIPTION OR COPIES of official documents, such as sublicenses, assignment, prior 
license, etc.
D.  ACCOUNTING PROCEDURES for determining sales, net sales, sale value of stock, or other 
property
E.  EXISTING LICENSES AND/OR SUBLICENSES
F.  SPECIFICS OF EQUITY ARRANGEMENTS
G.  RESEARCH PROGRAM DETAILS
3.	 ConCluSion
This license checklist is a comprehensive tool useful for capturing very important concepts and terms 
in a complex license. Nonetheless, the checklist can and should be modified by each institution to re-
flect the way it does business. Having key concepts available to the negotiator and license draftsperson 
with a quick reading of a checklist can save much aggravation and potential misery should a deal go 
bad during its lifetime. It is much more cost effective to craft a sound license up front, having key terms 
as well-defined as possible, than it is to fix the problem through arbitration or litigation later on. ■
Donna BoBroWicz, Technology Transfer Specialist, Loyola University Chicago, Stritch School of Medicine, 2160 S. First 









License negotiations involve substantial real or potential 
value. They therefore should be supported by a team of 
experts. The essential skills and expertise needed for con-
ducting successful negotiations include: business strategy 
and development for leading the negotiations, marketing 
for estimating commercial potential, law for evaluating 
IP and patents and carrying out a variety of related tasks, 
science and medicine for evaluating new and potential 
health products, manufacturing and production know-
how to determine equipment and additional training 
needs, and finance for analyzing input from other experts 
on the team to combine into a comprehensive report. The 
strength of such a team is in its interdisciplinary compo-
sition; each of the skill areas can complement the other. 
From the perspective of international licensing, licensors 
can seek to improve the availability of health products in 
developing countries, possibly moving from the “tradi-
tional” approach to licensing toward one that incorpo-
rates public sector needs. The best approach for a public 
sector organization negotiating an agreement with a pri-
vate sector entity is usually to offer initial terms that the 
organization would be willing to agree to if it were on the 
other side of the table. Negotiating a fair licensing agree-
ment should not be seen as a process of “bargaining.” 
Rather, a licensing agreement is establishing, in written 
form, the rules of operation for an ongoing relationship 
where mutual trust and confidence will be necessary for 
success.
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potentially have a very large market, while the 
other party has research, manufacturing, or dis-
tribution capabilities essential to reaching that 
market. Therefore, the key to successful negotia-
tion is having a clear understanding of the value 
each party brings to the relationship. Value has 
several facets. There is an objective value: repre-
sented by, for example, how many units can be 
sold at a certain price, yielding a certain level of 
profit. There are also qualitative values illustrated 
by these examples: (1) One company feels that a 
particular product, owned by a second company, 
would enhance or complete a particular product 
line. For instance, it produces hepatitis B vaccine 
and would like to have a hepatitis A vaccine; and 
(2) One company may believe that access to a cer-
tain product, owned by a second company, would 
allow it to develop the expertise to handle other 
similar products. By learning how to produce 
recombinant DNA hepatitis B vaccine, the first 
company enhances its capability to produce other 
recombinant health products in the future. It is 
important that both parties to a potential agree-
ment think carefully about the benefits that will 
or could be obtained through a license agreement. 
Only with a clear understanding of the transfer of 
value can both parties intelligently and fairly ne-
gotiate an agreement.
This chapter should be of help mainly to 
the public sector R&D organization that is 
CHAPTER 12.1
1.	 InTRoduCTIon
An agreement is a means of transferring value be-
tween two parties. Each party has something of 
value that the other party needs or desires. For 
example, one party may have a product that can 
Mahoney RT. 2007. Negotiating an Agreement: Skills, Tactics, and Best Practices. In Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Ox-
ford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. RT Mahoney. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
Negotiating an Agreement: 
Skills, Tactics, and Best Practices
RICHARD T. MAHONEY, Director, Vaccine Access, Pediatric Dengue Vaccine Initiative,  
International Vaccine Institute, Republic of Korea
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either in-licensing the technology it needs or 
out-licensing technology it has developed. The 
discussion applies to a technology that is quite 
advanced in development. Nevertheless, the in-
formation should also be of use to university 
technology transfer managers and others who 
are not necessarily directly connected with on-
going R&D programs. 
We discuss the licensing process from three 
points of view: the skills needed, the tactics used, 
and the practices employed to protect the inter-
ests of the public sector.
2.	 SkIllS	needed
Because a license negotiation involves substantial 
real or potential value, it should be supported by 
a team of experts. Private sector managers com-
monly complain that public sector organizations 
are poorly prepared to undertake effective nego-
tiations, often demand unrealistic conditions, 
and cannot present a convincing case about the 
reasonableness of their demands. Obviously, we 
can do better.
There may be only one or two persons con-
ducting the negotiations, but they should be able 
to call upon experts in different areas. The follow-
ing are essential skills for negotiations: 
• business strategy or business development 
• marketing 
• law 




Often, the business strategist is the lead negotiator. 
With considerable experience in structuring busi-
ness relationships, the strategist will use the inputs 
of all the other experts to assemble the negotiating 
package. This person needs to have a clear sense 
of how the particular negotiation relates to the 
overall goals of the organization. This is important 
because without this sense, the negotiations may 
lead to a result that will not be useful to the orga-
nization. After all, signing an agreement does not 
necessarily mean that negotiations were success-
ful. The business strategist’s goal is to maximize 
the benefits to all parties. Of particular concern is 
developing a strategy to be implemented by public 
sector organizations that helps to ensure that the 
resulting product is available, appropriate, adopt-
able, and affordable by the poor in developing 
countries. Such a strategy, known as a global ac-
cess strategy,1 has been the focus of much analysis 
recently, and the business strategist and his or her 
team should have prepared a global access strat-
egy, as appropriate for their product. The negotia-
tions of a license agreement should lead to terms 
that help achieve the specific goals of the strategy, 
which are defined in the agreement.
2.2 Marketing
Expertise in marketing and market analysis is es-
sential to negotiating a good agreement. Omission 
is dangerous because it can lead either to an over-
estimation or underestimation of the market po-
tential, which, in turn, can lead to a suboptimal 
agreement or a rejection of an agreement that 
could have been successful. Lack of marketing 
knowledge may also make it difficult to negoti-
ate the best (fairest) deal. In the context of this 
Handbook, we define markets as both private sec-
tor markets and public sector health systems. For 
products such as a malaria vaccine, the public sec-
tor market will often be the most important, but 
an understanding of the travelers’ market in devel-
oped countries will also be essential. A marketing 
specialist should ask the following questions:
• What level of sophistication is required to 
market the product? 
• How does the new product complement or 
compete with existing products? 
• Would the product be directed at old or 
new customer groups? 
• If the product is to be sold in both the pub-
lic and private sectors, what are the barriers 
to achieving a profitable market? 
• What types of information would be need-
ed to promote the product to both the gov-
ernment and the private sector? 
• What are feasible prices and would these 
prices be sufficient to support the project? 
• How fast would the market grow and 
what would be the minimum sales for 
sustainability/profitability? 
CHAPTER 12.1
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With the answers to these questions in hand, 
the public sector agency will be well prepared to 
conduct negotiations. 
2.3 Law	
The need for legal assistance is clear.2 The lawyer 
should possess IP expertise, be able to evaluate 
patents, and have a variety of additional skills or 
be able to access those skills. A party wishing to 
license a technology will need to be able to assess 
the value of the patents. This assessment will in-
clude an evaluation of the claims of other similar 
patents. While patent offices try to avoid granting 
patents with duplicate claims, it is very common 
to find many patents with the same or similar 
claims, especially for health products—a num-
ber of patents may be issued that claim different 
methods to produce the same health product. 
The lawyer will need to determine the potential 
for claims of patent infringement. The lawyer 
might also advise on the need to obtain a license 
from another patent holder before using the of-
fered patent. This assessment (called a freedom to 
operate assessment) will help in determining the 
true value of a patent. Such an assessment would 
answer the questions: Are there other patents that 
actually are more important? Who owns them? A 
lawyer will also be needed to advise on the laws 
of the various countries in which work would be 
carried out. For example, it may be necessary to 
evaluate the legal aspects of various arrangements 
for paying up-front fees and royalties. Some coun-
tries tax royalty payments quite heavily but have 
low or no tax on legitimate charges for technol-
ogy transfer. Other legal, country-specific matters 
include validity of termination conditions and 
validity/enforcement of milestone conditions.
2.4 Science,	medicine,	and	regulations
The negotiating team should have scientists and 
medical experts who are knowledgeable about the 
products under discussion. In this age of highly 
sophisticated science, a lead negotiator would be 
ill-advised to proceed without obtaining good 
scientific advice about a new health product tech-
nology. Not only is it important to assess the fea-
sibility of the new product from a scientific point 
of view, but it is also important to know what 
is going on in the field broadly. One must ask, 
for example, if there were several methods for 
production of a health product: Which is best? 
Which is easiest to control? What are the safety 
considerations of each? It is also important to un-
derstand the regulatory framework, or lack there-
of, for the potential new product. What kinds of 
clinical trials, in how many settings, and for what 
length of time will be needed? In the absence of a 
regulatory framework for a truly innovative prod-
uct, how can such a framework be created and 
how long will it take? 
2.5 Production
The production staff also should be involved in 
the licensing negotiation. They need to contrib-
ute their knowledge about required production 
equipment, the needs for additional training, and 
facility requirements. Production experts can also 
provide cost estimates for establishing produc-
tion and for approximating variable costs at given 
production volumes. (Variable cost studies help 
determine the extent to which cost is sensitive to 
production volumes.) Production staff will also 
be able to advise on requirements for adequate 
quality control. For codevelopment agreements, 
production experts can be indispensable for ad-
vising on production feasibility. Product devel-
opers working in the lab often are unrealistically 
optimistic about how easy it will be to produce 
a product in commercial quantities. Production 
staff can bring reality to the discussions. A final 
topic for production experts is to understand the 
potential costs that might be incurred in differ-
ent settings (for example, developed versus de-
veloping countries). It may be desirable to seek 
production in a developing country to ensure the 
lowest costs. 
2.6 Finance
Before negotiating, carrying out a careful finan-
cial assessment of the project is essential. The as-
sessment will help the manager determine what 
new funds will be required to launch and sustain 
the project, which will require factoring in such 
variables as the cost of funds (interest payments), 
hard currency requirements, break-even points 
(the length of time it takes to recover the initial 
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investment given certain assumptions about sales 
and costs), return on investment, impact of roy-
alties and other technology acquisition fees, and 
opportunity costs (involving the question, could 
the money be used more profitably in some other 
way?). The financial analyst will take inputs from 
all the other experts and combine them to pre-
pare a report. 
It should be clear that each of the skill areas 
complements the others. For example, in a tech-
nology licensing agreement, it will be necessary 
to assess the relative capabilities of the potential 
licensee’s production and marketing depart-
ments. A licensee might be strong in production 
but weak in marketing, or strong in marketing 
but weak in production. If the differences are too 
great, implementing the agreement may be dif-
ficult. In these cases, the agreement should have 
tangible performance obligations for activities in 
which the firm is weak and flexibility where the 
firm is strong. The marketing, finance, and pro-
duction staffs will need to work together to com-
plete these assessments. 
Not all groups have direct access to a com-
plete complement of staff resources. In those 
cases, expertise could be obtained through con-




Once two organizations have decided to seek to 
conclude a licensing agreement between them, 
the first step is to designate the negotiating teams. 
Each organization should clearly indicate who the 
members of the negotiating team are and what 
their respective responsibilities are. The principle 
line of communication should be between the 
two lead negotiators. However, the two groups 
may need to exchange technical information. For 
example, it may be necessary for one organization 
to share scientific information with the other. In 
that case, the scientific staff of each organization 
should carry out the exchange. Or it may be nec-
essary to go into technical detail about produc-
tion issues, in which case the production staff 
of each organization should be involved. When 
there is an exchange of technical information, the 
discussion should be limited to the information 
itself, and the technical individuals should not 
enter into any negotiations with respect to the 
licensing agreement unless such involvement is 
requested by the lead negotiator.
In general, the public sector organization 
should offer the first draft of a licensing agree-
ment. This approach is much easier than trying to 
work from a draft prepared by the private sector 
organization because the draft needs to cover a 
number of topics of particular concern to public 
sector organizations, and these topics probably 
would not be addressed in a private sector organi-
zation’s draft. The topics of concern are jurisdic-
tion, liability issues, ownership of IP, protection 
of the public sector, and others. It is much easier 
to start with a draft that has all of these issues 
clearly laid out—and is based on previous expe-
rience—than to try to insert those issues into a 
draft that does not include them. 
The public sector organization’s lead nego-
tiator may ask for examples of the kind of agree-
ment that the other organization feels comfort-
able with. The lead negotiator may extract some 
of the key wording in clauses from the example 
agreements and insert them in the prototype of 
the public sector organization agreement. In cer-
tain cases, primarily for in-licensing, it may be 
necessary to use the private sector organization’s 
standard agreement, either because the organiza-
tion requires that its agreement be used or be-
cause it has extensive experience in the kind of 
licensing agreement at issue, and time and energy 
would be saved.
One variation in developing a first draft of 
a license agreement is to prepare a term sheet. A 
term sheet lists the major issues that are expected 
to arise in the negotiations and indicates the out-
come that the proposing party hopes to achieve. 
For example, if the agreement includes the devel-
opment of a commercially viable production pro-
cess, the term sheet would indicate a schedule for 
achieving various stages of production capability, 
the number of units to be produced, and the qual-
ity standards that the units would have to meet. 
A term sheet is a straightforward way for the par-
ties to discuss key issues without having to wade 
CHAPTER 12.1
 HANDBOOK OF BEST PRACTICES  | 1159 
through a long document that contains a lot of 
routine boilerplate. Table 1 provides an example 
of a term sheet for a clinical testing agreement.
The best approach for a public sector orga-
nization negotiating an agreement with a private 
sector entity is usually to offer initial terms that 
the organization would be willing to agree to if it 
were on the other side of the table. Negotiating a 
fair licensing agreement should not be seen as a 
process of “bargaining.” This is because a licensing 
agreement establishes, in written form, the rules 
of operation for an ongoing relationship where 
mutual trust and confidence will be necessary for 
success.
At the beginning of the negotiations, it is 
important for each group to clearly state what it 
hopes to achieve from the negotiations, although, 









Funding 100% paid by [DATE]
Phase III conducted by [DATE]
Initiation 2009 or 2010
Completion 2012
Subjects 10,000
Funding 100% paid by [DATE]
Diligence
Phase I/II initiation by [DATE] 1/1/07
Phase III initiation by [DATE] 1/1/10
Regulatory submission by [DATE] 1/1/12
Clinical trial design by [DATE] Licensor consent
Manufacturing Licensor or its agent
Transfer prices to [DATE]
ncGMP (noncurrent good manufacturing practice) material for 
phase I/II trial
Paid by licensor
cGMP (current good manufacturing practice) material, per 
unit
US$10
Cost sharing for manufacturing scale-up To be determined
Investigational New Drug (IND) preparation by licensor $0
Quality control monitor for clinical trial 100% paid by [DATE]
Regulatory license holder [DATE]
Indemnification [DATE] indemnifies licensor
MAHONEY
1160 | HANDBOOK OF BEST PRACTICES
information that cannot be revealed. The public 
sector organization may be interested in work-
ing with a group that can develop a superb and 
economical production methodology for a new 
product that the public sector organization has 
developed. The counterpart organization may be 
interested in participating in the development 
of regulatory guidelines for a particular kind 
of product. By stating their primary objectives 
clearly at the beginning of the negotiations, it 
will be easier for both parties to take into ac-
count the needs of the other.
Negotiating a license agreement often takes 
much longer than either party would like. This 
can be frustrating for the technical staff of the 
public sector organization, who would like to re-
sume research and development activities as rap-
idly as possible but have to put on hold many 
such activities until the license agreement is 
signed. There are a number of reasons why license 
negotiations often take longer than anticipated. 
The license must be approved at multiple levels in 
each organization and will undergo review from 
technical, financial, legal, and other experts with 
varying points of view. Often the views may differ 
internally, which requires internal negotiations 
that take some time to resolve.
4.	 pRACTICeS	To	pRoTeCT	The	InTeReSTS	
of	The	puBlIC	SeCToR	
Table 2 illustrates how licensors can seek to im-
prove the availability of health products in devel-
oping countries. It summarizes the “traditional” 
approach to licensing and then indicates a more 
public sector option. 
Two examples of a clause pertaining to ter-
ritory are provided below. The clause is for use 
in agricultural research and development but can 
be adapted to health research and development. 
The clause would be used in a license issued by a 
university to a private company.
Example 1: Public Intellectual Property 
Resource for Agriculture (PIPRA)3
Definition of Humanitarian Use:
Definitions:
 “Humanitarian Purposes” means (a) the use 
of Invention/Germplasm for research and 
development purposes by any not-for-profit 
organization anywhere in the World that has 
the express purpose of developing plant ma-
terials and varieties for use in a Developing 
Country, and (b) the use of Invention/
Germplasm for Commercial Purposes, includ-
ing the use and production of Germplasm, 
seed, propagation materials and crops for hu-
man or animal consumption, in a Developing 
Country.
 “Commercial Purposes” means to make, 
have made, propagate, have propagated, use, 
have used, import, or export a product, good 
or service for the purpose of selling or offer-
ing to sell such product, good or service.”
 “Developing Country” means any one of 
those countries identified as low-income 
or lower-middle-income economies by the 
World Bank Group at the time of the ef-
fective date of this agreement and all other 
countries mutually agreed to by Licensor 
and Licensee.
Reservation of rights
 Notwithstanding other provision of rights 
granted under this agreement, University 
hereby reserves an irrevocable, nonexclu-
sive right in the Invention/Germplasm 
for Humanitarian Purposes. Such 
Humanitarian Purposes shall expressly ex-
clude the right for the not-for-profit orga-
nization and/or the Developing Country, 
or any individual or organization therein, 
to export or sell the Germplasm, seed, 
propagation materials or crops from the 
Developing Country into a market out-
side of the Developing Country where 
a commercial licensee has introduced or 
will introduce a product embodying the 
Invention/Germplasm. For avoidance of 
doubt, not-for-profit organization and/or 
the Developing Country, or any individual 
or organization therein, may export the 
Germplasm, seed, propagation materials 
or crops from the Developing Country of 
origin to other Developing Countries and 
all other countries mutually agreed to by 
Licensor and Licensee.
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This clause specifies the limitations 
on the application of the patent in 
developing products. The simplest 
approach is to grant the licensee 
an exclusive right to all possible 
applications of the patent, including 
not only those specified in the patent, 
but others that may emerge as further 
research and development proceeds. 
The clause could grant an exclusive 
license only for those products 
that the licensor actually wishes to 
pursue. Also, the clause could grant 
an exclusive license only for those 
products that were unlikely to have a 
significant market among the poor in 
developing countries.
Territory This clause specifies the geographic 
areas in which the licensee has the 
right to exercise the patent. The 
simplest approach is to grant the 
licensee an exclusive right to all 
possible territories. Usually a license 
is valid only in the countries where a 
patent has been filed, but the license 
can give the licensee the right, at the 
licensee’s expense, to file for patent 
protection in additional countries.
The clause could grant an exclusive 
right to a major portion of developed 
countries, for example, North America. 
The licensor could grant another 
exclusive limited license to countries 
in Europe. Finally, the licensor could 
grant nonexclusive licenses to 
both licensees for an agreed list 
of developing countries. Then the 
two primary licensees would have 
to compete for sales to developing 
countries.
Price In most licensing agreements, there 
will be no conditions with respect 
to price. The licensor assumes the 
licensee will determine the best price 
to ensure the greatest return on 
investment.
The licensor can consider several 
options of setting a condition of the 
price to the public sector in developing 
countries.
• The price could be specified, for 
example, US$0.30 per tablet. This 
is feasible only when the licensor 
has detailed technical knowledge 
of the production, marketing, and 
distribution costs. 
• The price could be set at cost of 
production plus a reasonable 
markup, for example, 15% of cost of 
production. This is feasible when 
the licensor has a reasonable 
expectation of being able to 
monitor the cost of production.
• The price could be set at “no higher 
than the lowest price offered to 
any private sector buyer.” This may 
be preferred in cases where it is 
expected there will be large bulk 
purchases by private sector buyers 
who are good at negotiating the 
very best price. 
continued on next page
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Example 2: Donald Danforth Plant
Science Center
Reservation of IP Rights 
for Humanitarian Purposes
 COMPANY and Danforth shall diligently 
and in good faith negotiate the terms of the 
license, making provision for preserving the 
availability of the Intellectual Property for 
meeting the needs of developing countries.
 or
 Danforth shall retain the right to use Phase 
I Materials and Phase II Materials for both 
academic and commercial research pur-
poses, which shall include the right to use 
such technology for the benefit of countries 
eligible for International Development 
Association funds as reported in the most 
recent World Bank Annual Report.
This clause has been part of the Donald 
Danforth Plant Science Center’s IP policy since 
2002.4
5.	 ConCluSIon
The negotiation of licenses is a complex undertak-
ing that involves various tactics and a variety of 
skills. To meet the needs of the public sector, the 
negotiations should include special considerations 
in many clauses of the agreement. Moreover, be-
cause IP management involves matters of real or 
potential considerable value, it should be given 
the resources and personnel it needs to do the job 
well. No serious private sector company would 
enter into IP negotiations without allocating 
an appropriate level of resources and personnel. 
Because public sector research organizations are 
Topic Basic	concept public	sector	consideration
Labeling In most licensing agreements, there 
will be no conditions about labeling. 
The licensor assumes the licensee 
will prepare labeling in conformity 
with national drug regulatory agency 
requirements. 
The licensor can help ensure that 
the product is licensed properly, 
especially in developing countries 
where national regulatory agency 
requirements for labeling may not be 
rigorous or enforced. For example, if 
some of the research that led to the 
patent was supported by the World 
Health Organization (WHO), the 
license can specify that the name of 
WHO cannot be used without prior 
written approval of WHO. Additionally, 
the license could state that any claims 
for the use, safety, and effectiveness 





This concept has been developed by 
the U.S. National Institutes of Health. 
It calls for the licensee to undertake 
some specific actions that will benefit 
the public sector.
The licensor can ask for a number of 
actions including donation of product 
for clinical evaluation in public sector 
research programs, joint efforts 
to develop markets in developing 
countries, free supply under specified 
condition to developing countries, 
and so on. 
Table	2	(continued)
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concerned with saving human life, their impera-
tive to do the same should be no less. ■
RICHARD T. MAHONEY, Director, Vaccine Access, Pediatric 
Dengue Vaccine Initiative, International Vaccine Institute, 
San Bongcheon-7dong, Kwanak-ku, Seoul 151-818, 
Republic of Korea. rmahoney@pdvi.org 
1 Mahoney RT, A Krattiger, JD Clemens and R Curtiss. 
2007. The Introduction of New Vaccines into Devel-
oping Countries IV: Global Access Strategies. Vaccine 
(in press). See also Krattiger A, et al. 2006. Global Ac-
cess Strategy for the live recombinant attenuated 
Salmonella anti-pneumococcal vaccine for newborns. 
Arizona State University: Tempe. www.biodesign.asu.
edu/centers/idv/projects/, and Anonymous. 2006. 
Strategic Plan. Dengue Vaccines: The Role of the Pedi-
atric Dengue Vaccine Initiative. Strategic Partnerships, 
Supportive Research & Development, Evaluation, and 
Access. International Vaccine Institute: Seoul. http://
www.pdvi.org/PDFs/PDVI%20Strategic%20Plan.pdf.
2 See, also in this Handbook, chapter 6.10 by J Dodds and 
chapter 6.9 by M Goldman.
3 www.pipra.org/docs/HumResLanguagePIPRA.doc. See, 
also in this Handbook, chapter 2.1 by AB Bennett.
4 Beachy R. 2006. Donald Danforth Plant Science Center. 
St. Louis, U.S.A. Personal communications. See, also in 
this Handbook, chapter 17.9 by K Schubert.

ABSTRACT
This chapter describes marketing concepts and how to 
use them to create marketing plans for newly developed 
technologies in the health and agricultural sectors. The 
traditional marketing model invokes the “four Ps” of mar-
keting: product, price, place, and promotion. This chap-
ter, however, concentrates on the “five Ws” of marketing, 
which are more relevant to early-stage technologies: who? 
what? where? when? and why? The author then discusses 
the concept of the unique selling proposition (USP) and, 
finally, considers the marketing of technology transfer ac-
tivities, or internal marketing.
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Of course, a for-profit company will not be suc-
cessful unless it sells products; this means that the 
company must understand its markets. However, 
the same is true for a not-for-profit or a govern-
ment agency: neither can be successful without 
understanding the markets for its technologies. 
The reason for this is that the need of these types 
of persons to have users who will be interested in 
the technologies. If there are no users, the tech-
nology will not be adopted.
Next, marketing early-stage technologies has 
little to do with advertising. While understanding 
how markets become aware of technology is im-
portant (a key concern of advertisers), this is only 
one of many pieces of information required to 
understand how a market will respond to a spe-
cific early-stage technology. Advertising is only 
one small part of an overall marketing strategy for 
any product; advertising promotes awareness of a 
product inside potential markets. However, in the 
case of early-stage technologies, other aspects of 
marketing are more important: after all, if some-
one does not know where their potential markets 
are, advertising will likely be ill-conceived or pre-
pared. Marketing includes identifying markets as 
well as the features of the technology that will be 
of interest to those markets.
Third, marketing is frequently characterized 
as a type of behavior-modification technique that 
alters buyers’ intentions and makes them buy 
CHAPTER 12.2
1. inTRoDuCTion
Because marketing is usually taught only in for-
mal business programs, it is often not understood 
by scientists, technologists, and engineers. This 
lack of understanding can impede the transfer of 
technology from the laboratory to the commer-
cial sphere.
Common misconceptions about marketing 
include that it is:
• only relevant to for-profit companies
• just a fancy name for advertising
• making buyers buy things they do not 
need
• just about one’s skill in selling something to 
others
Let us begin with the first misconception: 
Marketing is only relevant to for-profit companies. 
Mongeon MD. 2007. An Introduction to Marketing Early-Stage Technologies. In Intellectual Property Management in Health 
and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., 
and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. MD Mongeon. Sharing the Art of IP Management: Photocopying and distribution through the Internet for non-
commercial purposes is permitted and encouraged.
An Introduction to Marketing  
Early-Stage Technologies
marcel D. mongeon, Intellectual Property Coach, Mongeon Consulting Inc., Canada
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products they do not need based on deceptive ad-
vertising. It is true that if a product is advertised 
as having features or benefits it does not have, 
buyers will be dissatisfied. Children discover this 
common sense, for example, when a doll they 
have seen advertised on television proves not to 
be able to dance!
Finally, although “selling skills”—such as 
“cold-calling” a prospect, introducing a poten-
tial investor/licensee to the idea of an early-stage 
technology, and conducting a licensing negotia-
tion—are certainly important, such skills are only 
one aspect of marketing.
Put simply, marketing is:
Understanding the buyer’s needs and how to 
satisfy those needs.
Accomplishing these simple objectives, how-
ever, often requires a complex strategy. 
2. “puSh”	AnD	“pull”
A frequent criticism of technology transfer is 
that people are too concerned with “pushing” 
technologies into the market rather than allow-
ing buyers’ needs to “pull” those technologies 
in naturally. But the real problem is that, very 
often, buyers don’t even know what their needs 
are!
For example, consider the Internet. 
Although today, most people who use it would 
say they can’t live without it (or they need it), 
20 years ago, the idea that all computers might 
be connected by some overarching network 
was the stuff of science fiction. However, few 
science-fiction writers envisioned that such a 
“web” might allow us to place orders for goods 
and services or to receive communication and 
information. However, once Internet technol-
ogy was pushed on to consumers, a market was 
created. Consumer demand has pulled more 
and more technologies into the market ever 
since. The original Internet technology was 
created despite any study of consumers’ need 
for it; The success of the Internet technology 
was not anticipated until the early-1990s other 
than by a few visionaries. Rather, consumers 




In this chapter, it will be important to understand 
two key concepts: technology transfer and early-
stage technology.
Technology transfer refers broadly to any 
means of moving a scientific idea from a labora-
tory to practical use application in a production 
environment. Technology transfer can be formal 
and well-regulated: for example, assigning intel-
lectual property ownership for a new technology, 
licensing the technology, and starting up a new 
company based on the new technology.
Some technology transfer is informal and less 
regulated. For example, many of the technolo-
gies that contributed to the personal computer 
revolution (such as the laser printer, Ethernet, 
WYSIWYG, and the mouse) were developed at 
Xerox’s Palo Alto Research Center in the 1970s. 
Xerox did not capitalize on these technologies by 
actually bringing any of them to the market as 
products, and they were eventually transferred to 
other companies when the employees who had 
originally worked on those projects left Xerox.
Technology transfer is also generally used to 
refer to the process used to ensure that research 
findings are translated into actual use. Rather 
than relying on inventors to determine the practi-
cal uses of their inventions and put the appropri-
ate structures in place to bring that use to market, 
an intermediate person or department (referred 
to as the technology transfer office [TTO]) takes 
responsibility for that work.
Early-stage technology refers to a scientific, 
technical, or engineering finding that is not em-
bodied in an existing product and that does not 
obviously lend itself to a commercial enterprise.
Early-stage technology, for example, led to 
the creation of the Roundup Ready® line of genet-
ically modified seeds sold by Monsanto. A gene 
that makes a plant tolerant to glyphosate had 
been discovered. In itself, the finding had little 
practical value. However, the already existing her-
bicide Roundup® was based on glyphosate, and 
researchers discovered that plants containing the 
new gene could be safely used with the herbicide. 
The herbicide kills weeds, but does not harm the 
Roundup Ready® crops.
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Careful marketing work (usually done by the 
TTO) can help an organization turn an early-
stage finding into a commercial product. The 
TTO accomplishes this by determining possible 
uses for the finding, identifying potential users, 
recognizing the features of the end product that 
will attract users, and then getting the resulting 
product to those users.
Utility is what a product allows the customer 
to do. Using a bicycle, for example, allows some-
one to get from point A to point B faster than on 
foot. Marginal utility is what a particular product 
does better than any other. A bicycle may have 
limited marginal utility since it may not be the 
only way that someone can travel a short distance, 
and it may not be the best way, either. A bicycle 
with square wheels, designed to roll over a roadbed 
comprised of inverted catenary structures (also 
known as a “washboard” surface)1 would likely 
have a limited marginal utility for almost every-
one. Such a bicycle would only appeal to people 
who not only want or need a bicycle but who also 
live near a lot of roads with surfaces that follow 
a very specific, very unusual structure. However, 
for a few people, a square-wheeled bicycle would 
have a very high marginal utility, since no other 
vehicle could travel over such roads.
Let us consider an example of an early-stage 
technology. A new membrane designed for the 
separation of proteins has a utility that is similar 
to many existing technologies such as filter paper 
or gel electrophoresis. However, if our new mem-
brane has the additional benefit of being able to 
separate proteins based on their ionic charge, 
then the marginal utility becomes the ability to 
separate proteins on this basis. Those users who 
are interested in this feature (which is likely to 
be a large number) will be interested in the new 
product’s marginal utility over the general utility 




When marketing a product, it’s first important 
to know who will be buying it: What if we were 
dealing with a new drug that has been identified 
for hypertension (high blood pressure)? Who is 
the “buyer” of this drug?
We might begin by assuming that the buyer 
is the patient because he or she actually pays the 
pharmacist for the drug. Upon further reflec-
tion, however, we realize that it is the prescribing 
physician who makes the decision about which 
drug to prescribe. In fact, the patient has little 
input into that decision; so, in effect, the buyer 
may be the prescribing physician. Then again, in 
many jurisdictions, larger organizations—HMOs 
(health management organizations) or govern-
ments—decide for which drugs, and under what 
conditions, patients will be reimbursed. Thus, the 
buyer of our new drug may not be the same from 
jurisdiction to jurisdiction.
Now, let us turn to a different sort of product, 
an early-stage technology. A researcher has identi-
fied a specific genotype that makes pigs much more 
susceptible to porcine stress syndrome (PSS). Pigs 
that have PSS are significantly smaller than those 
without it (do not have the genotype). Farmers 
who raise the pigs (producers) sell the pigs to 
slaughterhouses, which in turn sell the carcasses to 
processors. Processors will pay less money to the 
slaughterhouses for PSS carcasses, and the slaugh-
terhouses, in turn, pay less to the producers.
Who is likely to buy PSS-identification 
technology: the producers, the processors, or 
the slaughterhouses? Most likely, the producers: 
by using the technology, they can cull PSS-posi-
tive swine from their stock and save themselves 
the cost of raising inferior animals. In turn, the 
producers can sell to the slaughterhouses with the 
promise that their herds are PSS free. 
4.2 The	what	of	marketing
What do buyers want? In order to understand the 
market, TTO professionals must understand: 
• how buyers will use the product
• what factors buyers will consider when 
making decisions to buy
• what product characteristics buyers find 
attractive
It is dangerous not to understand exactly 
what buyers want and what they are willing to pay 
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for what they want. For example, the Concorde 
airplane was able to cut the usual trans-Atlantic 
flight time (approximately seven hours) by a little 
more than half. However, in order for the com-
pany to turn any profit at all, a Concorde flight 
cost more than three times the price of the aver-
age nonsupersonic flight. As you probably already 
know, the Concorde went out of business. 
What went wrong with the Concorde’s mar-
keting concept? In all likelihood, the marketers 
overestimated the amount that buyers of long-dis-
tance travel were willing to pay for reduced flight 
times. In the 1950s, buyers of long-distance travel 
had certainly been willing to pay more for faster 
travel: they opted to pay substantially higher pric-
es in order to travel by air rather than rail or ship. 
Because buyers were happy to make the trade-off, 
the size of the air-travel market expanded rapidly, 
which allowed airlines to reduce costs, leading to 
further market expansions (a so-called virtuous 
circle). Ultimately, this led to the almost complete 
replacement of rail and sea travel by air travel. But 
while travelers in the 1950s were happy to pay 
for improved travel technology that saved them 
days worth of travel, Concorde customers did not 
feel that the prices they were being charged were 
worth a mere four-hour time savings (a three-hour 
flight rather than a seven-hour one). 
Consider another example. A new set of ob-
stetrical forceps2 has been devised made from a 
molded plastic rather than the existing standard 
of metal. The plastic allows a limited amount of 
play at the fulcrum point of the forceps. This play 
ensures that no more than a set amount of force 
will be put on the head of the baby being deliv-
ered. The new technology meets with a great deal 
of resistance in the marketplace. Why?
In part the answer comes from misunder-
standing the what of marketing. Buyers (which 
include obstetricians) obviously consider many 
factors in purchasing such a device. The use of 
plastic rather than steel was likely perceived as a 
deficiency due to the perception that somehow 
that material is less sterile than metal, which is 
well known in delivery rooms. In addition, the 
change in material results in a significant change 
of weight and the perception that the plastic 
device is less robust than its metal counterpart. If 
these perceptions of buyers had been considered, 
alterations to the product may have resulted in an 
easier adoption of the technology.
4.3 The	why	of	marketing
Once we have established who will buy our prod-
uct and what they want to buy, we need to ask 
why someone should buy our product as opposed 
to someone else’s. In order to answer this ques-
tion, we must ask a broader one: why does a com-
pany (after all, most early-stage technologies are 
not sold to consumers) buy anything? To put it 
another way what are the drivers or forces acting 
on a company? 
Michael Porter suggests that there are five 
such forces:3
1. Competition among businesses in the 
industry
2. The threat of new businesses in the 
industry
3. The threat of new, competing products
4. The bargaining power a company has with 
its suppliers
5. The bargaining power a company has with 
its buyers
By understanding these forces, marketers can 
determine what is of interest to potential users for 
any early-stage technology. If the technology can 
help the user address a company’s concerns in any 
of these forces, it is more likely that the technol-
ogy will be adopted; if there is no effect in any of 
these forces, there is little likelihood that the user 
will be interested. 
If we analyze these forces for a user decid-
ing whether or not to adopt a product derived 
from an early-stage technology, we find that the 
new product must give the user an advantage in 
one of the five areas. For example: does the new 
product: 
1. Lessen the potential competition among 
those already in the industry. This could 
be accomplished by creating a new class of 
products that competitors will not be able 
to create for a number of years.
2. Lessen the threat of new companies coming 
into an industry. For example, increasing 
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the barriers to entry for new companies 
would make this happen.
3. Lessen the threat to companies within the 
industry of new, competing products. By 
ensuring that there is good IP protection 
around the new product, the possibility of 
new, competitive products is lessened.
4. Affect reliance on existing suppliers. By 
either reducing the amount required from 
existing suppliers or by bringing new sup-
pliers into the picture, the new product 
would provide added bargaining power 
over suppliers.
5. Affect the relationship between buyers. A 
new product can significantly alter the rela-
tionship with buyers by, for example, provid-
ing buyers with product features that they 
are not able to obtain from anyone else.
It is important to articulate which of these 
forces a technology will help the business cus-
tomer address—something we might call the “So 
what?” test. In order to answer this question, you 
need to consider what your product offers cus-
tomers in the way of:
• features (the obvious attributes of your 
product)
• advantages over other, similar products
• benefits to the user
Remember that it is a f-a-b idea to make sure 
that your product is competitive! 
Furthermore, any product or early-stage 
technology needs a unique selling proposition 
(USP): that is, something that distinguishes your 
product from any other (discussed in section 5).
4.4 The	where	of	marketing	
We have figured out who will buy our products. 
Next we must ask: where are products or early-
stage technologies sold? After all, there is no eBay 
for technologies yet (although a number of tech-
nology exchanges are in the works). 
Products typically move through “channels 
of distribution.” Let us take the example of a hy-
pothetical new technology that allows us to am-
plify DNA. How can we get that technology into 
use? What channels of distribution would exist? 
First, there could be use in research laboratories. 
Laboratory use could be subdivided into aca-
demic and for-profit (such as in a pharmaceutical 
company) research labs. There is also use of the 
amplification technology with various practical 
tests for patients: paternity testing and predictive 
genetic testing, as well as forensic crime-scene 
testing. Finally, the amplification technology 
could also be used in certain drug-production 
processes. Without much work we can see how 
one relatively simple early-stage technology may 
have a large number of uses.
These different uses have an intellectual prop-
erty implication. Although that aspect is beyond 
the scope of this chapter, it is important to realize 
that certain types of uses for a technology may be 
prohibited by IP protection making it important 
to derive as many different uses as possible: some 
of these may be hindered from use by IP consid-
erations; others may be free for use.
Consider another example: software that 
helps hospitals use their imaging equipment. 
What channels of distribution do marketers 
need to consider? Depending on the jurisdiction, 
hospitals may be free-standing private institu-
tions, part of a health-management organization 
(HMO), or part of a government or quasi-gov-
ernment organization. In addition, a hospital may 
not be entirely independent: it may be associated 
with other hospitals or healthcare providers in a 
buying group.4 In other words, the person who 
makes the buying decision (or even lists a soft-
ware product in a catalog) may be some distance 
from the users of the software.
Furthermore, should the software company 
be separate from, or in alliance with, the com-
panies that sell the imaging equipment? This 
is not a trivial decision, because it is likely to 
determine who the buyer is. For example, an 
equipment vendor is more likely to sell directly 
to medical staff, whereas a software vendor is 
more likely to sell to the computing and infor-
mation services department. Not only are there 
a number of potential buyers within the hospital 
in at least two different departments, but also 
the hospitals or departments may buy software 
through a number of different channels (directly 
from equipment manufacturers, or through one 
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or more buying groups). There are at least eight 
channels5 of distribution! 
4.5 The	when	of	marketing
The last question to ask is when can you sell some-
thing to buyers? 
4.5.1  The	long-term	when
Many technologies exist long before people be-
come interested in them as products. For ex-
ample, after the discovery of the double-helix 
nature of DNA in the 1950s, it took approxi-
mately 40 years (until the 1990s) before actual 
products depending on DNA were generally 
available. This long-term aspect becomes impor-
tant when one considers that the term of patent 
protection is usually limited to twenty years. In 
other words, even if the original discovery of the 
structure of DNA had been patented, any ac-
tual revenues resulting from the discovery would 
only have been seen after the expiry of the rel-
evant patents.
Another technology that took more than a 
century to be adopted by the public was the fax 
machine. It was invented in the early 1800s, but 
it was initially too slow: transmission took six 
minutes or more per page. Public interest in the 
fax machine only arose in the late 1980s, when 
digital compression technology allowed a page of 
data to be sent in less than one minute. 
4.5.2 The	short-term,	seasonal,		
or	cyclical	when
Governments and institutions have differing 
equipment needs, depending on where they are 
in their annual budget cycles, how old or up-to-
date their equipment is, and whether or not regu-
lations have recently changed. For example, the 
software that allows accountants to create non-
tamperable digital images of documents moves off 
the shelves most slowly in February, March, and 
April. Why? The answer is simple: at that time of 
year, accountants are too busy dealing with their 
clients’ taxes to consider purchasing new tools for 
their own administrative needs.
4.6 The	how	of	marketing
Thus far, we have considered the five Ws:
• Who is going to buy our product
• What product features should be 
emphasized
• Why buyers should want to buy the 
product
• Where we should sell the product and where 
along the distribution channel buyers are
• When buyers will be most interested in the 
product
So how should marketers use this 
information? 
Usually, the how is answered with a market-
ing plan, a written document that answers each 
of the previous questions in detail. If the product 
is an early-stage technology, there are probably 
not going to be any concrete answers. In fact, it 
may be sufficient to identify possible answers and 
their ramifications. The early marketing plan can 
also be considered a provisional document that 
will be regularly revised as research and develop-
ment continue.
It is essential to point out that this marketing 
plan is likely an important function of the technol-
ogy transfer office. The creation of such a plan will 
be done once the office answered the questions that 
we have posed in this chapter and add considerable 
value to the early-stage technology. Value is added 
by identifying potential markets, products that can 
be sold into those markets and the features, advan-
tages, and benefits those products will have.
Although there may be no hard answers at 
this point, market research will never go to waste. 
It may come in handy when the company consid-
ers licensing or spinouts. Also, potential buyers 
can be contacted early, and their responses can 
be useful for later market research. Moreover, 
people who work in early-stage technology are 
usually happy to cooperate with someone who is 
researching the market for a new technology. 
5. The	unique	Selling	pRopoSiTion
The unique selling proposition is the advantage or 
benefit that the product offers to the buyer, not a 
description of the technology that creates that ad-
vantage or benefit. To see the difference, consider 
the following examples.
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During the California Gold Rush in the 
1870s, miners complained that their pants wore 
out very quickly. In response, a tailor named Levi 
Strauss put copper rivets at the corners of the 
pockets of his denim pants. Miners quickly rec-
ognized the superiority of these pants, and to this 
day the USP of Levi’s jeans is their durability. The 
copper rivets are the source of that durability, but 
they are not the advertised feature.
USPs are also used in the automobile industry. 
Volvo represents the ultimate in safety, Ferrari rep-
resents the ultimate in speed, Rolls-Royce repre-
sents the ultimate in luxury, and Toyota’s Prius the 
most environmentally friendly hybrid car. These 
companies advertise the concepts of safety, speed, 
luxury, or environmental friendliness—not the 
technologies that make their cars safe, fast, luxuri-
ous, or environmentally friendly. Brands such as 
GM and Ford, which no longer have any USP as-
sociated with their mark, are doing rather badly 
compared to those with clearly defined USPs. 
Likewise, the computer industry uses USPs. 
Apple, for example, emphasizes how easy its 
computers are to use rather than advertising the 
specific technologies that make its computers 
user-friendly. 
In order to develop an attractive USP for an 
early-stage technology, marketers must emphasize 
what buyers need over what the technology can 
offer. The tendency of many marketers to over-
emphasize the technology may explain why they 
are often accused of “pushing” their products into 
the market rather than letting them be “pulled” in 
by virtue of consumer demand.
Let us take, for example, a technology that 
allows certain vaccines to be administered using 
an aerosol rather than an injection. There is no 
question that the science may be exciting and of 
interest to potential users. However, the USP has 
nothing to do with this exciting science. Rather, 
the real potential which will increase user de-
mand is to point out that aerosol vaccine delivery 
will allow significantly easier (and painless) de-
livery to the end users as well as potentially an 
easier storage and delivery of the vaccine prior to 
administration.
Sometimes a USP is bound up with the busi-
ness model of the company. FedEx guarantees 
overnight package delivery; Domino’s Pizza spe-
cializes in extremely rapid, hot, home-delivered 
pizza. Both of these companies have business 
models that allow for unusually fast delivery of 
products or services. With this kind of USP, of 
course, it is vital that delivery be as timely as 
promised: even small delays may send customers 
elsewhere.
6. ConCluSion
Marketing is the technique of identifying mar-
kets. For early-stage technologies, it can be a dif-
ficult process given the uncertainty of what uses 
the technology can be put to. Nonetheless, for 
some early-stage technologies, the work done in 
the marketing phase can actually add significant 
value, since it identifies potential uses and buyers 
that may not have been considered by the original 
scientists. ■
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5 The actual distribution channels for such a product, 
defined by those who might make the decision to 
buy this product, include: (1) the radiologists who are 
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administrators of the hospitals; (3) the information 
technology department in charge of software at the 
hospital; (4) the purchasing department in charge of 
purchasing imaging equipment; (5) a buying group 
that acts on behalf of an aggregate of hospitals such 
as an HMO; (6) a paying authority thatauthorizes any 
new acquisitions such as a government department 
or an HMO; (7) the manufacturer of the equipment 
looking to integrate the software; and (8) individual 
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Finding out how to market your technology to potential 
licensees can be a perplexing process. There is no common 
consensus about how to approach technology licensing, 
and workshops on the topic tend to offer a haphazard mix 
of tools and strategies that cannot be applied generally. 
This chapter emphasizes the importance of actively mar-
keting your technology. It offers a systematic marketing 
approach supported by numerous models for contacting 
and prioritizing your contacts. The chapter also includes 
numerous helpful worksheets to guide and focus your ap-
proach. By following the steps laid out in this chapter, 
you will have learned a great deal about the market for 
your “merchandise,” its potential licensees, and its value. 
You may have even found a licensee!
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just like about everyone else learns the tricks of 
their trade: by experimenting with hit-or-miss 
techniques. This haphazard approach probably 
explains why most training workshops on the 
topic offer smorgasbords of tools and strategies 
that one person or a few people found useful 
and that may or may not be useful to someone 
else; the workshops never offer much guidance 
about which tools to use, when to use them, or 
in what order.
The following materials suggest that it is 
possible to construct a marketing plan that 
will (1) work for both the novice and the ex-
pert in most, if not all, situations and (2) allow 
the licensing professional to continually refine 
his or her marketing strategy by systematically 
examining the feedback received from various 
sources.
2. moving	meRChAnDiSe
To fully appreciate how important technology 
marketing is to your licensing program, consider 
this simplified step-by-step plan of how technol-
ogy marketing works: 
1. You begin by having to market technolo-
gies that are “raw materials.”
CHAPTER 12.3
1.	 inTRoDuCTion
If you ask ten seasoned licensing professionals 
about how they locate potential licensees, you 
are almost guaranteed to receive ten different 
answers. The truth is that technology marketing, 
although one of the most important and difficult 
aspects of technology licensing, is rarely carried 
out in a systematic way.
There is no consensus about the best way to 
approach technology licensing, and many people 
are not willing to share their expertise. Marketing 
experts in technology transfer learned the ropes 
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2. By investing capital in patent applications 
or other IP protection, you convert the raw 
materials into “merchandise.”
3. Licensing converts your merchandise (non-
liquid IP assets) into capital (liquid assets). 
These assets fall into two categories: recov-
ered capital and profits.
4. Recovered capital (and, optionally, profits, as 
well) can be re-invested with the aim of con-
verting more raw materials into merchandise, 
the licensing of which will generate more re-
covered capital and additional profits.
5. If the rate of licensing is slower than the 
rate at which raw materials are converted 
into merchandise, your inventory will grow. 
Eventually, most of your capital will be tied 
up in nonliquid assets, and you will go out 
of business.
The point is that you must move your 
merchandise. 
3. how	To	mARKeT		
Our approach to technology marketing makes 
use of the telephone extensively and requires that 
each call to a prospective licensee be followed up 
in writing. 
Although direct mail communication with 
potential licensees is perhaps the least costly ap-
proach, the response rate to such mailings is ex-
tremely low, and there is no way to answer any 
questions that potential licensees might have. The 
same can be said for computer databases and bul-
letin boards, which require potential licensees to 
log on, search for, and find advertisements and 
information about your technology. The limita-
tions of such an approach are evident. 
In an ideal world, the licensing professional 
would personally meet with all potential licensees: 
much more information can be communicated in 
person, and the response to the presentation can 
be gauged more easily. But few companies have 
the resources to keep their marketing profession-
als on the road. Although conferences are an ef-
ficient way to meet many potential licensees in 
person, they do not happen frequently enough 
to be adequate as a sole source of new contacts; 
besides, not all companies send representatives to 
such meetings. 
Although telephone conversations are not 
quite as good as face-to-face meetings, phone con-
versations are a close second choice. The greatest 
advantage of using the telephone is that you can 
easily and inexpensively communicate with po-
tential customers who are geographically distant 
and dispersed. Follow up each phone call with a 
brief letter and a nonconfidential description of 
the technology you hope to license. This follow-
up activity will remind your potential customer 
about your offer and allow you to offer materials 
that can be sent to his or her company’s scientists 
for further consideration.
4. DiSClAimeR
Keep in mind that the ideas shared in this chap-
ter are new and have not yet been put to the test 
in the “real world.” However, they are based on 
more than 20 years of experience by licensing 
professionals. We believe that these are practical 
materials, and we hope that you will put these 
materials to the test. We look forward to hearing 
your comments and criticisms.
The strategy outlined here is meant to serve 
as a template. We expect each user to modify it 
to suit his or her own needs and personal style. 
Some professionals may eventually choose to 
abandon this strategy altogether for a more free-
form approach to marketing.
Finally, we have recommended particular ref-
erence texts or databases with reluctance; some 
professionals in the field might feel that we are 
promoting the interests of certain companies. 
We would like to point out, however, that 1) 
not one of the contributors has ownership inter-
est in any of the companies recommended here 
and (2) none of us has received any compensa-
tion or consideration for our recommendations. 
Furthermore, we acknowledge that many other 
services and resources may be just as good as those 
we have recommended, and some may be far bet-
ter; many more resources exist that we have been 
able to personally evaluate. We therefore invite 
you to explore the alternatives for yourself. The 
Association of University Technology Managers 
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(AUTM) Web site contains a section on market-
ing resources in its business section that can help 
you to begin your exploration.1 
5. SySTemATiC	mARKeTing
This systematic technology marketing approach 
can be divided into four major activities:
Step 1. Collect information from the inventors.
1. Attach the marketing information sheet 
shown in Box 1A to your disclosure form 
(all Boxes are at the end of this chapter). 
This form explains the importance of tech-
nology marketing to the inventors.2
2. Attach the subquestionnaire, shown in Box 
1B to the disclosure form, which asks the 
inventors to consider a variety of market-
able applications for their invention. Each 
inventor should fill out this portion of the 
questionnaire: each person is likely to have 
different ideas and different contacts.
3. Based on any information you have on hand 
(or that you can reasonably estimate) about 
the current situation of the market(s) into 
which the invention might be introduced, 
fill in the summary sheet shown in Box 
1C. Fill out one sheet for each hypothetical 
product or service envisioned by you or the 
inventor(s). Keep this sheet updated as you 
collect relevant information.
4. In order to collect further information that 
may aid in marketing the invention, con-
sult with the inventor(s) about the contents 
of the summary sheet in Box 1C, and ask 
them the questions on the checklist in Box 
1D.
5. For each target market, prepare a tailored, 
single-page, nonconfidential disclosure, in 
accordance with the guidelines and sample 
text shown in Box 1E.
Step 2. Collect information about potential 
licensees.
1. Begin with online searches. You may de-
cide to manually search for potential li-
censees, for example, using the CorpTech 
hard-copy directory.3 
2. Subscribe to a service that provides an on-
line database that you can search for po-
tential licensees (for example, Knowledge 
Express Data Systems [KEDS] or another 
system of your choice).
3. Install the database software by follow-
ing the tutorials and step-by-step in-
structions provided. Review any addi-
tional instructional materials that come 
with the database, paying particular at-
tention to information on how to use 
the database. 
4. Develop both a list of keywords that will 
help you identify potential licensees and a 
profile describing your ideal licensee, and 
also develop a CorpTech-like profile for 
your ideal licensee.
5. Search the databases using the param-
eters you have collected: your keywords, 
CorpTech profiles of companies that might 
be possible customers, and the profile you 
created of the ideal licensee. Identify the 
five companies that seem to be the best 
matches for your technology. If you are 
having trouble identifying the top five, use 
the worksheet in Box 2 to narrow down 
your list of companies. 
6. If you are using KEDS, you can sub-
stantially expand the number and focus 
of hits by using the Knowledge Express 
“hypertext” function. This function al-
lows you to quickly determine which of 
the many available databases have en-
tries that match the keywords you have 
identified. You can then search each da-
tabase individually for possible licensing 
prospects. The hypertext function will 
often find entries on advanced tech-
nologies in the CorpTech and BioScan 
databases (the latter is a database that 
focuses on biotechnology and related 
disciplines), Business News (which con-
tains current information and lists com-
panies that are not listed elsewhere), 
and SBIR (which lists awards made by 
the Federal Small Business Innovative 
Research program for small, high- 
tech companies). 
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Step 3. Review and prioritize your prospects list.
 Examine your list of prospects. Using the 
worksheet in Box 3, assign each of the top 
five corporate prospects a rank from 1 to 
5, with 1 the highest priority and 5 the 
lowest priority.
Step 4. Make contact with potential clients.
1. Review the guidelines (Box 4A) for finding 
the right person to talk to. Write down the 
company’s telephone number, and, if pos-
sible, make a list of names and titles of po-
tential contacts. 
2. Review the three cold-call transcripts (Box 
4B) and familiarize yourself with the sorts of 
conversations you can expect, depending on 
whether your prospects are very interested, 
not at all interested, or somewhat interested.
3. Review the “What to Get Across to Your 
Contact When You Call” checklist (Box 
4C), and make sure you have all of the 
information you will need to convey. You 
may want to write it down so that you do 
not forget any of it.
4. Make the call. Call the company with the 
lowest priority of the five you have selected. 
Box 4A explains how to find the right per-
son to talk to.
5. During and after the call, record infor-
mation about the prospective company 
and how your contact responded on the 
“Reaction Data Sheet” (Box 4D).
6. Send the prospect a follow-up letter, mod-
eled after one of those in Box 5, along with 
a copy of the nonconfidential disclosure 
(regardless of whether or not the prospect 
requested one).
7. Repeat steps 4 through 6 for each of the 
other prospects, working from the one with 
the least potential to the one with the great-
est potential (in other words, beginning with 
number 4, then number 3, and so on).
8. Next, call those prospects ranked 6, 7, 8, 
and so on in order of decreasing potential.
9. If you have found a licensee, congratula-
tions! But do not stop. One prospect is 
fine, but two or more prospects are bet-
ter: if you are planning to offer an exclu-
sive license, more prospects will give you 
more bargaining power; if you are plan-
ning to offer nonexclusive licenses, each 
new prospect means more payoff for your 
marketing efforts. If, on the other hand, 
you have not been able to find a licensee, 
assess your results using the guidelines in 
Box 6 and decide what you want to do 
next: Continue looking for prospects us-
ing the same strategies? Continue looking 
for prospects using new strategies? Wait a 
year and try again? Write off, as a loss, the 
capital invested in IP protection for this 
invention?
6. 	ConCluSionS
By following these steps, you will have learned a 
great deal about the market for your merchan-
dise, its potential licensees, and the value of your 
product. You may have even found a licensee. 
Build on whatever success you have found by tak-
ing the time to learn from your experience and by 
analyzing the feedback you have obtained from 
your systematic marketing approach. And share 
what works with others. 
For further information, suggestions, or guid-
ance regarding this marketing strategy and how it 
might be customized or refined, please feel free to 
contact the authors at the numbers shown below. 
We would also appreciate your feedback on how 
this approach has worked for you, and how you 
believe it might be improved. Please share with 
us copies of any revisions you may make to the 
instructions or forms. ■
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1 www.autm.net (accessible to AUTM members) First 
select “Business,” then “Marketing,” then “Resources to 
Review.”
2 See, also in this Handbook, chapter 8.4 by DR McGee.
3 www.corptech.com.
4 See, also in this Handbook, chapter 7.2 by SP Kowalski 
and A Krattiger.
5 See, also in this Handbook, chapter 11.8 by S Shotwell.
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Box	1:		Collecting	Information	from	the	Inside	(Step	1)
A.	filling	out	the	invention	questionnaire
When you complete the attached Invention Questionnaire, you will notice that it includes questions 
not only about the technical aspects of your invention, but also about its potential commercial 
market(s).
If you are like most inventors, you will probably not be very interested in thinking about how to 
market your invention. However, your answers to these questions are at least as important, if not 
more important, than your answers to the technical questions. Why? Remember that a patent is, 
first and foremost, an economic vehicle. It gives patent holders a monopoly on the manufacture, 
use, and sales of an invention for the life of the patent. The government grants such monopolies 
in order to provide an incentive for individuals and companies to invest the resources and effort 
needed to bring new products to the marketplace.
If patents were free, we could patent every invention and make profits on whichever ones reached 
the marketplace. Unfortunately, obtaining a patent is always costly. The application procedure for 
a typical U.S. patent costs between $10,000 and $20,000 from start to finish, and foreign patent 
applications can cost more than $100,000 for a single invention.
Therefore, we, as technology transfer specialists, have to try to determine in advance which 
inventions are likely to be of interest to licensees. The goal is to license each patented invention in 
exchange for a royalty, so that we can both recover the costs of the patent application process and 
generate additional revenues. If we patent inventions without first considering their licensing 
potential, we risk losing the money we have invested in patenting costs. 
Granted, market exploration is not your job—it is ours. However, though you may not think that 
you know anything about marketing, experience has shown that inventors are one of the most 
valuable sources of market information. You know your new technology better than anyone else. 
You probably know how it might be used, and you might even know who would be interested in 
licensing it. 
Now you know why we are asking you for help with marketing. Please answer the following 
marketing questions to the best of your ability. If you do not know the answer to a question, or 
are unsure whether you really understand the question, try to answer it anyway, and make your 
answer as comprehensive as possible. Please feel free to provide additional information that we 
have not specifically requested.
(Continued	on	next	page)
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B.	invenTion	queSTionnAiRe
Docket Title
Date Completed by Form ___of___
Please feel free to attach additional sheets if you need more room or if you want to explain your responses. 
In addition, please attach any materials that you think might help illustrate or supplement your answers.
pRoDuCTS	AnD	SeRviCeS
List as many products or services (whether actual or hypothetical) as you can think of that might 
benefit from your invention. Be adventurous: try to think of both broad and narrow applications, 





List as many existing products or services, and the companies that provide them, as would be in 
competition with your new invention if it were to be used for all the functions you listed on the 
Products and Services form. You may wish to refer to catalogs or databases in completing this 
next list. Please attach any relevant product brochures or descriptions.






List the names of companies you think would be interested in using your invention to make, use, 
or sell products or services. If you have a contact at any of these companies, be sure to provide a 
name and telephone number. (We will obtain your permission before we contact anyone.)
 Company Contact  Phone
1.   
2.   
[etc.]   
ADvAnTAgeS
If we are to convince companies to invest in the commercial development of your invention, we 
will have to be able to explain why it is superior to alternative products, processes, or services. 
List all of the advantages of your invention. Attached is a list of possible advantages for you to 
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B.	invenTion	queSTionnAiRe	(continued)
POSSIBLE ADVANTAGES OF YOUR INVENTION
CHEAPER  The invention is cheaper to make or use than currently available products or processes.
EASIER TO USE The product or process is less complicated, less labor intensive, or more user friendly than 
those of currently available products or processes.
EASIER TO MAKE The product is less complicated to make, or its manufacturing process is less complex, than 
those of currently available products.
SAFER  The product or process is safer for the operator, bystanders, or animals than currently 
available products or processes.
MORE  The product or process recycles materials that usually end up in landfills or is less  
ECOLOGICAL  polluting than currently available products or processes.
FASTER  The product or process works faster than currently available products or processes.
MORE PRECISE  The product or process yields a more exact result than those produced by currently available 
products or processes.
MORE  The product would be attractive to a broader segment of the marketplace than those 
ATTRACTIVE products currently on the market.
NOVEL The product or process is novel: people would ask, “Why didn’t I think of it?”
CLEAR VALUE Other products or processes are similar enough that the value of this one will be apparent.
QUIETER The product or process is quieter or the sound it produces is less irritating than is true of 
currently available products or processes.
SMELLS BETTER The product or process produces no smell, or a more pleasant smell, than is true of currently 
available products or processes.
TASTES BETTER The product (if intended to be tasted) tastes better than currently available products.
BETTER SIZE The product is more compact, or is larger and has greater capacity, than currently available 
products.
BETTER WEIGHT The product is lighter or heavier (whichever is preferable) than currently available products.
MORE DURABLE The product is more durable than currently available products.
MORE RELIABLE The product breaks down less frequently, or the process is more consistently successful, than 
currently available products or processes.
EASIER TO FIX The product is less complicated or costly to fix or adjust than currently available products.
LARGE MARKET There is already a large market for this product or process, or the appeal of the product or 
process will likely create a large market where one did not previously exist.
GROWING  There has been steady growth in the target market for your product or processes over the 
last MARKET several years.
LASTING MARKET The need or demand for the product will last a very long time.
EASY FOR  The product or process is similar enough to currently available products or processes 
MANUFACTURERS  that users or manufacturers can easily switch. 
TO SWITCH
HARD TO Competitors will have difficulty producing an equivalent product or process, or to solve 
DUPLICATE  problems without it.
HIGHER PROFIT  The product or process is easier and cheaper to make than currently available products or 
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C.	mARKeT	SummARy	DATA
Docket Title
Date Completed by Form ___of___
Note to reader: Since this sheet is completed before any systematic research is performed, the information 
is likely to be both highly speculative and incomplete. You may need to fill out a separate form for 
each product or service that you envision for this invention. Use this form as a guide when discussing 
marketing issues with the inventor(s).
Product or service






Competing products or services
 
Market cycle status growing stable contracting
Regulatory requirements
Expected regulatory costs ($ million)
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D.	queSTionS	foR	invenToR	inTeRview
Ask each of the inventors the following questions, preferably in person or by telephone, rather than 
in writing. Depending on the direction the conversation takes, you may decide to ask other questions 
that occur to you that are not on this list. You may find that the inventors are more candid if you speak 
to each of them privately.
1. Do you have any family members, friends, or ex-classmates who work for a company that 
might have an interest in your technology?
2. Do you have a company of your own? Are you interested in starting a company?
3. Do you have any consulting or other relationships with companies? Would these companies 
be interested in your technology?
4. When we license the technology, would you be willing to collaborate with the licensing 
company as a principal or as a technical advisor?
5. Do you know of anyone who might want to invest in this technology (venture capitalists or 
private investors, for instance)?
6. Where did you work before you started working here? Do you know anyone from your 
previous position(s) who might be of help?
7. Would you be willing to spend a little time calling friends and colleagues to find out what 
they think about your technology and its possible applications?
8. Can you give us a few names and telephone numbers of people with whom we could speak 
about your technology and possible licenses?
9. Would you be willing to speak to potential licensees about your technology?
10. Would you be willing to make prototypes or samples, or carry out demonstrations, in order 
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e.	DRAfTing	The	nonConfiDenTiAl	DiSCloSuRe
A nonconfidential disclosure (NCD) should be nonenabling, that is, it should not contain enough information 
to allow a person skilled in the field to reproduce the invention without undue experimentation. The NCD 
should, however, contain enough information to pique the interest of the person reading it. Only on very 
rare occasions should an NCD exceed one page in length.  There are many possible formats for an NCD, but 
we recommend the following one:
1st	Section.	Begin with an introductory sentence such as: “A novel dengue virus vaccine has been developed 
by BioReplicon Corp. and is available for licensing.” The remainder of this section should give a punchy, brief 
explanation of the field of the invention.
2nd	Section.	Briefly describe the state of the art before the invention, and then highlight the important 
advantages that the invention offers over the currently available alternatives.
Keep in mind that you can often disclose performance data without giving anything else away. For example, 
you can say, “Vials of one milliliter in volume, having walls 0.1 millimeter thick, were able to withstand 
sustained pressures measuring in excess of ten atmospheres.” A reader would be able to see that the 
material in question is very sturdy without being able to figure out what it was or how it was made.
If at all possible, refer to and append any data (charts, tables, graphs) that show the invention’s technical 
superiority and/or compare the technology with currently available alternatives.
3rd	Section.	Describe the terms of licensing and provide contact information, should the reader wish to 
make further inquiries.
4th	Section (optional). Provide brief biographies of the inventors, especially if they are well known in their fields.
An example of an NCD follows:
new	invention
A novel method for manufacturing piezoelectric composites has been developed at Moorhead University 
and is available for licensing.
Piezoelectric composites are composed of two layers, an “active phase” and a “passive phase.” The active phase 
physically deforms when an electrical current is applied, thereby producing sound waves. By improving the 
match between the sound impedance of the active phase and the target of the sound waves (for example, 
the skin), the passive phase improves the efficiency of sound transmission. Piezoelectric composites are 
used in medical imaging devices, hydrophones, and various sensor applications.
The industry currently uses a “dice-and-fill” method to make such composites. This method involves sawing 
slits into blocks of active-phase material, and then filling them with passive-phase polymer. Our new method 
overcomes many of the disadvantages and limitations of the dice-and-fill method:
improved	efficiency: The process takes fewer manufacturing steps to produce the same composite.
less	waste:	No material is lost, because no slits have to be sawed.
increased	flexibility: The dice-and-fill method can create only two-phase composites, but our method can 
create multiphase composites. (See attached page for diagrams of the types of multiphase composites that 
are possible to make using our technology.)
improved	 preformation: Our method allows for the variance of active-phase volume content, thus 
decreasing the out-of-plane distortions of the transmitted signal.
This new technology is available on an exclusive or nonexclusive basis.  
For further information, please contact:
  John Smith 
  Technology Licensing Associate
  Office of Technology Transfer
  Someplace University
  Somewhereville, LA 12345
  Phone +1-800-555	1212, Fax +1-800-555	1213
  smight@someplace.edu
Dr. Arnold Smuthers, co-inventor of the described invention, is a world-renowned authority in the field of 
piezoelectrics, and holds over 30 U.S. and foreign patents. 
Box	1	(continued)
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Date Completed by Form ___of___
Because you have already collected some information about the technology and its market from the 
inventor(s), developing a licensee search strategy should be easy. Ask yourself:
1.	 in	 what	 product	 development	 areas	 might	 potential	 licensees	 be	 interested?	 List single- and 
multiple-word descriptions that might be used as search identifiers. Keep in mind that you may 
want to find several licensees, each holding a license to make, use, and sell licensed products in a 
different field of use. 5
2.		 Do	i	already	know	of	a	few	companies	that	might	be	good	licensees	for	this	technology? Search 
for information on these companies, and then use that information as a guide to search for other, 
similar companies.
3.	 Create	a	profile	of	the	ideal	licensee. Imagine the ideal licensee (or describe a licensee known to you 
that you think would be ideal) for the technology. Complete one copy of this form for each product 
or service that you have envisioned for this technology. Use additional copies as necessary.
Company size  large   medium   small  start-up
Structure  private   public  nonprofit
Country  U.S.   foreign  multinational
State/province 
Sales per year $ (million)
No. of employees 




1. What is our product development focus? How does this product fit?
2. What kind of personnel do I have? What kind of personnel would I need if I were to license this 
technology?
3. What is my existing manufacturing capability? Can I manufacture this technology? Can I create 
the ability to manufacture it? Can I outsource its manufacture?
4. Do I have access to complementary technology?
5. What kind of capital resources do I have? Where will the research funds come from? 
6. What kind of marketing expertise do we have? If it is limited, can we partner with other companies 
that have more marketing expertise?
7. Is it important for this technology to have international markets? Do we have the ability to develop 
international markets?
8. What regulatory issues are involved? Can we handle these, given our current levels of resources 
and expertise?
9. Do we have experience with this type of early-stage technology? (For example, [the applicable 
type of technology].)
Now, go back and re-address questions 1,	2, and 3.
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Box	3:		Ranking	prospects:	A	worksheet	(Step	3)
For each of the potential licensees identified, assign a score for each, using the criteria listed below. 
If you have no information, leave the space blank. Rank the companies, with the most promising 
prospect being the company with the highest total score. If you have more than five prospects, use 
additional sheets.
Write the names of the prospect 
companies in the spaces at the right, 
and on the similar spaces on the 
next page.
CRiTeRiA		 SCoRe	(1-5)
Portfolio includes products like this one     
Has large share of relevant market     
Could expand its share of that market     
Has patents on related technology     
Has personnel needed     
Has relationship with you or your office      
Has relationship with inventor     
Company not too big or small     
Company already expressed interest     
Good fit with other company products     
Located nearby     
Has known licensing experience     
Good fit with company R&D focus     
Has long history, established management     
Known for being an innovative company     
Respected by the inventors     
Has introduced new products recently     
Has membership in professional association     
Is well known, has good reputation     
Has large marketing and sales force     
Has international marketing capability     
Has successfully licensed from you in the past     
Would big part of company’s business     
Can manufacture or out-source it     
Can afford necessary re-tooling     
Has product development resources     
Can afford up-front, minimum payment     
ToTAl     
RAnK	     
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Box	4:	making	Contacts	(Step	4)
A.	ConTACT	iDenTifiCATion	guiDelineS
As you contemplate which individual in a company might be best to contact, it is worthwhile to consider how 
someone wishing to license to or from your organization would identify you. You hope the person would find 
you, but, in the end, the path between you and that person might not be direct. Furthermore, it may take a 
few calls before you identify the “right” person at the company you have identified as a licensing prospect.
The following guidelines should help you to make contact with the right person.
1. Utilize the knowledge of secretaries
 Receptionists and secretaries are often knowledgeable about who does what at their company. Secretaries 
of higher-level executives generally are the most knowledgeable about sophisticated functions such as 
licensing. If you are having trouble finding out who to talk to, try asking the secretary of a vice president 
or the president. The secretary for the legal department may also be quite helpful. Describe carefully who 
you are and what you need.
2. Try to look up your contact
 Regardless of the apparent size of a company, it is always worth the time to first look up the company 
in the LES directory and the AUTM directory. Even small companies sometimes belong to one or both of 
these organizations, and if the target company is listed, any one of the members included in the listing 
is most likely a “direct hit.”
 If the company has more than one member, look up all of the members’ titles before you decide who to 
call. If the company is fairly large, unless your technology is a revolutionary invention, you are probably 
better off calling the second or third most senior licensing person. He or she is more likely to spend the 
time to hear you out, and to take the time to follow up after the call is over.
 If the company is of substantial size, look up the company in CorpTech, Dunn & Bradstreet’s, or Moody’s 
directory, if available (you can also do this online). Look under the corporate officer’s listing, and look 
for titles such as:
• director of licensing • director of new product development
• director of technology acquisition • vice president for new product development
• vice president for new ventures • new technology analyst
• patent counsel • director of marketing
• general counsel • vice president for research and development
 The listing should give the officeholder’s name. Although that person might not be the person you need 
to speak to, having a name and title that is at least somewhat relevant make
3. Make a call or two
 If you have found a name or at least a title that looks promising, call the company and ask for the 
person, or the person with that title. In all likelihood, a secretary will answer. Tell him/her your name, 
the organization you are from, and explain that you have a new technology that you think the company 
would be very interested in acquiring. Ask if the person you have called is the right person to speak to. 
The secretary may believe that someone else is the right person or that a different department would be 
better able to help; in either case, ask to be transferred. On the other hand, the secretary may not know 
who or which department to refer you to. If that is the case, ask to speak to the person you called. Then, 
give that person the same introduction and ask if he or she is the right person to speak to. If he or she is 
not the right person, ask to be transferred.
 Whenever you are transferred to another line, start by saying, “[name’s] office thought you might help 
me,” or “The president’s office thought you might help me,” for example. This will avoid the possibility 
of being referred back to someone you’ve already spoken with and will suggest to the second person 
that the first person thought it was worthwhile to help you, so they should, too. Introduce yourself as 
described above, and proceed in the same way.
 For a company that is not listed in the LES directory, the AUTM directory, CorpTech, Dunn & Bradstreet’s, 
or Moody’s, it is likely that the company is fairly small. For fairly small companies, it is sensible to start “at 
the top.” Call and ask to speak to the president. Usually an executive secretary will screen the president’s 
calls and will ask why you have called. Give your name and the name of your organization, and 
explain that you have a new technology you believe the company would be very interested in. You 
will likely be connected to the president, a vice president, or research director. Introduce yourself, 
and ask if you were properly directed. Proceed as described above.
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B.	ColD-CAll	TRAnSCRipTS
The following transcripts illustrate the sorts of conversations you might encounter when talking with 
a prospective licensee. Keep in mind that these are examples and that you should be prepared for 
conversations that do not follow any of these patterns. However, we do not mean to suggest that 
a company of one size is a better prospect or will be more receptive to your call than a company of 
another size. Good licensing deals can be made with companies of all sizes.
Also, do not assume that the length of these transcripts is necessarily representative of the length of 
the conversations you will have with potential licensees. Conversations can be quite long and cover 
many subjects, especially if your contact is very interested in what you have to say. Be sure to leave 
plenty of time for the call, and hope that you need it.
1.	The	call	we	all	want.	(it	really	does	happen	this	way	sometimes.)
Licensor: Hello, this is Jake Sinclair, and I’m from the University of Maui. I’m calling because our 
Professor Mahalo has invented a new fiber-optic stethoscope that we thought your company 
would be interested in.
Prospect: University of Maui, huh? I went there as an undergraduate. Great school. Who did you say 
was the inventor?
Licensor: Professor Mahalo.
Prospect: Oh, yeah! I took a course on biomedical engineering with him about ten years ago. I’m sure 
anything he’s invented is really good. What can you tell me about it?
Licensor: Well, it has an electronic pickup device that picks up even very faint sounds. It then converts 
the signal to a light beam, and transmits the beam through a fiber-optic fiber to a decoder 
that is about the size of a large felt-tip marker. The decoder electronically filters out 
background noise, then transmits the filtered sounds to a pair of headphones.
Prospect: A fiber-optic stethoscope. Pretty neat. As you know, stethoscopes are our only business here 
at Stethoscope Technologies.
Licensor: Yes, we know. That’s why we thought of you. Also, you have an excellent reputation in this 
field.
Prospect: And, as it turns out, we have been looking for a high-tech product to sell to the top end of our 
market. But it would be very important to us that the device we sell look and handle like our 
other, more traditional stethoscopes.
Licensor: Dr. Mahalo feels that the pickup and decoder could be miniaturized enough for that with a 
little engineering work.
Prospect: Well, this certainly seems interesting. Do you have any patent protection?
Licensor: Yes, we have applied for two U.S. patents, and on one of them, we have already filed a 
worldwide application under the PCT [Patent Cooperation Treaty].
Prospect: Hmm. Wow, this sounds like it may be just what we have been looking for. Could you send us 
some detailed technical information so we can talk with our product design team about it?
Licensor: Sure. Of course, we will need to have you sign a confidentiality agreement first.
Prospect: Oh, that’s no problem for us. If you would fax one to me, I’ll courier it back to you tonight, 
and maybe you could send us a copy of the patent applications. After we’ve had a chance to 
review them, if we’re still interested, we could come visit you and Dr. Mahalo next week on 
our way back from Japan.
Licensor: Sounds great. However, we would prefer not to show you the claims until it becomes more 
certain that you are interested in a license.
Prospect: That’s fine.
Licensor: Well, I’ve really enjoyed talking to you, and I’ll fax you the confidentiality agreement right 
away.
Prospect: Great. And tell Dr. Mahalo that I look forward to seeing him again.
Licensor: Sure will. Bye.
Box	4	(continued)
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Licensor: Hello, my name is James Sulkind and I am in charge of out licensing for the Omed Marine 
Corporation. I’m calling because one of our scientists has developed a radio beacon 
technology that is simply too high tech for our manufacturing capability, but we thought it 
might be right up your alley.
Prospect: Radio beacons? We make televisions and FM receivers, but we’ve never made marine stuff. 
The market’s too small.
Licensor: Well, we know the market is relatively small now, but marine radio equipment is growing 
increasingly sophisticated, even in pleasure boats, and we thought it might be a new and 
growing market for you.
Prospect: Nah, we’re volume producers, and that market will never be big enough for us to bother with. 
We even gave up the portable radio market, and that was probably ten times bigger than the 
one you’re talking about.
Licensor: Are you sure you wouldn’t be interested?
Prospect: Yes, I’m sure. But why don’t you send me something anyway?
Licensor: Sure, be happy to.
Prospect: Thanks. Bye.
Interestingly, even if the person is not interested, he or she usually wants something in writing anyway. 
Some may circulate it to their R&D and marketing staff, just to double check that your technology is 
not something they want to pursue. Others may just want a nonconfidential disclosure to attach to 
their monthly reports in order to show their bosses that they have been actively considering new 
technologies. Regardless of your contact’s intentions, follow up on the phone call and send the written 
disclosure. It may or may not get a second look, but at the least, it will encourage that individual to 





Licensor: Hello, my name is Beverly Houghton, and I’m a licensing associate at Ethridge University. I’m 
calling because Dr. Cuthbert of our computer science department thought that you would 
be quite interested in his new neural network approach to “just in time scheduling” for 
automotive parts production.
Prospect: Neural networks? We just got our computerized production scheduling system on the market 
last year. I don’t think we are ready to make any big changes in it at this point. Coordinating 
all of our warehouses and car dealers was an enormous investment. Besides, our inventories 
are already stable and at very low levels compared to the old days.
Licensor: Well, Dr. Cuthbert is familiar with your system, and he thinks that it could really benefit from 
this new approach. He also thinks it could be implemented easily and quickly.
Prospect: Oh, really? What does he think would be the benefit?
Licensor: Dr. Cuthbert says he thinks that the processing time would be reduced by at least 50 percent, 
and that this time savings would be directly translated to increased speed at the parts 
department terminals.
Prospect: Well, node speed has been an issue.
Licensor: Yes, and you could increase node speed by, say, 20 percent, and then have processing time 
left that would allow you to receive and transmit more data in real time. This increased 
information transit may allow you to have even lower levels of standing inventory than you 
currently think possible.
Prospect: Interesting. What does Dr. Cuthbert think it will cost us to do this?
Licensor: In terms of hardware, nothing. On the software side, he already has compatible software 
elements that he and your programmers could easily weave in.
Prospect: But there’s a catch, right?  You guys aren’t going to let me use this for free.
Box	4	(continued)
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Licensor: You’re right. But because we hope to license this technology to others, too, the cost to you 
should be relatively low.  We would like to get something up front, plus about $100 per node 
per year. Of course, there would also be some costs for Dr. Cuthbert’s time, and we are looking 
for about $50,000 per year for use of his neural-network system software.
Prospect: Well, when you add it up, that’s a fair amount of money. Besides, if we tell our dealers that 
we’re going to mess with this system again, they’ll scream bloody murder.
Licensor: Only until they see what it can do.
Prospect: Well, maybe. What can you send me about this?
Licensor: For starters, I can send you a nonconfidential disclosure. If you’re still interested, I can send 
you a copy of the patent application, and maybe have you talk to Dr. Cuthbert.
Prospect: Well, at this point, just send me the nonconfidential stuff. If the operations guys are interested, 
I’ll call you back.
Licensor: It’s on its way. If you like, maybe we could also set up a demonstration for your operations 
guys.
Prospect: Well, since you’re right here in Detroit, maybe that isn’t such a bad idea.
Licensor: How about if I have Dr. Cuthbert call you to set it up?
Prospect: Well, let’s not get ahead of ourselves. I’ll give you a call after we’ve thought about it here.
Licensor: Great. I look forward to your call. Bye. (After hanging up.) Who knows? I better make a note to 
call him back.
C.		“whAT	To	geT	ACRoSS	To	youR	ConTACT	when	you	CAll”	CheCKliST
The following checklist should help you make sure that you cover the basics on each call. Of course, 
there may be something else you want to get across that is not on this checklist. Also, the person you 
call will likely ask questions that are listed here.
To some extent, the level of your contact’s interest will determine how far down this list you get. In any 
event, failing to get some things across is not fatal.
In the beginning, you may want to write notes to yourself to make sure that you know exactly what you 
need to say. But don’t sound as if you’re speaking from a script. Even when you have more experience, 




A general overview of the technology
Who the inventor is (if he/she is an academic or well known)
Why you think the company should be interested in the technology
The advantages that the new technology offers over existing products,  
processes, or services
Whether prototypes or demonstrations of the technology are available
Whether you have applied for patents, copyrights, and/or trademarks;  
whether there are trade secrets
Whether you are looking for an exclusive or nonexclusive licensee  
(or are undecided)
Whether other licenses have already been granted 
That you can provide written nonconfidential information about the technology
That you would be willing to enter into a confidentiality agreement  
with the company
What confidential information you could provide 
Box	4	(continued)
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D.	ReACTion	DATA	SheeT
Docket Title
Date Completed by Form ___of___
Complete a copy of this form after each call to each potential prospect. Make sure to review any prior 
forms before you make each call. They will help you remember what the person’s personality is like 
and help you interpret his or her reactions.
The checklist is a general barometer of your prospect’s reactions. It is a supplement to, but not a substitute 
for, the notes you will take during the call regarding what was said and what needs to be done.
IDENTIFYING INFORMATION








Date of call 
Company size large medium small start-up
Location U.S. foreign multinational
Structure private public nonprofit
CONTACT’S MOOD
 calm hurried somber annoyed curious
 amused angry tired guarded happy 
CONTACT’S ATTITUDE
 receptive enthusiastic sarcastic disinterested encouraging
 sincere mysterious sinister secretive confused
 aloof friendly condescending respectful nervous
CONTACT’S COMMUNICATION STYLE
 hardly spoke asked questions made suggestions made jokes
 made small talk talked about company conversant gave opinions
 talked about market talkative talked about LES talked about family
Box	4	(continued)
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Box	4:	making	Contacts	(Step	4)	continued
CONTACT’S LEVEL OF INTEREST
 expressed a lot of interest expressed minor interest moderately interested
 disinterested expressed a lot of interest bored
 expressed some interest expressed lack of interest
NEGATIVE COMMENTS CONTACT MADE ABOUT THE TECHNOLOGY
 retooling costs too high technology too complex technology too costly
 market too small market too committed market too unpredictable
 benefit not worth price benefit too small prototypes not available
 technology not proven licensor/inventor not known demonstrations not available
 similar technology flopped market in decline profit margins too low bad fit with market needs
POSITIVE COMMENTS CONTACT MADE ABOUT THE TECHNOLOGY
 modest retooling costs technology not too complex technology inexpensive
 market large market would be receptive market predictable
 benefit well worth price large benefit satisfies current and future market needs
 technology well proven high profit margins likely market expanding
CONTACT’S REASONS FOR BEING DISINTERESTED IN THE TECHNOLOGY
resources are already committed to other projects technology is a bad fit with the company’s other products
company is not innovative working on better one
company doesn’t like in licensing got burned last time
economy is bad  technology is a bad fit with the company’s goals
company has no licensing experience company has a small sales/ R&D staff
CONTACT’S REASONS FOR BEING INTERESTED IN A LICENSING DEAL
product is a good fit with the company’s other products company prefers high-technology products
ample resources available  company has in-licensing experience
the company is innovative product is just what they need
company has strong R&D, marketing and sales capabilities licensor/inventor is known and respected
working on inferior version company likes to in license
economy is good  product is a good fit with company goals
CONTACT’S REASONS FOR NOT LIKING THE TERMS
does not understand the technology  wants a different degree of exclusivity
wants to limit up-front licensing costs wants to limit royalty burden
does not like confidentiality agreements does not like usual license terms
 FOLLOW-UP ACTION YOU PROMISED
provide nonconfidential disclosure provide a confidentiality agreement
provide a demonstration/sample have an inventor or scientist call
send a sample arrange a demonstration
call again
MACWRIGHT & RITTER
1192 | HANDBOOK OF BEST PRACTICES
 FOLLOW-UP ACTION PROMISED BY THE CONTACT
 ask technical staff about the technology
 review the technology with management
 provide a confidentiality agreement
 get in touch if interested (“don’t call us, we’ll call you”)
 call back (“we’ll call you, but we don’t mind if you call, too”) 
 CONCLUSION ABOUT THE CHANCES FOR PROSPECT
 SuRe	Thing: We have a deal in the making.
 hoT	pRoSpeCT: Good follow up will likely make a deal.
 luKewARm	pRoSpeCT: Hard work might make it happen.
 long	ShoT: Miracles can happen!
 ToTAl	DeAD	enD: Forget it.
Box	4	(continued)
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Box	5:	follow-up	letters
Follow up with your licensing prospect by sending a letter similar to one of the following examples. 
Decide which letter format to use based on whether the reaction from your licensing prospect was 
hot, lukewarm, or cold.
In writing such a letter, keep it short and personalize it a bit: for example, mention something from the 
conversation to show that you were truly interested in what the person was saying. Remember, these 
are just examples; improvise!
1.	letter	to	a	hot	prospect
Dear Charles:
I very much enjoyed speaking with you this afternoon about our new rotary device for applying 
plaster casts. Although I knew that CastCorp was a major supplier of plaster for hospitals and 
physicians’ offices, I did not know that you also made plaster-room and operating-room equipment, 
as well as orthopedic surgical supplies. No wonder you were so interested in our new invention.
As promised, a nonconfidential description of the rotary cast applying device is enclosed. Since 
you were quite interested in the technology, I have taken the liberty of sending a copy of our 
standard confidentiality agreement. Of course, we would be happy to discuss the agreement with 
you and address any concerns you might have about it. If the agreement seems reasonable to 
you, we can send you a copy of our patent application. Also, we would like to invite you to see a 
demonstration of the device.
Should you have any questions about the technology or the confidentiality agreement, please 
feel free to call me [phone #]. We look forward to hearing from you soon.
        Sincerely,
        Lawrence Muvaney
        Licensing Associate
2.	letter	to	a	lukewarm	prospect
Dear Ms. Hollister:
Thank you for taking the time to speak to me today about Dr. Mortimer’s new gene-therapy vector 
system. We are aware, as you pointed out, that there are quite a few similar systems already on the 
marketplace. However, Dr. Mortimer and his colleagues feel that this new system is substantially 
simpler and more flexible than the systems currently available.
As promised, I have enclosed a nonconfidential description of the vector system. I hope that the 
description encourages you and your scientists to find out more about it. If you should have any 
specific questions, please feel free to call me at any time at [phone #].
        Sincerely,
        Janice Datillio
        Licensing Assistant
3.	letter	to	a	long	shot
Dear Mr. Corman:
Thank you for taking the time to speak with me today about Dr. Kaufman’s new process for making 
microcrystalline polypropylene fibers. I understand that at this time PolyCo only manufactures 
bulk polypropylene. However, perhaps the enclosed nonconfidential description of our new 
process will encourage PolyCo to consider making specialty products in the future.
If you have any questions, please feel free to call me at [phone #].
        Sincerely,
        Martin Howard
        Licensing Associate
MACWRIGHT & RITTER
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Box	6:	Assessing	your	Results
Docket Title
Date Completed by Form ___of___
By this point, you have spoken to at least five companies about your new technology. Go back and look 
at your Reaction Data Sheets.
If you heard at least some maybes, it may be worth continuing to look for prospective 
licensees. At the very least, make sure you follow up with those “maybes.”
If you only heard nos, ask yourself:
• Was there a pattern in the reasons people gave for saying “no”? If so, consider them 
carefully. They may point to a flaw in the technology or your marketing strategy.
• Did people give reasons for saying no that seemed to focus on the unsuitability of the 
technology for this particular company, or for the market in general?  Comments in the 
former category suggest that you may still be able to persuade them that the technology 
is advantageous to them: perhaps the technology could be more effectively marketed to 
another type of company.
 
Based upon your answers to the above questions as well as your gut instincts, check off one of the 
boxes below. You have spent a fair amount of time with this market and this technology by now, and 
you are entitled to make an honest assessment. If it looks bad, go ahead and say so.
CONCLUSIONS ABOUT THE TECHNOLOGY
A	SuRe	winneR: We just need to find a receptive company.
A	gooD	pRoSpeCT: A close match will likely make a deal.
An	unCeRTAin	pRoSpeCT: We might find a licensee with hard work,  
but it may not be worth it. 
A	long	ShoT: Maybe someone will love it.
ToTAl	DeAD	enD:	There is no possibility and no hope.
If your technology is a sure winner or a good prospect, go back to Step 2, and find other potential 
licensees and contact them in order of their ranking. If it’s an uncertain prospect or a long shot, you 
may want to revisit the technology in six to 12 months: the situations of the market and/or potential 
licensees might have changed, or the technology might be improved by its inventors. But if it’s a total 
dead end, write it off—at least in your own mind—and focus your energy on moving your other more 
promising merchandise. 
ABSTRACT
The management of intellectual property is all about 
managing innovation with the procedures and processes 
that are required to turn that innovation into valuable 
patent rights. A truly strategic approach to IP manage-
ment will span conception to product market release. 
Integrating IP management into the R&D, advance de-
velopment, and product development cycles seamlessly 
provides opportunities to gain and enhance IP protection 
while offering the potential to reduce risk and lower costs. 
The following chapter discusses some of the key elements 
of IP portfolio management and how the combination of 
the right IP tools, procedural know-how, and organiza-
tional attributes and behaviors can contribute to success-
ful implementation.
 HANDBOOK OF BEST PRACTICES  | 1195 
• data mining and databases for information 
gathering and storage
• state-of-the-art software tools and processes 
for data acquisition and analysis
• program management methodologies
• effective communication across technical, 
business, and legal teams
Couple these with effective, continuous im-
provement processes, and you have a recipe for 
efficient generation and management of intellec-
tual property with predicted outcomes and bal-
anced risk (see Figure 1).
2.		 ipm:	The	woRK	pRoDuCT
The planning, gathering, and analysis of IP in-
formation is vital in any organization engaged in 
efficient competitive intelligence and strategic de-
cision making. From the perspective of IP-port-
folio management, the processes and tools that 
enable acquisition, analysis, and organization of 
IP information are usually the same, regardless of 
whether the final outcome is supporting a tactical 
or a strategic approach. However, the breadth and 
scope of a patent search, resultant IP analysis, and 
delivery of information is often quite different. 
Information developed to support tactical deci-
sion making may be narrower in scope and rely 
on a well-defined product specification within a 
CHAPTER 12.4
1.	inTRoDuCTion
The role and importance of patent professionals 
in IP (intellectual property) portfolio manage-
ment (IPM) are increasing significantly within 
business, academic, and legal entities. Driven by 
the speed and magnitude of today’s technological 
development, the sheer volume of patent infor-
mation, and the increasingly competitive, global 
environment, there is a need to more effectively 
manage the patent process to enhance efficiency 
and gain a competitive edge in the marketplace. 
In many respects, this means deploying tools and 
processes that have been prevalent in the business 
world:
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known competitor landscape. Conversely, gener-
ating reliable, accurate IP information to support 
a strategic decision usually requires, among other 
things, a much broader scope of patent-informa-
tion search, multiple analysis methods, and vari-
ous information-delivery vehicles.
A unique blend of skills is required to man-
age intellectual property successfully. Portfolio 
managers, or an IPM team, need broad technical 
knowledge, business acumen, strong communi-
cation skills, and a thorough knowledge of U.S. 
and foreign patent laws and procedures. State-of-
the art patent search and analysis tools are needed 
to gather and analyze patent data, while robust 
IP database tools maintain invention records, 
patent information, patent prosecution files, 
and associated business, licensing, and financial 
information.
The type and scope of IP analysis that IPM 
professionals are called upon to research and 
deliver varies immensely in complexity. Table 1 
defines and describes most of the main defined 
IP-analysis tasks, along with their scope and 
complexity.
Commercially available IP databases such 
as Derwent,1 STN,2 Thomson,3 Delphion,4 
and Micropatent5 offer comprehensive cover-
age and are well-suited to both simple que-
ries and complex searches limited by patent 
class or extended-Boolean-technology keyword 
strings. Free patent searching is available at the 
U.S. Patent and Trademark Office (PTO),6 the 
European Patent Office (esp@cenet),7  and other 
country-specific office databases, but is currently 
unsuitable for detailed patent searches. Databases 
such as esp@cenet are useful for rapid screening 
of IP data that has been generated using commer-
cial databases, providing rapid access to an indi-
vidual patent publication, or an issued patent, in 
a convenient, user-friendly interface.8
IPM professionals are usually trained to gen-
erate complex keyword strings from the initial 
invention disclosure, a combination of invention 
disclosure, and provided references, or following 
a technology scan in the technology area of the 
invention. Synonyms of key technologies will be 
determined and a search will be performed using 
specific combinations of technology keywords, 
with Boolean logic deployed between main 
searches or search subsets. Patent classification 
systems are powerful tools, and intelligent use of 
patent classification (either alone, or in combina-
tion with other keyword searches) is extremely 
effective for relevant patent retrieval. The major 
patent classification systems are the International 
Patent Classification (IPC), European Patent 
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Ip	Task definition,	Scope,	and	Complexity
Technology	Scan High-level scan of the patent and nonpatent literature to 
gauge current technology status. Used prior to invention 
conception or may facilitate technology brainstorming
Current	Awareness/ip	
Surveillance
Monitoring of newly published patent applications or 




Patent portfolio maintenance, patent-prosecution support, 




Targeted IP search and analysis to determine similar, 
overlapping, or identical technology. A search is conducted 
within the full specification of U.S. and foreign patent 
applications and issued patents
patent	landscape Analysis of IP in one or more specific areas of technology; 
integration of detailed IP analysis information into defined 
format such as a “landscape” enabling both high-level 
overviews or detailed analysis (may support patentability or 
claims analysis activities)
infringement Targeted IP claims analysis to determine if one or more patents 
may be infringed by a new product release to market
validity A search for a prior-art reference that may render a target 
patent or patents invalid
Table	1:	Ip	portfolio	management	Task	definitions
BURDON
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A brief scan of the patent and nonpatent lit-
erature is usually performed to provide a quick 
analysis of a particular technology area. This task 
may precede or facilitate technology brainstorm-
ing, or may be used to aid in and verify inven-
tion conception. With the availability and access 
of free online search tools for literature and pat-
ent searching, the task is often performed directly 
by the scientist or engineer without the need or 
support of an IPM professional. If the technology 
concept is in its early stages or is broad in nature, 
an IPM professional may help to focus the IP 
search, eliminate irrelevant search data, and help 
in the analysis and interpretation of the results.
IP surveillance is simply the monitoring of 
newly published patent applications or issue pat-
ents, usually in well-defined technology areas. This 
activity is usually ongoing with research, advanced 
development, and product-development activities 
and supports “patent intelligence”/“competitive 
intelligence.” Currently available commercial 
patent-search tools allow the generation of so-
phisticated search terms with automated search 
frequency and delivery of the results via e-mail. 
The level of analysis and delivery of that analysis 
is user-defined. In most circumstances, it is nec-
essary only to provide the patent number, title, 
and assignee (if known). Individual patent docu-
ments can be provided if the number is small, or 
alternatively, a list with direct hyperlinks to the 
patent document can be generated. Occasionally 
it may be necessary to provide a brief summary of 
the patent document, and/or provide a list of the 
independent claims. The IPM professional can 
generate this data, often, by performing a brief 
scan of the patent specification and claims. IP 
with complex specifications may require a more- 
extensive analysis to derive an understanding of 
the claimed invention. Alternatively, commercial 
services such as Derwent are available to provide 
a summary of the invention.
Licensing and business-development support 
activities including patent portfolio maintenance, 
patent-prosecution support, patent-status infor-
mation updates, and generating reports on IP sta-
tus are key responsibilities of IPM professionals. 
IP management software systems such as Inteum 
C/S®9 are indispensable database management 
tools capable of integrating patent data (inven-
tion disclosure, patent applications, issued patent 
information, and so forth) with current financials 
(licensing, fees, patent prosecution, annuity and 
maintenance fees, and so on). In most circum-
stances, data will be extracted from the IPM da-
tabase and an updated patent search performed 
and cross-referenced to ensure the most accurate 
patent status? It may also be necessary to access 
the current prosecution status using the PTO’s 
PAIR10 or by communicating with the prosecut-
ing attorney to ascertain the most current status.
A patentability, or novelty, search is a search 
and analysis to uncover technology that may be 
similar, overlapping, or identical to the intellectu-
al property for which the patent is being sought. 
A search is conducted within the full specifica-
tion of U.S. and foreign patent applications and 
issued patents (in other words, it is not limited to 
the claims, as a patent or patent publication is po-
tentially prior art for all that is disclosed). In most 
cases, a patentability search is best conducted by 
a patent professional. Depending on the nature 
of the technology and scope of the invention, the 
volume of search results can quickly become un-
manageable. A well-structured search can greatly 
reduce the search time, eliminate irrelevant search 
data, and streamline the analysis. It is highly de-
sirable to have completed a patentability search 
prior to writing claims and generating a patent 
application. It is often the responsibility of the 
IPM professional to ensure that this key step is 
performed, providing analysis of the results rela-
tive to the invention disclosure.
A patent “landscape,” or “map” is generally 
an analysis of IP in one or more specific areas of 
technology. IP search results are analyzed and 
the information integrated into a defined for-
mat such as a visual landscape, or map enabling 
both high-level overviews or detailed analyses of 
specific patent documents. The level and com-
plexity of a patent landscape are defined by the 
question posed. A patent landscape may be useful 
for providing information on potential areas of 
research and invention, indicating current posi-
tion strength, (comparing new disclosures, prefile 
applications, patent applications in prosecution, 
and issued patents relative to competitors), or 
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defining technology “gaps” or “white space.” The 
IPM professional should be cautious when em-
ploying a patent landscape/map to define a tech-
nology pathway or the potential patentability of 
an invention, particularly if the data interpreta-
tion does not include a detailed analysis of the 
patent and what information has been disclosed. 
A technology space may seem to be extremely 
crowded if defined at a high level with a simple 
(broad) search strategy, or even somewhat com-
plex (narrow) search strategies. Successive re-
finement of the landscape using additional sub-
searches may be required to define ‘white space,’ 
and a detailed analysis at the disclosure level for 
patentability should be performed to assure there 
are no lost opportunities. In short, it is only when 
the patent data is analyzed (which usually means 
reading each patent in the landscape search) that 
an accurate IP landscape can be generated.
An IPM professional may provide patent search 
and analysis support for an infringement, for free-
dom to operate (FTO), or for a validity opinion. 
An infringement analysis involves a search only at 
the claims level of a patent and has the purpose of 
determining whether one or more patents may be 
infringed by a new product release to market. A va-
lidity search is performed for a prior-art reference 
that may render a target patent or patents invalid. 
The complexity of a validity search is similar to 
that of a technology scan or patentability search. A 
search at the claims level for an infringement/FTO 
search is simpler, however, the data analysis will be 
more complex. Here the claims are analyzed in the 
form of a “claims chart,” which allows compari-
sons from each element of the claim to elements 
or features of the potentially infringing product. 




Phased-gate innovation management is a process 
for managing the development of new technol-
ogy, widely used by mid- to large-size technology 
companies. The process provides a framework for 
evaluating a “funnel” of conceptual ideas and ear-
ly-stage concepts while providing a mechanism 
for reducing the investment risk. Figure 2 illus-
trates a phase-gate development process for (A) 
product development and (B) research and de-
velopment scenarios. At the end of each stage, 
numerous input and output factors are analyzed, 
and the risk, based on the status of the technol-
ogy, the business impact, market environment, 
and financial status is analyzed prior to moving 
to the next gate.
The timely development of a robust patent 
position, effective patent portfolio management, 
and continuous monitoring of patent informa-
tion for competitive analysis and infringement 
are all important for reducing risk. 
Typically, however, IP strategy is applied only 
at the initial conception stages and at the later 
stages of product development (after product 
definition and prior to product release). Patent 
applications may be filed on early-stage concepts 
without regard to further modifications or im-
provements, and monitoring of the competitive 
IP position. This can leave R&D and business 
development groups with a false sense of security, 
believing that the simple act of filing provides 
solid IP protection.
Embedding the IP management process into 
the technology-development process is a key stra-
tegic approach to new technology development, 
IP portfolio development, and strategy. By in-
tegrating IPM continuously into the phase-gate 
development process—from conception through 
R&D—advance development, and product de-
velopment, an organization may evolve a stron-
ger patent position, optimize R&D costs, reduce 
patent expenses over the long haul, and minimize 
the potential for patent infringement and litiga-
tion risk. This approach is illustrated in Figure 3, 
which shows a phase-gate technology develop-
ment with integrated IP management processes.
During the initial phase of project defini-
tion or concept development, the use of patent 
landscape or mapping methods may be useful for 
providing information about potential areas for 
research and invention, partnering, or licensing 
opportunities. There may be relevant disclosure in 
one or more patent applications already in pros-
ecution, patent protection may already exist in a 
specific technology area of preliminary interest, 
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or there may be an opportunity to license-in the 
technology. Discovery of prior applications or is-
sued patents can be advantageous or detrimental 
depending on the breadth and scope of the inven-
tion as disclosed in relation to what may now be 
perceived to be new and novel. Prior disclosure 
may not be enabling for the new invention, how-
ever, an earlier published application or issued 
patent may be prior art. Given a analysis of the 
current IP portfolio, there may be opportunities 
to amend applications in process, abandon and 
refile, or file for reissue to gain broader protec-
tion. In-licensing may provide an opportunity to 
gain access to a key technology in the very early 
stages of product development, providing an op-
portunity to significantly lower the cost of devel-
opment and decrease time to market. IP develop-
ment will be most active during the early-concept 
and R&D/advanced-development stages, taper-
ing off in the later stages of product development 
as the product becomes more defined. However, 
effective IPM processes need to be maintained in 
these later stages to ensure that patent prosecu-
tion is adequately supported. Provisional patent 
applications filed during the initial stages may 
at this stage be nonprovisional applications that 
are one or two years into prosecution, or PCT 
applications may be reaching the national stage. 
Continued advanced-development activities or 
product development may involve generating 
new inventions requiring patentability analysis 
and tactical or strategic positioning relative to 
the growing patent portfolio. Meanwhile, con-
tinuous patent monitoring may indicate that the 
competitor IP landscape is shifting, opening up 
the possibility of minor or major modifications 
being needed with respect to the product devel-
opment strategy. 
4.	 ConCluSion
Technology development and IP management 
need to be intertwined to ensure commercial 
success and company viability. The increased 
complexity of high-technology research and de-
velopment, the need to develop global-market 
strategies, reduction of product-life-cycles, and 
broadening product portfolios require an integra-
tion of IPM practices and procedures into inno-
vation and product development. Organizations 
can capitalize on the integrated IPM approach by 
blending state-of-the art IP search and analysis 
tools and techniques, IP database management 
systems, continuous improvement processes, and 
seamless communication between R&D, busi-






































































this model can enable the transformation of inno-
vation into value, by defining strategic direction 
and the protection of rights based on a broad, 
high-quality patent portfolio. ■
JeremY BUrDon, Director of Intellectual Assets, Health 
Science Ventures, Arizona Technology Enterprises, LLC, 699 










8 See, also in this Handbook, chapter 14.3 by H Thangaraj, 
RH Potter and A Krattiger.




Marketing an institution’s intellectual property (IP) is 
essential but challenging work. This chapter provides 
helpful information about how to locate potential licens-
ees, how to determine whether or not they are qualified 
to manage a particular technology, and how to persuade 
them to begin licensing negotiations. The chapter stresses 
the importance of self-knowledge: having a clear sense of 
your institution’s own IP goals, as well as the institution’s 
strengths and weaknesses. Having this awareness makes 
it possible for a technology transfer office to choose 
wisely when it evaluates the strengths and weaknesses of 
potential marketing targets. Indeed, the chapter, rather 
than simply providing a basic overview of the market-
ing process, offers concrete suggestions and tough ques-
tions for those who aim to successfully market academic 
intellectual property.
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inventions) are not developed in response to 
market needs. Thus, a TTO must convince 
businesses of the marketability of potential 
products before businesses have recognized the 
usefulness of such products—and the existence 
of which they may have never even imagined. 
Of course, university inventions are early-stage 
technologies. Often, the technology has not been 
demonstrated: the buyer (the licensee) cannot 
“touch the merchandise,” and the inventors 
themselves may have a hard time defining the 
technology’s utility. In fact, no one may even be 
sure that it will work.
Moreover, persuading potential customers 
to begin license negotiations is difficult because a 
business takes on considerable risk when licensing 
intellectual property. Of course, there are license 
fees, but greater costs come in the form of reori-
enting internal resources and priorities, investing 
enormous sums in development, and changing 
company behavior (in terms of manufacturing 
processes, kinds of products offered, and so on). 
And if the invention is a “bust,” it is the licensee 
who usually bears the financial burden. 
On the other hand, everyone knows that 
new technologies can offer the promise of enor-
mous value. Innovation is the engine behind any 
CHAPTER 12.5
1. inTRoDuCTion
The goal of marketing IP is to bring motivated 
parties to a license negotiation. Technology 
transfer managers must locate potential licensees 
and make them aware of a technology’s promise. A 
technology transfer office (TTO) can best attract 
licensees by placing the right information in the 
right hands of the right companies at the right time. 
Getting all of these “rights” right is a challenge 
for any marketing effort, but some marketing 
challenges are unique to marketing intellectual 
property. First of all, the products (university 
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growing business. Therefore, for a marketer of an 
institution’s intellectual property, the task is to 
make a licensing deal as attractive as possible by 
reducing the risk/promise ratio. 
2. geTTing	STARTeD
To overcome the difficulties, one must begin at 
home. Indeed, when we think of “selling” an in-
stitution’s intellectual property, a logical place to 
start is to ensure that the objectives of the TTO 
match those of its institution. The TTO and the 
institution it works for have a common goal and 
a common vision. This may seem rather obvious, 
but it is best for the institution to understand 
and endorse how the TTO operates (including 
its policies for such issues as conflict of interest, 
equity holdings, royalty splits, and even the direc-
tion of the research being licensed). Without this 
endorsement, a technology transfer manager’s 
marketing efforts will not be supported and, in 
a worst-case scenario, a negotiating process that 
took a great deal of time and effort to achieve will 
be rejected by your institution. If the objectives 
of the TTO are not clearly in line with that of the 
institution, it will also be difficult to create and 
maintain an atmosphere of trust and cooperation 
between the TTO and the university—much less 
between the TTO and its potential customers.
A written policy—approved by the appropri-
ate authorities and available to all investigators—
will establish the ground rules for the TTO’s op-
erations. In addition to emphasizing the need to 
create economic benefit both for the institution 
and the community, this policy should reflect the 
philosophy of the institution. The following are 
sample objectives one might consider.
1. To increase research support from industry 
while maintaining these principles:
• free and open communication among 
colleagues
• collaborative research, as appropriate, 
among colleagues
• an atmosphere of cordiality and mutual 
respect among scientists and clinicians
2. To provide guidelines for fairly distributing 
the economic benefits of academic–indus-
try relationships and to ensure that these 
relationships enhance the institution’s basic 
mission in the areas of teaching, research, 
and community outreach
3. To provide reliable, expeditious processes 
and procedures for resolving conflicts of 
interest in academic–industry relationships
4. To ensure that partnership companies act 
ethically and in a socially responsible man-
ner, so that they diligently promote the 
development and dissemination of the in-
stitution’s research products for the greatest 
possible public benefit
Publicly articulating such principles for the 
campus community will make the TTO’s efforts 
more focused, transparent, and effective. This is 
partly because the institution will be able to get 
behind the TTO wholeheartedly and partly be-
cause sharing these goals with potential business 
partners can go a long way toward fostering mu-
tual understanding, which is always helpful for 
facilitating the negotiation process.
3. TeChnology	AuDiTS	
A common TTO complaint is that “no one has 
time to audit the inventory of inventions.” If 
technology transfer managers do not know what 
is in the pipeline, then it will be impossible to 
organize a coherent sales or marketing strategy. 
Understanding what inventions are in the patent 
process, what investigators are actively working 
on, and whether this work matches the depart-
ment chairperson’s expectations is valuable, not 
least because such understanding lays the founda-
tion for an effective sales strategy.
Auditing the status of each technology is such 
a critical starting point that it could be worth 
the expense to bring in an outside consultant to 
augment the review of the invention disclosures, 
understand the patent situation, evaluate the 
commercial potential, and recommend commer-
cialization alternatives. 
3.1 Resource	assessment
Once a technology transfer manager knows the 
“inventory” of the TTO, the manager can assess 
the resources needed to implement a sales strategy, 
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especially in relation to staffing. Balancing cases 
among available licensing professionals, for exam-
ple, will allow for an even allocation of time for 
those cases that are close to closing. A technology 
transfer manager would not want to have one pro-
fessional attempting to close ten cases, while anoth-
er has none closing. In general, a caseload of up to 
40–50 inventions in various stages of qualification 
per person is possible if good planning is in place.
However, realistically allocating cases among 
available resources may result in a shortfall. Once 
again, an outside consulting group may need to 
be brought in to handle a series of unattended 
cases. Moreover, it is always difficult to decide 
when to drop a case—the institution risks incur-
ring unrecoverable patent expenses by carrying a 
case too long. Therefore, TTOs should not have 
cases lying dormant without having a strategy for 
eventually marketing them. Giving the case to a 
consulting group on a success-fee basis, with a 
small retainer to manage expenses, may be a logi-
cal action plan for cases that cannot be attended 
to by TTO personnel. The challenge is to ensure 
that the consultant’s approach is fully aligned with 
the strategy and personality of the TTO in order 
to match the mission of the institution, manage 
the interface with the commercial targets, and 
make sure the investigator is feeling the technol-
ogy is adequately being attended to, rather than 
being overlooked or pushed aside.
3.2 Sales	strategy
Keeping up with the ongoing stream of new in-
ventions, managing the existing portfolio of proj-
ects, and negotiating and closing the transfer of 
technology—all of this provides lessons in prior-
ity setting and planning. Careful preparation al-
lows a technology transfer manager to be efficient 
and fair to all parties involved. After all, a scientist 
with a technology of little value may invent the 
next blockbuster royalty generator for the institu-
tion. The key to success in all of these areas is to 
keep up with the technology stream while build-
ing up an inventory of cases.
If building a long-term royalty stream is a 
goal for the institution, a manager cannot do this 
without closing contracts. The technology transfer 
manager should therefore consider creating an 
objective for the TTO of closing a certain num-
ber of contracts per year. Having this goal as a 
cornerstone of the sales strategy will create a sense 
of urgency, enhance office performance, and pro-
vide a sense of focus for the staff. A TTO might 
consider holding a monthly “to do list” meeting 
that realistically sets goals for the next 30 days, 
with the primary goal being a task related to clos-
ing a contract. Academic settings often revolve 
around fiscal years or semesters, while the TTO 
customers revolve around monthly, or at most, 
quarterly objectives. Having a TTO work around 
shorter-term priorities can potentially enhance 
the velocity at which the office either moves tech-




To develop a sales strategy, a technology trans-
fer manager needs to thoroughly understand the 
customer so that he or she can ensure that the 
customer best matches the technology’s require-
ments and potential. Exactly who the customer is 
in a technology transfer is not always evident. On 
the one hand, the TTO must enter into tough ne-
gotiations with research sponsors and other pro-
spective licensees; on the other hand, the TTO 
serves the institution and research scientists. The 
bottom line is, however, that the manager needs 
to remember that the industrial sponsor/licensee 
pays the royalties. To be sure, the scientist is the 
producer of the package to be sold, so treating 
that person as the TTO’s client and partner is 
equally important. The TTO must maintain a 
delicate balance.
Listening to the customer throughout the 
process can be a difficult challenge, but a deal 
could very well depend upon how well the TTO 
staff is listening. In particular, the manager must 
recognize that the technology is usually compet-
ing with other priorities in the company’s devel-
opment plan. Open communication will allow 
the manager to respond to the customer’s needs 
and also let the TTO determine whether the cus-
tomer is right for the technology.
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4.2	 Finding	potential	licensees
For most technologies, a list of potential partners 
can be easily generated. Indeed, the explosion of 
Web-based databases makes it simple to get a list 
of potential customers that may be appropriate to 
contact.1 Sites like biospace.com, not only allow the 
technology transfer professional to “reach out” and 
find customers, but maintaining your own Web 
site, that is updated routinely, allows companies to 
“reach in” to the institution portfolio. A TTO may 
be surprised at how companies are getting more so-
phisticated in searching university Web sites. The 
Massachusetts Association of Technology Transfer 
Offices has gone a step further and maintains a 
central Web site that can search 19 institutions 
through the use of key words.2 The site is updated 
nightly for any additions/deletions made by an in-
dividual institution. Other programs like TechEx.
com also allow companies to reach in to the insti-
tutional portfolio from members worldwide who 
have listed their available technologies. Such lists, 
however, need to be sifted through before drawing 
up a targeted prospect list.
Another useful source of industry contacts 
is the team of scientists working at your institu-
tion. Scientists will often already have an industry 
contact for a given technology, and a scientist’s 
relationship with a company is invaluable for ini-
tiating negotiations. In fact, AUTM data have 
shown that 54% of licensees were initiated due 
to investigator-company relationships.3 So TTO 
staff must be sure to ask the scientists about their 
contacts. (Knowing where their graduates have 
gone can often provide useful leads.) When ex-
ploiting an inventor’s personal contact, however, 
one must make sure that the technology transfer 
manager is serving the best interests of the tech-
nology and not limiting its possibilities by defer-
ring to the inventor/scientist.
Other sources of contacts may come from 
the TTO members’ industrial experience, 
experience from previous cases, AUTM members 
who have dealt with the targeted field of tech-
nology, or other members of the institution who 
have dealt with the company. Industry directo-
ries, professional association directories and ma-
terials, and trade publications and newsletters can 
all provide useful leads.
Of course, if you are a TTO manager, remem-
ber to think about your own contacts! Who do 
you know? Who do your friends know? Who has 
come to see you in the recent past? Networking 
begins with you.
4.3	 Qualifying	potential	licensees	
Evaluating companies means asking at least these 
four key questions: 
1. Does the technology fit the company’s need?
2. What is the company’s time frame to de-
velop the product?
3 Does the company have the budget to de-
velop the product? 
4. Is there any reason why the company 
would be unwilling to work with the  
institution/scientist?
It is often difficult to get accurate answers to 
these questions. The company contact may not 
be able to answer them, which may require the 
technology transfer manager to try to get the 
company to open up and explain its position. A 
simple tip is to ask questions beginning with the 
words “who, what, when, where, and why.” With 
these types of questions, the contact cannot give 
a simple yes or no answer. Most importantly, the 
TTO manager must remember to listen after ask-
ing the question! It is pointless to ask a question 
and then have a colleague (or yourself ) answer it 
instead of the customer.
5. Key	quAlifying	queSTionS	
5.1	 Does	the	technology	fit	the	need?
The good way to start is by asking, clearly, wheth-
er the technology field matches the company’s 
current business development strategy. The ques-
tion should be posed to the scientific contact at 
the company, as well as to the business contact, 
preferably at the executive level or at least with 
the top business development manager. The tech-
nology transfer manager should be on the look-
out for company scientists eager to work in an 
area that does not match the company’s overall 
business goals. While such scientists may have the 
capability to fund initial work for the technology, 
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he or she will most likely be unable to move the 
technology any further.
Asking for a review of the company’s busi-
ness strategy is appropriate, and good customers 
will want to provide this—confidentially—to 
ensure that everyone knows where this poten-
tial partnership would fit. After all, the compa-
ny’s scientific efforts must be matched with its 
marketing endeavors for a licensed technology to 
be commercialized.
The company should also be able to provide 
a sense of the market for the proposed product. 
Such information should include market size, 
trends, participants, and contacts, as well as recent 
deals relevant to the market and the company’s 
overall approach to the market. Specific questions 
might include the following:
• Does the product fit into an easily identi-
fied market niche?
• What is the total market potential (range)?
• How fast is the overall market growing?
• Is the market prone to frequent innovation 
or is it a traditional/static market?
• Is market demand stable, cyclical, or 
seasonal?
• How many major competitors exist?
• Is market power diffused among many par-
ticipants or concentrated in a few?
• Is the market characterized by critical price 
constraints, (for example, regulation, in-
dustry, association, dominant price leader, 
and so on)?
• Are competitors generally aggressive or rel-
atively passive in their marketing?
• Are others working on similar 
developments?
• What competing research/development ef-
forts exist?
• How easy would it be to duplicate the 
product?
• At what stage of development are others 
involved in this area of technology?
• How large are barriers to entry in this 
industry?
• How large a market share would be required 
to achieve the company’s objectives?
• How fast will consumers recognize and re-
spond to this innovation when available?
Ideally, both parties come to the table with a 
clear idea of their needs. The TTO will have a list 
of the strengths of the technology, the strengths 
of the investigator, and the strengths of the insti-
tution, while the company will arrive with a clear 
definition of what it needs to accomplish its stra-
tegic goals. A close match will allow the manager 
to move on to the next qualifying question.
5.2	 Do	time	frames	mesh?
Where does the project fit in with the company’s 
development plans? The due diligence clauses 
in the contract need to match the answer to 
this question. The technology transfer manager 
might have negotiated a terrific royalty on prod-
uct sales, but the company may not have plans to 
insert the technology into its product develop-
ment group until the year 2015. Reviewing the 
business plan would be helpful in assessing the 
intentions of the company.
The company needs to express its intent to 
commercialize the technology in an acceptable 
time frame in order for the negotiation to pro-
ceed. Too many TTOs have been surprised by 
their partners’ lack of diligence, and asking this 
question in the beginning establishes the ground-
work for moving on to the next qualifying ques-
tion. Diligence can be ensured by attaching mile-
stone payments, minimum annual royalties, or 
research-funding-level commitments to develop-
ment activities.
5.3	 Is	the	company’s	budget	adequate?
How much money does the company have 
budgeted to develop this technology? The an-
swer must match both the institution’s and the 
company’s needs. Will the scientist be comfort-
able with this level of funding? What research 
should be carried out at the company versus at 
the institution? The answers to these questions 
may reveal a flaw in the company’s intentions. 
For example, it may desperately want this tech-
nology to round out a portfolio that would help 
the company raise additional funds but not re-
ally have the budget to undertake the project. 
The TTO might then miss the opportunity to 
license the technology to another party who has 
adequate funding available. 
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Typically, this question can come down to 
a company having any funds versus having the 
right funds. While having “any funds” may be 
acceptable, all involved need to understand this 
prior to entering into an agreement.
5.4	 Do	prejudices	exist?
Prejudice against an institution, TTO, or scientist 
should not be overlooked in the qualification pro-
cess. The TTO, for example, may have found the 
ideal company for commercializing a technology, 
but it turns out that the scientist is a leading con-
sultant for the competition. Or perhaps the com-
pany has a major program in this field with another 
institution, and wants to avoid diluting its efforts. 
Perhaps previous negotiations with the company 
have been poorly handled, and so the company is 
reluctant to negotiate with the institution again.
Such prejudices need to be addressed. Any of 
these situations can cause negotiations to break 
down or even never begin. If historical prejudice 
involved former personnel or a situation that no 
longer exists, then the prejudice may be irrelevant, 
but there need to be assurances from the company.
6.	 mARKeTing	pACKAge
6.1	 Tailoring	to	your	customer
The marketing package depends on the stage of 
customer qualification. Initially, when inventory 
is made, a short, nonconfidential abstract of the 
technology should be prepared. Organizing these 
abstracts by market segment allows the TTO to 
provide tailored packages to prospects. The tech-
nology transfer manager must understand that 
industrial business development offices receive 
hundreds of technology proposals. Proposals that 
align with the interests of such offices will have a 
much better chance of getting attention. Do not, 
however, overplay this aspect. Potential custom-
ers will reveal their level of market knowledge 
when they are qualified in the “technology to fit 
the need” questioning. It is extremely dangerous 
to tell a company how to conduct business in its 
field, even if a scientist thinks the company is ap-
proaching it incorrectly. Boxes 1 and 2 present two 
approaches for initiating the search for a company 
to license  and develop a technology. Rifle-shot 
marketing4 (Box 1) is most appropriate when the 
TTO has a handful of good partnering prospects. 
The shotgun-marketing approach (Box 2) pro-
vides advantages for small tech-transfer offices.5 It 
is a no-frills approach that allows for a wide range 
of notification without a huge investment of time, 
but it requires careful orchestration.
An up-to-date Web site, with available tech-
nologies easily accessible, will augment your mar-
keting approach. Make it easy for customers to 
navigate to a technology area and provide your 
nonconfidential abstracts. It could also be helpful 
to allow a link to pdf files of the abstract and of 
other publications so that the person searching can 
easily share the information with other internal 
staff. The TTO might also consider developing a 
list of quick pitches on video with the investiga-
tor taking 3–4 minutes to explain the technology. 
Technology today can produce videos relatively in-
expensively, and setting a goal of adding 1–2 per 
month will help build the inventory without di-
verting too much energy from other tasks.
6.2	 Getting	it	(confidentially?)	right
An even more targeted approach than that of rifle-
shot marketing will give the right information, to 
the right person, at the right time. Such precision 
requires a tremendous amount of effort, and man-
agers should evaluate the opportunity cost of pur-
suing this approach in relation to other technolo-
gies that could be marketed using other methods. 
To pursue the “right-right-right-right” method,6 
be sure to offer the “right information” including:
• title
• abstract
• patent or serial number
• summaries and digests
• catalogs and lists
• patent applications
• venture summaries
• business plan outline
• inventor discussions
As far as knowing how much information to 
give—and the form in which to give it—be sure 
to emphasize the benefits of the invention rather 
than its features. Describe what the invention 
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Box	1:	Rifle-Shot	marketing
	
1. Present to one company at a time (or at most three or four).
2.  Do not spend time and money publishing lists of “available cases.”
3. Present technologies handpicked for your contacts—but do not wear out your welcome.
4. Send as much nonconfidential information as you can, including published papers, if possible.
5.  Do not send confidential information uninvited, but include a confidentiality agreement for easy 
access to more information.
6. Include the names of all the inventors; for example, “R. Jones and Albert Einstein” not “Jones, et al.”
7. Send a cover letter that explains: 
• what the case is all about (one paragraph) 
• why the case might interest the company 
• what the licensing situation is 
• how to get more information
8. Don’t be unnecessarily protective of information.
9. Do answer phone calls and letters promptly.
Box	2:	Shotgun	marketing
	
Principle features of the shotgun marketing approach:
• many companies notified at once
• “cold mailings” used instead of targeted mailings
• preference to hit “more” instead of “less”
• follow-up time reduced
Special techniques for using the shotgun approach: 
• provide a marketing package with a nonconfidential abstract for the invention/technology
• use letterhead, stationery, and other paper goods that clearly identify the institution
• use careful selection criteria to identify marketing targets
• maintain as much contact as possible with technology liaisons of the primary marketing targets
• explain to potential licensees why you are using this approach
KEIllER
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does rather than how it does it. Compare the 
invention to one or more current alternatives, 
and highlight the invention’s advantages but 
be prepared to knowledgeably discuss its 
disadvantages. Identify and evaluate the market 
potential, estimate production methods (and 
costs, if possible), and estimate the investment 
required to commercialize the invention. For the 
latter, be sure to consider what other technical, 
marketing, or distribution resources would 
be required. Also, share knowledge you may 
have of any regulatory, governmental, or other 
factors that are important to commercializing 
the particular technology. Finally, develop an 
intuitive feel for how the invention would fit 
in a company’s strategic technical plans. As part 
of this attempt, try to use a title that will have 
marketing appeal, instead of a patent-type title. 
For example, turn “Synthesis of Conducting 
Tim Films by Nitridation of Spin-on Oxides” 
into “Improved Fabrication for Titanium 
Nitride Films Using a Sol-Gel Process.” This will 
show that you have carefully thought not only 
about how the potential product would fit into 
the company’s product portfolio but also how it 
might fit more generally into the market. 
To get your information into the “right 
hands” at the “right company,” you will need 
to have identified who the “right hands” are. 
Consider what company level or function is most 
suitable for your pitch:
• top: chief executive officer, president, gen-
eral manager, vice president, director
• bottom: scientist, engineer, operations staff, 
marketing/sales personnel
• middle: licensing, patent counsel, tech 
transfer
• by function: R&D, engineering, market-
ing, business development
Be sure to take full advantage of alumni 
employees, departed inventors, and others who 
may still have very useful contacts and informa-
tion that can help you get your materials into the 
right hands. Of course, before you can identify 
the right hands, you will need to have identified 






• professional and trade associations
• scientific conference attendees/speakers
• government contacts (for example, Small 
Business Innovation Research grantees)
To find the right time to contact the right 
hand at the right company with the right infor-
mation, you will need to be aware of changes in 
government regulation, shifts in business focus, 
external circumstances (for example, war or mac-
roeconomic changes), personnel changes, tech-
nical breakthroughs, and other relevant current 
events. Think hard, then roll the dice.
It is possible to provide even more detailed 
information after confidentiality agreements have 
been signed. But more and more companies are 
scrutinizing their willingness to sign such agree-
ments, especially for devices. At any rate, in con-
fidence, more scientific detail may be provided, 
including a more detailed patent-status descrip-
tion. Depending upon the opportunity’s poten-
tial size, the TTO may go further and provide a 
full business plan to prospective investors.
The key to any successful information pack-
age is to find answers to as many questions as 
possible as to what companies would partner well 
with the institution, and then tailor the package 
to handle any objections raised by the customer. 
Be sure to emphasize the benefits of the invention 
related to the market. For example, could the in-
vention lead to any of following?
• a product or service that performs an en-
tirely new function
• improved performance of an existing 
function
• improved manufacture of an existing 
product
• additional functions of an existing product
• an existing product in a new market
• integration of two existing products
If the answer is yes, be sure to say so. Finally, 
and most importantly, follow up and keep track 
of contacts. 
CHAPTER 12.5
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7.	 CloSing	The	TRAnSACTion	
7.1	 Terms
Hopefully, the basic terms of the technology 
transfer will become evident after the qualifica-
tion effort is complete. However, it would not be 
unusual for the terms to reveal the true answers to 
qualification questions. This is when it is critical 
for both sides to really understand what is expect-
ed from each party. Budget and remuneration is-
sues should certainly be resolved at this stage and 
not left to the execution copy stage.
The technology transfer manager should not 
take a term sheet lightly. The institution attorney 
will caution the TTO that the term sheet could 
be construed as a binding document. Therefore, 
it should not be used for loose negotiating, but 
instead as a sincere effort to understand each 
other’s responsibilities for the transaction. This 
includes not only the financial commitments, 
but the personnel, laboratory, institutional, and 
corporate resource commitments.
7.2	 Transaction	time	and	negotiation	process
Transaction time, or the time taken to negotiate 
a contract from start to finish, is critical to the 
TTO if it is going to keep up versus build up its 
inventory. Lengthy negotiations, long meetings 
without agendas or outcomes, and lack of prepa-
ration all contribute to prejudices that could in-
terfere with current and future transactions.
The technology transfer manager should keep 
in mind that royalties cannot begin without the 
completion of the transaction. A six-month delay 
due to a lack of focus or commitment may mean 
six months of lost revenue to the company and lost 
royalties to the institution. Moreover, competitive 
technologies often have a limited window of op-
portunity. It is a real disservice to all involved if 
an opportunity is missed because of an inability 
to work through the issues. One should always re-
member that, instead of languishing, it is usually 
better to determine quickly that a potential partner 
is not actually a qualified customer and then move 
on to another party that is more capable. The TTO 
has to look at such options as an opportunity cost: 
there are always other cases that could be moved 
forward but for a delayed qualification process.
This author has found it helpful as a mem-
ber of a technology transfer department to re-
view regularly the top three to six projects that 
are nearest to closing. Department members 
contribute to the process by suggesting ways to 
move things toward closing. The exercise also 
reminds the professional to spend an appro-
priate amount of time completing the task. In 
short, the TTO often needs to be the facilitator 
as much as the negotiator. 
7.3	 Follow	up
The signatures on the execution copy of the con-
tract are usually (1) the signal for celebration 
and (2) the opportunity to move on to the next 
case. However, the follow-up to a contract is of-
ten overlooked, and this can be a costly mistake. 
One must maintain contact in order to ensure 
that the company’s original goals with respect to 
the technology remain the same. Be aware that 
the company may have been saying yes, when it 
really meant no, to questions during deal nego-
tiations or during the ongoing commercialization 
of the institution’s technology. This indecision 
can manifest itself when the TTO has presented 
a technology to a company that either does not 
want to, or cannot, make a decision about com-
mercialization. The institution, for example, may 
be a big customer of the company’s existing prod-
ucts, and the company does not want to upset the 
current relationship by passing on an opportunity 
to license a technology. But because the company 
does not know what to do, it does nothing, and 
the technology sits.
There is also no alternative to tracking con-
tracts to make sure that payments are made and 
milestones are reached. Indeed, the diligence of 
all parties needs to be assured in order to eventu-
ally see a product enter the market. A database 
program should be used to automatically flag 
events, activities, and payments so that the TTO 
can more effectively follow up with the sponsor, 
collect fees, and monitor progress. By following 
up and measuring the success of a program, one 
gains useful information for future contracts. 
Indeed, a relationship can be built with the 
company that allows for more-efficient future 
negotiations. 
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8.		ConCluSion
Marketing intellectual property has unique chal-
lenges, not the least of which is trying to sell un-
developed (and, therefore, unproven) technology. 
The intangible and uncertain nature makes finding 
companies to develop such technology difficult, 
and yet critical to bringing the technology to mar-
ket. Taking the many special considerations into 
account, marketing intellectual property can keep 
a technology transfer manager on top of IP devel-
opments at his or her institution, be an intellectu-
ally and socially stimulating part of the job, and 
be a successful foundational element of a TTO’s 
overall achievements. ■
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ABSTRACT
A small agricultural biotechnology (agri-biotech) com-
pany needs to establish a strong IP portfolio. Such a port-
folio provides a foundation for R&D, encourages outside 
investment and funding, and supports product commer-
cialization. An important step in establishing an IP port-
folio is in-licensing patent rights from third-party patent 
holders. Nonexclusive licenses typically give a company 
freedom to operate and open up the possibility of creating 
commercializable products. Exclusive licenses give a com-
pany an exclusive position for commercialization under 
the patents in question.
This chapter discusses in-licensing as it applies to small 
agri-biotech companies. It describes the types of technol-
ogies that may be subject to in-licensing, the procedures 
attendant upon in-licensing, and the terms that may be 
delineated by in-licenses.
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a position of exclusivity, which provides a unique 
competitive position. Acquiring license arrange-
ments and the FTO or exclusivity they provide 
increases a company’s value, its attractiveness to 
funders, and its chances for acquisition or public 
offering. 
Company-owned intellectual property is an 
important part of any company’s portfolio, but 
R&D to develop IP takes time and money. In-
licensing allows a company to obtain IP rights 
at an early stage, without having to invest in 
research. Nonexclusive in-licensed rights, that 
is, rights granted to more than one licensee (see 
below), provide FTO under the given patent 
rights. On the other hand, exclusive in-licensed 
rights, that is, rights that are granted to only a 
single licensee (see below), provide FTO under 
the given patent rights and assure the licensee of 
a commercial position of exclusivity on produc-
tion, sales, or use, at least for a certain length of 
time.
A strong IP portfolio is key for companies 
based in countries with established patent sys-
tems.  A strong IP portfolio can also be an as-
set for companies in the rest of the world: it 
makes them more competitive in their home 
countries. Moreover, a strong IP portfolio may 
be necessary if such a company wishes to export 




In order to be successful, a technology company 
needs to build a proprietary position in intellectual 
property (IP); that is, it needs to build a strong IP 
portfolio. The portfolio should be composed pri-
marily of both company-developed patent rights 
and patent rights acquired through licensing, but 
it may also include know-how, trade secrets, copy-
rights, and trademarks. The IP portfolio should 
include a diverse set of IP rights that provide the 
company with both freedom to operate (FTO), 
which clears the path to commercialization, and 
Neagley CH. 2007. Patent Licensing for Small Agricultural Biotechnology Companies.  In Intellectual Property Management 
in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: 
Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. CH Neagley. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
Patent Licensing for Small Agricultural 
Biotechnology Companies
clinton h. neagleY, Associate Director, Technology Transfer Services, University of California, Davis, U.S.A.
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2.	 nonexCluSive	AnD	
exCluSive	liCenSeS
An IP license (or IP license agreement) is a con-
tract in which a holder of IP rights (the licen-
sor) grants certain rights to another party (the li-
censee) in return for compensation (monetary or 
otherwise). The scope of a license depends on the 
rights that are licensed, as well as how, when, and 
where these rights may be used or practiced. The 
rights granted by a patent license include rights 
granted under the patent itself, but may also in-
clude trademark rights, copyrights, know-how 
rights, or rights over tangible material (personal 
property). The characterization of an IP license 
depends on one’s perspective: the licensee con-
siders it an in-license (because the licensee takes 
the license, as well as responsibilities and benefits 
thereof, into its IP portfolio) and the licensor 
considers it an out-license (because the licensor 
grants IP rights out of its own portfolio). In the 
case of a cross-license, parties pay for in-licenses 
from each other by granting out-licenses to each 
other.
In-licensing of patent rights may be either on 
a nonexclusive or an exclusive basis. Each type of 
licensing arrangement serves a different purpose, 
involves different contractual terms, and comes 
with a different price tag. 
In general, a nonexclusive license gives the li-
censee FTO for the patented technology, but not 
an exclusive position. The licensor may grant li-
censes to others for the same technology. A non-
exclusive license may contain a nonassert clause: 
that is, the licensor agrees not to assert any other 
patents against products developed by the licens-
ee using the original license. It is not uncommon 
for small agri-biotech companies to acquire a se-
ries of nonexclusive licenses so that they have the 
right to develop technologies that they can even-
tually use to create new products. 
In contrast, an exclusive license gives the li-
censee FTO for the patented technology and an 
exclusive position on its use; in other words, hav-
ing an exclusive license to a patent is, in certain 
ways, like holding the patent itself. Exclusive li-
censes can help a new company to establish itself 
in a research area and to generate income for its 
own research activities. The trade-off is that an 
exclusive license typically costs more than a non-
exclusive license. 
“In-between” licensing positions may also 
be possible. For example, a company could seek 
a nonexclusive license with the option within a 
certain period of time to convert the nonexclu-
sive license to an exclusive license. Such an option 
grant is normally more costly for the licensee than 
a nonexclusive license alone because the licensor 
agrees not to grant licenses to others during the 




A small agri-biotech company should develop 
a competitive IP portfolio that includes patents 
and licenses for enabling technology, trait tech-
nology, and also plant material.
Enabling technologies (in other words, research 
tools) are used to bioengineer new organisms. 
Enabling technologies include plant transforma-
tion technologies; promoters and other expression 
systems, including constitutive, inducible, tissue-
specific, and temporal-specific promoters; mark-
ers, including selectable and screenable markers; 
vectors; gene-suppression technologies; leaders, 
transits, and signals; excision technology; and oth-
er components introduced into a bioengineered 
plant that are not trait- or phenotype-specific.
In-licensing is typically nonexclusive for en-
abling technologies. Nonexclusivity allows the 
licensor to grant many licenses and thus widen 
its revenue base; at the same time, the licensee 
can acquire technology and FTO at a lower cost. 
At times, however, in-licensing of enabling tech-
nologies may be exclusive, either for broad use or 
for specifically defined use, such as a defined crop 
area or a defined trait area. Licensing enabling 
technologies may involve a transfer of rights over 
tangible property (for example, DNA sequences) 
that may be regulated by material transfer agree-
ments or bailments.1
Trait- or phenotype-specific technologies can be 
used to create plants with new genes that express 
desirable traits. The genes may be derived from 
any type of organism, for example, viral, bacterial, 
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fungal, plant, or mammalian. The genes may be ex-
pressed as desirable agronomic traits, for example, 
biotic or abiotic resistance, or desirable consumer 
traits such as color, flavor, texture, or fragrance. 
In-licensing is often exclusive for trait-specific 
technologies. A license may only authorize the li-
censee to work with a particular crop or group of 
crops. Exclusive licenses allow the licensor to be 
compensated for genes that it is not currently ex-
ploiting itself; at the same time, such licenses allow 
the licensee to hold an exclusive position with re-
spect to the use of these technologies and to devel-
op new commercial products with them. Licensing 
of trait technologies may involve a transfer of rights 
over tangible property, for example, genes or gene 
constructs, which may also be regulated by mate-
rial transfer agreements or bailments. 
A third type of technology is the plant ma-
terial into which enabling technology and trait 
technology can be introduced. Plant material en-
compasses model plants, for example, Arabidopsis, 
that are used in early-stage research, as well as 
commercial-crop plant material (either breeding 
material or varietal material) that is used both in 
research and later-stage development or commer-
cial work. 
Plant material can be in-licensed if it is pro-
tected by patents (or plant patents) or by plant 
variety protection/plant breeder’s rights. If the 
plant material is not protected by intellectual 
property, access may be through material transfer 
agreements or bailments. However, not all plant 
material is protected by IP laws; some is in the 
public domain or freely available, for example, 
from the U.S. Department of Agriculture.
4.	 liCenSing	pRoCeDuReS
Licensing is a time-consuming and expensive 
procedure. Normally, each company involved in 
licensing has a team that includes one or more 
in-house technical people (and often the head of 
research), as well as one or more business people. 
In addition, in-house and outside patent special-
ists should be available to provide input. Patent 
specialists include patent counsel (in the United 
States, lawyers who are qualified to practice before 
the U.S. Patent and Trademark Office, or PTO) 
and patent agents (in the United States, nonlaw-
yers with technical training who are qualified to 
practice before the PTO). If the company is not 
large enough to have in-house patent counsel, 
then outside counsel who understand the compa-
ny’s technology and budget requirements should 
be retained. Even when in-house patent counsel 
(and/or in-house patent agents) is present, outside 
patent counsel should still be held at the ready to 
assist with difficult or special situations. 
The company should develop a patent plan 
for each R&D project it hopes to undertake. In 
addition to planning IP protection for company-
developed inventions, the patent plan should 
identify the existence and status of third-party 
patents for which it would be useful to obtain li-
censes. As the research plan matures, and as the 
third-party patent landscape changes, the patent 
plan will need to be revised.
The process of identifying third-party patents 
is detailed elsewhere in this Handbook.2 But brief-
ly, third-party patents may be identified based on 
information available from a number of sources, 
including published patent applications, patent 
grants, publications, conference presentations, 
Web sites, Securities and Exchange Commission 
submissions, and the popular press. Patent ap-
plications are published by the PTO; by the 
World International Patent Organization, which 
publishes patent applications under the Patent 
Cooperation Treaty; and by individual foreign 
patent offices.
Although it is important to consult pub-
lished patent applications, a few caveats are called 
for. First, the patent application is published 18 
months after the patent is filed, so it does not 
contain up-to-date information. Second, the 
published patent application normally contains 
the claims as filed, not as may be amended in 
prosecution or as will be granted. After the pat-
ent application is published, however, the patent 
file is made available to the public and it will be 
possible to track any changes of the patent claims 
during the patent prosecution. Third, there is no 
guarantee that the patent application will issue as 
a patent. Fourth, it is not uncommon for more 
than one applicant to seek patent rights for the 
same invention. In countries outside the United 
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States, the general rule is that the first to file a 
patent application is entitled to the patent. In 
the United States, however, it is the first to invent 
who is entitled to the patent. 
Once important third-party patents are 
identified, they and their file histories should be 
studied to determine the scope of patent claims 
and their applicability, or lack thereof, to the 
project being considered. If the patent is appli-
cable to the project, if a license is available, and 
if its price is within the company’s budget, the 
company might decide to seek the license. If the 
patent is applicable to the project but a license 
is unavailable, or not economically feasible, the 
project plan should be reevaluated; there may be 
work-arounds, that is, alternative ways of achiev-
ing the same results, that avoid the patent. 
If the company decides to seek a license, the 
company should determine whether it wants 
nonexclusive or exclusive rights, decide what it 
is willing to pay for them, and decide whether 
it wants license rights or option rights.3 Contact 
with the patent holder (the potential licensor) 
can be made directly or through an intermediary, 
such as an outside law firm. Using an intermedi-
ary may be useful if the company does not want 
to identify itself to the potential licensor until it 
is certain that a license is available. Negotiations 
can be direct or conducted through an intermedi-
ary and are often governed by mutually agreed-
upon confidentiality agreements. During the 
negotiations, the licensor may ask for a business 
plan from the potential licensee(s) if the licen-
sor is deciding among several potential licensees 
and/or in order to calculate the level and type of 
compensation it will request. The negotiation is 
normally conducted under the direction of, or at 
least with the input of, each company’s business 
and legal team. Typically, discussions lead to the 
creation of a term sheet, which in turn is followed 
by negotiation of the terms and language of the 
license agreement. 
5.	 TeRmS	of	liCenSe	AgReemenTS	
The core of a patent license agreement consists of 
two parts: first, the rights to be granted to the li-
censee, and second, the compensation to be paid 
to the licensor. The rights granted are generally de-
termined by the scope of the patent, though not 
always. The license may also delineate other rights 
that are to be granted, for example, tangible prop-
erty rights, copyrights, know-how, trade secrets, 
or trademarks. The licensor receives compensa-
tion by way of a negotiated payment arrangement 
of fixed fees and/or royalty fees. Other key pro-
visions of the license agreement typically include 
responsibility for liability; diligence requirements 
(defined below); the licensee’s rights of participa-
tion in patent procedures; the term or duration of 
the agreement; and license assignability (defined 
below). 
5.1	 	Patent	rights
The rights conferred by a license, or patent rights, 
are normally based on the rights covered by one 
or more defined patent applications or patents, 
along with rights to any related filings (such as 
continuations, divisionals, and reissues). If the 
license is to be applicable in a foreign country, 
patent rights will also include rights under the 
counterpart patent(s) of that country. As noted 
above, the license may also confer rights under 
any other patents of the licensor that cover prod-
ucts covered by the defined patents (nonassert 
clause). 
5.2	 Rights	granted	to	the	licensee
According to a strict definition of an exclusive li-
cense, the licensor keeps the title to the patent 
but retains no other rights for itself (although, 
as noted below, in practice the license will often 
specify certain retained rights for the licensor). In 
a sole license, the licensor grants a single license 
while retaining full rights for itself. In a coexclu-
sive license, the licensor grants licenses to a de-
fined number of licensees (typically two).
There are several key ways that a license grant, 
either nonexclusive or exclusive, can be limited or 
defined. First, the grant can be limited territori-
ally, for example, it can be restricted to certain 
countries, or certain geographical areas within the 
United States. Second, the grant can be limited in 
terms of duration, for example, it can be limited 
to the life of a given patent, or some other defined 
period of time. Third, the grant can be limited to 
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a defined field of use (for example, research use, or 
use of certain crops or traits).
The grant, even where exclusive, may also be 
limited by specified retained rights of the licensor, 
that is, those rights that continue to be held by 
the licensor or that can be granted by the licensor 
to other licensees interested in a different busi-
ness area, in a different territory, or for different 
fields of use. For instance, the Public Intellectual 
Property Resource for Agriculture (PIPRA) rec-
ommends that agri-biotech licensors retain rights 
that will allow them to license their technology to 
others for humanitarian purposes.4 If a patented 
technology is developed using U.S. government 
funding, any license is subject to the rights of, 
and the obligations owed to, the U.S. govern-
ment (Bayh-Dole Act, 35 U.S.C. § 200 et seq.). 
Normally, the grant will specify whether or 
not the licensee has the right to grant sublicenses 
to affiliates, other corporate partners, or other 
third parties. There may also be express sublicense 
rights to allow others to make or sell products on 
behalf of the licensee. Exclusive license agree-
ments often allow broader sublicensing rights 
than do nonexclusive license agreements.
In addition, the grant may also provide for 
release or forgiveness for past acts of infringement 
by, or on behalf of, the licensee. The license may 
also grant additional rights in the form of most-
favored-nations clauses, in nonexclusive licenses, 
or in the form of right-of-first-refusal clauses for 
future licensor improvements.  A most-favored-
nation clause provides that, in the event the li-
censor grants more favorable terms in a license 
with another party for the same patent rights, the 
licensor will offer the same more favorable terms 
to the original licensee. A right-of-first-refusal 
clause provides that, in the event the licensor de-
velops improvements of the licensed patent rights 
and chooses to make those improvements avail-
able for licensing, the licensor will offer to license 
such improvements to the licensee before offering 
to license them to others.
5.3	 	Compensation	due	to	the	licensor
Compensation may be a combination of fixed 
fees, which can be paid up-front and/or periodi-
cally, and earned royalty fees. Both the level and 
timing of compensation are important to the 
company with respect to its planning and budget. 
In determining what compensation it is willing to 
pay, the company will need to estimate the poten-
tial value of the licensed technology and assess the 
potential value of any commercialized products 
that might be developed under the license. This 
analysis should take into account many factors, 
including the product’s potential market size, its 
likely market share, the nature of any competi-
tion, the strength of the licensor’s patent rights, 
the scope of the license, advantages (whether 
monetary or otherwise) of in-licensing, projected 
costs of future development, and the likelihood 
that the product will be successfully commercial-
ized. Previous licensing agreements for the same 
or similar technology are relevant to the analysis. 
The licensee may seek to pay less if it must obtain 
licenses from other licensors in order to commer-
cialize a product covered by the license agreement 
(stacking royalties).5
Compensation may also take nonmonetary 
forms: stock in the licensee company, an exchange 
of license grants, or cross-license arrangement, or 
a grantback to the licensor. Grantback compen-
sation involves the licensee granting the licensor 
rights to future inventions made by the licensee 
using rights received from the licensor. 
5.4	 Liability
The licensee may want the licensor to provide 
assurance of the right to license, and assurances 
with respect to the scope or strength of the li-
censed patents rights. The licensor may want the 
licensee to indemnify the licensor against liability 
resulting from licensee’s activities under the li-
cense agreement. Additionally, the licensor may 
seek to impose insurance requirements on the li-
censee. Such liability-related clauses often are the 
subject of negotiation.
5.5 Diligence	terms
The licensor typically wishes to ensure diligence 
on the part of the licensee in developing prod-
ucts and making certain that the products reach 
the commercial market. Diligence is particularly 
important for exclusive licenses, since the licen-
sor may not receive sufficient benefit from its 
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patent rights absent diligent licensee activity. In 
nonexclusive licenses, diligence on the part of the 
licensee may likewise be important as a means 
of ensuring both that the license arrangement 
provides some value to the licensor and that the 
products created by the licensed technology will 
enter the marketplace. 
Diligence terms (or requirements), particu-
larly in the case of exclusive license agreements, 
typically identify milestones. These are specified 
steps in the process of research, development, and 
commercialization that the licensee is required 
to reach by specified dates. In agri-biotech, such 
milestones may include the development of a 
model plant system, the development of a crop 
system, field trials, obtaining regulatory approval, 
initial commercialization, and commercialization 
at predetermined levels. If the licensee fails to 
achieve the specified milestones at the specified 
times, the licensor may terminate the license or, if 
the license is exclusive, reduce it to nonexclusive 
status. The diligence terms may include a provi-
sion for extending timelines in exchange for ad-
ditional compensation. The licensee will want to 
protect itself against a loss of rights if unforeseen 
circumstances slow down the process of develop-
ment and commercialization; the licensor, on the 
other hand, will want to make certain that it has 
recourse in case the licensee does not fulfill its end 
of the bargain. 
In addition to, or occasionally in place of, 
the fulfillment of milestones, diligence terms 
may require the licensee to make periodic pay-
ments (often minimum annual payments), re-
gardless of the licensee’s level of sales under the 
license agreement. Such payments may be set at 
a fixed amount or be gradually increased accord-
ing to business projections. The licensor may ask 
for both periodic payments and the fulfillment of 
milestones, in order to ensure that it will receive 




In a nonexclusive license agreement, the licensee 
may not be required to pay patent costs, that is, 
the costs of filing, prosecution, and maintenance 
of patent filing; under such an agreement, the li-
censee typically will not have the right to partici-
pate in patent decisions, such as the opportunity 
to review and comment on patent submissions. 
On the other hand, a nonexclusive licensee may 
be asked to pay a pro rata share of patent costs; or, 
if it is the first licensee, it may be asked to pay all 
the patent costs until other licenses are granted. 
In an exclusive license agreement, the licens-
ee is often asked to pay patent costs. In return, the 
exclusive licensee typically has the right to par-
ticipate in patent decisions. The exclusive licensee 
may also have the right to opt out of patent costs 
in the event such steps as appeals, interferences, 
or oppositions are undertaken, but the licensee 
may give up its own rights to such filings by opt-
ing out. The exclusive licensee may also have the 
right to control prosecution and maintenance of 
any licensed filings that the licensor chooses to 
abandon. 
License agreement terms may delineate the 
licensee’s rights in case of patent enforcement 
procedures, for example, if and when a licensee 
is entitled to participate in enforcement actions, 
or how or whether the licensor and licensee, or 
licensees, will share the costs of enforcement pro-
ceedings and any compensation that may result 
from them. 
5.7	 	License	term	and	termination
The term of a patent license agreement typically 
extends for the life of the patent. The licensee is 
typically allowed to terminate the agreement at 
any time, so long as the licensee provides ad-
equate notice and pays any accrued fees and any 
applicable patent costs. In contrast, the licensor is 
usually only allowed to terminate the agreement 
if the licensee violates the license, for example, by 
a material breach or failure to satisfy the diligence 
requirements. 
5.8	 Assignability	
A small company licensee will likely be concerned 
about the assignability of the license agreement 
by the licensee, that is, the licensee’s right to 
transfer the license to another party in the case 
of corporate restructuring or acquisition of the 
licensee. The licensor may not wish to agree to 
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such assignability in advance because the licensor 
cannot know who the successor licensee will be. 
In order to resolve such conflicts, various in-be-
tween terms are possible; assignability might be 
allowed only in certain situations, for example. 
The licensee, on the other hand, may want an ex-
press clause to the effect that in any assignment of 
the license by the licensor, the new holder of the 
license (new licensor) will be bound by the terms 
of the license agreement.
5.9	 Other	provisions	
License agreements typically contain a number of 
other provisions, often called boilerplate or stan-
dard clauses, such as clauses for reporting of the 
licensee’s progress; confidentiality of communica-
tions; procedures for arbitration or litigation of 
disputes between licensor and licensee; compli-
ance with requirements of applicable laws and 
regulations; and choice of governing law. 
6. ConCluSionS	
A small agri-biotech company, whether based 
in a developed or developing country, can help 
substantially to build its patent portfolio and 
commercialization position through patent li-
cense agreements with third parties. The compa-
ny should determine what license rights it wants 
to seek, whether it wants to seek these rights on 
a nonexclusive or exclusive basis, and under what 
terms it is willing to license the rights. Such li-
cense agreements can provide the company with 
an important complement to its company-owned 
intellectual property, both in terms of the com-
pany’s freedom to operate and in terms of the 
company’s exclusive proprietary position. ■
clinton h. neagleY, Associate Director, Technology Transfer 
Services, University of California, Davis, 1850 Research 
Park Drive, Suite 100, Davis, CA, 95618-6134. U.S.A. 
chneagley@ucdavis.edu 
1 See, also in this Handbook, chapter 7.3 by AB Bennett, 
WD Streitz and RA Gacel.
2 See, also in this Handbook, chapter 14.2 by SP Kowalski.
3 See, also in this Handbook, chapter 11.7 by M. Anderson 
and S Keevey-Kothari.
4 See, also in this Handbook, chapter 2.1 by AB Bennett.
5 See, also in this Handbook, chapter 11.9 by K Jones, ME 
Whitham and PS Handler.

ABSTRACT
Given the expertise of large agricultural companies with 
respect to product development from cutting-edge re-
search, these companies often choose to in-license tech-
nologies from small biotechnology companies and uni-
versities rather than relying solely on in-house efforts. 
This chapter provides an overview of the interest of large 
industry players in sourcing early-stage technologies from 
companies, how best to communicate those opportunities 
to companies, and what to expect in terms of valuing the 
technology and structuring a licensing deal. Large com-
panies are generally interested in creating new products 
or new technologies that are commercially viable and that 
help establish sustainable agricultural economies. But, in 
addition, they generally support providing products and 
technologies that bolster subsistence farming and human-
itarian efforts, while recognizing the need to protect the 
company’s intellectual property against unauthorized uses 
for commercial or other unintended purposes.
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and funds, such investment is economically feasible 
because it has inherently less risk than investment 
in early-stage research. Partnerships and collabora-
tions with other entities allow large organizations to 
diversify away the higher risk associated with early-
stage research by creating the opportunity to access 
a much larger portfolio of technologies developed 
by thousands of different entities, as opposed to re-
lying solely on the large organization’s own internal 
research programs. Smaller companies and univer-
sities can focus on cutting-edge research and dis-
covering new solutions, without carrying the bur-
den of investing resources, and instead can realize 
value from their discoveries through licensing and/
or partnering with larger companies for subsequent 
product development and commercialization. This 
model has been adopted by the pharmaceutical in-
dustry: in its quest to discover blockbuster drugs, 
most large pharmaceutical companies have chosen 
to in-license technologies from small biotechnology 
companies and universities rather than relying on 
in-house research alone.
2. The	AgRiCulTuRAl	inDuSTRy
Although the agricultural and pharmaceutical 
industries have come to share the model of in-
licensing new early-stage technologies as opposed 
to investing internally in higher-risk research, a 




Not unlike most other industries, large companies 
in agriculture excel in the product development 
portion of research and development (R&D). 
Nevertheless, they have come to recognize that a 
large share of the innovative, early-stage, cutting-
edge research in agriculture takes place at universi-
ties and smaller companies. Large companies have 
invested heavily in the infrastructure needed to de-
velop, register, and bring products to market. While 
product development requires significant resources 
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to the model exist between the two industries. 
These differences are reflected in how the phar-
maceutical and agricultural companies tend to 
structure the relationships and agreements with 
their technology partners. 
The length of time required to develop seed 
products is considerable. When using classical 
breeding approaches, developing a conventional 
seed product takes a minimum of five years, on 
average. When transgenic traits are involved, 
the time needed to develop and commercialize 
a new seed product, including the time needed 
to obtain regulatory approvals in multiple coun-
tries for the import, export and cultivation of 
the crop, can be seven to ten years.
There are additional reasons for the lengthy 
development time lines, including limited 
planting times, long growing cycles, and rigor-
ous multilocational testing for efficacy and en-
vironmental impacts. From an investment per-
spective, an early-stage–genetic-trait technology 
may not begin to return a profit until ten years 
from the initial discovery, if it ever does. 
The cost of bringing an agricultural prod-
uct to market can be less than a pharmaceuti-
cal product, and the per-unit value of an agri-
cultural product is also far less. Additionally, 
in the agricultural arena there are only a few 
major crops of interest, and within those crops 
a relatively small number of higher-value ag-
ronomic traits—for example, drought, insect, 
disease, and herbicide tolerance as well as a 
number of quality traits—that can justify the 
investments needed to develop a transgenic 
crop solution. This is different from the situa-
tion in the pharmaceutical industry where there 
are many different therapeutic areas companies 
can target. It should be no surprise that the few 
large agricultural companies investing in the 
development of early-stage technologies have 
significantly overlapping interests, making the 
industry extremely competitive, with a strong 
focus on protecting IP (intellectual property) 
rights. As evidence, over the last decade there 
has been significant consolidation, and today 
there remains only a handful of major competi-
tors investing in new technologies for the agri-
cultural industry. 
Similar to companies in the pharmaceutical 
industry, agricultural companies vigorously pro-
tect against competitors and do so through vari-
ous means including patent protection, plant 
variety protection, trade secrets, and trademarks. 
Also, unlike most small companies, which have 
only a regional focus, large companies look to 
market their products worldwide, including in 
developing and emerging markets. 
Companies are also partnering in new ways, 
with foundations and public sector institutions, 
to support basic research, local markets, and sub-
sistence farming in developing countries. In ad-
dition to the more immediate humanitarian and 
capacity-building benefits, the ultimate objective 
of these partnerships is to develop new, profit-
able and sustainable agricultural markets for lo-
cal farmers and growers, ensuring a reliable and 
safe food supply in those countries. Companies, 
including Syngenta, have provided strong sup-
port and donated proprietary technologies 
through a number of foundations, including the 
Syngenta Foundation for Sustainable Agriculture. 
Companies are generally willing to offer their 
proprietary products and technologies in support 
of subsistence farming and humanitarian efforts, 
while recognizing the need to protect their intel-
lectual property against unauthorized uses, such 
as for commercial or unintended purposes. This 
good will is often simpler to extend to places 
where commercial opportunities are limited. 
3. mARKeTing	new	TeChnologieS		
To	lARge	CompAnieS
In contacting a company, there are generally 
two approaches: (1) contact a licensing or busi-
ness-development individual or (2) contact a 
company’s research organization. With respect 
to the first approach, it is possible to develop 
relationships with licensing and business-devel-
opment professionals by being active in orga-
nizations, such as the Association of University 
Technology Managers (AUTM), Biotechnology 
Industry Organization (BIO), and Licensing 
Executives Society (LES). This way, relationships 
can be easily established through networking and 
through these contacts professionals can gain an 
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understanding of a potential partner’s interests 
and how well matched those interests are to a 
subject technology that one may be hoping to 
out-license. Companies have a tendency to be 
more responsive to people they know and with 
whom they have shared experiences. Also, com-
panies are able to be more responsive when they 
are provided information that seeks to target their 
needs and interests. If no personal contact inside 
the company has been established, a promoter 
can at least visit a company’s Web site and review 
the available information on that company’s cur-
rent products and research interests. Targeting 
specific technologies to specific companies that 
are likely to take an interest in the technologies 
usually has a much greater impact than does us-
ing mass e-mails to describe multiple technolo-
gies to potential partners. A technology that may 
be of interest to a company can be overlooked 
in a long list. Also, having an up-to-date, easy-
to-navigate Web site with technologies displayed 
allows a company to see, on their own time, what 
is of interest. 
When sending information to a company’s 
licensing department, it is important to note that 
often such information is reviewed quickly and, 
only if it has some quality or aspect that fits spe-
cifically with the needs and strategic interests of 
the company, does it gain further review by per-
sonnel who may be able to gauge the relevance 
and value of the technology. Thus, it is important 
to include clear information on the potential uses 
and commercial value of the technology. Without 
this, depending on how quickly the information 
is read, something of a highly technical nature 
may end up being overlooked. 
The second method for approaching a com-
pany is on a scientist-to-scientist basis. This typi-
cally provides a more direct route into a company, 
because scientists (especially those used to oper-
ating in a commercial environment) are usually 
uniquely situated to see the fit of a technology 
and determine whether it provides a solution to a 
real business need. Companies rely, among other 
things, on their researchers to scout technologies, 
in their respective areas of expertise, that could 
result in new products that further the company’s 
business objectives. 
4. whAT	CompAnieS	ARe	looKing	foR
Agricultural companies look to in-license tech-
nologies that have commercial applications, re-
sulting in better products or more efficient meth-
ods of producing existing products. Ultimately, 
a technology will be reviewed in terms of its fi-
nancial impact. Many technologies are interest-
ing from a scientific point of view but do not 
have clear commercial applications. Licensors 
can make their technologies more attractive to 
agricultural companies by focusing on the poten-
tial commercial relevance of the technology. The 
commercial applications must also be financially 
feasible from a product development and com-
petitive perspective.
Ultimately, every technology needs a champi-
on within the target company, someone who has 
identified and believes in the scientific and com-
mercial relevance of the technology. Champions 
are usually the very scientists who will ultimately 
develop the technology for market. Champions 
on both sides of a deal are critical if the deal is 
to be successful. Too many times, technology is 
in-licensed and sits on the shelf or is applied in-
appropriately because champions were absent or 
were under-resourced. Part of the due diligence 
for in-licensing any technology should be to 
ensure that the project is resourced sufficiently 
and that champions are identified and are able 
to make the project move in accordance with 
agreed-upon timelines.
4.1 Risks	of	technology
Most technologies from universities or small 
companies are at an early stage and so, by nature, 
carry significant risk from a product development 
perspective. Licensors need to recognize the sig-
nificant time, resources, and money required to 
move a project through development to a success-
ful launch. Costs include R&D expenditures, IP 
and patent costs, regulatory-approval costs, and 
production and marketing costs. All of these need 
to be taken into account when allocating the value 
associated with bringing the technology to mar-
ket. Later-stage technology (such as one that has 
already been proven in a relevant crop) would of 
course have a higher value. How data is generated 
to prove a technology also needs consideration. 
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Studies conducted in a greenhouse or in non-elite 
germplasm do not always translate well into the 
field where the product may be exposed to the full 
range of environmental and other effects. Many 
times, a company will want to evaluate a technol-
ogy over the course of two or three years in order 
to understand how it works, across multiple envi-
ronments outside of the laboratory or greenhouse 
environment, before agreeing to negotiate final 
commercial terms. Because of the risk associated 
with technology, large companies often prefer to 
start with a research or evaluation license, with an 
option for a commercial license, building in key 
terms to the option that ensure that commercial-
izing the product, if field trials are successful, will 
be economically feasible. 
4.2 Type	of	technology
Different types of technologies have different ap-
plications and so have different values associated 
with them. An agricultural technology can gen-
erally be classified in one of two ways: (1) as an 
enabling technology that helps or enables a prod-
uct to be created (for example, gene promoters 
that drive the expression of proteins or tools that 
enable or enhance the ability to transform a par-
ticular crop) or (2) as a technology that is itself a 
product or that causes a seed product to contain 
a characteristic or trait that provides a benefit to 
the grower, the manufacturer, or an end-user of 
the product and for which the seed company can 
derive additional value. 
Enabling technologies are helpful for bring-
ing products to market, but in many cases such 
technologies are only alternatives or improve-
ments on other methods or technologies that 
accomplish similar tasks. Because a number of 
substitutes may exist for an enabling technology, 
they are usually of less value than technologies 
that embody products. Accordingly, large agri-
cultural companies are likely only interested in 
a nonexclusive license for enabling technologies, 
allowing freedom to operate with the technology. 
The companies are likely hesitant to pay running 
royalties, preferring instead up-front fees, annual 
fees, or milestone payments. It should be noted 
that while enabling technologies often are used 
across a number of projects, the majority of these 
technologies and projects will not progress to 
market. 
Product technologies, on the other hand, are 
those that are brought to market. For this category 
of technologies, agricultural companies are often 
interested in exclusive rights in order to obtain a 
strategic advantage in the marketplace. Because 
such technology directly translates to sales and 
revenues, it has an inherently higher value. 
5. TeChnology	vAluATion
Valuing technologies is a difficult and complex 
task because of all the uncertainties in getting a 
technology to market. Often, there is a dispar-
ity in the value attributed to a technology by the 
licensor and by the licensee. This is particularly 
true in the agricultural industry due to an asym-
metry of information: one company having ac-
cess to more complete information than the other 
for determining the cost of bringing a product 
to market and the potential revenue sales of the 
end-products would bring. In the agricultural 
industry there are not always comparable deals 
with which to compare prospective products, es-
pecially as companies embark on new market ar-
eas that involve traits outside of established traits, 
such as insect resistance and herbicide tolerance. 
Additionally, in order to sell certain traits in the 
market, the traits must be combined with other 
input or agronomic traits to which the licensor 
has not contributed. Value will also be influenced 
by the presence of competitive traits in the mar-
ket. This adds additional complexity to the value-
capture discussion.
The value of an early-stage technology needs 
to be discounted based on time to market, the 
time value of money, technical risk, and the risk 
associated with obtaining regulatory approvals. 
Value also must account for the amount of re-
sources invested in commercialization. Many li-
censors discount or overlook these factors because 
they are deemed to be out of their control, but 
the risks remain and should influence the value-
sharing discussion. Other factors that effect value 
sharing include whether additional licenses are 
needed for commercialization for ensuring that a 
product can be brought to market with maximum 
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freedom to operate. If other licenses are needed to 
bring a technology to market, the issue of “roy-
alty stacking” comes into play, whereby multi-
ple royalties on a product can exceed the profit 
margin on the product, making it impractical to 
commercialize. 
Traditional royalties based on net sales rarely 
work in agricultural licensing deals because of the 
issues associated with royalty stacking and the 
fact that many technologies—from early-stage 
enabling technologies to trait-related technolo-
gies—may be employed in developing the final 
product. Companies understandably try to avoid 
paying royalties to licensors on the value contrib-
uted by other technologies, whether in-licensed 
or developed by the company. For the same rea-
sons, large companies also try to avoid paying 
product-based royalties on enabling technology 
because the enabling technology by itself may not 
drive additional revenues. 
In most cases, companies can agree to a roy-
alty based upon the value that a particular tech-
nology adds in the marketplace. Models such as 
a percentage of trait-related revenue or fixed-fees 
per unit are available to licensors. 
6. TeRmS	of	The	liCenSe
When companies choose to in-license technolo-
gies, especially in the agricultural and biotechnol-
ogy industries, the parties need to consider several 
issues that must be specified in the license:
• payments: Fees for a deal need to be bal-
anced in accordance with the use and risk 
profile associated with a technology. In some 
instances, this balance will be achieved over 
the life of the license during which pay-
ments through license fees, milestones, and 
royalties can be paid on net sales. In other 
instances, for example, involving a nonex-
clusive license to enabling technology, this 
may be a one-time payment. For product 
technologies, payments are traditionally 
spread out over the life of the license, reflec-
tive of the risk factors and the development 
timeline, so that when there is heavy R&D 
spending, license costs are not excessive, 
and do not become disincentives, but do 
reflect the time frame over which revenue is 
actually obtained from the product. 
  It is important for a licensor to maintain 
flexibility with regard to how payments are 
structured, in order to meet the needs of 
agricultural companies, especially as new 
markets are explored. Many times small 
start-up companies are seeking to exit with-
in three to five years from the time they are 
established, usually because of the expecta-
tions of the venture-capital-investor com-
munity. This can create tension in getting 
a deal done because of the expectation to 
be paid out, while there is still significant 
development and product risk remaining, 
long before the company begins to see rev-
enue from the investments it has made and 
is making. 
• exclusivity: Every company would relish 
being able to exclude others from obtain-
ing a strategic advantage in the market, but 
sometimes obtaining exclusivity may be 
neither necessary nor cost effective. Many 
factors will effect the need or desire for ex-
clusivity, including financial implications, 
the opportunity to block or license com-
petitors, and the opportunity to create a 
competitive position in the marketplace.
• field of use: For licenses where the licensor 
intends to carve out exclusivity in a field of 
use, the licensor will want to ensure that 
fields don’t overlap and that fields are di-
vided in such a way as to not destroy value 
for other potential licensees. Agricultural 
companies will many times consider specif-
ic fields of use (for example, specified crops, 
or specific traits of interest) as a way to ob-
tain exclusivity in a particular market.
• diligence: With regard to diligence provi-
sions, the parties need to acknowledge that 
these provisions and timelines should be 
reasonable but flexible. This is especially 
true for certain agricultural technologies, 
for example, seed products, due to the un-
certainty and risks associated with it, in-
cluding technical, field and environmental 
risks, and regulatory science-related risks. 
Agricultural companies recognize the desire 
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of the licensor in having diligence provi-
sions, but overly restrictive provisions can 
put a license at risk. Most companies wel-
come reasonable diligence requirements as 
they ensure that a technology will be evalu-
ated and developed in a commercially rea-
sonable timeframe. The role of champions 
to encourage open and ongoing communi-
cation between the licensor and the licensee 
with regard to diligence provisions, making 
adjustments as necessary so that the technol-
ogy develops to the benefit of both parties.
• publication: Licensors need to work with 
the large agricultural companies to ensure 
that publications made after the license 
term begins (especially for exclusive licens-
es) do not interfere with the opportunity 
to capture intellectual property and, there-
fore, diminish the value of the technology. 
Close cooperation should ensure that the 
right to publish is not compromised while 
ensuring that appropriate protections are 
obtained before making the publication. 
Mechanisms for handling publication are 
fairly well established between public sec-
tor institutions and industry. 
• improvements: In order for a technology 
to reach its full potential, it will be in the 
interest of both parties to allow agricultural 
companies to access improvements to the 
underlying technology. 
• timelines: It is important for the licensor 
and the licensee to be responsive when ne-
gotiating a license agreement. In instances 
where delays are expected, these should be 
communicated promptly as the business 
may be relying on a particular timeline to 
drive product development. Excessive de-
lays can result in a loss of interest and/or a 
loss of funds. 
• after the deal: Transfer of know-how or 
materials as provided for in the license 
needs to be carried out in a timely manner. 
The agreement should define whom the ap-
propriate contacts are to ensure that the po-
tential of the technology can be fully real-
ized, especially in those instances where the 
company is evaluating the technology and 
questions may arise. Often times continued 
access to technology experts is expected and 
should be welcomed in order to realize the 
full benefit of the license.
7. ConCluSion
Large agricultural companies are interested in ac-
cessing and utilizing technology that helps them 
gain competitive advantages in the marketplace. 
Universities and research institutes can, through 
licensing agreements, partner with these com-
panies, which have the resources, as well as the 
product development and marketing capabilities 
to translate early-stage technologies into products 
that bring benefit to consumers. Furthermore, 
such technology partnerships can result in prod-
ucts or new technologies that can provide, not 
only humanitarian benefits in the developing 
world, but also can help establish sustainable ag-
ricultural economies in all countries. ■
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ABSTRACT
Understanding biotechnology and pharmaceutical com-
mercialization alliances in the context of several evolving 
business models has implications for university technol-
ogy transfer offices (TTOs), as well as for public policy-
makers intending to promote biotechnology regionally. 
This chapter identifies the principal structural and eco-
nomic elements of biotechnology and pharmaceutical 
commercialization alliances and the factors that influ-
ence partner selection for a particular alliance. The four 
characteristics of an alliance that generally define the al-
location of value between an originator and a commer-
cialization partner include stage of development, prod-
uct supply, market opportunity, and scope. The chapter 
explains the types of economic terms typically found in 
biotechnology alliances and makes an empirical analysis 
of the economic terms from a sample of biotechnology al-
liances established between 1981 and 2000. Four specific 
alliances entered into at different stages of development 
are detailed as case studies. Several recommendations are 
provided for university TTOs, along with guidelines for 
drafting commercialization alliances.
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chemists, who isolated natural products from mi-
croorganisms, plants, and animals, designed ana-
logs and, sometimes, stumbled upon molecules 
with completely unexpected activity.
The emergence of biotechnology over the past 
several decades has transformed the drug business 
and ushered in a host of new participants and 
several novel business models. In the early 1980s, 
recombinant DNA and monoclonal antibody 
(mAb) technologies formed the basis of the first 
biotechnology business model, based on intellec-
tual property (IP) relating to the isolation and/or 
production of novel compounds. Strong IP posi-
tions and difficult-to-master production methods 
would presumably allow biotechnology start-
ups to initially partner with, and then compete 
against, established pharmaceutical companies. 
Assuming a series of novel products and increas-
ingly favorable terms from partners, this model 
purported to be a blueprint for becoming a fully 
integrated pharmaceutical company, or FIPCO. 
Although most of the more than 100 biotechnol-
ogy companies that went public prior to 1992 
adopted this model, Amgen and Genentech are 
the only two companies from this era to have at-
tained FIPCO characteristics to date.
By the early 1990s, two new biotechnology 
business models emerged. The first of these—a 
technology-platform model—was based on the 
CHAPTER 12.8
1.	 inTRoDuCTion
Since the 1940s, the pharmaceutical industry has 
largely followed a vertically integrated business 
model. This was the period when the first antibi-
otics were being introduced, leading to augment-
ed manufacturing capabilities and, soon after, to 
the development of sales and marketing organi-
zations. Over the next half century, the industry 
was sustained by the productivity of its medicinal 
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use of novel techniques to discover new drugs and/
or to increase the productivity of the drug discovery 
process. With a broad platform, a biotechnology 
company could perform fee-for-service research for 
multiple pharmaceutical partners while accumulat-
ing expertise to pursue programs for its own ben-
efit. The earliest technology-platform companies 
developed novel assays for screening compounds. 
However, these screening companies depended on 
pharmaceutical partners for compounds to screen, 
and the terms were generally unattractive. 
Other types of technology platforms soon 
emerged, including those using proprietary tech-
nologies to produce novel compounds from oli-
gonucleotides (for example, antisense and gene 
therapy), lipids, carbohydrates, peptides, and com-
binatorial chemistry. With the sequencing of the 
human genome in the late 1990s, the technology-
platform model broadened yet again to include 
companies that discover and validate novel drug 
targets. Joining them were companies making the 
instrumentation and software to handle the in-
creased throughput of genomic materials, combi-
natorial libraries, and structural information. 
These technology-platform companies had 
in common a fundamental reliance on corporate 
partners to pay for at least a portion of the plat-
form’s utilization and enhancement while adding 
to the biotech’s infrastructure and expertise. Gilead 
Sciences and Vertex Pharmaceuticals are current 
examples of successful companies that have adopt-
ed the technology-platform business model.
A third business model to emerge in the early 
1990s focused on diseases with significant unmet 
needs and specialized patient populations, such as 
cancer, dermatology, and neurodegenerative dis-
eases. These companies sought to capture more 
of the value of innovative products by retaining 
commercial rights into clinical development—
and potentially through to commercialization for 
selected market niches. Using this strategy, dis-
ease-focused companies attempted to create a bal-
anced mix of discovery, development, and some-
times commercial-stage programs. However, the 
latter were typically less innovative products, used 
primarily to build a sales infrastructure and pre-
pare the organization to eventually sell the more 
innovative products under development. Amylin 
and MedImmune are current examples of suc-
cessful companies that have adopted the disease-
focused business model.
By the mid-1990s, however, many of these 
disease-focused biotechnology companies had 
curtailed their drug-discovery programs owing 
to lack of investor interest. Similarly, technol-
ogy-platform companies that had partnered their 
top drug-discovery programs to pharmaceutical 
companies came to view discovery research as an 
unattractive use of resources. With the consoli-
dation of major pharmaceutical companies, these 
companies recognized that product-acquisition 
opportunities would emerge that were “flying 
below the radar” of ever larger drug companies. 
These companies turned their attention to in-li-
censing of approved and late-stage development 
compounds from pharmaceutical companies. 
Since most of these biotechnology companies 
focused on specialty markets that could be ad-
dressed with relatively small sales forces, such as 
cancer, anti-infectives, and dermatology, by the 
late 1990s investors came to view this group as 
a new business model, dubbed specialty pharma. 
Cephalon and Celgene are current examples of 
successful companies that have adopted the spe-
cialty-pharma business model.
The collective impact of these four biotech-
nology business models on the pharmaceutical in-
dustry has been to significantly enhance pharma’s 
opportunity to obtain and divest compounds via 
licensing. This has eroded pharma’s vertically in-
tegrated business model, to the point where most 
pharmaceutical companies now derive 25 to 50 
percent of their product pipelines from external 
sources. In turn, pharmaceutical companies are 
the principal mode of commercialization for bio-
technology products—of the 100 top-selling bio-
technology drugs in 2005, 63 were partnered in 
development for at least some territories, as were 
eight of the ten top-selling biotechnology prod-
ucts in 2006.
Understanding biotechnology and pharma-
ceutical commercialization alliances in the con-
text of these several evolving business models has 
implications for university technology transfer of-
fices (TTOs), as well as for public policy-makers 
intending to promote biotechnology regionally. 
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First, under certain circumstances and with sig-
nificant intellectual property  and/or compounds 
to offer, TTOs may be in a position to play a role 
comparable to biotechnology companies as the 
licensor to a commercialization partner, whether 
that partner is a traditional pharmaceutical com-
pany, an emergent biotech, or a regional market-
ing company. Frequently, however, a TTO will 
be the upstream licensor of intellectual property 
and/or compounds that are bundled and devel-
oped by a biotechnology company before being 
sublicensed to a commercialization partner. In 
these instances, it may be important to under-
stand, and perhaps influence, the likely terms of 
an eventual commercialization alliance in order 
to protect or augment the value contributed by 
the TTO’s technology.
This chapter aims to identify the principal 
structural and economic elements of biotechnol-
ogy and pharmaceutical commercialization alli-
ances1 and the factors that influence partner selec-
tion for a particular alliance. Section 2 describes 
four characteristics of an alliance that generally 
define the allocation of value between an origi-
nator and commercialization partner. Section 3 
discusses the types of economic terms typically 
found in these alliances. Section 4 consists of an 
empirical analysis of the economic terms from a 
sample of biotechnology alliances established be-
tween 1981 and 2000. Section 5 describes four 
specific alliances entered into at different stages 
of development. Section 6 concludes with several 





Drug development is broken into phases largely 
shaped by the regulatory requirements for new- 
drug approval. These are often referred to as 
discovery, lead, preclinical, investigational new 
drug (IND) filing, Phase I clinical trials, Phase 
II clinical trials, Phase III clinical trials, new drug 
application (NDA) filing, approval, and postap-
proval (Phase IV) clinical trials. Generally, the 
later in drug development an agreement is struck, 
the higher the share of consideration paid to the 
originator.2 This industry practice reflects, in part, 
the cumulative investments of the parties to date, 
as well as the increased likelihood of getting the 
compound approved and on the market. 
For example, as a compound successfully 
navigates various stages of drug development, 
there is less risk associated with the compound, 
and this increases the total value of the economic 
benefits that parties to an agreement will share. 
Other things being equal, a license negotiated 
later in a compound’s development will bear a 
higher share of consideration paid to the origina-
tor than if the same license were negotiated earlier 
in the compound’s development. 
Conversely, a company in the early stages 
of developing a new compound faces substantial 
costs and risks as it invests in developing a new 
product that will probably fail. In order to have 
adequate incentive to take on those risks, the li-
censee of such a compound will demand a larger 
share of the expected sales or profits from the new 
product if it proves to be successful. 
At the far end of the development spectrum, 
a company that has a fully developed product 
with a track record of increasing sales and sub-
stantial profit margins in one or more geographic 
markets faces relatively little risk as it attempts to 
expand the geographic reach of the product. All 
else being equal, the marketing partner of such a 
product will receive a much smaller share of the 
expected sales or profits from their efforts in ex-
panding the geographic reach of the product.
In most instances, an originator has few non-
reimbursable development obligations following 
the signing of a commercialization agreement 
at each stage of development. This reflects, in 
part, the commercialization partner’s interest in 
controlling the pace and expenditures required 
for commercialization, as well as the originator’s 
interest in retaining any prelaunch consider-
ation paid for rights to the compound or tech-
nology. Exceptions occur, however, when the 
originator continues to have significant develop-
ment obligations after signing. Such exceptions, 
generally associated with co-development or 
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distribution alliances, are discussed in Section 3.2 
and typically would require that a higher share of 
consideration be paid to an originator.
2.2 Product	supply
While many commercialization alliances simply 
provide a license to intellectual property  and/or 
know-how associated with a compound or tech-
nology, some agreements additionally provide 
that the originator will undertake to supply all, or 
a portion, of a compound through commercial-
ization. In such instances, the originator will in-
cur greater costs and risks than in the absence of 
such supply obligations. As a result, alliances in-
volving an obligation on the part of the originator 
to provide at least primary or bulk manufactur-
ing of a compound through clinical development 
and commercial supply will typically increase the 
share of consideration paid to the originator.
2.3	 Market	opportunity
The gross margins of marketed pharmaceuticals 
have been high historically, often in the range 
of 75 to 95 percent. This is due to the benefits 
new products often bring compared to alternative 
treatments and the high costs and risks of devel-
opment, combined with the significant regula-
tory and intellectual property barriers faced by 
new market entrants. With high gross margins 
and significant economies of scale in sales and 
distribution, top-selling pharmaceuticals (the so-
called blockbusters) drive the overall profitability 
of major pharmaceutical companies. As a result, 
competition to access compounds with the great-
est potential market size is intense. By contrast, 
compounds having relatively small market po-
tential, such as those intended for niche markets, 
attract far less interest and less-favorable terms to 
the originator. Typically, therefore, the more at-
tractive the market opportunity, the higher the 
share of consideration paid to the originator.
2.4	 Scope
The scope of any particular commercialization 
alliance refers to a broad array of nonfinancial 
terms that either limit or broaden the rights con-
veyed under the agreement. Such terms might 
include whether the license granted is exclusive, 
semiexclusive, or nonexclusive, with greater ex-
clusivity generally yielding a premium to the 
originator. Similarly, the larger and more eco-
nomically attractive the territory, and the longer 
the duration of the alliance, the higher the share 
of consideration paid to the originator. This is be-
cause rights and any associated economic benefit 
would generally revert to the originator post-ter-
mination. Other things being equal, therefore, 
one would expect to see higher consideration 
paid to an originator for a long-term alliance than 
for one of limited duration entered into at the 
same time. 
Should the alliance provide that one or more 
additional compounds or fields of use might be 
included as an option for the commercialization 
partner, such an element would also typically 
increase the share of consideration paid to the 
originator. Such an option potentially provides a 
broader pipeline to the commercialization part-
ner, while minimizing this party’s expenditure 
and development risk for the sustenance of such a 
pipeline. From the originator’s viewpoint, grant-
ing a multicompound or multifield option to a 
commercialization partner would foreclose alter-
native arrangements, including forward integra-
tion by the originator itself, and so would nor-





Commercialization alliances typically will include 
an initial (so-called up-front) payment. The up-
front payment may be due upon execution of the 
agreement and/or staged over a period of months 
or several years, but in the latter instance the pay-
ment obligation is noncancelable. This is not the 
case with development-milestone payments (see 
Section 3.3), wherein the payment obligation is 
contingent upon the achievement of predeter-
mined events.
The up-front payment represents a “buy-in” 
by the commercialization partner, reflecting all or 
a portion of the originator’s expense and risk in 
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bringing the compound or technology to its stage 
at signing. Discovery-stage deals may also entail 
an up-front payment, often described as a tech-
nology access fee.
For biotechnology companies, up-front pay-
ments are an important signal to investors that the 
partnered program is of high quality and that the 
commercialization alliance is being struck from a 
position of strength, rather than weakness. Such 
payments are generally nonrefundable, once paid, 
so their inclusion in an agreement will increase 




With respect to the research and development 
(R&D), manufacturing, and launch costs incurred 
during the course of bringing a pharmaceutical 
product to market after signing, commercializa-
tion alliances involving biotechnology companies 
are generally one of three types, although these 
types are sometimes blended or combined by 
product or territory.
Most biotechnology agreements are in the 
first category, wherein the commercialization 
partner takes over all costs after signing, includ-
ing reimbursement of the originator’s post-sign-
ing costs of continued R&D and manufacturing, 
as well as paying directly all other costs associated 
with the product’s development, manufacture, 
regulatory approval, and launch. Such costs can 
be very substantial, and the risk of failure in de-
velopment is largely borne by the commercializa-
tion partner.
Alliances that require reimbursement of the 
originator’s R&D expenses after signing typically 
require that the originator provide a specified 
number of full-time equivalent scientists (FTEs) 
per year for one to five years, along with quarterly 
reimbursement at a maximum fixed rate per FTE. 
The originator is at risk for cost overruns, how-
ever. For example, if the FTE reimbursement rate 
is US$250,000 per FTE per year for ten FTEs, 
and the actual annual R&D expenditure by the 
originator is US$2.7 million, only US$2.5 mil-
lion is reimbursed. Conversely, if the actual R&D 
expenditure by the originator is US$2.2 million, 
a credit of US$300,000 is carried forward to the 
next year’s R&D reimbursement.
In the second category are alliances with re-
gard to which both parties share costs (so-called 
co-development). In co-development alliances, 
up-front and milestone payments are generally 
used to adjust the parties’ interests in the R&D 
program, and subsequent development and other 
costs are shared. In a typical co-development al-
liance, an originator may possess only a portion 
of the capability or resources to complete clinical 
development, commercial supply, and/or launch 
of a compound. Such alliances tend to have profit 
splits during the post-commercialization period, 
reflecting the parties’ respective interests in the 
product. While the percentage or level of cost 
sharing varies by agreement, such alliances usu-
ally provide a mechanism whereby one party may 
reimburse excess costs incurred by the other, of-
ten at a premium.
With respect to the third category of allianc-
es, the originator continues to incur all or substan-
tially all development, manufacturing, and regula-
tory costs after signing, but the commercialization 
partner bears some or all launch costs and ongo-
ing sales and marketing expense. Alliances of this 
third type are generally described as distribution 
agreements, if the originator relinquishes all sales 
and marketing responsibilities, or else co-promo-
tion or co-marketing alliances, if both parties are 
involved in commercialization of the product.
Although a commercialization partner may 
commit substantial resources to a biotechnol-
ogy alliance in the form of FTE reimbursements, 
such payments are not enriching to the origina-
tor, unlike up-front and development-milestone 
payments. Other things being equal, therefore, 
the share of consideration paid to an originator 
will be lowest for the type of alliance with respect 
to which all post-signing costs are borne by the 
commercialization partner, in the mid-range for 
co-development deals, and highest for distribu-
tion-type agreements. This industry practice re-
flects, in part, the total expected investments of 
the parties through product launch, as well as 
the proportion of risk borne by the commercial-
ization partner that the compound will fail in 
development.
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3.3	 Development-milestone	payments
Most biotechnology alliances involve contingent 
(so-called development milestone) payments 
that track the progression of the R&D program 
through the sequential stages of development 
achieved after signing of the agreement. 
For an early-stage alliance, typical develop-
ment milestones might be technical feasibil-
ity, patent issuance, lead compound designation, 
IND filing, start of Phase II clinical trials, start 
of Phase III clinical trials, NDA filing, and first 
regulatory approval. For a late-stage alliance, 
development milestones might track individual 
medical indications or market entry into major 
markets such as the United States, Japan, or the 
European Union.
Like up-front payments, development-mile-
stone payments are generally nonrefundable once 
paid, so their inclusion in an alliance will increase 
the risk-adjusted share of consideration paid to 
the originator.
3.4	 Equity	investments
Approximately 15 to 20 percent of biotechnol-
ogy alliances include one or more minority-eq-
uity investments by the commercialization part-
ner in the biotechnology’s equity as a component 
of the agreement. Such equity purchases usually 
involve newly issued shares, so the investment 
proceeds are available for use by the company. If 
the securities of the biotechnology company are 
publicly traded at the time of such an investment, 
the commercialization partner may purchase the 
shares for the fair market value (FMV) or may 
agree to pay a specified premium over FMV at the 
time of purchase. Shares purchased in nonpublic 
biotechnology companies, as part of an alliance, 
are typically purchased at a 20 to 50 percent pre-
mium over the FMV of shares sold in the most 
recent prior round of share issuance. 
Unlike up-front and development-milestone 
payments, however, equity investments involve an 
exchange of capital for an ownership interest, so 
the extent of enrichment to the originator, if any, 
depends on the premium paid by the commercial-
ization partner as compared to the FMV of the 
shares. 
3.5	 Post-commercialization	payments
Post-commercialization payments usually consist 
of one or more of five types: (1) royalties on prod-
uct sales paid by the commercialization partner 
to the originator; (2) payments for manufactured 
goods (so-called transfer prices) paid by the com-
mercialization partner to the originator as sup-
plier of bulk or final product; (3) one-time pay-
ments on achievement of post-commercialization 
milestones (so-called sales-threshold payments) 
paid by the commercialization partner to the 
originator; (4) a net profit allocation between the 
parties (so-called profit splits); or (5) marketing 
fees paid by the originator to the commercializa-
tion partner.
3.5.1		Royalty	rates
The royalty rate paid by the commercialization 
partner to the product’s originator commonly in-
creases with greater product sales. For example, 
an alliance will specify a base royalty rate that will 
pertain to annual (or cumulative) product sales up 
to a certain sales level. Above this level, a higher 
royalty rate will apply until a second sales thresh-
old is met, at which point a still higher rate will 
pertain, and so on, through three to five different 
royalty tiers. This practice is consistent with the 
industry’s preference and competition for block-
busters over products for niche markets.
3.5.2 	 Transfer	prices
Transfer prices for bulk or final product supplied 
by the originator to the commercialization partner 
are typically specified via one of three approaches: 
as cost plus a specified margin, as a specified price 
per unit, or as a percentage of the product’s selling 
price. Since commercialization agreements are 
usually silent on the actual or anticipated cost of 
manufacture, it is difficult to ascertain the profit 
contribution from the transfer price. Of the three 
approaches, agreements that specify a transfer 
price as a percentage of the product’s selling price 
are most informative, insofar as general industry 
practice is to attempt to price a new product such 
that the cost of manufacture is typically 5–10% 
of the product’s selling price. This implies that a 
transfer price in excess of 10% of the product’s 
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selling price is usually enriching to the extent of 
the excess.
3.5.3		 Sales-threshold	payments
Sales-threshold payments may be paid to a prod-
uct’s originator as one-time events. As with de-
velopment-milestone payments, sales-threshold 
payments are typically nonrefundable.
3.5.4	 Profit	splits
Profit splits may vary by time period, or licensed 
region, and may or may not be inclusive of other 
types of payments specified by the alliance. In 
co-development deals, following the buy-in pay-
ments that adjust the parties’ positions for pre-
existing risk taken and preexisting value created, 
profit splits tend to track the level of each party’s 
clinical development expenditure after signing—
for example, a party paying 40 percent of develop-
ment costs would be entitled to 40 percent of net 
profits. In such agreements, the parties precisely 
define the development, manufacturing, regula-
tory, launch, and marketing expenditures that are 
deemed “allowable” for purposes of reaching or 
adjusting the agreed-upon profit split.
3.5.5  Marketing	fees
Marketing fees paid by the product’s originator 
to the commercialization partner generally apply 
only in the event that the originator is responsible 
for booking the sale of the product, as is some-
times the case in distribution and co-promotion 
alliances. Such fees are often termed royalties, ex-
cept that the originator pays them to the market-
ing or co-promotion partner. In such agreements, 
there may be a static or moving level of sales (a 
so-called baseline) below which the commercial-
ization partner is not compensated, reflecting the 
originator’s capability to sell the product in the 




Biotechnology companies that are publicly trad-
ed on stock exchanges in the United States are 
required by the U.S. Securities and Exchange 
Commission (SEC) to file material documents. 
Biotechnology companies have historically in-
terpreted this requirement conservatively and 
often file their contracts involving alliances with 
commercialization partners, as well as upstream 
licenses with universities and other technology 
providers. 
Recombinant Capital’s (Recap) Alliances 
Database contains copies of more than 20,000 
research, development, license, supply, co-devel-
opment, distribution, and similar alliances estab-
lished since 1973. Recap analysts collected these 
agreements from SEC filings, predominantly by 
biotechnology companies, as material disclosures. 
In aggregate, Recap’s analysts have tracked the 
SEC filings of approximately 1,400 companies, 
the vast majority of which consist of biotechnol-
ogy companies engaged in pharmaceutical dis-
covery and development.
Companies can and usually do request confi-
dential treatment for sensitive business informa-
tion in these alliances, including royalty rates and 
other payments, but such grants of confidential-
ity are time limited. Recap’s analysts first collect 
these SEC-filed agreements and then attempt to 
secure unredacted copies through use of Freedom 
of Information Act (FOIA) requests made to the 
SEC. 
Figure 1 shows the number of alliances se-
lected for inclusion in a sample of development-
stage R&D alliances entered into between 1981 
and 2000 by the 20 most active biotechnology 
and pharmaceutical commercialization partners. 
The “Top 20” commercialization partners were 
selected on the basis of their total number of bio-
technology alliances over the past three decades, 
including alliances established by commercializa-
tion partners subsequently acquired by one of the 
Top 20. For example, Novartis has in aggregate 
more than 700 biotechnology alliances, including 
those entered into by Ciba-Geigy and Sandoz. 
Thirty-two Novartis alliances are included in the 
sample. These are all of the unredacted, develop-
ment-stage R&D alliances involving Novartis as 
the commercialization partner in Recap’s Alliances 
Database as of February 2006. A similar process 
was followed for the other 19 most active com-
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mercialization partners of biotechnology R&D 
programs, resulting in a final sample of 259 unre-
dacted development-stage R&D alliances.
4.2	 Prelaunch	payments	
Figures 2 and 3 show the average and median pre-
launch payments, respectively, for biotechnology 
alliances established by the Top 20 commercial-
ization partners between 1981 and 2000. The al-
liances are grouped by the stage of development 
at signing, where mid stage refers to alliances 
signed at the preclinical or Phase I clinical trials 
stages, and late stage refers to alliances signed at 
the stages of Phase II or III clinical trials or NDA 
filing.
The data in Figures 2 and 3 supports the ob-
servation that the later in drug development an 
agreement is struck, the higher the amount of 
consideration paid to the originator. For exam-
ple, median prelaunch payments to originators 
of mid stage alliances were US$21.8 million, but 
US$30.7 million for late-stage deals. While me-
dian prelaunch payments for discovery-stage alli-
ances exceed those for lead-stage deals, the largest 
component of such discovery-stage payments are 
for R&D reimbursement, and so are not enrich-
ing to the originator.
4.3	 Royalty	and	other		
post-commercialization	payments	
Figures 4 and 5 show the average and median 
effective royalty rates (that is, rates adjusted for 
royalty tiers) and maximum royalty rates (which 
include consideration from transfer prices), re-
spectively. This data also supports the observation 
that the later in drug development an agreement 
is struck, the higher the amount of consider-
ation paid to the originator. For example, the 
data shows that the median effective royalty rate 
promised to a product’s originator in the event of 
annual sales of US$500 million was seven percent 
for discovery-stage alliances, eight percent for lead 
stage, 9.6 percent for middle stage and 15 percent 
for late stage. Likewise, on average, the effective 
royalty rate increases with greater annual sales of 
the product.    
When transfer prices and the maximum roy-
alty rate are combined, the analysis shows that the 
median compensation to a product’s originator 
increases to eight percent for discovery-stage al-
liances, 10 percent for lead stage, 15 percent 
for middle stage and 20 percent for late stage. 
However, none of these average or median post-
commercialization payments includes the effect 
of the 44 alliances that involve profit splits, since 





In May 1997, Eli Lilly and MegaBios (later 
merged to become Valentis) signed a worldwide 
alliance to develop gene-therapy products to treat 
cancer. At the time of commencement, MegaBios 
had a technology platform for gene therapy, but 
no lead compounds had yet been developed in 
the field of cancer. 
As shown in Figure 6, the technology origi-
nator, MegaBios, received no up-front payment, 
but Lilly committed to US$7 million in FTE 
and manufacturing-process payments over two 
years. Lilly was responsible for all other devel-
opment, clinical, manufacturing, and regula-
tory expenses. Development-milestone payments 
totaled US$27.5 million, consisting principally 
of amounts associated with the clinical devel-
opment of compounds to treat ovarian and 
breast cancer. Lilly purchased US$3 million of 
MegaBios’ equity at signing. In the post-com-
mercialization period, Lilly committed to pay-
ing tiered royalties to MegaBios, increasing with 
annual net sales from six to 13 percent. Such 
royalties would be due for either the life of any 
issued patents, or the seven-year-period follow-
ing product launch, whichever was longer, on 
a country-by-country basis, after which Lilly 
would retain a paid-up license.
5.2	 Lead-stage	alliance
In December 2000, Novartis and Celgene signed 
a worldwide alliance to develop treatments for 
osteoporosis. At the time of commencement, 
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Celgene had several lead compounds based on se-
lective estrogen-receptor modulators (SERMs).
As shown in Figure 7, the compound origi-
nator, Celgene, received a US$10 million up-
front payment, plus US$4 million in FTE pay-
ments over two years. Novartis was responsible 
for all development, clinical, manufacturing, and 
regulatory expenses. Development-milestone 
payments totaled US$30 million. There was no 
equity investment. In the post-commercialization 
period, Novartis committed to paying to Celgene 
tiered royalties that increased with annual net 
sales from ten to 12 percent. Such royalties would 
be due for either the life of any issued patents or 
the ten-year–period following product launch, 
whichever was longer, on a country-by-country 
basis, after which Novartis would retain a paid-
up license.
5.3 Midstage	alliance
In November 1997, Eli Lilly and Ligand 
Pharmaceuticals signed a co-development, li-
cense, and co-promotion alliance for worldwide 
rights to RXR retinoids for the treatment of dia-
betes. At the time the parties entered into the al-
liance, several of Ligand’s RXR compounds were 
undergoing preclinical testing.
As shown in Figure 8, the compound origina-
tor, Ligand, received a US$12.5 million up-front 
payment. There were US$49 million in FTE pay-
ments over five years, and Lilly was responsible 
for all development, clinical, manufacturing, and 
regulatory expenses. Development-milestone 
payments totaled US$73 million, divided among 
six separate types of compounds and ranging 
from US$6.5 million to US$14 million per com-
pound. There was no equity investment. In the 
post-commercialization period, Lilly committed 
to pay tiered royalties to Ligand, increasing with 
annual net sales and varying by type of compound 
from five to 12 percent of net sales. Such royal-
ties would be due for either the life of any issued 
patents or the ten-year–period following product 
launch, whichever was longer, on a country-by-
country basis, after which Lilly would retain a 
paid-up license.
5.4	 Late-stage	alliance
In December 1993, Burroughs Wellcome (later 
acquired by GlaxoSmithKline) and Centocor 
(later acquired by Johnson & Johnson) signed a 
co-development, license, distribution, and supply 
alliance for rights outside of Asia to Panorex, a 
monoclonal antibody for use as adjuvant therapy 
for the treatment of colon and colorectal can-
cers. When the parties entered into the alliance, 
Panorex was undergoing Phase III clinical trials.
As shown in Figure 9, the compound origi-
nator, Centocor, received US$19 million in 
up-front payments, US$10 million on signing, 
plus an additional US$9 million when the ter-
ritory was expanded to include Asia in 1994. 
There were no FTE payments, and Centocor was 
responsible for the completion of Phase III tri-
als. Development-milestone payments totaled 
US$47.5 million. Wellcome purchased US$23.5 
million of Centocor’s equity—US$20 million on 
signing plus an additional US$3.5 million when 
the territory was expanded. In the postcommer-
cialization period, Centocor committed to paying 
a transfer price of 50 percent on the first US$200 
million in annual net sales, then 40 percent on 
the next US$200 million, then 35 percent on net 
sales greater than US$400 million. The term of 
the agreement would be for the duration of prod-
uct supply by Centocor.
6.	 ReCommenDATionS	AnD	ConCluSionS
Although lacking vendor booths or trading floors, 
a robust marketplace exists for the exchange of 
discoveries, intellectual property, and services 
related to the development and commercializa-
tion of products in the life sciences. After sev-
eral decades of trial and error, biotechnology and 
pharmaceutical companies have settled upon the 
principal structural and economic elements in the 
identification, creation, and sharing of value in 
this marketplace. 
As the authors have noted in previous publi-
cations,3 the economic stakes of university TTOs, 
primarily in the United States and Great Britain, 
as upstream licensors and enablers in this market-
place are also well established.
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New entrants to this marketplace, especial-
ly university TTOs representing institutions in 
territories other than the United States, Great 
Britain and, to a lesser extent, Canada, Germany, 
and France, have an opportunity to join this 
marketplace with knowledge of its inner work-
ings. At a minimum, new entrants should be in 
a position to undertake programs of technology 
or compound development with the knowledge 
that downstream events that would be likely to 
be perceived as value creating. Conversely, should 
these institutions be able to assemble significant 
intellectual property and/or compounds to offer, 
such TTOs may choose to supplant biotechnol-
ogy companies and take it upon themselves to 
deal directly with prospective commercialization 
partners, be they traditional pharmaceutical com-
panies or regional marketing firms.
This chapter has attempted to identify the 
principal structural and economic elements of 
biotechnology alliances and the factors that in-
fluence their selection. In the interest of brevity, 
only the most important structural terms have 
been discussed. Other provisions that are usually 
addressed in these alliances are noted in Box 1. ■
marK g. eDWarDs, Managing Director, Recombinant 
Capital, Inc., 2033 N. Main St., Suite 1050, Walnut 
Creek, CA, 94596 U.S.A. medwards@recap.com
1 Since this chapter is principally concerned with de-
velopment-stage biotechnology R&D programs, the 
term alliance is used to describe generally the relation-
ship between the parties. Such relationships typically 
involve a license and/or sublicense, as well as other 
rights and responsibilities of the parties. Except where 
specifically noted, the terms alliance, agreement, deal, 
partnership and license are used interchangeably in 
this chapter. 
2 In this chapter the term originator refers to one who 
licenses (a licensor) a compound or technology to a 
commercialization partner. When the originator is a 
biotechnology company, the conveyed intellectual 
property may include one or more sublicenses of 
university-derived intellectual property.
3 Edwards M, F Murray and R Yu. 2003. Value creation and 
sharing among universities, biotechnology and pharma.  
Nat. Biotechnol. 21: 618–24. Also Edwards M, F Murray 
and R Yu. 2006. Gold in the ivory tower: equity rewards 
of outlicensing. Nat. Biotechnol. 24: 509–15.
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• Nature of the collaboration
• Field of research
• Method of joint development
• Identify key research terms
B.	 Research	period
• Term of sponsored research program 
(if any)
• Note possible extensions
C.	 Reimbursement	Basis	or	Cost	Sharing
•  R&D payments (amount and type)
•  FTE (full time equivalent) reimbursement 
rates
D.	 upfront	payment
•  Payment(s) upon signing (or calendar 
based)
• Technology access fees
•  Credit given for option payments 
received prior to signing?
e.	 Benchmark	Amounts
• Pre-commercial milestones (i.e., IND, 
NDA)
• Sales-based milestones
• Creditable against royalties? Credit 
limitations
f.	 Technology	Acquisition	fees





• Approved in advance?
• Are budgets appended to agreement?
i.	 Reimbursement	Start	Date
• Typically on signing
J.	 Regulatory	filings
• Who controls and pays for regulatory 
filings?
• Do responsibilities vary by stage, territory 
or product?
K.	 Specific	Capital	Requirements
• Capital equipment paid for by licensee
• If special equipment is purchased, who 
keeps it upon termination?
• Transfer of materials
l.	 patent	ownership
• Know how, patents, IP, material 
ownership
• Who owns the patent rights?
• Joint inventions
m.	 patent	filing	Costs
 Who pays filing, prosecution, 
maintenance costs?
n.	 patent	Defense	Costs
• Who has first right to sue third-party 
infringers?
• Who pays for the patent defense costs?
• Allocation of recovery from such action
o.	 Third-party	patents
• Who has first right to respond to 3rd 
party suits for infringement?
• If royalties due to third-party, typically 
50% of such payments are creditable 
against 50% of amounts due to licensor
p.	 non-compete	provision
  Each party can or cannot compete in the 
Field
q.	 publications
• Approval procedure 
• Licensee may request delay for patent 
prosecution
R.	 Core	Technology
• Who owns core technologies?
• Visiting scientists, retained rights, etc.
S.	 Cancellation	Amounts
• Any amount due in the event of 
termination?
• May include wind-down of sponsored 
R&D
T.	 Termination
 Termination rights include
 (i) mutual, (ii) licensor, (iii) licensee.
(Continued	on	next	page)
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u.	 product	Reversion
• Who keeps product rights after 
termination?
• Royalties due to the non-terminating 
party?
v.	 Change	in	Control
• Typically “not assignable without the 
prior written consent of the other party”
• Are co-promotion and/or supply rights 
lost in the event of change in control?
w.	 options/other
• Additional research options (i.e., added 
fields, products)






• License grant(s), including make, have 
made
• Exclusive, nonexclusive or semiexclusive 
(note limitations)
• Commercialization rights (right to 
sublicense?)
• Is know-how included?
B.	 product	field	of	use
• Define product field of use
• Does IP have utility beyond scope of 
license?
C.	 Territory	Splits
• Define territory; what are major markets?
• Are there territory options for inclusion/
exclusion?
D.	 Royalty	Rate
• Royalty rates and/or profit splits
• Adjustments under certain conditions 
(type of IP protection, gross margins, 
competition)
• Note limitations to royalty offsets for 
third party patents and/or credits for prior 
payments
e.	 Right	to	Sublicense
• Is prior consent required?
• Impact on royalty rates
• Pass-through payments to upstream 
licensor
f.	 Term/patent	life
• How long does license agreement last? 
• Term of royalty obligations (“life of 
license”) (“continue until the last to expire 
patent….”)
• What happens to exclusivity upon 
expiration of royalty obligations?
• Note any rights of licensee to sell product 
after expiration (subject to royalty?)
g.			 license	maintenance	and	Diligence
• Annual license maintanence fees and/or 
minimum royalties 
• Due diligence (e.g., IND, Phase I, NDA filing 
by certain dates, “use reasonable efforts 
to develop,” etc.)
• Terminate or non-exclusive for non-
performance
h.	 Royalty	Accounting
• Define “net sales” or equivalent
• Other defined terms for royalty 
calculations?
• Audit provisions
• Late-payment fees, penalties, interest
i.	 patent-Royalty	Tie-in
• Are royalty rates tied to the granting of 
patents?
• Step-down rates for know-how only
• Treatment of pending patents by country 
if product launched prior to patent 
issuance
J.	 options/other
• Co-promotion rights, if any








• Who has the right to manufacture? 
• ID on packaging 
• What about second source or  
   back-up supply?
B.	Bulk/Dosage	form 
• Bulk or final form 
• Does this change by stage of  
   development or scale?
C.	Territory 
  Supply territory
D.	Reimbursement	Basis 
• Define basis of payment (e.g., fixed price  
   per unit, manufacturing cost plus  
   markup,   percentage of net sales) 
• If transfer price, inclusive/exclusive of  
   royalty?
e.		process	Development	Terms 
• Terms with respect to manufacturing  
   process development 
• Who is responsible for manufacturing  
   program? 
• Timing of orders and delivery  
   commitments 
• Ownership of production equipment
f.	Clinical	use	manufacturing 
• Who supplies compound for 
   clinical trials? 
• Reimbursement basis for clinical  
   supplies
g.	Shipment	Terms 
• FOB (freight on board) place of shipment 
• Standard cost for bulk? 
• Terms for replacement of  
   non-spec shipments
h.	financing 
• Is licensee providing financial  
   arrangements for Licensor to meet   
   supply obligations?
i.	escape	Clause 
• If Licensor cannot satisfy supply  
   requirements, right of licensee to make  
   or have made such quantities 
• Trigger event(s) of default 
• Temporary or permanent? 
• Product/territory specific?
J.	product	liability
 • Indemnification, including standard and  
  limitations 
• Insurance requirements
K.	options/other 
• Supply options 
• Options to repurchase product
Iv.		Collaboration	management:
A.	Representation	
• Governance of program 
• Committees established between the  
   parties 
• Make-up of committee, mandates
B.	quorum	
 Any specific quorum?
C.	Basis	of	Actions	
 Unanimous vote or majority rule?
D.		meetings	
		How often does the committee meet?
e.	Disagreements	
• Dispute resolution (escalation procedure) 
• Arbitration or mediation and applicable  
   rules 
• Appeal?
f.		Buyout/windup	
• Applicable for JV arrangements 
• Purchase option(s) in the event of 
   termination/ expiration of the JV
g.	options/other	
• Any other terms relating to the 
   governance of collaboration
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• Board seats granted? 
• Specific individual or named by party 
   when relinquished
D.	Research	Tie-ins
     If proceeds must be used for R&D
e.	options	&	Rights	
• Additional equity purchases 
• Convertible loans 
• Rights/obligations of purchaser:
   - registration rights
   - anti-dilution protection
   - sales restrictions
   - standstill
   - market standoff



















































































Discovery	(Nb=112) Lead (Nb=48) Mid Stage	(Nb=55) Late Stage (Nb=44)
Upfront R&D Milestone Equity Total
Source: Recombinant Capital www.recap.com
a  Average nonzero payments, by type
b Number of alliances




















Discovery (Nb=112) Lead (Nb=48) Mid Stage (Nb=55) Late Stage	(Nb=44)
Upfront R&D Milestone Equity Total
Source: Recombinant Capital www.recap.com.
a Median nonzero payments, by type



















Source: Recombinant Capital www.recap.com.
a Maximum royalty includes transfer prices but not profit splits




















Discovery (Nb=112) Lead (Nb=48) Mid Stage (Nb=55) Late Stage	(Nb=44)
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Source: Recombinant Capital www.recap.com.
a Maximum royalty includes transfer prices but not profit splits










Source: Recombinant Capital www.recap.com.
Valentis
(was MegaBios) Lilly
6% for aggregate net sales < US$250 million, 
8% for aggregate net sales $250–500 million, 
11% for aggregate net sales US$500–US$1,000 
million, and 13% for aggregate net sales > 
US$1 billion
gene	Therapy	for	Cancer	(5/97)
• US$3 million equity purchase (US$10.50/share)
•  Two years sponsored R&D (16 FTEs in year 1,  
12 FTEs in year 2; $220,000/FTE)
• US$27.5 million in total milestones (US$9.5 million for 
ovarian and US$18 million for breast)
• Lilly funding support for manufacturing and process 
development (US$475,000 in year 1, US$350,000 in year 2)
Valentis transfers 
manufacturing to 
Lilly after Phase I
Lilly pays 4% 
royalty to Myriad 
for BRCA-1
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figure	7:		An	Illustrative	lead-Stage	Alliance	(all	figures	in	u.S.	dollars)
Celgene has the right to partner SERMs for estrogen 








• US$10 million upfront fee
• $2 million in FTEs for	two years (@ $250,000/FTE)
• $1 million on choice of a preclinical compound
• $3 million on IND submission
• $2	million on Phase II start
• $4	million on Phase III start
• $6 million on New Drug Application filing
• $8 million on U.S. Food and Drug 
Administration approval
• $4 million on European approval
• $2 million for Japan
SERMs for estrogen 
alpha that are useful 
in oncology are 






release subject to 
ROFN 
figure	8:		An	Illustrative	mid-Stage	Alliance
Ligand has the option to co-develop SERM oncology product, 
by paying 33% of development costs after Phase II, and for one-







 US$12.5 million on signing
 US$49 million R&D over five years.
US$73 million in total milestones (divided 
among six product classes, 
US$6.5–14 million/product)
Source: Recombinant Capital  www.recap.com.
Source: Recombinant Capital www.recap.com.
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figure	9:		An	Illustrative,	late-Stage	Alliance
Centocor shall supply finished Panorex.
Supply price equals	50% on first $200 million, 
then 40% to $400 million, then 35%
panorex	mAb	for	colon	&	colorectal	cancer	
(Dec.	1993-nov.	1999)
 • US$10 million license fee, plus US$9 million for 
expansion into Asia in 1994
 • US$20	million in equity at signing, plus US$3.5 million 
for territory expansion in 1994
• US$45 million in milestones for targeted indications, 
plus US$2.5 million for Japan
Centocor pays 
$10–14 million to 
complete trials for 
targeted indications
US$25 million in 
license payments 
if BW takes 
over supply of 
product(s)





The mission of global health product development part-
nerships (PDPs) is to develop effective, affordable health 
products and make them available and affordable to those 
in need. The not-for-profit product development partner-
ships (PDPs) often seek for-profit partners to access es-
sential technology, expertise, and resources. These may be 
early-stage companies, leveraging philanthropic and gov-
ernment resources to develop a platform technology or 
established companies building out from existing markets 
or testing new technologies. Such not-for-profit/for-prof-
it partnerships require unique product development and 
IP (intellectual property) strategies that both recognize 
the company’s need for commercial benefit and deliver 
important health products to developing countries.
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ble health-care products that treat the diseases of 
the developing world. PDPs seek to serve under-
served and disadvantaged markets where there is 
little or no competition from other pharmaceuti-
cal companies. In some instances, their products 
also will reach private, profitable markets in de-
veloped countries, but it is not their main goal to 
serve these markets. 
The efforts of PDPs have significantly in-
creased the number of products currently be-
ing developed for diseases that affect developing 
countries.2 Products under development include 
drugs, vaccines, and diagnostics for diseases such 
as AIDS, tuberculosis (TB), malaria, meningi-
tis, dengue fever, shigella, and cholera, among 
others.3 
2.	 ChARACTeRiSTiCS	of	pDpS
Although they are not-for-profit organizations, 
PDPs have similarities with both for-profit com-
panies and research institutions. For one thing, 
the IP (intellectual property) goals of PDPs are 
similar to those of other types of organizations: to 
respect valid third-party patents; to ensure their 
own freedom to operate (FTO)—in other words, 
to use their own IP without constraint and to use 




“Thus we come to the conclusion that patents are nei-
ther inherently bad nor inherently good for this pur-
pose, but—like most tools—must be used wisely.”1 
Lita Nelson’s words are particularly appropriate 
for thinking about global health product develop-
ment partnerships (PDPs), which today are har-
nessing the power of both the private sector—es-
pecially its intellectual property (IP)—and the IP 
system itself to help deliver public sector goods. 
The mission of a PDP is to develop, man-
ufacture, and deliver affordable and accessi-
Shotwell SL. 2007. Product Development and IP Strategies for Global Health Product Development Partnerships. In Intel-
lectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Ma-
honey, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. SL Shotwell.  Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
Product Development and IP Strategies for Global 
Health Product Development Partnerships
sanDra l. shotWell, Managing Partner, Alta Biomedical Group, LLC, U.S.A.
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Research institutions usually have neither the 
funding nor the expertise to take products to the 
marketplace. Therefore, they rely on corporate 
partners to develop their technologies into prod-
ucts for public use. They use patents to attract 
corporate interest in their projects, seeking patent 
protection in countries where corporate partners 
will want a competitive advantage.
Like research institutions, PDPs have non-
profit missions, rely largely on philanthropic and 
government support, and do not plan to manu-
facture and market the products that reach cus-
tomers.4 PDPs prefer to partner with for-profit 
companies so that they can draw on their manu-
facturing expertise, production facilities, market 
channels, and sometimes their R&D expertise, as 
well.
For-profit companies try to gain advantages 
over their competitors in order to maximize their 
market share and profits. They reduce the risk of 
developing new products by assiduously protect-
ing their intellectual property. PDPs also work 
to protect the intellectual property produced 
through their partnerships, but their goal is, like 
research institutions, to leverage their intellectual 
property for access to other intellectual proper-
ty or for other uses that will contribute to their 
mission.
Like for-profit companies, PDPs develop 
products that will someday be introduced to the 
marketplace. They manage portfolios of products 
that are at various stages of development, project 
and establish markets, and work to overcome lo-
gistical and social barriers to product adoption. 
However, their IP strategies are different from 
those of for-profit companies, for several reasons. 
They have no need to protect their market share 
or profits. In fact, they aim to achieve the lowest, 
rather than the highest, possible product pricing. 
They welcome the presence of other organiza-
tions that are developing products for the same 
market. They are open to sharing knowledge, re-
sources, and projects. Thus, there IP strategy does 
not include the for-profit motive of keeping com-
petitors out of their market or increasing market 
share. 
In spite of these differences, most PDPs are 
evolving product development and IP strategies 
that are very similar to those of for-profit com-
panies. In pursuit of their humanitarian goals, 
PDPs may license their own intellectual prop-
erty or access the intellectual property of their 
corporate partners. In fact, if a company has al-
ready developed a product that is ready for im-
mediate use, there may be no need for a PDP to 
get involved at all. This situation can occur, for 
example, when companies are directly engaged 




In order to attract the interest and investment of 
for-profit partners, PDPs must protect their own 
intellectual property. It can be expensive and 
time consuming to obtain patents in develop-
ing countries, and the markets tend to be small, 
but the existence of an enforceable patent is of-
ten a strong inducement to potential industrial 
partners.
PDPs follow a wide range of business mod-
els: virtual pharmaceutical-development organi-
zations (such as TB Alliance6), in-house research 
capabilities (such as the International AIDS 
Vaccine Initiative7), the inclusion of manufactur-
ing capabilities (such as Aeras Global TB Vaccine 
Foundation8), and nonprofit pharmaceutical 
companies (such as Institute for OneWorld 
Health, iOWH9). All PDP business models draw 
heavily on public and philanthropic support 
(such as the Bill and Melinda Gates Foundation 
[BMGF]), as well as on extensive partnering with 
not-for-profit, government, philanthropic, and 
for-profit partners. 
Examples of the many partnerships PDPs 
develop with companies are presented in the 
case studies in the Handbook Executive Guide.10 
The product development and IP strategies vary 
considerably based on the technology, the stage 
of development, and the nature of the market. 
Most products developed by PDPs fall into one 
of two broad categories: those that incidental-
ly have large, profitable markets in developed 
countries (such as those that treat AIDS or TB) 
and those that do not. Examples of how the 
CHAPTER 12.9
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TB affects both the developed and the develop-
ing world. One PDP, the TB Alliance, seeks to 
develop more affordable, more effective prod-
ucts with shorter dosing regimens that increase 
the likelihood that patients will complete their 
courses of medication.11 A major component of 
the TB Alliance’s product-development strategy 
is the formation of partnerships with companies 
that own the rights to approved, IP-protected 
drugs that could be repurposed to treat TB. It has 
therefore partnered with Bayer Healthcare AG 
to perform clinical studies on Bayer’s drug moxi-
floxacin; it is hoped that this drug will be effective 
in three or four months rather than the standard 
six months. The agreement states that Bayer do-
nates the drug and covers regulatory costs; the TB 
Alliance will coordinate and help cover the cost 
of the trials, and seek to leverage support from 
corporate partners. 
In 2006, another PDP, AERAS, exclusively 
licensed patent rights to a vaccine technology 
from Vanderbilt University so that it could de-
velop a TB vaccine; the university retained the 
right to license the technology to other partners 
engaged in non-TB development. The exclusive 
license gives AERAS access to the technology 
and university expertise, as well as freedom to 
operate; if the organization is able to develop 
a TB vaccine (or even to make some improve-
ments on the existing technology), it will be 




Different strategies are needed when developing 
products for markets with low (or no) profit po-
tential. It may be difficult to find a for-profit cor-
porate partner that is already working to develop 
such products. However, there are companies 
with relevant expertise, technology, and products, 
and they can be encouraged to partner with PDPs 
to their mutual benefit. 
Malaria is found disproportionately in de-
veloping countries, though for-profit markets 
are growing in such places as India and among 
travelers and military personnel from developed 
nations.12 There is currently no approved malaria 
vaccine. The PDP Malaria Vaccine Institute part-
ners with universities, government labs, and both 
early-stage and established companies in order 
to advance malaria vaccine candidates. It is cur-
rently working with the for-profit company GSK 
Biologicals to test its vaccine in African children. 
The vaccine has proven to be effective for at least 
18 months, reducing clinical malaria by 35% 
and severe malaria by 49%. Time magazine de-
clared this project to be one of the most impor-
tant accomplishments in the field of healthcare 
in 2005.
The PDP iOWH has licensed a technology 
based on technology developed at the University 
of California at Berkeley. This technology is use-
ful for producing a precursor to artemisinin, a 
natural product in short supply that is used in 
malaria treatment. The PDP iOWH teamed up 
with a spinout company, Amyris Biotechnologies, 
in late 2004. With support from the BMGF, the 
three-way agreement benefited all parties: the 
university’s technology was advanced, Amyris 
fine-tuned its production processes, and iOWH 
developed a malaria drug candidate. 
4.		ConCluSionS
The developed world has a growing commitment 
to meeting the healthcare needs of the developing 
world. Successful product development and IP 
strategies are just two of the many issues involved 
in the commitment to developing products for un-
derserved markets. The engagement of various reg-
ulatory jurisdictions, local political and legal issues, 
the management of liability, the delivery of prod-
ucts to areas with limited infrastructure or security, 
and cultural acceptance of new products—all of 
these issues need to be addressed and managed in 
order for PDPs to achieve their goals. ■
sanDra l. shotWell , Managing Partner, Alta Biomedical 
Group, LLC, 7505 S.E. 36th Avenue, Portland, OR, 
97202, U.S.A. shotwell@altabiomedical.com
SHOTWEll
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1 See, also in this Handbook, chapter 1.4 by L Nelsen and 
A Krattiger.
2 Moran M, A Ropars, J Guzman, J Diaz and C Garrison. 
2005. The New Landscape of Neglected Disease Drug 
Development. LSE Pharmaceutical R&D Policy Project. 
The Wellcome Trust: London. www.lse.ac.uk/collections/
LSEHealthAndSocialCare/documents/PRPP/Thenew-
landscapeofneglecteddiseasedrugdevelopment.pdf.
3 See, for example, www.mihr.org, www.tmgh.org, and 
www.gatesfoundation.org for information about PDPs 
and their projects.
4 A notable exception is the Aeras Global TB Vaccine 
Foundation, which setup an in-house manufacturing 






10 Krattiger A, RT Mahoney, L Nelsen, JA Thomson, AB 
Bennett, K Satyanarayana, GD Graff, C Fernandez and 
SP Kowalski. 2007. Intellectual Property Management 
in Health and Agricultural Innovation: Executive Guide 
to Best Practices. MIHR: Oxford, U.K., and PIPRA: Davis, 
California, U.S.A. 
11 “Working with the best in both the public and private 
sectors, we collaborate formally with leading university 
laboratories, large pharmaceutical companies, 
biotechnology companies, and government agencies. 
Our work is also informed by constant dialogue with 
other organizations working to develop TB treatments.” 
TB Alliance. 2006. Next Steps Now. Annual Report 









The Public Sector and Entrepreneurship

ABSTRACT
This chapter is about university spinouts: why they are 
created, who founds them, and how they are developed. 
It also considers many of the issues that a university and 
its faculty have to address to successfully launch and de-
velop new for-profit ventures. Spinouts carry risks, but 
they may also be the best vehicle for developing early-
stage university technologies and providing a host of 
other benefits. The chapter offers examples from the past 
five years at Yale University, as well as from the private 
sector, that suggest ways to minimize the risks and maxi-
mize benefits.
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partners who possess the requisite resources. The 
most common means available to universities 
for attracting such partners are licenses. Patents, 
copyrights, and other instruments of intellectual 
property (IP) protection safeguard investments 
made by the university’s corporate partners. In 
general, universities license technologies to three 
classes of private sector entities: established com-
panies with more than 500 employees (large com-
panies), established companies with less than 500 
employees (small companies), and newly formed 
companies (spinouts). The term university spinout 
refers to those companies that are formed around 
one or more faculty inventions, with involvement 
of the faculty inventors and the cooperation of 
the university licensing office, in the licensing of 
university assets.
This chapter is about university spinouts: 
why they are created, who founds them, and how 
they are developed. The chapter also considers 
many of the issues that a university and its faculty 
has to address to successfully launch and develop 
new for-profit ventures. Many of the examples 
are drawn from the authors’ experiences at Yale 
University over the past five years; other examples 




In the course of fulfilling university research 
and educational missions, faculty often create 
intellectual assets that can benefit society. These 
assets may include patentable inventions, copy-
rightable works, and ideas that form the basis 
for new products and services. As they emerge 
from university laboratories, these inventions 
are not mature commercial products. To fully 
realize their potential requires significant re-
sources, both human and financial. These re-
sources are not generally found within the uni-
versity environment.
Therefore, commercial development of the 
invention requires the participation of for-profit 
Brown A and J Soderstrom. 2007. Creating and Developing Spinouts: Experiences from Yale University and Beyond. In 
Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT 
Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us 
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM 
Technology Transfer Practice Manual (Part XIII: Chapter 1).
© 2007. A Brown and J Soderstrom. Sharing the Art of IP Management: Photocopying and distribution through the Inter-
net for noncommercial purposes is permitted and encouraged.
Creating and Developing Spinouts:  
Experiences from Yale University and Beyond
alFreD (BUz) BroWn, Director, Office of Cooperative Research, Yale University School of Medicine, U.S.A.; 
Currently: Managing Director, BCM Ventures, U.S.A.
Jon soDerstrom, Managing Director, Office of Cooperative Research, Yale University, U.S.A.
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2. why	univeRSiTy	SpinouTS?
University spinouts provide many benefits. 
Among them are:
• the public may have access to new products 
or services 
• success is maximized
• enhancement of the university’s and the 
faculty’s image
• improved faculty retention 
• local, regional or national economic 
development
• economic returns to the university and 
inventor(s)
2.1 Public	benefit
The academic mission and goals of major univer-
sities include engaging in research that is useful 
to society. To translate this research into ben-
eficial commercial products requires a significant 
investment of human and financial resources. 
Commercializing inventions is generally not a 
central focus of academic or non-profit institu-
tions; such endeavors are more central to the 
missions of companies. However, in order for a 
company to justify making investments in the 
development of inventions from universities, 
the university typically must first protect its IP 
through patents, copyrights, or trade secrets. 
During the course of managing, protecting, 
and commercializing university discoveries, the 
technology transfer manager has many choices, 
and often there is no apparent best option. A spin-
out company is rarely a university’s first choice for 
a partner in the private sector. If an existing com-
pany has the interest, capability, capacity, and fi-
nancial resources—and the intent to reach broad 
markets—a university might prefer to work with 
that company. Sometimes, however, the market 
dictates that a spinout should be formed around 
a collection of technologies. One of the funda-
mental principles of the Office of Cooperative 
Research (OCR) at Yale is to make decisions that 
increase the probability of technology’s successful 
commercialization. 
Spinouts carry a number of risks that may 
exceed those found in established companies. 
Managers are often less experienced, and person-
nel may be working together for the first time. 
Company financing depends on funds from ven-
ture investors, who frequently react to environ-
mental changes in ways that are not always in 
the best interests of the company. For example, 
during periods of low economic growth, venture 
investors may elect to invest more in existing 
portfolio companies and in secondary and mez-
zanine financings of existing companies. During 
economic expansions, however, investors active-
ly seek to invest in new companies—sometimes 
at premiums that hurt future financing.
With certain factors in place, however, a 
spinout can represent the best opportunity for 
developing early-stage university technologies. It 
is crucial to identify a management team for the 
spinout company, including at least a chief exec-
utive officer/chief operational officer and a chief 
technology officer. Adequate financing must also 
be obtained; ideally, the business team will have 
experience and can convince others to invest at 
a premium to the initial financing of the com-
pany. Finally, a spinout’s business strategy must 
be solid and serve a broad customer base.
Spinouts formed around university tech-
nologies have a vested interest in the success of 
those technologies. Company management, con-
sultants and science advisors, board members, 
and staff are recruited because they believe in, 
and are committed to, the success of university 
technologies. Initial investors are especially com-
mitted to the success of the initial technologies. 
In contrast, when technologies are licensed to 
existing companies, there is often strong initial 
support for a new licensed technology, although 
the commitment is rarely as strong and as last-
ing as it is with spinouts. Existing companies 
may not identify as strongly with the recently 
acquired technology, and support may wane in 
the face of obstacles that a spinout might be able 
to overcome. Given the larger number of prod-
uct opportunities in development at bigger and 
more-established companies, business priorities 
and personnel can change rapidly, leaving the 
university’s assets undeveloped.
2.2 Economic	development
New ventures formed to undertake the commercial-
ization of inventions can promote the development 
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of a local economy. This may not be compelling in 
the technology-rich environments of Boston, San 
Diego, and the San Francisco Bay area. However, 
the economy in New Haven, Connecticut, which 
declined significantly from 1970 through the early 
1990s, clearly benefited from the development of 
technologies created at Yale. A regional economy 
can experience growth when spinout ventures decide 
to remain in the area. By 2007, more than 30 com-
panies had been formed around Yale technologies, 
with more than half locating in New Haven. These 
ventures provided more than one thousand jobs for 
highly skilled workers in the year 2000 alone. The 
ventures generated many joint-research projects un-
dertaken by these companies and the university. The 
companies have made New Haven both a bioscience 
center for the state and a magnet for the relocation of 
existing companies to the city and region.
2.3 Faculty	recruitment	and	retention
Faculty that are being recruited by Yale increas-
ingly inquire about opportunities to become in-
volved with existing and spinout companies in the 
area. A recently recruited department chairman, 
with significant entrepreneurial experience at the 
medical school, cited the university’s successful 
technology commercialization efforts and the ro-
bust bioscience industry as key in the decision to 
relocate. A vibrant local and regional technology 
economy can provide significant job opportuni-
ties for the spouses of new faculty hires. Regional 
technology-based spinouts often have state-of-
the-art research tools and expert staff that can 
be valuable to academic researchers, and faculty 
members often view the opportunity to collabo-
rate with these ventures as necessary to stay ahead 
of rapid developments in their fields. If spinouts 
remain in the region and faculty inventors remain 
active consultants and advisors to these compa-
nies, they can be a powerful force in keeping these 
inventors at the university.
2.4 Financial	incentives
Equity, in the form of stock, options, or war-
rants, is frequently part of the consideration 
for IP licensed to spinouts; equity may also be 
granted as consideration for assisting in the for-
mation of a new venture. At Yale and many other 
institutions, equity-only licenses are rarely used. 
License agreements with equity consideration 
usually include cash considerations as upfront 
license fees, minimum annual and/or milestone 
payments, royalties on sales, and a percentage 
of sublicense income. However, upfront fees are 
frequently reduced when equity consideration is 
part of the license package. Stock is viewed as 
a reasonable business solution to enhance the 
overall financial package—a solution acceptable 
to the company and its investors—while provid-
ing an opportunity for the university to increase 
its potential return.
Financial returns on equity are independent of 
the success of the licensed technologies; therefore, 
equity can be a way to capture value even if the 
initial licensed technology isn’t successful or if the 
company chooses another market. A few universi-
ties view equity as a way to generate large amounts 
of revenue to benefit their program or the univer-
sity. To date, this is not a proven strategy. Big win-
ners in equity deals are perhaps even rarer than big 
winners in traditional licensing deals.
3. how	To	CReATe	A	SpinouT
3.1 Investable	CEO
While a major part of determining whether or 
not a spinout represents the optimal commer-
cial path has to do with technology and market 
assessments, an equally critical aspect is finding 
an experienced business manager to join the 
founding team. We often refer to this individ-
ual as an investable CEO, because he or she has 
a track record in the technology area that can 
create added value in the eyes of professional 
investors. Such an individual must be able not 
only to understand and communicate with the 
founding scientists and inventors but also be ca-
pable of strategic, tactical thinking and action. 
The investable CEO must have had operational, 
preferably profit-and-loss responsibility, in small 
high-growth technical companies and must 
be able to work successfully with university 
founders and scientists. Such individuals are 
difficult to find. At Yale we succeeded by us-
ing the knowledge of industry professionals 
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and senior managers of comparable companies 
to locate potential candidates. As existing bio-
science companies mature in the New Haven 
area, these become an important source of 
next-generation CEOs. Fortunately, some of 
the best CEOs are serial entrepreneurs; once 
they have had a taste of success with a spinout, 
they are eager for another. Furthermore, some 
individuals would prefer not to work at large 
bureaucratic organizations.
A typical spinout CEO will:
• possess a successful venture-backed, spin-
out track record
• understand, accept, and manage risk
• comprehend science, discovery, and devel-
opmental processes
• be capable in academic and business 
environments
• have realistic expectations compatible with 
the university and the investors
• have an entrepreneurial attitude
3.2 IP	assessment
There are two major questions that investors will 
almost certainly ask of the technology: (1) Are there 
technologies or products that can block the devel-
opment and commercialization of your technology? 
And (2) can your technology dominate and pre-
vent others from entering the marketplace? While 
the OCR rarely commissions formal due-diligence 
opinions, which we consider to be the responsibil-
ity of the licensee, we do conduct literature and pat-
ent searches to investigate the relative strength of 
the IP. Although these searches often are initiated 
prior to identifying a CEO candidate, once such an 
individual has been identified, the office enlists him 
or her to assist with the assessment.
3.3 Market-opportunity	analysis
The key decision in determining the most ap-
propriate path for commercializing any univer-
sity-controlled IP is whether to license it to an 
established enterprise or to a new business ven-
ture. Regardless of the commercialization path, 
market and opportunity assessments are con-
ducted on most technologies. Such an assessment 
looks to balance the perceived technical and mar-
ket risks with potential return on the investment, 
for both the university and the potential licensee. 
Conducting such an analysis includes consider-
ing the following questions: 
• What are the market applications of the 
technology?
• Who are the potential customers, and why 
would they want to buy the technology?
• How are the needs currently being served 
for each application?
• How does the invention compare to exist-
ing technology?
• What is the character of the competition in 
the market?
• What is the market structure of competing 
technologies?
• What are the major obstacles to adopting 
the technology?
• What would it take to make the technology 
attractive to industry?
• What additional features should be designed 
to make the invention more attractive?
• What price would the market be willing to 
pay for this technology?
• What rate of adoption could be expected 
for the technology?
• What would the competition be in particu-
lar markets after the technology has been 
introduced?
• What are the regulatory requirements and 
success rates for technologies of this nature 
and at this stage of development?
All of the above questions help define a 
product scenario for the technology. Managers 
and staff need to know enough about the final 
product to be able to develop preliminary rev-
enue and expense projections over the life of the 
IP. Obviously, assumptions must be made, and, 
to the extent possible, these assumptions need to 
be based on comparable product sales, margins, 
and expenses. However, when dealing with med-
ical needs or technologies there are frequently no 
comparables, and sometimes an educated guess 
is all that is possible.
3.4 Financial	projections
For every spinout where Yale is the founder, the 
licensing office puts together a set of financials 
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that capture the basic elements of the business. 
Linked spreadsheets are an ideal tool for this 
purpose. Spreadsheets include numbers of cus-
tomers, product scenarios, revenue, expenses (in-
cluding personnel, administrative, equipment, 
and marketing), and cost of goods sold. We use 
a summary sheet to roll up all of the individual 
sheets. Identifying key variables (such as numbers 
of customers and pricing) and linking related ele-
ments of the plan (such as numbers of employ-
ees or the development status of a new product) 
can greatly facilitate scenario testing and useful 
projections. We have found that these projec-
tions are of great value in developing product 
scenarios and business and operational plans, but 
that they often contain more information than 




In our experience, business plans are most use-
ful to the founders and company management, 
while investor presentations are directed to the 
potential funding audience. While investors will 
use business plans to challenge the thinking and 
assumptions made by the founding group, they 
will most generally use the investor presenta-
tion to make the initial decision on whether or 
not to pursue an opportunity. Accordingly, we 
use the business plan as a management tool to 
profile the business opportunity, and we use the 
investor presentation to raise capital. The inves-
tor presentation does, however, usually flow from 
the business plan, or, at least, makes use of the 
thinking and assumptions that went into the 
business plan.
We have found that the ideal investor presen-
tation is 20 minutes long and contains no more 
than about a dozen overheads or computer-driven 
slides. The logic is that most investment groups 
allocate about an hour for the initial meeting, 
and about half of that time is usually taken up by 
questions. Assume another ten minutes for intro-
ductions and setup and only about 20 minutes 
are left for the actual presentation. Box 1 presents 




For a number of important reasons, the preferred 
approach in recent years at Yale has been an inten-
sive, hands-on approach to founding companies 
around university technologies. Yale’s OCR has 
developed business plans for companies, secured 
the rights to other institutions’ technologies (or 
parts thereof ), recruited management, developed 
and made investor presentations, negotiated fi-
nancing agreements, and even assumed the role 
of interim management for these companies. To 
be clear, two things we have not done are to invest 
university funds in spinouts, or to personally take 
equity or any other incentives from these spin-
out companies. To a large degree, the OCR has 
performed these functions because New Haven 
lacked a strong biomedical entrepreneurial and/
or venture investment community. There was 
also the desire to both maximize the success of 
Yale technologies and to expand the economy 
of New Haven and the surrounding communi-
ties. Another very important lesson that we have 
learned from these activities is that when the 
office undertakes a leadership role in founding 
these companies—particularly when recruiting 
management—the companies should locate close 
to New Haven. This is especially important for 
the founding scientists and inventors who consult 
for the company, since it reduces travel and facili-
tates company–university interactions.
4.2 Hands-off	approach
During the early years of establishing spinout com-
panies at Yale, the hands-off approach produced 
variable results, and certainly few successes. There 
was a time when the university wouldn’t even per-
mit faculty members to hold meetings on univer-
sity property to discuss the prospect of forming 
a company. Companies still surviving from these 
times are frequently considered to have persisted 
despite the activities of the licensing office, rather 
than as a result of them. By policy, many universi-
ties assume a much less proactive role in forming 
companies. In many cases, institutions market 
spinout activities (for example, license opportu-
nities) by sending out mass mailings; in other 
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Box	1:	elements	of	a	Successful	presentation
problem/need
What is the unsolved problem or unmet need that the business/products will address? This 
is comparable to reverse engineering the technology—what market opportunities does the 
technology meet?
Technology/products
What is the technology, and how will it result in new products, or how will it be incorporated into 
new products? What products will result from the technology?
long-term	plans
Assuming a ten-year cycle, what will the business look like in the second half of the cycle?
Short-term	plans	
What will the business look like, in one-year intervals, during the initial funding period and for 
the remainder of the first half of the business cycle? Discuss initial product-development plans, 
partnering and hiring strategies, and market and revenue opportunities.
Ip	and	market	protection	
What is the current status of the IP licensed or developed by the company, and how will the IP be 
protected in the future? Discuss freedom to operate versus the ability to exclude others from the 
marketplace. What are the plans for acquiring or developing proprietary IP in the future?
Competition
What is the current competition, and what will be the competition when the technology is 
commercialized? Distinguish the company from the competition.
management/founders	
Who are the scientific founders? Who is the management? Who are the anticipated scientific and 
business advisors?
Capital	needs
What are the capital needs for the first two years or for the initial funding period? What are 
the expected funding needs after the first two years but prior to exit, initial public offering, or 
profitability?
uses	of	funds
What are the specific accomplishments that will enhance valuation of the business during the 
first two years or the initial funding period?
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cases, investors interact directly with university 
scientists to develop product scenarios and busi-




Our office has adopted a proactive approach 
with respect to spinouts. We take founders eq-
uity in the new company separate and distinct 
from consideration for technologies that are be-
ing licensed to the spinout. When we initiate the 
hands-on activities described above, we negotiate 
an agreement with the other founding members 
of the company that delineates the roles of the 
respective parties and the compensation (found-
ers equity) that each party will receive. The value 
of the equity when the initial founders agreement 
is made, before the company has any IP assets or 
capital, is negligible. Therefore, it is best to deal 
in percentages of founders equity rather than 
absolute amounts. For example, if there is one 
university scientist who participates as a founder, 
one investable CEO, and the university, we would 
typically agree to split the founders equity equally 
and to assign a per-share value of US$0.01, par val-
ue. In our experience, not all university inventors 
are founders and not all founders are university 
inventors. This may seem inconsistent with stan-
dard licensing practices, where university inven-
tors are generally treated equally under university 
patent policies. But not all inventors choose to be 
entrepreneurs, so our approach benefits both those 
who want to be founders and those who do not. 
Founders equity is generally issued as common 
stock, and although the various founders may have 
different vesting parameters, all have similar share-
holder rights.
5.2 Equity	as	technology	consideration
Our experience has been that founders equity 
is frequently confused with equity that may be 
granted as consideration for technology rights. At 
Yale, we have a policy against all-equity license 
deals, and typical terms for licenses to university 
spinouts are similar to those that would have been 
negotiated with existing companies. Therefore, 
our typical licenses to spinouts include license is-
sue fees, milestone payments, royalties on revenue 
and sublicense fees, annual minimums, and dili-
gence requirements. Once we have identified the 
investable CEO and negotiated a founders’ agree-
ment with the founders, we will begin the process 
of negotiating license terms with the investable 
CEO. Because most of the IP licensed to spinouts 
is early stage product leads and technologies, the 
upfront licensing fees are generally low—in the 
range of US$50,000 to US$250,000. In many 
cases, common stock may be substituted for the 
license issue fees. However, license consideration 
equity is often granted at a par value greater than 
founders’ equity because the license transaction 
occurs sometime after the founders’ agreement 




University founders represent the university in 
spinout activities. At Yale, the OCR performs this 
function. Many of the founding activities are rou-
tinely reviewed with representatives of the general 
counsel’s office, the provost’s office, and the dean 
of the appropriate school. The ultimate internal 
approval process varies from university to uni-
versity. Equity received is held by the university 
and is liquidated according to the equity policy of 
the university. The following list includes activi-
ties that are routinely conducted by our office in 
launching university spinouts:
• provide IP development and patenting
• create product scenarios
• develop business models and strategy
• identify and develop preliminary rela-
tionships with potential development 
partners
• find and recruit key management
• establish a founding team
• develop revenue and expense projections
• write an executive summary
• prepare investor presentations
• initiate conflict-of-interest clearance
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• manage relationships with outside counsel, 
IP, and/or transactional attorneys
• negotiate interinstitutional agreements 
and obtain technology rights from other 
universities
• structure and negotiate technology access 
term sheets and licenses
• structure and negotiate capital investment
• negotiate investment capital terms
• represent the university in technical and IP 
due diligence
• review and approve company documents, 
including shareholders agreements and 
stock purchase agreements
• hold board seats in spinout companies
6.2 Inventors	and	faculty	founders
The structure and policies at Yale University per-
mit faculty inventors to be founders of spinout 
companies. In our experience, it is rare for an 
inventor not to want to participate as a found-
er once the decision to form a spinout has been 
made. However, we believe our faculty members 
need to make that decision individually, espe-
cially in cases where there are multiple inventors, 
some of whom may be students, postdoctoral sci-
entists, and untenured faculty who may not have 
time to participate as founders. It is also possible 
for faculty who are not inventors to participate as 
founders of a spinout. We have a number of cases 
where senior faculty members have expressed 
an interest early on in participating as heads of 
scientific advisory boards (SAB) and taking on 
many of the functions of a university founder. 
Participation in a spinout can be a particularly re-
warding experience for faculty inventors and sci-
entists, not only financially, but also because they 
can contribute more to their invention’s eventual 
practical applications.
University faculty founders commonly:
• aggressively pursue research consistent with 
the university’s responsibilities and mission
• participate in developing product scenarios 
and business strategy
• assist with identifying development part-
ners and preliminary talks with them 
• assist with the recruitment of key company 
management and scientific advisors
• assist with fundraising and presentations to 
investors 
• participate in technical and IP due 
diligence
• participate on, or lead, a scientific advisory 
board
7. mAnAging	The	SpinouT	CompAny	
In most cases, management decisions fall to the 
investable CEO. However, should the CEO have 
weaknesses or lack critical experience, the follow-
ing capabilities/functions may be undertaken by 
a variety of individuals:
• develop product scenarios, business mod-
els, and strategy
• identify and develop preliminary relation-
ships with potential development partners
• find and recruit key operations and techni-
cal team members
• help establish the founding team
• develop revenue and expense projections
• write an executive summary
• prepare investor presentations
• participate in developing an IP protection 
strategy
• negotiate licensing terms and agreements
• structure and negotiate capital investment
• negotiate investment terms
• represent the company in technical and IP 
due diligence
• review and approve company documents, 
including shareholders agreements and 
stock purchase agreements
8. SpinouT	inveSToRS
The sources of capital for university spinouts range 
from individual angel investors to large, multina-
tional, professional venture funds. The practice at 
Yale has been to work almost exclusively with larger 
professional funds specializing in technology-based 
spinouts. These funds have the ability to lead both 
current and successive rounds of financing. In the 
last few years, we have seen initial investments in 
spinouts increasing in size from US$500,000 to 
US$5 million, with many recent spinouts raising 
in excess of US$10 million in the first round. This 
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may be because many of the larger venture capital 
funds have more money to invest. 
Correspondingly, the pre-money value of 
many spinouts has also increased. We carefully 
choose the initial group of prospective investors 
based on prior investments, technical strength in 
the field of opportunity, and their ability to make 
follow-on investments. Typically, we target six in-
vestment funds and hope that we will be able to 
obtain a lead investor and one or two co-invest-
ment firms from this initial group.
9. DeAl	STRuCTuRe	AnD	exAmpleS
Figure 1 presents an overly simplified example 
of the structuring of a Yale university spinout 
representing the period of time between the ini-
tial founders’ agreement and company forma-
tion and the point of an initial public offering.
The initial distribution of equity is equal 
among founders: the university, university inven-
tor, university scientist, and founding CEO. This 
example assumes one inventor and one scientist/
noninventor from the university.
When the company is formed, each founder 
is issued an equal number of founding common 
stock at a nominal US$0.001 per share. When the 
scientific advisory board (SAB) is initially formed, 
members are issued stock options from the com-
pany stock-option pool with a nominal value, or 
exercise price, of US$0.01 per share. When the 
technology is licensed to the company, shares are 
issued to the university, instead of license issue fees, 
at US$0.50 per share. The initial capital is invested 
at US$1 per share. Thus, there is an increase in pre-
money value in the company, because of signifi-
cant events, like retaining a world-class SAB, and 
not because SAB members, or the university, are 
issued stock at these set values (Figure 2).
Given an equal distribution of initial found-
ers equity between the founding members of the 
company, the initial equity distribution upon 
company formation will be as follows (Table 1). 
Founders’ equity is the designation given to the 
common stock issued to founders, and it will 
have the same value as common stock issued to 
employees and advisors. The cost of acquiring 
this equity for the founding members is nominal 
figure	1:	Initial	founders’	Agreement
Yale University Yale Inventor
Yale Scientist CEO
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(US$0.001 per share or US$100 for each mem-
ber), which can be issued at this price because 
the company, at this point, has minimal value.
In the example above, the company recruits a 
number of leading international advisors (technical, 
clinical, and business experts) who will serve on the 
SAB and on the company’s board of directors. These 
boards are formed after company formation but be-
fore the initial financing, thus building additional 
value in the company prior to financing. In this ex-
ample, this equity is issued in the form of stock op-
tions, as opposed to common stock, because of the 
immediate value that the recruitment of these key 
individuals brings to the company. The company 
then negotiates licenses for three technologies on 
terms outlined in Table 2.
For technologies A and B, the university re-
ceives stock instead of the initiation fee, resulting in 
the stock division (Table 3). For technology C, the 
company elects to pay the license issue fee in cash.
After setting aside an option pool for man-
agement, SAB, the board of directors, and others 
(at the discretion of the board), the initial invest-
ments total US$15 million, and the stock distri-
bution is as listed in Table 4 and Figure 3.
10. RiSKS	of	equiTy	pARTiCipATion
While a university’s active participation in creat-
ing new business ventures can significantly en-
hance both financial and nonfinancial benefits 
to the university, such participation increases the 
figure	2:	Initial	equity	Cycle
Founders @ US$0.001/share
Scientific Advisory Board (SAB) 
@ US$0.010/share
Technology @ US$0.50/share


















Shareholder founders’	equity %	class Total	issued	and		outstanding %	total
University 100,000 25% 100,000 25.0%
Inventor 100,000 25% 100,000 25.0%
Scientist 100,000 25% 100,000 25.0%
CEO 100,000 25% 100,000 25.0%
Totals 400,000 100% 400,000 100%
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university’s exposure to various financial, legal, 
and ethical risks.1 As universities become increas-
ingly more engaged in venture formation, they 
must be cognizant of the risks and prepared to 
aggressively manage them. The risks include:
• impacts on tax-exempt status
• creation of taxable, unrelated business 
income
• exposure to liability
• creation of conflicts of interest and/or con-
flicts of commitment
• creation of conflicts with the mission of the 
university
10.1  Protecting	tax-exempt	status
To protect its tax-exempt status under Section 
501(c)(3) of the Internal Revenue Code, a uni-
versity’s activities must be charitable, educational, 
or scientific. The Internal Revenue Service has 
not defined a strict test to determine the quan-
tity of unrelated activities that can be under-
taken before jeopardizing exempt status. Loss of 
exemption, however, is not commonplace and 
considered unlikely if commercial business activi-
ties are insubstantial relative to exempt activities. 
Because intermediate sanctions have been devel-
oped to punish certain inappropriate activities 
Table	2:	license	Arrangements
Technology	A Technology	B Technology	C
Initiation fee US$100,000 US$50,000 US$10,000
Royalty 6% 3% 1.5%
Minimum royalty US$100,000 US$50,000 None
Milestone payments
- Investigational New Drug (IND) filing US$250,000 US$50,000 US$50,000
- Phase 2 clinical trial US$500,000 US$250,000 US$100,000
- Filing of New Drug Application (NDA) US$2,000,000 US$1,000,000 US$500,000
- Drug registration/licensure US$10,000,000 US$5,000,000 US$1,000,000
Shareholder founders’	equity %	class Common	stock %	class
Total	issued	and	
outstanding %	total
University 2,000,000 25% 0% 2,000,000 24.1%
Inventor 2,000,000 25% 0% 2,000,000 24.1%
Scientist 2,000,000 25% 0% 2,000,000 24.1%
CEO 2,000,000 25% 0% 2,000,000 24.1%
Technology A 0% 200,000 67% 200,000 2.4%
Technology B 	 0% 100,000 33% 100,000 1.2%
Totals 8,000,000 100% 300,000 100% 8,300,000 100%
Table	3:	equity	division
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by nonprofit organizations, caution is advised 
when a university forms new business ventures. 
Technology transfer managers should carefully 
monitor the extent of the university’s control over 
day-to-day activities of the for-profit entity to 
avoid a possible finding of private inurement or 
exposure to other liabilities.
10.2  Accounting	for	income	tax
Income generated from business activities unrelat-
ed to an exempt organization’s primary purpose, 
conducted regularly either directly or through 
other partnerships, may be subject to unrelated, 
business income tax (UBIT). There are impor-
tant statutory exceptions from UBIT. Specifically, 
passive investment income is not generally taxed. 
Such income includes most of the major sources 
of financial remuneration universities would ex-




• receipt or sale of stock 
• exercise of stock options
But even passive income, if derived from an 
entity that is more than 50% controlled by the 
tax-exempt entity, may be taxed if the controlled 
entity claims the payment as a deduction in com-
puting its own taxes.
Exempt status is not at risk if unrelated ac-
tivities are insubstantial in relation to the overall 
exempt activities. Careful records must be main-
tained, however, to permit the identification of 
taxable and exempt income, as well as related ex-
penses. The university needs to evaluate whether 
a passive revenue stream that is typically exempt 
from UBIT, such as royalties, may be tainted 
by other aspects of an agreement between the 
university and the licensee—and thus subject 
to UBIT. This could be the case, for example, 
if services are provided by the university to the 
licensee.
The impact of any new venture activities on 
university facilities that were constructed using 
tax-exempt bonds should also be investigated, so 
that these activities do not jeopardize the bonds’ 
exemption. Generally, no more than 5% of the 
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an unrelated trade or business. This test applies 
to the use of bond-financed facilities as well, 
though special exceptions may apply to the use 
of university research facilities for corporate-
sponsored research.
10.3  Exposure	to	liability
Any time a person or organization participates in 
a commercial transaction with another party, the 
risk of injuring another party increases. The party 
injured by the tort may sue the wrongdoer for 
damages. Such injuries include nonperformance 
of provisions of a contract, or property damages 
or personal injuries caused by a faulty product. 
When individuals engage in business activities 
where they might be sued, they will most often 
form a corporation. Through the formation of a 
corporation, the shareholders are shielded by the 
corporate veil and granted limited liability, or in-
sulation, from court-assessed damages that may 
result from the commission of a tort.
The use of the corporate form for new ven-
tures probably maximizes the university’s protec-
tion against such risks while it is actively engaged 
in commercialization efforts. As long as the univer-
sity does not control the venture, either in terms 
of stock ownership or day-to-day management, 
the university will likely not be held liable for 
debt and liabilities incurred by the corporation in 
which it holds stock. Moreover, if it serves mainly 
as a passive investor, the university’s tax status will 
not likely be jeopardized by the type or extent of 
business activities conducted by the corporation. 
10.4  Conflict	of	interest
When a university interacts with external cor-
porate ventures, the interests and commitments 
of the various parties involved—the university, 
individual faculty and staff, government, and in-
dustry—are complex and not necessarily aligned. 
These interests may conflict. A conflict of interest 
exists when an individual has sufficient external 
incentive and the opportunity to affect university 
activity. 
Conflicts of interest may arise when an indi-
vidual is involved in making a university’s financial 
decisions regarding investments, loans, purchases 
or sales of goods or services, and accounting. 
An individual’s economic interest may be de-
rived from:
• employment, independent contractor, or 
consulting relationships 
• management positions, board member-
ships, and other fiduciary relationships 
with for-profit organizations 
• ownership of stock or other securities and 
financial interests such as loans 
• any other activity from which the individual 
receives or expects to receive remuneration
Such conflicts can arise naturally and do not 
necessarily imply wrongdoing on anyone’s part. 
It is likely that the number of such conflicts will 
increase as universities expand their commercial-
ization activities. When conflicts do arise, howev-
er, they must be recognized, disclosed, and either 
eliminated or properly managed.
10.5 The	university’s	public	face	
Yale’s Policy on Conflict of Interest and Conflict 
of Commitment states that Yale is committed to 
ensuring that its interactions with outside ven-
tures are “conducted properly and consistently with 
the principles of openness, trust, and free inquiry 
that are fundamental to the autonomy and well-be-
ing of a university and with the responsible manage-
ment of the university’s business.”2 Most universities 
have similar policies. As universities become more 
active in the commercial arena, occasions when 
the above policies might be violated will likely 
become more frequent.
A primary concern is that, whether violations 
be actual or perceived, the public could question 
the integrity of academic research and those con-
ducting such research. For example, a faculty 
member might be involved in a new venture that 
brings to market a technology that is seriously 
flawed. Although the university may have done 
nothing improper in this case, it is visibly and in-
extricably linked to the inappropriate actions of 
others associated with it.
An additional conflict may arise between 
industry’s desire to protect proprietary rights 
and the academic commitment to freedom of 
communication and publication of research re-
sults. Entwined with this issue are concerns about 
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protecting the rights and interests of postdoctoral 
research associates and graduate students who 
may be involved in industry-supported research 
and whose interests may not be consistent with 
those of the faculty.
When such conflicts arise, they have the real 
potential to compromise the atmosphere of free 
inquiry that is vital for universities. Such conflicts 
must be promptly and properly addressed. Left 
unchecked, they may seriously damage not only 
the credibility of the individuals involved, but the 
university as well.
10.6 Minimizing	risk
Although risks may arise, the threat, by itself, 
should not preclude a university’s participation 
in venture formation. However, a university 
should establish procedures to identify and ag-
gressively manage perceived risks. An active risk-
management approach for new ventures makes a 
number of reasonable and prudent actions stan-
dard practice. These include:
• Protecting the university’s nonprofit sta-
tus and avoiding intermediate sanctions. 
Although not strictly required by the tax 
laws, a university should protect its abil-
ity to demonstrate that an investment 
is not an active trade or business. This is 
best done by limiting the equity interest in 
new ventures to a minority position and 
prohibiting active day-to-day involvement 
of university personnel in the venture’s 
business activities. The university should 
carefully scrutinize any arrangements 
where private inurement or benefit might 
be found.
• Accounting for tax consequences. The 
university should limit its exposure to un-
related business income tax by remaining a 
minority shareholder in business ventures 
and relying primarily on the income de-
rived from the passive, tax-exempt sources 
cited earlier.
• Minimizing exposure to liability. When 
creating new business ventures, the univer-
sity should use the corporate form to maxi-
mize protection against the risks of prod-
uct, tort, or contract liabilities. 
• Guarding against conflicts of interest/
commitment. According to most univer-
sity conflict-of-interest policies, faculty are 
required to report annually on investments 
in, positions held at, and advisory or con-
sulting relationships with any company in 
which the university holds license-derived 
stock or has a contractual relationship. This 
information often must be disclosed in any 
publication of research involving the com-
pany. These types of policies should be well-
publicized and rigorously implemented. 
  To help protect the university from se-
curities law and conflict-of-interest prob-
lems resulting from the appearance of 
insider trading, the university should con-
sider holding stock only until the stock is 
publicly traded and any trading restrictions 
are lifted, or until the company is acquired 
by a third party. University representatives 
on the boards of directors of spinout ven-
tures should be prohibited from holding 
personal equity of any size. This prohibi-
tion should continue until the company 
goes public.
  Business relationships with new ventures, 
such as licensing or sponsored-research 
agreements, should be handled at arm’s 
length. These relationships also should be 
permitted only after a review by an appro-
priate body determines that there are no 
perceived or real conflicts of interest.
• Enhancing university image. Any decision 
to participate in the formation of a new 
venture should always consider its likely 
impact on the university’s image. The ques-
tion, How would this look on the front 
page of the Wall Street Journal? should be 
on the minds of those university decision 
makers.
11. mAnAging	The	pRoCeSS
In addition to these guiding principles, universi-
ties need to establish a management process to 
guide their technology transfer office’s (TTO’s) 
evaluation and management of these risks and 
opportunities. This review process will serve as 
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a mechanism for dealing with issues surround-
ing the formation of new ventures and will help 
establish a formal mechanism for university of-
ficials to provide guidance on commercialization 
activities. 
When the TTO is responsible for forming 
new ventures (for example, creating business 
concepts, recruiting management teams, and 
raising venture capital) the responsibility for ap-
proving formation and reviewing the status of 
new ventures should reside in another part of the 
university, such as the office of the provost. The 
oversight office would be best advised by a com-
mittee, which could include:
• university officers, such as vice presidents 
of finance and administration, and general 
counsel
• deputy provosts representing the major 
physical- and life-science research areas
• senior administrators from the relevant 
schools within the university
12. equiTy	mAnAgemenT
A university may receive equity in one of three 
ways: (1) in lieu of cash for a license to a technol-
ogy, (2) for its activities in helping to found a new 
venture, and (3) in the case of some universities, 
for direct purchase of stock as a financial inves-
tor in a venture. Once a decision has been made 
to accept stock from a company, the university 
should have in place a set of policies and proce-
dures for the management and disposition of the 
stock, particularly after it acquires value in pub-
lic markets. Eventually, the university will want 
to sell some or all of its shares to generate cash, 
and the university should establish and publicly 
announce a policy for when and how it will ac-
complish this. Such a pronouncement avoids the 
potentially damaging impact on a newly publicly 
traded venture that may occur when the university 
begins to divest itself of its equity position (sug-
gested guidelines and policies are provided in 
Boxes 2 and 3 at the end of this chapter).
13. ConCluSionS
Many technology licensing offices have begun tak-
ing a more strategic approach to commercializing 
IP assets. The approach has led some to focus 
more attention on the spinout of new ventures. 
Spinouts provide opportunities to receive royalty 
income and capital appreciation of a university’s 
equity stake, and a university’s involvement can 
be instrumental in deciding to locate facilities 
near the university. Such involvement in venture 
formation may, however, increase exposure to 
new and different risks. This should not preclude 
the university’s participation, but the university 
should establish mechanisms devoted to identify-
ing and aggressively managing them. ■
alFreD (BUz) BroWn, Director, Office of Cooperative 
Research, Yale University School of Medicine, U.S.A.; 
Currently: Managing Director, BCM Ventures, Eleven 
Greenway Plaza, Suite 2900, Houston, Texas, 77046, 
U.S.A. bbrown@bcmventures.com
Jon soDerstrom, Managing Director, Yale University, Of-
fice of Cooperative Research, 433 Temple Street, New Haven, 
CT, 06511, U.S.A. jon.soderstrom@yale.edu
1 This section is intended to be a brief overview of the 
types of risks to consider. Much of this material is 
adapted from an unpublished monograph titled Trad-
ing Technology for Equity: A Guide to Participating in 
Spinout Companies, Joint Ventures, and Affiliates by RM 
Goodman and LA Arnsbarger, attorneys with Morrison 
and Foerster LLP in Washington, D.C. 
2 Yale University. 1995. Policy on Conflict of Interest and 
Conflict of Commitment. Memorandum from Provost 
Alison Richard to all faculty and principal investigators, 
August 1995.
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Box	2:	Suggested	guidelines	for	Acquiring		
equity	holdings	in	new	ventures
1.1 If the university does decide to make cash investments in a spinout venture (outside of any 
venture capital funds in which the university investments office may have holdings), it is 
recommended that such direct financial-investment decisions be made at arm’s length to 
avoid any perceived or real conflict of interest or commitment. Such investment decisions 
should be undertaken only as part of the investment office’s normal investment activities, 
or as part of other special university initiatives. Decisions to invest in later rounds, however, 
should be made by personnel insulated from the management of the license-derived stock. 
1.2 The equity position of the university should be a minority one, and subject to the same 
dilution as other shareholders, as the company raises additional capital.
1.3 Many universities, as an institution, retain the right to designate a representative, either as 
an observer or as a full voting member, to the board of directors of new ventures in which it 
holds equity. 
1.3.1 If the university designates a board member, it is recommended that the representative 
resign from the board prior to the company’s registration with the Securities and 
Exchange Commission for an initial public offering. 
1.3.2 During the term of board participation, any fees or other forms of compensation 
accruing to the board member should be the property of the university and credited to 
the appropriate account.
1.3.3 If an individual is designated to serve on the board as a full voting member, he or she 
will require indemnification through the university or the venture’s insurance policy to 
the extent permitted under state law.
1.4 Faculty and staff participation in new venture activity (whether by stock ownership, board 
membership, consulting agreement, or otherwise) should be governed by the university’s 
policy on conflicts of interest and conflicts of commitment and must comply with that 
policy in all respects. 
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Box	3:	Suggested	general	policies	for	the	
	management	of	equity	in	new	ventures
1.1 Stock acquired through the activities of the technology licensing office should be subject to 
the same policies and procedures as govern other equity holdings of the university. 
1.2 If the stock is received in lieu of cash in consideration for a license, the stock will be treated 
as royalty income and distributed to inventors in a timely manner in accordance with the 
university’s royalty-sharing policies. For the purposes of this distribution, the stock should be 
valued at the per-share value that it held when originally issued to the university. Following 
issuance of the stock to the inventors, it is then the sole responsibility of the inventors to 
manage their shares and to comply with any tax, legal, or contractual obligations associated 
with the distribution, ownership, or disposition of those shares.
1.3 Universities tend to follow one of two options in managing and disposing of stock held for 
the benefit of the university.
1.3.1 One option is to immediately transfer the shares to the university investment office 
to be managed in the same manner as other equity holdings in the endowment 
portfolio. Of course, all restrictions, such as any lock-up period where shares cannot be 
traded after an initial public offering, must still be observed. Because most universities 
maintain a legal wall between the investment office and the rest of the university, 
such a practice may help mitigate any perceived or real conflicts of interest. There 
are some potential difficulties with this approach, including the investment office’s 
lack of knowledge and/or expertise in managing individual shares in private ventures, 
establishing a value for the shares at the time of transfer, and accounting for the value 
if the shares are not immediately liquidated. 
1.3.2 An alternative approach is for the technology licensing office to hold and manage the 
shares until a public market exists for the shares (for example, after any restrictions on 
the sale of the shares has expired). When a public market exists, the shares could be 
transferred to the investments office in return for a transfer of funds to the appropriate 
income accounts equal to the value of the stock at the close of trading on the day of 
transfer. The investment office is then free to manage the orderly liquidation of the 
stock much as it would any other gift of stock to the university.
ABSTRACT
This chapter provides a practical guide for organiza-
tions seeking to transfer their intellectual property (IP) 
rights to a spinout company (normally through a licens-
ing agreement) so that the company can convert the IP 
into products or services that benefit the public. Based 
on experiences at Stanford University over the past three 
decades, key issues have been identified for negotiating 
transfer to a spinout, and guidance on best practices for 
reaching a successful agreement is provided. The chapter 
briefly reviews potential conflict-of-interest and conflict-
of-commitment issues that inevitability arise when em-
ployees of public research organizations become involved 
in spinout companies.
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what roles it will or will not play in the forma-
tion of new companies that utilize PRO technol-
ogy and/or PRO employees. The most common 
model for U.S. TTOs is passive involvement. 
Referrals are provided to resources that can assist 
in the spinout process, but the TTO itself is not 
actively involved. Active involvement does occur 
when the TTO engages in some, or all, of the fol-
lowing activities: writing or help in writing the 
business plan, assisting with incorporation of the 
company, finding initial seed funding, recruiting 
a management team, and securing the first-round 
venture funding. Such active involvement can be 
very time consuming and normally requires peo-
ple with special skills and experience.
Spinout companies are frequently formed be-
cause spinouts are the only alternative available for 
converting a technology into useful products or 
services. Of course, it is the products and services 
stemming from new technology that improve our 
health and standard of living—not the technology 
itself. Often, however, inventions are undeveloped 
and unproven, and established companies are un-
willing to commit resources to license and devel-
op the technologies. The inventors, on the other 
hand, may believe strongly in the social value of 
the inventions, and so will assume risk and make 
deep commitments to foster an invention’s further 
development into products. The inventors often 
do so by getting involved in spinout companies.
CHAPTER 13.2
1. inTRoDuCTion
Public Research Organizations (PROs) often cre-
ate spinout companies to commercially develop 
and market the PRO’s inventions. The new com-
pany may be formed by PRO faculty, staff, and/
or students, by entrepreneurs not affiliated with 
the PRO, or by a combination of these parties. 
In almost all cases, investors in the new company 
desire a relationship with the inventors of the li-
censed technology. The investors recognize that 
the know-how, “show-how,” and detailed knowl-
edge of the technology possessed by the inventors 
will be important to the company’s success. 
The technology transfer office (TTO) has an 
important role to play in this process, one that can 
take many forms. The TTO must be clear about 
Sandelin JC. 2007. Dealing with Spinout Companies. In Intellectual Property Management in Health and Agricultural In-
novation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, 
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The AUTM (Association of University 
Technology Managers) surveys show that in re-
cent years, 5% to 10% of licenses annually grant-
ed by U.S. universities are granted to spinout 
companies. In 2003, U.S. universities reported 
374 licenses to spinout companies, or about 7.5% 
of the total licenses granted. Sold equity totaled 
US$39 million, which was about 3% of total roy-
alty income in 2003. 
Over the past 15 years, Stanford University 
has taken equity as part of its licensing agree-
ments with 140 spinout companies. As of 2005, 
Stanford holds equity in 85 companies. Fourteen 
percent of the companies in which Stanford 
has taken equity have failed, making the equity 
worthless. For 18% of the companies, equity has 
been sold. Two companies generated more than 
80% of the total amount of cashed-in equity 
(US$22.5 million). Spinout companies have paid 
earned royalty income and annual minimum pay-
ments, but no data exists for these categories. As 
is true for licensing in general, when licensing and 
supporting spinouts, the focus should not be on 
how much income can be generated, but on the 
value flowing from a new partnering relationship 
(for example, consulting opportunities for profes-
sors, sponsorship of research, hiring of graduating 
students, and donations and gifts of equipment) 
and on the public benefits from the products and 
services the spinout may produce. Spinout com-
panies can be a significant source of new jobs and 
of local, state, and federal taxes. They can produce 
exports. A few spinouts (for example, Hewlett-
Packard in Silicon Valley) have grown into major 
corporations that are regional anchors, attracting 
entrepreneurs and other companies.
2. evAluATing	The	enviRonmenT
The role the TTO plays with spinout companies 
will be strongly influenced by the general attitude 
of the PRO’s senior administration and members 
of the governing board toward spinouts. These in-
dividuals can be encouraging, supporting, merely 
tolerating, or discouraging. One can see why in 
some cases their views may be less than positive. 
The involvement of PRO personnel with spinouts 
can create conflicts of interest, and valued faculty 
members who take a leave of absence to work in 
a spinout may not return. Moreover, leaves of 
absence require changes in teaching assignments 
and graduate-student supervising. If leaves are 
not taken, the commitment of faculty members 
to spinouts may lead faculty members to neglect 
teaching or research responsibilities (such conflict 
issues are covered in detail later in this chapter). 
Clearly, concerns of senior administration and 
board members about spinouts, involving PRO 
personnel, can be legitimate.
Almost all PROs in the United States at least 
tolerate spinouts, and the trend in recent years 
is toward greater acceptance of spinouts. Most 
faculty who are actively involved with spinouts 
speak positively about their experiences. If these 
individuals obtain significant wealth, usually 
through stock options, they serve as role models 
for others. Experience working with a spinout 
can also enhance faculty performance at the uni-
versity. John Hennessy, the president of Stanford 
University, took a one-year leave of absence in the 
1980s to be involved with a spinout named MIPS. 
He openly reports that the experience with MIPS 
was extremely valuable and useful for managing 
his teaching and research activities after returning 
to Stanford.
3. negoTiATing	A	liCenSe	AgReemenT
The TTO’s first involvement with a spinout is 
usually to provide a license to the technology that 
the company plans to convert into commercial 
products or services. In most cases, the licensed 
technology will be the company’s fundamental 
technology, and so the company will request an 
exclusive license. Investors want to be assured that 
their investments will be protected by patents or 
other intellectual property. In the license agree-
ment itself, investors will normally focus on:
• the length of the exclusive period 
• field-of-use limitations
• improvement inventions 
• agreement assignment provisions 
• financial terms
Investors almost always request a life-of-pat-
ent exclusive period. This is to be expected. In the 
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United States, because a large percentage of in-
ventions is generated through research supported 
by the federal government, the policy is to limit 
the exclusive period. In the initial Bayh-Dole Act, 
the U.S. government specified that the exclusive 
period would end either at five years from first 
product sale or eight years from the effective date 
of the license agreement, whichever came first. 
Although this requirement was later eliminated, 
it is still used as a guideline by many U.S. TTOs. 
In the United States, government guidelines 
are that the term of the exclusive period should 
be the shorter of eight years from the effective 
date of the license agreement or five years from 
the date of the first sale of the licensed product. 
Experience has shown that in most cases, a period 
of five years from the first licensed product sale 
allows a fair return. However, if the company can 
provide convincing evidence that a longer period 
would be needed in the company’s situation, such 
evidence would be evaluated and considered. If 
such evidence were not available at the time of 
licensing, but might appear at a later time, the 
new evidence could eventually justify extending 
the exclusive term.
Investors almost always prefer no limitations 
in the license. And if the TTO insists on a defined 
field of use, the investors will want a limitation as 
small as possible. Sometimes a compromise allows 
a grant of exclusive right for a specific field of use 
but permits access to other fields of use. Such an 
arrangement could be made by granting a nonex-
clusive right to other fields of use, or by specifying 
a right to add other fields at a later time, but with a 
requirement for a business plan, added payments, 
and appropriate diligence terms for licensed prod-
uct development in the added fields. 
Investors will also prefer to be automatically 
added to license-improvement patents that may 
emerge from continuing research in the area of 
the licensed technology. If the improvement has 
been described in the specification of the licensed 
patent, and the original invention and the im-
provement have common inventors, then the 
improvement could be filed as a continuation-
in-part (CIP) application. In such cases CIPs 
would normally be part of the definition of li-
censed patent(s). During the exclusive period, no 
one else could practice the improvement patent 
without rights to the dominant licensed patent, 
so the improvement patent has no value to the 
PRO. To add improvement patents that are not 
CIPs under the license agreement, the recom-
mended policy is to do this only with the express 
written consent of the potential inventors. 
Experience has shown that the most com-
mon exit pathway for PRO-based spinout com-
panies is merger and acquisition. Very few reach 
an initial public offering (IPO). Thus, the ability 
to assign the license rights to the merging or ac-
quiring party can be very important. The options 
for the TTO are: (1) no assignment without the 
written permission of the TTO, (2) automatic 
assignment to a party, of all of the assets of the 
licensee, without an added fee, or (3) automatic 
assignment to a party, of all of the assets of the 
licensee, with an added fee. The typical approach 
is to combine (1) and (3), so an assignment that is 
not part of a merger or acquisition requires writ-
ten approval, and an assignment that is part of a 
merger or acquisition is automatic but requires 
payment of a negotiated amount.
Spinouts must carefully manage their avail-
able cash; for license fees, the spinout will pre-
fer to trade equity for cash. Although fully paid 
licenses for equity are sometimes written, they 
are rare, and usually normal financial terms ap-
ply. The cash license fee is kept low (but usually 
not to zero), with equity taken as a substitute. 
The annual fee may start low and then increase 
over time. The earned royalty is targeted at what 
would be normal for the technology; however, in 
some circumstances, the spinout must also license 
from others to have all the rights needed to create 
a licensed product. In such circumstances, each 
of the licensing parties is asked for a reduction, 
so that the total earned royalty rate is reasonable. 
And with patent cost reimbursement, the pay-
ments are sometimes delayed until a certain fund-
ing level for the spinout is reached.
How much equity should the PRO receive 
for the technology license? This is a challeng-
ing question. Certainly the amount of equity to 
the PRO should not be so great that insufficient 
equity remains for successfully developing the 
business. Equity will be needed to secure fund-
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ing and to attract the best available people. Some 
entrepreneurs have proposed that the amount of 
founding equity for the technology should range 
from 1% to 10%. If the technology is an unprov-
en idea, then 1% would apply. If the technology 
is essentially ready for market, then 10% would 
apply. Following this rule, most PRO technol-
ogy, which is in the earliest stage of development, 
would fall within the 2% to 4% range. However, 
the specific situation may include other factors 
that affect how much equity is reasonable.
Another issue is whether the percentage 
ownership of the PRO should remain the same 
through subsequent funding rounds by antidilu-
tion clauses. Investors will not want the PRO to 
get an increasing number of shares at no cost at 
each funding round. This is reasonable. However, 
most will agree to some antidilution provision, 
such as nondilution through the initial venture 
round (usually called funding round A), or an-
tidilution until the company reaches a certain 
valuation.
Investors will also be concerned about dili-
gence terms, which require the spinout company 
to reach certain milestones or face the TTO’s 
termination of the agreement. Any clause that 
permits the TTO to terminate the agreement is 
cause for investor concern, but such diligence 
terms for the spinout are important because 
they ensure that the company does not become 
what John Preston (former director of the TTO 
of the Massachusetts Institute of Technology) 
refers to as the “living dead.” In such cases, the 
spinout company never grows beyond a few em-
ployees and never progresses beyond the prod-
uct development phase, or only manages to sell 
small quantities of licensed product, mostly for 
evaluation purposes. The intent of the diligence 
terms (reaching specified funding levels, having 
production facilities, and reaching certain sales 
volumes by agreed-to dates) is to ensure that the 
spinout doesn’t lose its viability.
Other sections of a license agreement that 
are typically discussed during negotiation are:
• Definitions, in which key words are 
defined
• Infringement provisions, in which the re-
spective responsibilities of the parties are 
defined in the event that infringement by a 
third party of licensed patents is detected
• Sublicensing, in which the parameters for 
sublicensing (including sharing of subli-
censing income) are defined
• Warranties and indemnities, in which the 
provisions for protection of the university 
are defined.
Definitions will normally be the first section 
of a license agreement. In this section, key words 
used in the agreement are defined. What is meant 
by “Licensed Products,” “Licensed Patents,” and 
“Licensed Field of Use” is extremely important. 
A definition should be clearly written so both 
parties fully understand the meaning; any pos-
sible future dispute over the meaning of a key 
term should be avoided utterly. It is therefore 
worth investing time to ensure that definitions 
are clear and unambiguous. Sometimes giving 
an example will make a definition more under-
standable. As is true with any of the agreement 
terms, if a person is presented with a definition 
that he or she does not fully understand (for 
example, it contains unfamiliar, legal wording), 
then the person can either rewrite it to reflect his 
or her understanding or ask the potential licensee 
to reword it so that it is understandable.
The Infringement provisions section describes 
what actions will be taken if infringement of the 
licensed patent(s) by a third party is detected. 
In the United States, infringement litigation is 
very expensive; if carried through to trial it can 
amount to many millions of dollars. Thus, the 
license agreement should not require the univer-
sity licensor to pursue litigation for any reason, 
and certainly not for an infringement. The most 
common approach to settling accusations of in-
fringement is for the parties to review the evi-
dence of infringement and then decide how to 
proceed. The most desired outcome is a solution 
that does not involve litigation. The university 
may be able to use its influence to find such a so-
lution—most companies wish to maintain good 
relationships with universities, so they will usual-
ly also seek a satisfactory solution. However, if it 
appears that litigation is the only possible course 
of action, then the licensee and the university can 
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agree to pursue the litigation jointly (and share 
both costs and awards), or if one party does not 
wish to join, the other party can pursue the litiga-
tion. The nonjoining party will provide reason-
able support as requested, but the litigating party 
would pay all costs and retain any awards that 
might result.
The Sublicensing section describes how the li-
censee may grant another party the right to make 
and sell licensed products under the third party’s 
brand name. Sublicensing does not apply to situ-
ations where the licensee is having components 
for a licensed product manufactured by others or 
where the licensee is using a distributor or other 
party to sell licensed products. A sublicensing pro-
vision is only included in an exclusive license. For 
a nonexclusive situation, the TTO will grant fur-
ther licenses to the licensed patent(s). The main 
issue in the sublicensing provision is how the sub-
licensing income will be shared. At the time the 
license is signed, the most common approach is 
to share sublicensing income equally. In practice, 
sublicensing is very rare, but if it does occur, it 
will occur well after the licensee has been sell-
ing licensed products. Typically many years will 
have passed since the license was signed and the 
50/50 sharing will probably have been renegoti-
ated. The sublicense, at the time of issue, would 
almost certainly include patents, know-how, and 
perhaps even training from the company issuing 
the sublicense. To be fair, the TTO should agree 
to compare the relative value of the original li-
censed patent(s) to what the company is adding 
under the sublicense to determine a fair distribu-
tion of sublicensing income.
Warranties and indemnities are provisions 
that protect the university. This is one area in 
which attorneys are necessary and legal terminol-
ogy may be required. If any significant changes 
to these provisions in the template agreement 
are requested during negotiations, the technol-
ogy transfer officer should stress that making any 
changes is very difficult and will need to be ap-
proved by the university’s attorneys. In most cases, 
university attorneys will not approve significant 
changes. Companies will usually complain that 
these provisions are too one-sided in favor of the 
university, but without such provisions, the risks 
to the university would be so great that licens-
ing would not be possible. Given that the parties 
are partners and not competitors, and that both 
have strong motivations to maintain a good rela-
tionship, disputes can often be resolved through 
discussion. Thus, the provisions in the warranties 
and indemnities section of the agreement are very 
rarely, if ever, invoked.
4. ConfliCT	of	inTeReST		
AnD	CommiTmenT
Conflict of interest and conflict of commitment 
are serious concerns for the PRO. The presidents 
and members of the governing boards of PROs 
are charged with maintaining and protecting the 
reputations of their institutions. These individuals 
worry about any type of activity or situation that 
could reflect badly on the integrity of the PRO, 
because a loss of public trust would have seri-
ous negative consequences, including lost gifts, 
donations, and funding from potential research 
sponsors. So it is not surprising that considerable 
attention is given to identifying and managing 
COI (a conflict resulting from a financial inter-
est held by a person employed by the PRO) and 
COC (a conflict whereby the commitments of 
the PRO employee to the institution are adversely 
affected).
Conflicts can result in: 
• loss of public trust in both the PRO and/or 
an individual connected to the PRO 
• unfulfilled commitments to research spon-
sors, students, and/or to general PRO 
responsibilities 
• bias, when reporting research results or not 
reporting research findings at all 
• exploiting the work of graduate students
• adverse and embarrassing reports in the 
media
Some potential outcomes due to conflict 
situations include: 
• research directions and priorities moving 
toward company interests
• restrictions on the distribution of research 
results 
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• pipelining of research results and related IP 
to a particular company 
• inappropriate access by a company or indi-
vidual to PRO facilities
Most PROs recognize that conflict situations 
are unavoidable in the current environment. 
If the PRO is to contribute to the public good, 
the PRO must enter into relationships in which 
conflicts can arise. Governments worldwide are 
looking more and more to PROs to contribute to 
economic development and growth, and legisla-
tion similar to Bayh-Dole is appearing all over the 
world. PROs therefore are creating “early warn-
ing systems” to identify when a potential conflict 
situation is developing. Attention can then be di-
rected to the situation to ensure it does not evolve 
into an actual conflict with negative results. A 
conflict situation in itself may not be bad, and 
in fact it may allow important benefits to flow to 
the individual and/or the PRO. But the conflict-
management system of the PRO must review 
and monitor conflict situations to avoid negative 
outcomes.
To manage conflict situations, many PROs 
implement an annual survey of all faculty mem-
bers. The faculty person lists all outside interests 
of himself or herself and his or her spouse (if any) 
that could create conflicts. The information is 
reviewed by the PRO administration, and any 
areas of concern are discussed with the faculty 
member. 
Most PROs have developed COI and COC 
policy statements that identify specific situations 
requiring an ad hoc conflict review. At Stanford 
University, if an employee (for example, a pro-
fessor) is to be involved with a spinout company 
that has applied for or been granted a license from 
the PRO, then an ad hoc conflict review would be 
required.1, 2
Box 1 sets out examples, involving conflicts 
of interest and commitment, that may clarify 
some of the issues PROs may confront. 
5. ConCluSionS
A spinout company may be the best, or perhaps 
the only, alternative by which newly discovered 
technology is converted into products or servic-
es for public benefit. Governments everywhere 
have, or are creating, policies and laws to en-
courage spinouts based on IP rights from PROs. 
Successful spinouts create new jobs and contrib-
ute to economic development, and they have the 
potential to grow into large multinational cor-
porations. Thus, creating an environment that 
nurtures and encourages the formation of spin-
out companies is a reasonable goal of all regional 
economies. The role of the TTO in such an en-
vironment can take many forms. The TTO must 
evaluate the environment in which it exists and 
determine what role it will play in the formation 
of the spinout company. One fundamental role 
is to provide the licensing agreement that will al-
low the spinout to seek funding from potential 
investors. In doing so, the TTO must balance the 
interests of the PRO it represents with those of 
the spinout, as well as with the interests of society. 
The TTO also must recognize potential damag-
ing conflict situations and participate in develop-
ing and implementing policies and procedures to 
avoid or minimize them. ■
Jon c. sanDelin, Senior Associate Emeritus, Office of 
Technology Licensing, Stanford University, 1705 El Camino 
Real, Palo Alto, CA, 94036, U.S.A. jon.sandelin@stanford.
edu, sandelin@stanford.edu 
1 See Stanford University’s policies on faculty conflicts of 
commitment and interest at www.stanford.edu/dept/
DoR/rph/4-1.html.
2 Other sources of COI guidelines include: (1) the October 
2001 Report on Individual and Institutional Financial 
Conflict of Interest published by the Association 
of American Universities (AAU), (2) the June 2003 
Recommendation of the Council on Guidelines for 
Managing Conflict of Interest in the Public Service 
published by the Organisation for Economic Co-
operation and Development (OECD), and (3) the 2004 
Approaches to Developing an Institutional Conflict of 
Interest Policy published by the Council on Government 
Relations (COGR).
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Box	1:	examples	Involving	Conflict	of	Interest	and	Conflict	of	Commitment
example	1:
This example is from the first of a series of symposia held at Stanford University in 1982 titled 
Universities, Industries, and Graduate Education (reported by Lee Randolph Bean in the October 
1982 Hastings Center Report). Stanford’s then-president, Donald Kennedy, presented this 
example to illustrate the problems that arise as faculty members move from the role of teacher/
investigator to that of entrepreneur. Although more than 20 years old, the example is as relevant 
today as it was then.
Dr. X and his graduate students work on a basic molecular biology project. Dr. X is a consultant 
and shareholder in Clotech, Inc., which has built a scaled-up facility for producing and testing 
a useful protein that is the primary gene product from a plasmid Dr. X first got from bacteria 
cells. Stanford, which has an assignment to the patent on the product, is now considering offers 
to invest in Clotech, and plans to offer an exclusive license to Clotech for a related process for 
which Stanford holds patent rights. Meanwhile, Mr. Y, a graduate student who is good at purifying 
the protein, has complained to the university ombudsman that Dr. X is using every means at his 
disposal to induce Mr. Y to accept outside employment with Clotech.
The issues Kennedy wished to bring forward for discussion at the symposia were:
Conflict of interest. Is Professor X devoting undue time and effort to Clotech because of his 
profitable consulting and equity arrangements, to the neglect of his teaching responsibilities? 
Do his outside ties create competing loyalties between Stanford and Clotech?
Secrecy. Has Dr. X kept past research results to himself, because his colleague, Dr. Z, works for a 
competitor company? Did Clotech ask Dr. X to delay publication of his work in order to secure an 
exclusive license from Stanford? [Author’s comment: Should Stanford have marketed the license 
to the patent(s) to others to determine if another party, perhaps one better qualified, would 
develop licensed products? Or should Stanford seriously consider offering nonexclusive licenses 
to all interested parties?]
Patents. Should scientific knowledge be owned and traded for profit? Should the university share 
in that ownership?
Research priorities. Does Dr. X’s involvement in a commercial production facility indicate a shift in 
his focus from basic to applied research? Will the future direction of scientific research be skewed 
to respond to the needs of private industry?
Graduate students. Have Mr. Y’s time and talents been exploited for the gain of his advisor’s 
company?
Public perception. Will extensive ties to the private sector erode public confidence in the 
detachment and trustworthiness of university research?
Scientific norms. The open and free sharing of information and a disinterested approach to 
research that puts the advancement of science first are norms that have traditionally governed 
science, according to sociologist Robert Merton. Are those norms disintegrating as the pull for 
commercial application of research and consequent profits intensifies?
(Continued	on	next	page)
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example	2:
This illustration and the following one were created by the author and are based on experiences 
at Stanford University.
Clotech has expanded and upgraded the scale-up facility to the point that it will now permit Mr. 
Y to run experiments in pursuit of his Ph.D.-, qualifying research work that he cannot do with 
the facilities in Dr. X’s lab. Mr. Y’s research is fully funded under a U.S. government grant. Clotech 
is willing to make its facilities available for the research project of Mr. Y, as the company realizes 
such work will be very relevant to their product plans. Clotech has requested a right to help guide 
the research work of Mr. Y and also requested a document signed by the university stating that 
any IP created by Mr. Y resulting from the use of their facilities will be owned by Clotech. Dr. X 
is encouraging Mr. Y to utilize Clotech’s facilities in his research, and is urging the university to 
accept the requests of Clotech. Clotech has indicated that it would be willing to hire Mr. Y as a 
paid consultant, as long as he follows the guidance of Clotech in his research, and that any IP 
created from the research would be owned by Clotech. Dr. X is supportive of Mr. Y being a paid 
consultant for Clotech under these terms.
Ms. Z in the Office of the Dean of Research has been asked to review the situation and inform 
Dr. X and Clotech as to what the university’s policies will allow in this case. After a careful review, 
including discussions with Dr. X and Mr. Y, her response is as follows:
• Any IP created by Mr. Y that is related to his research program for his Ph.D. degree, as specified 
under the work statement in the government grant that is funding Mr. Y’s research, will be 
owned by the university. This is regardless of where and with what facilities Mr. Y conducts 
such research.
• Mr. Y cannot be a paid consultant for research work that is also funded by the government.
• A designated professor in the department of Dr. X will become a co-advisor for Mr. Y and will 
be charged with ensuring the research work of Mr. Y is in full compliance with progress toward 
his Ph.D. degree.
• A collaboration agreement will be negotiated between the university and Clotech that will 
spell out clearly the terms of the proposed collaboration, including university ownership 
of IP created by Mr. Y and the right of Mr. Y to freely publish, at any time, the results of his 
research.
• A meeting will be held with Dr. X and the dean of research to discuss the situation and to 
ensure Dr. X understands that the university would not allow, under any circumstances, an 
outside company to direct the research of a graduate student and that ownership of any 
IP created by a graduate student, as part of his funded research work will be owned by the 
university.
example	3:	
Professor A in the university’s ophthalmology department, a renowned eye surgeon, disclosed an 
invention four years ago to the technology licensing office. This invention holds great promise 
for eye surgery. A patent, assigned to the university, has issued. The patent is exclusively licensed 
to the spinout company EyeCare, Inc., to which Professor A is both a consultant and the chair of 
the Scientific Advisory Board. Professor A has been given 100,000 shares of the company stock 
for her services. The university received 200,000 shares of stock as partial compensation for the 
exclusive license. In addition, EyeCare has sponsored research in Professor A’s lab for the past 
three years (ever since the company was formed). When EyeCare first proposed supporting the 
research of Professor A, the university established an oversight panel to review research proposals 
and results, as well as the involvement of graduate students with the company, and to advise 
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Because of this sponsorship, EyeCare has exercised its right to exclusively license three 
improvement patents resulting from the research. A separate conflict review was required before 
the exclusive license could be granted. The university licensing office submitted a report on its 
marketing the invention to other parties, and a statement that EyeCare is the best alternative 
for commercialization of the invention, in a timely manner. This conflict review very carefully 
evaluated how the relationship with EyeCare might impact the graduate students conducting 
research in Professor A’s lab, as the potential for altering the work of students to benefit the 
company was a major concern. 
The invention licensed to EyeCare has now reached the stage where clinical studies, with human 
subjects, will be required to obtain government approval to sell the medical device in the United 
States. The lab of Professor A is clearly the best source for coordinating such trails, with Professor 
A and her colleagues performing the procedures. However, the relationship of Professor A with 
EyeCare, through which she could profit handsomely if the clinical trails are successful, is a 
cause of great concern. The university must therefore carefully review the situation in order to 
determine if it will conduct the trails or not, and if it will permit conducting the trials, what level 
of oversight and controls will it exercise.
The university, following a review, decides to conduct the trials with the following oversight 
conditions:
• Professor A must sell all her shares in EyeCare and agree not to acquire any shares in the future, 
including options to acquire shares.
• The university will sell all its shares in EyeCare and agree not to acquire any shares in the 
future, including options to acquire shares.
• Professor A will participate in the clinical trails, but will not be the principal investigator for the 
trials.
• An oversight committee will be formed that will review the results from the trials and any 
publications related to the trials. The committee will include Professor B, a respected eye 
surgeon from another university medical center.
• Professor A will fully disclose her relationship with EyeCare in any publications or presentations 
related to any research connected to EyeCare.
• Professor A’s relationship to EyeCare must be fully disclosed and explained on the “informed 




Ready access to venture capital investments is vital to 
the success of start-up companies in the capital intensive 
high-technology sectors such as biotechnology. But there 
is a common misconception that an abundance of ven-
ture capital will spawn the formation of new companies. 
In fact, the opposite is true: new companies actually at-
tract venture capital. This chapter provides an overview of 
the venture capital system, explains its importance, and 
identifies what qualities of a company make it attractive 
to venture capital investors. Some of the factors can be 
influenced by government action, so the chapter offers 
several ways that governments can encourage venture 
capital investment.
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focus on development and marketing, and lose 
their agility and ability to innovate. Thus, large 
companies increasingly gain access to the innova-
tions of small companies through licensing agree-
ments, R&D partnerships, and acquisitions. 
Prior to the 1980s, most agricultural innova-
tion in the U.S. originated at land-grant universi-
ties; there were very few small start-up compa-
nies. Innovation was offered directly to farmers 
and to large agriculture companies via products 
and license agreements. Then with the onset of 
the go-go genomics era in the late 1990’s agri-
culture went through two major restructuring cy-
cles. The first cycle was based on the premise that 
understanding of life processes at the molecular 
level could be leveraged across agriculture and 
pharmaceuticals. So-called life science companies 
were formed. Small agriculture biotechnology 
(agri-biotech) companies were started based on 
new genetic technologies; these small companies 
were quickly acquired by larger companies as they 
raced to converted into life sciences companies 
through the acquisition of genomics technologies 
and germplasm. 
However, these large life science compa-
nies soon discovered the complexities inherent 
in managing business units with very different 
cost structures, market sizes, margins, and regu-
latory paths. Within two to three years, there-
fore, the large companies spun off freestanding 
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1. 	 inTRoDuCTion
Commercialization of biotechnology research is a 
long, expensive process that requires highly trained 
staff, sophisticated laboratory facilities, and costly 
regulatory approvals. A growing amount of this 
work is done by small companies. They are the 
primary source of innovation in biotechnol-
ogy and are performing an ever-increasing share 
of total U.S. R&D. According to data from the 
National Science Foundation, the value of small -
company R&D rose to US$40 billion, accounting 
for 20.7% of the value of all private sector R&D. 
These small start-up companies rely on venture 
capital investment to fund their R&D activities. 
As pharmaceutical and agriculture compa-
nies merge and become larger, they increasingly 
Wyse R. 2007. What the Public Sector Should Know about Venture Capital. In Intellectual Property Management in Health 
and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., 
and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. R Wyse. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommer-
cial purposes is permitted and encouraged.
What the Public Sector Should Know 
about Venture Capital
roger WYse, Managing Director and General Partner, Burrill & Company, U.S.A.
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pharmaceutical and agriculture companies. These 
rapid cycles of restructuring negatively affected 
small companies, because very few partnerships 
and acquisitions took place between 1998 and 
2004. Fortunately, the trend now seems to be 
reversing and large agri-biotech companies are 
again acquiring innovation from small compa-
nies, particularly in an era when agriculture in-
creasingly includes food production and biomass 
for fuels and materials. The ongoing challenge 
now is to create an environment that encourages 
entrepreneurship, the formation of small innova-
tive companies and venture capital investment.
2.	whAT	iS	venTuRe	CApiTAl?
Venture capital (VC) is high-risk capital that is in-
vested in early-stage companies. It is not a loan; 
it is an equity investment, with the investor own-
ing shares of the company. Venture capital com-
panies invest in high-growth, early-stage private 
companies when the technology risk is still high 
and, if successful, potential financial returns are 
also high. The VC is managed by companies with 
deep expertise in the sector and with experience 
in forming and nurturing start-up companies. 
Venture capitalists are not only a critical source of 
funding; they are also actively involved in helping 
to manage and develop small companies.
Some venture companies, called seed stage 
funds, focus on very early-stage companies. 
These funds are generally small, ranging in size 
from US$10–50 million. They will usually in-
vest US$250,000–3 million in a single company. 
Growth stage funds are larger, possessing US$75 
million–1 billion. They invest in later-stage com-
panies where investments of US$10–20 million 
are common.
VC companies raise money from institution-
al investors, corporations, pension funds, gov-
ernment agencies, and private individuals with 
high net worth. Most funds last for ten years. 
In the initial three- or four-year period, a fund 
typically invests money in a portfolio of 15 to 20 
companies.
Investors get a return on their investments 
only when portfolio companies are either sold 
via a trade sale or participate in an initial public 
offering (IPO), usually three to five years after 
the initial  investment. At that point, the inves-
tors are repaid their initial investment and any 
profits are split 80:20 between investors and 
the venture company. In general, venture capi-
tal companies can expect to achieve a return of 
20–40% IRR (internal rate of return) over the 
life of a fund. 
3. why	iS	venTuRe	CApiTAl	impoRTAnT?
The capital that drives the biotechnology indus-
try comes from many sources, but mostly from 
R&D and marketing partnerships between small 
and large companies. In 2005, US$34 billion 
was invested in U.S. biotech companies from 
all sources (Table 1). This amount was already 
exceeded by the end of the first three quarters 
of 2006. In 2005, approximately US$4 billion 
in investment capital came from venture capital. 
Over half of the total annual investment from 
all sources came from R&D partnerships estab-
lished between large and small companies. 
Venture-backed small companies also create 
new jobs, generate wealth, and contribute to eco-
nomic growth. Historically, 80% of new jobs in 
the United States are created by companies with 
fewer than 500 employees, many of which are 
venture financed. Between 1970 and 2003, ven-
ture-backed companies accounted for 10.1 mil-
lion new jobs in the United States and US$1.8 
trillion in revenues. 
The impact of venture-backed small com-
panies on local and national economies is most 
dramatic when two conditions are present: an 
entrepreneurial culture and a critical mass of 
small companies that attract venture invest-
ments. Most venture capital companies are lo-
cated in the United States, and most venture 
backed U.S. companies are found in California 
(in the San Francisco Bay area and San Diego), 
Boston, and along the Atlantic seaboard. Only 
six states in the United States account for nearly 
75% of all venture capital invested in all sectors 
(Table 2).
Venture capital is a vital element in establish-
ing a biotechnology industry but it is very diffi-
cult to accomplish. Few geographic locations have 
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  Public IPOa 819 567
  Follow-onsb 4,194 3,032
   PIPESc 2,376 1,817
   Debt 5,565 12,241
Private (Venture capital) 3,518 3,186
Other 1,114 303
ToTAl	CApiTAl 17,586 21,146
Partnering  17,268 (50%) 12,463 (37%)
ToTAl 34,854 33,609
a  IPO – initial public offering: a private company files to have a portion of its shares sold to the public on a 
regulated stock exchange,  such as NASDAQ .
b.  Follow-ons – When public companies sell additional shares on the stock exchange to raise additional 
cash.
c.  PIPES – Private investments in public entities: the sale of public shares to private financial institutions that 









Total of top six states 74.9.%
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been successful. Seventy five percent of all venture 
capital in the world is in the United States and 
about 75% of that is in six states.  However, the 
fundamentals for success are clear; the formation 
of new companies operating in an environment 





Early-stage companies are high-risk investments: 
they will always run into problems and they will 
always be short of capital. Therefore, it is vitally 
important to have a management team that can 
solve problems quickly and use limited capital ef-
ficiently to create real value. 
4.1.2   Viable	technology
Small companies should be founded on scien-
tific research published in peer-reviewed pub-
lications; however, many companies are started 
well before true proof of concept is demonstrat-
ed. Indeed, venture capitalists usually decide 
whether or not to invest in a company based on 
the quality of the science it does or plans to do. 
Venture capitalists will mitigate their own risk 
by offering funding in stages, investing more 
money as the company passes each technologi-
cal milestone.
4.2 IP	ownership	and	freedom	to	operate
The value of a biotechnology company is based 
on the amount of intellectual property (IP) it can 
acquire, develop, and protect—and on the poten-
tial market served and not on current revenues. 
Therefore, companies must acquire a strong IP 
position and have a good patent strategy. The 
company should ideally be based in a country 
with strong patent laws.
Patents are only valuable, however, if the 
company also has freedom to operate: that is, the 
ability to use the patented technology without 
having to rely on other technologies to which it 
does not own IP rights. 
4.3 A	large	potential	market	
Companies with products or technologies that 
have large markets are obviously more attractive 
to investors than those that have smaller markets, 
even though the cost of development of a small-
market technology is usually about the same as 
that of a large-market technology.
4.4 A	favorable	entrepreneurial	environment
Companies within an entrepreneurial environ-
ment of “critical mass”—that is, an environment 
that has a sufficient number of similar companies 
and therefore a critically large pool of talent—are 
more attractive to investors than companies out-
side of such environments. This is true for several 
reasons. First, when there are a number of small 
companies in the same area, CEOs can share 
ideas and develop solutions with each other. 
Should one company fail, employees can easily 
move to other companies, and there is enough 
management talent in the area to fill the needs 
of the companies. The area also likely supports a 
large number of attorneys and accountants who 
are familiar with the issues of small companies.
Venture capitalists never fully fund an in-
vestment alone. They almost always syndicate the 
investment with other local companies, particu-
larly those that have large funds. The presence 
of venture capitalists makes syndication easier. 
Venture capitalists who are not locally based will 
want to partner with other venture capitalists 





The ideal business culture rewards success, sees 
failure as a learning experience, and strongly 
believes that technology and innovation are the 
drivers of economic growth and wealth creation.
Indeed, success breeds success. The pres-
ence of a few local heroes who have taken risks 
and built successful companies encourages 
entrepreneurs to start companies and to stay the 
course when problems arise, as they always do. 
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Finally, already-existing networks of experienced 
CEOs/managers can help lead new companies or 
provide mentoring to young CEOs. 
5.1.2			Access	to	intellectual	capital
Successful biotechnology clusters are fed by 
the intellectual capital flowing from great re-
search universities. Such clusters are found in 
Boston (M.I.T. and Harvard University), the 
San Francisco Bay Area (Stanford Unviersity, U. 
C. Berkeley, and U. C. San Francisco), and the 
United Kingdom (the University of Oxford and 
the University of Cambridge).
5.3 	 Access	to	financial	capital
Financial capital includes funding for peer-re-
viewed research; seed capital, usually put up by 
angel investors (wealthy individuals); and early-
stage and growth capital, which is put up by ven-
ture investors. 
5.4		 Other	factors
The area must also contain appropriate, readily 
available facilities, such as low-cost laboratories 
and offices. It should have a sufficient number of 
lawyers and accountants, and a low cost of living 
and high quality of life are added advantages.
6.		venTuRe	inveSTmenTS	
in	AgRi-BioTeCh
Health care biotechnology has a 40-year history 
of successful venture capital investment and ex-
perienced venture-capitalists and CEOs, and 
the products have well-known paths to market. 
However, venture capital investment in other sec-
tors—such as agriculture and health & wellness, 
as well as the industrial application of biotechnol-
ogy—is only just beginning.
Investing in agriculture is particularly chal-
lenging. Market sizes and values are smaller than 
for pharmaceuticals, developing a new trait or 
enabling technology is costly, and the impact of 
new developments on established crops can be 
quite small. Since most crops are commodities 
used for food or feed, profit margins are low, and 
it is difficult to get an attractive return on a ven-
ture investment. It takes ten to 12 years for an 
agricultural product to come to market, about the 
same length of time it takes to bring pharmaceu-
ticals to market. However, the potential market 
value of agriculture products is less than that of 
pharmaceuticals. 
During the last ten years, the agri-biotech 
industry has become greatly consolidated. The 
number of potential R&D deals and acquisition 
opportunities has been reduced, and the sector is 
much less attractive to potential venture capitalists. 
Finally, the uncertain regulatory issues surround-
ing genetically modified organisms mean that in-
vestors consider agriculture a risky investment.
In order to encourage venture capitalists to 
invest in agri-biotech, the public sector must pro-
vide more funding for translational research, that 
is, research that moves a technology or product 
further up the value chain and closer to market, 
thus reducing both the investment needed for 
commercialization and the risk (Figure 1). The 
point of the figure is that knowledge-based bio-
tech industries in agriculture require a greater 
emphasis on translational research, compared to 
the pharma industry, to be able to attract the ven-
ture capital and corporate investment necessary 
to commercialize new products and technologies 
7. 	 how	CAn	goveRnmenTS	
enCouRAge	enTRepReneuRShip?
Governments cannot dictate or legislate entrepre-
neurial activity; they can only help provide an en-
vironment in which the skilled entrepreneur has 
ready access to capital, technology, and support. 
The following actions can help promote such an 
environment:
• Provide an educated workforce. The bio-
technology industry requires a pool of in-
dividuals with advanced degrees in biology, 
as well as people trained in mathematics, 
computer science, and advanced laboratory 
practices.
• Provide funding for basic and transla-
tional research. Innovation relies on the 
unrestricted pursuit of knowledge. Local 
and national governments should therefore 
assure support for universities. Depending 
on the circumstances, government grant 
WYSE
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money may be best used to fund applied, 
not basic, research. Local governments 
should fund translational research for agri-
biotech to make up for the lack of invest-
ment from large companies and venture 
capitalists.
• Enforce strong patent laws. Laboratory 
research, no matter how innovative, is of 
little social or economic value unless it is 
actively protected by strong patent laws. 
• Encourage proactive technology transfer. 
The transfer of technology from universities 
to the private sector is often a weak link in 
the innovation path. Such transfer should 
be performed proactively and efficiently. 
Technology transfer offices must recog-
nize that small companies are cash poor 
and and are working under severe time 
constraints. Therefore, they must be flex-
ible in the license terms being willing to 
take an equity position in lieu of cash pay-
ments. Also, funding for proof of concept 
research will lend clarity to the real value 
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to commercialize. This information can 
reduce the negotiating period needed to 
agree on the value of the license.  
• Use the bully pulpit. Governments must 
be strong advocates for biotechnology 
and entrepreneurs. They need to build 
an environment of expectation, address the 
naysayers, and signal that their locale is the 
place to grow a business in biotechnology. 
Press releases, exhibits, and advertisements 
by senior officials are just a few examples of 
actions that have proved successful.
• Provide a science-based regulatory environ-
ment. Investors and entrepreneurs are at-
tracted by a regulatory system that is based on 
science, that encourages development while 
protecting the environment and society, and 
whose decision-making is transparent.
• Provide financial incentives to investors 
and entrepreneurs. Creative financial in-
centives that attract risk capital, such as 
venture capital including R&D tax rebates 
(which must be tradable, if they are to be of 
value to small companies), deferred taxes, 
subsidized incubators, and low- or no-inter-
est loans. In some cases, the incentives may 
go directly to investors. A source of capital 
that matches VC investments in companies 
and tax offsets as enticements for investors 
to invest in venture funds reduce the overall 
risk to investors.
8.		Developing	A	TeChnology	CluSTeR
There is a common misconception that an abun-
dance of venture capital will spawn the formation 
of new companies. In fact, the opposite is true: 
high-quality new companies will attract venture 
capital. It is therefore important to establish a 
technology cluster: a group of small companies 
working in the same area and in the same or re-
lated sectors.
In order to build a technology cluster, certain 
ingredients are necessary: technology licensing, 
business-plan development, seasoned managers 
who can assist in developing business strategies 
and mentoring management teams, a pool of an-
gel investors, and venture capitalists with experi-
ence in seed-stage investing. All of these things 
will encourage entrepreneurs to start new compa-
nies and will accelerate the development of those 
companies.
The next step should be to encourage expe-
rienced, nonlocal venture capitalists who manage 
large funds to become involved with local com-
panies. Local capital will never be sufficient to 
fully fund the development of a successful biotech 
company, and larger venture funds are managed 
by individuals who have a great deal of knowledge 
and often participate in global networks. However 
these large investors are located in just a few loca-
tions primarily in the coastal states of the United 
States. They can be engaged in several ways, but 
the easiest is probably to invite them to investor 
meetings where companies from a certain region 
present their business plans. Since venture capital-
ists are very busy people, the more companies that 
attend these meetings, the better. Another strategy 
that is likely to be more successful is investing lo-
cal capital into the funds of a VC company and 
requiring that, in return, the company establish-
es a presence in the region. Once the company 
is established, it will be available to advise local 
companies. The company, however, would not be 
obligated to invest in local companies.
Finally, a local or national government may 
set aside a development fund and ask an external 
VC company to manage or co-mangage it. This 
system nurtures local venture-capital talent and 
brings venture capitalists with broad industry per-
spective to the region. This approach has several 
benefits and has a history of some success. It ad-
dresses the important issues of the global perspec-
tive necessary toward biotechnology and access to 
sufficient capital to fully fund a company through 
the various value-creating steps prior to an exit 
via IPO or acquisition. The large companies will 
have a network within the VC community, so 
they can syndicate the large follow-on investment 
required to complete the development of the 
company through an acquisition or IPO.  ■
roger e. WYse, Managing Director and General Partner, 
Burrill & Company, One Embarcadero Center, Suite 
2700, San Francisco, CA, 94111, U.S.A. roger@b-c.com

ABSTRACT
Intellectual Property (IP) can be commercialized via free 
distribution or licensing, or through new companies that 
develop and exploit it. These new companies are called 
spinouts, or start-ups. Establishing successful spinouts 
and start-ups requires a solid business plan, coordinated 
teams of professionals who share a common vision, a re-
spected managing director, and technology transfer inter-
mediaries. Intermediaries help bridge the cultural divide 
that often exists between the generators of intellectual 
property and the new companies.
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several ways for this intellectual property to be 
commercialized: it can be given away (either to a 
specific recipient or a more general audience via 
publication), licensed, developed, or exploited 
through a new company, so-called spinouts 
and start-ups. This chapter concentrates on 
the last option. It is important to remember, 
however, that spinouts and start-ups 
are not always the most appropriate IP 
commercialization option.
Inventors are usually creative, self-motivat-
ed, flexible individuals. However, the popular 
idea of the “mad scientist” who is oblivious to 
the surroundings and keeps going regardless of 
failure or discouragement is rather uncommon 
in real life. In fact, whether or not an inventor 
ever shows his or her invention to the outside 
world will depend on two variables: (1) whether 
or not he or she wants to disclose it and (2) 
whether the environment in which the inventor 
operates encourages or discourages disclosure.
Some factors, with respect to the inventor, 
encourage disclosure:
• passionate about the invention








What are the forces that encourage or discour-
age the commercialization of inventions? Part of 
the answer to this question can be found in the 
culture of IP-generating institutions and par-
ticularly the cultural barriers between academia 
and industry. Motivated technology transfer 
intermediaries can help overcome these barri-
ers to commercialization by mediating between 
inventors, developers, and marketers. The tactics 
behind such mediation efforts can be useful also 
for developing countries as they undertake tech-
nology transfer projects. 
2.		 ip	geneRATion	AnD	DiSCloSuRe
Individual inventors, commercial entities, 
academic institutions, and charitable foundations 
all produce commercializable IP. There are 
Cook T. 2007. The Role of Technology Transfer Intermediaries in Commercializing Intellectual Property through Spinouts and 
Start-ups. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A 
Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. T Cook. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncommercial 
purposes is permitted and encouraged.
The Role of Technology Transfer  
Intermediaries in Commercializing Intellectual  
Property through Spinouts and Start-ups
tim cooK, Director, Isis Innovation Ltd., U.K.
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Other factors, with respect to the inventor, 
discourage disclosure:
• not passionate about the invention
• not confident of the worth of the invention
• lacks self-confidence
• receives no encouragement to disclose
• resource poor
• lacks time to consider disclosure
• lacks financial support for disclosure
• no reward for disclosure is likely
Positive factors can sometimes compensate 
for negative ones. For example, if an inventor’s 
environment promotes creativity and is recep-
tive to invention disclosure, it will not matter 
as much if an inventor has less self-confidence 
or is less of a risk-taker. It is a well-established 
fact that the creation of a more-receptive en-
vironment often increases the number of com-
mercial ideas: this transformation occurred 
in the United Kingdom university system be-
tween the change of government in 1997 and 
the present.1 
This list of factors does not imply that those 
that favor disclosure should be pursued to an 
extreme. The best atmosphere for disclosure re-
quires a balance. If the environment becomes too 
receptive to invention disclosure, or if the inven-
tion process is overstimulated by generous gov-
ernment spending, a glut of noncommercializable 
inventions may be produced. Such inventions do 
little except consume resources that might have 
been better used elsewhere.
3. 	 new	CompAnieS
New companies—regardless of whether they 
are spinouts from universities or larger com-
panies, or stand-alone start-ups—are new! This 
means they have little momentum. Their man-
agement teams are still developing. The com-
panies themselves have no established market 
position, and they have the difficult job of 
convincing potential investors that they have 
a favorable future. Furthermore, they are usu-
ally understaffed and lack adequate resources. 
What this all means is that single-minded man-
agement direction and maximum efficiency are 
essential for such a company to even survive its 
first few years, let alone develop a strong posi-
tion in its field.
In most cases, commercial success is more 
likely if the inventor remains enthusiastically 
engaged with the project. The inventor does not 
need to be in charge of the process; indeed, inven-
tors are not usually the best people to implement 
commercial development plans. However, he or 
she should remain an active partner of the plan: 
not only can he or she prevent the repetition of 
unsuccessful experiments (“blind alleys”), but his 
or her creativity can be used to solve problems 
that may arise as commercialization proceeds.
The company employees need not be close 
friends, but they should respect each other. 
Choosing a respected managing director is espe-
cially important, since the director will implement 
the business plan. This plan must clearly and suc-
cinctly describe how the business will make mon-
ey: What is the company going to sell? Where is it 
going to get raw materials? Who is it going to sell 
the finished products to, and how? Implementing 
the answers to these questions will require both 
intelligence and leadership, which are obvious es-
sential traits for a managing director.
4.		BARRieRS	BeTween	ip	geneRAToRS	
AnD	new	CompAnieS
In the commercial world, research and 
development must follow a strict budget and 
schedule; if one element fails, the whole enterprise 
fails. However, inventors are usually less interested 
in the commercial ramifications of their work 
than the work itself. Furthermore, many inventors 
are academics. In academic research, changes of 
direction must be made almost daily: tomorrow’s 
experiment is decided by today’s results, and 
researchers are therefore extremely self-directed. 
Yet they are very willing to share their successes 
with their colleagues and competitors so that they 
can further advance their own research. Moreover, 
academic excellence is measured by the quantity 
and quality of publications; academia encourages 
the free exchange of ideas. Researchers in the 
private sector, on the other hand, will pursue 
experiments that are part of a larger corporate 
CHAPTER 13.4
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goal driven by market needs. While they may 
share their work with fellow researchers in 
the company, their efforts are usually kept 
secret from the general public because of the 
potential monetary value of the inventions the 
researchers generate.
Box 1 compares the forces that drive the 
two main types of research environment (aca-
demic and commercial). There are, of course, 
numerous counterexamples: some inventors in 
industry are publication driven and some aca-
demics are secretive. 
5. 	 BReAKing	Down	The	BARRieRS
To overcome the problems that may arise when in-
ventors must work with businesspeople, consider 
a parallel situation: two countries with different 
cultures and languages must work together on a 
joint plan. Obviously, the most effective method 
of helping the two countries interact with each 
other would be to hire bilingual intermediaries 
who have a deep understanding of both cultures 
and both vocabularies. Such intermediaries must: 
(1) understand the value systems of both cul-
tures; (2) be fluent in language of both cultures, 
so they can translate while retaining all linguistic 
nuances; and (3) be credible to members of both 
cultures (there may be a third “culture” involved: 
that of the financial investors).
Where do we find such intermediaries? How 
do we fit them into the overall process? And how 
do we motivate and reward them?
5.1 	Sources	of	competent	intermediaries
An industrialist can theoretically be taught how 
universities really work; an academic can theo-
retically be taught how industry works. Both 
methods have been tried (probably the latter 
more often than the former) with limited success. 
It is difficult for an individual who has spent all 
of his or her life in one environment to adapt to 
the culture of another. Experienced industrialists 
find it difficult to get over their belief that univer-
sities are “badly managed factories,” and senior 
academics find it difficult to adapt to industry’s 
need for discipline and conformity, which they 
see as “inflexibility.” Consequently, it makes sense 
to recruit intermediaries from the middle ranks of 
academia or industry, rather than from the top.
5.2	 	Where	competent	intermediaries	fit	
Intermediaries can be based in a university, its tech-
nology transfer company, in professional service 
companies (banks, accounting firms, law firms), 
or even in civil service. They may also be inves-
tors or employees of investors who are charged 
with generating investment opportunities (the 
author of this chapter was engaged in the latter 
from 1990 to 1997). Ultimately, of course, inter-




today’s result defines 
tomorrow’s experiment
unpredictable outcomes
relies on individual efforts
driven by market needs
tomorrow’s experiment  
is part of an overall plan
outcomes must be predictable
relies on cooperative activity
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effective. If the goal is to maximize the transfer of 
technology from a university, then it is sensible to 
locate the intermediary in that university, or in the 
university’s technology transfer company. 
5.3 	 	Motivating	intermediaries
Intermediaries can be rewarded based on their:
• financial success. They may be paid a per-
formance-related salary or be given a finan-
cial share in a successful deal.
• community-building success. Being part 
of a team engaged in a worthwhile activity 
is its own reward.
• civic or humanitarian contribution. 
Contributing to a national or local econo-
my is a satisfying accomplishment .
Of course, the most appropriate basis for re-
ward will vary from situation to situation; in some 
cases, it will not be appropriate to give any reward 
at all. There may be limitations on the kinds of 
rewards that can be given. An intermediary who 
is also a staff member in a university technology 
transfer office (TTO) may be forbidden from 
having any personal interest in technology trans-
fer agreements because of restrictions imposed by 
university statute or local or national law. 
An intermediary, however, who is em-
ployed by a technology transfer company that 
is owned by a university will not have any le-
gal restrictions on his or her personal financial 
interest in any technology transfer agreements. 
Still, any bonus that this kind of intermediary 
receives may negatively affect relationships with 
university colleagues. For example, at Oxford 
University, the technology transfer staff (who are 
not university staff members but are employed 
by a company owned by the university) work 
closely with members of the university admin-
istration on commercialization projects. If one 
such project were to produce a large financial 
gain for the technology transfer staff but not 
for the university employees, their relationship 
would be strained.
In addition, the success of one researcher 
might cause bad blood between the intermediary 
and her other clients. For example, each technol-
ogy transfer project manager in Oxford manages 
about 40 projects at a time: that is, each man-
ager supports at least 40 individual researchers 
(Figure 1). If one such project were very suc-
cessful, both the technology transfer manager 
and the researcher who generated the technol-
ogy would of course be pleased. However, the 
other researchers in the manager’s portfolio may 
feel that their own projects had not been given 
proper attention, and their relationships with 
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If intermediaries are employed by investors, 
rather than by a university or a university’s tech-
nology transfer company, it is quite appropriate 
for them to receive compensation for their efforts 
and to apply those efforts where they would be 
expected to be most lucrative. After all, the job of 
this kind of intermediary is to help the company 
or institution realize a profit, and the intermedi-
ary is under no obligation to support all research-
ers from a particular university.
An intermediary who is neither employed 
by a university nor by investors faces a some-
what murkier situation. In general, the closer to 
the public sector one works, the less appropriate 
are technology transfer deals motivated only by 
financial reasons. 
Probably the most powerful motivator for 
many intermediaries is not financial but intellec-
tual: the pride inherent in associating with cre-
ative scientists and collaborating in the creation 
of new products. It is profoundly rewarding to 
be the person who brings an invention, whether 
it is a drug or a software product, from a uni-
versity researcher’s desk to the market. Indeed, it 
is rewarding to employ one’s skills to bring to-
gether the academic, financial, and commercial 
communities and make something new happen. 
Of course, this sort of intangible motivation only 
works if the TTO pays its staff well, provides ex-
cellent working conditions, and recognizes that 
job satisfaction can be a powerful motivator. 
6. 	 impliCATionS	foR	
Developing	CounTRieS
The commercialization of intellectual property 
(IP) is a potential contributor to economic de-
velopment. In order to successfully commercial-
ize IP, a country must have a stable economic 
and institutional environment, sources of in-
vestment capital, sources of commercializable 
IP, a commercial environment that can accept 
intellectual property and commercialize it, and, 
as this chapter has suggested, competent tech-
nology transfer intermediaries. 
Technology transfer of any sort is only likely 
to succeed if there is sustained commitment at 
the most senior levels of both government and 
research institutions. In order for a developing 
country to create the right conditions, it must 
make certain commitments:
• general national framework conditions
• a strong commitment to education and 
training at both the elementary and sec-
ondary level
• a commitment to strengthen the condi-
tions that will allow major established firms 
to develop: the rule of law, labor-market 
flexibility, infrastructure, financial market 
efficiency, and management skills2
“Business angels” (that is, individual private 
investors), rather than venture-capital companies, 
are the initial source of funding for many U.K. 
university spinouts. They work with fledgling 
companies, contributing their skills, experience, 
and contact network. These angel investors have 
an edge over more traditional venture-capital 
companies because they are more flexible: they 
can offer smaller sums of capital and can make 
decisions more quickly, because they do not rely 
on the cumbersome analytical machinery of big 
investment houses. Once a new spinout is estab-
lished, it becomes more attractive to conventional 
investors, who want to see a complete manage-
ment team, a clear business plan, and, ideally, a 
good track record. 
In a developing country, business angels 
are less common, so new ventures must rely on 
international investor networks, in which re-
searchers in a developing country team up with 
researchers in industrialized countries in order 
to raise money. Such networks may be created 
through academic links or through personal 
or industry connections. When a new compa-
ny grows, it can become too large to depend 
on the financial resources of private investors; 
hopefully, by that time, it will be attractive to 
venture-capital companies.  ■
tim cooK, Director, Isis Innovation Ltd., Ewert House, 
Ewert Place, Summertown, Oxford, OX2 7SG, U.K.  
tim.cook@isis-innovation.oxford.ac.uk
1 See Wright M, M Binks, A Vohora and A Lockett. 2003. 
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Annual Survey of Commercialization of University 
Technology. UNICO/NUBS/AURIL, Nottingham.
2 Acs ZJ. 2004. Overview of the Global Entrepreneurship 
Monitor. 2004 Executive Report (Key Findings from 
the Global Entrepreneurship Monitor Report of 
2004). London Business School: London, U.K. www.
gemconsortium.org/download/1166438555062/overvi
ew%20of%20gem%202004.pdf. For the full report, visit 
www.gemconsortium.org/download.asp?fid=364. 
ABSTRACT
Universities are eagerly seeking ways to commercialize 
their innovations. The recent success of spinout com-
panies has made that commercialization option more 
popular, but commercialization may not be the most ef-
ficient approach for research institutions. The risks must 
be weighed, as well as the benefits, and this chapter offers 
an overview of the hidden costs of setting up a spinout. 
Exploring the necessary supporting conditions that can 
improve the potential for success, the chapter also consid-
ers start-ups and incubation centers as potentially better 
options.
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an Initial Public Offering (IPO) in a few years. 
To those concerned with economic development, 
the formation of new, successful, high-tech com-
panies is considered a route to local economic de-
velopment: it creates high-paying, high-tech jobs, 
as well as a number of other jobs (three for every 
one high-tech job1) supported by high-growth, 
new technology spinouts. Many countries have 
specifically tried to support this trend by form-
ing “business incubators” and science parks to 
create a supportive environment. This chapter 
will explore the advantages and disadvantages of 
bringing new technologies to market by creating 
new companies. The chapter also will explore the 
necessary supporting conditions that can improve 
the potential for success.
This chapter does not specifically address 
how to deliver direct public benefits to develop-
ing countries from technologies via spinouts.2 
Technology spinouts typically depend on ven-
ture capital, which is predicated on high rates 
of return through profit growth or through the 
growth of capital through increases in share price. 
A typical return expected by a venture capital 
investor is likely to be around 30% at exit, and 
such expectations leave little room to substitute 
social outcomes for profits and company growth. 
A profitable market is therefore key to obtaining 
the necessary venture funding in the first place. 
Such markets may exist in developing countries, 
CHAPTER 13.5
1.	 InTRoduCTIon
Since the late 1990s, a great deal of attention has 
been focused on how new companies can com-
mercialize technology from research institutions. 
This route is seen as an attractive alternative to the 
licensing of technology to an existing company. 
Even within large R&D-intensive firms, “corpo-
rate incubation” has become a trend. By forming 
new companies, large companies have begun try-
ing to generate value from technology that is not 
considered core to their existing business.
The attraction of new companies to the own-
ers of the technology and to those concerned with 
regional economic development is compelling. 
The venture capital boom of the late 1990s cre-
ated the impression that forming a new company 
was the route to rapid wealth for the founders be-
cause it enabled a company to go from spinout to 
Garner C and P Ternouth. 2007. New Companies to Commercialize IP: Should You Spinout or Start-up? In Intellectual Prop-
erty Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L 
Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
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PHILIP TERNOUTH, Associate Director, R&D and Knowledge Transfer, Council for Industry and Higher Education, U.K.
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and it is important for individuals in developing 
countries to assess how spinouts might help ad-
dress public health needs.
Perhaps more importantly, the creation of 
spinout companies has indirectly been a major 
economic driver, as new businesses and local jobs 
create public benefits. This trend of generating 
new companies from academic research began in 
the United States, partly because of the contri-
butions of universities to national defense during 
World War II. That experience of early spinouts 
emphasized the need for a strong commitment 
to partnerships and linkages among industry, 
academia, and government-research sectors. The 
value of university research in this respect was 
first recognized by Vannevar Bush, the science 
policy adviser to President Franklin D. Roosevelt 
in the 1940s.3 Bush saw it as a vehicle to enhance 
the economy by increasing the pool of knowledge 
that industry—supported by government—could 
use. Likewise, the story of Silicon Valley and its 
legendary spinout successes was enabled by the 
contributions of universities.4
Currently in the United States, there is a lot of 
spinout activity. In the financial year 2000, some 
500 new companies were formed to exploit the 
technology based on academic discoveries made 
in the 121 universities that responded to the 
Association of University Technology Managers 
(AUTM) survey. Notably, for 80% of these com-
panies, each was based in the university’s home 
state. The more than 600 licenses to these new 
companies accounted for 14% of the total num-
ber of licenses reported. An additional 50% of 
all licenses were to small companies (those with 
fewer than 500 employees). Similarly in the U.K., 
a recent report on U.K. universities showed that 
licensing income fell in recent years, possibly be-
cause public authorities have been pressing for 
the creation of more spinouts.5. In U.K. universi-
ties there are signs of a more-balanced approach 
developing. Still needed for successful inception 
and growth of spinouts are increased recognition 
of market conditions, internal and external sup-
port, and management and intelligent early-stage 
finance. This is reflected in a wider range of met-
rics being adopted by central government for as-
sessing knowledge transfer performance. 
2.	 new	CompAnIeS	AS	The	AppRopRIATe	
RouTe	To	mARkeT
Given the major worldwide interest in the forma-
tion of new companies to commercialize technol-
ogy, surprisingly little systematic work has been 
published on the circumstances conducive to 
their success.
A number of perspectives should be taken 
into account when deciding whether to form 
a new company to commercialize a piece of 
technology. However, there can be little doubt 
that from the perspective of successfully intro-
ducing a new product to the market, the new 
company route is higher risk than a traditional 
out-license to an existing company. In general, 
the circumstances that favor establishing a new 
company to develop products and take them 
to market are those in which the same “offer 
to market” cannot be made by licensing the 
technology to an existing company. Conversely, 
where such a licensing arrangement is available, 
a new company is unlikely either to generate 
the same value for the owners of the technology 
or to succeed in making the product as avail-
able as it would have been through a licensing 
arrangement.
In most circumstances, an existing company 
with the necessary infrastructure already in place 
(such as channels to market, facilities, commer-
cial management, sector knowledge, and an exist-
ing contacts network) is likely to be a lower risk. 
However, where the new technology is disruptive 
and/or where it is far from the market (as is the 
case for university research-based technologies), 
then creating a new company may be the only re-
alistic alternative. In addition, the political prior-
ity for new jobs and local economic development 
brings additional pressures and benefits from the 
new-company route.
Nonetheless, universities find it hard to 
build such companies from the ground up, es-
pecially when new markets have to be created. 
Marketing expertise needs to be in place to posi-
tion new product categories in crowded markets, 
and carrying out these tasks is costly. Moreover, 
figuring out how to meet the university’s social 
mission to deliver public sector benefits may be-
come critical in deciding whether or not to form 
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a new company. For example, making products 
available in developing countries may be one 
social consideration that universities could take 
into account when considering the route to mar-
ket. If this were the prime consideration, then 
establishing a new company would not be realis-
tic. Markets in the developing world are unlikely 
to be sufficiently robust to persuade investors to 
commit enough funds to support establishing a 
new company. When a potential market for the 
product and the licensing arrangement is un-
available, a new company may be the only avail-
able route to market. This could be because the 
market or product category is completely new. 
In this case, a qualified licensee (one with a bet-
ter package of expertise and infrastructure than 
could be developed with the required speed by 
a new company) might not exist. However, the 
costs for developing new markets or marketing 
new product categories are very high. Adequate 
resources have to be put in place, and the time-
to-market and to significant sales and revenues 
might be long. These factors need detailed analy-
sis so that initial funding needs can be calculated 
with a suitable break-even outlook and a realistic 
picture for investment returns. Such consider-
ations are rarely systematically assessed in a uni-
versity situation, because the institution’s wish to 
meet its political goals and the inventor’s wish 





For the purposes of this chapter, a start-up6 is a 
company created by people outside of a research 
institution. A start-up is built on a license for 
one or more technologies, but draws its other re-
sources (such as management) from elsewhere. In 
contrast, a spinout company is created when an 
institution invests its own resources to form and 
incubate the company up through the first round 
of venture capital investment. The creation of a 
spinout usually involves the transfer of existing 
university staff into the new company, either on 
a permanent or on a secondment basis. A special 
case of the start-up modality is that practiced by 
the partnerships between some universities in 
the U.K. and the IP Group7 in which resources 
are made available to universities under package 
agreements giving access rights to IP. We have 
yet to establish the extent to which such agree-
ments might have negative affects, for example on 
the university’s wider missions or their research 
agenda. 
Opting for a spinout may lead to the under-
exploitation of the economy’s intellectual assets 
and may be a drain on the experienced resources 
of a university. Research institutions are normally 
limited in terms of staff resources and capabilities 
that can be devoted to commercializing technolo-
gy. It follows that such institutions will be able to 
create fewer businesses using their own resources, 
particularly when compared to the number and 
the quality that they could deliver by attracting 
resources into the institution. Forming a start-up 
company by attracting new resources to the insti-
tution is likely to be more efficient, not only in 
terms of the use of scarce resources, but also in 
terms of the available experience that can be ap-
plied to developing and managing a commercial 
business and company in a limited timeframe.
3.1 Risks	and	rewards
From a university’s perspective, the choice may 
be based on balancing risk and reward. A uni-
versity setting up spinouts will retain a higher 
percentage of equity in new companies because 
the university builds the value in the company 
before seeking external investment. Using the 
start-up approach, the university will have had 
to cede founder’s equity to the incoming entre-
preneur; effectively, it will have merely adopted a 
license for equity role. On the other hand, when 
building a spinout in-house, the institution is 
using its fixed resources (people) and trading off 
their time for high equity stakes. In the 1990s, 
the markets might have indicated that this was 
indeed a good risk/reward balance. However, 
two issues should encourage universities and re-
search institutions to naturally prefer obtaining 
licenses to building spinouts. First, experience 
has shown that rather than the technology per 
se, the management of a new company is the 
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critical element for success. Spinouts formed 
with inexperienced management are more likely 
to fail, so start-ups are preferable when manag-
ers are inexperienced. Second, the high level of 
risk associated with high-growth–new-technolo-
gy businesses (where investors plan for nine out 
of ten to fail), suggests that universities would 
be more certain of a return from their commer-
cialization activities if they adopted a portfolio 
approach. Universities should ensure that as 
much technology as possible is made available 
for licensing—whether to established firms or 
to new companies built by external managers. 
Acquiring smaller equity shares in a larger num-
ber of companies would be a safer investment 
strategy than using high levels of fixed resources 
to create one or two major spinouts. Universities 
have fixed and limited resources to undertake 
technology transfer, and so from a conventional 
capital appraisal, it is difficult to see how spin-
outs can be justified when alternatives are avail-
able, either from an economic-good or a social-
good perspective.
3.2 Economic	and	social	return
The intensity and challenge of managing sev-
eral spinouts through to venture capital invest-
ment can be exciting and may also seem to offer 
greater control for the hosting institution. But 
given an institution with limited, fixed resources 
available for technology transfer, the achieve-
ment and eventual realization of value created 
by individual projects has to be set against the 
growing value of an expanding portfolio of un-
derexploited technology that would have ac-
cumulated while resources were focused on se-
lected projects. In fact, from the perspective of 
the economy and the lost opportunity for creat-
ing a social return from the use of the technol-
ogy, the contrast between the economic value 
and the social value is likely to be far greater. 
The value to the economy is measured by the 
number of jobs or the number of quality com-
panies created, not by the equity retained by the 
university. And the social return is a factor of 
the public benefit created (for example, making 
new health care products available and having 
used the available funds wisely and optimally). 
Focusing research institutions’ resources on 
managing their financial resources optimally is 
of even greater importance than the subsequent 
decision as to whether a limited number of spin-
outs is created or a potentially larger number of 
start-ups facilitated. The ultimate objective is to 
ensure that technologies have the best opportu-
nity to come to the market. Current pressures 
on research institutions to become the engines 
of economic growth in their local regions tend 
to emphasize the number of new companies 
created rather than the successful commercial-
ization of technologies. Too often, universities 
have confused objectives and a multiplicity of 
performance targets, all of which drive technol-
ogy transfer efforts toward inefficient commer-
cialization. Indeed, the policy of the institution 
needs to be clear on whether commercialization 





The creation of new companies from research 
institutions can benefit from a virtual company 
phase. This phase can last for a long time using 
the spinout approach from universities, and in-
deed there have often been companies, solely 
within universities, existing without clearly de-
fined boundaries. The virtual phase can be use-
ful in preparing the company for a stand-alone 
existence. In times of volatile venture-funding 
for specific technology sectors, the virtual phase 
may allow new technologies to be brought closer 
to market without the burdens of a formal legal 
existence. In the U.K., under certain economic-
development seed funding (for example, the 
Scottish Enterprise Proof of Concept Fund8), the 
virtual model is a condition of funding. However, 
companies must take on a separate existence in 
due course, and they are typically legal entities 
(corporations) in their own right established to 
conduct a business. Whatever way a business is 
conducted and whatever legal form it takes, some 
key aspects (given in Box 1) are essential for the 
business’s viability and success.
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Box	1:	Critical	Success	factors	for	new	Companies
Experience has shown that the following factors are critical to success or failure: 
technology.
A technology that provides a substantial but incremental improvement over an existing product 
category (as opposed to a platform technology) is most likely to be effectively licensed. Existing 
products have existing markets with existing channels and customers, and it is risky to compete 
with existing products. Companies will be in competition for the market, and those who are 
second or third, in terms of market share, will be eager to exploit innovations and take market 
share from the leader. Although in most cases the market leader is best positioned to turn a 
product/technology into maximal value, the leader might risk cannibalizing its existing market 
and try to keep a new product out. In such circumstances, any license to the market leader would 
best be supported with strong performance clauses (milestones). 
With regard to platform technologies (which enable a range of different products to be 
produced, possibly for different markets), forming a new company will frequently be the way to 
get the best value and ensure that the technology is fully exploited. This may or may not address 
the markets directly, depending on the marginal costs and benefits arising from the technology. 
Platform technologies are often attractive to investors, because the range of potential markets 
that can be developed offers a greater security of return if the initial intended application fails. 
Likewise, there is an implicit chance of greater returns than with a single product technology.
market Development. 
An existing market (defined as the sales of products of a particular type to a defined group of 
customers) is most likely to be served by entrenched competitors with existing customer loyalties 
and established distribution channels. The circumstances are likely to be similar to those in which 
the technology is an incremental improvement, which suggests that the best option will be close 
to the licensing end of the spectrum. Conversely, when a market is new, the licensing route may 
be unavailable or will have higher marginal costs for a prospective licensee. Accordingly, forming a 
new company may be a better option financially, provided that potential market demand exists.
Product, system, or component? 
If the intended product is a complete system, then it will be theoretically possible to form a 
start-up or spinout to take it to market, because the company may be capable of providing 
a solution to end users. If the intended product is a component of a larger system, then the 
product will need to be channeled via established companies in the field who will embed it in a 
complete system. 
management availability. 
Developing a technology relies heavily on capable management. This is one of the potential 
advantages of start-ups as opposed to spinouts. By marketing the technology well (presenting it 
in the context of its compelling benefits in product form), the technology assets can be used to 
leverage these management resources from the marketplace. Conversely, attracting management 
to a proposition proves difficult, this may be because the other requirements for forming a new 
company have not been met. Choosing a licensing route effectively co-opts the management of 
existing companies into a new product’s channel to market. 
(Continued	on	next	page)
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market concentration. 
A concentrated market has the majority of its value in a limited number of customers. A diffuse 
market has its value dispersed in a large number. It is easier to locate and access a limited 
number of large customers than to locate and sell to a large number of small ones. Exploiting an 
existing distribution channel via a distributorship arrangement may be the only economical way 
of addressing the latter, even if there is genuine new product or company potential. 
complexity of sales task. 
If the sales task is complex and the type of product is unknown to the customer and the benefits 
unproven—which it may well be for a new product concept—only perhaps the originators can 
describe the product’s features adequately and work with innovative customers to prove its 
utility. In such circumstances, the best option is to work with a capable marketer and adequate 
training mechanisms to enable the marketer to present the product correctly. 
availability of investment. 
For development that goes all the way from technology to market, investment may be unavailable 
for the complete project because of the high costs and risks involved. A licensing route or license 
to develop may be the only way that investment can be made available. If feasible, then the other 
factors that favor licensing are also likely present. The classic example is the drug development 
and marketing process, where the costs of clinical trials and regulatory processes may be over 
U.S.$100 million, and the attrition rate higher than 90%.
complexity of Delivery. 
If the delivery of a product or service is highly complex, the undertaking may require detailed 
knowledge of the technology underpinning the product and the services of a coordinated team. 
Such a situation, which is common, for example, in software development and in the installation 
of health technologies in their infancy, may argue for a more extended period of in-house 
development, at least in the early stages of market introduction.
Box	1	(continued)
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New companies intending to exploit bio-
technology are entering an environment that 
requires collaboration. There are many differ-
ent processes needed in a complex value-chain, 
running through target identification, com-
pound design or synthesis and screening, and 
drug development and market. A supporting 
infrastructure is needed that might include the 
production of animal models of disease, bioin-
formatics, gene sequencing, chemical synthesis, 
combinatorial chemistry, drug delivery, formu-
lation and manufacturing, clinical trials man-
agement, biostatistics, and managing regulatory 
approvals. 
The interdependencies of different skills and 
specializations mean that producing a start-up 
company to develop and market its own products 
is unlikely to succeed. Moreover, the global pace 
of scientific advance makes it hard to simply keep 
up-to-date with relevant discoveries. Interpreting 
their implications for existing projects or new 
opportunities is even harder. For example, the 
sequencing of the human genome has generated 
more potential disease targets than even the larg-
est pharmaceutical company can handle. These 
circumstances together make collaboration essen-
tial. Through collaboration, large companies can 
increase their project pipeline, and small compa-
nies can obtain the resources they need to develop 
their products.
The ability of research institutions to col-
laborate and access resources in other companies 
is a competitive capability in its own right, and 
it follows that new biotech companies should 
plan their strategy around developing this abil-
ity. Early in their development, companies 
should identify potential partners. This requires 
an openness and a readiness to work with other 
companies to identify potential collaborative 
projects. At the same time, a high degree of pro-
fessionalism is needed to protect commercial 
interests. This includes the protection of com-
mercially sensitive information and materials 
under Non-Disclosure and Materials Transfer 
Agreements, and, above all, the protection of 




There is a growing trend for new, technology-
based companies to be supported by incuba-
tors that are located often in close proximity to 
research institutes. No discussion or presenta-
tion on spinout or start-up companies would 
be complete, therefore, without some consid-
eration of business incubation and incuba-
tors. Some internationally renowned research 
institutes, such as the Massachusetts Institute 
of Technology (M.I.T.) and the University of 
Cambridge (U.K.), are surrounded by an en-
vironment that strongly supports the develop-
ment of new business. It provides a local pool of 
management talent, funding, professional sup-
port (such as patent agents and attorneys), and 
a cluster of existing companies that may act as 
potential collaborators. The importance of such 
an Innovation Ecology‚ has been documented in 
a recent publication9 detailing the case histories 
of some 30 companies in and around Oxford. 
Where this kind of environment does not exist, 
a more studied and deliberate approach may be 
made to provide the benefits of such an environ-
ment through specifically designed incubators.
Incubators provide to a new company a 
number of potentially valuable services that 
can enable management to focus on running 
their core business. The best incubators also 
provide access to a network of contacts whose 
expertise can be leveraged to develop the busi-
nesses. Government and other public sector 
agencies often see investing in incubators as 
key to stimulating knowledge-based economic 
development. In fact, incubation can provide 
the facilities, resources, and expertise that may 
be difficult to access during the early stages of 
a business. Such access may have a critical part to 
play in ensuring that the business achieves early 
commercial success. But incubators should 
not be seen as a long-term source of support 
for businesses that, perhaps because of a lack 
of market opportunity, are unlikely ever to be 
more than marginal.
The critical business-acceleration aids 
that an incubator can provide include a rapid 
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introduction to a network of individuals who 
may include those with relevant market and 
management experience. Some of these individ-
uals may be able to guide and mentor inexperi-
enced management either formally (perhaps as 
employees of, or consultants to, the incubators) 
or informally. Other individuals may include 
business people with customer contacts who 
might themselves assist in turning the technol-
ogy around to “face the market” and in shaping 
the business to achieve its first revenues. Just 
as important are contacts with potential early-
stage funders, especially those “added value” 
funders who can help by shaping the business, 
identifying and fulfilling its investment poten-
tial, and sourcing the potential members of a 
growing commercial team. These key func-
tions of the virtual incubator are well described 
in Networked Incubators: Hothouses of the New 
Economy.10 The best incubators also provide ac-
cess to a network of professional support ser-
vices (often provided pro bono), such as basic 
advice on patenting, incentive agreements for 
employees, and licensing agreements.
Incubators may also be formed to develop 
and accelerate business in specific market sec-
tors. In the case of biotechnology, for example, a 
key contribution is made by obtaining access to 
an international network of contacts, which in-
cludes potential research or product development 
collaborators in the complex drug-development 
value chain. These may provide useful regulatory 
advice and guidance. Additionally, they may in-
clude access to very high-cost capital equipment, 
such as scanning electron microscopes and nu-
clear magnetic resonance machines.
Incubators can also assist by providing basic 
business and office support facilities and services, 
such as accommodation, payroll management, 
bookkeeping, and high-bandwidth Internet ac-
cess. A lack of these facilities and services can 
steal attention from the management of a busi-
ness, especially since such matters may be unfa-
miliar to those with a predominantly technical 
background. 
Incubated companies will expect to pay low-
er-than-market rates for the services they receive 
from incubators, at least in the early stages of in-
cubation. These lower rates are made possible by 
one or more of the following:
• Achieving economies of scale by combin-
ing the otherwise uneconomic provision of 
professional and business support services 
for a number of smaller customer compa-
nies in the incubator
• Public (for example, local or regional gov-
ernment) subsidies made in anticipation of 
economic development
• Incremental occupation and service charg-
es that are lower at the outset and increase 
progressively as the company obtains com-
mercial success
• Paying for a proportion of the occupation 
and support charges in the form of equi-
ty (a key strategy in the case of for-profit 
incubators)
A number of successful incubators operate 
using the model described here, but many do no 
more than provide accommodation. These latter 
incubators have been severely criticized in the 
United States.
6.	 ConCluSIonS
There are many success stories about start-ups 
and their impact on the growth of local econo-
mies, such as in Silicon Valley, California, and 
Route 128 on the East Coast of the United 
States. This chapter, however, has pointed to 
the complexity of developing a successful start-
up enterprise. Choosing the route to market 
strategy for new technologies requires making 
a set of complex decisions that many universi-
ties and research institutions are not specifically 
equipped for. The conventional licensing route 
for technologies may not only involve lower risk 
for the institution, but may also deliver more 
technologies from the institution’s scientific re-
search. Universities and research institutions 
with the primary mission to deliver social and 
economic goods rather than investment returns 
should carefully consider how to achieve this 
mission most effectively. Establishing spinouts 
that disproportionately consume their in-house 
resources might not be the best approach. The 
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current pressure from governments to create new 
companies and new local jobs from university re-
search should not be accepted without the new 
resources to support this activity.
Once created, new companies face many chal-
lenges to achieving sustained growth and success-
fully delivering value to shareholders. Technology 
alone is rarely sufficient to reach this goal. Good 
management, awareness of market forces, and a 
good supporting environment in the early stages 
are all more important. Still, while failure rates 
are high, for those companies that succeed, the 
returns to the founders, the institutions, and the 
local economy can be significant. ■
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ABSTRACT
Business incubators, as economic tools, have become in-
creasingly common in the last decade and a half for stim-
ulating local development. Incubators provide facilities 
and services (for example, business planning and legal, 
accounting, and marketing support) to catalyze small-
business growth. In fact, incubated companies have a dra-
matically higher rate of survival than an average spinout 
does. This chapter explains what steps to take to set up an 
incubator, including the basic structure and the kinds of 
services generally offered. Successful incubator programs 
are discussed, and a helpful bibliography focused on case 
studies is provided.
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moving an invention into the marketplace. To 
succeed, three components must be assembled: 
capital, organization, and facilities. 
This chapter focuses on the last of these. It 
is intended to provide fundamental background 
information for use by the technology transfer 
practitioner and includes information on termi-
nology, incubator formation, and successful incu-
bator programs, as well as a helpful bibliography. 
2. inCuBAToRS
Smilor and Gill define an incubator as an organi-
zation that “seeks to give form and substance—that 
is, structure and credibility—to start-up or emerging 
ventures. Consequently, a new business incubator is a 
facility for the maintenance of controlled conditions 
to assist in the cultivation of new companies.”1  
Commonly classified by ownership and capi-
tal sourcing, there are three types of incubators: 
public, private, and university. Numerous sets of 
subclassifications of the latter two types exist, de-
pending on their status as for-profit or nonprofit 
entities. Other attributes of the business incu-
bator that distinguish it from other commercial 
enterprises include the range of services, the ease 
by which tenants can cancel their lease, and the 
CHAPTER 13.6
1. inTRoDuCTion
An invention sometimes requires the efforts of a 
spinout enterprise to be commercialized. Without 
a corporate infrastructure to execute an estab-
lished commercialization process, an institution, 
such as a university, may be reluctant to invest in 
the steps needed to move technology out of the 
laboratory. In contrast, a spinout may be more 
favorably positioned to embrace new technolo-
gies because of access to capital and grant monies. 
Philosophically, moreover, a spinout is generally 
more willing to accept risk than an established 
concern constrained, perhaps, by shareholder in-
terest. Forming a spinout is a critical option for 
Zablocki EM. 2007. Formation of a Business Incubator. In Intellectual Property Management in Health and Agricultural In-
novation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us 
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM 
Technology Transfer Practice Manual (Part IV: Chapter 3) co-authored with DE Massing. 
© 2007. EM Zablocki. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
Formation of a Business Incubator
eDWarD m. zaBlocKi, Office of the Vice President for Research, University at Buffalo, State University of New York, U.S.A.
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In the 1980s, small became big in economic de-
velopment circles. During this period, state and 
regional economic development strategies shifted 
from seeking to attract companies from elsewhere 
(industrial recruitment) to focusing on assistance 
for the homegrown entrepreneur. This shift in 
economic development strategy occurred for 
good reason. Seminal studies by David Birch at 
M.I.T.2 showed that almost all job growth in the 
U.S. economy was attributable to small compa-
nies. While the validity of Birch’s findings has re-
cently come into question, their impact on policy 
circles at the time is undeniable. Economic de-
velopment officials and policy planners sought to 
create jobs in their states and regions by fostering 
the growth of small companies. 
Small business incubators became a preferred 
vehicle for providing assistance to new compa-
nies. In the 1980s, incubators were referred to 
as the most potent economic development tool 
to be introduced in this decade. Only a handful 
of incubators were present at the beginning of 
the decade, but the National Business Incubator 
Association’s report in 1992 on the state of the 
incubation industry illustrates their dramatic 
growth.3 Of 147 respondents to the NBIA’s sur-
vey, only four had opened by 1980, with nearly 
two-thirds opening between 1988 and 1991. 
Today, there are more than 500 incubators. 
The incubator concept is simple and appeal-
ing. An incubator is a multitenant facility pro-
viding affordable space and an environment that 
promotes the growth of small companies. Initially, 
some incubators provided an inexpensive physi-
cal environment to spinouts in what had been 
old or vacant buildings. Later incubators con-
centrated on the companies themselves, helping 
them to grow by creating an entrepreneurial en-
vironment. A range of services was developed to 
assist the small company: shared support services, 
such as the availability of secretarial help, a re-
ceptionist, and access to copiers and professional 
services, including business planning and legal, 
accounting, and marketing support. Access to 
working capital was also arranged through provi-
sion of debt financing and equity financing, gov-
ernment grant/loan assistance, and connection to 
a financial network of angels, bankers, and ven-
ture capitalists. Today, however, most incubators 
prefer the company-centered approach, charging 
market rates for rent and offering services as the 
value-added benefit of locating in the incubator. 
Thus, incubators are probably best defined as pro-
grams rather than facilities.
Nonprofit entities operate almost 90% of 
incubators. Their purpose is to stimulate job 
growth in various sectors of the local economy. 
Some incubators, particularly those with ties to 
higher education, emphasize technology-based 
development. Communities that lack the critical 
infrastructure of technology-related business and 
research-intensive universities may direct incuba-
tors to serve developing companies in the manu-
facturing and service sectors. Incubators have also 
been used to encourage entrepreneurial activ-
ity among disadvantaged populations, including 
women and minorities. For example, the New 
Enterprises for Women Building in Greenville, 
Mississippi, targets assistance to low-income, mi-
nority women. 
These varied economic development purpos-
es are reflected in the 1991 NBIA survey, which 
found that the most important objectives of incu-
bators were economic development (91.3%) and 
economic diversification (60.9%), followed by 
research commercialization, technology transfer, 
women/minority opportunities, and neighbor-
hood revitalization, among others. The great va-
riety of the types of companies incubated further 
confirms the diversity of purpose in business in-
cubation. The most common company types are 
service (36%), light manufacturing (20%), tech-
nology products (15.9%), R&D (10.7%), and 
wholesaler/distributor (7.8%). 
Small business incubators have proven to 
be effective economic development tools, even 
though they may not have fulfilled early opti-
mistic expectations for job creation. Their great-
est benefit may be enhancing company survival 
rates. Incubated companies have a dramatically 
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higher rate of survival than the average spinout. 
Incubator managers report that somewhere be-
tween 80 and 90% of companies that have in-
cubated with them are still in existence after five 
years. This figure vividly contrasts with the Small 
Business Administration (SBA) statistic that finds 
that only 50% of start-ups survive their first five 
years. These figures are less surprising when one 
considers that nine of ten companies fail because 
of management deficiencies, and that 90% of 
these deficiencies could have been foreseen. Job 
creation statistics are more modest. The average 
incubator in the 1991 study was four years old 
and occupied a space of about 20,000 square 
feet in size. Each incubation facility averaged 
12 tenants with 54 employees. Graduate com-
panies (those that relocated from the incubator) 
provided an average of 85.3 full-time jobs per 
incubator. 
The establishment of new incubators peaked 
in 1987, and the new wave of economic devel-
opment initiatives in the1990s focused on help-
ing existing businesses survive and prosper in 
the face of global competition. Small business 
incubation is now an entrenched and accepted 
economic development tool used in both urban 
and rural areas throughout the United States. 
Incubators are now used to promote the growth 




Conducting a feasibility study for a proposed 
incubator can achieve a number of important 
objectives and, if properly done, can provide a 
solid basis for judging the economic and political 
viability of the proposed project. The feasibility 
study represents the first in a series of early devel-
opment phases that, for planning purposes, can 
be described as follows:
• feasibility: 3 months 
• development: 9 months 
• renovation: 3-12 months 
• early-stage operations (up to anticipated 
break-even point): 18 months 
Meeder4 suggests a number of reasons why 
conducting a feasibility study is wise. These 
include: 
• helps to forge a consensus among key orga-
nizations and civic leaders 
• catalyzes the involvement of organizations 
that can provide the incubator with a range 
of resources including facilities, funding, 
equipment, and human resources 
• allows for the completion of plans for 
both the facilities and the services to be 
provided 
• helps secure funding from government 
sources at all levels 
• educates  public and private sector con-
stituencies about business incubation in 
order to avoid confusion and unwarranted 
expectations 
• provides an occasion to contact successful 
incubator programs in similar communi-
ties to learn their best practice lessons 
A feasibility study should also reveal exam-
ples of critical errors made with respect to other 
incubator programs. Such errors might involve 
facility and site selection, structure of the gov-
erning board, funding arrangements, income 
assumptions, or the nature of the business assis-
tance program. 
Meeder suggests that a thorough feasibility 
study will help avoid the two classic errors of in-
cubator formation: accepting the worst building 
in town and thinking that the management as-
sistance program will somehow take care of itself. 
While recommending the use of a consultant, 
Meeder notes that selecting a consultant without 
direct incubator experience can result in a study 
that provides general analysis, but lacks concrete 
recommendations. Specific recommendations 
can make the difference in an incubator’s long-
term success. An adequate feasibility study will 
answer essential questions about how to proceed 
in a systematic fashion and how to secure fund-
ing during all the phases of incubator develop-
ment. Indeed, a thorough study by a qualified 
consultant can and should provide the informa-
tion necessary to determine whether the project 
should be pursued. 
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4.2	 Building	support	
A core group committed to starting a business 
incubator must recognize that its efforts cannot 
be pursued in a vacuum. The dream of a few 
must become the dream of many. An incubator 
represents an important community investment, 
both practically and symbolically, and requires 
broad-based community support to be feasible. 
In Forging the Incubator, Meeder suggests that 
meetings with community leaders can achieve 
several objectives. Community meetings allow 
proponents of the incubator to:
• provide information on the business incu-
bation industry 
• invite reaction to the prospects for a local 
business incubator 
• solicit referrals to people, companies, orga-
nizations, and facilities that can assist the 
process of feasibility and/or development
• offer the opportunity of direct participa-
tion, to seek specific leads to entrepreneur 
prospects, and/or gather information that 
had been overlooked
 
Engaging in this process should clarify the 
prospects for starting an incubator. The process 
should help to identify potential sites, funding 
sources, project champions from key organiza-
tions, and sources of assistance and support, 
both individual and organizational. The pro-
cess may, however, also uncover serious impedi-
ments to realizing the project. Meeder suggests 
that project supporters make serious efforts to 
placate opponents; indeed, project supporters 
should not assume that the project will be suc-
cessful in the face of persistent opposition. Real 
estate developers, for example, may resist the 
project because they believe an incubator will 
cut into their market. A persuasive argument, 
in this case, is that the incubator will only incu-
bate companies for a limited period of time and 
that the incubator should serve to increase both 
the quantity and quality of companies seeking 
to rent space. Community consensus building 
should help locate organizations that will iden-
tify with the successes and failures of the pro-
posed incubator. These organizations are known 
as stakeholders. 
4.3 Identifying	and	securing	stakeholders
A stakeholder is any group or individual who can 
affect or is affected by achievement of an orga-
nization’s objectives. While each incubator’s cir-
cumstances are unique, anticipated stakeholders 
would likely include local and state governments 
and a variety of public and private sector organiza-
tions (universities, major corporations) interested 
in fostering new-business development in the re-
gion. Stakeholders might also include economic 
development organizations that could fund the 
rehabilitation of a facility and/or the operation 
of the incubator program. The support of these 
stakeholders is critical to initiating an incubator 
program. At the same time, potential supporters 
of the incubator effort understandably have var-
ied motivations and expectations. Their level of 
understanding of the purposes and methods of 
business incubation will vary greatly. 
Stakeholders need to be identified and then 
cultivated. The first step is to secure commitment 
from potential stakeholders who have the stron-
gest interest and who are most likely to provide 
financial support for the endeavor. Once stake-
holders have committed to the project, the or-
ganizational structure needs to be formalized. A 
governing body, typically a board of directors, 
provides the organizational vehicle for maintain-
ing, building, and strengthening commitment to 
the incubator program. 
One of the board’s tasks is getting interested 
parties to agree to a clear articulation of the mis-
sion and goals of the incubator. This articulation 
of the incubator’s goals brings the stakeholders 
together with a common purpose. Experience has 
shown that incubators that fail to achieve consen-
sus on mission and goals invite trouble from their 
board, since members will create their own tacit 
mission statement and begin to act accordingly. 
Incubator managers should seek to expand 
the number of valid stakeholders. New stake-
holders should be welcomed as long as they have 
something tangible to contribute. On the other 
hand, allowing tenants to serve on the board can 
create conflicts of interest, so tenant participation 
on the board should be evaluated on a cost-ben-
efit basis. Additionally, incubator managers must 
remain sensitive to external conditions, which 
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may strengthen or weaken the commitment of 
stakeholders to the incubation enterprise. Finally, 
by-laws are crucial. They provide an objective 
means of removing nonparticipatory board mem-
bers and, at the other extreme, board members 
who are exerting undue influence. 
4.4 Identifying	a	market	niche	
A business incubator will operate in a particular 
locale with its own rich history, so it must act with 
an eye to the regional economy and institutions. 
To become an accepted part of this complex social 
fabric, an incubator must establish its distinctive-
ness and unique purpose. From a business per-
spective, the incubator needs to identify its mar-
ket niche. Successful businesses carefully attend to 
the work of defining the market position of their 
products and services relative to their competitors, 
as well as to modifying their market position in 
response to changing customer preferences. 
Developing a market niche for a business 
incubator requires similar attention to these 
tasks. An incubator’s competitors come from the 
spheres of real estate and economic development. 
Within the real estate market, the incubator 
must distinguish itself from other multiple-ten-
ant properties. For a technology-related incu-
bator, the distinction may be readily apparent, 
for example, in that incubator facilities may of-
fer wet and dry lab space. Incubators also differ 
from conventional real estate agents in that they 
often offer short-term leases and flex-space for a 
company’s expansion. Certainly, rent subsidiza-
tion can be attractive to cash-poor start-ups. The 
availability of shared support services is another 
appealing feature of incubator facilities, although 
provision of such services by for-profit organiza-
tions has become a growth industry.
Economic development programs for small 
businesses proliferated in the 1980s. These pro-
grams have been referred to as “incubators with-
out walls.” Well-managed incubators often distin-
guish themselves by serving as a focal point for 
access to the broad spectrum of available business 
services. Incubator managers thus provide the 
point of contact for entry into various programs. 
Many efforts to assist small business are, by con-
trast, programmatic in nature and limited by the 
scope of their intent. A well-positioned incubator, 
on the other hand, will help its tenants access the 
range of existing programs and, in addition, pro-
vide access to informal networks for business and 
financial advice and assistance. For example, a re-
tired executive may agree to help out a struggling 
firm or a business angel may appear, discretely 
looking for new investment opportunities. 
The incubator program may also delimit it-
self and define its market by the type of company 
or client served. While high-tech incubators may 
limit their scope of service to technology-focused 
companies, some incubators may be even more 
targeted (for example, restricting their services to 
biotech companies). The customer for the incu-
bator should be determined during the feasibility 
phase, during which new-business registrations, 
by industry type, are classified and certain indus-
try sectors identified for their spinout potential.
Whatever the mix of services offered and the 
assessment of the market to be served, the incu-
bator must somehow package its product to ef-
fectively position itself. 
5. The	foRmATion	pRoCeSS	
The basic structure of an incubator facility is de-
termined by owner attributes and regional demo-
graphics. The following owner/sponsor classifica-





• private nonprofit 
• federal government 
A typical organizational format includes ex-
ecutive and advisory boards, a CEO or opera-
tions manager, and support staff. Selections for 
board positions and other representative forums 
may come from the following: private enterprise, 
educational institutions, government, organized 
labor, development and investment community, 
and private citizens.
The role of the manager or chief executive of-
ficer of the incubator is both internal and exter-
nal. This person is chiefly responsible for:
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• incubator policy and planning
• marketing and recruitment
• tenant selection and lease negotiation
• facility operations management
• tenant service and administration 
The manager has multiple constituent 
groups representing both the sponsoring (fund-
ing) segments and the user (spinout) population. 
Appropriately selecting advisory board members 
allows the manager to establish and maintain net-
works for the dissemination of information and 
policy to these disparate groups. Table 1 provides 
typical staffing levels for incubators.
An important function is marketing the 
incubator, which will be driven, in part, by the 
results of the market analysis conducted during 
the feasibility study. The market analysis should 
consider the following major aspects of the local 
economy: 
• characteristics of large corporations in the 
area 
• level of entrepreneurial activity in the 
community 
• demand for incubator-type space 
• small-business support services by industry 
type, if feasible. 
Large corporations can supply an important 
market for new businesses and are also the chief 
sources of spinout companies in a region. The 
number, type, and rate of filing of new-business 
permits can provide important indicators of po-
tential demand for incubator space. An inventory 
of available space broken down by type (office, 
manufacturing, and so on) is essential for deter-
mining potential demand. 
Market information can also be secured by 
offering a workshop or seminar that highlights 
some of the proposed business-service compo-
nents of the incubator (for example, a workshop 
on developing an effective business plan or one 
on the accounting needs of small businesses). 
This information can provide the basis for a 
market strategy that is integrated into the overall 
incubator budget. 
Proactively gathering market information is 
recommended over a reactive mode, which does 
not typically serve to effectively market the incu-
bator. A reactive approach is tempting when an 
incubator manager is stretched thin with other 
responsibilities. However, a written marketing 
strategy allows other parties (board of directors, 
advisory board, related organizations) to assist. As 
Meeder6 points out, the most successful sales or-
ganizations have a standard sales script or routine 
with which everyone involved is familiar. 
The marketing effort should include typical 
means of communication, including brochures, 
newsletters, and press releases about new tenants, 
tenant successes, and graduations. One of the 




Median number of administrative staff 1.60 1.90 3.50
Median number of business consulting staff 1.40 2.10 2.10
Ratio of business consultants to firms 0.13 0.12 0.12
Managers with previous business experience 70% 67% 92%
Managers with business consulting duties 73% 67% 93%
Source: National Council for Urban Economic Development5
CHAPTER 13.6
 HANDBOOK OF BEST PRACTICES  | 1311 
to help develop these promotional materials. In 
addition, the incubator story may be included in 
the communications of sponsoring organizations. 
Other organizations may also be interested in co-
sponsoring seminars of interest to entrepreneurs. 
Such marketing efforts are necessary but not 
sufficient. Studies have shown that most entrepre-
neurs learn about the incubator through word of 
mouth. To market the incubator effectively, it is 
incumbent on the incubator manager to continue 
to develop and maintain a network of contacts 
in real estate, banking, patent law, business and 
economic development, both formally, through 
boards of directors and advisors, and informally, 
through professional organizations and business 
contacts. Individuals in an incubator’s local com-
munity are often the first to alert a nascent entre-
preneur of the benefits of locating in a small-busi-
ness incubator. 
6. SeRviCeS
As the incubator concept has evolved, the range 
of services offered by incubators has greatly ex-
panded. Early incubators provided access to a 
photocopier and a conference room, clerical sup-
port, and perhaps switchboard services. Today, 
incubators themselves provide, or provide access 
to, a broad spectrum of office, business consult-
ing, and professional services. The most common 
in-house and outside services offered are given in 
Table 2.
In recent years, incubators have greatly ex-
panded the variety of office services they provide. 
For example, the menu of office services offered 
by an incubator based in Pennsylvania in opera-
tion for three years includes:8 
• clerical services 
• switchboard services 




Office services 81 2
Business/strategic planning 65 32
External debt financing 59 7
Government grant/loan assistance 58 28
Training/educational programs 52 29
Financial management 51 36
Sales/marketing 51 37
External equity financing 47 27
Employment assistance 31 41
Lab equipment access 29 24
Bookkeeping 23 30
Government procurement 19 52
R&D/product development 19 43
International trade 14 52
Accounting or tax assistance 8 59
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• electronic mailbox 
• telephone equipment 
• FAX service 
• postal service 
• overnight courier service 
• notary services 
• photocopier 
• VCR/TV equipment 
• audio-visual equipment 
• conference room 
• printing services 
• furniture rental 
• laser printing/graphics 
• auto service discounts 
• sports ticket purchasing
Business consulting services may include 
business plan preparation, financial planning, 
advertising and marketing, strategic planning, 
technical and commercial communications, relo-
cation planning, capital development (equity and 
debt services), business taxes, employee relations, 
R&D, and government procurement. 
Professional services include legal/patent 
services, accounting, business development (in-
cluding sales/marketing), and technical/scientific 
support, among others. Professional services may 
be provided at special discounts to incubator ten-
ants. Some incubators arrange for new tenants to 
initially receive some professional services at no 
cost or at a deep discount. Given that entrepre-
neurs have no time to spare, professional service 
providers are often regularly available at an incu-
bator and make themselves available for support 
and consultation. 
In developing the spectrum of services for 
a new incubator, several options need to be ex-
plored. First, there is the essential question of 
which services will be offered. Next, incubator 
managers must consider which of these services 
will be offered in-house. This will depend on in-
ternal resources and the external availability of 
business services. The availability of qualified out-
side sources will depend on the success of forging 
informal alliances with a range of service provid-
ers in the public and private sectors. For those 
services offered in-house, the question of cost re-
covery will need to be addressed. Several services 
are typically included as a standard feature in a 
tenant’s rental agreement. These most commonly 
include janitorial service, management assistance, 
utilities, shared office services, and financing as-
sistance. Other services, such as clerical assistance, 
are charged back to the company on an at-cost or 
cost-plus basis. The quality, range, dependability, 
and accessibility of these services are the value-
added features that will provide the strongest lure 
for attracting entrepreneurs to an incubator. The 
incubator should solicit feedback from tenants to 
ascertain whether or not the services are effective-
ly meeting their needs and to determine whether 
additional services should be added. 
7. STRATegiC	plAnning
While the previous sections have addressed dis-
crete issues related to incubator formation, the 
need for strategic planning—and the integra-
tion of these various elements into a coher-
ent, multi-phased plan—should be apparent. 
Determinations about one aspect of the plan will 
affect other aspects. A rather obvious example is 
the effect that the facility’s net available square 
footage will have on rental income. More subtle 
considerations might include expectations for 
the facility’s long-term self-sufficiency. Managers 
should consider whether self-sufficiency can be 
achieved solely from rental income, through sub-
sidies from sponsoring organizations, or through 
grants.
Strategic planning compels incubator man-
agement to confront tough issues. How will the 
incubator continue to operate if revenue projec-
tions from rental income are not achieved? How 
will major facility repairs (for example, a ruptured 
boiler) be paid for? Addressing these worst-case 
scenarios through strategic planning can pro-
vide both a clear course of action if things go as 
planned and, if they do not, the necessary contin-
gency plans to navigate what may be a difficult 
beginning. 
Strategic planning usefully determines not 
only what will be done but when it should be 
done. The initiation of a new phase of the incu-
bator may or may not be made contingent upon 
the successful completion of an earlier phase. 
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Can the operation begin as an “incubator with-
out walls,” providing business services before the 
facility is ready for occupancy? At what point in 
the development process is the manager hired? 
The notion that timing is everything is certain-
ly true in strategic planning for an incubator 
spinout. 
8. CASe	STuDieS	
Detailed case studies in the literature are cited 
but not restated in this chapter since these studies 
are generally quite lengthy. Some of the incuba-
tors noted below are not in operation today, but 
the histories may still provide useful information. 
As a guide to the reader, these studies are classi-
fied in outline form to permit selection based on 
interest. 
The first set of examples is facility-based:9 
• university-related incubator:  Renssalaer 
Polytechnic Institute—The Advanced 
Technology Development Center 
• community-sponsored incubator: The 
Fulton-Carroll Center for Industry 
• corporate/franchise incubators: Control 
Data Corporation Business and Technology 
Centers 
• private incubator: The Rubicon Group
 
The second group is objective based:10
• promote economic diversification: St. Paul 
Small Business Incubator 
• provide a base for advanced technology 
development: Ohio University Innovation 
Center 
• opportunities for targeted populations: 
New Enterprises for Women Building 
(NEW Building) 
In sum, principal factors for successful incu-
bator strategies include: 
• Know the community and its strategic 
strengths and weaknesses. 
• Locate entrepreneurial opportunities. 
• Design (tenant) selection criteria to match 
goals and objectives. 
• Determine the space and service needs of 
tenants. 
• Locate the facility in a site that can be de-
veloped within the cost parameters of tar-
get companies. 
• Find opportunities to link up with exist-
ing sources of business and management 
services. 
• Recruit an entrepreneurial personality to 
manage the incubator. 
• Build an overall environment for 
entrepreneurship. 
9. ConCluSion
Incubators have been formed to serve entrepre-
neurs of every ilk; they have been established 
by a wide variety of sponsors. It is therefore not 
surprising that their missions, programs, and ob-
jectives have differed substantially. Nevertheless, 
over the past 15 years, examples of best practices 
have emerged. Some general factors critical to an 
incubator’s success include:11 
• on-site business expertise 
• access to financing and capitalization 
• in-kind financial support 
• community support 
• entrepreneurial networks 
• entrepreneurial education 
• perception of success 
• selection process for tenants 
• ties to a university 
• concise program milestones with clear poli-
cies and procedures 
Along a more practical vein, some of the spe-
cific practices known to affect the relative success 
of incubator operations include:12 
• Incubators with less than 30,000 square 
feet have generally been unable to reach fi-
nancial self-sufficiency. 
• Incubators without an articulated policy 
for collecting past-due rent have experi-
enced high levels of bad debt. 
• An incubator manager’s most effective 
use of time is to evenly balance attention 
to tenant services and facility upkeep. 
Initially, the demands of the facility will 
predominate. Subsequently, the manager 
should concentrate on achieving balance 
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by expanding time spent in the provision 
of services. 
• Terms and conditions of tenant leases 
are critical for protecting the incubator 
program. 
• The phone system is an essential link 
for companies and must be structured 
appropriately.
• The board of directors must be clear about 
its authority regarding management deci-
sions versus policy decisions. 
• The structure of service provision should 
include ways to increase effectiveness with-
in the budget. Methods include the use of 
third-party service providers and collecting 
fees for services. 
• Exit policies should encourage, but not 
mandate, tenant graduation. ■
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Freedom to operate (FTO) is—first and foremost—a 
strategic management tool. It is the synthesis of scientific, 
legal, and business expertise coupled with strategic plan-
ning. Strictly speaking, however, FTO is a legal concept. 
It is a legal opinion by patent counsel on whether the 
making, using, selling, or importing of a specified prod-
uct, in a given geographic market, at a given time, is free 
from the potential infringement of third-party intellec-
tual property (IP) or tangible property rights. As such, 
it is one type of input among many that managers use 
to make strategic risk-management decisions in relation 
to R&D and product launch. For academic and public 
research institutions, bringing products to market is often 
not a main goal. However, as a portion of their research 
moves downstream into product development, FTO 
becomes—or should become—an integral component 
of their endeavors. This is particularly relevant for prod-
uct-development partnerships (PDPs) in health and for 
various public–private partnerships (PPPs) in agriculture, 
as well as for the Consultative Group on International 
Agricultural Research (CGIAR) and national agricultural 
research systems (NARS), all of which are concerned 
about global access. 
Research exemptions exist in many jurisdictions, so 
most university research does not generally need to be 
concerned with FTO unless product development takes 
place. But PDPs, such as the Malaria Vaccine Initiative 
or the TB Alliance, are in a different category since their 
purpose is directly related to the distribution of products 
in the developing world. This chapter discusses three 
main categories of options that are available to reduce 
risk and obtain a manageable level of FTO. In practice, 
a combination of two or more options will often be pur-
sued concurrently. These are:
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• Legal/IP management strategies: license-in, cross-
license, oppose third-party patents, seek nonassert 
covenant, seek compulsory license
• R&D strategies: modify product, or invent 
around
• Business strategies: merge and/or acquire, wait and 
see, abandon project
Each option presents its own risks and opportunities. Any 
action—including the decision not to take action—car-
ries risk. Delaying the licensing of third-party intellectual 
property, for example, could lead eventually to expensive 
licensing terms, the inability to obtain a license, or the 
possibility of being sued for patent infringement. But 
for some organizations, such as those developing geneti-
cally modified crops, the reverse may be the case. For the 
public sector, the challenge will be to balance the various 
types of risks that each option presents. 
The chapter concludes by urging the public sector to 
judiciously evaluate whether and when FTO concerns 
should be considered, and to build in-house capacity to 
conduct patent searches and cursory FTO analysis (as op-
posed to legal opinions). This will lead to benefits like bet-
ter competitive intelligence and culture change in public 
sector organizations engaged in product development. An 
FTO strategy, therefore, is a plan that begins with research 
and evolves into an attitude throughout a product’s R&D 
and commercialization/distribution cycle.
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1. inTRoDuCTion:	fTo	AnD		
RiSK	mAnAgemenT
Successful freedom to operate (FTO) strate-
gies require forming partnerships, both within 
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institutions and with third parties. Although 
FTO is often narrowly considered as only a le-
gal issue, when approached from a more practical 
standpoint, FTO is a strategic risk-management 
tool; it relies on a synthesis of scientific and le-
gal expertise, business development, and strate-
gic planning. An FTO opinion is legal advice or 
input that managers use to make business deci-
sions based on a full range of criteria (business 
goals, competitors’ position, financial goals, and 
so forth).
FTO has two fundamental aspects. First, it is 
a legal concept: an FTO opinion, rendered by pat-
ent counsel, will advise senior management about 
whether the making, using, or selling of a specified 
product in a given geographic market would in-
fringe a third-party’s intellectual property (IP) or 
tangible property right. The legal opinion is based 
on a detailed analysis of the product or service 
under consideration, an analysis that primarily 
involves searching patents (though other forms of 
intellectual property, such as trademarks, will also 
be considered). The analysis also involves examin-
ing the claims of such patents, reviewing possible 
material transfer or contractual obligations, and 
providing a legal interpretation of the analysis. 
Second, FTO indicates the nature of the 
business constraints imposed on the institution, 
such as whether regulatory approvals have been 
granted or import or export licenses have been 
obtained. Third, the word freedom in freedom to 
operate does not imply absolute freedom from 
the risk of infringing another party’s intellectual 
property. It is a relative assessment based on the 
analysis and knowledge of IP landscapes for a 
given product, in a given jurisdiction, at a given 
point in time. This point underscores a critically 
important concept: there is no such thing as a 
risk-free decision. Whether an organization de-
cides to perform an FTO or not, both options 
carry an element of risk. Not making a decision is 
itself a decision. 
This chapter focuses on legal, research, and 
business strategies for resolving the legal as-
pects of patent infringement—in other words, 
on strategies for minimizing IP constraints. 
Companies deal with these challenges routine-
ly. Early or cursory FTO reviews1 are typically 
conducted during the conceptualization of re-
search projects to indicate early on how to reduce 
IP/licensing constraints that may emerge further 
down the road. This makes it possible for a com-
pany to decide in advance which components, 
technologies, and processes are best incorporated 
into the product under development. Certain 
R&D projects may even be stopped fairly early—
or may never be pursued—when the FTO situa-
tion seems too uncertain or too costly to resolve. 
Hence, with any FTO strategy there will be other 
business-related considerations, including market 
potential, geographic location, short- and long-
term business opportunities, and the positions of 
competitors.
One of the big questions the public sector 
has struggled with is whether, when, and how to 
concern itself with FTO. University researchers 
generally do not need to be concerned with com-
mercial FTO unless they are engaged in research 
that aims specifically at product development. 
This kind of engagement is becoming more preva-
lent in the public sector, not least through collab-
orations with product-development partnerships 
(PDPs), where the primary reason for funding the 
research is the development of products to help 
the poor. Such is the case for the research cen-
ters of the Consultative Group on International 
Agricultural Research (CGIAR) and for many 
national agricultural research systems (NARS). 
Universities, too, are shifting their research focus; 
some manage their innovations in novel ways. For 
example, Arizona Technology Enterprises LLC, 
the technology commercialization arm of Arizona 
State University (ASU), in-licenses (or assembles) 
IP to establish core technology platforms around 
ASU inventions, and then licenses the bundled 
IP as solutions, offering quicker market access 
and greater commercialization opportunities.2
These trends within the public sector require 
the building of various types of partnerships. 
Indeed, the very process of seeking and obtain-
ing FTO, which requires myriad licenses and 
other forms of institutional arrangements, leads 
to partnership building. But partnerships carry 
risks—as does acting independently. Risk can-
not be avoided completely. Instead, researchers 
and administrators must be aware of the different 
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types of risks and ask themselves how they can 
best be balanced. 
2. fTo:	fRom	AnAlySiS	To	STRATegy
The approach to FTO follows a logical sequence 
(Figure 1). It begins with an FTO analysis, which 
is an investigation whereby the planned or exist-
ing product is dissected into its component parts. 
For each of these, a search is conducted for any 
intellectual and tangible property rights. The re-
sults of such an analysis allow patent counsel to 
provide an FTO opinion that discusses the likeli-
hood that the product or process infringes identi-
fied IP rights or tangible property rights of others. 
The resulting FTO status becomes the baseline 
for formulating an FTO strategy, which then al-
lows management to weigh different risks and 
make informed business decisions.
An FTO opinion usually divides third-party 
intellectual property into three classes (lawyers 
may not use the terminology used here):
1. Patents that have a high likelihood of being 
infringed and therefore require a license
2. Patents that may be infringed, depending 
on how claims are interpreted 
3. Patents that are clearly outside the field of 
the product and require no license
Unfortunately, many patents will not have 
a clear status that would place them squarely in 
category 1 or 3. Many will instead fall into the 
more uncertain category 2. The classification is 
based in part on the analysis of the meaning and 
scope of the patent claims, the detailed portion of 
the patent text that specifically defines what the 
invention is and lays out a conceptual boundary 
or property line around the patented invention. 
Legal protection is awarded only to what is cap-
tured in the claims; anything outside the claims is 
open to the public. 
Patent claims are analogous to the “metes and 
bounds” described in real estate deeds. As with a 
deed for land, claims delineate the limits (the di-
mensions and borders) of the invention. However, 
as distinguished from the tangible property rights 
to a deeded piece of real estate, patents deal with 
intangible property rights. Finding the precise 
limits of IP rights is thus not a quantitative activi-
ty; it is, therefore, open to interpretation, because 
one cannot see or touch the actual property in a 
patent (it is “intellectual,” or of the mind). The 
boundaries can only be described with words, yet 
the meanings of words are not precise. They are 
always open to interpretation, especially given 
their context.3 For these reasons, it is useful to 
further subdivide category 2 patents into subsets 
defined by the possible outcome of legal action:
2(a). It could be argued with some level of 
certainty that, if defendant were taken to 
court by plaintiff, defendant would prob-
ably lose a patent infringement lawsuit. 
2(b). It could be argued with some level of 
certainty that, if defendant were taken to 
court by plaintiff, defendant would prob-
ably win a patent infringement lawsuit. 
Counsel can advise senior management about 
the number of patents that fall into each of these 
categories—1, 2(a), 2(b), and 3—and about the 
institutions that would have to be contacted to 
form a partnership or licensing deal. But counsel 
would not be able to tell which options made the 
most sense from an R&D, institutional, and busi-
ness perspective. From a purely legal perspective, 
obtaining licenses for all the patents that fall into 
category 1 and 2 would minimize risk. Lawyers will 
tend, therefore, to identify licensing as the lowest 
risk option. To what extent this makes business, 
financial, and strategic sense, however, requires 
considering other options explained below. 
3. when	To	SeeK	fTo
For companies, FTO has to be considered very 
early in the product-development process. Once 
millions of dollars have been invested in the re-
search, development, regulatory compliance/ap-
proval, formulation, and manufacture of a prod-
uct, it would be difficult to obtain beneficial 
licensing terms from third parties. The more re-
sources invested, the more difficult the bargaining 
position, though other factors may be equally im-
portant. For example, a company that has good 
marketing networks already in place might find it 
easier to negotiate licenses.
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In practice, performing a detailed FTO analy-
sis on every product or process early in the pipeline 
would be impractical and prohibitively expensive. 
Therefore, even the early decision on whether or not 
to commit resources to perform an FTO analysis 
for a given project or product candidate must itself 
be based on a preliminary, or cursory, assessment. 
Such a preliminary assessment can help determine 
when to perform a more-detailed FTO analysis and 
at what level of sophistication and depth. 
For public sector entities, the same principles 
usually apply to FTO but with important differ-
ences. For universities the organization’s primary 
mission or focus is research, teaching, and shar-
ing knowledge. The freedom to engage in these 
endeavors derives from the norms of academic 
freedom and, in some countries, is codified as aca-
demic research and fair-use exemptions under IP 
law. Downstream business development consider-
ations are often a secondary or derivative focus. 
figure	1:	fTo	Strategy	in	Context
Source: SP Kowalski, personal communication.
fTo	Analysis
An FTO analysis is a focused and intense investigation, performed by meticulously 
dissecting a biotechnological product or process into its fundamental components and 
then scrutinizing each for any attached, unlicensed intellectual property (such as patents, 
plant variety protection, or trade secrets) and tangible property of third parties. 
fTo	opinion
Based on the results of the FTO analysis, patent counsel will draft an FTO opinion that 
indicates the likelihood that the biotechnological product or process infringes the IP rights 
or tangible property rights of others. The likelihood of such infringement might be either 
low or high, depending on the results of the FTO analysis.
fTo	Strategy	
The FTO status establishes a baseline for formulating a strategy for product development. 
This involves business and legal considerations to balance potential risks with anticipated 
benefits. The FTO strategy considers all options and then decides on the approach that best 
fits the mission of the organization and its tolerance for risk. 
fTo	Status
The FTO opinion will inform, with respect to the overall status of FTO for a given product—
depending on the time and place—the level of potential risk associated with contemplated 
R&D and/or commercialization activities. Such risks vary; hence, FTO status is relative.
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This is why university technology transfer offices 
typically license inventions (patents) and, in some 
cases, trademarks and plant varieties, but do not 
develop and sell finished products. However, for 
PDPs and many nonprofit organizations, product 
distribution and access often are their main pur-
pose, even if they may not be the party that will 
actually produce and distribute the products. Their 
missions focus on the development of products for 
the marketplace (whether considered nonprofit or 
for humanitarian purposes). The main questions, 
therefore, are simply when to initiate the exami-
nation of FTO and when to begin the process of 
assembling the necessary intellectual property.
Should the assembly4 of intellectual property 
be done early or late in the product-development 
process? Timing the licensing of third-party in-
tellectual property is an important strategic deci-
sion, and like any decision carries certain risks. 
By deciding to delay, an institution accepts the 
following possibilities:
• that higher licensing terms will be extract-
ed (Once an institution invested years and 
millions of dollars into R&D, its bargain-
ing power is often reduced.)
• that no license will be obtained
• that a lawsuit will be filed for patent 
infringement
Conversely, by seeking to in-license early on, 
an institution accepts other risks. In agricultural 
biotechnology, for example, one of the biggest 
obstacles for public sector institutions in obtain-
ing IP licenses from companies is their lack of 
trust and confidence in the public sector’s abil-
ity to produce a high-quality product and to 
be a responsible steward of the technology and 
product. Few public sector entities have expe-
rience in developing biotechnology products. 
Understandably, companies may therefore be 
reluctant to grant licenses—especially those for 
humanitarian purposes—to entities that have 
not demonstrated credible product-development 
plans and that lack the requisite resources for 
product stewardship throughout the product’s 
life span. Public sector entities may therefore 
find it easier to obtain licenses on preferential 
terms once they have demonstrated a product’s 
quality and their overall institutional capacities, 
especially their capacity in IP management, reg-
ulatory management, and high-quality produc-
tions. Demonstrated capability generates confi-
dence and trust, which translates into a greater 
willingness by companies to provide licenses and 
to enter into partnerships. This is one reason for 
the creation of AATF: the stewardship of agricul-
tural applications.5
In sum, there is no textbook strategy. Each 
case must be reviewed and evaluated, and the best 
strategy—or strategies—will depend on many 
factors, including:
• the mission of the organization
• the range of existing partnerships
• the ease with which the organization inter-
faces with companies
• the type of product under consideration 
• the degree of overlap between public and 




Companies determine their overall FTO strate-
gies, generally speaking, through a combination 
of decisions by boards, senior executives, business 
managers, marketing executives, R&D managers, 
and legal counsel. Although this chapter has so 
far stated that most IP issues related to FTO are 
about deal making, in-licensing, and partnership 
building, such deals are the results of choosing 
from among a combination of ten main options 
(Table 1). 
To be sure, not all of the options apply 
equally well to public sector research institutions. 
Bringing products to market is not their major 
concern, but to the extent that their research is 
used downstream, such as in collaboration with 
the private sector, FTO is becoming more inte-
gral to their endeavors.
4.1 Legal/IP	Management	Strategies
4.1.1  License-in
All FTO issues can be resolved by acquiring (in-
dividually or through consortia) a commercial 
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Table	1:	The	Ten	Strategic	fTo	options
option pros Cons key	challenge	for		the	public	sector
1.	 legal/ip	management	Strategies
License-in Is relatively 
straightforward
May not foster in-house 
R&D initiatives and may 
be costly
Determining the right time to 
initiate licensing discussions/
negotiations
Cross-license Involves give and 
take
In certain cases, antitrust 
issues may arise




Can be cost 
effective
Can be expensive 
and result might be 
undesirable (stronger 
and/or broader patent)
Policies of public sector rarely 





Is cheap and 
effective
Rarely allows for the 
in-licensing of valuable 
know-how 
Might require lobbying by 









Will not allow for 
the in-licensing of 
know-how and brings 
many constraints and 
complexities with it
Many conditions need to 
be fulfilled for compulsory 




Can be fairly 
simple if planned 
early in R&D 
stage
May not be possible due 
to lack of readily available 
alternatives; incurs 
opportunity costs
Requires early FTO review and 
business-driven R&D strategy
Invent around Could lead to 
cross-licensing 
position
Could lead to delays 
in product launch and 
might be costly; incurs 
opportunity costs
IP/licensing department 
would need to drive, or at 
least influence, researchers 
and the direction of research
3.	 Business	Strategies
Wait and see Gives time 
for strategic 
positioning






Is simple and 
effective
May be costly (need 
to write off R&D 
investments already 
made, incurs opportunity 
costs)
Difficult to determine when, 
how, and by whom such a 
decision is made (unless the 








A	combination	of	several	options	implemented	concurrently Requires strategic mindset
Source: A Krattiger
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license from the certified owners/assignees for 
each IP right that the product under study is like-
ly to infringe. Negotiating a license is the most 
common option and perhaps the most logical. 
It may be broad—a grant to make, have made, 
use, have used, import, export, offer to see, sell, 
or have sold all products and product parts and 
all related products and processes—or it may be 
more restrictive. 
Licenses are agreed to every day, and in many 
circumstances entering into licensing agreements 
is almost a mechanical matter.6 However, we hear 
of special cases when licenses have been difficult 
to obtain, when licenses were refused, or even 
when license disputes have ended up in court. 
Considering the number of licenses executed each 
year, these special cases are rare, but they seem to 
receive an inordinate amount of attention. The 
main question is not whether to license, but when 
to initiate licensing discussions/negotiations (or 
when and how to pursue other options discussed 
here). But, to reemphasize, licensing is just one of 
many options.
4.1.2		 Cross-license
Cross-licensing occurs when two IP holders li-
cense intellectual property to each other: “A” li-
censes a set of patents to “B,” and in exchange 
B licenses a set of patents to A. This approach 
is often adopted when one entity holds a patent 
on an invention and another has an improve-
ment on it. For example, assume that A holds 
the rights to a promoter that is only effective in 
cereal species. B, however, has modified the gene 
so that it is now also useful for dicotyledonous 
species (which are non-cereal species). A can 
continue to practice its invention on cereals but 
could not use it in beans (since they are dicoty-
ledonous species). Yet B cannot use its improve-
ment in beans because it would require a license 
from A. Cross-licensing inventions in this case 
allows both A and B to both apply their inven-
tions in beans.
Some companies have entire teams of re-
searchers conducting research to place the com-
pany in a stronger cross-licensing position with 
certain competitors. Due to costs, public sector 
institutions are probably not in a position to do 
this; nonetheless, cross-licensing should not be 
dismissed outright.
4.1.3  Oppose	third-party	patents
It is generally presumed that, after issuance, a 
patent is valid. But patents can be challenged. 
Essentially, there are three components to pat-
ent validity under U.S. law: novelty, utility, and 
nonobviousness. A successful challenge on any 
of these grounds will annul a patent claim, and 
sometimes the entire patent. A patent claim can 
also be declared invalid if it can be shown that the 
written description requirement was inadequate. 
When considering litigation, two certainties must 
be kept in mind: the cost of litigation is high, and 
the outcome is uncertain. Furthermore, prepara-
tion for a patent-invalidity challenge will involve 
research and analysis that is comparable to, if not 
greater than, that involved in an FTO analysis. 
Cost must be carefully considered when thinking 
about this option. Other possible drawbacks are 
that the assignee/inventor comes back with ad-
ditional claims (as happened with the Enola bean 
case at first).7 
4.1.4  Seek	nonassertion	covenant
Many companies are, in principle, willing to li-
cense their valuable intellectual property for de-
veloping country and humanitarian uses. But 
quite naturally, they are reluctant to take on risks 
for activities that do not generate cash flow or 
profits. One way for them to manage some of the 
risks is through nonassert covenants, or nonassert 
agreements, through which an IP rights holder 
essentially assures the IP rights user that it will 
not enforce the IP right. These are fairly simple 
agreements to execute and may be in the form 
of public statements or bilateral or multilateral 
agreements.8
In this new era of “humanitarian” licensing, 
the international community is struggling to de-
velop and distribute new products and to extend 
the benefits of those the developed world already 
enjoys. Dealing with all of the FTO issues, how-
ever, can be daunting. Just obtaining licenses 
can be complex, time consuming, or impossible. 
Companies may be reluctant to license due to lia-
bility issues. This is especially so with agricultural 
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biotechnology applications (partly brought about 
by the Cartagena Protocol’s ongoing internation-
al negotiations on liability and redress) and with 
vaccine technology. Fortunately, many of these 
complexities can be circumvented with a simple 
nonassert covenant. 
4.1.5  Seek	compulsory	license
Most countries have provisions for the issuing 
of compulsory licenses to national producers in 
national emergencies, provided that certain con-
ditions are met according to the Agreement on 
Trade-Related Aspects of Intellectual Property 
Rights (TRIPS). The country must have the 
manufacturing capacity to produce the patented 
invention and must also have attempted to nego-
tiate a license in good faith (although the World 
Trade Organization’s Council recently instituted 
a waiver to the original TRIPS Agreement that 
allows developing countries without manufactur-
ing capabilities to import patented drugs from 
sources other than the originator company). 
Compulsory licensing has to be initiated by gov-
ernments for public non-commercial uses and 
may take one or more years to complete: it is a 
complex process and requires significant govern-
ment resources and experience.9
Production under compulsory licenses pres-
ents several operational challenges. Patent holders 
are unlikely to license and transfer their know-how 
under compulsory licenses, so companies in devel-
oping countries will need to develop know-how 
internally. Exports, moreover, may only be made 
to certain countries under specific conditions, 
which limits economies of scale and potentially 
increases production costs significantly. But com-
pulsory licensing can also be a beneficial tool (for 
example, as a negotiation strategy). Furthermore, 
international IP standards mandated by TRIPS 
already allow member nations considerable dis-
cretion to enact laws and provisions that not only 
meet treaty obligations, but also support national 
innovation policies, development priorities, and 
cultural values. This includes voluntary pricing 
and licensing arrangements. Other options pri-
marily relate to national policies and laws be-
yond the purview of this chapter (for example, 
permitting and regulating the government use of 
patented inventions, taking actions through pat-
ent courts to protect public interests, and the ju-
dicious framing of competition law and policy). 
Importantly, when compulsory licenses are issued, 
the licensor has no obligation to transfer know-
how/trade secrets or any safety, efficacy, or clini-
cal data. In other words, the compulsory license 
may be limited to the information disclosed in a 
patent specification, which frequently represents 
only an invention’s early best mode. It will not 
include subsequently developed and/or ancillary 
technical know-how or related show-how.
Given the range of necessary licenses and the 
time required to issue a compulsory license, this 
option might not permit a developing country 
to quickly develop a product. That especially ap-
plies to licensing vaccines, for which know-how 
is a major component of the intellectual property. 
Moreover, even raising the possibility of compul-
sory licensing would significantly deter future 
investments. A “false alarm scenario,” in which 
a national emergency is proclaimed to justify 
compulsory licensing when the conditions may 
not fully warrant such a proclamation, might 
be a harmful approach, since such compulsory 
licensing could act as disincentive for future in-
vestments. Granted, the threat of a compulsory 
license can prompt an early licensing agreement, 
but seeking a commercial license early is probably 
more effective in most circumstances. 
4.2 R&D	Strategies
4.2.1  Modify	product
An alternative to licensing is to change the prod-
uct specifications. In agriculture, for example, in-
stead of using a certain (patented) promoter that 
would require a license, the vector design would 
include a different type of promoter unencum-
bered with intellectual property. 
Such a strategy will succeed only if (1) there 
are alternatives in the public domain that would 
work at least as well as the encumbered promoter 
and (2) an FTO analysis is performed relatively 
early during the R&D stage (preemptive FTO 
analysis). Otherwise, many years of work would 
be lost, and a license might suddenly seem quite 
appealing, if not necessary, in order to gain FTO. 
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A license may also come with regulatory know-
how/trade secrets, data, and trademarks. Of 
course, it is critical that this approach include 
analyses of any viable alternatives so that their 
likelihoods of FTO can also be assessed. One 
does not want to exchange a sick pony for an even 
sicker burro!
4.2.2 Invent	around
Choosing the invent-around option would re-
quire a research team to search for alternative 
ways to develop the product in question. Taking 
again the example of a promoter, the team would 
seek to isolate a new, unknown promoter and 
concurrently seek patent protection. This option 
would delay product development but could lead 
to significant benefits in terms of new inventions, 
new intellectual property for cross-licensing, and 
perhaps even better products. The main down-
side is that costs would be high, so in many cases 
the option might not be feasible for public sector 
organizations. The costs of licensing versus the 
costs of an all-out development of a new product 
should be weighed using a risk/benefit analysis. 
Given the frequent open-ended cost structure of 
research and development, licensing might be 
more feasible. In industry, inventing around is 




The simplest option is to commercialize the 
product under question and wait to see if the IP 
holder contacts you for a license. If and when 
that happens, it would still be possible, perhaps, 
to come to a licensing arrangement (discussed in 
Section 4.1.1). Alternatively, the option of op-
posing a third-party patent (discussed in Section 
4.1.3) could be pursued as a form of defense. In 
addition, a cross-license (discussed in Section 
4.1.2) might be offered in return. However, in 
the United States, the potential downside is that 
if it can be proven that the infringer willfully in-
fringed the particular IP rights of the other party, 
then a court may assess damages as high as three 
times the IP owner’s lost revenue. In exceptional 
cases, the court may also award reasonable attor-
ney fees to the prevailing party (that is, the owner 
of the IP rights). 
4.3.2 Abandon	project
If all else fails, a project may simply have to be 
abandoned, freeing investments for safer and 
less-risky ventures. Naturally, the best time to 
decide to abandon a project is before initiating 
any research and development. For this reason, 
companies typically hold regular project/product 
planning meetings that include scientists, busi-
ness-development managers, and legal counsel.
Public sector institutions often find it diffi-
cult to abandon projects since promises to donors 
have often been made for several years. Scientists 
in the public sector also often have a lot of auton-
omy compared to their corporate counterparts. 
That is why a donor’s IP policy is so important 
for determining when, how, and by whom such 
a decision is made (unless the financial donor has 
a clear IP policy).10 The requirement of the Bill 
and Melinda Gates Foundation (as well as other 
donors) for a global access strategy is particularly 
welcome and important in this context.
4.3.3 Merge	and/or	acquire
Any company, regardless of its size, may acquire, 
through mergers and acquisitions, a number of 
smaller companies, just to expand its IP portfo-
lio. Although not a feasible option for academic 
institutions, in the private sector this practice is 
an important step in obtaining FTO.
Nonprofit PDPs and other nongovernmental 
organizations (NGOs), moreover, might gain by 
considering mergers, perhaps not so much as a 
strategy to obtain FTO, but as a way to increase 
the potential for innovation. For example, in the 
1990s, when the world around the centers of the 
CGIAR became more complex, with many more 
actors and spheres of influence, rather than re-
group and focus, the CGIAR expanded (with a 
constant or reduced budget in nominal terms) 
and has since become an increasingly diffuse 
entity. This is particularly problematic because 
the work of this group is conceivably more im-
portant than ever from strategic and humanitar-
ian points of view. Paradoxically, over the same 
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period, the private sector undertook mergers and 
acquisitions, reducing the number of key players 
from more than 20 to a mere five or so. This hap-
pened during a time when development agencies, 
NGOs, and a plethora of other service organiza-
tions increased and multiplied.11
5. ConCluSionS
For public sector institutions, planning for FTO 
early in the research phase is neither necessarily 
appropriate nor feasible. Indeed, since much of 
the research conducted in academic institutions 
is not directly intended for commercial use, 
there is and indeed should be little concern over 
FTO. But public sector institutions, particularly 
the NARS and CGIAR in agriculture, and the 
PDPs in health, are increasingly dealing with the 
complex interface of proprietary science and the 
public domain. Moreover, donors such as the 
Bill and Melinda Gates Foundation are requiring 
them to develop global access strategies that spell 
out how intellectual property will be managed to 
make the products from the grants available to 
the poor. This will increasingly require FTO con-
siderations as products are moving downstream.12 
Significantly, however, while the steps involved 
in an FTO are straightforward, their execution is 
complex and time consuming, and the implica-
tions of an FTO are difficult to translate into a 
product-development strategy.13 As mentioned 
in the introduction, FTO opinions provide only 
snapshots of the intellectual property related to 
a product at a given point in time. For example, 
the patent landscape changes daily as the speci-
fications of the product become modified and 
improved, as the legal landscape evolves (for in-
stance, rules are issued for what type of invention 
is patentable), and as patent applications are filed 
and patents issue, expire, or are invalidated. 
A sound strategy for obtaining FTO for a giv-
en product or process should consider all options 
and an assessment of the risks of each in relation 
to the institutional context, the product type, and 
market dynamics. In practice, several options are 
pursued concurrently. Strategies will need to be 
regularly revised and tactics adapted in response 
to changing circumstances. In practice, some 
options may be more feasible during the R&D 
stages (such as inventing around), whereas others 
may become the only option if all else fails (such 
as litigation or abandonment of a product).
All of the options outlined in this chapter 
require, in some way, the formation of partner-
ships, both internal and external. First, manag-
ing potential IP infringement requires coopera-
tion and partnerships between and among R&D 
personnel and professionals in business develop-
ment, finance, strategy, law, and even governance. 
Moreover, translating this coordinated, focused, 
and informed risk management into a solid, re-
liable, and thorough FTO strategy should be a 
shared goal for all involved. Indeed, everything in 
the end is driven by relationships, both internal 
and with third parties outside the organization 
seeking FTO. If a decision is made to passively 
manage such risks, unexpected problems could 
arise and opportunities could be missed. 
Above all, as with any strategic issue, the key 
is not so much to have an FTO strategy—but to 
execute it. Strategy is not so much a plan but an 
attitude. Take a positive attitude to facing prob-
lems, view them as opportunities, chart the best 
course action, and then implement it. ■
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and M Bokanga.
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and Product Licensing.  
7 Rattray GN. 2005. The Enola Bean Patent Controversy: 
Biopiracy, Novelty and Fish-and-Chips. Duke L. & Tech 
Rev 0008 (3 June). 
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9 See, also in this Handbook, chapter 3.10 by CM Correa.
10 See, also in this Handbook, chapter 5.2 by Z Ballantyne 
and D Nelki.
11 For this, and other reasons, it has been proposed to 
restructure the CGIAR and FAO, for a consortium 
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service (see Krattiger AF. 2003. Technology transfer 
to developing countries and technology diffusion: 
The future role of institutions in capacity building, 
regulations, IPRs and funding. In Handbook of Plant 
Biotechnology eds. P Christou and H Klee. John Wiley 
& Sons, London. pp. 987–1010. http://www.wiley.com/
WileyCDA/WileyTitle/productCd-047185199X,descCd-
tableOfContents.html).
12 One of the first major FTOs conducted for a public 
sector consortium was for GoldenRice. It was 
commissioned by the Rockefeller Foundation on behalf 
of the International Rice Research Institute (IRRI) and 
the Humanitarian Board for GoldenRice (see Kryder 
D, SP Kowalski and AF Krattiger. 2000. The Intellectual 
and Technical Property Components of pro-Vitamin A 
Rice (GoldenRice™): A Preliminary Freedom-to-Operate 
Review. ISAAA Briefs No 20. ISAAA: Ithaca, NY. www.
isaaa.org/kc/bin/isaaa_briefs/index.htm. See also 
www.goldenrice.org/Content2-How/how9_IP.html.
13 See, also in this Handbook, chapter 14.2 by SP Kowalski, 
and supra note 1.

ABSTRACT
Freedom to Operate (FTO) is the ability to proceed with 
the research, development and/or commercial produc-
tion of a new product or process with a minimal risk of 
infringing the unlicensed intellectual property (IP) rights 
or tangible property (TP) rights of third parties. The 
procedure for assessing whether the product or process 
possesses FTO is called the FTO analysis, performed by 
meticulously dissecting the product or process into its 
fundamental components and then scrutinizing each for 
any attached IP or TP rights. The early preparations for 
an FTO analysis are crucial, because they will influence all 
that follows and hence determine the quality of the work 
product. Thorough preparation will lay a solid founda-
tion, supporting a credible and reliable FTO analysis. This 
chapter explains these preparations through an example.
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research, development, and eventual commer-
cialization of an agri-biotech or pharma prod-
uct. This technical complexity mirrors the cor-
responding intellectual property (IP) rights and 
tangible property (TP) rights complexity; that 
is, each component, process and/or combina-
tion thereof that went into the product might 
have either IP rights (for example, patents) or TP 
rights (for example material transfer agreements 
[MTAs]) of other parties attached. Hence, an 
agri-biotech or pharma product/process might 
not be “clean” in a legal sense, meaning that 
moving ahead with research, development, and 
commercialization could constitute infringe-
ment of another’s IP or TP rights. However, the 
risk of infringement liability can be systemati-
cally managed and dramatically reduced. This is 
what freedom to operate (FTO) is all about. 
Broadly defined, FTO means the ability to 
proceed with the research, development and/or 
commercial production, marketing or use of a new 
product or process with a minimal risk of infring-
ing the unlicensed IP rights or TP rights of third 
parties.1 The procedure for assessing whether or 
not the product or process possesses FTO is called 
the FTO analysis. An FTO analysis is performed 
by meticulously dissecting the product or process 
into its fundamental components and then scru-
tinizing each for any attached IP or TP rights. It 




Access to agricultural biotechnology (agri-bio-
tech) and pharmaceutical (pharma) products, 
including vaccines, and processes can help de-
veloping countries improve public health and 
nutrition, contributing to the well-being of 
those most in need. Such products and processes 
are categorically technically complex. A cursory 
glance at a “materials and methods” section of 
any paper published in a scientific or medical 
journal reveals the plethora of components and 
processes that are routinely employed in the 
Kowalski SP. 2007. Freedom to Operate: The Preparations. In Intellectual Property Management in Health and Agricultural 
Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, 
U.S.A. Available online at www.ipHandbook.org.
© 2007. SP Kowalski. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
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analysis neither explicitly nor implicitly denotes 
an absolute freedom to operate, but is instead a 
risk management tool, the purpose of which is to 
assess the likelihood for infringement-litigation li-
ability associated with the new product or process: 
an FTO is therefore an informed, reasoned, and 
calculated best estimate of infringement liability, in 
a given jurisdiction, at a given period of time (that 
is, a snapshot assessment of the contours, canyons 
and crevasses of the IP/TP rights landscape for the 
specific product or process).2 
Thus, an FTO analysis will inform an insti-
tution or company that the research, develop-
ment, and commercialization of the new prod-
uct or process may proceed with a minimal risk 
of infringing the unlicensed IP rights and/or TP 
rights of others.3 However, as the IP/TP rights 
and legal landscape changes, shifts, and evolves, 
the dynamics and results of the FTO analysis may 
also change. (For example, patents may issue, ex-
pire, or be invalidated; licenses may be granted 
or terminated; patents may be assigned and then 
reassigned.) Also, patent rights are strictly terri-
torial,4 meaning that a product/invention might 
possess FTO in one jurisdiction (a nation where 
a relevant patent has not issued) but, on the 
other hand, would not possess FTO in another 
jurisdiction (a nation where a patent has issued). 
Therefore, the results of an FTO analysis must 
be periodically reassessed and updated where and 
when appropriate.5 
1.2 FTO	analysis	preparations:	overview
The FTO analysis must be organized, logical, me-
thodical, meticulous, and carefully documented. 
An important initial step in a thorough FTO anal-
ysis (that patent counsel may then subsequently 
use to draft an FTO opinion) is the completion 
of the following preparations:
• assembling the FTO team
• analyzing, understanding, and dissecting 
the technology
• assessing plant pedigrees
• recognizing pharmaceutical technical 
considerations
• interviewing the researchers
• locating notebooks, lab records, and com-
puter files
• finding MTAs, bag-tags, bags of seed, and 
any unknown property trail
• formulating the series of FTO questions
• selecting scientific databases
• selecting patent databases
• identifying special resources for pharma-
ceutical patent information
• understanding U.S. Patent and Trademark 
Office (PTO) information (file wrappers 
and disclosures)
• remaining aware of the 18-month “period 
of silence”
• maintaining due diligence throughout the 
FTO analysis
In this chapter, each of the aforementioned 
preparative steps is explained within the context 
of preparing for and conducting a successful FTO 
analysis. Applicable technologies might be either 
agri-biotech or pharma. Although the materials, 
methods, and tools used may be dissimilar from 
agri-biotech to pharma, the fundamental FTO 
principles and procedures remain unwavering for 
each of these. Hence, by following this FTO anal-
ysis blueprint, a series of sound FTO questions 
can be formulated, so as to lay a solid foundation 
from which a reliable FTO analysis will be able 
to develop. Patent counsel can then draw upon 
this analysis to formulate either one or a series of 
FTO opinions. 
1.3 Illustrative	example
Throughout this chapter, in order to help clarify 
and exemplify the topics covered, an illustrative 
hypothetical will be employed. It is a purely fic-
tionalized situation, presented solely for the pur-
pose of focusing the discussion and facilitating 
understanding.
1.3.1  Background	
Recently a new viral disease has emerged in east 
Africa. The causative agent is a virus, simian in 
origin, having been asymptomatically endemic in 
an isolated population of pygmy desert baboons 
for millennia. The scourges of war, famine, and 
drought have impelled many people to seek sus-
tenance from bush meat, which they eventually 
find by scouring the wilderness for days on end. 
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It is believed that the pathogenic virus made the 
leap from baboon to human when famished refu-
gees consumed uncooked baboon meat infected 
with the virus, which likely rapidly entered the 
bloodstream via the portals of ulcerated oral le-
sions caused by advanced scurvy. Upon entering 
the new host, the virus migrated to skeletal mus-
cles, where, in contrast to the primary baboon 
host, the virus causes progressive muscular de-
generation with symptoms resembling myasthe-
nia gravis. It is colloquially referred to as the “fall-
down disease” (FDD). The most serious concern 
with this emergent disease is that it appears to be 
readily transmissible from human to human via 
bodily secretions. Hence, it may have the capacity 
to spread throughout crowded refugee facilities, 
creating even more suffering and death. 
The sudden appearance of this deadly virus 
has prompted a series of research and develop-
ment efforts across the globe. These include de-
veloping techniques to raise the virus (it can only 
be cultured in monkey cells), sequencing and 
characterizing the viral genome, cloning the bat-
tery of genes that encode the viral proteins, and 
developing candidate vaccines. 
An east African nation is home to the Institute 
of Dry Land Crop Research (IDLCR). This na-
tion has recently acceded to the World Trade 
Organization (WTO) and is serious about be-
coming compliant with the Agreement on Trade-
Related Aspects of Intellectual Property Rights 
(TRIPS) so that it can increase economic growth, 
for example by attracting greater foreign direct 
investment, particularly in the areas of emerging 
technologies, such as, biotechnology. As a result, 
a greater number of foreign interests are filing 
patent applications for their biotechnological ap-
plications and technologies in this nation, usually 
as part of the national-phase filing pursuant to 
the Patent Cooperation Treaty (PCT). 
In response to the looming crisis of the emer-
gent viral disease FDD, the IDLCR, in conjunc-
tion with this nation’s leading medical research 
center, has launched a program to produce a 
large quantity of viral antigen in recombinant 
grain sorghum, transformed with the most im-
munogenic of the viral antigens. This will then 
be used to produce large amounts of vaccine to 
immunize thousands of displaced refugees. Such 
a research and development program will inevita-
bly entail numerous proprietary components and 
techniques, likely having the IP and TP rights of 
third parties attached. Therefore, FTO issues will 
be a very real and constant concern. 
2. ASSemBling	The	fTo	TeAm
2.1 Skilled	leadership	of	the	FTO	team	
From the very start of an FTO analysis, it is ab-
solutely essential to establish credible, capable, 
competent leadership so that the FTO analysis 
is properly conceived, organized, and conducted. 
Because an FTO analysis is a multidisciplinary 
endeavor, the team leader must ensure that it 
remains focused, on-course, and precise. Under 
ideal circumstances, that is, qualified patent 
counsel is available and affordable, such counsel 
should lead the way. However, in many situations 
this might not be possible. Also, depending on 
the stage of the FTO analysis, patent counsel 
leadership might not be required. For example, 
early stages of a preliminary FTO analysis can be 
performed in lieu of counsel, possibly in order to 
assess or survey the IP rights landscape. Counsel 
may be sought later when and if it is warranted, 
possibly at later stages of the FTO analysis when 
questions of legal significance arise (for example, 
patent claims analysis). At such a stage, one pos-
sible route would be to seek pro bono counsel via 
services provided by public interest associations 
(for example, Public Interest Intellectual Property 
Advisors [PIIPA]). 
In order to be most effective, the FTO team 
leader ideally should have expertise in agri-bio-
tech and/or pharma, depending on the exact 
product and/or process undergoing FTO analy-
sis. Furthermore (if patent counsel will not ini-
tially lead the FTO team) the FTO team leader 
must be the available professional with the 
greatest expertise in IP-related issues (for exam-
ple, a technology-transfer professional officer, 
an intellectual property practitioner such as a 
patent agent or a scientist who has participated 
in various IP rights and technology-transfer 
courses, workshops, and/or seminars). The FTO 
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team leader must understand the dynamics of 
the step-by-step process of FTO analysis, not 
only within the legal paradigm, but also from a 
sophisticated technical and scientific perspective. 
Because an FTO analysis is conducted at the in-
terface of science and law, the FTO team leader 
must be professionally amphibious (that is, capa-
ble and comfortable in two different professional 
environments).6 
2.2 The	FTO	team	is	multidisciplinary
The FTO team leader selects who will be part of 
the FTO team. FTO team members should in-
clude: scientists who had supervised the project, 
technology transfer personnel, and technicians/
support staff. The last are absolutely essential, as 
they frequently know what really happened dur-
ing product research, development, and commer-
cialization. The FTO team might also include 
business personnel (depending on the stage of 
commercialization) and possibly administrative 
staff. The latter might have information pertain-
ing to relevant communications, documents, and 
agreements. It is also very important to note that 
the FTO team may, or may not, be the same as 
the client. For example, the actual client might be 
a research institute, and the FTO team would be 
composed of employees. 
2.3 Work	product	doctrine	and	patent	counsel
One important reason that it is judicious to have 
patent counsel lead the FTO team, particularly 
at later steps in the analysis, pertains to main-
taining the confidentiality of documentation. 
In the event that a claim of patent infringement 
arises, the FTO analyses and opinions, prepared 
under the guidance of patent counsel, may be 
protected from discovery (the compulsory dis-
closure of documents to an opposing party), 
pursuant to the attorney work-product immu-
nity doctrine. However, it is unclear how far this 
immunity reaches, and so one must exercise cau-
tion. In general (in the United States), “[pursu-
ant to the U.S. Federal Rules of Civil Procedure, 
Rule 26(B)(3)] written material and mental im-
pressions prepared or formed by an attorney in 
the course of performing legal duties on behalf of 
a client are protected from discovery as the attorney’s 
‘work product’ in the absence of undue prejudice or 
hardship to the party seeking discovery.” In spite 
of this, “there has been disagreement among courts 
construing this language as to its proper interpreta-
tion and its integration with other doctrines im-
pacting on discovery jurisprudence … With respect 
to the standard of protection from discovery which 
an attorney’s opinion work product should be given, 
a few courts have held that Rule 26(b)(3) mandates 
absolute protection, while a growing number of the 
more recent decisions have held that the standard 
of protection is less than absolute, with the strict 
protection generally afforded an attorney’s opinion 
work product allowing for exceptions in certain 
circumstances.”7 Such complex issues relating to 
work-product immunity, and the extent to which 
it might reach, further illustrate the advisability 
of having qualified patent counsel as the FTO 
team leader. 
After the FTO team is assembled, the leader 
coordinates, leads, and guides the team through-
out the entire FTO analysis.
2.4 The	importance	of	scientific	understanding
In the case of FDD vaccine development, the 
IDLCR FTO team leader must carefully select 
a cadre of scientists who will, collectively, com-
prehend the spectrum of biological, genetic, ag-
ronomic, and biotechnological components and 
techniques that will go into the research, devel-
opment, and commercialization of the vaccine. 
These individuals will form the basis of the FTO 
team. In addition, other professionals might be 
selected, such as technology transfer officers, ad-
ministrators, and business managers. This team 





As the initial step in the FTO analysis, the FTO 
team must thoroughly know the precise nature 
of the technology itself, whether it is a prod-
uct, process, or combination thereof (referred to 
hereinafter as the product/invention). In order 
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to accomplish this, the FTO team must work 
closely with all of the research and development 
staff, so as to understand the nature of the tech-
nology to such an extent that it can be “disas-
sembled” into its fundamental components, that 
is, deconstructed.8 
Therefore, in the deconstruction phase of 
the early preparations for the FTO analysis, the 
FTO team and any other scientists, collabora-
tors, or staff, work together to resolve the prod-
uct/invention into the fundamental processes 
used to make it, the components that went into 
its construction, and any possible combinations 
of processes and/or components potentially 
pertinent.
3.2 Research	tools
At this stage it is important to identify any re-
search tools that were used during research and 
development of the product/invention.9,10,11 
Research tools, integral for the efficient devel-
opment of commercial applications both in 
agri-biotech and pharma, are defined by the 
National Institutes of Health (NIH) as the “full 
range of resources that scientists use in the labora-
tory including [a fragment of a gene, a gene], cell 
lines, monoclonal antibodies, reagents, animal 
models, growth factors, combinatorial chemistry 
and DNA libraries, clones and cloning tools (such 
as PCR), methods, laboratory equipment and 
machines, databases and computer software.”12,13 
Identifying them is a critical step in the early 
FTO analysis preparations, because, although 
seemingly ubiquitous and readily, even “free-
ly,” available in many laboratories, there nev-
ertheless appears to be no research tool usage 
(experimental use) exemption in the United 
States. To assume otherwise would be to un-
wisely overlook and thereby disregard impor-
tant steps in the product/invention undergoing 
FTO analysis.14 
3.3 Components	of	the	vaccine
In the case of FDD vaccine development, the pro-
duction and deployment of a vaccine from trans-
genic sorghum would entail numerous components 
and technologies, including, but not limited to:
• monkey cell culture (for viral propagation)
• antibodies against the viral proteins
• the viral genome
• individual viral genes
• research tools used to clone the viral genes 
(for example, the polymerase chain reac-
tion [PCR], and related techniques)
• plant transformation techniques (for ex-
ample, agrobacterium and/or bio-projectile 
methodologies)
• plant genetic transformation constructs 
(for example, vectors, promoters, transit 
peptide sequences)
• plant cell culture techniques and cell lines
• sorghum germplasm used for genetic 
transformation
• procedures for harvesting and purifying ex-
pressed antigen
• formulation, production and delivery of 
the actual vaccine
Each of the above would most likely repre-
sent a deconstructed piece of the contemplated 
final vaccine, and each would therefore constitute 
an FTO question (see section 8) that the FTO 
team would subject to thorough scrutiny in the 
FTO analysis. 
4. ip	AnD	Tp	RighTS
At this stage, it will be instructive to briefly and 
clearly define some of the forms of IP and TP 
rights that are commonly encountered in an FTO 
analysis. 
4.1 Patents
Patents, as referred to in this paper, are utility pat-
ents: a grant by a government to an inventor, for 
the right to exclude others from making, using, 
or selling his or her invention, for a specified term 
of years. This is done in exchange for the inventor 
fully disclosing the invention in the patent docu-
ment (typically the specification). Hence, a patent 
can be viewed as a contract between the inventor 
and the government, wherein the inventor provides 
full disclosure of the invention in exchange for 
absolute exclusivity to the IP rights for a specified 
term. Patents are applicable to both agri-biotech 
and pharma.15 
KOWAlSKI
1334 | HANDBOOK OF BEST PRACTICES
4.2 MTAs
MTAs are legal instruments that typically accom-
pany the transfer of TP. They usually (possibly ide-
ally) document what is transferred, who transfers 
to whom, as well as the provisions, uses, scope of 
rights, confidentiality, and term of the agreement.16 
MTAs are legally defined as bailments.17 So, the 
question naturally arises, what is a bailment? A 
bailment is the delivery of an item of TP from one 
party to another, for a specific purpose, pursuant 
to the terms of a contract. However, in a bailment 
it is critical to remember that although there is a 
change in the actual physical possession of the prop-
erty, there is no transfer of ownership: title remains 
with the owner (bailer)—even though possession 
has shifted to the recipient (bailee).18 In addition to 
being a bailment, an MTA also entails contractual 
obligations, and hence, as a binding contract, the 
terms and provisions of an MTA must be taken 
very seriously by both parties involved in the trans-
fer/transaction, so as to avoid the possibility of 
breach of contract liability.19 
The terms and provisions of MTAs can vary 
considerably, particularly when comparing MTAs 
executed by the nonprofit sector (for example, uni-
versities) with those executed by the for-profit sec-
tor (for example, corporations).20 Confidentiality, 
publication rights, and reach-through rights may 
vary significantly, and one must exercise caution 
so as not to agree to an MTA with potentially 
onerous terms.21 If the material used in the devel-
opment of the product or process was obtained in 
violation of an MTA between two other parties, 
then the “obtainer” of the material may be liable 
for unauthorized use. For example, Andy transfers 
(technically speaking bails) a plasmid to Roberta 
(with specified contractual obligations attached), 
which is then “obtained” by Carl, via trick, theft, 
or other nefarious means, and Carl then uses it to 
either develop, or incorporate into, his product/
invention. Carl might very likely have a liability 
problem—possibly misappropriation of Andy’s 
tangible property.22 MTAs are applicable to both 
agri-biotech and pharma.
4.3 Bag-tags
Bag-tags, a type of agri-biotech TP rights protec-
tion, are enforceable contracts23 that restrict the 
licensee (grower) in the use and/or reuse of seed.24 
The bag-tag license is analogous to shrink-wrap, 
box-top, and tear-me-open software license trans-
actions, such that an implicit contract is formed 
when the seal is broken, which then obligates the 
grower to the terms of the license as articulated 
on said seal.25, 26
4.4 Plant/germplasm	protection
4.4.1  Plant	IP	rights	statutes
Germplasm IP rights protection (agri-biotech) ex-
ists in various forms, with each form addressing 
different types and levels of what is protected. In 
the United States, the Plant Patent Act (PPA), the 
Plant Variety Protection Act (PVPA), and Utility 
Patents for Plants (UPP) are the statutory forms 
of germplasm IP rights available.27 The PPA pro-
vides IP rights protection for asexually (vegetative) 
propagated plants, (for example, plants that are 
propagated from cuttings or by budding or graft-
ing); tuber-propagated plants (potato varieties) 
are not covered by the PPA. The PVPA provides 
IP rights protection for sexually propagated plant 
varieties, F1 hybrids, and also tuber-propagated 
plants (potato varieties); plant varieties must meet 
the new, distinct, uniform, and genetic-stability 
requirements. With UPP, the level of IP rights 
protection is much broader than that afforded by 
either the PPA or the PVPA. The PPA and PVPA 
only confer IP rights protection for certain plant 
varieties, but UPP can claim plants, plant variet-
ies, plant parts, seeds, and tissue cultures.28, 29
4.4.2 Plant	IP	rights	treaties
In addition to the PPA, PVPA, and UPP, there are 
two treaties that address germplasm IP rights pro-
tection: the International Treaty on Plant Genetic 
Resources for Food and Agriculture (PGRFA)30 
and the Convention of the International Union 
for the Protection of New Plant Varieties 
(UPOV).31 In PGRFA, important provisions 
include an agreement not to claim IP rights for 
any of the germplasm resources “in the form re-
ceived” from the multilateral system. There is also 
a benefit-sharing scheme triggered by the com-
mercialization of new plant varieties.32, 33 A treaty 
seeking to impart international conformity in 
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plant variety protection, UPOV, fundamentally 
consistent with the PVPA, specifies that the fun-
damental criteria for IP rights protection are dis-
tinctiveness, uniformity and stability.34 
4.5 Technology-use	licenses
Technology-use licenses may need to be sought 
for the use of certain research tools (see section 
6.2), which frequently are indispensable in order 
to facilitate the research and development phase 
of an agri-biotech or pharma product, process, 
or application.35 Although there is currently con-
siderable debate as to whether the patenting and 
licensing of research tools should be subject to 
either experimental use exceptions or compul-
sory licensing schemes,36 the basic presump-
tion should remain that there is no experimen-
tal use exemption for research tools, regardless 




When analyzing an agri-biotech product/inven-
tion, it is necessary to determine the pedigree of 
the germplasm forming its very foundation. In 
other words, the trail of germplasm, with as much 
detail as possible, must be traced and documented. 
If detailed breeding records are available, this task 
will be much easier. Hence, the FTO team must 
ask these questions: What type of germplasm is 
the product/invention embedded in? Where did 
this germplasm come from? What is the detailed 
pedigree of the germplasm? 
Furthermore, as already discussed herein-
above, plant germplasm may be protected by 
various overlapping forms of IP rights:
• trade secrets (primarily for proprietary in-
bred lines, for example, in hybrid maize 
breeding)38 
• utility patents39 
• Plant Variety Protection Act (PVPA)40 
• Plant Patent Act (PPA)41 
• UPOV (as consistent with the PVPA)42 
• PGRFA (for germplasm accessed from the 
multilateral system)43 
Hence, the FTO team must remain aware of 
the possibility of a complex IP/TP rights situation 
with regard to germplasm. It must therefore pro-
actively corral as much information as possible. 
5.2 Germplasm	issues
Concerning in planta expression of viral antigen 
in transformed sorghum, varieties contemplated 
for genetic transformation with the viral gene(s) 
will likely present complex germplasm consid-
erations during the FTO analysis. For example, 
overlapping forms of IP and TP rights protection 
might apply: an ideal sorghum line could simul-
taneously have third-party patent and plant vari-
ety protection rights attached. Since the nation 
where the IDLCR is located is seeking to comply 
with the TRIPS Agreement, it will likely have a 
UPOV-harmonized PVPA enacted as statutory 
law, and certainly also a patent statute. Hence, 
germplasm issues, occasionally (and foolishly) 
subordinated to patents in an FTO analysis, will 




As with agri-biotech, when examining a phar-
ma product/invention the FTO team will need 
to consider pharma-product/process-specific 
components.44 






The types of pharmaceutical compositions 




The methods, steps, and components in-
volved in the product synthesis are also critical 
(see also section 6.2):
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• steps and the reagents and techniques that 
compose each step
• intermediates (For example, for a five-step 
synthesis, there are at least four intermedi-
ates to clear and four sets of the reagents that 
are used to convert the intermediates.)45 
• reagents (For example, “Before launching an 
all-out patent search, it is often productive to 
search your old organic chemistry/biochemistry 
textbooks and Aldrich/Sigma catalogs, and ask 
two questions: (a) what chemical utilities and 
processes are clearly within the public domain, 
or (b) can be purchased from vendors that can 
sell them to you for unrestricted use?”)46 
• purification techniques and protocols
• handling techniques and procedures
Methods of use, that is, downstream consid-
erations, also are important to keep in mind:
• modes of treatment
• dosimetry
• limiting side effects
6.2 Research	tools	
And finally, but no less important, research tools 
must be considered. Biotechnology research 
tools are used in the development of drug prod-
ucts, therapeutic devices, or diagnostic methods. 
These research tools are not themselves physically 
incorporated into the final product/device/diag-
nostic. Hence, they represent the full range of 
resources used in drug discovery and develop-
ment.47 (See also section 3.2.)
6.3 Vaccines
In the case of vaccines, there are additional FTO 
analytical considerations specific for vaccine re-
search, development, manufacture and deploy-
ment, including:





• delivery devices48 
As with the pharma product/invention, the 
FTO team must carefully analyze each of these 
and, using the results of this analysis, formulate 
an appropriate series of FTO questions (see sec-
tion 8). In the case of the FDD vaccine FTO 
analysis, there will be:
• upstream considerations (for example, the 
viral genes, monkey cell culture, cloning) 
• midstream considerations (for example, 
sorghum germplasm and plant transforma-
tion, in planta antigen expression) 
• downstream considerations (for example, 
vaccine formulation, production, optimi-
zation [adjuvant selection] and delivery) 
As already discussed, each of these will 





To ensure success when performing the FTO 
analysis, a continuing rapport between the FTO 
team and scientific and technical staff is essential. 
This will help keep everyone involved on the same 
track, maintain momentum, and keep the FTO 
analysis up and running. Such informal dialogues 
with research personnel can reveal critical snippets 
of information, such as the trail of acquisitions. 
(For example, who got what from whom, and was 
it with or without proper authorization as to em-
bedded IP and/or TP rights?) Consider this hypo-
thetical scenario: Andy obtains a product compo-
nent from Roberta, who had previously obtained 
it from Carl. However, there was no proper autho-
rization (for example, no MTA) for such a transfer 
in the first instance, which is definitely something 
that the FTO team needs to know. 
Such anecdotal narratives can never be found 
in a paper trail; these are solely preserved in the 
“oral history” of the laboratory. Thus, the FTO 
team must, at times, function as investigative cul-
tural anthropologists, sorting through the history, 
habits (possibly bad habits), and “traditions” of a 
laboratory and research group. Additionally, this 
sort of dialogue will also help researchers to recall 
more fully what they had done, allowing them to 
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fill gaps in the written records. What is in the lab-
oratory notebooks may only be part of the story. 
7.2 The	paper	trail
Still, the FTO team must tenaciously pursue every 
paper trail, searching the laboratory offices, green-
house, and even the field house, in order to track 
down notebooks, laboratory records, associated 
paperwork, computer files, MTAs, bag-tags, bags 
of seed, and any evidence suggesting an unknown 
tangible property trail, misappropriated property, 
or unauthorized access to a third party’s confiden-
tial information. A comprehensive review of the 
research and development group’s written and oral 
records and related information will thereby en-
able the FTO team to acquire a sophisticated un-
derstanding of what the product/invention is and 
what IP and TP rights might be involved. 
After the FTO team has identified and un-
derstood each of the fundamental units of the 
deconstructed product and/or process, they then 
can use this information to frame a series of “FTO 
questions.”
7.3 Template	for	FTO	questions
For the FDD vaccine, the product deconstruction 
table (Table 1) concisely summarizes the compo-
nents and process that go into its research, de-
velopment, and commercialization, as well as the 
potentially appurtenant third-party IP and TP 
rights. This is the template, the roadmap, from 
which the FTO questions (see section 8) can be 
formulated, addressed and analyzed.
8.  foRmulATing	The	fTo	queSTionS
Following the technical deconstruction of the 
product/invention, a series of FTO questions 
are formulated.49 These questions are structured 
to systematically analyze the dissected processes, 
components, and any combinations thereof, for 
potentially embedded IP rights (for example, 
patents and trade secrets) and TP rights (for 
example, MTAs and bag-tags50, 51). Each FTO 
question, therefore, asks whether a method to 
make, a material used to make, or any combi-
nation of methods and materials, has, or may 
have, third-party IP or TP rights attached. Thus, 
a single material or method, used in the develop-
ment of either an agri-biotech or pharma prod-
uct/invention, may have multiple proprietary 
issues, that is, both an IP right (for example, a 
patent right) and a TP right (for example, an 
MTA) of potential relevance. The gravity of 
formulating a correct series of FTO questions, 
then, underscores the necessity for caution and 
meticulousness at this early stage in the FTO 
analysis, because all the work that follows is 
built upon this foundation. 
9.  SCienTifiC	DATABASeS
Note: scientific database searches and patent data-
base searches are mutually reinforcing, that is, the 
two support, verify, guide, and inform each other 
throughout the process of the FTO analysis. For ex-
ample, inventors might be authors; institutions might 
be assignees; scientific discoveries might be the actual 
invention (disclosed in a scientific publication).
Scientific database searching, along with 
patent database searching, are integral to the 
FTO analysis. This is where the FTO team as-
sembles the piles of raw information and data, 
both written and anecdotal, that will subse-
quently be parsed, analyzed, and organized in 
order to address the FTO questions that the 
FTO team has formulated. Furthermore, the 
FTO team needs to know what types of scientific 
informational resources are available, both freely 
and also on a premium, value-added, pay-per-
view basis. Furthermore, the FTO team needs to 
understand what constitutes the value added for 
the pay-per-view databases, so that they will be 
used according to specific needs at certain times 
in the FTO analyses in the most cost-effective 
manner. 
There are many examples of scientific data-
bases. For example, freely available ones include: 
• Agricola52
• Google™53
Whereas premium value-added, pay-per-
view databases include: 
• Biosis54
• Current Contents55 
• Cab Abstracts56 
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Monkey cell culture (for viral 
propagation)
IP Rights, TP Rights patents, MTAs 
Antibodies against the viral 
proteins
IP Rights, TP Rights patents, MTAs 
The viral genome IP Rights patents 
Individual viral genes IP Rights patents
Research tools used to clone the 
viral genes (for example, the 





Plant transformation techniques 





Plant genetic transformation 
constructs (for example, vectors, 
promoters, transit peptide 
sequences)
IP Rights, TP Rights patents, MTAs 
Plant cell culture techniques and 
cell lines
IP Rights, TP Rights patents, MTAs
Sorghum germplasm used for 
genetic transformation
IP Rights, TP Rights, 
possibly trade secrets (for 
example, if variety was 
developed using parental 
lines protected as trade 
secrets)
patents, plant variety 
certificates, possibly 
MTAs (for example, if 
germplasm is covered 
by the PGRFA), bag-tag 
licenses 
Procedures for harvesting and 
purifying in planta expressed 
antigen
IP Rights patents
Formulation, production, and 
delivery of the actual vaccine
IP Rights, TP Rights, 
trade secrets  
(for example, confidential 
third-party know-how 
and/or show-how 





 HANDBOOK OF BEST PRACTICES  | 1339 
10.  pATenT	DATABASeS
10.1 Free	and	premium	databases
As with scientific databases, the FTO team needs 
to know what resources are available vis-à-vis pat-
ent databases, both freely available and premium 
value-added, pay-per-view. The FTO team should 
also know the type of value added for the pay-
per-view databases. These databases can then be 
accessed according to specific needs at key stages 
in the FTO analyses.57




And premium pay-per-view (with value-add-
ed features) patent databases include: 
• Delphion60 
10.2 Pay-for-view,	value-added	features
For purposes of illustration, some of the value-
added features of Delphion that distinguish it 
from either the PTO or esp@cenet are discussed 
here. While free patent research sites can provide 
patent records, they do not offer the analytical 
and productivity tools needed to make sense of 
the data in those records. What follows are some 
of the key features of Delphion that can make this 
fee-based service the right choice at the right time 
in the FTO analysis.61
Rather than presenting just a patent re-
cord, the primary display record on Delphion 
is an integrated view that provides a cross-col-
lection of information without the need to per-
form extra queries. Included in the integrated 
view are:
• family information showing the countries 
in which an invention is protected
• the Derwent World Patents Index (DWPI) 
title and abstract written in English using 
clear, concise, industry-specific terms
• accessible references to both patent and 
nonpatent prior art
• extensive hyperlinking to a variety of re-
lated information—including definitions 
for the fields contained in the integrated 
view
Delphion offers pay-per-use searching of 
the value-added DWPI database, which covers 
13 million unique inventions and has a unique 
hierarchical system of coding allowing extra pre-
cision and accuracy in searching. DWPI data 
can be used in most of the Delphion analytical 
and productivity tools. The Delphion Snapshot 
analytical tool creates quick, easy-to-read bar 
charts allowing summarization of key biblio-
graphic data—and then further refinement of 
those summaries. Delphion Work Files allow 
the saving of result sets or groups of patents that 
are to be reviewed for future reference. One can 
easily share these Work Files with colleagues, 
thus allowing worldwide collaboration. And 
one can also use analytical tools, like Snapshot, 
to perform further analyses of these groups of 
hand-selected records. Delphion allows a user 
to save frequently used queries, thus eliminat-
ing the need to reconstruct them each time. This 
saves time and decreases the chance for errors 
to occur in queries. Saved searches can be set 
to run automatically, advising one of the search 
results. Data Extract exports more than 50 key 
bibliographic fields in formats designed for use 
in other popular applications. The Family Legal 
Status reports the current legal status of the fam-
ily members of the invention being examined, 
which means that there is no need to individual-
ly search for each member of the family in order 
to ascertain the overall view of the protection 
in each jurisdiction. Delphion, as part of the 
Thomson Scientific family of IP solutions, offers 
all the advantages of working with a worldwide 
company, including a robust infrastructure and 
support network, interoperability with other 
Thomson Scientific solutions, and a global per-
spective on IP research and management.
11.  phARmACeuTiCAl	pATenT	
infoRmATion	
A pharma product/invention, has, in addition 
to the standard patent search tools and resources 
listed hereinabove, its own patent resource mate-
rials. These include the Orange Book, the Merck 
Index, and the actual physical “shoes” at the 
PTO. 
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11.1 The	Orange	Book
The Orange Book, “is an FDA-published document 
available in paper and electronic form that lists all 
FDA-approved drugs with any patents pertaining 
thereto.”62 The Orange Book contains approved 
drug products with therapeutic equivalence,63, 64 
as well as the expiration dates of patents on thera-
peutic small molecules and on approved indica-
tions and compositions.65 The Orange Book is 
available as a printed, bound edition, complete 
with an orange cover, or online.66
11.2 The	Merck	Index
The Merck Index lists patents and publications 
on older drugs and reagents.67 It is available as a 
printed edition or online.68
11.3 PTO	shoes
When working with a pharma product/inven-
tion, a hand search of the “shoes” in the PTO 
may be prudent.69 This is an actual physical pa-
per search, within the shoes: the boxes contain-
ing patent prior art.70 This is sometimes necessary 
due to the differences in nomenclature used by 
various patent drafters, differences that might not 
be readily identified and sorted out in electronic 
searching. Hence, under certain circumstances, 
the physical shoe search is an added measure of 
due diligence. 
12.  pTo	infoRmATion
In addition to searching scientific and patent da-
tabases, and checking the Orange Book, Merck 
Index, and the PTO shoes, there are several other 
resources of which the FTO team needs be aware. 
These include patent applications and the patent 
file wrapper. 
12.1 The	patent	file	wrapper
A very specialized informational resource is the 
patent file wrapper. The file wrapper is a physical 
folder, held by the PTO. It contains documents 
pursuant to the patent application and prosecu-
tion, including the original patent (or trademark) 
applications, as well as any amendments, affi-
davits, and written arguments submitted by the 
applicant, and the actions taken by the examiner 
concerning the application.71 The file wrapper 
becomes publicly available only after the patent 
issues. The file wrapper can be either physically 
accessed,72 or accessed via a searchable, writable, 
PDF format, which requires an up-to-date version 
of Adobe® Reader® and sufficient RAM (random-
access memory) on the searcher’s computer.73 
12.2 Patent	counsel	analyzes		
the	patent	file	wrapper
Since the file wrapper is such a specialized infor-
mational resource, it will typically be accessed 
and analyzed during an FTO analysis specifical-
ly to address very technical issues (for example, 
claims interpretational queries, usually done only 
near the terminal phase of the FTO analysis). 
Furthermore, the file wrapper should be searched 
and analyzed only by qualified patent counsel, 
who ideally, at this late stage in the FTO analysis, 
is the leader of the FTO team. This is because 
counsel, by reviewing any patent claim amend-
ments or disclaimers, will be using the contents of 
the file wrapper to carefully construe the precise 
meaning and scope of the claim language.74, 75 It is 
important to recall that an FTO analysis proceeds 
from broad and general to narrow and precise. 
Correspondingly, the analysis of patents proceeds 
from the patent itself (the abstract, claims and 
specification) to the claim language construction, 
to the file wrapper contents.76 Hence, the greater 
the precision and specificity of the analysis, the 
greater the advisability for patent counsel partici-
pation: the ability to understand the legal basis of 
claim meaning and scope become critical at the 
later stages of the FTO analysis. 
12.3 Patent	applications
Patent Applications are filed with the PTO, the 
PCT, and also in the various National Phase 
Applications. Although patent applications do not 
technically confer statutory IP protection, they 
nevertheless are a good indicator of what might be 
subject to protection pending patent issuance. 
13. The	“peRioD	of	SilenCe”
It is critical to understand that patent applications 
will not be available prior to publication, and so 
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their contents remain unknown for a period of 
18 months after the earliest effective filing date.77 
Therefore, whereas such inventions are held in 
trade-secret status during this period, they never-
theless are still pending as potential future patents. 
However, under U.S. law, if the patent application 
is only to be filed in the United States, then the 18-
month rule may not apply. (That is, the applicant 
may opt out of the 18-month requirement, and in 
that case the invention, as disclosed in the patent 
application, remains a trade secret until patent is-
suance.78) The 18-month period of silence, there-
fore, has implications in the FTO analysis, in that 
there may be pending IP rights, still below the sur-
face, but nonetheless relevant to the FTO analy-
sis. A diligent analysis of the published scientific 
literature, including conference papers, abstracts, 
and presentations, might suggest what pertinent 
IP rights are lurking in patent applications still 
hidden during the 18-month period. 
14. Due	DiligenCe
During the preparation, set-up, data accumula-
tion, and FTO question-formulation stages of 
an FTO analysis, due diligence is required. Due 
diligence, broadly defined, is “Such a measure of 
prudence, activity, or assiduity, as is properly to be 
expected from, and ordinarily exercised by, a reason-
able and prudent [person] under the particular cir-
cumstances; [Due diligence is] not measured by any 
absolute standard, but [depends] on the relative facts 
of the special case.”79 From a practical standpoint, 
due diligence necessitates a methodical approach, 
such that all forms of IP and TP rights are gar-
nered, organized, and assembled into a coherent 
document, for example, a Microsoft Excel spread-
sheet.80 The question often arises, as to how much 
diligence is enough. The answer? When one finds 
oneself treading the same ground, then the re-
quirements of due diligence are satisfied. 
15. ConCluSionS
The preparations for an FTO analysis will de-
termine the quality of the final work prod-
uct. Organization, thoroughness, meticulous 
documentation, and solid leadership by a capable 
FTO team leader will all combine to contribute 
to a successful outcome. A comprehensive check-
list of what must be established during the early 
stages of the FTO analysis serves as a helpful 
tool.81 For example, the list should include:
• possible pertinent patents, including their 
prosecution and/or litigation status
• patent applications
• third-party trade secrets, including whether 
they might have been misappropriated 
• all third-party TP rights
• all research tools used to make the agri-bio-
tech product or pharmaceutical innovation
• any agreements (for example, trade secret 
licenses, MTAs, bag-tag [shrink-wrap], or 
technology-use licenses, noting conditions 
and restrictions appurtenant) 
And finally, it is imperative that all records 
are properly maintained. Consistent records of all 
searches and search terms must be documented 
and organized. This should include:
• spreadsheets of all FTO search results
• records of search terms used
• databases searched
• interviews with researchers, with notes
• notes and annotations by patent counsel
Having spent the early phases of the FTO 
analysis with the disciplined rigor laid out in this 
chapter, the later steps in the FTO analysis should 
proceed with a minimum of problems. Diligence 
will pay off in the end with a solid and reliable 
FTO analysis that can be routinely updated and 
revised and that can also provide patent counsel 
with the requisite information for drafting FTO 
opinion letters. ■
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Emphasizing patents and patent searching, this chapter 
will put readers on the initial path to understanding and 
protecting intellectual property (IP). By exploring pat-
ent information on the Web site of the European Patent 
Office and other Web sites listed in this chapter, the 
reader can begin to learn by doing and quickly gain ex-
perience that should improve his or her searching skills. 
Other resources dealing with IP in general are described. 
This collection is by no means exhaustive, given the vast 
amount of information on IP that is present on the Web, 
but the sites listed here should be valuable in accessing 
unbiased, useful information about the IP landscape, es-
pecially for key areas of technological interest. The value 
of IP searches for a typical technology transfer office is 
also discussed.
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But the ubiquitous and egalitarian nature of 
the Internet raises some problems—the biggest 
problem is that it is overloaded with essentially 
unchecked and often highly partisan informa-
tion. For this reason, a novice searcher needs 
some background on how to obtain relevant in-
formation and how to properly assess the reliabil-
ity of a source. Simply typing patent or intellectual 
property into a search engine is likely to get hits, 
from many highly biased sources, on the desir-
ability (or otherwise) of a patent system and the 
wealth-creating or wealth-destroying nature of IP 
regimes. Providing you with some good, general, 
and, we hope, unbiased places to start is one of 
this chapter’s main goals.
A great deal of valuable information on IP 
rights can be found in the databases of patents 
and patent filings, which are now becoming more 
accessible; however, the databases do not provide 
comparable levels of interpretation and can be 
somewhat idiosyncratic. With databases, as with 
many other things, one gets what one pays for, 
and fee-based subscription services are always go-
ing to have more value. That does not mean that 
the free services are without value: a great deal can 
be achieved using these free sources alone.
One proviso has to be included before con-
tinuing: any searches you can perform yourself are 
not likely to be as complete or as well-prepared as 
CHAPTER 14.3
1.	 InTRoduCTIon
One of the major advantages of the information 
age is the ability for almost anyone to access in-
formation and resources that would otherwise be 
available only to specialists. The Internet—and 
its offspring, the World Wide Web—have be-
come so pervasive that there is now little infor-
mation that cannot be obtained from your desk 
for free or at a relatively low cost. Information 
about patents and other intellectual property 
(IP) is now almost instantly available; however, 
it takes a certain level of knowledge and experi-
ence to get there.
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those prepared by a professional patent agent or 
patent attorney. For any kind of IP related opin-
ion, about which there may be legal or financial re-
percussions, retaining the services of an attorney is 
a necessity. However, for preliminary searches, for 
finding background information, for keeping up 
with the most current technological developments, 
and even for personal interest, knowing where to 
look to find patent information is very useful.
2.	 pATenT	SeARCheS	
Many people assume that IP is all about patents 
and that searching patent databases is a good 
way to identify when a product has some pro-
tected IP components. Although this is not nec-
essarily true, patent searching is of great impor-
tance to technology transfer offices (TTOs) and 
IP management offices in public sector research, 
academic institutions, and research councils. 
Indeed, patents are a central tool in technol-
ogy transfer and commercialization strategies in 
both the public and private sectors. The reasons 
are described below.
2.1 Freedom	to	operate
Freedom to operate (FTO) is becoming increas-
ingly important for both the research and com-
mercialization phases of the development of 
important products and technological processes. 
While most countries have generous research 
exemptions incorporated into their national leg-
islation for the use of patented technologies in 
research, the scope and nature of the research 
exemption will vary from one jurisdiction to 
another. In the United States, the exemption 
is narrow and restrictive; in other jurisdictions, 
such as European countries, academic establish-
ments tend to benefit from this exemption over 
industry, sometimes regardless of whether there 
are any commercial objectives. Nevertheless, 
this exemption may be subject to periodic re-
view by events in judicial law, such as litigation 
proceedings. It is often difficult to determine 
clearly when early research will result in com-
mercial activities, and so it is necessary to exer-
cise judgment about the best time to start evalu-
ating FTO.
When a research activity does produce com-
mercialization initiatives, the scope of the research 
exemption likely will be significantly narrowed. 
Due diligence and thorough searching of back-
ground patents, therefore, will establish the scope 
of FTO. Patenting inventions generated in public 
sector institutions can also establish FTO. In this 
instance, extensive searching of patent databases 
is necessary for a researcher to establish whether 
he or she has a patentable invention.1
2.2 Transfer	of	technology	for	the	public	good
Some public sector institutions take patenting 
strategies very seriously in order to protect tech-
nologies that can be developed and transferred for 
the public good. Such strategies are likely to gain 
increasing acceptance in many other institutions. 
Not surprisingly, the generation of revenue from 
these patents is often a secondary consideration. 
Developing core technology is frequently 
thwarted when it is simply released into the pub-
lic domain. This is because the development of 
the technology most often requires a commer-
cial partner who needs incentives to invest in the 
costly and risky development phase. Incentives 
include exclusivity facilitated through patent pro-
tection. For an example of such strategic consid-
erations adopted in the public sector, see the IP 
draft guidelines document by the Indian Council 
for Agricultural Research (ICAR).2
That ICAR document considers patenting 
strategies for securing FTO, enabling food secu-
rity, and “cater[ing] to the agricultural and techno-
logical need of Indian farmers/citizens by maximising 
[referent] capacity for innovation and ensuring rapid 
transfer of technologies.” (Note that the ICAR docu-
ment is not yet final and is accessible for feedback 
purposes at this stage.) In order to achieve the goals 
of food security, institutions need to balance the 
need for patenting with the need to release the 
innovation into the public domain. The strategy 
the institution adopts depends on which strategy 
will fulfill the institution’s basic mission. The op-
timum strategy can be determined only on a case-
by-case basis, depending on, among other factors, 
the nature of the individual technologies to be 
transferred. Of course, good patent-searching tools 
CHAPTER 14.3
 HANDBOOK OF BEST PRACTICES  | 1347 
and expertise are essential for achieving the stated 
aims.
2.3 Mining	technical	information
Patent descriptions contain a lot of scientific in-
formation, which makes them useful alternatives 
to published papers. With strong encouragement 
from journal editors to shorten primary papers, 
the materials-and-methods sections of papers 
are often little more than reference lists, which 
necessitate a paper chase if a researcher wants to 
discover the actual process. Patent application 
descriptions, however, often contain excellent 
methodological detail in the enabling disclosure 
section, which is the quid pro quo of the monop-
oly patent right. In other words, the invention 
is disclosed in a manner that enables the repro-
duction of results. Often patents may be the sole 
source of technical information about new tech-
nology that involves either products or processes. 
One example is a recently published application 
assigned to Moraga Biotechnology Corporation, 
which discloses an invention related to totipotent 
nonembryonic stem cells (Application number: 
WO 06028723A1). Not only are the methods 
for isolating cells presented in a level of detail 
that covers media compositions, cell culture tech-
niques, and surgical procedures, but no peer-re-
viewed journal had published anything similar at 
the time of patenting. 
2.4 Avoiding	wasted	research	efforts
Simply searching journals will not uncover all 
the available technological areas of research and 
product development, particularly those areas 
that have been more recently developed. Patent 
searching can quickly uncover newer areas of re-
search and can help avoid the duplication of ef-
forts in a given area of technology. However, re-
searchers must remember that there is a time lag 
of up to 18 months, sometimes more, in many 
jurisdictions between the filing and publication 
of an application.
3.	 pATenT	SeARChIng	STRATegy
Searching for patents on a particular topic or 
product is not always straightforward. Patents are 
national rights, so it is necessary to give thought 
to where—in geographic terms—the product or 
invention needs protection. Important inventions 
are commonly patented in more than one country 
and—since these inventions involve the biggest 
potential markets—searching the patent offices of 
the United States, Europe, and Japan frequently 
covers nearly all of the potential patents and pat-
ent filings. A more recent system of international 
preliminary patent applications—the Patent 
Cooperation Treaty (PCT) system—is also a use-
ful resource since inventors filing through the sys-
tem have the possibility of protection in any sig-
natory state of the PCT. Inventors have up to 30 
months after filing the preliminary application to 
decide in which countries to file full applications.
There are no universal rules for good patent 
searches, and the following guidance is based on 
the personal experiences of one of the authors of 
this chapter. Starting from a position of limited 
or no knowledge of the technology in question, 
the first step is to carry out a standard biblio-
graphic search on scientific publication databas-
es. The online database Pubmed,3 specialized 
technical journals, and other scientific search 
sites (including sites such as Google’s™ scholar4) 
are good places to start. It is also worth trawl-
ing for information using general Internet search 
engines such as Google. Communicating with 
scientists involved in the technology is another 
essential requirement for the technology transfer 
officer/searcher. Developing effective communi-
cation between these groups may require some 
time and effort. 
Once armed with essential information, 
patent databases are queried with technical 
search words or inventor, applicant, or com-
pany names. There are no standardized forms 
for company names, so one must try various 
options to use that search field, particularly be-
cause companies may be listed as different enti-
ties in different countries. Also, many databases 
do not update these fields. So it is valuable to 
search using older names, such as Ciba-Geigy, 
Novartis, and Syngenta, as many name changes 
occur when companies merge or are taken over. 
Once relevant patents are found, it is possible to 
obtain their “equivalents” or “family members” 
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through databases such as the European Patent 
Office (EPO). Patent families are explained lat-
er in this chapter.
It is very important to have a structured 
search strategy. Although the strategy can vary 
according to invention type, a structured strategy 
involves breaking into its essential elements an 
invention or a field of technology and emphasiz-
ing those elements that are expected to be novel 
and inventive. This approach creates a series of 
useful search words. Often it is impossible to 
determine useful terms before the search, and 
further elements can be identified as the search 
progresses. Using the citations within individu-
al patents will further aid the search along the 
complex patent trail. Lastly, IPC (International 
Patent Classification) codes are useful for simpli-
fying the retrieval of documents (more on this 
topic to follow).
Although many national patent offices make 
possible online searches of granted patents and 
applications issued in their jurisdictions (for ex-
ample, the U.S. Patent and Trademark Office5), 
some Web sites (such as that of the Singapore IP 
office6) support searches of multiple sites at one 
time. Some have even collected multiple patent 
publication information into a single database 
(like the European Patent Office site7).
Many sites contain links to other sites with 
useful IP information, and one of the most 
comprehensive lists is maintained by the British 
Library,8 but, as with all such lists, it is most likely 
incomplete.
Below is an annotated list of selected sites 
and some information about their usefulness.
4.	 AvAIlABle	ReSouRCeS
Depending on available resources, individual 
TTOs may wish to have a dedicated searcher or 
to outsource the searching function, although 
this may be an expensive option in the long 
term. Requisite in-house resources include at 
least one well-trained staff member committed 
to performing patent searches. Ideally, this per-
son should have a scientific background with the 
aptitude to absorb and understand technologi-
cal concepts from a variety of disciplines. This 
is a talent-driven competence, so insistence on 
strict minimum qualifications can sometimes 
be unwise. 
Investment in computer hardware is essential. 
Also, a fast Internet connection is ideal because 
many of the electronic documents that researchers 
will download are large. A good relationship with 
a local patent attorney also is advisable, especially 
in situations where the accuracy of the informa-
tion under analysis is crucial and additional input 
is necessary. Investing in at least one commercial 
database (such as Delphion and/or Derwent) is 
highly recommended if financial resources permit 
and if the frequency and volume of searches re-





The Web portal of the European Patent Office 
(EPO) contains bibliographic (front page) infor-
mation from patent publications worldwide.9 As of 
late 2006, the site contained information from more 
than 60 million documents from 72 countries. No 
full-text versions of the documents are available in 
the html page views, but many of the documents 
can be viewed and downloaded as pdf files.
Below is a detailed description of the EPO 
site using the esp@cenet engine and an illustra-
tion of how to search patent databases.
Esp@cenet can be accessed and searched us-
ing the following steps:
1. Go to www.espacenet.com in the browser 
window. This will bring you to the home 
page of esp@cenet. Figure 1 shows what 
you will see on your computer screen. 
2. Scroll down the page to find a list of 
different servers located at the EPO, 
European Commission, and the national 
offices of members of the European Patent 
Convention and other European (“invit-
ed”) states.
3. Click on the link that takes you to the EPO 
server (ep.espacenet.com).
4. Choose the search option you want from 
the menu on the left side of the screen.
CHAPTER 14.3
 HANDBOOK OF BEST PRACTICES  | 1349 
A. Quick search
A quick search may be useful for simple search-
es using keywords, including the name of an in-
ventor or a company. Figure 2 shows what you 
will see on you computer screen after selecting 
“Quick Search.”
The default search part of the “Worldwide” 
database is shown above. Other choices are 
“EP” and “WIPO,” which are in the drop-down 
menu. To perform a search, select either “Words 
in the title or abstract” or “Persons or organi-
sations.” Next, type in the words or names as 
appropriate in the search box. This box allows 
Boolean search operators such as “AND” and 
“OR.”
B. Number search
A number search allows rapid access to publica-
tions and applications. Click on the “Number 
Search” option on the left side of the screen. 
Type in the application, access, publication, or 
priority numbers. If typing in the document 
“type” code (A1, A3, and so on—sometimes 
known as the “kind” code), which is appended 
to the end of the publication number, ensure 
that the code is separated from the publication 
number by a single space.
As an example, searching with 
“EP1226178A1” may not produce a result. The 
“A1” publication type code should either be de-
leted or entered as “EP1226178 A1.” The “EP” 
code or any national (alphabet) code at the be-
ginning is optional. If difficulties arise, try leav-
ing out the national code in the beginning as 
well, bearing in mind the possibility of dupli-
cated numbers across different patent offices.
Checking the “Including family” box while 
performing the search will return all members 
of the same patent family relating to multiple 
filings of the same invention and sharing the 
same earliest priority date (the filing date of the 
earliest application in the family). This helps 
figure	1:	esp@cenet	portal	screen:	Access	page
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determine the geographic scope of protection 
worldwide, although it should be noted that 
patents filed in developing countries without 
easily accessible electronic information are of-
ten not listed. 
Figure 3 shows the results window of 
the search with the patent publication num-
ber “EP1226178” together with the checked 
“Including family” box. 
The results show multiple applications or 
publications in Great Britain, Japan, and Canada 
with their publication dates. These applications 
are related to each other by a common invention 
and a shared earliest priority date. In this case, all 
applications have an identical title, although this 
is not always the case for patents within a single 
family.
It is possible to examine the individual pat-
ent documents retrieved in more detail, including 
those documents retrieved through other search 
windows such as “Quick search,” by clicking on the 
titles. Clicking on the title “Recombinant Fusion 
Molecules,” application number EP1226178 A1, 
takes you to the page shown in Figure 4.
The page shows a variety of information, 
including the inventors and the abstract. In this 
case, the actual abstract displayed is that of an 
equivalent PCT application belonging to the 
same patent family. Clicking on the appropriate 
tabs shows the “Description” of the invention, 
“Claims,” the “Legal status” of the patent, and the 
“Original document” in pdf format. 
Click on the “Original document” tab shown 
in the esp@cenet document view window. You 
will see the screen shown in Figure 5.
This screen displays the full document in pdf 
format. Navigate it using the scroll bar. In order 
to save the document to a disk or other specified 
location, click on the “Save Full Document” link 
shown in red.
Note that if you attempt to save or print 
the displayed pdf document using the Adobe® 
figure	2:	“Quick	Search”	Screen
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Acrobat® menu icons displayed (the “save” and 
“print” icons of a disk or printer, respectively), 
you can only do so one page at a time. 
If a document is not available as a full down-
load, the site will display a message saying “No 
full document available” instead of the “Save Full 
Document” link. In many cases, recent docu-
ments are not available for complete download, 
even if the entire document is available to view in 
pdf format on the screen.
Clicking on the “Mosaics” tab enables the 
searcher to view six of the drawings in a single 
window. In the example shown above these draw-
ings are not available.
Clicking on the “View INPADOC pat-
ent family” (Figure 4) shows the related patent 
documents of the family or those patents that are 
linked by a common priority number or date.
Clicking on the “INPADOC legal status” gives 
useful information on the legal status of the patent.
If certain EP patents are not available as full 
downloads from the server, check their avail-
ability through the EPO publication server.10 
Simply key in or copy and paste the publication 
or application number from patent searches into 
the appropriate box.
C. Advanced searches
Advanced search techniques, which narrow 
searches by combining various search terms, are 
possible using the “Advanced Search” option. The 
search box can contain a maximum of four search 
terms using Boolean language. Figure 6 shows 
a keyword search for “Antibodies AND Plants” 
against “title or abstract.” The search is narrowed 
further to patents applied for by the “Scripps 
Research Institute,” where the inventor is “Mich 
Hein.” Additionally, the patent search is limited 
to those patents published in “1997” and “2001.” 
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into the “Publication date” box, for which the 
Boolean operator is “OR” by default—alterna-
tively, one can add the “OR” operator explicitly 
as “1997 OR 2001.” 
The results of this search are shown in Figure 7.
Here is an explanation of each of the search 
fields on the advanced search form (not shown in 
Figure 7):
• Keywords in title and/or ritle or abstract. 
A text search for the entered keywords. 
Up to four keywords can be entered into 
each box using Boolean operators such as 
“AND” and “OR.”
• Publication number. The number as-
signed to a patent or published applica-
tion. In some cases, a granted patent will 
retain the publication number assigned 
to the published application, but not all 
country systems do this. Granted and 
published patents are often distinguished 
by a “Kind Code” (attached to the end 
of the publication number), such as “A” 
for an application and “B” for a grant-
ed patent, followed by a numeral (for 
example A1 or B1) referencing to the 
EPO system.
• Application number. The number assigned 
to an application when filing. Rather con-
fusingly, this number is separate from the 
publication number. The numbers—also 
shown on the front page of publica-
tions—include the country of filing and 
the year, but can sometimes have a differ-
ent format. To further illustrate this, the 
application number for the example pub-
lication EP1226178 A1 shown above is 
EP2000000973028.
• Priority number. The application number 
of the priority application. Patents are often 
filed based on previously filed applications 
or applications filed in other countries. By 
including the application number of the 
figure	6:	Advanced	Search	view:	entering	your	Search	parameters
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first (or priority) filing, the applicant can 
take advantage of the earliest filing date. A 
patent family is a set of publications linked 
by a common priority number. This is a 
useful way of determining patent cover-
age in several different countries, especially 
since direct patent searches are only avail-
able in the United States and Europe. To 
further illustrate this, the priority number 
for the example publication EP1226178 
A1 shown above is GB1999000026084.
• Publication date. The actual publication 
date. Note that, although a range of years 
cannot be searched currently, up to four 
different years can be searched using the 
“OR” Boolean operator (as in the example 
above). It is also possible to search for pre-
cise dates using the yyyymmdd format.
• Applicant. Usually a company, university 
or other institutional entity, but can in-
stead be one or more individuals. Words 
can be combined with Boolean operators 
to form the title of an applicant.
• Inventor. Name of the person or per-
sons who discovered the invention. In 
the United States, the inventor must be 
noted on a patent or patent application. 
Although this is not strictly required in 
many other jurisdictions, inventors are 
usually included in practice. Often listing 
the authors of early papers in a field is ef-
fective in searching for related patents.
• European Classification. A designation 
used to classify technical content of patent 
documents based on the EPO’s European 
Classification, which is an extension of 
the International Patent Classification 
(IPC).
• International Patent Classification. The 
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sified according to the IPC. This is assigned 
by the publishing office and is thus inde-
pendent of the applicants, which makes it a 
good searching tool for patents in a specific 
area.11
D. Classification search
Finally, we consider the classification search. 
Using codes based on the EPO classification sys-
tem, this type of search is useful when searching 
for all patents in a particular technical area. It is 
a powerful search tool, indispensable to profes-
sional searchers. Full consideration of the use of 
the classification system is beyond the scope of 
this chapter. However, the following steps are in-
tended to give the reader some guidance on how 
to begin using the codes on esp@cenet.
Click on the “Classification Search” button.
A window, similar to the one in the Figure 
8, should appear. Key in the words “genetic engi-
neering” in the box labeled “Find classification(s) 
for keywords” and click “Go.”
This takes you to the following page (Figure 9).
A number of specific codes appear, along 
with descriptions. Assuming we are interested in 
further exploring “C12N15,” click on the code or 
the title next to it, and you will be led to another 
list of codes with hierarchical subclassifications 
and descriptions. Scroll down to examine the list 
of subclassifications (or finer categories), and ex-
plore each of these codes until you have identified 
the codes pertinent to your areas of interest. As 
you explore, you can copy any code or codes to 
your main search form by ticking the box against 
the code and then choosing “Copy.” The codes 
are then copied into the search form to narrow 
your searches to the relevant invention areas. 
Note, however, that this requires a lot of experi-
ence, and searching with multiple codes simulta-
neously may restrict the results.
You can also use codes with the “Advanced 
Search” form.
figure	8:	Classification	view
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Note that all search screens (Quick, Advanced, 
Number, Classification) contain “Quick Help” 
links that guide the reader through many com-
mon queries. Clicking on the “Get assistance” link 
on search pages will take you to the esp@cenet 
Assistant, an interactive training module that is 
useful for beginners. There are several other help 
pages that the reader should find while navigating 
the site.
We have only commented on basic search 
techniques in relation to esp@cenet, but one can 
search the sites of a number of national patent of-
fices, using generally similar techniques. At least 
two sites provide lists of links to national offices 
and to their patent collections.12
Selected patent search sites and scientific and 
instructional resources are briefly described below.
4.1.2  U.S.	Patent	and	Trademark	Office
The Web site of the U.S. Patent Office (PTO) 
contains the full text of granted patents from 
1976 to the present, as well as full-page images 
since 1790.13 Published applications date from 
15 March 2001. Searches include both quick and 
advanced features. Page images are only available 
a single page at a time, and one must download a 
Tiff-viewer to see them. At the same site, you can 
also search trademarks registered in the United 
States. The U.S. Patent Office site contains links 
to helpful information including an excellent 
book on searching, titled Patent Searching Made 
Easy, which is available in paperback.14
4.1.3  UK	Patent	Office
The patent site of the United Kingdom Patent 
Office15 is somewhat similar to the U.S. Patent 
Office site but offers less utility because an increas-
ing number of patents are now filed as EP (U.K.) 
patents (derived from filings for multiple jurisdic-
tions at the EPO). The U.K. site, therefore, ends 
up as more of a register of inventions registered 
in the United Kingdom after the granting of the 
figure	9:	keyword	Search	Results
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EP filing. One of its more useful features is the 
ability to access patent status information, such 
as changes in assignees (common with the current 
rounds of company takeovers) and the payment 
of maintenance fees.
4.1.4  WIPO	PCT	applications
Maintained by the World Intellectual Property 
Organization (WIPO), the WIPO PCT site al-
lows you to search PCT (Patent Cooperation 
Treaty) applications for international filings.16 
Both simple and “structured” (advanced) search 
options are available for more than a million in-
ternational patent applications.
Published on a weekly basis, The PCT Gazette 
gives up-to-date information on applications and 
publishes special notices relating to the treaty 
itself and its regulations. Weekly issues are also 
available.17 
4.1.5  CAMBIA	Patent	Lens
CAMBIA Patent Lens is an independent resource 
for patent information from the EPO, PCT, and 
U.S. filings.18 The files are selected on the basis of 
the international classification codes as related to 
agriculture/plant technologies. CAMBIA’s data-
base has approximately 5.5 million documents. 
A site search on the home page will also reveal 
links to various useful, comprehensive articles in 
key areas of interest to agricultural biotechnology, 
specifically in relation to patent landscapes. These 
papers are updated every few years to cover newer 
patent applications and grants. Areas covered in-
clude promoters for the expression of heterolo-
gous genes in plants, Agrobacterium gene transfer 
methods, and selected antibiotic and herbicide- 
resistance genes. The Agrobacterium document 
alone amounts to 350 pages of preanalyzed pat-
ent and scientific information.
For those who specialize in agricultural or 
plant-related research, this is a valuable resource. 
First, it is helpful to have plant technology-re-
lated patents from multiple databases prefiltered 
into a single resource. This saves a researcher 
from having to search multiple unfiltered da-
tabases (EPO, PTO, and PCT), each of which 
have different interfaces and idiosyncrasies. 
Users of multiple databases need experience 
with all such interfaces, whereas with Patent 
Lens, one needs familiarity with just one inter-
face. The Patent Lens search interface has both 
simple and advanced search options, including 
the ability to filter results according to granted 
patents or published applications. 
Second, the full text is downloadable. 
Until recently, even the EPO did not have this 
capability. 
Third, Patent Lens gives extensive coverage 
to understanding the IP world, including how to 
read and interpret a patent and its claims, with 
a particular focus on agricultural biotechnology. 
For example, inside the technology landscapes, 
there is expert commentary on patent protection 
for a given technology, structured in a manner 
that makes the patent maze more navigable and 
transparent. Each landscape explains the science 
behind the technology, the legal and expiry status, 
the claim scope of key patents, the key assignees of 
patents, and the geographical coverage of key pat-
ent families. Help pages for searching techniques 
are extensive. Considering that the CAMBIA 
initiative is an open-access project for the public 
good, such an achievement is remarkable. 
Despite these advantages, a professional 
searcher would use commercial search tools men-
tioned elsewhere in addition to Patent Lens. This 
is primarily because the collections of professional 
tools are more likely to be up-to-date and will also 
have extended geographic coverage. However, for 
researchers, small businesses, and TTOs, using 
Patent Lens would have certain advantages, not 
least of which is the ability to quickly search the 
prior art (in plant-related patents), thereby avoid-
ing wasteful reduplication of research efforts and 
investments. Besides, it is unlikely that TTOs in 
some developing nations would have access to 
commercial databases.
In summary, the CAMBIA database cannot 
be used in isolation. EPO, PTO, other patent of-
fices, and commercial databases are more likely to 
be current. In instances where there are combi-
nations of technologies, for example cloning and 
expression of a particular mammalian gene in a 
plant, one would want to look beyond CAMBIA. 
It is, however, an excellent and comprehensive 
starting point. 
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4.1.6 	 Intellectual	Property	Office	of	Singapore
The Web site of Singapore’s Intellectual Property 
Office is a good site for starting searches.19 It has 
links to other sites in “search results.”
4.1.7  Other	resources
There are numerous other resources related to 
patent and scientific information. Some of the 
more useful ones, though not related to national 
offices or databases, are:
• Intellectual Property and Biotechnology 
Handbook.20 Although several years old 
and, in places, somewhat out-of-date, 
this handbook remains a useful teach-
ing tool. Individual modules of the hand-
book are downloadable in pdf format, and 
Module Four is devoted to searching patent 
databases.
• Manual for Biotechnology and IP.21 This 
excellent manual, though somewhat out-
dated, on IP in biotechnology was pre-
pared by Patent and Trademark Attorneys 
Spruson and Ferguson. The manual in-
cludes searching strategies.
• Managing IP Web site.22 This is an excel-
lent and comprehensive guide to IP in the 
field of biotechnology. The site has lots of 
useful and current information. Although 
not all resources are instantly accessible 
without registration, many are. This site 
contains current information on various 
changes in IP laws, interpretation of these 
laws, and litigation outcomes related to IP 
disputes in a selection of jurisdictions. The 
articles are written by well-respected IP pro-
fessionals worldwide. The “International 
Briefings” link, which takes you to country-
specific articles, is particularly useful.
• patent blog sites. Recent trends have led to a 
rapid proliferation of so-called patent blogs. 
These are sites that allow anyone interested 
in patents to share information related to 
patents, including information from other 
blog sites. While many of these have limited 
or no moderation and so contain informa-
tion that may be highly opinionated or of 
no value, it is possible to find a lot of use-
ful information, such as announcements of 
patent seminars, new developments in the 
patent world, and patent searching tips. 
Blog sites are useful if you have queries that 
other users can help with. Some blog sites may 
deal with highly specialized areas such as search-
ing or licensing. This arena keeps changing, with 
new blogs being introduced and older ones disap-
pearing, but the net trend is an overall increase 
in these sites. A few of the blog sites are listed 
here—not as recommendations, but as starting 
points—and the reader is encouraged to search 
for more resources, like these, on the Internet:




• Promote The Progress®26
• Scirus27 




Commercial patent search engines offer tremen-
dous advantages over free databases, but they are 
only available for a fee. Depending on the specif-
ic requirements, the costs are easily offset by the 
added functionalities and options that are avail-
able only with these databases. Some of the most 
prominent and flexible commercial services are:
• Delphion.29 Delphion is a patent search da-
tabase owned and maintained by Thomson 
Scientific. There are two versions of 
Delphion:
1. A basic, free version that requires reg-
istration. This version enables the user 
to perform “quick searching” among 
granted U.S. patents, as well as “number 
searching” for worldwide patent collec-
tions. Through this version, pdf files of 
patents are available for download on a 
pay-per-use basis.
2. A fee-based subscription version with 
various levels of access to downloads 
and other features depending on the 
particular subscription options pur-
chased. In our opinion, Delphion is 
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one of the best—if not the best—search 
engine (subscription version). It is the 
most widely used search tool of pat-
ent attorneys and professional searchers 
worldwide. Its comprehensiveness and 
accessibility far outstrip individual free 
services/databases.30
• Derwent World Patent Index (DWPI).31 
DWPI (like Delphion) is a proprietary 
database owned by Thomson Scientific. It 
is different from other databases in that it 
consists of summary information about 
patent applications that are rewritten, an-
notated, and formatted by Thomson’s staff 
in a manner that makes the site more user-
friendly for beginner patent searchers. It 
also includes some powerful value-added 
features for both novice and advanced 
searchers. DWPI is useful if one wants to 
quickly determine the technical content 
of patents. It requires a paid subscription 
and is sometimes bundled as a companion 
product with Delphion since they are de-
signed for integration. A version of DWPI 
is available for use within the buildings of 
the British Library in London (free remote 
access is not possible).32
• Micropatent.33 Micropatent is another pop-
ular source for patent and trademark infor-
mation. The coverage is comprehensive and 
full-document delivery is available.
• Questel Orbit.34 The service hosts commer-
cial patent search tools. It offers fee-based 
search services.
• Nerac.35 Using this fee-based service, ana-
lysts and searchers can extract market in-




Several software tools and services exist that busi-
nesses use to extract information from large patent 
datasets, examine relationships between patents 
and patent sets, or create visual representations 
of search results and summarize the information 
in reports. It is possible to use these tools to, for 
example, find out key assignees and inventors in 
a particular field, view industry and technologi-
cal trends, and compare patent filings over time. 
But many of these tools come at a price. These 
may be of interest to universities or spinouts 
with advanced commercial activities, but prob-
ably not to the average TTO. A handful of tools: 




While patents are arguably the most important 
form of IP for research and product development 
in health and agricultural technologies, patent in-
formation may often be worth little if it is not 
examined in the context of other IP rights. For 
example, genetic information may not only be 
the subject of patent protection. It can also enjoy 
other forms of protection. A few key links related 
to a selection of IP rights are mentioned below to 
give the reader a starting point for exploring these 
IP rights in these fields.
4.4.1  Trademark	Searches		
A comprehensive collection of links to trademark 
offices in many jurisdictions, databases, search en-
gines, and official gazettes is available on a British 
Library Web page.41
4.4.2 Copyright	Issues
Issues of copyright are complex, involving various 
national laws and partial harmonization through 
regional and international treaties. Some good 
places to start examining the issues are the various 
conventions and treaties in the WIPO Web site.42 
4.4.3 International	treaties
The WIPO portal is a great way to begin explor-
ing international treaties on intellectual property 
rights (including the Agreement on Trade-Related 
Aspects of Intellectual Property Rights [TRIPS]) 
available through the WIPO portal.43
The WTO-TRIPS agreement is increasing-
ly affecting cross-border trade and national and 
international IPR regulation and enforcement. 
Useful resources include the WTO Web page on 
TRIPS.44
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In addition, the Resource Book on TRIPS and 
Development is available through the UNCTAD-
ICTSD Capacity Building Project on IP rights. 
This authoritative, practical guidebook to all aspects 
of TRIPS is downloadable in sections.45 Although 
the guide is written mainly for policy-makers and 
negotiators, its comprehensive coverage of subject 
matter is useful for all those interested in TRIPS.
5.	 ConCluSIonS
Patent searching is an art that requires a solid 
foundation in and understanding of the sciences 
related to specific searches. In addition to compil-
ing patents related to certain inventions (for FTO 
purposes, prior art, or scientific endeavors), it is 
important to pay attention to other aspects, such 
as regular updating. One free service for this is 
particularly noteworthy. FreshPatents allows us-
ers to track the publication of new patents related 
to certain well-defined fields of scientific endeav-
or.46 After registering and defining the fields of 
interest, weekly e-mails are sent that include a 
list of the patent applications by the U.S. Patent 
Office. Other services are also available, such as 
RSS feeds. ■
HARRY THANgARAJ, Director, Research, MIHR (Centre 
for Management of IP in Health R&D), Oxford Centre for 
Innovation, Mill Street, Oxford, OX2 0JX, U.K. harry@
mihr.org 
ROBERT H. POTTER, Senior Associate, Agriculture & 
Biotechnology Strategies, Inc., 106 St. John Street, PO Box 
475, Merrickville, Ontario, K0G1N0, Canada. rpotter@
agbios.com
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1 See, also in this Handbook, chapter 14.4 by GM Fenton, 
C Chi-Ham and S Boettiger; chapter 14.2 by SP Kowalski 
titled Freedom to Operate: The Preparations; and chap-
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24 On this blog site, at the time the chapter was written, 
there was a video seminar by a U.S. patent attorney 
about what universities should know about the patent 
review process and how an inventor can submit a 




28 The HINARI initiative was set up by the World Health 
Organization (WHO) along with several major 
publishers of academic journals, including Nature and 
Science. About 3,300 complete journals are available 
for free to health research institutions in countries 
with a “GNP per capita” of less than US$1000. A second 
group of countries with a GNP per capita of US$2000–
$3000 get low-cost access. However, it should be 
noted that some countries, like India, are excluded 
from both categories, despite fulfilling the eligibility 
criterion for free access, because the publishers have, 
in their agreement with the WHO, reserved the right to 
exclude markets where the publishers have significant 
sales. By clicking on “Eligibility” on the left-hand side 
of the home page, you can ascertain whether your 
country/institution is eligible for free or low-cost 
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30 For further information on the features of Delphion, 
including detailed instructions for use, visit www.
delphion.com/help/index#derwent.
31 scientific.thomson.com/products/dwpi/.
32 For further information on the features of Derwent, 



















In the fields of health and agriculture, it has become 
increasingly important to understand the role of patent 
infringement in research, development, and commercial 
production. If a patented technology is used without per-
mission, the patent holder may have the right to sue the 
researcher for patent infringement. Many companies rou-
tinely analyze the freedom to operate (FTO) of a research 
project or product, assessing whether it is likely to infringe 
existing patents or other types of IP rights. Private com-
panies more routinely engage in FTO analysis than public 
sector research institutions because the infringement risks 
they face must be directly considered in the calculus of 
profitability. Public and not-for-profit private institutions 
also are becoming increasingly aware of the need for bet-
ter FTO information, but FTO analysis is expensive, and 
its benefits must be weighed against its costs. This chapter 
provides an overview of the process, including consider-
ations of when to invest in FTO analysis, and particularly 
focuses on the law firm’s role and perspective.
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to sue the researcher or their employer for patent 
infringement. Many companies routinely analyze 
the freedom to operate (FTO) of a research proj-
ect or product, assessing whether making, using, 
or selling it is likely to infringe existing patents 
or other types of IP (intellectual property) rights. 
The resulting information contributes to a larger 
risk assessment that may involve a range of op-
tions: identifying in-licensing targets, consider-
ing the substitution of technologies, deciding to 
ignore the potential infringement, investing in 
work-around technologies, or perhaps deciding 
to abandon the project all together.
Private companies are more likely to engage 
in FTO analysis because the risks they face must 
be directly considered in their calculus of prof-
itability. Public and not-for-profit private insti-
tutions are becoming increasingly aware of the 
need for better FTO information. FTO analy-
sis, however, is expensive, and its benefits must 
be weighed against its costs. Researchers in pub-
lic institutions, not-for-profit institutions, and 
in developing countries must consider different 
factors when weighing the benefits and costs of 
FTO analysis. In particular, many technologies 
patented in developed countries are not patent-
ed in developing countries. Therefore, institu-
tions making, using, or selling the technologies 
are not at risk of infringing in those developing 
countries. However, if a product is imported to 
CHAPTER 14.4
1.	 ConCepTS	And	defInITIonS
In the fields of health and agriculture, it has be-
come increasingly important to understand the 
role of patent infringement in research, devel-
opment, and commercial production. Patenting 
has become so prevalent in some countries that 
agriculture and health researchers often use pat-
ented technologies daily in the course of their 
work. If a patented technology is used without 
permission, the patent holder may have the right 
Fenton GM, C Chi-Ham and S Boettiger. 2007. Freedom to Operate: The Law Firms Approach and Role. In Intellectual Proper-
ty Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, 
et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. GM Fenton, C Chi-Ham and S Boettiger. Sharing the Art of IP Management: Photocopying and distribution through 
the Internet for noncommercial purposes is permitted and encouraged.
Freedom to Operate: 
The Law Firm’s Approach and Role
gillian m. Fenton, Chief Intellectual Property Counsel, Emergent BioSolutions, Inc., U.S.A. 
cecilia chi-ham, Director, Biotechnology Resources, PIPRA, U.S.A. 
sara Boettiger, Senior Advisor, PIPRA and Chief Economist, M-CAM, Inc., U.S.A.
FENTON, CHI-HAM & BOETTIGER
1364 | HANDBOOK OF BEST PRACTICES
a country where patents on the technologies are 
in force, then the importer may be infringing in 
that country. 
This chapter and that by Kowalski1 together 
provide an overview of the FTO analysis process, 
including considerations of when (and whether) 
to invest in this type of analysis. Kowalski discuss-
es FTO analysis from the researcher’s perspective, 
whereas this chapter is particularly focused on the 
law firm’s perspective. In this chapter, we draw 
from a case study of the E8 promoter. One of 
many enabling technologies used in the genetic 
transformation of plants, the E8 promoter pro-
vides a concrete example of FTO analysis.
While patents are the most common type of 
IP right encountered, a thorough FTO analysis 
will assess all types of existing property rights in 
order to determine the likelihood that the re-
search project or the product being commercial-
ized infringes. As Kowalski2 and Krattiger,3 we are 
also concerned with both intellectual and tangible 
property rights. In biotechnology, tangible prop-
erty comprises the biological material of the in-
vention: one can physically possess such material. 
Common examples of tangible property in health 
and agriculture include cell lines, transgenic mice, 
germplasm, and plasmids. The transfer of tangible 
property often occurs under a contract that gov-
erns the terms under which the property changes 
possession but not ownership (commonly called 
material transfer agreements, or MTAs4). Unlike 
IP rights, ownership rights over tangible property 
do not expire. Tangible property rights provide a 
further source of protection for certain elements 
of an invention. Sometimes elements of an inven-
tion can be the subject of both types of rights. 
The use of a gene, for example, may require a 
license to a patent as well as a material transfer 
agreement governing possession of the DNA 
itself. 
IP is a category of intangible assets, and in-
cludes things such as creative works, inventions, 
or commercial secrets. Under United States law, 
IP rights are defined as exclusionary rather than af-
firmative rights. That is, the owner of IP generally 
has the right to exclude or prevent others from 
using the intellectual property. The owner can 
grant permission for use in the form of a license 
or similar contractual agreement. IP rights are 
granted by government entities (for example, 
the U.S. Government or other countries) or by 
multinational authorities pursuant to interna-
tional treaties (for example, the European Patent 
Office [EPO] acting under the European Patent 
Convention). A grant of IP rights thus confers 
exclusivity only within the territory controlled 
by the grantor and only for a limited number of 
years. 
The practice of IP rights in the absence of the 
owner’s permission is defined as infringement. 
U.S. law provides a number of remedies for in-
fringement, chiefly the award of damages (a mon-
etary award of the amount necessary to fully com-
pensate the IP owner for the harm resulting from 
infringement) and/or the grant of an injunction 
(a court order to cease infringing activity or to 
refrain from commencing such activity). In some 
cases, additional remedies may apply, such as the 
award of attorneys’ fees and/or the enhancement 
of damages (doubling or tripling of the award); 
these additional remedies may be awarded when 
the act of infringement has been willful.
Because IP rights are exclusionary, the gov-
ernment grant of an IP right, such as a patent, in 
no way confers an affirmative right to practice the 
intellectual property. This stands in fundamental 
contrast to the grant of, for example, a regulatory 
license by the U.S. Food and Drug Administration 
(FDA), which does confer the right to sell a new 
drug or medical device in the U.S. market. Thus, 
when pursuing a business goal, such as the devel-
opment and commercialization of a new technol-
ogy, one must be cognizant of the IP rights of 
others, because those others may have the right 
to block or impede progress toward the desired 
business goal. 
FTO is defined as the absence of third-party 
IP rights that impede progress toward a desired 
business goal. FTO is also sometimes referred to 
as clearance. As will be discussed below, FTO can-
not be conclusively established, but rather should 
be viewed as an ongoing investigative activity 
for as long as the corresponding business goal is 
pursued.
We distinguish the concept of exclusivity, 
as distinct from FTO, defining it as the benefit 
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conferred by a collection of IP rights amassed by 
a single owner, that the owner can use to prevent 
others, such as business competitors, from using 
a technology. It is possible, for instance, for an 
institution to have created a high degree of exclu-
sivity for a technology through patenting but still 
not have FTO because the making, using, selling, 
or exporting of the technology infringes another’s 
patents. 
A collection of IP rights in similar subject 
matter or a single technology is often referred 
to as an IP portfolio. On a practical level, such 
IP rights protect the present or future potential 
market of the owner. The portfolio should be 
designed so that it corresponds to, and therefore 
supports, a business goal. 
The concepts of exclusivity and FTO must 
be considered together when assessing the rela-
tive risk or desirability of pursuing a particular 
business goal. When initially formulating the 
business goal or assessing a new discovery, there 
may be little to no exclusivity or FTO (or at least 
knowledge about the status of either parameter) 
to consider at that time. It is customary to build 
an IP portfolio in parallel with the process of 
technology development; however, during the 
course of development it may be unwise to de-
fer an FTO investigation for too long. As noted 
above, a particular technology can accrue a high 
degree of exclusivity in the form of a well-round-
ed IP portfolio but still suffer from a lack of FTO. 
The risk associated with further development or 
commercialization of this technology may lead to 
remedial steps, such as thoroughly investigating 
FTO and entering into license agreements to im-
prove FTO status.
Conversely, some technologies, such as those 
in the public domain, can be commercialized with 
a relatively low risk of being found to infringe the 
IP rights of others. However, it is important to 
understand that public domain technologies are 
exposed to the full force of market competition 
through use by others—a product developer can-
not shelter them by the exercise of exclusionary 
IP rights. 
Accordingly, in the course of developing a 
new technology, it is important to consider build-
ing the exclusivity of an IP portfolio, while assess-
ing and preserving FTO. That is why this chapter 
focuses on the process of investigating and moni-
toring FTO while concurrently building an IP 
portfolio. Technology that corresponds to busi-
ness goals and that possesses maximal FTO and 
maximal exclusivity is the most likely to attract 
and retain investment capital. 
It is worth noting that public sector institu-
tions differ fundamentally from private companies 
in many of the elements discussed here. Consider, 
for instance, a university’s portfolio of relatively 
early-stage technologies in which the licensee, 
not the portfolio manager, is commercializing the 
technology. It is the licensee who assesses risks 
in relation to a particular business goal and who 
seeks maximal exclusivity and maximal FTO. For 
the technology manager, FTO is important partly 
because blocking patents may make a university 
technology unmarketable or otherwise limit its 
future implementation. 
In universities, moreover, faculty inventors 
often respond to a different set of incentives than 
technology transfer staff. Compared to a private 
company where incentives are more likely to be 
aligned around the successful commercialization 
of products, the bifurcated structure in universi-
ties between the production of intellectual prop-
erty and its management can make it very difficult 
to coherently assess risk or build an IP portfolio 
with particular business goals in mind. 
Public sector institutions may also pursue 
goals that are substantially different from those 
supported by IP management strategies in the 
private sector. In that sense, the calculus of their 
risk assessments may differ. For example, an in-
stitutional goal may be to preserve broad access 
to invented technologies or to ensure that new 
technologies are adopted as broadly as possible. 
While a public sector institution’s use of intel-
lectual property—and therefore its consideration 
of FTO and exclusivity—to achieve these goals 
may differ from private commercial companies, 
a sound understanding of the basic process and 
characteristics of FTO remains a common critical 
skill for successful technology management.
2.	 TypeS	of	ip	RighTS		
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AS	They	AffeCT	fTo
As summarized below, a number of distinct cat-
egories of IP rights can be used to build a port-
folio. This chapter emphasizes the types of rights 
typically encountered in the life sciences, such as 
biotechnology, pharmaceuticals, and medical de-
vices. Naturally, similar issues and opportunities 
are presented in many fields of technology.
2.1	 Patents	and	trade	secrets	
These first two main types of IP rights are based 
on the concepts of inventions and know-how. 
Inventions are the practical, useful aspects of dis-
coveries and are typically embodied in the devel-
opment of new technology. An invention can be 
protected by a utility patent if it meets the statu-
tory criteria specified by the relevant government 
entity. In the United States, patents are granted 
by the U.S. Patent and Trademark Office (PTO), 
which is part of the federal government. The cri-
teria include novelty, utility, and nonobviousness. 
Patents are granted in response to filed applica-
tions that provide an adequate written descrip-
tion of the invention, teach how to make and use 
the invention, and, in particular, point out and 
distinctly claim the essential elements of the in-
vention in one or more written claims. A patent 
is a government grant of the exclusionary right to 
prevent others from making, using, selling, offer-
ing to sell, or importing the invention as claimed. 
The patent is granted for a limited time: under 
current United States law, the patent grant expires 
20 years from the filing date of the first applica-
tion disclosing the claimed invention. A patent 
portfolio includes all patent rights, including both 
issued patents and pending patent applications, 
that correspond to the invention and its various 
aspects and uses.
The broader category of know-how includes 
technology and information that may be related 
to inventions or to their use, marketing, distribu-
tion, or sales but is not patentable. Such informa-
tion, if its proprietary status is maintained, may 
qualify for trade secret protection. Trade secrets are 
IP rights in unpatented technology and informa-
tion that confer a competitive advantage to the 
owner, and are generally unknown. Trade secret 
status depends on the vigilant preservation of the 
secret by limiting knowledge of it to those key em-
ployees or other workers who have a need to know 
and by using suitable nondisclosure agreements 
and policies. Examples of trade secrets include 
ingredients, manufacturing methods, busi-
ness methods, and customer lists. In the United 
States, whether information qualifies as a trade 
secret is determined in accordance with state 
law. Generally, the applicable law confers on the 
owner the right to prevent others from copying or 
pirating the secret. As with patents, the remedies 
available in the event of the misappropriation of 
a trade secret include damages and injunctions. 
However, no remedy is available where the secret 
is independently discovered by another who acts 
in good faith and does not engage in unfair busi-
ness practices. Also, trade secret protection ceases 
upon publication or other public disclosure of the 
secret by any party. Thus, while trade secrets may 
be an important component of the IP portfolio 
for a particular technology, they may not func-
tion as business assets in the same way or to the 
same degree as patent rights. For example, trade 
secrets cannot be showcased, as patent rights of-
ten are, to attract investment capital.
2.2	 Regulatory	rights	and	licenses
There are other categories of exclusionary rights 
besides patents and trade secrets. In the United 
States, one important additional category in-
cludes rights granted by the U.S. Food and Drug 
Administration (FDA) in accordance with the 
Federal Food, Drug, and Cosmetics Act. For ex-
ample, orphan drug status provides a seven-year 
period of exclusivity for a new drug developed 
to treat a disease or disorder afflicting less than 
200,000 individuals in the United States. Once 
entitlement to orphan drug status is established 
to the satisfaction of the FDA, the agency gen-
erally will refrain from granting any additional 
regulatory approvals to competing drugs devel-
oped for the same disease or condition until the 
exclusivity period expires. It is not necessary that 
the drug granted orphan drug status be patent-
able. Similarly, to encourage the development of 
new drugs for pediatric use, the FDA may grant 
a six-month period of pediatric exclusivity to the 
first developer to establish safety and efficacy in 
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pediatric-patient populations. Finally, to encour-
age the development of generic drugs upon ex-
piration of patent protection for an innovative 
drug, the FDA may grant a six-month period of 
exclusivity to the generic drug developer who is 
the first to file an abbreviated new drug applica-
tion (ANDA). These regulatory rights and li-
censes provide important business assets during 
the commercial lifetime of the technology, rather 
than at its inception or during the development 
phase.
2.3	 Copyright
Copyright is defined as the protection afforded to 
original works of authorship that are fixed in a 
tangible (perceivable) medium of expression that 
can be copied or otherwise reproduced. Copyright 
exists in literary works, musical works, pictorial 
works, audiovisual works, software code, and so 
on. It is important to bear in mind that copy-
right protects the expression—not the underlying 
concept or idea. Copyrighted assets that may be 
relevant to life-science industries include bioin-
formatics or other software, documents, content 
posted on Internet Web pages, and advertising 
and promotional materials. As with patents, 
copyright is the government grant of the right 
to exclude or prevent others from making and/or 
distributing copies of the works and also of the 
right to prevent others from preparing deriva-
tive works. There are limits and exceptions to the 
scope of this exclusionary right: the owner cannot 
prevent fair use, which encompasses reproduction 
for such purposes as news reporting, criticism, 
teaching, and research. Also, under current U.S. 
law, the copyright lasts only for the life of the au-
thor plus 70 years, or in the case of a work made 
for hire, for the later of 95 years from first publi-
cation or 120 years from creation. Remedies for 
copyright infringement include money damages, 
injunctions preventing copying or distribution, 
and court orders impounding or destroying un-
authorized copies or the means to create or dis-
tribute copies.
2.4	 Corporate	identity
In modern commerce, the principal types of IP 
rights that protect a technology owner’s corpo-
rate identity, or its effort to develop goodwill and 
brand identity, are trademarks, service marks, 
and top-level domain names on the Internet. A 
trademark is any word, phrase, brief slogan, de-
sign, symbol, or logo that identifies the owner 
as the source of particular commercial goods. 
In health and agriculture, trademarks can be 
used to brand products such as plant varieties 
or drugs. Similarly, a service mark identifies the 
owner as the source of commercial services. As 
such, trademarks and service marks become im-
portant assets during the commercial product 
lifetime, rather than during the research and 
development phases. The same is generally true 
for top-level domain names (TLDs), which may 
be identical to, or incorporate, the trademark. 
Under U.S. common law, trademark rights 
arise via actual commercial use of the mark. 
Preferably, however, the trademark is registered 
with the U.S. PTO either upon actual use in 
interstate commerce, or upon a showing of a 
bona fide intent to commence such use within 
a specified time limit. Federal registration pro-
vides nationwide rights of enforcement and 
constructive notice of the mark to infringers. 
The duration of a trademark right is coexten-
sive with actual use of the mark in commerce. 
Registration rights are granted for ten-year 
terms, which may be renewed indefinitely on a 
showing that the mark remains in actual com-
mercial use. Conversely, a mark can be cancelled 
from the register if it is shown not to have been 
continuously used in commerce during the first 
five years after registration, or at any time if it is 
shown to have become generically descriptive. 
Unauthorized reproduction or counterfeiting of 
the mark, or of a colorable (confusing) imitation 
thereof, is an act of trademark infringement, as 
is the unauthorized importation of trademarked 
goods. Remedies include the grant of a perma-
nent injunction against copying, recovery of the 
infringer’s profits, money damages, and costs. 
Infringing goods can be impounded and/or de-
stroyed. If the infringing mark is a counterfeit, 
treble damages and attorneys’ fees are available. 
In the case of a TLD, the remedy may be limited 
to the transfer of the registration to the rightful 
owner.
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2.5	 Plant	breeders’	rights
Plant breeders’ rights (PBRs) protect plant varieties 
that are deemed new, uniform, stable, and distinct 
against unauthorized sale for replanting. PBRs 
do not generally prohibit the use of germplasm 
as breeding stock for creating new varieties. 
However, an exception to this was included in the 
1991 version of the International Union for the 
Protection of New Varieties of Plants, commonly 
known by its French acronym UPOV. It prohibits 
the breeding of a variety essentially derived from 
a protected parent.5 In the United States, plant 
variety protection certificates (PVPCs) confer pro-
tection against the use of sexually propagated seed 
germplasm. PVPCs are administered by the U.S. 
Department of Agriculture (USDA) under the le-
gal authority of the Plant Variety Protection Act 
of 1970.
The foregoing is not an exhaustive list of the 
types of IP rights that may be relevant to a partic-
ular technology or product. For example, design 
patents may protect an attractive or distinctive 
original design of a useful article, such as a medi-
cal or diagnostic device. In the field of agricul-
tural biotechnology, although plants are generally 
protected by utility patent rights, either plant 
patents—which in the United States grant pro-
tection from unauthorized use of most clonally 
propagated plants—or PVPCs may be obtained 
in addition to or in lieu of utility patent rights. 
3.	 SuBJeCT	mATTeR	of	The	fTo
The first step in conducting an FTO investigation 
is to define what is to be searched. How precisely 
the subject matter can be defined will depend 
largely on the developmental stage of the product 
or other technology, as well as the nature of the 
technology itself. For example, a product candidate 
ready to enter preclinical development requires a 
more substantial search than a newly discovered 
gene or biological pathway. In addition, research 
tools and platform technologies may present 
unique restrictions on the scope of an FTO search. 
For example, the search may be limited to an an-
ticipated field of use, or a full search of all uses may 
be required. Manufacturing technology and meth-
ods of use likewise may permit more or less precise 
descriptions of the subject matter to be searched. 
Manufacturing typically involves a number of dif-
ferent technologies, such as gene-expression vec-
tors and host cells, as well as a number of differ-
ent process steps. Each of these technologies may 
require an individual search, or the search may 
center on specific combinations of technologies 
and/or processes. Methods of use may be broadly 
or narrowly defined; related fields and collateral 
uses (for example, off-label uses of a therapeutic 
agent) may also require searching. In addition, the 
country or countries to search in must be identi-
fied. These should include any countries in which 
the technologies are likely to be made, used, or 
sold, as well as any countries intended as destina-
tions for export. In general, the subject matter to 
be searched should be defined as precisely as cir-
cumstances permit. When a search is revisited or 
updated, care should be taken to refine the defini-
tion of the subject matter to be searched.
4.	 when	To	ConduCT	An	fTo	SeARCh
Prudence must be the watchword guiding the de-
cision of when to conduct an initial or updated 
FTO search. The decision depends, as a practical 
matter, on the nature of the risks involved and 
the level of risk tolerance acceptable to the client. 
The following is a brief survey of typical consid-
erations that may guide the decision to engage 
in an FTO investigation as well as how such an 
investigation should be defined.
4.1	 Business	goals	
One particularly useful rule of thumb in deter-
mining whether to conduct an FTO search is to 
review and rank the relative importance of an 
entity’s business goals. This should be done by 
the decision maker in consultation with counsel. 
For each business goal, counsel must ask the deci-
sion maker whether they could walk away from 
that goal, that is, cease all activities in pursuit of 
that goal. This assessment is dictated by the avail-
ability of permanent injunction as a remedy for 
infringement of a number of different types of 
IP rights, such as patents, trademarks, and copy-
rights. Several subsidiary considerations further 
guide this analysis. 
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First, it has become clear that, under United 
States law, there is effectively no research exemption: 
the decision in Madey v. Duke indicates that ex-
ploratory or basic research may constitute patent 
infringement. So far, commercial companies have 
not sued universities for the infringement of pat-
ents used by their faculty in research.6 Indeed, a 
commercial company’s decision to turn a blind eye 
toward infringement in the public sector makes 
some economic sense. Were a patent owner to sue 
and win a patent litigation case against a universi-
ty, the patentee would be titled to injunctive relief 
and damages, that, for the typical use of patented 
technologies in basic research, would likely be 
negligible and not worthy of multimillion dollar 
patent litigation. However, universities who wish 
to promote the further development and eventu-
ally the commercialization of their faculty’s re-
search may want to pay increasing attention to 
FTO issues so that they can understand how their 
technologies are situated with regard to other pat-
ents in the field and how they can reduce poten-
tial future impediments to commercialization.
There is, however, a safe harbor exemption for 
research and development relating to the submis-
sion of applications for regulatory approval by 
the FDA, including both clinical and preclinical 
studies. The scope and limits of this safe harbor 
have not been conclusively established, necessitat-
ing a case-by-case analysis. Also, many developed 
countries have similar laws governing whether ba-
sic research and research related to the approval of 
new drugs is exempted from patent infringement. 
The scope and precision of laws on this point may 
differ significantly from country to country, and 
a detailed discussion is beyond the scope of this 
chapter. 
Second, and in view of the above, one must 
consider the geographic scope of the market to be 
served by the business goal under consideration. 
Since IP rights are granted by governments and 
are territorial in nature, an FTO investigation 
should apply the laws of the country or countries 
in which activities are undertaken in pursuit of 
the business goal. For example, all research, devel-
opment, and manufacture may take place in the 
United States, but the commercial market may 
include Europe as well as the United States. In 
other situations, the inverse may be true. The cor-
responding FTO investigations should identify 
and assess third-party patent rights in both the 
United States and Europe. In the case of a world-
wide market, cost and a pragmatic assessment of 
risk may dictate that the FTO assessment be re-
stricted to major markets.
Third, it is important to consider how much 
has been invested in the business goal to date. A 
significant investment, or an investment repre-
senting a significant portion of total business as-
sets, heightens the need for an FTO search. This 
principle is illustrated below in the context of a 
biotechnology or a pharmaceutical for human 
healthcare. Another approach, suitable to assess-
ing FTO for a research tool or platform technol-
ogy, is to determine whether use of the technol-
ogy is limited to a specific (and minor) project. If 
the technology will be relied upon broadly, or will 
underpin an important long-term business goal, 
an FTO search should be considered early.
A related consideration is whether the early 
establishment and monitoring of FTO will in-
crease the attractiveness of the business goal to 
potential investors. Venture capital investors and 
large institutional investors tend to be quite so-
phisticated and keenly interested in the IP risks 
pertaining to a technology or business plan of in-
terest. More recently, a well-formulated IP strat-
egy is a requirement for funding agencies that, in 
addition to supporting research, are dedicated to 
ensure the prompt dissemination of a project’s 
outcome.
4.2	 Risk	of	IP	infringement	litigation
Another rule of thumb is equally important.
Counsel and the decision maker should assess to-
gether whether the client can tolerate the risk of 
litigation. Risk tolerance varies with government 
oversight and regulations, management style, 
and the nature of business activities, but is also 
closely tied to financial resources, including the 
availability and scope of relevant insurance. When 
assessing the risk and consequences of infringe-
ment litigation, one must bear in mind that, at 
least in the United States and Europe, the cost of 
defense is significant. Also, at least in the United 
States and the United Kingdom, damages awards 
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for patent infringement tend to vary from large 
to quite large. Legal costs and damages, taken 
together, can figure in the tens of millions to the 
hundreds of millions of U.S. dollars. 
As mentioned previously, another signifi-
cant risk of infringement litigation is that a court 
will issue a permanent injunction, for example, 
ordering the client to cease its infringing activi-
ties or, under certain circumstances, ordering 
the seizure, impoundment, and/or destruction 
of infringing goods. Thus, the risk assessment 
must take into account the value of lost business 
opportunities. There may be other risks conse-
quential to the initial infringement liability, such 
as shareholders lawsuits and investigation and/or 
enforcement actions by regulatory authorities 
(for example, the U.S. Securities and Exchange 
Commission [SEC]7).
It must be noted, however, that infringe-
ment litigation is also costly to the plaintiff and 
may not be pursued when the unauthorized use 
of the technology does not threaten the pat-
ent holder’s business goals. The use of patented 
technologies in the course of academic research 
in the United States, for instance, has been shown to 
constitute infringement, but infringement lawsuits 
against academic researchers are likely to provide 
little benefit to the patent holder either through 
injunction or through the recovering of damag-
es. Examining the economic and legal rationales 
for infringement litigation may be particularly 
important for assessing the risk of infringement 
litigation by researchers in public and not-for-
profit institutions and in developing countries.
4.3	 Level	of	investment
A third useful framework for deciding when to 
conduct an FTO search is to determine what busi-
ness decisions should trigger the search. It will be 
fairly straightforward to identify the types of de-
cisions that would significantly increase resource 
commitments to a specific business goal. Such 
discontinuities in business strategy or financial 
investment should signal the need for an initial or 
updated FTO search. Indeed, many companies 
have made projects pass a series of increasingly 
rigorous FTO studies during the course of devel-
opment. A sampling of the changes in investment 
that may merit new or updated FTO studies in 
the development of a novel biologic or pharma-
ceutical drug are illustrated in Box 1. Analogous 
investment changes that may warrant an FTO 
analysis also exist in other fields, such as agricul-
tural and industrial biotechnology.
5.	 SCope	of	The	TypiCAl	
fTo	inveSTigATion
A typical FTO search canvasses all reasonably 
available sources that are likely to reveal relevant 
third-party IP rights. For the most part, these 
are computerized databases and search engines 
capable of surveying publicly accessible patent, 
technical, and commercial literature. Issued pat-
ents, published patent applications, and scien-
tific/technical publications, as well as databases 
of meeting presentations and grant awards, can 
be searched using keywords, investigators’ names, 
assignee/owner names, and subject-matter classi-
fications. Biological sequence databases, includ-
ing both nucleic acid and protein sequences, 
can be searched using a query sequence. Patent 
assignment branch records should be searched 
to reveal the names of real parties in interest, as 
well as transfers of ownership. Patent annuity 
and maintenance-fee records should be searched 
to verify that patents identified as relevant are in 
fact still in force. On the commercial front, the 
SEC filings of identified assignee/owner busi-
nesses that are publicly traded can be searched 
on the electronic data gathering, analysis, and re-
trieval system (EDGAR)8. The filings of interest 
include companies’ quarterly (8-K) and annual 
(10-K) reports of progress toward their business 
goals, which include self-assessments of risk. A 
search of the records of known competitors may 
reveal common threats to FTO status, such as 
third-party IP rights in broad classes of molecules 
(for example, fusion proteins) or manufacturing 
technologies. When appropriate, press releases, 
industry-specific news reports, and stock analysts’ 
reports also should be investigated.
5.1 “Level	one”	FTO	investigation
As mentioned above, not every FTO investiga-
tion merits the same scope or depth of search. 
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Exploratory research into a specific biological pathway may reveal one or more 
genes or proteins that appear to be a suitable site for intervening in a disease 
process or other metabolic process. A druggable target is a molecule identified 
as pivotal to a biological process, with a structural feature such as a cleft for 
which a pharmacophore can be identified or designed. In many cases, IP rights 
encompassing the use of the target or compositions of matter corresponding 
to all of the target or specific parts of the target may exist. Universities and 
research institutions frequently own such IP rights.
A number of companies have developed business models based on providing 
tools and services to the research community, and these may be aggressively 
protected by IP rights. Affymetrics, for example, markets and sells nucleic 
acid microarray chips. The Harvard oncomouse, commercially available from 
DuPont, is another example.
The selection of a lead compound typically represents the transition from 
research to development. It is axiomatic that the structure of a lead compound, 
one incorporating a successful pharmacophore, cannot reliably be predicted 
based on knowledge of the target. Thus, the lead compound and the structural 
class to which it belongs represent both new opportunities for developing an 
IP portfolio and new risks in light of which FTO should be established before 
committing resources to a development-phase project. Both specific and 
general features of the lead compound should be investigated. For example, IP 
rights may be found to cover humanized antibodies or different types of fusion 
proteins. The same considerations apply to any back-up compound. 
The commencement of preclinical development means both a significant rise 
in the level of financial commitment and the beginning of the safe harbor 
from patent infringement. Here, activities focus on the development of data 
to be included in an investigational new drug (IND) submission to the FDA. 
Despite the safe harbor, this step represents a formal commitment to develop 
a new drug or biologic for eventual commercial use. Thus, from the investment 
standpoint, it is a critically important stage at which to conduct a thorough FTO 
search or update and refine a prior search. Also, at this stage, many ancillary 
aspects of commercialization may be established beyond the structure of the 
drug candidate, such as its formulation or dosage, its primary commercial 
indication for use, and basic manufacturing techniques.
In many instances, the manufacturing technology needed to support 
commercial scale production of a new drug will differ from that practiced 
at the research or even developmental stage. Because of the magnitude of 
resource commitment required for manufacturing, many companies have 
patented successful manufacturing techniques broadly. One example would 
be the patenting of a particular type of chromatography resin to purify a 
particular class of molecules (for example, humanized antibodies). Another 
example would be the type of host cell or a formulation found to enhance 
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A main or primary clinical indication for the new drug or biologic may 
have been selected based on an understanding of the target and its 
mechanism of action. As development progresses, however, additional 
indications may become apparent, as may additional channels of 
commercialization (for example, neurologists may find the drug 
attractive for one disease, while gastroenterologists may perceive its 
value for another distinct disease). Each distinct clinical indication may 
attract its own competitors, dictating the need for corresponding FTO 
studies.
An IND application is the document the FDA uses to decide whether 
to allow human trials of a new drug or biologic agent. Readiness to 
submit an IND and, even more so, holding an approved IND represent a 
critical achievement in the business life-cycle. The interest of investors 
and potential corporate partners or acquirers is piqued, and the value of 
a business is significantly enhanced. It is particularly important at this 
juncture to establish the feasibility of the business goals corresponding 
to the drug development project. Indeed, a number of pharmaceutical 
companies treat the FTO investigation conducted at this juncture as the 
go/no-go decision on commercialization.
A pivotal clinical trial is one that can generate statistically sound 
data that the FDA can use to decide whether to approve a drug for 
commercial sale. Depending on the clinical indication, such a trial may 
take from one to five years, and may involve from tens to thousands 
of patients. Initiating and conducting such a trial often represents the 
single largest investment made during the course of commercialization. 
In addition, starting such a trial signals a commitment to particular drug 
compositions, formulations, methods of manufacture, and methods of 
administration and use. This commitment alerts third-party IP rights 
holders to the value of their IP, raising the cost of establishing FTO 
by entering into license agreements or avoiding adverse IP rights by 
designing around them. 
The new drug application (NDA) or biologics license application (BLA) is 
the dossier submitted to the FDA for its decision on commercial approval 
of a new drug or biologic agent. FDA approval, which typically takes 
from two to four years, signals the end of the safe harbor from patent 
infringement. Thus, the period of NDA/BLA pendency represents the 
last stage at which any remaining FTO issues may be resolved without 
exposure to infringement litigation. 
This is the commencement of actual commercial activity, the stage at 
which a company is fully vulnerable to charges of IP rights infringement. 
Prudence dictates that FTO must be established prior to this stage and 
that periodic monitoring be conducted to ensure preservation of FTO 
throughout the product’s lifetime.
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Exploratory-stage research, or consideration of 
a new business goal, may require no more than 
an overview and risk identification. The question 
to be answered is whether there are any so-called 
blocking patents that would preclude pursuing the 
new goal. This is called a “Level One” FTO study 
to distinguish it from more in-depth analyses. The 
Level One study assesses only public information, 
typically in the following two categories:
•	 Patent database searches. Keyword, sur-
name, business name, and sequence search-
es of patent databases are conducted to 
reveal relevant patents and published appli-
cations (which are potential future risks).
•	 Patent ownership and status search-
es. Surname and business/entity name 
searches of assignment branch records are 
conducted to reveal ownership interests, 
transfers of ownership, and other recorded 
rights affecting ownership. If deemed pru-
dent, secretary of state records may also be 
searched to reveal any transfers or liens that 
may not have been recorded at the federal 
level. Searches of relevant annuity/mainte-
nance-fee databases are conducted to reveal 
whether any of the identified patent risks 
have lapsed for nonpayment.
5.2	 “Level	Two”	FTO	investigation
There are many ways to design and implement 
more in-depth FTO searches. The nature of each 
search is dictated both by the precise definition 
of the subject matter to be searched and by the 
decision maker’s desired degree of risk character-
ization. Both considerations rest, in turn, on the 
significance of the business goal and the amount 
of resources required to achieve it. 
A typical “Level Two” FTO investigation 
is considerably more sophisticated than a Level 
One, yet still only requires access to public infor-
mation. Assessing nonpublic information requires 
either cooperation among the relevant parties (for 
example, IP due diligence in support of a busi-
ness alliance) or court order (such as during the 
discovery phase of infringement litigation). Both 
are beyond the scope of this chapter.
Patent database searches are conducted as de-
scribed in the Level One investigation, but the 
analysis conducted on this raw data goes beyond 
mere identifying potential blocking patents. 
Instead, the patent rights are evaluated substan-
tively to construct a patent landscape in which 
the patent claims are grouped by subject matter. 
For example, one group may encompass expres-
sion vectors and be subgrouped according to 
the type of vector. Another may encompass host 
cells, including specific types of host cells and 
their culture methods. Yet another group may 
encompass the structural class to which the drug 
of interest belongs. For example, all patent rights 
on fusion proteins may be grouped together, with 
sub-groups defined according to the protein class 
of interest (for example, receptor-Ig fusion pro-
teins). The groupings can be configured to most 
effectively educate the business decision maker 
about how to proceed. 
Another very informative way to analyze the 
search results is to construct a timeline of patents 
on similar or overlapping subject matter. Ordering 
the patents and published applications according 
to their priority dates (also known as effective filing 
dates) reveals important relationships. For exam-
ple, it reveals which patents are prior art against 
newer patents. Since patents may only be grant-
ed if the claims are both novel and nonobvious 
over the prior art, this analysis reveals the relative 
dominance of earlier, broader patents over later, 
narrower patents. There are many circumstances 
in which broadly and narrowly defined claims 
covering the same subject matter can coexist and 
be owned by different parties. Analyzing the pri-
ority timeline will reveal whether some patents 
should be licensed or designed around by devel-
oping alternative technology. This analysis will 
also reveal which parties possess more leverage to 
seek higher license fees. Including published ap-
plications in the timeline enables the astute deci-
sion maker to make educated guesses about the 
scope of claims likely to issue from applications 
filed later. Finally, it provides insight into possible 
interferences. Unique to U.S. patent law, an in-
terference is an administrative proceeding before 
the Board of Patent Appeals and Interferences, 
in which two or more parties claiming the same 
subject matter in separate patent applications en-
gage in a contest to determine who was the first 
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to invent. The procedural rules are strict, and the 
winner is awarded the patent. Figure 1 in the case 
study below illustrates a typical patent-priority 
timeline. 
Scientific and patent literature, including 
patents and patent applications, illustrate the 
existing prior art at the time that related patent 
applications were filed. The priority dates of each 
patent and patent application relative to the pub-
lications dates of the main scientific literature are 
shown.
The analysis of priority claims in published 
patent rights also reveal family relationships 
among different patents and published applica-
tions. Patent families include both vertical and 
horizontal relationships. A vertical or lineage re-
lationship arises when a later patent application 
claims the benefit of an earlier, related applica-
tion that names the same inventor (or at least one 
common inventor, in the case of joint inventors). 
If the specification (text portion of the applica-
tion) is identical to the earlier application, but the 
claims cover different subject matter, the later ap-
plication is called a continuation or a divisional. If 
the specification has been edited to disclose more 
or less information, and corresponding changes 
have been made in the claims, the later applica-
tion is called a continuation in part. Horizontal 
relationships arise in foreign filings, counterparts 
of the original application filed in other countries 
or common patent territories. Such foreign filings 
are made under bilateral or regional treaties in 
which two or more governments agree to recipro-
cally recognize the priority of applications filed in 
each others’ territories. The main vehicle for gen-
erating horizontal families of counterpart appli-
cations is the Patent Cooperation Treaty (PCT). 
The PCT provides a preliminary clearinghouse 
in which the claims are searched, and optionally 
examined, by a single examining authority. Both 
figure	1:	Timeline	of	Tomato	e8	Scientific	publications	and	patents
1985 19951990
Deikman and Fischer (1988)
EMBO J. 7, 3315–20
Giovannoni (1989)





























Patent and patent  
application timeline
Literature timeline
Scientific and patent literature, including patents and patent applications, illustrate the existing prior art at 
the time that related patent applications were filed. The priority dates of each patent and patent application 
relative to the publication dates of the main scientific literature are shown.
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the PCT examination report and the PCT search 
report are publicly available. Figure 2 in the case 
study below provides an illustration of patent 
family relationships.
Very often, the foregoing analyses reveal a 
subset of identified patent rights that require 
close analysis, including advice to the decision 
maker about the scope of the patent claims. This 
type of analysis is known as claim construction. It 
requires counsel to obtain and evaluate the patent 
file histories. The file history (or prosecution histo-
ry) is the written record of negotiations between 
the patent applicant and the examiner. The pat-
ent specification (text portion) typically does not 
change during prosecution; however, the claim 
language does change, sometimes quite dramati-
cally. For example, the examiner may require that 
the claims be divided into subsets, which are then 
prosecuted separately in divisional applications. 
Other changes in claim language arise from the 
need to conform to patentability requirements, 
such as enablement, written description, clarity, 
novelty, and nonobviousness. Even where the 
claims have not been amended, the patent appli-
cant may have made remarks that define the scope 
of the claim or that disclaim a broad interpreta-
tion. Such remarks are referred to as file wrapper 
estoppel or prosecution history estoppel because the 
patentee is not allowed to assert a broader claim 
scope when enforcing the resulting patent.
In the United States, prosecution history 
analysis is restricted to the histories of issued pat-
ents and published applications, since the files 
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confidential by law. In most cases, the file histories 
of foreign counterpart applications are available 
to the public. Thus, one can obtain insight into 
the potential scope of patentable claims by ob-
taining and analyzing the file histories of one or 
more counterpart applications in a patent fam-
ily. European prosecution histories are available 
electronically as .pdf files. Australian histories 
can also be obtained and are often useful because 
the pace of examination in Australia is frequently 
more rapid than it is in other PCT member states. 
Each foreign counterpart application is examined 
in accordance with the granting country’s patent 
law, so one must expect to encounter more or less 
nuanced differences in the scope and format of 
patentable claims.
In addition to analyzing prosecution histo-
ries, it is necessary to check the appropriate patent 
litigation databases to determine if any patents 
of interest have been held invalid or unenforce-
able. The PTO Web site should also be checked 
for information on whether an interference has 
been declared involving a patent of interest. 
The interference proceedings are not public in-
formation, but the final decisions of the Board 
of Patent Appeals and Interferences are publicly 
posted. Similarly, the records of foreign patent 
offices should be checked to determine whether 
any newly-granted patents have been the subject 
of patent oppositions. An opposition is an ad-
ministrative proceeding in which any member of 
the public adversely affected by the patent grant 
may file arguments urging that the patent should 
not have been granted, that is, it fails to comply 
with the grantor’s laws on patentability. Europe 
and Australia are among the countries that permit 
the filing of oppositions within a specified time 
period following the patent grant. The record of 
opposition proceedings in each country is pub-
licly available.
Finally, a prudent and thorough FTO inves-
tigation includes searches of business and news 
records as well as of patent records. General and 
industry-specific news reports may reveal the 
names of business or nonprofit IP holders not 
revealed through the patent database searches. 
They may also provide useful overviews on the 
state of the art or the competitive marketplace. 
If available, stock analysts’ reports on an industry 
sector or an individual business are particularly 
helpful. Such reports often provide independent, 
expert assessments of business risk, including IP 
risks. As mentioned earlier, the annual report or 
SEC filings of an IP rights holder provides useful 
self-assessments of risk and competition. Perusing 
the patentee’s Web site and relevant press releas-
es will often reveal whether the patent rights in 
question correlate to a stated business goal. Such 
information provides the decision maker with 
valuable insight into both the business model of 
the patentee and the importance—and therefore 
value—that the patentee places on the patent 
rights of interest. For example, a university or 
nonprofit organization may have a stated policy 
of licensing its IP rights in order to pursue its mis-
sion of advancing public knowledge or providing 
public benefit. Similarly, research tool companies 
have adopted business models that rely on broad 
licensing of their IP rights. In contrast, innovator 
drug companies and biotech companies may be 
motivated to preserve their exclusionary rights, 
such that licenses may not be available, or offered 
only on unfavorable terms.
5.3	 Limitations
It is imperative for the decision maker to bear in 
mind, when considering the results of any FTO 
investigation or clearance search provided by 
counsel, that such searches are, by their very na-
ture, limited. First, the search is limited in time. 
New patents may have issued since FTO was last 
analyzed, and it is for this reason that periodic 
updates must be considered. Second, the search 
is limited to publicly accessible information. It is 
impossible to identify all of the new inventions 
made in the field of interest or to characterize 
the trade-secret rights claimed by competitors or 
other business entities. Similarly, no FTO search 
can identify or analyze unpublished patent ap-
plications. This category includes United States 
provisional patent applications, as well as utility 
applications that are less than 18 months old (as 
measured from the priority date). Under current 
United States law, older utility applications also 
may not be published if the applicant has re-
quested nonpublication and disclaimed the right 
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to file foreign counterpart applications. Also, as 
mentioned above, the file histories of unpub-
lished U.S. applications are not available to the 
public. For these reasons, an FTO investigation 
may need to be updated regularly. If desired, an 
automated, computer-based monitor may be in-
stituted to alert counsel of new patent informa-
tion as soon as it becomes publicly available.
Business information also may not be avail-
able. A company’s business goals and the status of 
its research and development projects, for exam-
ple, may not be publicly disclosed. Similarly, in-
formation about the competitive risks perceived 
by the company may not be publicly available. 
While lawsuits are a matter of public record once 
filed, invitations to license a patent, threats of 
litigation, licensing negotiations, and settlement 
discussions are usually not in the public record. 
Corporate documents, such as contracts affect-
ing the ownership of intellectual property (for 
example, assignments, security interests, joint 
development agreements, service contracts) also 
are usually not public records. Similarly, contracts 
affecting the use of IP rights (for example, licens-
es, settlements, options, material transfer agree-
ments, confidentiality agreements, employment 
agreements, consulting agreements, noncompeti-
tion agreements, service contracts) are usually not 
public records. Business information influencing 
the results or interpretation of an FTO study may 
not be revealed until a due diligence investigation 
is carried out as part of a license negotiation, or 
until the discovery phase of a patent infringement 
suit commences. In certain circumstances, how-
ever, the existence of a corporate document that 
affects ownership or use of IP rights material to 
a publicly traded company’s business may be re-
vealed in the company’s SEC filings. A document 
is considered material if it affects the value of the 
company’s stock.
Another key area that usually cannot be ex-
plored when using only publicly available infor-
mation is whether there are any adverse claims 
to inventorship of third-party patent rights. 
Increasingly, inventorship disputes are being 
considered in litigation and other adversary 
proceedings as a way to obtain a license from a 
newly added, sympathetic co-patentee. As with 
nonpublic business information, the existence of 
possible inventorship claims is often not revealed 
until a licensing due diligence investigation is car-
ried out with the consent of the patentee or the 
discovery phase of litigation commences.
6.	 The	pRoDuCT	of	An		
fTo	inveSTigATion
The product of an FTO investigation conducted 
by a law firm or an in-house attorney and com-
municated to the decision maker is uniformly 
recognized under U.S. state law as being attor-
ney-client privileged information, and depending 
on the circumstances may also fall under the work 
product privilege. The results retain their privi-
leged status as long as the client (who holds the 
privilege) chooses not to reveal the information 
to others, or it is not inadvertently disclosed. The 
attorney-client privilege applies to advice regard-
ing IP rights in most European countries as well 
as in the United States. It is important to keep 
in mind, however, that in some countries patent 
professionals are not attorneys; thus the degree of 
protection afforded to the results of an FTO in-
vestigation may vary and should be established in 
advance. Switzerland, for example, does not rec-
ognize privilege in the communications between 
a patent practitioner and a client, although it does 
so between an attorney and a client.
In many circumstances, for example, where a 
Level One FTO investigation is all that is needed, 
the results of the investigation may simply be 
the oral advice of counsel to the decision maker. 
Depending on the purpose of the FTO investiga-
tion, or where a more-detailed Level Two investi-
gation has been carried out, counsel may provide 
a written report to the decision maker. Typically, 
the report includes brief statements of the scope 
of the search, as well as a listing of the search strat-
egies used (for example, keywords, sequences, as-
signee names). The report also includes a listing 
of the identified third-party IP risks. A written 
report of the identified risks is usually brief and 
carefully worded because of the potential for such 
commentary to function as admissions against in-
terest of the client, if the attorney-client or work 
product privilege is lost or waived.
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The most important feature of any document 
reporting the results of an IP FTO investigation 
is that it is a living document—it should be up-
dated as new information comes to light through 
a monitor or through a regular schedule agreed 
to between counsel and the decision maker. 
The decision maker should understand that deci-
sions may have to be modified or reconsidered 
in light of updated information about changes in 
the nature of the IP risks being monitored, their 
status, or newly emerging intellectual property. 
This process should continue for as long as the 
business goal is pursued.
7.		 ip	RiSK	mAnAgemenT	STRATegieS
The process of securing or improving FTO does 
not stop once the results of an investigation are 
available. Rather, the results of a clearance study 
provide the tools and intelligence necessary to 
determine the most desirable course of action 
for the client (whether a business, a university, 
or other nonprofit entity) to take in light of the 
discovery of a so-called blocking patent. Counsel 
should work closely with the decision maker in 
developing IP risk management strategies. Box 2 
presents a representative but by no means exhaus-
tive survey of the principal strategies that may be 
considered. Any one or a combination of the risk 
management strategies shown in Box 2 may be 
employed, as deemed prudent and appropriate by 
the decision maker working in consultation with 





The purpose of this case study is to illustrate ba-
sic strategies for performing an FTO search of a 
technology that has both research and commer-
cial objectives. This particular example includes 
the decision maker’s considerations when engag-
ing in an FTO analysis, the process of gathering 
FTO information in-house, the evaluation by 
legal counsel, and the outcome of the analysis. 
Attorney-client confidentiality privileges have 
been waived for the sake of sharing the experi-
ences of this investigation. The end results of 
the analysis show that while the target technol-
ogy, per se, is in the public domain, FTO restric-
tions are present when it is combined with other 
technologies.
Legal counsel is often sought when develop-
ing commercial products. But the use of FTO 
searches is not limited to business plans; they 
may also be crucial to projects with research and 
social objectives. Platform technologies used in 
the early phases of product development are of 
special concern because failing to negotiate access 
could drastically affect subsequent research and 
development plans or the licensing value of the 
technology. Unlike established agricultural bio-
technology companies with in-house IP counsel, 
public sector scientists around the world may not 
have easy access to legal experts and consequently 
are often unaware of the IP restrictions on com-
monly used research tools. Fortunately, to facili-
tate the research and development of improved 
crops with commercial and humanitarian objec-
tives, the Public Intellectual Property Resource 
for Agriculture (PIPRA)10 is working to design 
agricultural biotechnologies that are technically 
strong and subject to minimal IP restrictions. 
Plant transformation vectors—the molecular 
shuttle vehicles that introduce desired genes and 
traits into bioengineered crops—are a key plat-
form technology in agricultural biotechnology. 
Plant transformation vectors combine numerous 
components, such as genetic regulatory elements 
(promoters), selectable markers, systems to re-
move those markers, and more. By virtue of the 
fundamental role that these technologies play in 
bioengineered crops, they are often protected by 
intellectual property. Moreover, the FTO pathway 
quickly becomes entangled and complex because 
these technologies are usually not used individu-
ally but combined with different traits and in 
numerous host plants. To steer clear of potential 
blocking patents, it is important to incorporate 
technologies and methods that are in the public 
domain (free of IP restrictions) or that can be 
used with permission. This is why PIPRA, in col-
laboration with scientific and legal experts, is re-
searching the FTO of various vector components, 
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Box	2:	options	for	strategic	use	of	the	results	of	an	fTo	investigation
If a blocking patent has been discovered and cannot be licensed or 
avoided, the decision maker must consider whether it is acceptable to 
abandon pursuit of the affected business goal or the affected business 
practice (such as the use of a particular research tool or methodology). 
Alternatively, it may be commercially reasonable to modify the 
business goal or practice and thus obviate the blocking effect. This 
process is called “designing around the blocking patent.” The effect 
and cost of the modification must be taken into account to consider 
the reasonableness of this approach. For example, the decision maker 
must consider whether FDA approval would be required to change a 
formulation or manufacturing processes
It is important to evaluate the likelihood that the owner of a blocking 
patent will accommodate the client’s business goal by granting an 
affordable license. Intelligence on this point can be gleaned from 
reviewing the mission statement of the business or non-profit 
patentee, as well as from reviewing SEC records or press releases to 
determine  whether the patent in question has been licensed to 
others. The financial effect the license will have on commercializing 
the product or technology must also be considered. Royalty payments 
and manufacturing expenses together account for the cost of goods 
sold (COGS), so a patent license in effect forces cost cutting in other 
areas. The pressure on manufacturing costs is even greater for products 
subject to royalty stacking, when multiple royalties under multiple 
licenses are needed to commercialize a single product.
Patent owners may consider relinquishing their IP rights in territories 
or fields of use when they do not foresee sufficiently large commercial 
markets. In addition, a patentee may find that the benefits of good 
public relations weigh in favor of relinquishing IP rights for particular 
humanitarian uses of a technology. In these cases, negotiating a royalty-
free license or a covenant not to sue may be possible. However, product 
liability and stewardship issues remain concerns for many patentees. 
In fact, potential licensees may find that a patentee is seeking to avoid 
a liability risk for any defective products incorporating the patented 
technology that enter the stream of commerce.
If the consequences of abandoning or modifying the business goal 
are unacceptable, or if the decision maker suspects or has established 
that a license may not be available from the patentee on commercially 
reasonable terms, or if it seems likely that the patentee may take some 
offensive legal action, counsel may be asked to provide a reasoned 
written opinion on the non-infringement or invalidity of one or more 
claims of the blocking patent. It is important for the decision maker 
to realize that such an opinion does not shield the client against 
infringement litigation. However, it may provide useful insight or 
leverage in licensing or settlement negotiations, as well as precluding 
a court holding of willful infringement (which would permit doubling 
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including promoters used to regulate the expres-
sion of desired traits in specific plant tissues. 
8.1	 Defining	the	subject	matter		
of	the	FTO	or	clearance	search
The target technology for this case study is a 
fruit-specific promoter from the tomato E8 
gene. Technically, the E8 promoter is often cho-
sen because gene expression under its control is 
triggered by developmental cues such as fruit 
ripening. Expression of the gene of interest is 
confined to the ripe fruit and is not detected in 
other organs such as leaf, root, or stem. In addi-
tion, the promoter can stimulate gene expression 
in response to a chemical stimulus (ethylene) also 
in organ-specific fashion. As such, this transcrip-
tion-regulation element has been used to improve 
nutritional and juice qualities, extend the vine life 
of tomato fruit, and express edible human vac-
cines in tomato fruit.
As previously described, the first step in an 
FTO investigation is to clearly define the target 
technology. In this case, PIPRA proposes to use 
the fruit-specific promoter exactly as described in 
the initial publications by Deikman and Fischer11 
and Giovannoni et al.12 The promoters in these 
publications are virtually identical and consist of 
about 2,100 nucleotides upstream of the E8 gene. 
Further promoter characterization disclosing the 
location and sequence of functional elements 
within the promoter and upstream nucleotide 
sequence was reported in Deikman et al.13 These 
publications draw the technical boundaries sur-
rounding the target promoter technology and, as 
we will discuss later, provide important prior art. 
8.2 Does	the	business	plan	
warrant	an	FTO	analysis?
The plan of a project sets the direction that an 
associated FTO investigation will take. In this 
case, PIPRA foresees that, once this particular 
promoter is integrated into plant transformation 
vectors, it will be used for both research and com-
mercial purposes, both within the United States 
and abroad. Since it will be part of a platform 
technology that may be broadly adopted, it war-
rants an in-depth analysis to determine FTO. 
Because the technology is being evaluated at 
an early stage and could be used in a wide range 
of projects, PIPRA cannot know all of the specific 
genes of interest that the E8-promoter might be 
used to drive. Therefore, PIPRA chose to limit 
the analysis to FTO on the promoter per se and 
not on its use in combination with specific genes 
of interest, with an understanding that future 
analyses will be needed to determine FTO for 
specific combinations of the E8 promoter and 
heterologous genes. As described before, com-
pounding technologies create a more complex IP 
landscape because of the potential for overlapping 
patent claims. This initial FTO analysis thus in-
dicates only the technology’s general availability. 
Still, evaluating limitations at an early stage pro-
vides researchers and business developers with 
leverage	the	client’s	
own	Ip	portfolio.
Another means of improving the odds of obtaining a license on 
commercially reasonable terms is to inventory the client’s own 
IP portfolio supporting the business goal (or even other business 
goals) to determine whether any existing claims (pending or 
issued) could provide a cross-blocking effect. Can any of the 
client’s claims impede the FTO of the blocking patentee? If none 
are issued or pending, a client’s new patent application may 
provide a good basis for drafting and prosecuting new claims in 
pursuit of a cross-blocking effect. Alternatively, if there are issued 
or pending claims in the client’s patent estate that overlap with 
the patentee’s blocking claims, it may be possible for the client to 
trigger a U.S. patent interference with the patentee. Each of these 
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important information about the technology’s 
FTO position and illustrates the legal limitation 
of a technology presumed to be in the public 
domain.
8.3   Case	study:	FTO	information		
and	legal	opinion
In this case, PIPRA provided the background FTO 
information to legal counsel, who subsequently 
conducted an FTO analysis. The background 
FTO information packet consisted of a detailed 
description of the proposed construct, proposed 
management strategy of the plant transforma-
tion vectors, scientific literature on the technol-
ogy, and IP search results. Legal counsel assessed 
the relevant patents, grouping them according to 
subject matter and assignee, constructed a prior-
ity timeline integrating relevant literature and in-
tellectual property (Figure 1), and then delivered 
an oral and written FTO opinion. The following 
is a detailed account of the process.
8.3.1   Client’s	FTO	background	information
The scientific literature in the background file 
included a list of publications describing the dis-
covery, characterization, and applications of the 
E8 promoter. Literature records were identified 
and extracted using keyword and author searches 
using online databases. Assembling a timeline of 
publications and contacting the original inventor/
author of a technology are advantageous when in-
vestigating whether patent protection was sought 
at the time of invention and publication. This is 
particularly important because it is possible that 
corresponding U.S. patent applications could 
remain unpublished and later emerge as issued 
patents. PIPRA contacted the principal investiga-
tor (PI) of the group that originally identified and 
characterized the E8 promoter, Robert L. Fischer, 
at the University of California, Berkeley, and dis-
covered that the inventors did not apply for pat-
ent protection prior to their seminal publication. 
The absence of patent applications by Deikman 
and Fischer14 was confirmed by subsequent inves-
tigations. Because at this point of the investiga-
tion it was presumed that the technology was in 
the public domain, documenting published lit-
erature or prior art was particularly crucial. 
The patent landscape included patents and 
patent applications that were closely related to the 
technology. Keywords and authors of key publi-
cations were used to search for patents or patent 
applications. The patent search engines used were 
Delphion,15 M-CAM,16 and the EPO.17 A sepa-
rate search was conducted to identify patents or 
patent applications that referenced the scientific 
publications describing the technology. In addi-
tion, patented DNA and protein sequence data-
banks were searched using the E8 promoter’s DNA 
sequence as a query. Because the target technol-
ogy was identified and characterized in the late 
1980s and early 90s, special attention was given 
to publications with a priority date around that 
time. After evaluating patents and patent applica-
tions, a list was distilled of patents with claims 
to regions from the tomato-derived E8 promoter. 
Furthermore, a schematic representation illustrat-
ing the claimed DNA sequence between the target 
technology and patent claims was incorporated 
(Figure 1). For legal counsel’s convenience, a table 
of patents and patent applications was provided 
that included record numbers, family members, 
assignees, publication, priority, and application 
dates, as well as relevant notes. The patent land-
scape documentation also indicated whether the 
patent’s nonpatent prior art section (field 56 on 
the patent coversheet) cited Fischer’s publications 
(evidence that this was considered prior art). 
Another independent search was conducted 
to identify specifically those patents that claim 
the use of the E8 promoter to drive genes of in-
terest. This search was conducted in the same 
manner as described above, using keywords for 
the E8 promoter to search within claims. The 
pertinent patents and patent applications were 
extracted and analyzed. Again, a table with the 
patent records was compiled and a written report 
with the described information was submitted to 
legal counsel. After verbal communications and 
revisions, additional information (such as patent 
family trees) was provided for analysis (Figure 2).
8.3.2		Legal	counsel’s	FTO	opinion
Using this background information, legal counsel 
constructed a priority timeline including the key 
scientific literature and the most closely related 
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patent records, which were assigned to Agritope, 
Epitope, and Monsanto (Figure 1). As shown, 
the Deikman and Fischer18 and Giovannoni et 
al19 publications initially describe the E8 tech-
nology. This precluded the novelty of any subse-
quent patent claims on the E8 promoter per se 
(for example, applications filed by Agritope and 
Epitope). While the detailed written FTO opin-
ion of legal counsel is not included in this report, 
counsel concluded that the tomato E8 promoter 
constructs per se (searched as described above, 
without considering association with any heter-
ologous gene) can be reasonably considered to be 
in the public domain. 
Since the analyses did not examine FTO 
with the E8 promoter in conjunction with oth-
er genes or other vector elements, appropriate 
FTO limitations and future considerations were 
highlighted. Interestingly, because the initial E8 
publications did not disclose the use of the tech-
nology with a variety of heterologous genes, sub-
sequently issued patent claims were able to limit 
use of the technology by covering novel combina-
tions of already known elements. Thus, while the 
technology itself is in the public domain, its use 
with particular genes of interest is not. This infor-
mation indicates to PIPRA that FTO should be 
reevaluated in more-advanced stages of the vector 
construction when other technology components 
are known. Though not exhaustive, some of the 
patents claiming chimeric constructs compris-
ing the E8 promoter and heterologous genes are 
shown in Figure 3. The patents can be grouped 
into three broad categories related to agronomic 
characteristics, biopharmaceuticals, and gene ex-
pression control. Notice the potential for claim 
overlap within these broad categories, for in-
stance, gene expression control patent claims may 
span uses in agriculture and pharma. 
Legal counsel conveyed the results of the 
analysis to PIPRA via oral communications and, 
subsequently, in a written report. It is important 
to note that FTO analysis materials are protected 
by attorney-client privilege and thus should only 
be shared on a confidential basis with personnel 
that have a need to know (for example, business 
decision makers). In the case of the E8 promoter 
FTO investigation, the client (PIPRA) decided 
after consulting with legal counsel to disclose the 
results of the investigation for public informa-
tional and educational purposes. ■
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ABSTRACT
Recent years have seen intense global debate about 
whether or not agricultural biotechnology—particularly 
genetically modified organisms (GMOs) and genetically 
modified crops (GM crops)—should be covered by a 
specially designed liability regime. This chapter examines 
common and statutory law theories of liability, various 
attempts at the national and international levels to design 
liability regimes for GMOs, and liability risk-mitigation 
measures.
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potential liability risks shared by stakeholders, in-




Common law forms a major part of the law of 
those countries of the world that were once 
British territories or colonies. It is the body of law 
derived from centuries of judicial rulings, rather 
than from statutes or constitutions.2 The com-
mon law provides a means of compensating for 
wrongful acts (known as torts), whether they are 
intentional or are caused by negligence; it is also a 
way to regulate contracts. 
The common law theories of liability include 
the following: negligence, which refers to the 
breach of a legal duty by one party that proxi-
mately causes damage to another party; trespass, 
which refers to an unlawful act committed against 
the person or property of another, including 
wrongful entry on another’s property; nuisance, 
which refers to an unreasonable interference in 
another person’s or other persons’ use and enjoy-
ment of their land (private nuisance and public 
nuisance, respectively); and the principle of strict 
liability, which is not fault-based and may apply 




Liability is the “quality or state of being legally 
obligated or accountable.”1 The word refers to the 
obligation of a person or institution to provide 
compensation for damage it is deemed to be re-
sponsible for. Historically, liability has been de-
termined using common and statutory national 
laws; however, when questions of liability over-
reach national borders—as they often do in such 
fields as agricultural biotechnology—historical 
legal methods are not always applicable. Indeed, 
there has been intense global debate about the 
creation of a liability regime for genetically modi-
fied organisms (GMOs) and genetically modified 
crops (GM crops or transgenic crops). 
This chapter examines the existing com-
mon law and statutory theories of liability; the 
various attempts to design liability regimes for 
GMOs at national and international levels; the 
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The main statutory3 theories of liability in-
clude strict liability and infringement of intel-
lectual property (IP). Strict liability was first de-
fined in the case Rylands v Fletcher,4 in which the 
defendant had a reservoir built on his land that 
caused flooding of the plaintiff’s mine. This case 
articulated the principle that liability would arise 
in cases where damage is not necessarily caused 
as a result of the defendant’s actual negligence 
or intent to harm but based on the breach of an 
absolute duty as, for instance, when his or her 
nonnatural use of land causes the accumulation 
of dangerous things, which then escape and cause 
damage. In modern statutory law, a use is con-
sidered to be nonnatural if it is a special use that 
creates an abnormal risk of damage to another 
person’s property.5 The occupier of the land is li-
able for damage caused by an escape and has sev-
eral defenses (for example, common benefit, act 
of a stranger, statutory authority, consent of the 
plaintiff, default of the plaintiff, or act of God). 
Infringement of IP refers to use by an unauthor-
ized party of any of the exclusive rights enjoyed 
by the owner over his or her own IP. 
3.	legAl	lIABIlITIeS	And	gm	CRopS
3.1 The	international	debate
There has been considerable international de-
bate about the liabilities associated with GMOs 
and specifically the liabilities with GM crops.6 
One school of thought believes that GMOs pose 
no unique risks and argues that GMOs can be 
covered by liability regimes commonly used for 
other agricultural technologies; the other school 
of thought maintains that agricultural biotech-
nology is fundamentally different from other 
forms of agricultural breeding technology and 
argues that special legal liability regimes are re-
quired to ensure that those who experience loss 
arising from GMOs can obtain adequate relief. 
Countries such as Canada, the United States,7 
the United Kingdom, and New Zealand8 adhere 
to the first school of thought and apply general 
agricultural liability laws to GM products. The 
European Union, which holds the opposing view, 
has proposed that GM products be subject to a 
special legal liability regime. Certain E.U. coun-
tries, such as Austria and Germany, have passed 
national laws that impose strict liability for par-
ticular types of loss (such as death, injury, and 
damage to property) caused by GMOs. Under 
Austrian law, in the event of an accident involv-
ing GMOs (such as contamination of the food 
chain), the releasing entity will be liable for any 
harm to health, property, or the environment, 
and must return any affected property to its 
“original” state. For example, Austrian companies 
that manufacture GMOs must obtain sufficient 
liability insurance. German law imposes liability 
for injury to property or human health caused by 
GMOs.9 German regulations place liability at the 
“manager level” of the company, or installation, 
an assumption that is likely to make farmers who 
grow GM crops (as installation managers) liable 
for any accidents that may occur. German law 
also makes liability insurance mandatory for GM 
operators.
3.2 The	African	Model	Law	approach
In the midst of this international debate, the 
Organization for African Unity (OAU), now 
known as the African Union (AU) and the 
Ethiopian Environmental Protection Authority 
developed the African Model Law on Safety in 
Biotechnology in 2001 that was intended to be 
a basis for formulating national laws concerning 
biotechnology.10 This model law proposed instat-
ing a strict liability regime for GMOs.11 To date, 
however, the liability regimes being proposed in 
the draft biosafety laws of African countries seem 




The issue of liability and redress for damage re-
sulting from the transboundary movements of 
GMOs was addressed by the Biosafety Protocol of 
the Convention on Biodiversity (which referred 
to GMOs as living modified organisms [LMOs]). 
The negotiators were, however, unable to reach a 
consensus regarding the details of a liability re-
gime. Therefore, in the final text of the protocol 
(Article 27), the Conference of Parties was urged 
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to develop an international liability regime with-
in four years.13 A group known as the Ad-Hoc 
Open-Ended Work Group of Legal and Technical 
Experts on Liability and Redress in the Context 
of the Cartagena Protocol on Biosafety has since 
been created in order to achieve this goal. The 
group has met twice, both times in Montreal, 
Canada, first on 25–27 March 200514 and again 
on 20–24 February 2006. In the second meeting, 
the group developed a list of criteria for assess-
ing the effectiveness of any rules and procedures 
referred to in Article 27 of the protocol and de-
veloped different options for operational text on 
scope, damage, and causation.15 The group has 
yet to agree on a liability regime.
Kershen and Smyth have argued that 
“Developers of new agricultural biotechnology crops 
and animals—be they public or private; be they 
industrialized or developing countries—would be 
hindered by the inclusion of speculative risks in a 
liability and redress regime, especially public re-
searchers in developing countries.”16 Kershen and 
Smyth contend further that an Article 27 liabil-
ity and redress regime would reduce the amount 
and availability of agricultural biotechnology and 
thus impede public research on behalf of the poor 
in developing countries.17 They also assert, and 
the author of this chapter agrees, that future li-
ability costs could adversely affect agricultural re-
search in public research institutes in developing 
countries, since such facilities may not have the 
requisite financial resources to absorb the costs of 
any future liability. Furthermore, future liability 
costs could increase operational costs and thus 
raise product costs. 
4.	 mAnAgIng	eXISTIng		
poTenTIAl	lIABIlITIeS
The production and use of GMOs can create 
many potential liabilities. For instance, the pro-
ducer or user of GM crops or animals may be 
liable for damage caused by GM crops or animals 
to the person or property of another person or 
to the environment.18 Pollen flow from transgen-
ic crops to nontransgenic crops may cause crop 
damage. For instance, transgenic pollen flow may 
ruin the “organic” status of crops or the purity of 
the genetic material of other seeds.19 Questions 
may arise as to whether transgenic crops or their 
food products are toxic, allergenic, or pose a long-
term health threat.
Claims for compensation in actions for per-
sonal or property damage could be based on a 
theory of negligence, trespass, nuisance, or strict 
liability, although there has not yet been a de-
finitive judicial decision on these. A class action 
suit brought by farmers and other parties against 
Aventis Cropscience, U.S.A., alleged that their 
corn had been contaminated by transgenic corn 
approved for animal feed and ethanol produc-
tion but not for human food. The court deter-
mined that plaintiffs who could prove the alleged 
contamination would have a claim based on the 
theories of negligence, private nuisance, and pub-
lic nuisance.20 This case, which was settled with 
the proposed payment of over US$100 million 
to members of the defined class,21 underscored 
the potential for liability arising from the devel-
opment, production, and use of agricultural bio-
technology products. 
4.1 Negligence
A person whose crops or property is damaged 
because a neighbouring farmer failed to take 
adequate precautions to contain his transgenic 
crops may have a claim against both the neigh-
bouring farmer and the biotechnology company 
that created the transgenic crop.22 To sustain a 
claim based on negligence, the claimant (plain-
tiff) would need to prove four elements: the de-
fendant’s duty of care—a legal obligation imposed 
on an individual requiring that they exercise a 
reasonable standard of care while performing 
any acts that could forseeably harm others—to 
the plaintiff, breach of that duty by unreasonable 
conduct of the defendant, a causal link between 
the alleged unreasonable conduct and damage, 
and damages (a harm or injury valued in mon-
etary terms). When a farmer growing GM crops 
knows that neighboring farmers (such as organic 
and GM-free farms) may be adversely affected by 
GMO contamination, he or she arguably owes a 
duty of care to such farmers and must keep his or 
her GMOs from spreading beyond the bounds 
of his or her property. However, because there is 
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no scientific proof regarding the extent to which 
pollen or seed may be dispersed, it is impossible 
to determine who is affected by the unintended 
spread of GMOs from the defendant’s land. A 
GM farmer’s breach of duty of care, and the dam-
ages that he or she must pay as a result, will be 
judged according to the standards of a reasonable 
person and may take into account such factors as 
the magnitude of the risk posed by the GMOs, 
the degree of probability that such contamination 
would naturally occur, and the expense, difficulty, 
and inconvenience to the GM farmer that would 
result if he or she were required to rectify the situ-
ation. Biotechnology companies and farmers may 
be obligated to take additional reasonable precau-
tions to contain certain transgenic crops if, for 
example, the agronomic evidence shows that a 
particular transgenic crop causes weediness, pol-
len flow, or volunteer plants to a greater degree 
than do nontransgenic crops.23 
Obviously, biotechnology companies and 
farmers must develop techniques that minimize 
pollen flow and the establishment of volunteer 
plants in order to protect themselves from liabil-
ity. For example, transgenic crops could be engi-
neered to have biological barriers against pollen 
flow or preventing volunteer survival through 
male sterility (preventing fertilization), seed ste-
rility (preventing volunteer crops), or control of 
flowering time (preventing cross-pollination with 
other, nontransgenic crops).24 Indeed, if such bi-
ological barriers can reasonably be incorporated 
into a transgenic crop, a biotechnology company 
that failed to incorporate these biological bar-
riers and was subsequently accused of causing 
damage to property or person might be liable 
for a product’s liability claim for design defect.25 
Furthermore, farmers of transgenic crops can 
adopt agronomic practices to prevent pollen flow 
or the establishment of volunteer plants: farmers 
can plant fields at isolation distances; plant bar-
rier crops, border rows, or refugia (non-GM areas 
of the same crop); or establish agronomic zones 
dedicated to non-GM crops.26 Biotechnology 
companies would likely have a duty to educate 
farmers, with whom the companies have entered 
into contracts, about these agronomic manage-
ment practices and possibly have the obligation 
to police farmers growing the companies’ crops. 
Farmers, for their part, would have duty of care 
to abide by the agronomic management practices 
recommended by the biotechnology companies.
However, given the nature of agriculture in 
most of the developing world, where subsistence 
farming and small landholdings are the norm, it 
would be impractical to expect developing-world 
farmers to adopt most of the agronomic practices 
mentioned above. Biotechnology companies that 
donate their technologies for humanitarian use 
would benefit from a technology transfer scheme 
that permits such companies to provide technol-
ogies, like genes and transformation systems, to 
developing-world farmers, while protecting them 
from liability risk in case the transgenic crops are 
misused. 
4.2  Trespass
Persons who believe they have suffered damage 
from transgenic pollen flow may bring a common 
law cause of action based on the theory of tres-
pass.27 In this case, trespass indicates the physical 
invasion by transgenic crops of the possessory in-
terests of the property (land) of the person claim-
ing damages. Technically, proof that transgenic 
pollen has spread to neighboring fields could be 
sufficient evidence to establish trespass. However, 
it is a biological fact that pollen flows between va-
rieties of the same crop and between related plant 
species. Therefore, if pollen flow constituted tres-
pass upon a neighbor’s crops, all farmers would be 
liable for trespass for almost every crop they grow. 
Jurisdictions such as the United States have dif-
ferentiated between pollen flow that constitutes 
trespass and pollen flow that is accepted as a bio-
logical fact of farming;28 to sustain a successful 
action in trespass, there must be proof that the 
alleged physical invasion caused damage (such 
as contaminated seed). Naturally, the extent to 
which a claimant could rely on this theory of li-
ability would depend on the local laws regulating 
seed and crop standards.
4.3 Private	nuisance
Unlike the common law claims of trespass, strict 
liability, and negligence, all of which focus on 
the conduct or activity that causes harm to the 
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person or property of another, the claim of pri-
vate nuisance focuses on a person’s interests be-
ing protected (that is, the right of an individual 
to use and enjoy, free from interference by oth-
ers, one’s private land). Fundamental to the pri-
vate nuisance claim is the notion that neighbors 
must be accommodating of one another so as 
to allow peaceful coexistence. A private nuisance 
claim must prove that an invasion (1) is either 
intentional and unreasonable or unintentional 
and otherwise actionable as a legal claim for tres-
pass, strict liability, or negligence; and (2) causes 
significant harm (the definition of which is based 
on the gravity of the alleged harm and its level of 
normality in a particular locality). In the case of 
GMOs, a claimant must prove that nearby fields 
of transgenic crops have unreasonably interfered 
with the use and enjoyment of his or her own 
land. The courts are unlikely to endorse a private 
nuisance claim that, for example, insists on zero 
tolerance of pollen flow or of volunteer plants, 
or which claims “significant [emotional] harm” 
from personal opposition to transgenic crops.29 
4.4 Strict	liability
Persons who believe their land or crops have been 
damaged by a neighbor’s transgenic crops may 
bring a tort claim in strict liability if the activity 
of growing transgenic crops is “abnormally dan-
gerous” when the following factors are taken into 
account: 
• the degree of risk of some harm to the per-
son, land, or chattels of others resulting 
from the growing of the crop
• the likelihood that the harm that results 
from growing the crop will be great
• the grower’s inability to eliminate the risk 
by exercising reasonable care
• the extent to which the grower’s activities 
are unusual or unapproved
• the inappropriateness of the grower’s ac-
tivities to the location in which they are 
conducted
• the extent to which the value of the grower’s 
activities are outweighed by their potential 
dangers
In the United States, where transgenic crops 
are grown on a wide scale and where agricultural 
biotechnology is not considered legally different 
in kind from other agricultural breeding technol-
ogies, liability claims based on any of the above 
theories are difficult to establish.30 It will be inter-
esting to see how the policy-makers and courts of 
the developing world will deal with the transgenic 
crops beginning to arrive on their shores.
4.5 Liability	for	infringement	of		
intellectual	property	rights	
IP rights are a category of intangible rights regard-
ing creations of the human intellect.31 The holder 
of an IP right may exercise exclusive control over 
its use for a limited period of time; any unauthor-
ized use of the IP right during the statutory period 
of protection would constitute an infringement. It 
is possible, therefore, that farmers whose crops are 
accidentally affected by the presence of GMOs (as 
a result of pollen flow or seed comingling) might 
be held liable for IP rights infringement. Recently, 
Monsanto successfully brought suit in Canada 
against a conventional farmer who replanted seeds 
that had been contaminated with genetic material 
from Monsanto’s genetically modified crops. The 
GMOs in question, Roundup resistant plants, 
contain a patented transgenic gene that confers 
herbicide resistance. The court held that the har-
vesting and sale of crops derived from seeds that 
were known, or suspected, to be Roundup toler-





The developers of GM products must adopt ap-
propriate scientific and technical safeguards for 
all products and advise stakeholders, including 
smallholder farmers, as to the appropriate use of 
technologies and products. Farmers of GM crops, 
for their part, need to comply with relevant license 
conditions, standards, guidelines, and directions 
regarding deployment or use of GM products. 
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Proper compliance with these guidelines can help 
protect all parties from liability risks.
5.2 Indemnification
Indemnification is a promise, usually contrac-
tual, to protect a party from financial loss. 
Indemnification may work by either direct com-
pensation to the injured or by reimbursement for 
any loss incurred. One way to manage liability 
is to include indemnification provisions in agree-
ments relating to the transfer, development, and 
deployment of technologies. Such a provision 
specifies that the indemnifying party will compen-
sate the indemnified party for any loss or damage 
that may be sustained by it as a result of the ac-
tions of the former. Under this approach, the first 
party (the indemnifying party) agrees to hold the 
second party (the indemnified party) harmless 
and to defend the second party and its officials 
against claims resulting from the first party’s ac-
tions and/or omissions.
In order to limit the risk of liability to what 
it can adequately control, AATF might reason-
ably agree to indemnify a technology donor for 
claims resulting from AATF’s use of the licensed 
technology, provided that the indemnity granted 
under these conditions excludes claims resulting 
from the technology donor’s own acts and/or 
omissions.33
5.3 Warranty	disclaimers
Another approach to managing liability is the use 
of warranty disclaimers. A warranty, either express 
or implied, is a guarantee that a particular prod-
uct or technology will serve a specified purpose. 
A warranty disclaimer enables one party, usually 
a technology developer or transferor, to expressly 
disclaim guarantees. Conceivably, technology de-
velopers or transferors could be held to one of two 
implied warranties: merchantability or fitness for 
a particular purpose. 
An implied warranty of merchantability is a 
warranty implied by law, such that if a merchant 
(someone who makes an occupation of selling 
things) sells an item, he or she is guaranteeing 
that the item is reasonably fit for the general 
purpose for which it are sold. GM-technology 
developers qualify as merchants and their tech-
nologies deemed to be reasonably efficacious 
for the general purpose for which they may be 
transferred to a user. Thus, the failure of GM 
technology could subject the developer/transfer-
or to liability for breach of the technology’s im-
plied warranty of merchantability. An implied 
warranty of fitness for a particular purpose, some-
times referred to simply as a warranty of fitness, 
is a warranty implied by law, such that if a seller 
knows of, or has reason to know of, a particular 
purpose for which an item is being purchased, 
the seller guarantees that the item is fit for that 
particular purpose. For instance, if a GM tech-
nology is developed for, or transferred to, a user 
for the purpose of addressing a particular agri-
cultural constraint, the technology developer 
would be deemed to provide a guarantee that 
the technology would indeed address the con-
straint. To manage potential liability claims re-
sulting from the GM technology failing to fulfill 
the general purpose for which it was developed 
or sold or effect the specific constraint the tech-
nology was meant to address, the technology 
developer/transferor would need, at the time it 
develops or transfers the technology, to expressly 
disclaim implied warranties of merchantability 
and fitness for a particular purpose. 
4.4 Letters	of	nonassertion
A letter of nonassertion assures the user that the 
technology owner will not enforce its IP rights. 
4.5 Technology/product	stewardship
Technology- and/or product-stewardship proce-
dures include: comprehensive risk analyses for 
projects and/or phases of projects; appropriate 
risk-mitigation strategies (including appropri-
ate insurance coverage, outlining specific uses 
for technology, management and oversight pro-
tocols, procedures to protect confidential infor-
mation, etc.); and compliance with all applicable 
laws. 
Adherence to appropriate technology/prod-
uct- stewardship best practice guidelines can 
help protect technology developers and users 
from potential liability as their actions would 
likely be deemed reasonable under the applicable 
circumstances.
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6.	 ConCluSIon
The international legal debate continues about 
whether or not GMOs should have special legal 
liability. Actors in agricultural development have 
a responsibility to develop and deploy safe and 
environmentally friendly products through the 
adoption of appropriate technology-and/or prod-
uct-stewardship measures. The legal, health, and 
environmental risks of using GMOs should be 
reduced as far as possible. Failure to manage risk 
appropriately may be extremely costly in terms of 
lost time and money. 
The African Agricultural Technology 
Foundation (AATF) is an institution that gives 
smallholder farmers in Sub-Saharan Africa access 
to technologies, including agricultural biotech-
nology. It is imperative that the AATF examine 
the potential liability issues associated with GM 
crops, identify the key liability risks for specific 
members of the agricultural communities, and 
suggest measures that may be implemented to 
minimize such risks. ■
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The National Institutes of Health Office of Technology 
Transfer (NIH OTT) administers technology licenses for 
the NIH, generating substantial royalties (in the millions of 
dollars). Although this revenue flow is important, the NIH 
OTTs principal mission is the timely introduction of new 
products and technologies into the marketplace to ensure 
that the fruits of NIH research and development are made 
commercially available to serve the greater public good. The 
NIH OTT utilizes six types of technology licenses: 
• commercial evaluation licenses (also known as 
options)
• patent commercialization licenses (either exclusive 
or nonexclusive)
• nonexclusive patent licenses (for internal use)
• biological materials licenses
• software licenses 
The NIH OTT insists that licenses are drafted with well-
defined financial terms and clearly delineated reporting ob-
ligations, so that both parties to the license (NIH as licen-
sor and, for example, a biotech firm as licensee) understand 
their respective obligations. The NIH OTT seeks to build 
cooperative relationships with its licensees in order to facili-
tate problem solving discussions, resolve outstanding issues, 
and identify possible opportunities for advancing commer-
cialization of products and/or services. As a best practices 
licensor, the NIH OTT carefully manages license admin-
istration by monitoring commercial development perfor-
mance benchmarks, reviewing sales reports, and enforcing 
other license obligations. The office will also, if necessary, 
impose sanctions in license enforcement and implement 
procedures for dealing with infringement of its patents. 
The policies, protocols, and procedures of the NIH OTT 
have broad applicability to both developed and developing 
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1.	 InTRoduCTIon
The National Institutes of Health Office of 
Technology Transfer (NIH OTT) strives to fulfill 
its mission of transferring technology to improve 
public health not only by licensing to commercial 
enterprises but also by working with and licensing 
to institutions serving disadvantaged populations 
in the United States and abroad. The administra-
tion of technology licenses is an important part of 
this process. License administration focuses on the 
licensee’s obligations to the licensor, such as period-
ic royalty payments and reports. In fiscal year 2005, 
the NIH collected over US$98 million in royalties 
from 750 licenses (out of a total portfolio of over 
1400 licenses). Royalties from commercial products 
made up nearly US$77 million of this amount.
Describing the different types of licenses used 
by NIH to carry out its technology transfer pro-
gram, this chapter explains the procedures for ensur-
ing that licensees meet their obligations. It provides 
an overview of the tools used to administer large 
numbers of technology licenses and offers advice 
on how to monitor commercial-development 
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countries; scientists, administrators, technology managers, 
intellectual property professionals, and even attorneys can 
learn from the NIH OTT, a good example of an office op-
erating effectively, efficiently, and profitably by employing 
best practices.
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performance benchmarks, review sales reports, 
and enforce other license obligations. This chap-
ter also discusses the use of amendments in license 
administration, sanctions in license enforcement, 
and suggests procedures to follow when nonli-
censed companies infringe on patented technol-
ogy. The policies and practices of the NIH OTT 
aim to further develop scientific discoveries that 
may lead to commercial products that improve 
public health. This overview of license admin-
istration at NIH seeks to provide guidance for 
others who are considering establishing and oper-
ating their own programs for administering tech-
nology licenses. 
2.	 TypeS	of	TeChnology	lICenSeS
Technology licenses include commercial evalu-
ation licenses (also known as options), exclusive 
and nonexclusive patent commercialization li-
censes, nonexclusive patent licenses for internal 
use, biological materials licenses for commercial 
sale, biological materials licenses for internal use, 
software licenses for commercial sale, and software 
licenses for internal use. Financial terms and re-
porting obligations vary with the type of license. 
Table 1 shows which obligations are typically in-
cluded for each type of license. Regardless of the 
type, licenses should be written with well-defined 
financial terms and reporting obligations that both 
parties understand. This section briefly describes 
each type of NIH license; a more detailed discus-
sion about the various types of technology licenses 
can be found elsewhere in this Handbook.1 
Commercial evaluation licenses (also known 
as options) are useful for companies to explore the 
value or appropriateness of a new technology for 
a limited time without committing the financial 
and other resources required by a standard exclu-
sive or nonexclusive patent license. Appropriately, 
these agreements have smaller financial terms and 
are for a short duration. If the licensee finds the 
technology meets their needs, then the parties 
will generally negotiate a new exclusive or nonex-
clusive patent commercialization license.
Patent commercialization licenses provide 
licensees with rights to patented technology or 
inventions described in patent applications that 
have been filed. An exclusive patent commercial-
ization license provides a single licensee the right 
to practice and exclude others from practicing 
the technology for a period of time limited by 
the term of the patent. In most fields of com-
mercial endeavor, an exclusive license provides a 
significant competitive advantage to the licensee 
and, therefore, the potential for a large financial 
return. Consequently, the royalty obligations and 
financial terms in such licenses are generally quite 
substantial. With exclusive licenses, the licensor 
also has a higher level of expectation that the li-
censee will diligently meet the performance mile-
stones agreed to in the license.
Nonexclusive patent commercialization li-
censes give patent rights for technology to mul-
tiple licensees. These may be for a limited time or 
for the term of the patent. Such licenses are often 
given when the patent technology has the poten-
tial to significantly benefit the broader public. By 
providing such technology to multiple licensees 
entry into the marketplace will be accelerated. 
Royalty obligations imposed on nonexclusive 
patent commercialization licensees vary widely, 
depending on the nature of the technology.
Nonexclusive patent licenses for internal use 
provide a licensee with access to a patented tech-
nology that may be useful as a tool or process but 
is not itself a marketable product. 
In the biotechnology field, biological ma-
terials licenses provide licensees with access to 
nonpatented materials or biological constructs 
that were prepared at great effort and expense 
and that may be available only from the labo-
ratories that made them. Nonexclusive biologi-
cal materials licenses for internal use provide a 
licensee with access to unpatented technology 
that is unique or difficult to replicate without 
significant expense. This saves the licensee time 
in its commercial development efforts. Biological 
materials licenses for commercial sale promote 
the wider use of unique materials or biological 
constructs in the research and commercial de-
velopment community. 
Similar to biological materials licenses, soft-
ware licenses provide licensees with access to non-
patented software that may only be available from 
the laboratories that developed them. As shown 
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Table	1:	Typical	license	obligations


























































































































License execution fees + + + + + +
Annual (minimum annual) royalties + + + + + +
Past patent-prosecution fees – + + – – –
Ongoing patent-prosecution and 
patent-maintenance fees – + + – – –
Annual, periodic, or final reports  
on commercial development or 
research progress
+ + + + + +
Report of performance benchmark 
achievement – + + – + –
Performance benchmark royalties – + + – – –
Report of first commercial sale – + + – + –
Annual, periodic, or final reports  
on sales and earned royalties due – + + – + –
Earned royalties on product sales – + + – + –
Report of sublicensing activity – + – – – –
Report of sublicensing considerations 
and royalties due – + – – – –
Sublicensing royalties – + – – – –
License renewal or term  
extension fees – – + + + +
Key: + = Generally in license.
 + = May or may not be in license.
 – = Generally not in license.
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in Table 1, the financial terms and obligations 
found in such licenses vary depending on the 
type of license.
NIH has used most of these license types to 
expand the transfer of technologies—specifically 
those for neglected diseases or that meet public 
health needs—to public and private institutions 
in developing countries.
3. TASkS	of	The	lICenSoR
To administer, monitor, and enforce technology 
licenses requires the licensor to follow-up on the 
execution of a license agreement. The licensee 
has agreed to fulfill various financial terms and 
reporting obligations in exchange for the right to 
practice a licensed technology for a limited period 
of time. Regular reminders may be needed to en-
sure that they fulfill these obligations throughout 
the term of the license.
The licensor should monitor compliance 
with royalty payment and reporting obligations 
during the license term, and reports submitted 
by licensees should be carefully reviewed on an 
ongoing basis. Routine correspondence with li-
censees about these matters is usually handled 
through invoices, form letters, and e-mail. 
However, license administrators will sometimes 
need to invest considerable investigative time 
and practice skillful communication to under-
stand the activities of the licensee and determine 
which actions should be undertaken to remedy 
any noncompliance. A cooperative approach 
that engages the appropriate licensee contact in 
problem solving is generally best. Such discus-
sions will resolve most issues and also provide 
feedback that may be useful for future technol-
ogy license negotiations. Utilizing these contacts 
also may allow the licensor to direct the licensee 
to financial, technical, and other resources that 
will help the licensee move its commercializa-
tion efforts forward. 
Most tasks performed in the administration, 
monitoring, and enforcement of technology li-
censes typically flow out of the financial terms 
and reporting obligations described in Table 1. 
The more-routine license administration tasks 
include: 
• arranging for shipment of licensed materi-
als to the licensee
• invoicing licensees for royalty payment ob-
ligations specified in the license
• recording royalty payments 
• verifying that the amount paid is correct 
• distributing royalty receipts
• requesting overdue royalty payments 
through reminder notices
• requesting overdue reports through re-
minder notices
• notifying licensees of license expiration 
Other license administration tasks related to 
monitoring and enforcement include:
• checking the accuracy of sales and earned 
royalty reports
• collecting overdue or underpaid royalties 
and imposing additional royalties for late 
payment
• reviewing progress reports against perfor-
mance benchmarks
• tracking and recording achieved-perfor-
mance benchmarks so that associated roy-
alty payments are invoiced at the proper 
time
• contacting licensees about license noncom-
pliance issues
• amending licenses to extend them, modify 
benchmark schedules or other license terms, 
or correct errors in the original license
• preparing and reviewing patent expense 





One of the most important tools for effectively 
administering, monitoring, and enforcing licens-
es is the list of licensee contacts. If contact in-
formation for royalty and reporting obligations 
is not available when the license is executed, it 
should be obtained immediately after. The list 
could include contacts in business development, 
legal affairs, licensing, finance, and research. The 
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names of senior-level executives should also be 
included. Ideally, full names, titles, mailing ad-
dresses, phone numbers, and e-mail addresses 
should be recorded for each contact. The contact 
list should be periodically reviewed and updated. 
These contacts are extremely important for be-
ginning discussions about royalty payments and 
other noncompliance issues that may develop. 
Without a contact list, valuable time can be wast-
ed trying to identify the appropriate contact.
4.2 Filing	system
A well-organized system for filing and retrieving 
documents, reports, correspondence, and other 
information related to a specific license is as im-
portant as licensee contacts. Depending on how 
things are organized, several different files may be 
needed to address and keep track of different as-
pects of license administration. For example, a file 
used only for archiving the original, executed li-
cense agreement may be set up. Another “working” 
file may be set up for daily use in filing, reviewing, 
and retrieving a reference copy of the license and 
any correspondence associated with the license. 
If a computer network and systems are available, 
the filing system may be set up electronically by 
scanning and converting all correspondence and 
license agreements into image files (for example, 
Adobe Acrobat® pdf files) that can be easily stored, 
searched, and retrieved. It is essential, of course, 
for any such system to be maintained.
4.3 Tracking	system	for	license	terms		
and	due	dates
To effectively administer license agreements, col-
lect royalties that are due, and monitor and en-
force license obligations, the licensor must have 
a reliable system to record and track the finan-
cial terms, performance milestones/benchmarks, 
reporting obligations, amounts due, due dates, 
invoice or overdue notice deadlines, payments 
receipts, and royalty payment distributions for 
individual licenses. 
The greater the number of licenses, the more 
important it is to use a computerized database 
for license administration. At the NIH Office 
of Technology Transfer, the database has been 
essential for monitoring, recording and updat-
ing contact lists, tracking due dates for financial 
terms, recording the amount of royalty payments 
received, tracking the due dates of performance 
benchmarks, recording the receipt of reporting 
obligations, recording completion dates for per-
formance milestones/benchmarks, and so forth. 
Ideally, the database should be designed to 
meet the needs of the entire technology transfer 
office. The NIH database consists of an integrat-
ed system of interactive modules that handle data 
about people (contacts), companies, inventions, 
invention marketing, patent prosecution, patent 
annuity payments, license applications, license 
royalty payment obligations, royalty receipts, li-
cense reporting obligations, and so forth. Queries 
can be made about the data, and a variety of re-
port types can be generated. The database sends 
reminder e-mails to individuals in the office and 
allows routine form letters and reports to be pre-
pared, edited, and printed. The database also al-
lows comments to be recorded and the attach-
ment of externally generated electronic files (such 
as scanned copies of licenses and correspondence 
or e-mails) to specific records in the database. 
These features help to maintain a historical record 
of each invention and license.
4.4 Technology	transfer	office	Web	site
The NIH Office of Technology Transfer recently 
reorganized and updated its Web site2 in order to 
answer licensees’ questions about license obliga-
tions and provide potential license applicants with 
information. A menu bar on the Web site provides 
links to licensing and royalties information; exam-
ples of Forms and Model Agreements; FAQs (fre-
quently asked questions) about royalty payments, 
reporting obligations, and other license matters; 
and contact information. By providing links to 
technologies currently available for licensing, the 
Web site helps market those technologies. Finally, 
neglected disease technologies available for licens-
ing can be shared via the web.3
4.5 Royalty	payment	obligations
When a license is fully executed, several royalty 
payments will often be due. These may include: 
(1) a license execution royalty payment, (2) a 
prorated minimum annual royalty payment, and, 
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for patent licenses, (3) a royalty payment for past 
patent prosecution costs. Typically, these pay-
ments are mailed to the licensee with individual 
invoices that state the license number, the type of 
royalty payment due, the amount due, the due 
date, and instructions for where the payment 
should be mailed. The database is used to record 
when payments are received and to alert license 
administrators when payments become due or are 
overdue. 
When royalty payments become 30 days 
overdue, a first overdue notice is mailed to the li-
censee. If there is no response within two weeks, it 
is often useful to contact the licensee to verify that 
the contact information is correct and determine 
why payment has not been made. If payment is 
not received within 60 days after the due date, a 
final notice is mailed out. This notice informs the 
licensee that failure to pay may result in license 
termination. If payment is not received within 90 
days of the due date, a license administrator con-
tacts the licensee to determine why payment was 
not made and to discuss possible sanctions that 
may be imposed if payment is not received within 
a short period of time (see below). 
4.6 Sales	and	earned	royalties	reporting
Licenses for the development and/or sale of com-
mercial products usually require periodic sales re-
ports and the earned royalty due. These reports 
may be annual, semiannual, or quarterly, depend-
ing on the product type and anticipated sales 
volume. Net sales figures quantitatively measure 
a license’s performance and are the basis for cal-
culating the earned royalties due. Licenses pre-
scribe in some detail the deductions allowed from 
the gross sales for calculating the net sales figure. 
However, ambiguities or misunderstandings often 
arise. Recognizing such issues early, when smaller 
amounts of money are involved, usually makes re-
solving them easier for both parties. If sales and 
earned royalty reports are not provided with the 
earned royalty payments submitted by the licens-
ee, the licensee should be reminded of its obliga-
tion to provide them, and a short-term deadline 
should be established for submitting the reports. 
The accuracy of reported sales figures can 
be verified in several ways. Comparison to prior 
period sales figures will show whether product 
sales are growing or declining and at what rate. 
Company press releases, annual reports, filings 
with governmental securities agencies (such as 
the U.S. Securities and Exchange Commission 
SEC), stock analysts’ reports, marketing reports, 
news stories, and so forth, are other resources 
that can be studied to verify reported sales fig-
ures. Many of these sources are available on the 
Internet. When the reported sales figures seem 
inconsistent with data from other sources, the 
licensee should be asked to explain the discrepan-
cies. If the license includes provisions for auditing 
the company’s sales to verify the figures reported 
for the licensed product, this may be the time to 
conduct an audit. 
4.7 Commercial	development	
or	research	progress	reports
Most technology licenses require periodic reports 
describing the progress of research, commercial-
ization, or product development. These reports 
serve several purposes: 
• they verify that the licensee is using the li-
censed technology or product 
• they demonstrate, for commercialization 
licenses, that an effort is being made to 
bring the licensed technology or product to 
market
• they provide verification that a license 
benchmark or milestone was achieved and 
when
Moreover, when benchmarks or milestones 
have associated royalty payments, the reports 
alert the license administrator to invoice the li-
censee for a royalty payment. If a licensee fails 
to provide these reports, the licensee should be 
contacted and reminded of their obligations. A 
short-term deadline should be set for the licensee 
to submit the report. 
Progress reports should be carefully reviewed 
and compared to the commercial development 
plan and the benchmarks or milestones described 
in the license. Are initial expectations being met? 
If not, why not? Are the problems technical? 
Are they due to insufficient financial resources? 
Regulatory issues? Has the company lost focus in 
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its desire to commercialize the product? Are there 
other issues not mentioned in the report? Getting 
answers to these questions usually requires con-
tacting the licensee for additional information. 
Once these answers are obtained, a decision can 
be made about what actions to pursue with the li-
censee. (See the sections “Amendments to license 




Patent claims should match the commercial goals 
of licensees. Since IP protection normally pre-
cedes licensing, those responsible for licensing 
inventions need to monitor patent prosecution 
to ensure that the goals pursued by patent agents 
and attorneys align with those of the licensees.
Patent licenses often include the reimburse-
ment of past patent prosecution costs incurred 
by the licensor for a licensed technology as a fi-
nancial obligation. The licensee may also agree 
to pay ongoing (future) patent prosecution and 
maintenance costs. Periodically, these costs need 
to be carefully tracked, documented, and billed 
to licensees. Patents are usually not assigned in 
technology licenses, so control of patent prosecu-
tion most often resides with the licensor and not 
the licensee. Like all legal fees, patent prosecution 
costs can quickly get out of control without care-
ful monitoring. Seeking timely reimbursements 
of patent costs incurred by the licensor is an im-
portant part of license administration. 
Occasionally, an applicant for a technology 
license may want to manage patent prosecution 
and be billed directly for the costs incurred. In 
this case, special oversight is needed to ensure that 
the licensor’s interests are protected. 
5.	 AmendmenTS	To	
lICenSe	AgReemenTS	
The outcome of an effort to commercially devel-
op a new technology is often difficult to predict 
because of technological, regulatory, financial, 
patent, and business issues. Licensees usually set 
timelines for meeting performance benchmarks or 
milestones with a best-case scenario in mind. Not 
surprisingly, delays are common. When a com-
pany is demonstrating diligence but has encoun-
tered unexpected delays that have a reasonable 
chance of being overcome, the appropriate action 
may be simply to amend the license to update the 
benchmark or milestone schedule. Such amend-
ments reflect mutually agreeable changes in the 
expectations of licensor and licensee. But when 
the company’s issues appear insurmountable, 
it may be better to terminate the license. Other 
considerations may lead to different approaches 
to such situations, but a successful conclusion will 
be based on establishing and maintaining good 
communications between the license administra-
tor and the licensee. 
License term extensions are normally simple 
modifications of a license that indicate the satisfac-
tion of both sides in the existing agreement and 
a desire to continue the agreement. Sometimes, 
term extension amendments also include changes 
to other terms or obligations. For example, mini-
mum annual royalties may be raised or lowered to 
reflect the current institutional costs of administer-
ing the agreement and the costs associated with the 
amendment process, or to better capture the value 
of the invention for the extended time period.
Financial hardship, changes in the cost struc-
ture of doing work, opportunity costs, or priority 
changes can make licensees want to change the 
financial terms of technology license agreements. 
Like most tangible assets, licensed IP assets depre-
ciate with time (due to the shrinking of the ex-
clusivity period, changing marketplace interests, 
and the degree to which the technology provides 
a competitive advantage over the industry’s stan-
dard technology). While it is not a good idea to 
set rules for changing financial terms, an effort 
to weight influencing factors can be useful. The 
licensor might weigh such factors as the probabil-
ity of getting paid, the probability of relicensing 
the technology (if the license is terminated), the 
present value of a payment reduction, and the 
costs involved. Consistently administering this 
amendment process will also prevent opportu-
nistic changes in licenses that are not linked to 
appropriate needs.
In addition to amendments, other changes 
can be made to existing agreements to increase 
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the chance that a technology will be successfully 
developed. Some areas that may need to be ad-
dressed include: 
• changing the field(s) of use 
• permitting the licensee to seek a patent 
term extension
• eliminating or adding certain technologies 
from or to a license
• allowing the licensee to seek sublicensing 
agreements 
• allowing the licensee to take on patent- 
prosecution responsibilities
Many of these issues may be more appro-
priately handled by licensing personnel than by 
license administrators. However, the latter should 
understand the ongoing development of the tech-
nology so that they know when deviation from 
the original agreement is warranted.
	6.	SAnCTIonS	foR	nonComplIAnCe	
When a technology transfer office has a large 
portfolio of inventions and technologies avail-
able for licensing, companies often will return 
to license additional technologies. This gives the 
licensor an opportunity to obtain some leverage 
for collecting late or underpaid royalties due on 
existing licenses with that applicant. The licensor 
may put on hold the execution or negotiation of 
new agreements until the licensee has fully paid 
any outstanding royalty obligations under exist-
ing licenses. All that is needed to use this sanction 
well is effective communication between license 
administrators and licensing personnel. 
The threat of terminating a license due to a 
licensee’s defaulting on the material obligations of 
a license is an important tool for enforcing com-
pliance. However, license termination procedures 
are usually not undertaken until the licensee has 
been given (1) several written notices describing 
the obligation(s) in default and (2) an oppor-
tunity to respond. If no satisfactory response is 
forthcoming, a written 90-day notice of license 
termination is given as the final step. If the licens-
ee’s response is still unacceptable after 90 days 
have passed, a final letter of termination is sent to 
the licensee.
Although other intermediate sanctions 
may be desirable, they are frequently unavail-
able. The licensor’s only choice then is to 
threaten license termination in order to recap-
ture the technology for relicensing. However, 
when a licensee’s breach causes a license to be 
terminated, license administrators should not 
forgive any outstanding financial obligations 
that predate the effective date of the license 
termination. Unpaid license financial obliga-
tions—such as minimum annual royalties, 
reimbursable patent costs, execution fees, and 
others—should be identified when a license is 
terminated, and serious efforts should be made 
to collect the monies owed. When a license 
expires, the licensor should conduct a similar 
review to capture any lost or missed milestone 
payments, patent-prosecution costs, minimum 
annual royalties, or other royalties. 
One of the hallmarks of a successful tech-
nology transfer program is maximizing the 
collection of license financial obligations. 
Technology transfer programs that operate as 
part of a government agency may have that 
government’s power to enforce debt collection, 
while nongovernmental technology transfer 
programs may have to rely on the courts for 
enforcement. 
7.	 lICenSe	eXpIRATIon	
At license expiration and during the ongoing 
monitoring of active licenses, license adminis-
trators can provide helpful feedback about the 
terms and structure of license agreements to 
those who negotiate them. Likewise, the per-
formance of licensees can be assessed during the 
term of a license and when it expires. Delays in 
development, ambiguous license terms, and fail-
ures to address license issues that may require 
an amendment during the term of a license are 
good examples of what can be identified from 
monitoring and expiration reviews. Capturing 
this knowledge and sharing nonconfidential 
information about best practices with other 
organizations can help build a knowledge base 
that continuously improves the technology li-
censing process.
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8. pATenT	InfRIngemenT
One enforcement task that does not flow out of 
existing license financial terms and reporting obli-
gations is the pursuit of suspected patent infring-
ers. When a company has not licensed a patented 
technology but is infringing a patent owned by the 
licensor, legal action should be undertaken. The 
first step is to notify the infringing company by 
letter that they are infringing and should immedi-
ately cease to do so. The company usually receives 
an offer at that time to license the technology in 
order to avoid legal action against the company 
by the patent holder. Follow-up may require ne-
gotiating a license agreement or, if the license is 
refused, additional legal action by the licensor.
9. ConCluSIon
Administering technology licenses gives a TTO 
an opportunity to monitor and participate in an 
invention’s development and commercialization. 
A successful effort requires good organization, 
good tools, diligent attention to detail, and the 
persistence to engage licensees in dialogue when 
license obligations are not being met. While 
many technology transfer organizations focus 
most of their time and effort on negotiating li-
cense terms, the overall success of a TTO also 
requires allocating resources and time to license 
administration, monitoring, and enforcement. 
Thorough, consistent follow-up with licensees 
will ensure that the licensor and inventors finan-
cially benefit. The licensee may also benefit from 
the discipline of an attentive partner and access 
to the knowledge and experience of the licens-
ing office. Above all, effective license administra-
tion ensures that economic development and the 
public good are well served by the timely intro-
duction of new products and technologies in the 
marketplace. ■
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A university’s intellectual property (IP) cannot be simply 
shelved and forgotten. IP, with patents as a particularly co-
gent example, must be managed, monitored, maintained, 
and policed in an ongoing “cultivation” of the IP rights. 
For patents, it is important to be able to identify potential 
infringement early, by means of coordinated surveillance 
by the technology transfer office. If, and when, possible 
patent infringement is detected, it will then be necessary 
to evaluate the type of infringement, that is, direct or con-
tributory, and also to assess whether the activity legally 
appears to be infringing, reading on each and every ele-
ment of a patent claim. Strategic and business consider-
ations must be considered as the university decides what 
course of action might be appropriate in response to an 
alleged infringement of a patent. Specifically, in the con-
text of litigation, the university must consider whom to 
sue (if there are multiple infringers), when to sue (if too 
late, could risk loss of IP rights), and where to bring suit 
(for a favorable venue). An even more critical consider-
ation is whether to even litigate at all. It may be wiser 
to seek one of various forms of alternate dispute resolu-
tion, for example, negotiation, mediation, or arbitration. 
It is important to never forget that litigation is expensive, 
risky, and unpredictable. Hence, it should be viewed as 
not the first option, but as the final one, and it should 
be approached as a cold business decision and not to give 
teeth to emotions or carry out revenge. Throughout the 
process of managing and policing its IP rights, a univer-
sity should have access to legal counsel. Finally, proac-
tive, good license hygiene is the best way to proceed, 
and the most effective way to avoid expensive litigation. 
By demonstrating credibility, conviction, and focus, the 
 HANDBOOK OF BEST PRACTICES  | 1405 
1. infRingemenT	of		
inTelleCTuAl	pRopeRTy
Infringement is any manufacture, use, sale, of-
fer to sell, or importation of intellectual property 
(IP) that has not been authorized by the legal 
owner of the IP. Forms of IP that are subject to 
infringement include patents, copyrights, and 
trademarks; these provide the owner of the IP 
rights with certain legal remedies for redressing 
infringement. Infringement of IP should be con-
sidered neither mysterious nor overly complex 
and technical. Basically, infringement is analo-
gous to trespassing on another person’s physi-
cal property or real estate: it is an invasion and 
misappropriation of another’s exclusive property 
right. Correspondingly, one can obtain permis-
sion to occupy, or to use, real estate by renting 
it or to use IP by licensing it; the two actions are 
entirely parallel. 
Identifying and taking action to remedy in-
fringement is an essential part of IP ownership. 
CHAPTER 15.2
Haeussler HW and R Cahoon. 2007. Policing Intellectual Property.  In Intellectual Property Management in Health and Ag-
ricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and 
PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
Editors’ Note: We are most grateful to the Association of University Technology Managers (AUTM) for having allowed us 
to update and edit this paper and include it as a chapter in this Handbook. The original paper was published in the AUTM 
Technology Transfer Practice Manual (Second Edition Part XV: Chapter 3).
© 2007. HW Haeussler and R Cahoon. Sharing the Art of IP Management: Photocopying and distribution through the 
Internet for noncommercial purposes is permitted and encouraged.
Policing Intellectual Property
h. Walter haeUssler, Director, Technology Transfer and Intellectual Property, Texas Tech University  
and Texas Tech University Health Sciences Center, U.S.A.
richarD s. cahoon, Executive Director, Cornell Center for Technology, Enterprise & Commercialization  
and Senior Vice President, Cornell Research Foundation, U.S.A.
university will show potential infringers that it is serious 
about policing its IP, and that they therefore won’t be able 
to escape the university’s diligent surveillance. Licensing, 
and not infringement, will then become the only sensible 
route to accessing the patent rights.
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Asserting IP rights is essential for preserving these 
rights and for maximizing their economic value. 
A university’s maintenance and assertion of its IP 
ownership rights, including a willingness to bring 
legal action if necessary, is essential for the licens-
ability of its IP. The perception on the part of in-
dustry and, in particular, potential infringers, that 
the university will take action to remedy infringe-
ment is critical for the focus, determination, and 
credibility of the university’s technology licensing 
effort and key to the value of its licensable tech-
nology. This chapter examines these issues in the 
context of U.S. patent law. 
2. how	To	iDenTify	infRingemenT
Infringement is a legal event, that the patent own-
er (patentee) bears the burden of proving. Proof 
of infringement proceeds by a two-step analy-
sis. First, the alleged infringed invention must 
be defined, by the court’s construing of the ac-
tual patent claims. Second, the patentee, through 
the strength (or preponderance) of the evidence 
must show that infringement actually occurred. 
Hence, the patentee can neither guess, think, nor 
presume infringement, but rather must prove in-
fringement. For example, if the patent in question 
is a process, the fact that a product sold by the 
“infringer” is identical to the university’s product 
does not prove the alleged infringer is liable; the 
alleged infringer could be using an entirely differ-
ent process to make the product.
Typically, literal infringement occurs when 
the infringer’s product or process reads on each 
and every element of a patent claim. The fewer 
the elements or steps in a patent claim, the more 
likely apparent infringement will turn out to be 
actual infringement.
With this in mind, it is important to con-
sider claim structure and scope when a university 
initially files a patent application. The university 
will be in much better position to protect its IP 
rights if the attorney who prepared and prosecut-
ed the application understood that the university 
has no need for narrow-claim, defensive patents. 
A university does not manufacture and therefore 
has no products to protect. Unless the claims of 
a university patent are sufficiently broad to have 
economic value (this cannot easily be avoided 
if one practices the technology), the patent will 
have little, and perhaps even negative, value. For 
example, negative value may arise if the inventor 
exclaims, “Look at this infringer,” and the univer-
sity responds, “Yes, the company is practicing your 
invention, but our claims were drafted too narrowly, 
and our patent is therefore not infringed.” At that 
point all may painfully realize that during the 
actual prosecution of the patent application, it 
would have been better to appeal to the patent 
office for, and then lose on, broader claims. The 
inventor would thereby have realized that a pat-
ent with real economic potential was unattainable 
from the start, rather than only becoming disap-
pointed later, accusing the licensing office of not 
doing its job with adequate diligence, when the 
patent is only then determined to be worthless. 
The key message here is this: patent pros-
ecution must be conducted with an eye toward 
winning future infringement litigation should 
it arise. The whole point of patent prosecution 
should not be to have a given claim or any claim 
allowed so a patent will issue, but rather to have 
a claim approved that is consistent with the uni-
versity’s mission, has economic potential in the 
marketplace, and will be enforceable.
Assuming the university owns a patent with 
strong claims, how can the university determine, 
especially when not actively engaged in the mar-
ketplace, whether that patent is being infringed?
2.1	 Establishing	surveillance		
for	possible	infringement
Inventors should be contacted on a regular ba-
sis and asked if they know of anyone who is or 
might be infringing their patent. If nothing else, 
the effort could lead to licensing possibilities and 
reveal who is interested in using the patented 
invention.
Technology transfer staff members should re-
view key media related to the technology on a reg-
ular basis to watch for potential infringers. Again, 
this is doubly advantageous because it can also 
generate licensing possibilities. The focus of the 
marketplace reviewers in the technology transfer 
office must not be on marketing alone, but also 
on infringement and licensing opportunities.
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Therefore, to the greatest extent possible, one 
must know the marketplace. It is critical to make 
an effort to talk to existing licensees, alumni, others 
who are knowledgeable in the relevant areas, and 
to potential licensees of related technology in order 
to learn what they and their peers are doing and/or 
thinking of doing. In other words, it is essential to 
build and maintain professional networks. 
2.2 Evaluating	infringement
Unless the technology transfer manager is an IP 
legal professional who can assess the possibility 
of infringement, it will be necessary to initially 
seek the opinion of counsel in order to be cer-
tain of potential infringing activity. As previously 
stated, the burden of proving infringement is on 
the patentee. Therefore, the university cannot 
expect the apparent infringer to willingly help 
prove there is actual infringement. While certain 
industries typically respect university patents and 
are forthcoming, others have a “catch me if you 
can” attitude. If the university has a process pat-
ent where the process does not leave a footprint 
on the product, proving infringement may be 
extremely difficult.
Literal infringement requires that each and 
every element or recitation in a particular claim 
must be infringed. If there are five steps in the 
claim and the apparent infringer practices only 
four of those steps or combines a different fifth 
step with the university’s first four steps, there 
may be no infringement. Being close to in-
fringement does not usually count towards an 
infringement determination.
There is, however, the Doctrine of 
Equivalents, which is a more flexible rule of 
claim interpretation. The doctrine provides that, 
even though a claim is not literally infringed, a 
case for infringement can still be made if the 
infringer has used a variant of the patented in-
vention that is substantially the same as what 
is actually claimed as the invention. If a tech-
nology transfer manager thinks that the ap-
parent infringer is too close to be allowed to 
escape infringement, the manager should get 
an expert opinion to help the university decide 
whether the Doctrine of Equivalents may be 
applicable.
It is important to note, however, that the 
Doctrine of Equivalents cannot be employed 
where the patentee narrowed the claims in re-
sponse to a substantive rejection by the patent 
office during patent prosecution. This creates 
a bar to the use of the doctrine (File Wrapper 
Estoppel), because it would be unfair to initially 
argue during prosecution that the claims were 
narrow enough to avoid prior art and hence be 
patentable, but then later, during infringement 
proceedings, attempt to expand the scope of the 
claims beyond their literal language by invoking 
the Doctrine of Equivalents, that is, to attempt to 
reclaim in litigation what was surrendered during 
prosecution of the patent application. Once the 
scope of the claims is narrowed, it is narrowed 
for good. 
2.3 Record	keeping	and	evidence	gathering
In general, the better the records kept by the in-
ventors, the better the patentee’s (or applicant’s) 
ability to win in an infringement action. However, 
in litigation, the patentee’s records, while a source 
of validation of assertions in the patent, are ac-
cessible to the opponent and may be searched 
for contradictory statements or adverse data that 
was not given to or considered by the patent ex-
aminer. A possible defense raised, if such adverse 
data is found by the alleged infringer, may be 
considered fraud against the patent office. This is 
a form of inequitable conduct perpetrated by the 
patentee during prosecution of the patent appli-
cation, by which the patentee deceives the patent 
office by either withholding material or submit-
ting false information, thereby rendering the pat-
ent unenforceable. The patentee should search its 
own records so that it is not later surprised by any 
data that might be subsequently used against it. 
The best way to avoid this problem is to pay close 
attention to the duty of disclosure to the Patent 
Office during the prosecution of the patent appli-
cation, that is, better to take a proactive and pre-
ventive approach early on than to be sorry later.
When gathering evidence of infringement, 
if the university has other licensees, they will 
usually help the university to acquire informa-
tion and analyze samples. If necessary, the uni-
versity may have to buy an infringing product 
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and analyze it. The university will need to docu-
ment exactly where the infringer is selling the of-
fending product, for example, whether directly, or 
through agents or distributors. When the infringer 
is manufacturing or using the infringing product, 
the evidence must be hard, including documents, 
materials (with analysis of the materials), and eye-
witness testimony (for example, a signed affidavit 
as to what a person would testify to if called as 
a witness). Hearsay will not prove the university’s 
case. “My brother-in-law told me that he had seen 
...” won’t work. Actually proving infringement, 
and exactly when and where it occurred or contin-
ues to occur, is necessary but frequently quite diffi-
cult. Issues of venue, that is, where legal action can 
be brought, may cause the university to want to 
prove infringing acts in a certain geographic area; 




If the person using the technology or inventions 
has not signed a license agreement, usually a con-
tract of some sort, then the university’s only prac-
tical litigation recourse is usually a suit for patent 
infringement. If there is another legal relationship 
such as a license agreement where the licensee 
has ceased to pay royalties, or a material transfer 
agreement where it appears that the infringer is 
improperly using material received from the ma-
terial transfer agreement, there are alternatives to 
consider, such as breech of contract actions. It is 
possible that the location of litigation (or the is-
sues) may be in the university’s favor, or the price 
of litigation may be cheaper if the university brings 
suit on an existing contract rather than a suit for 
patent infringement. It is therefore important to 
examine, in depth, all the business relationships 
existing between the infringer and the university, 
which may include consulting contracts between 
the inventors and the infringer.
3.2 Whom	can	the	university	sue?
If there is more than one possible infringer, then 
it is important to weigh the pros and cons of su-
ing each infringer. Sometimes the choice is clear; 
at other times consideration must be given to se-
lect the target of litigation. A patent owner need 
not sue all infringers at the same time. A single 
suit against a single member of a group of infring-
ers is the usual tactic.
Patent litigation is expensive and, as in a 
poker game, it is difficult to win against a player 
who has an order of magnitude more money than 
the rest of the players. The player who has more 
money can unfairly distort the game. The same 
is true in patent litigation, and it is usually inad-
visable to litigate against the party that has the 
largest financial resources or the largest financial 
interests in the outcome of the litigation. On the 
other hand, the party having the largest financial 
interest may indeed be the one to sue, because 
in a practical sense, if the litigation is successful, 
then the issue will have been essentially resolved, 
with the largest part of the market secured and 
other infringers likely to fall into line and comply 
with licensing terms. 
Other considerations include the conve-
nience of the forum, ease in collecting damages, 
and existence of issues that are particular to a giv-
en infringer that might enhance the university’s 
chances of winning. For example, clear statements 
that an infringer’s actions were knowing and de-
liberate may indicate selection of that particular 
infringer to sue. The alleged infringer has made 
himself a target for litigation. 
One method of managing the venue of the 
lawsuit is to sue a party in the distribution chain 
in a location of the university’s choice: for exam-
ple, a party who through purchase is an infringer. 
Frequently the original infringer becomes in-
volved in such a lawsuit because of an obligation 
to indemnify the purchaser. Therefore, the uni-
versity can potentially access the most important 
infringer in a favorable venue, which otherwise 
might have been difficult or even impossible. 
The patent law provides recourse and rem-
edy not only against direct infringement, but 
also against contributory infringement and in-
ducement to infringe. A party can infringe by ac-
tively and knowingly assisting in another’s direct 
infringement. The most common type of con-
tributory infringement is where a company sells 
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a component to the infringer in a situation where 
the company knows or should have known that 
the only practical use for that component was to 
make infringing devices or create an infringing 
use. As for inducement to infringe, the patent stat-
ute states, “Whoever actively induces infringement 
of the patent shall be liable as an infringer.” Hence, 
inducement to infringe is where the party actively 
and knowingly aids and abets another in direct 
infringement. Whether a company intends to in-
duce infringement is a factual determination.
3.3	 Where	can	the	university	sue?
In the United States, since patents are enforced 
in the federal courts, theoretically, a university 
can sue for infringement anywhere in the United 
States, but there are jurisdictional requirements, 
venue, and service requirements that usually limit 
the number of actual forums available. When 
considering where to file a suit, proximity to the 
court may be a major issue. The university must 
also consider where its trial counsel and inventors 
or other witnesses are located, whether there is a 
need to compel certain witnesses to attend, and in 
what jurisdiction the university can likely prevail. 
Of course, specifically inconveniencing the party 
one intends to sue should not be overlooked as a 
useful strategy. 
Certain courts are busier than others, and 
therefore, if the university looks for a speedy trial, 
it may want to pick a forum that has a small back-
log or one that has developed an attitude, capac-
ity, and reputation for rapidly processing cases.
Furthermore, the attitude of a particular 
judge or a group of judges in a particular court 
may influence the choice of forum. If the univer-
sity can determine that the judge has an identifi-
able track record for deciding certain underlying 
issues, then it may, or may not, choose that court, 
based upon the record of the judge’s rulings, phi-
losophy, and apparent priorities.
If a jury trial is selected, then the location of 
the forum can have a substantial impact on the 
nature and attitude of the jurors. A state universi-
ty that has a long history of agricultural extension 
no doubt has an advantage if the jury consists of 
local farmers. On the other hand, if the univer-
sity sues an infringing company, seeking venue in 
a small town where the company is the largest 
single employer, then it can expect that the jury 
might be biased against the university and favor 
the accused infringer.
U.S. federal law and a section on the venue of 
particular U.S. federal courts states that, “Action 
for patent infringement may be brought in the judi-
cial district where the defendant resides, or where the 
defendant has committed acts of infringement and 
has a regular and established place of business.” The 
federal courts are split as to what is a regular and 
established place of business. Some courts have 
held that there has to be a formal office and others 
have held that a sales representative operating out 
of his or her home may satisfy the requirements.
3.4  When	can	the	university	sue?
A university cannot initiate patent litigation until 
after there is an actual act of infringement. At the 
other extreme, the university must bring the suit 
before the suit is barred by the potential equitable 
defenses pursuant to the statute of limitations, 
the doctrine of laches, or equitable estoppel. 
From a strictly legal technical point, there is 
no such thing as a statute of limitations in the 
patent law. That is, there is nothing in the pat-
ent statute that absolutely bars the bringing of an 
infringement suit. However, the statute does bar 
recovery of damages for infringing activity that 
occurred more than six years prior to the filing of 
the infringement action. 
Laches can be defined simply as the paten-
tee waiting too long to take action for no good 
reason. The federal circuit has held that laches 
bars relief on a patentee’s claim only with respect 
to damages that occurred prior to the suit. It is 
important to note that there are two elements to 
laches. First, there must be an inexcusable delay 
for an unreasonable length of time in initiating 
litigation. Second, the defendant must show that 
the litigation was prejudiced by the delay. The 
longer the delay, the less is needed to show spe-
cific prejudice. Usually there has to be a consider-
able delay before the doctrine of laches has any 
relevance. There is a presumption of laches after 
six years, but the patentee can overcome this with 
suitable evidence rebutting the two elements that 
establish laches. 
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Another defense against a patent infringe-
ment action is equitable estoppel, which sim-
ply means that there is a particular reason that 
the university, as the patentee/plaintiff, should 
be barred from suing the particular defendant. 
Equitable estoppel usually results when the pat-
entee intentionally communicates with the in-
fringer such that the infringer relies upon and is 
then mislead and materially harmed by the deeds, 
actions or words of the patentee. For example, the 
officers of the patentee through affirmative con-
duct induced the infringer to believe that the pat-
entee had abandoned its claim against the alleged 
infringer, and therefore, the infringer kept manu-
facturing. Clearly, there should be an equitable 
estoppel. It is important to note that the silence 
of the patentee alone will not constitute an equi-
table estoppel, although that silence over a long 




There are no right or wrong answers for how soon 
to involve counsel. Before doing so the university 
should determine that there is in fact an infringe-
ment. If the answer is yes, the university should 
then determine whether the usual licensing routes 
been explored and a negative response received? If 
the answers to these questions are also yes, then 
the university should recognize that the case is 
not an ordinary one and that there are valid busi-
ness reasons to consider infringement action. At 
that point, the university should have preliminary 
discussions with its counsel prior to making any 
decisions.
4.2 Who	will	serve	as	counsel?
There are several very important issues that must 
be contemplated in selecting counsel. If the uni-
versity (the client) does not control the proceed-
ings, and therefore, does not control the cost, 
the result typically is extraordinary financial 
bleeding. If the university finds that it is work-
ing with counsel who tends to say, “Just leave it 
in our hands; we know best,” the university can 
expect the fees to be high. It is important to 
pick counsel who has a perspective as to the way 
proceedings are conducted and the way costs 
are controlled that is compatible with the phi-
losophy of the technology transfer office and the 
university. For example, does the university in-
tend to be represented at every deposition held 
by the other side? What level of discovery is the 
university going to seek? Is the selected coun-
sel comfortable working solo or with one other 
people in the firm, or does the intended counsel 
suggest that there be a team of four people, plus 
a backup team of two people (as a precaution)? 
These attitudinal differences vastly affect the 
kind of litigation that is going to be conducted 
and the cost of that litigation. 
The amount of money spent has some bear-
ing on the outcome of the litigation, but the at-
titude should be, “I want to spend the least amount 
of money necessary to win,” not, “Let’s do everything 
imaginable so that nobody can ever accuse us of los-
ing because we failed to do (and spend) enough.”
The university may have trial lawyers on staff. 
Those trial lawyers can be invaluable for interfac-
ing between the university and outside trial coun-
sel, and also for helping the university manage 
the issues, even though in-house trial lawyers may 
not have any experience with patent litigation. 
A decision to hire outside counsel leads to 
the question of whether one attorney, one firm 
of attorneys, or multiple attorneys should be in-
volved. One can argue that lawyer(s) rendering 
opinions as to whether infringement exists and, 
if so, a strong likelihood of prevailing in litiga-
tion, should be independent of the lawyer(s) who 
ultimately litigate. For example, if the lawyer ren-
dering the opinion recognizes that he or she will 
not financially benefit from a statement that there 
should be litigation, then the university is more 
likely to get an unbiased answer. The same is true 
on the issue of infringement. If the lawyer under-
stands that he or she will not have the benefit of 
the litigation if he or she gives the opinion that 
there is infringement, then the university may get 
a more objective opinion. This is not necessarily 
the case, for example, if the university has a solid, 
trusting relationship with counsel, and counsel 
recognizes that sooner or later, given a legitimate 
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case, he or she indeed will have involvement in 
litigation, then the university can comfortably 
use the same lawyer(s) for both opinion work and 
litigation. After all, the more a university works 
with an attorney or firm, the more likely the tech-
nology transfer manager and other institutional 
legal counsel will generate useful opinions and 
advice.
There are no right answers to selecting coun-
sel. The bottom line is to pick a trial lawyer who 
accepts the fact that he or she will be required to 
justify how and why the money is spent and to 
give the university clear choices so that it can con-
trol costs. Keep in mind that the actions of the 
opposing side have a large impact on costs. Once 
litigation is commenced, while the university may 
diligently work to control costs, the actions of the 
other side can make that job difficult. Frequently 
the best estimates of cost before litigation starts 
are discovered to be completely inaccurate after 
the litigation is under way and the issues are re-
vealed. Therefore, it is important to select counsel 
who is willing to revisit the issues of control of the 
proceedings, including control of costs and strat-
egy, so that the university can continue to make 
intelligent choices.
5. iS	The	univeRSiTy	ReADy	To	liTigATe?
Patent litigation is expensive, involves substantial 
risk, and endangers the university’s IP rights. A 
frequent defense to an accusation of infringement 
is patent invalidity. Therefore, the university can 
lose the litigation on a judgment that the indi-
vidual is not an infringer and can also lose on a 
judgment that its patent is invalid. However, an 
issued patent is presumed valid by statute, and 
the accused infringer carries the burden of prov-
ing (by clear and convincing evidence) that the 
patent is indeed invalid. Still, in the event of a 
declaration of patent invalidity, the university has 
no further opportunity to license the technology 
and any existing licensees will stop paying royal-
ties. On the other hand, if the university has a 
group of licensees and there is a party substantially 
infringing without licensing, ultimately all of the 
university’s licensees will recognize this and possi-
bly also stop paying royalties unless the university 
takes action. As a result, the university may be in 
the position where it will bleed to death slowly or 
have an instant death if it loses the litigation. In 
any event, the only way to preserve the long-term 
economic viability of the proprietary technology 
is to bring suit.
5.1 Warning	letters
After identifying a likely act of infringement, 
the technology transfer manager may enter into 
a dialogue with the infringer in an effort to end 
the infringement; this is frequently resolved by 
entering into a license negotiation. At some point 
there will be a written communication stating 
that the university believes the party may be an 
infringer and that if it neither ceases nor licenses, 
the university will consider taking legal action. 
The manager should understand that if the uni-
versity clearly and precisely accuses a party of 
infringement and threatens the party with litiga-
tion, then the situation may rise to the level of 
an actual case/controversy, triggering the accused 
party’s right to seek a declaratory judgment. This 
involves asking the court to declare that there is 
no infringing activity and/or that the university’s 
patent is invalid. Therefore, the right to seek le-
gal relief becomes not only the university’s, but 
also that of the party accused of infringement; 
in other words, the table has turned. Therefore, 
caution is important. As long as the university’s 
letters fall short of making an actual accusation 
of infringement and of threatening litigation, 
then the decision to go to court remains solely 
with the university. If a manager is not comfort-
able, experienced, and skilled in drafting such 
letters, then a warning letter should be reviewed 
(and possibly even written) by counsel before it 
is mailed. Clearly, the wrong warning can lead to 
unintended consequences and come back to hurt 
the university in several ways.
5.2 Beware	of	oversights	in	record	keeping  
A university is not ready to litigate until it has 
investigated its own records and spoken with the 
people on the university’s side who are associat-
ed with the potential litigation (and who might 
be witnesses) to discover whether there is any 
knowledge or written correspondence or records 
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that would have an embarrassing or otherwise 
negative impact on the outcome of the litigation. 
The university should not let the infringing par-
ty discover these damaging oversights; it should 
know about them ahead of time because this may 
greatly impact the decision of the university’s trial 
counsel of whether to proceed with litigation.
5.3	 Exhaust	all	alternative	means		
of	settling	the	controversy
Before the university litigates, it should consider 
involving a third party for informal dispute reso-
lution or possibly proceeding with formal arbitra-
tion or alternative dispute-resolution mechanisms 
in order to find a solution short of court.
5.4 Valuing	the	alternatives
The alternatives to litigation include changing the 
licensing terms or creating licensing scenarios that 
take into account issues raised by the infringer as 
reasons for not taking a license. It is a wise strat-
egy to consider offering license terms that make 
opposition to paying royalties economically irra-
tional (when compared to the costs of litigation) 
for the infringer. When valuing the alternatives 
and seeking alternative resolution, the university 
must consider other licensees and the existence of 
favored nation clauses in other license agreements. 
The university may have to extend the same terms 
to all its other licensees, and therefore, alternative 
dispute resolution may have a financial impact 
beyond the particular infringing activity, with a 
potentially broader impact and implications for 
the value of the technology.
The university must reach an approximation 
of the true cost of litigation, which is more than 
the cost of outside attorneys. Litigation requires 
an enormous amount of staff time, not only of the 
technology transfer office, but of the university’s 
counsel office as well. Also, litigation can involve 
much of the inventor’s time and anguish, since the 
inventor’s skill and integrity may be challenged in 
the litigation. Ultimately, of course, there is the 
dollar cost. Importantly, the university must rec-
ognize that past infringement, the cost of the liti-
gation, and the impact on the future value of the 
technology are issues that have to be separately 
assessed when considering alternatives.
5.5 Making	a	difficult	business		
decision:	Walk	away	or	litigate?
Because patent litigation is expensive and puts the 
university’s IP at risk of being declared invalid, the 
vast majority of patent disputes are settled before 
they ever come to court. For both sides, it is usu-
ally better to resolve the dispute than to litigate. 
But ultimately, the technology transfer manager 
may be required to make a very hard business 
decision on behalf of the university. A manager 
should never litigate out of anger or pride. The 
university should only litigate if it makes absolute 
business sense, that is, if it is economically bet-
ter to litigate than not to litigate, and only after 
the university has examined all of the issues, in-
cluding the risk of losing versus the value of win-
ning, and finds, on balance, that it makes sense 
to litigate.
5.6 The	effect	of	the	Markman	decision
The way patent litigation is conducted was signif-
icantly impacted by the Supreme Court decision 
in Markman v. Western Instruments, Inc.1 Claim 
interpretation was taken away from the jury and 
handed to the court. The result of Markman and 
related later cases was that claim interpretation 
could occur at any time in the litigation, and not 
just before, during, or after the trial.
In Vitronics, Inc. v. Conceptronic, Inc.2 the 
federal circuit held that it is the rare case where 
patent claims should be interpreted based on 
anything other than the patent, the specification, 
and the file history (the public record). Therefore, 
the hope was that claims could be construed ear-
ly so that the parties would know the meaning 
and scope of the claims before starting discovery. 
Since discovery is often over one-half the cost of 
expensive patent litigation, if it can be narrowed 
to more-specific issues, cost should be less, en-
hancing the chance for early settlement.
The results of the Markman and Vitronics 
decisions have been mixed. District courts have 
shown little uniformity with respect to the timing 
of claim interpretations. Some courts make their 
interpretations very early in the process; some as 
part of a conference just before the trial starts (and 
after discovery is complete); and some courts do 
so during or at the end of the trial. Most courts 
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now have formalized a “Markman procedure.” 
Some have built claim construction hearings into 
their local rules. Finally, whether extrinsic evi-
dence can be used in a claim construction hearing 
is far from being settled.
Clearly, claim construction is a critical ele-
ment in litigation that now has assumed an inde-
pendent place in the litigation process. If one can 
obtain early claim construction, doing so should 
be a significant benefit with respect to the cost of 
the litigation; if there is a serious issue regarding 
the scope of the claims, claim construction may 
prompt settlement or dismissal.
5.7 The	university’s	role	if	the	licensee	litigates
Some universities may give their licensee the first 
right to litigate. This is quite common in cases 
where an exclusive license has been granted. But 
even in that case, the university should pay very 
close attention to what is happening and may 
want to participate in key strategy sessions held 
by the licensee and its counsel and/or have the 
university’s own counsel participate and/or review 
all documents. Where the university’s personnel 
are deposed or where discovery is held on the 
university’s documents, the university’s counsel 
should be involved. But, if the university granted 
the licensee the right to litigate, thus saving the 
university the cost of litigation, why should the 
university incur significant expense to look over 
the licensee’s shoulder?
There are a number of valid reasons why the 
university should remain active in the litigation. 
On many points the licensee’s and university’s in-
terests may not exactly correspond, and, in cer-
tain situations, a choice may be made that reflects 
badly on the university, though it would bene-
fit the licensee. This is very important, as there 
should always be concern for the university’s good 
reputation and the reputation of the researcher/
inventor. Both can be at risk in litigation. It is 
critical to keep in mind that the actions, words, 
skill, or integrity of the researcher/inventor may 
be put at issue, which could become traumatic 
for the researcher/inventor in the unpredictable 
process of litigation. Another reason to maintain 
involvement is the potential for a loss of property. 
As pointed out previously, once a patent is de-
clared invalid, it is forever invalid, so the univer-
sity could lose its valuable IP rights. The licensee 
may not have as much at stake; it may only lose 
by gaining a competitor. 
Just because the university lets the licensee 
assume the burden of litigation, the patentee 
should still be vigilant as to the licensee’s determi-
nation, skill, and strategy for litigation, as well as 
its attitude toward the university and the univer-
sity’s researchers. The patentee should also remain 
aware of a licensee’s financial status. Letting the 
licensee carry the burden of litigation may sig-
nificantly ease the university’s financial burden 
and the level of technology transfer staff involve-
ment. However, because it is the university’s pat-
ent, and because the university’s staff may be vital 
witnesses, the university will almost always have a 
critical, although reduced, role. 
5.8 The	licensee’s	promise	to	hold	harmless
In most instances where the licensee is litigating, 
there is a license obligation to hold the university 
harmless in the litigation. Even so, the university 
must look closely at the state and condition of the 
licensee at the time of the litigation. If things go 
badly and the university is at risk, can the licensee 
perform adequately on its promise to protect? 
Does it have sufficient assets to pay an adverse 
judgment? Is it going bankrupt? Is there collect-
able insurance available? There may be a rude 
awakening, if the university is not attentive to 
the meaningfulness of a hold-harmless promise, 
both at the time of entering into the license agree-




A technology transfer manager should review the 
university’s license agreements on a regular basis 
to make sure that its licensees are current in their 
payments and all other obligations. The technol-
ogy transfer manager should be talking to the 
university’s licensees about the marketplace and 
should listen if licensees are complaining that 
there is a party performing unauthorized acts. 
The manager should talk to the inventors or other 
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people who are knowledgeable in the technology 
field, so that if there are infringers, the university 
can contact those parties early and they will not be 
led to believe they are free to act. The single most 
likely cause for litigation between a university and 
industry occurs when an industry member has 
the perception that the university won’t litigate, 
or that the university is inadequately represented 
and doesn’t know what it is doing. Clearly, com-
municating with conviction and credibility that 
the university indeed will sue, and emphasizing 
that the university has, or will, retain competent 
counsel and pay the price necessary, will go a long 
way toward bringing the infringer to the table to 
discuss the issues.
A final word of advice for the university: write 
the good things, and say the bad things. Although 
the attorney-client privilege is real, it is frequently 
penetrated. Consider anything in writing acces-
sible to the other side in litigation and available 
for use against the university. ■
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ABSTRACT
As multinational technology-development partnerships 
have become more common, so have disputes between 
the parties. Litigation, however, is not the only option for 
resolving such disputes. In fact, for partnerships between 
entities in developing and developed countries, litigation 
may be a complicated, time-consuming, expensive, and 
doubtful process. Arbitration and mediation may offer 
the promise of more effectively resolving disputes, and 
this chapter explains how these methods work, their ad-
vantages and disadvantages, and suggests which questions 
should be asked (especially for a developing country in-
stitution) to begin to establish a dispute prevention and 
resolution strategy. The chapter offers both strategic and 
practical insights about how to use these mechanisms to 
resolve disputes and preserve partnerships.
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transactions, therefore, should be aware of dis-
pute-resolution methods and have a specific dis-
pute-prevention and resolution strategy. Dispute-
resolution procedures too often are unwittingly 
selected when a relationship begins, often years 
before a dispute actually arises. The dispute-reso-
lution clauses will therefore have been inserted 
into contracts by people no longer involved in the 
issues. Moreover, clauses frequently are inserted 
with a limited awareness of their specific implica-
tions in a dispute-resolution scenario.
Litigation, the formal, public process for 
resolving disputes before national courts, is the 
most conventional method of dispute resolution. 
Particularly for transnational disputes, litigation 
may be risky, frequently protracted, and may at 
times require seemingly unlimited legal costs and 
management time. Moreover, a dispute taking 
place in multiple jurisdictions may result in dif-
ferent outcomes depending on which court de-
cides the case.
This chapter explores alternative dispute reso-
lution (ADR) procedures for resolving IP disputes, 
focusing on the interests of developing countries. 
ADR encompasses a range of options for resolv-
ing disputes outside of formal court procedures. 
These options differ in terms of formality, party 
control, and finality. Each option, moreover, of-
fers benefits uniquely appropriate to different 
circumstances. This chapter concentrates on two 
CHAPTER 15.3
1.	 inTRoDuCTion
Institutions in developing countries are increas-
ingly entering the IP market, and multiparty, 
multinational IP relationships are becoming 
more common, and even essential to socio-
economic development. Through transactions 
involving these relationships scientific, technical, 
entrepreneurial, creative, and traditional knowl-
edge is exchanged. Nonetheless, a protected right 
also tends to increase the likelihood of disputes 
related to that right.1 While parties seek to reduce 
the frequency of disputes by rigorously manag-
ing their IP rights and obligations, disputes will 
inevitably arise. When they do, they can nega-
tively affect both sides. Parties involved in IP 
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representative ADR procedures, arbitration and 
mediation.
2.	 DiSpuTe	SCenARioS
The following dispute scenarios discuss some 
specific circumstances that apply to health or 
agricultural IP disputes. The scenarios may have 
particular relevance for institutions in develop-
ing countries. Parties to the types of disputes 
in these scenarios will most likely first consider 
resorting to litigation in national courts. They 
will, however, often find court action stymied 
because of the challenges involved: cost, length 
of procedure, legal uncertainty, decision makers’ 
lack of expertise, confidentiality/publicity, the dif-
ficulty of seeking action in foreign jurisdictions, 
and the negative impact on existing business rela-
tionships. Given these difficulties, parties should 
consider whether there are practical alternatives 
to expensive and protracted court proceedings.
2.1	 Research	collaboration:	ownership	dispute
Researchers in a medical research center in a 
developing country (Center X) build a research 
partnership with a leading university in a devel-
oped country (University Y). They collaborate on 
pursuing leads for pharmaceutically active com-
pounds. The partners exchange data and discuss 
research directions. University Y has a well-estab-
lished policy of patenting campus research, and 
an invention disclosure is filed with the technol-
ogy transfer office (TTO). This becomes a patent 
application in the name of University Y, citing 
three of its researchers as inventors. There is no 
notice to, nor recognition of, the researchers in 
Center X. The researchers at Center X denounce 
the behavior of University Y and request that their 
names be included as inventors. When University 
Y refuses this request, the researchers contemplate 




A research institute obtains patent protection for 
a cell line developed from genetic material ob-
tained from one of the institute’s patients. The 
patient is from an indigenous group that lived 
an isolated existence until very recently. The 
indigenous group seeks redress, claiming own-
ership of interest in the patent and breach of 
fiduciary obligations by the research institute. 
The research institute asserts that it proceeded to 
commercialize the research result based on the 
patient’s prior consent to treatment. The contro-
versy, with claims of biopiracy, rapidly escalates 
into a global public debate.
2.3	 Claims	based	on	traditional	rights
An ethnobotanist collects traditional medical 
herbs and associated knowledge about their ther-
apeutic use from an indigenous community. The 
community is led to believe that this is the per-
sonal research of the ethnobotanist; the researcher 
acquires some of the knowledge after he falls ill 
on site and is treated by a traditional medicine 
man. The customary law of the indigenous com-
munity constrains both the dissemination and 
use of this knowledge within the community. 
The researcher subsequently publishes the knowl-
edge, and details about the plants he collected, 
in a noncommercial academic publication. This 
publication is widely distributed and used by sev-
eral private companies in their medical research. 
The disclosure of the information leads to pat-
ents, not directly on the traditional knowledge, 
but on further innovations, which are guided by 
and dependent upon the traditional knowledge. 
These patents acknowledge the prior publication, 
but give no direct reference to the traditional 
community itself. The traditional community 
attempts to seek relief but quickly finds that the 
legal remedies at their disposal are unclear and 
inappropriate for dealing with the cultural and 
spiritual harm incurred. 
2.4	 Agricultural	products	and	patents
Farmers in a developing country have cultivated 
for centuries a certain type of grain that gains 
popularity in global markets. A biotechnological 
corporation obtains patents on the grain by in-
troducing genetic modifications. Farmers in 
the developing country denounce their loss of 
international market share resulting from the 
actions of the biotechnological corporation. 
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The farmers are concerned, however, that any 
inherent right they may claim will be overshad-
owed in court by the economic, technical, and 
legal prowess of the corporation.
2.5	 David	v.	Goliath?
An inventor in a developing country holds 
patents in a number of countries on components 
used in consumer goods. The inventor enters into 
a license agreement regarding these patents with 
a multinational manufacturer. A dispute arises 
regarding royalty payments under the license 
agreement. The inventor wants to enforce his 
rights, but does not dare to engage in protracted 
and expensive multijurisdictional litigation. 
Furthermore, the inventor hopes to maintain his 
profitable relationship with the manufacturer. 
3.	 The	ARBiTRATion	opTion2
Seeking resolution to the above disputes through 
litigation promises much pain and little certainty 
for parties in developing countries. An alternative 
approach to litigation, however, could offer better 
results. Arbitration, for example, involves submit-
ting a dispute, by agreement of the parties, to one 
or more arbitrators who make a binding decision.
3.1	 Arbitration	procedure
To send a dispute to arbitration, the parties must 
sign an agreement to submit their existing or fu-
ture disputes to arbitration. Such an agreement is 
the foundation of an arbitration arrangement.3 It 
demonstrates the parties’ genuine willingness to 
settle the dispute through arbitration and limits 
the parties’ right to take the dispute to court. 
Arbitration may be conducted in different 
ways, and it is up to the parties and the arbitrator(s) 
to decide how the procedure should unfold, sub-
ject to any applicable rules and public policy re-
quirements. Parties may agree on the number of 
arbitrators, type of arbitration (ad hoc or institu-
tional), place of arbitration, language of arbitral 
proceedings, and the applicable substantive law.
 Figure 1 describes the principal steps in a typ-
ical arbitration, referencing the Arbitration Rules 
of the World Intellectual Property Organization 
(WIPO)4 (see also section 6.2 below).5
3.2	 Role	of	the	arbitral	tribunal
An arbitral tribunal operates differently from a 
judge in national court. Judges have powers de-
fined by national laws. The powers of an arbi-
tral tribunal are limited to those the parties have 
conferred to it. An arbitral tribunal may only 
determine the disputes stipulated by the par-
ties involved, and may only do so using powers 
conferred by the parties through the arbitral 
clause and adopted rules.
Since the arbitral tribunal is the dominant 
authority in settling the dispute, the appointment 
of the tribunal is probably the single most deter-
minative step in an arbitration. Parties should, 
therefore, be able to exert as much influence as 
possible on the establishment of the tribunal. 
Parties can normally agree on the appointment 
procedure, the number of arbitrators to be ap-
pointed, any required qualifications of the arbitra-
tors (including nationality), and persons to be ap-
pointed as arbitrators. In reviewing these factors, 
parties will have to weigh considerations of cost 
and efficiency against the weight and complexity 
of the dispute. The legal, cultural, and economic 
backgrounds of the parties will be reflected in the 
tribunal appointment process. 
3.3	 Legal	framework	of	arbitration
While arbitration is a private mechanism, it is not 
altogether free from regulation by national laws. 
In international arbitration, different systems of 
law, most notably the law governing the substance 
of a dispute and the law governing the arbitration 
procedure, will typically interact. In general, par-
ties are free to choose, by agreement, which laws 
will apply.
Parties may agree on which national law 
should govern the substance of the dispute. Parties 
may also agree that the dispute be determined 
on the basis of what is just and good (ex aequo et 
bono). In certain fields of consequence to devel-
oping countries, such as agriculture, biotechnol-
ogy and traditional knowledge, the legal regime 
is actively evolving, and the basis and extent of 
rights and obligations can be controversial. In 
these cases the possibility of dispensing with law, 
and deciding the dispute in equity, may be an at-
tractive option. 
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figure	1:	principal	Steps	in	a	Typical	wIpo	Arbitration
A WIPO arbitration begins with a claimant 
submitting a request for arbitration to the 
WIPO Arbitration and Mediation Center. 
The request for arbitration should contain 
summary details concerning the dispute.
REQUEST FOR ARBITRATION
30  Days
ANSWER TO REQUEST FOR ARBITRATION












Within 30 days of receipt of the request for 
arbitration, the respondent must file an answer 
to the request. 
The parties may choose the number of 
arbitrators that will sit on the tribunal. In the 
absence of an agreement by the parties, the 
WIPO Center will appoint a sole arbitrator, 
except where the WIPO Center determines 
that three arbitrators are appropriate.
The statement of claim must be filed within 30 
days of the constitution of the tribunal.
The statement of defense must be filed within 
30 days of the receipt of the statement of 
claim.
The tribunal may schedule further submissions.
By party request, or by tribunal discretion, a 
hearing may be held for the presentation of 
evidence by witnesses and experts, and for oral 
argument.
When the tribunal is satisfied that the parties 
have had adequate opportunity to present 
submissions and evidence, it will declare the 
proceedings closed.
The final award by the tribunal should be 
delivered within three months of the closure 
of the proceedings.
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The law applicable to the arbitration 
procedure (lex arbitri or arbitral law) is the law 
that governs the procedural framework, such as 
whether a dispute is arbitrable, the availability 
of interim measures of protection, the conduct 
of the arbitration, and the enforcement of the 
award. The arbitral law need not be the same as 
the law applicable to the substance of the dispute. 
A tribunal may, for example, be subject to the ar-
bitral law of Switzerland, but may be required, 
by party agreement, to apply Indian law to the 
substance of the dispute.
4.	 The	meDiATion	opTion
Arbitration is not the only option to litigation. The 
parties can also opt for mediation, a non-binding, 
confidential procedure in which a neutral inter-
mediary assists the parties in reaching a mutually 
satisfactory settlement of their dispute.6 
4.1	 Mediation	procedure
The starting point of a mediation, like an arbitra-
tion, is the agreement of the parties to submit 
their existing or future disputes to mediation. 
Once a dispute arises and there is an agreement 
(either ex ante or ex post) to mediate, a party 
will initiate the process by informing the other 
party of the commencement of mediation. The 
mediation procedure is then largely determined 
by the parties, together with the mediator. 
Figure 2 describes the principal steps in a typical 
mediation. 
4.2	 Role	of	the	mediator
Unlike a judge or an arbitrator, whose mandate is 
to issue a binding decision or award, a mediator 
does not have any power to impose a settlement 
on the parties. The role of a mediator is to serve 
as a catalyst for party negotiations. A mediator 
works to improve communication between the 
parties, helps parties clarify their understand-
ing of their mutual interests and concerns, sheds 
light on the strengths and weaknesses of each 
party’s legal position, explores consequences of 
not settling, and helps generate options for a mu-




With the creation and exploitation of inter-
national IP rights, disputes are increasingly 
multijurisdictional. Resolving transnational dis-
putes through litigation requires the expense 
and complexity of pursuing parallel proceed-
ings in a number of countries and confronting 
multiple rounds of appeals in each jurisdiction. 
Furthermore, despite broad harmonization of 
substantive IP laws, national prejudices and dif-
ferences in approaches still remain. Therefore, in 
a multijurisdictional dispute, a win in one juris-
diction will not necessarily translate into a win 
in other jurisdictions. The risk of inconsistent 
results is significant. 
Through arbitration or mediation, the par-
ties can agree to resolve, in a single procedure, 
disputes involving intellectual property in a num-
ber of countries. For a deep-pocketed party that 
has an interest in broadly manifesting its strong 
IP enforcement policy, litigation may be a more 
appealing option. The threat of drawn-out court 
procedures in multiple jurisdictions may be an 
effective strategy to induce the other party with 
limited resources to accept a quick settlement. 
On the other hand, for a party seeking a timely, 
cost-efficient resolution of the immediate dispute, 
resolution through a single arbitration or media-
tion procedure may be more advantageous. 
5.2	 A	neutral	dispute-resolution	forum
Litigation between parties of different nationali-
ties means that the home party enjoys an advan-
tage, since the other party bears the burden of a 
foreign and unfamiliar jurisdiction. In arbitration 
or mediation, parties may resolve a transnational 
dispute on neutral territory, so neither party is 
subjected to foreign court procedures, laws, cus-
toms, languages, and prejudices. In arbitration 
or mediation, parties may appoint an arbitrator 
or mediator of a neutral nationality and choose a 
neutral language and venue of procedure. In arbi-
tration, parties may agree on neutral substantive 
and procedural law. 
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APPOINTMENT OF A MEDIATOR
INITIAL CONTACTS BETWEEN 
THE MEDIATOR AND THE PARTIES
• setting up the first meeting
• agreeing on preliminary exchange  
of documents, if any
FIRST AND SUBSEQUENT MEETINGS
• agreeing on ground rules for  
the process
• gathering information and  
identifying issues
• exploring the interests of the parties
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Recourse to arbitration or mediation in a 
convenient, neutral forum may be especially at-
tractive when public entities are party to a dis-
pute.7 If a dispute is between a state entity and a 
private party, the private party will be disinclined 
to go to the court of the state entity, and the state 
party will not want to submit to the jurisdiction 
of the courts of another state. In such a case, a 
neutral procedure such as arbitration or media-
tion may be the only option acceptable to both 
parties. This feature may be particularly relevant 
in IP transactions involving entities in developing 
countries, where public institutions often largely 
own IP rights.
5.3	 Autonomy
Arbitration and mediation are based on consent 
of the parties. It follows that arbitration or me-
diation proceedings require party autonomy and 
that parties largely retain control over the dispute-
resolution process.
In principle, parties are free to agree on the 
procedure to be followed in the arbitral proceed-
ings. Depending on their needs, parties can se-
lect streamlined or more extensive procedures 
and choose the applicable procedural and sub-
stantive law, place and language of the arbitral 
proceedings, and the arbitrator(s). Thus, the par-
ties can adapt an arbitration procedure to fit the 
dispute.
Mediation offers parties control over not only 
the procedure to follow, but also the outcome of 
the process. Parties may fashion the mediation 
process to their specific needs. Commencement 
of the mediation is based on the parties’ agree-
ment to resolve the dispute through mediation, 
and continuation of the process depends on the 
parties’ continued acceptance of the terms of the 
mediation. Unlike arbitration, a party that has 
submitted the dispute to mediation may with-
draw at any time from the mediation. The out-
come of a mediation also depends on the will 
of the parties. While the mediator will assist in 
the procedure, it is ultimately up to the parties 
to determine whether they will settle the dispute 
in accordance with their interests or seek resolu-
tion in a different forum, such as litigation or 
arbitration. 
5.4	 Choosing	relevant	expertise	
Judges often have varying degrees of experience 
and qualification, and national courts are fre-
quently ill equipped to deal with technically com-
plex issues presented in IP disputes. 
In arbitration, parties normally participate in 
selecting arbitrators and are, in principle, free to 
appoint arbitrators of their choice. Arbitrators may 
be chosen for their skill and expertise in a specific 
legal, technical, or business field. Arbitrators with 
relevant expertise will ensure proper understand-
ing of facts and law and, therefore, contribute to 
a timely, cost efficient resolution of the dispute. 
When the dispute involves parties of different 
cultural and economic backgrounds, an arbitra-
tor’s knowledge of cultural or social sensitivities 
may also be helpful. 
As in arbitration, parties select their media-
tors. A mediator’s role, however, is fundamentally 
different from that of a judge or an arbitrator. 
The mediator’s role is not to render a decision 
but to facilitate the process through which par-
ties endeavor to settle their dispute. The mediator 
may inject a degree of detachment and objectivity 
into the dispute. The role of the mediator as an 
intermediary may be especially crucial when 
the share of information and bargaining power 
between the parties is unequal. An effective 
mediator will address these concerns.8 A mediator 
also will help parties rebuild trust to increase the 
chances for settlement.9 
The success of an arbitration or a mediation 
depends largely on the quality of the arbitrator(s) 
and mediator(s), and the challenge is often to 
find candidates that have both arbitration or me-
diation skills and experience with the specialized 
knowledge of the disputed subject matter. 
5.5 Confidentiality	
Parties to arbitration or mediation can keep the 
proceedings and any results confidential. In do-
ing so, parties can focus on the merits of their 
dispute and avoid distraction from external fac-
tors, such as unwanted negative press coverage. 
Confidentiality may be especially important 
where the terms of the parties’ relationship are 
undisclosed to the public, as in most licensing 
agreements, and where commercial reputation 
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and trade secrets are at stake. Particularly in me-
diation, the private nature of the procedure allows 
parties to engage in frank, exploratory settlement 
negotiations and not be intimidated by formal le-
gal procedures.10 
On the other hand, if one of the parties wish-
es to establish a public precedent to dissuade oth-
er parties from engaging in similar conduct, the 
confidential nature of arbitration and mediation 
may make these options less desirable. In certain 
cases, it may be more effective to take the case to 
the public and seek the support of public organi-
zations or nongovernmental organizations. A de-
gree of publicity may at times assist in negotiating 
a settlement.11 For disputes involving issues of 
broad public concern, which is often the case in 
health and agriculture, it may be inappropriate 
to keep the existence of the dispute, and its 
outcome, confidential. When appropriate, parties 
may agree to employ mediation or arbitration to 
resolve the dispute and consent explicitly to make 
the process and result public. 
5.6	 Preserving	relationships
As multiparty, complex IP relationships become 
more common, partnerships between actors in 
government, academia, and industry in devel-
oping and developed countries occur regularly 
and, frequently, expand beyond a single short-
term transaction. The multiparty nature of 
such relationships exacerbates the complexity of 
dispute resolution. When disputes arise out of 
these relationships, a party’s desire to resolve the 
immediate dispute should not eclipse safeguarding 
the relationship.
The adversarial nature of litigation often 
fosters hostility and resentment between the 
parties, rendering the dispute intractable and 
potentially destroying a working relationship. 
On the other hand, the consensual nature of 
mediation, and to a certain extent arbitration, 
accommodates a long-term approach. Parties can 
resolve the dispute at hand and still maintain a 
working relationship. In this way, antagonism 
between parties can be mitigated and mutual 
understanding fostered. This feature of mediation 
and arbitration may be particularly relevant for en-
tities in developing countries that rely on alliances 
with foreign enterprises. Developing countries are 
still dependent on foreign sources for technology, 
and so there is a marked need to maintain these re-
lationships. Also, a large proportion of innovation 
occurs in university or government laboratories, 
after which rights are exploited in collaboration 
with foreign companies. Foreign IP rights hold-
ers will demand a particular level of protection; 
entities in developing countries, especially those 
in the public sector, may need to accommodate 
these demands with national development goals 
or other vested interests.12 
5.7	 Arbitration’s	finality	
The protracted nature of litigation, which pushes 
parties into multiple rounds of appeals, is a com-
mon problem when litigating transnational dis-
putes. In addition, it is difficult to enforce any court 
judgment outside the court’s jurisdiction. The end 
result of arbitration is, on the contrary, a final, 
binding award. Normally appeals are not allowed, 
and awards are directly enforceable by national 
courts under the Convention on the Recognition 
and Enforcement of Foreign Arbitration Awards 
(New York Convention).13 This convention, cur-
rently ratified by 139 countries, greatly facilitates 
the enforcement of awards across borders by pro-
viding for recognition of awards on a par with 
domestic court judgments, without review on the 
merits. The convention only permits awards to be 
set aside in very limited circumstances. 
5.8	 Mediation’s	nonbinding,		
interest-based	procedure	
In litigation or arbitration, the outcome of a 
case is determined by the facts of the dispute 
and the applicable law. Mediation, on the other 
hand, involves more than the exercise of rights 
and obligations set within legal parameters. It is 
often a coordinated exercise of legal rights, with 
consideration given to other economic and social 
variables.14 With mediation, the dispute resolu-
tion options are broadened, allowing the parties, 
with the help of the mediator, to craft innova-
tive, common-sense solutions that amicably settle 
the dispute. Parties may find a solution to their 
dispute by considering their business or social in-
terests. They may also reach package deals that 
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include nonmonetary benefits, such as technol-
ogy transfer agreements, training programs, or 
infrastructure development.
In certain circumstances, mediation may be 
the only option available for resolving the dispute. 
Parties in a dispute may each have a claim that 
is valid and enforceable and, yet, impossible to 
fulfill.15 The dispute may involve a subject matter 
where there is no established legal framework, or 
where there are certain interests that may not be 
adequately addressed by traditional legal means.16 
In such cases, the only strategy to break the impasse 
may be a cooperative solution, such as mediation. 
The nonbinding nature of mediation means 
that a decision cannot be imposed on the parties 
and that all involved must voluntarily agree to ac-
cept the settlement. Any settlement may be re-
corded in a contract; if either party does not per-
form the contract, actions for breach of contract 
may be brought. Of course, if the outcome of a 
mediation represents the interests of the parties, 
the outcome is more likely to endure as a long-
term solution to the conflict.
5.9	 Mediation—minimal	risk
Even when the parties have agreed to submit a 
dispute to mediation, if a party feels that it is not 
making any progress, that the procedure is becom-
ing too costly, or that the other party is not act-
ing in good faith, the party may withdraw from 
the mediation process at any time and seek to re-
solve the dispute through litigation or arbitration. 
Accordingly, mediation involves low risk. Should 
mediation not produce a settlement, the procedure 
might still assist the parties by defining the facts 
and issues of the dispute, thus preparing parties for 
subsequent arbitration or court proceedings. 
5.10	 Comparing	options	at	a	glance
Table 1 provides an overview of the different 
strengths and weaknesses of litigation, arbitra-
tion, and mediation.
6.	 pRACTiCAl	ConSiDeRATionS
Since arbitration and mediation are private pro-
ceedings, the support of lawyers and experts 
skilled in the process is essential. Institutions in 
developing countries will want to exercise care in 
retaining appropriate counsel when exploring ar-
bitration and mediation options. 
6.1	 Controlling	costs	
The validity of a claim may be irrelevant if the 
concerned parties are unable to afford the appro-
priate dispute-resolution procedure. Institutions 
will need to confront any financial constraints 
that might complicate the choice of a dispute-
resolution strategy. 
Arbitration and mediation are essentially 
private processes, and a number of advantages, 
including party autonomy, confidentiality, neu-
trality, and expertise, stem from the private na-
ture of the proceedings. This private nature, 
however, also means that parties are obliged to 
bear the costs. The parties involved in a dispute 
do not pay judges in national courts, but they do 
pay arbitrators and mediators. 
In an arbitration, parties must cover le-
gal fees, plus the additional fees and expenses 
of arbitrators. If an institution administers the 
arbitration, administrative fees must also be paid. 
Thus, arbitration may not necessarily be less costly 
than litigation. However, parties can consciously 
try to limit costs by expediting the procedure and 
by selecting cost-efficient venues for meetings 
and hearings. Parties can also endeavor to ap-
point an arbitrator that is sensitive to the finan-
cial constraints of parties, and choose an arbitral 
institution that charges reasonable administrative 
fees. Furthermore, while arbitration may be 
costly, the finality and enforceability of arbitral 
awards may make arbitration less costly than liti-
gation, which often involves multiple appeals and 
requires a judgment to be enforced in a foreign 
jurisdiction.
In mediation, costs are more easily con-
tained. Mediation costs include the legal fees of 
each party, the mediator’s fees, and administrative 
fees (if an administering institution is present). 
Parties can monitor the costs and progress of the 
mediation to determine whether to continue it. 
While the cost of mediation is generally shared 
equally between the parties, parties may agree to 
change this allocation of costs depending on the 
economic power of each party. 
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International solution limited to 
court’s jurisdiction
multiple proceedings 
under different laws, 
with risk of conflicting 
results
possibility of actual or 
perceived advantage 
to party that litigates 
in its own country
global solution
a single proceeding 
under the law 
determined by parties
arbitral procedure and 
nationality of arbitrator 
can be neutral to 
law, language, and 





and nationality of 
mediator can be neutral 
to law, language, and 
institutional culture of 
parties
Technical decision maker might 
not have relevant 
expertise
parties can select 
arbitrator(s) with 
relevant expertise
parties can select 
mediator(s) with 
relevant expertise
Urgency procedures often 
drawn out
injunctive relief 
available in certain 
jurisdictions
arbitrator(s) and 
parties can shorten the 
procedure
arbitration may provide 
provisional measures 




parties can shorten the 
procedure
while provisional 
measures are not 
available in mediation, 





court generally applies 
only its national laws
applicable law may be 
determined by parties;  
absent party agreement, 
arbitrator(s) will select 
the law(s) that it 
determines appropriate 
to the dispute
multiple national laws 
may concurrently apply
tribunal may decide 
in equity (rather than 
specific law)
procedure less governed 
by law and more by the 










Finality appeal possible limited appeal option any settlement 
agreement is binding 
between parties as a 
matter of contract law
Confidential/
trade secrets 
and risk to 
reputation







parties may or may 
not be in a continuing 
relationship
dispute may be 
resolved without 
adverse party’s active 
participation
adversarial nature of 
litigation may further 
antagonize parties
parties often in a 
continuing relationship
parties often in a 
continuing relationship
mediation shields the 
relationship by fostering 
an amicable resolution 
of dispute
Table	1	(continued)
Whether in arbitration or mediation, par-
ties should bear in mind that the procedure is 
largely under their control and costs will vary 
depending on the choices made throughout the 
procedure. 
6.2	 Ad	hoc	or	institutional	procedure?
Arbitration and mediation may take place ad 
hoc or under the aegis of an institution. In an 
ad hoc procedure, the parties, with the arbi-
trator or mediator, administer the proceedings 
themselves. This requires sufficient cooperation 
among the parties and the arbitrator or me-
diator, as well as considerable experience in 
arbitration/mediation procedures. In an insti-
tutional arbitration or mediation, the institu-
tion provides a procedural and administrative 
framework for initiating and conducting the 
procedure, and oversees the integrity and in-
dependence of the process. Especially where 
parties are inexperienced in dispute resolution, 
they should consider opting for an institutional 
procedure. Administrative fees vary greatly by 
institution and will be a factor in selecting 
one. However, the cost of using a moderately 
priced institution will guarantee consider-
able benefits, including administrative and 
technical assistance, availability of a tested set 
of procedural rules, and access to qualified ar-
bitrators and mediators.
MIN
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Governments and public institutions can 
help make arbitration or mediation procedures 
accessible and available by identifying and sup-
porting neutral institutions that can provide 
cost-efficient, timely dispute-resolution services, 
and by catering to the needs of local enterprises, 
government agencies, and foreign entities. The 
Arbitration and Mediation Center of the World 
Intellectual Property Organization17 (the WIPO 
Center) is worth keeping in mind. Established in 
1994 to promote the timely, cost-effective reso-
lution of IP disputes through alternative dispute 
resolution, the WIPO Center has created, with 
the active involvement of many ADR and IP prac-
titioners, the WIPO mediation, arbitration, and 
expedited arbitration rules and clauses. Together 
with its extensive network of IP and ADR experts, 
the WIPO Center ensures that WIPO procedures 
are at the cutting edge of IP dispute-resolution 
techniques and that these procedures meet the 
needs of parties of different economic and social 
backgrounds. 
6.3	 Drafting	clauses
Arbitration and mediation are premised on 
party agreement; it is uncommon that these 
procedures are adopted after a dispute arises, 
when animosity between parties generally over-
shadows their interest in resolving the dispute. 
Therefore, arbitration and mediation clauses 
often refer to potential disputes under a par-
ticular contract, including those conflicts that 
might emerge regarding patents, know-how and 
software licenses, franchises, trademark coexis-
tence agreements, distribution contracts, joint 
ventures, R&D contracts, technology-sensitive 
employment contracts, and mergers and acqui-
sitions with important IP aspects. These clauses 
generally determine a number of the procedure’s 
essential elements, such as its specific type, lan-
guage, number of arbitrators or mediators, and 
the applicable law. Arbitration and mediation in-
stitutions generally make available model claus-
es. Adopting these clauses will help to avoid any 
uncertainty that might unnecessarily burden the 
arbitration or mediation proceeding. Parties may 
introduce certain cost-saving models in appro-
priate circumstances.18 
Dispute-resolution clauses can provide for a 
multitiered process, namely, by mandating me-
diation followed, in the absence of settlement, by 
arbitration. Even mediation may be preceded by 
direct party negotiation, which may be particu-
larly relevant in disputes in public settings. When 
opting for a multitiered process, it is useful to 
stipulate time periods for each procedure in order 
to prevent protracted discussions and delays 
between the procedures.19
Public sentiment may not always support the 
development of and participation in ADR pro-
cedures. Public ADR pledges may be useful to 
handle this. Furthermore, legislative authorities 
may consider adopting procedural laws referring 
to or integrating ADR methods.
7.	 ConCluSion	
Entities in developing countries face a number 
of challenges, when a dispute arises, with entities 
in developed countries. The entities in developed 
countries will often have greater financial power 
and technical expertise with which to pursue a 
favorable dispute resolution. Since technology 
transfer is tied closely with economic develop-
ment, disputes may trigger public reaction. 
Moreover, language and cultural barriers can be 
obstacles to effective communication, and ques-
tions may arise about how rights asserted by de-
veloping countries may be accommodated by the 
existing IP regime. 
Having a dispute-resolution policy can help 
to address these concerns. It can also provide 
strategic benefits and minimize the risk of 
disputes escalating. The dispute-resolution strat-
egies should therefore be crafted with regard to 
the specific circumstances of the dispute and the 
background of the parties. Ideally, a procedure 
that assists in mitigating economic inequalities 
between parties should be identified and imple-
mented. Technical, commercial, legal, and social 
interests may need to be considered. In certain 
cases the result will be compromise; in other cas-
es, robust enforcement will be sought. 
Litigation, arbitration, and mediation oper-
ate within very different paradigms. To adopt the 
most appropriate dispute-resolution strategy for 
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a potential or existing dispute, parties should un-
derstand the differences between the procedures 
and determine which is most appropriate to the 
circumstances of the conflict. Remember, litiga-
tion is not the only option. Arbitration or me-
diation may offer a sustainable solution that will 
satisfy all the parties involved. ■
acKnoWleDgments
While much of this chapter provides information which 
is also subject of the WIPO Center’s provision of resourc-
es, the views expressed herein are not necessarily those of 
WIPO or any of its Member States.
eUn-Joo min, Senior Legal Officer, Arbitration and 
Mediation Center, World Intellectual Property Organization, 
34 Chemin des Colombettes, 1211 Geneva 20, Switzerland. 
eunjoo.min@wipo.int
1 O’Connor SN. 2005. Intellectual Property Rights and 
Stem Cell Research: Who Owns the Medical Break-
throughs? New England Law Review 39: 665.
2 Information in this section is largely extracted from the 
Guide to WIPO Arbitration. WIPO Publication no. 919. 
www.wipo.int/freepublications/en/arbitration/919/
wipo_pub_919.pdf.
3 Redfern A and M Hunter. 2003. Law and Practice 
of International Commercial Arbitration. Sweet & 
Maxwell: London. pp. 135.
4 See, also in this Handbook, chapter 3.6 by A Taubman.
5 Parties who place a premium on time and cost 
effectiveness can opt for the procedural framework 
established by the WIPO Expedited Arbitration Rules, 
which condenses the principal stages of an arbitration 
under the WIPO Arbitration Rules.
6 Information in this section is largely extracted from the 
Guide to WIPO Mediation. WIPO Publication no. 449(E). 
www.wipo.int/freepublications/en/arbitration/449/
wipo_pub_449.pdf.
7 See supra note 3, p. 42.
8 Williams BA. 2000. Consensual Approaches To 
Resolving Public Policy Disputes. Journal of Dispute 
Resolution 8 (2): 144.
9 Ibid..
10 Crowne CH. 2001. The Alternative Dispute Resolution 
Act of 1998: Implementing a New Paradigm of Justice. 
New York University Law Review 76 (6): 1768.
11 Boettiger S and A Bennett. 2006. The Bayh-Dole 
Act: Implications for Developing Countries. IDEA: 
The Intellectual Property Law Review 46(2), cites the 
example of the inventor of Golden Rice™ recounting 
that “publicity sometimes can be helpful: Only a few days 
after the cover story about golden rice had appeared in 
Time, I had a phone call from Monsanto offering free 
licenses for the company’s IP rights involved.”
12 Reichman JH and D Lange. 1998. Bargaining around 
the TRIPS Agreement: the Case for Ongoing Public-
Private Initiatives to Facilitate Worldwide Intellectual 
Property Transactions. Duke Journal of Comparative 
and International Law 9(11): 50-54.
13 See the full text of the New York Convention, with the 
list of its contracting states, at www.wipo.int/amc/en/
arbitration/ny-convention/. 
14 See supra note 12.
15 See supra note 1, p. 669. Herein is cited the example of 
patentable inventions being assigned to two or three 
different funding sources, each assignment being 
legally binding, yet impossible to fulfill.
16 See supra note 8, p. 139.
17 See supra note 4.
18 See the WIPO Center’s recommended clauses at www.
wipo.int/amc/en/mediation/contract-clauses/.
19 See, for example, the WIPO-recommended clause for 
submission to mediation followed, in the absence of 




This chapter provides guidance about parallel trade to de-
veloping country policy-makers and other stakeholders in 
intellectual property. What is parallel trade? And how can 
it be utilized to promote access to medicines and support 
poor farmers in developing countries? Engaging in parallel 
trade is an option provided by the Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS) 
under the World Trade Organization. Furthermore, the 
2001 Doha Declaration on TRIPS and Public Health 
confirmed that developing countries could use parallel 
imports to support public health. As a result, develop-
ing countries can ensure access to lower-priced patented 
and/or branded products, such as medicines and basic ag-
ricultural inputs, by incorporating legislation to allow for 
parallel imports. When implementing measures to facili-
tate parallel trade, developing countries can establish and 
maintain an effective system by adequately regulating the 
quality, safety, and health of parallel imports. At the same 
time, developing countries need to prevent low-priced 
patented products available in their countries from enter-
ing high-priced developed country markets.
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agreement, has been authorized by the patent, 
copyright, or trademark holder to market the 
protected product. Naturally, when the licensed 
dealer has an exclusive agreement, he or she ex-
pects to be the only party supplying the product 
in the local market.
Parallel trade does not refer to unofficial, 
illegal, or informal-sector activities that may 
take place inside a country or among countries. 
Moreover, parallel trade is not trade in pirated or 
counterfeit products. The latter are unauthorized 
versions of products that infringe an IP right. 
Parallel imports (also called gray-market imports) 
are genuine, often branded, products that do not 
violate an IP right. Importing the products from 
one country to another, however, may not be 
authorized by the right holder. 
The main difference between parallel im-
portation and “official” importation is that the 
parallel imports probably were produced origi-
nally for sale in a particular market and then were 
passed through an unauthorized dealer before 
reaching the consumer. Parallel imports may dif-
fer in superficial ways from those made available 
by the local dealer—they may be packaged dif-
ferently or lack the original manufacturer’s war-
ranty—but otherwise they will be identical to the 
official import being marketed locally.1
When parallel importation occurs, the prac-




Parallel trade occurs when products produced 
under the protection of a patent, trademark, 
or copyright in one market are subsequently 
exported to a second market and sold there 
without the authorization of the local owner of 
the intellectual property (IP) right. Often, the 
local owner of the IP right will also be a local 
dealer who, through a license or other exclusive 
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product becomes available locally from multiple 
sources. Parallel importing allows dealers to by-
pass official or authorized local suppliers or li-
censees and obtain products directly from over-
seas suppliers. The enhanced market competition 
between sources of the same products tends to 
drive prices down.
Indeed, the incentive for parallel importation 
is the fact that there are price differences between 
identical products in different markets. Parallel 
importing usually occurs when the price differ-
ences are high, because then the potential gains 
(price savings, product availability, profit) for 
most stakeholders are large enough to compen-
sate for the transaction costs, including shipping 
costs and complying with customs regulations. 
The price differences can be due to a variety of 
factors. In the case of the pharmaceutical market, 
where important price differentials exist between 
countries, price differences can result from gov-
ernment-enforced price controls, pricing manip-
ulated by the owner of an IP right holder, fluctua-
tions in currency values, a combination of these 




The regulation of parallel trade involves balanc-
ing the interests of producers and consumers. An 
important public policy mechanism for develop-
ing countries, parallel importation can be used to 
protect the interests of consumers, particularly 
with regard to pharmaceutical and agrichemical 
products. Countries can introduce legal provi-
sions to permit parallel importing in order to en-
sure adequate access to imports. Parallel import-
ing also allows the government to shop around 
in different markets for the lowest price on an IP 
protected product.
The prospect of parallel imports of prod-
ucts protected by IP rights is particularly im-
portant in the public health sector, where prices 
for medicines in developing countries may be 
higher than most people can afford. By utilizing 
parallel imports, developing countries can access 
alternative sources of medicines at lower prices, 
guaranteeing greater access and availability of 
medicines. Hospitals, pharmacies, and health 
insurance companies can acquire pharmaceuti-
cal products at lower prices from other markets 
through parallel trade, which can potentially 
lower prices in the local market.
Parallel imports can also be used to access 
basic inputs to agricultural production (such as 
pesticides and fertilizers) at lower prices than 
those charged locally by the owner of an IP right. 
These reduced costs could contribute to im-
proving poor farmers’ incomes and livelihoods. 
Developing countries can also use parallel im-
porting to curb anticompetitive practices: it al-
lows them to ensure adequate price competition 
in the local market and a competitive supply of 
products from a variety of sources. Section 3.0 
of this chapter provides more information about 
how developing countries can make effective use 
of parallel importing.
2.2 Benefits	to	consumers
Potentially, consumers have much to gain from 
parallel imports. By increasing the options for 
alternative supplies of products, parallel imports 
can allow consumers to gain access to the prod-
ucts they need from another market at lower 
prices than are being charged in their own mar-
ket. In developing countries, it is often the case 
that essential products such as medicines are 
unavailable or inaccessible to a large portion of 
the population because they are unable to afford 
them at the prices charged by the  IP right holder, 
and the government is unable to subsidize their 
purchase.
2.3 Retailers,	wholesalers,	and	traders
Parallel imports can be attractive to traders when 
price differences are significant enough to ensure 
profits. Similarly, parallel importing gives lo-
cal retailers and wholesalers the ability to obtain 
patented and/or branded products directly from 
multiple overseas sources. Doing so may offer 
better prices than obtaining the products from 
the local authorized dealer. By bypassing the lo-
cal licensed dealer, retailers may be better able to 
meet the needs of their consumers.
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2.4 The	view	of	right	holders	and	local		
licensed	owners	
IP right holders, including authorized import-
ers, licensees, and other agents, generally support 
restricting parallel trade because they directly 
benefit from having an exclusive right to import 
protected products. In the absence of parallel im-
porting, local licensed dealers do not face com-
petition, in terms of price, for the same products. 
In markets where no alternative sources are avail-
able, the product can be sold at the highest price 
the local market can tolerate. Moreover, restric-
tions on parallel importing allow right holders 
to take advantage, on a regional or international 
scale, of market segmentation and differential 
pricing strategies. Where parallel imports are 
not permitted, right holders may charge differ-
ent prices in different markets. Right holders can 
also control distribution, pricing, and other as-
pects of the local market for products produced 
under IP rights.
Right holders often argue that parallel im-
portation should be restricted because driving 
down prices might reduce incentive to invest in 
research and development in the pharmaceu-
tical and agrichemical sectors. Parallel impor-
tation may also reduce the incentive for right 
holders to donate products at low cost or free 
of charge to developing countries, since there 
would be a risk that those products would be 
diverted back into developed country markets 
and sold at higher prices than were intended. 
Parallel importation may also hinder the ability 
of governments in different countries to main-
tain price controls on pharmaceutical products 
within their territory. Furthermore, rights hold-
ers or licensed local owners may pay marketing 
costs that the suppliers of parallel traded goods 
benefit from for free. In the long term, there is 
the possibility that this will reduce the willing-
ness of rights holders or licensed local owners to 
supply particular markets.
In developing countries where some type of 
parallel importation is permitted, local licensed 
dealers may seek to overcome the competition 
of parallel traders by offering after-sale service, 
warranties, and so forth that parallel traders, gen-
erally with small profit margins, may be unable 
to offer. When price differences between markets 
tend to be large, as in the case of medicines, IP 
right holders can apply differential pricing poli-
cies, charging lower prices for medicines in lower-
income markets than in higher-income markets. 
Price differentiation to ensure lower prices for 
patented medicines in developing countries may 
reduce the incentive there for parallel imports. If 
parallel imports are properly regulated in both 
exporting and importing countries, however, 
differential pricing agreements still can function 
without displacing IP right holders and local li-
censed dealers. 
2.5 Reimportation	and	other	problems
Developed countries with parallel trade in prod-
ucts protected by IP rights frequently identify a 
potential problem: IP right holders, particularly 
in the pharmaceutical industry, could be dis-
couraged from pricing their products differently 
in different markets to benefit developing coun-
tries. Prices for medicines protected by patents 
or trademarks in developing countries tend to 
be high. Some argue that if developing countries 
allow parallel importation, patented medicines 
that the industry could potentially sell for a low 
price in a low-income country may find their 
way back to high-income markets and sold at 
higher prices. Reimporting medicines protected 
by patents or trademarks would mainly benefit 
intermediaries and reduce the incentive for in-
dustry to sell medicines protected by patents 
or trademarks at lower prices in developing 
countries. Furthermore, developed countries 
are concerned that parallel trade could chan-
nel counterfeit and/or pirated products into the 
market.
As noted above, however, parallel trade does 
not concern substandard products. Moreover, 
countries can and should address these concerns 
by adequately regulating and monitoring parallel 
imports and exports. To reduce the risk of reim-
portation and to maintain effective pro-poor (or 
humanitarian) differential pricing arrangements 
for medicines in developing countries, developed 
countries can adopt measures to prevent paral-
lel imports into higher-priced markets.2 For ex-
ample, developed countries can (and do) enact 
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The legal question with regard to parallel trade 
is: To what extent should countries allow or 
limit the ability of IP right holders within 
particular national/regional territories to con-
trol the movement of products across different 
markets on the basis of local ownership of IP 
rights? Countries are entitled to regulate paral-
lel trade involving intellectual property in their 
own best interests. Indeed, parallel imports 
have been admitted in many developed and 
developing countries on a regional or interna-
tional scale.3
The Agreement on Trade-Related Aspects 
of Intellectual Property Rights (the TRIPS 
Agreement) gives World Trade Organization 
(WTO) members the freedom to design their 
own regimes for the exhaustion of IP rights (ex-
haustion occurs when a right holder’s control over 
a product ceases). Because the exhaustion of rights 
cannot be challenged as a violation of the TRIPS 
Agreement under the WTO dispute-settlement 
mechanism, the TRIPS Agreement allows paral-
lel importation. According to Article 6:
For the purposes of dispute settlement under this 
Agreement, subject to the provisions of Articles 3 and 4 
nothing in this Agreement shall be used to address the 
issue of the exhaustion of intellectual property rights. 
Moreover, the Doha Declaration on TRIPS 
and Public Health4 reaffirmed this freedom, giv-
ing developing countries greater certainty about 
their ability to use parallel importation to protect 
their interests, particularly for safeguarding pub-
lic health. According to Article 5(d) of the Doha 
Declaration:
The effect of the provisions in the TRIPS 
Agreement that are relevant to the exhaustion of 
intellectual property rights is to leave each member 
free to establish its own regime for such exhaustion 
without challenge, subject to the MFN and national 
treatment provisions of Articles 3 and 4.
A country’s decision about their exhaustion 
of rights doctrine will either restrict or allow par-
allel importation policies in their territories.
The doctrine describes three types of exhaus-
tion of rights:
• national exhaustion (first sale doctrine). 
Also known as first sale doctrine, national 
exhaustion holds that the exclusive rights 
of IP right holders over protected products 
cease after the first sale of the product with-
in national borders. 
 Implication: Right holders can block paral-
lel imports from entering the local market, 
even though their rights are exhausted in 
that market. Example: United States. 
• regional exhaustion. The exclusive rights 
of IP right holders over protected prod-
ucts cease after the first sale in the regional 
market. 
 Implication: Parallel trade is allowed within 
the group of countries, but right holders can 
ban parallel imports from countries outside 
the region. Example: European Union.
• international exhaustion. Right holders’ 
exclusive rights over protected products 
cease after the first sale in any market.
 Implication: Right holders cannot exclude 
parallel imports from entering the local mar-
ket because their rights with respect to that 
market are exhausted. Example: Kenya.
Accordingly, developing countries can in-
corporate into their national laws the principle 
of international exhaustion of rights, thus al-
lowing for parallel imports on an international 
scale.5 Put differently, developing countries can 
decide whether or not to allow parallel importa-
tion for all or particular IP rights. Allowing for 
parallel imports of patented or trademark pro-
tected products, that is, the application of the 
international exhaustion principle to the rights 
of patent holders, is an option made available 
by TRIPS to developing countries. Though rele-
vant to all fields, the potential benefits of parallel 
importing are particularly important for patents 
and public health. As noted above, importing 
patented medicines from a market where they 
are sold at lower prices may give those who need 
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them in the importing country greater access. 
Concerns about the possible negative effects of 
parallel imports, moreover, can be dealt with 
through adequate monitoring and regulation, 




This section provides TRIPS-compliant model 
provisions that would enable parallel importa-
tion of patented products into a country when 
incorporated into a national patent law. The 
model provisions adopt the principle of interna-
tional exhaustion (see Box 1). 
Model provision 1 is the narrowest interpre-
tation of the international exhaustion principle, 
allowing only for parallel importation of patent-
ed products that have been placed on the market 
by the patent holder. Model provision 2 extends 
the exception by allowing for parallel importa-
tion of patented products that have been placed 
on the market by any authorized agent (that 
is, a local licensed dealer) of the patent holder. 
Finally, model provision 3 provides the broad-
est exception to the exclusive rights of a patent 
holder allowing parallel imports originating from 
any country. Under this provision patent hold-
ers’ rights may also be exhausted based on the 
sale or marketing of the product authorized by a 
government under a compulsory license. Hence, 
patented products that have been produced and 
placed on the market by a compulsory licensee 
may be parallel imported.7 
While each of the three provisions have been 




Policy makers in developing countries should 
seek to utilize fully the options available under 
the TRIPS Agreement for promoting access to 
medicines and supporting poor farmers. Since 
these options include applying the principle of 
international exhaustion, policy-makers in devel-
oping countries should seek to take full advantage 
of the possibilities afforded by parallel trade. They 
can ensure that a patent holder does not have the 
right to prevent imports of a product covered by a 
patent when the patent holder has put that prod-
uct on the market in another country. To utilize 
this flexibility to the fullest, countries should con-
sider adopting a version of the model provisions 
for enabling parallel importation. ■
DUNCAN MATTHEWS, Senior Lecturer in Intellectual Property 
Law, Queen Mary Intellectual Property Research Institute, 
Centre for Commercial Law Studies, Queen Mary University 
of London, John Vane Science Centre, Charterhouse Square, 
London EC1M 6BQ, U.K. d.n.matthews@qmul.ac.uk 
VIVIANA MUNOZ-TELLEZ, Programme Officer, Innovation 
and Access to Knowledge Programme, South Centre, CP 228, 
1211 Geneva 19, Switzerland. munoz@southcentre.org 
Box	1:	model	provisions6
1. A patent holder shall not have the right to prevent acts of importation of a product covered 
by a patent that has been put on the market in any country by the patent holder or with his 
or her consent.
2. A patent holder shall not have the right to prevent acts of importation of a product covered 
by a patent that has been put on the market in any country by the patent holder, with his or 
her consent or in any other legitimate manner.
3. A patent holder shall not have the right to prevent acts of importation of a product covered 










How do biotech patent systems affect indigenous peoples, 
particularly in relation to health products? This question 
raises two distinct issues. First, the question of biopira-
cy—to what extent do patent systems necessarily exploit 
traditional indigenous knowledge to produce valuable 
medicinal products? Second, the question of patenting 
gene-sequence and gene-product information taken from 
living organisms, especially human beings—how can we 
justify patenting naturally occurring substances? And how 
should we negotiate the myriad ethical issues that arise 
from doing so? This chapter argues that the core of the 
biopiracy problem is not the availability of patents based 
on traditional indigenous information but rather the un-
fair acquisition of knowledge and the inequitable sharing 
of profits derived from developing such information into 
a valuable product. Solving this problem requires ensur-
ing that traditional information is fairly acquired and that 
fair compensation is paid to the group from which the in-
formation derives. In regards to patenting gene-sequence 
and gene-product information, this chapter concludes 
that such issues equally affect indigenous and nonindig-
enous populations and that the best way to address them 
is by making policy changes.
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biotechnology issues specific to the interests of 
indigenous peoples are apparent.3 This paper 
therefore tries to bring to light some of the is-
sues involving patent rights in biotechnology that 
have become the legitimate concerns of indig-
enous peoples.
Two issues, in particular, dominate the litera-
ture about biotech patents in the context of glo-
balization and indigenous peoples’ rights. The first 
is the use of traditional indigenous knowledge as 
a starting point for producing a valuable product, 
such as a medicine. The second is the patentability 
of gene-sequence and gene-product information 
taken from living organisms, especially human 
beings. While the two are perhaps related (when, 
for example, the genetic information is taken 
from an indigenous group), it may be helpful to 
attempt at least a conceptual separation between 
the two issues in order to clarify the analysis. The 
first issue raises questions of so-called biopiracy of 
indigenous information by developed countries. 
As such, the issue directly implicates the rights of 
indigenous peoples, even though, as discussed be-
low, most problems can be resolved when a few 
basic principles of patent law are brought to the 
fore. The second issue, especially when informa-
tion concerning the human genome is involved, 
necessitates important ethical inquiries and poses 
fundamental questions for patent law and pat-
ent policy. Most of these problems, however, are 
CHAPTER 16.1
1.	 InTRoduCTIon
Much has been written on the general subject 
of how modern systems of intellectual property 
do, can, and should affect the lives and welfare 
of indigenous peoples.1 When the focus is on 
biotechnology, however, copyright does not play 
much of a role in protecting functional inven-
tions,2 and while trade secret is important, no 
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not specific to biotech patents as they impact indig-
enous peoples, and indeed many of them impact 
everybody, whether they live in a developing or a 
developed country. Parts 2 and 3 of this chapter 
develop these arguments. 
Having set aside patents as an important 
cause of biopiracy and having shown that gene 
and gene-product patents do not pose indig-
enous-peoples-specific problems, Part 4 attempts 
to outline the real problems that the world pat-
ent system poses for developing countries. Part 
4 concludes that, while it is difficult to make the 
case that adopting a modern patent system direct-
ly benefits developing countries, the worldwide 
patent system also has little direct adverse effect. 
The problem is not so much that the existence of 
patents prevents the diffusion of biotechnological 
advances in developing countries but that there 
is a danger of leakage through the parallel im-
portation of patented products from developing 
countries back to developed countries with strong 
patent systems. Too much leakage can impair in-
centives for innovation even within the developed 
world, and that is not good for anybody.
This last conclusion rests upon a basic as-
sumption that underlies the entire paper. It re-
mains a matter of serious debate whether and to 
what degree patent law in general serves as an 
incentive to innovate or commercialize innova-
tions. Is patent law too strong or too weak? Is the 
period of patent protection too long or too short? 
We do not know very much about how the in-
centives of our IP systems, especially patent and 
copyright, work in practice.4 This paper does not 
aim to undertake a fundamental analysis of the 
patent system generally. It therefore assumes that 
the patent system in developed countries, some-
how or another, generally achieves its basic goal 
of stimulating innovation by providing a period 
of exclusive rights to those whose intellectual cre-
ations qualify for patents.5
2.	 BIopIRACy	And	pATenTS
2.1	 The	basic	problem
The biopiracy problem is exemplified by the tak-
ing of indigenous peoples’ information about the 
medicinal effects of a plant or other natural sub-
stance and the developing of that substance into 
a patented and popular drug by a large pharma-
ceutical company.6 The fundamental question is 
whether or to what degree it is fair for outsiders 
to use, and especially to profit from, knowledge 
of this type. Paterson and Karjala have consid-
ered this problem from the point of view of in-
digenous rights outside of the traditional patent 
and copyright regimes, concluding that a statute 
based on traditional principles of contract and 
unfair competition law could address and likely 
resolve this problem without raising the funda-
mental difficulties that would result from using 
traditional IP rights under patent or copyright to 
achieve the desired goal.7 This paper addresses the 
problem from the other side: What, if anything, 
about patent law creates or exacerbates the prob-
lem of biopiracy?8 
2.2		 Physical	vs.	informational	resources
In considering the problem of biopiracy, it is 
vital to distinguish between the use of a physi-
cal resource and the use of an informational 
resource. Physical resources are depletable, and 
what one person uses is no longer available for 
another. Informational resources are nondeplet-
able (infinitely multipliable) in that one person’s 
use of information does not prevent another 
from making the same or a different use of it.9 
In one of the strongest condemnations of bio-
colonialism that I have seen, Professor Whitt 
states, “By allowing access to and exportation of 
data, biocolonialism concentrates knowledge about 
a people and their environment in the hands of an 
imperial power.”10 This is simply wrong. Publicly 
available knowledge cannot be “concentrated” 
in the hands of anyone. Perhaps Professor Whitt 
intended to say that the use of some indigenous 
knowledge is concentrated under the patent 
system in outsiders who obtain foreign patents 
based on some of the exported data. But even 
that would not be correct if the implication is 
that the source peoples can no longer use their 
traditional knowledge in their traditional ways.
On the other hand, it is also incorrect to say, 
in general, that a patent owner is not harmed by 
the sale of unauthorized copies of the patented 
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product, on the ground that the patent owner 
remains free to sell any amount of the prod-
uct he chooses. There is absence of harm only 
if the purchase of the pirated product is not a 
substitute for purchase of the patented prod-
uct. While this is often the case because some 
purchasers of pirated products would wholly 
forego use of the product rather than pay the 
higher price for an authorized version, there are 
likely to be at least a few people who would pay 
the higher price if less expensive versions were 
unavailable. Moreover, if pirated drugs sold at 
a low price in poorer countries do not reach pa-
tients unable to afford the authorized version, 
and these drugs find their way back to devel-
oped countries, they may displace further sales 
and thereby reduce the patentee’s profits.
IP is thus fundamentally different from 
tangible property, which is why the legal rules 
relating to IP must also be different. This point 
is obvious, indeed almost trite, to IP scholars, 
but it seems to be often overlooked in the lit-
erature on biopiracy. Nondepletability of infor-
mational resources implies that, once the infor-
mation is publicly available, it is economically 
inefficient to afford exclusive rights in it.11 We 
grudgingly accept the limited-term exclusive 
rights of patent and copyright, notwithstand-
ing the ex post economic inefficiency, because 
we believe that they serve as an incentive to the 
creation of desirable works. In other words, we 
accept the immediate economic inefficiency for 
the duration of the rights in the belief that in 
the long run we will have more and more desir-
able works overall. Calls for exclusive rights in 
information outside the patent and copyright 
regimes, especially for rights in information 
that is already publicly known, cannot be justi-
fied by a similar creation incentive. Some other 
justification is necessary. 
I will note only in passing that the other 
justification will be difficult to find in so-called 
“natural rights” theory. Natural rights theory 
(“I made it so it’s mine.”) carries no limitation 
on the duration of protection, nor does it dis-
tinguish between the rights afforded by patent 
and copyright for works that are equally intel-
lectually creative. Some of the most creative 
works of human history, like Newton’s theory 
of gravity or Einstein’s theories of relativity, get 
no protection anywhere under either the pat-
ent or the copyright regime, which is difficult 
to explain if natural rights to one’s creative 
ideas and discoveries are the basis for exclusive 
rights. In the case of indigenous populations 
who assert natural-rights based exclusive rights 
in information they have developed or discov-
ered, mutuality demands a similar recognition 
of rights in information developed elsewhere. 
Such recognition, however, would surely cost 
any given group much more than it gains.
2.2.1		 Depletion	of	physical	resources
To the extent that criticism of biopiracy focus-
es on the depletion of a physical resource, the 
problem may be controlled under the environ-
mental regulation of the source country.12 In 
other words, this is not an IP rights question 
but a tangible property question. There is no 
significant debate today about whether taking 
such resources without authority (theft) or by 
fraud should be unlawful. But a patent else-
where on the active ingredient of a plant sim-
ply has nothing to do with the problem of en-
vironmental depletion with regard to the plant. 
If the patentee can manufacture the active in-
gredient synthetically, that activity does not 
contribute to further depletion. If the patentee 
needs the plant itself but can grow it away from 
its original source, again there is no contribu-
tion to depletion in the source country. And 
if the plant grows only in the source country, 
the existence of a patent abroad or even in the 
source country itself gives no right to take the 
physical plant in order to manufacture the pat-
ented product. Although a patent on the active 
ingredient, if recognized in the source country, 
would give the patentee the legal right to pre-
vent others from taking the physical plant for 
the purpose of extracting the active ingredient, 
exercise of that right would likely mean less 
depletion of the physical resource, because it 
would no longer be in anyone’s economic inter-
est to take more of it than whatever is required 
by traditional uses. The patent thus may add a 
little something to the source country’s power 
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to regulate depletion, but it cannot exacerbate 
the depletion if the source country chooses to 
prohibit the patentee’s taking of the plant.
2.2.2   Depletion	of	informational	resources
Where the complaint is that the source coun-
try’s people are not rewarded for supplying the in-
formation leading to the invention, several points 
should be borne in mind. First, if the information 
is obtained legally and results in a patented inven-
tion, that patent cannot cover any prior use that 
the source country’s people made of the original 
resource.13 Indeed, if the end product is a natu-
rally occurring substance, that country may be in 
a position to refuse a patent altogether. Even U.S. 
patent law denied patents on naturally occurring 
substances until relatively recently, regardless of 
whether they had been isolated and purified.14 
Trade-Related Aspects of Intellectual Property 
Rights (TRIPS) requires member states to have 
patent laws that protect inventions that are “new, 
involve an inventive step, and are capable of indus-
trial application,”15 but TRIPS nowhere defines 
what new means. Any member state is therefore 
free to deny patents covering naturally occur-
ring substances or traditionally used methods of 
treatment on the ground that they are not new. 
According to TRIPS Article 27(3)(a), a member 
state can also deny method patents covering the 
use of naturally occurring substances, purified or 
not, for therapeutic or diagnostic purposes. More-
over, following traditional U.S. law, a member 
state could find that isolating and purifying such 
substances lacks invention and therefore does not 
involve an inventive step. 
Second, where the end product is a substan-
tial modification of the original source16 and con-
stitutes a true invention that has, let us assume, 
greater therapeutic value than the original source, 
a patent in the source country will indeed have 
the effect of allowing the patentee to charge, for 
the period of the patent, a monopoly price in that 
country for use of the new drug (assuming there 
is no effective substitute that could hold down 
the price). If people in the source country can-
not afford the new drug, their position is no dif-
ferent from that with respect to any other new 
drug, whether or not patented, or indeed any 
other product, that they cannot afford. They have 
not lost anything that they previously had. They 
can continue to use the original source as they 
always did, and they now have, in addition, the 
possibility of more effective therapy (if they can 
afford it), as will indigenous (and other) peoples 
elsewhere who never before had even the origi-
nal treatment.17 The wider availability of both the 
original treatment and the newly developed drug 
after biopiracy perhaps deserves more emphasis. 
In her article referenced above, Professor Whitt 
states:
Across the planet, at an accelerating pace, collec-
tively owned traditional medicines and seeds are be-
ing privatized and commodified. Altered sufficiently 
to render them patentable, they are transformed into 
the ‘inventions’ of individual scientists and corpora-
tions and placed on sale in the genetic marketplace.
But it is difficult to see just how the people 
who collectively owned the forerunners of the 
now improved medicines and seeds have been 
harmed. Moreover, the improved products are 
now available to a much wider range of users, in-
cluding indigenous peoples from other parts of 
the globe. The patent may, indeed, mean that the 
price everywhere is higher than it would be were 
the product available without patent protection. 
It remains a fair question, however, whether the 
improved product would exist at all but for the 
patent incentive. We must bear in mind that no 
one is forced to buy the new product. Everyone 
is free to continue using whatever he or she has 
used in the past. Those who do choose to buy 
patented seed, for example, presumably believe 
that the higher seed cost is more than compen-
sated by the beneficial improvements brought 
about by the newer product. It is true that patent 
law does not do much to alleviate the most im-
portant problems facing the people of developing 
countries, such as poverty, contaminated water, 
and lack of education. In developing countries, 
840 million people currently suffer from malnu-
trition and 1.3 billion are afflicted with poverty.18 
But, to the extent that patent law serves as an 
incentive to the development of new products, 
especially medicines and improved agricultural 
varieties, it increases the options of everyone, 
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including indigenous peoples, marginally to 
improve their lives. If the goal is to alleviate the 
wretched conditions under which many people 
in developing countries live, it cannot be right to 
say that information held by some of them that 
could be useful in addressing parts of the problem 
should remain confined to the small group dis-
covering it, provided at least that the information 
is acquired in ways that are both legal and moral. 
It is also important to note that most indigenous 
groups will have no resources at all, genetic or 
otherwise, on which profitable products can be 
built. All such people potentially benefit if patent 
law serves as an incentive to create products that 
meet important human needs.
Third, denying patents in these cases will 
not necessarily stop the supposed misuse of the 
original information. It may well be commodified 
by an outsider anyway, in the hope of sufficient 
return from first mover or secrecy advantages. If, 
therefore, we are to accept the economic ineffi-
ciency of recognizing exclusive rights in informa-
tion held by indigenous societies, some justifi-
cation that outweighs the inefficiency should be 
offered. As mentioned above,19 creation incen-
tives are not involved, which distinguishes infor-
mation collected from indigenous peoples from 
information that can be protected by patents and 
copyright. Claims of unfairness in these scenarios 
should articulate precisely what is unfair about 
developing, perhaps at great expense, something 
new and useful out of existing knowledge (which 
is what the patent incentive is all about). If the 
unfairness in a particular case is acquisition of in-
formation by fraud or other surreptitious or dis-
honest means, existing legal principles may sup-
ply a remedy, or at least an approach for statutory 
regulation. If the unfairness is lack of equal bar-
gaining power because of ignorance of western 
legal customs, again a limited statutory approach 
setting default assumptions on agreement to pay 
a royalty or some other compensation may be in 
order. Cases in the United States show that using 
information to create a patented product with-
out adequate disclosure to the source of the in-
formation is not limited to developing countries 
or indigenous populations.20 Breach of a confi-
dential relationship, fraud, invasion of privacy, 
and even more general notions of unfair compe-
tition may, in a given case, justify accepting the 
economic inefficiency of protecting traditional 
information.
It is possible that the availability of patents 
based on information derived from indigenous 
peoples creates a perverse incentive for western 
scientists and their employers to attempt to gain 
information through nefarious means, such as 
fraud or breach of confidence. One could surely 
find examples of creative inventors who have 
been cheated out of the financial return that 
would have been theirs under patent law by the 
illegal or unsavory actions of others. By provid-
ing exclusive rights, patent law does produce the 
occasional bonanza for the patentee, and logically 
the hope of such a bonanza would lead to at least 
some activity aimed at getting an unfair share of 
the prize. But this is again simply a general feature 
of patent law and property rights in general. The 
existence of property rights is indeed a prerequi-
site to theft. Biotech patents would seem an un-
likely candidate for supplying a special incentive 
in this regard, given that most inventions require 
a huge investment to convert the initial informa-
tion into a commercial product and test it for 
health and safety. Indeed, the numerous enclosure 
laws that a number of developing countries have 
adopted to maintain control over their genetic 
heritages may be driving researchers away from 
bioprospecting, due to the difficulty of identify-
ing source material that will lead to a valuable 
product and to the complexity of achieving the 
necessary consents.21 In other words, the causal 
link between a biotech patent and any assumed 
fraud in obtaining the information on which it 
is based from indigenous sources is weaker than 
for many other products. Moreover, the vast 
majority of patents, biotech and otherwise, are 
the result of unobjectionable behavior (that is, 
for example, there exists no fraud or breach of 
confidence). We therefore return to the need 
to identify the behavior that is wrongful when 
information derived from indigenous sources is 
turned into a patented product and to look for 
an appropriate sanction for that behavior.
Some commentators assert more gener-
ally that indigenous peoples often object to the 
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use of their traditional knowledge on ethical 
grounds, arguing that IP should be treated as 
a pure public good.22 Indeed, as Sabrina Safrin 
has argued, the numerous enclosure laws that a 
number of developing countries have adopted in 
an effort to maintain control over their genetic 
heritages may be driving researchers away from 
bioprospecting, due to the difficulty of identify-
ing source material that could lead to a valuable 
product and to the complexity of achieving the 
necessary consents. No one can say that this view 
is wrong, as it comes down in the end to a ques-
tion of fundamental values. Still, the question 
remains whether the members of any group fol-
lowing this belief should retain exclusive rights, 
with respect to people outside the group, to use 
information they have discovered.  If the infor-
mation is freely available simply by visiting the 
group and observing their lifestyle, and if a visitor 
does this without fraud or duplicity, saying that 
the visitor cannot use the information as the basis 
for creating a new, and perhaps patentable, prod-
uct is equivalent to recognizing exclusive, perhaps 
group, rights in the information. Maybe such 
recognition can be justified on the ground that 
the group’s culture should be respected by out-
siders. But if this is the claim, we should be able 
to articulate it in terms of western notions like 
breach of confidence or privacy rights. Something 
besides “We discovered it so it’s ours” is necessary 
unless one takes the extreme step of embracing 
a full-fledged natural rights basis for IP or one 
simply has a preference for economic inefficiency 
over economic efficiency. 
A related view is that patents impoverish in-
digenous cultures by ultimately providing prod-
ucts that displace traditional sources and methods, 
leading to a loss of biodiversity and, eventually, an 
irretrievable loss of crucial elements of traditional 
knowledge and culture. Few would deny that 
such losses occur and that these losses represent 
ones suffered not only by the indigenous group 
but by all who, but for the displacement, might 
later have learned from such knowledge how to 
improve the physical or spiritual quality of their 
lives. If preventing the loss of indigenous culture 
is the goal, however, it is quite myopic to focus 
attention on patents derived from traditional 
information. Most indigenous groups do not end 
up being the source of information that leads 
to profitable patents. Moreover, even for those 
groups that do supply information leading to a 
patent, that specific information is only a small 
part of their entire cultural heritage, much of 
which is under threat from other sources, like 
music, films, and clothing. Indeed, to the extent 
that patents inhibit technology transfer to indig-
enous cultures (due to higher prices or lack of 
local implementation know-how), those patents 
should actually impede slightly the deleterious ef-
fects of the onslaught of western culture. Elimi-
nating patents for advances in biotechnology will 
not eliminate biotech innovation or the adverse 
effects of patented and unpatented advances in 
other fields of technology. Needless to say, elimi-
nating biotech patents will have no effect on cul-
tural losses resulting from the adoption of west-
ern style music, cinema, clothing, and fast food. 
In short, the harmful influences of western life 
style for indigenous cultures are serious and real. 
Unfortunately, they will not be ameliorated by 
what would inevitably be minor adjustments to 
patent law in western countries or in locales of 
traditional cultures.
The core of the biopiracy claim thus appears 
to be not the availability of patents based on tra-
ditional indigenous information but rather the 
unfair acquisition of the knowledge and the ab-
sence of fair sharing of the profits that ultimately 
derive from developing it into a valuable prod-
uct. The problem to be addressed becomes one of 
ensuring that traditional information is acquired 
in a fair and equitable way and that fair com-
pensation is paid to the group from which the 
information derives. Some developing countries 
have proposed amending TRIPS to mandate dis-
closure of the source of genetic resources used in 
an invention, of evidence that the country of ori-
gin had consented, and of evidence of fair shar-
ing of the benefits as conditions to the issuance 
of a patent. My colleagues George Schatzki and 
Ralph Spritzer have suggested to me the possi-
bility of refusing to enforce any patent based on 
information that has been unfairly acquired, or 
of placing on enforcement the condition that a 
fair sharing exists (as determined by court ruling) 
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between the patent holder and the people who 
served as the information source. This would not 
be a major extension of the doctrines of patent 
and copyright misuse, under which the intellec-
tual property rights owner is denied enforcement 
until the abuse is cured.23 It is important to keep 
in mind that without the patent there would be 
no profit for any compensation to be paid. 24
One policy implication of this analysis for 
developing countries is straightforward: to the ex-
tent one is concerned about biopiracy, it is a mis-
take to focus on patent law as a crucial, or even an 
important, part of the problem. Addressing the 
real problems associated with biopiracy is much 
more difficult. To the extent a given country or 
group considers its traditional knowledge sacred 
and not available for economic exploitation, rules 
and statutes can always be created that make il-
legal any attempt to learn or exploit such infor-
mation. That will surely discourage what would 
otherwise be legal activities leading, perhaps, to 
products that could improve the lives of many, 
both within the source country and without. But 
that is the expected cost of attempting to respect 
the local view concerning traditional knowledge. 
The problem is that, in the long run, such an ap-
proach is unlikely to work. It takes just one person 
who has knowledge of information to transmit it 
outside the group, and once the information is 
out it is impossible to make secret again.
To the extent that a given group’s biological 
knowledge or makeup is considered an economic 
resource, it is important to encourage exploita-
tion of that resource by those who are willing to 
pay for it. Policy-makers must define, or find ways 
of allowing markets to define, what is fair and 
equitable compensation for indigenous peoples’ 
contribution of information to what ultimately 
becomes a profitable product and who is entitled 
to such compensation. Then policy-makers must 
seek ways of rendering potentially valuable infor-
mation inaccessible without prior agreement con-
cerning compensation. And they must do this in 
ways that do not raise the costs of bioprospecting 
so much that they discourage people and compa-
nies that could potentially make valuable use of 
the information from seeking it. None of this is 
easy. The proper direction in which to look for 
legal approaches, however, is in areas like contract 
and unfair competition law.
3.	 TeChnICAl	ISSueS	Involved		
In	gene-RelATed	pATenTS
Patents on genes, especially human genes, and 
gene products (such as proteins and enzymes) 
raise some important technical issues in the in-
terpretation of current patent law.25 In addition, 
there is always the basic policy question for pat-
ents of whether the gain from affording patent 
protection (new products and processes that, but 
for the patent incentive, would not have been in-
vented or disclosed) justifies the harm that flows 
from a government-enforced monopoly for the 
patent period (such as higher prices for products 
that would have been invented anyway and in-
hibitions on further research). Finally, some bio-
technology patents raise ethical issues of a very 
different type than patent law has faced in earlier 
periods. 
3.1	 Naturally	occurring	substances	
Analysis of biotech patent issues under U.S. law 
always begins with Diamond v. Chakrabarty, in 
which the Supreme Court held that the law did 
not preclude patents on living organisms (447 
U.S. 303 (1980)). The court stated that the pat-
entability line was “not between living and inani-
mate things, but between products of nature, wheth-
er living or not, and human-made inventions.” 
The case is justifiably controversial for such a 
broad interpretation of section 101 of the Patent 
Act, which allows a patent for one who “invents 
or discovers any new and useful process, machine, 
manufacture, or composition of matter.” Living or-
ganisms do not fit easily into any of these cat-
egories.26 For present purposes, however, the most 
important aspect of Chakrabarty was its express 
retention of the long-standing prohibition on the 
patenting of naturally occurring substances. Up-
holding and distinguishing an earlier case27 that 
the Chakrabarty court characterized as denying a 
patent for merely discovering “some of the handi-
work of nature,”28 Chakrabarty emphasized that 
the bioengineered microorganism at issue was 
not “a hitherto unknown natural phenomenon” but 
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rather a “product of human ingenuity” that differed 
markedly from anything found in nature.29 
Genes and gene products, as they exist or are 
created in the cells of living organisms, are natu-
rally occurring substances. They may be difficult 
to find, but we know they are there and that they 
can be found if enough effort is put into the proj-
ect. One would have thought that the prohibi-
tion on patenting naturally occurring substances 
would have ruled out at an early stage patents for 
genes and gene products.30 Yet, notwithstanding 
the highest court’s reaffirmation of the prohibi-
tion on patenting naturally occurring substances, 
lower U.S. courts and the Patent and Trademark 
Office (PTO) have deviated substantially, further 
expanding patent coverage in the process. In the 
case of genes, the discussion got sidetracked at an 
early stage into the issue of whether a raw gene 
sequence, without disclosure of the gene’s func-
tion or utility, could satisfy the utility require-
ment of the Patent Act.31 In response to argu-
ments that inventions are patentable, but mere 
discoveries (such as a particular gene) are not, the 
PTO held that:
[W]hen the inventor ... discloses how to use the 
purified gene isolated from its natural state, the ap-
plication satisfies the “utility” requirement. That is, 
where the application discloses a specific, substantial, 
and credible utility for the claimed isolated and pu-
rified gene, the isolated and purified gene composi-
tion may be patentable.32
Thus, while a gene in its natural state inside 
the cells of a living organism is not patentable, 
anyone who succeeds in isolating and purifying 
a gene (even by a perfectly routine methodology) 
and discloses an appropriate utility for it can ob-
tain a patent on the gene.
Many commentators have decried treating 
an isolated and purified form of a naturally oc-
curring substance as patent subject matter just 
because the purified form does not exist in na-
ture.33 Professors Linda Demaine and Aaron 
Fellmeth have recently supplied a thorough and 
convincing analysis criticizing this contention 
and demonstrating that it deviates substantially 
from precedent.34 They argue that section 101 
of the Patent Act mandates invention rather than 
mere discovery,35 based on the express statutory 
requirement that the object of the patent be new 
and something that arises from application of hu-
man intellectual thought. They point out that the 
isolated and purified interpretation abrogates the 
requirement for invention and allows patents for 
essentially any alteration of a naturally occurring 
substance if increased commercial or therapeutic 
value results. As they point out, under this ratio-
nale to patentability, the first person to purify wa-
ter or blood cells could have patented them. 
Demaine and Fellmeth recommend a test 
of whether the naturally occurring substance has 
been transformed in such a way as to create a new 
product that is substantially different in biological 
function from the naturally occurring phenome-
non. For biological substances, passing such a test 
would require in practice a change in molecular 
structure, because biological function is largely, if 
not wholly, determined by molecular structure. 
By requiring a substantial change in function, 
this test obviates the otherwise thorny problem of 
deciding whether a slight structural change (for 
example, adding or removing an extraneous atom 
or two) is sufficiently creative to deserve a patent. 
If the gene or its product still function as they do 
in nature, the new version will simply not be suf-
ficiently creative under their test to be patentable. 
For naturally occurring substances unmodified 
by human-initiated structural change, another 
possibility would simply be to state expressly that 
only process patents, covering new and nonob-
vious uses of the now isolated and purified sub-
stance that occurs in nature, will be available.36 
Either approach would leave the substance itself, 
purified or not, free for research and for yet ad-
ditional uses not envisioned by the owner of the 
use patent. (According to the PTO, a product 
patent covers all uses of the product, whether or 
not they are disclosed in the patent.) Finding a 
new use for such substances may well involve sub-
stantial investment and require the incentive of 
patent protection. While process patents are gen-
erally considered weaker than product patents, if 
a purified gene or gene product is used in a spe-
cific therapeutic method, there may be no readily 
available substitute, so the method-patent owner 
would maintain exclusive rights to that use.
CHAPTER 16.1
 HANDBOOK OF BEST PRACTICES  | 1445 
A more substantial objection to method pat-
ents for new and nonobvious uses of genes and 
gene products derives from the TRIPS rule that 
permits excluding from patentability “diagnostic, 
therapeutic, and surgical methods for the treatment 
of humans or animals” (TRIPS Article 27(3)(a)). 
Much of Europe and many other countries have 
availed themselves of this exclusionary possibil-
ity. While the U.S. does not preclude patents on 
therapeutic processes, it does exempt medical 
practitioners from liability for infringement aris-
ing in the course of performing a medical activ-
ity (35 U.S.C. § 287(c)(1)). Among other exclu-
sions, however, the immunity does not apply to 
infringements arising from practicing a process 
“in violation of a biotechnology patent” (35 U.S.C. 
§ 287(a)(2)(A)). This would seem to leave unim-
paired, in the U.S. at any rate, a patented method 
for using a naturally occurring substance derived 
through biotechnology. In any event, whether and 
to what extent therapeutic methods should be 
protected under patent law involves fundamen-
tal policy issues. If patent law today, under the 
TRIPS permissive exclusion, supplies insufficient 
protection to therapeutic methods, that aspect of 
it should be amended. It is not a satisfactory solu-
tion to make an end-run around the current spate 
of exclusions for therapeutic methods by protect-
ing naturally occurring substances as products.37 
In any event, while U.S. law has deviated 
from its long-standing prior position that naturally 
occurring substances are unpatentable and that 
merely extracting them in purified form does not 
make them patentable, arguments are available ev-
erywhere else in the world that such substances are 
not patentable because they are not new. TRIPS re-
quires patents only for inventions that are new, and 
member states are free to decide whether or not a 
naturally occurring substance, like a gene or gene 
product, is new in the sense required by their pat-
ent statutes. Moreover, merely finding raw genes 
is not particularly difficult or inventive. Conse-
quently, denial of patents on raw genes could also 
be predicated on absence of an inventive step.38
3.2	 Patent	conditions	for	biotech	inventions
Many biotech inventions, as in Chakrabarty, will 
creatively alter a naturally occurring substance. In 
such cases, an objection to patenting based on the 
absence of something new, in the sense of not pre-
viously existing, is unavailable. Neither, at least in 
many cases, is an objection based on the absence 
of sufficient human creativity in the final product. 
Consequently, if a product, like the microorgan-
ism in Chakrabarty, otherwise meets the require-
ments for a patent, such as the technical stan-
dards for novelty and the substantive standards 
for nonobviousness, there are no grounds in the 
Patent Act itself for denying a patent.39 TRIPS, 
of course, allows for the exclusion of plants and 
animals (other than microorganisms) from pat-
entability,40 and many countries may choose to 
do likewise on ethical grounds. But the absence of 
patent protection for genomic innovations does 
not ensure that no products based on modified 
genes or gene products will appear. Moreover, 
recognition of patents in this area does not mean 
that there can be no regulation or even outright 
prohibition by specific legislation. We should 
bear in mind that a huge potential exists for ge-
netically modified organisms to contribute to the 
elimination of hunger and disease in developing 
countries, particularly if access to the technology 
is available. If patents on such products, at least 
in developed countries, serve as an incentive for 
their creation—meaning that without patents we 
would all have the benefit of less innovation—
outright denial of patent rights would appear to 





Whether or not patents on gene sequences or nat-
urally occurring gene products conflict with the 
earlier prohibition on the patenting of naturally 
occurring substances, until the Supreme Court 
addresses the matter we must accept that the 
courts and the PTO have expanded the notion 
of patent subject matter to include them, pro-
vided that they have been isolated and purified. 
Still, does this expansion of traditional patent law 
make sense as a matter of policy?
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Professor Epstein has articulated the basic 
policy issue that must be examined in decid-
ing whether to recognize gene-related patents: 
Do the incentives for the creation of these in-
ventions justify the restrictions on output that 
follow from exclusive rights?41 Few, if any, have 
argued on economic grounds that gene-related 
patents should be wholly proscribed. But many 
able commentators have argued cogently that 
patents on raw gene sequences could inhibit, 
rather than promote, the progress of science and 
the development of products that are actually 
useful. Gene sequences alone, even in their iso-
lated and purified forms, rarely have any direct 
use.42 Useful products are normally the result of 
implanting the gene into the genome of an or-
ganism, such as a bacterium, that will then man-
ufacture the protein or enzyme encoded by the 
gene. Then that protein or enzyme must be ex-
tracted from the cellular environment in which 
it was produced by the vector organism (in this 
case, the bacterium) and ultimately tested for 
safety and efficacy in its hypothesized use. These 
latter downstream activities that go from the gene 
itself to a useful product usually require a huge 
effort, quite often more than the upstream effort 
required to determine the gene in the first place. 
Thus, patents on basic upstream tools can inhib-
it, rather than promote, valuable downstream 
research.43 Indeed, Professors Demaine and Fell-
meth point out that when an upstream patent 
lacks ingenuity (which is the case for naturally 
occurring gene sequences), the patent incentive 
may not even be necessary to induce innovation 
but may still strongly preclude downstream re-
search.44
It has also been argued that patents on raw 
genes may result in too much investment in the 
search for genes and insufficient investment in 
developing new products and carrying them to 
market.45 Such patents can also inhibit informa-
tion flow, which in turn duplicates research.46 
Finally, Professors Heller and Eisenberg have 
argued that gene-sequence patents can lead to a 
tragedy of the anticommons, in which many over-
lapping claims to gene fragments or stacked rights 
established by reach-through license agreements47 
between upstream patentees and downstream 
researchers must be coordinated to develop a use-
ful product. Too many such claims may make ne-
gotiations among all affected parties difficult or 
impossible.48 Moreover, a biotech anticommons 
is more likely to endure than in other areas of 
IP because of higher transaction costs, heteroge-
neous interests among owners, and cognitive bi-
ases of researchers.49 
These policy arguments, therefore, suggest 
that it was a mistake for U.S. law to deviate from 
its traditional refusal to protect naturally occur-
ring substances, even though purified, in the case 
of gene sequences. Like the argument against 
such patenting based on the absence of invention 
or newness, however, nothing in it suggests dif-
ferential treatment of indigenous peoples from 
anyone else. If patenting genes or gene products 
is wrong on either statutory or policy grounds, 
we should correct the law, not because it imposes 
a particular burden on indigenous peoples, but 
because it imposes an unreasonable burden on 
everyone.50
4.2	 Modified	genes	and	their	products
In the cases of human-created DNA sequences 
that do not occur naturally, and products de-
rived from such sequences, we can no longer say, 
in general, that there is no invention or that the 
invention is not new. Such inventions, like the 
oil-spill-eating bacterium at issue in Chakrabarty, 
have much potential for ameliorating some of 
humankind’s worst afflictions. Whether and to 
what extent patents supply the necessary incen-
tive to undertake the research leading to such in-
ventions is, as with all inventions, a difficult and 
unresolved question. However, I see no reason to 
distinguish these genomic inventions from any 
other on this score. 
5.	 eThICAl	ISSueS	ARISIng	fRom	
gene-RelATed	pATenTS
Patents confer upon their owners the right to ex-
clude all others from making, selling, or using the 
patented invention. Thus, patents covering genes 
of living organisms, particularly patents covering 
pieces of the human genome, raise ethical ques-
tions concerning: 
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•	 whether such private control over genes or 
their products involves monopolization of 
the common heritage of mankind
•	 whether they denigrate human life by re-
ducing life to a commodity 
•	 whether they interfere with individual or 
collective privacy
•	 whether they promote distributive justice 
when they are concentrated in a few eco-
nomically developed countries
Patents on crop varieties have also been said 
to threaten biodiversity.51 These are serious issues 
that will continue to be examined for some time. 
I only touch upon them here, because it seems to 
me that indigenous and nonindigenous popula-
tions are equally affected or, at least, where there 
are differences in how costs or benefits deriving 
from gene-related patents are distributed, analysis 




We should first note that any objection to gene-
related patents as monopolizing the common 
heritage of mankind must in fact refer only to 
patents on human genes, as it is those genes that 
have been passed down to us over the genera-
tions. If all living things were deemed part of the 
common heritage of mankind, there could be no 
property rights at all, let alone patent rights, in 
domestic animals, or indeed even plants. This 
objection to human-gene-related patents would 
seem to be subsumed in the naturally occurring 
substance controversy. If we upheld the traditional 
ban on patents covering naturally occurring sub-
stances, whether or not isolated and purified, hu-
man genes and their protein products would not 
be patentable.52
On the other hand, it is at least possible that 
a full-fledged cost/benefit analysis might show 
gains, from recognizing patents in genes and their 
products, that outweigh the losses. Patents may 
actually serve as an incentive to discover these 
products and their desirable uses to such an ex-
tent that the disadvantages of temporarily higher 
pricing and reduced information-flow should be 
accepted. If we assume for the moment that this is 
in fact the case, we must deal with the claim that 
human-gene-related patents should be denied, 
notwithstanding their economic advantages, be-
cause they would amount to undesirable monop-
olies on the common heritage of mankind.
This claim is most potent if a patent on a hu-
man gene or its protein product were construed 
to cover the naturally occurring processes that 
take place within human cells, where the gene 
itself resides and causes the manufacture of its 
protein product. Literally, the cell, and thus the 
human being to whom the cell belongs, is making 
the gene every time the cell divides, and the cell 
uses the gene in the process of making the gene 
product. Thus, it would appear that a patent cov-
ering the gene or its product would be infringed 
by these natural activities.53 Although the patent 
only issues upon the applicant’s claim that the 
product has been isolated and purified from its 
natural form, once issued the product (or com-
position-of-matter) patent covers any use of the 
chemical composition. A patent on a new drug, 
for example, will cover any form of chemical 
packaging into which the drug is incorporated or 
mixed. If it did not, the patent would be worth-
less. Thus, the logic of composition-of-matter 
patents on naturally occurring genes and their 
products leads to an absurd result when applied 
to living organisms and represents a basic flaw in 
the theory.54 
The problem arises, however, not because 
genes are part of the common heritage of man-
kind but because gene and gene-product patents, 
by their nature, cover things that are not inven-
tions. One can imagine, for example, someone or 
some group whose cells contain a unique muta-
tion in a particular gene that gives the gene some 
special value. It is not part of the common heri-
tage of mankind because, by hypothesis, at most 
a limited group carries the gene.55 Moreover, by 
limiting focus on human genes, the common 
heritage approach would leave naturally occur-
ring genes in other plants and animals free for the 
patentable taking. It would therefore seem that 
opposing gene patents on the ground that genes 
comprise the common heritage of mankind is less 
fruitful analytically than simply staying within 
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the bounds of traditional patent law and seeking 
denial of patents on the ground that patents on 
naturally occurring genes and gene products give 
a theoretical monopoly over the life processes of 
the organisms from which they derive. Such a 
monopoly, even though apparently more theoret-
ical than practical at the moment, is simply unac-
ceptable, regardless of the economic cost/benefit 
analysis.
In any event, and of most relevance for the 
present topic, nothing in the common heritage 
argument distinguishes indigenous from non-
indigenous peoples. If it is bad for indigenous 
peoples that anyone should get a patent in a piece 
of the common heritage of mankind, it is equally 
bad for everyone else.56 
5.2	 Reduction	of	life	to	a	commodity
Many maintain that patents on pieces of the hu-
man genome are morally wrong because they 
reduce life to a commodity.57 While this argu-
ment has a certain rhetorical ring, its high level of 
generality renders analytical application difficult. 
A patent on a gene that is useful for diagnosing 
potential disease, for example, may mean that 
anyone who wishes to undergo the genetic test 
will have to pay more than if the gene were in 
the public domain. It is not clear to me, however, 
how this commodifies human life any more than 
a patent on any other medical diagnosis device or 
procedure. Slavery commodifies human life. Pat-
ents on the whole genome might well be said to 
commodify human life. While at bottom it may 
come down to questions of fundamental ethical 
or religious values,58 to me no single gene or gene 
product can be meaningfully deemed human life. 
While the entire human genome may validly be 
thought of in many contexts as a blueprint for hu-
man life, no patents are going to issue anywhere 
on the entire human genome. A product is com-
modified when it becomes the subject of market 
transactions—it is widely available, like aspirin, 
against payment of the purchase price. It is easy 
to imagine markets in unpatented products based 
on human genes, and such products, like aspirin, 
will be commodities. They are no less commodi-
ties if they were never subject to a patent, or if 
the patent has expired, than they are while they 
are under patent. Moreover, the unavailability of 
patents will not stop scientific activity on human 
genes or all market activity in gene products.59 
Conversely, the availability of patents is not syn-
onymous with commodification.60 
Finally, this again raises the question of how 
making and selling a product based on a human 
gene differentially affects indigenous and nonin-
digenous peoples. It may be more likely that an 
indigenous group that has managed to remain 
relatively isolated from the onslaught of modern 
society will have in its collective genome a ge-
netic characteristic of particular interest to those 
who would seek to develop genes into patentable 
products.61 But it is difficult to see how studying 
the genetic characteristic of interest reduces to a 
commodity the lives of the people from whom 
the information is derived. More often, the com-
plaint is that these people should be able to ben-
efit from any profits that are eventually derived 
from the results of such studies, which is simply 
the human genome variant of the more general 
biopiracy problem discussed above with respect 
to nonhuman resources. Indeed, if it is true that 
the benefits of developments in modern medicine 
are slow to reach many indigenous societies, it is 
difficult to see how commodification in devel-
oped countries affects them at all.
5.3	 Privacy	and	human	dignity
Many have decried the recognition of gene-re-
lated patents as being fundamentally in conflict 
with norms of privacy and human dignity.62 The 
underlying notion seems to stem from the inti-
mate relation between an individual’s genes and 
his or her phenotype, as expressed in physical, 
intellectual, and emotional characteristics.63 Be-
cause genes are also part of our collective make 
up, it has been suggested that gene patenting may 
violate some sort of collective privacy right as 
well.64
At the individual level, there is no doubt that 
knowledge of someone’s genome, in particular 
the presence of specific genes known to have a 
causal relationship to a particular disease, can be 
put to unfair discriminatory use in areas like em-
ployment or insurance.65 To the extent that such 
a gene is known to be differentially preponderant 
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in a specific group, the danger of group stigma-
tism is also very real. Without downplaying the 
importance of either of these problems, it is 
difficult to see how gene-related patents exacer-
bate the problems. Genomic research has been 
going on for some time and is not likely to stop, 
regardless of the availability of patents. Indeed, it 
is the identification of the gene and its function 
that sets the stage for any subsequent discrimi-
nation that may occur, individual or collective. 
One of the major policy arguments against pat-
enting such naturally occurring substances is that 
patents are not necessary as an incentive for this 
kind of research.66 There is good reason to hope 
that much of this research, even when it identi-
fies a particular set of genes with a given generally 
undesirable phenotypical response, such as a dis-
ease, will ultimately lead to valuable therapeutic 
interventions, or at least methods of prevention. 
Withdrawing the patent incentive will almost 
surely be detrimental for these developments. 
Interference with privacy norms and affronts 
to human dignity through the misuse of the re-
sults of genomic research would also seem to be 
at least as problematic for people in developed 
countries as it is for indigenous peoples. The most 
likely worst case scenario for indigenous peoples 
might be the finding of a gene specific to a par-
ticular group that plays a causal role in some un-
desirable phenotypical attribute (as viewed from 
outside the group). Such a discovery could un-
fairly stigmatize the group in the eyes of outsiders. 
Patents, however, would seem unrelated to such 
a discovery. When outsiders have sought patents 
based on the genetic make up of an indigenous 
group, it is usually because the group is perceived 
as having a genetic advantage over the rest of hu-
mankind.67 By the nature of the patent incentive, 
it is unlikely that the possibility of a patent would 
encourage anyone to look for a gene causing what 
is perceived in developed countries as a disadvan-
tage that is unknown in those countries. 
5.4	 Crop	monocultures	and		
monopolization	of	crop	genomes
Even outside the human genome some commen-
tators have raised ethical questions concerning 
the appropriateness of gene patents. Patents on 
crop varieties, for example, may result in mono-
cultures and the use of expensive inputs, such as 
fertilizers, that cause environmental harm.68 It 
has been claimed that broad plant variety patents 
have conferred on a few corporations virtual mo-
nopolies on the genomes of important crops.69 
Here again we find some potentially serious 
problems. If all the world’s wheat is a single va-
riety, for example, and if that variety turns out 
to be susceptible to a rapidly spreading blight 
of some sort, a significant portion of the world’s 
food supply could be wiped out, with catastroph-
ic consequences. Still, we must consider the role 
patents might play in creating or exacerbating 
these problems. If the use of expensive inputs is 
the problem, it would seem that not everyone 
would use the variety (in particular, those who 
cannot afford to pay). It should be borne in mind 
that a patent on a crop variety obligates no one 
to buy the seed. All farmers are free to continue 
using their traditional varieties in their traditional 
ways. Patents can serve as an incentive for find-
ing or commercializing environmentally friendly 
crops and other inventions, and the existence of a 
patent can reduce resort by the distributor to eco-
nomically inefficient and perhaps environmen-
tally dangerous self-help approaches.70 Moreover, 
if environmental harm is the problem (and a sus-
ceptible monoculture is one such example), envi-
ronmental regulation is most likely necessary to 
remedy it.71 Because of the human tendency to-
ward free riding, no one can be expected to adopt 
an environmentally friendly approach to food 
production without the assurance that his com-
petitors are operating at the same (economic) dis-
advantage. Moreover, if a given but advantageous 
variety is unpatented, it is likely to be adopted 
even more widely than if it is patented, increasing 
the danger of dependence on a monoculture.
6.		polICy	ImplICATIonS
This section demonstrates that the major policy 
problem for patent law in biologic materials is 
not peculiar to indigenous peoples or developing 
countries. Rather, it is the treatment under cur-
rent U.S. and European law of naturally occurring 
chemicals (DNA sequences and genes, and their 
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natural products) as patent subject matter when 
extracted in isolated and purified form. Nothing 
in the language of the extant patent statutes or 
in the international IP or trade agreements com-
pels this treatment. Allowing patents for naturally 
occurring substances goes against a long patent 
tradition even within the United States, and so 
far no one has made a convincing policy case 
that such a radical change from traditional patent 
principles should be made. Policy-makers in de-
veloping and developed countries should there-
fore resist pressure to adopt such a change, not 
because such patents have an untoward effect on 
privacy and human dignity but because denying 
patents on naturally occurring substances is sim-
ply good patent policy.
6.1 	 Patents	and	developing	countries
Any country that wishes to have the free-trade ad-
vantages supposedly supplied by the World Trade 
Organization (WTO) must comply with the IP 
requirements of TRIPS. Among other things, 
TRIPS mandates that its member states adopt 
patent laws in keeping with those of the developed 
nations of the United States and the European 
Union. Many commentators have argued that 
developing countries have little to gain from rec-
ognizing foreign patents, as required by TRIPS, 
except to avoid trade retaliation.72 A lively debate 
continues over whether patent laws promote or 
inhibit technology transfer to developing coun-
tries. That, in turn, raises the question of whether 
the costs of establishing a patent system, largely 
for the benefit of developed countries, are out-
weighed by the benefits. In addition, some com-
mentators have raised ethical and human rights 
issues outside the specific realm of biotechnology. 
These include issues of distributive justice73 and 
access to pharmaceuticals.74 Other commentators 
have asserted that developing countries may view 
IP as a community (public domain) asset that no 
individual should own.75 Patenting, in particular, 
has been said to clash with indigenous knowledge 
and value systems.76
6.1.1	Technology	transfer
There is little doubt that TRIPS impedes the abil-
ity of developing countries to determine their own 
IP standards and policies in the hope of achiev-
ing a better fit to their own economic and social 
conditions.77 In particular, TRIPS does not allow 
the choice of simply not recognizing patents for 
inventions by nationals of other member states.78
The advantages to developing countries of 
having a patent law have also been seriously ques-
tioned. It has been claimed, for example, that rec-
ognizing patents stimulates technology transfer, 
allowing the patenting country to gain not only 
the knowledge supplied in patent applications 
themselves but also the necessary know-how to 
start going into many of these fields of technolo-
gy themselves. Others have disputed these claims, 
however, arguing that foreign patents deter de-
veloping countries from appropriating new tech-
nologies and products.79 The needs of developing 
countries are often quite basic, for example, and 
some lack the ability to assimilate the latest tech-
nologies. A foreign patent owner may have little 
incentive to transfer technological know-how re-
lated to a patented invention if profits are avail-
able from imports. Most obviously, the informa-
tion contained in a patent application is always 
available in the developed countries in which the 
invention is patented. Therefore, if a developing 
country is indeed capable of making use of such 
information in local industry, it would have ac-
cess to the information without having its own 
patent law, and its citizens could make use of the 
information sooner, or at least without having to 
license it.80
6.1.2		 Access	to	inventions
It is routine to observe that patented goods that 
reach the market will have a higher price than if 
they were not patented.81 To the extent that this 
is true, it reduces access to the patented goods if 
there is any elasticity in demand, because people 
at the margin, by definition, could afford a lower 
price but not the higher one. It has been argued, 
moreover, that a patent owner might choose nei-
ther to enter a market nor to authorize local pro-
duction, thereby reducing access in that country.82 
Probably the most convincing argument against 
patent laws in developing countries is Professor 
Oddi’s observation that few inventions are pat-
ent-induced with respect to a given developing 
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country.83 That is, most inventions likely would 
have been invented, anyway, regardless of wheth-
er any given developing country has a patent law 
that might protect it. To the extent that an inven-
tion is not patent-induced in this sense, patent 
protection in a developing country necessarily 
adds to that country’s costs, because institutions 
in that country have access to the information in 
the patent in the countries where the invention 
is patented, so recognizing such a patent brings 
nothing more to the table.84
6.1.3		 Balancing	the	costs	and	
	 benefits	of	patent	law
The above analysis implies that patents in devel-
oping countries can add significantly to those 
countries’ costs with respect to new inventions,85 
and this cost is likely not offset by an increase in 
local technological development or in access to 
inventions that are, indeed, patent-induced. Still, 
consideration of the most dramatic case, which 
is access to vital pharmaceuticals, shows that the 
problem is more complex than this basic theoreti-
cal analysis would suggest.
In an effort to investigate the effect of patent 
laws on access to effective treatment in developing 
countries, Attaran and Gillespie-White looked at 
the availability of antiretroviral drugs for AIDS 
treatment in Africa.86 Somewhat surprisingly, and 
contrary to conventional wisdom, they found no 
correlation between access to antiretroviral treat-
ment and patent status across Africa.87 Access 
to these drugs was found to be uniformly poor 
across Africa, independent of whether and where 
the drugs were patented.88 Thus, at least in the 
poorest countries, access to potentially life-saving 
drugs seems not to be inhibited by patents but by 
the lack of funding to obtain access to these drugs 
at any price reflecting the cost of their production 
and administration.89
This suggests that the problem of access to 
inventions, and technology generally, in develop-
ing countries will not be solved by the denial of 
patents in those countries. It certainly will not be 
solved by denying patents in the developed world, 
if such denial eliminates the incentive for their 
discovery—the innovations would then be avail-
able to no one. The issue brings us back to the 
fundamental nature of IP and, in particular, its 
infinite multipliability without reduction of sup-
ply.90 We can ask, for example, why the owner of 
IP should care whether the product embodying 
such IP is copied and distributed in that market 
if a given market offers no expected return from 
the exploitation of IP, such as a patent. 
Consider an extreme case for the sake of il-
lustration. Suppose country X has zero dollars to 
pay for a patented, potentially life-saving drug. 
The patentee could not have been thinking of X 
as part of his expected return while developing 
the drug, and indeed the patentee gets no return 
from X after the drug is on the market, whether 
or not the drug is copied and distributed in X. The 
copying and distributing of the drug in X does 
nothing to the patentee’s exclusive right to market 
the drug in other countries where it is patented 
and where people can afford to pay something for 
it. This activity thus has utterly no effect on the 
patentee, provided that all of the drug that is cop-
ied and distributed in X actually stays in X and 
is used solely for the benefit of X’s citizens. The 
problem for the patentee, then, is not the copy-
ing and distribution in X but rather the potential 
for grey-market leakage into markets where the 
drug is profitable for the patentee, because such 
leakage could potentially bring down the price 
of the drug in those markets.91 There is no eco-
nomic reason, therefore, why the patentee (on 
these extreme facts) would not be willing to sell 
the drug in X at cost, provided the patentee could 
ensure that none of it would leak back into his 
or her more lucrative markets.92 In other words, 
the presence or absence of a patent law in X is 
essentially irrelevant to the patentee, whose only 
concern is with competition in his or her other 
markets from drugs originally distributed in X.
In any realistic situation, of course, there will 
always be at least a few people who can afford to 
pay the patentee’s price, so selling the drug at cost 
would actually reduce the patentee’s return. 
For the poorest countries of the world, how-
ever, the number of such people will be very 
small. For other countries, where more resources 
are available for health care, discriminatory pric-
ing (charging more where the demand is inelas-
tic and less where it is elastic) will likely result in 
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wider access to drugs in developing countries and 
a profit to the patentee.93 But even these schemes 
will be avoided by patentee drug manufactur-
ers if products sold at a low price in one coun-
try find their way back to their more lucrative 
markets elsewhere.94 Moreover, under any price 
discrimination scheme aimed at maximizing the 
patentee’s profits, the price will likely be higher 
than it would be in the absence of the patent’s 
exclusive rights, which to that extent continues 
to reduce access below that of a completely free 
market.
Another variation of the problem of balancing 
public access with the need for incentives occurs 
in university research, because research universi-
ties both actively seek the financial returns that 
are available from patented research and engage 
in public service. It was recently reported that a 
number of research universities had formed the 
Public-Sector Intellectual Property Resource for 
Agriculture in an effort to standardize their licens-
ing practices to allow them to engage in humani-
tarian endeavors. Some of these universities are 
owners of valuable biotech patents that they have 
licensed away and now find themselves needing to 
use in efforts to create new crops that could feed 
impoverished people. The patent rights thereby 
stand in the way of their humanitarian mission. 
One idea is to include a humanitarian use clause 
in future licenses to make sure that universities 
retain the right to engage in such activities.95
TRIPS does allow for some amelioration of 
the exclusive rights of a patent through compul-
sory licensing.96 The Doha Declaration on the 
TRIPS Agreement and Public Health expressly 
gives member states the freedom to determine 
the grounds on which compulsory licenses can 
be granted.97 For countries that lack the facilities 
and technological expertise to manufacture com-
plex pharmaceuticals locally, the TRIPS Council 
adopted a decision, which was implemented by 
the WTO in 2004,98 waiving the obligations of 
an exporting member under Article 31(f ) with 
respect to a compulsory license to produce and 
export pharmaceuticals to eligible importing mem-
bers, subject to conditions like producing no more 
than necessary to meet the needs of the eligible 
importing country.
We may conclude that access to patented 
inventions, especially pharmaceuticals, is not as 
readily available as it might be were these inven-
tions unpatented everywhere in the world. TRIPS 
is part of the problem, and the perceived danger 
of parallel importing is another.99 It is important 
for these problems to be resolved in a way that 
maximizes worldwide access to all types of inno-
vation, but especially to life-saving pharmaceuti-
cals. Solutions should avoid undercutting incen-
tives for more innovation in developed countries. 
To many it seems just plain wrong not to pro-
vide universal access to life-saving innovations in 
pharmaceuticals.100 We are forced, however, to 
make a tradeoff between universal access to exist-
ing technology and future access to new technol-
ogy. If the attempt to supply universal access to 
a given innovation reduces or eliminates future 
innovation, the ultimate result is no, or at least 
reduced, access to innovation for anybody.
7.	 ConCluSIonS
Understanding the effect of patent rights in bio-
technological inventions on the interests of indig-
enous peoples requires a more nuanced analysis 
than has generally appeared in the literature. The 
problem of so-called biopiracy, for example, is 
not one of the availability of patents based on 
traditional indigenous information but rather the 
failure to share fairly the profits that ultimately 
derive from developing the information into a 
valuable product. Patents on naturally occurring 
genes and gene products raise serious problems 
under traditional patent law on both technical 
and policy grounds, and they raise important 
ethical questions as well. These problems and 
questions, however, are not unique to indigenous 
peoples. Rather, they should, and must, be ad-
dressed by all peoples in the world, developing 
and developed. The basic problem with respect 
to indigenous peoples is patent law generally, be-
yond mere biotech patents, and whether its forced 
adoption by TRIPS will result in a net benefit 
to developing countries. Serious questions have 
been raised concerning whether local adoption 
of a patent law will improve technology transfer 
or increase access to desirable inventions in those 
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countries. The issue boils down to the extent that 
the absence of patent protection in developing 
countries erodes the incentive for innovation in 
developed countries, either through the absence 
of a profitable market in countries lacking a pat-
ent law or through grey-market arbitrage that 
allows patented products to flow back into the 
markets that do serve as incentives to innovate. ■
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seed by initial purchasers).
71 Id. at 318 (arguing that where new technologies 
are harmful to environmental goals, the existence 
of a patent at least does not exacerbate the harm, 
because a patent’s right to exclude does not provide 
an affirmative right to use the technology by the 
patentee, so such use can be regulated or prohibited).
72 See Carroll, supra note 45, at 2471 (citing ET Penrose, 
The Economics of the International Patent System 116–
17 (1951)).
73 See Looney, supra note 33, at 240.
74 Lazzarini Z. 2003. Making Access to Pharmaceuticals 
a Reality: Legal Options Under TRIPS and the Case of 
Brazil. Yale Hum. Rts. & Dev. L.J. 6:103, 115–119 (arguing 
that access to pharmaceuticals should be thought of 
as a human right).
75 See Sturges, supra note 22, at 244.
76 See Whitt, supra note 9, at 240.
77 See Chapman, supra note 46, at ¶ 16. One commentator 
has said that forcing countries to adopt patent laws 
and accept conditions of technology transfer laid 
down by the holder of the patent is “technological 
colonialism.” See Carroll, supra note 45, at 2466-67.
78 Anawalt HC. 2003. International Intellectual Property, 
Progress, and the Rule of Law. Santa Clara Computer 
& High Tech. L.J. 19:383, 404 (“The linkage of WTO 
membership to mandatory intellectual property rights 
and procedure should be ended”).
79 See Gutterman, supra note 22, at 122, 137; compare 
Downes, supra note 56, at 22–23 and Lazarini, supra 
note 74, at 111 (both concluding that the empirical 
evidence on the inhibiting or beneficial effects of 
intellectual property rights on technology transfer 
is scanty); see Seeratan, supra note 10, at 383 (noting 
that industrialized countries did not adopt strong 
intellectual property laws until they themselves had 
reaped the benefits of nonprotectionist policies). Even 
within the United States there is much anecdotal 
information that recent advances in medicine do not 
reach many of those who need it or their physicians, 
often even years after the information is publicly 
available. For example, Begley S. Too Many Patients 
Never Reap Benefits Of Great Research. Wall Street 
Journal, Sept. 26, 2003, at B1.
80 On these issues see Oddi AS. 1987. The International 
Patent System and Third World Development: Reality 
or Myth? Duke L.J. 831–52.
81 See Carroll, supra note 45, at 2468; see Chapman, supra 
note 46, at ¶61; see Seeratan, supra note 10, at 375 
(asserting that the TRIPS requirement for both product 
and process patents will substantially increase the cost 
of pharmaceuticals).
82 See Gutterman, supra note 22, at 122-23. One might 
question why a patent owner would adopt this 
strategy, however. It would seem that if he or she is 
unwilling to import into a given country, one would be 
better off economically by licensing local production. 
One possible explanation is fear of grey market 
“leakage” that is difficult to control by contract. But 
even this explanation is unsatisfying, because under 
TRIPS, if the country has the local ability to manufacture 
the invention, it may grant a compulsory license. TRIPS 
Article 31. Of course, any such compulsory license is 
supposed to be primarily for local consumption. Id. 
Article 31(f). However, if grey market leakage is a problem 
under a negotiated license, where the patentee has 
direct contact with the licensee, it would seem to be an 
even bigger problem under a compulsory license.
83 See Oddi, supra note 80, at 844; see also Seeratan, 
supra note 10, at 386 (“None of the pharmaceutical 
companies really depend on achieving profits in 
developing countries, which generally only account 
for a minimal percentage of drug sales worldwide”); 
compare to Anawalt, supra note 78, at 397 (“Adequate 
incentives for innovation do not depend on mandatory 
international intellectual property rules”).
84 See Oddi, supra note 80, at 846.
85 Additional costs of a patent system come in the form 
of training patent officials, lawyers, and judges. See 
Carroll, supra note 45, at 2468.
86 Attaran A and L Gillespie-White. 2001. Do Patents 
for Antiretroviral Drugs Constrain Access to AIDS 
Treatment in Africa? J. Am. Med. Ass’n 286:1886.
87 Id., at 1890. They also discovered that the option to 
patent antiretroviral drugs often went unexercised, 
surely the result of the meager expected financial 
return from very poor countries. This supports the 
conclusion of Professor Oddi that increased incentive 
for innovation from the possibility of obtaining patents 
in poor countries is negligible, that is, none of these 
drugs is “patent-induced” with respect to the patent 
law of any given African country. See Oddi, supra note 
83 and accompanying text.
88 See supra note 86, at 1891. Attaran and Gillespie-White 
blame lack of international funding, even to purchase 
drugs at cost, rather than patents, for the low level of 
antiretroviral treatment in Africa.
89 See supra note 86; see Lazzarini, supra note 74, at 
135. Aaron Fellmeth has reminded me in a private 
communication that an effective monopoly might 
result not only from a patent but also from trade 
secret law or pursuant to exclusive pharmaceutical 
marketing approvals.
90 See Lemley, supra note 8 and (text at) note 11.
91 See Scherer FM and J Watal. 2002. Post-TRIPS Options 
for Access to Patented Medicines in Developing 
Nations, J. Internat’l Econ. L. 913, 928 (“When prices are 
higher in one nation than in others, there is a tendency 
for arbitrage to occur through what is known as ‘parallel 
trade’.”); see also supra note 82.
92 More generally, enforceable and accurate price 
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discrimination should push output to the full 
competitive output level, but for this to occur arbitrage 
between high- and low-value users must be prevented. 
See Kieff, supra note 24, at 311 and note 23.
93 See Scherer and Watal, supra note 91, at 9:25–28; see 
Lazzarini, supra note 74, at 125.
94 They will also be avoided to the extent the developed 
countries adopt notions of “reference pricing,” 
requiring, for example, that their own domestic prices 
to be no higher than those charged elsewhere. See 
Scherer and Watal, supra note 91, at 929.
95 Blumenstyk G. 2003. Coalition Seeks to Make 
Agricultural-Biotechnology Tools More Widely 
Available. Chr. Higher Ed., July 11. chronicle.com/daily/
2003/07/2003071105n.htm.
96  TRIPS Article 31; See Lazzarini, supra note 74, at 125.
97 World Trade Organization, Ministerial Conference, 
Doha Declaration on the TRIPS Agreement and Public 
Health, No. 01-5770, Nov. 14, 2001, ¶ 5(b). In most 
cases compulsory licenses can be granted only after 
good faith negotiations with the patentee have 
failed to result in a voluntary license “on reasonable 
commercial terms and conditions.” TRIPS Article 31(b). 
However, nothing in TRIPS supplies any standard of 
reasonableness, so the failure of the patentee to agree 
to a member state’s good faith offer to pay what it 
believes it can afford, given its other obligations and 
the country’s needs, should suffice to permit going 
ahead with the compulsory license. Moreover, even the 
obligation to negotiate is waived in cases deemed to 
be a “national emergency.” 
98 World Trade Organization General Council, 
Implementation of Paragraph 6 of the Doha Declaration 
on the TRIPS Agreement and Public Health, Decision of 
30 August 2003, WT/L/540, 43 I.L.M. 509 (2004). 
99 Some drug manufacturers have begun experimenting 
with “out-licensing,” under which the patentee licenses 
generic manufacturers who agree to supply medicines 
to poorer countries. Friedman MA, H den Besten and A 
Attaran. 2003. Out-licensing: a practical approach for 
improvement of access to medicines in poor countries. 
The Lancet 361:341. Requiring pills to have different 
colors and shapes could be helpful in inhibiting parallel 
importing back into the more lucrative markets. Id. at 
343; see also Hensley S. Pharmacia Nears Generics Deal 
On AIDS Drug for Poor Nations, Wall Street J., Jan. 24, 
2003.
100 See Seeratan, supra note 10, at 403–4 (“Many human 
rights activists assert that the TRIPs provisions on the 
patenting of pharmaceuticals violates basic human 
rights by compromising the ability of poor countries to 
access essential medicines”). The Universal Declaration 
on the Human Genome and Human Rights demands 
that “Benefits from advances in biology, genetics, and 
medicine, concerning the human genome, shall be 
made available to all, with due regard for the dignity 
and human rights of each individual.” See Universal 
Declaration, supra note 56, Article 12(a). Another 
commentator argues that distributive justice requires 
providing all countries with access to the benefits 
of gene research. See Looney, supra note 33, at 240 
(“Gene patenting is ethically suspect if it concentrates 
genome benefits in those few countries fortunate 
enough to have the resources to obtain gene patents, 
when all humans should enjoy such benefits”). In 
these situations, however, it is not clear why gene 
patents or even medicine generally are singled out. 
Starvation is a huge problem in the world, which has 
a production capability more than sufficient to supply 
everyone alive with at least a minimal food supply. 
Unequal distribution of resources, both natural and 
human-made, almost inevitably raises questions of 
distributive justice. To the extent that patent law 
serves as an incentive for innovation, a patent does 
not create the injustice. It only brings more clearly into 
focus that there is widely different access to valuable 
resources between rich and poor countries. Without 
the patent, by assumption, nobody would have access 
to the innovation. With the patent, some relatively 
wealthy people do. But the poor are no worse off than 
they were before the innovation became available.

ABSTRACT
The rules that govern the collection and use of biologi-
cal matter have changed dramatically in the last 15 years. 
Arising out of the Convention on Biological Diversity 
(CBD), the Access and Benefit-Sharing (ABS) project 
applies to research carried out for either purely scientif-
ic or commercial reasons, for which organisms or parts 
thereof and/or related traditional knowledge are obtained 
from countries that are party to the CBD and their lo-
cal and indigenous communities. Other agreements have 
added new ABS legislation to govern the acquisition 
and use of biological material and related information. 
Everyone—including tourists, nature conservationists, 
scientists, photographers, and journalists—is subject 
to these new regulations. But scientists and researchers 
who seek to access and use proprietary genetic resources, 
biological matter, and related information (such as tradi-
tional knowledge and farming know-how) are especially 
affected by the ABS project. It is essential for scientists 
and researchers to understand the fundamental principles 
of ABS. This includes knowing the relevant rules, regula-
tions, laws, customs, and conditions for benefit sharing 
in the country where one intends to conduct research 
and/or collect samples. One must carefully plan ahead for 
any such activities by contacting key organizations and 
filing the proper documentation. Lack of planning may 
lead to unfortunate and undesired outcomes, including 
fines, imprisonment, deportation, and denied future ac-
cess. Planning is critical.
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found. So, with regard to ownership, biological 
resources are no different from mineral resources, 
oil, or timber. However, in recent years there have 
been times when this principle of ownership has 
not been respected. Resources were exported, de-
veloped, and commercialized without the consent 
of the countries that provided them and without 
enabling those countries to partake in the benefits 
that resulted from these activities. In order to pre-
vent this biopiracy and create a climate of mutual 
trust, the community of states undertook to regu-
late the handling of genetic resources in a binding 
international agreement referred to as the CBD. 
CBD implementation is not only a moral ob-
ligation, but also a legal one that binds member 
states. The goal of the CBD is to conserve biolog-
ical diversity and to promote its sustainable use in 
conjunction with the fair and equitable sharing 
of benefits. Responsibility for implementing the 
agreement is given to the state in which the bio-
logical material originates. However, all states have 
a responsibility to cooperate in implementing and 
enforcing the agreement. For industrialized coun-
tries, this means supporting biodiversity-rich, but 
often economically poor countries in their efforts 
to conserve and manage biodiversity. The keys to 
these collaborative efforts are technology trans-
fer and cooperative research. The CBD contains 
rules that clarify the rights and responsibilities of 
all of the parties involved in these efforts. 
CHAPTER 16.2
1.	 InTRoduCTIon
According to the Convention on Biological 
Diversity (CBD), biological resources belong 
to the states in whose territory the resources are 
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To advance its mission, the Conference of 
the Parties (COP) of the CBD decided in 2004 
to create the Access and Benefit-Sharing (ABS) 
project, an international program overseeing ac-
cess to genetic resources and the sharing of ben-
efits arising out of their utilization. Negotiations 
over ABS began in 2005. It is anticipated that it 
will take up to ten years for it to be completely 
established. 
Correspondingly, over the last decade a 
number of new legally binding agreements re-
garding biological material/related informa-
tion have been signed and ratified by United 
Nations member countries. Examples are the 
CBD, the Agreement on Trade Related Aspects 
of Intellectual Property Rights (TRIPS), treaties 
of the International Union for the Protection of 
New Varieties of Plants (UPOV, particularly the 
1991 treaty), the International Treaty on Plant 
Genetic Resources for Food and Agriculture 
(the Treaty), the Intergovernmental Committee 
on Intellectual Property and Genetic Resources, 
Traditional Knowledge and Folklore (ICGTK) 
that meets under the World Intellectual Property 
Organization (WIPO), the Cartagena Protocol 
on Biosafety under the CBD, and the nonbind-
ing Global Crop Diversity Trust, among others. 
All these agreements add new legal dynamics 
to ABS legislation that addresses the acquisition 
and use of biological material and related infor-
mation (such as ethnobiology and traditional 
knowledge). Indeed, there is a new world order 
emerging in relation to biological matter, a fact 
that changes the nature of public and private sec-
tor research and development efforts. 
Everyone, including tourists, nature con-
servationists, scientists, photographers, and 
journalists, are subject to these new regulations. 
Particularly targeted are scientists and researchers 
who make significant use of proprietary genetic 
resources, biological matter, traditional knowl-
edge, and farming know-how. Such knowledge 
may, in national legislation, be considered intel-
lectual property (IP) or trade secrets, and, as such, 
neither in the public domain nor available for un-
authorized appropriation. 
Violation of the new access laws (for example, 
by scientists conducting unauthorized collection 
activities) can result in fines, imprisonment, and 
denial of future visits to the collection area. A 
violation may result in increased transaction time 
for obtaining formal access permits. A violation 
may also result in a prohibition on other scientists 
working in a country. 
Unfortunately, it can take a lot of time to get 
the requisite permissions for collecting biological 
specimens. In Brazil, approximately 400 applica-
tions to use biological materials are received an-
nually. The processing rate for these applications 
is 25–50 per year. This is due to strict ABS legis-
lation. A similar situation prevails in Colombia, 
which has received some 50 access applications 
over the last five years. Of the 50 applications, 22 
were denied due to improper access behavior, and 
one application (for biological research on dol-
phins) was approved. The remaining applications 
are still being processed.
2.	 The	new	geneTIC-polICy	lAndSCApe
Below is a brief summary of each agreement in 
the new genetic-policy landscape, with regard to 
use of biological matter.
•	 The CBD, adopted in 1992 at Rio de 
Janeiro, provides national sovereignty over 
genetic resources and access conditions for 
other sovereign parties.
•	 TRIPS, adopted in Marrakesh in 1994, 
provides a minimum IP protection stan-
dard for biological matter such as plant va-
rieties, microorganisms, and microbiologi-
cal processes.
•	 ICGTK  was set up in 2001 by WIPO to 
discuss IP issues relating to access to genetic 
resources and the protection of traditional 
knowledge, including disclosure require-
ments in patent applications. 
•	 UPOV provides legal protection for plant 
varieties fulfilling the NDUS criteria (new, 
distinct, uniform, and stable), while in-
cluding a breeder’s exemption and farmer’s 
privilege.
•	 The International Treaty on Plant Genetic 
Resources for Food and Agriculture, adopt-
ed in Rome in 2001, provides a multilateral 
system of access and benefit sharing under a 
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revised material transfer agreement (MTA) 
in relation to some 35 defined crops.
•	 The Global Crop Diversity Trust, set up 
in 2002, is an attempt by the Food and 
Agriculture Organization (FAO) of the 
United Nations and the World Bank to 
establish a trust fund for global ex situ col-
lections of germplasm of relevance for food 
and agriculture.
•	 The Cartagena protocol, adopted in 
Montreal in 2000, provides rules for the 
transfer of genetically modified living or-
ganisms across borders.
•	 In 2002, the CBD adopted the Bonn 
Guidelines on Access to Genetic Resources 
and Fair and Equitable Sharing of Benefits 
Arising out of their Utilization. A volun-
tary supplement to the CBD, the Bonn 
guidelines offer basic information about 
the rules on access and concrete procedures 
(or protocols) to follow. The objectives of 
the Bonn guidelines in relation to academic 
research are: 
-	to promote awareness of the implemen-
tation of relevant provisions of the CBD
-	to provide parties to the CBD and stake-
holders with a transparent framework 
to facilitate access to genetic resources 
and ensure fair and equitable sharing of 
benefits
-	to provide information about the prac-
tices and approaches to be adopted by 
users and providers in the context of ac-
cess and benefit sharing 
-	to promote capacity building and the 
transfer of appropriate technology to 
providing parties
3.		 Ip	RIghTS
IP rights are temporary, exclusive ownership rights 
to the application of an idea. Such rights may be 
granted in the form of patents, trademarks, in-
dustrial designs, copyrights, geographical indica-
tions, or trade secrets. Given the breakthroughs 
in biotechnology and information technologies 
in the last few decades, intellectual property has 
expanded considerably into the area of biological 
matter. For example, in the area of agricultural re-
search the following biological matter falls under 
various IP regimes:
•	 plant seeds or other propagative plant parts 
collected after 1994 
•	 plant and animal cell lines
•	 plasmids 
•	 other recombinant vectors 
•	 gene promoters 
•	 gene markers
•	 transformed bacteria 
•	 isolated plant DNA 
•	 plant cDNAs 
•	 isolated animal DNA 
•	 bacteria (other than the transformed 
bacteria) 
•	 isolated/purified proteins (other than 
those obtained by purchase of laboratory 
reagents) 
•	 equipment for specialized laboratory 
purposes 
•	 information regarding laboratory methods 
•	 genomic sequence database(s) 
•	 other nucleotide sequence database(s) 
such as PCR primer databases, cDNA 
sequences
 
Traditional and farming knowledge is also 
protected under the CBD and the Treaty, sub-
ject to national legislation. In general, research-
ers in the public sector, using proprietary bio-
logical materials and related information owned 
by private sector companies, may have to sign 
agreements stipulating further use and confiden-
tiality conditions. Furthermore, public research 
products using proprietary materials and meth-
ods may be required to sign license and royalty 
agreements with those who hold the relevant IP 
rights.
It should always be remembered that IP 
protection is territorial; it may be recognized 
in some countries and not in others. This ter-
ritoriality of intellectual property has implica-
tions for scientists’ freedom to operate: what 
they may be able to do in one country may not 
be possible in another country without an ap-
propriate license. 
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4. 	The	emeRgIng	new	woRld	oRdeR	
RegARdIng	BIologICAl	mATTeR
The new national sovereignty over biological 
and genomic matter mandates new rules for the 
access and use of biological matter and related 
information. Examples of recent legislation in 
Latin America include the Andean Pact Decision 
391/96: Common Regime on Access to Genetic 
Resources.1 Peru, in accordance with its National 
Strategy on Biological Diversity (Decreto 
Supremo No. 102-2001-PCM), recently added 
legislation relating to traditional knowledge (Law 
27.811, August 2002), and a special national au-
thority (INRENA) has been established to deal 
with ABS issues. In Africa, the Organization for 
African Unity (OAU, now the African Union) 
Model Law for the Protection of the Rights of 
Local Communities Farmers and Breeders and 
the Regulation of Access to Biological Resources 
(adopted in Addis Abeba, December 2001) has 
been used by some nations as a model for regulating 
access to biological material. In 2001, India ad-
opted a bill to protect plant varieties and farmer’s 
rights (Bill No. 123 of 1999) and, in 2000, a bio-
diversity bill (Bill No. 93 of 2000). 
These examples illustrate the different kinds 
of regulations now facing foreign parties, whether 
scientists, commercial prospectors, or nature con-
servationists, who seek access to biological material 
and information. The examples suggest a need for a 
coherent understanding of researchers’ obligations 
under TRIPS and the International Treaty on Plant 
Genetic Resources for Food and Agriculture.
5.		 oBTAInIng	ReSeARCh	peRmITS	wITh	
ABS	pRovISIonS
The following issues should be addressed before 
collection leading to R&D begins:
•	 Under which conditions may I, as a scien-
tist, enter another sovereign state in my sci-
entific capacity?
•	 Under which conditions may I, as a scien-
tist, collect biological material and related 
information?
•	 Under which conditions may I, as a scien-
tist, carry out or export biological material 
and related information from that sover-
eign state?
•	 Under which conditions may I, as a scien-
tist, make further use of collected biological 
material and related information?
Before collecting for purposes of research, 
contact your counterpart in the country to find 
out which rules apply. It is useful to also contact 
that country’s embassy/consulate/legation in your 
own home country. Information on the following 
topics would be useful:
•	 requirements for foreign parties to access 
biological material and information
•	 conditions of benefit sharing
•	 conditions regarding applying IP rights
•	 national focal point for handling ABS 
issues
•	 ABS conditions (are written instructions 
available to foreign parties?)
6.		pRepARIng	youR	ReSeARCh	
peRmIT	ApplICATIon
After having checked with your counterpart or 
the relevant embassy, fill in any research permits 
provided by relevant authorities in the country 
you plan to visit. If ABS issues are not specified, 
then do the following:
•	 Present briefly the scientific objectives, re-
fer to your national counterpart, and in-
clude specifics about what biological mat-
ter and related information is planned for 
collection.
•	 Indicate how you will collect the material 
and with whom, and state if duplicates will 
be deposited in the country where collec-
tion is carried out.
•	 Indicate that, if necessary according to the 
country’s laws, you will apply for an export 
permit. 
•	 Indicate how further use of the collected 
material will be made upon your return, 
such as: 
-	showing material and sharing informa-
tion at seminars and lectures 
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-	sharing collected material and informa-
tion with other scientists, botanical gar-
dens, and/or private companies
-	using the collected materials and/or in-
formation in the R&D of products that 
may eventually be commercialized 
•	 Indicate, in case of possible commercializa-
tion, what steps you have taken to comply 
with relevant national ABS provisions in 
the country concerned.
7.		 If	you	geT	InTo	TRouBle	
Should you encounter difficulties, or just have 
questions related to ABS, consult the clearing-
house or the legal department of your research in-
stitution, university, or college for specific advice 
and information about the policies and guidelines 
your home institution has implemented to com-
ply with the CBD and other agreements.
If the answers you get are inadequate, then 
consult your country’s ABS focal point or ask 
research funding agencies about colleagues who 
have contacts in the country concerned. Contact 
the embassy of the country concerned in case their 
national authorities do not answer; try direct con-
tact by telephone. Remember that it is usually far 
easier to be cautious and proceed correctly than it 
is to fix a problem after it has happened. 
8.		 ISSueS	of	unCeRTAInTy	
Unfortunately, there is still uncertainty concern-
ing the potential restrictions of accessing, using, 
and transferring biological material and related 
information. These include, but are not necessar-
ily limited to:
• international seas and arctic areas, which 
are not covered by national laws. ABS is-
sues regarding these areas are not fully regu-
lated in international conventions
• protection of traditional/indigenous 
knowledge, which is still being established. 
Such protection is possible under CBD 
Article 8 (j), subject to national legislation. 
At present there are some 20 national leg-
islations in place using the sui generis pro-
visions. However, these have not yet been 
tested by the TRIPS Council and are still 
under discussion in the Intergovernmental 
Committee.
• global consensus on Access and Benefit 
Sharing for all genetic resources, which 
is still being developed. This initia-
tive, following the CBD Bonn guide-
lines on ABS, is mainly discussed in the 
Intergovernmental Committee. Today ac-
cess and exchange of the Treaty through 
the Treaty will be multilateral, according 
to a standardized Prior Informed Consent/
Mutually Agreed Terms and a standardized 
MTA agreed by the governing body of the 
Treaty. Access to and exchange of all other 
genetic resources and material (excluding 
human material) is presently subject to bi-
lateral provisions set in national legislation. 
Some 35 countries have legislation in place, 
including India, Brazil, and the Andean 
Community. The ABS project under CBD 
and the Intergovernmental Committee is 
an attempt to try to standardize ABS for 
non-Treaty material.2
• legal protection of plant varieties inside/
outside UPOV. Landraces and farmer va-
rieties/primitive cultivars are protected, 
subject to national legislation under CBD 
Article 8 (j) and the Treaty Article 9. The 
NDUS criteria of UPOV do not normally 
cover landraces and farmer varieties/primi-
tive cultivars, but these are still the result 
of intellectual innovation, mainly by local 
farmers. In TRIPS Article 27.3 (b) provi-
sions are given to introduce sui generis pro-
tection of such plant material. India’s plant 
variety protection and farmer’s rights bill 
provide such protection. 
• Certificate of Origin / Disclosure 
of Origin (CO) in IP applications. 
Discussions are ongoing in CBD and in the 
Intergovernmental Committee regarding a 
compulsory requirement in IP/patent law 
that applicants must provide a Certificate 
of Origin that verifies bona fide access 
(CBD’s Prior Informed Consent/Mutually 
Agreed Terms) of genetic resources used. 
Controversy exists with regard to CO 
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“when possible” vs. “always required” for 
granting intellectual property.
• nonlist material in the Treaty, nonpar-
ties, and repatriation of genetic resources. 
Questions remain, for example, regarding 
material that is currently designated under 
the agreement between the Consultative 
Group on International Agricultural 
Research (CGIAR) and FAO of 1994, but 
that is not on the Treaty crop list (such as 
groundnuts and soybean). The roles and 
rights of parties who have not signed/rati-
fied the Treaty still remain open questions, 
as are provisions in the MTA accompany-
ing repatriation to parties/nonparties of the 
Treaty. 
• requests for germplasm samples. The 
CGIAR genebank collections will form the 
base of multilateral crop material under the 
Treaty. The majority of requests for germ-
plasm presently come from developing 
countries, which increasingly (referring to 
the Cartagena protocol) require that cen-
ters of the CGIAR shall fully guarantee 
that delivered germplasm does not contain 
genetically modified crops. Checking every 
such delivery for a CGIAR center repre-
sents significant costs. 
9.	 ConCluSIonS
The implementation of the ABS system is ongo-
ing, both at the national and international levels. 
Thus, the relevant authorities may therefore not 
be clearly designated, and the established proce-
dures may not be transparent and smooth. If the 
scientists can choose where to carry out research 
and collection activities, he or she should exam-
ine the relevant experience of other researchers 
and institutes. The national law of the provid-
ing countries regulates the ABS procedure. This 
includes the definition of the competent govern-
ment agency and of the other stakeholders that 
must be involved. If relevant national legislation 
does not yet exist, access permits may be issued 
on a case-by-case basis, based on general princi-
ples of law and similar proceedings and rules. 
The ABS procedure may also be com-
bined with other licenses and permits, includ-
ing for research, collection, and export, as 
well as Convention on International Trade in 
Endangered Species of Wild Fauna and Flora 
(CITES) permits and so forth. However, ABS 
will not yet apply in most cases and countries. 
Standardized MTAs and benefit-sharing agree-
ments for similar resources and similar uses may 
already exist (taxonomy, collection, research, 
commercialization). 
The Bonn guidelines recommend public par-
ticipation at the local level with regard to all gov-
ernment decisions concerning issues involving 
resources and permits that affect the public. This 
may lead to the need for stakeholders at different 
levels to grant their prior informed consent, which 
may ultimately cause the ABS procedure to be-
come more complex and time consuming. Based 
on its current complexity, ABS legislation can be 
divided into four broad categories:
1. No ABS situation. The research does not 
involve any access situation or genetic re-
sources. Thus no ABS contract is necessary. 
However, other research permits may be 
required. 
2. Simple ABS situation. The research in-
volves the collection and transfer (includ-
ing export) of samples for an inventory. A 
(standardized) MTA is sufficient. 
3. ABS situation. The export of samples is 
required for further analysis and study in 
a laboratory abroad. No further exploita-
tion is planned. A simple ABS contract is 
sufficient. 
4. Complex ABS situation. The proposed 
research involves various steps, including 
possible research for commercial purposes 
or the use of traditional knowledge. A full 
ABS contract is required. 
Whatever the ABS situation turns out to be, 
in the final analysis the most critical aspect will 
be to understand the ABS regime; to thoroughly 
research the laws, rules, regulations, and customs 
of the country where you intend to conduct re-
search and/or collect; and to plan ahead for all 
foreseeable contingencies. This will make a re-
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warding trip far more likely, and your subsequent 
research activities will have broad benefits that are 
consistent with the spirit and goals of the ABS 
project. ■
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ABSTRACT
The Convention on Biological Diversity (CBD) contains 
rules that clarify the rights and responsibilities of parties 
accessing biological resources from member nations. One 
aspect of the convention addresses the system that governs 
access to genetic resources and how the benefits arising 
from their use are shared. This legislation is commonly 
called the Access and Benefit-Sharing (ABS) program. 
Anyone pursuing collection activities, whether of tan-
gible materials or intangible information, may be subject 
to these new regulations. Especially targeted are scientists 
and researchers who make significant use of proprietary 
genetic resources, biological matter, and related informa-
tion, such as traditional knowledge and farming know-
how. Therefore, it is important for all potential collectors 
to be familiar with the fundamental principles of ABS law 
as well as the procedures that must be followed in order 
to be fully compliant with the rules and regulations of the 
countries where collecting occurs. Well in advance of any 
collection activities, researchers should review the ABS sit-
uation, determine who could best answer questions about 
ABS, find authorized partners in the country of interest, 
locate relevant information on the specific ABS regime, 
and, most importantly, execute the documents, letters and 
agreements necessary to proceed with collection activities.
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community undertook to regulate the handling 
of genetic resources in the CBD, a binding inter-
national agreement. 
The goals of the CBD are to conserve biologi-
cal diversity, promote its sustainable use, and en-
sure the fair and equitable sharing of benefits aris-
ing from its use. Responsibility for implementing 
the agreement is given to the state in whose terri-
tory the biological material is found. The CBD, 
however, contains rules that clarify the rights and 
responsibilities of all of the contracting parties. 
One relatively recent addition to the convention 
addresses the system governing access to genetic re-
sources and the sharing of the benefits arising from 
their use: Access and Benefit Sharing (ABS). With 
this new legislation, a new world system for the use 
of biological matter now exists that has changed the 
nature of public and private sector R&D efforts. 
Anyone pursuing collection activities, wheth-
er of tangible materials or intangible information, 
may be subject to the new regulations. Especially 
targeted are scientists and researchers who make 
significant use of proprietary genetic resources, 
biological matter, and related information, such 
as traditional knowledge and farming know-how. 
Such knowledge may, in national legislation, be 
considered intellectual property (IP) or trade se-
crets, and as such not in the public domain or 
available for unauthorized appropriation. 
CHAPTER 16.3
1.	 InTRoduCTIon
According to the Convention on Biological 
Diversity (CBD), the rights to biological re-
sources belong to the state in whose territory the 
resource is found. In order to prevent biopiracy 
and create a climate of mutual trust, the global 
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Violation of the new access and benefit-
sharing law, for example, by scientists conduct-
ing unauthorized collection activities, can result 
in fines, imprisonment, and the denial of future 
visits. Violation may also increase the transaction 
time needed to obtain a formal access permit. 
Therefore, it is essential not only to know the rele-
vant policies, principles and laws, but also to have 
a practical understanding of the various potential 
ABS scenarios and the agreements, documents, 
applications, and other required procedural steps 
necessary for full compliance. 
2.	 fouR	ABS	SCenARIoS
We provide here the basics of ABS law, follow-
ing four categories suggested in a recent publica-
tion by the Swiss Academy of Science,1 providing 
some examples of agreements currently or soon 
to be in effect. Please note that on the Internet 
you may find thousands of examples of letters of 
intent, research permits, prior informed consent/ 
mutually agreed terms (PIC/MAT) agreements, 
material transfer agreements (MTAs), and con-
fidentiality agreements. To find out which type 
of agreement fits your project best, please con-
sult the legal department at your university or 
college. 
2.1 No	ABS	situation
For some projects, research does not involve any 
access to genetic resources for which ABS con-
tracts are necessary. However, other research per-
mits may be required. A research permit request 
may ask for more details than necessary in this 
situation. Possible situations might include:
• research performed on human biological 
resources; human biological resources and 
genetic material are not covered by CBD. 
You would need, instead, a research per-
mit and approval by an ethical committee. 
Therefore, make appropriate contact with 
local academic partners and/or the national 
center for medical research.
• research performed locally on national 
biological resources, without any involve-
ment of indigenous people. If you are em-
ployed by a national academic institution, 
normally a research and work permit is nec-
essary. Contact a local academic colleague.
• using Sweden as an illustrative example, 
research in Sweden, on Swedish material, 
or on material introduced before 1992. If 
animals are included, an ethical committee 
permit is needed. Research that includes 
collection of red listed species necessitates 
a permit from Swedish regional authorities 
(called Länsstyrelse in Swedish).
2.2 Simple	ABS	situation
In the simplest scenario in which access and ben-
efit sharing are relevant to research involves the 
collection and transfer (including export) of sam-
ples for an inventory. A (standardized) MTA is 
normally sufficient. In some countries this could 
be done with a standard research permit applica-
tion that includes the MTA (see section 3.2 deal-
ing with the research permit).
Other situations will require different 
actions:
• No standard research permit is available; 
the researcher/collectors will need to find 
a national colleague and formulate both a 
PIC and a MTA.
• When working with genetic resources de-
posited at the institutes of the Consultative 
Group on International Agricultural 
Research (CGIAR), standardized agree-
ments are often available. This is, however, 
only the case for certain species used as crop 
plants.
• If the collection necessitates cooperation 
with indigenous people, a separate contract 
must be signed and the situation is more 
complex.
• If humans or animals are included in the 
research, a permit from the national ethical 
committee will need to be obtained.
2.3	 ABS	situation
A third scenario involves a situation in which the 
export of samples is required for further analysis 
and study in a laboratory abroad. No further ex-
ploitation is planned. In this scenario, PIC, MAT, 
and MTA are all necessary. For the most part, 
completion of the documents mentioned in the 
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simple ABS situations described in Section 2.2 is 
sufficient; however, each document will be more 
extensive. In the more-elaborate research permit 
applications, these additional documents are in-
cluded. Confidentiality agreements also might be 
requested.
2.4 Complex	ABS	situation
The most complex scenario involving access and 
benefit sharing is a situation in which proposed 
research involves several steps, including research 
for commercial purposes and possible use of 
traditional knowledge. Initially, confidentiality 
agreements and letters of intent could be signed, 
followed by PIC, MAT, and MTA. In the MAT, 
issues concerning benefits have to be elucidated 
and agreed upon. Terms like interest, profit, and 
return, as well as payment times, have to be dis-
cussed and jointly interpreted by all stakeholders.
3.	 IlluSTRATIve	exAmpleS	And	
TemplATe	AgReemenTS
In order to better assist the reader of this chap-
ter in understanding the various ABS scenarios 
and the documents, letters, and agreements that 
might be applicable, we present examples of:
1. Letter of intent    
2. Research permit   
3. PIC   
4. MAT   
5. Template MTA
6. Confidentiality agreement   
In addition, we also provide examples of ABS 
legal principles in various countries, along with 
useful online links where information can be ob-
tained. It should be noted that the examples of 
template contracts or agreements presented be-
low are for illustrative purposes only and in no 
way refer to specific existing agreements. The ex-
amples are meant to provide input for the devel-
opment of real documents, which will need to be 
adapted to each specific circumstance. 
3.1	 Letter	of	intent
The letter of intent is a document in which the 
partners in the project describe their intentions. 
It is not legally binding as are the PIC and the 
MTA. It is mainly useful as a vehicle by which 
the parties can convey to one another their expec-
tations and anticipated degree of involvement. 
A letter of intent could be used later as a basis 
for a PIC. A project could be financed through 
a planning grant, based on a letter of intent, and 
signed by all cooperating partners and stakehold-
ers. The planning grant should finance the ne-
gotiations resulting in a PIC, MAT, and MTA. 
Planning grants have to be prepared three to four 
months before the deadline for submitting proj-
ect proposals.
The examples given here (Boxes 1A–1D; all 
Boxes are at the end of this chapter) are hypo-
thetical but use features from the real world. It 
describes a study in a developing country where 
local scientists and indigenous people working 
together study herbs used for malaria and vec-
tor control. Stakeholders in the project could 
be the National Government (represented by 
the University of Vientiane and the Ministry of 
Environment and the Ministry of Health), local 
authorities in the province, national park officials 
where the study is performed, and indigenous 
people (represented by village representatives and 
individual healers).
3.2	 Research	permit
To be able to research in several foreign coun-
tries outside the E.U., you will need a research 
permit. In some countries, this is easy to obtain 
using a standard procedure with standard fees. 
In other cases, it can only be obtained in coop-
eration with a national partner or through prior 
informed consent contracts. For an example, see 
Box 2.
3.3	 Prior	informed	consent
PIC is a description of the project signed by all 
stakeholders and other concerned parties. It can 
be difficult to determine who exactly is affected 
by the project; another problem is financing the 
information and negotiations. It can also be prob-
lematic to have to devote all the work and gener-
ate expectations for a project that does not have 
any guaranteed financing. The prior informed 
consent is normally written to fit a commercial 
THORNSTRÖM & BJÖRK
1472 | HANDBOOK OF BEST PRACTICES
bioprospecting project. But how does it work 
with a basic noncommercial program?
Near-term, medium-term, and long-term 
benefits should be considered, including up-front 
payments, milestone payments, and royalties. The 
benefit-sharing time frame should be definitively 
stipulated. Furthermore, the balance between 
near-term, medium-term, and long-term benefits 
should be considered on a case-by-case basis.
The prior informed consent includes:
• conditions for export of biological material 
and related information
• conditions for use of the material and re-
lated knowledge
• conditions for how and what to make 
public 
• patents and country of origin
• how and where to solve disputes
Prior informed consent means that every-
one concerned has to be informed about the 
project and its terms before the project starts. If 
indigenous people are concerned, they must be 
informed so they understand the project. It may 
be necessary to translate the project into native 
languages or make a clear presentation with pic-
tures. If the indigenous people do not give their 
consent, the project cannot start.
A letter of intent could be used to introduce 
the project and start negotiations, even before the 
project is financed. When the project is financed, 
the letter of intent could be integrated into the 
PIC. Remember that most academic organizations 
are not familiar with using letters of intent. Also, 
it is also important to identify and understand the 
respective roles of the legal entities involved:
• The scientist who is collecting should sign, 
in addition to the director of the institute, 
unless he has delegated the right to sign. 
The government, in the country where the 
collection is performed, could be represent-
ed by the ministry responsible for natural 
resources or another delegated unit. The 
government is legally considered the owner 
of the rights to the genetic material.
• If the project is performed in cooperation 
with a local university or institute, a lo-
cal legal representative from the university 
should sign. In some countries, cooperation 
with a local university is a prerequisite for a 
project to be accepted. Depending on local 
laws, a cooperating scientist is sometimes 
expected to sign.
• If the project is performed within a nation-
al park, park authorities have to sign. This 
could also make the collection easier.
• If indigenous people are involved, their lo-
cal representatives have to sign. This can be 
a complicated task, as several local com-
munities may be involved and sometimes 
it is not clear who is a legal representative. 
A local community can also refuse to sign, 
and that will prevent the project from be-
ing performed in their legally defined area. 
• If local individuals contribute to the proj-
ect, they also are considered concerned par-
ties. This may be the most complicated part 
to determine, as it is not easy to judge who 
will contribute prior to the project start. In 
Sweden, the scientist, if not otherwise stat-
ed in his or her contract, has the right to his 
or her inventions and intellectual property, 
which should then also be regulated in the 
PIC.
The above concerns and others are addressed 
and discussed in the following examples (Boxes 
4A–4E) and their analysis.
The PIC should always set a time schedule. 
The duration could be a couple of months, for 
a specific collection, to up to five years or so if 
the project includes a Ph.D. program. The PIC 
must also define what happens with material and 
results after the time schedule has ended (see  Box 
4C).
Geographical area or areas shall also be de-
fined realistically. This could be the whole nation 
or a local area. It is better to include any areas that 
could be of interest, rather than make it necessary 
to start new PIC negotiations, since these take a 
lot of time. An area could also be defined as a cer-
tain biotope in different geographical areas (see 
the examples in Box 4D). 
Scientists often specialize in collecting ge-
netic resources within a certain family or selected 
genera. However, often material also is collected 
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for colleagues interested in other species. If this is 
the case, it should be mentioned in the PIC, which 
should also state if the material will be given to a 
third party, how it will be used, and by whom. The 
genetic resources can be living or dead specimens, 
and also parts of specimens, such as genes, enzymes, 
or specified chemicals or extracts. Whole material 
from families or material from several genera can 
be included. The PIC can also include new deriva-
tives made from the collected material. Questions 
to ask include: Why is the collection being made? 
How shall results be used? Is material to be taken 
out of the country? What information can be pub-
lished? What species/samples can be transferred to 
a third party? What research methods may be in-
volved? Have these provisions been set out in your 
project proposal for financing? Does publication of 
material obtained from indigenous people necessi-
tate their consent? Is the project classified as com-
mercial or as noncommercial? Box 4E offers several 
relevant examples.
3.4	 Mutually	agreed	terms
In accordance with Article 15, Paragraph 7, of 
the Convention on Biological Diversity, each 
contracting party shall “take legislative, adminis-
trative or policy measures, as appropriate [...] with 
the aim of sharing in a fair and equitable way the 
results of research and development and the benefits 
arising from the commercial and other utilization of 
genetic resources with the Contracting Party provid-
ing such resources. Such sharing shall be upon mu-
tually agreed terms.” It is therefore important to 
assist parties and stakeholders in the development 
of mutually agreed terms to ensure the fair and 
equitable sharing of benefits.
3.4.1 	 Basic	requirements
Everyone signing PICs and MTAs should under-
stand the content, consequences, and meaning of 
certain terms. Mutually agreed terms take into ac-
count the different capacities and needs of those 
involved, including governments, indigenous 
and local communities, holders of ex situ collec-
tions, and the intended user organizations. This 
approach will contribute to fair negotiations and 
equitable shared benefits. Mutually agreed terms 
facilitate:
• legal certainty and clarity
• minimization of transaction costs
• inclusion of provisions on user and provid-
er obligations
• development of different contractual agree-
ments (for example, template agreements)
• different uses: taxonomy, collection, re-
search, commercialization
• negotiated efficiently, within a reasonable 
period of time
• codification of written agreements
The following principles or basic require-
ments could be considered for the development 
of mutually agreed terms: 
• legal certainty and clarity
• minimization of transaction costs by: 
− establishing and promoting awareness 
of the government’s and relevant stake-
holders’ requirements for prior informed 
consent and contractual arrangements 
− ensuring awareness of existing mecha-
nisms for applying for access, entering 
into arrangements, and ensuring the 
sharing of benefits 
− developing framework agreements, un-
der which repeated agreement under ex-
pedited procedures can be made 
− developing standardized MTAs and 
benefit-sharing arrangements for simi-
lar resources and similar uses (the online 
version of the Handbook includes the 
BIO-EARN MTA with suggested ele-
ments of such an agreement) 
• inclusion of provisions on user and provid-
er obligations
• development of different contractual ar-
rangements, for different resources and for 
different uses, and development of template 
agreements 
• different uses may include taxonomy, col-
lection, research, and commercialization, 
among other things 
• mutually agreed terms should be negotiated 
efficiently and within a reasonable period 
of time 
• mutually agreed terms should be set out in 
a written agreement 
THORNSTRÖM & BJÖRK
1474 | HANDBOOK OF BEST PRACTICES
The following elements could be considered 
as guiding parameters in contractual agreements 
and as basic requirements for mutually agreed 
terms: 
• regulating the use of resources in order to 
take into account ethical concerns of the 
particular parties and stakeholders, in par-
ticular of the indigenous and local commu-
nities concerned 
• making provision to ensure the continued 
customary use of genetic resources and re-
lated knowledge 
• provision for the use of IP rights, including 
joint research and the obligation to obtain 
rights on inventions and to provide licenses 
by common consent 
• the possibility of joint ownership of IP rights 
according to the degree of contribution
3.4.2	 Typical	terms
A list of typical mutually agreed terms would in-
clude the following: 
• type and quantity of genetic resources 
and the geographical/ecological area of 
activity 
• any limitations on the possible use of the 
material 
• recognition of the sovereign rights of the 
country of origin 
• capacity building in various areas to be 
identified in the agreement 
• a clause addressing whether the terms of the 
agreement, in certain circumstances, could 
be renegotiated 
• whether the genetic resources can be trans-
ferred to third parties and conditions to be 
imposed in such cases. 
• whether the knowledge, innovations, and 
practices of indigenous and local commu-
nities have been respected, preserved, and 
maintained, and whether the customary use 
of biological resources in accordance with 
traditional practices has been protected and 
encouraged 
• treatment of confidential information 
• provisions regarding the sharing of ben-
efits arising from the commercial and other 
utilization of genetic resources and their 
derivatives and products
Mutually agreed terms for access to and spe-
cific uses of genetic resources (or derivatives), in 
accordance with Article 15, Paragraph 4 of the 
Convention on Biological Diversity, may also 
include conditions for transfer of such genetic 
resources to third parties, subject to national leg-
islation of countries of origin.
3.4.3 The	Bonn	guidelines	on	MAT
The development of mutually agreed terms 
should be based on the principles of legal cer-
tainty and minimization of cost. These principles 
were included in the Bonn Guidelines to respond 
to the concerns of scientific researchers and us-
ers of genetic resources that national procedures 
for obtaining access could be too complex and 
burdensome. The guidelines enumerate a detailed 
description of the type of provisions that could 
form part of a contractual arrangement. Some of 
the proposed provisions are quite innovative and 
include the specification of uses, the regulation of 
those uses in light of ethical concerns, the con-
tinuation of customary uses over genetic resourc-
es, the possibility of joint ownership of IP rights 
according to contributions, and the existence of 
confidentiality clauses and sharing of benefits 
from commercial and other utilization of genetic 
resources, including derivatives thereof. The prin-
ciple subjects to be agreed upon as listed in the 
Bonn Guidelines are:
• type and quantity of resources
• limitations on possible use
• recognition of sovereign rights of country 
of origin
• capacity building
• whether terms of agreement can be 
renegotiated
• whether genetic resources or derivatives can 
be transferred to third parties
• whether traditional knowledge is respected
• treatment of confidential information
• types of benefits
• timing of benefits
• distribution of benefits
• mechanisms for benefit sharing
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3.4.4	 Convention	on	Biological		
Diversity:	MAT	guidelines
Box 5 provides the relevant sections on mutually 
agreed terms from Decision VIII/4 of the CBD.
3.5	 Material	transfer	agreements
If you need to transfer biological material from a 
foreign country, you must sign an MTA with the 
authorities of the foreign country. This could cov-
er extracts for isolation of chemical compounds, 
as well as dried or otherwise preserved biological 
material. The material could be used in the na-
tional herbarium or for breeding purposes. The 
MTA should include:
• a definition of the material to be transferred
• reasons for the transfer
• restrictions or stipulations on how it can be 
used
• an explanation of the costs of the transfer 
and who will pay the costs
• start and termination dates
• settlements of disputes provisions 
See Box 6 (at the end of chapter) for a 
sample MTA that puts into place the above 
considerations.
3.6	 	Confidentiality	agreements
Before information of possible commercial value 
is given to another party, normally a confidential-
ity agreement is signed. The confidentiality agree-
ment states what must be kept secret and stipulates 
a time frame for confidentiality. The agreement 
also includes paragraphs on how to proceed if 
confidentiality is broken. The Bonn Guidelines 
suggest that a confidentiality agreement be includ-
ed in the PIC. Before signing any confidentiality 
agreement, a researcher should contact the legal 
affairs office at his or her university.2 See Box 7 for 
a sample confidentiality agreement.
5.	 fIndIng	ABS	InfoRmATIon
Now that you have an understanding of the basic 
steps to take to ensure ABS-compliance, how do 
you find out about the ABS rules of a given coun-
try? Which kind of legislation exists in the coun-
try you want to work in? Which conventions on 
biological material have they signed? In order to 
find answers to these questions, many countries 
have specific Web sites.3
5.1	 Europe
The E.U. and member states have signed CBD. 
The E.U. is now implementing ABS, but there 
is no common law. The E.U. Parliament and the 
Council directive have suggested introducing the 
country of origin in patent law (Directive 98/44/
EG). The EC ABS portal covers: Austria, Belgium, 
Cyprus, Czech Republic, Denmark, Estonia 
Finland, France, Germany, Greece, Hungary, 
Ireland, Italy, Latvia, Lithuania, Luxemburg, 
Malta, Netherlands, Poland, Portugal, Slovakia, 
Slovenia, Spain, Sweden, and the United Kingdom. 
Some specific country information follows:
• Austria: With regard to benefit-sharing ar-
rangements, access to natural genetic re-
sources is free in Austria, as long as the ani-
mal and plant species are not protected by 
nature-protection laws, such as endangered 
species, national parks, hunting, and, of 
course, private-property laws. If somebody 
gets financial support from the State for sci-
entific research and profits from the results, 
she or he has to pay back only the subsidy.
• Greenland: In late 2006, Greenland 
Home Rule Parliament adopted an Act on 
Commercial and Research-Related Use of 
Biological Resources.
• Iceland: Iceland has introduced access leg-
islation related to microbe prospecting in 
volcanic areas.
• Norway: Norway recently adopted access 
legislation, regarding boreal coral reefs, 
among other things.
• Sweden: There is no specific legislation on 
ABS. Sweden follows E.U. legislation with 
few of its own initiatives. There is no au-
thority that can certify country of origin. 
Material deposited in the Nordic gene bank 
or in Swedish botanical gardens after 1992 
is available under international law.4
5.2	 Asia
The ASEAN framework agreement on access to 
biological and genetic resources has been signed 
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by Brunei, Cambodia, Indonesia, Laos, Malaysia, 
Myanmar, Philippines, Singapore, Thailand, and 
Vietnam. However, there is still great uncertainty 
in several countries about how to formulate con-
tracts. Thailand, Malaysia, and Philippines are 
uncomplicated, while the situation in Laos and 
other countries is relatively complex.5 
The Philippines was the first country to im-
plement legislation to regulate access to biologi-
cal resources. Executive Order No. 247, signed 
by the president of the Philippines in May 1995, 
was the product of discussions between govern-
ment agencies, nongovernmental organizations, 
indigenous peoples, and academic consultants. 
The legislation established a framework to regu-
late biodiversity prospecting having four basic 
elements: 
1. An interagency committee to consider and 
enforce research agreements and coordinate 
further policy development 
2. A procedure to get prior informed consent 
for access to traditional knowledge 
3. A two-tiered system of mandatory research 
agreements, incorporating benefit-sharing 
terms, between collectors and the govern-
ment: an academic research agreement, val-
id for five years, and a commercial research 
agreement, valid for three years 
4. Minimum requirements to conform to envi-
ronmental protection laws and regulations. 
A material supply (or transfer) agreement 
is required for material leaving an institution. It 
should set out any relevant original terms of ac-
quisition and state any additional terms of use, 
transfer, and benefit sharing. The Indigenous 
People’s Rights Act, 1997, includes a Code of 
Conduct for Academic Collector of Biological 
and Genetic Resources for collectors working in 
the Philippines.6 
Other countries that passed such legisla-
tion include Bangladesh,7  Pakistan,8 and India.9 
Some countries in Asia plan to regulate access 
to genetic resources to ensure PIC and ben-
efit-sharing mechanisms. These include Fiji, 
Nepal, Pakistan, Papua New Guinea, Samoa, 
the Seychelles, the Solomon Islands, South Sri 
Lanka, and Vanuatu.
5.3	 Africa
In Africa, the OAU model law on the protec-
tion of the rights of local communities, farmers, 
and breeders and the regulation of access to bio-
logical resources (OAU, Addis Ababa, December 
2001) has been used by some nations as a model 
for regulating access to biological material.10 So 
far, mainly Cameroon’s legislation follows the 
African Union principles. Case studies from 
Cameroon include contrasting benefit sharing in 
the pharmaceutical and phytomedical industries 
in relation to Ancistrocladus korupensis and sus-
tainable harvesting of Prunus africana on Mount 
Cameroon.11 Nigeria12 and South Africa13 also re-
cently passed legislations.
5.4	 Latin	America
Costa Rica has been one of the first countries 
globally to take a lead in biodiversity-related leg-
islation. Information about regional groups, na-
tional governments, or state governments already 
regulating access to genetic resources to ensure 
prior informed consent and benefit-sharing can 
be found in the Ley de Biodiversidad  No 7788, 
which has been in force since 1998.14 The rules 
on access to biodiversity (Presidential Decree 
No. 31-514) have been in force since 2003.15 
The decree covers the following topics: access to 
genetic resources, equitable sharing of benefits 
arising out of the utilization of genetic resources, 
equitable sharing of benefits from the utiliza-
tion of traditional knowledge, innovations and 
practices, intellectual property rights related to 
genetic resources and/or protection of traditional 
knowledge, innovations, and practices related to 
genetic resources.
More broadly in Latin America, the Andean 
Pact decision 391/96 on the Common Regime 
on Genetic Resources is leading the tone of the 
discussions. Peru, under its National Strategy on 
Biological Diversity (Decreto Supremo No. 102-
2001-PCM), recently added a regime on tradi-
tional knowledge (Law 27.811, August 2002). In 
Peru, a special national authority (INRENA) has 
been established to deal with access and benefit-
sharing issues. 
The countries of the Andean region (Bolivia, 
Colombia, Ecuador, Peru, and Venezuela) decided 
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to take a regional approach to regulating access to 
their genetic resources. The Andean Pact Decision 
391 Agreement (1996) established a common rule 
on access to genetic resources for member coun-
tries, leaving implementation up to national reg-
ulation. The thinking behind this approach was 
that it made little sense for one country to regulate 
access strictly, when a neighboring country, with 
similar flora and fauna, had little or no regulation 
in place.16
Other countries where laws have been passed 
include Argentina,17 Bolivia,18 Brazil,19 Mexico,20 
Panama,21 and Peru.22
5.5	 Australia	and	the	United	States
Despite the fact that the United States has nev-
er signed the Convention, most organizations 
and universities follow the CBD and the Bonn 
Guidelines.23 Several U.S. projects are financed 
with universities, together with NCI or NIH, and 
coordinated by the Fogarty International Center.24 
Australia already regulates access to genetic re-
sources to ensure prior informed consent and 
benefit sharing (the states of Western Australia 
and Queensland).25
6.	 ConCluSIonS
Depending on the ABS situation (that is, no ABS 
situation, simple ABS situation, ABS situation, or 
complex ABS situation), a series of procedural steps 
will need to be taken pursuant to relevant national 
legislation. Accordingly, researchers must have a 
clear understanding of what documents need to be 
executed. These documents might include:
• Letter of intent    
• Research permit   
• Prior informed consent/PIC  
• Mutually agreed terms/MAT 
• Material transfer agreement (MTA)  
• Confidentiality agreement 
 
For each of these, it will be important to 
know who the authorized counterparts are in the 
country where collection activities are anticipated. 
In addition, it will be necessary to know where to 
find accurate and current information about the 
precise ABS legislation that prevails.
Although this might initially seem daunt-
ing, full compliance is necessary. Careful plan-
ning and proactive management will pay off in 
the long term, by minimizing the possibility of 
misunderstandings and possible legal problems, 
including detainment or expulsion.
Perhaps most importantly, these ABS regimes 
are in place to facilitate the building of equitable, 
sustainable, and solid networks for sharing bio-
logical resources for R&D programs. We all hope 
that the regimes ensure that any benefits that ac-
crue will extend to all involved. ■
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Box	1A:	Simple	letter	Agreement	for	the	Transfer	of	materials	
Ministry of Environment, People’s Democratic Republic, represented by Mr./Mrs. __________; and 
the Department of Systematic Botany, Uppsala University, represented by Dr. Barbro Sundberg, 
hereby declare their intentions to develop a cooperative project in systematic botany and 
ethnobotany within the Nam-Nam National Biodiversity Conservation Area. 
Dr. Barbro Sundberg and her Ph.D. student, Hugo Brun, Uppsala University, and Ph.D. Mak Naeng, 
of the National University of the PDR, are given permission to collect plant material, in the form of 
herbarium vouchers, within the Nam-Nam NBCA in order to study the floristic biodiversity of the 
area and the documentation of the PDR genetic resources. All specimens are collected in triplicate 
and processed, and will be detained in the NU herbarium, in the Uppsala University (UPS), with 
one specimen going to the Stockholm Natural History Museum (S). 
All samples are marked with catalog number and the text: “The rights to this material belong to 
the PDR. Any distribution or DNA sampling of this material necessitates a specific permit from the 
Ministry of Environment of the PDR.” All publications deriving from the study of this material 
should acknowledge the Ministry of Environment of the PDR, and botanical publications should 
be published with consent of the curator of the NU Herbarium.
All expenses for the above-mentioned project are planned to be financed by the Swedish 
International Development Cooperation Agency. The project is planned to take place from July 1, 
2007, to June 30, 2010. This letter of intent covers that time period only.
The Capital, February 10, 2007
The Ministries of PDR Barbro Sundberg Mak Naeng
NU Herbarium officer Hugo Brun
Box	1B:	letters	of	Intent—derivatives
The Ministry of Health, the People’s Democratic Republic, represented by Mr./Mrs. _________; 
and the Department of Systematic Zoology, Uppsala University, represented by Dr. Åke Mattsson, 
hereby declare their intentions to conduct a cooperative project in biology within the Nam-Nam 
NBCA that concerns traditional techniques for malaria control and development of vector control. 
Dr. Åke Mattsson, Professor Dr. Thomas Lundberg, and Ph.D. students Nils Svensson, Uppsala 
University, and Mai Moeng, National University of the Capital, are given a permit to collect plant 
material and insect samples within the NBCA for documentation. 
All specimens are collected in triplicate and processed to be detained in the NU herbarium, in the 
Uppsala University (UPS), and at the Stockholm Museum of Natural History (S). 
All samples are marked with catalogue number and the text: “This material belongs to the PDR. 
Any distribution of this material to a third party requires a specific permit from the Ministry of 
Environment of PDR.” Prepared plant extracts are transferred to Uppsala University for analysis. 
All extracts are marked with catalog number and the text: “This sample belongs to the PDR. Any 
transfer of material to a third party necessitates a permit from the Ministry of Health, PDR.”
All expenses for the project are to be financed by the Swedish International Development Agency. 
The project is planned to take place from April 1, 2007 to August 31, 2009, and this letter of intent 
covers that time period only.
The Capital, March 3, 2007
The Ministry  Åke Mattsson  Thomas Lundberg
Mai Moeng  Nils Svensson
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Box	1C:	letters	of	Intent—Bioprospecting	and	Traditional	Knowledge
The representative of the Council of Village Heads of Nam Rew and Nam Chaa Valleys, representing 
the people of the villages in the Nam Rew and Nam Chaa Valley, Nakay-Mai District, Nua Province, 
PDR and the Department of Systematic Botany, Uppsala University, Sweden, represented by 
Martin Stigberg, hereby declare their intention to cooperate on a project concerning plants used 
for traditional medicine and mosquito control. The project aim is to improve mosquito and health 
control for the people in the villages. 
All field equipment used for this control will be donated to the villages after the project time 
expires.
All rights to findings, in the form of possible patents and marketable products, and profits from 
possible commercialization will be divided according to the following schema:
• 5% given to local informants and/or their families
• 25% put into a village development fund controlled by the Council of Village Heads of the villages in the 
Nam Rew and Nam Chaa Valleys 
• 25% is to be used by the Ministry of Health for active disease control in the PDR 
• 25% to be used by the Ministry of Environment for preservation of biological biodiversity 
• 20% of gains are put into a research fund with Dr. Martin Stigberg (Lecturer in Ethnobotany, Uppsala 
University), Prof. Maria Karlsson (Professor in Medical Entomology, Uppsala University) and Dr. Sue-Trong 
(Dean of the Faculty of Sciences, National University) are board members. The fund should be used for 
the education of promising Ph.D. students from the PDR within the field of biology. 
The project is planned to be financed by the Swedish International Development Cooperation 
Agency. Project time July 1, 2007, to June 30, 2011.
Nam-Nam NBCA, February 28, 2007
Chief ……………….  Martin Stigberg 
Representative of the Council of                      Department of Systematic Botany, 
Village Heads of Nam Rew and                                Uppsala University, Sweden
Nam Chaa Valley
Box	1d:	letters	of	Intent—education/Training	Situation
The Faculty of Sciences, National University of the PDR (represented by Dr. Sue-Trong) and 
Department of Systematic Botany, Uppsala University, Sweden (represented by Dr Lisa Svensson), 
hereby declare their intention to cooperate on an ethnobotany project within the Nam-Nam 
NBCA, the People’s Democratic Republic.
From the Faculty of Science, Mr. Mak Naeng MSc and Mr. Mai Moeng MSc will take part as Ph.D. 
students, with Dr. Lisa Svensson and Prof. Birgitta Eriksson from Uppsala University as supervisors. 
From Uppsala University, Hugo Brun is financed as a Ph.D. student. 
Financing for Mr. Naeng and Mr. Moeng is from the bilateral program of the Swedish International 
Development Cooperation Agency (Sida) and NUOL. Financing for Mr. Brun is from a grant from 
the Sida/SAREC to Dr. Lisa Svensson. 
Vientiane, February 25, 2007
Dr. Sue-Trong   Dr Lisa Svensson
Dean of the Faculty of Sciences, Department of Systematic Botany
National University of PDR  Uppsala University, Sweden
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Box	2:	Research	permit	examples
foRm	B-00127
ENVIRONMENTAL PROTECTION AGENCY/EPA APPLICATION FOR SCIENTIFIC AND/OR COMMERCIAL 
RESEARCH ON BIODIVERSITY IN THE COOPERATIVE REPUBLIC OF GUYANA
The EPA welcomes applications from persons interested in conducting biodiversity research in 
Guyana.
NOTES TO THE APPLICANT
a. A non-refundable fee of US$75 is required for the processing of each application. The fee, along 
with the method of payment, can be found online.
b. All questions must be answered. Separate sheet(s) may be used for answers to any or all 
questions.
c. All applications must be typewritten. Failure to do so will result in a delay in processing the 
application.
d. Two (2) copies of the completed Application Form must be submitted, not later than three (3) 
months prior to the commencement of the research, to the Environmental Protection Agency 
for review.
e. All current sponsors, employers, collaborating institutions, and affiliations with commercial 
entities, relating to any or all of the researchers, and for the proposed research, must be 
specified (see 11 below).
f. Any change in the details of the application (for example, in the membership of the research 
team, or current sponsors/institutions), which occurs after approval has been given, should be 
reported to the EPA in writing.
g. The kinds and quantities of information, samples, and specimens proposed to be collected as 
part of the research are expected to be justified by the aims and objectives of the research, 
and quantities of materials to be removed are to be reasonable in relation to the abundance 
of any particular species (see 5 to 12 below).
h. It is recommended that applications be submitted before funding arrangements for the 
research are finalized with funding agencies, or, at the latest, prior to the departure of the 
research team for Guyana.
i. If you are intending to conduct research as an individual, you must submit a letter of 
recommendation from a recognized Institution/Body/Society. In the case of student applicants, 
the name and signature of the supervisor is required.
j. The Researcher must ensure that all necessary precautions be taken with regard to the health 
(vaccinations) of the research team.
k. The researcher/research team must work in accordance with the approved Guidelines for 
Biodiversity Research.
Please provide the information specified in the items below:
1.    Name of authorized signatory to this application
2.  Agency/institution on whose behalf the application is being made, if any
3.  Postal address, telephone, fax and e-mail
4.  Descriptive title of the proposed project
5.  Summary of the proposed project (please attach a copy of the project proposal)
6. Objectives; proposed site(s) of the research (give as precise geographical delineation as 
possible); description of the proposed research, including methodology(ies):
7.  What kinds of material/information are to be collected/produced/imported? (Please check 
appropriate boxes)
[ ] Specimen/sample collection (specify nature and numbers)
[ ] Recordings (audio and video)
[ ] Photographs
[ ] Written notes
(Continued	on	next	page)
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[ ] Computer entries
[ ] Reports
[ ] Articles and scientific papers
[ ] Other outputs (specify) _________________________________________
8. Anticipated intermediate and final destinations of all information/reports and specimens and 
materials:
9. Is your project intended for commercial or exclusively academic purposes? Please specify your 
exact intentions. Commercial purposes here include but are not limited to:
(i) The use of samples or specimens, photographic and audiovisual materials and 
illustrations, for commercial purposes
(ii) Chemical, pharmacological, and biotechnological study
(iii) The use of materials or specimens for propagation or breeding purposes
Academic purposes here refer to only taxonomic, conservation, ecological, and biogeographical 
investigations
10. Time schedule (arrival in/and departure from Guyana, including dates in hinterland)
11. Composition of research team (attach very brief CVs). Also attach a statement on current 
sponsors.
12. Expected environmental impact of the research (brief statement)
13. Expected source of funding (see Notes to the applicant [d]). Please attach the budget proposal 
that will be or has been submitted to the funding agency, including foreign and (estimated) 
local costs.
14. Proposed linkage(s) with local institution(s), if any. (State whether each institution has been 
formally approached and indicate (very briefly) its response.)
15. Training component for local counterparts
16. Do you intend to conduct research on lands legally owned or occupied by indigenous or local 
communities? If so, where?
17. Give a brief description of how Guyana will benefit from your research, including what 
compensation you anticipate immediately and in the long term for Guyana (cash, barter, 
services, specimens, sharing future production possibilities from research, royalties, equipment, 
or materials).
Signature of applicant
Signature of supervisor, if applicable
Office held in the Agency/Institution
Date
Environmental Protection Agency
IAST Building, U.G. Campus, Turkeyen
Greater Georgetown, GUYANA
 
Source: EPA, Republic of Guyana.28
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Box	4A:	prior	Informed	Consent—Biodiversity	and	ethnobotany:		
garcinia	sensu	lato	(Clusiaceae)	in	Cuba
EXCHANGE CONTRACT FOR ACCESSING BIOLOGICAL RESOURCES BETWEEN THE NATIONAL 
BOTANICAL GARDEN OF CUBA (JBN) AND THE INSTITUTE OF EVOLUTION, GENOMICS AND 
SYSTEMATICS, UPPSALA UNIVERSITY, SWEDEN
ON BEHALF OF THE FIRST PART: The National Botanical Garden under ownership of Havana 
University, Ministry of Education, JBN in advance, with legal address in Carretera El Rocio Km 3, 
Calabazar, Boyeros, 19230—Havana, Cuba, represented in this document by Dr. Angela T. Leiva 
Sánchez, as head director of the institution.
ON BEHALF OF THE OTHER PART: The Department of Evolution, Genomics and Systematics, 
Uppsala University, Uppsala, Sweden, IEGSU in advance, with legal address in Norbyvägen 18D, 
SE-752 36 Uppsala, Sweden, represented in this document by Dr. Britta Ekholm as head of the 
Ethnobotany group of the Department of Systematic Botany at the Institute EGS, Uppsala 
University, Uppsala, Sweden.
Both Parts Manifest:
• that they have mutual interest to establish a bilateral collaboration for accessing biological 
resources, with the specifications, obligations, and conditions that figure in the present 
document
• that both parts have the means and resources needed to get the exchange of experiences in 
the best conditions with the requested quality
• that they commit themselves to observing the strict fulfillment and respect of the Convention 
on Biological Diversity which both parts have signed
• that they acknowledge the mutual benefits that such a collaboration will represent for the 
contracting institutions and both countries
BOTH PARTS: Acknowledging the person and legal entity which they sign on this document, 
agree to subscribe to the present contract following the next specifications, obligations and 
conditions:
FIRST: The objective of the present bilateral contract is to access the Cuban alive biological 
resources for scientific purposes, for taxonomical studies, ethnobotanical studies, the 
investigation of chemical compounds and molecular studies on Cuban tropical plants of the 
genus Garcinia L. (Clusiaceae), in cooperation between JBN and EGS; the biological alive plant 
resources being accessed will be sent from Cuba to Sweden, as a sample big enough to achieve 
the above mentioned studies, from the wild harvest or donations of the Botanical Gardens in the 
National Network of Cuba.
SECOND: The alive plant biological resources of Cuba from wild harvesting or donations of the 
Botanical Gardens in the National Network of Cuba will always have a herbarium sample that 
will be kept as part of the herbarium collections HAJB of the National Botanical Garden and UPS 
under ownership of the Uppsala University Museum of Evolution, and they will not be utilized for 
commercial purposes or exchange; if new species are described from this material, the holotypes 
must be deposited at the HAJB herbarium.
THIRD: JBN will manage and pay the expenses for the official permits needed to access the 
natural areas, the biodiversity, exportation, and plant care.
FOURTH: EGS will pay the expenses in Cuba of the Cuban partner for the supervisor, the driver 
that will take part in the expeditions and the plant care revision, the customs fee, and the 
transportation for the plant biological material.
(Continued	on	next	page)
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FIFTH: The live Cuban biological resources sent from JBN to EGS, collected from germination 
and cultivation will not be used for commercial purposes under any circumstances, if either 
the material’s origin is wild collected or is a donation from the Botanical Gardens in the Cuban 
National Network.
SIXTH: The results derived from the chemical and molecular studies will be for mutual benefit 
and will be shared by JBN and IEGSU, in the way of scientific publications or otherwise, as agreed 
by the parts.
SEVENTH: The transportation from JBN to IEGSU of the living plant biological resources will 
be done by EGS researchers directly from the International Airport José Martí, Havana, to 
Stockholm.
EIGHTH: Possible modifications or additions to the present contract should be made through a 
formal agreement between the parties as included as an appendix to the present Agreement.
NINTH: The present Contract of collaboration between JBN and EGS will be valid for two years 
from the signature date, extendable by equal periods, provided that no party terminates the 
agreement early.
TENTH: Any difference or difficulty caused in relation with this Contract interpretation or 
execution, while in effect, will be resolved by means of friendly negotiations between the parties. 
In case an agreement cannot be reached, the conflict will be solved in the Arbitration Court of the 
Chamber of Commerce of the Cuban Republic.
ELEVENTH: The applicable law is the portion of Cuban Law that agrees with the Convention on 
Biological Diversity, which both parties have signed.
Two exact copies of the Contract will be signed, and both copies will be legally valid and will carry 
the approval of the Cuban Authority of the Centre for Inspection and Environmental Control. Each 
party will keep a copy in its possession.
The present document is signed on 3 March of the year 2007.
National Botanical Garden of Cuba Institute of Evolution, Genomics and Systematics
_____________________________ _________________________________
Fdo. Dr. Enrico Chavez  Fdo. Dr. Britta Ekholm
Head Director   Head of the Ethnobotany group in the
    Department of Systematic Botany
_____________________________
Vto. Bno. Ing. Tomás Rivera Amarán
Director del C.I.C.A.
Science, Technology and Environment Ministry
Box	4A	(continued)
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Box	4B:	prior	Informed	Consent—	
description	and	Inventory	of	the	flora	of	malgonia
PROJECT 1: DESCRIPTION AND INVENTORY OF THE FLORA OF MALGONIA 
Parties: Institute of Systematic Botany, Uppsala University, Sweden, The prefect, Dr. Sven Berg, and 
the performing scientist, MSc Anna Skool, Institute of Applied Botany, University of Malgon,
Malgonia, The director Dr. Marin Marais, the government of Malgonia represented by the director 




- Institute of Systematic Botany, Uppsala University, Sweden, The prefect, Dr. Sven Berg and the
performing scientists, Eva Lund, Dr. Mikael Engström, and MSc Birgitta Karlsson
- National University of Laos, faculty of Science, the dean, Dr. Boukaone Nourinam, National
University of Laos, faculty of Medicine, Dr. Bourisak Nam, NUOL represents the Government.
Box	4C:	Time-frame	examples
Project 1. Description and inventory of the Flora of Malgonia
The project is planned and financed for a three-year period with an additional six months for 
publishing and reporting. 
Time schedule: January 1, 2007 until June 30, 2010
Project 2. Inventory and use of the flora in Nam Noi Valley, Laos
The project is financed over a three year period, but two Ph.D.s in a sandwich program are expected. 
The time schedule of the PIC could only be signed for three years but a renewal is prepared.
Time schedule: January 1, 2007 until December 31, 2009, with possible renewal from January 1, 
2009 until December 31, 2012.
Box	4d:	examples	of	geographical	definitions
Project 1. Description and inventory of the Flora of Malgonia.
The project area is defined as “mountain areas throughout the country.” With respect to the 
Northeastern part of the country, a special permit is necessary and hereby given.
Project 2. Inventory and use of the flora in Nam Noi Valley, Laos 
The project area is defined as the Nam Noi Valley and the nearby Nam Pheo Valley between Nam 
Theun, Laos and the Vietnamese border. The project is permitted to expand to the Nam Theun 
basin, which is planned to be flooded.
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Box	4e:	description	of	material
Example 1: Description and inventory of the Flora of Malgonia
The PIC concerns flowering plants without specific limitations. Species within the family Acrididiae 
will be collected for Dr. Grazia Hopper at the Museum of Natural History in Amsterdam. Reference 
specimens will also be given to the Museum of Natural History in Malgon. Collected specimens 
will be marked: Property of Malgonia.
Example 2. Inventory and use of the flora in Nam Noi Valley, Laos
The relevant genetic resources are species and their derivatives used for malaria and vector 
control. A specific permit is given to Professor Gunnar Sellström for collection of insects within the 
genus Anopheles. Collected specimens are treated the same as collected plant species. Collected 
specimens should be marked: Property of Lao PDR.
Example 3. Description and inventory of the flora of Malgonia
The project is noncommercial and intended to improve knowledge of the Malgonian flora. 
The project will result in the description of species and the collection of herbarium specimens. 
Triplicates of the specimens will be deposited at the herbaria in Malgon, Uppsala, and Stockholm. 
A separate MTA is signed for material deposited in Stockholm and Uppsala. The results should 
be published in well-known, scientific journals and will also be at the disposal of the committee 
of the Malgonian flora. Collected specimens will be marked: Property of Malgonia. Transfer of 
material to a third party requires a permit, granted by the Malgonian Environment Ministry. 
Material transferred to Dr. Grazia Hopper, Amsterdam University, is described in a separate MTA. 
The project is used to introduce PCR techniques and training of Staff at NUM.
Example 4: Inventory and use of the flora in Nam Noi Valley, Laos
While collecting an inventory of the flora is noncommercial, the ethnobotanical study of the use 
of plant may contain commercial aspects. The long-term objective of the project is improved 
knowledge of the genetic resources in Laos, with the hope of establishing local production. The 
project will have two basic dimensions:
1.  Inventory of species within the Zingiberaceae family, botanical and chemical. The chemical 
evaluation will concentrate on the essential oils from seeds and roots. Steam distillation 
techniques will be introduced on sight. Identification and structure determination of 
chemical compounds in the essential oils will be done through GC-MS in Lund, Sweden. 
2.  Ethnobotanical study of plant material used to cure and control malaria and mosquitoes. 
Open-ended or semistructured interviews of members of different ethnic groups in the area 
will be followed by statistical analyses, identification of species, evaluation of processing 
influence on chemical composition, literature studies on species and isolated compounds, 
and screening for biological activity. 
Active compounds are identified using GC-MS and HPLC-MS. The project will serve technology 
transfer and technique training for Ph.D. students at NUOL. Blood sampling and analysis is 
performed by scientists of the medical faculty at NUOL. Ethical permits for blood sampling are 
obtained by the faculty. Expected outcome: improved malaria control among the population in 
the studied valleys and identification of possible products for malaria control. At least two PhD 
students will use the project to complete their exams. 
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Box	5:	CdB	on	mAT
1.  [Minimum conditions for the fair and equitable sharing of the benefits arising out of the 
use of genetic resources, derivatives or products shall be stipulated in relevant national 
[access] legislations [or] [and] under the international regime] and [shall] [may] be taken 
into consideration in mutually agreed terms [shall] [may] be based on prior informed consent 
between the provider and user of given resources.] 
2.  [Mutually agreed terms conditions may stipulate benefit-sharing arrangements regarding 
derivatives and products of genetic resources.] 
3.  The conditions for the sharing of the benefits arising out of the use of traditional knowledge, 
innovations or practices and associated [with] genetic resources [derivatives and products] 
[will] [may] be stipulated in mutually agreed terms [between users and the competent 
national authority of the provider country with active involvement of concerned indigenous 
and local communities] [between the indigenous or local communities and the users, and 
where appropriate with the involvement of the provider country]. 
4.  [Mutually agreed terms may contain provisions on whether intellectual property rights may 
be sought and if so under what conditions.] 
5.  Mutually agreed terms may stipulate monetary and/or non-monetary conditions for the use 
of genetic resources, [their derivatives and/or products] and associated traditional knowledge, 
innovations and practices. 
6.  [The international regime should establish basic benefit-sharing [obligations] [conditions], 
including the distribution of benefits through the financial mechanism, to be applicable in 
the absence of specific provisions in access arrangements.] 
7.  [Where the country of origin of the genetic resources or derivatives accessed cannot be 
identified, the monetary benefits there from shall accrue to the financial mechanism and the 
non-monetary benefits shall be made available to those Parties that need them.] 
Source: CBD.29
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This overall Material Transfer Agreement (MTA) will govern the exchange of selected biological 
material between the University of Nangijala and the University of Uppsala, jointly referred to 
below as the Parties. This MTA is based on a collaborative research contract between the parties 
and may be amended where any national laws or regulations require it, or upon the mutual 
agreement of the contracting Parties. It is understood that all exchange of biological material 
will be done strictly in accordance with the principles set out in the Convention on Biological 
Diversity. 
The Parties therefore agree to the following terms and conditions:
1: Definitions 
Biological material means any material of a plant or animal, or microorganisms or other genetic 
resources or derivatives thereof.
Provider means provider of biological material and may be the country providing a genetic 
resource collected from in situ or ex situ sources, including populations of both wild and 
domesticated species, according to the principles of the Convention of Biological Diversity. 
Provider may also be an institution providing part of a plant or animal, or microorganisms or 
other genetic resources or derivatives thereof. 
2: Designation of Implementing Agency 
Depending on the situation in the countries of the respective Parties, several options for the 
designation of implementing agency are possible: 
2.1  University X hereby designates an authorized representative from Faculty Y as the 
competent University X representative for the purposes of this MTA. Such a representative 
should be at the level of Director/Dean/Chairperson, or be an appropriate representative. 
For clarification, it is agreed that the Faculty Y shall be responsible for ensuring that 
all national laws and procedures in force in Country U, relating to the exchange of 
biological material, are respected. Faculty Y shall make reasonable efforts to inform 
individual researchers/investigators of the national laws and procedures relevant to this 
Agreement.
2.2 If the University has not designated an authorized representative, the University is 
represented by the Head of the Administration, and the Administration shall be responsible 
for ensuring that all national laws and procedures in force in Country U relating to the 
exchange of biological material are respected. The Administration shall make reasonable 
efforts to inform individual researchers/investigators of the national laws and procedures 
relevant to this Agreement.
3: Purpose
The primary purpose of this Agreement is to provide a framework for the exchange of selected 
biological material for the purposes of research and education.
4: Ownership
4.1 Biological material exchanged in accordance with this Agreement, including any material 
contained or incorporated in modifications, wherever located, shall at all times be the 
property of the provider and shall not be used by, or transferred to, third parties without 
the knowledge, consent, and written authorization of the provider in accordance with the 
principles in the Convention on Biological Diversity. The ownership of any new intellectual 
property derived from material transferred under this Agreement shall be governed by the 
terms described in Article 7 of this Agreement. For the purpose of this MTA, the provider 
is defined as the Department or the University that has provided the biological material 
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[Note: In the absence of specific legislation vesting ownership of biological material 
held by research institutions, it is prudent to have it vested in the Faculty or University. 
The Faculty in both Parties’ countries need to rigorously follow the developments in the 
emerging access legislation and respond to any legal developments accordingly.] 
4.2 The Parties agree to refer to each other any requests for the use of material from third 
parties not defined under this MTA. 
5: Implementing Letter of Agreement
For all material to be exchanged or transferred under this Agreement, the Parties shall execute 
an Implementing Letter of Agreement (ILA), describing the nature of the material to be collected 
or transferred under this Agreement. Each ILA shall be concluded before any authorization for 
the transfer of material is granted. ILAs must contain the signatures of the relevant principal 
researchers that are providing and receiving the defined material in each ILA. The ILA must 
explicitly reference the rights and responsibilities of the Parties as defined by this MTA. 
[The purpose of this section is to avoid a situation in which an MTA would need to be concluded 
for every single exchange of material. The section will accurately define the nature of the material 
that is transferred under each MTA.]
6: Conditions relating to the use of biological material
6.1 The Parties agree that the material collected and transferred under this agreement is to be 
used for teaching and academic research purposes.
6.2 It is agreed that any other application or use of the material provided, including any 
modification thereof, for commercial purposes shall be allowed at the sole discretion of 
the provider. If either of the Parties wishes to use the material, or derivatives thereof, for 
purposes other than that described in Article 6.1 of this MTA, the authorization for such 
use shall be at the sole discretion of the providing institution as described in this MTA, and 
such authorization shall not be reasonably withheld. 
6.3 Each of the Parties agrees to comply with the terms of this Agreement. This includes any 
scientists or any person(s) of either Party who may come to possess the material in the 
ordinary course of his/her business as an employee of the Parties. Such person(s) shall not 
make available the material or any part thereof, or related information to any person(s) or 
third parties other than those personnel under the Parties’ immediate and direct control.
7: Intellectual Property Rights
Any inventions that are derived in whole or in part from the biological material transferred under 
this MTA shall be assigned in accordance with the relevant laws governing intellectual property. 
Each assignment shall (1) identify the provider of the material and (2) identify the country of 
origin of the material used in any commercialized product(s). The assignees of inventions of any 
commercialized product(s) shall negotiate a good faith, mutually acceptable agreement with 
the provider of the material, according to the principles set out in the Convention on Biological 
Diversity. 
8: Publication
Copyrighted publication generated from research exchanged under this agreement or extracted 
from biological material collected in the pursuance of this agreement shall not include any 
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Box	6	(continued)
9: Duration of the Agreement 
This MTA shall be valid until the end of 2001, according to the BIO-EARN project contract. The 
agreement may be renewed for a new BIO-EARN Programme period (2002–2005) upon mutual 
agreement of the contracting Parties. 
10: Termination
10.1 Unless otherwise agreed, this MTA will terminate at the expiration of the present 
cooperation program.
• The Parties shall remain bound to each other by the least restrictive terms applicable 
to the material obtained in the pursuance of the purposes of this Agreement, and any 
modifications thereof, in accordance with Article 7 of this Agreement.
• The Parties will discontinue their use of the material and may destroy or return any 
remaining material to the country of origin.
• If for any reason, either of the Parties wishes to terminate this Agreement before the 
completion of the research, each of the Parties agrees that it will to the other Party give 
written notice six months prior so as to enable the completion of ongoing research. Such 
written notice shall be provided to each representative of the Parties’ signatory to this 
Agreement.
10.2 Nothing in this Agreement shall be interpreted as having the effect of preventing or 
delaying the publication of research findings resulting from the use of the material or 
modification thereof.
11: Settlement of disputes
11.1 In the event that a dispute arises regarding the interpretation or application of the 
provisions of the Agreement, the Parties shall initially resolve their disputes in an amicable 
manner through consultations. 
11.2  If the Parties fail to resolve their disputes amicably within a period of six months, they 
shall resort to arbitration.
11.3 Each Party shall nominate two arbitrators, and a fifth arbitrator shall be nominated by the 
United Nations Legal Affairs Office. The latter shall be the Chair of the Arbitral Tribunal. 
The decision of the arbitrators shall be final. Decision shall be passed by consensus. If 
consensus cannot be achieved, the decision shall be made by vote. 
12: Miscellaneous
The Parties acknowledge that the biological material provided in pursuance of this Agreement 
may have characteristics that are unknown or difficult to determine and which may be potentially 
hazardous. Neither Party makes any warranties, express or implied, as to the safety, quality, 
viability, or purity of the material, or its merchantability or fitness for any particular purpose.
University/ Research Institute in the Nation concerned  
Name of University
Full Address                                                                              
Authorized Officer
Title        
Signature 
Date    
(Continued	on	next	page)
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Box	6	(continued)
University in Sweden 
Name of University
Full Address 
                                                                            
Authorized Officer
Title         
Signature    
Date    
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Box	7:	Sample	Confidential	disclosure	Agreement
This Confidential Disclosure Agreement (“Agreement”) is made and entered into as of the _____ 
day of ____________, 20__ (the “Effective Date”) by and between ___________________________
____________________________________________ (hereinafter referred to as “LENDER”) having 
its principle address at ______________________________________________________________
_________, and ___________________________________________________________________ ( 
hereinafter referred to as “BORROWER”) having its principle office at ________________________
_______________________________________________.
The LENDER and the BORROWER are each hereinafter sometimes referred to individually as a 
“Party” and collectively as the “Parties,” for the purpose of protecting the patent, trade secret, 
and other proprietary rights of the LENDER and the BORROWER in the following subject matter, 
which may be mutually beneficial to the Parties to disclose for evaluation:
Subject Matter Description:
The Parties agree as follows:
Neither Party will directly or indirectly divulge to unauthorized persons any information received 
from the other Party that relates to the subject matter of this Agreement, except as otherwise 
required by law. As a condition to receiving such information, each Party to the Agreement hereby 
acknowledges that all information provided by either Party to the other in connection with 
the subject matter of this Agreement is confidential and proprietary with regard to the Party 
providing such information. Information to be subject to this Agreement shall be disclosed in 
writing or, if it is verbally or electronically disclosed as confidential at the time of disclosure, its 
confidentiality shall be confirmed in writing within twenty (20) days of disclosure by the Party 
making the disclosure.
Each Party, as recipient of such proprietary information from the other Party, will disclose 
such information only to its employees, directors, agents, consultants, bankers, and advisors 
(“Representatives”) for the purpose of evaluation, and any Representatives to whom such 
information is disclosed shall be informed of the proprietary nature of the disclosure and of 
this Agreement and shall agree to hold such information in confidence and be bound by this 
Agreement in the same manner that each Party is bound. Each party shall be responsible for any 
breach of this Agreement by its Party Representatives.
Neither Party will use such information received from the other Party for any purpose except 
evaluation, testing, research, and related activities and will not disclose such information 
to anyone except its Representatives, unless prior written consent is obtained from the Party 
providing such information or as required by law.
This Agreement shall be binding on both Parties for a term of ______ (   ) years from the effective 
Date of this Agreement, except under the following conditions:
1. If a Party can show that such information was in its possession at the time of the disclosure; 
or
2. If the information disclosed by one Party to this Agreement is or becomes publicly known 
during the term of this Agreement other than through a breach of that Party’s obligations 
under this Agreement; or
3. If the Party later receives such information from a third Party as a matter of right; or if such 
information is developed by one Party independently or any disclosures made under this 
Agreement, as evidenced by that Party’s written records.
This Agreement shall be governed by the laws of _______________________________.
(Continued	on	next	page)
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Box	7	(continued)
To evidence their Agreement to the foregoing, the Parties have, through duly authorized 











There is an upward trend in demand for intellectual 
property protection in agriculture. While international 
agreements exist to protect agricultural biodiversity, the 
specific rights, benefits, and responsibilities of parties en-
tering into commercial agreements that involve the use of 
genetic resources still must be clarified. This chapter pro-
vides practical guidance for creating agreements around 
the use of biodiversity resources, as well as guidance that 
may provide valuable insights for creating similar agree-
ments on the use of unique agricultural resources.
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the ecological complexes of which they are part: this 
includes diversity within species, between species and 
of ecosystems.” With respect to IP rights, naturally 
occurring living organisms cannot be protected; 
nonhuman living things that have been modi-
fied by man can be protected. Bioprospecting is 
the exploration or screening of natural biodiver-
sity or agricultural biodiversity in order to iden-
tify potential commercial applications from those 
genetic resources. Bioprospecting should not be 
confused with biopiracy, which is the unauthor-
ized and uncompensated taking of biological or 
genetic resources.1
This chapter seeks to aid parties in creat-
ing biodiversity access agreements (BAA) for the 
use of unique genetic resources that require ad-
ditional development to commercialize. There is 
considerable—although not widespread—experi-
ence to date in creating BAAs involving microbial 
genetic resources. This general discussion of bio-
diversity access agreements will not encompass 
all of the factors necessary to create every kind of 
commercial agreement, but it may prove useful 
for the following:
• a reference model. For creating a relation-
ship for the use of a resource for which 
there are international guidelines, but for 
which, in most cases, clear procedures for 
structuring specific agreements do not exist. 
This lack of guidance has forced the public 
CHAPTER 16.4
1.	 InTRoduCTIon
Intellectual property (IP) rights protection is in-
creasingly available for many aspects of agricul-
ture, particularly through utility patents and plant 
variety protection (PVP), known also as plant 
breeders’ rights. Globally, however, the kinds of 
intellectual property rights that can be exercised 
over living things vary greatly. This is especially 
true for the living things that make up the biodi-
versity of the planet—the millions of naturally ex-
isting species and their attendant gene pools—as 
well as for agricultural biodiversity—that subset of 
biodiversity involving cultivated crops used for 
food, materials, fertilizers, energy, and so on. It 
is useful to recall that the United Nations (UN) 
Convention on Biological Diversity defines bio-
diversity as “the variability among living organ-
isms from all sources, including, inter alia, terres-
trial, marine, and other aquatic ecosystems, and 
Costanza C, L Christoffersen, C Anderson and JM Short. 2007. Deal Making in Bioprospecting. In Intellectual Property Man-
agement in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). 
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. C Costanza et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for non-
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and private sectors to cooperate to achieve 
a mutually beneficial and sustainable rela-
tionship based on the commercial use of a 
unique genetic resource.
• resource valuation. For valuing resources 
that may hold significant commercial poten-
tial and may also require significant invest-
ment for developing a marketable product 
(capital, technology, and management).
• stakeholder identification and value con-
tribution. For valuing resources in which 
many stakeholders have overlapping inter-
ests. (Proper valuation of these resources 
requires the consideration of traditional 
knowledge, farmers’ rights, and other his-
toric rights. The present condition and 
composition of a resource, such as an iso-
lated natural compound or unique variety 
of plant, may be the result of multigenera-
tional trials and errors. These and other fac-
tors need to be considered when determin-
ing the appropriate value of the resource so 
that benefits from commercial development 
can be fairly distributed.) 
• benefit sharing. For the sharing of benefits 
between parties to an agreement.
2.	 BIodIveRSITy	And	Ip
2.1 The	international	agreements
Biodiversity is addressed by the UN Convention 
on Biological Diversity (CBD). The objectives of 
the CBD are:
• conservation of biodiversity
• sustainable use of the components of 
biodiversity 
• fair and equitable sharing of the benefits 
from the use of genetic resources
By recognizing a national government’s sov-
ereignty over all genetic resources within its bor-
ders (Article 15) and facilitating access to these re-
sources based on “mutually agreeable terms” subject 
to the “prior informed consent” of the country of 
origin, the CBD provides firm conceptual ground-
ing which can be adapted to guide commercial 
agreements.
Agricultural biodiversity in particular is gov-
erned also by the International Treaty on Plant 
Genetic Resources for Food and Agriculture (the 
Treaty). This agreement encourages open access 
to plant genetic resources and requires sharing the 
benefits of these resources through the exchange 
of information, access to technology transfer, ca-
pacity building, and the sharing of financial and 
other benefits of commercialization.2 
The Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) agreement of the World 
Trade Organization (WTO) provides minimal 
guidance on the issue of agricultural biodiversity, 
exempting both plants and animals that are not 
classified as modified microorganisms. Article 7 
of TRIPS states that the protection and enforce-
ment of IP rights should contribute to: 
• the promotion of technological innova-
tion and the transfer and dissemination of 
technology 
• the mutual advantage of producers and us-
ers of technological knowledge that is con-
ducive to social and economic welfare 
• a balance of rights and obligations
 
The TRIPS agreement requires that signa-
tories either provide patent protection of plant 
varieties or devise an effective sui generis (a spe-
cifically dedicated and unique) system for plant 
variety protection. 
Currently, there is an effort to standardize 
countries’ sui generis plant variety protection 
systems through the International Union for the 
Protection of New Varieties of Plants (UPOV) 
Convention, the purpose of which is to “ensure 
that the members of [UPOV] acknowledge the 
achievements of breeders of new varieties of plants, 
by granting them an intellectual property right, on 
the basis of a set of clearly defined principles.” 3,4,5 
The CBD, the Treaty, TRIPS Agreement, and 
UPOV Convention provide general guidance for 
parties engaged in developing their own agree-
ments for access to genetic resources. It is impor-
tant to realize, however, that the existing (interna-
tional) agreements are based on broad standards 
of conduct. The agreements provide overarching 
principals but not instructions on how to meet 
the requirements of every unique situation. The 
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Bonn Guidelines, adopted by the COP in 2001, 
serve as a first step in bridging the gap between 
international agreements and the requirements 
of parties negotiating access to biodiversity re-
sources. In 2005 the Biotechnology Industry 
Organization (BIO) developed and published 
its own guidelines for members engaged in the 
discovery of natural products such as enzymes, 
chemicals, and small molecules.6
From the perspective of two parties attempt-
ing to come to an agreement on providing or ob-
taining access to a unique genetic resource, which 
may or may not become a successful commercial 
product, the international agreements leave many 
questions unanswered. Parties must use com-
mon sense to strike a balance between protecting 
rights and providing fair compensation, on the 
one hand, and working within limits imposed by 
markets and legal frameworks on the other.7 In 
the case of commercializing biodiversity, the par-
ties must agree upon ownership of the resource 
and the subsequent product, the amount of in-
vestment required to bring the product to market, 
and the distribution of benefits resulting from the 
sale of the product. 
One commentator8 has noted a difference in 
negotiating access to agricultural genetic resourc-
es and nonagricultural (particularly microbial) 
genetic resources: whereas microbial biodiver-
sity governed under the CBD has been seen as 
bilateral bargaining, the Treaty puts a premium 
on open access, seeking to keep access costs low 
and bolster global food security by encouraging 
breeding and research. The model provided in 
this chapter does emphasize sharing in a manner 
consistent with the Bonn Guidelines of the CBD 
and many of the financial and nonfinancial ben-
efits outlined in the Treaty.
2.2 Beyond	international	agreements
Given the limited guidance on terms for biodi-
versity agreements, the private and public sec-
tors have had to collaborate to create biodiver-
sity access agreements (BAA) on a case-by-case 
basis. Over time, some companies have devel-
oped frameworks based on internationally ac-
cepted principles for creating BAAs. For example, 
Diversa, a publicly traded U.S. biotechnology 
firm (NASDAQ: DVSA), has entered into many 
BAAs with partners including Alaska, Antarctica, 
Australia, Bermuda, Costa Rica, Ghana, Hawaii, 
Iceland, Indonesia, Kenya, Mexico, Puerto Rico, 
Russia, the San Diego Zoo, South Africa, and 
Yellowstone National Park. The company, which 
is involved in the discovery and evolution of novel 
genes and genetic pathways from unique environ-
mental sources, sees access to microbial biodiver-
sity as critical to ensuring a greater diversity of 
genetic material; this access increases the chances 
of discovering a novel and unique gene for a new 
product or application. During a time when few 
or no models, guidelines, or requirements exist-
ed, Dr. Jay M. Short, then chief executive officer 
and chief technology officer of Diversa, and his 
team of intellectual property, commercial, and 
scientific specialists developed and refined a set 
of principles for selecting areas of the world in 
which to work, selecting partners, and creating 
agreements with governments, academic institu-
tions, and private companies to help ensure long-
term relationships based on the sustainable use of 
biodiversity.
Through its decade of experience with BAAs, 
the Diversa biodiversity team determined that 
there are three main factors that lead to a success-
ful biodiversity collaboration:
1. Efficient and reasonable benefit-sharing 
negotiations 
2. Efficient and reasonable permit systems 
(requiring three months or fewer to secure 
a permit and oblige the permit holder to 
reasonable reporting criteria). It should be 
understood that all national, regional, or 
local regulation that affects an agreement 
should be sufficient to provide reasonable 
regulatory oversight without creating an 
unnecessary burden on the parties
3. Capacity building
Based on the experience of Diversa, the fol-
lowing characteristics have been useful for evalu-
ating the best locations to establish biodoversity 
collaborations: 
• legal framework and political will. As is the 
case with access to agricultural biodiversity, 
many countries have not yet fully addressed 
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the legislative and regulatory issues required 
for BAAs. Other countries may have sig-
nificant legislation on biodiversity that is so 
comprehensive and complicated that it be-
comes too cumbersome for BAAs. In other 
cases, problems may lie with IP protection. 
Countries that have not previously conclud-
ed BAAs often lack the basic administrative 
procedures, such as approvals for the export 
of DNA samples, required to fulfill such 
agreements. In these cases, the government’s 
political will to help orient and train their 
officials about bioprospecting is critical to 
the success of any international bioprospect-
ing initiative. 
• equal treatment for all companies. Although 
no national laws regulating access to biodi-
versity may exist in a particular country, it 
should view all potential commercial col-
laborators equally (these frequently include 
academics who are conducting research 
funded by a private commercial research 
interest), such that all commercially orient-
ed researchers collecting samples should be 
required to enter into a government-sanc-
tioned BAA that follows the guidelines and 
supports the objectives of the CBD. 
• strong scientific and conservation part-
ners. Appropriate scientific capabilities 
speed the process of narrowing the search 
for target organisms. As these collaboration 
partners receive training, they are able to 
provide more value-added services. 
• unique and protected habitats. A greater 
diversity of habitats translates to a greater 
diversity of genetic material, and, conse-
quently, increases the chances of discover-
ing novel and unique genetic material for a 
new product or application. Protected hab-
itats are important because they indicate 
that there are sufficient genetic resources 
to support a long-term biodiversity (or bio-
prospecting) collaboration.
Once a collaboration partner has been iden-
tified, the terms of the BAA must be decided. 
Highlighted below are key issues that influ-
ence the success of BAAs. This list has evolved 
significantly both through the implementation of 
BAAs (based on assessments and guidance from 
companies and biodiversity collaborators9) and 
through monitoring and adapting to changes 
within international conventions. The main is-
sues include: 
• legal rights to genetic resources. Countries 
that are able to efficiently assign and clearly 
define a company’s legal rights with respect 
to the use of environmental samples and 
associated genetic material make attractive 
potential collaboration partners. Assigning 
and defining these rights reduces the risk of 
future claims being made against any com-
mercial discoveries. 
• prior informed consent. Recognizing that 
land owners and managers have a stake in 
bioprospecting activities, companies should 
require that biodiversity collaborators se-
cure informed consent from landowners 
and managers prior to collecting samples. 
• rights to patent and commercialize. The 
rights to patent and commercialize are criti-
cal to the creation of benefits that can be 
shared among the parties to a BAA. The way 
benefits are to be distributed will be out-
lined in the agreement. Diversa, in its BAAs, 
maintains the rights to patent and commer-
cialize its inventions, including genes and 
gene products derived from samples.
• competition between biodiversity collabo-
rators. Many companies have proprietary 
technologies that are necessary to commer-
cialize their biodiversity-derived products. 
Companies do not want their biodiversity 
collaborators to use the proprietary tech-
nology transferred as part of the BAA to 
compete against them (the companies). 
Accordingly, strict and conservative in-
terpretations of confidentiality are critical 
ingredients for developing a productive 
relationship. 
• transfers to third parties. For some com-
panies, their greatest competitive advantage 
is proprietary technology, and it is critical 
that it not be shared with third parties. 
Technology transfer to a collaborator is for 
the benefit of the collaborator in the context 
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of its own capacity building. Companies 
should respect and protect the confiden-
tiality of their biodiversity collaborators’ 
proprietary knowledge and information. 
Further, terms should be included in their 
agreements that prevent companies from 
transferring samples to third parties without 
the written permission of the biodiversity 
collaborators. 
• exclusivity requirements. The terms of the 
BAA should not restrict biodiversity collab-
orators from cooperating with other com-
panies. The more biodiversity collaboration 
agreements that exist, the more viable is the 
biodiversity collaborator and the more re-
sources it has to preserve biodiversity in its 
country because of the added benefits and 
experience it receives from other industrial 
or commercial collaboration. However, 
many companies may resist collaborator in-
volvement with competitors with regard to 
specific projects, due to their own confiden-
tiality requirements or their need to secure 
a competitive advantage through access to a 
unique source of genetic material.
 
Countries also must evaluate the potentially 
collaborating corporations, nongovernmental 
organizations (NGOs), or academic institutions 
to judge their suitability as partners. Criteria for 
evaluation include
• low-impact sample collection. Biodiversity 
collaborators should understand that while 
biodiversity can be the raw material for com-
mercial products and the potential source 
of untold scientific discovery, biodiversity is 
also a precious, limited resource. Therefore 
all sample-collecting regimes should be 
adapted to minimize the impact on the en-
vironment in order to preserve biodiversity 
(for example, sample sizes and collection 
frequency should be kept to a minimum). 
• adherence to international conventions 
and best practices. Partners must dem-
onstrate an understanding of and adher-
ence to the principles of the CBD and the 
TRIPS Agreement. Partners with expe-
rience in BAAs may also have their own 
criteria based on international convention 
and practical experience.
• track record. Countries and collaborators 
should understand their commercial part-
ner’s experience with BAAs. BAAs have been 
and continue to be closely watched by the 
international community, and many compa-
nies have an established track record. If they 
do not, countries and collaborators should 
scrutinize, and if possible, compare to other 
agreements the proposed terms of benefit-
sharing arrangements, protocols for sample 
collection, and conditions related to trans-
fers to third parties. If partners have been 
criticized for past BAAs, countries should 
determine how they have changed their pol-
icies or their approach. What assurances are 
they willing to provide to ensure that those 
mistakes are not repeated?
3.	 BIodIveRSITy	ACCeSS	AgReemenTS
Once the parties have determined that they want 
to create a BAA, the challenge is to formulate a 
relationship that will provide access to a necessary 
stream of processed raw material (for example, 
novel genetic material) while ensuring the sus-
tainability of that resource and compensating the 
party granting access by sharing benefits. BAAs 
contain basic elements that are common to all 
standard contracts, but they also contain very 
specific information that changes from agreement 
to agreement. This section discusses the necessary 
elements for a BAA. 
3.1 Parties	to	an	agreement
The most basic element of the BAA is to deter-
mine the appropriate parties to the agreement. It 
is critical to identify who has the proper author-
ity to grant access to the particular biodiversity 
resource. In addition, it is important to identify 
all parties affected by access to the biodiversity re-
source, such as those people who live and work 
in proximity to it. Specifically, the parties need to 
identify the following:
• individuals or groups who legally control ac-
cess to the resource in question (Ownership 
rights and authority can be documented 
COSTANZA, CHRISTOFFERSEN, ANDERSON & SHORT
1500 | HANDBOOK OF BEST PRACTICES
through permits, and that documentation 
should be included as an appendix to a 
BAA.)
• authorities who are authorized to grant ac-
cess (the so-called competent authorities)
• individuals or groups who have been the 
“stewards” of the resource 
• individuals who have been tenants of the 
land on which the resource is located
• individuals or groups who are currently us-
ing the resource
• individuals or groups who want access to 
the resource for commercial development
• universities, NGOs, researchers, conserva-
tionists, and so on, who will use access for 
nontraditional purposes
The National Focal Point for Access and 
Benefit Sharing (ABS) is frequently a good starting 
point for clarifying issues of authority, jurisdiction, 
stewardship, and tenancy.10 As a practical matter, 
the company should request that the prospective 
biodiversity collaborator11 provide evidence that it 
has authority to enter into a BAA, collect samples 
from designated areas, and share in the benefits 
that may arise from such collaborative work.12
3.2 Duration	of	the	agreement
The period of time that the BAA is in effect should 
be indicated in the initial agreement. It is impor-
tant for this time horizon to be referenced in later 
sections regarding the future ownership and dispos-
al of genetic or other material obtained under the 
agreement, as well as the future benefits that may be 
derived from the commercialization of a biodiver-
sity-based product. It is advisable for the parties to:
• determine how long the access agreement 
will be in place
• indicate how parties may terminate the 
agreement
• determine whether the agreement can be 
renewed or negotiated and what the terms 
are for a possible renewal or renegotiation
3.3 Jurisdiction
Parties must agree on the legal framework within 
which the agreement will function. Doing so re-
quires that the companies determine:
• which country’s laws will take precedence 
in the contract
• to what degree international conventions 
will be incorporated into the contract
• what method of dispute resolution will be 
required in the event of disagreements (ar-
bitration versus litigation)
3.4  Contribution	of	each	party
The parties must agree not only on what they 
propose to contribute to the deal but also on how 
to value the contribution. For the creation of 
BAAs, firms will see biodiversity as raw material 
for a biodiversity-derived product, the realization 
of which will require their processing, manufac-
turing, and marketing to make the collaboration 
commercially viable. Countries contributing the 
biodiversity resource must consider the many 
values of the genetic resource when creating the 
BAA. A variety of benefit-sharing mechanisms, 
both financial and nonfinancial, can be used to 
compensate parties for their contributions to the 
venture. Valuation of the biological or genetic re-
source and equitable benefit sharing are ultimate-
ly the responsibility of the parties to the BAA and 
must be detailed in the BAA. 
As companies, research institutes, academic 
institutions, and government agencies cooperate 
on exploring biodiversity for commercial appli-
cations and products, they enter into agreements 
that govern access and also define a regime for 
sharing benefits. This requires the valuation of a 
genetic resource as an input into the development 
of the product. Significant effort in the form of, 
for example, processing, manufacturing, or mar-
keting required to transform the microbial bio-
diversity into a marketable product must also be 
considered. The market will determine the value 
of a biodiversity-derived product. Companies 
will know the commercialization costs and their 
target profit margin. For the company to see the 
project as economically viable, biodiversity ac-
cess royalties, collection fees, and other benefits 
to collaboration partners would have to be cov-
ered by market value of the product less commer-
cialization costs less target profit. The uniqueness 
of the biodiversity (that is, the fact that it has not 
previously been commoditized) will influence 
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the value placed on it by a company, with a high-
er degree of “uniqueness”13 being more highly 
valued.
In practice, as this is a relatively new mar-
ket in terms of the formation of such collabora-
tions and formal agreements, it may be difficult 
to convince companies to recognize the full value 
of the biodiversity resource and the contribution 
of the biodiversity collaborator to the satisfaction 
of the international environmental community. 
Companies and biodiversity collaborators must 
find a middle ground where the negotiated ben-
efits to the collaborator are not economically pro-
hibitive to product development but do provide 
incentives to the collaborator to participate in the 
BAA. As the market matures, biodiversity col-
laborators should be able to increase the value of 
their contribution as they increase their capacities 
through training and the transfer of technology 
that they receive from companies. Moreover, as 
companies become more accustomed to these 
collaborations, the companies are likely to be 
more open to increasing benefits to their collabo-
rators. Many BAAs have been abandoned due to 
ambitious demands for benefit-sharing terms that 
are economically unfeasible. Parties to the BAA, 
therefore, must carefully and collaboratively de-
termine the value of their contributions to the 
overall development and marketing of the prod-
uct as a percentage of the entire contribution. 
Finally, financial benefits are finite and may 
not be realized immediately. They also may re-
quire significant, long-term investment to be re-
alized. Fortunately, there are a number of non-
financial benefits potentially available that could 
encourage participation in a deal, as described 
below in the section on benefit sharing. 
3.5 Rights	and	responsibilities	of	each	party
In addition to each party’s contribution, the BAA 
should provide specific information about the ex-
pectations of action and conduct that the parties 
have for themselves and one another. 
3.5.1  Rights	
The BAA will generate many questions about IP 
rights. Typically, the collaborator will provide 
access to the resource, and depending upon its 
scientific capacity, collection samples and isolated 
strains. These samples or isolates are then further 
developed by the company. Between the stages of 
granting access and the commercial sale of a prod-
uct resulting from a BAA, there are intermediate 
stages, many of which create IP rights issues.
• use of samples. Parties should determine 
how samples collected under the BAA can 
be used by the parties. For instance, can 
the samples be distributed to third parties 
(such as research partners of either party)? 
If so, does doing so require written notifica-
tion from the other party, and what is the 
required time for a response?
• IP rights for inventions, samples, and de-
rivatives. Any IP rights resulting from the 
BAA must be fully explained and addressed 
within the BAA. Diversa, for example, 
maintains its right to own its inventions 
based on unique genetic material obtained 
under a BAA. It is important to note that 
this does not limit a biodiversity collabora-
tor’s right to benefits from the invention. 
This is negotiated under the benefit-shar-
ing section of the agreement. Diversa also 
maintains the ownership rights of the de-
rivatives that it makes from samples. The 
samples themselves remain the property of 
the biodiversity collaborator.
• publication of knowledge. Parties must de-
termine who will have the rights to publish 
novel information resulting from the BAA.
3.5.2 	 Responsibilities	
The parties must also determine their respective 
responsibilities. Examples of operational respon-
sibility include sample collection and processing, 
regular reporting, communications, and admin-
istrative filings. Below is an excerpt from a BAA 
which outlines the responsibilities of the parties: 
Collaborator will be responsible for the collec-
tion, processing and shipment to [the Company] of 
environmental samples from diverse habitats and/
or DNA samples isolated from such environmen-
tal samples using the [the Company’s] technology. 
Collaborator shall further be responsible for planning 
and execution of collection trips with and without the 
participation of [Company] personnel. Collaborator 
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will provide laboratory space for the collaboration 
activities. Environmental samples shall include, but 
not be limited to, soils, sediments, mire, earth, mi-
crobial mats and filaments, plants, ecto and endo 
symbiont microbial communities, endophytes, fungi, 
animal and/or insect excrement, marine and terres-
trial invertebrates, air and water. Collaborator will 
provide to [the Company] a minimum of [number] 
environmental samples per year.14 
3.6 Benefit	sharing
Once the parties have agreed upon the value of 
their contributions to the deal, they must discuss 
the sharing of benefits that encourage the sustain-
able use of the genetic resource. There are many 
options for sharing benefits, both financial and 
nonfinancial.15 Table 1 provides an extensive list 
of financial and nonfinancial benefit-sharing pos-
sibilities, and divides them into short-, medium-, 
and long-term categories. An appropriate, deal-
specific mixture of financial and nonfinancial 
benefits will enable a company to provide incen-
tives for biodiversity collaboration while working 
within international guidelines and remaining 
responsible to shareholders. 
3.6.1  Sharing	financial	benefits	
The short-term financial benefits listed in Table 1 
deal with up-front access payments, sample col-
lection fees, contribution to collaborator research 
budgets, and use-based contributions to funds set 
up to preserve biodiversity. In the medium term, 
financial benefits include milestone payments 
for the achievement of certain goals during col-
laboration and research funding. Longer-term 
benefits include a share in the profit from sales 
and increased opportunities to earn money for 
performing value-adding tasks in the production 
process.
Several observations can be made about the 
negotiation process for determining these ben-
efits. For markets with relatively small potential 
payouts, biodiversity collaborators may favor re-
ceiving sure payments for performance up front 
versus some portion of unknown future royal-
ties. Conversely, when there are many potential 
applications coupled with potentially large reve-
nues, biodiversity collaborators may be interested 
in a larger share of royalties at the expense of up-
front payments, hoping for a percentage of a larg-
er payout. In this case, biodiversity collaborators 
would have to weigh the importance of receiving 
money sooner versus the potentially larger payout 
of up to 15 to 20 years or more later.16
In many cases, the market potential of the 
collaboration will be obvious at the outset; in 
other cases it will not. Where the potential is not 
obvious, graduated royalties could be used, which 
change the percentage of proceeds from product 
sales according to such variables as the sales vol-
ume or end-product market segment. 
3.6.2 Sharing	nonfinancial	benefits	
There are many nonfinancial benefits at the par-
ties’ disposal. Many have noted that for access 
and benefit-sharing agreements for both mi-
crobial biodiversity and plant genetic resources, 
nonfinancial benefits may be more valuable to 
developing countries than financial benefits.17, 18 
Nonfinancial benefits can be shared in the short-, 
medium-, and long-term as well. Over the life of 
the collaboration, these benefits will accrue to the 
biodiversity collaborator on all levels (national, re-
gional, institutional, and individual). Professional 
development for individuals and capacity build-
ing and technology transfer at the country, re-
gional, and institutional levels will enable the col-
laborator to perform more value-added work. As 
a result, the biodiversity collaborator can generate 
additional revenues and access more upside po-
tential by contributing more to the development 
of products resulting from the BAA.
Short-term, nonfinancial benefits may in-
clude biodiversity collaborator access to facilities 
and proprietary databases that may otherwise 
be inaccessible. In the medium term, technical 
know-how, training in specific technologies, new 
equipment, and more reliable stocks of laborato-
ry supplies can enhance the biodiversity collabo-
rator’s scientific capacity. In addition, including 
biodiversity collaborators in planning and deci-
sion making increases their administrative capac-
ity for additional projects. Longer-term benefits, 
aside from the cascading effects of the above, 
may include ownership of IP rights and access 
to technologies and products that result from the 
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Table	1:	Short-,	medium-,	and	long-Term	Benefits:	nonfinancial	and	financial
Time	
frame     Benefit Type monetary Nonmonetary
Short-
term
access to corporate facilities and databases X
advance payments X
bioprospecting fees (up-front fees) X
payments per sample (sample fees) X
share in research budget or equipment X
fees to trust funds for conservation and sustainable 
use of biodiversity
X
research support for a project that is considered 
important or critical for the biodiversity collaborator
X X
publications that stem from the research activities 
of the biodiversity collaboration that is written by all 
parties to the agreement
X
joint development and pursuit of grant oppor-





acknowledgment in publications X
joint research and scientific capacity building X
administrative capacity building X
participation in planning and decision making X
protection of local existing applications of IP rights X
technology transfer (equipment, material donation, 
sharing of know-how)
X
training in bioprospecting, collection, and preparation 
of samples; biodiversity monitoring, socioeconomic 
monitoring, and/or nursery and agronomic tech-
niques (increased conservation capacity)
X
(Continued	on	next	page)
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Time	
frame     Benefit Type monetary Nonmonetary
Medium-
term
research support for a project that is considered 
important or critical for the biodiversity collaborator
X X
publications that stem from the research activities 
of the biodiversity collaboration that are written by 
all parties to the agreement
X
joint development and pursuit of grant 
opportunities to support and expand the biodiversity 
collaboration
X





co-ownership or sole ownership of IP rights X
development of alternative income generating 
schemes
X
free access to technology and products resulting 
from agreements
X
research support for a project that is considered 
important or critical for the biodiversity collaborator
X X
publications that stem from the research activities 
of the biodiversity collaboration that are written or 
approved by all parties to the agreement
X
joint development and pursuit of grant oppor-
tunities to support and expand the biodiversity 
collaboration
X
percentage royalties on net sales X
gross sales, license issue fees, and other revenues X
participation in value added X
Source: Adapted from Liebig and from Tides Center/Biodiversity Action Network.19
Table	1	(continued)
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collaboration. Across all three time frames, the 
parties could consider pursuing grant opportuni-
ties to expand their research activities, as well as 
working together to produce publications. The 
biodiversity collaborator might consider asking 
the company to provide research support for a 
project that is important to the biodiversity col-
laborator and is more easily implemented by in-
corporating the company’s technology.
Box 1 contains an excerpt from a benefit-
sharing section of a BAA and provides instanc-
es of both financial and nonfinancial benefits. 
While the actual percentages and dollar volumes 
have been removed (as they provide no useful in-
sight without the details of the entire deal), this 
example illustrates a very specific royalty payment 
scenario in which sources of income have been 
separated and shared differentially. The agree-
ment envisions revenue from both direct sales of 
the product by the company and from licensing 
to third parties. Proceeds from direct sales are 
shared on a graduated basis. The biodiversity col-
laborator receives a percentage of net direct sales 
up to a certain dollar limit. Should net direct sales 
exceed that amount the biodiversity collaborator 
will receive additional income. As an example, as-
sume the net direct sales of US$150 million. If the 
agreement held that the biodiversity collaborator 
receives 0.5% of the first US$75 million in net 
direct sales, and 1.0% of net direct sales exceed-
ing US$75 million, the biodiversity collaborator 
would receive US$1.125 million. For revenues 
derived from licensing, the agreement provides a 
similar graduated benefit-sharing mechanism. 
The agreement presented in Box 1 has a roy-
alty stacking provision. Royalty stacking occurs 
when there are multiple patents that affect the 
final product. It is often the case that a number 
of different patented items have been licensed for 
the development of a new product. The company 
developing the product may have to pay for the 
use of each of these patents, adding to the cost 
of commercialization. When multiple patents are 
held by third parties, the royalty structure may 
make a deal financially unattractive.20 When one 
company holds multiple patents involved in the 
process, determining final royalty allocation is 
simplified. For the purposes of this discussion, 
each patent owner’s rights to the product should 
be understood and considered in the business 
decision to proceed with the BAA. (For a more-
detailed discussion on royalty stacking, see the 
World Intellectual Property Organization’s Web 
site.21) 
In addition to royalties, which are based on 
the overall success of product sales and licensing 
efforts on the company’s part, the biodiversity 
collaborator also receives milestone payments. 
These payments are performance-based pay-
ments rewarding the biodiversity collaborator 
for competently executing its responsibilities. 
The milestone payment is pro-rated to the level 
of collaborator performance. In the example in 
Box 1, the maximum amount is established as a 
percentage of the annual funding that the biodi-
versity collaborator receives from the company 
and can be based on a range reflecting the de-
gree of success or progress achieved by the biodi-
versity collaborator. Alternatively, the milestone 
can be based on the completion of stages toward 
product development. One of the drawbacks 
associated with this latter approach is that it is 
frequently predicated on the company’s success 
and leaves the biodiversity collaborator with lit-
tle ability to influence the amount of payment 
received. Hence the former option is sometimes 
considered the preferred approach. 
The excerpt in Box 1 also provides two ex-
amples of nonmonetary benefits. These non-
monetary benefits address technology transfer 
and on-site training (both at the company’s and 
the biodiversity collaborator’s laboratories). In 
this case, the company is training the collabora-
tor in both advanced scientific methods and in 
the use of its proprietary technology. In addi-
tion, the company encouraged the collaborator 
to send employees to the company for training. 
This not only improves the scientific capacity of 
the employees, but also gives the employees ac-
cess to professional resources that may not be 
available in their own laboratories. The training 
that takes place in the biodiversity collaborator’s 
laboratory is critical. Often collaborator labora-
tory infrastructure requires updating, and lab 
protocols need to be changed, with the guidance 
of the company, to support different equipment 
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Box	1:	Typical	Benefit-Sharing	Section	in	a	BAA
1.	 Royalties
 For each calendar year during the term of this Agreement, The Company shall pay to 
Collaborator a royalty based on Product(s) sold by The Company, its Affiliates and/or licensees 
as follows:











payments	on	sales	of	Product(s)	by	such	 licensee,	 then	The	Company	shall	 further	pay	
to	Collaborator	a	royalty	of	E%	of	all	 license	fees	actually	 received	by	The	Company	 in	
consideration	of	such	a	license,	 including,	but	not	limited	to,	 license	issue	fees,	annual	
maintenance	fees	and	sublicense	revenue.
No royalties are due on products made available to third parties for testing only. 
All royalties are subject to a royalty stacking provision and a pro rata share of products made 
using the company’s proprietary technology. 
2.	 milestones
Further, The Company shall provide to Collaborator, on an annual basis, a list of goals that shall be 
directly related to Collaborator’s work under this Agreement. Such goals may include, but not be 
limited to, items such as the following:
(i) 100% complete environmental/isolate sample data sheets submitted for all environmental 
samples received by The Company within five (5) business days of receipt of the sample 
each calendar year;
(ii) Providing DNA for each sample when requested (for soil samples ensuring that both DNA 
and soil are sent for each sample);
(iii) 100% compliance with The Company protocols for DNA isolation;
(iv)  100% compliance with shipping protocols;
(v)  Fulfilling specific sample requests according to sampling capabilities of Collaborator;
(vi)  Achieved maximum coverage of biotopes or habitats; and 
(vii) Responds to requests in a timely and professional manner.
In the event that Collaborator achieves all of such goals, then The Company shall pay to Collaborator 
a milestone payment in an amount of Z percent (Z%) of Collaborator’s annual funding hereunder. 
In the event that only a portion of such goals are achieved, then The Company will determine 
what portion of the milestone shall be paid based upon percentage of the milestones completed 
and the relative value of the completed milestones.
3. The Company shall also provide Collaborator with training in technology for the molecular 
phylogenetic analysis of different habitats, including the following techniques (“Technology”): 
a) techniques for nucleic acid extraction from environmental samples; b) techniques for 
generating gene libraries; c) techniques for PCR cloning of genes directly from environmental 
samples; and d) information technology for DNA analysis.
4. Additionally, Collaborator may designate employees, at its sole discretion and expense, to visit The 
Company’s facilities for purposes of training in the technology for an equivalent of one person for 
one month’s time (for example, two people for two weeks, four people for one week, etc.).
Source: Excerpted and generalized from a redacted Diversa BAA that was submitted by 
the University of Hawaii to the Office of Information Practices in the State of Hawaii. 
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and supplies. It is also not uncommon for the 
biodiversity collaborator to improve protocols 
for the company and provide training and edu-
cation in the opposite direction. This further en-
hances the biodiversity collaborator’s probability 
for increasing its share of the benefits. While a 
superb example of a highly desirable and valu-
able nonmonetary benefit, it is not often avail-




The above guidance is meant to provide a practi-
cal framework highlighting the major issues for 
consideration when constructing a BAA. It has 
been distilled from more than a decade of experi-
ences of companies and biodiversity collaborators. 
However, no discussion of BAAs could be com-
plete without a cautionary note on the business 
and political circumstances under which the BAA 
will be created and implemented. These factors 
are as important as any listed above, and failure 
to adequately deal with them could prove fatal for 
the BAA. They can also add substantially to the 
costs of creating a BAA as they require significant 
time, effort, and resources to resolve. A brief dis-
cussion of these issues is presented below.22 
4.1 Valuation	versus	negotiation
Given that there is no established market for bio-
diversity resources or databases with details of 
other BAAs, valuation of the biodiversity resource 
will ultimately come down to discussions between 
the biodiversity collaborator and company. As 
with all negotiations, parties are well advised to 
understand the motivations and interests of their 
negotiation partners. Biodiversity collaborators 
and companies will need to have the overarching 
goal of making cooperation work, and will have 
to be flexible enough to incentivize their partners 
(and to respond to any incentives partners offer) 
fairly, in the context of the agreement. 
From the collaborator’s point of view, the 
best knowledge to have when negotiating for 
monetary benefits would be the level of profit 
that the company expects. In practice, this figure 
would be very difficult for the collaborator to ob-
tain. Companies will be reluctant to share pro-
jections for many reasons, not the least of which 
is their desire to maximize profit. Even the best 
projections of future profit are just that, projec-
tions, and subject to varying degrees of risk, only 
a portion of which can be mitigated. Moreover, a 
corporate proclamation of an attractive potential 
profit will provide incentive for other companies 
to compete, possibly reducing the value of their 
future profit. Regardless of the reasoning, col-
laborators are unlikely to get an accurate picture 
of the expected profits from the deal. 
Companies, too, would do well to study the 
terms of any previous BAAs available, especially 
those concluded with the intended biodiversity 
collaborator. Information about which non-
monetary benefits a collaborator would value 
would enhance the company’s position and re-
lieve some of the pressure to negotiate away pro-
jected profit.
Ultimately, the parties will either identify 
the right mixture of monetary and nonmonetary 
benefits to be distributed in the BAA, or lose pa-
tience with or confidence in their partners and 
walk away from the negotiating table without an 
agreement. 
4.2 Politics	and	perception
Although the mechanics and structure of negotiat-
ing BAAs have become somewhat clearer over the 
past decade, not much has been clarified when it 
comes to the difficulties in politics and perception 
that companies face when attempting to create 
BAAs with biodiversity collaborators. Although 
biodiversity permit systems may be in place, the 
proposal of a BAA almost always creates contro-
versy. Once a company states that it would like to 
create a BAA and establish a new standard for se-
curing genetic resources from around the world, 
the most common response is for the governing 
authority to move extremely slowly, fearing that 
it will be accused of authorizing an inequitable 
agreement that undervalues their biodiversity and 
does not support their country’s development. 
This problem can be further complicated by 
watchdog groups that consider the private sector 
to be inherently corrupt. No matter what benefits 
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the company offers, such groups will criticize the 
deal as inequitable to the biodiversity collabora-
tor. Ironically, this reaction reflects negatively 
on the very companies that are taking the lead 
in supporting the CBD. Unfortunately, those 
companies wishing to construct BAAs based on 
the principles of international conventions are 
seen in the same light as those companies that 
continue their research without any benefit-shar-
ing arrangement and without permits. All of this 
has created an atmosphere in which life science 
corporations have been given every incentive to 
avoid engaging in bioprospecting and divulging 
or sharing any information about such endeav-
ors. This actually makes it more important for 
biodiversity collaborators to seek out companies 
that are willing to take the step towards build-
ing a new approach to discovering products from 
nature, an approach that respects the economic 
interests and property rights of the nation provid-
ing the biodiversity (genetic resources).
Another complicating factor is that par-
ties to the CBD have been slow to implement 
legal frameworks that facilitate legal access to 
their biodiversity and provide guidance on ac-
cepted or preferred benefit-sharing arrangements. 
Furthermore, the measures taken to date have 
been diverse in terms of their scope and their clar-
ity. Compared to those countries that have cre-
ated a simple, efficient approach, countries that 
have chosen a more cumbersome, comprehensive 
approach have generally had little participation 
from bioprospectors. Nonetheless, many coun-
tries remain without any legal frameworks to gov-
ern bioprospecting, allowing some companies to 
engage in bioprospecting without securing legal 
access to collect environmental samples and with-
out providing associated equitable benefits. 
The case of politics and perception is simi-
lar to that of benefit sharing in that both parties 
must demonstrate a willingness to make the BAA 
and successive agreements work. This requires 
each party to set aside short-term self-interest.
4.3 The	shortcomings	of	business	as	usual
In addition to the practical challenges of nego-
tiation and politics, there are several issues with 
current research sampling practices that will 
continue to grow in importance as more BAAs 
are concluded and the market for products de-
veloped as a result of the BAAs develops further. 
Often, samples collected for research purposes 
will be “contaminated” with types of biodiver-
sity other than the target type. This unintended 
transfer of genetic material may constitute giv-
ing away potentially valuable (with respect to 
its potential for commercialization) biodiver-
sity. Another issue that will become increasingly 
contentious is that limiting access to biodiver-
sity may have a detrimental effect on scientific 
research. While these issues may not surface in 
a BAA between a company and its biodiversity 
collaborator in the near term, they will certainly 
have to be addressed in the longer term for the 
sake of scientific advancement and the conserva-
tion of global biodiversity.
4.4 Addressing	the	pitfalls
Many of the problems identified above could 
be mitigated or eliminated by improving the 
information available to parties to the BAA as 
well as to the larger pool of stakeholders in-
terested in the outcomes of these agreements. 
Parties to the BAA want to know that they are 
being fairly treated. Collaboration partners 
want to understand the fair value of access and 
local value-added processing. Companies need 
to understand the amount and composition 
of compensation required to create the BAA. 
Companies can face higher commercialization 
costs in the absence of this information. The rel-
ative lack of standard information on BAAs can 
engender feelings of mistrust not only among 
the parties to the BAAs but also in stakeholders 
outside the agreement. Standards for creating 
BAAs, based on the experiences of many bio-
diversity collaborators and companies, would 
give the parties to the agreement a reliable and 
acceptable framework to aid decision making, 
negotiations, and communications about the 
agreements. These standards could even extend 
beyond the terms of the BAA to include model 
legislation and regulations to provide consis-
tency to the legal and administrative environ-
ments in which BAAs will be created. Standards 
for BAAs could address the longer-term issues 
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as well by explicitly discussing the rights and re-
sponsibilities of researchers and providing guid-
ance on accessing IP-protected biodiversity for 
noncommercial purposes. 
Participation by NGOs may be one way to 
address these issues. The main benefit of NGO 
involvement would be credibility. NGOs op-
erating independently as neutral third par-
ties can build trust among partners on both 
sides of the BAA. This neutrality could satisfy 
stakeholders outside the BAA, concerned with 
broader issues of biodiversity conservation and 
continued access to biodiversity for scientific 
research. NGOs would be able to leverage the 
expertise and experience of governments, re-
search organizations, other NGOs, and com-
panies globally to provide standards that are 
broadly applicable. 
An example of an NGO making progress in 
this direction is the E. O. Wilson Biodiversity 
Foundation. Through the creation of its BioTrust, 
envisioned and initiated by one of the authors, Jay 
Short, the foundation seeks to ensure fair terms 
between countries and companies for access to 
biodiversity while preserving the biodiversity re-
sources. BioTrust consortium establishes strategic 
relationships predicated on the notion that all 
countries (especially developing counties) con-
tain wealth in the form of biodiversity and that 
they should be compensated for its exploitation. 
Saddled with the burden of long-term steward-
ship, most countries are currently without a finan-
cial incentive to continue. 
By acting as an honest broker using a master 
agreement that binds the interested parties to a 
quid pro quo relationship, BioTrust ensures the 
fairness sought by the parties to the access agree-
ment and the continuation of biodiversity con-
servation. Under this model, companies, as well 
as academic and research institutions, can sample 
and analyze genes, small molecules, and proteins, 
but a portion of revenues produced from any 
resulting products flows back to the country of 
origin for purposes of conservation. BioTrust par-
ticipants agree to participate in capacity building 
through technology access and/or education for 
source nations.23
5.	 ConCluSIonS
The experience of companies and countries in 
creating BAAs to share access to microbial bio-
diversity offers lessons that can be adapted for 
use with agrobiodiversity. These lessons will help 
interested parties bridge the gap between broad 
international guidance on the commercial use of 
biodiversity and the practicalities of deal making. 
Just as important as any technical aspect of deal 
making is the commitment of both parties to a 
sustainable and rational use of biodiversity in a 
way that encourages commercial development 
and protects the unique resource. Both parties 
need to conduct the due diligence on each other 
to foster the trust required for cooperation. 
Companies should devise a set of operating 
principles based on the CBD and provide part-
ners with real incentives for cooperation, which 
should include both equitable monetary and 
nonmonetary benefits. Countries must develop, 
clarify, or streamline administrative and permit 
procedures to encourage the sustainable, com-
mercial use of biodiversity. They must also have 
the resolve to operate in a principled manner, 
consistent with international consensus (CBD). 
Both parties should be willing to engage in open 
debate with domestic and international critics 
to demonstrate the value of making progress 
in this field, despite having limited knowledge 
about the market potential of biodiversity-de-
rived products. 
There are a number of practical challenges to 
concluding BAAs. Many of these challenges could 
be addressed by improving information available 
to all stakeholders. NGOs could play a critical 
role in facilitating fair access to biodiversity for 
commercialization while preserving scientific ac-
cess to biodiversity for research purposes. ■
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ABSTRACT
The ICBG (International Cooperative Biodiversity 
Groups) program, through which institutions located 
in biotechnology-rich countries in the North collabo-
rate with institutions located in the biodiversity-rich 
countries in the South (with the support of an indus-
trial partner) to discover and develop natural-product 
drugs, is an experiment in the design of bioprospect-
ing efforts. This chapter describes the general aims and 
organization of the ICBGs and describes in great detail 
the agreements that governed the University of Illinois 
at Chicago-Vietnam-Laos ICBG. The chapter includes 
material concerning IP (intellectual property) rights is-
sues, informed consent, various forms of benefit sharing 
(including the sharing of short- and long-term, namely, 
royalty, benefits), capacity building, and community 
reciprocity. It offers a model for other such agreements.
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One model of a biodiversity prospecting 
effort is a program called ICBG (International 
Cooperative Biodiversity Groups). Based in the 
United States, ICBG falls under the auspices of the 
Fogarty International Center (FIC) of the United 
States National Institutes of Health (NIH). It 
also collaborates with the National Science 
Foundation (NSF) and the U.S. Department of 
Agriculture (USDA).3 A five-year cycle program, 
it went into operation in 1993 in response to a 
request for applications issued by FIC in 1992.4 
The ICBG second cycle began on 1 October, 
1998, as a result of new and recompeting propos-
als in response to a request for applications issued 
by FIC in 1997.5 On 17 October 2002, a request 
for applications for a 2003–2008 ICBG cycle rec-
ompetition was again issued.6
2.  The	ICBg	pRogRAm
International Cooperative Biodiversity Groups, 
or ICBGs, address the interdependent issues of 
drug discovery, biodiversity conservation, and 
sustainable economic growth. They are founded 
in the belief that efforts to examine the medicinal 
CHAPTER 16.5
1.  InTRoduCTIon
The term bioprospecting or biodiversity prospecting 
has been defined as “the exploration of biodiversity 
for commercially valuable genetic and biochemical 
resources,”1 or “the search for wild species, genes, and 
their products with actual or potential use to hu-
mans,”2 or the search for commercially valuable 
biochemical and genetic resources in plants, ani-
mals, and microorganisms.
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potential of the earth’s plants, animals, and mi-
croorganisms are urgently needed, and that con-
tinuing habitat destruction and ever-diminishing 
biodiversity will make it increasingly difficult to 
do so in the future. If bioprospecting directly 
benefits local communities and source country 
organizations, ICBGs believe that they will have 
strong incentives to preserve and support sustain-
able use of the environment.7
As a result of the 1992 and 1997 ICBG 
award competitions, eight ICBGs were estab-
lished.8 Each ICBG has as its administrative base 
a U.S.-based institution that is paired with other 
organizations (governmental and nongovernmen-
tal, including industrial/pharmaceutical) that are 
located both inside and outside the United States; 
one of these organizations is a host institution in 
one or more developing, biodiversity-rich coun-
tries, usually in the South. The personnel, organi-
zational structure, specific aims, and methods of 




ICBG proposals must address access and ben-
efit-sharing (ABS).10 ABS is based on contractual 
agreements that take into account: 
1. The benefits that may be derived from 
bioprospecting. These may include royal-
ties from the sales of drugs developed from 
bioprospecting, advance payments (ac-
cess fees or payments for samples when a 
commercial partner is involved), capacity 
building (equipment, training, infrastruc-
ture), and focus on the priority areas in the 
country(ies) of the host institution(s), such 
as priority diseases or collections and iden-
tification in geographic areas or biological 
groups that are high priorities for conserva-
tion needs.
2. The recipients of the benefits. These may 
include individuals and communities, 
government institutions (including na-
tional parks, forest services, national her-
baria), and nongovernmental institutions 
(including universities, conservation and 
development service organizations, and 
private companies). Whether or not useful 
ethnomedical knowledge comes from the 
bioprospecting efforts, communities must 
receive both short- and long-term benefits 
for collaborating in the research process. 
3. The negotiation process. Negotiators 
should consider the following elements:
• Informed consent, from informal disclo-
sure of the potential uses of their knowl-
edge offered by individuals or commu-
nities, to formal documentation in the 
form of project descriptions and related 
materials
• Consensus building among communities 
and government and nongovernmental 
organizations
• Independent legal advice for all consor-
tium members
4. The structure of the agreement between 
the recipients. ICBG models include the 
one-contract model, the contract wheel, the 
dual-contract model, and the wheel-tri-
angle model.11 All of these agreements in-
clude research and benefit-sharing terms, 
intellectual property (IP) rights, material 
transfer, confidentiality, and other terms. 
Often, specific agreements may address 
components of the above, including ma-
terial transfer agreements (MTAs), know-




The members of the UIC ICBG Consortium 
were the University of Illinois at Chicago (UIC); 
the Vietnamese National Center for Science and 
Technology (NCST), based in Hanoi, Vietnam; 
Cuc Phuong National Park (CPNP), in Ninh 
Binh, Vietnam; the Traditional Medicine Research 
Center (TMRC), based in Vientiane, Laos, (for-
merly named the Research Institute for Medicinal 
Plants [RIMP]); and Glaxo Wellcome Research 
and Development (GW), based in Greenford, 
U.K. (today known as GlaxoSmithKline [GSK]).
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The grant award (made on 29 September 
1998) represented a cooperative agreement 
between the U.S. Government and UIC. The 
letter of award (Terms and Conditions of Award) 
indicated that the U.S. government agreed to fund 
the work (via the FIC) of the UIC-based ICBG, 
so long as certain criteria were met: the principles 
of ABS were fulfilled, the progress of the project 
was satisfactory, and funds were available.12
The general background of the ICBG (the 
events that led to the writing of the proposal, the 
selection of partner institutions, and the submis-
sion of a Letter of Intent to submit a proposal to 
the FIC), as well it’s the structure of the ICBG 
(personnel, organization, research plan, and poli-
cies toward IP rights and informed consent) have 
been described in an earlier paper.13 
4.2	 The	aims	of	the	consortium
The specific aims of the UIC-Vietnam-Laos 
ICBG were:
• The discovery of biopharmaceuticals in the 
plants of Vietnam and Laos and the devel-
opment of drugs to treat cancer, AIDS, ma-
laria, tuberculosis, pain, and diseases that 
affect the central nervous system (particu-
larly Alzheimer’s disease)
• Creating a biodiversity inventory and con-
serving biodiversity, with a specific focus on 
plants of Cuc Phuong National Park and 
medicinal plants of Laos
• Aiding economic development in cooperat-
ing communities
• Capacity building among the collaborating 
institutions in the host countries
4.3	 Negotiations	among	consortium	members
After the Letter of Intent was submitted to the 
FIC on 3 October 1997, discussions were held be-
tween the principal investigator and the director 
of UIC’s IPO (Intellectual Property Office). An 
important element of discussions was the prin-
ciple stated in the so-called Manila Accord (at the 
1990 Regional Workshop for the Chemistry of 
Natural Products in Southeast Asia), which states 
that at least 51% of the income generated from 
the commercialization of a drug derived from a 
plant collected in a particular country should go 
to the institution located in the plant’s country of 
origin. The eventual outcome of these discussions 
was a Memorandum of Agreement (MOA) that 
bound the five members of the UIC ICBG. The 
ICBG proposal and the draft MOA (which had 
been accepted by member institutions but not 
signed) were sent to the FIC on 20 January 1998.
The new ICBG, Studies on Biodiversity 
of Vietnam and Laos: The UIC-based ICBG 
Program, was created on 1 October 1998. Its bio-
prospecting program was not fully functional un-
til nine months later, when the MOA was signed 
by all parties on 28 June 1999. In the negotiation 
process, the principal investigator of this ICBG 
advised NCST, CPNP, and TMRC to consult at-
torneys regarding the draft MOA.20
4.4 	 The	Memorandum	of	Agreement
The MOA consists of 15 pages of text plus 5 
Addenda (which total 5 pages). Addenda I and II 
are included at the end of this chapter (Figures 1 
and 2) and are further discussed below. It should 
be noted that the natural product program at 
GSK was phased out in 2000 as a result of the 
merging of GW and Smith Kline Beecham, so 
GW/GSK withdrew from the consortium in 
November of 2001.
4.4.1		 The	MOA	structure
The University of Illinois at Chicago, which is 
bound in a contractual agreement with the U.S. 
government, is the administrative seat of the con-
sortium. The transfer of funds (grants, not IP 
rights or benefit-sharing agreements) from UIC 
to the other member institutions (except Glaxo) 
was outlined in separate subcontract agreements. 
Glaxo was not a recipient of ICBG funds and did 
not provide any funding to the consortium; it did, 
however, agree to contribute to capacity building 
of scientists and institutions in Vietnam and Laos.
4.4.2 	 Clauses	of	the	MOA
Part I of the MOA defines the consortium 
members’ Scope of Cooperation. Part II defines 
the General Areas of Cooperation of the 
consortium members, including the exchange 
of faculty members or scientific personnel, joint 
research activities, joint participation in seminars 
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and scientific meetings, the exchange of academic 
and research materials and other information, 
and the participation in special short-term 
academic programs. Part III describes the details 
of the joint research activities and consists of five 
sections (III-A/Precedents, III-B/Purpose, III-
C/Objectives, III-D/Responsibilities, and III-E/
Finance and Services).
• III-A/Precedents contains clauses that de-
scribe the considerations that led to the 
cooperation, such as the previous track 
record of collaboration between UIC and 
the member organizations, the proposal 
writing, the funding award, the key per-
sonnel and organizational structure/com-
ponent roles, and a reference to the terms 
and conditions of the ICBG award.
• III-B/Purpose defines the purpose of the 
cooperation: to discover and develop new 
medicines, to conserve and sustainably use 
the flora of the Cuc Phuong National Park 
in Vietnam and the medicinal flora of Laos, 
and to increase development in both coop-
erating communities and in the ICBG host 
institutions.
• III-C/Objectives spells out the specific 
aims of the consortium, including its ap-
proaches to plant selection, disease targets, 
the inventory of the seed plants of CPNP, 
biomass production of biologically active 
and promising species, capacity build-
ing, conservation education, economic 
improvement of local communities, in 
the CPNP area in Vietnam, and medici-
nal-plant inventory and databasing (and 
community reciprocity) in Laos, as well as 
human-resource development and infra-
structure strengthening of the ICBG host 
institutions in Vietnam and Laos.
• III-D/Responsibilities spells out the respon-
sibilities of each member organization and 
their joint responsibilities.
- III-D-1 defines the responsibilities of 
UIC (23 clauses).
- III-D-2 defines the responsibilities 
of NCST, IBT, ICH and IEBR (14 
clauses).
- III-D-3 defines the responsibilities of 
CPNP (12 clauses).
- III-D-4 defines the responsibilities of 
RIMP/TMRC (11 clauses).
- III-D-5 defines the responsibilities of 
Glaxo/GW (ten clauses).
- III-D-6 defines the joint responsibili-
ties of the member institutions and the 
industrial partner (eight clauses). It in-
cludes the time period the MOA is in 
force, conditions for withdrawal of any 
of the member organizations, amount of 
samples at initial collection for screen-
ing and recollection for isolation and 
structure determination, conditions for 
exchange of personnel as part of capaci-
ty building, the requirements for techni-
cal reports, how the materials and data 
may be used in the event the agreement 
is terminated, the limitations on the col-
laborative use of genetic materials, re-
quirements for acknowledging the grant 
in publications, and the requirement 
that international arbitration must be 
sought in the event of disputes.
• III-E specifies the source of fund-
ing as the FIC/NIH (ICBG Grant 
1UO1-TW01015-01).
Part IV defines the period of validity of the 
MOA; the conditions for termination, extension, 
and amendment of the MOA; and the number 
of copies of the MOA that must be signed by 
members of the consortium.
The signature page states that the five ad-
denda to the text of the MOA will become bind-
ing upon the signing of the legal representatives 
whose names are affixed therein. These include 
the chancellor and two representatives of the 
board of trustees (for UIC), the director of the 
Institute of Biotechnology and an ICBG-NCST 
liaison (for NCST, representing IBT, ICH, and 
IEBR), director and vice director of Cuc Phuong 
National Park, director and deputy director of 
TMRC, and director for scientific research of 
GW.
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• Addendum I (Figure 1) describes a long-term 
benefit-sharing scheme that will go into ef-
fect in the event that discovery of a biophar-
maceutical is made by UIC (in cooperation 
with ICH) and that Glaxo develops and 
commercializes the drug. In this scheme, 
the royalty stream is distributed among the 
organization members of the Vietnam-Laos 
ICBG (excluding Glaxo, which waived its 
share of any royalties) and the communities 
in the ICBG host countries.
• Addendum II (Figure 2) presents a long-
term benefit-sharing scheme to go into 
effect in the event that Glaxo discovers, 
develops, and commercializes the drug. 
As in Addendum I, in this second scheme, 
the royalties are distributed among the 
member organizations (excluding Glaxo) 
and the communities in the ICBG host 
countries.
• Addendum III grants rights to GW in 
the event of the licensing of discoveries 
made at UIC-ICH under the framework 
of the ICBG and GW’s rights of first 
refusal.
• Addendum IV defines the milestone pay-
ments that GW will make in the event a 
drug is discovered at UIC. The amount of 
payment is determined by the following 
variables: the site of the screen (UIC ver-
sus GW), the selection of compound for 
clinical trial, entry to Phase II and Phase III 
clinical trials, and approval of NDA (New 
Drug Application).
• Addendum V defines milestone and roy-
alty payments for any drug developed and 
commercialized by GW. The payments are 
determined by the patent rights on, and 
the chemical structure of, the GW develop-
ment compound, as well as by the target 
activity (in other words, whether or not the 
target is one of those in which ICBG is in-
terested). Milestone and royalty payments 
will be made on new drugs that are deriva-
tives of natural compounds discovered in 
collected plants, as well as on the natural 
compounds themselves.
4.5.	 IP	rights	issues
In the event of a relevant UIC discovery, 
the IPO of UIC-PCRPS will determine 
the ownership of any resulting IP with the 
assistance of all members of the Group. The 
named inventors may consist of individuals 
from any or all of the consortium members. 
The question of ownership shall be determined 
in accordance with the applicable laws of the 
country in which the invention or discovery is 
made. With the assistance of all members of the 
consortium, the UIC IPO will obtain patent 
protection for the invention or discovery and/
or seek such other IP protection, as UIC deems 
appropriate. UIC IPO will be responsible for 
the management and licensing of the invention 
or discovery in accordance with the terms of 
the agreement. 
In the event that an invention or discovery 
is made at GW based on plants that were col-
lected or acquired within the ICBG framework, 
GW will determine the ownership of any result-
ing intellectual property with the assistance of all 
members of the consortium. The named inven-
tors may consist of individuals from any or all of 
the consortium members. The question of own-
ership shall be determined in accordance with 
the applicable law of the country in which any 
invention or discovery is made. GW will obtain 
patent protection for such invention or discov-
ery and/or seek such other intellectual property 
protection, as GW deems appropriate with the 
assistance of all members of the Group. GW will 
be responsible for the management and licensing 
of such protected inventions. The parties further 
agree that they will make available all relevant 
information to GW (including the country of 
origin of the sample and its taxonomic identity, 
where appropriate) so that GW will be able to 
register IP rights.
GW will have the rights to file for patent pro-
tection for a discovery it makes that is based on 
plant samples or extracts received by GW under 
the framework of the ICBG, but it will consult 
with the consortium in determining co-inventor-
ship of the discovery. GW also agrees to notify 
the consortium in the event a decision is made to 
proceed with the development of a compound or 
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compounds derived from plants supplied by the 
ICBG.21
4.6		 Informed	consent
There are two provisions regarding informed 
consent in the Vietnam-Laos ICBG agreement: 
(1) informed consent in the case of collection and 
use of plant/genetic materials and (2) informed 
consent of individuals and their communities 
regarding the traditional medicinal use or uses 
of a plant. 
Thus, in Vietnam, “informed consent (collect-
ing permits) of the Government of Vietnam, the own-
er of the samples (genetic materials) and derivatives 
thereof, will be secured before the implementation of 
the work proposed as described in the ICBG propos-
al,” and ICBG through IBT, IEBR, and CPNP 
“will liaison with the Government of Vietnam in 
matters related to permit for the collection and ex-
port of plant samples or their extracts for use in the 
ICBG project.” In Laos, TMRC/RIMP will collect 
plant samples from various sites in Laos “through 
prior informed consent of the Government of Lao 
PDR, the owner of the samples (genetic materials) 
and derivatives thereof.” Prior informed consent 
(collecting permits) will be secured before the 
implementation of the work. The governments of 
Vietnam and Laos are acknowledged as the own-
ers of genetic materials and their derivatives in 
their respective countries.
In Vietnam, ICBG investigators “will seek the 
informed consent of individuals and/or communi-
ties for the recording and use of data on the medici-
nal and other uses of the plants in the Cuc Phuong 
National Park, for the intended study as described in 
the ICBG proposal.” In Laos, ICBG investigators 
“will seek the prior informed consent of individuals 
and/or the communities for the recording and use 
of data on the medicinal and other uses of plants 
of Laos, for the intended study as described in the 
ICBG proposal.”
4.7 Royalty	distribution
The full scheme of royalty distribution in 
Addenda I and II of the MOA (Figures 1 and 
2) has been presented in an earlier paper.14 
At the time of ABS negotiations, UIC chan-
neled the net royalty stream (after deduction of 
out-of-pocket costs) received from an industrial 
partner or licensee into two equal portions. The 
first 50% (referred to as the “common fund”) 
is to be distributed to the collaborating institu-
tions, the inventors, and the UIC administra-
tion, while the other 50% is to flow back to 
communities in the country of origin of the 
genetic material of the commercialized prod-
uct, through a trust fund.
The distribution of the first 50% share may 
happen in two different ways. In the first scenario, 
UIC investigators discover a drug, and a pharma-
ceutical company develops and commercializes 
the compound. In the second scenario, a drug is 
discovered, characterized, developed, and com-
mercialized by a pharmaceutical company that is 
an ICBG industrial partner (in other words, UIC 
inventors do not hold IP rights).
In the first instance (UIC inventors hold 
IP rights) the common fund is to be distributed 
as follows: (1) the inventors will receive a 40% 
share of the 50% portion (equal to 20% of to-
tal net royalty), as an incentive for future inven-
tions; (2) the collaborating institutions (PCRPS 
and counterpart institutions) will receive a 20% 
share of the 50% portion (equal to 10% of total 
net royalty) for their research contributions; and 
(3) the UIC administration will receive a 40% 
share of the 50% portion (equal to 20% of to-
tal net royalty) for their administration and legal 
contributions.
In the second scenario (UIC inventors do 
not hold IPR), the common fund is to be dis-
tributed as follows: (1) the collaborating institu-
tions will receive a 40% share of the 50% por-
tion (equal to 20% of the total net royalty); (2) 
UIC-PCRPS will receive a 20% share of the 
50% common fund (equal to 10% of the total 
net royalty) for its research contribution; and 3) 
the UIC administration will receive a 40% share 
of the 50% common fund (equal to 20% of the 
total net royalty). 
The full details of the UIC-based Vietnam-
Laos ICBG benefit-sharing scheme are spelled 
out in a 2002 paper.15 In November 2002, fur-
ther discussions and analyses of the above royalty 
distribution schemes at UIC led to the applica-
tion of the policy to joint drug-discovery efforts: 
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Sixty percent of the split of the net royalty would 
go to the collaborating institutions, while 40% 
would go to UIC. Despite the change of this 
benefit-sharing policy, the original benefit-shar-
ing schemes set down and agreed to by the UIC 
ICBG consortium and embodied in the ICBG 
MOA remain in force to this date.16, 22
Funds provided by GSK at the time of its 
withdrawal are being used to establish two trust 
funds: the Nature Conservation Foundation 
(NCF), Vietnam, and the Laos Biodiversity Fund 
(LBF). The objectives of the NCF and LBF in-
clude conservation of resources, capacity build-
ing, biodiversity research, and community reci-
procity.17 These funds will serve as the conduit for 
the 50% of the royalties that are due to flow back 
to the communities in question.
4.8	 Community	reciprocity
Community reciprocity measures are imple-
mented in the Vietnam-Laos ICBG.18 Both the 
UIC and the host-country institutions have 
responsibility for implementing community 
reciprocity.
5. ConCluSIon
The success of an ICBG depends on the goodwill 
and understanding of the collaborating parties to-
ward the achievement of a common goal, namely, 
the conservation of biodiversity, the discovery 
and development of pharmaceutically beneficial 
products, and the equitable sharing of the ben-
efits that may result. In setting up the arrange-
ment, multiple, complex requirements must be 
satisfied, the most important of which is the con-
tractual agreement. Eight ICBG bioprospecting 
groups have so far been created, each with various 
models of contractual arrangement. The com-
mon features of these models, however, are their 
satisfactory arrangements for IP rights issues, in-
formed consent, and benefit sharing.
The UIC-based Vietnam-Laos ICBG 
is one example of such a North–South 
collaborative arrangement. Parties to this 
ICBG have successfully achieved goodwill and 
understanding. Despite the short time it has 
been in operation, the accomplishments of this 
ICBG to date indicate that the ICBG model 
works.19, 23
Bioprospecting endeavors such as these are 
also unique in the way in which they involve local 
communities. In order to effectively carry out this 
sort of activity, collaboration at the local level—
with poor farmers, rural villagers, many of whom 
have only limited education or opportunities in 
life—is crucial. The ICBG allows rural villagers 
participation in conservation, economic and 
development initiatives in a way that is not often 
seen in “macro,” nation-wide efforts to promote 
conservation, development or new economies. 
(Often, villagers are told what to do or are 
displaced by these new initiatives.) And the ICBG 
also allows villagers input on a number of issues—
health care delivery, education, local economics, 
conservation, and development—which is a 
natural by-product of forming the ICBG project 
and determining what benefits “make the most 
sense” to the local communities with which the 
ICBG works. 
Often times in the implementation of 
international, national or even provincial 
development, conservation or economic 
initiatives, the peasant-farmer is left out of the 
dialogue entirely, or is told to change/is displaced 
from life-long patterns of living and working. 
Under these circumstances, the peasant-farmer 
does not have a voice, and new schemes for 
economy, conservation, and development are 
imposed upon villages from the outside rather 
than collaboratively developed with villagers, in 
accordance and consideration of the local needs 
of villagers in different regions of the country. 
Projects such as the ICBG can provide a model 
for how to successfully implement national policy 
initiatives at the “micro” level—that is, figuring 
out the best ways to improve health care access and 
delivery systems, or to implement new economic, 
development, and conservation initiatives that 
are in keeping with local village practices and 
rhythms of life, especially when it turns out that 
local villagers have their own, traditional practices 
that may directly or indirectly contribute to 
conservation, economic, and development efforts. 
While the governments of Vietnam and Lao 
PDR do attempt to take into consideration the 
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Gross income from drug company 
($500,000; a hypothetical figure)
Less UIC’s direct costs: the cost of patent filing 
(variable; $30,000 is used for this model)
NET REVENUE
($470,000)
(0.5 x $470,000 = $235,000)
Intended for the country of origin of the genetic  
material of a commercialized compound
TRUST FUND
(50% of net revenue)
FUNDS TO BE SHARED 
(50% of net revenue)








(0.2 x $235,000 = $47,000) 
(Inventiveness)
(0.4 x $235,000 = $94,000)
Split equitably among inventors 
(UIC non-UIC inventors) (if four 




(0.4 x $235,000 = $94,000)
(President Office,OVCR,  
IPO, PR, etc.)
If the compound is derived from a 
plant from Vietnam
If the compound is derived from a 
plant from Laos
Vietnam (75% share) 
(0.75 x $47,000 = $35,250) 
UIC/PCRPS (25% share)
(0.25 x $47,000 = $11,750)
Lao PDR (75% share)
(0.75 x $47,000 = $35,250)
UIC/PCRPS (25%)
(0.25 x $47,000 = $11,750)
Vietnam 80% share)
(IBT-IEBR-ICH + CPNP)
(0.8x $32,500 = $28,200) 
Lao PDR (20% share)
(RIMP)
(0.2 x $47,000 = $7,050)
Lao PDR (80% share)
(RIMP)
(0.8 x $35,250 = $28,200)
Vietnam (20% share)
(NCST-IEBR-ICH + CPNP)
(0.2 x $35,250 = $7,050)
IBT-IEBR-ICH (50% share) 
(0.5 x $28,200 = $14,100) 
CNP (50% share)
(0.5 x $28,200 = $14,100)
IBT-IEBR-ICH  (50% share)
(0.5 x $7,050 = $3,525)
CPNP (50% share)
(0.5 x $7,050 = $3,525)
Note: In this scenario: a) the total amount of funds from the net royalty income that remains in the United States will be: 
$30,000 (direct) + $94,000 UIC share + $11,750 PCRPS share + $70,500 inventors’ share = $206,250 or 41.25% of gross royalties. [If 
all inventors are UIC scientists, the UIC share will be: $30,000 direct costs + $94,000 UIC share + $11,750 PCRPS share + $94,000 
Inventors’ share = $229,750 or 45.95% of gross royalties.] and b) the total amount that will go back to the source country (Vietnam 
and Laos) will be: trust fund ($235,000) + ICBG institution share ($35,250) + Inventors’ share (in the above scheme with one non-
UIC inventor, $23,500), for a total of $293,750 or 58.75% of gross royalties. [If all inventors are UIC scientists, the share of the source 
country (Vietnam and Laos) will be: $235,000 trust fund + $35,250 ICBG institution share = $270,250 or 54.05% of gross royalties.
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Note: Since UIC does not file a patent in this case, no direct costs to UIC are deducted.
In this scenario, the total amount of funds from the net royalty income that remains in the United States will be: $50,000 
UIC/PCRPS, share + $100,000 UIC/IPO share = $150,000 (or 30%). The total amount that will go back to the source countries 




Gross income from drug company 
($500,000; a hypothetical figure)




(0.5 x $500,000 = $250,000)
Intended for the country of origin of the genetic  
material of a commercialized compound
TRUST FUND
(50% of net revenue)
FUNDS TO BE SHARED 
(50% of net revenue)
(0.5 x $500,000 = $250,000)






(Research Efforts + Contribution  
+ Inventiveness equivalent)
40% share (UIC’s policy)
(0.4 x $250,000 = $100,000) 
(Overall research efforts)
20% share (UIC’s poilcy)
(0.2 x $250,000 = $50,000)
(Overall administrative/ 
legal efforts)
40% share (UIC’s policy)
(0.4 x $250,000 = $100,000)
If the compound is derived from a 
plant from Vietnam
If the compound is derived from a 
plant from Laos
Vietnam (80% share)  
(0.8 x $100,000 = $80,000) 
Lao PDR (20% share)
(0.2 x $100,000 = $20,000)
Lao PDR (80% share)
(0.8x $100,000 = $80,000)
Vietnam (20%)
(0.2 x $100,000 = $20,000)
IBT-IEBR-ICH (50% share) 
(0.5 x $80,000 = $40,000) 
CNP (50% share)
(0.5 x $80,000 = $40,000)
IBT-IEBR-ICH  (50% share)
(0.5 x $20,000 = $10,000)
CPNP (50% share)
(0.5 x $20,000 = $10,000)
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needs of local villagers when implementing new 
policies designed to improve the quality of life in 
rural areas, projects such as the ICBG can act as a 
model for obtaining additional data on the actual 
living conditions of rural villagers, and how to 
work with and for local communities, because of 
the close association between the ICBG and local 
village authorities and councils. 
Moreover, the rural villagers begin to 
see themselves as stakeholders interested in 
the outcomes of conservation, economic, 
development, and health care delivery efforts 
because of their direct participation on the process 
of locally implementing national policies. Instead 
of feeling alienated by the process of reform, rural 
villagers realize their direct contribution to the 
process itself when they are actively engaged and 
participating in local projects—and when their 
contributions to the process are valued. 
The ICBG might not be the only model for 
implementing change at the local level, and in 
a way that is welcomed and guided by villagers 
(since it is in cooperation with improving the 
quality of life at the village level); but it is a 
model currently in use and from which lessons 
and “best practices” may be gleaned and then 
replicated elsewhere worldwide. In this way, the 
ICBG contributes to the larger knowledge base 
of solutions for effective cooperative endeavors 
between North and South. ■
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Traditional knowledge (TK) is the information that peo-
ple in a given community, based on experience and adapt-
ed to local culture and environment, have developed over 
time and that continues to develop. This knowledge is 
used to sustain the community and its culture, as well 
as the biological resources necessary for the continued 
survival of the community. Since 1948, international hu-
man-rights standards have recognized the importance of 
protecting intellectual property. Yet, to date, intellectual 
property (IP) rights are not adequately extended to the 
holders of TK. The requirements for IP rights protections 
under current IP regimes remain largely inconsistent with 
the nature of TK. As a result, it is neglected and consid-
ered part of the public domain with no protections or 
benefits for the knowledge holders, or expropriated for 
the financial gains of others, often referred to as biopiracy. 
This chapter presents basic IP concepts in the context of 
TK with specific attention to identifying, classifying, and 
protecting elements of TK. The advantages and disadvan-
tages of the various IP protection options are discussed, 
and a number of case studies are presented to facilitate a 
better understanding of each option or issue.
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continued survival. Key examples of TK are these 
uses of biological resources:
• plao-noi in Thailand for the treatment of 
ulcers
• the hoodia cactus by Kung Bushmen in 
Africa to stave off hunger
• turmeric in India for wound-healing
• ayahuasca in the Amazon basin for sacred 
religious and healing purposes
• j’oublie in Cameroon and Gabon as a 
sweetener
TK includes mental inventories of local bio-
logical resources, animal breeds, and local plant, 
crop, and tree species. It may include such infor-
mation as which trees and plants grow well to-
gether and which are “indicator plants” (plants 
that show soil salinity or are known to flower at 
the beginning of the rains, for example). TK in-
cludes practices and technologies, such as seed 
treatment and storage methods and tools used for 
planting and harvesting. It also encompasses belief 
systems that play a fundamental role in peoples’ 
livelihoods, maintain their health, and protect 
and replenish the environment. TK is dynamic in 
nature and may include experimentation in the 
integration of new plant or tree species into exist-
ing farming systems or a traditional healer’s tests 
of new plant medicines. 
CHAPTER 16.6
1.	 InTRoduCTIon
Traditional knowledge (TK) is information that 
people in a given community, based on experi-
ence and adaptation to a local culture and envi-
ronment, have developed over time and continue 
to develop. The knowledge is used to sustain the 
community and its culture and to maintain the 
genetic resources necessary for the community’s 
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The term traditional used in describing this 
knowledge does not imply that it is old or un-
technical in nature, but that it is tradition based. 
It is traditional because it is created in a man-
ner that reflects the traditions of the originating 
communities, therefore not relating to the na-
ture of the knowledge itself, but to the way in 
which that knowledge is created, preserved, and 
disseminated.1 
TK is collective in nature and is often con-
sidered the property of the entire community, 
not belonging to any single individual within the 
community. TK is transmitted through specific 
cultural and traditional information-exchange 
mechanisms—for example, orally through elders 
or specialists (breeders, healers, and so on)—
and often to only a select few people within a 
community. 
The knowledge and uses of specific plants for 
medicinal purposes (often referred to as tradition-
al medicine) is an important component of TK. 
Once, traditional medicines were a major source 
of materials and information for the development 
of new drugs. In the 20th century, however, new 
sources for pharmaceuticals led to a decline in 
the importance of ethnobotany in drug-discovery 
programs. However, new discoveries of poten-
tially potent anticancer agents in plants (such as 
turmeric and taxol), as well as a rapidly growing 
herbal remedies market, have revived industry 
interest in traditional medicinal knowledge and 
practices. As interest in traditional medicine is 
rekindled, indigenous knowledge of the cultiva-
tion and application of genetic resources is being 
exploited at an alarming rate. 
IP (intellectual property) rights should guar-
antee both an individual’s and a group’s right to 
protect and benefit from its own cultural discov-
eries, creations, and products. But Western IP re-
gimes have focused on protecting and promoting 
the economic exploitation of inventions with the 
rationale that doing so promotes innovation and 
research. Western IP law, which is rapidly assum-
ing global acceptance, often unintentionally facil-
itates and reinforces a process of economic exploi-
tation and cultural erosion. It is based on notions 
of individual property ownership, a concept that 
is often alien to indigenous communities and can 
be detrimental to them. An important purpose of 
recognizing private proprietary rights is to enable 
individuals to benefit from the products of their 
intellect by rewarding creativity and encouraging 
further innovation and invention. But in many 
indigenous worldviews, any such property rights, 
if they are recognized at all, should be extended to 
the entire community. They are a means of main-
taining and developing group identity, as well as 
group survival, rather than promoting or encour-




Patents provide a legal monopoly over the use, 
production, and sale of an invention, discovery, 
or innovation for a specific period of time (usu-
ally about 20 years). A monopoly is the right to 
exclusive control over the use, development, and 
financial benefits derived from a patented item. 
In order for an invention or innovation to be 
patentable, it generally must meet three criteria: 
novelty, nonobviousness, and industrial applica-
tion (or utility). Indeed, it must meet all of these 
criteria, and if one can be disproved, the patent 
cannot be approved. 
Novelty refers to the “newness” of an in-
vention, in other words, there is no prior art. 
Prior art is the knowledge base that existed 
before the invention was discovered or before 
the invention was disclosed by filing a patent 
application. 
Nonobviousness refers to the presence of an 
inventive step, that is, the invention or innova-
tion must not have been obvious at the time of 
its creation to anyone having “ordinary skill in 
the art.”3 
Industrial application, or utility, refers to the 
very reason for patent protection, that is, to pro-
mote the progress of the useful arts. For a product 
or process to be useful it must, at least, work, al-
though it does not have to work perfectly or even 
better than any competing products or processes, 
nor does there have to be a market for the inven-
tion (nor even a potential market).
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For several reasons, patents might not rep-
resent the most advantageous form of IP rights 
protection for TK. First, applying for a patent 
requires full disclosure of (making public) the 
invention or innovation. Shortly after the pat-
ent is approved, the information is placed in the 
public domain by making the patent application 
publication available to the public. In the United 
States, a patent is made public 18 months after 
it is approved. If the TK is considered a trade 
secret, a patent may not be the most appropri-
ate IP solution. Second, the invention or inno-
vation must be novel according to patent-office 
standards. The patent applicant must prove that 
the invention or innovation is not part of the 
current prior-art base as defined by each coun-
try’s legal definition of novelty. In many coun-
tries, TK may be considered, de facto, part of 
the prior-art base. This task can either be simple 
or somewhat difficult, but nonetheless, it must 
be demonstrated. 
2.2	 Petty-patent	models	
Petty patents allow for protections similar to 
those of patents, but for knowledge consisting 
of a less-detailed inventive step.4 The knowledge 
must still meet the novelty and industrial-ap-
plication criteria. The term of protection for a 
petty patent is typically between four and six 
years, which is shorter than the term for the 
standard patent. 
The petty patent exists only in a few coun-
tries and is not mentioned in the Agreement on 
Trade-Related Aspects of Intellectual Property 
Rights (TRIPS) as a minimum standard for IP 
protection. However, some countries are pushing 
for the inclusion of petty patents in the TRIPS 
Agreement. Petty patents may be more suitable 
for TK, as TK is not typically documented in 
the same manner as Western science. Despite 
the fact that petty patents are not globally rec-
ognized as a minimal standard for IP protection, 
some countries have enforced the mechanism as 
a way of protecting TK. For example, a type of 
petty patent is mentioned in Kenyan legislation 
in order to protect indigenous claims to tradi-
tional herbal medicine.5 Although the current ap-
plication of petty patents is relatively small, their 
implementation at a broader level could serve TK 
as a viable IP protection option. 
2.3	 Plant	variety	protection/	
plant	breeders’	rights
Many countries protect plant varieties with the 
plant variety protection certificate. This mecha-
nism is used to protect the rights of breeders of 
sexually reproducing (by seed) varieties of plants. 
Breeders’ rights protect the commercial interests 
of the breeder so that economic incentives exist 
for continued breeding of new plant varieties, 
ultimately serving farmers or those who grow 
the varieties. Importantly, unlike utility patents, 
plant variety certificates do not require the autho-
rization of the breeder for use of the variety by 
others for further breeding purposes.
The criteria for a plant variety protection 
certificate are fairly uniform across countries that 
offer them. The variety must meet all of these 
criteria:





The International Convention for the 
Protection of New Plant Varieties (UPOV) is not 
a legal mechanism per se. Rather, UPOV is an 
international treaty and an organization that sets 
certain standards. A country can only become 
a member of UPOV if its plant variety protec-
tion schemes meet these minimum standards. 
Importantly, under the TRIPS agreement, coun-
tries are bound to enact sui generis protection for 
plants, and the UPOV requirements are generally 
considered to meet such standards. 
Proposals for legislation in Nicaragua have 
included provisions that require ten unique char-
acteristics in order to distinguish a variety as 
distinct; to exclude protection for “discovered” 
plants; and, not to extend plant breeders’ rights to 
plants used for food or sown directly by farmers. 
Zambia has cited the Convention on Biological 
Diversity (CBD)7 in developing its plant variety 
protection mechanism and states that any final 
legislation must recognize and reward indigenous 
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innovation. India’s Plant Variety Protection Act 
(2001) declares that the rights of the farmer su-
percede those of the breeder. The Plant Varieties 
Protection Act of Bangladesh (1998) states that 
a variety must have “immediate, direct and sub-
stantial benefit to the people of Bangladesh,”8 and 
protects both community and farmers’ rights.9 
These examples demonstrate that options other 
than UPOV can be established that effectively ad-
dress the needs of TK holders. 
2.4	 TK	registries
Public registries place information in the public 
domain and serve as a form of prior art or defen-
sive disclosure. They can be public or private. A 
defensive disclosure, by describing information in 
a printed publication or other publicly accessible 
medium, helps to establish prior art capable of 
preventing patents. 
2.4.1		 Public	registries
TK registries are official collections of documen-
tation that describe TK (see Box 1). Registries 
can be established and maintained either locally 
(within a community) or outside a community 
(external), even for an entire country (see Box 
2). With a locally maintained registry, the com-
munity may collectively decide what is to be in-
cluded in the registry and what knowledge is to 
be shared and/or disclosed to people outside the 
community. 
2.4.2 Private	registries
Private registries do not place knowledge in the 
public domain. But private registries can be ef-
fective as: 
• protection mechanisms for TK in instances 
where a sui generis system is in place
• preservation mechanisms when cultural 
and historic preservation is a goal
• tools for access and benefit-sharing 
agreements
Since the information in a private registry is 
documented but is not in the public domain, it 
may not constitute prior art capable of prevent-
ing a patent based on the knowledge by an out-
sider. The knowledge in a private registry cannot 
prevent the approval of a patent under most IP 
systems unless the knowledge constitutes prior 
art through a sui generis mechanism and dis-
closed to patent authorities. However, it may be 
possible to challenge and revoke a patent with 
knowledge documented in a private registry if 
patent law recognizes prior art not disclosed to 
the public as being admissible under a sui gene-
ris system. Reexamination requests of patents can 
be both costly and time consuming. Also, the 
knowledge may need to be disclosed to the pub-
lic if no sui generis protection mechanism exists 
that would prohibit its public disclosure during 
reexamination. 
Because the recognition and effectiveness of 
private registries varies from country to county, 
private registries are most effective as a mecha-
nism for preservation of knowledge and as a tool 
for access and benefit-sharing agreements. A pri-
vate registry can serve as a catalog for knowledge 
that can be licensed to outside parties for research 
and product development. As a mechanism for 
cultural preservation, the private registry serves as 
a cultural library that documents and maintains 
TK belonging to a community and helps prevent 
loss of the TK (see also Box 2). 
A typical form of registry is a computer data-
base. The Internet is an ideal location for public 
databases containing TK, as they can serve as a 
vehicle for defensive disclosure and are accessible 
to patent offices worldwide as a source of prior 
art. The World Intellectual Property Organization 
(WIPO) is in the process of compiling a list of 
TK-related databases for international patent of-
fices, and several large public databases collect TK 
as a means of defensive disclosure against the mis-
appropriation of IP. 
The benefit of both public and private reg-
istries lies in their ability to prevent or revoke 
inappropriate claims of IP rights. In order to 
be effective in this manner, it is essential that 
national patent offices are made aware of the 
public registry for use in prior-art searches. The 
public registry has the additional benefits of ne-
gating the application of IP rights on TK prior 
to patent approval and promoting free use of 
the knowledge in the public domain for every-
one’s benefit. 
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Box	1:	An	example	of	TK	documentation
To illustrate how a claim may be documented, an entry from the Honeybee Network’s Innovation 
Database is provided here. That database is a large online database of grassroots innovations 
detailing contemporary and traditional innovative practices.
To illustrate how a claim may be documented, an entry from the 
Honeybee Network’s Innovation Database is provided here. That 
database is a large online database of grassroots innovations 




Hirabhai Kodarbhai Raval has a special way of treating his 
animals for stiffness of the body. He prepares a mixture of 250 
g variyali (Foeniculum vulgare), 50 g turmeric powder, and 500 g 
Dalda ghee. This, when given to the animal to drink, loosens the 
stiffness in the body of the animal and relieves joint pains. Half 
this dosage is prescribed for very young animals.






Note that this database entry contains the following information:
Claim	being	made: Curing joint pains (In this format for documentation, the claim also serves 
as the name or descriptive title for the claim.)
name	of	the	inventor	or	claimant: In this example, the inventor is an individual, but this 
could be the name and/or location of a community as well.
details	of	the	invention: It is a mixture consisting of the following ingredients and amounts: 
250 grams of variyali (Foeniculum vulgare), 50 grams of turmeric powder, and 500 grams of 
Dalda ghee.
how	applied: It is given to the animal to drink.
dosage: As mixed and half dosage for very young animals
Results: Loosens the stiffness in the body of the animal and relieves joint pains
a Term added by the authors.
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2.5	 Trade	secrets
Trade secrets protect undisclosed knowledge 
through access agreements, which may involve 
paying royalties to knowledge holders for access 
to and the use of their knowledge. Three elements 
are required for knowledge to be classified as a 
trade secret. The knowledge:
• must have commercial value
• must not be in the public domain
• is subject to reasonable efforts to maintain 
secrecy
TK that is maintained within a community 
could be considered a trade secret. But once the 
knowledge is made public, this option no longer 
exists. A trade secret is only enforceable as long 
as it remains a secret. Trade secrets have no legal 
protection except in cases of “breach of confidence 
and other acts contrary to honest commercial prac-
tices.”12 This means that one must be able to prove 
some form of malicious intent on the part of a 
contracting party as the cause for a trade secret’s 
diffusion to the public in order to be compen-
sated for the loss of secrecy. 
It is important to remember that knowledge 
considered a trade secret can be used by anyone 
if the knowledge is leaked into the public do-
main, is independently discovered by another 
individual, or is reverse engineered. It is difficult 
to protect trade secrets against misappropriation 
due to lack of legal entitlement to the bearer of 
the secret. When applied to knowledge belong-
ing to a community, the community must make a 
reasonable effort to maintain the secrecy. If there 
is not a reasonable effort to maintain secrecy with 
respect to the TK, then trade secret protection is 
not applicable to it.
2.6	 Trademarks
The U.S. Patent and Trademark Office (PTO) 
defines trademark as “a word, phrase, symbol or de-
sign, or a combination of words, phrases, symbols or 
designs, that identifies and distinguishes the source of 
the goods of one party from those of others.”13 In oth-
er words, trademarks are a way of protecting the 
use of words, phrases, symbols, designs, or any 
combination of these associated with a product. 
Once a trademark is established, it can be used to 
Box	2:	A	public	Registry	in	India
One example of a public registry is the people’s biodiversity registers (PBRs) in India. Recognized 
in the Indian Biological Diversity Bill of 2000, the PBRs consist of records of people’s knowledge 
of biodiversity, its use, trade, and efforts for its conservation and sustainable utilization. The 
PBRs are developed at the village level by a local school and college teachers, students, and 
nongovernmental (NGO) researchers, and villagers. Biodiversity registers are then compiled 
in the form of computerized databases at the levels of talukas, districts, states, and the entire 
country, in order to provide information to the public, government, and industry. These PBRs have 
been recognized by the Indian Biological Diversity Bill as a form of prior art in the evaluation of 
patent applications, as well as serving to ensure equitable access and benefit sharing.  
External registries are maintained outside the community, often on the national or international 
level, by governments, NGOs, museums, or libraries. These registries can be collections of TK 
specific to one particular community or to several communities. Local communities may have 
control over what is entered into the registry, but may not be responsible for the registry’s 
maintenance. Distinguishing between local or external registries is at the discretion of the TK 
stakeholders.
A disadvantage of the public registry is the disclosure of knowledge to others outside the 
community. When placing knowledge in the public domain, the knowledge may lose its 
commercial value, limit options for IP protection for the community, and may be used by the 
public without permission. 
CHAPTER 16.6
 HANDBOOK OF BEST PRACTICES  | 1529 
identify and differentiate similar products. Think 
how often names, images, and photos are always 
used in marketing products.
Trademarks are based on two principles: dis-
tinctiveness and avoiding confusion. Being dis-
tinct means that the trademark does not resemble 
any other existing word, phrase, symbol, design, 
and so on, associated with a similar product. 
Avoiding confusion as to the source of a prod-
uct is important for consumers purchasing these 
products. Trademarks distinguish products in or-
der not to mislead consumers into thinking that 
a product is something that it is not or that it 
comes from another source.
How can trademarks be applied to TK? 
Suppose a company sells a product composed of 
maca, a plant native to the Andean region. An 
indigenous community in the Andes, the origi-
nal knowledge holders of maca’s uses, may also 
want to sell maca or profit from their own natural 
resources and knowledge. They could register a 
trademark like the example below:
The indigenous group can register the above 
trademark and sell maca using this symbol to dis-
tinguish the brand.
2.7 Geographical	indicators	
A geographical indicator identifies a good as 
originating in a territory or region, or locality in 
that territory, where a given quality, reputation, 
or other characteristic of the good is attributable 
to its geographical origin.14 Like trademarks, geo-
graphical indicators are typically words or terms, 
but when associated with a product, positive-
ly attribute a known quality to the product that is 
associated with a specific geographical location. 
A geographical indicator cannot be used to 
describe a product unless it originates in the region 
associated with the name. For example, Swiss 
watches are associated with a tradition of high 
quality, so the term Swiss watch is a geographi-
cal indicator that assumes a watch came from 
Switzerland. Roquefort cheese (from France) is 
another product associated with high quality and 
constitutes a geographical indicator. Roquefort 
cheese can only be used to describe cheese pro-
duced in Roquefort-sur-Soulzon, France, and 
aged in the traditional caves (a practice also as-
sociated with the geographical indicator). 
Other examples of geographical indicators in-
clude Bordeaux wine (France), Parma ham (Italy), 
Stilton cheese (United Kingdom), Darjeeling tea 
(India), Cognac (France), and Queso Murcia 
(Spain).
Geographical indicators serve four main pur-
poses. They:
• identify where the product is from (its 
source)
• indicate the unique qualities of a product
• promote the product with a distinguishing 
name (for business purposes)
• prevent infringement and unfair competi-
tion by establishing a legal basis for using 
a location name to avoid confusion with 
similar products 15
A specific form of geographical indicator is 
called an appellation of origin. Appellations of ori-
gin specify the quality of a product based on its 
geographical environment and are protected un-
der the Lisbon Agreement of 1958. Twenty coun-
tries are party to the Lisbon Agreement. In 1998, 
of the 766 protected appellations of origin, 95% 
belonged to European countries.16 Countries such 
as India and Bulgaria have recently been highly 
active in seeking appellation of origin protection 
for many of their products.
Preemptive protection of geographical indi-
cators will ensure that they are commonly known 
and documented. This can be done by placing the 
geographical indicator in the public domain via 
a database or other publicly accessible medium. 
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The second option is to apply for a certification 
mark that is an official registration (as opposed 
to an unofficial disclosure of the indicator in 
the public domain). The certification mark is a 
type of trademark. Currently, international reg-
istry protection is available only for wines, and 
all other products are subject to national registry 
laws.17 
If a country is party to the TRIPS Agreement, 
it is the country’s international legal obligation 
to formulate legislation protecting geographical 
indicators. Article 22 of the TRIPS agreement 
states that members must provide legal means to 
prevent: 
the use of any means in the designation or pre-
sentation of a good that indicates or suggests that 
the good in question originates in a geographical 
area other than the true place of origin in a man-
ner which misleads the public as to the geographical 
origin of the good.18
 
Additionally, the TRIPS Agreement requires 
the protection of what is defined as unfair compe-
tition in the Paris Convention.19 “All acts of such a 
nature as to create confusion by any means whatever 
with the establishment, the goods, or the industrial 
or commercial activities, of a competitor” shall be 
prohibited under this article.20 
What does all this mean in the everyday life 
of a TK holder? Let’s examine an example that ad-
equately explains the importance of a geographi-
cal indicator. The maca plant is native to the high 
peaks of the Andes Mountains where it thrives in 
the high altitudes. Suppose a Western company 
was to modify the plant so that it could grow in 
lower elevations. Then, that company was to grow 
large quantities of the plant in the United States 
and market the plant product as “Andean maca.” 
This is a clear violation of the provisions that 
protect against the improper use of geographical 
indicator. Andean maca is associated with a dis-
tinguished quality, and by using the name, the 
product, which is not produced in the Andes, 
misleads consumers into believing both that:
• the product was actually cultivated in the 
Andes
• the product is of the quality as that pro-
duced in the Andes
Only maca grown in the Andes, then, is permit-
ted to be marketed as “Andean Maca” if: 
• Andean-grown maca is commonly known 
to be of superior quality to other maca, 
and this fact is documented in the public 
domain
• a certification mark has been officially 




When determining whether a claim is novel, ei-
ther through the filing of a patent application or 
during the patent application review process, the 
prior-art base (the public domain) is examined. 
If the invention or claim is found described in 
the prior-art base or has been offered for use or 
sale for more than one year, it is not entitled to a 
patent. In U.S. patent law, prior art is defined as a 
publication printed either in the U.S. or a foreign 
country describing the invention or discovery 
and dated more than one year before a patent’s fil-
ing date or, simply, dated before the act of inven-
tion or conception. A publication may include 
any document accessible to persons working in a 
certain profession or field and therefore skilled in 
the relevant art. These could include magazines, 
trade or scientific journals, newsletters, newspa-
pers, and Web sites, to name but a few.
The European patent system does not limit 
evidence of prior art solely to printed publica-
tions, but includes everything made available to 
the public by the means of a written or oral de-
scription, by use or by any other way, anytime 
before the patent application filing date.21 The 
difference between the U.S. and European defini-
tion of prior art has serious implications for the 
recognition of TK as prior art, as much TK is not 
documented nor published, but is shared orally, 
or publicly known through demonstrated and 
public use.
Prior art is taken into account for the non-
obvious requirement in applying for a patent. In 
many cases, the prior art may prove to be very 
similar, but not exactly like the claim or inven-
tion itself, but the differences would be obvious 
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to someone with ordinary skill in the area and 
who knew, or had relatively easy access to, the 
prior-art base.
3.1	 Defensive	disclosure
Defensive disclosure refers to information or 
documentation intentionally made available to 
the public as prior art in order to render any sub-
sequent claims of invention or discovery ineligi-
ble for a patent. A defensive disclosure provides 
evidence of the invention, knowledge, or use of 
the invention by others before it was claimed by 
another inventor or offers evidence of public use 
or sale more than one year before the filing date 
of the patent.22 
Defensive disclosures can be made anony-
mously without attributing the knowledge to a 
particular person or community. Anonymous 
disclosures might have a benefit for those who 
want to disclose information but at the same 
time not want to attract unwelcome attention to 
a community. 
There are basically two types of mechanisms 
for defensively disclosing information. One con-
sists of the traditional methods of publication: 
scientific, academic, technical, and business jour-
nals, and so on. The other mechanism is electronic 
publication through the Internet. In recent years, 
many Internet sites have been developed solely 
for the purpose of defensive disclosure. There are 
many Internet-based Web sites and databases that 
contain information on TK. 
A community registry could serve as a viable 
means of defensive disclosure. This would involve 
placing the registry on the Internet for all to ac-
cess (this would also include patent examiners 
during prior art searches), or if a country has a sui 
generis system in place, limiting outside access to 
only the patent office.
3.2 Prior	informed	consent
The CBD declares the obligation to obtain prior 
informed consent for accessing genetic resources. 
The Bonn Guidelines (2002)23 further link genet-
ic resources with TK in the obligation to acquire 
informed consent. Prior informed consent is the 
approval in advance for the use of one’s genetic 
resources and any associated TK. Prior indicates 
that the approval must come before access is al-
lowed or others use the knowledge. Informed 
means that information is provided on how the 
resource and/or knowledge will be used. Consent 
means permission to use the resource or knowl-
edge. Sufficient information should be provided 
to a community, either by the IP office or other 
party, regarding the aims, risks, or implications of 
using the knowledge, including its potential com-
mercial value. 
Does a community possessing TK legally 
have the right to prior informed consent if some-
one accesses its genetic resources and related TK 
and wishes to use them? The answer: maybe. If 
the country where the community is located has 
ratified and implemented the CBD, access to TK 
should be subject to prior informed consent of 
the knowledge holders under Article 8(j). 
Perhaps an example is the best way to under-
stand how prior informed consent works. Suppose 
a scientist is traveling in South America and be-
gins to work with a community in the Amazon 
region. The scientist is particularly amazed when 
he or she observes the methods used by a local 
community to process and apply a local plant to 
heal wounds. The scientist, now aware of the ge-
netic resource and local knowledge of its use, can 
do one of two things: he or she can do nothing 
with the knowledge or can use the knowledge. 
If the scientist does nothing, there is obviously 
no need to obtain prior informed consent. If the 
scientist wishes to use the resource or knowledge 
(publish the knowledge in a journal article, apply 
for a patent, etc.), he or she must obtain prior 
informed consent of the appropriate national 
authorities if that Amazonian country has imple-
mented the CBD. 
4.	 SuI	geneRIS	pRoTeCTIon	SySTemS
Sui generis literally means “of its own kind” and 
consists of a set of nationally recognized laws and 
ways of extending plant variety protection (PVP) 
other than through patents. TRIPS itself does not 
define what a sui generis system is or should be. 
And although TRIPS does not mention UPOV, 
it is generally agreed that the UPOV standards 
meet the requirements for a sui generis system for 
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plants. However, countries do not have to join 
UPOV to implement a sui generis system to com-
ply with TRIPS.24
A sui generis system might consist of some 
standard forms of IP protections combined with 
other forms, or none at all, for genetic resources. 
For example, a country could provide patent pro-
tections for inventions, plant variety certificates 
(PCV) for plant varieties or just certain varieties, 
and/or exclude plants from any form of IP pro-
tection at all (although this could conflict with 
TRIPS compliance).
Potentially, a sui generis system could be 
defined and implemented differently from one 
country to another. In addition, a sui generis sys-
tem might be defined to create legal rights that 
recognize any associated TK relating to genetic 
resources and promote access and benefit sharing. 
The government may choose to extend protec-
tions to genetic resources and/or knowledge to a 
community in the form of patents, trade secrets, 
copyrights, farmers’ and breeders’ rights, or an-
other creative form not currently established in 
the IP regime. 
In addition, a sui generis system may adopt 
measures of protection specific to TK in order to 
nullify inappropriate patents. For example, the 
Andean Community’s Decision 486 states: 
patents granted on inventions obtained or de-
veloped from genetic resources or traditional knowl-
edge, of which any member state is the country of 
origin, without presentation of a copy of the proper 
access contract or license from the community shall 
be nullified.25
A sui generis system may legally acknowl-
edge and protect knowledge related to the use 
of genetic resources even when it is not officially 
documented, but instead exists in the form of 
oral information, and traditional and historic 
use. Even though protections might be extended 
here, the government’s IP office needs to know 
about the knowledge or practice in order to en-
force protection. Therefore, if a country has some 
form of a sui generis system in place, it is impor-
tant for local communities to establish a working 
relationship with the IP office. In addition, these 
offices may privately maintain inventories or reg-
istries of locally held knowledge, and can assist in 
its protection. For example, this office can deny a 
patent application if the knowledge it is based on 
is already held in the registry.
Under a sui generis system, and as called 
for by the CBD, any person interested in gain-
ing access to a community’s biological resources 
or knowledge for scientific, commercial or in-
dustrial purposes would need to obtain the prior 
informed consent of the indigenous peoples who 
possess the knowledge in question unless the 
knowledge is already in the public domain. This 
would allow the community to decide on access 
to and use of its genetic resources and knowledge, 
with the option to share or not to share them. If 
consent is granted, the person or persons wishing 
access to lands held by indigenous communities 
or a conservation area, its biological resources, 
and associated knowledge would need to present 
evidence of this consent to either the IP office or 
to the proper authority.
5.	 ACCeSS	And	BenefIT	ShARIng
Access refers to granting permission to enter an 
area for the purpose of sampling, collecting, and 
removing genetic or other resources. Benefit shar-
ing refers to all forms of compensation for the use 
of genetic resources, whether monetary or non-
monetary. This might also include participation 
in scientific research and development of genetic 
resources, as well as the sharing the findings of 
any potential benefits resulting from this work.
Articles 1 and 8(j) of the CBD encourage 
the equitable sharing of benefits arising from TK 
for conservation and sustainable use of biologi-
cal diversity. In benefit-sharing arrangements, all 
parties share the benefits arising from the use of 
genetic materials and TK of their uses. For the 
local community, this involves the sharing of 
TK and resources with contracting parties and 
others who wish to use it for research and/or de-
veloping new products based on this knowledge. 
The contracting parties in turn would share any 
advancements, benefits (including financial), 
or products that made use of the resources 
developed from local resources with the local 
community. 
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Article 15 of the CBD states that access to 
genetic resources and any transfer of technology 
be provided and/or facilitated under fair and mu-
tually agreed-upon terms. This may include types 
of financial arrangements described later in the 
CBD (Articles 20 and 21). 
Benefits include a wide range of options and 
often beneficiaries receive more than one type of 
benefit. They may include:
• Start-up/upfront benefits. Payments paid 
as a lump sum (if a financial arrangement) 
or delivered (if a cooperative or capacity 
building project). (These benefits would 
include equipment such as computer hard-
ware, software, or extraction and screening 
facilities.) 
• Process benefits. Derived during the pro-
cess of research and development. (In addi-
tion to financial payments, process benefits 
may include capacity, expertise, or know-
how building, and training through joint 
research.) 
• Product benefits. Paid after commercializa-
tion of the final product. (These may in-
clude royalty payments that may be negoti-
ated according to the contribution of the 
genetic resource or the amount of or role of 
local knowledge that was used in creating 
the final product.) 
• Moral and relation benefits. Unlike the fi-
nancial benefits described above, not trans-
ferred according to a formalized arrange-
ment, but based on the interaction of the 
participants.26 
As an example, let us consider a case in 
Ecuador. In that country, the Inter-American 
Development Bank (IDB) and several NGOs have 
launched a project titled “The Transformation of 
TK into Trade Secrets.” The goal of the project 
is to catalogue TK and then maintain the da-
tabase at regional centers, access to which will 
be safeguarded. Each participating community 
will have its own file in the database and will 
not be able to access files of any other commu-
nity. The collected knowledge will be reviewed, 
and knowledge that is not common to multiple 
communities may be negotiated as trade secrets 
through material transfer agreements (MTA). 
The benefits from any MTAs are to be split be-
tween the Government of Ecuador and the com-
munities that deposited the knowledge in the 
database. Payments to communities will then be 
used to finance public projects previously identi-
fied by each community.27
Contractual agreements28 are at the heart of 
any benefit-sharing mechanism. They are legally 
binding documents between parties. In relation 
to TK, they are generally used to outline and 
enforce access and benefit-sharing agreements, 
as well as trade secrets. Contracts relative to TK 
may explain or clarify the following points:
• parties to the agreement
• duration of the agreement
• knowledge included in the agreement
• uses of the knowledge
• restrictions placed on the knowledge’s use
• restrictions placed on confidentiality
• specifics for benefit sharing
Some types of contracts that might be em-
ployed for access and benefit sharing in compli-
ance with the CBD include: 
• confidentiality (also known as non-disclo-
sure agreements)
• exclusive licenses 
• nonexclusive licensing agreements 
• material transfer agreements29
The type of contractual arrangement will 
vary according to the knowledge and/or genetic 
resources in question, as well as the interests and 
cultural components related to the knowledge. If 
considering a contractual agreement, make sure 
that the selected type of contract corresponds to 
both the short-term and long-term interests of 
the community (see also Box 3).
6.	 loCATIng	And	IdenTIfyIng	TK
In order to protect or preserve TK utilizing the 
Western framework of IP rights, it is necessary to 
first locate and identify this knowledge according 
to the epistemological constructions recognized 
under this system. TK can be identified in: 
• daily activities including, among other things: 
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- farming
- gardening
- animal breeding and care
- food and nutrition
- healthcare and reproductive health
- water-resource use
- spiritual and religious activities
- folklore, songs, poetry, and theater
• community records (Although TK is mostly 
transmitted by word of mouth, some oth-
er forms of record keeping may exist, for 
example, maps, boundary markers [trees, 
poles, stones, and so on], drawings, paint-
ings or carvings, and many other forms.) 
• people working with the community, such 
as NGO researchers, academics, scientists, 
and development specialists who may have 
been collecting TK
• secondary sources such as journal articles and 
books, unpublished documents, databases, 
videos, photos, museums, and exhibits.31
 
An element of TK for which IP protections 
could potentially apply is called a knowledge claim. 
A TK claim contains three essential components: a 
genetic resource, a preparation or process, and an 
end result or product derived from a preparation 
or process. The genetic resource is typically a plant. 
The process encompasses the various ways of using 
the plant for an end result. Processes may include 
methods of growing, harvesting, extracting, pre-
paring, or applying the plant. The end result is the 
benefit from using the biological resource and the 
process. Let’s look at an example (Figure 1).
The three categories (Plant, Process, Product) 
can be combined in a variety of ways producing 
several claims. For example, from the simple fig-
ure below, it is possible to deduce six claims of 
process methods involving the plant:
• growing maca to cause an increase in live-
stock reproduction
• preparing maca to cause an increase in live-
stock reproduction
• administering maca to cause an increase in 
livestock reproduction
• growing maca to improve human fertility
• preparing maca to improve human fertility




After identifying a TK claim, the next step is 
to determine whom the knowledge holders and 
stakeholders are for the claim. The knowledge 
holders are the people who hold and/or use 
the knowledge, and stakeholders are the people 
in the community with a direct interest in the 
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to a specific knowledge claim, one must consult 
all of the stakeholders of that claim (which is often 
the entire community and/or other communities 
as well) before making a final decision about how 
any IP rights should be applied. 
TK can either originate within a commu-
nity or enter a community from the outside. 
If the knowledge is not originally from within 
the community in question, then it may not 
be subject to any IP rights and may already be 
part of the public domain. If the knowledge is 
from within the community, then the next step 
is to determine who holds the knowledge. The 
holder(s) of the knowledge can be an individ-
ual, multiple individuals, or the community as 
a whole. 
The next step is to determine who uses or has 
access to the knowledge. Knowledge claims can 
either be held or practiced by no one, an individ-
ual, multiple individuals, a community, or people 
outside the community. 
Any potential IPR options will depend on 
how many people are aware of the knowledge and 
who these people are. Based on these variables, a 
knowledge claim can fit into on of three groups:
1. Known and used by an individual
2. Known and used by several individuals or a 
community
3. Diffused broadly and in the public domain.
Figure 2 can assist in determining who holds 
the knowledge and who the stakeholders are 
in order for help in deciding which options to 
pursue for an identified knowledge claim.32 The 
dashed box in the figure represents knowledge 
that may fall within IP rights protections and that 
is not part of the public domain. If the knowl-
edge crosses outside the box, the knowledge may 
already be in the public domain (with or without 
prior informed consent33 and with no options for 
IP rights protection [see Section 3.2]). 
8.	 IdenTIfyIng	Ip	opTIonS
8.1	 Determining	cultural	aspects
The scientific aspect of TK is only one aspect of 
a larger culture of knowledge. For this reason, 
culture cannot be ignored when applying IP 
rights to TK. Cultural aspects that are important 
to TK are described below under six general cat-
egories. Each category should be considered inde-
pendently, and in combination, when evaluating 
the place of a specific claim in its cultural context 
and in the IP rights regime.
1. Spiritual. knowledge that not only has 
a useful or functional purpose but also 
some form of spiritual, religious, or sacred 
importance
2. Subsistence. knowledge necessary for the 
basic survival of the community, including 
knowledge used for food production or any 
knowledge vital for life and survival 
3. Economic. knowledge with strong ties to 
the economic survival or benefit of the TK 
stakeholders 
4. Traditional secret. knowledge that is 
held as a secret among the community 
(Disclosing knowledge within this category 
to the general public would be culturally 
inappropriate.) 
5. Medicinal. knowledge used to cure 
or prevent medical ailments within a 
community
6. Historic. knowledge that is of historic im-
portance to the community 
8.2	 Determining	community	goals
When evaluating a knowledge claim and deter-
mining potential options for protection, the goals 
and interests of the community are important to 
consider. Five categories may be used for deter-
mining community goals for a claim:
1. Profit. commercializing and receiving fi-
nancial gains or other economic benefits 
from TK
2. Dissemination for public good. sharing 
TK in order to benefit others (This goal is 
particularly applicable to TK with medici-
nal or agricultural uses.)
3. Avoiding exploitation. preventing the 
harming or usurpation of culture and envi-
ronment (Control over knowledge, the way 
it is used, and its concurrent effects on the 
culture and environment are important to 
the TK stakeholders.) 
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Knowledge claim identified
Where did this claim 
originate?
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No one else - C
Another individual - C
Multiple inidviduals - A
Community - A
Outside community





No one else - A
Another individual - A
Multiple inidviduals - A
Community - A
Outside community
No one else - A
Another individual - A
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4. Avoiding inappropriate IP claims. avoid-
ing IP claims on community knowledge or 
resources by outsiders (The protection of 




Once TK has been identified and the cultural and 
goal-oriented dimensions of the knowledge ex-
plored, stakeholders should cross-reference these 
cultural values and goals with relevant IP options 
available in a given country.
9.	 ConCluSIonS
This chapter explains possible IP mechanisms that 
might be applied to protect TK and biological re-
sources. Our experience shows that it has served 
more as an educational resource to alert TK hold-
ers to the possible risks of others seeking IP rights 
protection than as a resource for seeking IP rights 
protections themselves. Yet, it is true that over the 
past several years a growing number of TK hold-
ers have started to explore the potential use of IP 
protections. Still, for many reasons, TK remains 
elusive to current IP laws. 
Local and indigenous peoples’ management 
and protection of IP rights associated with their 
biological resources and TK remain a challenge. 
In order to address this challenge, it will be 
necessary to properly recognize and protect TK 
and also to employ global mechanisms for eq-
uitable benefit sharing. In the more-immediate 
term, existing mechanisms of IP rights protec-
tion will need to be effectively utilized in order 
to confer adequate protection and benefit shar-
ing. However, in the longer term, changes to 
both the domestic and global IP regimes might 
be required. Yet, regardless of the exact type of IP 
rights protection employed, the end result must 
always be aimed toward a balance, that is, to bet-
ter protect and provide equitable benefit to the 
originators of that TK while serving the broader 
public interest. In other words, access, develop-
ment, and distribution must be balanced against 
equitable benefit sharing, sustainable develop-
ment, and conservation. ■
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ABSTRACT
In the years since the Convention on Biological Diversity 
was adopted, issues of traditional knowledge have come 
to affect the legitimacy of the multilateral trading system, 
in general, and its IP (intellectual property) aspects, in 
particular. In order to engage indigenous knowledge in 
furthering socio-economic development, policy-makers 
will need to reconsider the prevailing notion of a fun-
damental dichotomy between indigenous and scientific 
knowledge and begin to challenge both types of knowl-
edge. This chapter concentrates on traditional knowl-
edge—and how it relates to the ecology of agriculture, 
in all of its variants—and compares it to recent advances 
in scientific knowledge and the resulting applications of 
biotechnology in global agriculture. 
The chapter argues that this dichotomy between tra-
ditional and scientific ways of knowing is not only arti-
ficial but problematic, in that it hinders exchange and 
communication between the two. The dichotomy be-
tween traditional knowledge and scientific knowledge is 
most apparent in, and lies at the root of, perceived differ-
ences between the approaches of today’s organic farming 
and technology-intensive farming systems. While indeed 
there are important differences, traditional knowledge 
and scientific knowledge share important similarities. 
Knowledge, in both cases, is based on human observation 
and experience and is tested, replicated, and transmitted 
within its respective community through social insti-
tutions and mechanisms put in place for that purpose. 
Moreover, deeper examination of the genetic integrity of 
plants used within organic and biotechnology-based ag-
ricultural systems shows that the respective crop varieties 
being used under each system are more similar than they 
are different. Increasingly, organic farming is building on 
scientific knowledge, and agricultural biotechnology is 
seeking to draw on traditional knowledge.
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1.		 InTRoduCTIon:	gloBAl	TRendS	In	
BIodIveRSITy	pRoTeCTIon
Since the adoption of the Convention on 
Biological Diversity in 19921 the legal status of 
plant genetic resources and traditional knowledge 
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This chapter challenges policy-makers and scientists to 
examine and, ultimately, to move beyond those concep-
tual worldviews, or constructs, that maintain the current 
divide between traditional knowledge/organic agriculture 
and scientific knowledge/agricultural biotechnology. 
By building the bridge between traditional knowl-
edge and science and becoming free to draw upon the 
best existing ideas and practices from both, a larger palate 
is available to draw from. But, more importantly, by in-
tegrating the innovation systems of both traditional and 
scientific communities, a much larger range of new ideas 
and practices could be generated. The chapter calls such 
dynamic integration the “participatory approach” to agri-
cultural innovation, building upon the “unifying power of 
sustainable development” and leading to balanced choices 
in agricultural production chains and rural land use. 
Such an integration would require adaptations of 
Western social institutions and mechanisms of intellectual 
property in order to interface in a more nuanced fashion 
with quasi-public-domain knowledge that is external to 
the published records of Western science and IP systems. 
At the same time, indigenous communities will need to 
learn to adapt their social institutions and mechanisms 
that govern what is, in a sense, sovereign or communal 
property to coexist with and at times be translated into 
formal IP rights and practical uses that are external to 
their traditional systems.
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has received increasing attention in international 
fora, non-governmental organizations (NGOs), 
and academic research. Several factors have stim-
ulated this ongoing debate: the steady loss of bio-
diversity in plant genetic resources;2 the contrast 
between protected plant varieties and genetically 
engineered products, on the one hand, and tradi-
tional crops and landraces in the public domain, 
on the other hand; the advent of the Agreement 
on Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) under WTO; and the 
International Treaty on Plant Genetic Resources 
for Agriculture.3 The Doha Agenda Ministerial 
Declaration4 explicitly endorsed the issue of tradi-
tional knowledge as a subject for further negotia-
tion. What was, some years ago, a concern limited 
to the ecological aspects of preserving biodiversity 
has moved to center stage. Today, policy-makers 
recognize that traditional knowledge affects the 
legitimacy of the multilateral trading system, in 
general, and its intellectual property aspects, in 
particular, as well as its interface with modern ag-
ricultural and environmental policies. 
One of the difficulties in advancing toward 
any resolution or consensus in this debate is the 
relationship between varying negotiation pro-
cesses in different fora. Another related problem 
involves the contradictory relationships between 
regulatory agencies at different levels (interna-
tional, regional, and local) in dealing with tra-
ditional knowledge.5 While it will be of prime 
importance to move toward a reconciliation be-
tween the CBD and the TRIPS agreement,6 any 
progress must take into account the full complex-
ity of issues related to biodiversity.7, 8 Such recon-
ciliation will not come easily. 
To productively engage indigenous knowl-
edge in efforts for economic development, 
policy-makers will need to reconsider the no-
tion of a dichotomy of indigenous and scientific 
knowledge and begin to challenge both types of 
knowledge. Doing so will mean developing both 
greater autonomy for participating in the pro-
duction of new knowledge and envisioning new 
approaches to regulating science. The Cartagena 
Biosafety Protocol, in particular, is today seen 
by many in the scientific community as having 
gone too far, imposing inordinately high levels 
of regulation, focusing excessively on transgenic 
plants (as opposed to other potential biosafety 
risks), and taking into account only the risk side 
of the equation of human welfare. Agricultural 
innovation has always been knowledge based, re-
lying foremost on farmers’ experience. With the 
development of modern science and its applica-
tions to agriculture, the situation has changed 
considerably. Without a doubt, agriculture owes 
many of its recent advances to the rapid growth 
of scientific knowledge, in both ecology and mo-
lecular biology. Yet, this advancement has been 
accompanied by a lack of awareness of tradi-
tional agricultural knowledge and even an active 
disregard for it.
To move toward a possible resolution, terms 
of the debate, it is of prime importance to rec-
oncile the terms of the CBD and the TRIPS 
Agreement. In critiquing what some would call a 
utopian attempt to strengthen the position of in-
digenous peoples relative to other populations, it 
is necessary to examine the basic question of how 
power structures knowledge. Otherwise attempts 
to address the interests of indigenous people will 
inevitably fail. This will also necessitate challeng-
ing and changing government policies, ques-
tioning science, and strengthening independent 
decision-making processes among indigenous 
peoples. Simply to document traditional knowl-
edge will not be enough. To bring indigenous 
knowledge to bear on agricultural and economic 
development, we must go beyond the dichotomy 
of indigenous versus scientific knowledge and 
work toward a better integration of the two. 
It is also essential to adapt the regulation and 
application of IP systems to include humanitar-
ian (that is, nonmarket) aspects of knowledge 
use in order to reconcile science-based agricul-
ture with the needs and practices of traditional 
agriculture. Industry leaders and academicians 
in the field of biotechnology have recognized 
this, voluntarily developing and introducing 
new approaches to IP management that begin to 
affirm the inextricably public aspects of knowl-
edge generation and to acknowledge that the 
extremely low cash flow of smallholders in the 
developing world will not generate significant 
royalties.9, 10
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It will be necessary to overcome the compart-
mentalized views held within the halls of Western 
science and begin to integrate traditional knowl-
edge into the scientific learning process. The Rio 
Convention is a remarkable framework document 
toward these ends. It succeeds in creating an open-
ing for this kind of shift by focusing, not merely on 
conservation, but also on the sustainable use of ge-
netic resources and the fair sharing of benefits that 
may arise from them. In particular, the provisions 
concerning access and benefit sharing (ABS) and 
the protection of traditional knowledge emerged 
as a viable way forward, creating room for the de-
velopment of innovative solutions. 
In addition, the dichotomy between Western 
science and traditional knowledge has caused a 
growing divide in the views held by the leaders 
of the international agricultural research com-
munity. The concept of biodiversity has too often 
in the public arena evolved into an unreflected 
mantra of environmentalists. While many today 
can agree that agriculture needs to become more 
sustainable—and that sustainability, in a broad 
sense, does have an important relationship with 
measures of biodiversity—what is needed is a 
precise analysis of the role of biodiversity within 
the actual context of all the complex elements of 
global agriculture, including the compelling need 
for ever-higher productivity.
This chapter concentrates on traditional 
knowledge—and how it relates to the ecology of 
agriculture in all of its variants—and compares 
it to recent advances in scientific knowledge 
and the resulting applications of biotechnol-
ogy in global agriculture. The notion of a deep 
contrast between agriculture that is based on 
traditional knowledge and agriculture based on 
scientific knowledge is challenged. While on the 
surface there are major cultural and philosophi-
cal differences in the conceptual underpinnings 
of traditional and scientific knowledge, there are 
also striking similarities. In order to overcome 
major misunderstandings and to create new 
and sometimes surprising understandings, this 
chapter advocates a discursive system of debate 
that takes into account different kinds of knowl-
edge and proceeds under a recognition of the 
“symmetry of ignorance.”11 
2.		 defInITIon	of	
TRAdITIonAl	Knowledge
Comparing indigenous cultures and Western cul-
ture, the contrasts in mode and structure seem 
obvious, leading to the assumption that the think-
ing of human beings from such diverse situations 
must somehow be intrinsically different. The 
religious rites and rituals of indigenous peoples 
can be perceived to be without parallel in con-
temporary postindustrial Western society. Worse 
yet, the tendency of some Western intellectuals 
is to romanticize indigenous cultures, celebrating 
the untapped richness—yet thereby making the 
perceived contrast even greater and obscuring or 
ignoring the commonalities in human thinking 
across all cultures.
According to Berkes, et al.,12 traditional 
knowledge is a way of knowing similar to that 
of Western science in that it is based on an ac-
cumulation of observations, but it is different 
from science in several other fundamental ways. 
The anthropologist Levi-Strauss13 argued that tra-
ditional knowledge and Western science are two 
parallel modes of acquiring knowledge about the 
universe, yet he observes that “the physical world is 
approached from opposite ends in the two cases: one 
is supremely concrete, the other supremely abstract.”
Similarly, the philosopher Feyerabend14 dis-
tinguished between two different traditions of 
human thought: abstract traditions (to which 
science belongs) and historical traditions (which 
include most systems of knowledge by people 
outside Western science), the latter being those 
through which knowledge becomes encoded in 
rituals and in the cultural practices of everyday 
life. 
Traditional knowledge may be holistic in 
outlook and adaptive by nature, gathered over 
generations by observers whose lives depended 
directly on the quality of information and its use. 
It often accumulates incrementally, its reliability 
is assessed through trial and error, and it is trans-
mitted to future generations orally or by shared 
practical experiences.15
Case studies reveal that there exists a diver-
sity of local, or traditional, practices for ecosys-
tem management.16 These include multiple-spe-
cies management, resource rotation, succession 
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management, landscape-patchiness management, 
and other ways of responding to and managing 
ecological pulses and surprises. Social mecha-
nisms behind these traditional practices include 
a number of adaptations for the generation, ac-
cumulation, and transmission of knowledge, 
the use of local institutions to provide leaders/
stewards and rules for social regulation, mecha-
nisms for cultural internalization of traditional 
practices, and the development of appropriate 
world views and cultural values. The use of the 
term traditional ecological knowledge has become 
established, among others, through the work of an 
international conservation union (IUCN) work-
ing group17, 18 and traditional ecological knowledge 
and wisdom (TEKW) has become established as a 
major term in all fields of ecology, including agri-




Agrawal22 and Agrawal23 both claim that by dis-
tinguishing indigenous knowledge from scientific 
knowledge, theorists are caught in a dilemma. 
Focus on indigenous knowledge has gained in-
digenous peoples an audible voice in develop-
ment circles. Yet, this distinction creates and 
perpetuates the dichotomy between indigenous 
and scientific ways of knowing. This dichotomy 
is especially problematic because it often hinders 
exchange and communication between the two. 
Further, both Agrawal and Agrawal argue that the 
basic distinction between indigenous and scien-
tific knowledge is artificial. 
This artificial barrier, I will contend, is one of 
the primary reasons why there appears to be such 
a distinct contrast between traditional organic or 
subsistence farming and technologically intensive 
agricultural methods, including biotechnology. 
Most scientists depict traditional knowledge as 
somehow unable to learn from experience, fuzzy 
in its concepts, and closed to conceptual inputs 
from the outside, whereas science is open to new 
thought, precise in its empirically tested prog-
ress, and responsive to the real needs of farmers. 
Critics of science, however, mistrust it for being 
too abstract, analytical, and divorced from the 
needs of real people. 
The reality in both cases is different from the 
perception. Closer consideration reveals that the 
differences are indeed much smaller. Traditional 
knowledge that has accumulated since ancient 
times and been transmitted by oral tradition has 
often turned out to be strikingly precise when 
tested against empirical observation. Indeed, 
given the test of time, traditional knowledge is 
verified or falsified by experiment and observa-
tion. And, in Western science, oral tradition is 
certainly present: scientific communities with dif-
ferent views and lexicons continue to exist region-
ally despite the homogenizing influences of the 
scientific literature and the Internet (for instance 
in botanical nomenclature). Feyerabend notes 
critically, that scientists are often closed to mat-
ters outside science.24 However, as Karl Popper25, 26 
rightly claims, a line must be drawn when a theory 
cannot be falsified: in such a case a theory should 
not be called scientific. Traditional knowledge is 
of course open to similar scrutiny.
Indeed, there are a number of authors who 
emphasize the commonalities between scientific 
and traditional knowledge without making the 
mistake of turning the terms into synonyms. 
Horton, 27, 28 for instance, cannot understand why 
some persons, familiar with theoretical thinking 
in their own Western tradition, have failed to 
recognize its African equivalents. He contends 
that they simply have been blinded by differences 
in idiom and that exhaustive exploration of fea-
tures common to Western and traditional African 
thought should come before any enumeration 
of differences. The same can be argued for the 
comparison between Western, science-based ag-
riculture and all kinds of traditional agricultural 
practices. 
The following sections seek to advance such 
a comparison between two apparently very dif-
ferent approaches to agriculture. In this case, the 
comparison is between organic agriculture and 
biotechnology-based agriculture, leaving out, for 
reasons of simplicity, the wider range of other 
agricultural approaches. Based on the lines of 
reasoning developed above, effort is made not 
to be distracted by the “idiomatic” contrasts or 
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distinctions drawn between the two, but to ex-
plore the commonalities. In fact, both strategies 
considered here comprise elements of traditional 
knowledge and empirical precision. Differences 
drawn between the two are based on emphasiz-




Organic farming (including some aspects of agro-
ecological approaches to farming as referred to 
by Altieri and Nicholls29) started as a heteroge-
neous set of alternative-management methods in 
agriculture. This explains the multiple origins of 
organic farming and the fact that certifications of 
organic-farming practices have been introduced 
separately in various times and places. Organic 
farming is now growing rapidly and becoming 
a viable industry in its own right. Harmonizing 
standards and regulations are being developed and 
imposed more or less strictly on organic farms, 
both by states, like California,30 and by national 
government agencies, like the U.S. Department 
of Agriculture. 
Today, the International Federation of 
Organic Agriculture Movements (IFOAM) is 
serving to unite the various organic movements 
of the world, with members in 108 countries 
and support from the UN Food and Agricultural 
Organization (FAO). IFOAM advances basic 
views on organic farming, such as the following 
four principles:31
1. Principle of health. Organic Agriculture 
should sustain and enhance the health of soil, 
plant, animal, human and planet as one and 
indivisible.
2. Principle of ecology. Organic Agriculture 
should be based on living ecological systems 
and cycles, work with them, emulate them, 
and help sustain them.
3. Principle of fairness. Organic Agriculture 
should build on relationships that ensure fair-
ness with regard to the common environment 
and life opportunities.
4. Principle of care. Organic Agriculture 
should be managed in a precautionary and 
responsible manner to protect the health and 
well-being of current and future generations 
and the environment.
Specific rules for organic agriculture are still 
the subject of international debate, given efforts 
to improve them, to find the right mix between 
regulatory strictness and diversity of applica-
tions. Some important documents in circulation 
intentionally go beyond the basic agreed-upon 
principles of organic farming 32,33,34,35 in order to 
stimulate discussion and to propose targets.
The main Swiss rules for organic agriculture 
are as follows:36 
• Natural cycles and processes are respected.
• The use of chemical-synthetic substances is 
avoided.
• The use of GMOs is not allowed, nor their 
derivatives, exception: products for veterinary 
medicine.
• The products shall not be treated with radia-
tion, and no products having undergone ir-
radiation shall be used. 
Since 2005 an official definition document 
on organic agriculture37 has been in a process of 
transparent deliberation and elaboration. The lat-
est language, which has not yet received definite 
approval, describes it as follows:
Organic agriculture, as defined by IFOAM, 
includes all agricultural systems that promote en-
vironmentally, socially and economically sound 
production of food and fibers. Recycling nutrients 
and strengthening natural processes helps to main-
tain soil fertility and ensure successful production. 
By respecting the natural capacity of plants, animals 
and the landscape, it aims to optimize quality in all 
aspects of agriculture and the environment. Organic 
Agriculture dramatically reduces external inputs by 
refraining from the use of synthetic fertilizers and 
pesticides, Genetically Modified Organisms and 
pharmaceuticals. Pests and diseases are controlled 
with naturally occurring means and substances ac-
cording to both traditional as well as modern scien-
tific knowledge, increasing both agricultural yields 
and disease resistance. Organic agriculture adheres 
to globally accepted principles, which are imple-
mented within local socio-economic, climatic and 
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cultural settings. As a logical consequence, IFOAM 
stresses and supports the development of self-support-
ing systems on local and regional levels.38 
It is notable that debate over the very definition 
of organic agriculture persists. The problem is that 
top-down regulation of organic agriculture means 
coming to terms with standards met also in tradi-
tional agriculture, such as defining levels of toxicity 
for biopesticides, which is often not easy.39
Altieri summarizes agroecology, following 
Reijntjes, Haverkort, and Waters-Bayer,40 with 
the following principles:41,42,43,44 
• Enhance recycling of biomass and optimizing 
nutrient availability and balancing nutrient 
flow 
• Securing favorable soil conditions for plant 
growth, particularly by managing organic 
matter and enhancing soil biotic activity
• Minimizing losses due to flows of solar radia-
tion, air and water by way of microclimate 
management, water harvesting and soil man-
agement through increased soil cover
• Species and genetic diversification of the agro-
ecosystem in time and space
• Enhance beneficial biological interactions and 
synergisms among agrobiodiversity compo-
nents, thus resulting in the promotion of key 
ecological processes and services
Details of modern breeding methods are still 
controversial in organic agriculture communities. 
While genetic engineering itself is widely reject-
ed, IFOAM agrees to the use of tissue culture and 
genetic assays, including genetic-marker-assisted 
breeding.45 Note that Altieri and colleagues do 
not explicitly exclude transgenic plants in princi-
ple, while they clearly do not agree with the prac-
tices of multinational corporations advancing this 
technology. Some organic rules do not take any 
position on mutagenesis (traits introduced by 
genetic changes resulting from exposure to ra-
diation or chemicals). This may not be unusual, 
since many successful crop traits have come from 
this method in the past. 
Another breeding-related controversy is that 
of new hybrid crops: whereas many organizations 
in organic agriculture accept hybrid maize, since 
this is a biological phenomenon that cannot be 
easily reversed or avoided, most are opposed to 
the introduction of more hybrids in other crops. 
In summary, organic farming has strong roots 
in traditional-agricultural knowledge. Today, it is 
drawing more and more on scientific research. 
Finding the right balance between these two 
sources of knowledge will continue to precipitate 
discussion within organic agriculture communi-
ties. Furthermore, the spectrum of different vari-
ants within organic and agroecological farming 
continues to expand and widen, ranging from 
integrated-pest-management techniques, used 
in conventional farming, to mainstream organic 
forming, to agroecological farming, and even to 
extreme forms of biodynamic farming.
In a number of developing countries, there 
are clear intentions to develop transgenic plants 
for use in subsistence farming, as indicated by sta-





Van Bueren, et al.,48 explore the nature of genetic 
engineering at the molecular level, in an effort to 
explain why organic farming cannot accept plant 
varieties manipulated by biotechnology. Following 
Verhoog, et al.,49 they posit “naturalness” as not 
only the avoidance of synthetic chemical inputs 
and the application of agroecological principles 
in cultivation, but also the maintenance of the 
“intrinsic integrity” of the organisms being cul-
tivated, including the integrity of their genomes. 
Their definition of the integrity of plant genomes 
is as follows: 
The general appreciation for working in conso-
nance with natural systems in organic farming ex-
tends itself to the regard with which members of the 
movement view individual species and organisms. 
Species, and the organisms belonging to them, are 
regarded as having an intrinsic integrity. This integ-
rity exists aside from the practical value of the species 
to humanity, and it can be enhanced or degraded 
by management and breeding measures. This kind 
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of integrity can only be assessed from a biocentric 
perspective … Organic agriculture assigns an ethical 
value to this integrity, and encourages propagation, 
breeding, and production systems that protect or en-
hance it. 
And further:
... biocentric perspective, organic agriculture 
acknowledges the intrinsic value and therefore the 
different levels of integrity of plants as described 
above. The consequence of acknowledging the in-
trinsic value of plants and respecting their integrity 
in organic agriculture implies that the breeder takes 
the integrity of plants into account in his choices of 
breeding and propagation techniques. It implies that 
one not merely evaluates the result and consequences 
of an intervention, but in the first place questions 
whether the intervention itself affects the integrity 
of plants. From the above described itself affects the 
integrity of plants.
Then, based on the nature of plants and their 
characteristics, a number of criteria, characteris-
tics, and principles for organic plant breeding and 
propagation are excluded for violating the integ-
rity of plants: for example, all breeding methods 
using chemicals or radiation—such as colchicine 
or gamma-radiation-induced mutants—all meth-
ods not allowing a full life cycle of the plant, and 
all methods manipulating the genome of the or-
ganisms. Unfortunately, the authors do not in-
quire very deeply into questions of the extent to 
which the structures and assembly of common 
crop species DNA has in fact been changed or 
manipulated by centuries of traditional selection 
and breeding.
For example, all varieties of wheat used to-
day—by organic as well as conventional farm-
ers—are a product of processes by which the 
genome has been subjected to numerous funda-
mental changes, and those changes have been suc-
cessfully integrated inside the organism known 
today as wheat. These modifications include the 
addition of chromosome fragments, the integra-
tion of entire foreign genomes, and radiation-in-
duced mutations (in the case of Triticum durum). 
Indeed, chromosome inversions and transloca-
tions are well documented in most major crops. 
Thus, the reality of all systems of agriculture 
is such that most of the principles of genomic 
integrity, as advocated by Van Bueren and col-
leagues,50,51,52 have long since been violated in 
almost all existing crops, and the naturalness or 
genomic integrity cannot be regained, unless the-
oretically one goes back to the ancestral genomes 
(which, in the case of each of the major crops, 
have not survived the intervening centuries of 
classical breeding). So, in reality, the principle of 
the “intrinsic integrity” of agricultural plant ge-
nomes is, at best, a fiction. 
Other advocates of preserving the intrinsic 
integrity of organisms advise against crossing the 
natural hybridization barriers between species. 
Yet, species barriers have been overcome by tradi-
tional-breeding methods for decades, as well as by 
methods of biotechnology. Here the most salient 
example is somatic hybridization, which involves 
the nonsexual fusion of two somatic cells. The ad-
vantage of this method is that, by the fusion of 
cells with different numbers of chromosomes (for 
instance, from different species of Solanum) fertile 
products of the crossing can be obtained imme-
diately. As a result, the polyploid plants that are 
obtained contain all of the chromosomes of both 
“parents,” instead of the usual half set of chro-
mosomes obtained through sexual reproduction. 
In order to achieve such somatic hybridization, 
required are cells, the walls of which have been 
digested away by enzymes, that are then enclosed 
only by their cell membranes (so called protoplast 
cells). With the loss of their cell walls, protoplasts 
also lose their typical shape and become spherical, 
like egg cells. The mixture of cells is then exposed 
to electric pulses to induce fusion. In order to get 
the “right“ fusion product (since the fusion of 
two cells from the same parent plant can also oc-
cur) distinct selectable markers are necessary from 
each of the original parent plants. Only cells that 
survive this double selection are genuine products 
of fusion. The easiest way of implementing two 
such selectable markers is by genetic engineer-
ing, such as incorporating antibiotic resistance 
genes into the original parent plants. Such pro-
cesses of protoplast fusion have been investigat-
ed and applied to potatoes, for instance. Under 
European Union (E.U.) regulations concerning 
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the deliberate release of GMOs into the environ-
ment, somatic hybrids are not considered GMOs 
and do not require authorization. In fact, the 
most recent draft of E.U. organic regulations, in 
which the introduction of GMOs in organic cul-
tivation is forbidden, follows the definition given 
earlier.53, 54 
The concept of the naturalness or intrinsic in-
tegrity of plant genomes is also challenged by ob-
servations of Arber (a 1978 Nobel laureate) of the 
insertion of genes across natural species barriers 
in the case of naturally transgenic grasses.55 Arber 
compared designed genetic alterations (including 
genetic engineering) with spontaneous genetic 
variations, those variations on which natural se-
lection then operates to drive evolution:56
Site-directed mutagenesis usually affects only 
a few nucleotides. Still another genetic variation 
sometimes produced by genetic engineering is the re-
shuffling of genomic sequences, e.g. if a given open 
reading frame is brought under a different signal for 
expression control or if a gene is knocked out. All 
such changes have little chance to change in funda-
mental ways, the properties of the organism. In ad-
dition, it should be remembered that the methods of 
molecular genetics themselves enable the researchers 
anytime to verify whether the effective genomic alter-
ations correspond to their intentions, and to explore 
the phenotypic changes due to the alterations. This 
forms part of the experimental procedures of any re-
search seriously carried out. 
Interestingly, naturally occurring molecular 
evolution, i.e. the spontaneous generation of genetic 
variants has been seen to follow exactly the same 
three strategies as those used in genetic engineering. 
These three strategies are: 
(a) small local changes in the nucleotide 
sequences,
(b) internal reshuffling of genomic DNA seg-
ments, and
(c) acquisition of usually rather small segments of 
DNA from another type of organism by hori-
zontal gene transfer. 
However, there is a principal difference between 
the procedures of genetic engineering and those serv-
ing in nature for biological evolution. While the ge-
netic engineer pre-reflects his alteration and verifies 
its results, nature places its genetic variations more 
randomly and largely independent of an identified 
goal. Under natural conditions, it is the pressure of 
natural selection which eventually determines, to-
gether with the available diversity of genetic vari-
ants, the direction taken by evolution. It is inter-
esting to note that natural selection also plays its 
decisive role in genetic engineering, since indeed not 
all pre-reflected sequence alterations withstand the 
power of natural selection. Many investigators have 
experienced the effect of this natural force which 
does not allow functional disharmony in a mutated 
organism.
Genetic modifications of plant genomes may 
in fact be common. Recently, another natural 
transgenic plant was discovered by Ghatnekar, 
Jaarola, and Bengtsson,57 involving the introgres-
sion of a functional nuclear gene from Poa to 
Festuca ovina. Yet other work reinforces the com-
parison, at the genomic level, between natural 
evolutionary processes and modern modifications 
of plant genetics through biotechnology.58,59,60 
Still, despite such similarities, there is one 
major difference: natural genetic variation and 
selection acts on a completely different timescale 
from transgenic agriculture. Naturally occurring 
mutants that survive in the wild can take from 
hundreds to millions of years to survive selection 
pressures and finally take over against their pre-
existing competitors. With transgenic crops the 
timescale is totally different. They run through 
a research, development, and regulatory process 
that lasts, on average, 15 to 20 years after which 
the successful ones are completely deregulated. 
These can then be propagated nationally and cov-
er millions of hectares within an extremely short 
time span on the evolutionary clock.
This basic insight of molecular biologists has 
been confirmed in analysis of modern breeding 
processes. The best example here is a comparison 
at the genomic level between transgenic and non-
transgenic wheat by Shewry et al.: 61
Whereas conventional plant breeding involves 
the selection of novel combinations of many thou-
sands of genes, transgenesis allows the production 
of lines which differ from the parental lines in the 
expression of only single or small numbers of genes. 
Consequently it should in principle be easier to 
predict the effects of transgenes than to unravel the 
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multiple differences which exist between new, con-
ventionally-produced cultivars and their parents. 
Nevertheless, there is considerable concern expressed 
by consumers and regulatory authorities that the 
insertion of transgenes may result in unpredictable 
effects on the expression of endogenous genes which 
could lead to the accumulation of allergens or toxins. 
This is because the sites of transgene insertion are not 
known and transgenic plants produced using biolis-
tics systems may contain multiple and rearranged 
transgene copies (up to 15 in wheat) inserted at sev-
eral loci which vary in location between lines.62,63 
Similarly, this apparently random insertion has led 
to the suggestion that the expression of transgenes may 
be less stable than that of endogenous genes between 
individual plants, between generations and between 
growth environments. Although there is evidence 
that the expression of transgenes introduced by bi-
olistic transformation is prone to silencing in a small 
proportion of wheat64,65… recent reviews66,67,68,69  ... 
demonstrate the utility of biolistics transformation as 
a basis for stable genetic manipulation.
Such studies confirming the stability of trans-
genic integrations70,71 have been extended to oth-
er methods of transformation, such as the direct 
insertion of DNA fragments,72 with some ques-
tions remaining about the long-term stability of 
agrobacterium-mediated transformations.73 But, 
some of the most interesting observations in this 
line of inquiry about genome integrity have been 
documented by Baudo, et al., 74 showing that the 
measured genomic disturbances from traditional 
breeding can be greater than the genomic distur-
bances from genetic transformation:
Detailed global gene expression profiles have 
been obtained for a series of transgenic and conven-
tionally bred wheat lines expressing additional genes 
encoding HMW (high molecular weight) subunits 
of glutenin, a group of endosperm-specific seed stor-
age proteins known to determine dough strength 
and therefore bread-making quality. Differences in 
endosperm and leaf transcriptome profiles between 
untransformed and derived transgenic lines were 
consistently extremely small, when analyzing plants 
containing either transgenes only, or also marker 
genes. Differences observed in gene expression in the 
endosperm between conventionally bred material 
were much larger in comparison to differences be-
tween transgenic and untransformed lines exhibit-
ing the same complements of gluten subunits. These 
results suggest that the presence of the transgenes did 
not significantly alter gene expression and that, at 
this level of investigation, transgenic plants could 
be considered substantially equivalent to untrans-
formed parental lines.
An ironic consequence of such results is that 
organic farming—by definition seeking to main-
tain the integrity of the plant genome by mini-
mizing artificial DNA disturbances—should 
in such cases favor the genetically engineered 
variety. A more general conclusion may be that 
transgenic crops should not have been subject 
to regulations based purely on the fact that they 
resulted from the methodology of genetic engi-
neering. Rather, it would have been more con-




The social impacts and implications of modern 
agricultural biotechnology have their origins in 
the Green Revolution, a term coined by William 
Gaud at a 1968 meeting of the U.S. Agency for 
International Development (USAID) referring to 
the extremely successful agricultural movement 
through which new crop varieties, improved ir-
rigation, adopted fertilizers and pesticides, and 
installed mechanization resulted in crop yields 
increasing dramatically, particularly in Asia. 
One of the key innovations that drove the 
Green Revolution was the genetic improvement 
of plant varieties, especially the introduction of 
dwarf and semi-dwarf traits, in which stem height 
was reduced but the size of panicles, and thus 
seed production was not reduced. However, the 
yield gains of the Green Revolution also depend-
ed upon the application of high doses of chemi-
cal fertilizers and copious irrigation. Abundant 
yields attracted a variety of pests, and, therefore, 
chemical pesticides needed to be applied in great-
er volume. In addition, new crop varieties were 
also selected for photo-insensitivity, so that they 
could be adapted for multiple cropping sequenc-
es, patterns, and latitudes. 
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Evenson and Gollin75 provide a thorough as-
sessment of the Green Revolution, showing how 
over the period 1960 to 2000 the international 
agricultural research centers, in collaboration with 
national agricultural-research programs, contribut-
ed to the development of modern varieties in many 
crops. These varieties contributed to large increases 
in crop production. Productivity gains, however, 
were uneven across crops and regions. Consumers 
generally benefited from the resulting decline in 
food prices, but farmers benefited only where cost 
reductions exceeded those price reductions.
Two names are intimately linked to the 
Green Revolution: Norman Borlaug (who was 
awarded the Nobel Peace Prize in 1970)76,77,78 and 
Monkombu Sambasivan Swaminathan (who was 
awarded the World Food Prize in 1987).79,80 Yet, 
very early on, Swaminathan warned of unwelcome 
developments related to the Green Revolution: 
The initiation of exploitive agriculture without 
a proper understanding of the various consequences 
of every one of the changes introduced into tradi-
tional agriculture, and without first building up 
a proper scientific and training base to sustain it, 
may only lead us, in the long run, into an era of 
agricultural disaster rather than one of agricultural 
prosperity. 81
As the successes of the Green Revolution 
were becoming manifest together with its detri-
mental effects—including the upsurge of insect 
pests, growing insect resistance against widely 
used pesticides, and negative effects on the soil 
fertility—Swaminathan felt obliged to call for an 
Evergreen Revolution, beginning as early as 1968, 
yet continuing all the way through 1990.82, 83 
Unfortunately, farmers’ access to free electricity 
to draw groundwater for irrigation, the negli-
gence of legumes in crop rotations, and the in-
discriminate application of chemical fertilizers 
and pesticides culminated in the degradation 
of soil and water. The damage to the ecological 
foundations essential for sustainable advances in 
productivity led to the onset of fatigue in agri-
cultural systems.
Lessons drawn from the Green Revolution 
are that steps taken toward productivity en-
hancement should concurrently address the 
conservation and improvement of soil, water, 
and biodiversity, as well as providing for the at-
mosphere and renewable energy sources. Keeping 
these goals in focus, the goals of the Evergreen 
Revolution for achieving higher productivity in 
perpetuity were developed. What this calls for is 
a system of agriculture that involves sustainable 
management of natural resources, while progres-
sively enhancing soil quality, biodiversity, and 
productivity. 
Only much later has biotechnology proven to 
be able to contribute to the goals of the Evergreen 
Revolution, since it helps to enhance some of 
the ecological factors.84,85,86,87 Biotechnology has 
proven to reduce pesticide use, positively influ-
ence nontarget insect populations, and induce 
no-tillage management practices that are benefi-
cial to soil fertility.88, 89 
An example of new biodiversity strategies 
fostered by a company known for the production 
of pesticides has been published by Dollaker and 
Rhodes.90, 91 They propose to integrate crop pro-
ductivity and biodiversity within pilot projects, 
jointly addressing the challenges of achieving 
crop productivity and biodiversity conservation 
objectives. Three pilot initiatives, developed by 
Bayer CropScience in Brazil, Guatemala, and 
the U.K. in collaboration with a variety of lo-
cal stakeholders, illustrate how conservation ob-
jectives can be embedded in land-management 
practices that enhance agricultural productiv-
ity and profitability, thereby addressing both 
food security and biodiversity-conservation 
challenges.
A new variant of industrial farming, develop-
ing in the United States, is called precision farm-
ing. It is a management system based primarily 
on a combination of information technologies, 
including networked computing, satellite moni-
toring, and automated guidance systems for farm 
machinery. Precision farming can save time and 
energy and, by reducing unnecessary applica-
tions of chemicals and irrigation, can lead to a 
more ecological farming with higher yields.92,93,94 
Methods of precision farming do not contradict 
the main principles of organic farming and, thus, 
could be seriously considered as helpful auxiliary 
methods.
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6.	 SuSTAInABIlITy	And	BIodIveRSITy
All agricultural systems must include the ability 
to provide an economic return to the farmer; un-
profitable agricultural systems will not survive un-
less they are subsidized. In the cases of the United 
States and Europe, such policies are problematic 
in the long run for many reasons. Today’s farming 
systems must provide opportunities to produce 
more food on smaller acreages.
Related to this imperative are issues concerned 
with maintaining and enhancing output, such as 
soil fertility and reducing losses to weeds and pests. 
It is less easy to argue that a natural or diverse eco-
system is a critical input to sustainable agriculture. 
While ecologists frequently stress the inter-
relationships between species, it is difficult to see 
how the existence of species such as the swallow-
tail butterfly or a rare orchid could contribute to 
a farming system’s sustainability.95 The degree of 
redundancy in ecological communities is largely 
unknown and remains a rich field of investigation 
for ecologists. Agricultural systems can benefit 
from a higher biodiversity (not necessarily within 
the production surface) by presenting in the near 
vicinity of the production fields, biological net-
works hosting highly diverse arthropod popula-
tions, making the whole region more resistant to 
rapid pest invasions.96, 97 This is not to say that 
agriculture could continue in the absence of all 
nonfarmed species. Rather, there is a suggestion 
that only a subset of all existing species is essential 
for food and fiber production.98, 99
6.1	 About	sustainability	in	farming	systems
Definitions of sustainability are manifold. Some, 
such as that of the FAO100 concentrate on ecologi-
cal factors alone, while others concentrate only on 
management factors. The question that concerns 
us is whether organic farming or biotech farming 
is more sustainable. The answer is not clear, since 
the comparison often does not involve the same 
basic elements. 
In one example that challenges the common 
view, Edward-Jones and Howells101 come to the 
conclusion that organic-farming systems are not 
sustainable in the strictest sense. Considerable 
amounts of energy are put into organic-farming 
systems. The majority of the compounds utilized 
in crop protection are derived from nonrenew-
able sources and incur significant processing and 
transport costs prior to application. Nevertheless, 
the long-term balance of inputs clearly favors 
organic-farming systems.102,103,104,105 Whereas 
nutrient (nitrogen, phosphorus, and potassium) 
inputs into the organic systems seem to be 34 to 
51 percent lower than with conventional systems, 
mean crop yield was only 20 percent lower over a 
period of 21 years, indicating on balance an effi-
cient production. In the organic systems, the en-
ergy to produce a dry matter unit of crop harvest 
was 20 to 56 percent lower than in conventional 
agriculture and correspondingly 36 to 53 percent 
lower per unit of land area. 
On the other hand, many of the “biopesti-
cides” used to control pests are not without toxi-
cological hazards to humans and the environment. 
As an example, there are a number of research 
groups working on the difficult question of how to 
avoid, or at least reduce, the input of copper sul-
phate as a biopesticide. It is clear from some stud-
ies, that copper deposited in high concentrations 
has a negative impact on soil microbes. Pedersen, 
et al.,106 found that total microarthropod abun-
dance was highest at intermediate copper con-
centrations and linearly related to grass biomass. 
For single-species populations, no clear picture 
of abundance in relation to soil copper was seen, 
but two collembolan species, Folsomia quadriocu-
lata and Folsomia fimetaria, were among the most 
sensitive. The resulting Shannon-Wiener index 
of biodiversity decreased linearly with increasing 
soil copper concentrations. Those results imply 
that a short-term strategy would be to avoid high 
concentrations of copper in the soil, but in the 
long run it will be better to avoid copper sulfate 
as a biopesticide altogether.
Sustainability can also be measured on a 
larger scale with methods developed in Europe to 
measure landscape quality.107 Results need to be 
verified, but show positive influence of organic 
farming in Norway. What we can learn from this 
is that sustainability on all kinds of farming strat-
egies depends on the local circumstances and may 
not submit to overall categorization. It certainly 
depends on the weight given to specific factors 
of sustainability. In the author’s view, population 
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size and feeding the growing number of people 
should have a very high priority on any such 
scale. Again, the claim is made that traditional 
knowledge can contribute in important ways to 
developing sustainable practices in agriculture 
and silviculture.108
6.2	 Biodiversity	and	farming	systems
It is important to distinguish between overall 
biodiversity in a given farming-landscape sys-
tem, including the production area and biodi-
versity within the production system itself, the 
farm fields. The latter is often illusionary. Weeds 
within harvested fields are to be avoided, either 
by old-fashioned tilling or by various environ-
mentally acceptable herbicides. The reason is 
simple: for example, in wheat production systems 
some of the weeds cherished by conservationists 
such as Agrostemma ghitago are highly toxic be-
cause of their saponin and githagenin contents 
and can spoil the harvested grain even in low 
quantities.109
Many of the crops growing in farming sys-
tems around the world have ancestral parents that 
lived originally in natural monocultures.110 There 
are many examples of natural monocultures, 
such as the classic stands of kelp, Macrocystis pyr-
ifera, which was, in fact, analyzed by Darwin.111 
Ecologists now recognize that simple, monodomi-
nant vegetation exists throughout nature in a wide 
variety of circumstances. Indeed, Fedoroff and 
Cohen112 reporting on Janzen113, 114 use the term 
natural monocultures as analogous with the term 
crops. Monodominant stands may be extensive. In 
one example, Harlan recorded that for the blue 
grama grass (Bouteloua gracilis) “stands are often 
continuous and cover many thousands of square ki-
lometers” of the high plains of the central United 
States. It is of the utmost importance to agricul-
tural sustainability to determine how these exten-
sive, monodominant, natural grassland communi-
ties persist when we might expect their collapse. 
More examples are given of wild species 
in Wood and Lenne,115 including Picea abies, 
Spartina townsendii, Sorghum verticilliflorum, 
Phragmites communis, and Pteridium aquilinum. 
Early cultivars are also cited extensively,116 wild 
rice (Oryza coarctata), for instance, reported 
in Bengal as simple oligodiverse pioneer stands 
on temporarily flooded riverbanks.117 Similarly, 
Harlan 118 described and illustrated harvests from 
dense stands of wild rice in Africa (Oryza barthii, 
the progenitor of African cultivated rice, Oryza 
glaberrima). Oryza barthii was also harvested wild 
on a massive scale and served as a local staple 
across Africa, ranging from the southern Sudan 
to the Atlantic. Evans119 reported that the grain 
yields of such wild-rice stands in Africa and Asia 
could exceed 0.6 tons per hectare—an indica-
tion of the stand density in monocultures of wild 
rice. 
Botanists and plant collectors have, accord-
ing to Wood and Lenne,120 repeatedly and em-
phatically noted the existence of dense stands of 
wild relatives of wheat. For example, in the Near 
East, Harlan121 noted that “massive stands of wild 
wheats cover many square kilometers.” Hillmann122 
reported that wild einkorn (Triticum monococ-
cum subsp. boeoticum) in particular tends to form 
dense stands, and when harvested its yields per 
square meter often match those of cultivated 
wheats under traditional management. Harlan 
and Zohary123 noted that wild einkorn “occurs in 
massive stands as high as 2000 meters [elevation] 
in south-eastern Turkey and Iran.” Wild emmer 
(Triticum turgidum subsp. dicoccoides) “grows in 
massive stands in the northeast” of Israel, as an an-
nual component of the steppe-like herbaceous 
vegetation and in the deciduous oak park forest 
belt of the Near East.124 According to Wood and 
Lenne125 they are the strongest examples embrac-
ing wild progenitors of wheat. And Anderson126 
recorded wild wheat growing in Turkey and Syria 
in natural, rather pure stands with a density of 
300/m².
There are grounds for seriously rethinking 
the view of many agrobiologists that appear to 
uncritically accept that there was a loss of genetic 
diversity following the introduction of high-yield-
ing Green Revolution wheat and rice varieties in 
the 1960s and 1970s. The same is feared to fol-
low the rapid adoption of superior GM crops to-
day. There are several reasons for caution in these 
interpretations. 
There is evidence for genetic simplifications 
having occurred in ancient times. According to 
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the analysis of Fedoroff,127 thousands of years ago 
maize underwent a streamlining of its genome. 
Similar phenomena often occur in weeds like the 
chenopod Atriplex prostrata and are considered 
to have contributed to their exceptional migra-
tion ability since the last Glacial Maximum some 
18,000 years ago.128 
We can also paradoxically encounter an en-
hancement in genetic diversity in modern soy-
bean breeding. For example, Sneller129 looked at 
the genetic structure of the elite soybean popu-
lation in North America, using a coefficient of 
parentage (CP) analysis. Whereas common sense 
would tell us that soybean genetic diversity has 
diminished considerably in the wake of genetic 
engineering, there is hard data proving that the 
trend is not so simple, in fact, to the contrary, 
genetic diversity can also be enhanced through 
the introduction of herbicide-tolerant traits. The 
introduction of herbicide-tolerant cultivars with 
the Roundup Ready® trait was shown to have had 
little effect on soybean genetic diversity because 
of the widespread use of the trait in many local-
ized breeding programs. Only 1% of the variation 
in CP among lines was related to differences be-
tween conventional and herbicide-tolerant lines, 
while 19% of the variation among northern lines 
and 14% of the variation among southern lines 
was related to differences among the lines from 
different companies and breeding programs. 
In more-simple numbers of soybean traits: 
the new management conveniences associated 
with the herbicide-tolerant soybeans allowed 
for a more-liberal use of varieties, most of them 
transgenic.130 These include nearly 400 nema-
tode-resistant varieties of soybean from 48 seed 
companies and five universities. All but seven of 
the varieties listed contain nematode resistance 
derived from a certain breeding line PI 88788. 
Of the varieties listed, 286 are resistant to the her-
bicide Roundup®, six are tolerant to sulfonylurea 
herbicides, and the remainders are conventional, 
nonresistant varieties.
Similarly, when Bowman, May, and Creech131 
examined genetic uniformity among cotton vari-
eties in the United States, they found that genetic 
uniformity had not changed significantly with 
the introduction of transgenic cotton cultivars. 
In fact, when they compared the years before and 
after the introduction of transgenic cultivars, they 
observed that both the percentage of the crop 
planted with a small number of cultivars and the 
percentage planted with the most popular culti-
var had declined. Thus genetic uniformity actually 
decreased by 28% over the period of introduc-
tion of transgenic cultivars. In light of the data, 
the theoretical concepts of Gepts and Papa,132 
that GM crops are likely to be responsible for a 
biodiversity decline within crops is not very con-
vincing. It remains to be said that the continued 
use of locally adapted traits gained in traditional 
breeding should play an important role.133, 134
Several reviews135,136,137 contend that the neg-
ative impact of modern biotech agriculture on 
biodiversity has been overestimated, and perhaps 
even overstated, by the organic-farming commu-
nity for the purpose of marketing its alternatives 
on the grounds of their environmental character-
istics. We begin to see that, contrary to the pre-
ponderance of negative views, there are beneficial 
effects stemming from no-tillage, the reduction of 
pesticide amounts applied to fields, and enhanced 
biodiversity.
But there are also many studies that show 
that organic farming has definite advantages over 
conventional agriculture, particularly regarding 
biodiversity. One extensive review138 cites many 
field studies showing a wealth of evidence that 
now points to agricultural intensification as the 
principal cause of the widespread declines in 
European farmland bird populations,139,140,141 as 
well as of the reduction in abundance and diver-
sity of plant and invertebrate taxa over the past 
decades (well documented by Donald,142 Preston, 
et al.,143 and Wilson, et al,144 and others).
Only a few studies have sought to integrate 
the changes in soil conditions, biodiversity, and 
socio-economic welfare linked to the conversion 
from nonorganic to organic production (Cobb, 
et al.).145 Conclusions may not be representa-
tive for all organic conversions, but the findings 
are of relevance at a time of debate over chang-
ing patterns of subsidies and other incentives in 
agricultural policy. The study showed that there 
were demonstrable differences in overall environ-
mental conditions in the comparison of organic 
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and nonorganic farming, showing evidence of 
increased regional species diversity, and an even-
tual improvement in the profitability of the or-
ganic-farming regime. The study also showed that 
variations in farm-management practices strongly 
influence the notion of on-farm and off-farm en-
vironmental consequences. 
The same positive effects of organic farming 
are shown in a 21-year study in Switzerland (the 
so called DOK study).146 Part of the data has been 
published in Science.147 The organic farming ben-
efits related to biodiversity are well documented, 
especially with soil microbial diversity: root length 
colonized by mycorrhizae in organic-farming sys-
tems was 40 percent higher than in conventional 
systems.148 Biomass and abundance of earthworms 
were higher by a factor of 1.3 to 3.2 in the organ-
ic plots as compared with conventional.149 At the 
same time yield is, compared to traditional farm-
ing, dropping 20 percent. This fact triggered a 
debate in Science concerning whether such a drop 
in yield is tolerable with regard to the protection 
of biodiversity, since today we should realize the 
imperative to produce more food on a shrinking 
amount of arable land.150,151,152 Potato yields in the 
organic systems were 58 to 66 percent of those 
in the conventional plots, mainly due to low po-
tassium supply and the incidence of Phytophtora 
infestans. Winter wheat yields in the third crop-
rotation period reached an average of 4.1 metric 
tons per hectare in the organic systems. This cor-
responds to 90 percent of the grain harvest of the 
conventional systems. In an overall comparison, 
provided the lower energy input is also taken into 
account, one can conclude that, theoretically, in 
some favorable conditions organic farming can be 
the more-efficient production strategy. A rather 
negative point is the safety of organic food: infec-
tions with the infamous Echerichia coli O157-H7, 
with its sometimes deadly consequences, seem 
to be a problem with respect to organic food. A 
number of papers demonstrate the legitimacy of 
these concerns.153,154,155,156,157,158,159
Only a very few studies exist (such as Roush)160 
that concentrate on a circumscribed agricultural 
practice comparing organic and biotech farming. 
This early paper compares directly Bt sprays used 
in organic farming and Bt transgenic crops, and 
the case is clear: Bt transgenic crops have advan-
tages. Also, it has to be said that detailed studies 
of the impact of organic farming on various envi-
ronmental factors are still scarce.
7.		 ConSequenCeS	And	ConCluSIonS
Following the lines of reasoning presented here 
to their logical ends would, foremost, advocate 
a refrain from fostering the notion of a divide 
between agriculture using transgenic crops and 
organic-management systems. It is difficult to 
consistently maintain any divide along the lines 
of breeding technologies or the use of agrochemi-
cals. The current perception of large differences 
in practices are mostly the result of differences in 
world view, often built, as has been argued here, 
on unfounded theories and even quasi-religious 
beliefs. 
A successful integration of present-day 
management systems needs a new communica-
tion strategy. Such a strategy should embrace a 
dialogue with the public utilizing the “Three E 
Strategy” (entertainment, emotion, and educa-
tion), which, according to Osseweijer161,162 could 
initiate a decision-making process along the lines 
of the “Systems Approach,” a discursive decision-
making process for socially contentious issues.163 
But a dialogue, in itself, will not create agri-
cultural-management systems that build on local 
conditions, help poverty alleviation, respect ele-
ments of traditional knowledge, and combine it 
in a successful relationship with science. Building 
those bridges, in reality, need more than public 
acceptance. And more than decision-making pro-
cesses, the effort will require making real deci-
sions and following through on them. 
Such an effort also needs the initiation of a 
mechanism like the participatory projects proposed 
by Slingerland et al.,164 a working team from 
Wageningen that started a participatory farm-
ing project in Ouagadougou in West Africa with 
sorghum. Addressing iron deficiency caused by 
malnutrition in West Africa, this became an in-
terdisciplinary program targeting the food-chain. 
In Africa current interventions are dietary diversi-
fication, supplementation, fortification, and bio-
fortification. But such interventions alone have 
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only moderate chances of success due to low pur-
chasing power of households, lack of elementary 
logistics, lack of central processing of food, and the 
high heterogeneity in production and consump-
tion conditions. Slingerland165 proposed, based 
on excellent theoretical views, a staple food-chain 
approach, integrating parts of current interven-
tions as an alternative. The research was carried 
out in several villages in Benin and Burkina Faso 
to take ecological, cultural, and socio-economic 
diversity into account. The interdisciplinary ap-
proach aimed at elaborating interventions in 
soil-fertility management, improvement, and 
choice of sorghum and other crop varieties and 
food processing, to increase iron and decrease the 
phytic acid-iron molar ratio in sorghum-based 
foods. The phytic acid-iron molar ratio was used 
as a proxy for iron-bioavailability in food. Synergy 
and trade-offs resulting from the integrated ap-
proach showed their added value. Phosphorous 
fertilization and soil organic amendments applied 
to increase yield were found to also increase the 
phytic-acid content of the grain and thus decrease 
its nutritional value, countered by new food pro-
cessing reducing the phytic-acid levels again.
Ultimately, only a participatory approach 
building on the “unifying power of sustainable 
development” will lead to balanced choices be-
tween “People, Planet, and Profit” in agricultural 
production chains and rural land use, in build-
ing the bridge between traditional knowledge 
and science. The Golden Rice project166 and 
the SuperSorghum project167 both need to take 
account of these ideas in order to make those 
projects real successes. They include transgenic 
plants and, thus, need special efforts in partici-
patory management in order to bring them to 
fruition. 
Synergies will be of considerable importance, 
as soon as we begin to refrain from unproductive 
controversies over breeding and management 
methodologies. In the face of the urgent situa-
tion in many countries in the developing world, 
there is no time for contention and the overload 
of regulations. These prevent or at least slow the 
introduction of socially beneficial nutritional in-
novations, in the very countries where they are 
needed most. ■ 
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Putting Intellectual Property to Work: 




This chapter presents Brazil’s intellectual property (IP) 
system and identifies relevant experiences of IP manage-
ment in the fields of health and agriculture. Brazil takes 
advantage of the flexibilities offered by relevant inter-
national agreements, such as the Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS), 
and attempts to implement an equitable system. During 
the 1990s, Brazil revised its industrial property and copy-
right laws, and other related laws, and enacted new legis-
lation that includes provisions for plant variety protection 
and for access to biological resources.
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in 1886, the UPOV Convention in 1961, the 
Convention on Biological Diversity of 1992, and 
the 1994 Agreement on Trade-Related Aspects 
of Intellectual Property Rights (TRIPS). These 
international agreements are the instruments of 
such changes.2, 3, 4, 5 An important characteris-
tic of a system of IP protection is its impact on 
various industries and countries. The degree of 
impact depends on, among other factors, infra-
structure and the level of training of individu-
als working in technology and science. Thus, the 
National System of Innovation places the IP sys-
tem in context, providing necessary substance.6 
Heterogeneity of national laws also impacts IP 
protection as a function of the differences in 
terms of the way laws are applied in each coun-
try, because, in spite of the homogenization pro-
cess that has accompanied TRIPS, flexibility in 
the formulation and implementation of national 
laws is possible.7 
The reform of the legislation related to IP, 
which took place in Brazil in the second half of 
the 1990s as a consequence of TRIPS, brings with 
it opportunities as well as obstacles. These relate 
to the type of protection (including, for indus-
trial property: patents, trademarks, geographical 
indications; for copyrights, in general; for com-
puter programs; and for sui generis protection of 
plant varieties and biological diversity), or to the 
CHAPTER 17.1
1.	 InTRoduCTIon
Brazil is considered to be an innovative devel-
oping country,1 with a robust scientific research 
structure in both health and agriculture. The 
Brazilian trend toward innovation will become 
even more relevant in the years ahead as a result 
of the recent Policy for Industry, Technology, and 
Foreign Trade of 2004, which prioritizes these 
economic sectors. In addition, the country has 
engaged in continuous revision of its IP policies 
to keep up with advances in science and technol-
ogy, approved an Innovation Law in 2004, and 
continues to strengthen its presence in interna-
tional research and innovation.
IP is a social institution, changing in form 
and function through, for example, the Paris 
Convention in 1883, the Bern Convention 
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national scientific and technological capability to 
generate new and useful knowledge.8, 9
An important aspect of TRIPS is its link-
ing of IP protection to international commerce. 
Traditionally, agreements in the field of IP, es-
pecially the Paris Convention, linked IP to the 
technological and economic development of the 
countries participating in those agreements. This 
change in emphasis gave rise to some relevant is-
sues. One issue is the enlargement of asymme-
tries between countries, in terms of the kinds of 
economic development occurring. These asym-
metries can be of obvious concern to developing 
countries, particularly those that are lacking the 
infrastructure, scientific, technological and in-
dustrial capability for assimilating the technolo-
gies more strongly protected pursuant to TRIPS 
standards.10, 11 
There is a new structure of international 
trade regulation that restricts the use of incen-
tive policies for stimulating local production. 
This is similar to industrialization in developing 
countries, especially where import replacement 
is based upon direct subsidies and the closing of 
national markets. In addition, policies supporting 
industrialization, competition, and scientific and 
technological growth embed innovation, con-
verging towards policies of science, technology 
and innovation. In the context of innovation and 
industrial policy, IP is important, augmenting the 
positive impacts and reducing the potential em-
barrassment that might be caused by restrictions 
to technological development deriving from the 
TRIPS agreement.12
Specific policies can and should be developed by 
nation states, particularly starting from the national 
scientific and technological asset base. Brewster and 
colleagues13 believe that the promotion of access to 
innovations in the fields of health and agriculture 
to groups of lower income in developing countries 
should be the basis of those IP policies. 
Brazil presents two outstanding examples of 
IP policy applied in those specific sectors in the 
controversy over the drug cocktail for the AIDS 
program of the Brazilian government: (1) the role 
of EMBRAPA (Institute of Agricultural Research 
of the Ministry of Agriculture) in the Brazilian 
seeds market; and (2) the role of FIOCRUZ (an 
institute of the Ministry of Health that works in 
research, education, technological development, 
and production in the field of the human health). 
In the first case, supported by an IP policy in the 
area of plant varieties, EMBRAPA was able to 
assemble partners, both public and private, who 
worked on the development of new plant variet-
ies, allowing the country to keep the majority of 
national plant varieties after the promulgation of 
the Plant Variety Protection Law in 1997, pursu-
ant to TRIPS requirements. FIOCRUZ, through 
Far Manguinhos, its drugs production unit, pro-
vided the Ministry of Health with a cost struc-
ture for the drugs that constitute the drug cock-
tail used in the AIDS program and identified the 
necessary technology for production of the drug 
cocktail.14
In both FIOCRUZ and EMBRAPA, a 
new standard of research organization is being 
implemented: the search for partnerships and 
the sharing of proprietary results. The search for 
complementing competences, which would be 
impossible to find in a single research institu-
tion or national economic agent, is a main fac-
tor. The rationale underlying the role of public 
research may be centered in the relevant markets, 
without losing focus on the mandate and ratio-




In Brazil, TRIPS is viewed as representing an 
initiative on the part of developed countries to 
increase the protection of IP. Further, TRIPS 
is seen as having sought to expand interna-
tional commerce and the technological con-
tent of these exports, as well as to consolidate 
the new concepts of global production, where 
the control of technology obtains a differenti-
ated qualitative dimension as compared to the 
environment in which the Paris Convention 
was ratified. (Brazil was one of the originators 
of that convention and has adhered to all of 
its revisions16). Two benefits of TRIPS, how-
ever, seem unequivocal: first, the maintenance 
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of compulsory licensing with the possibility 
of implementing parallel import mechanisms, 
and second, the use of sanctions panels within 
the World Trade Organization (WTO), which 
minimizes the negative effects of unilateralism. 
Importantly, both of these elements can be ex-
ploited to the greatest advantage of developing 
countries if the countries have a certain level of 
technical and scientific capacity.
Prior to the present Industrial Property Law 
of 1996 (Law No. 9279), Brazil had already re-
formed its legislation concerning the protection 
of industrial property, instituting the Industrial 
Property Code in 1971 (Law No. 5772). The 
code prohibited the patenting of chemical 
products, food- and chemical-pharmaceutical 
products or processes, and did not recognize 
transgenic microorganisms as patentable. Due 
to Article 27 of the TRIPS agreement, the new 
Industrial Property Law recognized these fields as 
patentable matter. 
Further relying on TRIPS, Brazil intro-
duced a new legislation for authors’ rights (the 
Authorship Rights Law of 1998 (Law No. 9610), 
a Computer Programs Law of 1998 (Law No. 
9609), and the Plant Variety Protection Law of 
1997 (Law No. 9456). The latter aims to encour-
age private investment in plant breeding. The law 
is widely perceived in Brazil as a radical change 
with regard to the protection of IP. 
2.2 Institutional	aspects
The following federal agencies are responsible for 
the administration of IP systems in Brazil:
• for industrial property and computer pro-
grams. Instituto Nacional da Propriedade 
Industrial (National Institute of Industrial 
Property [INPI]), an economically self-
sufficient and independent government 
agency subordinate to the Ministério do 
Desenvolvimento, Indústria e Comércio 
Exterior (Ministry of Development, 
Industry and Foreign Trade [MDIC]). The 
INPI handles the processes for the grant-
ing of patents for inventions and utility 
models, the protection of trademarks, the 
protection of industrial designs, the pro-
tection of geographic indications, and 
the registration of computer programs. 
Furthermore, the country’s legal dispo-
sitions established the requirement of 
prior approval by the Agência Nacional 
de Vigilancia Sanitária (National Health 
Surveillance Agency [Anvisa]), subordi-
nate to the Ministério da Saúde (Ministry 
of Health[MS]), to subsidize the analysis 
process of patents on drugs, in accordance 
with the prerequisites established by Law 
No. 9279/96.
• for plant variety protection. The Serviço 
Nacional de Proteção de Cultivares 
(National Plant Varieties Protection Service 
[SNPC]), created by Law No. 9456 (of 
1997) and subordinate to the Ministério 
da Agricultura, Pecuária e Abastecimento 
(Ministry of Agriculture, Livestock, and 
Food Supply [MAPA]), is accountable for 
its administration.
• for authors’ rights. This is a field of protec-
tion that does not demand registration in 
order to guarantee rights. Computer pro-
grams, which are included in this category 
of IP protection, are registered at the INPI, 
as mentioned above. All other work pro-
tected by authors’ rights, may be registered 
at various institutions, however, registration 
is not required. Works can be registered at 
the National Library (literary works), the 
Councils of Engineering and Architecture 
(plans, maps, and designs), and the School 
of Music of the Federal University of Rio 
de Janeiro (music, musical arrangements), 
and at other institutions. The policies for 
authors’ rights are established by the au-
thors’ rights board within the Ministry of 
Culture. Additionally, the Interministerial 
Committee Against Piracy, subordinated 
to the Ministry of Justice, coordinates and 
implements enforcement policies, focusing 
on those works that are protected under the 
various fields of protection (that is, plant 
variety protection, industrial property, and 
so on) with greatest emphasis being placed 
on authors’ rights. 
• genetic resources. With the publication 
of Provisional Measure No. 2186-16 (of 
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2001), legislation relating to genetic assets 
was altered with respect to the conservation 
of biological diversity, the integrity of genet-
ic assets, and associated traditional knowl-
edge. As with Provisional Measure No. 
2186-16 and Decree No. 3945/2001, ac-
cess to and dispatch of the country’s genetic 
assets are determined by the Council for the 
Management of Genetic Assets, whereby 
the benefits are liable for distribution, and 
the exchange and dissemination of compo-
nents of genetic assets as well as associated 
traditional knowledge of indigenous and 
other local communities are preserved, pro-
vided doing so benefits them and is based 
on common practice.
One action that has had, and should continue 
to have, repercussions in the field of health and 
agriculture research is the promulgation of the 
Innovation Law of 2004 (Law No. 10973). An 
increase in the number of partnerships between 
companies, universities, and scientific and tech-
nological institutes is expected. The greater like-
lihood of attracting university researchers to es-
tablish companies dedicated to innovation is also 
expected. The law serves as a stimulus to the crea-
tion of technology-based companies that would 
be capable of marketing the results of research 
undertaken in universities and research institutes. 
Participation of these researchers in the manage-
ment or administration of private companies is 
now allowed, so the new law provides the freedom 
for these professionals to realize their entrepre-
neurial potential. In addition, the law allows the 
sharing of space and infrastructure between public 
research and private companies. The law promotes 
the elimination of various bureaucratic hindranc-
es, such as the requirement of a bidding process 
for the licensing of patents when these belong to 
a public agency.
The Innovation Law demands the establish-
ment of technological innovation offices at uni-
versities and research centers. This innovative 
and potentially powerful incentive is expected to 
encourage the protection and commercialization 
of academic inventions, fostering economic dy-




The use of biotechnology as a tool for the im-
provement of traditional plant varieties has been 
an important issue. Expectations concerning the 
implementation of the Plant Variety Protection 
Law were very diffuse at first. Some authors ar-
gued that the law would promote the privatiza-
tion process derived from the recognition of 
proprietary rights, thus displacing the public re-
search sector, cooperatives, and producers’ associ-
ations.17 Others argued that the impact tended to 
be differentiated, in terms of the dynamism of the 
cultures and of the technical and scientific condi-
tions. The technical and scientific training of the 
public sector and synergy among associations and 
producers’ associations, would help it to maintain 
its production release capacity of new plant va-
rieties.18 Either way, only time will tell how the 
impact of the law will play out.
Currently, the main assignees of protected 
plant varieties are the national public research insti-
tutes (39%), foreign private companies (38%), and 
producer associations or related foundations (20%) 
(see Table 1). Local companies and universities each 
hold marginal positions, with a participation of less 
than 2% of the total protected plant varieties. Seven 
of the protected plant varieties are among the 10 
most important in terms of the amount harvested 
during the 2001–2002 harvest season.
EMBRAPA is the economic player of great-
est relevance in the production of protected soy 
seeds. Individually, it holds 23% of the registered 
protected plant varieties of all cultivated species. 
If its partnerships are included, EMBRAPA’s par-
ticipation increases to 36%. By itself, EMBRAPA 
holds the registry of 27% of the protected plant 
varieties employed in the production of seeds, 
and, including its partnerships, EMBRAPA’s par-
ticipation amounts to 41%. 
For the harvest of 2001–2002, in terms of 
bearing registration of protected plant varieties, 
Monsanto Co., through the firm Monsoy, has a 
position superior to that of EMBRAPA, when 
the latter is considered on its own. Monsoy is the 
bearer of 55 protected plant varieties (30% of the 
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total), 13 of which are genetically modified. This 
participation, however, falls to 23% when con-
sidering only the protected plant varieties used 
as seeds. Thus, Monsoy assumes second place in 
terms of the protected plant varieties used in the 
production of seeds and third place in terms of 
the quantity of seeds produced using protected 
plant varieties. 
Another relevant economic player is the 
Central Cooperative for Agricultural Research 
(Coodetec), linked to the Cooperative 
Organization of Paraná (OCEPAR). For the 
harvest of 2001–2002, Coodetec participated 
with 10% of registered protection for soy plant 
varieties, having three intended for derivation 
and three genetically modified. The company’s 
participation was slightly more than 13% when 
considering the use of protected plant varieties. 
Coodetec’s participation in the amount of seeds 














EMBRAPA,	with	partners3 67 37 43 41 217 51
Monsoy 55 30 24 23 89 21
Coodetec 19 10 14 13 94 22
Pioneer	Hi-Bred	
International,	Inc.
8 4 6 6 11 3
Fundação	mato	grosso	
(fmt)
10 5 5 5 1 0
Other	bearers 25 14 13 12 15 3
total of protected 
plant varieties
184 100 105 100/52c 427 100/56d
Nonprotected	varieties
(as	percentage	of	total)
0 0 96 48 338 44
total 184 100 201 100 765 100
Source: Carvalho19 
a Number of protected plant varieties and varieties in use as seeds
b Volume of basic seed obtained from plant varieties in use as seeds
c FMT, CPTA, Epamig, Agrop. Boa Fé, Copamil, APSEMEG, Emater-GO, Agrosem, Ag. Rural-GO, CPTA, Empaer-MS
d Percentage of protected plant varieties as part of total plant varieties harvested of 2000–2001
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Participation of the players may be under-
stood by reviewing the trajectories of EMBRAPA, 
Coodetec, and Monsoy with regard to soy pro-
duction. Both the public research institutions 
and the rural producer organizations tend to have 
a relevant role in the generation and adoption of 
new technology processes, particularly where the 
capacity for the appropriation of the generated 
innovation tends to be small. With the exception 
of seeds for hybrids, where biological characteris-
tics increase the capacity for appropriation, pri-
vate companies demonstrate little interest in the 
improvement of autogamous species, the seeds 
of which are capable of being reused by the rural 
producer. 
The three economic players mentioned main-
tain trajectories with supplementary involvement 
that allow a highly competitive environment. 
There is a coevolution process of these players 
paralleling the institutional changes, particularly 
those changes that have affected statutes for the 
protection of plant varieties. 
However, the introduction of new Brazilian 
players and economic units fuels the debate on the 
range of protection of innovations in the agricul-
tural field, and, especially, the role of the national 
company. When prohibiting gene sequence pat-
enting in 1996, the Brazilian legislation of indus-
trial property aimed at ensuring the preservation 
of the national industry, as it was thought that 
it would not otherwise be able to compete with 
mostly transnational companies of larger size and 
more invested in technology. 
The initial investment effort in scientific and 
technological training in the identification and 
genome sequencing in Brazil (Xylella fastidiosa 
and Xanthomonas citri among others) brought 
about conditions for the establishment of com-
panies as a result of this research, for example, 
the venture capital fund of Votorantim Ventures, 
linked to the huge homonymous Brazilian in-
dustrial group, Scylla Bioinformática and Alellyx 
Applied Genomics.20 
Scylla Bioinformática was formed by a 
group of researchers from the State University 
of Campinas (Unicamp)21 and offers computing 
solutions and software development for com-
panies and research centers that use or develop 
biotechnology. Alellyx Applied Genomics is a 
research and development company in applied 
genomics. The company’s initial investment was 
around US$2 million. It is currently focused on 
research with soy, orange, eucalyptus, and sugar-
cane. Complementarily, the company performs 
contracts for the use of the genes by customers, 
invests in the development of an IP culture, and 
monitors global databases. Alellyx uses public 
domain information as well as information that 
is internally generated. IP is considered funda-
mental to the company’s growth, particularly 
with respect to patent protection for genes. The 
strategy of the company has been to apply for 
patents in the United States on genes with po-
tential value. 
Evidently, restrictions on gene patenting 
in Brazil are somewhat of a bottleneck, because 
the Brazilian legislation on industrial property 
does not protect the genes themselves, but only 
the genetically modified organisms. Besides, the 
Brazilian Plant Variety Law forbids double protec-
tion, making the legislation on plant variety pro-
tection the only form of protection for plants. 
In one sense, the current institutional picture 
tends to affect those activities in a regressive way, 
because the system of IP protection does not cre-
ate incentives for those companies. 
3.2 IP	in	health
3.2.1  Antiretroviral	access
Since the end of the 1980s, the Brazilian Ministry 
of Health has supported policies for the provi-
sion of antiretroviral drugs as well as drugs for 
opportunistic infections. In 1991, Zidovudine 
was already provided with government support 
to serum-positive patients, although the supply 
suffered from eventual discontinuities. Decree 
No. 9313 (of 1996) ensured to all HIV-infected 
patients free access to all the medication necessary 
for their treatment. The distribution of drugs for 
triplex therapy with protease inhibitors began in 
December 1996.
Currently, 17 antiretrovirals (ARVs) are 
available from the Ministry of Health, eight of 
which are produced locally. Some are not pro-
tected by patents, entering the market before 
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Law No. 9279 was enacted. The ARVs that have 
patent protection are considerably more expen-
sive. There is a natural tendency for newer drugs 
to overtake older ones (in the marketplace), 
because many patients develop resistance to 
drugs and begin to seek out new (drug) treat-
ments. Access to drugs has become increasingly 
expensive.
The strategy for maintaining the antiretrovi-
ral access policy has various dimensions: 
• systematic follow-up of patents in force
• monitoring what is in the public domain
• negotiations with suppliers
• local production and importation of gener-
ic medicines
• intensification of local R&D activities in an 
effort to minimize the technological gap
• adjustments in the legal procedures to fa-
cilitate access measures 
Five companies in Brazil have industrial and 
technological capabilities for the production of 
generic ARVs. The national access policy also 
includes intense participation by various public 
laboratories.
Government expenditure for its access pol-
icy was around US$34 million in 1996 and has 
grown steadily to US$332 million in 2000. In 
2004, government expenditure with the acquisi-
tion of ARVs jumped to US$238 million (80% 
from imports, 20% from local production). The 
increase in expenditure is mainly due to the 
increase in the number of patients under treat-
ment, the increase in the proportion of patients 
needing more complex therapies, and the updat-
ing of therapy recommendations. The threat of 
compulsory licensing, a government recourse, 
forced the dropping of the price of three drugs 
in 2001: indinavir, produced among others by 
Merck and Co., Inc., (by 64.8%); efavirenz, 
also from Merck (by 59%); and nelfinavir, from 
Roche, (by 40%).
Aside from the direct benefits of the Brazilian 
program to individuals in Brazil infected by the 
HIV virus, as evidenced by the reduction in the 
AIDS mortality rate and the rate of opportunis-
tic infections, the program has indirectly ben-
efited other countries by providing a model in 
their efforts to combat AIDS. These countries 
include Angola, Nigeria, Venezuela, Guyana, and 
Mozambique, all of which are in now cooperat-
ing with the Brazilian government to develop 
production capability for antiretrovirals.
3.2.2	 Intangible	assets	in	health	biotechnology
Concerning health research evolution indica-
tors in Brazil, the most indicative at this stage 
is the number of publications. A recent article, 
published by the National Science Foundation 
(NSF),22 indicates the increase of scientific pub-
lications in Latin America. The number of Latin 
American articles tripled during the period from 
1998 to 2001, with most articles being written by 
Brazilian, Argentine, Chilean, and Mexican au-
thors. Considering only the Brazilian contribu-
tion, the number of articles quadrupled during 
this same period. 
In the last two decades, Brazil rose from 27th 
to 18th place in the world ranking for science and 
technology publishing. There were 1,887 articles 
published in periodicals indexed by the Institute 
for Scientific Information (ISI) in 1981, which 
corresponds to 0.44% of the world output. By 
2001, this number had risen to 10,555 articles, or 
1.44% of the world total. The number of articles 
in the medical and biomedical research areas has 
also increased.
In Brazil during the period from 1997 to 
2001, the medical research community pro-
duced 7,365 articles (0.9% of the worldwide 
total) and ranked 23rd in the world. Medical 
research was 3rd in an internal ranking, repre-
senting 16.9% of the total articles indexed for 
the country on the basis of the ISI figure. The 
biomedical community had an even greater 
output than did medical research, with 8,366 
articles for this period (0.9% of the worldwide 
total). With this output biomedical research was 
in the 21st place in the world ranking and sec-
ond place in the internal ranking. Biomedical 
research contributed 19.0% of all the country’s 
articles indexed on the basis of the ISI Deluxe.23, 
24Despite a large part of Brazilian scientific pro-
duction taking the form of published articles, 
it is possible to protect knowledge by means of 
IP rights.
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Other indicators are somewhat less positive. 
Brazilian participation in triadic patents25 re-
mains very low at 0.2%. This low participation 
reinforces the necessity of developing specific in-
centive programs for technological research. In 
Brazil, the assessment of projects undertaken by 
agencies still judges researchers chiefly by their 
results in terms of publications. Progressively, the 
matter of IP is beginning to be incorporated into 
the analysis criteria of researcher productivity, but 
this is not an established routine in the academic 
community yet.
Data from the Directory for Research 
Groups of the National Council for Scientific and 
Technological Development (CNPq) indicates 
that groups that undertake health research produce 
a considerable amount of work with predominant-
ly bibliographic-academic characteristics. Among 
each 10 published works only one represents re-
search of a technical nature that results in some 
kind of protection for the purpose of eventually 
obtaining IP rights. Not all institutions have ad-
equate support for providing protection to IP or 
for the identification of patentable subject matter.
The low participation by companies, in the 
areas of science, technology, and innovation 
(ST&I), and the lack of ability to transfer knowl-
edge generated in universities to industry and 
various service sectors, partly explain the predom-
inance of bibliographic-type work production. 
The ST&I activities are relatively concentrated 
in the university setting and in some research in-
stitutions that are dedicated to specific purposes. 
The development of these activities inside private 
companies of the productive sector is small de-
spite efforts aimed at their expansion.
One of the more important effects of modern 
biotechnology is that it has greatly contributed 
to the closing of the gap between science and the 
market.26 Because of this, academic medical and 
biomedical research may be viewed as appropri-
able technology, subject to formal IP protection. 
A lack of appropriation of academic research in 
Brazil, however, indicates both that the culture 
for IP is still undeveloped in academic institutes 
and that the sponsors of medical and biomedical 
research have a biased perception, still bound by 
the obsolescent dichotomy between basic research 
(freely disseminated) and applied research (ap-
propriated for IP protection). This is reflected by 
the scant participation of Brazilian patents in the 
area of unquestionable scientific and technologi-
cal competence (assuming that the inventions in 
these areas have a strong academic component). 
Our research group is presently evaluating 
protection by means of patents in biotechnology 
in Brazil. Preliminary research was undertaken 
in some of the fields of the International Patent 
Classification related to the protection of biotech-
nological inventions. Despite being in the early 
stages of the research, our analysis of the database 
of the National Institute of Industrial Property 
(INPI) revealed patent applications and/or pat-
ents in all the verified fields. The research involved 
overall numbers, regardless of the origin of the 
application priority and numbers relating to the 
application priorities of Brazilian origin. Table 2 
summarizes the results collected for a period from 
1992 to 2005.
The correlation between publications and ap-
plications for patents is not linear. However, as the 
above data show, in the field of biotechnology in 
health, the volume of Brazilian publications grew 
intensely. The numbers of patents or patent appli-
cations shown (Table 2) having Brazilian priority 
are relatively modest. In all the fields of patents, 
the ratio of Brazilian priority to overall priority is 
low. Despite the very early stage of our research, it 
is possible to discern that biotechnological inven-
tors seeking patent protection are predominantly 
foreign. It can be noted that there is a bias for pro-
tection in fields C12M, C12P and G01N33/50 
with regard to patent applications being first filed 
in Brazil (which can be interpreted as technology 
developed in Brazil). Thus, the data seems to in-
dicate that Brazilian technological production is 
focused in enzymology, microbiology, fermenta-
tion, or chemical analysis of biological material. 
Applications in the field of genetic engineering 
represent a mere 8.8%. These figures should be 
investigated more closely, as should the reason for 
these results. Deeper analysis may explain the dis-
parity between scientific domain (publications) 
and technological domain (patents). 
The recent approval of the Innovation Law 
and the structuring of technological innovation 
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offices in universities and research centers indi-
cates that patenting intensity of biotechnology 
should soon increase. 
4.	 ConCluSIonS	And	fuTuRe	
dIReCTIonS
One of the most important elements of the regu-
latory process is the area of IP rights. Especially 
since the 1980s, the results of research in biotech-
nology have been liable to protection through 
various mechanisms of IP. There is a trend to-
ward a progressive increase in the scope of what 
can be considered patentable. The patent proves 
to be the most relevant and controversial asset; 
with other assets also being considered as such: 
trademarks, plant varieties, traditional knowl-
edge, geographical indications, trade secrets, and 
so on. Common practice shows an intensive and 
complementary use of several of these assets; the 
possible combinations depend on the sector of 
activity (human health, animal health, agribusi-
ness, and so on).
In the recent reorganizations of IP systems, 
countries and blocks seek to adopt more or less 
consistent positions in accordance with indus-
trial and technological development. Both the 
1980s and 1990s were marked by strong pro-
patent movement tendencies; however, this ap-
proach was heavily criticized by many groups. 
The passing of the Bayh-Dole Act prompted the 
opening of more than 200 IP offices in U.S. uni-
versities.27 Patenting with academic ownership 
became aggressive, altering standards of generat-
ing restrictions for the access to research results. 












C12M 228 58 25.4
C12N 4,020 353 8.8
C12P 1,521 318 20.9
C12Q 940 82 8.7
C07K 2,523 171 6.8
G01N33/50 (including	subdivisions) 171 27 15.8
A61K39 1,290 128 9.9
A61K48 260 7 <0.1
A01H 710 63 <0.1
Others n/a 42 3.5
total 11,663 1,249 100.0 
Table	2:	health	Biotechnology	patents	in	Brazil
* Fields of International Patent Classification
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of negotiations between the academic and corpo-
rate fields. Universities began to be summoned 
to court, being frequently questioned concerning 
the exaggerated broadness of the scope of various 
patents, which hindered access to certain markets 
(very high royalty rates, questionable conditions 
of exclusivity, and so forth). In this context, ben-
efits such as the research exemption faced extinc-
tion. The patent race U.S. universities entered 
into was also taken up by European institutions 
and, on a smaller scale, by Brazilian institutions. 
In Brazil, during the mid-1990s, a series of legal 
mechanisms motivated the IP protection of aca-
demic inventions. More recently, the Innovation 
Law was enacted.
In accordance with evidence advanced by 
several authors, patents have a crucial role in the 
biomedical industry.28, 29, 30, 31 The introduction 
of a new drug demands great expenditure for re-
search, development, and preclinical and clinical 
tests. There exists a relative ease of imitation with-
out requiring the same amount of investment 
made by the innovating company, especially if the 
imitator possesses a technological capability simi-
lar or even close to that of the innovator. Patents, 
therefore, serve as the equivalent of a mediation 
contract between public and private interests. 
Thus, having made a technique public through 
publication of a patent document, the bearer of 
the patent is granted the right to exclude third 
parties from exploiting the invention.
The biomedical sciences also see the fraction-
ing of existent rights, chiefly patent rights. Heller 
and Eisenberg32 point to an intriguing phenom-
enon concerning the present commercialization 
of patents in the biomedical field. The grant of 
broad-scope patents and the grant of many pat-
ents with overlapping claims, whereby the de-
termination of the exact limits of each one is 
difficult, has lead to what the authors term the 
“tragedy of the anticommons.”
The metaphor corresponds to a situation in 
which many persons fight for the rights of ex-
clusion in an environment of meager resources. 
The negotiations to ensure the rights of different 
bearers may stall, imposing obstacles to further 
development of the invention. The development 
of new drugs dependent on the multiple patents 
referring to DNA fragments and other interme-
diaries and research tools becomes vulnerable due 
to this “patent thicket.” The eventual payment of 
the various license rates raises costs, making many 
products far too expensive. 
The group of patents to be negotiated to 
make a product viable may belong to one or sev-
eral bearers. If the bearers of the rights to be nego-
tiated are distinct companies or institutions, there 
arises a further difficulty: that of dealing with a 
heterogeneous environment, each party having 
its own purpose, culture, and administrative ex-
perience. It should not be forgotten that the area 
of biomedical research is a heterogeneous envi-
ronment composed of multinational corpora-
tions, small- and medium-sized technology-based 
companies, universities and research institutes. A 
further obstacle exists in the form of each inven-
tion as such. After licensing a biotechnological 
invention, the investor still has much work to 
do, with development needed—and uncertainty 
concerning success ever present—until the final 
product is marketed. 
In Brazil, IP rights are consistent with a spe-
cific level of technological and industrial develop-
ment. The country takes advantage of the (now, 
almost minimal) degree of freedom offered by 
the international agreements for the conform-
ance/harmonization of IP rights (the TRIPS 
Agreement, for example) to innovate more eq-
uitably at the national level. Since the 1990s, 
Brazil has promoted a broad and deep revision 
of various legal instruments (Industrial Property 
Law, Copyright Law, and so on) and has inau-
gurated certain approaches (for example, through 
the Plant Variety Law and the Regulation for the 
Access to Biological Resources).
IP protection in biomedical fields differs from 
protection in the agricultural field due to the dis-
tinctive nature and dynamics of each. In health 
biotechnology, patents perform a fundamental 
role. The agents organize themselves to achieve 
protection (especially simultaneous protection, 
through patents and trademarks) and try to maxi-
mally extend the term of protection. On the other 
hand, the rationale of the developing countries is 
confounded by the dilemma of prices and the ac-
cess to technologies. The issue of access has been 
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broadly described in literature and in practice. 
The Brazilian Antiretroviral Access Policy reflects 
these dilemmas and difficulties. Thus, is it possi-
ble to reconcile IP protection and also provide the 
population with access to advanced technology at 
prices compatible with the local economies? 
The impact of the incentive brought about 
by the IP is idiosyncratic, differing in terms of 
sections, of industries (and inside of a same sec-
tion and a same industry), of companies (differing 
in their use of the strategies in different markets 
and segments), and of countries. Thus, the abil-
ity to appropriate innovation will equally present 
variations. The protection offered by the different 
protection fields (in the case in analysis, industrial 
property and plant improvers’ rights) is different 
and related to the scientific and technological 
qualification and to the market and industrial 
structure in Brazil. Equally important is the way 
that institutional structures for the formulation 
and execution of public policies differentiates in 
the economic sector impact as linked to the pro-
tection fields. 
In this way, specific characteristics of creation 
and incorporation of inventions/innovations tend 
to develop different intervention backgrounds. In 
the case of inventions/innovations in plant varie-
ties, willingly or not, sponsored or not, there is no 
way for a foreign organization to introduce plant 
varieties that are not adapted to the area and the 
productive pattern where the plant variety will be 
used. This is a fundamental distinction between the 
areas of health and agriculture. In the case of the 
health, the companies do not find themselves un-
der the contingency of setting up R&D structures 
in the countries where the drugs will be used. 
In the case of the seeds industry, companies 
are structured either alone or in partnership with 
public and/or private research institutions. To 
be granted protection, plant varieties must pass 
tests that evaluate performance in the actual 
conditions of the country. Furthermore, the way 
legislation was negotiated, for the international 
treaties (TRIPS and UPOV), differs from nego-
tiations for industrial property, hence creating 
more favorable conditions for a national project 
in the particular sector. For that, one should rec-
ognize the crucial contribution of institutional 
training by EMBRAPA, which organized part-
nerships for the development and licensing of 
new proprietary varieties, allowing for the main 
agents (public research, multinational corpora-
tions, and rural producers organizations) to es-
tablish complementary, yet synergistic, paths. 
The drug market presents a rather different 
situation. It is worthwhile to stress the point con-
cerning the need for the pharmaceutical industry 
to maintain R&D structures, either alone or in 
partnership. To enter the Brazilian market, mul-
tinational corporations do not need such struc-
tures locally. Besides, before the 1996 Industrial 
Property Law, national industries manufactured 
similar products, in other words, copies, modified 
or not, of the innovative products launched in 
both foreign and internal markets. As from 1997, 
when the new legislation came into effect, the 
traditional national producers’ catalogue of drugs 
tended toward obsolescence as copying became 
illegal except for drugs already available (that is, 
nonpatented). 
The government policies universalizing drug 
distribution to serumpositives in Brazil, on the 
other hand, was unable to foster the develop-
ment of the national industry (national capital 
private companies) even with a massive govern-
ment purchase program. The rationale underly-
ing the negotiations on the industrial property 
legislation resulting in the current legislation, 
was highly regressive, with respect to industry 
and the national interest. Giving up the flex-
ibilities offered by the TRIPS Agreement, espe-
cially the possibility of obtaining up to 10 years 
for the recognition of new drugs (even adopting 
the pipeline) the country’s local production of 
active principles by the national industry was 
vastly hindered. 
In spite of the contradictions of the adopted 
policies, they were able to answer the challenges 
imposed by the industrial property legislation. 
The country managed to overcome much embar-
rassment, transforming industrial development 
opportunities. Those opportunities, however, 
will not be sustainable long without a clear ar-
ticulation between industrial property and the 
innovation policy, focusing on the enlargement 
of the competence and training of the national 
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private companies in the maintenance of the 
present standard of excellence of the state labora-
tories and, mainly, in the creation of incentives, 
inductive or mandatory, to the international 
pharmaceutical companies, so that they focus 
R&D efforts toward the national scientific and 
technological structure. The protection instru-
ments to the IP will play a central role in that 
process. 
On the other hand, there are business op-
portunities consequential to the national scien-
tific and technological training, as well as the 
venture investment in innovation undertaken 
by national companies, that are not protected by 
Brazilian laws. This creates a contradictory pic-
ture, in which fear of occupation of economic 
space in the Brazilian market by transnational 
corporations inhibits the activities of the na-
tional companies. That phenomenon is clear in 
the case of Alellyx Applied Genomics. Perhaps, 
the best way to ensure the access of developing 
countries to technology is less in the legislation 
and more in the defense against competition and 
in market regulation. The case of Brazilian ag-
riculture seems to point in that direction.33 On 
the other hand, the impact of IP in the field of 
health is central. Any discussion on the subject 
of protection should take into account the deep 
technological dependence of Brazil in the field. IP 
policy should be linked to scientific, technologi-
cal development, and innovation and, also, be an 
integral part of the agricultural, health, industrial, 
and foreign trade policies.
Countries that present rich biodiversity, such 
as Brazil, still need to acquire the ability to act 
more actively in the dynamic environment of pro-
tection and exploitation of IP, whether to protect 
local inventions or to gain the knowledge to ac-
quire technology developed by third parties. The 
demand for highly qualified professionals in this 
field of work is most urgent, as is the strengthening 
of the National Institute of Industrial Property. 
More energetic and integrated actions on the part 
of Brazil’s public administration would contribute 
to a more mature policy in the area of industrial 
property and to the development of a configura-
tion for a more competent system for innovation 
and IP management. ■
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ABSTRACT
This chapter presents an operational model used by 
Fundación Chile to develop commercial biotechnology 
products. The first section highlights the challenges faced 
by a developing economy of which the main crops are 
so-called orphan crops. Fundación Chile’s experience has 
shown that establishing public–private collaborations and 
a solid international network are critical to overcoming 
obstacles and increasing the probability of success. Indeed, 
accessing various technology components and managing 
intellectual property and regulatory issues are serious chal-
lenges for a small, export-oriented economy like Chile, 
and Fundación Chile´s response has been to implement 
a model that includes the participation of companies and 
local research organizations with specific expertise at dif-
ferent points along the value chain. International agencies 
complement the activities and contributions of these lo-
cal organizations. The chapter’s second section gives some 
specific examples of new products being developed with 
the new tools of biotechnology.
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lower economic returns for developing products 
grown in limited areas, such crops have difficulty 
competing for investors. In fact, the major agri-
biotechnology companies focus on global vision 
crops that involve large planted areas. Crops cov-
ering limited areas can nevertheless be important 
for specific regions. These crops can be developed 
by focusing local R&D and leveraging resources 
through public–private collaborations, which 
can help to overcome major challenges, such as 
critical mass in R&D, freedom to operate, and 
regulatory issues. A similar approach is useful for 
commercially developing other types of region-
ally important biotechnology applications.
2.			TeChnology	And	Ip	ISSueS	
Developing a commercially viable transgenic 
plant product requires inputs that include:
• high-quality germplasm 
• gene cassettes for the engineering of a spe-
cific trait, including appropriate coding se-
quences and regulatory regions
• a transformation system for the species and 
genotypes of interest
Materials and technologies in each of the cat-
egories may be covered by one or more types of IP 
(intellectual property) rights, including patents, 
plant breeders’ rights, and copyrights, as well as 
CHAPTER 17.2
1.	 InTRoduCTIon
In ten years the area planted with genetically engi-
neered varieties in Chile has grown to more than 
81 million hectares.1 Just four crops—soybean, 
maize, cotton, and canola/rape—account for al-
most 100% of this area. Agricultural biotechnol-
ogy can potentially add significant value to a wide 
range of crops, but the development of geneti-
cally engineered varieties requires a wide range 
of skills, access to many technologies, and many 
years of research and development. Because of the 
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contractual agreements, such as material transfer 
agreements. IP rights are granted by individual 
countries and so, can vary from country to coun-
try, which often complicates the situation for 
export-oriented industries (for example, Chile’s 
fruit industry).
Consolidation of the agri-biotechnology in-
dustry now means that a few large multinational 
companies control a large part of the intellectual 
property related to the genetic engineering of 
crops.2 These companies are often reluctant to 
provide technology for specialty crops or so called 
orphan crops because of liability concerns arising 
from others’ use of the technology. 
Public sector laboratories have made, and 
continue to make, important contributions to ag-
riculture, but they have emphasized the develop-
ment of novel specific components, without con-
sideration of the IP rights for other components 
needed to further develop or commercialize com-
plex products such as transgenic crops. As a result, 
although these public institutions frequently can 
offer rights to components (for example, a DNA 
sequence coding for a specific gene of interest or 
a promoter that drives expression in a particular 
tissue), the institutions are rarely able to license a 
complete transgenic plant, or even an entire cas-
sette, for transformation. It is essential to consider 
IP issues in the R&D program from the outset, 
because restrictions on freedom to operate can be 
a barrier to attracting the investment necessary to 
develop and commercialize products.
Such difficulties have been described for 
specific cases, such as pro-Vitamin-A containing 
golden rice.3 Organizations that are attempting to 
address these issues on a more general level include 
the International Service for the Acquisition of 
Agri-biotech Applications (ISAAA),4 CAMBIA,5 
and the Donald Danforth Plant Science Center.6 
Recently, a group of several leading universi-
ties and research institutes in the United States 
formed the Public Intellectual Property Resource 
for Agriculture (PIPRA),7 which has expanded 
to include a number of nonprofit institutions 
in other countries, including Fundación Chile.8 
Although a major motivation for such initiatives 
has been to ensure the availability of biotechnol-
ogy for humanitarian purposes in developing 
countries, these organizations are also facilitat-
ing the commercial development of minor crops 
through public–private partnerships.
3.	 RegulAToRy	ISSueS
Regulatory issues are currently a major factor 
when commercializing transgenic plants and the 
products derived from them. To avoid problems 
that can prevent or delay commercialization, po-
tential regulatory issues must be considered at the 
inception of R&D planning and throughout the 
R&D process. Even during the research phase, it 
is critical to understand and comply with regu-
lations regarding the handling and movement of 
genetically modified organisms.
Regulatory issues related to R&D in the ge-
netic engineering of plants can be complex, in-
volving biosafety, environmental impacts, food 
safety and so on. Transferring materials, espe-
cially among international collaborators, can in-
volve phytosanitary regulations and international 
agreements such as the Convention on Biological 
Diversity. 
Considerations that may affect choices logi-
cal of R&D strategies include the source of genes 
or gene products (allergenic organisms, food 
crops, nonfood plants, animals), properties of 
gene products or related proteins (toxicity, al-
lergenicity, antinutritional effects, resistance to 
digestion), choice of selectable markers, and the 
design of vectors and transformation procedures, 
as well as the selection of specific transformation 
events to minimize the presence of DNA and 
gene products from other species.
As Chile’s agricultural industry is largely ex-
port oriented, the policies and regulations of both 
domestic and major export markets must be tak-
en into account. There are big differences, more-
over, between the United States and Europe, and 
these present significant challenges. Regulations 
change continuously and must be monitored 
continually.
4.	 A	CollABoRATIve	model
Solving the difficulties requires the participation 
of many different types of professionals. Indeed, 
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it is difficult for a small biotechnology program 
with a narrow focus to maintain in-house all the 
types of expertise required. Fundación Chile’s ap-
proach has been to develop international networks 
of parties, with complementary capacities and re-
sources, for the initial development of products. 
These products are commercialized through new 
companies with specific commercial foci. The col-
laborations involve existing companies with stra-
tegic positions at different places along the value 
chain (for example, nurseries with access to germ-
plasm and experience in introducing new variet-
ies to market). The general scheme is illustrated in 
Figure 1. 
4.1	 The	R&D	consortium	
In this model, the initial task is to form a research 
and development consortium with a specific 
focus. Each of the partners in the initial R&D 
consortium has a largely complementary primary 
role critical for success:
• R&D organizations: research capabilities 
for the adaptation of technologies to local 
conditions and the development of prod-
ucts addressing local priorities
• technology partner: identification, as-
sessment, and global access to addition-
al appropriate research capabilities and 
technologies
• local technology transfer organization: 
initial R&D funding, assistance in obtain-
ing grants and other funding, incubation of 
new technology company
• strategic private sector partner: under-
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introduce or use the novel products in the 
target sector, initial R&D funding
Depending on the specific situation, each 
of the participants may contribute in additional 
ways. For example, researchers in the R&D or-
ganizations are likely to know about specific 
technologies of interest and may already have rel-
evant relationships with other R&D centers. The 
private sector partner may already have rights to 
some intellectual property useful for developing 
the new products. The technology consultants 
may be from an entity that will also contribute to 
R&D funding.
In the biotechnology programs of Fundación 
Chile, the R&D consortia have made it possible 
to leverage investment through public support 
and the use of existing public research institu-
tions. National agricultural research institutes and 
universities provide infrastructure (laboratories, 
green houses, equipment) and human resources 
to carry out the work.
The consortium is the repository of new in-
tellectual property generated during the project. 
However, in most cases it is expected that the 
R&D consortium will not produce final prod-
ucts. In the Fundación Chile model, this is un-
dertaken by a new technology-based company, to 
which the consortium will license rights to intel-
lectual property in exchange for a royalty or other 
compensation.
4.2	 The	R&D	network
The goal of the consortium is to provide the criti-
cal inputs necessary for successful R&D in the 
specific area. In most cases, achieving significant 
results in a reasonable time frame requires taking 
advantage of relevant results from other laborato-
ries. Moreover, licensing and option agreements, 
research contracts, and collaborative research 
agreements between the R&D consortium, or 
its members, and other research institutions and 
companies are critical to establishing an adequate 
research network. Whenever possible, Fundación 
Chile has incorporated provisions for training lo-
cal personnel as part of such agreements. 
4.3	 The	channel	for	commercialization
Later commercial development usually will re-
quire different capabilities and considerable 
additional resources in the early R&D phase. In 
general, in Chile there is likely to be a significant 
gap between the results of projects conducted in 
public research institutions and industry’s ability 
to use them. The model includes creating one or 
more new technology-based companies focused 
on commercially developing specific products. 
The companies will license the results of the 
R&D consortium and will be responsible for 
their commercialization. Achieving the latter will 
require different partners with different interests 
and resources. Once development has advanced 
to a stage at which existing companies can pro-
duce or use the product, licensing to a company 
with an established reputation in the area and 
with its own existing infrastructure may be most 
appropriate. In cases where an established com-
pany with plant breeders, nurseries and so forth 
does not exist, a new company may be created to 
produce and sell the product directly.
Establishing, early on, a commercial entity 
with rights to the outputs of the R&D consor-
tium has advantages. Doing so provides a ve-
hicle for licensing any additional rights required 
for commercialization and for raising additional 
investments. 
5.	 The	geneTIC	engIneeRIng	of	gRApeS
A program to genetically engineer grapes was 
initiated in 2000 by the Chilean Institute for 
Agricultural Research (INIA),9 Fundación Chile, 
InterLink Associates, Inc. (Princeton, U.S.A.), and 
Agrícola Brown Ltda. (Los Andes, Chile) with sup-
port from the FONDEF program of CONICYT.10 
The relationships of the entities involved in the 
program are summarized in Figure 2. 
The program is one of several initiatives in 
plant biotechnology for which Biogenetic S.A. 
(Santiago, Chile)—a joint venture formed in 
1998 between Fundación Chile and InterLink 
Associates, Inc.—has contributed to the devel-
opment and implementation of strategies for 
applying biotechnology to problems of strategic 
importance for Chilean agriculture. InterLink 
provides expertise in technology scouting and 
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assessment. In addition, it assists in negotiating 
agreements with a number of different providers 
of technology components (such as tissue-culture 
methods and gene candidates) for engineering 
specific traits in the United States and Europe.
Making use of INIA’s existing human re-
sources and infrastructure, the collaboration im-
proved INIA’s capacities through the acquisition 
of additional equipment, construction of new 
culture rooms and greenhouses, and training of 
INIA personnel in specific grape-tissue-culture 
methods at a laboratory in the United States.
The leading producer of grape planting stock 
in Chile, Agrícola Brown has pioneered the in-
troduction of proprietary varieties of table grapes 
and also produces and exports grapes. Agrícola 
Brown’s knowledge and experience help to ensure 
that the grape R&D program addresses the right 
targets and that any products introduced would 
be thoroughly evaluated.
The participants in the project formed 
TecGenVides (Sociedad Tecnológia Genetica en 
Vides Ltda.) as the entity that would own the 
results of the initial R&D project. TecGenVides 
would license intellectual property and materials 
generated in the project to GenVitis S.A., a new 
subsidiary of Biogenetic, for further commercial 
development. 
GenVitis would pay a royalty based on its 
revenues related to the licensed property. In this 
case, it has been agreed that the major part of 
the royalty received by TecGenVides will be dis-
tributed to the research institution (INIA), with 
a minor part shared by the other members, who 
also have the opportunity to benefit from value 
captured at later stages.
It was agreed at the start of the project that 
the new technology company, GenVitis, would li-
cense the production and sale of transgenic plants 
in Chile to the strategic partner, Agrícola Brown, 
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which would also participate in the downstream 
commercial development of products. 
More than 1,000 transgenic lines of table 
grapes have been produced, with most of them 
containing combinations of candidate genes for 
increasing tolerance to fungal diseases. The first 
field trials were planted in 2005. The transforma-
tion technology platform developed for this effort 
also would be used to engineer additional traits.
6.	 AddITIonAl	exAmpleS
Programs with similar structures but involving 
different partners have been established for de-
veloping recombinant vaccines for salmon, bio-
technology applications for radiata pine (pinus 
radiata), and the genetic engineering of stone 
fruit trees.
The program for developing novel vaccines 
to protect salmon is a collaboration between 
Fundación Ciencia para la Vida and Fundación 
Chile. The genome of the salmon pathogen 
Piscirickettsia salmonis was sequenced though a 
contract with a U.S. Department of Energy labo-
ratory. Annotation of the sequence, and identifi-
cation of protein domains predicted to be highly 
immunogenic, was carried out by a network of 
Chilean and foreign researchers. AquaGestión, a 
company affiliated with Fundación Chile, per-
formed the initial testing of vaccine candidates. 
Rather than developing production capabilities 
for a single product, the production and market-
ing of the vaccine was licensed to Syngenta A.G. 
(Basle, Switzerland), which was not a participant 
in the R&D project. A multiple recombinant 
protein vaccine for P. salmonis was expected to be 
introduced soon thereafter. 
The radiata pine biotechnology program 
includes improvement through clonal selection 
and genetic engineering. In this case, Fundación 
Chile established a forestry biotechnology labo-
ratory on the campus of Universidad Austral in 
space rented from Cefor S.A. (Valdina, Chile), 
a company affiliated with the university. Some 
of the investigators were employed directly by 
Fundación Chile.
The clonal forestry program includes com-
mercialization in Chile by a new company, 
GenFor S.A. (Talcahuano, Chile). Using somatic 
embryogenesis and cryopreservation technology 
developed by CellFor Inc. (Vancouver, Canada), 
the material was developed by CellFor in collabo-
ration with Bioforest S.A. (Concepción, Chile) 
and Rayonier Inc. (Jacksonville, U.S.A. and New 
Zealand). Field tests of clones were initiated in 
2000. The initial selection of material for scale-up 
and commercialization is being made in 2005.
Projects for engineering radiata pine for re-
sistance to insects, for wood composition, and 
for resistance to fungal diseases have been sup-
ported in part by the Fund for Development 
and Innovation of the Economic Development 
Corporation (CORFO). The R&D network has 
included GenFor, Cefor, Universidad Austral, 
INIA, InterLink, New Zealand Forest Research, 
New Zealand HortResearch, and Carson 
Associates Ltd. (Rotorura, New Zealand). A 
number of additional universities and companies 
have provided candidate genes. 
The structure of the stone-fruit genetic en-
gineering program is very similar to that of the 
grape program, but the stone-fruit program in-
volves a different strategic partner. With sup-
port from CORFO, the program was initiated 
in 2002 by Fundación Chile, Biogenetic, INIA, 
and the Andes Nursery Association (ANA; Paine, 
Chile). ANA is a company focused on developing 
new fruit varieties that are owned by six nurser-
ies. In addition to an extensive testing program 
in stone fruit, ANA has initiated a breeding pro-
gram in peaches and nectarines, in collaboration 
with the Universidad de Chile, that is focused on 
improving the fruit’s storage life and post-storage 
quality.
As in the case of the grape program, the 
products built upon the results of the research 
consortium will be commercially developed by 
a new subsidiary of Biogenetic, CaroGen. ANA 
has a right to license traits developed by CaroGen 
for commercialization in Chile. The research 
network includes Okanagan Biotechnology Inc. 
(Summerland, Canada), which has research col-
laborations with the Pacific Agri-Food Research 
Centre of Agriculture and Agri-Food Canada and 
the U.S. Department of Agriculture Appalachian 
Fruit Research Station.
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Tissue culture and transformation work in 
the stone-fruit program is being carried out in 
the same laboratory at which the grape genetic 
engineering program is based (INIA, La Platina, 
Chile). This colocation has allowed some synergy 
among the programs. ■
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10 FONDEF (the Fund for the Promotion of Scientific 
and Technological Development of Chile) was 
founded in 1991 as a direct government initiative to 
improve the level of R&D. CONICYT is the National 




During its relatively brief history of IP (intellectual prop-
erty) rights protection, China has achieved early success, 
thanks to the strengthening of governmental IP rights 
legislation, the establishment of an IP rights management 
system, the promotion of public knowledge about IP 
rights, and increasing opportunities for international ex-
change and cooperation. IP rights protection in the fields 
of health and agriculture has increased investment in these 
sectors, encouraged innovation in health and agricultural 
science, increased farmers’ incomes, and improved the 
quality of life for Chinese citizens. Dramatic increases 
in patent applications in China suggest that widespread 
implementation and greater enforcement of IP rights are 
stimulating inventive activity, encouraging technology 
transfer, and driving greater and greater innovation.
 HANDBOOK OF BEST PRACTICES  | 1585 
(TRIPS) while promoting the development of its 
own IP rights protection system. The CPA was 
renamed the State Intellectual Property Office 
(SIPO)1 in 1998.
China’s patent system has developed quickly 
in the past 20 years. IP rights regulations, man-
agement systems, and publicly available informa-
tion have gradually improved. In 2006, China 
ranked fifth in the world for the number of pat-
ent applications filed.
Chinese IP rights protection covers the 
following five categories of intellectual prop-
erty: (1) patents and technological secrets; (2) 
trademarks and business secrets; (3) software; 
(4) copyrights; and (5) know-how about tech-
nologies, information, instructions, and so on 




In 2006, 573,178 patent applications were filed 
for three kinds of patents (invention, utility-
model, and design). This figure was 4.6 times 
the number of patent applications filed in 1998. 
Numbers of patent applications increased by an 
average of 19.4% each year from 1998 to 2006. 




The China Patent Administration (CPA) was 
founded in 1980. China joined the World 
Intellectual Property Organization (WIPO) in 
March 1980. The first Chinese patent law was 
passed in March 1984 and became effective on 1 
April 1985. China joined the Patent Cooperation 
Treaty (PCT) in 1994, indicating that China’s 
IP rights legislation was consistent with inter-
national standards. China became a member of 
the World Trade Organization (WTO) in 2002 
and pledged to follow the Agreement on Trade-
Related Aspects of Intellectual Property Rights 
Chen ZL, W Gao and J Xu. 2007. IP Rights in China: Spuring Invention and Driving Innovation in Health and Agriculture. In 
Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT 
Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
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for inventions, 14.0% for utility models, and 
21.4% for designs.
Between 1985 and 2006, the total number 
of patent applications was 3,334,374, including 
1,089,521 inventions (32.6%), 289,868 utility 
models (38.7%), and 954,985 designs (28.7%).
The total number of patents granted by the 
SIPO from 1998 to 2005 was 1,469,502, includ-
ing 238,717 inventions (16.2%), 730,573 utility 
models (49.7%), and 500,212 designs (34.1%).
In 2006, 82% of patent applications came 
from domestic applicants; 18% came from for-
eign applicants. The number of foreign applica-
tions (all of them for inventions) was four times 
higher in 2006 than it was in 1985. (Table 1)
In the period between 1985 and 2006, 
296,507 Chinese patents were awarded. Of these, 
37.9% represented domestic applicants and 
62.1% represented foreign applicants. 
The ten regions with the greatest number of 
patent applicants are all located in eastern China 
(Table 2), in areas with strong science and technol-
ogy bases and stronger economies than average.
3.		 Ip	RIghTS	In	The	heAlTh	SeCToR
There are four ways to protect intellectual prop-
erty in the Chinese health industry: (1) through 
“administrative” protection, which is used to 
protect new and traditional medicine; (2) with 
patents; (3) as trade secrets; and (4) through laws 
and regulations, such as trademark protection.
Patents for medicine, veterinary science, and 
health are represented by the code “A61,” accord-
ing to the international patent classification. Table 
3 below shows that the total number of A61 patent 
applications was 24,875 in 2005, four times the 
number of patent applications for 1994 (6,227). 
There is a strong annual growth trend. The total 
number of patents granted in 2005 was 10,179, 
or 3.5 times the number granted in 1994.
Ninety-seven percent of domestic applica-
tions for A61 patents in the “medical” subsector 
were for traditional Chinese medicines. Foreign 
applicants filed 92% of the applications for 
nontraditional pharmaceuticals; there were few 
domestic applications for nontraditional phar-
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(48%) of the patent applications for modern 
medicines. However, the number of domestic ap-
plications for creative patents fell well short of the 
number of foreign applications; this is an area for 
future improvement.
Overall, the Chinese medical and health sec-
tor seems to lack qualified personnel and an IP 
rights concept. The government needs to promote 
research and development, capacity building, tech-
nical innovation, and the promotion and modern-
ization of industry, in order to increase China’s 
competitiveness in the medical and health sector.
4.		The	CuRRenT	STATe	of	AgRICulTuRAl	
Ip	pRoTeCTIon
The Patent Law of the People’s Republic of 
China, passed in 1984, stipulated regulations for 
IP protection of plant varieties. China entered 
the International Union for the Protection of 
New Varieties of Plants (UPOV) in April 1999 
as its 39th member. The State Regulation for 
Protection of Place of Origin and Products was 
issued in 1995 and the Seed Law was passed in 
2000.
To date, China has granted protection for a 
total of 62 categories and species of crops and 78 
species of trees. In the agricultural sector, there 
are more than 150 kinds of products protected 
by trademarks, and more than 600 varieties have 
plant variety protection certificates.
New regulations that protect plant variet-
ies have encouraged investment in agricultural 
research and development. A survey conducted 
by the Ministry of Agriculture (MOA) of more 
than 500 patent applications and patent grants 
revealed that companies contributed 83% of the 
money invested in the research and development 
of new plant varieties; the government contrib-
uted only 17%.
These new regulations have promoted agri-
cultural innovation. In the last 40 years, China has 
successfully cultivated more than 40 new varieties 
of different crops and more than 6,000 new variet-
ies. One outcome of this innovation is a 30-40% 
of increase in grain production in recent years. 
The regulations mean that plant breed-
ers have begun to receive economic benefits for 
their work, which in turn has encouraged them 
to put still more effort into research and innova-
tion, thus benefiting farmers. As a result, farmers’ 
incomes have increased. In addition, the MOA 
survey mentioned earlier found that nearly 43 
million hectares (ha) had been planted with new 
plant varieties, increasing yields by 56.3 million 
tons and increasing farmers’ profits by US$2,886 
million. Another investigation found that the 
new, protected varieties of paddy rice protected 
by IP rights could produce an average profit of 
US$562 per ha in east China’s Jiangsu Province; 
while ordinary varieties of rice produce an average 
profit of only US$420 per ha, which is US$142, 
or 13%, less. The investigation also indicated 
that the new varieties of paddy rice in southwest 
China’s Sichuan Province produced a 37% higher 
yield than ordinary varieties. 
As Table 4 illustrates, the number of agricul-
tural patent applications has steadily increased. 
There were 6,802 applications filed in 2005, 4.4 
times the number of applications filed in 1994. 
In 2005, the total number of patents granted was 
3,157, which was 4.5 times the number granted 
in 1984.
China is one of the most prolific filers of ap-
plications for IP protection of new plant variet-
ies. According to statistics provided by MOA, the 
number of applications for variety rights protec-
tion increased from 115 applications in 1999 to 
nearly 1,000 in 2006. There were 3,879 variety 
rights applications filed in the period from 1999 
to the end of 2006, and 899 patents were even-
tually granted. During the same period, foreign 
applicants filed 144 patents and five patents were 
granted (see Table 5). Most applications for vari-
ety rights are filed for field crops (90.5%); paddy 




China has a long history of producing cotton 
and has been a major cotton-producing country 
for some time. After China joined the WTO, 
Monsanto quickly established two subcom-
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panies in China and introduced its transgenic 
pest-resistant (GMPR) cotton. Ninety-six per-
cent of the cotton planted in Hebei Province 
from 1999 to 2001 was American GMPR cotton. 
In 1999, 400,000 ha of Chinese soil was planted 
with American GMPR cotton. In 1999, 65% of 
the pest-resistant cotton planted was American 
GMPR cotton; 80% was American GMPR cot-
ton in 2000. Monsanto has since obtained a total 
of nine biosafety certificates from the MOA: four 
for corn, one for soybeans, one for oilseeds, and 
three for cotton.
The Chinese government realized that it was 
important to protect the pest-resistant cotton 
varieties developed by Chinese scientists. Less 
American GMPR cotton is now planted, and 
there is healthy competition between Chinese 
and American scientists for the GMPR cotton 
business. To date, China has protected 55 new 
varieties of GMPR cotton, which makes up 10% 
of the total amount of all cultivated cotton. More 
than 6.7 million ha of Chinese GMPR have been 
planted, yielding profits of close to US$2 billion.
5.2	 Hybrid	rice
Hybrid rice has contributed remarkably to 
Chinese food security. To date, hybrid rice has 
been planted on more than 300 million ha of 
Chinese soil. The current annual yield has been 
increasing since 1976, and it now feeds 60 mil-
















Field cropsa 3,510 90.0 831 92.5
     -Paddy rice 1,222 31.5 261 29.0
     -Corn 1,531 39.5 344 38.3
     -Soybeans 126 3.2 34 3.8
     -Wheat 357 9.2 89 9.9
Vegetables 164 4.2 34 3.8
Flowers 101 2.6 13 1.4
Fruit 101 2.5 21 2.3
Grasses 3 0.8 0 0.0
Total 3,879 100.0 899 100.0
a This list of individual crops is not complete but represents the major crops. Hence, the totals of field 
crops is higher than the combined total of paddy rice, corn, soybeans, and wheat.
 
Source: Ministry of Agriculture.7
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After approval by the Ministry of Agriculture 
and the State Import & Export Commission, 
U.S. Western Petroleum’s Ring Round Co. paid 
for the rights of transferring the Hybrid-Rice 
Technology via the China Seed Corporation in 
March 1980. It was the first time in China’s his-
tory that it made such a paid-technology transfer 
to the outside.
Since the passage of the Regulation for the 
Protection of New Variety of Plants of the People’s 
Republic of China, a total of 3,879 patent ap-
plications have been received for plant varieties; 
899 patents have been granted, 280 of them for 
paddy rice.
The Food and Agriculture Organization of 
the United Nations has listed Chinese hybrid 
rice as the most important technology for com-
bating food insecurity in developing countries, 
especially low-income and food-deficit countries. 
Vietnam sowed 600,000 ha of hybrid rice in 2003 
and achieved a high average yield of 6.3 tons per 
ha. The country plans to increase the area planted 
with hybrid rice to one million ha in 2010. India 
sowed 280,000 ha of hybrid rice in 2003 and 
700,000 ha in 2005; the hybrid rice produced a 
15–20% higher yield than ordinary rice would 
have produced. With China’s assistance, the 
Philippines has greatly expanded its hybrid-rice 
production areas. In the Philippines, 200,000 ha 
of hybrid rice were planted in 2004 and one mil-
lion ha will be planted in 2007. In the United 
States, 20,000 ha of hybrid rice were planted in 
2001 and 87,000 ha in 2006. An estimated 30% 
of all paddy rice planted in the United States in 
2007 will be hybrid rice.
The protection of variety rights has encour-
aged research institutions and private companies 
to make continuous innovations with regard to 
hybrid rice. The Hunan Hybrid Rice Research 
Center developed 36 varieties of hybrid rice in 
five years (2001–2005), which was 1.5 times 
the amount developed in the previous ten years 
(1990–2000). 
The protection of new varieties of plants, not 
only creates direct economic benefits for China, 
but also helps coordinate the efforts of those 
working in different areas of the hybrid-rice sec-
tor: seed breeding, research, and extension. Sixty-
seven million ha of the Pei’ai 64S, the most popu-
lar photoperiod- and temperature-sensitive strain, 
have been planted in China, producing US$10.3 
billion, up to year 2004. 
5.3	 Pharmaceuticals
According to the Derwent Innovation Index, the 
United States is ranked first in the world for the 
production of new pharmaceuticals, with 1,676 
patent applications. China is ranked second, with 
1,083 patent applications. China is followed by 
Japan, with 88 applications. Of the ten compa-
nies in the world with the greatest number of pat-
ent applications, eight of them are American and 
two of them are Chinese. 
The Shanghai Shengyuan Gene Development 
Co. Ltd. in China is mainly involved in the re-
search and development of human cDNA. It has 
a strong technical team and is well equipped. It 
has identified more than 500 gene elements and 
has submitted 851 patent applications for genes, 
more than any other company in the world.
5.4	 The	case	of	Jiangsu	Provincial	Academy	
of	Agricultural	Sciences
The Jiangsu Provincial Academy of Agricultural 
Sciences applied for its first patent in 2000 in or-
der to protect a new variety of double-line hybrid 
paddy rice named Liangyou-Beijiu. By the end 
of 2004, the Academy had applied for 32 patents 
and received 23 grants.
The academy could get a benefit of more than 
US$2.5 million by transferring a series of new va-
riety rights of new wheat seeds cultivated by the 
academy to a total area of 4.5 million ha. This 
would provide great social benefits represented by 
more than US$1.2 billion in value.
6.	 ConCluSIonS
Developing countries must protect their IP rights 
in order to promote domestic innovation, in-
crease resource utilization, improve farmers’ in-
come, and promote international cooperation 
and competition. The following four steps are 
essential for protecting IP rights: (1) the passing 
of government legislation; (2) the establishment 
of a national IP rights-management system; (3) 
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publicity and promotion of the IP rights concept; 
and (4) international cooperation. 
In general, IP rights protection in developing 
countries is inferior to that in developed coun-
tries. This is because the international IP system 
may not be fully understood, the legal system may 
be incomplete, and the human capacity for IP 
work may be weak. To overcome these obstacles, 
it is important for developing countries to draw 
on the experiences of developed countries.
China still lags behind many other countries 
in IP matters. According to the WIPO IPRS Report 
of 2006, an average of 148 patents were filed for 
each million people in 2004. Japan filed 2,884 
patents per million people; Korea filed 2,189; the 
United States filed 645; and China filed only 51, 
putting it in 27th. The global average for patent 
applications per US$1 billion GDP was 19 ap-
plications in 2004. For the Republic of Korea, the 
number was 116.2 applications; for Japan, 107.3 
applications; and for China, only 9.4 applica-
tions, putting it in 17th place.
Over the last decade, led by a cadre of world-
class scientists and researchers, China’s invest-
ment in biotechnological R&D has dramatically 
increased. This has generated remarkable devel-
opments and successes, benefiting the people of 
China in many ways. However, in order to sustain 
and continue to drive this enormous leap in prog-
ress, greater human and institutional capacity in 
IP law and management will be necessary. Such 
capacity will serve to further foster and encourage 
even more inventive activities, innovative initia-
tives, and the development of the next generation 
of advances in health and agriculture, for the ben-
efit of all in China. ■
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ABSTRACT
Health and agriculture are at the very core of the European 
Union’s policies for socio-economic development. One 
of its most active efforts is the Framework Programmes 
for Research and Technological Development. With a 
specific focus on international cooperation, this is the 
European Union’s main financial instrument to promote 
and strengthen research and technological cooperation 
within the European Union (E.U.). Through the E.U. 
Framework Programmes, actors from different coun-
tries and sectors (industry, research centers, small- and 
medium-sized enterprises, universities, and so on) work 
together to improve science and create a better standard 
of living. 
Given the massive movement of scientists and experi-
ences exchanged through these Programmes, it seems that 
the E.U. is on the right track. However, these Programmes 
can only be used to their fullest potential when partici-
pants understand and appropriately handle the intellec-
tual property rules governing them. 
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and add to reservoirs, many of which were be-
low 25% capacity. That same summer, Central 
and Eastern Europe experienced one of the worst 
floods in recent years. 
The summer of 2006 was not better in terms 
of forest fires and climate conditions. Countries 
like France and Belgium experienced unusually 
high temperatures. In recent years, in southern 
Europe, global climate change has made obtain-
ing (and adequately storing) drinkable water a key 
concern and a central focus of its research poli-
cies. The countries of the E.U. face many of the 
same environmental challenges as other countries 
of the world—plagues, ecological accidents and 
attacks, and natural disasters. This illustrates the 
problems E.U. member states encounter and the 
need to take a coordinated approach to manag-
ing natural resources and planning their use and 
exploitation. 
E.U. countries have their own policies and 
initiatives for the optimal and responsible use 
of their natural resources. Many technological 
efforts focus on rural areas and businesses that 
could develop E.U. agriculture, fisheries, and 
food industries. Using new technologies in rural 
areas is one of the most common ways to help 
farmers and small enterprises compete with large 
corporations. 
Apart from the Framework Programmes 
(hereafter FPs), which are the subject of this 
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1.	 InTRoduCTIon	
In the increasingly large group of countries that 
compose the European Union, there are not 
only large differences in the climate and natu-
ral resources, but also large contrasts in terms of 
cultural traditions and economic development. 
Together, these create the specific needs and chal-
lenges of E.U. citizens. As an example, in the sum-
mer of 2005, a good part of Spain and Portugal 
saw woods and mountains burn and not a drop 
of rain to interrupt a sustained period of drought 
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chapter, there are other Community actions that 
benefit the E.U. and partner countries (like those 
actions promoted under the European Regional 
Development Fund [ERDF], aimed at regional 
development, or those projects funded under the 
MEDA Programme, the objective of which is to 
improve the socio-economic conditions of coun-
tries in the Mediterranean region).
2.	 The	fRAmeWoRK	pRogRAmmeS	And	
TRAnSnATIonAl	CoopeRATIon
Created by the treaty that established the European 
Community (the European Community Treaty), 
the E.U. Framework Programmes for Research 
and Technological Development are a financial 
tool to support research and innovation. The 
multiannual Programmes commenced in 1984. 
Currently, the Sixth Framework Programme 
(FP6) is being implemented. FP6 started in 2002 
and will run until the end of 2006. (FP7 will start 
in 2007 and end in 2013.)
While the general objective of the FPs is to 
boost research and innovation in the E.U., FP6 
aims particularly at contributing to the creation of 
the European Research Area (ERA), which would 
be a single market for R&D. FP6 seeks to play a 
significant role in achieving the ambitious chal-
lenge of Lisbon 2000: for the European economy 
to become, by 2010, the world’s most competitive 
and dynamic knowledge-based economy. To meet 
this objective, R&D in Europe needs to be over-
hauled. Europe has prominent scientists and re-
searchers, but establishing stable, durable coopera-
tion schemes and turning research into tangible and 
exploitable results must be an ongoing priority. 
To foster European excellence in R&D and 
innovation, FP6 is based on scientific and tech-
nological cooperation at a transnational level. To 
achieve this cooperation, FP6 has a total budget 
of €17,883 million.1 Of this amount, €12,438 
million is devoted to the so-called “FP6 Thematic 
Priorities.” The priorities represent seven areas in 
which research is considered a key need. They 
are, along with amounts budgeted to accomplish 
the goals: 
1. Life sciences, genomics, and biotechnology 
for health (€2,514 million) 
2. Information society technologies (IST) 
(€3,984 million) 
3. Nanotechnologies and nanosciences, 
knowledge-based multifunctional materials, 
and new production processes and devices 
(€1,429 million)
4. Aeronautics and space (€1,182 million)
5. Food quality and safety (€753 million)
6. Sustainable development, global change, 
and ecosystems (€2,329 million)
7. Citizens and governance in a knowledge-
based society (€247 million)
The FP6 budget acknowledges that small- 
and medium-sized enterprises (SMEs) are princi-
pal engines of the E.U. economy (accounting for 
approximately 99% of all businesses, giving jobs 
to almost 95 million people, and accounting for 
66% of private employment).2 In order to help 
SMEs innovate and develop, they are assigned 
at least 15% of the general amount budgeted 
for thematic priorities. In addition, SMEs have 
€473 million of the total FP6 budget for funding 
SME-specific actions. 
Besides the thematic priorities, other activity 
areas (such as SME-specific actions, researchers’ 
mobility and training, and international coopera-
tion) share the remaining €5,445 million of the 
FP6 budget. Nuclear energy and training in this 
field has a special programme: FP6/EURATOM, 
with a budget of €1,230 million.
2.1 Health	and	agriculture	within		
the	FP6	thematic	priorities
Of the total budget for the first thematic priority 
(life sciences, genomics, and biotechnology for 
health), €1,209 million is set aside for research on 
advanced genomics and its applications for health 
(first subpriority), and €1,305 million is assigned 
to combating major diseases (second subpriority). 
One of the main interests of E.U. society is the 
advancement of cancer research and treatment, 
and so from the budget of the first thematic pri-
ority, up to € 475 million goes exclusively to can-
cer-related research. Agriculture is covered by the 
fifth priority, food quality and safety. For the sixth 
priority (sustainable development, global change, 
and ecosystems), €890 million is planned for 
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research on sustainable energy systems (first sub-
priority). €670 million is devoted to sustainable 
surface transport (second subpriority) and €769 
million is for research related to global change 
and ecosystems (third subpriority).
2.2 Participation	and	funds
Fundamental participants in projects funded un-
der FP6 are legal entities (universities, research 
centers, enterprises, and sometimes individu-
als) from E.U. member states. Entities from the 
E.U.-associated candidate countries (Bulgaria, 
Romania, Turkey and Croatia3), and entities 
from other countries associated with the FP6 by 
means of particular agreements (Iceland, Israel, 
Liechtenstein, Norway, and Switzerland) partici-
pate in projects funded under FP6 on the same 
footing as entities from E.U. member states: They 
have the same funding options and, in addition, 
there is the possibility for a consortium made up 
exclusively of entities from those countries. 
However, one of the features that make the 
FPs attractive to any research entity is the pos-
sibility of participation by entities from countries 
that are not associated with the FP6. Although 
there are different modalities for participation and 
funding, entities from these non-E.U. member 
countries can also participate via thematic priori-




The E.U. is a world leader in development aid, 
and, under FP6, entities from non-E.U. member 
states can participate even if they are not specially 
linked with the Programme. The INCO activity, 
however, best reflects the Programme’s interna-
tional dimension. 
INCO is an FP6 activity specifically aimed 
at cooperation with third countries, and in par-
ticular with INCO target countries: develop-
ing countries, Mediterranean partner countries, 
Russia and the other New Independent States 
(former members of the Soviet Union), and the 
western Balkan countries.4 For this specific activ-
ity, FP6 reserves €346 million. 
Up to €312 million is allocated to support 
the participation of entities from non-E.U. coun-
tries in thematic priorities and other activities, 
which provide a total of €658 million for the par-
ticipation of non-E.U. member entities. In addi-
tion, resources from the general budget of €1,732 
million for Marie Curie actions are available to 
fund research training and mobility in Europe 
for researchers coming from non-E.U. member 
countries.
2.2.2 How	it	works
FP6 funds research and related activities. Actions 
for funding are open to potential participants 
(usually, groups of entities, or consortia, coming 
from different countries) through calls for pro-
posals, which establish the main requirements of 
an activity (for example, the minimum number 
of participants, origin, objectives of the activ-
ity, and deadlines for submitting the proposal). 
These calls are published on the Internet in the 
Official Journal of the European Union and on the 
CORDIS Web site5 (a key service for anyone in-
terested in E.U. R&D and innovation), amongst 
others. Consortia are generally made up of a 
minimum number of participants from different 
E.U. member states or associated states. Once 
the minimum number is reached, more par-
ticipants from the same or other countries, even 
from non-E.U. countries, are welcomed, always 
taking into account the optimum magnitude of 
each project. 
Generally, once a person or group is consid-
ering opting for a research project funded under 
any FP6 priority or subpriority, the person or 
group has to find enough partners to form a proj-
ect consortium. Many entities know others in the 
field with which they would like to partner in re-
search. If this is not the case, CORDIS and other 
sites provide a partners’ search tool. 
Deciding on the type of project is a next step. 
FP6 has a wide range of project types, includ-
ing integrated projects (IP), networks of excel-
lence (NoE), specific targeted research projects 
(STREP), specific targeted innovation projects 
(STIP), cooperative research projects (CRAFT), 
collective research projects (the last two, represent 
SME-specific actions), specific support actions 
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(SSA), which can be carried out by a single entity, 
and Marie Curie actions (fellowships).
Each project type has its own “personality” 
and focuses on specific aims. Proposers will need 
to choose the type that best fits their needs in 
terms of size (some projects, like integrated proj-
ects, are designed for large consortia; others are 
better managed by a small ones, like the specific 
targeted research projects), time (some projects 
can last longer than others; for example, SME-
specific actions are relatively short, lasting about 
two years), and objectives (some projects, such as 
integrated projects, are focused on developing a 
specific product or technique through in-depth 
research; other projects, such as networks of ex-
cellence, aim to achieve long-lasting integration 
of research forces).
Taking all of the above into account, inter-
ested parties submit their proposals by a deadline 
established in the relevant call. These propos-
als are then evaluated by independent experts. 
Depending on the proposal’s scientific interest, 
input in R&D, level of innovation, and potential 
for fulfilment of the aims of the call in question, 
the proposal may be selected for funding.
Addressing intellectual property (IP) rights 
issues is crucial for the success of any research 
project. A competitive proposal has to consider 
IP aspects carefully in order to convince evalua-
tors that it deserves to be funded. Generally, ap-
plicants will be asked about their plans for using 
and disseminating the expected research results. 
The applicants need to know what they have, 
what the state of the art is in the field in question, 
whether or not there are patents that cover some-
thing (for example, a molecule) they may need 
during the course of their research, what IP they 
need to work with, what would make them ask 
for a license, how to share their IP resources for 
work purposes, what results may be expected, and 
how these results can be managed and exploited. 
Of course, the level of detail and scientific cer-
tainty of these plans would not usually be very 
high, but they should be as complete as could be 
reasonably expected at that stage.
In order to have a well-managed project (and 
to make the most of the results to be obtained), 
participants need to be familiar with the FP6 
rules for participation and EC model contracts.6 
Furthermore, apart from the FP6-specific rules, 
participants should take into account other ele-
ments, such as other research concurrent with 
their FP6 project, some national laws (for exam-
ple, regarding employees’ creations or joint own-
ership), and competition rules, since they may 
affect the FP6 project.
It is worth mentioning that the IP related 
rules under FP7, even if maintaining features of 
FP6, will be likely to change somewhat to the 
benefit of the project participants, partly by giv-
ing them more autonomy. Entities interested in 
having their research activities funded under FP7 
can start now to get familiar with the new rules. 
(Relevant documents on FP7 can be found, i.e., 
on the IPR-Helpdesk Web site.7)
2.2.3 Do	not	forget
Taking part in an E.U.-funded project involves 
sharing, collaborating, exchanging know-how, 
and effort. Besides the rules, participants have to 
be aware of this basic requirement from the very 
beginning (even before the proposal is selected) 
to pave the way for their cooperation.
3.	Ip	RIghTS	ISSueS	In	An	fp6	pRojeCT	
Dealing with IP rights-related issues is essential 
for any research project, and this is even more 
true for a transnational project than for a project 
with a narrower focus. The diverse nature of the 
participating entities (enterprises, public/private 
research centers, universities, and so on) and their 
origin (different countries with different laws and 
cultures) are responsible for the richness of these 
projects but can be also an obstacle if consortia 
and resources are not managed adequately.
The relevance of IP related questions is re-
flected in the attention those questions receive 
under FP6. The E.U. Framework Programmes 
provide participants with a set of rules and guide-
lines that are very detailed in comparison with 
other funding programs. The rules are laid out in 
the contract that participants enter into with the 
European Community (EC)—the EC contract. 
The contract mirrors the rules for participation in 
the Framework Programme. Participants will find 
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in the contract the basic norms that are to govern 
their research project and also several obligations 
and rights to be exercised at the conclusion of the 
project (the exploitation-of-results phase). 
The EC contract is a pre-established con-
tract that cannot anticipate all the specificities of 
a single project and consortium. For this reason, 
participants sign a complementary contract (the 
consortium agreement) to which the European 
Community is not a party. Due to the importance 
of this agreement for implementing the project, it 
is compulsory under FP6, unless the relevant call 
specifies otherwise. (Indeed, signing this agree-
ment is particularly obligatory in SME-specific 
actions, integrated projects, and networks of ex-
cellence, while it is usually optional, but highly 
recommended, in other actions.)
The IP rules concentrate on managing IP re-
sources during the project, with a forward focus 
on the use of the results obtained from the proj-
ect. These rules deal with four main aspects: 
1. Ownership of the results obtained during 
the project
2. Protection of results (by means of IP 
rights)
3. Access rights (licensing)
4. Use and dissemination of results 
There are ancillary issues (such as confidenti-
ality, IP related costs, and so forth) that are also 
important for good IP management and are also 
considered in the rules.
3.1 Basic	terms
To understand the IP related rules and their 
practice, it is necessary to explain some FP6 
terminology: 
• pre-existing know-how. Even though the 
definition of pre-existing know-how given in 
the FP6 rules may seem complex, it is actu-
ally quite simple: any information and IP 
resources that participants have before en-
tering the FP6 project or that they obtain 
in parallel to it (that is, any information 
participants acquire independently of their 
participation in the FP6 project). The defi-
nition applies to any information, not just 
technical know-how. 
• knowledge. In the context of FP6, knowl-
edge means any results of the project and 
the related IP rights. 
• access rights. The frequently used term ac-
cess rights refers to licenses or user rights to 
knowledge or pre-existing know-how.
• use. The meaning of use is also very spe-
cific and distinct from its common mean-
ing. In the terminology of FP6, use means: 
the commercial/industrial exploitation 
of results obtained or their application in 
further research activities, either by their 
owner or by an authorized third party. 
• dissemination. The concept of dissemina-
tion refers to another activity that FP6 
project participants need to carry out: 
disclosure of the results of a project by any 
appropriate means. The rules specify, “ap-
propriate means other than publication re-
sulting from the formalities for protecting 
knowledge.” This wording helps to clarify 
that, for example, publication of the patent 
application by a patent office is not consid-
ered dissemination. Scientific publications, 
general information on Web sites, confer-
ences, and the like are good examples of 
dissemination.
3.2 Who	owns	the	project	results?
One of the questions that arises within research col-
laboration activities is who owns the results. FP6 
ownership provisions strive to be logical and lucid, 
which makes it easier for people who are unfamiliar 
with legal issues to understand them. The provisions 
also mirror the general principles of modern IP 
laws, which provide a fair degree of legal certainty. 
The basic rule is that the results obtained in 
a project are owned by the participant who has 
carried out the work leading to those results. 
Importantly, the participant is the entity that en-
ters into the EC contract—for example, a uni-
versity—not the department or research group 
actually working on the project.
Where several participants work together toward 
the results of a project, and their respective portions 
of the work cannot be ascertained, the participants 
are considered joint owners and must agree on the 
allocation and terms of exercising ownership. 
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In SME-specific actions, the cooperative 
(CRAFT) and collective research projects, only 
the SMEs and the enterprise groupings, respec-
tively, get (joint) ownership of the results (even if 
the results have been generated by other partici-
pants). This is because these actions are designed 
to benefit SMEs. 
3.2.1  Practical	issues	of	joint	ownership
Joint ownership established by the EC contract is 
a guarantee for the working parties; they can agree 
to continue under a proper co-ownership regime 
(therefore establishing the rules to be followed) or 
agree on other options. The EC contract tries to 
avoid situations of conflict between weaker and 
stronger participants by guaranteeing that, where 
work is carried out in common, all parties must 
give their opinion before any decision is made. 
Joint ownership, however, may arise from 
either common work or voluntary decision. Its 
regulation will generally be left at first to the 
agreement of the parties concerned. Any loop-
hole in the regime will be closed by the applicable 
law, which changes from one country to another. 
Accordingly, and to avoid difficulties as much as 
possible, if the parties decide to continue with a 
co-ownership regime, they should seek the assis-
tance of a professional in order to draft an ade-
quate agreement that deals in detail with the most 
important aspects of the ownership regime.
3.2.2 Taking	personnel	rights	into	account
It goes without saying that the EC contract does 
not replace participants’ national laws, rules, stat-
utes, and so on. Of all these rules, perhaps the 
most relevant ones are those dealing with em-
ployees’ and other personnel rights. Policies differ 
from country to country, so each participant has 
the responsibility to check its position toward its 
personnel. The participant and relevant person-
nel should sign appropriate agreements—and, if 
necessary, transfer ownership—in order to avoid 
future claims about the ownership of the results. 
For the purpose of this rule, “personnel” may 
be:
• staff employed by the participants 
(employees) 
• doctoral students 
• personnel made available by a third party 
(invited professors or lecturers)
• subcontractors, and so on
Special care should be taken with those who 
are not regular employees. In many countries, the 
situation of employees regarding IP ownership is 
controlled under labor or IP laws. However, the 
situation is usually less clear when the work is car-
ried out by scholars or when it is a commissioned 
work.
3.2.3 Transfer	of	results	
Transfers of ownership (including transfer be-
cause of takeovers and mergers) are allowed but 
with some conditions (participants implement 
their projects thanks to E.U. funds). 
The participant transferring ownership has to 
pass on to the assignee its obligations under the 
contract (including those related to compulsory 
licensing, use, and dissemination). Therefore, 
the assignee gets a “pack of rights and obliga-
tions” with regard to the EC and the partici-
pants in the project. The transferring party has 
to give prior notice about the transfer and the 
assignee to the European Commission (hereafter 
the Commission) and to the other participants. 
The Commission may particularly object when 
the assignee is an entity not established in a E.U. 
member state or associated state, if such a transfer 
is not in accordance with the interests of the E.U. 
economy or is inconsistent with ethical prin-
ciples. The other participants may object if their 
licensing options could be affected.
3.3 How	to	protect	the	results	obtained
Adequately protecting results with commercial or 
industrial application is one of the participants’ 
obligations. After all, a new product, process, or 
technique can only be properly commercialized 
when it is adequately protected. 
3.3.1  Options	for	protecting	results
The participant who owns the results of a project 
is obliged to ensure their protection. However, the 
Commission may take over these duties should 
the owner fail. According to the FP6 rules, the 
owner should adequately and effectively protect 
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results, while having due regard for its own legiti-
mate interests. This allows for flexibility and gives 
participants room for decision. 
A decision-making process to consider the 
most appropriate way to protect the results of 
an FP6 project follows the same path that a uni-
versity, laboratory, enterprise, or research center 
does to protect an invention or a piece of work. 
The decision to seek protection would take into 
account such factors as the nature of the results 
obtained (which would lead to the consideration 
of certain types of IP rights and the dismissal of 
others; see Figure 1), the level of novelty and in-
ventiveness of the results, the likely market and 
possibilities for commercial expansion, financial 
resources, and so on.
The above should lead to the application of 
the most appropriate IP rights. It should also 
point to countries for which it would be advis-
able to seek protection for the results (remember 
that IP rights are territorial rights). For the best 
outcome, the participants should get the advice 
of an expert in the field.
Finally, there is flexibility in the EC contract 
concerning the kinds of protection and exploita-
tion that are appropriate. If the circumstances of 
the case warrant it, participants may, for example, 
decide to opt for trade secret protection rather 
than applying for a patent. Participants may 
choose other options in different situations, for 
example, follow a standardization process or dis-
tribute their software under open source licenses.
3.3.2 Protection	and	publishing
Protecting and publishing are two activities that 
should be carefully balanced under FP6. Academic 
participants in particular should be aware of the 
following: 
• Protection prevails over dissemination. 
When results come up, before disclos-
ing them to the general public or special-
ized public, participants need to appraise 
the commercial/industrial potential of the 
figure	1:	Basic	Types	of	Ip	
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results. If they can be commercially/indus-
trially applied, dissemination will need to 
be postponed until protection is ensured. 
For example, if the option of applying for 
a patent is being studied, a prior publica-
tion may preclude the novelty needed to 
obtain the patent. Therefore, publication 
should be postponed until the patent ap-
plication is submitted to the patent office. 
Even though this principle may be difficult 
to follow for those working in academia, 
universities and research centers, they 
should not be deterred from participating 
in FP6. In the European Union (in contrast 
with the United States), there is no grace 
period allowing for publication without 
prejudicing novelty. Publishing in Europe 
has been considered the traditional activ-
ity of academia, but in the last two decades 
patenting in universities has become more 
commonplace. For these innovative univer-
sities, the waiting approach is already prac-
ticed, because protecting first; publishing 
after is the general principle they follow to 
turn their research results into profits.
• Publications are conditioned. The FP6 
rules establish that publication is to be 
carried out by the owner of the results (or 
with the owner’s consent). In SME-specific 
actions, the technological partners (RTD 
performers, in the FP6 terminology) can 
also publish the results they have generated 
(even if, as has already been mentioned, 
ownership vests in the SMEs or enterprise 
groupings). The Commission and other 
participants in the project must be notified 
in advance of any planned publication, and 
they can object if the planned publication 
affects the protection of their results.
3.4 Sharing	resources	among	participants
3.4.1  Granting	access	rights
Whether generated by their own team or by oth-
er participants in the project, the result obtained 
benefits all participants; participants may need 
to be licensed or be granted user rights, or ac-
cess rights, by one another. It is compulsory for 
participants to grant licenses to each other if ei-
ther of the following conditions exist: It is neces-
sary to carry out the project, or it is necessary for 
using one’s own results. 
In the first case, a participant needs informa-
tion or IP resources from other participants in or-
der to carry out its work in the project, and they 
shall be required to grant the requester access to 
the resource in question by means of a license or 
user right.
Example: The research project aims to devel-
op a new product for the massive cleaning of con-
taminated water. One of the project participants 
is in charge of testing a pilot process in its labora-
tories but needs biomaterials (bacteria) from one 
of the research centers taking part in the project. 
In this situation, the latter shall grant access to 
the bacteria.
The access is granted at no cost if the request-
er needs results obtained in the project by another 
participant. Accessing pre-existing know-how is 
also free (unless partners agreed on a fee before 
the EC contract was signed).
In the second case, a participant needs infor-
mation or IP resources from other participants so 
that it can use the results it has obtained in the 
project, and the latter shall be required to grant 
the requester access to the resource in question.
Example: One of the participants in a proj-
ect has developed a robotic arm to help disabled 
people at home. However, to exploit the arm, the 
participant needs a chip owned by another par-
ticipant. In this case, the latter shall give the other 
participant access to the chip. 
Access is to be granted under fair and non-
discriminatory conditions if the pre-existing 
know-how of the other participant is requested. 
Access will be free of charge (unless an alternative 
is agreed upon before the EC contract is signed) 
to a participant’s results. 
3.4.2 Other	issues
There are other factors which affect the sharing of 
resources and information:
• Compulsory licensing is activated by writ-
ten request, and regarding pre-existing 
know-how, the required participant has to 
be free to grant access to it. This condition 
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may seem quite obvious, but the FP6 rules 
make a point of requiring this. It is com-
mon for research entities to enter into agree-
ments (for example, MTAs or common li-
censes) with other entities (whether from 
research or industry) involving day-to-day 
research. It may happen that participants 
in an FP6 project have already concluded 
agreements on their pre-existing know-
how that prevent them from granting the 
other project participants further access to 
it. In such cases, the participant concerned 
should inform the other participants of its 
limitations as soon as possible, in order to 
avoid false expectations or conflict. 
• Participants may condition the grant of li-
censes on the conclusion of certain further 
agreements (for example, on confidential-
ity) that guarantee the proper use of the 
licensed resources.
• It is possible (and desirable) to grant more 
favorable or additional licenses. Licensing 
third parties (that is, licensing the results 
obtained outside the project partners’ 
group) is also permitted and encouraged.
• As a general rule, sublicensing is not al-
lowed unless expressly agreed upon by the 
participants concerned. Whatever commit-
ments may be reached, participants’ poten-
tial rights have to be preserved and rules of 
competition observed.
3.4.3 Terms	for	request	
The Programme’s rules include various other pro-
visions related to the sharing of intellectual prop-
erty among participants:
• Access rights for carrying out project work 
may be requested until the end of the proj-
ect (even if the participant concerned leaves 
before the project is completed). 
• Access rights for use can be requested up to 
two years after the end of a project or end 
of participation of the contractor (which-
ever is sooner) if the contractor leaves be-
fore the project is completed, unless the 
partners had previously agreed to extend 
the period.
• Duration of access rights has to be agreed 
upon by the parties involved and stated in 
the licensing agreement.
3.4.4 Exclusion	of	pre-existing	know-how	
Even though sharing and cooperating is the ba-
sis of FP projects, policy-makers are aware that 
participants’ legitimate interests may sometimes 
be compromised by giving access to specific re-
sources. FP6 offers participants the possibility of 
excluding certain pre-existing know-how from 
their obligation to grant access rights to the other 
participants.
This possibility only exists under two circum-
stances—before the EC contract is signed and be-
fore a new contractor joins the project—and the 
exception always has to be responsibly exercised. 
It requires good faith negotiation among all par-
ticipants (some or all may oppose it if the project 
or their interests are significantly affected), and 
it can only apply to specific or concrete pieces of 
resources (massive or implicit exclusions are not 
allowed). Remember that the rule was designed 
to promote sharing, not excluding.
What if the cause of the exclusion is that an 
entity fears losing valuable information? In prin-
ciple, this should not be a reason for excluding 
access to IP resources, because participants shall 
preserve the confidentiality of the sensitive infor-
mation they share. It is advisable to sign confi-
dentiality agreements from the moment valuable 
information is exchanged (if possible, before the 
project even starts). Once the project is under 
way, the EC contract requires participants to pre-
serve the confidentiality of the information iden-
tified as such (diligence is required). The partici-
pant shall guarantee confidentiality for any third 
party to which sensitive project information is 
communicated.
3.4.5 Licensing	third	parties
The FP6 rules expressly admit the possibility of 
granting third parties licenses to project results. 
However, E.U.-oriented benefits also imply that 
the Commission can object when the planned 
license is not in accordance with the interests 
of the E.U. economy or is unethical. This mea-
sure is rarely taken (or needed) but in any case 
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participants have the obligation to inform the 
Commission in advance when a grant is planned 
and they think the above-mentioned risks may be 
present. 
How can participants be sure that nothing 
contrary to the wellbeing of the E.U. economy or 
unethical is going on? Participants may have an 
idea about practices that are unethical (as this is 
a matter frequently in the news). Knowing (even 
roughly) when the interest of the E.U. economy 
would be affected would seem to be another story. 
Aware of this difficulty, the Commission published 
a note that provides examples of possible scenarios 
that might be risky. (A typical example of a situa-
tion that might affect the economic interests of the 
E.U. could be that of a planned exclusive license to 
a company established in a third country.)
In any case and to be on the safe side, it is 
advisable to inform the Commission when-
ever a minimum doubt arises. Informing the 
Commission does not necessarily mean that it 
will object. Experts will always evaluate the case 
in the light of its specific circumstances.
3.5 After	the	results	are	in
The E.U. funding should lead to the use and 
dissemination of the project’s results. The 
Commission’s supervisory role is obvious with re-
gard to the participants’ obligation to state their 
goals and intentions in the plan for using and dis-
seminating the knowledge.
The first draft of this plan is to be included in 
the project proposal. This shows how important 
it is to have clear ideas on IP management and ex-
ploitation at the very beginning. Once the project 
is under way, a periodic report is required. The 
report must communicate the participants’ inten-
tions regarding the protection, use, and dissemi-
nation of the results generated under the project.
A final report (at the end of the project) creates 
post-contractual obligations for the participants 
and may be subject to a technological audit (up 
to five years after the end of the project). The final 
report must be approved by the Commission.
3.5.1  Use	of	the	results
Participants shall use the results they own in ac-
cordance with their interests. This can be done 
through the exploitation of the results or by car-
rying out further research activities. Both types of 
activities can be carried out directly by the owner 
or by a third party that is authorized by the owner. 
This usually means licensing the results to other 
participants or third parties. Other options may 
exist, such as assignments or the creation of a new 
entity (for example, a spinout).
3.5.2  Dissemination	of	the	results
The E.U. funding aims to provide for the dissem-
ination of the results to a wider audience. This 
means disclosing the results obtained, an obliga-
tion when protection and use are not affected. 
Participants should disseminate the results within 
two years after the project ends. Should they fail 
to accomplish this, the Commission may take 
over these duties. 
Results can reach the public through many 
different channels: Web sites, conferences or sem-
inars, articles for specialized journals, and so on. 
When studying dissemination (whether by the 
participants themselves or by the Commission), 
it is necessary to consider the IP rights involved, 
promptness, confidentiality, and the participants’ 
legitimate interests.
3.5.3  Helpful	sites
There are many Web sites and services that help 
consortia to use and disseminate the results of 
their research by giving publicity or facilitating 
contacts (Web addresses for these sites can be 
found in the endnotes8). Among the most use-
ful sites is CORDIS, which offers its Technology 
Marketplace. This feature records research re-
sults with commercial potential into a database 
arranged thematically using the fields: biology/
medicine, energy, environment, IT-telecommu-
nications, and industrial technologies. Other 
CORDIS services are the RTD Results Supplement 
(a supplement to the CORDIS Focus magazine) 
and CORDIS Wire. 
Apart from these services, many technology 
platforms exist at the Community and national 
levels. The European Technology Platform for 
Sustainable Chemistry is an example of the for-
mer. The Gate2Growth Initiative is also a useful 
resource; a pan-European business platform for 
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business matching, knowledge sharing among 
technology investors or knowledge transfer of-
fices, amongst other services. The Commission 
has published a catalogue to help innovators find 
local technology transfer institutions.9
3.6 Financing	post-research	phases
The projects work under a co-financing prin-
ciple (something covered by the participants 
themselves, and main part of costs covered by 
E.U. funding). To be eligible, costs must fulfill 
the general requirements stated in the FP6 rules. 
Among these costs are included costs that are 
“actual, economic, incurred within the duration of 
the project, and necessary” for the project. If IP 
related costs comply with these general require-
ments, they can be funded. Eligible costs may 
be related to IP protection (patent searches, IP 
rights filing), the dissemination of results (semi-
nars, publications, and so on), and activities 
promoting exploitation (for example, feasibility 
studies, take-up activities).
3.7 Other	IP	related	obligations
Having a particular research initiative funded by 
the E.U. goes, to some extent, beyond the inter-
ests of the participating entities. Ancillary provi-
sions try to ensure wide access to the results ob-
tained. These obligations may last longer than the 
project itself and are always covered by confiden-
tiality guarantees. 
These complementary rules include com-
municating results data to the Commission for 
evaluation purposes or to standardization bodies 
(whenever participants have results that may con-
stitute technical standards), giving information 
to the Commission about results that might be 
relevant with regard to public policy in member 
states or associates states, and providing the nec-
essary publicity to the funded project. 
4.	ConCluSIon
Fostering E.U. research and development re-
quires managing the IP resources of different 
projects. The entire process, from pure research 
to the exploitation of research results, has to be 
well planned.
The E.U. Framework Programmes are an 
ambitious tool for helping to implement this 
process. Mirroring modern IP laws, FP6 (and 
FP7) rules seek to facilitate IP management and 
increase legal certainty. They also try to balance 
public and private interests, but the success of 
these research actions cannot be left to the rules. 
The goals of the E.U. Framework Programmes 
can be met only if the participants involved are 
aware of these rules and do their best to imple-
ment them. An open sharing of information and 
experience will develop the essential trust, good 
relationships, proper planning, and solid coop-
eration needed to achieve the Programmes’ goals. 
Indeed, success very much depends on the par-
ticipants’ commitment and effort. ■
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ABSTRACT
This chapter describes the current status of IP (intellec-
tual property) management in the areas of health and 
agriculture in India with a focus on post-2005, at which 
time India became fully complaint with the Agreement 
on TRIPS (Trade-Related Aspects of Intellectual Property 
Rights). The major policy trends existing in India include 
(1) public sector expenditure for R&D is on the rise and 
is currently about US$5.0 billion (one US$ equals about 
4 Rs); (2) pharma industry R&D expenditures were 
on the rise and had reached Rs 15.0 billion, or close to 
4.0% of their turnover; (3) several major policy initia-
tives had been undertaken by the government, including 
the National Health Policy (2002), National Policy on 
Indian Systems of Medicine and Homeopathy (2002), 
and National Biotechnology Policy (2005). Other ma-
jor initiatives to promote IP generation include the cre-
ation of a Central Drug Administration, a new national 
body for the registration of medical devices, a National 
Registry for Clinical Trials, and a law similar to the Bayh-
Dole Act that provides for the sharing of IP with inven-
tors. The Departments of Science and Technology and 
Biotechnology, the Council of Scientific & Industrial 
Research, the Indian Council of Medical Research, the 
Indian Council of Agricultural Research, and so forth, 
have initiated large R&D programs in the health sector 
for the generation of new diagnostics, vaccines, and drugs 
largely focused on current health problems of India. A 
few indigenous products are being tested for safety and 
efficacy before use in the public health system. A new 
thrust and focus are being given for public–private 
partnerships involving both national and international 
partners. In agriculture, besides a substantial allocation 
of funds for R&D, two new initiatives—the National 
Agricultural Innovation Project (NAIP) and the Indo-
U.S. Agricultural Knowledge Initiative (AKI) were start-
 HANDBOOK OF BEST PRACTICES  | 1605 
ed in 2005. The NAIP is a World Bank-supported project 
worth approximately Rs 11.7 billion that is expected to 
strengthen basic and strategic research in agriculture in 
India. The AKI is expected to address a large number of 
issues including education, research services, and com-
mercial linkages in agriculture.
1.	InTRoduCTIon
Compared to many developing countries, India 
has a strong science and technology base. When 
India gained its independence in 1947, many sci-
ence and technology institutions already existed 
there. Moreover, during the past 50 years, India 
has made rapid strides in science through a se-
ries of policy initiatives promoting high-quality 
research. This chapter focuses on developments 
in the last few years, especially since 2005, when 
India became fully complaint with the Agreement 
on TRIPS (Trade-Related Aspects of Intellectual 
Property Rights). 
The past five years have seen an important 
change in science and technology primarily due 
to the anticipated impact of the TRIPS agree-
ment on IP regimes in India. Globalization and 
liberalization, which have primarily affected the 
economy and business, also have triggered inno-
vative R&D, as Indian companies have realized 
that unless they learn to become globally compet-
itive, they may not survive. The pharmaceutical 
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and biotechnology industries have been among 
the first to understand the implications of the 
new patent regime and the need to carry out in-
novative R&D. Some companies have increased 
their research budgets to as much as 10% of their 
total budgets. Even public sector institutions have 
realized that there is a need to reconsider their 
IP policies. Agencies like the Indian Council of 
Medical Research (ICMR) have adopted IP po-
lices to promote innovative R&D, encourage 
partnerships with industry, create incentives for 
patent filing and systems of royalty sharing with 
inventors, and so on. In the more recent past 
there have been attempts to create, through part-
nerships of the ICMR with agencies such as the 
National Institutes of Health (NIH) and MIHR 
(the Centre for the Management of Intellectual 
Property in Health Research and Development), 
a strong force of technology transfer profession-
als. The formation in 2005 of the Society for 
Technology Managers (STEM), accomplished 
with the help and cooperation of AUTM (the 
Association of University Technology Managers) 
is a watershed in IP management in India. 
2.		 expendITuRe	on	R&d
2.1  Government	sector
Publicly funded biomedical research and devel-
opment (R&D) in federal laboratories in India 
is carried out by the ICMR, the Council of 
Scientific and Industrial Research (CSIR), the 
Department of Biotechnology (DBT), and a few 
institutes of the Department of Atomic Energy 
(DAE). The ICMR has 21 research institutes and 
six regional medical research centers. There are at 
least six laboratories of the CSIR, four DBT insti-
tutions, two DAE centers, six autonomous insti-
tutes that carry out significant medical research, 
and approximately 25 medical colleges, a few of 
which belong to the private sector. The colleges 
are supported by nongovernmental scientific re-
search organizations (perhaps about a hundred) 
that are registered with the Government. Still, a 
significant chunk of biomedical research is car-
ried out with only government support. The 
public-sector R&D effort primarily focuses on 
mapping disease burdens, profiling infectious 
diseases, carrying out preventive and/or therapeu-
tic interventions, testing the efficacy of available 
new therapeutic interventions (such as drugs and 
diagnostics), finding new drugs and diagnostics 
for more cost-effective interventions, and carry-
ing out basic research to improve understanding 
of biological systems. 
No reliable data exists with regard to total 
expenditures for health and biomedical R&D. 
Estimates by one researcher, based on expendi-
tures on R&D by major agencies, suggest that 
total expenditures (excluding expenditures by the 
pharma sector) about US$5.0 billion (one US$ 
equals approximately 4 rupees [Rs]), or approxi-
mately 2.5% of the estimated direct government 
expenditure on health. 
2.2  Research	and	development	in	
the	pharma	industry
In the private sector, the pharma industry spends 
the majority of its R&D funds on biomedical re-
search. This started a few years ago, primarily be-
cause India’s impending globalization and TRIPS-
compliance spurred the pharma industry to carry 
out more innovative research to create new mol-
ecules in order to remain globally competitive. 
Recently, technologically competent small and 
mid-sized firms collaborating with multinational 
corporations and Indian generic companies have 
emerged. Some Indian pharma companies have 
already reoriented their R&D strategy from busi-
ness-driven research (generic manufacture) to 
research-driven business (developing new mol-
ecules, novel drug-delivery systems, and so on). 
From 1999 to 2003, the number of U.S. patents 
granted for drugs and pharmaceuticals to India 
grew significantly. In 2003, India filed the most 
drug master files (DMF) applications (126) with 
the U.S. Food and Drug Administration (FDA), 
which was more applications than had been sub-
mitted by China, Italy, Spain, and Israel combined. 
India has the largest number of FDA-approved 
manufacturing facilities (more than 60) outside 
of the United States. R&D investment inside 
India is on the rise. For the year 2003–2004, the 
top-ten pharma companies spent more than Rs 
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9.7 billion on R&D (greater than 6.0% of their 
turnover). The pharma sector spent more than Rs 
13.0 billion (almost 4.0 % of its turnover), which 
was the highest R&D investment of any Indian 
industry sector. 
In addition, publicly funded institutions 
like the DST, CSIR, and DBT, support research 
in pharmaceutical R&D (including biopharma-
ceuticals) through various schemes, such as the 
New Millennium Indian Technology Leadership 
Initiative (NMITLI) and the Pharmaceutical 
Research & Development Support Fund 
(PRDSF). 
3.		 polICy	InITIATIveS
The Government of India recently implemented 
a series of policy initiatives that have energized 
and focused R&D on generating new knowledge 
that could lead to new products and processes of 
public-health importance. 
3.1  National	Health	Policy	in	2002 
Recognizing changing demographics, altered 
disease patterns, the health needs of its diverse 
populations, and the intensification of technol-
ogy interventions in delivering health care, the 
Government of India announced the National 
Health Policy (NHP-2002). This initiative seeks 
to: (1) expand and improve primary healthcare 
facilities; (2) meet the health needs of disad-
vantaged sections of the population (women, 
children, elderly, and tribals) through special 
programs; and (3) mount programs to eradicate 
polio, yaws, leprosy, kala-azar, and filiarasis and 
to control diseases like HIV/AIDS, TB, and ma-
laria within specified time periods. To achieve 
these objectives, the Government has committed 
to raising public spending on health to 2–3% of 
GDP (gross domestic product). Although the 
NHP-2002 does not explicitly state it, there has 
been a focus on generating new drugs, diagnos-
tics, and vaccines for diseases of public-health 
importance like TB, HIV/AIDS, and so on. This 
attention is evident from the new initiatives to 
generate new diagnostics and vaccines through 
various public–private partnerships with nation-
al and international partners. 
3.2  Biotechnology	Policy 
The new Biotechnology Policy of the Government 
of India (2005) draws a clear roadmap for 
developing biotechnology R&D in India. Some 
of the major initiatives proposed include encour-
aging R&D in academia, entering into partner-
ships with industry and support to industry per 
se, granting tax breaks and other incentives to 
biotechnology companies, and setting up bio-
technology parks, special economic zones, and 
so forth. To help industry quickly bring prod-
ucts to market, the regulatory framework is be-
ing streamlined through a new set of simplified 
guidelines for the approval of all recombinant 
DNA products. Also, a single biotechnology 
regulatory authority (BRA) for clearing biotech-
nology products is being created. A series of bio-
clusters will be developed around existing bio-
technology centers and some identified institutes 
of excellence. A strong focus on human resources 
development is evident from new programs, 
such as a new M.D.-Ph.D. program, an Asian-
level United Nations Educational, Scientific 
and Cultural Organization (UNESCO) Center 
for teaching and training in biotechnology, and 
training fellowships abroad for cutting-edge areas 
like stem-cell technology and nanobiotechnology. 
The National Jai Vigyan Science and Technology 
Mission also provides support for developing new 
products and processes. Finally, the new Small 
Business Innovation Research Initiative (SBIRI) 
aims to provide early-stage funding to scientists 
in private industries for high-risk, innovative, or 
commercializable product proposals.
3.3  Policy	on	traditional	medicine
Traditional systems of medicine have always 
figured prominently in India’s healthcare de-
livery system because the practitioners of 
Indian Systems of Medicine and Homeopathy 
(ISM&H), comprising Ayurveda, Unani, Siddha, 
and Homeopathy, have a significant presence in 
India’s rural areas. Recognizing the importance of 
Indian systems of medicine (ISM) in healthcare, 
in 1995 the Indian Government established a 
full-fledged Department of ISM&H, not only to 
promote curative aspects of ISM but also to ener-
gize R&D in this area. In 2002, the Government 
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announced its National Policy on ISM&H to 
address inadequacies in existing mechanisms, 
initiating new strategies to (1) improve the qual-
ity of teaching in ISM courses, (2) ensure the 
availability of quality raw materials for thera-
peutics, (3) formulate and implement standards 
(for example, good manufacturing practices), 
(4) encourage research in ISM&H to generate 
new drugs, and (5) address IP protection for tra-
ditional remedies. 
Some steps have already been taken. These 
include setting up the National Medicinal 
Plants Board to provide quality material for 
herbal drugs, as well as establishing drug testing 
laboratories to ensure quality-assurance stan-
dards for bringing out pharmacopoeia in ISM, 
and so forth. Traditional systems of medicine 
are important because they offer therapeutic al-
ternatives for some lifestyle, degenerative, and 
age-related ailments, such as rheumatism, for 
which other satisfactory therapies are lacking. 
Industry has been encouraged to carry out in-
novative research to bring traditional-medicine 
formulations to contemporary dosage standards 
through concentration of the liquids, modifica-
tions in the physical forms, developing appro-
priate delivery formats, increasing shelf life, en-
suring stability in storage, enhancing sensorial 
acceptance, undertaking limited clinical trials 
for validating drug safety resulting from new 
forms and procedures for preparations, stan-
dardizing formulations based on active markers 
and fingerprint profiles, and, most importantly, 
adapting, modifying, and designing processing 
equipment to handle the botanical materials at 
appropriate processing conditions. A dynamic, 
continuing process, the initiative is spearheaded 
by about a dozen large, leading Indian pharma 
companies and a few publicly funded R&D 
and academic institutions. As an example of 
the work that’s being done, a recent innovation 
by CSIR provides quantitative scientific repre-
sentations of various Ayurvedic concepts using 
three-dimensional high-throughput liquid chro-
matography (HPLC) techniques. This invention 
has been patented in the United States and other 
countries. The Golden Triangle program (see be-
low) is an example of how traditional systems 
of medicine and modern research and medical 
systems can work together to bring new drugs 
to the market.
3.4  New	IP	rights	regime 
In 1970, India enacted the Indian Patents Act, 
which came into force in 1972. Some significant 
features of the Patent Act include restricting to 
process patents these products in the areas of 
food, drugs, and agrochemicals; limiting patent 
life to seven years; and providing more liberal 
compulsory licensing provisions. The act’s prima-
ry objective was to promote the development of 
the domestic pharma industry. Without product 
patents, it was hoped that the Indian public could 
get affordable drugs, and indeed the act encour-
aged industry to manufacture and distribute ge-
nerics. The policy helped build a strong domestic 
industry that tapped India’s scientific strength, 
especially in chemistry, to churn out generic 
equivalents that not only catered to local needs 
but also built a formidable bulk-drug export mar-
ket. The act triggered significant growth and rev-
enues through the export of bulk drugs. In the 
bargain, it also created a demand for testing and 
evaluation technologies and quality-control sys-
tems in the pharma industry. More importantly, 
this growth created opportunities for the indus-
try to invest in reverse engineering R&D, which 
created a world-class generic industry. The Patent 
Act fully served its purpose of providing afford-
able medicines to the poor. 
As a founder-member of the World Trade 
Organization and signatory to the TRIPS 
Agreement, India was expected to make its pat-
ent laws fully TRIPS compliant by January 2005. 
Accordingly, the Patents Act was amended three 
times to become TRIPS compliant. It now pro-
vides for product patents in all fields of technol-
ogy and for other provisions stipulated under the 
Agreement. Due to these changes, multinational 
pharma companies have started to consider in-
vesting in India for R&D and manufacturing 
facilities. The companies see the ready availabil-
ity of qualified people, infrastructure, and the 
advanced regulatory environment. These policy 
changes have been received very positively by the 
pharma industry, as is evident from the increased 
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Abbreviated New Drug Application (ANDA) fil-
ings over the past four years by the top-ten Indian 
companies. In the short period of six years begin-
ning in 1995, patent filing in the drug industry 
nearly quadrupled. Today, some pharma multi-
national companies have started to expand their 
presence: their share in the Indian market is ex-
pected to double in the next five years. 
3.5  Regulatory	environment—creation	of	the	
Central	Drug	Administration 
R&D in the pharma sector can be promoted only 
if an appropriate and reliable regulatory system 
is in place. India’s disorganized drug-control ad-
ministration has been seriously criticized, espe-
cially regarding spurious drugs. Manufacturing 
licenses for drug formulations are being issued by 
the drug controllers of various states and Union 
territories, with no coordination between them or 
the drug controller general of India (the regula-
tor of the federal Ministry of Health & Family 
Welfare). Often, the drug controllers of various 
states were violating their authority by issuing li-
censes for drugs that were banned by the federal 
government. As a result, thousands of irrational 
and harmful combinations are on the market.
A committee under the chairmanship of Dr. 
R. A. Mashelkar, director general, CSIR, was 
formed to examine this problem and suggest how 
to revamp India’s drug-regulatory system. The 
committee’s recommendations focused on how 
to bring central monitoring and intervention ac-
tivity to bear on the actions of state drug-con-
trol agencies in order to uniformly implement 
the Drugs & Cosmetics Act. The committee 
proposed elevating the Central Drugs Standard 
Control Organisation to the level of a Central 
Drug Administration (CDA), a federal body 
reporting directly to the federal health ministry 
that would, among other things, have complete 
control over the licensing of manufacturing units 
in the country—a power that was earlier vested 
with drug departments at the state level. The 
committee called for the creation of a specific 
medical-devices division to properly manage the 
approval, certification, and quality assurance of 
medical devices in India. The committee under-
scored the need to globally harmonize regulatory 
and scientific requirements. It also addressed reg-
ulating the activities of healthcare providers and 
the Indian systems of medicine and food supple-
ments. The report recommends that drug regula-
tory administration be system based, with every 
activity justified within a clear policy framework 
and supervised for uniform implementation and 
the timely, transparent disposal of license applica-
tions, renewals, and so on. Finally, the commit-
tee recommended upgrading the present Central 
Drugs Standard Control Organisation (CDSCO) 
to the level of a Central Drug Administration 
(CDA), a federal body reporting directly to the 
federal Health Ministry, somewhat like the U.S. 
FDA.
3.6  Medical	devices	registry
More than 80% of the estimated amount spent 
on medical devices and other critical-care equip-
ment purchased in India (about US$1.5 billion) 
is now made up of products that are imported. 
Several academic and research organizations, as 
well as private entrepreneurs, have started taking 
an active interest in the development and pro-
duction of medical devices. Important devices, 
such as heart valves, orbital implants, coronary 
stents, oxygenators, cardiac catheters, eye lasers, 
external cardiac pacemakers, and critical-care 
ventilators, have emerged from high-technology 
research spinouts of the research laboratories of 
CSIR, the Defense Research and Development 
Organization (DRDO), DST, and others. Many 
products are also at advanced stages of develop-
ment/clinical evaluation. Successes in this field—
especially when sustained—are impressive.
Biomedical devices are technology based and 
have a shorter market life span. Unlike drugs, bio-
medical devices do not work via chemical action 
within or on the body by pharmacological/chem-
ical/immunological means or by being metabo-
lized within the body. Regulations of biomedical 
devices with regard to safety, health protection 
and performance, characteristics, and authoriza-
tion differ from country to country. 
In the United States, the FDA has a separate 
department to evaluate and regulate medical and 
radiological devices; in Europe, the safety and ef-
ficacy of a product and its quality assurance are 
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the responsibility of the manufacturers them-
selves. Avoiding the pitfalls and drawbacks of 
the U.S. FDA system, the European regulatory 
model has evolved into one of the most effective, 
efficient systems in the world today. Although 
expensive for the manufacturer, the onus of qual-
ity assurance is on the producers; any infringe-
ment in quality control leads to judicial penalties 
(as with the U.S. FDA). Indian officials recognize 
that the country acutely needs a regulatory body 
to control biomedical devices  and ensure that the 
public is protected from poor-quality products—
both indigenous and imported. In addition, a 
regulatory body could help the various segments 
of the developmental chain: the R&D groups, 
the manufacturers, the clinicians, and finally the 
patients. 
To address this issue, the ICMR, New 
Delhi, and the Society of Biomedical Technology 
(SBMT) of the DRDO jointly worked to find a 
suitable structure for regulating medical devices. 
The proposal was made available on a Web site 
for comments, and suggestions were invited 
from a representative group of physicians, sur-
geons, and other experts using medical devices. 
A draft report was discussed with a group of 
experts. In the end, the proposal for an Indian 
medical devices regulatory authority (IMDRA) 
was submitted to the Government of India. The 
IMDRA will be responsible for implementing 
the country’s regulations for medical devices. 
The proposal remains with the Government for 
implementation. 
3.7  Clinical-trial	registry	
Attempts to register clinical trials being con-
ducted in India have been minimal, because not 
many trials are carried out, and even the few that 
are carried out are not reported. But given the 
availability of large numbers of patients, quali-
fied professionals, and hospitals with infrastruc-
ture that can perform clinical trials in accordance 
with global standards of good clinical practices, 
India is expected to become a global clinical trial 
hub. In fact, several contract research organiza-
tions have already set up their offices in India. 
There is, however, serious concern about a lack 
of transparency for trial data, especially in light 
of the conduct of unethical trials that the media 
has uncovered. The flouting of ethical guidelines 
has been on the rise, and so the Government 
of India is seriously considering bringing all 
clinical trials under strict regulatory control 
through a trial registry. Mandatory trial regis-
tration is bound to positively affect the quality 
of clinical trials conducted in both private and 
government sectors. So far, the government has 
entrusted the ICMR with the responsibility of 
setting up a clinical-trials registry. Efforts are al-
ready underway to establish a registry at ICMR, 
New Delhi. 
3.8  Awards
There are more than 15 different awards estab-
lished by Indian Government agencies like the 
CSIR, DSIR, National Research Development 
Corporation (NRDC), and DBT. Significantly, 
the nature of these awards has been changing. 
The thrust and focus of earlier awards was on im-
port substitution and/or the indigenization of a 
technology. Recent instituted awards, however, 
emphasize the generation of innovative technol-
ogy. For example, the CSIR Diamond Jubilee 
Technology Award (Rs 1.0 million) is given for 
the “most outstanding technological innova-
tion that has brought prestige to the nation.” 
Moreover, the CSIR Diamond Jubilee Invention 
Awards for School Children encourage a culture 
of innovation at a young age.
3.9  Innovation	and	IP	ownership
A major portion of innovative R&D carried out 
in Indian universities is not IP protected. This 
is partly because India’s university system lacks 
technology transfer offices that could help uni-
versity researchers protect and exploit new inno-
vations. In addition, as a matter of policy, most 
government agencies own all of the IP generated 
through research funded to the universities extra-
murally. Therefore, little incentive exists in terms 
of inventors sharing the royalties of new IP. This 
situation is widely considered to be the crippling 
factor that explains both why little innovative 
work takes place in the university sector and why 
enthusiasm is lacking to commercialize the few 
innovations that are IP protected. To address 
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this issue, the Government of India is seriously 
considering enacting legislation modeled after 
the Bayh-Dole Act in the United States, which 
would allow university inventors to own IP gen-
erated from federally funded projects. 
3.10  Entrepreneurship	development-new	policy	
on	contract	research
The policy of contract research, a system through 
which public sector R&D institutes collaborate 
with industry, has been in existence in India 
for more than 20 years in major scientific or-
ganizations like the CSIR and the ICMR. This 
scheme has recently been liberalized to allow sci-
entists and institutes to work with industry on 
projects of mutual interest. The time scientists 
could spend on R&D projects with industry 
(person days/year) and the amount of honoraria 
they could earn from such projects per year has 
been increased. Scientists are encouraged to take 
up R&D projects from industrial partners from 
India and abroad that would create products 
and processes for industrial application. In addi-
tion, some institutes have also made provisions 
for scientists to be entrepreneurs while holding 
their regular position within the organization (for 
example, the CSIR and the Indian Institute of 
Science, Bangalore). The impact of these initia-
tives has been positive. Some scientist-entrepre-




Infrastructure–Creation of new institutes of 
excellence: National Institutes of Sciences. If 
India hopes to become a global leader in science 
and technology, it must raise science education 
standards. A good science education is available 
in only a few institutes of excellence, such as 
the Indian Institutes of Technology, the Indian 
Institute of Science, Bangalore, and a few fed-
erally supported universities. Many population 
centers in India have no institute of excellence 
nearby, which discourages bright students from 
taking up science. Accordingly, four new centers 
of excellence in science education are being set up 
in different parts of the country. These institutes 
would be established at Allahabad near Allahabad 
University (in northern India), at Chennai near 
Anna University (in southern India), at Pune 
near Pune University (in western India), and at 
Bhuvaneswar near Utkal University (in eastern 
India). The centers primarily would offer an inte-
grated, five-year basic and applied program in sci-
ences leading to a master’s degree. Linked with na-
tional research labs, science agencies, and industry 
right from their inception, these institutes will be 
“incubated” within the existing premier universi-
ties. But, although they will be connected to the 
universities, the institutes will enjoy complete ac-
ademic, administrative, and financial autonomy. 
The corresponding university will initially award 
educational and research degrees to an institute’s 
scholars and students, but the institute will have 
complete, total freedom to set out its academic 
programs, frame suitable course structures, and 
establish its own methods of teaching and evalu-
ation. This organic link with the universities will 
be crucial in the initial phases. Administrative 
and financial details have been worked out and 
the proposal is in the approval process. 
4.2  National	Biotechnology	
Development	Strategy
Ever since the full-fledged Department of 
Biotechnology (DBT) was set up in 1986 under 
the Ministry of Science & Technology, the DBT 
has played a pivotal role in R&D, education, tech-
nology management, and support to nascent in-
dustry. Both health and agri-biotechnology have 
received considerable support, and now there is a 
vibrant industry, a growing number of competent 
biotechnologists, and a regulatory framework that 
helps put products on the market. 
The DBT has drawn up a ten-year strategy to 
put India on the global-biotechnology map. This 
National Biotechnology Development Strategy 
was unveiled by the Minister for Science and 
Technology, Kapil Sibal, on March 31, 2005. 
Highlights of the strategy include 100% of bio-
technology units funded by foreign direct invest-
ments (FDI), priority sector lending tags, tax 
credits for money spent on international patent 
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filings, and the creation of ten biotechnology 
parks with special economic zone status, among 
others. 
The DBT and the Ministry of Environment 
and Forests have released a set of guidelines for 
the approval of all recombinant DNA prod-
ucts. This is expected to give a huge boost to 
the biotechnology industry, because about 90% 
of the organisms used by biotechnology compa-
nies will be outside the purview of the Genetic 
Engineering Approval Committee (GEAC). For 
recombinant pharma products derived from liv-
ing modified organisms (LMOs) but for which 
the end product is not an LMO, applications can 
be submitted for approval directly to the drug 
controller general of India (DCGI).
The Government is setting up a single bio-
technology regulatory authority for clearing bio-
technology products, and a high-level committee 
is figuring out how to create such an authority 
and rationalize the legislative and regulatory re-
gime. Presently, several agencies under federal 
Ministries—Agriculture, Health and Family 
Welfare, Environment and Forests, Science and 
Technology, and Biotechnology—are involved in 
clearing biotechnology products. 
Another important step being taken by the 
DBT to build the biotechnology industry is that 
of fostering bioclusters. Developed around ex-
isting biotechnology centers, a series of bioclu-
sters will be formed by strengthening research 
in medical colleges (both translational biology 
and clinical research in the cities of Bangalore, 
Hyderabad, and other centers that have poten-
tial). The National Center for Biological Studies 
(NCBS), Bangalore, and the Christian Medical 
College, Vellore, are working to strengthen and 
transform CMC Vellore into a molecular medi-
cine, translational, and clinical-research center. 
Likewise, a translational research institute is 
planned in Gurgoan with links to the National 
Brain Research Centre (NBRC) there. Biotech 
parks are being planned also on the Delhi-
Gurgoan belt with the purpose of attracting 
industry. In Hyderabad, the DBT is creating a 
stem-cell R&D cluster (in addition to the one in 
Bangalore) and an agri-biotechnology corridor is 
being developed in Punjab.
Support to industry would be extended 
through (1) a quick, responsive regulatory frame-
work; (2) support for late-stage development; 3) 
training in clinical validation; (4) a third-party 
associate for technology transfer projects with 
international companies/scientists; (5) encour-
aging industry participation in international sci-
ence meetings; 6) creating an industry research 
support cell; and 7) direct industry funding for 
SMEs. The institutional sector will be strength-
ened by:
• expanding existing support for science edu-
cation and training 
• supporting the creation of new innovation 
centers and centers of excellence 
• increasing contact and engagement between 
cross-disciplinary professionals through 
special grants and interdisciplinary centers 
of excellence 
• a niche-area overseas training program 
• large infrastructure grants
• five-year grants for translational research 
The DBT has also funded the creation of 
“good manufacturing practice” facilities at several 
institutions and is working with Reliance and two 
other companies to support clinical research on 
DBT’s products. On the international front, vari-
ous collaborative programs are being considered 
that emphasize building strategic partnerships. 
A major program for animal vaccines and im-
munostimulants in aquaculture has been firmed 
up with the government of Norway, and another 
agreement was signed with Australia. Strategic 
partnership agreements have also been signed 
with Denmark in the area of agriculture and food 
biotechnology, with the UK in relation to cutting-
edge biology, and with Finland in diagnostics.
Other new initiatives include: 
• consolidating support services for regula-
tions relevant to trade 
• partnering with the Ministry of Health on 
GM food testing 
• introducing biotechnology methods into the 
judiciary through a DNA academy funded 
at the Center for DNA fingerprinting 
• improving the capacity for clinical trials in 
the country 
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• setting up new life-sciences institutions 
(like the translational health-science insti-
tute in Faridabad and the UNESCO center 
for training and education in Delhi) 
• creating an animal biotechnology institute
• creating two policy centers (a center for 
health technology policy and a center of 
agriculture and allied areas). 
Furthermore, the DBT is launching the Small 
Business Innovation Research Initiative (SBIRI), 
which provides early-stage funding to scientists 
in private industries for high-risk, innovative, or 
commercializable product proposals.
Some initiatives in human resources include 
identifying an Asian-level UNESCO Center for 
teaching and training in biotechnology. There is 
also a proposal to award 25 special overseas fel-
lowships to students doing research in stem-cell 
technology and nanobiotechnology, as well as a 
plan to support 20 undergraduate colleges across 
the country (one per state) focusing on high-qual-
ity teaching in the life sciences (this is in addition 
to summer project support for students and skill-
enhancing training for teachers). Further efforts 
to develop quality human resources include: 
• a masters program begun in 2007 in health 
and clinical sciences, as well as a Ph.D. pro-
gram in health sciences 
• initiating similar educational programs for 
the environment, agriculture, marine, and 
other sectors 
• providing summer project support in di-
verse life-science fields 
• upgrading teachers’ skills by developing 
one high-quality life-science college in ev-
ery city 
• launching an institutional innovation 
grants scheme 
• substantially increasing the number of 
Ph.D. and postdoctoral fellowships
• creating a national pool of jobs. 
4.3  DBT’s	technology-mission	programs
Recognizing India’s native intellectual capacity, the 
Ministry of Science and Technology has identified 
21 technology missions for integrated technical 
development that would benefit rural people. The 
mission covers the areas of plant genetic-resource 
conservation, the development of new-genera-
tion vaccines, biotechnological approaches to 
herbal product development, genomic research, 
the development of light transport aircraft, and 
ocean-thermal-energy conservation. The basic 
aim of these technology-mission programs is 
“Science in the service of common man.” Of the 21 
National Jai Vigyan Missions initiated by various 
departments, four were launched by the DBT to 
generate new vaccines, develop herbal products, 
improve coffee, and establish mirror sites of ge-
nomic databases in India. 
4.4		 Developing	new-generation	vaccines	and	
diagnostics
The main objective of DBT’s mission has been 
to develop candidate vaccines for cholera, rabies, 
Japanese encephalitis, tuberculosis, malaria, and 
HIV infections using novel strategies. Such strat-
egies include recombinant proteins; DNA vac-
cines; recombinant/peptide vaccines for cholera, 
malaria, tuberculosis, Japanese encephalitis, ra-
bies (for animals and humans); and preventive/
therapeutic DNA candidate vaccines for HIV 
infection. 
Current work in support of this mission 
includes:
• cholera vaccine. An indigenous recom-
binant oral vaccine based on the VA 1.3 
strain of Vibrio cholerae was jointly devel-
oped and tested by the National Institute 
of Cholera and Enteric Diseases, Kolkata 
(NICED); the Institute of Microbial 
Technology, Chandigarh (IMTECH); 
SAS, Kolkata; SGPGIMS, Lucknow; and 
PGIMER, Chandigarh. Phase I clinical 
trial results indicate that the vaccine is safe, 
and an extended Phase I/Phase IIa study 
is currently underway in about 1,000 vol-
unteers. Simultaneously, site preparation 
work in Kolkata for Phase III clinical tri-
als has been initiated by determining the 
baseline antibody levels in a cohort. The 
IMTECH Chandigarh is also scaling up 
the production of the VA 1.3 strain of V. 
cholerae.
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• DNA rabies vaccine. Rabies continues to 
be a serious public-health problem in many 
countries, especially poorer ones. An indig-
enous, unique, low-cost antirabies vaccine 
has been jointly developed by the Indian 
Institute of Science (IISc) and Indian 
Immunologicals Ltd (IIL). The world’s first 
combination rabies vaccine, it contains 
DNA vaccine and a low dose of cell-culture 
vaccine. Costing much less than the exist-
ing vaccine (Rs 300-400), this new vaccine 
will be affordable for India’s people. In ad-
dition, it may be stable at room tempera-
ture, which would make refrigeration un-
necessary. Human trials are being initiated. 
• Japanese encephalitis (JE). This candidate 
DNA vaccine for JE virus was developed 
by the National Institute of Immunology, 
New Delhi. The tissue-cultured vaccine 
could provide about 70% protection in 
animals following intracereberal challenge. 
This new vaccine will be able to replace the 
existing Japanese encephalitis vaccine. 
4.5		 Public–private	partnerships
The New Millennium Indian Technology 
Leadership Initiative (NMITLI) is an innova-
tive public–private partnership started by CSIR 
in 2000 to make India a global leader in the 
field of science and technology. The strategy of 
the NMITLI is to catalyze innovation centered 
in scientific and technological developments in 
order to allow Indian industry to attain a global 
leadership position in selected niche areas. The 
Initiative seeks to identify and synchronize the 
strengths of publicly funded R&D institutions, 
academia, and industry. NMITLI supports two 
types of projects: those initiated by the program 
and those initiated by industry. In both types of 
projects, the best public institutions and indus-
try are identified and a joint project formulated. 
To date, more than 40 projects in various fields 
(biotechnology, bioinformatics, agriculture and 
plant biotechnology, drugs and pharmaceuticals, 
and so on), with more 400 groups in R&D labs, 
academia, and industry, have been supported.
Some areas that have received support 
include: 
• new targets, drug-delivery systems, bio-
enhancers, and therapeutics for latent 
Mycobacterium tuberculosis 
• novel herbal therapeutics for degenerative 
disorders 
• osteoarthritis and rheumatoid arthritis 
• diabetes mellitus type II (NIDDM) 
• hepatic disorders and hepato-protective 
agents 
• development of an oral, herbal formulation 
for the treatment of psoriasis 
• a new process for manufacturing Tamiflu® 
(a drug for avian influenza) 
• the oral delivery of insulin
• the development of Lysostaphin (a novel 
biotechnology therapeutic molecule) 
One major achievement is the development 
of the new antimycobacterial molecule Sudoterb 
(LL 4858) by Lupin laboratories in collaboration 
with other R&D partners. Sudoterb is the first 
anti-TB drug in the past 40 years. Tests in labora-
tory animals have shown that, when given in com-
bination with conventional drugs like rifampicin 
and pyrazinamide, Sudoterb was able to reduce 
the duration of TB treatment, from the current 
six to eight months, to three months. The new 
molecule is undergoing a Phase I clinical trial. 
Another significant new drug developed through 
the NMITLI program is LL 4218 (Desoside-P), 
a single plant-based herbal drug for psoriasis that 
is undergoing Phase II clinical trials. Currently 
there is no drug treatment for psoriasis, which af-
fects millions of people the world over. Trials have 
shown that this Ayurvedic drug was able to reduce 
psoriasis symptoms by about 70% in 16 weeks. 
Just Rs 700 million was spent by Lupin Labs to 
develop this drug. Lupin Labs collaborated on this 
project with an R&D laboratory (Central Drug 
Research Institute, Lucknow) and an academic 
institute (National Institute of Pharmaceutical 
Education and Research, Chandigarh).
Recognizing the need to support indigenous 
R&D in the drug and pharma sector, DST ini-
tiated the Drugs and Pharmaceuticals Research 
Program in 1994–95, providing funds of Rs 1,500 
million. The program aims to promote R&D col-
laborations between industry and institutions for 
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all areas of drug R&D that would help indige-
nous industry pursue innovative R&D and devel-
op new molecules. Support is available for R&D 
projects proposed by industry, academic institu-
tions, and laboratories. Funding is also provided 
to establish state-of-the-art facilities for drug 
R&D in India. In addition, soft loans at a simple 
interest rate of 3% per annum are being offered 
to industry with in-house R&D laboratories and 
nonprofit industrial research organizations. A 
drug-development promotion board has been set 
up to run this program. 
Funded by the DSIR, New Delhi, the 
Technology Development and Innovation 
Program aims to promote the development and 
demonstration of indigenous technologies, the 
development of capital goods, and the absorp-
tion of imported technologies by Indian industry. 
The DSIR provides partial financial support to 
research, development, design, and engineering 
projects related to new or improved product and 
process technologies (including those for special-
ized capital goods) for both domestic and export 
markets. The program also supports projects that 
absorb and upgrade imported technology. The 
partial financial support by DSIR is primarily 
meant to cover costs for prototype development 
and pilot plant work, the testing and evaluation 
of products flowing from such R&D, user trials, 
and so on. Industry funds a major portion of the 
cost for these projects.
4.6  Golden	Triangle
The Golden Triangle partnership was conceived in 
2003, when it was decided to set up and provide 
special budgetary support for an integrated tech-
nology mission focused on the development of 
Ayurveda and traditional medical knowledge that 
synthesizes modern medicine, traditional medi-
cine, and modern science. The CSIR and ICMR 
are working with the Department of Ayurveda, 
Siddha, and Homeopathy to bring out safe, ef-
ficacious, and standardized classical products for 
identified disease conditions. New Ayurvedic and 
herbal products for diseases of national/global 
importance are also being pursued. Innovative 
technologies are being used to develop single 
and poly-herbal-mineral products, which have 
the potential for IP protection and commercial 
exploitation by national/multinational pharma 
companies.
Some areas identified include Rasayana (re-
juvenators/immunomodulators) for healthy ag-
ing, joint disorders, memory disorders, bron-
chial allergy, fertility/infertility, cardiac disorders 
(cardio-protective and antiatherosclerotic), sleep 
disorders, and diabetes. Identifying the strengths 
and weaknesses of existing modern medical prod-
ucts, the strategy seeks to develop new products 
to address gaps; formulate an appropriate R&D 
strategy for standardization, quality control, IP, 
and other related issues; take up toxicity/efficacy 
studies in government laboratories, medical col-
leges, and universities; prepare detailed dossiers 
of effective formulations; and negotiate with an 
identified industry partner to begin commercial-
ization after clinical trials are carried out using 
standard protocols. 
This ambitious multiagency program pro-
poses to spend more than Rs 350 million in the 
next three years. Several areas have already been 
identified and research is underway. 
4.7  Promoting	innovation	in	
traditional	knowledge
The Traditional Knowledge Digital Library 
(TKDL) is a CSIR initiative aimed at provid-
ing easy access to traditional Indian systems like 
yoga, Ayurveda, and Unani. The initiative also is 
intended to prevent IP piracy and promote inno-
vation through the use of traditional knowledge. 
TKDL will publish an encyclopedia with more 
than 30 million pages in electronic format. The 
encyclopedia will contain information on tradi-
tional medicine, along with exhaustive references, 
photographs of plants, and scanned images from 
original texts of traditional systems. Traditional 
text in the original Persian, Hindi/Sanskrit, or 
other Indian languages is being translated into 
English, French, German, Japanese, and Spanish. 
Ten million pages have already been converted 
into electronic format, which is a big step towards 
the TKDL’s goal of minimizing the biopiracy of 
India’s indigenous wealth. 
The TKDL is expected to be an authen-
tic source for patent examiners in major global 
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patent offices (like the U.S. Patent Office) to 
conduct prior art searches. Currently, examin-
ers are often unable to determine the novelty of 
inventions based on traditional knowledge/plant-
based drugs because they have no ready access to 
authentic sources. Although well documented in 
various regional languages, the Indian traditional 
knowledge sources are readily available to patent 
examiners from other countries; this has resulted 
in the granting of patents like the patent on haldi 
granted by the U.S. Patent Office. 
The TKDL encyclopedia should help exam-
iners cross-check the validity and originality of 
patent applications. It should assist examiners 
in determining whether an invention is already 
known and recorded in ancient literature. The 
availability of the TKDL may also help avoid 
litigation regarding granted patents, thus saving 
time and money in litigation. This is especially 
important for India, which has spent almost 
US$6 million fighting legal battles against just 
two patents on turmeric and neem. Significantly, 
as of 2000, the number of patents on plant-based 
products granted by the U.S. Patent Office was 
about 5000, of which an estimated 80% were 
possibly plants of Indian origin. 
To conform to international standards, 
the TKDL follows the International Patent 
Classification (IPC) system, having consider-
ably expanded the IPC group AK61K35/78 on 
medicinal plants to incorporate detailed infor-
mation about traditional knowledge with a new 
section titled Traditional Knowledge Resource 
Classification. The IPC Union of WIPO (World 
Intellectual Property Organization) is closely as-
sociated with this project through a multinational 
task force. More than 36,000 ancient Ayurvedic 
formulations have been translated into current sci-
entific/medical terminology, classified as per the 
modified IPC subclass, and put in digital format. 
The TKDL has made it possible for all traditional 
knowledge to be brought under IPC, which should 
significantly help protect the traditional knowledge 
of India from being unfairly exploited by others.
4.8		 ICMR	as	Department	of	Health	Research	
To encourage medical and health research and, 
more importantly, to ensure better coordination 
and promotion of India’s national health pro-
grams, the government is considering upgrading 
the ICMR to the Department of Health Research 
(DHR). This would put the ICMR on par with 
other departments in science and technology.
Creation the DHR will help better coordinate 
such sister scientific departments as the depart-
ments of science and technology; biotechnology; 
scientific and industrial research; agricultural re-
search and education; and space, atomic energy, 
and ocean development, all of which are headed 
by secretaries to the Government of India. The 
ICMR’s collaborative health projects with these 
departments will be further strengthened, and 
they will be better placed to foster such comple-
mentary interagency partnerships. The secretary 
of the DHR will also be in a better position to ar-
ticulate the policies of the Ministry of Health and 
Family Welfare and to further the Government’s 
programs and policies in this area. During na-
tional emergencies, when critical science and 
technology inputs are required from other agen-
cies, the DHR would function more effectively. 
Technologies and products developed by other 
science and technology agencies will transition 
more easily into the healthcare sector. In addition, 
a coordinated effort with other agencies in cut-
ting-edge science (stem-cell research, functional 
genomics, molecular medicine, proteomics, and 
so on) will be vital for identifying and support-
ing the best scientists with timely and adequate 
budgetary support. This effort should send better 
drugs and devices to market more quickly. The 
DHR could help translate research results into 
policy through a vibrant health-research system. 
Unlike ICMR, the DHR could address labor and 
infrastructure requirements for medical and health 
research in India because it would be seamlessly 
linked with other agencies (and thereby avoiding 
potential duplication of efforts). 
4.9 	 Small	Business	Innovation	Research	
Initiative
The DBT has introduced a new scheme to boost 
public–private partnership efforts. It supports 
both high-risk, pre–proof-of-concept research 
and late-stage development for small and medium 
companies led by innovators with backgrounds in 
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science. The Small Business Innovation Research 
Initiative (SBIRI) has a unique process for gen-
erating ideas. Bringing together technology users 
and producers, it seeks to promote products that 
could be created only with the help of the private 
sector. National consultations are to be held every 
three to six months to generate ideas in different 
sectors of biotechnology (medical, agriculture, 
food, industry, and environment).
The SBIRI aims to:
• strengthen private industrial units whose 
product development is based on in-house 
innovative R&D 
• encourage other smaller businesses to in-
crease their R&D capabilities and capacity 
• create opportunities for starting new tech-
nology-based or knowledge-based busi-
nesses by science entrepreneurs 
• use private industries to stimulate innova-
tion and thereby fulfill Government objec-
tives in fostering R&D 
• increase private-sector commercialization 
derived from Government-funded R&D 
 
The scheme covers all areas in biotechnol-
ogy that are related to healthcare, agriculture, 
industrial processes, and the environment. This 
unique scheme, which directly funds industry, is 
a big boost for small companies. It took off very 
well: the DBT received 70 proposals in just the 
first month. In the year 2005–2006, about 12 
companies were financed. The DBT is planning 
to expand the scale of this program to Rs 1000 
million per year.
4.10   National	Innovation	Foundation
Created by the Department of Science and 
Technology, the National Innovation Foundation 
(NIF) seeks to recognize, respect, and reward 
grassroots technological innovators and tradi-
tional-knowledge experts. Established as an au-
tonomous society in 2000, its mission is to make 
India an innovative, global leader in sustainable 
technologies. It was patterned upon the Honey 
Bee Network established in 1989, which sought 
to connect creative people across language cul-
tures, acknowledge the contribution of innova-
tors, expand policy and institutional space for lo-
cal knowledge experts, and ensure the fair sharing 
of benefits. The honeybee model was chosen for 
the NIF because it reflects how innovations are 
collected without making the innovators poorer 
and how innovators themselves create connec-
tions. It provides a platform to foster innova-
tors who have solved a technological problem 
through their own intellect with little govern-
ment or industry help. Located at Ahmedabad, 
Gujarat, the NIF has a corpus fund of about Rs 
20 crores, the interest on which is used to fund 
the activities of NIF. 
Similarly, the Gujarat Grassroots Innovations 
Augmentation Network (GIAN) picks up inno-
vations from the Honey Bee Network database, 
performs market research, builds links with de-
sign, research, and development institutions 
to improve the technological efficiency of the 
innovation, helps test the product, and devel-
ops business plans and a market-launch strat-
egy. Conceived in 1997 with support from the 
Government of Gujarat, IIM Ahmedabad and 
SRISTI, the GIAN helps with filing patents and 
licensing the innovators’ technologies. GIAN 
now has separate offices in the north (Jaipur), 
west (Ahmedabad), and northeast (Guwahati) 
India. Although protecting IP rights still remains 
difficult, 29 technologies have been licensed since 
GIAN was launched.
More than 12,000 contemporary innovations 
and outstanding traditional-knowledge examples/
practices have been documented by the network, 
but none of the innovations documented have led 
to viable businesses, because the innovators had 
neither the resources nor the expertise to com-
mercialize their inventions. To address this is-
sue, the NIF was set up in 2000 to help promote 
these inventions and to build an entire value 
chain around them. So far, about 37,000 inno-
vations and traditional knowledge examples have 
been identified from more than 350 country dis-
tricts. Currently, the NIF database has more than 
50,000 innovations from more than 400 districts. 
The challenge is to incubate these technologies so 
that they generate commercial and noncommer-
cial opportunities to improve productivity, gener-
ate employment, overcome poverty, and conserve 
the environment.
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4.11  Society	of	Technology	Management
To steer tech transfer towards a brighter future 
and promote better tech transfer management, 
the Society of Technology Management (STEM) 
was launched at the international workshop 
on Intellectual Property Rights, Technology 
Transfer, Licensing, and Commercialization 
convened by Cornell-in-India and Sathguru 
Management Consultant on April 17, 2005. 
The society was conceptualized by a group of vi-
sionary professionals to promote best practices 
among technology management professionals in 
south Asia.
The objectives of STEM include:
• offering guidance and assistance to inven-
tors and corporations IP matters 
• providing learning opportunities to dealing 
with the real-world aspects of IP law 
• increasing the general awareness of IP laws 
and their increasing importance 
• promoting best practices in technology man-
agement and engaging in capacity-building 
among technology management profession-
als in India and neighboring countries
• catalyzing the professional development of 
technology managers for the commercial 
benefits of innovations
STEM hopes to achieve its objectives through 
a well-formulated strategy that allows genuinely 
interested Indian researchers and technology ex-
perts to network with global technology managers. 
Annual meetings and seminars will be organized to 
benefit tech transfer professionals nationwide, and 
STEM will promote the economic growth of its 
constituent members and the organizations those 
professionals represent. STEM has the support of 
all the major research funding bodies, academic 
institutions, and private-research enterprises in 
India. To build links with similar organizations, 
STEM participated in the Asian tech transfer 
meeting in Singapore in 2005 and the Association 
of University Technology Managers (AUTM) 
meeting in 2006.
The International Federation of Technology 
Transfer Organizations, the Southern African 
Research and Innovation Management Association, 
AUTM, and the Association of European Science 
and Technology Transfer Professionals have ex-
tended their wide support to STEM.
5.		 InTeRnATIonAl	CoopeRATIon	foR	
CApACITy	BuIldIng
India continues to greatly benefit from tech-
nical, financial, material, managerial, and 
human-resource inputs and assistance from in-
ternational agencies, developed countries, and, 
more recently, international not-for-profit orga-
nizations for capacity building in the healthcare 
sector. Initially, such assistance was mainly for 
human-resources development through training, 
infrastructure development, and financial and 
material assistance. But as India has advanced in 
the healthcare sector, the programs have shifted 
toward capacity building in the community for 
health delivery and networking, policy frame-
works, and so on. These ongoing initiatives en-
compass a large number of programs and projects 
(for example, there are more than 30 ongoing 
programs with more than 700 activities being 
implemented in collaboration with the World 
Health Organization [WHO]). 
5.1  International	collaboration	in	promoting	
technology	management
With the support of the NIH in the United States, 
the Technology Forecasting and Assessment 
Council (TIFAC) of the Department of Science 
& Technology has just initiated a joint program 
to train young technology managers at the NIH 
tech transfer system for five weeks. The first batch 
of two interns was at the NIH in the summer of 
2006. 
The ICMR, in collaboration with MIHR, 
organized a very successful joint symposium on 
TRIPS and Public Health followed by a one-
day workshop at the ICMR headquarters, New 
Delhi. More than 20 young, mid-level scientists 
and technology transfer professionals participated 
and shared experiences with Richard Mahoney 
and Lita Nelson on technology transfer issues. 
The Government of India has decided to enter 
into a formal agreement with MIHR to utilize the 
expertise of U.S. technology managers to train a 
new cadre of health technology managers. 
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In agriculture, the major government depart-
ments in India engaged in agricultural technol-
ogy are the Department of Agriculture Research 
and Education (DARE) and the Department of 
Biotechnology. DARE coordinates and promotes 
agricultural research and education. It provides 
the necessary government links for the Indian 
Council of Agricultural Research (ICAR), the 
country’s premier research organization with 
more than 6,000 members and a countrywide 
network of 47 institutes (four with university sta-
tus), five national bureaus, 31 national research 
centers, 12 project directorates, 89 all-India co-
ordinated-research projects, and 38 agriculture 
universities. 
DARE is the nodal agency for international 
cooperation in the area of agricultural research 
and education. The department liaises with for-
eign governments, the United Nations, CGIAR, 
and other multilateral agencies concerned with 
agricultural research. DARE coordinates the ad-
mission of foreign students in various Indian ag-
ricultural universities and ICAR Institutes. Some 
of its specific activities include:
• international cooperation and assistance 
in the field of agricultural research and 
education, including relations with foreign 
and international agricultural research and 
educational institutions (It participates in 
international conferences, associations, 
and other bodies dealing with agricul-
tural research and education, and follows 
up on decisions at such international 
conferences.) 
• fundamental, applied, and operational re-
search in higher education, including co-
ordination of such research in agriculture 
(agroforestry, animal husbandry, dairying 
and fisheries, agricultural engineering) and 
horticulture (agricultural statistics, eco-
nomics, and marketing) 
• coordination and determination of food 
and agricultural standards in higher educa-
tion, research, and scientific and technical 
institutions (This includes animal husband-
ry, dairying, and fisheries.) 
• development of human resources in agri-
cultural research/extensions and education 
• access for financing to the Indian Council 
of Agricultural Research, and community 
research programs other than those relating 
to tea, coffee, and rubber 
• sugarcane research 
5.2  New	policy	initiatives
In addition to DARE, recent new policy initia-
tives include:
• increased allocation for agricultural research 
• research program on microorganisms
• one Krishi Vigyan Kendra (KVK) in each 
district of India
• National Museum on Agricultural Sciences
• National Agricultural Innovation Project 
(NAIP)
• new intellectual property rights manage-
ment, that is, new IPR management is be-
ing developed to enable the smooth trans-
fer of agricultural technology for benefit 
sharing with all stake holders.
• Indo-U.S. Agricultural Knowledge Initiative 
(AKI)
• a range of activities related to human 
resources and institutional capacity 
building
With a specific focus on agricultural technol-
ogy, the following is the proposed work plan un-
der the agreed priority areas: 
• Education, learning resources, curriculum 
development and training: Building human 
and institutional capacity and strengthen-
ing public–private partnerships. Private-
sector-sponsored chairs in India or the 
United States will be created for R&D on 
strategic/niche areas. This will help estab-
lish close collaboration between the public 
and private sectors, which in turn will lead 
to the commercialization of technologies at 
a faster pace. In addition, each year, indus-
try scientists and faculty from premier U.S. 
and Indian business/management schools 
and agri-business institutions will be in-
vited to a workshop (in India or the United 
States) to devise synergistic strategies for 
exploring the emerging trends and needs in 
the agriculture sectors of both countries. It 
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will seek to orient education, training, and 
research to contribute to economic growth. 
The workshop will inventory, upgrade, and 
build on existing agri-business programs to 
match students or professionals with prac-
tical internship experiences. 
• Food processing, use of by-products 
and bio-fuels. The AKI Board agreed that 
developing agricultural marketing and 
processing industries is now a priority for 
India’s increasingly need-based, demand-
driven, market-oriented agricultural sector. 
The following initiatives seek to meet this 
need: 
 Joint research programs. Technology 
to rapidly detect and control biotoxins, 
chemical contaminants, and heavy met-
als in agricultural produce and by-prod-
ucts: Food quality and safety are essential 
for both domestic and export markets. 
Developing or acquiring rapid test equip-
ment and protocols to ensure food qual-
ity at various points in the value chain 
would be developed through training 
and joint-applied research programs. 
 Biotechnology. The Initiative recog-
nizes that both partner countries share 
the common goal of translating lab re-
sults into beneficial products delivered 
to farmers. Subject to funding from 
the U.S. and Indian governments, and 
bearing in mind possible private sector 
engagement, focus will be on transgen-
ic crops, genomic, molecular breeding, 
diagnostics, and vaccines and training.
 Water management. The improvement 
of water quality and water-use efficiency 
will be vital to the continued growth and 
productivity of the agricultural sector in 
both India and the United States. The 
Board agreed to cooperate on capacity 
building and joint research activities 
to develop improved technologies and 
management practices in a framework 
that incorporates the needs of multiple 
stakeholders from lab to farm. 
6.		ConCluSIonS
The transition of India from a protected econ-
omy to be an open, global-economic power has 
prompted India to take a series of steps to face 
the new challenges of globalization. All the pub-
lic sector science and technology agencies have 
realized the importance of IP and its creative 
management and have initiated steps toward 
generation of knowledge that could be IP pro-
tected. This is especially important as the health 
products of diseases of poor countries need to 
be indigenously developed in view of the lack 
of interest by large multinational companies 
that have little interest in the development of 
such products. Public–private partnerships with 
both Indian and foreign collaborators is being 
explored with some measure of success. In addi-
tion, active steps are being taken to strengthen 
IP protection systems and policies and also to 
create a trained cadre of technology transfer pro-
fessionals in the areas of health and agriculture. 
An important means of skill building in the area 
of IP include international collaboration and 
networking with agencies abroad. Early experi-
ence has shown that it is only through indig-
enous development that new health products 
could be developed, introduced, and marketed. 
Strengthening R&D and establishing policies 
for the creation and management of IP and pub-
lic-partnerships are important steps for making 
available products of public-health importance 
in all poor countries. ■
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ABSTRACT
This chapter describes current and historical trends and 
issues related to intellectual property (IP) management 
in Japan. It gives a history of Japan’s national IP system 
in order to provide an understanding of the nature of the 
system and why and how it was established. The chap-
ter also describes current government efforts to provide 
insights into the system’s future. With regard to current 
IP issues, two topical issues are discussed: industry-uni-
versity collaboration on R&D and employees’ inventions. 
Japan’s efforts to resolve these issues may be helpful for 
other countries that are grappling with similar issues.
The chapter also details health and agricultural IP is-
sues in Japan. It discusses and compares with the practices 
of other countries the patentability of medical methods 
and exemptions for the experimental use of patented 
products. Furthermore, the chapter offers an overview of 
Japan’s national policy on agricultural R&D and biore-
source centers (the functioning of which greatly involves 
the transfer of materials with IP rights). RIKEN (The 
Institute of Physical and Chemical Research) is offered as 
a case study to clarify the policies and issues discussed. 
Finally, for the benefit of other countries that are 
coming to terms with IP management issues, the chap-
ter offers some lessons learned by Japan that have helped 
shape its national IP policy, strategy, and institutional IP 
management.
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policy, in effect between 1603 and 1867, a time 
during which other advanced countries were be-
ginning to establish their patent systems. Once 
international trade resumed in Japan, it estab-
lished its own patent system, incorporating stan-
dards set by other countries and adapting them to 
domestic circumstances. Since the 1980s, Japan’s 
national IP policy has changed significantly. 
Former Prime Minister Junichiro Koizumi’s 
policy of “Chitekizaisan-Rikkoku (Nation Built 
on IP)” in 2002 reflected the country’s new pro-
patent policy. Since 2002, IP policy and a legal 
framework for IP rights protection have been 
reasonably well established for all categories of 
industrial invention. 
In pursuing this recent national IP policy 
and strategy, however, issues have been raised 
by various stakeholders, involving industry–aca-
demia collaborative partnerships and the status 
of employees’ inventions. To address the former, 
the Japanese government has made great efforts 
over the last decade to promote university–in-
dustry partnerships to effectively commercialize 
research results. In regard to employees’ inven-
tions, provisions in Japan’s patent law were en-
acted rather early in its patent-legislation history. 
After several revisions, the current provisions 
came into effect in April 2005. Still, even after 
these revisions, several lawsuits by former em-
ployees claiming better remuneration from their 
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1.	 InTRoduCTIon
Japan’s recognition of the importance of IP—and 
the importance of good IP management to eco-
nomic and scientific development—at one time 
lagged behind that of other developed countries. 
This was partly due to Japan’s national isolation 
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employers for their inventions have raised sig-
nificant debate.
Japan’s status as a highly industrialized, devel-
oped country has been achieved partly through an 
IP rights protection system that, since 1975, has 
been harmonized with major international legal 
instruments,1 including the World Intellectual 
Property Organization (WIPO). Japan partici-
pates in the following treaties associated with IP 
laws: the Paris Convention for the Protection of 
Industrial Property (1899 [years in parenthesis are 
those when Japan ratified/acceded to the conven-
tion or institution]); the Bern Convention for the 
Protection of Literary and Artistic Works (1899); 
the Universal Copyright Convention of 1952 un-
der the United Nations Educational, Scientific, 
and Cultural Organization (UNESCO, 1956); the 
Patent Cooperation Treaty (PCT, 1978); and the 
Union for the Protection of New Varieties of Plants 
Convention (UPOV,1982). Japan has a branch of-
fice of AIPPI (Association Internationale pour la 
Protection de la Propriété Industrielle) (1956), 
called AIPPI-JAPAN.2 The country is a member 
of the Convention on Biological Diversity (CBD, 
1993), which emphasizes the importance of genet-
ic resources, traditional knowledge, and access and 
benefit-sharing—including IP rights protection.
On the other hand, Japan has not signed the 
International Treaty on Plant Genetic Resources 
for Food and Agriculture (PGRFA).3 These ab-
stentions are principally due to concerns about 
the protection of IP rights that may not synchro-
nize with WIPO and the Agreement on Trade-
Related Aspects of Intellectual Property Rights 
(TRIPS) under the World Trade Organization 
(WTO). In the near future, when IP matters are 
better understood in domestic debates and cor-
responding laws are made, Japan may agree to 
actively participate in these major international 
treaties. 
In addition, IP laws in Japan have peculiari-
ties with regard to health and agriculture: 1) some 
aspects of medical technology, such as surgical 
operation methods, cannot be protected due to 
public equity concerns in IP laws (this is not the 
case in the United States); and 2) as in the major-
ity of developing nations, traditional knowledge 
in agriculture is recognized as a public good. 
2.	 jApAn’S	Ip	polICy	And	STRATegy
Japan’s IP policy and strategy developed from a 
relatively primitive level through the formation, 
addition, and revision of patent laws since the 
Meiji era (1868–1912), when Japan abandoned 
its policy of national isolation after the Edo era 
(1603–1867). For more than 200 years (1616–
1854), the government had banned foreign con-
tact, except for very limited contact with only a 
few countries.4 Japan refused to import or utilize 
advanced technologies developed in the United 
States and Europe. After reopening the country 
to trade in 1858, however, Japan began to work 
to catch up with industrially advanced countries 
by introducing invention-promotion systems and 
a national patent system.
During the last five years, in addition to devel-
oping patent laws, the government has promoted 
its national IP policy and strategy by developing 
general national frameworks and establishing a 
special function in the Cabinet. All of this was 
initiated by former Prime Minister Koizumi. 
2.1		 History	of	Japanese	patent	law
In 1624, England adopted a patent ordinance 
that is the basis for today’s British patent system. 
The adoption of this first patent ordinance was 
followed by the adoption of patent legislation 
in the United States in 1790, and in France in 
1791.5 During this period (the Edo era), Japan 
pursued a policy of national isolation, and the 
manufacturing of new products based on tech-
nologies developed in European countries and in 
the United States was prohibited. In the 1870s, 
the Meiji government sought to establish the 
Japan’s first patent law.6
In 1871, the first patent law — known as the 
Exclusive Right Law—was passed and enacted. 
The government, however, was not prepared to 
implement such a law: there was no government 
office to accept patent applications and no of-
ficials to handle them. Furthermore, the public 
were generally against proprietary inventions, 
and so the new patent system was not widely ac-
cepted. Ultimately useless, the law was abolished 
one year after it was passed. Without a patent 
law, imitations and misappropriations of inven-
tions were widespread, and inventors frequently 
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lost profits from royalties. In 1885, a new patent 
law was passed that followed the U.S. and French 
patent laws. Having learned from the failure of 
the Exclusive Right Law, the government estab-
lished a patent bureau in the Agriculture and 
Commerce Ministry and staffed it with a direc-
tor, three judges, an examiner, and an assistant 
examiner. By 1899, the bureau had expanded to 
five judges, 15 examiners, and 20 assistant exam-
iners; and the number of patent applications was 
doubled in 1887, reaching 1,515 in 1899.7 The 
patent ordinance, however, was still imperfect 
and far from its modern version. 
Since 1887, Japan’s patent system and law 
have been revised many times, mainly because of 
pressure from domestic proponents and devel-
oped countries. The modernization of the pat-
ent law began in 1921 through a revision that 
aimed to accommodate the increased demand 
for Japanese products as substitutes for foreign 
products during World War I (international 
trade had been suspended and high-quality for-
eign technologies and materials could not reach 
Japan during those years [1914–1918]). After 
World War II (1945–1949), Japan’s principal 
economic objective was “quantitative recovery, 
ignoring efficiency.” This changed only after the 
1950s, when economic control and subsidies 
were gradually abolished, the market mechanism 
was largely restored, private international trade 
began, political independence was regained un-
der the San Francisco Peace Treaty (1951), and 
U.S. economic assistance to Japan ended.8 
Japanese industry began to pursue efficiency 
and competitiveness, which required cost reduc-
tions and higher-quality products. Moreover, 
“it was a time when the number of patent appli-
cations resulting from active industrial investment 
in research and development was increasing, caus-
ing a variety of problems to emerge, such as late 
examination, etc.”9 Despite these circumstances, 
the patent law remained unchanged until 1959. 
The revision in 1959 was intended to cope with 
the needs of a newly liberalized economy and 
developments within international patent sys-
tems. More revisions followed in 1970, when 
technological development had become increas-
ingly rapid and industrial property issues were ex-
tremely significant for Japan. 
Japan’s rapid economic growth stalled in the 
early 1970s, demonstrating that Japan had caught 
up with developed countries and had matured 
economically and industrially. At such a point in 
a modern economy’s development, the economy 
can no longer grow through imitation but must 
innovate to spur growth. Japan’s revision of pat-
ent law in 1975 aimed not only at the creation of 
new technologies but also at international harmo-
nization. The revision included a substance-pat-
ent system and a multiclaim-application process.
As international harmonization proceeded in 
the 1980s and 1990s, various kinds of new insti-
tutions for pro-patent policies were introduced. 
The most influential factor was pressure from 
advanced countries represented by the United 
States, which feared the incremental rise of Japan’s 
export market and strongly promoted a domestic 
pro-patent policy during that period. Local voices 
called for the strengthening of Japan’s patent sys-
tem to further development and prevent an in-
creasing risk of the country’s original technologies 
and products being copied abroad, especially by 
developing countries, such as China, that were 
trying to catch up with developed countries.10 
Japan’s pro-patent policy has expanded the scope 
of patent protection, extended the patent period 
for pharmaceutical products, and strengthened 
deterrence against infringement.
In 1990, the Japan Patent Office (JPO) 
was the first patent office in the world to start 
a paperless system to accept and handle patent 
applications.
2.2		 Recent	IP	policy	and	strategy
Having recognized its need for more creative and 
advanced technological innovations, Japan has 
emphasized a pro-patent policy since the early 
1990s. In line with this position, former Prime 
Minister Junichiro Koizumi’s policy statement in 
February 2002, proclaiming that he would make 
Japan a country built on IP, followed the passage 
in 1998 of a “law on promoting technology trans-
fer from universities to industry,” so-called “TLO 
Law,” and the Japanese version of the Bayh-
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Dole Act (Article 30 of the 1999 Law of Special 
Measures for Industrial Revitalization).11
During its period of high economic growth, 
Japan had been good at exporting technologies 
based on imported technologies. After reach-
ing the global technological frontier, however, 
Japan’s advantage came under attack, especially 
by neighboring countries, such as China, that 
had plentiful, cheap labor and increasing techni-
cal and economical power. Japan suffered from 
an economic recession in the 1990s and created 
a plan to break the impasse of the recession. The 
Chitekizaisan-Rikkoku plan would add value to 
the technologies, products, and culture created in 
Japan for export overseas by further strengthen-
ing the nation’s IP regime and management. This 
entailed specific, concrete provisions for planning 
and policy implementation. 
Having been regarded as fundamental for 
national development, the former patent system 
had been established largely to stimulate domes-
tic industries. Under the Chitekizaisan-Rikkoku 
plan, Japan began to make more substantial ef-
forts to develop and implement an IP strategy, 
focusing on IP rights generated not only from 
the private sector but also the public/university 
sector.
In March 2002, one month after the gov-
ernment’s policy statement, the prime minister’s 
cabinet inaugurated the Strategic Council on 
Intellectual Property, which discussed the details 
of the plan. The Council created an Intellectual 
Property Policy Outline in July 2002.12 It referred 
to an “intellectual creation cycle”: the cycle of the 
creation, protection/establishment, and exploita-
tion/utilization of IP/IP rights (Figure 1). Aligned 
with other global IP systems, the cycle established 
a mechanism to create high-quality IP protected 
by patents. Protected IP is exploited throughout 
society, and the resulting profits are used to re-
coup the cost of original R&D and to invest in 
the creation of new IP. The cycle is considered 
fundamental to the government’s intellectual 
property policy outline and to Japan’s recent IP 
strategy.
Furthermore, the December 2002 Basic 
Law on Intellectual Property14 was promulgated 
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stipulated the establishment of the Intellectual 
Property Policy Headquarters (established March 
2003 in the cabinet). In July 2003, at the fifth 
meeting of the Intellectual Property Policy 
Headquarters, a promotion program (called the 
“Program for Promoting the Creation, Protection, 
and Exploitation of Intellectual Properties”15) 
was initiated. This program set out specific goals 
and time frames for implementing the new IP 
strategy. The program has been implemented 
and reported upon annually since then as the 
“Intellectual Property Strategic Program.”16  The 
reports are composed of five sections: Creation 
(of IP), Protection (of IP), Exploitation (of IP), 
Expansion of Content Business, and Developing 




Japanese central and local governments have pro-
moted partnerships among industry, academia, 
and government—particularly between industry 
and academia. Industry provides information 
on public or market needs; academia provides 
the seeds for commercializing technology (that 
is, inventions); and the government plays the 
role of agent or mediator between industry and 
academia. 
Measured in terms of publications and in 
acquiring publicly available competitive grants, 
national universities have been the leading aca-
demic institutions in basic research. Out of more 
than 500 universities registered by the Ministry 
of Education, Culture, Sports, Science, and 
Technology (MEXT), the top 20 universities 
acquiring extramural funding are national uni-
versities involved in all fields of research. In the 
medical, pharmaceutical, and physical sciences, 
certain private universities have an advantage 
over others due to specialization, but national 
universities generally lead. National universities 
have also been more engaged in collaborations 
with industry for some time. In 2004, 92.2% of 
national universities had established an office for 
cooperation with industry, such as a technology 
transfer office (TTO) or a technology licensing 
office (TLO); this compares to only 42.8% of pri-
vate universities and 59.6% of national research 
institutes.17 However, the effectiveness of such 
collaboration has been hindered due to unclear 
R&D policies with industry, poor IP controls, 
lack of incentives for researchers at universities, 
legal constraints stemming from the nature of 
national universities, and general administrative 
slowness. 
At leading private universities, implement-
ing industry–university collaborations has been 
much easier due to the relative ease of contractual 
negotiations, administrative procedures, and the 
lack of restrictions on the dissemination and use 
of funds. Still, only a limited number of private 
universities have been able to accommodate very 
active collaborations. 
3.1 	 Reforming	national	universities
In 2004, all national universities were separated 
from the direct supervision of MEXT and be-
came independently managed administrative 
institutions. Currently 89 national universities 
and four educational research institutions have 
reformed. The numbers will be further reduced 
by mergers and acquisitions. The key aspects of 
increased independence are: (1) all decision mak-
ing can be made by each university’s administra-
tion and council instead of requiring approval 
from MEXT; (2) a medium-term plan for each 
six years is used as an achievement evaluation 
point; (3) funding is granted by MEXT based on 
the medium-term plan; (4) profit acquiring and 
commercial activities are permitted; (5) academic 
faculty members have more flexibility in creating 
business ventures; (6) TTO and IP controls are 
enforced at each institution, with the resulting 
expectation that university–industry collabora-
tion will be boosted; and (7) faculty members are 
provided incentives to innovate. Despite all this, 
the overall system still needs to be revised, and 
governance needs to be improved to enhance the 
implementation of R&D and technology transfer 
from academic institutions.
With the reform of the national universities, 
the government now increasingly promotes aca-
demic institutions to enhance industry–academic 
institution collaborations and to establish TTOs. 
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The development of small business ventures by 
faculty members has also been encouraged in or-
der to commercialize their research. According to 
the Intellectual Property Strategic Program 2005, 
the number of new venture companies derived 
from universities was 199 in fiscal year 2003, and 
129 in fiscal year 2004, for a total of 1,112 by 
the end of fiscal year 2004. Universities provide 
support grants for such business attempts, but 
often overall strategic plans are missing on the 
university side. Insufficient consideration is given 
to IP rights, which are a strong driving force to-
ward venture-business success. Each university 




Under Japan’s former national academic institu-
tion system, it had been difficult to exploit IP 
rights because: (1) IP rights, particularly patents, 
were owned by the Japanese government; and (2) 
many academic institutions lacked the systematic 
capacity to form university–industry liaisons. The 
old national university system deterred the pro-
motion of invention and proper legal handling. 
Additionally, it seems that universities did not 
give scholars much incentive to innovate and 
invent. Faculty members also often would aban-
don patent applications due to high costs and 
the university’s propensity for rejecting patent 
applications. Instead, faculty members often al-
lowed ownership rights to be transferred to the 
private sector in return for gift donations for their 
research. This in turn hindered the development 
of research and business opportunities from uni-
versities. A survey of the top-ten major national 
universities in terms of extramural research-grant 
acquisition, revealed that legal and administrative 
systems often lagged far behind the private sec-
tor’s ability to facilitate collaboration or complex 
contractual matters.
Due to changes in the law, however, the past 
ten years have seen robust growth in the estab-
lishment of TTOs at universities. University IP 
offices take care of governance issues, and TTOs 
support the technology transfer process. In gen-
eral, university TTOs have four functions: (1) IP 
rights protection, (2) marketing of university-de-
rived technologies, (3) licensing, and (4) promo-
tion of commercial ventures by faculty members. 
TTOs have been legally supported by the govern-
ment since 1998. The TTOs that have been ap-
proved by MEXT and the Ministry of Economic, 
Trade, and Industry (METI), “approved” TLOs 
are entitled to special treatment under the TLO 
Law and the “Japanese Bayh-Dole” Law. The 
treatment could include direct funding by min-
istries and free or discounted fees for the mainte-
nance of patent rights and examination requests. 
Between 1998 and April 2006, 41 such TLOs 
were established. In addition, there were four 
“accredited” TLOs as of April 2006. These TLOs 
are assigned nationally owned patents and then 
out-license them, while the approved TLOs reg-
ister patents for university faculty—and exploit 
their inventions. Guidelines and reports for these 
TTOs have been published.18 (A detailed list of 
approved and accredited TLOs is available upon 
request from the authors and from the METI 
JPO Web site.19)
Japanese universities are recognizing the im-
portance of their own IP for commercializing 
research and establishing technology-based com-
panies. There are an increasing number of univer-
sity-derived companies (generally referred to as 
spinouts), particularly in the area of biotechnol-
ogy, compared with five years ago.20
3.3		 Human	resource	needs
Generally, the key IP issue at academic institutions 
is processing ability. Establishing a contract on 
applied R&D takes time and requires specialists 
on legal matters. Universities are short of practical 
lawyers and officers, and it is common for most of 
the officers to be transferred to a different section 
of the university within two or three years, which 
prevents these individuals from gaining sufficient 
skills and knowledge.21 This hinders efforts to 
implement and disseminate research results and 
applications promptly and smoothly. Japanese 
universities are in great need of institutional re-
form related to the administration of contractual 
matters and industry–university collaborations.
While the number of patent attorneys who 
specialize in various disciplines of modern tech-
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nologies in Japan has dramatically increased, an 
overall understanding of the IP management by 
patent attorneys is crucial. Patent attorneys may 
have specific know-how related to recent changes 
in the patent law, but joint activities with law-
yers are often required to identify or challenge in-
fringements of IP rights. With regard to the com-
mercial aspects of IP management, much needed 
are multiskilled specialists who are competent in 
both the legal and technical aspects of technology 
transfer in marketing, licensing, and integration 
of IP rights. 
The Intellectual Property Strategic Programs 
emphasize using university infrastructure to de-
velop IP specialists. Such individuals are not only 
needed to manage IP in universities but also in 
the wider business market. Multidisciplinary 
graduate school programs are increasingly be-
ing offered at many universities, but profession-
als with such know-how are still few, so TTOs 
often offer seminars/workshops on IP education 
and practical operations for their faculty mem-
bers and senior graduate students. Through these 
efforts, IP courses are becoming popular at many 
universities.
4.	 employeeS’	InvenTIonS
Information surveys, such as those published 
by the Mitsubishi Research Institute,22 point to 
Japan’s lack of strong incentives for researchers 
and engineers as a potential pitfall. The problem 
is caused by the weak support for employees’ in-
ventions created through the work service. Article 
35 of Japan’s patent law defines employees’ in-
ventions, but the law is often criticized for not 
promoting employees based on their record of 
inventions and formal IP, especially at public in-
stitutions. Compared to the United States, where 
public institutions file for many patents, relatively 
few patents are filed by Japan’s public institutions. 
This is true especially for the national universi-
ties. Instead, Japanese academia recognizes and 
rewards publishing, which is used as almost the 
sole criterion for promotion.23 MEXT and its 
subsidiary organization, JSPS (Japan Society for 
the Promotion of Science), have noted the low 
number of patent filings at academic institutions 
and have used grants to encourage promotions 
based on the patenting of inventions.24 Over 
the last few years, patent filing and registration 
have drastically increased under the Research for 
the Future Program promoted by MEXT and 
JSPS.25
The debate between employers and employ-
ees about their proportional ownership of inven-
tions at universities dates back to the 1970s.26 
After some argument, MEXT reported in 2002 
that inventions created by faculty at universities 
should be owned by universities. This principle 
has since been the basis of university IP manage-
ment strategies. Meanwhile, according to a sur-
vey conducted in 1997 by the Japan Institute of 
Invention and Innovation (JIII),27 more private 
companies have been providing relevant regula-
tions and rules and have been increasing remu-
neration and employee incentives to generate in-
ventions. The survey revealed that: 
1. An increasing number of companies have 
regulations and rules established. 
2. Remuneration is made at different mile-
stones, such as patent application, patent 
registration, and exploitation/working. The 
proportion of companies adopting such re-
muneration rules has increased for all the 
milestones.  
3. The amount of remuneration is fixed for 
some companies; others value it in pro-
portion to the profit acquired from the 
invention.
4. In both cases, the average amount of remu-
neration generally has increased.
The recognition and awareness of employees’ 
inventions and their remuneration have been ris-
ing for the last decade; nevertheless, various issues 
remain.
4.1	 Laws	on	employees’	inventions
The Patent Law of 1909 gave the patent right to 
an employee invention to his or her employer, but 
ownership reverted to the employee under the 
1921 Patent Law. The 1921 law aimed to protect 
employees by ensuring that they received reason-
able remuneration when the right of ownership 
was passed to the employer (in accordance with 
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contracts made in advance).28 The Patent Law of 
1959, Article 35, revisited these provisions gov-
erning employees’ inventions. The law declared 
that if an employee’s patented invention was clas-
sified as an “employee’s invention” (as defined in 
the patent law29), the employer had the right to 
a nonexclusive license. The same law stipulated 
that the employee is entitled to reasonable remu-
neration if he or she assigns the patent right, or 
an exclusive right to such invention, to the em-
ployer in accordance with contracts, regulations, 
and other stipulations. The law also provided that 
the remuneration amounts would be decided by 
referring to the profits that the employer would 
make from the invention and to the amount of 
the employer’s contribution to the invention.
4.2	 New	policy	and	strategy	on	
employees’	inventions
As mentioned earlier, the Intellectual Property 
Strategic Program 2003 was adopted in July 
2003. The Creation part of the program states the 
following provision to employees’ inventions:
Abolishing or Amending the Provision 
Regarding Employees’ Inventions under the Patent 
Law.
For the purpose of securing R&D incentive for 
inventors, reducing patent management cost and 
risk in individual companies, and strengthening the 
industrial competitiveness of Japanese industry, the 
GOJ (Government of Japan) will consider necessary 
issues on an employee’s invention, while taking into 
account the changes in the social environment, and 
submit a bill to abolish or amend the provision in 
Article 35 of the Patent Law to the ordinary session 
of the Diet in 2004. 
Consequently, in December 2003, a METI 
committee of professionals from universities and 
from the public and private sectors, with expertise 
in law and in science and technology, created a 
report titled “What employees’ inventions should 
be.”30 The report suggested amending the provi-
sion regarding employees’ inventions instead of 
abolishing it. The National Forum for Intellectual 
Property Strategy appeared at the same time. 
With a range of expertise including lawyers/pat-
ent attorneys, research scientists, business ex-
ecutives, and journalists, members of the forum 
asserted that the provision should be abolished. 
The details of the various views are discussed be-
low. Based on the METI committee’s report, the 
amendment of Article 35 of the patent law went 
into effect in April 2005.31
4.3	 Amendment	of	Article	35
An employee’s invention is defined in the law as 
an invention “which by reason of its nature falls 
within the scope of the business of the employer, etc. 
and an act or acts resulting in the invention were 
part of the present or past duties of the employee, 
etc. performed on behalf of the employer, etc. (Article 
35.1).” In other words, an employee’s invention 
results from R&D conducted by an employee as 
part of his or her work within the scope of the 
employer’s business. There are two other types of 
inventions mentioned in the law: those created 
by an employee, but outside of his or her work 
service, and those created by an employee outside 
of the employer’s scope of business. These dif-
ferences in the three types are explained in the 
provisions. Although the employee’s invention is 
created by the employee’s own efforts and abili-
ties, the employer contributed to the creation by 
providing salary, facilities, equipment, and ex-
penses. Considering such contributions, the law 
provides that the employer shall have a nonexclu-
sive license on the patent right in order to gain 
appropriate remuneration (Article 35.1).
Article 35.2 stipulates that, provided the 
invention is the employee’s invention, the con-
tractual provision, service regulation, or other 
stipulation made in advance shall be valid, and 
the employer shall be given the right to the pat-
ent or to the exclusive license. This provision is 
said to protect employees from being exploited 
if inventions fall outside of the scope of the em-
ployee’s invention. The employee shall have the 
right to reasonable remuneration when he or she 
has transferred the right to the employer in ac-
cordance with the contract, service regulations, or 
other stipulations (Article 35.3).
Although there has been no amendment for 
Article 35.1 to 35.3 since the 1959 Patent Law, 
the subsequent two sub-clauses, Article 35.4 
and 35.5, were amended. As mentioned above, 
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Article 35.4 of the 1959 Patent Law stipulated 
that the amount of the remuneration shall be de-
cided by referring to the profits that the employer 
will make from the invention and to the employ-
er’s contributions to making the invention. The 
new Patent Law of 2005 stipulates that when 
the contractual provision, service regulation, or 
other stipulation between the employer and em-
ployee determines the criteria for remuneration, 
the criteria should be reasonable. Reasonableness 
shall be determined by considering the decision 
process of the criteria, such as the conditions of 
discussion between the employer and employee, 
hearing of the employees’ views on the calcula-
tion, and the disclosure status of the criteria.
If judged as unreasonable in accordance with 
Article 35.4, the amount of remuneration shall 
be decided in light of the profit, expenses, and 
other contributions of the employer regarding 
the invention, the treatment of the employee, and 
other circumstances (Article 35.5).
4.4	 Current	issues	regarding	
employee’s	inventions
In the last few years, the increasing number of 
employees who have resigned from their compa-
nies have been suing their former employers due 
to dissatisfaction with the remuneration paid for 
inventions the employees created during their 
employment. The surge in the number of law-
suits reflects an increasing awareness of IP among 
employees and has aroused the public’s interest 
in IP and employees’ inventions. The most fa-
mous case, known for the exceptional amount 
claimed by the employee, is the lawsuit between 
Dr. Shuji Nakamura and his former employer, 
Nichia Corp., Ltd., a chemical maker, concern-
ing his invention of a blue light-emitting diode 
(LED). Originally claiming 20 billion JPY, the 
court decided Dr. Nakamura was entitled to re-
ceive about 600 million JPY (plus interest pay-
ments of about 240 million JPY) from his for-
mer employer. The case had been reviewed by the 
Tokyo District Court (2004) and the Tokyo High 
Court (2005) before it was settled in 2005. It is 
noteworthy that there was an enormous differ-
ence between the percentages that the two courts 
identified as Dr. Nakamura’s contribution: 50% 
in the district court and 5% in the high court. 
Dr. Nakamura certainly lost a large amount, but 
generally the case is considered to be a victory for 
the employee.
Over the last few years, other former employ-
ees have gained more than their former employ-
ers had expected to pay. The Japan Intellectual 
Property Association (JIPA)32 cautions against 
extreme legal moves to support remunerations 
for employees’ inventions because overestimated 
valuation of inventions may destroy some em-
ployer companies. The purpose of Article 35 is 
primarily to appropriately balance the interests 
of employers and employees. Both the employer 
and employee require significant—and often dif-
ferent—incentives to ensure that appropriate, rel-
evant investments are made to enable and stimu-
late innovation.
History suggests that the provisions for em-
ployees’ inventions under the patent law have been 
ineffective. Some groups, such as the National 
Forum of Intellectual Property Strategy, and some 
private companies fearing huge employee remu-
neration costs have argued that Article 35 should 
be abolished or, at least, amended.33 The critics 
contend that the individual contractual provision, 
service regulation, and other stipulations made in 
advance between the employer and employee (or 
individual agreements) should be considered rea-
sonable unless they were made under conditions 
of fraud, duress, or other unreasonable process-
es.34 Individual agreements, not Article 35 per se, 
should be applied to settle disputes between the 
employer and employee regarding the employee’s 
invention. 
The same critics argue that the following issues 
regarding employee’s invention under the current 
Patent Law (Article 35) are also important:
• Criteria for calculating the amount of re-
muneration have varied from court to 
court and from case to case. Without any 
rigid criteria, the decision is vulnerable to 
the subjective calculations of the judge (as 
seen in the Nakamura case)
• Criteria for judgment of an “unreasonable” 
payment in accordance with Article 35.4 
are obscure
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• Ultimately, it is dubious whether or not a 
court has the ability and capacity to judge 






In Japan, medical methods are out of the scope of 
patentability; however, pharmaceutical products 
and medical equipment products are patentable. 
This is inconsistent with U.S. and E.U. practices. 
In the United States, methods relating to medical 
activities and practices are generally patentable. 
Under 35 U.S.C. 287 (c)(1),35 however, a medical 
practitioner can use patented medical methods 
without risking infringement. In the European 
Union, under the European Patent Convention 
(EPC), Article 52 (Patentable inventions)36 stip-
ulates that methods to treat the human as well 
as animal body by surgery or therapy, as well as 
diagnostic methods practiced on the body, shall 
not be regarded as inventions that can be ap-
plied industrially. In other words, the methods of 
operation, treatment, and diagnosis of the human 
body are not protected by patent rights. However, 
as an exception to that rule, the first two of the 
three stages in diagnostic methods: data collec-
tion, their comparison, and decision making of 
medical treatment, have been interpreted as pat-
entable according to the EPC.37 
In Japan, first and most fundamentally, med-
ical methods fall out of the scope of patentability 
according to patent law Article 29 (1).38 In other 
words, they are regarded as inventions that are not 
industrially applicable because of their humanitar-
ian implications in the medical field. It was feared 
that patients’ wellbeing might be jeopardized by 
patent protection, which could have effectively 
deterred medical practitioners from utilizing cer-
tain methods if they did not have a license from 
the patent owner. Secondly, medical activities 
including R&D are generally regarded as being 
not for profit, and it is widely held that incen-
tives should be based on academic appraisal and 
rewards rather than economic gain. Additionally, 
innovation in the medical field was largely con-
ducted by universities and public institutions 
that were sufficiently funded by the public sector, 
which eliminates the need to rely on the modern, 
private model of patenting and receiving royalty 
earnings from licensing.39 Consequently, the de-
cision was made that medical methods should be 
excluded from patent protection. 
However, many players in both academia and 
industry regard this decision as outdated because 
of various changes that have taken place in Japan 
over the last decade.
5.1.2	Trends	in	perspective	
The most prominent issue relating to the nonpat-
entability of medical methods is the lack of in-
centives for pursuing costly, risky innovation in 
the medical field. In addition to the major roles 
of universities and public research institutions 
in medical innovation, bioventures (biotechnol-
ogy ventures) and spinouts have increased their 
role over the last decade because of the increased 
recognition of IP rights and the establishment of 
TTOs in universities and public research institu-
tions. Needless to say, such privately run compa-
nies cannot expect public funds to cover the costs 
of this increasing investment, much of which is 
directed at the universities and public institutions. 
Instead, it is increasingly expected that investment 
costs will be covered by patenting and licensing. 
However, companies have no way to generate 
returns on investments into medical method in-
ventions. Moreover, their inventions can be easily 
copied and utilized freely by others. Not surpris-
ingly, therefore, potential bioventure companies 
are not eager to enter the field.40 In the absence 
of actively nurturing this sector, many believe that 
Japan’s competitiveness in this field will weaken 
because investments in medical innovation will 
always be deterred. In the long run, patients 
may lack access to new, highly effective diagnosis 
or treatment methods that could be developed 
locally. There may also be negative economic 
consequences. 
Some critics argue that excluding methods 
and processes from patent protection does not 
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comply with the TRIPS Agreement, which stipu-
lates that patents shall be available for all inven-
tions, whether products or processes, in all fields 
of technology, provided they are new, involve an 
inventive step, and are capable of industrial ap-
plication (Article 27).41 
Thus, it is increasingly felt that not just medi-
cal products, but also methods, should be consid-
ered inventions with industrial application that 
should be given patent protection.
Based on the above analyses, the government 
of Japan is reconsidering patent protection for 
medical methods. In response to recent changes 
in circumstances and views, the government es-
tablished a task force on “the protection of patents 
of medical-related acts.” The task force committee 
was established under the Intellectual Property 
Policy Headquarters and began consultations in 
October 2003.
The main purpose of the meetings was to 
discuss whether or not medical methods should 
be covered by patent protection. The committee 
published a summary report of their discussions 
in November 2004,42 which involved hearings 
from not only committee members but also other 
professionals from various fields, such as medi-
cal science, the medical industry, medical econo-
mists, and the legal field. The report also included 
public comment. After 11 meetings, the summary 
report made the following recommendations:
• From a humanitarian standpoint, the meth-
ods relating to medical activities by medical 
practitioners should be excluded from pat-
ent protection. 
• Operational methods of medical equip-
ment should be covered under the scope 
of patent protection, with the exception of 
those related to medical activities by medi-
cal practitioners.
• With regard to methods for generating 
new potent and efficacious medicines for 
production and sale, the possibility of ex-
panding patent protection should be pur-
sued by allowing product patents rather 
than process patents to begin with. Process 
patents could be discussed and pursued 
later on. The limited protection reflects 
the potentially obscure distinction between 
medical activities by medical practitioners 
and others.
In April 2005, based on the committee’s 
recommendations, the government amended 
the practical examination criteria of medical in-
ventions for patents and utility models.43 The 
amendment makes explicit provisions for patent-
ing methods and processes related to the use of 
medical equipment, but methods and processes 
related to medical activities by medical practitio-
ners are not patentable.44
5.1.3		 Issues	for	the	near	future
Although the examination criteria have been 
amended, some issues and arguments still require 
resolution. The report recognizes that medical 
methods for patients who need access to state-
of-the-art medical practices should be excluded 
from patent protection. However, no such law 
has yet been passed, and legal guidance similar 
to the U.S. provision in 35 U.S.C. 287 (c)(1) is 
urgently needed.
Despite the report’s conclusion, expanding 
the scope of process patents in the medical field 
to cover whole methods is still widely debated. 
Some argue that amending the examination crite-
ria is insufficient and that Japan’s competitiveness 
in the medical field will not be enhanced without 
protecting medical process inventions.
5.2 	 Limitations	of	the	patent	right
The limitation of the patent right or the exemp-
tion from patent infringement for the experimen-
tal use of a patented invention affects all fields 
in science and technology. Given its impact on 
public health outcomes, however, this limitation 
is important especially for biotechnological and 
medical experimentation.
5.2.1		 Background
Article 69 (1) of the Japanese patent law provides 
that “the effects of the patent right shall not extend 
to the working of the patent right for the purposes of 
experiment or research (Limits of Patent Right).” 
The original purpose for establishing the patent 
law was “to encourage inventions by promoting their 
protection and utilization so as to contribute to the 
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development of industry (Article 1),” and extending 
the patent right to experimentation and research 
is considered contrary to this purpose. Such limi-
tations to the patent right were originally inserted 
into the patent law of 1909, which was reaffirmed 
in Article 69 (1) of the patent law of 1959. Article 
68 of the patent law also provides that a paten-
tee shall have an exclusive right to “commercially” 
work the patented invention. The word commer-
cially leads some to conclude that experiments 
and research conducted in universities and public 
research institutions will be excluded from patent 
protection because they are largely considered as 
nonprofit. 
The patent law, however, does not clearly dis-
tinguish between profit and nonprofit purposes in 
terms of the effects and limits of the patent right. 
The above interpretation has depended solely 
upon legal theory, and very few judicial prec-
edents have emerged regarding the interpretation 
of “experiment or research” provided for in Article 
69 (1). Therefore, failing to obtain a proper license 
for utilizing a patented invention in experiments 
and research in universities and public research 
institutions can potentially be considered as in-
fringement. Moreover, patent owners have a clear 
right to require universities and research institu-
tions to obtain licenses for each invention used 
in their experiment or research. These procedural 
requirements and the related royalty payments 
deter researchers. If patent protection extends to 
experimentation and research linked to techno-
logical advancement, it could eventually thwart 
the evolution of national industry. 
5.2.2		 The	current	situation	and	precedents
The accelerated progress of biotechnology, the 
increased collaboration between academia and 
industry, and the enhanced awareness of IP strat-
egy among various players over the last decade 
have heightened concerns over obscurity in the 
patent law. In the Intellectual Property Strategic 
Program 2003, the government decided to review 
and clarify the extent to which experiments or re-
search are exempted from patent infringement. 
This review would investigate current situations 
and precedents not only in Japan but elsewhere, 
and the results would be widely disseminated to 
both the public and private sectors in order to 
reduce the possibility of conflict. Composed of 
experts and leaders from various areas, including 
executives of private companies, patent attorneys, 
faculties of universities, and representatives of 
TTOs, a working group on patent strategy estab-
lished under the METI in 2003 discussed the is-
sue in a report on issues relating to effective use 
of patented invention.45 Completed in November 
2004, the report focused principally on three as-
pects: the experiment or research, generally, clini-
cal trials for approval of generic medicines, and 
experimentation and research in universities and 
public research institutions.
According to the report, very few judicial 
precedents in Japan interpret experiment or 
research, so guidance has been sought in legal 
theory instead of judicial rulings. The most 
widely accepted theory was described by Keiko 
Someno in 1988.46 It limits experiment or re-
search to the purpose of “progress in technology,” 
such as the examination of an invention’s pat-
entability, the examination of an invention’s 
function, and experiments to improve or de-
velop the invention.
The results of the investigation of other 
countries are summarized in Box 1 (see end of 
chapter). While the wording and scope vary from 
country to country, on the whole the laws provide 
an exemption from patent infringement for ex-
perimental use. In some countries, however, the 
interpretation of the provision is incoherent due 
to a lack of case history—and even the theories 
are variable in such countries. Still, in most of 
the countries, clinical trials to obtain regulatory 
approval are exempted, while there is no or very 
little case history regarding experimental use in 
universities.
The report concluded that Someno’s theory is 
appropriate for Japan and in line with the situa-
tion and precedents of other countries. The report 
recommended its use to clarify the scope of the 
experiment and research exempted from the pat-
ent infringement. According to the theory (and 
given the fact that Japanese patent law does not 
distinguish between for-profit private companies 
and nonprofit universities and public research 
institutions when it comes to experiment or re-
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search using a patented invention for the effects 
of patent right), experimentation and research 
conducted in universities and public research in-
stitutions are potentially infringement unless li-
censes are obtained from the patent owner. If the 
subject of the experiment or research is a patented 
invention itself and the purpose is technological 
progress, however, utilization is exempted from 
the license requirement. Likewise, Article 69 (1) 
is not likely to apply to the utilization of research 
tools unless the subject of the research is the pat-
ented invention itself and its purpose is for tech-
nological progress.
There have only been a few occasions when 
universities and public research institutions uti-
lizing a patented invention for their experiment 
or research have been sued by private companies 
owning the patent right in Japan. However, the 
report notes an increased concern about such law-
suits, particularly because universities are more 
likely to create profits from experimentation and 
research using patented products through in-
creased collaboration with private industry than 
in the past. Besides, the report emphasizes the 
importance of disseminating information and 
generating a consensus on this issue in both the 
public and private sectors in order to minimize 
the number of such conflicts.
6.		AgRICulTuRAl	BIoTeChnology	
6.1		 National	policy	on	R&D
Japan has pursued R&D in agricultural biotech-
nology in the public and private sectors since the 
1980s, with the government and relevant public-
funding supports determining priorities. While 
basic R&D has contributed to global plant bio-
technology communities, Japan has not taken 
the leadership in the business development of 
agri-biotechnology.48 Furthermore, even though 
academic publications are recognized within 
global R&D networks, Japan’s national policy 
lacks a strategic vision in the area of technology 
commercialization. 
Despite the huge investment made by the 
public and private sectors between 1980 and 
1999, no fruitful commercialization has taken 
place in Japan,49 except for small cases relating to 
transgenic flowers. Many factors have been sug-
gested for this: the weakness of decision making 
by the public sector’s senior administration—and 
the private sector’s correlating impatience; an 
overall shortage of adequate human resources; the 
lack of a strategic approach to commercialization; 
disorganized IP strategies; poor accountability, 
particularly in public-funded research; poor pub-
lic communication approaches and consequent 
negative sentiment; and unfavorable regulations 
for R&D, despite government policies to support 
overall biotechnology.50 Compared with other 
biotechnology areas, no major venture capitalists 
or investment banks are actively funding Japanese 
plant biotechnology R&D.51 On the other hand, 
investors need patience. In general, agri-biotech-
nology R&D is a slow process, which is reflected 
in the slow growth of related industry.
On the upside, policy related to general sup-
port for biotechnology as a national priority has 
been reformed by the Council for Science and 
Technology Policy (CSTP)52 under the cabinet of-
fice. Under supervision from METI, government 
funding agencies, such as the Research Institute 
of Innovative Technology for the Earth (RITE),53 
the New Energy and Industrial Technology 
Development Organization (NEDO)54 and the 
Ministry of Agriculture, Forestry, and Fisheries 
(MAFF), have refocused research on crop-genome 
and crop-biotech applications, while MEXT and 
JSPS continue to fund basic research. This may 
drive policy toward the developmental outcomes 
of the Kyoto Protocol on environmental biotech-
nology applications (including transgenic appli-
cations). In the long term, these developments 
could revive overall agricultural biotechnology, 
including genetically modified (GM) crops. Also, 
as is the case in the United States and Europe,55 
the private sector in plant biotechnology could 
restructure by redefining and limiting its business 
context and partners.
6.2	 Agri-biotechnology	industry	and	IP	rights
The Japanese biotechnology industry is very large 
in terms of assets and investments and is grow-
ing rapidly. Biotechnology research in Japan cov-
ers a wide range of areas from the elucidation of 
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biological mechanisms to the development of new 
functional materials. Due to the broad spectrum of 
biotechnology, however, it is becoming increasing-
ly difficult for a private company to monopolize, 
or even to know about, all the patents in a single 
product. Without intending to do so, a company 
can use another’s patented technology inappropri-
ately. The possibility of such patent infringement 
reaching the courts is increasing, and a complicat-
ing factor is the variety of national and interna-
tional laws. In the field of agri-biotechnology, for 
instance, for new plant varieties it is unclear how 
laws/treaties on patent and those on plant variety 
protection should coexist or be applied.56
The number of ventures and spinouts in the 
area of biotechnology has increased, particularly 
since the reform of national universities into in-
dependently managed administrative institutions. 
Nevertheless, investors see agri-biotech companies 
as a high risk; their long-term efforts and contri-
bution have been stagnant.57 Major venture capi-
talists or investment banks are less likely to fund 
Japanese plant biotechnology R&D in compari-
son to other areas. Japanese companies have lost 
opportunities as a result, and key patents on plant 
biotechnology have been swept away by U.S. and 
European private companies, which strongly and 
adversely affected Japan’s agricultural biotechnol-
ogy industry. Numerous obstacles have contrib-
uted to this situation: (1) the complication of 
patenting inspection; (2) the tendency to grant 
wider coverage of patentable subjects, such as 
DNA sequences; (3) the changes in laws regard-
ing patentable “process”; and (4) slow follow-up 
on litigation in agri-biotech IP rights.58
6.3	 Bioresources	centers/genebanks
Genetic resources have been well recognized as a 
key resource for R&D in Japan. To ensure syn-
ergy among germplasm banks, a consortium has 
been established that includes individual aca-
demic agencies. Similar to GRIN (Germplasm 
Resources Information Network)59 in the United 
States, this information system is being further 
elaborated. There is common understanding of 
the uses of the germplasm acquisition agreement 
(GAA) and materials transfer agreement (MTA) 
from public bioresources centers/genebanks to 
different stakeholders in Japan. Details within 
MTA documents vary because each academic 
agency has to determine its own policies and rules 
under the common government framework. 
The private sector also establishes its own 
MTA documents. These are based on different 
cases of use, such as basic research collaboration, 
R&D toward commercial orientation, collabora-
tion with other private companies, and so forth. 
Although largely confidential, surveys made by 
the Japan Bioindustry Association (JBA) clearly 
reveal a system designed to accommodate various 
scenarios, particularly in relation to microorgan-
isms. Plant genetic resources, however, are dif-
ferent, and Japanese seed companies still need to 
comprehend and tackle access and benefit-shar-
ing issues under international debate—including 
the CBD and Treaty.
Case examples of access and benefit sharing 
(ABS) with southeast Asian countries empha-
sizing industrial applications include Indonesia 
with some pharmaceutical companies, Pathein 
University in Myanmar with the National 
Institute of Technology and Evaluation (NITE)60 
bioresources center, and the Forest Research 
Institute of Malaysia (FRIM) with Nimura 
Genetic Solutions (NGS),61 a biotech venture-
ABS company.  
With the efforts of such intersectoral liai-
sons as JBA, some progress has been made in 
promoting and developing models for ABS-based 
R&D. However, Japanese academic institutions 
will be better able to address this matter by pay-
ing more attention to contemporary internation-
al discussions, such as those of the PGRFA, that 




RIKEN63 is one of Japan’s most distinguished 
public research institutes in the natural sciences. 
Its history began in 1913, when Jokichi Takamine, 
a Japanese scientist who discovered Taka-diastase 
and adrenaline, pointed out the need for a na-
tional science-research institute. Through the ef-
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forts of Takamine and others, including Eiichi 
Shibusawa, a businessman who greatly contrib-
uted to Japan’s industrialization in the early 20th 
century, a bill to establish RIKEN was passed by 
the 37th Imperial Diet in 1915. A “Proposition 
relating to the establishment of RIKEN” was sub-
mitted to the government in 1916, followed by 
a “Bill for governmental subsidy of a semipublic or-
ganization to conduct research in the physical and 
chemical sciences.” RIKEN was eventually found-
ed in 1917 as a private research foundation. 
In 1927, Rikagaku Kogyo was incorporated 
exclusively to make marketable products from 
RIKEN’s inventions. In other words, Rikagaku 
Kogyo had a similar function to a TTO.64 
Subsequently, other new companies were creat-
ed to manufacture the products. By 1939, there 
were 63 companies and 121 plants. The group 
was called RIKEN Industrial Group, otherwise 
known as “RIKEN Konzern.” It included some 
successful companies, such as RICOH, that 
survived and flourished even after the dissolu-
tion of the Konzern. RIKEN registered 0.7% 
of all patents registered in Japan during the 
period from 1918 to 1944 and actively trans-
ferred its technologies to the RIKEN Konzern 
companies, many of which were commercial-
ized. Simultaneously, the proportion of royalties 
from patents as a percentage of RIKEN’s entire 
revenue dramatically increased from 0% in 1927 
to 48.4% in 1939, reaching a high of 60.4% in 
1940.65 
Dissolved by the General Headquarters of the 
Allied Powers after Japan’s defeat in World War II, 
RIKEN was later reorganized and incorporated as 
a private corporation called Kaken Kagaku Ltd. 
(Scientific Research Institute Ltd.) in 1948. The 
corporation covered its research expenses with 
royalties earned by out-licensing its inventions. 
However, royalties gradually became insufficient 
to cover research costs, so government funding 
became necessary. 
RIKEN was reinvented and inaugurated in 
1958 as a special public institution operated by 
the RIKEN Law, for comprehensive research in 
science and technology under the jurisdiction of 
the Science and Technology Agency (STA, later 
integrated as the MEXT). In October 2003, 
special public institution reforms by the govern-
ment reorganized RIKEN into an independently 
managed administrative institution. Since the re-
organization, RIKEN and other public research 
institutions and national universities (see Section 
3) have had more independence and autonomy 
to make decisions about research activities and 
finances. On the other hand, this greater respon-
sibility requires more transparency and account-
ability in relation to fiscal and administrative 
management.
RIKEN’s total budget in fiscal year (FY) 2005 
was 86,769 million JPY. Medical science and bio-
science account for large shares of the budget. 
Funding is provided by the government (about 
80%) and by RIKEN itself (about 20%).
RIKEN has full-time and part-time employ-
ees. Full-time employees are either permanent or 
contract-based employees (usually one-year and 
renewable). The number of full-time employees 
is approximately 3,000, more than 70% of which 
were contract-based in FY 2005. Part-time work-
ers also number about 3,000. Both full-time and 
part-time employees include foreign researchers. 
The total number of foreign researchers has in-
creased from 352 in FY 1993 and 519 in FY 1998 
to 576 in FY 2002. Chinese researchers account 
for a quarter of the foreign researchers at RIKEN. 
Many other foreign researchers come from Korea, 
the United States, France, and Russia. The por-
tion of researchers from European countries has 
expanded gradually, but China consistently is 
most strongly represented. RIKEN’s personnel 
reflect a diversity of positions and backgrounds—
a significant asset in today’s globalized world. 
RIKEN is headquartered in Wako, Saitama, 
and there are eight other RIKEN research sites 
across Japan’s mainland. Each one specializes in a 
specific research field. In addition to the domestic 
branches, RIKEN has three overseas branch in-
stitutes: one in the United Kingdom and two in 
the U.S. Research facilities have been established 
at these locations in collaboration with the host 
laboratories. In April 2006, RIKEN launched an 
office at Biopolis, a biomedical research hub in 
Singapore with both public and private sector 
researchers. In partnership with regional research 
institutions and Singapore’s Agency for Science, 
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Technology, and Research (A*STAR), this new 
office is a hub for research collaboration in Asia.
RIKEN has always collaborated with domes-
tic universities and built close ties by accepting 
their research students. In addition to graduate-
student partnerships with 23 Japanese universi-
ties as of 2005, RIKEN has established similar 
partnerships with several universities in other 
Asian countries. RIKEN jointly conducts various 
official research projects with over 50 overseas 
research institutes—unofficial collaboration and 
exchanges of material and information greatly 
swell this number.
7.2	 RIKEN’s	IP	policy	and	strategy
Under the RIKEN law, the institute’s objectives 
are to conduct comprehensive research in science 
and technology and to disseminate research re-
sults. RIKEN carries out research in many fields, 
including physics, chemistry, medical science, bi-
ology, and engineering, that ranges from basic re-
search to practical application. In its previous role 
as a special public institution, RIKEN empha-
sized basic research over practical research. In the 
last few years, however, the institution has focused 
more on practical applications. Especially since 
becoming an independently managed administra-
tive institution in 2003, RIKEN has emphasized 
earning its own funds through commercialization, 
instead of relying on government funds. As part 
of this effort, RIKEN established the Center for 
Intellectual Property Strategies (CIPS) in April 
2005.66 CIPS was charged with handling IP pol-
icy, strategy, and management. CIPS addresses 
these issues comprehensively and has been able 
to deal successfully with the increasing numbers 
and varieties of researchers, laboratories, centers, 
and institutes within RIKEN.
7.2.1	 	 IP	status	
Figure 2 shows the number of patents newly filed 
each year and retained by RIKEN domestically 
and overseas. The number of newly filed domes-
tic and overseas patents has gradually increased, 
while the number of domestically owned patents 
has generally decreased. Overseas ownership has 
gradually increased. These trends have two im-
portant implications:
For one, RIKEN’s efforts to file IP rights 
(principally patent rights) for as many inventions 
as possible, whether domestic or overseas, have 
increased the number of patent filings. Also, 
RIKEN has become increasingly selective in re-
taining its patent rights because to do so is costly. 
Every year, owners are required to pay on patents, 
not only filing and registry fees, but also mainte-
nance fees. RIKEN’s status as an independently 
managed administrative institution has made it 
adopt a more cautious approach to retaining pat-
ent rights. It has decided which patents to aban-
don by reviewing and assessing the value of each 
invention in terms of its potential profit and li-
censing prospects. This is another reason why the 
number of domestic patent rights has declined. 
For overseas patents, the selection was less pres-
sured because it is more difficult to identify the 
value of each invention for the international mar-
ket. Consequently, the number of overseas pat-
ent rights retained has increased—in FY 2003 it 
outnumbered the domestic.
Figure 3 shows the number of licensed pat-
ents owned by RIKEN and the royalties earned 
through licensing each year. RIKEN’s exploita-
tion/licensing rate68 is currently about 12%. This 
is below RIKEN’s own expectations—as are the 
royalty amounts earned—so it is assumed that 
many of the inventions generated at RIKEN are 
not practical for commercialization. RIKEN has 
made the following efforts to raise the rate:
7.2.2	Objectives	for	IP	policy
RIKEN’s fundamental IP policies are driven by 
three main objectives: (1) to promote greater pro-
tection of IP rights on inventions, particularly 
patent rights; (2) to partner with industry; and 
(3) to generate profits through licensing.
1.  Promotion of IP rights. The promotion of 
activities relating to filing patent rights is 
aimed at contributing to the public domain 
by disclosing RIKEN’s inventions through 
patent applications and at generating prof-
its through licensing patented inventions to 
industry.
(A) Patent liaison staff. To promote IP pro-
tection, RIKEN deploys about 10 staff 
members called “patent liaison staff.” 
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Their responsibilities range from iden-
tifying inventions to protecting them 
through consultation with RIKEN’s in-
ventors. The staff is made up of qualified 
patent attorneys; incumbent staff em-
ployed and temporarily transferred by 
private companies or attorneys’ offices 
with relevant experience; and retirees 
of private companies. There is no staff 
member with tenure deployed for patent 
liaison. It is felt that none of RIKEN’s 
tenured staff have adequate knowledge 
and experience in IP and technology 
management because staff are rotated 
to other divisions every three or four 
years under the organization’s personnel 
policy. 
(B) Employee invention regulations. 
Compared to other public institutes in 
Japan, RIKEN set up regulations for em-
ployee inventions comparatively early. 
The regulations were amended in April 
2004. Previously, employee inventors 
had to decide whether to retain owner-
ship of an applied or registered patent 
(or other form of IP right) jointly with 
RIKEN—and shared equally—or to 
waive the whole right to their invention 
and assign it to RIKEN. If they decided 
to own half, they were required to bear 
half of the expenses for applying, reg-
istering, and retaining the IP (RIKEN 
paid the other half ). Meanwhile, the 
employee could benefit from a variable 
percentage of the royalties that would 
be paid based on the amount of received 
royalties. Furthermore, a fixed amount of 
remuneration was paid to the inventors 
for both the application and registration 
of the patent. RIKEN was seeking to 
promote patent rights, and to encour-
age researchers to make more inven-
tions, with the potential for economic 
returns by providing remuneration to 
the inventors.
The new regulations of April 2004, 
however, eliminated the inventor’s op-
tion to own half the IP rights. The 
whole right would from then on be 
owned solely by RIKEN. The rationale 
for the change was that sole ownership 
by RIKEN would enable the institu-
tion to manage the entire technology 
transfer process, enabling it to deter-
mine licensing issues itself and to decide 
upon licensing details. The licensees are 
also likely to welcome RIKEN’s sole 
ownership because the process is easier. 
Moreover, the number of one-year em-
ployment contracts within RIKEN has 
greatly increased over the last few years. 
Most researchers and inventors are newly 
employed and could resign one or a few 
years later. This fluidity makes it difficult 
to jointly own IP because the institute 
has to chase down inventors who have 
left RIKEN in order to obtain consent 
for exploiting or waiving rights. Besides, 
a number of inventors had not, in fact, 
chosen the option of joint ownership in 
the previous system. This was largely be-
cause of the risk and ambiguity involved 
in exploitation, as well as the high costs 
of applying for, registering, and retain-
ing patent rights. 
Another amendment relates to pro-
visions for remuneration. The remu-
nerations for application and registra-
tion were combined and paid together 
one year after the application, while 
the provision related to remuneration 
for licensing remained as it was. This 
amendment was a result of the increased 
fluidity of personnel: the registration 
process takes a few years—during or af-
ter which time the inventor may have 
left RIKEN—making the payment pro-
cedure ineffective.
(C) Raising Awareness. RIKEN has made ef-
forts to promote IP by raising awareness. 
Seminars and consultations about vari-
ous IP rights issues are regularly held in 
not only the headquarters but also the 
branch institutes and centers. Because 
the frequent turnover of employees hin-
ders the diffusion of knowledge about 
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RIKEN’s IP policy and strategy, RIKEN 
requires newcomers to attend specific 
explanatory lectures that are held several 
times a year. This is in addition to the 
regular IP rights seminars. As a conse-
quence of those efforts, the number of IP 
rights applications by RIKEN has been 
increasing. 
2. Partnership with industry. RIKEN belongs 
to the academic sector. It makes a public 
contribution by providing the seeds of in-
novation to industry. Since becoming an 
independently managed administrative in-
stitution, generating profits through licens-
ing has become increasingly significant for 
RIKEN. Its IP strategy focusing on part-
nerships with industry is a tool that allows 
RIKEN to generate social and economic 
returns simultaneously.
  Such partnerships involve not only tech-
nology transfer but also research collabora-
tion. CIPS is highly involved in coordinat-
ing, funding, providing research space, and 
hosting industrial researchers for the col-
laboration. One of the programs RIKEN/
CIPS formally organizes is the Fusional 
Cooperative Research Program. Started in 
2004, the program transfers researchers 
employed by private companies to RIKEN 
to conduct collaborative research for several 
years. Under contract with RIKEN, the re-
searchers can become team leaders of their 
research in RIKEN. RIKEN has published 
on its Web site70 a database of its researchers 
who have registered for this program. The 
database includes their research activities 
and interests. A private company interested 
in a RIKEN researcher and his/her research 
applies for the program with a collabora-
tive research proposal. The collaborative 
research under the program enables the 
rapid commercialization of the technol-
ogy by the parallel creation of “seeds” and 
“needs” from the very beginning of the re-
search planning stage. RIKEN contributes 
research expertise and facilities, and the pri-
vate company contributes commercializa-
tion expertise and shares management tools 
to increase efficiencies. Expenses are borne 
by both RIKEN and the private company. 
The contracted term is generally five years. 
As of April 2006, ten teams have been cre-
ated and are pursuing collaborative research 
under the program. 
3. Promotion of exploitation. RIKEN has 
adopted some strategies to promote the ex-
ploitation of inventions that its researchers 
generate. These strategies include dissemi-
nating information about patents owned 
by RIKEN, coordinating and facilitat-
ing technology transfer, and the “RIKEN 
Venture” system.
(A)  Disseminating information about pat-
ents owned by RIKEN. RIKEN has ac-
tively tried to promote the exploitation 
of inventions by disseminating informa-
tion about its patents, which is expected 
to increase private companies’ abilities 
to find and exploit them. Information is 
disseminated via the Journal of RIKEN 
Patents published by CIPS. A patent data-
base is published online at the R-BIGIN 
(RIKEN-Business Information for Global 
IP Network) Web site, and RIKEN also 
exhibits its technologies at external fairs 
relating to technology transfer.
(B) Coordination of technology transfer. 
RIKEN deploys several coordinators in 
CIPS to increase the transfer and exploi-
tation of its technology. Similar to the 
patent liaison staff, the coordinators in-
clude current private sector employees, 
who have been temporarily transferred 
to RIKEN, and experienced retirees from 
the private sector. Their responsibili-
ties are to search for licensees, negotiate 
terms, and conclude licensing contracts. 
In addition to the coordinators, RIKEN 
outsources contracts to some large enter-
prises to coordinate technology transfer 
with private companies. These enter-
prises have varied, detailed information 
about potential licensees, and this exter-
nal coordination facilitates technology 
transfer from RIKEN to industry.
 
CHAPMAN & WATANABE
1640 | HANDBOOK OF BEST PRACTICES
(C)  The RIKEN Venture system.
 Set up in 1998, RIKEN Venture system 
supports and encourages employees to 
establish and operate private compa-
nies based on inventions generated at 
RIKEN. In addition to enabling RIKEN 
employees to retain a post at the private 
company, RIKEN provides preferential 
treatment to the company:
– RIKEN licenses its patent rights relat-
ing to the invention exclusively to the 
company
– RIKEN allows the company to utilize 
its research space and facilities for col-
laborative research with RIKEN
– RIKEN provides the company with 
office space and equipment for man-
agement at preferential rates
These advantages make it easier for in-
ventors to exploit and distribute their 
own inventions to the public, which cre-
ates yet another incentive for researchers 
to make or adapt practical, profitable 
inventions. Additionally, innovations 
that existing companies find difficult 
to exploit can be given another chance 
by their inventors. The program offers 
support to each company for five years, 
which can be extended for an additional 
five years. As of July 2005, the program 
has supported 16 companies: seven are 
in the field of biomedicine. 
7.3		 RIKEN	BioResource	Center	(BRC)
In 2001, RIKEN founded the BioResource Center 
(BRC)71 at the Tsukuba Research Institute. After 
a gene bank service was established at RIKEN in 
1987, the BRC was founded to expand the scope 
of the collected resources. The Japan Collection 
of Microorganisms, which had initially been es-
tablished at RIKEN headquarters, was integrated 
within the BRC in 2004. Integration enabled 
the BRC to offer a distribution service for a wide 
range of resources including animals, plants, cells, 
genes, and microorganisms. The RIKEN BRC has 
been supported by Japan’s national bioresources 
project. 
The principal contribution of the BRC to 
life sciences research is to collect, preserve, breed, 
and distribute biological resources to and from 
researchers in Japan and overseas. Other BRC ac-
tivities include the development of bioresources 
and new technologies to increase their value. The 
BRC has made a great effort to foster transfers 
of bioresources for both collection and distribu-
tion since its foundation. All transfers are carried 
out based on the conclusion of MTAs, for which 
RIKEN has created its own forms and procedures. 
Although some details vary among the types of 
resources, the grounds for transfer are generally 
as follows:
1. Collection (resources are deposited or as-
signed by originators).
– An MTA must be concluded between 
RIKEN BRC and the originator for the 
deposit/assignment. The MTA form for 
deposit or assignment is provided by the 
BRC.
– The originator is entitled to choose to 
deposit the resources and retain the IP 
rights to the resource or to assign the re-
source with the IP rights to RIKEN.
– Whether it is a deposit or an assignment, 
resources are collected by the BRC with-
out any remuneration to the originator. 
(RIKEN bears the expenses of shipment 
for collection.)
– In addition to the requirements set by 
RIKEN BRC, a third party’s minimum 
requirements for using resources, such as 
acknowledgement in publication of re-
search results, can be added to the MTA 
by the originator. 
– By the deposit/assignment, the origina-
tor can, for no charge, be credited and 
provided with other resources collected 
by the BRC, according to the number of 
resources that he or she provides.
2. Distribution (resources are transferred from 
the BRC to a third party [recipient/user] 
for their research use).
– An MTA between RIKEN BRC and a 
user must be concluded and signed for 
the distribution to occur. The MTA 
form is provided by the BRC.
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– The user bears the expenses of shipping, 
handling, part of production, and other 
costs related to preparing or distributing 
the resources. Allocations of costs are dif-
ferentiated between public and private 
partners, with private partners assuming 
the greater burden.
– The user is required to specify a research 
theme for which the resources are used. If 
resources are used for another theme, pri-
or notification to the BRC is required.
– When research results that used the 
resources are published, the user is re-
quired to make it clear that the resources 
were provided by RIKEN BRC.
– The user cannot transfer or make the re-
sources available to other parties for any 
purposes.
The BRC is becoming recognized as one 
of the major bioresource centers in 
the world. Furthermore, the BRC/
Experimental Animal Division is one of 
the founding members of the Federation 
of International Mouse Resources 
(FIMRe),72 along with such outstanding 
mouse resource centers as the Jackson 
Laboratory (U.S.) and European Mouse 
Mutant Archive (EMMA). The FIMRe 
is a collaborating consortium group of 
mouse repository and resource centers 
worldwide whose collective goal is to 
archive and provide to the research com-
munity strains of mice, as cryopreserved 
embryos and gametes, embryonic stem 
(ES) cell lines, and live breeding stock. 
The mouse-strain resources deposited 
or assigned to the RIKEN BRC—and 
related pieces of information—are regis-
tered and published on the database of 
the FIMRe, known as the International 
Mouse Strain Resource (IMSR),73 
Registration promotes and facilitates 
global access by researchers to BRC re-
sources. Additionally, the RIKEN BRC 
receives complementary support for the 
specific management of IP protected 
microorganism collections from NITE, 
which is under supervision of METI. 
This interagency collaboration facilitates 
the coordination of R&D.
8.	 ConCluSIon
Japan’s patent system was established at the end 
of its national isolation policy. The system is rea-
sonably effective. Emphasizing the importance 
of national and institutional IP management in 
its policy and strategy for national development 
over the last decade, the government has revised 
aspects of the patent law and reformed related 
systems, including those related to national uni-
versities and public institutions. Some of the 
revisions and reforms have been geared towards 
international harmonization and the adoption of 
precedence established in other countries. Others 
have been intended to establish sui generis laws 
and systems to suit the country’s unique interests. 
Despite this progress, some issues and arguments 
have yet to be conclusively addressed. 
Regarding collaborations between indus-
try and academia, for example, the reform of 
national universities and public institutions in 
the early 2000s has catalyzed partnerships, largely 
because of the expanded freedom and responsi-
bilities given to universities by the government. 
Over the last decade, universities have established 
TTOs in order to create, transfer, and exploit IP 
rights derived from their research projects, an 
increasing number of which are carried out in 
partnership with industry. Nevertheless, human 
resource shortages plague the system. Personnel 
with expertise in both legal and technical aspects 
are especially in demand.
Since the early stages of Japan’s industrial 
development, the Patent Law has made provi-
sions for employees’ inventions. Over the last 
decade, an increasing number of institutions 
and companies have recognized the significance 
of rules and regulations for employees’ inven-
tions and taken steps to establish them. This has 
been supported by the new government’s policy 
and strategy: a Nation Built on IP. In 2005, the 
provisions (Article 35 of the patent law) were 
amended in favor of inventors so that the cri-
teria for remuneration for inventions would 
be reasonable for them. Since a few years prior 
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to the amendment, the number of lawsuits in 
which a former employee sued his or her for-
mer employer because of dissatisfaction with 
their remuneration has increased. Some lawsuits 
have been settled, but various questions remain 
unresolved.
Japan’s IP system and management is in some 
ways unique in relation to the health and agricul-
ture sectors. IP rights for health care have been 
recognized as publicly shared knowledge and skills 
with equitable properties rather than personalized 
trade secrets or proprietary knowledge and skills, 
although some incentives have been furnished to 
enable the sharing and development of individual 
invention and know-how. Agriculture has tradi-
tionally been in the public domain, while specific 
technology has been protected as individual trade 
secrets. In the past, crop varieties were recognized 
as common heritage. Due to plant variety protec-
tion law and the recent paradigm shift in inter-
national and domestic arenas affecting IP laws, 
however, the use and status of the varieties has 
been in question, with business incentives rather 
than the public good driving the changes. 
Overall, the stakeholders in health and ag-
riculture will recognize IP increasingly in Japan. 
Diverse ways of adapting IP protection are being 
considered, and a sui generis approach may be ad-
opted to tackle many subjects. Public awareness 
is likely to be promoted through public engage-
ment in IP management, particularly in health 
and agriculture. ■
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(1)  The effects of the patent right shall not extend to the 








(A)  The theory that has been the most widely accepted is the one 
that limited the experiment or research applicable to Article 
69 (1) to those for the purpose of  “progress in technology.” 
(B)  Many theoreticians assert that private companies cannot use 
others’ patent rights in clinical trials (for obtaining regulatory 
approval for manufacturing generic medicines), but past legal 
judgments have been variable and reflected both sides of the 
argument. The Supreme Court’s judgment in 1999, however, 
set a legal precedent that confirmed that trials for the purpose 
of obtaining regulatory approval should be exempt.
(C) Historically, in determining cases of exemption, the courts 
have not distinguished between university and industry 
(private companies). That is, there is no exemption for 
universities because of their academic and educational 
nature. However, based on the principle that experiment/
research aimed at technology advancement is exempted 




It shall not be an act of infringement to make, use, offer to 
sell, or sell within the United States or import into the United 
States a patented invention (other than a new animal drug or 
veterinary biological product [as those terms are used in the 
Federal Food, Drug, and Cosmetic Act and the Act of March 4, 
1913] which is primarily manufactured using recombinant DNA, 
recombinant RNA, hybridoma technology, or other processes 
involving site specific genetic manipulation techniques) 
solely for uses reasonably related to the development and 
submission of information under a Federal law which regulates 
the manufacture, use, or sale of drugs or veterinary biological 
products.
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united	States
(continued)
(A)  Experiment or research using patented products for commercial 
purposes is considered to be an infringement. The Federal 
Circuit Court of Appeals has reconfirmed in several cases 
that the scope of exemption from infringement in relation to 
experimental use should be very narrow.
(B)  The case of Eli Lilly & Co. vs. Medtronic, Inc. in 1990 confirmed 
that the Bolar Provision (inserted into U.S. patent law in 1984) 
covers clinical trials using not only medicines but also medical 
tools, but the application of the Bolar Provision is limited to 
the development and submission of information to the FDA 
(Food and Drug Administration).
(C)  With regard to experimental use in universities, there have been 
very few cases. One is the case of Madey vs. Duke University in 
2002, which confirmed that the scope of exemption should be 
very narrow. The exemption was not applied in this case.
european	union
united	Kingdom
(A)  Experiment or research using patented products for 
commercial purposes are distinguished between those trials in 
which products are merely being tested for quality, which are 




Rights conferred by a European patent: (3) Any infringement of 
a European patent shall be dealt with by national law.
CPC (Community Patent Convention), Article 27, Limitation of 
the effects of the Community patent. The rights conferred by a 
Community patent shall not extend to:
(a)   acts done privately and for noncommercial purposes;
(b) acts done for experimental purposes relating to the 
subject matter of the patented invention; etc.
patent	Act	1977
Article	60
Section	 5. An act which, apart from this subsection, would 
constitute an infringement of a patent for an invention shall 
not do so if:
(a) it is done privately and for purposes which are not 
commercial;
(b) it is done for experimental purposes relating to the 
subject matter of the invention, etc.
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germany
(A)  Experiment or research using patented products either to 
obtain information regarding the subject of the patented 
products (for noncommercial use) or to enable scientific 
investigation is exempted from patent infringement. From 
the viewpoint of public benefit, patent rights do not extend to 
cases interfering with technological progress.
(B)  In the Clinical Tests II case in 1997, it was confirmed that trials 
to clarify areas of uncertainty or trials aiming at acquisition 
of new knowledge relating to the subject of the patented 
products fall under the scope of exemption. 
(C)  There have been no cases establishing precedent relating to 




(A) The case of Babolat vs. Redeye (1992) set a precedent that 
experimental use for the purpose of evaluating the commercial 
effect of a patented product on consumers would be considered 
an infringement.
to a third party or used for quality enhancement in other 
products provided to a third party, which are considered 
within the scope of infringement.
(B)  The trials and manufacturing of patented products for the 
purpose of obtaining regulatory approval is out of the scope 
of exemption and regarded as patent infringement.
(C)  There have been no cases establishing precedent relating to 





The effects of a patent shall not extend to:
1.  acts done privately and for noncommercial purposes;
2.  acts done for experimental purposes relating to the 
subject matter of the patented invention; etc.
Intellectual	property	law
Art.	l.	613-5.	(Amended	in	1978)
The rights afforded by the patent shall not extend to:
(a)  acts done privately and for noncommercial purposes;
(b)  acts done for experimental purposes relating to the subject 
matter of the patented invention; etc.
CHAPMAN & WATANABE
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Republic	of	Korea
(A) There have been no cases establishing precedent relating to 
experimental use.
(B) There have been no cases establishing precedent relating 
to clinical trials. Theoreticians regard this as exempt from 
infringement.
(C) There have been no cases establishing precedent relating to 
experimental use in universities.
Box	1	(continued)
China
(A) Exemption is not always applicable in cases relating to 
experimental use in general R&D activities. Exemption from 
infringement applies when experimentation relates to 
technical appraisal of patent rights and regarding the patented 
technology per se.
(B)  It is generally considered that clinical trials for the purpose 
of obtaining regulatory approval are not an infringement if 




(B) The cases of the Wellcome Foundation Ltd. vs. Parexel 
International, Flamel Technologies & Créapharm (2001) and 
Science Union & Servier vs. Expanpharm (2002) confirmed 
that trials for the purposes of obtaining regulatory approval 
for substitutes of marketed medicines (that is, generics) 
and of obtaining regulatory approval fall under the scope of 
exemption.
(C)  There have been no cases establishing precedent relating to 
experimental use in universities.
patent	law	96
(1)  The effects of the patent right shall not extend to the 
following:
(i)   working of the patented invention for the purpose of 
research or experiment; etc.
patent	law,	Article	63
None of the following shall be deemed an infringement of the 
patent right:
(4)  Where any person uses the patent concerned solely for the 
purposes of scientific research and experimentation.
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Box	1	(continued)
(A)  There have been no cases establishing precedence or coherent 
theory regarding the exemption of experimental use as 
Singapore’s patent system and law is rather young (since 
1994).
(B)  The Amendment to the Patent Act in 2004 exempted clinical 
trials for the purpose of obtaining regulatory approval.
(C)  There have been no cases establishing precedent relating to 
experimental use in universities.
India
Singapore
(C) There have been no cases establishing precedent relating to 




66.-(2)	 An act which, apart from this subsection, would 
constitute an infringement of a patent for an invention shall 
not do so if:
(a) it is done privately and for purposes which are not 
commercial;
(b) it is done for experimental purposes relating to the subject 
matter of the invention;
(h) it consists of the doing of any thing set out in subsection 
(1) in relation to the subject matter of the patent to support 
any application for marketing approval for a pharmaceutical 
product, provided that any thing produced to support the 
application is not:
   (i)  made, used, or sold in Singapore; or 
   (ii) exported outside Singapore, 
other than for purposes related to meeting the requirements 
for marketing approval for that pharmaceutical product; etc.
patent	Act
47. The grant of a patent under this Act shall be subject to the 
condition that:
(3) any machine, apparatus or other article in respect of which 
the patent is granted or any article made by the use of 
the process in respect of which the patent is granted, 
may be made or used, and any process in respect of which 
the patent is granted may be used, by any person, for the 
purpose merely of experiment or research including the 
imparting of instructions to pupils; and etc.
(Continued	on	next	page)
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TRIpS
TRIpS	Article	30
Exceptions to Rights Conferred
Members may provide limited exceptions to the exclusive 
rights conferred by a patent, provided that such exceptions 
do not unreasonably conflict with a normal exploitation of 
the patent and do not unreasonably prejudice the legitimate 
interests of the patent owner, taking account of the legitimate 
interests of third parties.
Box	1	(continued)
India
(continued) 107A. For the purposes of this Act:
(a) any act of making, constructing, using, selling, or importing 
a patented invention solely for uses reasonably relating to 
the development and submission of information required 
under any law for the time being in force, in India, or in a 
country other than India, that regulates the manufacture, 
construction, use, sale, or import of any product; 
… shall not be considered as an infringement of patent rights.
(A)  There have been no cases establishing precedent or coherent 
theory regarding the exemption of experimental use.
(B)  The Amendment to the Patent Act in 2002 (Sec. 107A) exempted 
clinical trials for the purpose of obtaining regulatory approval.
(C)  There have been no cases establishing precedent relating to 
experimental use in universities.
Source: Tokkyohatsumei-no enkatsu-na shiyou-ni kakawaru shomondai-ni tsuite (Report on issues 
relating to effective use of patented invention)47
ABSTRACT
This chapter provides an analytical overview of technol-
ogy transfer in South Africa. Technology transfer offices 
(TTOs) are relatively new in the country, and not all 
South African universities have explicit IP policies. The 
chapter discusses and analyzes the current performance 
of TTOs. Among other things, the results show that the 
income accruing to universities from technology transfer 
activities is not substantial, that there is a time lag before a 
TTO can generate sufficient income to become self-sup-
porting, and that the performance of TTOs at different 
institutions varies widely. A history of public policy ef-
forts to strengthen technology transfer in South Africa is 
provided, and the government’s 2006 publication of the 
Framework for Intellectual Property Rights from Publicly 
Financed Research receives considerable analysis. Other 
measures being undertaken to support technology trans-
fer are also discussed, as are the problems that such efforts 
still face.
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that a handful of institutions set up TTOs. 
There are currently six universities and sci-
ence councils with well-established technol-
ogy transfer activities.1 The main catalyst for 
setting up these TTOs appears to have been 
an awareness of international trends—the first 
offices were established before any meaningful 
attempts by government to better utilize re-
search outputs. Some TTOs function as dedi-
cated offices within their organizations. They 
are sometimes responsible for other functions, 
such as sponsored research, development, con-
tract management, or industry liaison, and ac-
tivities are sometimes dispersed among some 
of these offices. Other institutions have set up 
associated companies that are wholly or partly 
owned by the organization concerned to per-
form their technology transfer activities. In one 
case, a company was set up to manage jointly 
the IP from a science council and a university, 
but the partnership has since dissolved. The 
number of TTOs continues to grow. Several 
institutions have newly established offices, 
and those without TTOs are in the process of 
setting up offices. Institutions without TTOs 
either contract external service providers for 
assistance on a case-by-case basis or do not 
actively engage in technology transfer as an 
institution, although individual researchers or 






Institutional technology transfer offices 
(TTOs) are a relatively new development in 
South African universities and research orga-
nizations and are not yet found in all research 
institutions. While some efforts were made to 
promote technology transfer activities as early 
as the 1980s, it was not until the late 1990s 
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1.2 Ownership	of	intellectual	property
1.2.1  Within	the	institution
Pending the introduction of legislation govern-
ing the ownership of IP developed by staff and 
students in the course of university activities, 
not all South African universities have explicit IP 
policies. Where policies are in place, these are not 
uniform across institutions. In some cases, IP is 
owned by individuals (unless specifically assigned, 
for example as a condition for the award of certain 
funding); in other cases, the university owns IP, 
depending on internal policies, conditions of em-
ployment, and student rules. Ownership rights of 
student IP vary widely, even for universities with 
clear policies that allow for institutional owner-
ship of staff IP. When rights are assigned to the 
university, proceeds generated from the exploita-
tion of IP are generally shared between the insti-
tution (possibly divided among multiple entities 
within the institution, such as research grouping, 
department, faculty, and to the central adminis-
tration) and the individual inventor/s concerned, 
according to a formula set out in the IP policy.
1.2.2  In	respect	of	third	parties
While most institutions prefer to retain owner-
ship of their IP and facilitate exploitation through 
licensing, and while most make every effort to ne-
gotiate this whenever possible, research sponsors 
frequently insist upon the assignment of IP as a 
key condition of a research funding agreement. 
This applies both to certain public sector and pri-
vate sector funders, and may or may not include an 
obligation on the part of the assignee to share with 
the institution any future benefits derived from 
the exploitation of the IP. Ownership policies for 
IP that arises from government-funded research 
vary widely, ranging from unfettered ownership 
by the research institution, to shared ownership 
between the research institution and the funding 
agency, to full ownership by the funding agency, 
with benefit-sharing mechanisms applicable in 
some cases. The trend is for government entities 
to take a greater interest in IP matters than in the 
past, which often leads to more complicated fund-
ing contracts and longer negotiation periods to fi-
nalize them and release the research funding.
Industry research sponsors typically insist on 
owning technology that arises from research they 
fund, on the grounds that they have financed it. 
This does not, however, take into account the fact 
that universities also contribute to supporting 
these projects financially, because universities do 
not generally apply principles of full cost recovery 
when pricing these contracts. Research universi-
ties are therefore grappling with how to cost and 
price research contracts more effectively without 
alienating industry funders.
Companies wishing to access technology de-
veloped at a research institution that they have 
not funded are more likely to be open to a licens-
ing arrangement, depending on the technology 
and the license terms.
1.3 Performance	of	South	African	TTOs
No comprehensive benchmarking of the perfor-
mance of South African TTOs has yet been per-
formed.2 Table 1 provides rough data and estimates 
for four universities offering technology transfer 
services. These data have been compiled from an-
ecdotal evidence and collegial information sharing 
among technology transfer professionals. While the 
data is incomplete (lacking some of the most impor-
tant benchmarks, such as invention disclosures and 
patenting activity) and is not necessarily fully com-
parable in all cases across the surveyed institutions, it 
provides initial evidence to demonstrate that South 
African activity corresponds with experience else-
where. Among other things, the Table indicates that 
the income accruing to universities from technol-
ogy transfer activities is not substantial, that there 
is a time lag before a TTO can generate sufficient 
income to become self-supporting, and that the per-
formance of TTOs at different institutions can vary 
widely. This is in line with what might be expected 
for a technology transfer system in its early days.
1.4 The	Southern	African	Research	and	
Innovation	Management	Association
Established in 2002, the Southern African 
Research & Innovation Management Association 
(SARIMA) is a stakeholder organization that 
provides a platform for individuals from govern-
ment, academia, and industry, with an interest in 
research and innovation management, to interact 
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on common issues. SARIMA’s objectives include 
the professional development of those persons in-
volved in managing research and in the creation of 
intellectual capital; promotion of best practices in 
the management and administration of research 
and in the use of intellectual capital to create val-
ue for education, public benefit, and economic 
development; advocacy of appropriate national 
and institutional policy to support research and 
generate intellectual capital; and advancement of 
science, technology, and innovation.3 SARIMA 
has links with several local, African, and interna-




With a new democratic regime in place since 
1994, policy developments in South Africa have 
been numerous. Much attention has been given 
to supporting innovation, in acknowledgement 
of its critical role in promoting development, 
enhancing competitiveness, and improving qual-
ity of life. The 1996 White Paper on Science and 
Technology established the concept of a National 
System of Innovation (NSI).4 The paper created 
the framework for a set of key enabling policies 
and strategies to inform the strategic develop-
ment of science and technology in South Africa. 
In an effort to sustain the White Paper’s vision for 
an effective, well-managed NSI and to improve 
the impact of the policy, the National R&D 
Strategy was released in 2002. This recommended 
specific strategic interventions to address identi-
fied weaknesses, including the commitment of 
substantial additional resources from govern-
ment to support research and innovation.5 Under 
the umbrella of the R&D strategy, various other 
initiatives have emerged, including the National 
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Strategy.7 These aim to build on and enhance ex-
isting strengths in these key sectors, while devel-
oping human resources and generating research 
outputs to help South Africa to become more 
globally competitive and address some of its so-
cio-economic problems. Of particular relevance 
to technology transfer practitioners was a pro-
posal contained in the National R&D Strategy 
to introduce measures to encourage better protec-
tion and exploitation of IP arising from publicly 
funded research projects. This has recently been 
expanded upon with the release in 2006 of the 
Framework for Intellectual Property Rights from 
Publicly Financed Research.8
This framework is intended to bridge the 
“innovation chasm,” which describes the gap in 
South Africa between knowledge generators (in 
particular, universities and research institutions) 
and the market. Although research organizations 
are performing some high-quality basic and stra-
tegic research, and while industry has some rela-
tively sophisticated manufacturing operations, 
South African technology-led companies typi-
cally access their technology from abroad—lo-
cal innovation has had relatively little impact on 
economic growth. The framework calls for a con-
sistent approach to protecting IP developed with 
public financing, based on good practice globally 
while remaining responsive to the local context. 
Institutions will be required to put in place IP 
policies consistent with this legislation within a 
limited timeframe after the legislation takes ef-
fect. This will ensure a level of harmonization 
across institutions. One of the more significant 
provisions is that these policies would obligate 
employees and students to disclose all IP that 
they develop.
The framework draws heavily on the U.S. 
Bayh-Dole Act and proposes the adoption of sev-
eral similar provisions. These include:
• conferring on institutions the responsibility 
to seek protection for their IP in exchange 
for the right to own and exploit it
• a reporting duty to a designated government 
agency about IP management activity
• an obligation to share revenues earned from 
the exploitation of IP with the individual 
inventors or creators of the IP concerned
• a right for government to a “free license” to 
IP should this be in the national interest
• a preference for licensing to local compa-
nies and small business
Additional provisions are proposed to address 
unique local conditions. In this vein, a further 
preference for licensing to Broad-Based Black 
Economic Empowerment (BEE) companies is 
recommended.9
A short public consultation process was car-
ried out to give stakeholders the opportunity to 
comment on the framework. Legislation based 
on the framework, and taking into account re-
sponses received as part of the public consultation 
process, was being drafted at the time of writing.
2.2 Innovation	Fund
The Innovation Fund is one of the main agencies 
responsible for implementing the R&D Strategy. 
It aims to promote competitiveness by investing 
in “technologically innovative R&D projects, 
the effect of which will be new knowledge and 
widespread national benefits in the form of novel 
products, processes or services.”10
In its early days, the Innovation Fund was es-
sentially a funding agency that supported research 
projects carried out by consortia (typically a com-
bination of universities, science councils, and/or 
firms).11 More recently, though, it has assumed 
a more proactive role in promoting technology 
transfer and assisting eligible South African insti-
tutions and researchers in their technology trans-
fer activities. 
The Intellectual Property Management 
Office (IPMO) and the Innovation Fund 
Commercialization Office (IFCO) are units with-
in the Innovation Fund that support IP manage-
ment and technology commercialization, respec-
tively. They also assist in building capacity for 
the exploitation of IP, having co-hosted a series 
of training courses for technology managers with 
MIHR ( the Centre for the Management of IP in 
Health Research and Development) and other or-
ganizations. An internship program in partnership 
with a multinational business consulting and ad-
visory service firm has also been put in place.  The 
Innovation Fund holds subscriptions to patent 
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and marketing databases that can be accessed by 
universities and public research organizations at 
no cost or at subsidized rates. The Patent Support 
Fund allows universities and science councils to 
reclaim up to 50% of their patent expenditures 
annually. As an incentive to increase patenting 
activity, the Patent Incentive Scheme makes cash 
awards to inventors who have assigned their rights 
in an issued patent to a South African university 
or public research organization. The Innovation 
Fund has also provided financial support for vari-
ous ad hoc initiatives, such as the establishment 
of university technology transfer offices and a 
university chair in intellectual property. It is pro-
posed that the Innovation Fund be the designated 
reporting agency responsible for overseeing the 
implementation of the IP framework.
Other support measures for commercializing 
R&D include several directed-funding programs 
for research, development, and innovation, ac-
cessed on a competitive basis, funds from these 
programs are accessed on a competitive basis. 
Business incubators and government venture-




Technology transfer in South Africa shows en-
couraging signs of progress:
• A handful of TTOs have been operating for 
several years and are now regarded as estab-
lished entities within their organizations.
• Several new TTOs have recently been set 
up or are in the process of being launched.
• A track record of licensing deals and spin-
out companies is gradually being built up.
• A core exists of professional, experienced 
technology transfer practitioners who are 
enthusiastic about sharing their skills with 
newcomers to the profession.
• A vibrant stakeholder organization provides 
a platform for networking and professional 
development in the field.
• Links have been forged that strengthen 
research collaborations and technology 
transfer partnerships with organizations 
elsewhere on the African continent and 
internationally.
• All of this is underpinned by support from 
government. 
3.2 Constraints
Despite these advances, however, it must be ac-
knowledged that technology transfer performance 
can, and indeed must, be improved. It is therefore 
instructive to identify the constraints and discuss 
how to overcome them.
3.2.1  Few	invention	disclosures
South African TTOs generally receive a weak 
flow of invention disclosures. There are several 
reasons for this. Some overburdened academics 
juggling heavy teaching loads, research respon-
sibilities, and administrative duties are reluctant 
to take on the additional obligations that fol-
low an invention disclosure. Other researchers 
are unaware or skeptical of the role of the TTO. 
Research funding levels are also fairly low, which 
limits overall research output (and thus the subset 
with commercialization potential). Furthermore, 
the typical funding mix of South African univer-
sities leaves them with a relatively small propor-
tion of unencumbered IP. Few South African uni-
versities substantially contribute to research from 
their own internal budgets. Government funding 
makes up a relatively small proportion of total re-
search expenditure, and so the greatest share of 
research funding comes from external sources, 
including local and international companies, 
philanthropic organizations, development agen-
cies, and nongovernmental organizations. The 
research projects carried out with such funding 
are governed by research agreements that, among 
other things, lay out terms for the use and owner-
ship of project IP. Commercial entities frequently 
insist on the assignment of any project IP, and 
even not-for-profit funding entities are increas-
ingly demanding more stringent IP provisions 
(although generally for different reasons, such as 
ensuring their own freedom-to-operate for utiliz-
ing or disseminating the results of the research 
they fund).
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The rate of invention disclosure could likely 
be improved to some extent by proactive actions 
on the part of the TTO (for example, more effec-
tive marketing of its services to potential clients 
within the institution, more frequent IP audits 
of research groups, or the introduction of inter-
nal procedures for compulsory disclosure prior 
to publication). But ultimately, more examples 
of successfully commercialized technologies are 
needed to persuade skeptical researchers that dis-
closing inventions is worthwhile.
3.2.2 High	costs	associated	with	patenting
Patenting costs are a problem. A new TTO typi-
cally struggles to secure a reasonable budget allo-
cation for patent filing and prosecution. The TTO 
is sometimes viewed as competing with research-
ers, many of whom would prefer this funding to 
go directly to research. Patent protection is rarely 
worthwhile if pursued only in South Africa be-
cause the local market is not very large. The vola-
tility of the currency makes it difficult to budget 
properly for international patent filing. Moreover, 
because of the pressure academics face to publish 
their research, patenting often takes place earlier 
than would be optimal, with the result that the 
technology is insufficiently developed to interest 
a licensee by the time it must be filed internation-
ally. Universities cannot rely on licensees to as-
sume foreign patent costs; at best, they can hope 
to be reimbursed at a later date, if and when the 
technology is finally licensed. TTOs are therefore 
severely constrained in terms of the number of 
patenting opportunities they can pursue.
This has been partially addressed by the 
Innovation Fund’s Patent Support Fund, which al-
lows universities and public research organizations 
to reclaim up to 50% of their expenditure on pat-
ent-related costs retrospectively.
3.2.3 Limited	capacity
Local training opportunities are limited. There 
are only a few experienced technology transfer 
practitioners to act as mentors and share good 
practice. At the same time, the number of new 
entrants and available positions in the profession 
are too few to sustain specialized extended train-
ing programs. As a result, capacity-building ini-
tiatives consist of short courses that try to draw a 
wide audience by covering a broad range of gen-
eral subject matter. Opportunities for continuing 
education on more advanced topics are rare and 
are often included as part of courses with a large 
proportion of beginners’ content.
Longer-term capacity-building programs 
are being investigated, and some organizations 
have set up internship programs, but the system 
is probably still too immature to assess future 
needs accurately. The costs of an ambitious ded-
icated program will only be justified if there is a 
large enough pool of candidates. It is difficult to 
determine how quickly the system will be able 
to absorb new entrants as well as to estimate 
the number of technology transfer professionals 
needed to establish and sustain an effective sys-
tem. Much of this will depend on when institu-
tions without TTOs begin requiring technology 
transfer services (whether through an institu-
tional TTO or via external service providers). 
Ongoing monitoring and refinements are likely 
to be required. Meanwhile, training opportuni-
ties overseas are also being explored.
3.2.4 Unclear	expectations	and		
objectives	for	TTOs
The rationale for university technology transfer is 
frequently misunderstood, which makes it diffi-
cult to obtain support from the broader university 
community. Income-generating objectives often 
assume greater importance than they should, and 
revenues accruing to an institution from tech-
nology transfer activities remain one of the main 
measures of success, despite the fact that most 
institutions explicitly acknowledge that income 
generation is not a major driver of their technol-
ogy transfer activities. Among other things, this 
leads some academics to criticize the TTO on the 
ideological grounds that universities should not be 
undertaking commercial activity. Others resist the 
idea that the university has any right to IP that they 
feel entitled to own personally. Executive manage-
ment often has unrealistic expectations about the 
financial returns that are likely to be generated by 
the TTO. When these fail to materialize quickly, 
they withdraw support or redirect the focus of 
the TTO. Clear objectives must therefore be set 
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(preferably in conjunction with stakeholders) and 
communicated to all frequently and effectively.
3.2.5  Difficulties	with	IP	management		
in	the	life	sciences
The IP landscape has become increasingly com-
plex, particularly with respect to biotechnological 
inventions. Available expertise, however, is limit-
ed. Only a handful of local patent attorneys have 
life sciences training, and those with advanced 
degrees are even rarer. Freedom-to-operate con-
straints are often encountered. Access to propri-
etary biological material, reagents, or tools for 
research purposes (for example, under an MTA) 
could facilitate the development of a new inven-
tion, but negotiating the rights for commercial 
use may prove too time-consuming or compli-
cated to pursue, or the terms offered might be 
prohibitive. 
3.2.6 Limited	licensing	opportunities
Licensing opportunities for existing compa-
nies are lacking. Domestic firms often lack the 
markets or distribution channels for viable ex-
ploitation. Without a track record or personal 
contacts to facilitate meaningful links, market-
ing to overseas companies can be difficult. At 
the same time, spinout opportunities for new 
businesses are few and far between. Financing 
is not easily raised from risk-averse financial in-
stitutions and venture capitalists, who are par-
ticularly wary of biotechnology because they 
do not understand it. Angel investors are few 
and far between.
4.	 ConCluSIon
Clearly, the impact of the IP Framework will be 
one of the most critical factors shaping the fu-
ture prospects of South African technology trans-
fer. Still, the ultimate success of this initiative is 
likely to depend on the implementation of details 
that are not provided in the Framework. These 
will have to be sufficiently flexible to accommo-
date the varying levels of resources, expertise, and 
capacity in research, research management, and 
technology transfer in different organizations.
Expectations will have to be managed care-
fully. A growing body of evidence shows that 1) 
substantial investments in technology transfer are 
needed to generate downstream benefits, 2) there 
is typically a significant time lag before net bene-
fits are realized, and 3) the distribution of returns 
is very skewed (for example, analysis of AUTM 
surveys).12 But in South Africa it remains a fairly 
common perception that the main motivation 
for undertaking technology transfer activities at 
a university is to generate income. This is fortu-
nately not a universal perception, but technology 
transfer practitioners, government, and agencies 
such as the Innovation Fund will have to dispel 
such misperceptions via effective communication 
strategies.
One of the greatest benefits that the envis-
aged legislation might provide would be to align 
the IP policies of public funding agencies, which 
would reduce the transactions costs of navigating 
the complex and varied structures that are cur-
rently in place and that often require protracted 
negotiations. It is not apparent, however, that the 
legislation will achieve this.
Similarly, by providing clear guidelines for 
the use and ownership of IP developed at pub-
lic research institutions with industry funding, 
negotiations around sponsored research agree-
ments could be simplified and expedited. The 
Framework proposes a default position of own-
ership by the public organization, which can be 
altered if certain criteria are met. This establishes 
a useful starting point, as long as the process for 
exceptions to the default position is not made 
too cumbersome. Private-sector funding rep-
resents a higher proportion of overall research 
funding in South Africa than in many other 
countries (estimated at 28% overall according 
to CENIS13), and universities will want to avoid 
creating disincentives for their industry research 
collaborators and sponsors. At the same, such re-
search support comes at a price because it seldom 
fully recovers costs and overhead charges. The IP 
Framework will strengthen the bargaining posi-
tion of institutions in this respect by making it 
easier to price research contracts appropriately.
The Framework for Intellectual Property 
Rights has successfully drawn attention to the 
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need for more effective exploitation of publicly 
funded research, stimulating a robust debate 
among stakeholders around the country. The 
real test of its impact, of course, will come with 
implementation. A positive outcome may be ex-
pected if a cooperative, enabling approach is tak-
en that draws on the experience of organizations 
active in the field for some time. An approach 
that is too prescriptive and lacks sufficient flex-
ibility to take into account unique circumstances 
will likely yield much less valuable results. ■
ROSEmARY wOLSON, Intellectual Property Manager, R&D 
Outcomes, Council for Scientific and Industrial Research 
(CSIR), PO Box 395, Pretoria 0001, South Africa. 
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ABSTRACT
This chapter provides a conceptual overview of Arizona 
State University’s mission, and explains how the universi-
ty’s “technology translation” efforts support that mission. 
The chapter offers a rationale for why effective technol-
ogy translation and commercialization are economically 
and socially relevant. A case study illustrates how a pro-
gram established by Arizona State University’s technology 
commercialization group has led to significant returns 
for the university and the local community. The authors 
conclude that public and private institutions in both 
developed and developing countries can implement the 
concepts and strategies for technology commercialization 
described in the chapter.
social vitality of the state of Arizona in the south-
western part of the United States. 
In the 2002 inaugural address to ASU faculty 
and administrators, Crow1 unveiled a vision and 
strategy for a dynamic, inclusive university that 
assumes a share of responsibility for the economic 
and cultural development of the society it serves. 
The university would commit itself to outcome-
focused excellence, both in the use-inspired re-
search agenda it pursues and in the diversity of its 
student body. The university would become—to 
put it simply—a New American University. 
As a New American University, ASU has 
been structured on fundamental design impera-
tives (Box 1). The spirit of these design impera-




In order for ASU’s research to be transformative, 
the university must have the staff, institutional 
and resource capacity to identify cutting-edge 
innovations and find creative ways to convert 
them into products that improve the quality of 
life. Within the framework of the New American 
University, the term technology transfer is aban-
doned in favor of technology translation. The 
1.	 BACKgRound	And	InTRoduCTIon
Arizona State University (ASU) is becoming rec-
ognized for having adopted one of the most for-
ward-thinking university models in the United 
States, a new model of excellence and access, 
where connection to community is an expecta-
tion. Since one of the co-authors of this chap-
ter, Michael Crow, became president of ASU in 
July 2002, the university’s stature as a leading 
transdisciplinary research institution has grown 
significantly. Along with investments in transdis-
ciplinary research infrastructure and new faculty, 
ASU has completely overhauled its technology 
commercialization capabilities and implemented 
programs that have improved the economic and 
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1.	 leveraging place:	Addressing	the	challenges	of	the	region






5.	 focus on the Individual:	Looking	beyond	the	academic	background	of	incoming	students	to	
seek	greater	diversity	of	the	student	body







latter more appropriately captures the university’s 
role, which is not simply innovating and trans-
ferring but, more importantly, framing innova-
tions within the context of social and economic 
relevance. 
Technology translation is predicated on 
building strong partnerships with the commu-
nity and commercial entities so that the technol-
ogy needs of the business and investment com-
munity are well understood. These partnerships 
are built around the university’s core-technology 
competencies so that opportunities for technol-
ogy development can be identified more effec-
tively. Indeed, through technology translation, 
ASU provides a partnering experience more in 
line with the expectations of a commercial en-
terprise. In order to pursue this more market fo-
cused approach to building links with industry 
partners, ASU established a private enterprise so 
it could bring technologies to market more effi-
ciently. In November 2003, ASU created Arizona 
Technology Enterprises, LLC (AzTE).2 Figure 1 
provides an overview of AzTE’s technology-trans-
lation process and structures, which are discussed 
in the following sections. The translation process 
begins with the design of process elements that 
position AzTE between the market and the uni-
versity. It is in this space where the work of trans-
lation can occur.
2.1		 Arizona	Technology	Enterprises	
AzTE is a private nonprofit, wholly owned 
subsidiary of the ASU Foundation.3 The ASU 
Foundation was established to manage ASU’s en-
dowment and to make strategic investments for 
the benefit of the university. AzTE is responsible 
for evaluating, protecting, and translating ASU’s 
technology portfolio. AzTE handles all of ASU’s 
licensing, spinout company formation, consortia 
development, and joint venturing activities with 
commercial partners. Fundamentally, AzTE was 
founded on the notion that strong partnerships 
can only be established by being flexible, remov-
ing obstacles to doing business, and focusing on 
speed to market as a key driver in a university’s 
dealings with its partners. AzTE’s autonomy as a 
private organization, with most decisions being 
made internally, enables it to operate with the 
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The individuals who make up AzTE’s busi-
ness-development team have industrial back-
grounds and strong product-development exper-
tise. This expertise gives the company significant 
insight into the commercial drivers and hurdles 
of technology adoption in the private sector. The 
skills and network of AzTE’s core team are supple-
mented by a board of directors, which is composed 
of venture capitalists, industry executives, tech-
nologists, and ASU leadership, as well as members 
of other ASU entrepreneurial programs (such as 
ASU Technopolis,4 an education and networking 
program offered to the local business community). 
AzTE’s strong network enhances its ability it to 
build relationships with industrial and financial 
partners. 
AzTE provides to its spinout enterprises and 
commercial partners myriad services, including 
technology assessment, strategic business devel-
opment, creative deal structuring, and capital for-
mation. AzTE also offers advice on business strat-
egy and is often instrumental in acquiring capital 
and management for ASU’s spinout companies. 
Moreover, through the extensive network of 
ASU, the AzTE team, and its board of directors, 
AzTE acts as a source of business-development 
contacts for its partners.
In order to further develop promising tech-
nology platforms that may not have sufficient 
funding to achieve market viability, AzTE es-
tablished the Catalyst Fund. Capital from the 
Catalyst Fund is invested by AzTE to conduct 
proof-of-concept experiments, develop proto-
types, and provide seed funding to emerging ASU 
ventures. The Catalyst Fund has also been used to 
co-invest with industrial partners to develop ASU 
technology platforms. The company has found 
that small amounts of strategically allocated capi-
tal can exponentially improve the chances of a 
technology reaching the market. 
2.2	 AzTE’s	market-focused	model
In addition to helping faculty incubate technolo-
gies in the existing ASU research portfolio, AzTE 
spends a significant amount of time meeting with 
industry-leading– and venture-capital companies 
to better understand their technology needs. By 
maintaining an ongoing dialogue with the busi-
ness community, AzTE can continually con-
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translation opportunities at ASU. This outside-in 
approach has significantly benefited the universi-
ty. The approach provides a better understanding 
of societal needs and helps the university decide 
how to fill those needs. Moreover, these interac-
tions have significantly contributed to the selec-
tion of ASU by many leading institutions as a 
partner of choice for technology acquisition. 
2.3	 Knowledge	entrepreneurship
AzTE has developed programs that offer students 
many opportunities to gain unique, practical 
experience in technology-based transactions. In 
addition to hiring graduate students in business 
administration to work in AzTE’s offices, AzTE 
has established the Technology Venture Clinic 
(TVC). The TVC is a multidisciplinary clinic 
that utilizes students from ASU’s Sandra Day 
O’Connor College of Law, the W. P. Carey School 
of Business, Fulton School of Engineering, and 
the College of Liberal Arts and Sciences. TVC stu-
dents evaluate ASU technologies, perform market 
research, identify commercialization opportuni-
ties, and assist with transaction negotiations. In 
exchange for their service, TVC students receive 
credit toward graduation. Privately funded by a 
leading corporate law firm in Phoenix, Arizona, 
Rogers & Theobald, LLP, the activities of the 
TVC offer unique experiences for its students and 
provide highly skilled assistance to the university’s 
technology commercialization efforts.
In addition to the TVC, AzTE developed 
the Lisa Foundation Law Fellowship. Sponsored 
by a private foundation, the fellowship is offered 
each year to two top ASU law students with an 
interest in intellectual property (IP) law. With the 
guidance of an IP law firm, Steven G. Lisa, Ltd. 
(Chicago, Illinois), Lisa fellows learn how to draft 
and assess patent claims, search for prior art, and 
bolster claims of existing ASU filings. Like the 
TVC, the Lisa Foundation Law Fellowship gives 
a unique experience to students while providing 
an invaluable service to the university. 
2.4	 External	technology	acquisition
There are few institutions (either public or private) 
with an internally generated technology portfolio 
that, standing alone, can solve the world’s most 
pressing health care and technology challenges. 
In order to develop an entity that can sustain-
ably commercialize technology, be continually 
transformative, and create long-term value for 
the university and the community, AzTE strives 
to identify technologies developed by other in-
stitutions that can bolster the quality and value 
of ASU’s technology portfolio. Bundling ASU 
IP with external portfolios is part of an ongoing 
dialogue between ASU and its commercial part-
ners, and it has lead to joint development proj-
ects between ASU and other institutions, such 
as the Sun Health Research Institute (a leader in 
Alzheimer’s research) and the Mayo Clinic. AzTE 
has begun to manage technology portfolios from 
other institutions that can be strategically bun-
dled with ASU technologies to create new licens-
ing and spinout opportunities. For example, one 
of AzTE’s recent spinout companies was based on 
a sensor portfolio developed at Northern Arizona 
University.5 
AzTE acquires access to external portfolios 
using a variety of structures including:
•	 management-service agreements to provide 
commercialization service in exchange for 
fees and/or on a contingency basis
•	 joint-commercialization agreements, where-
by AzTE takes the lead on commercializing 
joint inventions
•	 acquisition or optioning of specific technol-
ogies of interest from another institution
•	 taking donations of technology portfolios 
from a public or private entity
Bundling technologies from other public 
and private sources that are synergistic with 
ASU’s portfolio is an important part of AzTE’s 
continued success. That is why AzTE is continu-
ally looking for opportunities to bring portfolios 
together where their combined effect is worth 
more exponentially than the sum of their indi-
vidual effects. 
2.5	 Speed,	simplicity	and	certainty
Technology translation and commercialization 
is sometimes called a contact sport. Transactions 
can take up to 18 months to consummate, and 
the proportion of patented innovations that 
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actually make it to market is relatively small. It is 
therefore essential for any organization engaging 
in technology commercialization to adopt a disci-
plined approach to deal making. AzTE strives to 
move from first contact to consummating a deal 
in four months. Table 1 illustrates the progression 
of an AzTE transaction.
The AzTE transaction team has devel-
oped three key guiding principles that govern 
all of its business negotiations, regardless of 
deal size or structure: “Speed, Simplicity, and 
Certainty.” 
• Speed. AzTE’s autonomy and culture allow 
it to move quickly to consummate transac-
tions. This is essential in today’s dynamic 
technology marketplace. Speed in deal mak-
ing is crucial for establishing strong partner-
ships. If a party is unable to move swiftly 
through the due diligence- and documen-
tation processes, it may lack commitment 
to the project, or there may be insufficient 
buy-in at higher levels within the organiza-
tion. This can affect a project’s success. 
• Simplicity. Early-stage technology transac-
tions and joint-development projects are 
inherently complex. Given the numerous 
risks involved (for example, a technology 
not achieving its commercial endpoint or 
a partner’s change in priorities), the odds 
of most early-stage technology transac-
tions achieving success are low. Because of 
this, it is important that the structure of a 
transaction be kept as simple and flexible 
as possible. Many transactions fail because 
parties are unable to agree on terms that, in 
the end, do not fundamentally matter to a 
project’s success. 
• Certainty. The promise of value can be elu-
sive if the counterparty to the transaction 
is difficult. Successful technology develop-
ment transactions are based on successful 
relationships. Indeed, effective deal making 
requires the discipline to prefer a lower of-
fer from a party with whom one might suc-
ceed, to a higher offer from a party that is 
less likely to see the project through. 
Table	1:	progression	of	an	AzTe	Transaction
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2.6	 Faculty	engagement	in	the	technology	
assessment	process
For many faculty researchers, a significant por-
tion of the time they will spend with the AzTE 
team involves the process of evaluating their 
inventions. As a result, AzTE has developed a 
technology evaluation process that, in addition 
to evaluating the commercial relevance of a dis-
closure, is designed to provide an opportunity for 
faculty to get to know the AzTE team and gain 
insight into how evaluation decisions are made. 
ASU researchers work alongside the AzTE team 
to evaluate the technology. The team shares with 
the researchers all of the technology and market 
due diligence performed. If a technology does not 
meet the university’s investment criteria after be-
ing thoroughly evaluated, the technology is gen-
erally returned to the inventor along with all due 
diligence materials compiled during the evalua-
tion process. Including inventors in the process 
has helped to minimize disputes over whether 
an investment decision was fairly determined. 
Additionally, close interaction between the AzTE 
team and researchers has taught inventors to bet-
ter appreciate market needs and expectations, 
which has increased the quality of invention dis-




Between the research institutions that create in-
novations and the customers who eventually use 
them sit the technology adopters. These are the 
industrial companies, development companies, 
and other enterprises that adopt early-stage ideas 
and convert them into useable products and ser-
vices that address market needs. A number of 
trends are providing significant opportunities for 
universities with effective technology commer-
cialization programs to build strong partnerships 
with these technology adopters. A few of these 
trends are discussed below. 
Only about 15% of the market capitalization 
of companies that make up Standard & Poor’s 
500 share index (a division of the McGraw-Hill 
Companies, Inc.) can be tracked to balance sheet 
net asset value.6 This means that approximately 
85% of these companies’ market values can be 
attributed to intangible assets. The growing ap-
preciation of the importance of intellectual assets 
has prompted leading companies to manage their 
patents with a level of scrutiny that was once re-
served only for “brick and mortar” assets. Many 
companies are hiring senior level intellectual as-
set managers. Such a manager would continu-
ally evaluate whether the company’s IP strategy is 
aligned with its business strategy, and whether the 
acquisition of additional technology portfolios is 
necessary for success. Some of the factors influ-
encing technology-focused companies to look be-
yond their internal R&D efforts to find the next 
big thing include:
• Market Competition. In order to become 
more competitive in the global market-
place, today’s companies are more likely to 
in-license core technology platforms so that 
they can get to market quicker and access 
greater opportunity.
• Technology Convergence. Cutting-edge 
technology platforms are complex and re-
quire multidisciplinary expertise. For exam-
ple, the next generation of flexible display 
technology will require in-depth expertise 
in engineering, material sciences, microelec-
tronics, and nanotechnology. Such a diver-
sity of disciplines is prohibitively expensive 
for many companies to develop internally.
• Innovators’ Dilemma. Many larger com-
panies have difficulty innovating in a way 
that significantly changes their business. As 
a result, many internal R&D programs fo-
cus on incremental improvements to exist-
ing product lines. To remedy this problem, 
companies look outside of their internal 
programs to identify disruptive, “game-
changing” technologies.
• Lack of R&D Productivity. Better tools 
and access to information have enabled 
companies to more efficiently assess the 
return on their internal R&D programs. 
Internal development projects that are not 
productive can be terminated in favor of 
acquiring technology elsewhere.
CHAPTER 17.8
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3.2	 Public	sector	benefits
Companies in developed nations struggle with 
the economics of selling products in develop-
ing regions. Because universities are not as pres-
sured by the competitive, profit-focused aims of 
the private sector, they can deploy significant re-
sources to tackle some of the most vital challenges 
in these societies. Moreover, well-run technology 
translation programs can implement strategies to 
enhance the adoption of licensed technologies in 
developing countries. The following are some ex-
amples of strategies that ASU and other research 
institutes have pursued:
• reserving carve-out rights in licensing agree-
ments to continue to allow the university 
to use and provide, for charitable purposes, 
private access to the technology
• favoring commercial partners that are will-
ing to commit to providing technology ac-
cess in developing regions over those who 
will not
• encouraging partners to set up regional 
joint ventures with companies capable of 
bringing technologies to market in devel-
oping regions
• providing to partners financial flexibility in 
the form of reduced royalties and other dis-
counts to help make product development 
and marketing in developing countries 
more attractive
• providing field-of-use licenses and region-
al/geographic use licenses to ensure that the 
best commercialization partners are select-
ed for geographic regions 
Public and private research-granting organi-
zations recognize the importance of technology 
translation for ensuring that funded research 
programs result in products that improve the 
quality of life throughout the world. Many grant-
ing agencies require that grant applicants provide 
in their applications a technology adoption and 
commercialization plan along with the research 
plan. As part of this trend, AzTE participates in 
ASU’s application and acquisition of grants from 
public and private sources. In 2004, AzTE par-
ticipated in developing the Intellectual Property 
Sharing Plan for a US$43 million grant, which 
ASU received from the U.S. Army, to establish 
the Flexible Display Consortium, a university/
industry consortium developed and led by ASU 
to create the next generation of flexible display 
technologies. Box 2 provides a summary of IP 
management terms that public research institu-
tions can adopt when structuring a public/private 
consortium.
3.3	 Local	economic	development	benefits
University technology translation and market-
based commercialization can significantly affect 
the local economy. Consider the following exam-
ple of a recent ASU transaction that is helping to 
grow the economy in Phoenix, Arizona. 
Agilent Technologies, Inc. is a premier 
measurement-instrument and technology com-
pany with revenue in excess of US$5 billion per 
year. In November 2005, Agilent Technologies 
purchased Molecular Imaging Corp. (based in 
Tempe, Arizona), an ASU spinout company that 
has become a leader in atomic-force microscopy 
(a technology widely used to measure properties 
of materials at the nanometer scale). 
In 1993, an ASU professor, Dr. Stuart 
Lindsay, developed his groundbreaking measure-
ment technology. With the assistance of ASU’s 
technology commercialization office, Dr. Lindsay 
and his team founded Molecular Imaging. 
Through a sponsored-researcher relationship with 
ASU, the company continued to leverage the 
university’s research capability and infrastructure 
to develop its products. To build the company, 
Dr. Lindsay attracted entrepreneurial talent and 
capital to Arizona from across the United States. 
In fact, many employees were offered research po-
sitions at ASU. Discussions with Agilent during 
and after negotiations revealed that it valued the 
strong partnership between Molecular Imaging 
and ASU. Partly because of this, Agilent declared 
its commitment to keeping the Agilent business 
unit in Tempe and to growing the business local-
ly. Agilent’s investment in Arizona will yield sig-
nificant benefits, including new-technology part-
nering opportunities, partnership opportunities 
for local businesses, and more technology-related 
jobs. Soon after the acquisition closed, AzTE began 
working with some of the founders of Molecular 
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Imaging on the next promising entrepreneurial 
spinout venture. AzTE is also in discussions with 
Agilent regarding additional technology licensing 
opportunities. Despite the obvious benefits of the 
deal to Agilent and Molecular Imaging sharehold-
ers, this transaction serves as a billboard for the 
power of technology translation and its impact 
on local economic development. 
4.	 ConCluSIon
The importance of effective technology transla-
tion is profound. Since the enactment of the 
Bayh-Dole Act in 1980,7 products derived from 
the research community have accounted for more 
than $40 billion8 in market value alone, even 
without considering the positive impact on the 
economy. In the three years of AzTE’s existence, 
the company has started 13 other companies, 
entered into over 80 commercialization transac-
tions, and generated more than US$8 million in 
revenue. During the last 24 months, three of the 
13 companies were sold to acquirers located in 
Arizona that plan to continue to grow these com-
panies locally. 
From a research institution’s perspective, an 
effective technology translation program not only 
generates significant revenue for research, but 
also develops an entrepreneurial culture among 
university researchers and private researchers. 
For the international community, technology 
translation can be an important catalyst for eco-
nomic development and a significant source of 
partnerships with the business community. 
Although President Crow’s model for the New 
American University may not be adoptable com-
pletely for all institutions, its principles of social 
engagement and creative technology partnering 
can be adapted for use by other public and private 
institutions and can yield significant returns for 
those institutions in developing regions through-
out the world, while benefiting people in those 
regions. ■
PETER J. SLATE, Chief Executive Officer, Arizona 
Technology Enterprises, LLC, 699 South Mill Avenue, 
Suite 601, Tempe, AZ, 85281, U.S.A. pslate@azte.com
mICHAEL CROw, President, Arizona State University, 
300 E. University Drive, Fulton Center, Suite 4104, 
Tempe, AZ, 85287-7705, U.S.A. Michael.Crow@asu.edu
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7 35 U.S.C. 200-212
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University. Arizona State University, Tempe, AZ. 
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“Center	Technology”	means	all	Technology	 that	has	been	 conceived:	 (1)	 by	one	or	more	Center	
Members	or	UNIVERSITY	on	a	Center	Project	using	the	center	facilities,	or	personnel	of	the	Center	
or	UNIVERSITY	or	personnel	of	a	Member	that	are	dedicated	to	the	Center	or	(2)	by	one	or	more	
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Box 2 (Continued)



















With	respect	 to	 Improvements	of	UNIVERSITY	or	Members	on	Center	Technology	 that	has	been	
publicly	disclosed,	neither	UNIVERSITY	nor	the	Member(s)	are	required	to	license	the	Improvement	
except	 to	 the	 extent	 of	 any	 non-commercial	 license	 required	 under	 Section	 3	 above	 if	 the	
Improvement	constitutes	Background	Technology.
4. disclosure of Center technology
Members	must	 promptly	 disclose	 to	 the	Center	Director:	 (a)	 all	 Center	Technology	 on	 a	 Center	
Invention	and	Discovery	Disclosure	Form,	(b)	patent	filings,	and	(c)	details	of	licenses	entered	into	
for	Center	Technology.







1672 | HANDBOOK OF BEST PRACTICES 
of	patents	and	copyrights	are	shared	equally	by	Inventing	Members.	Each	Member	is	responsible	
for	the	prosecution	for	patent	application	for	its	own	Background	Technology.	













For the People’s Republic of China, intellectual property 
(IP) is a new legal and social concept. Formal legislation 
was first introduced in the 1980s and was later strength-
ened. Due to recent publicity, however, social awareness 
of IP rights in China has grown. Following a series of 
ministerial and commission rules concerning technology 
transfer, universities now usually own the IP resulting 
from government-funded research. Not surprisingly, the 
number of patent applications filed by Chinese univer-
sities has increased rapidly, exceeding 13,000 in 2004. 
But such numbers may reflect a trend for researchers and 
institutions to use patents as a way of enhancing their 
reputations, rather than for actually transferring or com-
mercializing technology. Most universities still lack insti-
tutional IP policies and independent offices responsible 
for IP management. Rates of technology transfer and 
commercialization, while difficult to observe, remain 
low. Still, some world-class universities, such as Tsinghua 
University and Beijing University, have become adept at 
IP management. These are both an exception to and an 
example for other universities in China, having success-
fully adapted IP management policies and practices to the 
country’s legal and economic circumstances.
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was a milestone for the establishment of a modern 
IP rights regime in China. A Chinese patent law 
followed 1984, and a Chinese copyright law was 
adopted in 1990.
These three laws have been amended several 
times to improve the protections they provide. 
The first amendment of the patent law, in 1992, 
expanded the scope of patent protection to chem-
ical products and extended the term of utility pat-
ents to 20 years and design patents to ten years. 
In 2001, the patent law was amended again to 
offer new judicial and administrative protections, 
improved application procedures, and simpli-
fied enforcement procedures. The trademark law 
has been amended twice since its adoption; the 
copyright law has been amended once. The lat-
est amendments of these three laws have offered 
stronger protection of IP rights in line with the 
requirements of the World Trade Organization 
(WTO) and the Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS).
In an effort to bring its IP protection into ac-
cord with international systems, China has active-
ly participated in most of the major international 
IP organizations and treaties since 1980. It is 
now a member of the World Intellectual Property 
Organization (WIPO), the Paris Convention for 
the Protection of Industrial Property, the Madrid 
Agreement Concerning the International Deposit 




The formulation of laws and regulations to govern 
IP rights in China began in the early 1980s. The 
protection of trademarks and copyright has, to 
some extent, existed in China for a long time, but a 
formal Chinese trademark law wasn’t promulgated 
until 1982. The enactment of the trademark law 
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the Protection of Literary and Artistic Works, the 
Patent Cooperation Treaty (PCT), and WTO, in-
cluding TRIPS.
In all of Chinese legislative history, no laws 
have received more attention than those con-
cerning IP. The Chinese government has tried 
to establish a legal system that meets the current 
level of IP protection in the world system. Of all 
the laws in China, these IP laws are the closest 
to corresponding laws in developed countries. 
In other words, China has tried, in 20 years’ 
time, to reach the level of IP protection that it 
took developed countries more than 100 years 
to reach. One result of such rapid progress is 
that the resulting laws actually go beyond the 
common recognition and practice of society. In 
the past 20 years, China has been transitioning 
from a planned economy to a market economy. 
For the Chinese, IP is something of a new phe-
nomenon, and all issues involving IP in China 
should be understood in the light of this. Under 
the centrally planned economic system, typi-
cally only a few patent applications were filed, 
and they had little meaning. With the new leg-
islation and the publicity associated with it in 
recent years, social awareness of IP rights in the 
country has gradually increased.
2.	 RegulATIng	enTITlemenT	
of	Ip	RIghTS
In Chinese patent and copyright law, only general 




An invention made by a person during the execu-
tion of tasks for an employer, or involving the use 
of materials and technical means belonging to, or 
provided by, the employer is considered to be a 
service invention, or work for hire. For a service 
invention, the right to apply for a patent in China 
belongs to the employing entity. After the pat-
ent application is approved, the employing entity 
shall be the patentee.
For an invention that is not a service inven-
tion, the right to apply for a patent belongs to 
the inventor. After the patent application is ap-
proved, the inventor shall be the patentee.
With respect to an invention made by a per-
son using the material and technical means of the 
employer, where the employer and the inventor 
have entered into a contract that provides for the 
right to apply for and own patents, the terms of 
the negotiated provision shall apply.
2.1.2		 Article	8
For an invention made by an entity or an indi-
vidual working under commission or contract for 
another entity or individual, the right to apply for 
a patent belongs, unless otherwise agreed upon, 
to the entity or individual that made the inven-
tion. After the patent application is approved, the 
entity or individual who made the application 
shall be the patentee.
2.2 Copyright	law
2.2.1		 Article	16
Work created by an individual in the fulfillment 
of tasks assigned to him or her by a legal entity 
or organization shall be deemed to be a work 
created in the course of employment. The author 
shall hold the copyright to such work, provided 
that the employing legal entity or organization 
shall have a priority right to exploit the work 
within the scope of its professional activities. 
For the two years after the completion of the 
work, the author shall not, without the consent 
of the employing legal entity or organization, 
authorize a third party to exploit the work in 
the same way as the employing legal entity or 
organization does. 
The author of a work created in the course 
of employment shall enjoy the right of author-
ship, while the employing legal entity or orga-
nization shall enjoy other rights included in the 
copyright and may reward the author, as in the 
following cases: 
• drawings of engineering designs, product 
designs, and maps, computer software, and 
other works are created in the course of 
employment mainly with the material and 
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technical resources of the legal entity or or-
ganization and under its supervision 
• works created in the course of employment, 
in accordance with laws, administrative 
regulations, or contracts, enjoyed by the 
legal entity or organization. 
2.3	 Ownership	of	IP	created	under		
government	funding
Before 1994, there was no uniform government 
policy regarding IP created with government 
funding, and the government took title to all 
IP rights resulting from work that it funded. 
In China, almost all universities and research 
institutes undertaking government projects 
were legally considered state-owned entities. 
The government was thus entitled de jure to IP 
rights from them. However, rights were held de 
facto by the universities or research institutes. 
Because there was no government policy regard-
ing the entitlement and transaction of IP made 
under government funding, universities had no 
impetus to engage in IP management. In addi-
tion, few universities or institutes understood 
the importance of IP. Accordingly, IP manage-
ment in universities and research institutes was 
virtually nonexistent.
In 1994, the former National Commission of 
Science and Technology issued a regulation titled 
Measures for Intellectual Property Rights Made un-
der the Governmental Funding of the National High 
Technology Program. It provided specific rules for 
the ownership of intellectual property rights to 
inventions developed with government funding 
and contains several important provisions:
• When the government signs a contract with 
the university or institute, the ownership of 
the IP rights should be provided for.
• Unless otherwise stipulated in the contract, 
the university or research institute is enti-
tled to all IP rights pertaining to inventions 
funded by the government. 
• The university or institute should disclose 
the results to the funding government 
agency within 30 days after completing the 
project, and decide whether to file a patent 
application. In addition, the university or 
institute has the option to keep the results 
as a trade secret.
• The university or institute must submit a re-
port with a plan for utilizing the invention 
to the funding government agency within 
six months after completing the project.
• The university or institute is entitled to the 
copyright on the work, including software 
funded by the government.
• The university or institute can use, assign, 
and exclusively license IP or trade secrets 
funded by the government.
Although this is only a ministerial rule, it is 
the first uniform government policy in China re-
garding the ownership of IP on inventions funded 
by the government.
In 2002, the Ministry of Science and 
Technology and the Ministry of Finance jointly 
issued Measures for Intellectual Property Made 
under Government Funding, which are often 
called the “Chinese Bayh-Dole Act.” Based on the 
previous regulation, it goes even further:
• The university or institute is entitled to IP 
made under government funding.
• The funding government agency may de-
cide, for compelling reasons (such as the 
security of the state, other vital interests 
of the state, or vital interest of the public), 
that title to the IP should be vested in the 
government.
• The university or institute can use the re-
sults or IP by itself or can assign or exclu-
sively license them to a third party.
• The government retains a nonexclusive, 
royalty-free license to practice inventions 
made under government funding.
• The university or institute is entitled to re-
ceive revenue from commercializing the IP, 
but the university or institute must share 
with the inventor(s) a portion of any rev-
enue received.
• Under certain circumstances, the govern-
ment can require the university or institute 
to grant a license to a third party.
• Universities or institutes must give prefer-
ence to the inventor when commercializing 
an invention.
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• When a university or institute applies for 
government research funding, the applica-
tion should contain an analysis of the feasi-
bility of obtaining a patent.
• IP costs are to be borne by the university or 
institute.
In 2002, the Commission on Science, Tech-
nology, and Industry for National Defense issued a 
regulation titled Measures for Intellectual Property 
Rights Made under Governmental Funding of De-
fense Technology Projects. It states that:
• Unless separately provided for in a con-
tract, the contractor is entitled to IP con-
tained in inventions developed as defense 
technology projects and made under gov-
ernment funding.
• The funding government agency may 
decide, for compelling reasons (such as 
the security of the state, other vital in-
terests of the state, or vital interest of 
the public) that title to the IP should be 
vested in the government.
• Under certain circumstances, the govern-
ment can require the contractor to grant a 
license to a third party.
According to the above measures, IP result-
ing from research funded by the government is in 
practice usually owned by universities. However, 
there is still no law in China specifically covering 






After ministerial and commission rules were 
issued and IP rights enforcement was strength-
ened, the number of patent applications filed 
by universities increased rapidly. Figure 1 
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This increase is mostly due to Chinese uni-
versities’ growing awareness and recognition of 
the value of IP and has been accompanied by a 
growing acceptance of the idea of IP in Chinese 
society. Still, the rapid increase of university pat-
ent applications is also partly due to government 
policy. Recently, with regard to a university’s rep-
utation or an individual faculty member’s chances 
at promotion, the number of patent applications 
has become almost equal in importance to outside 
reviews and number of publications. For some 
universities and their faculty, patent applications 
have become a substitute for publications (pat-
ent applications are considerably easier to obtain 
than publications). Additionally, in some univer-
sities students are required to submit a publica-
tion or patent application to graduate. Recently, 
the Ministry of Education has ranked universi-
ties based on the number of patent applications 
filed. Universities have begun to pay significant 
attention to patents because they closely correlate 
with institutional reputation. But because patents 
now garner institutional prestige, universities are 
filing patent applications for inventions that are 
not patentable or have little commercial value. In 
fact, despite this surge in the number of patent 
applications, some real problems with IP man-
agement in Chinese universities remain.
3.2 Lack	of	institutional	IP	policies		
and	understanding	
Despite the numbers, the loss of potential IP by 
universities is a serious problem. Most universities 
do not have a clear IP policy. While Chinese 
patent and copyright laws articulate, in principle, 
what constitutes an employee’s invention and a 
work for hire, most Chinese universities lack clear 
interpretations and policies to implement. There 
is often no definition in place for what constitutes 
an employee invention or a work for hire, and no 
common procedure for disclosing inventions or 
for filing patent applications. Clauses related to IP 
appear seldom in employment contracts between 
universities and faculty, and many universities 
lose IP due to the mobility of faculty members, 
students, and visiting scholars among universities 
and between universities and industry. Even at 
universities that do have an established employee 
IP policy, it is often unclear to whom that policy 
applies. With the increasing recognition of the 
value of IP, more and more issues are arising about 
who owns patents or software. 
While growing, faculty and student awareness 
of IP issues still falls short of what is needed, and 
even basic concepts are not always understood. 
While many Chinese universities offer some form 
of IP education to faculty members and students, 
it is seldom systematic or regular and, in most 
cases, has little effect.
Most faculty members do not have a con-
cept of a publication bar. Patent applications are 
often filed at the same time or even after results 
are published or disclosed publicly. Many patent 
applications are therefore rejected because of the 
publication bar1 or because of a lack of novelty.
3.3.  Lack	of	institutional	offices	of	IP	
management	or	technology	transfer
Most universities lack an independent office 
responsible for IP management or technology 
transfer. Such functions usually fall to the of-
fice of research and technology. The primary 
responsibilities of this office are to apply for 
government research funding, supervise proj-
ects, report the results of projects to the fund-
ing agency, and facilitate publication of articles 
based on the projects by faculty. Typically, there 
is not even a single full-time staff member re-
sponsible for IP management. 
Under the past, centrally planned economic 
system, the most important duty of the office 
of research and technology was to report on a 
project’s results to the corresponding committee 
of experts at the government agency that 
funded the project. Even now, such reporting 
is still common in most Chinese universities 
and research institutes. All project results are 
appraised for awards through a process of review 
and discussion by the agency’s committee. Prizes 
are awarded to those projects whose results 
were determined to be sufficiently advanced. 
These prizes have a significant impact on the 
reputation of universities and the promotion of 
individual faculty members, as do publications. 
Publications and award appraisals emphasize 
final outputs. Indeed, in administering research 
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projects, most attention is generally focused 
on the final stages and outputs of the research 
process. In most universities, there is almost no 
administrative oversight of the early stages of 
research projects.
Since the university office of science and 
technology, which is in charge of IP management, 
focuses its work on the outputs of the research 
process, not much thought is given to the patent-
ability of a technology when applying for project 
funding. And during the course of research, little 
attention is paid to prior art as it is articulated in 
patent law. For most projects, assessing patent-
ability and prior art is only done after the work 
is completed. 
Since the office of research and technology 
concentrates most of its efforts on project ad-
ministration, members of that office are called 
upon to manage IP only as a part-time job. As a 
result, IP management is a secondary consider-
ation compared with the daily work of the office. 
The lack of professionals who specialize in IP at 
Chinese universities partly reflects the rarity of 
professionals with expertise in IP in China.  
3.4 	 Growth	in	patent	applications	does	not	
mean	growth	in	technology	transfer
For most Chinese universities, IP management 
essentially means making patent applications. 
Most Chinese universities do not have anyone 
specifically responsible for technology transfer. 
Without a technology transfer office (TTO) or 
anyone in charge of technology commercializa-
tion efforts, little effort is made to promote the 
actual transfer or commercialization of the result-
ing patents. In many cases, patents and commer-
cially valuable research results are simply left on 
the shelf. Little is done to publicize them, mak-
ing it hard for industry to learn about new tech-
nologies. Even when an entrepreneur might be 
informed and interested in licensing a patent, it 
is often unclear who in the university has the au-
thority to negotiate.  
Some universities authorize external IP agen-
cies to manage their IP, but usually such agencies 
merely concentrate on filing patent applications. 
The available external agencies likewise lack pro-
fessionals with expertise in IP transactions.  
Another reason for the low level of technol-
ogy transfer is that patents are often applied for 
without any investigation into the market de-
mand for the invention, which means that much 
of the university’s IP lacks commercial value. 
The very low commercialization rate at 
Chinese universities produces insufficient rev-
enues to cover patent costs, and this, in turn, af-
fects the university’s ability to obtain and main-
tain patents. Patent costs are covered exclusively 
by the universities and usually come out of re-
search funding lines. Many patents are not be-
ing maintained because universities lack funds 
to pay maintenance fees. As patent costs increase 
in China, and because it is much more expensive 
to file in foreign countries, universities may in-
creasingly hesitate to file patent applications be-
cause of budget concerns. Unless it is backed up 




Most Chinese universities lack clear policies about 
how revenue from IP will be shared with the in-
ventor. And for those that do have such policies, 
the proportion of revenues shared often does not 
accurately reflect the inventor’s effort or contribu-
tion. With no definition provided by university 
policy about what hired to invent or work for hire 
means, or to whom these terms should be applied, 
and with no restrictions imposed by the employ-
ment contract, many faculty members prefer to 
increase their personal advantage by collaborating 
directly with industry. Recently, faculty members 
have engaged more and more in part-time em-
ployment or contracting with industry. Resulting 
conflicts of interest between faculty obligations to 
the university and to industry are very common. 
Still, most Chinese universities lack any policy re-
garding faculty conflict of interest.
In collaborative research agreements be-
tween industry and universities that are funded 
by the industry partner, universities often give up 
the rights to ownership of IP made under such 
sponsorship. IP clauses in industry sponsored re-
search agreements can sometimes be interpreted 
as inequitable to the university, especially when 
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the contract is with a large or influential com-
pany. Typically, the company will not give owner-
ship of resulting IP to the university, nor will it 
share revenue with the university. In some cases, 
the company may even seek to include a nonex-
clusive license to background IP that it did not 
fund. Some companies seek guarantee clauses in 
research agreements governing collective projects 
that place on the university all responsibility for 
the infringement of other’s IP rights. Additionally, 
some companies will not agree to give the uni-
versity rights to use the resulting IP for teaching 
or research purposes. There is no university as-
sociation in China to advocate for the interests 
of universities. Not surprisingly, outside of a few 
famous universities, most Chinese universities are 
in an inferior position when negotiating spon-
sored research agreements with large companies. 
They have to accept any adverse contract terms in 
order to obtain the research funding.  
3.6 Regional	imbalances
Finally, there is significant imbalance among 
Chinese universities in terms of IP management. 
Economic development in China is proceeding at 
very different rates in different regions. In some 
of the most developed regions, like Shanghai and 
Beijing, there are world-class universities that do 
quite a good job managing their IP. 
4. CASe	STudy:	Ip	mAnAgemenT	
AT	TSInghuA	unIveRSITy
Tsinghua University has an IP committee that 
consists of a university vice president and manag-
ers drawn from the university’s functional depart-
ments. The committee oversees an office simply 
called the Intellectual Property Office, which is 
in charge of the university’s IP policy and man-
agement. The specific responsibilities of the of-
fice include: 
• drafting university policies regarding IP 
• monitoring policy implementation 
• establishing systems and procedures for IP 
management 
• educating faculty 
• examining IP clauses in contracts between 
the university and industry  
More recently, the Intellectual Property 
Office has also begun providing services in pat-
ent searching and infringement consulting. The 
intellectual property office appoints at least one 
member of each department to manage IP as part 
of his or her daily work.
Tsinghua University created its IP policy about 
ten years ago. The policy applies to all university 
employees, including faculty and nonfaculty re-
searchers, provisionally hired employees, students, 
post-docs, and visiting scholars. All employees to 
whom it applies sign a pledge that they will com-
ply with the policy. IP is defined under the policy 
to include patents, trade secrets, know-how, trade-
marks, copyrights, and any related rights. It clearly 
defines what constitutes employee work. It also 
states that when a project is completed, the in-
vestigator should disclose all results to the admin-
istrative department first, and the administrative 
department should then decide whether to apply 
for a patent. Publication and any public appraisals 
that would trigger the publication bar are forbid-
den before filing a patent application. If results 
appear to have commercial value but are not suit-
able for a patent, it is to be kept as a trade secret, 
and measures to maintain confidentiality are to be 
taken. An industry-sponsored research agreement 
must have a clause on ownership of resulting IP, 
allocation of patent costs, sharing of revenue made 
from the IP, and so on, and the contract must be 
examined by the intellectual property office be-
fore it becomes effective. When a faculty member 
or other employee goes to another domestic or 
foreign university or institute and does research, 
any IP resulting from that research should be as-
signed, or at least jointly assigned, to Tsinghua 
University, unless there is an agreement between 
that researcher and the other university or insti-
tute. Under the university policy, at least 25% of 
revenue generated by a piece of IP is to be shared 
with the inventor(s) as cash or equity.  
Tsinghua University has spared no effort to 
educate its faculty members and students about 
IP and the university’s IP policy. The policy is 
printed as a brochure. All members and students 
get one on their first day of joining the university. 
The university also propagates information about 
IP on its Web site. The intellectual property office 
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periodically reports news, IP-related laws, and 
updates on its work. IP is also covered in a course 
called Fundamentals of Law, which is taught by 
Tsinghua Law School and required for all stu-
dents. All appointed faculty members in charge 
of IP management for each department receive 
training periodically.  
The intellectual property office has also set 
up procedures and rules for examining collabora-
tive research agreements and sponsored research 
agreements between the university and other insti-
tutions or companies. Taking into consideration 
past contract disputes, the office has designed a 
standard contract for research agreements. There 
is also a special fund to pay patent costs, includ-
ing application fees, examination fees, agency 
fees, and maintenance fees for the first three years 
after a patent is issued.  
Together, the above measures have resulted 
in Tsinghua University owning the most patents 
of all Chinese universities. From 1985 to 2000, 
Tsinghua University filed 1,587 patent applica-
tions. Since 2001, the average annual growth rate 
of the university’s patent filings has been 26%. 
In 2004, the university filed 43 foreign applica-
tions (including Patent Cooperation Treaty fil-
ings). The numbers of patents issued to the uni-
versity were 121 in 1999, 187 in 2001, 501 in 
2003, and 537 in 2004. Other universities with 
a similar level of IP management include Peking 




Given that China has only a limited number 
of high-tech companies, there is limited in-
dustry demand for the technology generated 
by universities. Most Chinese companies have 
neither sufficient R&D capabilities nor suf-
ficient commitment to the long duration and 
great expenses of developing new products 
from patents. As stated above, most university 
inventors do not consider market demand but, 
instead, file patent applications to bolster the 
university’s reputation or to assure the inven-
tor’s promotion. Taken together, these factors 
negatively affect the rate of technology transfer 
from Chinese universities.  
Because the R&D capabilities of most 
Chinese companies are so low, when they do get 
involved, they tend to simply acquire patented 
technologies from universities. Ownership of IP 
rights is usually included up front as an assign-
ment or licensing clause in a research agreement. 
There usually is no additional negotiation or con-
tract for licensing between the university and an 
industry sponsor. Therefore, the exact data on 
rates of technology transfer cannot be found. But 
based on interviews with the faculty of Tsinghua 
University, it appears that the transfer rate of the 
university’s IP is not high. The contract value 
of industry-sponsored research agreements and 
collaborative research agreements might proxy 
for the level of technology commercialization to 
some extent. For Tsinghua University, the con-
tract value of industry-sponsored and collabora-
tive research agreements was US$31.5 million in 
1999 and US$45 million in 2004.  
In 1999, the Ministry of Education issued 
a plan to develop Chinese higher education for 
the 21st century. One highlight of the plan was 
to accelerate the transfer of university technolo-
gies by encouraging universities to set up high- 
tech companies. Noticing the tendency for high- 
tech companies to advance the local economy, 
many local and regional governments within 
China supported this plan by providing their 
local universities with low interest or interest-
free loans, housing, land, and tax concessions. 
The most developed city in China, Shanghai, 
provides interest-free loans of about US$15 
million each year to local universities. Many lo-
cal governments also adopt policies to encour-
age local university faculty members to start up 
companies and to encourage universities to take 
part in establishing technology parks. There are 
now about 40 technology parks associated with 
universities throughout China. A large number 
of the companies in these technology parks are 
startups founded by university faculty members 
based on their own technologies. 
In one prominent example, a US$50,000 invest-
ment by Peking University in 1986 started Founder 
Group.2 The technological basis of Founder Group, 
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protected under a patent named Laser typesetting 
system, was invented under government funding 
at Peking University. After successfully developing 
products from this patent, Founder Group revo-
lutionized printing technology in China. Founder 
Group now dominates about 85% of the domestic 
print market, and their products are exported to over 
30 countries. Flush with capital, Founder Group has 
built up a strong R&D department. Founder Group 
now acts as an IP incubator for Peking University. 
Founder Group is committed to developing its own 
IP, transferring Peking University’s IP, and sponsor-
ing research at the university based on market de-
mand. Founder Group now owns, or jointly owns 
with Peking University, 128 Chinese patents in the 
fields of print technology and information technol-
ogy, as well as copyrights on software in the fields 
of digital information management, multimedia, 
and the Internet. With a total staff of over 20,000, 
Founder Group now owns five companies listed 
on the securities exchanges of Shanghai, Shenzhen, 
Malaysia, and Hong Kong, as well as more than 
20 companies wholly funded by Founder Group 
or through joint-ventures. It achieved revenues of 
almost U.S. $3 billion in 2004.
In another prominent example, Tsinghua 
Tong Fang Co., Ltd., was floated in an IPO (ini-
tial public offering) in 1997 on the Shanghai Stock 
Exchange with Tsinghua University as the main 
shareholder. The company acts as an incubator of 
Tsinghua University’s IP in two ways. One way is 
by attracting capital for the commercialization of 
university inventions; the other is by sponsoring 
research at the university related to the company’s 
understanding of market demand. The company 
now owns more than 300 Chinese patents in in-
formation technology, energy resources and the 
environment, and applied radiation technologies, 
as well as 44 copyrights on software. In just the 
first half of 2005, the company achieved sales of 




Given the difference between the present status 
of IP management in most of China’s universities 
and the much more successful cases mentioned 
above, the following proposals and suggestions 
might be usefully implemented by those universi-
ties with less-successful IP management policies:3
1. Constitute an institutional IP policy that 
provides for at least the following key 
points: 
• a definition of employee invention and 
work for hire
• identification of parties for whom the 
institution’s IP policy is applicable
• procedures ranging from disclosure of 
inventions to filing of applications
• measures to avoid publication bar
• terms for the sharing technology transfer 
revenues with university inventor(s)
2.  Establish an independent IP management 
office staffed with full-time professionals 
familiar with IP.
3. Educate the university’s faculty and stu-
dents on the IP policy.
4.  Establish companies to incubate technologies 
and accelerate technology transfer. Given cir-
cumstances in China, this is often more ef-
fective than just a licensing strategy. ■
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ABSTRACT
An independent nonprofit research institution, the Donald 
Danforth Plant Science Center has an international mis-
sion to address global challenges in human health, nutri-
tion, agricultural sustainability, and the environment. 
The Danforth Center contributes to fulfilling this mis-
sion through collaborative research, training, and capacity 
building. As part of this objective, the Office of Technology 
Management and Scientific Partnerships at the Danforth 
Center, lead by the author of this chapter, has emerged as a 
leader in developing and implementing terms for humani-
tarian access to technology and has been actively involved in 
licensing enabling technologies for humanitarian projects. 
These activities include active participation and support for 
the creation of PIPRA, among other nonprofit organiza-
tions. The current chapter discusses the Danforth Center’s 
philosophy with respect to the protection and sharing of IP 
(intellectual property) rights, the reservation of rights for 
humanitarian projects, and best practices to enhance and 
maximize value creation through technology licensing. The 
chapter provides examples of the Danforth Center’s best 
practices and model documents for the establishment of 
interinstitutional and international collaborations and sci-
entific partnerships. Included with the chapter are specific 
examples of the Danforth Center’s humanitarian-use lan-
guage, interinstitutional agreements, nonasserts, enabling 
technology licenses, memorandums of understanding 
(MOUs), and other framework documents.
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improve the human condition through plant 
science. This vision is exemplified in the Danforth 
Center’s logo “Discover, Enlighten, Share and 
Nourish.” Research at the Danforth Center in-
cludes efforts to enhance the nutritional content 
of plants, improve human health and well being, 
increase agricultural production for a sustainable 
food supply, preserve and renew our environ-
ment, and build scientific capacity and thereby 
contribute to economic growth in the develop-
ing nations of the world. The Danforth Center is 
built on the principles of collaboration and shar-
ing. The center attains its goals through collabo-
rations and scientific partnerships and continu-
ously offers opportunities for scientific exchange 
and training, capacity building, technology trans-
fer, and translational research. 
2.	 The	dAnfoRTh	CenTeR	And	Ip	RIghTS
To begin, I would like to describe the Danforth 
Center’s general philosophy regarding intellec-
tual property (IP) and then, more specifically, 
address our philosophy on reservation of rights 
for humanitarian use. My individual philosophy 
is to protect and maintain the Danforth Center’s 
IP rights to maximize value and potential for ap-
plication while equally respecting the IP rights of 
others. We, at the center, expect in return no less 
CHAPTER 17.10
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SChuBeRT
1684	|	hAndBooK	of	BeST	pRACTICeS
than the same values and respect of our intellectual 
property. Inherent in this philosophy is the innate 
understanding that the center shall not violate or 
infringe the IP rights or misuse the materials and 
rights entrusted to the Danforth Center, even if 
the actions would involve no illegalities.
The Danforth Center’s policies and objectives 
regarding intellectual property are consistent with 
those of the Public Intellectual Property Resource 
for Agriculture (PIPRA), which are to promote 
the management of intellectual property related to 
agriculture and to achieve freedom to utilize agri-
cultural innovations for research, commercial use, 
economic development, specialty crops, and hu-
manitarian purposes. In line with these objectives, 
the Danforth Center encourages the development 
of research innovations for use in agriculture while 
also retaining rights needed to fulfill the mission of 
research and product development for the broader 
public benefit. The center seeks to facilitate access 
to enabling technologies for research and com-
mercial use and/or humanitarian purposes by our 
scientific collaborators and the international sci-
entific community and work to identify strategies 




The Office of Scientific Partnerships is a preferred 
and valued partner for plant-science research and 
collaboration, recognized and respected interna-
tionally for its research integrity and innovative 
policies and practices for the protection, manage-
ment, and stewardship of intellectual property 
rights. The office strives to be:
• a world-class provider and developer of 
novel cutting-edge solutions seeking to 
meet global challenges in agriculture, the 
environment, and human and animal 
health and nutrition
• an engine and catalyst for economic growth 
and the creation of wealth and value from 
the intellectual and human capital and a 
return on the research investment of the 
Danforth Center
• a recognized leader at facilitating national 
and international research collaborations 
and public–private partnerships that bring 
the world closer together.
In all agreements between the Danforth 
Center and public and/or private institutions, the 
Danforth Center strives to reserve and protect 
the IP rights conceived and reduced to practice 
directly by Danforth Center staff or jointly with 
researchers from partnering institutions.
3.2	 The	Danforth	Center	and		
developing	countries
An integral part of the center’s philosophy relates 
to the desire to be able to share in the benefits of 
research and discovery endeavors with develop-
ing nations. This includes providing assurances 
that all parties benefit from the intellectual prop-
erty developed through the center’s collabora-
tions and scientific partnerships. To ensure that 
the Danforth Center retains and maintains the 
rights to use technology developed by Danforth 
Center researchers or through collaborations, 
the center includes a section in sponsored-re-
search and license agreements that provides for 
the reservation of rights to use technology de-
veloped for the benefit of poor and underserved 
peoples of the developing nations. Under these 
provisions, the Danforth Center and our coop-
erators retain the rights to develop, have devel-
oped, produce, have produced, distribute and/or 
have distributed (in other words commercialize) 
the products of our basic and applied research 
and our joint collaborative research and to share 
this freely with partnering organizations in de-
veloping countries.
In each agreement, the detailed terms may 
be modified to reflect the interests and needs of 
the parties and to achieve a mutually beneficial 
relationship. The terms of licensing reflect our in-
terest in maximizing the opportunities to capture 
and create value from our intellectual pursuits 
and ensure that the benefits of our scientific re-
search will benefit the broader international com-
munity, especially addressing grand challenges in 




This philosophy is exemplified by the center’s 
policy not to grant broad worldwide exclusive 
licenses to its technology that could limit the 
center’s ability to create the maximum benefit 
from any intellectual property conceived by the 
researchers and through collaborative research 
projects, as well as from any technology devel-
oped through these activities. Instead, the cen-
ter grants only nonexclusive or limited exclusive 
licenses and, further, restricts the license rights 
granted to specific and/or limited fields-of-use, 
specific crops, and specific territories. Thus, the 
center retains the maximum opportunity to ex-
ploit the technology. 
3.3	 Facilitating	access	to	new	technologies	
Traditionally, technology transfer and IP rights in 
agriculture have centered around intensive agri-
culture in the developed countries and reflect the 
commercial forces and drivers that dictate a focus 
on commercially relevant agricultural priorities 
and targets for commercial crops in the developed 
nations. From these research activities, new tech-
nologies are developed including enabling and 
platform technologies, which may have relevance 
in addressing needs in the developing world. 
Access to this “developed country technology” has 
been the target of many foundations and organi-
zations focused on humanitarian efforts and pro-
grams. These programs aim to facilitate transfer of 
the technology to developing countries, including 
making IP rights and materials available to these 
countries. PIPRA and other groups are playing a 
key role in facilitating access to such technologies, 
while still protecting the IP assets of the inventor’s 
institution for use in commercial agriculture, both 
for major crops and for minor or specialty crops. 
The goals of much of the Danforth Center’s 
research and the research of the center’s scientific 
partners seek to address specific agronomic and 
nutritional targets of the highest priority and im-
portance in developing countries that offer the 
greatest potential benefit to resource-poor subsis-
tence farmers in these countries. These targets in-
clude increasing the yield of staple crops, decreas-
ing the need for chemical pesticides in agriculture, 
increasing crop resistance to pests and pathogens, 
increasing tolerance to abiotic stresses such as 
drought, salinity and cold, increasing food quality 
and food safety, and enhancing nutritional con-
tent of staple and subsistence crops. From the re-
sults of our research and our research partnerships, 
intellectual property may be created that also has 
commercial value in the developed nations. 
4.	 gloBAl	peRSpeCTIve
Value is enhanced by retaining the rights and op-
tions to apply and to make the technology avail-
able in as many ways, in as many applications, 
in as many markets, and in as many territories 
as possible. To accomplish this, the center does 
not generally grant options for an exclusive and/
or worldwide license to Danforth Center or to 
joint intellectual property. Our policy and prac-
tices encourage granting options to license and 
licenses on a nonexclusive basis to use, make, 
and sell products incorporating the technology 
and to further segment and limit these licenses 
to specific applications of the technology, to spe-
cific fields-of-use, and to specific territories. In 
the latter case, these may actually provide limited 
and defined exclusivity to the licensee. The use 
of nonexclusive licenses or limited licenses en-
ables the broadest application of the technology 
and does not prematurely limit the benefits of 
the technology either for humanitarian or com-
mercial use. 
Unfortunately, access to innovative and en-
abling technologies is too frequently restricted 
by the granting of exclusive and often worldwide 
options and licenses to the private sector. Such re-
strictive terms mean that promising technologies 
may be inaccessible to address developing coun-
try needs. In some cases the technology may be 
shelved to prevent access by competitors, while 
in other cases access may be hindered by fiducia-
ry, liability, and stewardship considerations. The 
need for indemnification and technology stew-
ardship frequently forms a major barrier restrict-
ing open access to enabling and platform tech-
nologies. As part of the activities of the Danforth 
Center, the staff is attempting to find innovative 
strategies to reduce these barriers and to facilitate 




Box 1 represent examples of general language 
for a reservation of IP rights for humanitarian 
purposes (with a specific focus on developing 
countries) incorporated by the Danforth Center 
into its research and license agreements (specif-
ic language was taken from sponsored research 
agreements and/or license agreements).
Agreements must also provide for the indem-
nification of technology providers and for tech-
nology stewardship. Here is an excellent example:
Agreement Relating to COMPANY Patent 
Rights and to PROJECT/TRAIT Between 
COMPANY and the Donald Danforth Plant 
Science Center:
5.1 Danforth Center agrees to indemnify and 
hold COMPANY and its employees, directors, officers 
and agents harmless against any and all claims, loss-
es, liabilities or expenses (including court costs and 
reasonable fees for attorneys and other professionals) 
on account of any injury or death of persons or dam-
age to property to third parties or to COMPANY 
caused by, arising or alleged to arise out of 
Danforth Center’s or DEVELOPING COUNTRY 
COLLABORATING INSTITUTION’s activities 
under or in connection with this Agreement. Such 
right of indemnification under this Agreement shall 
be in addition to, rather than to the exclusion of, 




DANFORTH CENTER shall retain the right to use Danforth Center IP and Joint IP for both academic 
and commercial research purposes, which shall include the right to use such technology for the 
benefit of countries eligible for International Development Association funds as reported in the 
most recent World Bank Annual Report (“Developing Countries”). Such use of any Danforth Center 
IP and/or Joint IP for such humanitarian purposes shall require sixty (60) days written notice to 
SPONSOR of DANFORTH CENTER’s intent to so use such Danforth Center IP and/or Joint IP.
Terms	from	the	Article	on	grant	of	Rights:	
DANFORTH CENTER and SPONSOR shall diligently and in good faith negotiate the terms of any such 
license(s), provided, (a) any such license shall contain the terms set forth in Appendix [__], attached 
hereto, and (b) the parties shall in good faith negotiate provisions for preserving the availability 
of Danforth Center IP and/or Joint IP for meeting the needs of Developing Countries. Such option 
shall extend, on a patent application by patent application basis, for one (1) year after the filing of a 
utility patent application to protect Danforth Center IP and/or Joint IP, or for one (1) year from the 
termination of this Agreement, whichever is sooner (the “Option Period”), and may be exercised at 
any time during such period by SPONSOR in its sole discretion.
Terms	from	the	Article	on	options	and	licenses:	
Humanitarian Use Clause and Research Exemption. Notwithstanding anything herein to the contrary, 
the Parties agree that each of the Parties shall have and retain the right under Project Information 
and Project Patents to use Project Information for research purposes. In the case of Danforth Center 
this right shall be limited to the right to use such technology in research by or under the control 
of Danforth Center for the benefit of countries eligible for International Development Association 
funds as reported in the most recent World Bank Annual Report (“Developing Countries”), and 
the right to work with other not-for-profit Third Parties in connection with such research, and 
to publish the results of such research subject to the confidentiality, nonuse and nondisclosure 
provisions of this Agreement, provided that, Danforth Center shall grant no rights under the results 
of such research to any Third Party. Each Party shall provide the other Party at least sixty (60) days 
prior written notice of its intention so to use any Project Information. 
ChApTeR	17.10
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provisions of this paragraph will survive the term or 
termination of this Agreement for any reason.
5.	 TeChnology	TRAnSfeR
To understand the Danforth Center philoso-
phy regarding technology transfer, it is critical 
to keep in mind that the driving objective is to 
facilitate and enable access to technology and 
materials. Therefore, within this context, several 
examples of different agreements that facilitate 
such access and enable the center’s ability to 
share its technologies with collaborators and 
others are of specific interest. Pertinent exam-
ples include approaches for facilitating/enabling 
technology access, such as the enabling technol-
ogy license and the letter of nonassert. In addition, 
although generic material transfer agreements 
(MTAs) are commonly available, an example is 
included here, as some of the specific terms are 
useful when there are limitations on the transfer 
of enabling technologies or grant-back rights to 
the technology provider. 
Before considering any detail regarding spe-
cific strategies and practices to facilitate access to 
enabling technologies, the following should be 
noted: According to U.S. Patent Law, without 
the explicit right or grant of license to do so, the 
transfer by an entity within the United States of 
patented materials (that is, product or process in-
ventions protected by a U. S. patent) or compo-
nents thereof that could be used to reconstruct the 
patented technology to another party, even if this 
party is in a country in which the materials are 
not patented, might constitute an act of infringe-
ment by the provider, but not necessarily the re-
cipient, of the patent rights of the patent holder. 
However, this possibility depends on whether, or 
not, pertinent patent rights have been exhausted 
via legitimate sale of the patented item(s). Thus, 
this issue needs to be carefully considered with 
respect to any transfer of tangible property pur-
suant to an MTA (that is, the omnipresent pos-
sibility of third-party IP rights embedded in the 
transferred materials, for example patent rights). 
In some cases, MTA’s may have grant-back obli-
gations based on requirements of the provider or 
third party requirements. 
Examples of these more-restrictive MTA re-
quirements are provided below:
• Research Materials represent a significant 
investment on the part of Danforth and/or 
Providers and are considered proprietary 
to Danforth and/or Providers. Recipient 
therefore agrees to retain control over this 
Research Material and further agrees not 
to transfer the Research Materials to third 
parties without advance written approval of 
Danforth. Under no circumstances should 
materials be transferred outside the United 
States or to an agent acting on behalf of a 
foreign country, except as permitted by U.S. 
export control laws. Recipient agrees to give 
Danforth reasonable advance written no-
tice of any proposed transfer of Research 
Materials outside the United States or to an 
agent acting on behalf of a foreign country. 
Danforth reserves the right to distribute the 
Research Material to others and to use it for 
its own purposes. Nothing in this Agreement 
will prevent Recipient from engaging in any 
activity with regard to material that is ob-
tained from a source other than Danforth.
• The Research Materials will be used for 
internal research purposes only and specifi-
cally for the Research Project as described 
above and in detail in the Description of 
Research Project, appended hereto and in-
corporated herein. 
• Recipient will provide Danforth with a 
written semi-annual report (“Research 
Report”) of the progress and results of the 
Research Project and the Recipient’s ex-
perience in using Research Materials. The 
Research Report shall be due six (6) months 
from the Effective Date of this Agreement 
and every six (6) months thereafter with a 
final report due upon termination of this 
Agreement. Each Research Report should 
be provided to the attention of Dr. Karel 
R. Schubert, at the address included here-
in. Danforth may compile information 
contained in such Research Report for 
distribution among the members of the 




• Nothing in this Agreement is intended to 
prevent publication of results of Recipient’s 
research. Recipient will provide to Danforth, 
at least sixty (60) days in advance of sub-
mission or disclosure, an electronic copy 
for review of any abstract, presentation or 
manuscript describing the progress or results 
of the Research Project or Recipient’s use of 
the Research Materials (“Publication”) to 
be submitted for publication or otherwise 
publicly disclosed. Danforth agrees to a 
timely review of such proposed Publication 
by Recipient disclosing any confidential 
information of Danforth and/or Providers, 
as defined herein, and/or any Improvement 
(as defined in Section 9 hereof ) for which 
Danforth and/or Provider may wish to seek 
intellectual property protection. Recipient 
agrees to remove, at Danforth’s sole request, 
any confidential information and to delay 
publication for up to an additional thirty 
(30) days to permit filing for intellectual 
property protection on any Improvement. 
Public disclosures of research results will 
acknowledge Danforth’s and/or Provider’s 
contribution of Research Materials, in 
the accepted style, as appropriate under 
the circumstances. While Danforth does 
not transfer ownership of the Research 
Materials to Recipient, should Recipient’s 
use of Research Materials result in pat-
entable inventions, Recipient agrees to 
promptly provide Danforth with an en-
abling disclosure at least thirty (30) days 
prior to submission for public disclosure 
for Recipient and Danforth to determine 
the need to seek statutory protection.
• Recipient may make modifications or en-
hancements (“Improvements”) to Research 
Materials during the course of the Research 
Project. Recipient understands and agrees 
to promptly notify Danforth of any such 
Improvements of Research Materials (wheth-
er or not patentable) that Recipient makes to 
Research Materials within no more than nine-
ty (90) days of making such Improvement 
and to keep Danforth timely informed 
of any applications to obtain intellectual 
property protection to the extent claiming 
such Improvements. Such notification may 
be through (i) submission of the required 
semi-annual Research Reports to Danforth; 
(ii) through submission of Publications to 
Danforth for review; or (iii) through written 
notification to Danforth.
• In consideration of the contribution of 
Research Materials, Recipient grants to 
Danforth a royalty-free license, with the 
right to grant sublicenses to make and 
use such Improvement, and products and 
processes developed from or incorporating 
such Improvement for internal research 
purposes.
• Recipient grants to Danforth an option, for 
one (1) year following Danforth’s receipt of 
written notification of an Improvement, 
to obtain a royalty bearing nonexclusive 
commercial license, with the right to grant 
sublicenses to make, use, import, offer for 
sale, or sell products, and processes incor-
porating such Improvement. The terms of 
the license will be negotiated with diligence 
and in good faith among and between the 
Parties at the time Danforth, at its sole dis-
cretion, elects to exercise its option. The 
Danforth is under no obligation to negoti-
ate or enter into any definitive agreement 
with Recipient with respect to licensing.
6.	 pARTneRShIpS	And	Ip	RIghTS
This sections explains the center’s philosophy re-
garding the creation of scientific partnerships, col-
laborations, and alliances and provides some of 
the key elements of these agreements as they relate 
to IP rights and humanitarian use. Most research 
collaborations start with the signing of a general 
memorandum of understanding and agreement 
(MOA) between the parties (Box 2). These agree-
ments are generally nonbinding and reflect the 
intent of the parties to enter into more definitive 
agreements. The key elements of these agreements 
include the statement of purpose and the intent 
of the parties to enter into more definitive agree-
ments. Examples of two such generic MOA’s are 






1. Recent contacts established between the two organizations;
2. The expressed desire by the authorities of both organizations to establish long-term, fruitful 
collaboration in fields of common interest including improvement of cassava and sweet 
potato.
3. The anticipated benefits of such collaboration promoting agricultural research-for-
development in Sub-Saharan Africa, among others, through advances in applied plant 
biotechnology and the exchange of scientists and students, hence broadening the relative 
expertise of each organization;
4. The prospects and mutual benefits from the potential expansion of our respective expertise 
as well as our financial resources base.
The	parties	agree	as	follows:
Article 1: INSTITUTION and Danforth Center (the “Parties”) agree to explore opportunities for 
funding of collaborative projects, and once funding opportunities are identified, to 
jointly develop proposals for scientific research, development, and technology transfer 
in areas of interest for sustainable agriculture and development in Sub-Saharan 
Africa.
Article 2: Each one of the parties involved can initiate the search for request for proposals, and 
the development of such a proposal.
Article 3: This memorandum of understanding does not prevent any party from initiating and 
finalizing separate bilateral (or multilateral) agreements with other institutions. 
Nonetheless, both parties may continue to inform each other, as appropriate, about 
separate collaborative agreements in areas of mutual interest.
Article 4: Each one of the collaborative projects developed under this memorandum of 
understanding (the “MOU”) will be the subject of a specific addendum to this MOU, 
where the resources and responsibilities of each party or partner will be clearly 
defined.
Article 5: Each organization will designate a member of the institution’s staff to be responsible 
for the management and completion of each specific project. The development of any 
proposal will be a joint effort where full participation between scientists from both 
institutions is expected.
Article 6: As projects are jointly developed, both organizations will endeavor to successfully 
complete the collaborative research project.
Article 7: Pending availability of funds, and to the extent possible, both organizations will 
promote exchange of relevant technologies and interaction and cooperation amongst 
personnel from each organization.
Article 8: To the extent possible, each organization will grant visiting scientists, students and 
trainees from the other partner institution all facilities, privileges and responsibilities 




a general letter of intent used for the creation of a 
multi-institutional alliance or partnership.
At the Danforth Center, the next stage in 
the development of a scientific partnership and 
research collaboration between different insti-
tutions is the creation of an interinstitutional 
agreement (IIA) to serve as a broader umbrella 
agreement. The IIA provides background in-
formation on the interests of the participating 
organizations and general information on the 
purpose of the collaboration. The IIA generally 
does not include details about specific projects 
individuals are involved in, as these details are 
covered in subsequent, more-definitive agree-
ments. The IIA does provide details on the gen-
eral principles of confidentiality, ownership and 
rights of the parties, IP management practices 
and IP protection, financial considerations in-
cluding sharing of patent costs, publications and 
authorship, the use of marks and publicity, han-
dling of disputes, and the sharing of value de-
rived from jointly created intellectual property 
along with other general terms. 
As IP rights and ownership are essential 
considerations of any such agreement, the cen-
ter’s philosophy, as expressed in all such agree-
ments, is that the parties, whether public or pri-
vate, involved in the collaboration and pursuant 
to the creation of joint IP rights shall jointly 
own such intellectual property (with the rel-
evant limitations of joint ownership) and shall 
share equally in any value created through the 
use and/or licensing of such technology, unless 
the parties mutually agree (either beforehand or 
Article 9: The Danforth Center is not a degree-granting institution. When the exchange 
involves students who are interested in enrolling in coursework as part of a degree 
program within a local institution with the intent of obtaining an academic degree, 
the candidates must comply with the normal conditions of admission and candidacy 
within said degree-granting institution for the stated degree. 
Article 10: All rights to data, including laboratory and field notebooks, and material contained 
in such notebooks, and research results (including formal or informal reports) and 
products ensuing from partnership projects between both parties, shall belong jointly 
to INSTITUTION and the Danforth Center.
Article 11: Both parties consider that excluding others from accessing research products and 
results from their joint research-for-development is contradictory to their mandate 
and mission. Therefore, INSTITUTION and the Danforth Center agree not to secure 
patents or plant breeders’ rights from their partnership research unless such protection 
is deemed necessary to keep these materials or technologies available and freely 
accessible to its beneficiaries.
Article 12: Each of the parties reserve the rights to develop and commercialize the products and 
results from their joint research for use by small farmers.
Article 13: This memorandum of understanding will be effective upon signature by designated 
representatives from both organizations.
Article 14: This memorandum of understanding will be effective for a period of three years and 
will be renewed for the same period upon mutual consent of both parties.
Article 15: This memorandum of understanding can be modified, discontinued, or cancelled, by 
written notification of either party, at least six months prior to the effective date of 





subsequent to the invention) to a different for-
mula for value sharing based on, for example, 
differences in the intellectual and/or financial 
contributions of each party and/or the party’s 
employees. It is inherent in these agreements 
that the terms for any value sharing between 
the institutions and their inventors will be 
determined by the respective institutions and 
will be revenues and royalties that will be split 
and distributed according to defined princi-
ples and formulas of the inventors’ parent or-
ganization. The parties also agree to define the 
strategy and lead organization for the manage-
ment of the intellectual property, including fil-
ing, prosecution, and maintenance of patents, 
marketing and licensing the technology, and 
how costs for protecting intellectual property 
will be shared. These key general practices and 
considerations are addressed upfront in the 
umbrella agreement and then specific details 
and/or modifications may be incorporated 
into the subsequent, definitive project-specific 
agreements.
An example of the generic IIA used by the 
Danforth Center is included in its entirety in the 
supplemental materials.1 Excerpts from this ge-
neric IIA are represented in Box 3 at the end of 
the chapter, as they relate to some of these key 
elements. These excerpted, sample articles pro-
vide an overview of how such a document forms 
the basis for the general umbrella agreement and 
forms the framework for specific agreements. As 
such these sections can thereby be incorporated 
into the specific agreements. Once a technology 
is developed, a nonconfidential disclosure may be 
developed to aid in marketing joint technology. 
An example of a nonconfidential disclosure is in-
cluded in the supplemental materials.
7. ConCluSIonS
The Danforth Center regards its role in interna-
tional development as a critical component of its 
overall mission, which categorically involves pro-
moting the transfer of technological innovations 
arising out of the R&D efforts at the Danforth 
Center to developing countries around the globe. 
Protecting and managing intellectual property, 
regardless of whether it is owned by the Danforth 
Center, its partners/collaborators, or other third-
parties, is interwoven into this process of tech-
nology transfer. Thus, IP rights, managed effec-
tively, efficiently, and strategically, represent a 
mechanism for facilitating this process. Within 
this context, individuals at the Danforth Center 
have strived to organize and then implement an 
integrated, comprehensive and adaptable system 
for best practices in managing IP rights. The ex-
amples of agreements presented in this chapter 
are a manifestation of this system. They provide 
practical examples that other institutions might 
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Article 1. Purpose and Scope of Agreement
1.1. The purpose of this Agreement is to provide a contractual framework to govern 
collaborative research projects and other forms of collaboration undertaken by the 
Danforth Center and Collaborating Institution and is intended to apply in the absence 
of separate agreements between the Institutions governing specific cases.
1.2. In the event of any conflict or inconsistency between the provisions of this Agreement 
and the provisions of a separate agreement between the Institutions governing a 
specific matter, the provisions of such separate agreement shall control with respect 
to such matter.
Article 2. Definitions
  “Developing Countries” means the countries eligible for International Development 
Association funds as reported in the most-recent World Bank Annual Report as of the 
date applicable to such determination, or the substantively equivalent designation by 
the World Bank if such report is no longer published.
 “Joint Intellectual Property” means any Intellectual Property made or obtained jointly 
by Researchers of both the Danforth Center and Collaborating Institution or jointly 
owned by both Institutions by agreement or under applicable law.
Article 3. Material Transfer
3.1. From time to time a Researcher at either Institution may wish to request from the 
other Institution the transfer of certain Research Information or Research Material for 
research purposes. Both Institutions agree to use their reasonable efforts to cause each 
such request to be made by and to their respective Technology Management Offices 
and in accordance with such procedures and forms of written agreements as each 
Institution may establish from time to time for transferring material to, or receiving 
material from, another institution. In the event of any conflict or inconsistency 
between the terms of this Article and any separate written agreement between the 
Institutions that pertains specifically to a particular transfer of Research Information 
or Research Material, the terms of such separate agreement shall control with respect 
to that particular transfer of Research Information or Research Material.
3.2. In the event that, notwithstanding the foregoing, Research Information or Research 
Material is in fact transferred at any time from one Institution (the “Provider”) to 
the other Institution (the “Recipient”) without a written agreement between the 
Institutions relating specifically to such transfer, the terms of this Article shall govern 
each such transfer.
3.3. The Recipient shall have a nonexclusive, royalty-free license to use the Research 
Information or Research Material only in connection with academic and noncommercial 
research conducted by the Recipient. Research Material shall not be used in humans. 
The Recipient shall comply with all applicable laws, rules and regulations applicable to 
the use and handling of the Research Information and Research Material.
3.4. The Recipient shall not transfer the Research Information or Research Material to a 
third party except for academic and noncommercial research and the Recipient agrees 




Article 4. Confidential Information
4.1. In the event that Research Information or Research Material is also Confidential 
Information as defined above, then the provisions of this Article shall apply to such 
Confidential Information, notwithstanding the provisions of Article 3 with respect to 
Research Information and Research Material.
4.2. Each Institution agrees to use its reasonable efforts to obtain, or to assist the other 
Institution in obtaining, from each Researcher, employee and contractor of such Institution 
who receives Confidential Information from the other Institution, an agreement that 
such Researcher, employee or contractor: (a) will maintain such Confidential Information 
in the confidence normally accorded to internal confidential materials of the Researcher’s 
own Institution, but in any event using not less than reasonable care; (b) will not use 
the Confidential Information for any purpose other than academic and noncommercial 
research at such Researcher’s own Institution; (c) will not disclose the Confidential 
Information to others, other than to other Researchers at such Researcher’s own 
Institution, making them aware of the confidentiality obligations under this Agreement; 
and (d) will not make any copies of the Confidential Information composed of Research 
Materials without the other Institution’s prior written permission.
4.3. It is also agreed that each Institution will return or destroy the Confidential Information 
received from the other Institution within 60 days after the disclosing Institution so 
requests. Notwithstanding the foregoing, each Institution shall be entitled to keep 
one copy of the other Institution’s Confidential Information which must thereafter 
be restricted to use for legal purposes as a record of the Confidential Information 
returned under this Agreement.
Article 5. Ownership of Intellectual Property
5.1. Rights to all Danforth Intellectual Property shall vest according to the policies of the 
Danforth Center relating to such Danforth Intellectual Property.
5.2. Rights to all Collaborating Institution Intellectual Property shall vest according to the 
policies of Collaborating Institution relating to such University Intellectual Property.
5.3. All Joint Intellectual Property shall vest according to applicable principles of United 
States law and the policies of the respective Institutions as applicable to the legal 
interests and rights of each such Institution in and to such Joint Intellectual Property.
Article 6. Patents and Other Protection of Intellectual Property
6.1. The Danforth Center shall be responsible for all decisions and costs relating to 
the preparation, filing, prosecution, and maintenance of U.S. and foreign patents 
and patent applications and other forms of protection with respect to Danforth 
Intellectual Property and for the selection and compensation of legal counsel and 
other representatives with respect thereto. 
6.2. Collaborating Institution shall be responsible for all decisions and costs relating to 
the preparation, filing, prosecution, and maintenance of U.S. and foreign patents 
and patent applications and other forms of protection with respect to University 
Intellectual Property and for the selection and compensation of legal counsel and 





Article 7. Identification of Prospects for Commercial Development
7.1. The Institutions agree to form a “Joint Marketing Team” for the purpose of collaborating 
in the identification and pursuit of prospects for the commercial development of 
Danforth Intellectual Property, University Intellectual Property and Joint Intellectual 
Property. The Joint Marketing Team shall have an equal number of persons appointed 
by the Technology Management Office of each Institution. Each Institution shall have 
the right to change any or all of its representatives on the Joint Marketing Team at any 
time and from time to time, upon written notice to the other Institution. A quorum 
of the Joint Marketing Team shall consist of not less than a majority of the members 
of the Joint Marketing Team, provided that at least an equal number of members 
appointed by each Institution are present.
7.2. The Joint Marketing Team shall have the following responsibilities:
(a) to stay informed on the research being conducted by Researchers at each Institution 
in plant biology and its application to sustainable productivity in agriculture, forestry 
and allied fields;
(b) to stay informed on current developments in, and prospects for, the commercial 
application of technologies resulting from research in the plant sciences;
(c) to evaluate the prospects for commercial development of the research in the plant 
sciences being conducted by the Researchers at each Institution;
(d) to identify opportunities for the commercial development of Danforth Intellectual 
Property, University Intellectual Property and Joint Intellectual Property, and to 
promptly bring such opportunities to the attention of the Technology Management 
Offices of the respective Institutions;
(e) to identify future research projects that could be carried out by Researchers at one or 
both Institutions for which there is a favorable prospect of commercial development; 
and
(f) to identify and pursue funding support for the conduct of such research projects by 
Researchers at one or both Institutions.
Article 8. License Grants and Revenue Sharing
8.1. The Danforth Center shall be responsible for all decisions and costs relating to the 
grant of licenses with respect to Danforth Intellectual Property and shall, as between 
the Institutions, be entitled to retain all revenues derived therefrom.
8.2. Collaborating Institution shall be responsible for all decisions and costs relating to the 
grant of licenses with respect to University Intellectual Property and shall, as between 
the Institutions, be entitled to retain all revenues derived therefrom.
Article 9. Reservation of Use for Research and for Developing Countries
9.1. Each Institution shall have the right to use Joint Intellectual Property for both academic 






9.2. Each Institution shall have the right to use Joint Intellectual Property for the benefit of 
Developing Countries, and shall have a nonexclusive, royalty-free, irrevocable license, 
under such right, title and interest as the other Institution may have in and to the 
Joint Intellectual Property, to make, use, sell, offer for sale, import, or practice any 
Joint Intellectual Property within the Developing Countries, with the right to grant 
further sublicenses thereunder within the Developing Countries. The license granted 
hereunder includes any patent applications and issued patents claiming priority 
from, or the benefit of, the Joint Intellectual Property, and any reissues, extensions, 
substitutions, continuations, divisions, or continuations-in-part derived therefrom, 
or any foreign patents and patent applications corresponding thereto. In specific 
cases the Institutions may agree in writing to limit the license granted hereunder to 
specified fields of use or to one or more specified Developing Countries.
9.3. Each Institution agrees that any licenses granted by it to third parties with respect to 
any Joint Intellectual Property shall make provision for preserving the availability of 
such Joint Intellectual Property for meeting the needs of Developing Countries.
Article 10. Publications and Publicity
10.1. Recognizing each Institution’s desire to publish previously unpublished Research 
Information, and each Institution’s desire to develop the results of research for the 
earliest introduction to the public, each Institution agrees to submit to the other 
Institution copies of proposed publications or presentations as follows:
(a) each manuscript or details of each proposed public oral presentation first disclosing 
Joint Intellectual Property or disclosing Confidential Information of the other Institution 
shall be submitted to the Technology Management Office of the other Institution at 
least 30 days prior to submission for publication or the date of the proposed public oral 
presentation; and
(b) each abstract first disclosing Joint Intellectual Property or disclosing Confidential 
Information of the other Institution shall be submitted to the Technology Management 
Office of the other Institution at least 14 days prior to its submission for publication.
10.2. If within such 30-day or 14-day period, respectively, the reviewing Institution makes 
a good faith determination that such proposed publication, presentation or abstract 
contains patentable Joint Intellectual Property which needs protection or Confidential 
Information which requires removal or revision and notifies the submitting Institution 
accordingly, then the Institutions shall have an additional 60 days to agree upon 
revisions to the publication, presentation or abstract in order to protect Confidential 
Information and in order to file patent applications directed to patentable Joint 
Intellectual Property contained in the proposed publication, presentation or abstract. 
Upon the reviewing Institution’s receipt of written acknowledgement from the 
submitting Institution of the removal or revision of Confidential Information, or 
the filing of a relevant patent application, or the expiration of such 60-day period, 
as the case may be, the publication, presentation or abstract shall be released. The 
Institutions may agree to reasonable extensions, of the periods provided herein 
in order for reviewing Institution to complete the necessary review of publications, 
presentations and abstracts and for the filing of patent applications.
10.3. The determination of the persons who are to be identified as the authors of each 






10.4. Neither Institution shall use the name, trademarks, service marks, logos or other indicia 
of identity of the other Institution or of any Researcher of the other Institution, or any 
adaptation thereof, in any advertising or promotional literature or publicity without 
the prior written approval of the other Institution.
Article 11. Disclaimer of Warranties and Limitations of Liability
11.1. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT OR IN ANY SEPARATE 
AGREEMENT, NEITHER INSTITUTION MAKES ANY REPRESENTATIONS OR WARRANTIES 
OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, 
WITH RESPECT TO RESEARCH INFORMATION, RESEARCH MATERIAL, CONFIDENTIAL 
INFORMATION, DANFORTH INTELLECTUAL PROPERTY, UNIVERSITY INTELLECTUAL 
PROPERTY OR JOINT INTELLECTUAL PROPERTY, INCLUDING WITHOUT LIMITATION 
ANY IMPLIED WARRANTY RELATING TO MERCHANTABILITY, REGULATORY STATUS OR 
EFFICACY CLAIMS, WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, OR WARRANTY 
OF TITLE OR NONINFRINGEMENT.
11.2. No warranty is given by either Institution in relation to the collaborative research work 
by the Researchers of the two Institutions or the uses to which it may be put by the 
other Institution or its fitness or suitability for any particular purpose or under any 
special conditions notwithstanding that such purpose or conditions may have been 
made known to such Institution.
11.3. IN NO EVENT SHALL EITHER INSTITUTION BE LIABLE TO THE OTHER INSTITUTION UNDER 
THIS AGREEMENT OR UNDER ANY SEPARATE AGREEMENT FOR ANY DIRECT, INDIRECT, 
INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES, WHETHER BASED UPON 
PRINCIPLES OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, 
BREACH OF ANY STATUTORY DUTY, PRINCIPLES OF INDEMNITY OR CONTRIBUTION, 
OR ANY OTHER THEORY OF LIABILITY, IN CONNECTION WITH THIS AGREEMENT OR 
SUCH SEPARATE AGREEMENT, EVEN IF SUCH INSTITUTION HAS BEEN ADVISED OF THE 
POSSIBILITY OF SUCH DAMAGES.
Box	3	(continued)
ABSTRACT
This chapter summarizes how intellectual property (IP) 
arising from within the National Health Service in England 
is managed within the context of a national framework 
for managing IP from public sector research in the United 
Kingdom. Describing how the policy framework was de-
veloped and how National Health Service organizations 
were set up to manage IP, this chapter also charts progress 
in the administration of health R&D and the manage-
ment of IP and summarizes how IP management comple-
ments R&D in the National Health Service.
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health care, and prescriptions), and services avail-
able through hospitals. Healthcare provision is 
managed by a number of NHS trusts, self-gov-
erning organizations funded by the Department 
of Health. In 2006/2007 allocations were made 
to 176 acute trusts (consisting mainly of tradi-
tional hospitals), 31 ambulance trusts, 82 mental 
health trusts, and 303 primary care trusts. There 
are also nine care trusts, which are new organi-
zations that provide combined health and social 
care. The primary care trusts are the conduit for 
the bulk of the national budget for all health 
provision. They allocate funds to other trusts ac-
cording to needs and priorities. The trusts do not 
make a profit, although they are required to break 
even, and must deliver high-quality services, us-
ing the resources provided, based on a series of 
targets. Organizations are managed across nine 
regional areas: north, northwest, Yorkshire & 
Humberside, east Midlands, west Midlands, east, 
London, southeast, and southwest.
2.	 R&d	wIThIn	The	nATIonAl	
heAlTh	SeRvICe
Most hospitals engage in research, and clinicians 
of all disciplines participate in many thousands of 
projects of differing sizes and complexity. Most 
research takes place in the teaching hospitals, 




The National Health Service (NHS) is England’s 
national healthcare provider. It is managed by 
a government department, the Department of 
Health, under the secretary of state for health. 
Similar arrangements exist for the provision of 
health services in Scotland, Wales, and Northern 
Ireland. The healthcare system is almost entire-
ly administered and operated within the public 
sector—free at the point of use—with the mini-
mal involvement of a small private sector. The 
National Health Service in England is one of the 
world’s largest employers, with over 100,000 peo-
ple currently employed.
Healthcare provision is divided into servic-
es available in the home and community (such 
as general medicine, maternity services, home 
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major medical schools in England, each affiliated 
with several NHS trusts.
Until 1992, this research was unmanaged. 
Universities and other research organizations, in-
cluding commercial organizations, used the NHS 
infrastructure essentially as a free good to meet 
their requirements. But when the NHS R&D 
program began in 1992, the NHS became the 
only national health service to have its own R&D 
program. Its initial objectives were to:
•	 identify research questions that needed to 
be answered
•	 undertake research to answer the questions
•	 implement the answers to improve 
healthcare.
The resulting program based on these ob-
jectives has contributed significantly to the 
development of evidence-based healthcare 
internationally.
This is only part of the program. In 1994, 
an R&D budget (a levy on the total healthcare 
budget) was established by collecting together all 
the declared R&D expenditures of every hospital 
(R&D support funding). A budget for the NHS 
R&D program was also added. R&D support 
funding was divided into two budget headings: a 
budget to support noncommercial research done 
by others in receipt of their own external fund-
ing, and a budget to support research. The first 
budget meets all NHS costs for externally funded 
programs in universities and other agreed-upon 
research partners (research councils, medical 
charities, the Department of Health, and other 
government departments). The second budget 
only supports programs of the required quality. 
The NHS R&D program has now been extended 
from its original objectives to straddle such pro-
grams as Health Technology Assessment, Genetics 
Knowledge Parks, Research Networks, the 
Cochrane Collaboration and Systemic Reviews, 
and the expansion of a clinical research facility 
to support clinical trials. In 2004/2005, the total 
NHS R&D budget was UK£604 million, made 
up of UK£487 million for R&D support fund-
ing and UK£117 million for the NHS R&D pro-
gram. Details of the whole program and how it is 
developing (including plans to bring together the 
NHS budget and the Medical Research Council 
budget within a new National Institute for Health 
Research) can be found on the Department of 
Health Web site.1
The research governance framework for car-
rying out research in the NHS2 requires all those 
undertaking research to understand the impor-
tance of IP in their research and to take steps to 




NHS IP is generated in two ways:
•	 through R&D programs carried out by 
NHS researchers
•	 through the delivery and management of 
healthcare by NHS employees
The NHS carries out little fundamental non-
commercial medical research. This is normally led 
by universities whose funding is provided princi-
pally by research councils and charities, but of-
ten with NHS staff as collaborators (and funded 
by R&D support funding). There is a small (but 
growing) band of NHS employees employed prin-
cipally to do research. Much R&D expenditure 
in the NHS supports others, for example, univer-
sity researchers, and IP arising from this work is 
often generated jointly with the research partner. 
Even though about one in three academic papers 
in bioscience has an NHS author, the R&D pro-
grams in which NHS researchers participate are 
not the major source of NHS IP. The NHS em-
ploys around 100,000 people who can generate 
IP in their day-to-day jobs, and their potential to 
come up with ideas for new products, processes, 
and treatments is significant. This potential was 
the principle driver for developing the program 
to manage IP in the NHS.
3.2	 The	development	of	a	policy	framework
The development of a policy framework to man-
age IP in the NHS began in 1998 with the ap-
pointment of the author of this chapter as NHS 
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intellectual property advisor. R&D issues were 
addressed first. A health service circular (the 
method of publishing policy at that time) en-
titled A Policy Framework for the Management 
of Intellectual Property within the NHS arising 
from Research and Development3 was published 
in 1998. It set out, for the first time, the prin-
ciples of IP management. The circular was sup-
ported by two additional publications:
•	 Handling Innovation and other Intellectual 
Property: A Guide for NHS Researchers4
•	 The Management of Intellectual Property 
and Related Matters: An Introductory  
Handbook for R&D Managers and Advisers 
in NHS Trusts and Independent  
Providers of NHS Services5
The guide for researchers was designed to in-
form researchers about what constitutes IP, how 
to recognize it, and what to do. The handbook 
was for R&D managers (generally each research-
active trust has an R&D manager), but not for IP 
practitioners.
The policy framework had the following ba-
sic principles:
•	 IP generated in research belongs to the or-
ganization employing the researcher
•	 if the IP has commercial value, it should be 
protected and commercialized by a suitable 
organization on behalf of the owner
•	 income generated by commercialization 
should be shared between the inventor, the 
owner organization, and the commercializ-
ing organization
These principles were foreign to the NHS 
because they raised the possibility that one NHS 
organization could retain income generated by 
the commercialization of IP and not share it with 
fellow organizations. Although these principles 
were agreed to and the framework was published, 
it was recognized that it would be more difficult 
to get others to sign up for these principles out-
side an R&D context.
In 1998, it was too early to extend the pol-
icy to IP arising from all sources, particularly 
from patient care. Moreover, the set-up and 
use of companies by NHS organizations to aid 
commercialization was specifically not allowed at 
this time, although this restriction was seen as an 
impediment to commercialization; because NHS 
owners of IP could not have a stake in spinout 
companies, collaborative work with universities 
would be inhibited.
At the time that the NHS was publishing its 
policy framework for IP arising from R&D, the 
national climate for innovation was changing and 
the government was determined that the public 
sector should develop a knowledge-based econo-
my that would recognize IP, treat it as a national 
asset, and translate it into the benefits of jobs and 
prosperity. The treasury and the Department of 
Trade and Industry published a series of docu-




In 1985, U.K. universities had been given free-
dom to own and commercialize IP arising from 
their research funded by research councils. If 
universities wanted this freedom, they had to set 
up approved management systems. Almost all of 
them now have approved systems, and almost all 
are based on the principle of ownership by the 
university, an obligation to commercialize (or to 
give back to the researcher), and benefit sharing 
with the researcher.
Research is carried out in the United 
Kingdom not only by universities but also by a 
number of public sector research establishments 
(PSREs). In 1999, PSREs and NHS trusts spent 
UK£2.2 billion out of a total of UK£6.75 billion 
of research funding. Apart from the Institutes of 
the Medical Research Council, there was little 
history of government laboratories managing IP 
outputs. To try to change this position, the trea-
sury set up a task force, which in 1999 published 
the Baker Report.6 It made a series of far-reaching 
proposals that were accepted by the government,7 
which required all PSREs, many employing civil 
servants, to have systems in place to identify and 
commercialize IP of value. Moreover, the transfer 
of research outputs to benefit the wider national 
economy had to be part of a PSRE’s mission.
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The government confirmed that IP should be 
owned by the PSRE, which was usually the most 
appropriate organization (rather than its spon-
soring department) to transfer the benefit to the 
national good. It was also generally recognized 
that income derived from this activity should be 
retained by the PSRE and not reclaimed by the 
sponsor. It confirmed that researchers, many of 
whom were civil servants, should be allowed to 
share in the income generated, and that when 
commercialization is achieved through the setting 
up of a spinout company, the researchers could 
have an equity stake. An initial fund of UK£10 
million, against which PSREs could bid, was 
made available to allow PSREs to set up commer-
cialization offices and increase their capacity to 
manage IP outputs.
The Baker report and the government re-
sponse to it meant that all research outputs from 
public sector research would be managed under a 
common policy (mirroring that of universities). 
This policy fundamentally changed the position 
of researchers and their organizations. In addition, 
guidelines for the treatment of IP in government 
research contracts were published by the U.K. 
Patent Office.8 These were all major changes.
5.	 developmenT	of	The	nhS	
fRAmewoRK
The work behind the development of the Baker 
report paralleled and in part informed NHS de-
velopments. The ability of an NHS trust to retain 
income generated by the commercialization of IP 
was used as a precedent by the treasury task force, 
and the support for spinout activity in PSREs led 
to renewed efforts to allow NHS trusts this free-
dom. The NHS trusts had by now been catego-
rized as PSREs and were eligible to participate in 
funding schemes, particularly the fund that had 
been made available to set up IP management 
offices.
Despite the publication of the Baker Report, 
it was not until 2002 that the Department of 
Health was able to publish a policy document 
covering the full range of NHS outputs. This took 
nearly three years of intense effort. By 2002 it was 
no longer possible to prescribe policy; it had to 
be guidance against which progress (and compli-
ance) could be measured. Aimed at providing a 
common framework for all NHS organizations, 
the document was called The NHS as an inno-
vative Organization: A Framework and Guidance 
on the Management of Intellectual Property in the 
NHS.9
The title refers to the NHS as an innovative 
organization, which reflects the fact that by 2002 
innovation was recognized by the Department of 
Health at the highest level as an important part of 
the work of the NHS. This was largely the result 
of the new government agenda for supporting in-
novation within a knowledge-based economy.
The content of the framework and guidance 
covers three main areas:
1. The management framework
2. Employment and ownership issues for or-
ganizations and employees
3. Partnership in IP management with uni-
versities and other research funders
Each area had complex issues to be resolved; 
we explain below how the most important of these 
were overcome. The content itself was developed 
by closely working with Department of Health 
commercial lawyers, and although the document 
is more legalistic than might have been imagined 
initially, it was vital to ensure that the secretary of 
state for health was protected from any legal chal-
lenge in this frequently contentious area. 
5.1	 Extension	to	the	existing	policy	
framework	for	R&D
NHS IP can arise from NHS R&D and from the 
delivery of patient care by all those employed by 
the NHS. The 1998 circular sets forth the respon-
sibility of NHS organizations receiving R&D 
funding to identify IP arising from research, but 
NHS organizations were not responsible for sys-
tematically capturing IP associated with the de-
livery of patient care. This situation remains the 
same. However, trusts are expected to have access 
to a management structure (such as that described 
in section 5.7), so that when any IP is found 
employees have a place to go for expert advice. 
The position in the Framework and Guidance is 
that outputs from patient care should be man-
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aged in the same way as those from R&D. The 
Framework and Guidance recognizes that not all 
outputs will have a commercial endpoint and that 
some (indeed the majority) should be treated as 
opportunities to change practices by freely dis-
seminating them across the NHS.
The statutory purpose of commercializing 
IP in the NHS (captured in the 1977 and 1990 
NHS acts) is to make more income available for 
the health service. When an invention is exploit-
ed successfully and new products of commercial 
value are produced and sold, income will be gen-
erated (and shared with inventors). However, 
when the IP relates to a change of practice (usu-
ally covered by copyright), income generation 
is unusual. Nonetheless, because costs could be 
saved, it was agreed eventually that cost savings 
could be treated as income generation and so sat-
isfy the statutory requirement.
5.2	 Income	retention	by	the	trust	
following	commercialization
Sharing income with inventors is a fundamental 
part of IP management within the public sector in 
the United Kingdom, and the principle was readi-
ly accepted and supported by health ministers and 
NHS leaders. However, it was more difficult to 
get the wording of the Framework and Guidance 
accepted by those charged with managing NHS 
finances. This is because it ran counter to a fun-
damental tenet of the NHS: any surplus income 
should be shared with other NHS organizations. 
In the end, it was agreed that surplus income aris-
ing from the commercialization of IP after paying 
all costs, for example, inventors, could be retained 
by the trust and used at the discretion of the trust 
to improve healthcare. It could be used to improve 
a service but not, for example, to build car parks. 
A retention limit of 0.2% of the trust turnover 
was set before it was necessary to bring a successful 
commercialization to the attention of those pro-
viding funding to the trust. In practice this meant 
that, unless there was a blockbuster invention, the 
principle had been accepted.
5.3	 Ownership	of	NHS	IP
Under U.K. law, IP (patents, copyright, trade-
marks, design rights, and know-how) generated 
by an employee in the course of employment or 
normal duties belongs to the employer unless the 
employer and employee have agreed otherwise. 
The latter was rare because in 2002 few employ-
ees had contracts that addressed IP. 
However, for patented inventions the law 
gives additional conditions that must be met in 
order for the employer to own the rights. Not 
only must the invention be made in the course 
of normal duties, but it must also have been rea-
sonably expected that an invention would result 
from such duties. For example, this would be 
reasonably expected for an employee engaged in 
R&D, but it could be doubtful for a surgeon per-
forming an operation who suddenly realized how 
it could be done better. 
The view contained in the Framework and 
Guidance is that should a surgeon (or any other 
employee) invent something during normal du-
ties that requires a patent and needs development 
and testing before it can be used on patients, then 
the patent should be assigned to the employer to 
manage (as for all other IP) should the inventor 
want to use NHS resources to develop the inven-
tion. There is no requirement to assign the patent 
unless NHS resources are used, but since almost 
all such inventions would require development, 
and since the NHS would provide the most con-
venient test bed, the need to argue ownership 
through potentially costly legal procedures would 
be minimized. If an employee chose not to assign 
the invention to the employer, it would need to 
be developed, perhaps in the garden shed, with-
out using NHS resources. Such considerations 
become redundant if all NHS employees have 
appropriate conditions in their employment 
contracts.
5.4	 Employment	conditions
If a trust has employment conditions that set 
out the responsibilities of the employer and the 
employee on all aspects of IP, then questions of 
ownership generally disappear and the focus can 
be on using the IP.
The Framework and Guidance include mod-
el employment contracts and a model entry to a 
staff handbook or similar document. It also con-
siders staff appointed jointly with universities or 
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other organizations and staff who combine NHS 
duties with private practice.
During his tenure as NHS intellectual prop-
erty advisor, the author encountered examples 
of physicians who had made an invention, used 
NHS resources to develop it without informing 
the employer, and then claimed ownership when 
challenged because it was developed in private 
practice. In one case a new device had been pat-
ented and licensed to a U.S. medical device com-
pany without the knowledge of the employer. It 
was brought back into the ownership of the trust 
because it clearly arose from a research program.
A number of factors, foremost among them 
the high turnover of human resources staff and 
the lack of IP experience in the NHS, made it 
difficult and time consuming to clear this part 
of the Framework and Guidance through the 
Department of Health. Clearance was eventually 
given to the content when it was realized that only 
guidance was being given, so trusts could choose 
not to follow the guidance if they wished. In real-
ity trusts are pragmatic and follow the guidance 
because to do otherwise would involve them in a 
great deal of legal work.
5.5	 Partnership	with	universities	and	
other	NHS	research	partners
The NHS undertakes research jointly with univer-
sities and other research partners, such as charities 
and research councils. IP arises from this joint 
work, and ownership might not be clear. Before 
1998, the NHS had no structure to recognize or 
manage IP, and almost nobody in the NHS was 
in a position to do anything about it. Almost by 
default, ownership was claimed by the research 
partner. There were many examples where inven-
tions were realized through joint work but where 
no benefit came to the NHS.
Universities agreed in 2002 to a statement of 
partnership, which specified that when IP is gen-
erated by joint R&D between NHS trusts and 
universities (for example, by individuals holding 
a joint appointment), or where both the NHS 
and the university are partners in the research, 
then the organizations together should decide:
•	 which organization owns the IP
•	 which organization is to manage the IP and 
how costs are to be met 
•	 how any benefit is to be shared after paying 
all costs (for example, inventors)
These arrangements are for research per-
formed jointly, even if the inventor is solely em-
ployed by one organization. Frequently, the other 
organization contributes to developing the IP, and 
so by agreement it can be a beneficiary. The state-
ment of partnership expected that a collaborating 
university and NHS trust would have similar rev-
enue-sharing agreements with their inventors so 
that inventors from different organizations would 
be rewarded in a similar way when their inven-
tion generated income.
There is no rule that determines how ben-
efits are to be shared, but current recommended 
practice starts with equal shares for both parties. 
If the parties agree otherwise, it is adapted. In 
practice, university and NHS bodies are moving 
ever closer in their ways of working—the 50:50 
sharing model is becoming the norm, which is far 
removed from the previous 100:0 model!
5.6	 Spinout	companies:	The	Health	and	
Social	Care	Act	2001
Publication of the government response to the 
Baker Report opened the way for a bill to be 
placed before parliament in 2001 that allowed 
NHS organizations (NHS trusts, primary care 
trusts, and so on) to set up, participate, and in-
vest in companies to generate income. The scope 
was intended to be wider than just IP; in fact, the 
legislation does not even mention IP or spinout 
companies.10 The advantage of a wider provision 
became clear when some of the earliest uses of the 
legislation were for companies that had nothing 
at all to do with IP. 
If they are badly set up, the use of spinout 
companies carries inherent risk. NHS organi-
zations are generally not free to set up com-
panies without a business plan authorized by 
the Department of Health. The business plan 
must comply with Directions (which are legally 
binding) contained within the Framework and 
Guidance. This essentially protects the secretary 
of state for health against unnecessary risk, and 
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it has meant that the Department of Health (like 
other government departments) has had to de-
velop expertise in a new area of activity.
The Framework and Guidance includes de-
tailed guidance to trusts and employees on how 
companies should be established, the role of the 
trust, and the position of employees as directors 
or shareholders. The content follows national 




The Baker Report recommended that PSREs 
should establish management systems to deal 
with their IP. But how were the outputs from the 
acute trusts, the ambulance trusts, the mental 
health trusts, the care trusts, and the primary care 
trusts—a total of 601 organizations in 2006—to 
be dealt with? Although research outputs might 
be expected to concentrate around teaching 
hospitals and their partner universities, no such 
assumption could be made for innovations in 
patient care from doctors, nurses, scientists, tech-
nicians, and so on. It was clearly not cost effective 
or appropriate in terms of likely business to locate 
a management organization in each of the trusts. 
Extending the scope of university technology 
transfer offices was rejected because their inter-
est would be primarily in research-based innova-
tions; patient-care-led innovations were likely to 
be lost. Universities were already being stretched 
by the government innovation agenda. 
The agreed management solution was for 
nine regionally based NHS innovations hubs. 
These map on to the regional government struc-
tures (regional development agencies) in England. 
Each hub covers on average 60–70 organizations. 
Section six describes their operation in more 
detail.
5.7.2 The	hub	as	an	organization
A hub is either an unincorporated association of 
NHS bodies or a company limited by guarantee. 
It has a management board that decides struc-
tures and hires its own employees. In an unin-
corporated association, the employees are NHS 
employees; in a company limited by guarantee 
they are employed outside the NHS. Currently, 
the hubs are split approximately equally between 
the two models. Generally, the hubs have “branch 
offices” that reflect the region’s different geogra-
phies. The London hub, for example, has one 
central office with outposts located close to the 
five principal teaching hospitals. The southwest 
hub, which covers one of the largest geographical 
regions, relies more on electronic communication 
than direct contact.
5.8	 License	agreements	
The Framework and Guidance includes terms to 
be used in license agreements with commercial 
partners. It also includes, for developing coun-
tries, a specific appendix taken from MIHR 
(Centre for the Management of Intellectual 
Property in Health R&D) documentation that 
was produced for The Rockefeller Foundation in 
November 2001.
In the terms for license agreements, the 
Framework and Guidance recognizes that most 
commercializable items of NHS IP will have an 
international market and that licenses will cover 
manufacture and sale in more than one country. 
The Framework and Guidance states that license 
agreements should seek to include terms that are 
likely to give patients in developing countries ac-
cess to products at reasonable cost.
As stated earlier there was some dispute as 
to whether all NHS trusts should benefit from 
an invention made by another trust, particu-
larly whether products arising from the inven-
tion should be royalty free to the NHS. The 
Framework and Guidance says that those negoti-
ating the license agreement (the NHS innovations 
hub or another body) should seek to include pre-
ferred terms for sales to other NHS organizations. 
Essentially, however, the main way for a trust to 
benefit is through developing its own inventions.
5.9	 Independent	providers	of	health	services	
within	the	NHS
Some health professionals (such as general prac-
titioners, dentists, and pharmacists) are not NHS 
employees but work under contract with a prima-
ry care trust. Some of these professionals generate 
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IP through NHS research and others through 
their services. The framework and guidance rec-
ognizes that the NHS is unlikely to own IP out-
side R&D, but it offers these professionals the 
services of the NHS hubs under the same terms 
and conditions as NHS employees, if they assign 
the IP to the primary care trust.
6.	 The	woRK	of	The	nhS	
InnovATIonS	huBS
IP management is a complex task and has not 
been a core business for the NHS. Ideas for new 
technologies (new or improved devices, for ex-
ample) need to be protected, often by filing a pat-
ent application. Converting ideas into new prod-
ucts—and rejecting unsuitable ideas—require 
specialist skills, and the NHS innovations hubs 
have been set up to provide these services.
The first hub in the northwest began its op-
eration in 2001, which was followed by the other 
eight. The last hub was only recently established 
in the southwest.
A driving force for their creation was 
the UK£10 million PSRE fund set up by the 
Department of Trade and Industry against which 
PSREs could bid. In the first round of funding, 
UK£6 million was provided to create capacity for 
IP management in the public sector, and UK£4 
million for setting up seed funds. NHS trusts 
could apply, and bids for funding to create capaci-
ty were made from all regions through a lead trust. 
The fund was oversubscribed, but many NHS 
bids were successful in the first round of fund-
ing, receiving about one half of the total available 
funding. There have been two further rounds, 
and all hubs have now received funding from this 
source. This adds to core funding provided by the 
Department of Health; initially this was UK£2 
million per year but has since increased.
The hubs are developing their operation in 
close partnership with the nine regional develop-
ment agencies, government organizations set up 
to stimulate and support local business. Several 
of the regional development agencies provide ad-
ditional funding for the hubs in the expectation 
that they will be the source of new products, pro-
cesses, and businesses in their region.
The services that a hub provides include:
•	 identifying IP through clinics and similar 
activities
•	 providing training for NHS employees in 
the importance and understanding of IP
•	 evaluating IP and initiating additional 
R&D to produce evidence of clinical  
application
•	 protecting IP
•	 commissioning the production of 
prototypes
•	 advising on and exploiting IP through li-
censing or setting up of companies
•	 collaborating with universities and other 
third parties in the exploitation of IP  
generated jointly with trusts
Each hub establishes its own networks and 
determines its mode of operation. A national net-
work, the IP Forum, meets monthly or every two 
months. Most hubs charge a membership fee to 
their member organizations, and a large majority 
of the trusts have chosen to join their hub. Hub 
networks usually partner with networks of R&D 
managers. Geography plays its part, but members 
of a hub typically have much in common. They 
extend their scope through establishing a “prod-
uct champion” in a member trust who acts as the 
first contact point for the hub. Currently, hubs 
employ five to 20 people, depending on the hub’s 
state of development. Often the enthusiasm dis-
played by the trusts has to be constrained by the 
available resources of the hub.
A hub has the considerable task of usually 
working with between 60 and 70 trusts. Getting 
all NHS employees without previous training 
and experience to understand IP is an arduous 
task. Web-based training and other methods are 
being used to publicize the work of the hubs and 
to encourage employees to think about innova-
tion. The wage packet and trust newsletters are 
also effective communication tools. Regional 
competitions, in which employees are encour-
aged to submit their innovations to their hub for 
adjudication, have proved an excellent stimulus. 
The opportunity for publicity is very high, and 
the excitement generated in a small trust when 
it wins one of these competitions is remarkable. 
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Regional competition winners go forward to a 
national competition, and the publicity and en-
thusiasm generated by the competition, capped 
off with health ministers presenting prizes at a na-
tional event, bring IP and innovation in the NHS 
to the fore. 
Here are some highlights from 2004/2005:
•	 the number of hub pipeline opportunities 
increased from 497 in 2003/2004 to 1250, 
of which 257 were selected for further 
development
•	 40 licenses were brokered
•	 many hundreds of entries were made to re-
gional innovation competitions
•	 three new spinout companies were 
approved
•	 income generated approximately dou-
bled from its 2003/2004 level to UK£1.5 
million
Of the opportunities selected for further de-
velopment medical devices accounted for 49%; 
biotechnology and pharmaceuticals 8%; diagnos-
tics, 8%; IT and training, 28%; and other areas, 
7%. Around 30% of the potential innovations 
had a university link. The following examples 
show the breadth of these opportunities:
•	 a handheld device that measures accurately 
the size of the pupil of a patient’s eye at the 
scene of a road traffic accident
•	 an electrical device to overcome the effect 
of “dropped foot syndrome,” which is al-
ready being manufactured locally for the 
hub and is the basis of a spinout company
•	 a simple and low-cost device to eliminate 
incidents of patients receiving the wrong 
type of blood
•	 a device to allow the transfusion to a pa-
tient of all blood in a bag
•	 a company set up by a major hospital to 
measure glycemic index, important among 
other things in the management of diabe-
tes, using the expertise of a world-renowned 
laboratory
•	 a virtual reality treatment for lazy eye
A comment on time frame is important. 
When the PSRE Fund was established by the 
Department of Trade and Industry, the Fund rec-
ognized that it would take at least ten years before 
its success (or failure) could reasonably be mea-
sured. The first hub was established in 2001 and 
the last in 2005. Many of the products arising 
from the NHS program require extensive testing 
through trials and other research programs before 
they can be used on patients, and so success is 
never easily nor instantly obtained. Even the de-
vice to ensure that all blood is completely emp-
tied from a transfusion device would take time 
to develop and manufacture before it can provide 
the expected yearly savings of UK£20 million. 
Research and prototype testing of the dropped 
foot device began many years ago and it is only 
now being manufactured.
The growth in income generated in 
2004/2005 was satisfying, but much of this in-
come arose from innovations developed some 
years ago, before the hubs were established. The 
impact of the hubs and the performance indica-
tors used to measure it are themselves an impor-
tant piece of ongoing work. The impact reaches 
far beyond income and numbers of patents.
Each hub has its own Web site and all of 
them are accessible through the NHS innova-
tions Web site at www.innovations.nhs.uk. The 




The way that the NHS developed its framework 
and set up the hubs could be useful for developing 
countries. Perhaps the most useful aspects are:
•	 The NHS model will help developing 
countries if they can agree on a common 
way to treat IP. IP is difficult to deal with 
and differences in approaches across coun-
tries and organizations increases the degree 
of difficulty. The United States and United 
Kingdom models have similar operating 
principles and are recommended as tried 
and tested. 
•	 Scientists and other generators of IP in de-
veloping countries cannot all be IP experts, 
nor do they need to be. Generators of IP do 
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need to recognize that a particular output 
might be important, and be able to iden-
tify individuals who can help promote the 
innovations. The training for researchers 
should not focus on how to draw up license 
agreements but on how to record results, 
how to avoid disclosure, and how to recog-
nize valuable outputs. The principles con-
tained in the NHS Guide for Researchers  
(applicable to researchers outside the health 
fields) seem appropriate.
•	 Researchers need someone in their organi-
zation, to act as a “product champion” who 
can be their eyes and ears, similar to an 
R&D manager who often takes on this role 
in an NHS trust. This advocate does not 
need to understand the intricacies of draw-
ing up license agreements, but does need to 
understand the principles contained in the 
agreements and ensure that the researcher’s 
practices are aligned with those principles. 
Having a product champion is particularly 
important when new collaborations are be-
ing set up and a collaboration agreement is 
being established. The handbook produced 
by the NHS11 could be adapted for use by 
developing countries. Product champions 
could form learning networks as they do in 
the NHS.
•	 The IP office needs to be of sufficient scale 
that it offers the experience and expertise 
to deal with complex issues. Once a wrong 
agreement is in place, it cannot be corrected 
(though it can be amended but this often 
takes significant negotiation efforts), which 
is particularly important for developing 
countries with the variety of new technolo-
gies contained, for instance, in agriculture 
and plants. An IP office similar to that of 
an NHS hub, dealing with a number of 
organizations, has much to recommend it. 
Such an office could attract or have access 
to the necessary level of expertise, much 
of it from outside the country, to draw up 
the agreements that protect the interests of 
researchers, the developing country, and a 
collaborator or investor in a technology. 
8.	 ConCluSIon
The NHS hubs are meeting a need and show 
strong indications of success. Widely valued, they 
are rapidly becoming the “one-stop shop” for in-
novation in the U.K.’s national healthcare system. 
To further support innovation, the Department 
of Health is setting up a national innovation cen-
ter that will have a dedicated budget to put on the 
fast track to the marketplace particularly prom-
ising projects. The future looks good provided 
people are patient! ■
tonY Bates, Managing Director, Tony Bates Associates 
Ltd., The Old Vicarage, Vicarage Lane, Olveston, Bristol, 
BS35 4BT, U.K. tony@tbatesassociates.co.uk
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ABSTRACT
Technological innovation is increasingly recognized as an 
important tool for improving global health. The Office 
of Technology Transfer of the U.S. National Institutes of 
Health (NIH OTT) has increased its licensing of technol-
ogies for the prevention and treatment of neglected dis-
eases to partner institutions in developing regions of the 
world. Other efforts have focused on providing assistance 
to indigenous institutions in building their technology 
transfer capacity. In addition to helping to achieve the 
primary objectives of meeting global public health needs 
and strengthening local R&D capacities, NIH OTT ex-
pects such efforts to have a positive impact on national 
policies on intellectual property rights, and, ultimately, to 
increase multinational investments in developing coun-
tries, which will likely result in an even greater effort to 
develop accessible therapies for those in need.
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As part of this effort, NIH seeks to understand 
challenges that hinder the public availability of 
these inventions.
One might naturally ask why NIH, a domes-
tic agency, should involve itself in international 
technology transfer. Enhancing technology trans-
fer to developing countries, however, is an im-
portant humanitarian endeavor consistent with 
NIH’s mission to improve health and save lives. 
Such transfers allow these countries to introduce 
technologies appropriate to their own regional 
needs, building more independence and enabling 
local and regional public health solutions.1, 2, 3 
Because many of these markets are not a priority 
for most companies in developed countries, tech-
nology transfer efforts can be extended outside 
the United States, consistent with humanitarian 
and economic goals.
By necessity, the NIH mission of NIH ex-
tends beyond U.S. borders. The U.S. works to 
improve health worldwide not only for humani-
tarian reasons but also because diseases do not ob-
serve national boundaries. Moreover, improved 
public health allows nations to better maintain 
economic growth and political stability. 
One specific NIH goal for technology trans-
fer is to “strengthen the capacity of developing 





The mission of the U.S. National Institutes 
of Health (NIH), Department of Health and 
Human Services (HHS), is to support biomedi-
cal research that will reduce illness worldwide and 
extend healthy life. NIH’s Office of Technology 
Transfer (OTT) works with institutes and centers 
at NIH and the Food and Drug Administration 
(FDA) to manage the patenting and licensing of 
inventions made by their intramural scientists. 
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development into products, through education 
and technical assistance.”4 By extending R&D ac-
tivities outside U.S. borders, we transfer techno-
logical know-how to developing countries. This 
learn-by-doing approach enhances technological 
capabilities5 and facilitates the development of 
technologically capable partners, which, in turn, 
better leverages the value of technologies and ex-
tends scientific knowledge and practice. Overall, 
such technology transfer activities are likely to 
add value and provide social returns on exist-
ing inventions,6 either by addressing U.S. mar-
ket needs or by improving the health of people 
worldwide and preventing the spread of disease 
across U.S. borders. 
2.	 pARTneRShIpS	In		
TeChnology	TRAnSfeR
The most immediate incentive for OTT to engage 
in international activities is to help reduce the bur-
den of disease globally. Developing countries stand 
to benefit from licensed NIH inventions, because 
when developed locally the technologies are more 
readily available to local markets. Such technology 
transfers may play a particularly important role 
in turning early-stage technologies into biomedi-
cal products in developing countries. Additional 
benefits accrue locally from the development of 
technologies for the developing world by indig-
enous institutions. These include enhanced local 
capacity in research and development, increased 
market competitiveness, the growth of an experi-
enced work force, improvement of scientific excel-
lence, and the consequential growth of the bio-
technology infrastructure, all of which ultimately 
strengthen and stabilize developing countries’ 
economies.7 Figure 1 illustrates the potential im-
pact of technology innovation on global heath. 
The impact of globalization is not limited to 
international trade and economics. 
Globalization also exacerbates existing pub-
lic health challenges that in turn impact the na-
tional interests of industrialized nations. These 
challenges, though not limited to the developing 
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of technologies to developing countries. Indeed, 
the international community now widely recog-
nizes that some diseases that once were contained 
within regional borders now threaten the United 
States in two ways: 
• Emerging and reemerging infectious disease 
epidemics: With increased movement of 
goods, animals, and people, diseases spread 
rapidly across borders, posing direct threats 
to U.S. citizens. It suffices to mention epi-
demics of diseases such as HIV/AIDS, in-
fluenza, tuberculosis, cholera, and SARS, 
which threaten not only the regions where 
they originated but also the entire globe.8
• Risks from civil unrest: The spread of dis-
ease often fuels a cycle of poverty, suffer-
ing, and civil disorder. (Gaining access to 
drugs and medical technologies are genuine 
public welfare concerns in many develop-
ing countries.9,10 Providing access to these 
countries will reduce the burden of disease 
and help improve the quality of life, thus 
diminishing the threat of unrest in volatile 
areas of the globe.) 
While NIH focuses on making new meth-
ods of treating and preventing disease available 
to world markets, the agency also emphasizes the 
importance of making existing vaccines for pan-
demic diseases available to the countries in need 
For example, an effective vaccine for measles has 
been in use in industrialized nations for the past 
40 years, but most of the developing world has 
only recently gained limited access to the vac-
cine.11 In addition, the financial and logistical 
challenges of international efforts to provide anti-
retroviral drugs to treat HIV/AIDS in developing 
countries are well known. 
Other diseases in developed countries remain 
serious public health burdens in developing coun-
tries. Malaria was virtually eradicated through the 
use of insecticides and antimalaria drugs in North 
America and Europe, while Africa, Asia, and Latin 
America saw the development of increasingly re-
sistant mosquito vectors and malarial parasites. 
As malaria became a relatively low health risk in 
developed nations, the development of a malaria 
vaccine became a lower priority. This situation 
led the Bill and Melinda Gates Foundation to 
launch and support the Malaria Vaccine Initiative 
(MVI), an effort to address this serious shortcom-
ing and accelerate vaccine development.12 The 
foundation’s efforts supplement ongoing research 
supported by NIH and other Non-Governmental 
Organizations (NGOs).
Another approach to these public health 
challenges is for institutions, both national and 
international, to encourage and facilitate the 
relatively more technologically advanced devel-
oping countries to enhance their product com-
mercialization capacity to meet local needs. 
Several research studies indicate that this is the 
best approach to combating long-term neglected 
diseases in poor countries in Sub-Saharan Africa, 
parts of Asia, Latin America and the Caribbean, 
and Eastern Europe.13,14,15 Indeed, recent work 
by leading private foundations, such as the Gates 
and Rockefeller foundations, emphasizes devel-
oping countries’ “need for self-reliance and nation-
al production [of health technologies] to ensure that 
country-specific disease needs can be met.”16,17,18,19 
Ultimately, such investment will provide less-de-
veloped countries with sustainable benefits.20
The World Intellectual Property Organization’s 
(WIPO) Cooperation for Development Program 
is committed to tailoring the implementation of 
its IP strategies to the diverse infrastructures and 
needs of developing countries.21 Similarly, the 
Organisation for Economic Co-operation and 
Development (OECD) concludes that “the transfer 
of technology to developing countries is a key element 
so that countries can develop their own R&D infra-
structure and capabilities to meet their own needs.”22 
Developing countries that have reached a sufficient 
level of technological capacity are now encouraged 
to enhance their capabilities more dynamically by 
nurturing domestic assets and creatively blending 
domestic and foreign knowledge.23
NIH Office of Technology Transfer recog-
nizes the significance of assisting U.S. and foreign 
institutions in the development of technologies 
as a means to make medicines more accessible 
to everyone. By working with local institutions, 
international organizations, and private founda-
tions, OTT has identified technology transfer 
needs and opportunities related to HIV/AIDS, 
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pertussis, malaria, dengue, childhood diarrhea 
(rotavirus), meningitis, typhoid fever, cancer, and 
diabetes. Based on the extensive patent portfolio 
in neglected diseases (Table 1), OTT has already 
transferred technologies to public and private in-
stitutions in India, Mexico, Brazil, China, Korea, 
Egypt, and South Africa. The office expects to 
execute licenses in the near future with other in-
stitutions in Africa.
This experience demonstrates that governmen-
tal or not-for-profit research institutions should se-
riously consider transferring early-stage biomedical 
technologies to institutions in the developing world 
rather than focusing exclusively on pharmaceutical 
and biotechnology companies in the western world. 
Of course, this should not be done haphazardly. 
NIH OTT learned a key lesson while expanding 
its licensing activities with developing countries—
licensee institutions should have at least some re-
search and development capability, as well as clear 
national and regional public health objectives. 
When these two conditions are met, access to key 
technologies and models of successful product de-
velopment are more likely to produce new products 
to improve public health. By encouraging technol-
ogy transfer throughout the world, NIH contrib-
utes to its long-term global mission of reducing the 
burden of diseases that are particularly devastating 




With the goal of global public health in mind, 
there are many different strategies and tools that 
can be utilized in the management of IP. For in-
stance, commercialization licenses can involve 
the transfer of rights to utilize IP, not only in re-
lation to patents, but also for unique biological 
materials such as cell lines and microorganisms 
to be used in production or as candidate vaccines, 
and any associated gene expression constructs. 
Patent rights can only be enforced in countries 
where patents have been obtained for composi-
tions of matter (materials) or methods of produc-
ing or using a given technology. Thus, in order 
to enforce a patent in a particular country, the 
patented composition or method must be used 
or sold in that country (or in some countries, 
an unpatented product produced by a patented 
method can infringe the method patent when 
that product is imported into the country where 







Dengue 27 20 40
Rotavirus 19 2 28
Human Papilloma virus (HPV) 28 23 46
Lyme disease 7 1 6
Tuberculosis 16 1 14
Malaria 36 64 39
Source: Salicrup and colleagues. 33
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attenuated virus developed for use as a vaccine 
has been patented only in the United States and 
European countries, a commercialization patent 
license could be given to one company for the 
United States and Europe and possibly another 
company (as a biological materials commercial 
license) for the rest of the world, where no patent 
is in force. Since many institutions, particularly 
government or academic laboratories, have not 
obtained patent protection in many, or any, de-
veloping countries, the biological materials com-
mercialization license is an important commer-
cialization incentive tool.25 
In addition to commercial licenses under ei-
ther type of license, an institution can grant rights 
on a geographic basis, either exclusive, coexclusive 
or nonexclusive, in another country or to mul-
tiple countries within a geographic region, con-
tinent, or throughout the world. A strategy for a 
particular technology may be to permit multiple 
institutions around the world, each with a differ-
ent geographic market segment, to develop the 
technology in parallel. This strategy is used to in-
crease the opportunity for introduction of a prod-
uct in multiple regions nearly simultaneously with 
the aim of meeting public health needs with less 
delay. Each regional producer may want to tailor 
the product slightly differently to meet the pub-
lic health and regulatory demands of the region it 
represents. Finally, with this type of strategy, there 
will be back-up institutions to meet worldwide 
needs if one of the regional producers is delayed 
significantly or fails to produce the product. 
By law and policy, NIH favors nonexclusive 
licensing to promote market competition, unless 
an exclusive or coexclusive license is a necessary 
incentive for one or two parties, respectively, to 
bring a product to market. Thus, when an ex-
clusive license is not needed to encourage com-
mercialization in a given country or region, non-
exclusive licensing, regionally or worldwide, will 
allow multiple parties to compete in the market 
to develop a product. Like the regional strategy 
with multiple codevelopers, nonexclusive licens-
ing within a given market has similar advantages. 
When framing a marketing strategy for in-
ternational product development, all of these 
mechanisms can be utilized in complex ways to 
provide the appropriate incentives for each coun-
try or region. Otherwise, the licensing terms for 
institutions serving the public health needs of de-
veloping countries are comparable to NIH OTT 
licenses to institutions in developed countries. 
Royalty fees are negotiated on a case-by-case basis, 
depending on such factors as the marketing plan, 
market size, potential use for the public interest, 
and the need to license additional technologies. 
In developing markets, some of these factors (for 
example, market size and public health inter-
ests) may play a greater role in determining the 
license terms than licenses for markets in OECD 
countries. This paradigm allows OTT to fulfill its 
statutory requirement to favor U.S. small busi-
nesses and to use exclusive licensing strategies as 
a commercialization incentive only as needed and 
supported by the market players.26 
In recent years, NIH has increased its filing of 
patents for globally important vaccines and thera-
peutics in countries like China, India, Brazil, and 
Mexico so that the exclusive or coexclusive pat-
ent license mechanism is available for use as an 
incentive, as needed, to develop such products. 
This is particularly important for technologies 
where no unique biological materials are needed 
for commercialization and biological materials li-
censing is thus not an option. Additionally, NIH 
makes efforts to transfer know-how and critical 
documentation for manufacturing and marketing 
approval (when available) to help institutions in 
developing countries expedite their commercial-
ization plans. 
Through an ongoing analysis of its own port-
folio and the needs and capabilities of developing 
countries, OTT has found that a niche exists for 
international technology transfer that is consis-
tent with U.S. technological, public health, and 
economic interests. Such transfers, moreover, can 
provide solutions to the most socio-economically 
harmful diseases. OTT has already transferred ear-
ly-stage technologies to public and private institu-
tions in India, Brazil, China, Korea, Egypt, South 
Africa, and Mexico (see Table 2), and negotiations 
are in progress with institutions in Brazil, China, 
Argentina, India, Egypt, and Nigeria. For example, 
OTT licensed a vaccine conjugation technology to 
PATH, a nonprofit global health organization, to 
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develop a conjugated meningococcal vaccine in 
collaboration with the World Health Organization 
(WHO). PATH and WHO selected the Serum 
Institute in India to manufacture the vaccine for 
eventual distribution in Sub-Saharan Africa, the 
Middle East, Latin America and the Caribbean, 
and Eastern Europe. Another license agreement 
involves the transfer of NIH materials for the 
development of a conjugated vaccine against ty-
phoid fever to the International Vaccine Institute 
(IVI) in Seoul, Korea, which plans to sublicense 
manufacturing to public and private entities in 
Indonesia and India for ultimate distribution of 
the product in Asia. 
Table	2:	examples	of	nIh	oTT	Interinstitutional		
and	multiprong	license	Strategies
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Egypt
Africa and the 
Middle East
Source: Adapted from Salicrup and colleagues.34
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In some cases, a multiprong licensing strat-
egy can be developed for the same technology that 
utilizes different license types to multiple institu-
tions in different countries based on institutions’ 
needs and market dynamics. For example, OTT is 
licensing technology related to the development 
of a human-bovine rotavirus reassortant vaccine 
to several public and private institutions in Brazil, 
China, India, and the United States.27 Depending 
on the country and geographic region, the license 
is exclusive, coexclusive, or nonexclusive. The de-
gree of exclusivity was determined by the needs of 
the prospective licensees and the market dynam-
ics in each country. Surprisingly, not all nonprofit 
institutions were willing and able to accept a non-
exclusive licensing arrangement. By granting ex-
clusive rights only when needed to spur commer-
cialization in world market segments, the strategy 
allows the market to drive the degree of exclusiv-
ity. This strategy also increases the likelihood that 
the technology will be developed in parallel from 
multiple sites for eventual worldwide distribution 
from multiple companies and institutions. In the 
case of an effective human-bovine rotavirus vac-
cine, such a goal is critical to significantly reducing 
childhood deaths from this infection, throughout 
the developing world, without unnecessary de-
lays.28, 29
NIH OTT has found that international 
technology transfer requires a holistic and flex-
ible approach—a donor-recipient paradigm that 
eschews unequal partnerships and the conse-
quent challenges with trust, commitment, and 
reliability. Local scientists provide scientific 
support for the licensing strategy, and business 
managers directly participate in negotiations 
with NIH OTT as it pursues agreements with as 
much flexibility as possible to meet local needs. 
Hopefully, this strategy of enhancing technolo-
gy transfer to emerging markets will build inter-
national capacity and capabilities. It should also 
provide regional, multilateral, and philanthropic 
organizations with more options to work with 
licensee companies to distribute products at a 





NIH OTT also recognizes the relevance of as-
sisting in the development of a cadre of scien-
tists and technology managers experienced in IP 
management and other matters related to tech-
nology transfer. Overcoming this obstacle is nec-
essarily a long-term project but also, eventually, 
a self-sustainable one.30 As a first step, OTT is 
working in partnership with other stakeholders 
throughout the world to assess the technology 
transfer and training needs of institutions in de-
veloping countries. Moreover, OTT has initiated 
an international technology transfer capacity 
building program to train scientists and manag-
ers from developing countries. The first phase 
will include training of staff from institutions 
in China, Brazil, Argentina, India, South Africa, 
Philippines, Chile, Mexico, and Hungary. Future 
expansion of the program is envisioned for rel-
evant personnel from additional institutions in 
Africa, Latin America, Asia, and Eastern and 
Central Europe. 
NIH OTT, in collaboration with technology 
transfer offices at NIH Institutes and Centers, 
regularly invites individuals with particular ex-
pertise and experience with various aspects of 
technology transfer to give seminars at NIH. 
These experts include biotechnology and phar-
maceutical business people, lawyers, technol-
ogy transfer managers, governmental technol-
ogy transfer experts, representatives of charitable 
foundations and NGOs dedicated to supporting 
product access in the developing world, repre-
sentatives from nonprofit and for-profit insti-
tutions involved in commercialization efforts, 
and public health officials from throughout the 
world. Topics have included licensing strategies 
and terms, patents, public/private partnerships, 
MTAs, policy issues, and international agree-
ments. As part of their internship at OTT, inter-
national trainees attend these lectures as they are 
able. OTT is currently discussing how to enhance 
the participation in these training and presenta-
tion sessions of both technology managers from 
institutions in developing countries and scien-
tists and administrators from “resource limited” 
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institutions in the United States. Additionally, as 
part of the Curriculum Planning Workgroup of 
the Technology Managers for Global Health, a 
special interest group within the Association of 
University Technology Managers, NIH OTT 
participated in the design and development of an 
educational booklet geared to serve as a resource 
tool for technology managers of institutions in 
developing countries.31
OTT is working with the Patent Facilitation 
Centre at the Indian Ministry of Science & 
Technology, the  Bi-National S&T Endowment 
Fund (generally called the Indo-U.S. science and 
technology fund), the South African Council for 
Scientific & Industrial Research (CSIR), and the 
Developing Countries Vaccine Manufacturers 
Network (DCVMN) to develop and imple-
ment short courses, seminars, and workshops 
on issues pertaining to IP management that are 
geared to training technology managers from 
several universities and from research and devel-
opment centers in India, South Africa, Tanzania, 
Egypt, Brazil, Mexico, Argentina, Chile, China, 
Vietnam, and Thailand. 
Information and access to knowledge has 
been recognized as a crucial step in enhancing 
capacity in developing countries. NIH OTT and 
the technology transfer offices from several uni-
versities in the United States recently developed 
and implemented a database of neglected-disease 
technologies available for licensing from these 
institutions. This database is already available at 
the OTT Web site with discussions underway 
with other potential hosts.32 The database should 
be an important resource and capacity build-
ing tool for technology managers of universities 
and research centers in developing countries for 
identifying more readily such technologies and 
for coordinating work with the licensor institu-
tions. The expectation is that other universities 
and non-profit institutions with technology li-
censing opportunities in the area of neglected 
diseases will eventually join this initiative to 
provide information at a single Web site while 




As NIH OTT’s relationship with institutions in 
developing countries matures and the relation-
ships between the office and those institutions 
expand, the next steps may include an evalua-
tion study to explore the needs and opportuni-
ties related to technology transfer and training 
for people from institutions in developing coun-
tries. This evaluation would explore areas that 
affect technology transfer outcomes, such as IP 
policies, regulations, clinical trials capacity, IP 
management capabilities, and policies influenc-
ing public/private sector partnerships (PPPs). 
Thus, OTT has the potential to contribute to the 
scientific, technological, and health needs of de-
veloping countries by improving its own ability 
to bring to market technologies that will benefit 
local and regional public health. 
NIH OTT is committed to contributing 
expertise and sharing ideas, strategies, and prac-
tices mutually with other organizations, in both 
developing and developed nations, to advance the 
goals of international technology transfer. Such 
coordination can only enhance the individual ef-
forts of each of the institutions involved. In addi-
tion, OTT will continue to learn from partners 
throughout the world about creative alternative 
solutions to the challenges of transferring bio-
medical technologies to benefit global health.
6.	 ConCluSIonS
Building on a strong track record, NIH OTT is 
expanding its efforts at licensing technologies to 
institutions in developing countries, and it con-
tinues to work with other stakeholders to help 
build technology transfer infrastructures. These 
activities are helping NIH to fulfill an impor-
tant goal of its global public health mission: to 
reduce the devastating disease burden on people 
living in developing countries. Bringing biomedi-
cal inventions to populations in less-developed 
regions of the world can be achieved through 
various technology licensing models that fit the 
specific competencies of the research and devel-
opment infrastructure of the particular countries. 
Moreover, it is expected that OTT’s activities 
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in global technology transfer will promote well-
recognized, good licensing practices that meet 
regional and national health priorities and stan-
dards. As a result, these activities should enhance 
public availability of new technologies, attract 
new biotechnology R&D resources, obtain re-
turns on early-stage public investment, and stim-
ulate economic and social development. ■
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ABSTRACT
The history of technology transfer at Stanford goes back 
to an initial pilot program launched by Niels Reimers in 
1970, a program that put the university in an excellent 
position to take advantage of the Bayh-Dole Act. Enacted 
in 1980, the act gave U.S. universities ownership of any 
patents developed using federal funds. Today, Stanford 
University and successful technology transfer are almost 
synonymous. But success is more than just a matter of 
timing. Stanford’s Office of Technology Licensing (OTL) 
takes a flexible, broad outlook on the development of its 
intellectual property that has made Stanford a favorite 
business partner. This chapter reveals the secrets behind 
the success of Stanford’s OTL.
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in that country, and the practice is now so in-
stitutionalized that the Association of University 
Technology Managers (AUTM) can regularly at-
tract a cross-section of the world’s leading com-
panies, lawyers, and venture capitalists to its an-
nual conference. A number of universities can 
claim to represent the gold standard in this field, 
among them M.I.T., Columbia, Stanford, and 
the University of Wisconsin. But arguably none 
makes a stronger claim for shaping the global 
technology transfer market than Stanford, the 
California powerhouse, which Fortune magazine 
dubbed “the intellectual incubator of the digi-
tal age.”1 Credited with kick-starting the Silicon 
Valley high-tech industry, and subsequently 
spawning a hugely influential brood of physi-
cal- and life-science businesses across the United 
States and the world, Stanford’s technology trans-
fer efforts have clearly transformed our world.
2.	 BuIldIng	on	dnA
The brainchild of Niels Reimers, Stanford’s 
Office of Technology Licensing (OTL) was 
born more than 30 years ago, in 1970. It 
was Reimers who famously recognized the 
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1.	 InTRoduCTIon
Stanford University’s Office of Technology 
Licensing has a string of blockbuster success 
stories to its name—from DNA gene splicing 
to Cisco, Yahoo!, and Sun Microsystems. Since 
the office was founded in 1970, it has received 
US$594 million in cumulative gross royalties. 
No wonder the university is considered a world 
leader in technology transfer. 
Technology transfer is big business in the 
United States. The concept of taking intellectual 
property from laboratory to market originated 
Page N. 2007. The Making of a Licensing Legend: Stanford University’s Office of Technology Licensing. In Intellectual Proper-
ty Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, 
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huge potential in gene-splicing research being 
undertaken by professors Cohen and Boyer (of 
Stanford and the University of California, respec-
tively). It was Reimers who persuaded them to 
let Stanford try for a patent (which Stanford did 
and ultimately secured). And it was Reimers who 
went on to launch a licensing program that, by 
the time the so-called Cohen/Boyer DNA patent 
expired in December 1997, had generated more 
than US$250 million in royalties (split with the 
University of California), with Stanford licens-
ing a total of 468 companies on behalf of both 
universities. Having become an international 
consultant, Reimers saw merit in Stanford set-
ting up an OTL that would be a marketer—not 
just a patent office. The office would actively 
pursue discoveries, market them to potentially 
interested companies, and collect the royalties on 
them. Fundamental to its structure would be a 
preparedness to give its licensing associates the 
authority and responsibility they needed to do 
their job effectively, free—so far as that was pos-
sible—from the red tape that entangled so many 
other operations. Reimers’ initial pilot program, 
launched in 1968, produced, in one year, more 
than ten times the amount received by Stanford 
in its previous 15 years of licensing through an 
outside corporation. The idea was clearly a win-
ner. Not surprisingly, M.I.T. would later go on to 
seek out Reimers’ services and effectively trans-
form its own technology licensing office into a 
global force in its own right, with gross revenues 
of US$33.52 million in 2002.2
Stanford, however, is still out in front. 
According to the industry-standard 2002 AUTM 
Licensing Survey, Stanford received US$50.2 
million in adjusted gross license income for FY 
2002. Even in a tough economic climate, this 
amount was the second-highest in the OTL’s his-
tory, including an unexpected US$5.8 million 
in one-time royalties, with 42 of the OTL’s 442 
income-generating technologies each producing 
more than US$100,000 per year (see Box 1 for 
an overview of the economic impact of Stanford’s 
OTL). Since 2002, things have gotten even bet-
ter: in 2005, the OTL received on behalf of the 
university US$384 million.3
3.	 The	RIghT	plACe	AT	The	RIghT	TIme
So what is the secret of Stanford’s success? The 
university’s symbiotic relationship with Silicon 
Valley has played a vital role, giving life to many 
of the OTL’s most marketable technologies and 
providing the all-important local infrastructure 
of ideas, can-do thinking, and capital. But this 
climate of entrepreneurship did not grow up 
overnight. Back in the 1920s, Fred Terman was 
Box	1:	economic	Impact	of	Stanford	university’s	oTl
For FY 2001 (latest figures available), the largest companies founded or co-founded by those 
with a current or former affiliation with Stanford University (as alumni or faculty/staff) were 
responsible for generating 42% (US$106 billion) of the total revenue of the Silicon Valley 150 (an 
annual list of the largest Silicon Valley firms).
From FY 1975 to 2005, Stanford’s top six cases have been:a
 • recombinant DNA cloning technology (total royalties US$255 million)
 • chimeric receptors (total royalties US$124.7 million)
 • fluorescent conjugates for analysis of molecules (total royalties US$46.4 million)
 • functional antigen-binding proteins (total royalties US$30.2 million)
 • fiber optic amplifier (total royalties US$32.6 million)
 • FM sound synthesis (total royalties US$22.9 million)
a Sally Hines, Stanford University, Office of Technology Licensing, (personal communication).
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an electrical engineering professor at Stanford. 
Trained at M.I.T., Terman played a key role in 
demolishing the ivory tower mentality, unleash-
ing links with business that would ultimately en-
able Stanford’s OTL to market technologies with 
such phenomenal success. Needing local jobs for 
his engineering graduates, Terman recognized the 
importance of attracting companies to the area, 
and so he introduced the core founders of Varian 
Associates (the radar and microwave technology 
business). He encouraged William Shockley, co-
inventor of the transistor, to come to Palo Alto 
(before joining Stanford’s faculty in 1963). And 
Shockley brought two of his own students to-
gether, William Hewlett and David Packard, 
who went on famously to launch HP (Hewlett 
Packard) in a Palo Alto garage. Indeed, it is easy 
to see why Terman is referred to as the father of 
Silicon Valley.
Without Terman and Reimers, it is question-
able whether Stanford’s OTL (and indeed the whole 
U.S. technology transfer industry) would be even 
close to where it is today. Of course, a fortuitous 
geographical position, coupled with a thirst for en-
trepreneurial activity, is a quintessential prerequi-
site for success in the field of intellectual property. 
But without a vehicle to encourage, enable, and 
market inventions, the bridge from laboratory to 
market would be rickety indeed. That Stanford was 
thinking along the right lines back in the 1960s 
made it ideally positioned to take advantage of 
the pivotal Bayh-Dole Act passed by Congress in 
1980. It gave U.S. universities ownership of any 
patents developed using federal funds. 
4.	 geTTIng	IT	RIghT
External circumstances notwithstanding, a key 
feature of Stanford’s success has clearly been the 
preparedness of its leaders to think long and hard 
about the best possible means of implementing 
and running the university’s licensing operations. 
Katharine Ku, Director of the OTL since 1991 
and a major international name on the technolo-
gy transfer circuit, is initially hesitant when asked 
about Stanford’s success:
People often ask me what is our best practice? 
In some ways, it’s hard to know, since on paper our 
processes and attitudes are similar to those in place at 
other universities.” After reflection, she continues: 
“It is people that make the difference. Our team is 
scientifically trained, but we don’t always look for 
Ph.D.s Our work is, by its nature, very generalist. 
We have to know a little about a lot of different 
areas. And this is the opposite of a Ph.D’.s train-
ing. And we don’t look for lawyers—in fact, on the 
licensing side, we discriminate against them. Legal 
training is by its nature risk-averse—whereas to suc-
ceed, we have to be risk-takers.
Ku’s department is compact. Although it is 
one of the most active offices in the technology 
transfer field (managing more than 1,900 tech-
nology dockets), the core team includes fewer 
than 30 staff members, with no more than seven 
or eight licensing staff. These licensing associates 
evaluate technologies that have been disclosed to 
the OTL, before tailoring licensing strategies to 
fit the ones that, in their view, have commercial 
potential. Each associate is given what might ap-
pear to an outsider to be a surprising degree of au-
tonomy: he or she assumes full responsibility for 
a portfolio of dockets, from cradle to grave. The 
associates each have an area of technical expertise 
in life sciences, physical sciences, or both. One 
of Ku’s team, senior associate Hans Wiesendanger 
explained how the process begins: “First of all, the 
invention must be disclosed. To encourage disclo-
sures, every research contract stipulates mandatory 
disclosure (whether from government contracts or in-
dustry sponsorships), but that said, academics tend 
to do what they want. We can try to manage them, 
but we can’t control them.” (For case studies of the 
private sector working with Stanford’s OTL, see 
Boxes 2 and 3.)
5.	 TAKIng	on	TeChnology
Once an invention reaches the OTL, it is assigned 
to a licensing associate who assumes responsibil-
ity for it, initially evaluating the technology to 
identify its technical advantages. “First, we talk 
to the inventors,” explained Wiesendanger. “They 
will often, but not always, have a good perspective. 
We also talk to outside people—colleagues, compa-
nies we’ve worked with in the past and so on. Then 
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we decide on the strategy—whether to go for an 
exclusive or a nonexclusive license and whether to 
license by territory. Then we assemble a list of poten-
tial licensees that we might be interested in contact-
ing.” The licensing associate’s responsibilities are, 
at this point, still far from over: “They remain in 
charge of the project throughout the life-cycle of the 
license. They check that the royalties are being paid, 
which may mean arranging for an audit or a rene-
gotiation of the agreement in line with any changed 
circumstances.”
Wiesendanger’s explanation gives weight to 
what Katharine Ku identified as her department’s 
“X Factor.” Finding associates who are willing 
and able to take on this level of responsibil-
ity is no small challenge. As mentioned above, 
Stanford rarely uses lawyers to draw up agree-
ments. As Wiesendanger explained: “Some of our 
licensing deals are quite standard—we have boiler-
plates that can be modified as required and that are 
clearly very different depending on whether they ap-
ply to software or biological material. The licensing 
associate negotiates these agreements, with the full 
Box	2:	Alumnus	Case	Study	1:	dr.	mark	Zdeblick
“I’ve been lucky to experience Stanford’s technology transfer operation from both sides of the 
fence,” laughed Mark Zdeblick, founder of Redwood Microsystems, entrepreneur-in-residence 
with VC firm Spring Ridge Ventures, and CTO of, inter alia, Proteus Biomedical. “I’ve worked there 
as a grad student in a research team developing a blockbuster technology [atomic resolution 
microscopy]. I’ve set up my own company [Redwood] with Stanford licensing the [micro-valve 
chip] technology I’d developed there to the business. And with Proteus, we’ve approached Stanford 
to license their technology to the company. Typically professors/inventors hold most of the power, 
exerting considerable influence over the choice of licensee. But with Stanford’s OTL,” he said, “they 
have enough understanding to be able to influence the professors. When people have been prepared 
to trust them to do the right thing, they have done very well.” The fact that the OTL can strike 
a balance (most of the time) between the professor’s desire to tie strings to the license deal 
(obliging the company to pump research funds back into his or her department), and the logic 
behind commercializing the technology effectively, is a key variable. Commenting on Stanford’s 
successful management of the “brain drain” experienced elsewhere, Zdeblick commented, 
“Stanford often allows its professors the opportunity to take a leave of absence for two years to 
help spinout such technology. That level of commitment is often necessary to get backing from 
the private equity community. Most professors return after the two years, in which case they are in 
many ways much more valuable to the university. Of course, sometimes they don’t return.” When 
Stanford was licensing on his behalf, Zdeblick was impressed with the amount of marketing they 
took on: “They made a lot of calls on my behalf, seeking out interest among potential licensees, as 
well as undertaking a lot of the groundwork to establish the utility of the underlying patents. That’s 
more common now, but it was much rarer 20 years ago.” Another view of Zdeblick is Stanford’s 
ability to get results out of the more run-of the-mill technologies that come through the OTL’s 
doors: “It is easy with grand-slam technologies, where you can pull together nonexclusive licenses 
with everyone. The tricky thing is to get the whole portfolio working well and, as a rule, Stanford 
seems more willing than most other universities to take a bet and grant an exclusive license for an 
obscure technology.”
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Box	3:	Alumnus	Case	Study	2:	dr.	dari	Shalon
Now running Shalon Ventures (an early-stage life-science VC) with his brother, Dari Shalon’s 
experiences with Stanford OTL served him well. A former graduate student at the university, he 
went on to license his own invention from the OTL to launch Synteni, sold three years later to 
Incyte Genomics for US$100 million. According to Shalon, “The technology that ended up being 
licensed to Synteni was developed by me and Professor Patrick Brown [an arraying technique that 
became the basis of DNA microarray technology].” Although the OTL marketed the invention 
widely, no company expressed any serious interest, leading, in 1995, to Shalon starting his own 
company to develop the technology. “I had done an MBA at M.I.T.,” he explained, “and then chose 
Stanford as an interesting entrepreneurial university. My research project was deliberately selected 
to have commercial application.” Shalon remembered wandering into the OTL as a grad student in 
ripped t-shirt and jeans asking if he could file a disclosure: “I had a number of unsuccessful efforts 
where the technology didn’t work, but the OTL guys encouraged me to go back to the lab and keep 
trying. Finally I got it to the point of commercial feasibility and went ahead and filed.” At that stage, 
he recalled, he tried to get serious: “I turned myself into a businessman, with business cards and a 
suit, thinking I would step straight into the commercial sphere. What I’d failed to understand was 
Stanford’s own fiduciary obligations to its trustees. They had to market the technology to firms 
that I knew would be competitors further down the line. I held my breath for six months, but to 
my surprise and relief, no other company had the vision to take it on.” Things went from good to 
better—Shalon snagged Merck as his first customer, and shortly after pulled in US$5 million in 
venture financing from Kleiner Perkins Caufield & Byers. “Had I not held an exclusive license on 
the technology, there’s no way I would have been able to raise the capital I so desperately needed.” 
Throughout this process, he was impressed with the OTL’s flexibility and willingness to take a bet 
on him as exclusive licensee. “At the crucial point when Incyte showed interest in us,” he said, “and 
our license was key to the sale going through, Stanford was more than happy to transfer the license 
to the purchaser. And subsequently, when we got involved in litigation with a major competitor 
relating to our licensed intellectual property, Stanford stood by us. It made a huge difference to 
know there was a solid partner right behind us.”
authority to do so. It is only where something new 
crops up that he or she will consult a lawyer—there 
is certainly no obligation to get every deal approved 
by an external lawyer.”
6.	 pATenT	oppoRTunITIeS
This practice would hardly seem to be music to 
the ears of California’s finest IP law firms. That 
said, there is still plenty of work for external law 
firms (Stanford OTL has annual patent expenses 
of around US$5 million)—although, as Carol 
Francis, a name partner with Bozicevic, Field & 
Francis, LLP (a local law firm with a track re-
cord advising on OTL-linked patent prosecution 
matters) explained, the patenting activity gener-
ated by OTL maintains its focus on commercial 
viability: 
Stanford stands out for its ability to make quick 
assessments on when, and if, to go ahead and file a 
patent application, or to continue to prosecute an ap-
plication already filed. Their experience means that 
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they are adept at identifying an invention disclosure’s 
commercial potential early on; it also means that 
they’re prepared to take a flexible approach to fil-
ing, often in negotiation with the ultimate licens-
ee/s. Stanford OTL accomplishes this while at the 
same time respecting the academic inventors’ need 
to publish or make presentations at meetings. While 
Stanford OTL may file an application to preserve 
patent rights that might otherwise be impacted by 
an imminent public disclosure, they are at the same 
time particularly mindful that once an application is 
filed, it tends to take on a life of its own, with all the 
expense that that entails. This analysis at Stanford 
OTL benefits from the experience and leadership of 
its Director Kathy Ku, as well as the insights and con-
nections of the inventors themselves. Stanford OTL’s 
insistence that the inventors be involved—and the 
level of involvement they receive in response—is, I 
think, one of the keys to their success.4 
(See Box 4 for an overview of how inven-
tions move from ideas to commercial products at 
Stanford.)
7.	 noThIng	venTuRed	…
Silicon Valley has no shortage of lawyers—or 
venture capitalists (VCs). Not surprisingly, both 
camps frequently visit the corridors of Stanford, 
taking a keen interest in the activities of the OTL. 
That said, Ku pointed out that the OTL itself is 
not there to make contact with VCs: “Most usu-
ally, our researchers will identify their preferred VCs 
in Silicon Valley and then come to see us together. 
That’s the best approach—for technology transfer 
to work, where start-ups are concerned, the entre-
preneur needs to feel comfortable with her chosen 
VC. It’s up to them to get the chemistry right, which 
is not always something we can help them with.” 
Rob Chaplinsky, a general partner with Sand 
Hill Road early-stage VC firm Mohr, Davidow 
Ventures, has had considerable experience work-
ing with the OTL, and he characterized the re-
lationship in these terms: “Because Stanford is 
bang in the heart of Silicon Valley, we have access to 
their researchers and professors long before the OTL. 
By the time we go to see the OTL, it’s a matter of 
looking to see how we can amicably align everyone’s 
interests. In fact, we have a saying here that if you 
wait until the OTL guys have the patents and call 
you up, you’re way too late.” Prompted to outline 
Stanford’s formula, Chaplinsky said: “I get a lot 
of calls from other institutions asking how they can 
copy Stanford’s program—but it’s not as easy as that. 
Some of their formula is down to geography, they’re 
integrated in the world’s venture epicenter and their 
professors are embedded in the community. Then 
there’s the culture of the university—from the Dean 
down, they’re mostly academics and entrepreneurs. 
At Stanford you’re almost expected to start a com-
pany before becoming a tenured professor. There is 
something special there which can’t be replicated in 
a hurry.”
8.	 flexIBle	ConTRol
Where negotiations with Stanford OTL are con-
cerned, Chaplinsky has no doubt that terms are 
getting tougher. Still, he stressed Stanford’s will-
ingness to be flexible, with innovative blends of 
upfront license fees, royalties, and equity splits 
very much up for discussion: “Nothing’s ever cast in 
stone with their OTL. There’s always a door open to 
go back and renegotiate.” That said, an established 
modus operandi underpins the OTL’s position, 
and, as Ku explained, a big part of its rationale is 
the necessity to keep getting technologies out into 
the market: “Our job is to plant seeds, so—because 
it’s so hard to know which new technologies will 
eventually succeed—we do as many deals as possible. 
In some ways we’ve been helped in this by changing 
attitudes. Researchers nowadays are more interested 
in the potential of their technology, so we see more 
invention disclosures than we used to. We have to be 
realistic—only about seven inventions here generate 
US$1 million-plus a year.” Put bluntly, this means 
that only about 10% of the inventions taken on 
by the OTL have the potential to generate sig-
nificant income. Twenty to thirty percent won’t 
bring in a great deal and the remaining 60–70% 
will bring in almost nothing.
Depending on the sector and the technology, 
the technology transfer process can be straightfor-
ward or downright complex. Ku pointed out that, 
as a general rule, pharmaceutical and life-sciences 
companies have tended to be more in tune with 
the process: “They understand the long timelines 
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Conception	documentation:  lab notebooks, dated papers, or drafts witnessed.
disclosure: required by all sponsorship agreements for research; must include 
description (papers attached), information on who are inventors, 
what funding was used, when conceived, when first disclosed or 
published, signature(s) and date, and assignment to Stanford; fill 
in printed form or use Internet disclosure form; 
 must submit to OTL
Invention	by	inventor	(Inv)
Sign	in: OTL logs in, gives docket number, and assigns to specific 
licensing associate (LA) who now has complete responsibility 
and authority for handling the invention from evaluation to 
licensing and monitoring licensee performance
evaluation: LA discusses with INV; gets as much information as needed on 
details of technology, novelty, potential utility, and companies in 
the field
 LA also gets similar information from outside sources, usually by 
contacting sources in the field and supplying confidential data 
and details after executing a confidential disclosure agreement 
(CDA) 
Strategy: LA decides how to license: exclusive or nonexclusive, by territory 
or worldwide, for limited and specific uses and applications or 
unlimited; sublicensing permitted or not; kind of company to 
approach and how; key licensing terms to shoot for; suitability 
for a standard license that can be filled out on the Web site
Contact	potential	licensees: LA assembles list and makes first contact (mail, e-mail, fax, 
telephone, Internet); information on what invention may do, but 
not how; offers details after execution of CDA
patent	prosecution: LA decides whether and when to apply for a U.S. patent; selects 
outside patent attorney and charges him/her with filing (normal 
or provisional); monitors filing and prosecution, and decides filing 
of foreign applications; files only if deems reasonable chance of 
success for licensing or prospect of getting expenses paid (for 
example, in return for an option to a potential licensee) 
negotiations: LA negotiates with companies who respond positively; draws up 
a license agreement (starting with boilerplate and modifying 
that if/as necessary or advisable); if deemed necessary, consults 
with attorney for legal advice for special or unusual situations 
executed	agreement: OTL logs into database, documents terms and contact 
information, and programs database to generate reminders and 





1726 | HANDBOOK OF BEST PRACTICES
involved, whereas physical-sciences companies, be-
cause they are more accustomed to a cross-licensing 
model, can find dealing with us quite demanding. 
It’s really up to universities to work out how they 
can deal better with this side of the commercial spec-
trum.” Other aspects of the academic/commer-
cial relationship also have potential to complicate 
negotiations, as Ku said: “Because physical science 
companies are major sponsors of university research, 
some of them expect to own the inventions that flow 
from that research. I’d always hoped that that battle 
was over with Bayh-Dole, but perhaps because uni-
versities in other parts of the world are still prepared 
to give up title, some companies are still laboring un-
der a misconception on the IP ownership side when 
they deal with us.”
9.	 RemovIng	ConflICT
Like any university technology transfer office, 
Stanford has an effective system in place for 
managing potential conflicts of interest. As Hans 
Wiesendanger explained, “Anyone starting a tech-
nology transfer program for a university will be 
concerned about professors undertaking applied re-
search to make money—that can be very damaging 
to a university’s reputation. That said, there is no 
doubt that you can continue to be one of the world’s 
top research centers while playing a leading role in 
technology transfer. To do so, however, you do have 
to recognize that the potential for conflicts of interest 
does exist. Formal procedures for dealing with con-
flicts if and when they arise need to be instituted. 
That said, it is always important to remember that 
any researcher will be mainly interested in just one 
thing: his academic standing among his peers. So, 
in my view, the fear of conflicts can be somewhat 
overblown.”
10.	Ip	mAnAgemenT
Patenting is a core activity, handled as necessary 
by outside patent attorneys. Key issues that come 
to the fore here are whether the invention can 
be licensed as tangible research property, wheth-
er it can be licensed as copyright, whether it is 
likely to be both patentable and enforceable, and 
whether the invention has already been publicly 
disclosed. There’s no fixed way of handling this 
process; Wiesendanger explained, “It can happen 
at any time—and that decision is up to the licens-
ing associate involved. But we do have to be careful; 
it costs a lot and represents an ongoing commitment. 
Some universities patent everything, but we are un-
der pressure not to do so. Usually we’ll sign licenses 
before we have the patents in place, and we often 
start negotiations before we have even applied for 
them. Quite often we’ll look to the ultimate licensees 
to cover the filing expenses in exchange for a six-
month option on the technology. That can be very 
attractive, as that six-month period often represents 
a very significant competitive advantage.”
Although Stanford supports entrepreneurs, it 
does not “encourage” spinouts. Nor does it start 
companies itself, although comparatively recently 
the OTL was authorized by the university to take 
equity as part of license fees or royalties (provided 
that the licensee did not conduct clinical trials at 
the university), as well as to license companies in 
which the inventors have an interest. Stanford 
currently holds equity in approximately 75 com-
panies with cash-out to date of around US$22 
license	period: LA monitors performance: receipt of royalties and reports. OTL 
sends out automatic computer-generated invoices for fees and 
earned royalties. If performance deficient, LA follows up with 
reminders or, in extreme cases, termination.
 LA may have to renegotiate parts of license agreement if situation 
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million. Wiesendanger explained, “Stanford is very 
concerned about its image and we don’t want to be 
seen to be too involved in business. Just as Stanford 
has a tradition of encouraging cooperation with in-
dustry, we do not want business and university inter-
ests to affect each other in an operational way.”
11.	 SplITTIng	The	RevenueS
Once royalties start flowing, there’s a fixed split 
in operation. Fifteen percent is siphoned off 
by the OTL to cover its own administrative 
expenses, although, as Wiesendanger point-
ed out, not all of that gets used up—the re-
mainder is channeled into a number of funds 
created by Stanford, including the “birdseed 
fund” and the “OTL gap fund.” The former 
provides small amounts of money (typically up 
to US$25,000) to fund prototype development 
or modest reduction-to-practice experiments 
for unlicensed technologies; the latter sup-
ports development efforts up to US$250,000 
for unlicensed technologies with commercial 
potential. The remaining 85% of incoming 
royalties divides three ways—between the in-
ventor, the inventor’s department, and the in-
ventor’s school/faculty. In FY 2001–2002, in-
ventors received personal income of US$11.3 
million, departments received US$13.5 mil-
lion, and schools received US$13.1 million. 
“This split is designed to incentivize researchers,” 
Wiesendanger explained, “and some academics 
can do very well. But often inventors don’t take 
their share—they ask instead for it to be signed 
over to their personal lab account. Research mon-
ey with no strings attached is, as you can imagine, 
very desirable in a university.”
The nature of the beast means that it would 
be commercially naïve to set targets—either for li-
censing deals, or for royalty income. “On average, 
we expect to receive five or six new disclosures a week. 
We file patents on about half of them and license 
about one-third of them. Of course we look at how 
many licenses each licensing associate brings in rela-
tive to this average,” said Wiesendanger, “but there 
can be no absolute measures; fields vary hugely, and 
cyclically, in their appetite for new technologies.”
12. woRK	In	pRogReSS
Stanford’s model is working, but there has been, 
and will continue to be, some turbulence. In 
1995, for example, a faculty committee released 
a damning report on the barriers between the 
medical school and industry, a situation exacer-
bated by “a growing mutual distrust.” A survey 
of CEOs at Californian pharmaceutical compa-
nies underlined the problem when the results 
came back showing an almost unanimous aver-
sion to dealing with Stanford. In particular, 
Stanford’s attitude towards the ownership/pat-
ent status of intellectual property arising from 
clinical research projects was a source of fric-
tion. In response, the university focused on 
structuring research sponsorships that allowed 
funding companies to get rights to the technol-
ogy. Realizing that the federal budget for re-
search funding was in steep decline, the medical 
faculty had little choice but to be proactive with 
its industry benefactors. 
With hindsight, it’s clear that the acid test for 
Stanford’s model came at midnight December 2, 
1997—the moment when the (nonrenewable) 
Cohen/Boyer patent for recombinant DNA ex-
pired. This moment, referred to at the time by 
Stanford officials as “the cliff,” might have de-
feated some operations, but at Stanford the event 
acted to stimulate several years of intense activ-
ity, with the university opening up the campus to 
industry ideas as it never had before. As Ku said, 
the OTL was prepared: “We’d been moving steadily 
toward being more user-friendly to industry.” That 
it took just six years for Stanford to top its re-
cord royalty year with Cohen/Boyer underlines 
the firm foundation set down by Reimers—and 
points the way forward to an another exciting de-
cade in Silicon Valley. ■
nIGel paGe, Intellectual Asset Management (IAM) 
Magazine. For information on IAM, contact: Joff Wild, 
Editor, New Hibernia House, Winchester Walk, London 
Bridge, London, SE1 9AG, U.K. jwild@iam-magazine.com
1 Aley J. 1997. The Heart of Silicon ValleyWhy Stanford—the 
Nexus of Capital, High Technology, and Brainpower—Is 
the Intellectual Incubator of the Digital Age. Fortune 
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Magazine, July 7.  http://money.cnn.com/magazines/for-
tune/fortune_archive/1997/07/07/228653/index.htm. 




4 See also otl.stanford.edu/about/documents/Memo_
to_Outside_Counsel.doc.
ABSTRACT
The University of California (UC), based on its mission 
as a land grant university, has a long history of seeking 
intellectual property protection for its research discov-
eries and managing those technologies for the public 
benefit. By some measures, the UC technology transfer 
program is the largest public program in the world. The 
program has evolved over the years but has always been 
at the forefront of intellectual property protection. This 
article focuses on the history, policy, and organizational 
framework of the UC technology transfer program, and 
the information discussed herein may be instructive to 
administrators and others seeking to learn from the UC 
experiences. The program has been administered through 
six functional departments: Information Technology and 
Communications, General Counsel (legal), Licensing, 
Patent Prosecution, Financial Management, and Policy 
Analysis and Development. Perhaps the most distinc-
tive feature of the UC technology transfer system is the 
development of a distributed institutional network of 
ten university campuses, which operate under a com-
mon policy framework and share resources. At the same 
time, each office functions relatively independently of 
the others. This structure could be emulated and imple-
mented at different scales, from a relatively small-scale 
research consortium made up of a network of institu-
tions, to a larger-scale national network of universities, 
to a global-scale international network of research insti-
tutions linked by common policies and objectives.
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1.	 InTRoduCTIon	
The University of California (UC) is composed 
of ten semi-independent campuses: UC San 
Diego, UC Santa Barbara, UC Los Angeles, 
UC Riverside, UC Irvine, UC Merced, UC 
Santa Cruz, UC San Francisco, UC Berkeley, 
and UC Davis. While each campus represents 
a significant education and research institution 
in its own right, collectively, the University of 
California system is one of the strongest insti-
tutions of higher education in the world. This 
is particularly true with regard to research. The 
University of California is likely the largest pub-
lic research enterprise in the world. With annual 
research expenditures in excess of US$2.9 bil-
lion, the size of its collective research programs is 
comparable to the total research expenditures of 
entire countries. One of the results of this robust 
research activity is the generation of a significant 
technology portfolio that supports the universi-
ty’s mission to use its research to benefit society. 
In 2004, University of California researchers re-
ported nearly 1,200 new inventions, or approxi-
mately one invention for each US$2.5 million 
in research expenditure—a number that remains 
relatively consistent from year to year (the full 
range has been one invention for each US$2.5–
4.5 million). As a consequence, the University 
of California has developed an extensive technol-
ogy transfer program that provides a potentially 
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useful example for large multi-institutional net-




The University of California was established as a 
land grant university by the Morrill Act, which 
was signed into law by Abraham Lincoln in 1862. 
This Act provided each state of the United States 
with a grant of large acreages of public lands that 
the state could sell on the open market to raise 
funds to support at least one college at which the 
leading objective would be to broadly educate 
students in “agriculture and the mechanical arts.” 
But it was the Hatch Act of 1887 that extended 
the Morrill Act and the mission of land grant 
universities to encompass research as well as edu-
cation—specifically, research that contributed to 
an effective agricultural industry (Box 1). 
While originally focused on agriculture, the 
mission of land grant universities in the United 
States continues to be reflected in broad mission 
statements that recognize the university’s fun-
damental role in transferring research results to 
support applications in all industrial sectors. The 
principles embodied by the U.S. land grant uni-
versities have become important elements of the 
mission of many American universities and have 
played an important role in defining the context 
within which university technology transfer pro-
grams have developed.
2.2	 Technology	transfer	policy	development
Formal intellectual property protection and the 
management of patented technologies at the UC 
dates back to the 1920s. The first patent assigned 
to “the Regents of the University of California” 
covers technology for a “Film Holder for Dental 
Work” (U.S. Patent No. 1,657,230) awarded to 
Frank Simonton. Thus, there is a long history of 
biomedical research inventions. Other early UC 
patents describe methods of producing wood 
products (U.S. Patent No. 1,805,550 from 1931), 
an apparatus for cracking nuts (U.S. Patent No. 
2,238,368 from 1941) and a method of preserv-
ing microorganisms (U.S. Patent No. 2,376,333 
from 1945). 
In 1943, the first UC patent policy was 
adopted, which provided mechanisms for sup-
porting the licensing of patented inventions.1 
However, assignment of inventions to the univer-
sity was determined on a case-by-case basis and 
UC policy was silent on royalty sharing between 
the university and inventors. In 1963, the univer-
sity adopted a new patent policy that foreshad-
owed some of the requirements the Bayh-Dole 
Act (1980) later made mandatory, including 
making the assignment of rights to the univer-
sity mandatory and specifying a royalty-sharing 
formula (50/50 sharing of any licensing revenue 
between the inventor[s] and the university, after 
deduction of a 15% administrative fee). The pat-
ent policy has changed a few times over the inter-
vening years but has continued to include man-
datory disclosure and assignment of inventions to 
UC and a royalty-sharing formula that provides, 
It shall be the object and duty of the State agricultural experiment stations … to conduct 
original and other researches, investigations, and experiments bearing directly on and 
contributing to the establishment and maintenance of a permanent and effective 
agricultural industry of the United States, including researches basic to the problems 
of agriculture in its broadest aspects, and … as have for their purpose the … maximum 
contribution by agriculture to the welfare of the consumer.
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after deduction of direct expenses, 35% to the 
inventor(s), 15% to a campus research fund, and 
50% to a general pool for the campus at which the 
inventor is located. This patent policy is adminis-
tered by a “patent acknowledgement” (Figure 1) 
that is signed by all UC employees and that con-
tains a provision which specifically allows the UC 
to change the policy at any time in the future, 
including the royalty-distribution formula. This 
last feature is important because the UC has been 
sued by an inventor who objected to the change 
in royalty-distribution policy.2
2.3 Role	of	leadership	
The evolution of a policy framework to support 
technology transfer at the UC has been criti-
cal in developing the institutional capacity for 
technology transfer. However, the most impor-
tant element has been the academic leadership 
role of the UC in recognizing the importance of 
technology transfer and promoting it as an activ-
ity that is central to the university’s educational 
and research missions. The last two presidents of 
the UC, Richard Atkinson and Robert Dynes, 
clearly articulated how and why the UC should 
be actively engaged in technology transfer (Box 
2). University technology transfer programs take 
nearly a decade to begin to generate sufficient li-
censing revenue just to break even, and without 
strong support from academic leadership, tech-
nology transfer programs are unlikely to be con-
sistently supported at a level necessary to achieve 
successful outcomes. Because of its academic 
leadership, the UC technology transfer program 
has enjoyed several decades of solid support and, 
as a result, has been a net revenue generator for 
the university since the late 1980s.
2.4 Evolution	of	a	distributed	institutional	
network	for	technology	transfer
An ongoing trend in the UC technology transfer 
program has been its gradual movement from a 
highly centralized network to a decentralized, or 
distributed, network of semi-independent, cam-
pus-based technology transfer programs. The cen-
tral UC Office of Technology Transfer (OTT) was 
established in 1978 and for many years provided 
all technology transfer services from a central 
location in the San Francisco Bay Area. A single, 
central OTT providing services to such a large 
research enterprise allowed the investment of suf-
ficient resources in a single program to reach criti-
cal mass and achieve early success. However, while 
this location is very close to the UC Berkeley cam-
pus, it is over 500 miles from the UC San Diego 
campus, and the lack of direct connections to re-
searchers and the technology itself at more distant 
campuses proved to be problematic, especially as 
research programs grew dramatically in the 1980s. 
As a consequence, there has been an ongoing 
movement to establish local offices of technology 
transfer on each of the UC campuses. This trend 




The UC technology transfer program has been 
relatively successful in transferring technology to 
the private sector. In its best year (2002) the pro-
gram generated over US$100 million in revenue, 
which, after expenses and distribution to inven-
tors, provided approximately US$30 million to 
support education and research at the UC. While 
this represents good business for the university, 
the financial returns are modest when placed in 
perspective of the total UC research budget of 
approximately US$2.9 billion. Expenses for the 
program in 2004 included US$14.3 million in 
operating costs and US$13.9 million in unreim-
bursed legal expenses, reflecting the substantial 
investment that is required to manage a program 
on such a scale. A range of technology transfer 
performance metrics are reported annually by the 
UC, and there are several published reports that 
look at technology transfer trends in the UC in 
relation to other university programs.3, 4 
The administrative structure of the UC tech-
nology transfer program has been in a constant 
state of flux and evolution since its inception, but 
the program appears to be approaching a steady 
state, balancing the range of activities pursued and 
combining centralized and distributed approaches. 
The UC technology transfer program has been 
administered through six functional departments 
BENNETT & CARRIERE
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figure	1:	university	of	California	employee	“patent	Acknowledgement”
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Campus local	office	name year	established
UC Berkeley Office of Technology Licensing 1990
UC Los Angeles Office of IP Administration 1990
UC Irvine Office of Technology Alliances 1994
UC San Diego Technology Transfer and IP Services 1994
UC San Francisco Office of Technology Management 1996
UC Davis Technology Transfer Center 1999
UC Santa Cruz Office for Management of IP 2003
Table	1:	establishment	of	local	offices	of	Technology	Transfer	
within	the	uC	System
California’s economic rise is closely tied to the rise of its research universities. New 
industries have been invented, new products have been developed, and new medical 
techniques have been invented to both save lives and enhance their quality.
- UC President Atkinson (1995–2003)
Our mission is education, research, and public service. Technology transfer is a vehicle that 
helps us do all three. It boosts research support. It creates internships and educational 
opportunities for our students. It stimulates the regional economy. And hopefully, it 
benefits society.
- UC President Dynes (2003–present)
Box	2:	effective	Technology	Transfer	programs	Require	
Supportive	Institutional	leadership
that support all aspects of invention reporting, li-
censing, and administration. These departments are: 
Information Technology and Communications, 
the Office of General Counsel (legal), Licensing, 
Patent Prosecution, Financial Management, and 
Policy Analysis and Development. Each is de-
scribed in more detail below.
3.1	 Information	Technology	
and	Communications
The Information Technology and Communica-
tions department has focused on the development 
and maintenance of an intellectual property man-
agement database called the Patent Tracking Sys-
tem (PTS). This system is critical to all aspects of 
intellectual property management. A single sys-
tem that integrates invention disclosure, patent 
prosecution, licensing, and financial information 
is invaluable for effective IP management—but 
rarely available. Early attention to developing 
such a system was of particular importance for the 
UC system, since all IP, originating from multiple 
campus locations, is the property of a single legal 
entity, the Regents of the UC. As a consequence, 
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a single, integrated database provided the basis 
for integrated reporting and improved handling 
of the risks associated with management of IP at 
multiple locations within the system. With chang-
ing information technology infrastructure, it is 
difficult and costly to update and keep these sys-
tems current, but it should be a high priority for 
any technology transfer program.
The department is also responsible for com-
munications and reporting, which involves, for 
example, the publishing of an annual report 
and submission of survey information to the 
Association of University Technology Managers 
(AUTM). Because most of this reporting is de-
pendent on information aggregated in the data-
base, the department is the logical group to carry 
out this task. However, it has become increasingly 
important to also have regular strategic commu-
nications with both internal and external clien-
tele of the technology transfer program to ensure 
continued support for the mission and activities 
of the program.
3.2	 Office	of	General	Counsel	(legal)
Legal support for the technology transfer program 
is critical since it routinely enters into contracts 
(licenses) on behalf of the university. In the case of 
the UC, legal oversight for the technology trans-
fer program is carried out by a dedicated intellec-
tual property group within the Office of General 
Counsel (OGC). The OGC reports directly to 
the Regents and is charged with oversight of all 
legal issues and legal risks to the university. This 
structural arrangement assures that the business 
opportunity associated with a license agreement 
is not a consideration in the assessment of legal 
risk or exposure that the agreement carries with 
it. Because universities, in general, have a lower 
tolerance for legal risks than does industry, this 
arrangement is one feature that often makes ne-
gotiations with the UC difficult.
3.3	 Patent	Prosecution
This department is responsible for managing the 
outside counsel who draft and prosecute patent 
applications on behalf of the university. Primarily, 
the department performs a “docketing” function 
to ensure that external counsel meets critical filing 
or response dates and that fees are paid on time. 
The department works closely with licensing of-
ficers, inventors, and counsel during patent pros-
ecution to ensure that UC maximizes its IP rights 
and that it does not inadvertently lose rights due 
to failure to meet bar dates in the United States or 
foreign patent jurisdictions.
3.4	 Policy	Analysis	and	Development
Because the UC is a large, risk-averse institution, 
it operates in a policy-rich environment. The 
Policy Analysis and Development department is 
responsible for interpreting existing policy and 
providing consultation to licensing officers and 
researchers in order to assist them in their efforts 
to comply with university policy, as well as with 
state and national law. In addition, the depart-
ment plays an important role in analysis of na-
tional and state legislation and in developing new 
institutional policy to meet these changes as they 
occur. This analysis is important in developing 
positions for the UC with regard to new legisla-
tion that will impact the university’s capability to 
effectively transfer technology to industry. 
3.5	 Financial	Management
Depending on the scale of a technology transfer 
program, there can be significant infrastructure 
required simply to manage the program’s fi-
nances. For the UC this involves monitoring the 
receipt of approximately US$100 million annu-
ally, payment of approximately US$20 million in 
attorney fees, and the distribution of net revenues 
to inventors and to campuses where the technolo-
gy originated. This is an area where inconsistencies 
in financial management can lead to substantial 
losses in revenue, loss of IP rights, and exposure to 
lawsuits by licensees as well as the university’s own 
inventors. The Financial Management depart-
ment provides a dedicated financial management 
infrastructure for uniform and consistent financial 
management for the technology transfer program. 
It is important to recognize that the finances man-
aged by this group are somewhat less “routine” 
than those managed in other university programs. 
The department needs to understand the legal 
processes surrounding IP management and also 
balance the differences in culture and demands 
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arising from private industry, law firms, the uni-
versity community, and individual inventors, all 
of whom have significant interests in the financial 
outcomes of the technology transfer process.
3.6	 Licensing
The largest department within the UC technology 
transfer program is licensing. The UC has histori-
cally maintained sector-specific licensing groups 
in life sciences/pharmaceuticals, physics and engi-
neering, and agriculture. It is particularly helpful 
to have technical expertise in each group as well 
as to have knowledge of licensing norms in the 
various industry sectors, which differ significantly. 
Licensing officers typically have one or more tech-
nical degrees (usually a Ph.D.), a law degree, and/
or a business degree (M.B.A.), and are assigned 
primary responsibility for a case—defined as an 
invention disclosure—from its inception, through 
to licensing, and on to expiration. This practice 
has been referred to as “cradle to grave” manage-
ment and differs markedly from the practice, typi-
cal of many institutions, of segregating invention 
disclosure and patenting processes from licensing 
negotiations and postagreement management. 
Another chapter in this Handbook5 provides 
a case study on the strawberry licensing program 
at UC Davis that illustrates an example of the 
types of licenses and licensing programs that the 
university has entered into as a means to transfer 




Perhaps the most distinctive features of the UC 
technology transfer system are its size and the de-
velopment of a distributed institutional network 
of campuses that operate under a common policy 
framework and share certain resources, but func-
tion relatively independently. Valuable lessons 
can be learned from this system that may have 
applications in, or provide guidance to, other in-
stitutional networks seeking to develop capacity 
in technology transfer. 
The first lesson is that a situation where a de-
centralized technology transfer program is in close 
geographic proximity to major research centers 
can lend itself to success. Decentralization and 
proximity are particularly important because ac-
tive engagement by researchers in the technology 
transfer process typically requires a cultural shift 
that can only be made through continuous and 
systematic contact between technology managers 
and researchers.  
There are, however, elements of a technology 
transfer program that can be effectively central-
ized. Candidates for centralization are, specifi-
cally, those elements of the program for which (1) 
uniform activities are required to minimize legal 
or financial risk or (2) economies of scale can be 
achieved by a consolidation of the activities. 
Using these criteria, the UC technology pro-
gram has, in general, retained centralized finan-
cial management, information technology (data-
base) services, policy analysis and development, 
and legal oversight. These activities are generically 
referred to as our “back office” functions, which 
are essential for the program but do not require 
direct interface with our institutional clients (re-
searchers) or our external clients (licensees). 
In contrast, we have identified for local man-
agement those program elements that directly 
interface with researchers, research sponsors, li-
censees, or regional business interests. Based on 
this criteria, the following activities have been the 
focus of most of the campus-based technology 
transfer offices: invention disclosures and evalu-
ation, patent prosecution, technology licensing, 
and business development activities. 
The centralized/decentralized structure, or 
distributed network, described here could be em-
ulated and implemented at different scales, from 
a relatively small-scale research consortium made 
up of a network of institutions, to a larger-scale 
national network of universities, to a global-scale 
international network of research institutions 
linked by common policies and objectives.
5.	 ConCluSIon
The UC has a long history of seeking intellec-
tual property protection for its research discover-
ies and managing the technologies for the public 
benefit. By some measures, the UC technology 
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transfer program is the largest public program in 
the world. Although it has evolved over the years, 
it has always been at the forefront of this endeavor. 
This article has focused on the history and policy 
and organization frameworks of the UC technol-
ogy transfer program. We hope this discussion will 
be instructive to administrators and others seeking 
to learn from the UC experiences. ■
alan B. Bennett, Associate Vice Chancellor, Executive 
Director, PIPRA, Office of Research, University of California, 
Davis, 1850 Research Park Drive, Davis, CA, 95616, 
U.S.A. abbennett@ucdavis.edu 
mIChael CarrIere, Business Development and IP Manager, 
Office of Technology Transfer, University of California, 
Office of the President, 1111 Franklin Street, Oakland, CA, 
94607-5200, U.S.A. carriere@ucop.edu
1 Mowery DC, RR Nelson, BN Sampat and AA Ziedonis. 
2004. Ivory Tower and Industrial Innovation: University-
Industry Technology Transfer Before and After the Bayh-
Dole Act in the United States, Stanford Business Books: 
Stanford, California.
2 Shaw v. University of California, 67 Cal. Rptr.2d 850. 58 
Cal. App. 44 (1997). 
3 Graff G, A Heiman and D Zilberman. 2002. University 
Research and Offices of Technology Transfer. California 
Management Review 45:88–116.
4 See supra note 1.
5 See, also in this Handbook, chapter 17.25 by AB Bennett 
and M Carriere.
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One of the primary missions of the University of 
California Agricultural Experiment Station (AES) is to 
create knowledge and develop technologies that improve 
the productivity and environmental sustainability of ag-
riculture in California. In addition to the public release 
of information and the educational activities of coopera-
tive extension services, the University of California places 
the inventions of AES faculty directly into commerce 
through the process of patenting and technology trans-
fer. This channel is particularly useful—and often essen-
tial—when further financial investments are necessary to 
develop the technology for practical applications or to 
manufacture, market, and distribute new products that 
incorporate the new technology. This report documents 
the patenting and formal technology transfer activities 
of the University of California Agricultural Experiment 
Station over the last 40 years.
More than 800 inventions have been reported by AES 
researchers between 1960 and 2001. These inventions are 
categorized into the five broad technology areas: biotech-
nology (49%), plant varieties (19%), chemicals (14%), 
equipment/machinery (13%), and environmental (1%). 
Biotechnology inventions were entirely absent until the 
mid-1980s, but the category has grown rapidly over the 
last 15 years. The growth in the number of biotechnol-
ogy-related inventions has occurred not at the expense of 
inventions reported in the areas of plant varieties, agri-
cultural equipment, or novel chemicals, all of which have 
shown a relatively stable level of activity. 
Financial returns from the licensing of AES inventions 
was US$1.4 million in fiscal year 1982 (2.5 million in 
2001 dollars) but had grown to US$12 million by fiscal 
year 2001. After accounting for expenses associated with 
patenting new inventions and distribution of a share of 




The Agricultural Experiment Station (AES) at 
the University of California (UC) is composed 
of nearly 700 researchers in 60 disciplines, car-
rying out over 1,000 research projects. These 
AES researchers are in the College of Natural 
Resources on the Berkeley campus, the College 
of Natural and Agricultural Sciences on the 
Riverside campus, and the College of Agricultural 
and Environmental Sciences and the School 
of Veterinary Medicine on the Davis campus. 
The common research goal of the AES is to cre-
ate knowledge and develop technologies that 
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income to inventors, AES inventions returned over US$6 
million to the university in fiscal year 2001. Since 1982, 
the cumulative financial return has totaled US$105.2 
million in fees and royalties. About 87% of that income 
has been derived from the licensing of plant varieties in 
spite of the fact that they compose only 19% of the AES 
inventions, indicating the commercial importance of UC 
plant varieties. To date, relatively few biotechnology- or 
environmental-related inventions have been commercial-
ized, but the extensive and growing UC portfolio in these 
areas should provide a strong base for future licensing 
activity.
GRAFF & BENNETT
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improve the productivity and environmental 




Much of the AES faculty research makes its im-
pact on California and the world through the 
public release of new technologies or plant variet-
ies, through cooperative extension services, and 
through the teaching of university students who 
apply their new skills and knowledge in the field. 
In addition, the University of California 
places the inventions of AES faculty directly into 
commerce through the process of patenting and 
technology transfer. This channel is particularly 
useful—and often essential—when further fi-
nancial investments are necessary to develop the 
technology for practical applications or to manu-
facture, market, and distribute applications that 
take advantage of the new technology. In this situ-
ation, the researcher is able to make an invention 
disclosure to the University of California’s Office 
of Technology Transfer (OTT) at the UC Office 
of the President or to their individual campus’s 
Office of Technology Licensing (OTL). Either of-
fice—the UCOP Office of Technology Transfer or 
the campus Office of Technology Licensing—pro-
vides a number of services to the faculty inventor. 
The staff evaluates the invention, and, if the inven-
tion seems to hold commercial promise, engages 
in efforts to protect and to market the invention. 
Companies that think they may be able to use one 
of the university inventions can take the technol-
ogy for a test drive by buying an option on the 
technology; if a company decides that they indeed 
can use the technology profitably, they will sign a 
license agreement with the university. If the com-
pany feels that the technology is risky, is unde-
veloped, will require a lot of investment, or may 
have very uncertain returns, it may request that the 
option or license be sold only to itself (exclusive). 
Otherwise, options and licenses can be signed with 
more than one company (nonexclusive).
Following changes in U.S. laws in the early 
1980s, the results of publicly funded research can 
more easily be patented and managed by univer-
sities. Other changes made biological inventions 
much easier to patent. A number of UC research-
ers have been at the forefront of making research 
discoveries and, under these new laws, obtain-
ing patents with applications in agriculture. This 
chapter was produced in order to document the 
patenting and formal technology transfer activi-
ties of the California Agricultural Experiment 
Station over these last 20 years.
2. fIndIng	The	dATA	on		
uC’S	AeS	InvenTIonS
The UC Office of Technology Transfer maintains 
the Patent Tracking System (PTS) database con-
taining information on all inventions made by UC 
researchers and disclosed to the university since the 
early 1960s. PTS also includes complete annual fi-
nancial records on every UC invention since 1982. 
In order to identify those inventions made 
by AES faculty, rosters were obtained from the 
three host campuses—Berkeley, Riverside, and 
Davis—listing the names of all faculty mem-
bers that had held AES appointments between 
1980 and 2000. These names were then matched 
against the names of all UC inventors in the PTS 
database. The matches compiled showed that 283 
of the AES faculty had registered at least one in-
vention with the university (198 from Davis, 61 
from Riverside, and 24 from Berkeley.) Then, us-
ing this list of active AES inventors, it was pos-
sible to exhaustively search the PTS database 
for all of the inventions on which the inventors 
were listed as contributing inventors. This yield-
ed 808 invention disclosures, on which a total of 
574 patent applications were filed in the United 
States, resulting in 243 U.S. utility patents and 
76 U.S. plant patents issued to UC between the 
years of 1960 and 2001. For some of these AES 
inventions, foreign filings were submitted, result-
ing in the issue of 190 foreign utility patents and 




The 808 AES inventions are distributed among 
five broad technology areas (Figure 1a): 49% 
CHAPTER 17.15
 HANDBOOK OF BEST PRACTICES  | 1741 
are biotechnologies, including plant, animal, 
and human medical biology; 19% are plant vari-
eties, primarily strawberries, avocados, peaches, 
grapes, and various rootstock; 14% are chemicals 
(primarily for pest control); 13% are equipment 
and machinery (for agriculture, food processing, 
and medicine); and 1% are environmental tech-
nologies for toxic cleanup and remediation.
Changes in emphasis over the years by the AES 
in these broad technology areas are illustrated in 
Figure 2. The number of invention disclosures in 
each of these five categories is shown for each year 
since 1960. Before the 1980s, AES inventions con-
sisted entirely of equipment and machinery, chem-
icals, and plant varieties. Beginning in the 1980s, 
there was a large, sustained boom in biotechnolo-
gies. The rise of biotechnology, however, does not 
seem to have affected inventiveness in the other 
areas. Chemical inventions, while always sporadic, 
have continued, and there was a surge of new plant 
varieties in the late 1990s. The new, small area of 
environmental technologies emerged only in the 
1990s. Equipment and mechanical inventions 
have remained remarkably steady throughout the 
40-year timeframe. However, within the category 
of equipment and machinery, there has been a 
definite shift toward advanced technologies (com-
puter and scientific equipment) for agriculture and 
medicine and away from farm machinery. 
4. whAT	ARe	The	fInAnCIAl		
ReSulTS	of	AeS	InvenTIonS?
Four types of accounts are reported in the PTS 
data for each invention. 
• expenses. All expenditures made in inves-
tigating the legal and market potential of a 
new invention, applying for patents, pay-
ing patent maintenance fees, and, in rare 
cases when necessary, enforcing UC’s legal 
rights in patent litigation 
• reimbursements. From firms licensing a 
UC invention that agree to pay for some or 
all of the expenses incurred in patenting the 
invention
• fees/royalties. Payments made to UC by 
firms for a license to use (or the option to 
license) a UC invention
• disbursements. A designated proportion 
of the fees/royalty revenues that is paid 
directly to the UC inventors as personal 
income
Out of the 808 AES inventions on record, 
only 174 have generated any fee or royalty in-
come after 1982, when financial data began be-
ing recorded. The first 50 of these are listed in 
Table 1, ranked in order of revenue generated, 
from most to least. The most consistent “big hits” 
on the list are the strawberry varieties. The UC 
strawberry licensing program has been one of the 
brightest spots in the university’s entire technol-
ogy transfer enterprise.1 Figure 3 plots the total 
licensing revenues collected for each of the 174 
inventions and plots revenues from greatest to 
least. It is important to notice how skewed the 
distribution of revenues has been. The top 12 
AES inventions alone account for 88% of all AES 
licensing revenues over 20 years of the program. 
It is also important to note that the inventions 
with lower revenues, toward the bottom of Table 
1 and toward the right of Figure 3, tend to be 
more-recent inventions, which naturally show 
much less income, as they have had less time to 
generate royalties. 
Of particular note, the tomato harvester, 
invented in 1960, is the first invention recorded 
in the dataset. Even in its third and fourth de-
cades on the market (1982–2001), that invention 
brought in over US$160,000 in royalties to the 
university. 
From 1982, when detailed annual records 
began to be kept, through 2001, the licensed in-
ventions by AES researchers have earned a total 
of US$125 million in fees and royalties,2 with 
87% of that coming from the licensing of plant 
varieties, 10% from biotechnologies, 3% from 
chemicals, and 1% from equipment and machin-
ery (Figure 1b). It is very interesting to note that 
while plant varieties make up just 19% of the 
inventions, they generate 87% of the revenues, 
while chemicals and machinery, and particularly 
biotechnology, fall far behind in terms of reve-
nue generation relative to numbers of inventions 
(compare Figures 1a and 1b). Of the total amount, 
US$42 million was disbursed as inventor shares. 
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Expenses incurred in the patenting and market-
ing of these inventions totaled US$23 million, 
of which US$5.4 million was reimbursed by the 
licensing companies. 
Over time, the annual fees and royalties 
generated by AES inventions has increased from 
approximately US$3 million (adjusted) per year 
in the early 1980s to almost US$12 million a 
year today, with particularly strong growth in 
the 1990s. Expenses have also grown, but at a 
slower rate, and reimbursements continue to 
offset approximately one third of expenses. The 
increase in expenses in the 1990s (Figure 4) 
was largely a result of increased foreign patent 
filings, particularly for plant varieties. The re-
sulting foreign patents, however, have contrib-
uted directly to the large increase in revenues. 
Net income, that is, each year’s total amounts 
received (includes fees and royalties plus reim-
bursements) minus each year’s expenses, has 
continued to grow. Inventors’ shares are paid 
out of the net income, and what is left over is 
returned to the university and reinvested into 
new research projects or used to cover univer-
sity operating expenses.
5. ConCluSIonS
The formal process of technology patenting and 
licensing is just one of the many ways that the 
University of California AES contributes to the 
state’s agricultural economy and to the public 
welfare. In increasing numbers, inventions are 
being patented by the University of California on 
behalf of AES researchers and the income gen-
erated by this intellectual property is helping to 
support research and education at the university. 
A significant trend in invention disclosures is the 
tremendous increase in biotechnology-related 
inventions and the emergence of inventions in 
environmental technologies. At the same time, 
inventions reported in the areas of plant varieties, 
agricultural equipment, or novel chemicals have 









1 STRAWBERRY:CAMAROSA 1992 Davis
2 STRAWBERRY: CHANDLER 1982 Davis
3 STRAWBERRY: PAJARO 1978 Davis
4 STRAWBERRY: OSO GRANDE 1987 Davis
5 STRAWBERRY: SELVA 1982 Davis
6 STRAWBERRY: DOUGLAS 1978 Davis
7 LIPOSOME STORAGE METHOD 1984 Davis
8 STRAWBERRY: SEASCAPE 1989 Davis
9 N-AMINO-S INSECTICIDE 1972 Riverside
10 GRAPE: TABLE: REDGLOBE 1979 Davis
11 REPLACE PHOSPHATE BY PHOSPHITE 1990 Riverside
12 STRAWBERRY: TUFTS 1972 Davis
13 STRAWBERRY: PARKER 1982 Davis
14 ASPARAGUS: F 109 1979 Riverside
15 CHERRY: BROOKS 1987 Davis
16 ASPARAGUS: M 120 1979 Riverside
17 ROOTSTOCK: GRAPE: 039-16 1985 Davis
18 STRAWBERRY: FERN 1982 Davis
19 FOOD SURFACE DISCOLORA REDUCER 1993 Davis
20 STRAWBERRY: DIAMANTE 1997 Davis
21 STRAWBERRY: IRVINE 1988 Davis
22 ROTARY SHAKER TOMATO HARVESTER 1978 Davis
23 STRAWBERRY: AIKO 1975 Davis
24 AVOCADO: LAMB/HASS 1993 Riverside
25 MODULATION OF ETHYLENE LEVELS 1990 Davis, non-UC
26 AVOCADO: GWEN 1982 Riverside
27 STRAWBERRY: AROMAS 1997 Davis
28 STRAWBERRY: MUIR 1987 Davis
29 ROOTSTOCK: AVOCADO: THOMAS 1986 Riverside
30 STRAWBERRY: GAVIOTA 1997 Davis
31 ANTIMICROORGANISM FINISH 1996 Davis
32 VOLATILE ELECTROLYTES 1976 Davis
33 RICE RESISTANCE TO XANTHOMONAS 1995 Davis
34 TOMATO HARVESTER 1960 Davis
35 INHIBIT FROST DAMAGE TO PLANTS 1981 Berkeley
36 GRAPE: TABLE: CHRISTMAS ROSE 1979 Davis
37 STRAWBERRY: CARLSBAD 1992 Davis
38 STRAWBERRY: HECKER 1978 Davis
39 DNA/ICE NUCLEATION BACTERIA 1982 Berkeley, non-UC
40 STRAWBERRY: BRIGHTON 1978 Davis
41 PLANT CELL FERMENTATION 1993 Davis
42 STRAWBERRY: SANTANA 1982 Davis
43 CONTROL RELEASE BIOMATERIAL 1992 Davis
44 SOLUBLE EPOXIDE HYDROLASE 1992 Davis
45 HIPPELATES EYE GNAT-CHEMICAL 1974 Riverside
46 STRAWBERRY: CUESTA 1992 Davis
47 STRAWBERRY: TORO 1975 Davis
48 LYME DISEASE: ASSAY & VACCINE 1990 Davis
49 BOVINE PARASITE DIAGNOSTIC 1993 Davis
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The top 12 inventions alone generated 
88% of fee and royalty revenues.
The bottom 135 inventions did not  
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Relatively few biotechnologies or environmental 
technologies have been commercialized to date, 
but the extensive and growing portfolio in these 
areas should provide a strong base for expanded 
licensing activity in the future. 
Several elements of the process of technology 
transfer through patenting and licensing are help-
ing to advance the mission of the AES in new and 
more targeted ways than did the older mode of 
public release:
• The protection of technologies as intellec-
tual property means that a clear accounting 
is kept of the commercially viable results of 
AES research.
• Protection under foreign filings means that, 
when foreign competitors want to use a 
technology developed by California, they 
need to compensate California to use it.
• Protection also provides the opportunity to 
entice companies to invest in developing 
earlier-stage technologies that would other-
wise not likely be developed and thus not 
benefit the state’s economy. 
• The collection of licensing fees and royal-
ties works like a highly targeted tax. The 
companies and growers that benefit most 
from AES research are thereby directly 
supporting the kinds of research and edu-
cation at UC that commercially benefits 
them.
• The payment of an inventor’s share of roy-
alties works like a research prize, even if it is 
not quite as prestigious as the Nobel Prize. 
It rewards researchers for innovations that 
are effectively taken up in the state’s agricul-
ture in proportion to how significant their 
contributions have been to the economy. ■
GreGorY d. Graff, Research Economist, PIPRA, and 
Visiting Research Fellow, Department of Agricultural and 
Resource Economics, University of California, Berkeley, 
PIPRA, Plant Sciences, Mail Stop 5, University of California, 
Davis, CA 95616, U.S.A. gdgraff@ucdavis.edu
alan B. Bennett, Associate Vice Chancellor, Executive 
Director, PIPRA, Office of Research, University of California, 
Davis, 1850 Research Park Drive, Davis, CA, 95616, USA. 
abbennett@ucdavis.edu
1 See, also in the Handbook, section 4.1 of chapter 17.13 by 
AB Bennett and M Carriere.
2 Amounts are normalized to 2001 dollars to adjust for 
inflation.
ABSTRACT
This chapter discusses how Brazil has dramatically in-
creased technology transfer and innovation through the 
State University of Campinas, or Unicamp. The leader 
in patenting and licensing activities in Brazil and Latin 
America, Unicamp has vaulted to this position in the 
short span of two and a half years through its technology 
transfer office, Inova. Providing background information 
about Brazil’s legal framework and practices, especially 
as it concerns the ownership of intellectual property and 
benefit sharing, the chapter discusses government incen-
tives for innovation in light of Inova’s impressive results. 
Two successful cases of technology transfer are presented 
as guides to realistic expectations about investments, 
terms of license, and royalties.
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the same period, Inova applied for 153 new pat-
ents, 22 trademarks, and 24 software registrations. 
Additionally, ten companies from Unicamp’s busi-
ness incubator have become self-sustaining. They 
may leave the university, after which they will pay 
Unicamp a percentage of their income for the 
next five years. Although Inova is still very young, 
in its first six months it achieved more results in 
technology transfer than had been achieved in 
Unicamp’s entire history.
These outstanding results are unique for both 
Brazil and Latin America. The success of Inova 
has encouraged other Brazilian universities, as 
well as small- and medium-sized companies, to 
look to Unicamp as a management model.
2.	pATenTIng	ACTIvITIeS	AT	unICAmp
Founded in 1967, Unicamp has, on average, 
31,000 students; half of these are undergraduate 
students and half are graduate students. There 
are about 1,800 faculty members. With a total 
of 20 research units, Unicamp offers more than 
50 undergraduate degrees and more than 100 
graduate degrees. As a multidisciplinary univer-
sity, Unicamp pursues a variety of technologies 
in many fields. Inova has assessed all of them and 
has aggressively pursued new patent applications 
CHAPTER 17.16
1.	InTRoduCTIon
In the last two years, the University of Campinas, 
or Unicamp, a Brazilian university publicly fund-
ed by the state of São Paulo, has become a leader 
in technology transfer. The critical agent in this 
process is Inova Unicamp,1 the university’s tech-
nology transfer office. In the last two and a half 
years, Inova has signed 128 technology transfer 
agreements and licensed 45 technologies (41 pat-
ents and four cases of know-how) to both private 
companies and the government. These agree-
ments will last for more than ten years and have 
already generated royalties for the university. In 
Di Giorgio RC. 2007. From University to Industry: Technology Transfer at Unicamp in Brazil. In Intellectual Property Manage-
ment in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). 
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
Editors’ Note: This chapter is an edited and shortened version of an article that first appeared in les Nouvelles, Vol. XLI, No. 
2, June 2006, pp. 90–93.
© 2007. RC Di Giorgio. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
From University to Industry: 
Technology Transfer at Unicamp in Brazil
ROSANA CERON DI gIORgIO, IP and Partnership Development Director, Inova Unicamp  
Technology Licensing Office, Universidade Estadual de Campinas, Brazil
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and licensing deals for those that have been most 
promising.
Table 1 lists the most frequent patentors 
in Brazil between 1999 and 2003: Unicamp is 
ranked as number one. It is interesting to note 
that among the top 20 institutions, there are five 
universities and two donor agencies. This runs 
contrary to the norm in developed countries, 
where industries patent more than universities 
and R&D centers. 
The size of Unicamp’s IP portfolio is also 
growing rapidly. As of last year, Unicamp has a 
substantial IP portfolio:
• 48 patents granted and 377 filed
• 17 registered trademarks and 36 filed
• 66 registered software applications/inven-
tions and 66 filed
This portfolio is considered large for Brazil, 
showing that Unicamp’s community has a good 
Table	1:	patenting	Activities	in	Brazil:		
A	Ranking	of	Institutions	(Total	patents	Issued	from	1999	to	2003)
Source: Unpublished data from INPI (Instituto Nacional de Propriedade Industrial), Brazil.
Institution number	of		Issued	patents
Unicamp 191
Petróleo Brasileiro SA (PETROBRAS) 177
Arno SA 148
Multibrás Eletrodomésticos SA 110
Semeato SA Ind. e Com. 100
Companhia Vale Do Rio Doce 89
FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo) 83
Brasil Compressores SA 81
Dana Ind Ltda 71
Universidade Federal de Minas Gerais 66
Johnson & Johnson Ind. e Com. Ltda 56
Universidade São Paulo 55
Jacto Máquinas Agrícolas 54
Minas Gerais Siderurgia (Usiminas) 48
Electrolux do Brasil SA 45
EMBRAPA 42
Conselho Nacional de Desenvolvimento Científico e Tecnológico 42
Universidade Federal do Rio de Janeiro (UFRJ) 38
UNESP - Universidade Estadual Paulista “Júlio de Mesquita Filho” 34
Dixie Toga SA 31
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understanding of the importance of protecting 
research results. Figure 1 shows the evolution of 
patenting activity at Unicamp. One can recognize 
an increase in activity after 1996, when the new 
Brazilian IP law was released, allowing protection 
for food, drugs, and chemicals, areas in which the 
university is very strong. 
In terms of patent distribution by institute 
within Unicamp, patenting activities are not 
uniform within the university’s research units. 
The greatest contributor to the portfolio is the 
Chemistry Institute, which was responsible for 
48% of patents. As a result, most of the licens-
ing agreements are made with the pharmaceuti-
cal, chemical, and medical devices industries, 
employing technologies originating from the 
Chemistry Institute. Other technologies such as 
medical applications (17% of licensing agree-
ments), agribusiness (8%), and food (8%) occupy 
smaller places.
Inova’s patent database is available online.2 
Patents are organized by market sector and can 
be searched by key word. This structure simpli-
fies the localization of the available technologies 
by sector, which is useful for Inova’s commercial 




Unicamp is not only Brazil’s biggest patentor but 
also the country’s biggest licensor. According to 
Brazilian Law,3 an employer is the rightful owner 
of all of its employee’s results. Unicamp, there-
fore, owns 100% of its professors’ and research-
ers’ results. Although the Brazilian Innovation 
Law4 allows public institutions to give up owner-
ship to the inventor, Inova has not practiced this 
option. Its inventors lack commercial expertise, 
and it is more attractive to both the university 
and to the inventor for Inova to commercialize 
the technology and give the inventor part of the 
licensing fee.
Unicamp also commonly practices sponsored 
research. In such cases, ownership is normally 
split 50/50. In exceptional cases, where the in-
dustry partner or investor requires 100% owner-
ship, Inova compensates the university by selling 
Unicamp’s ownership to the partner.
Inova is driven by market demand. Instead 
of selecting Unicamp’s technologies and offering 
them to the market, Inova finds out the market 
demand first and then looks for the solutions 
available inside of the university in response to 
that demand. Our focus is on the customer first 
figure	1:	patents	filed	by	unicamp
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and on the technology second. Since Unicamp 
has a good and big technological production, 
normally we can provide to the market more op-
tions than they expect. Inova always tries to pro-
vide to the market a technology protected by a 
strong patent. 
This market-demand model is partly why its 
results are so impressive. Another factor that con-
tributes to Inova’s success is the professional staff 
involved in technology transfer: the commer-
cialization team comes from private institutions 
and has business skills. Most other universities in 
Brazil and Latin America use people from their 
research staff in technology transfer positions. 
But negotiation, market investigation, evalua-
tion, and so on, are best done by business people 
who are specially trained to do it.
The 128 technology transfer agreements 
signed in two and a half years make Unicamp 
the biggest technology transfer provider in Brazil 
and Latin America. As Unicamp has multidisci-
plinary competence, the agreements were made 
both with private companies and with the gov-
ernment, as well as in many different industry 
sectors. 
The licensing agreements last for more than 
ten years, and have already generated royalties for 
the university. These royalties range from 1.5% to 
10% of the net income derived from the licensed 
technology. Each case has particular issues: all 
licensing contracts include royalty auditing in 
order to confirm that the sales results that the li-
censees present are correct.
It is noteworthy that according to the 
Innovation Law public sector inventors must re-
ceive from 5% to 33% of royalties or licensing 
income, as an incentive to develop new inven-
tions and innovations. Unicamp grants inventors 
33% of royalty and licensing income. The follow-
ing cases make clear how much this income can 
realistically represent. Professors are paid for any 
consulting.
Two successful examples of technology trans-
fer involving technology developed at Unicamp 
and handled through Inova are detailed in Box 1. 
These cases are presented as guides to suggest real-




In recent years, the Brazilian government has 
provided new incentives for innovation. These 
include:
• tax benefits to companies that pay royalties 
(licensees)
• tax benefits to companies that invest in 
R&D, inside or outside the company (The 
latter includes funding R&D in universi-
ties, R&D centers, spinout companies, and 
independent inventors.)
• compensation for taxes paid for royalties 
abroad during the execution of technology 
transfer contracts
• no taxes on money paid to maintain pat-
ents, trademarks, and cultivar registrations 
abroad
• sponsorship/subsidy of 60% of the salary of 
a scientist hired by a company
All sectors are targeted by the law, but the 
Brazilian government has paid special attention 
to information technology, energy (electricity, oil, 
natural gas), semiconductors, biotechnology, and 
pharmaceuticals.
Importantly, the Innovation Law established 
that all government universities and R&D cen-
ters must have an office to take care of IP. This 
will increase patenting and licensing activities in 
public universities and R&D centers in the next 
few years.
5.	ConCluSIonS
In recent years, patenting and technology transfer 
activities have become institutionalized in Brazil. 
A concrete example is Inova, the technology li-
censing office of the State University of Campinas. 
Other public universities and R&D centers have 
been studying and trying to understand Inova’s 
model, in order to follow its example. With re-
gard to intellectual property, Brazil is at a crucial 
juncture. The government, especially in recent 
years, has released many incentives to innovation, 
which are reaching universities, R&D centers, 
and private companies. This certainly will increase 
patenting and technology transfer activities in the 
CHAPTER 17.16
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Box	1:	examples	of	unicamp	Technology	Transfer	Successes
Biphor	
licensee. Bunge (a global agricultural company)
Technology. white pigment based on aluminum phosphate nanoparticules (nanotechnology)
Target	market. water-based paints (world market estimated at US$5 billion per year)
Advantages	 over	 existing	 technologies	 (Tio2). whiter, cheaper, “green” (or environmental) 
chemistry, improved quality and durability
Bunge’s	terms. 
• investments of US$450,000  
• exclusive license for 20 years 
• target market share of 10%, worth an estimated US$500 million per year
unicamp	terms. 
• 1.5% royalties (approximately US$4.5 million per year for 20 years) 
• 33% of royalties (approximately US$1.5 million) to the inventors
Status.
• pilot plant running at 1,000 tons per year in sample production
• commercial plant to be running in five years at 100,000–200,000 tons per year
• sales price to be a little lower than TiO2 (product’s competitor), which costs US$3,000  
  per ton
Aglycon	Soy	
licensee. Steviafarma (medium-sized Brazilian pharmaceutical company)
Technology. concentrated phytoestrogen, extracted from soybeans using biotechnology (The 
unique process, developed at the university, employs a genetically modified microorganism 
owned by Unicamp and available at ATCC.)
Target	market. hormonal therapy
Advantages	 over	 existing	 technologies. improved efficacy without side effects caused by 
conventional drugs, anticancer agent, LDL cholesterol reducer, fungicide, anti-inflammatory, and 
antioxidant
Steviafarma’s	terms. 
• investment of R$100,000 
• exclusive license for ten years 
• target market share of R$36 million per year (Brazil only)
unicamp’s	terms.
• 6% royalties over ten years (approximately R$1.2 million per year for 10 years)
Status. 
• ANVISA registration granted
• production scheduled for September 2006
DI GIORGIO
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country and strengthen the relationship between 
public institutions (where the Brazilian research 
is mainly concentrated) and private companies, 
contributing strongly to innovation.
ROSANA CERON DI gIORgIO, IP and Partnership 
Development Director, Inova Unicamp TLO, Universidade 
Estadual de Campinas, 100 Bernardo Sayao St., P.O. 
Box 6131, Campinas, Sao Paulo 13083-080, Brazil. 
rosanadg@unicamp.br
1 Although a young organization, Inova now employs 20 
people in technology transfer. They include business 
managers, support and marketing specialists, lawyers, 
patent analysts, and administrative assistants. These 
people and the others responsible for accounting, 
financial planning, management, and other crucial 
tasks, are strongly motivated and always have an eye 
for synergy. Together they are responsible for Inova’s 
success. For further information, please visit www.
inova.unicamp.br.
2 www.inova.unicamp.br.
3 Law 9.279, May 1996.






Putting Intellectual Property to Work: 




PATH is an international, nonprofit organization that cre-
ates sustainable, culturally relevant solutions, enabling com-
munities worldwide to break longstanding cycles of poor 
health. By collaborating with diverse public and private 
sector partners, PATH helps provide appropriate health 
technologies and vital strategies that change the way people 
think and act. PATH’s work improves global health and 
well-being. Over the past 28 years, PATH has demonstrat-
ed that public–private partnerships (PPPs) can effectively 
address unmet public health needs, particularly when man-
aged with a clear understanding of both public and private 
sector objectives. Indeed, collaboration between public sec-
tor and private sector partners is an especially valuable way 
to develop and advance appropriate health technologies for 
use in developing countries. When developing and man-
aging PPPs, PATH recognizes that intellectual property 
(IP) is an especially important component in the range of 
variables that affect the economic, technical, and program-
matic feasibility of a new health technology intervention. 
Our goal, therefore, is to incorporate IP considerations as 
a fundamental part of the PPP process. We seek to manage 
IP strategically to avoid or quickly overcome any IP-related 
roadblocks. Using three case studies, this chapter illustrates 
PATH’s strategies for private sector collaboration, as well as 
PATH’s approaches to managing IP.
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CHAPTER 17.17
1.	 InTRoduCTIon	
In many parts of the developing world, public 
health services reach less than 50% of the popula-
tion. Weak infrastructure, poor living conditions, 
Brooke S, CM Harner-Jay, H Lasher and E Jacoby. 2007. How Public–Private Partnerships Handle Intellectual Property: The 
PATH Experience. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices 
(eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHand-
book.org.
© 2007. S Brooke, et al. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
How Public–Private Partnerships Handle  
Intellectual Property: The PATH Experience
steVe Brooke, Commercialization Advisor, Commercialization and Corporate Partnerships, PATH, U.S.A.
ClaudIa m. harner-jaY, Commercialization Officer, Commercialization and Corporate Partnerships, PATH, U.S.A.
heIdI lasher, Principal, Lasher Consulting, U.S.A.
erICa jaCoBY, Senior Program Associate, Commercialization and Corporate Partnerships, PATH, U.S.A.
limited individual and public resources, extreme 
environmental conditions, population growth, 
new migration patterns, violent conflicts, and 
a host of other conditions all pose challenges to 
achieving “health for all.” While healthcare for peo-
ple in the developing world over the past quarter 
century has improved enormously, recently there 
have been significant setbacks: the AIDS epidemic 
and development of resistant strains of diseases, to 
name a couple. Continued growth in populations 
and decaying infrastructure due to lack of rein-
vestment have exacerbated the problem. 
In this context, improving the effectiveness 
of healthcare services requires responsive, con-
stantly evolving public health initiatives that can 
harness recent advances in biotechnology to solve 
difficult healthcare problems in developing coun-
tries. For example, new vaccines for meningitis, 
malaria, and rotavirus would greatly reduce the 
impact of these deadly diseases, which kill mil-
lions of people each year in developing countries. 
New, rapid diagnostic tests would detect condi-
tions at the point of care, allowing treatment and 
counseling before the client has left the clinic. 
Heat stable and multivalent vaccines, prefilled 
injectors, and ice-free cooling would enhance 
health services and improve the effectiveness of 
immunization programs.
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1.1	 Why	are	public–private	partnerships	so	
critical	for	health	technologies?
Our experience suggests that one of the best 
ways to ensure that appropriate, affordable health 
technologies are developed and made available in 
developing countries is through public–private 
partnerships, or PPPs. Globally, most new health 
technologies come from the research and devel-
opment efforts of private industry. Commercial 
enterprises not only have the expertise, capacity, 
and resources to carry a product forward to mar-
ket, they also have strong market-driven incen-
tives to do so. Unfortunately, this drive to pursue 
projects with the highest potential profit means 
that private companies usually do not put a high 
priority on products and services for developing 
countries. Markets in those countries are often 
unstable, and so perceived risks diminish project-
ed return on investment. Pharmaceutical compa-
nies, for example, would rather invest in products 
that are targeted to large, lucrative therapeutic 
markets than pour research dollars into malaria 
or AIDS vaccines. 
Without private sector collaboration many 
badly needed public health products/ideas simply 
fail to come to fruition. By itself, the public sec-
tor lacks the capacity, resources, and experience 
to design, develop, produce, and distribute most 
new technologies. The “technology challenge” for 
public sector health organizations, therefore, is to 
shift market forces enough to attract private sec-
tor involvement in developing appropriate, cost-
effective healthcare technologies and to make 
them available to resource-poor populations. To 
accomplish this, the public sector must co-invest 
in necessary and suitable technologies, reduce 
risk, and invigorate private commercial invest-
ment through effective PPPs.
1.2		 What	has	PATH	learned	about	PPPs?
In the past two decades, the public sector has 
learned that the commercial sector can very ef-
fectively produce and distribute high-quality 
goods at low cost. It has also learned that before 
deciding to get involved in a project, the com-
mercial sector must perceive a reasonable re-
turn on its investment and an acceptable level 
of risk. Acting as a “bridging agency,” PATH 
helps to reconcile these differences by leveraging 
its technical innovation, knowledge of markets 
in developing countries, understanding of com-
mercial imperatives, and experience of managing 
intellectual property (IP). PATH negotiates mu-
tually beneficial solutions for both the public sec-
tor and private entities. Through public–private 
partnerships, the costs and risks of development 
are shared—and sometimes entirely funded by 
PATH with funds from donors, private founda-
tions, and governments—at the early stages of a 
project, which helps private companies see the 
potential for a reasonable return on their invest-
ment. In return, PATH can guide technology de-
velopment towards meeting the priority health 
needs of resource-poor populations.
Acting as a “value-added” intermediary be-
tween industry and the public sector, PATH has 
been involved in successfully commercializing 
and advancing over 50 new technologies for pub-




Typically, a project will begin by clearly identify-
ing a need or gap in the health system of a de-
veloping country that a new technology, at least 
in part, can address. PATH identifies potential 
partners, demonstrates the value of the technol-
ogy, and forms collaborations with commercial 
companies to become codevelopers and/or sus-
tainable suppliers of the technology to the devel-
oping world. Alternatively, the commercial com-
pany may own a technology that can be adapted 
for use in a developing country. In these cases, 
PATH may approach the company to collabo-
rate or gain access to their technology. Within 
these partnerships, PATH aims to meet three 
objectives: 
1. Availability: To guarantee supply for the 
developing world. Initially, PATH works 
to ensure that the company has adequate 
capacity to supply demonstration projects 
and/or clinical trials. Later, a company 
must be able to meet potential demand 
in targeted countries. Over the long term, 
companies must have capacity to meet 
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wider public sector demand in relevant de-
veloping countries.
2. Accessibility: To ensure that the product is 
available through distribution channels that 
actually reach target populations. Although 
many vulnerable populations get their ser-
vices through public sector channels, they 
also access healthcare through private sector 
channels. PATH helps facilitate access to 
both channels by working with traditional 
government health services and by creating 
alliances with social marketing groups that 
are able to reach target populations more 
broadly.
3. Affordability: To create health products that 
the developing world can afford. PATH will 
often negotiate with partners to agree upon 
different prices for different markets (that 
is, tiered pricing by country, or between 
private sector versus public sector consum-
ers). PATH also conducts cost-effectiveness 
studies to help decision-makers understand 
the value of the new product in relation to 
other potential health products.
1.2.2		 Principles	for	collaboration	with	
private	sector	partners
Once PATH has identified potential private sec-
tor partners, it follows a process of due diligence 
to examine a potential partner’s operations and 
management and to verify material facts. Such up-
front diligence significantly increases the chance 
of a successful partnership and assists planning. 
PATH needs to decide, for example, whether a 
company has enough resources to dedicate to a 
project, whether the company is stable and finan-
cially viable, whether the collaboration is appro-
priate given its current situation, and whether the 
company represents the best choice for a PATH 
partnership. Due diligence is an accepted—and 
often required—practice in the private sector, 
and it helps ensure the sustainability and impact 
of PATH’s PPPs.
In addition, PATH professionals have a re-
sponsibility to preserve PATH’s integrity and sta-
tus as a publicly funded nonprofit, nongovern-
mental organization and fulfill this responsibility 
by evaluating partnerships with respect to nine 
principles for private sector collaboration.1 From 
the perspective of IP management, the following 
two principles are most important:
1. Clear link to mission. PATH’s collabora-
tions with private sector companies must 
positively affect the availability, accessibil-
ity, and affordability of important health 
products for public health programs in de-
veloping countries. 
2. Recognition of private sector needs. 
PATH recognizes the company’s need to 
benefit commercially, which ensures a sus-
tainable commitment to the collaboration. 
PATH’s goals for availablity, accessibility, 
and affordability of products for develop-
ing country public health programs will 
likely be met if PATH’s expectations of 
the private sector collaboration are realis-
tic and take into account the full range of 
costs necessary from product development 
to commercialization.
2.	 how	do	pATh’S	pppS	hAndle	Ip?
Given its mission, PATH has an inherent inter-
est in managing IP to achieve maximum public 
health benefits. PATH’s approach to IP manage-
ment has common themes for all projects. PATH 
professionals review the existing and competing 
IP rights of all partners, negotiate with partners 
over the exact terms of ownership for all IP gener-
ated over the course of the project, agree on what 
happens if the partnership terminates before the 
project’s completion, and specify responsibilities 
for protecting project IP generated by partners 
and PATH. After a technology is developed, IP 
is managed in the context of a commercialization 
strategy and a licensing plan. 
Within each of these activities are myriad 
complexities that influence the specific strategies 
and tactics PATH adopts to negotiate IP. Perhaps 
the best way to understand PATH’s approach to 
handling IP, then, is through case studies. Two of 
the following case studies, the first involving cer-
vical-cancer screening diagnostics and the second 
involving a meningitis vaccine, are well along the 
product development pipeline. In these projects, 
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IP is managed to advance specific products through 
subsequent stages of development and commer-
cialization leading to use in developing countries. 
A third case study, involving vaccine stabilization, 
describes technologies in an earlier stage of R&D 
that will become components of final products 
rather than complete products themselves. In 
this case, PATH is pursuing the development of 
a portfolio of technologies simultaneously in or-
der to distribute risk and ensure progress toward 
a successful outcome. IP is managed to advance 
the technology portfolio, with the understanding 
that technologies developed over the course of 
the project will become important components 
of future final vaccine products. 
2.1		 Cervical-cancer-screening	tests:	two	is	
better	than	one
Although cervical cancer is preventable, about 
200,000 women die each year from it—often in 
their most productive years. Pap-smear screen-
ing programs help keep cervical cancer rates 
relatively low in wealthier countries; however, 
the success of these screening programs rely on 
regular visits to healthcare facilities, expensive 
pathology laboratories, and follow-up visits. Due 
to the cost, implementation challenges, and the 
complexity of properly screening and treating 
women in developing countries, the Pap-smear 
method has had only a limited impact in these 
areas. Not surprisingly, more than 80% of new 
cervical cancer cases occur among women living 
in developing countries. 
2.1.1	 	 How	the	public	and	private	sectors	
came	together
Because cervical cancer affects women in devel-
oped countries and developing countries,  private 
industry had already invested in research to im-
prove diagnostic screening tools for human pap-
illomavirus (HPV), the virus is associated with 
over 99% of cervical-cancer cases. However, these 
commercial enterprises had not taken an inter-
est in adapting their technology to make it more 
affordable and appropriate for developing-coun-
try health settings. This would have required a 
large investment in both product development 
and clinical studies—for a market that can afford 
prices that are only a fraction of those in devel-
oped countries. Hence, investing in HPV diag-
nostic technology for public sector markets in de-
veloping countries would never be a top priority 
for a commercial entity.
In 2003, PATH received funding from the 
Bill & Melinda Gates Foundation for its Screening 
Technologies to Advance Rapid Testing (START) 
project. This project includes support for clinical 
studies involving over 22,000 women in China 
and India, as well as support for developing low-
cost, easy-to-use, culturally acceptable tests for 
cervical cancer screening. Since the private sec-
tor had already developed relevant technologies, 
and since PATH possessed useful data, a PPP was 
a logical choice. Two testing formats appeared 
promising, so PATH orchestrated partnerships 
with two companies to develop the test formats 
to detect HPV (one using DNA, and the other 
using a biomarker protein).
Both companies in the PPP are working 
to create a test that is safe, accurate, afford-
able, simple to use, and acceptable to women 
and healthcare providers. Tests will be based on 
a cervical swab provided by a healthcare pro-
vider or a vaginal swab obtained by the woman 
herself. Health workers with minimal training 
and equipment should be able to process either 
test in one day. Both tests are expected to have 
a higher than 90% accuracy rate in detecting 
cervical precancer or cancer (the Pap-smear test 
has a 55%–65% accuracy rate). This means that 
women who get tested only once in their life-
time, using one of the new methods, will still 
have a high probability of avoiding cervical can-
cer disease.
2.1.2		 PATH’s	management	of	IP
When negotiating with partners, PATH often 
finds it helpful to articulate the different roles 
and responsibilities and the expected durations of 
the various phases involved in the project. For the 
START project agreements, there was the R&D 
phase, which would last approximately five years, 
and the commercial sales phase, which would last 
10 years from the date of first sale. In the R&D 
phase, PATH assumed responsibility for seven 
primary activities: 
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• funding a portion of each industry partners’ 
direct R&D costs
• providing biological samples during 
research
• conducting market and industry assessments 
• conducting some key product development 
tasks, specifically with lateral flow technology
• conducting program and product cost-ef-
fectiveness studies
• developing for the new tests an evaluation 
framework for public health program use 
• conducting multicenter, multicountry 
(India and China) clinical evaluations of the 
performance of the new test that would be 
suitable for the compilation of data required 
for product registration in those countries
In turn, PATH’s industry partners agreed to: 
• conduct product development activities as 
outlined in their agreements
• assemble and protect any needed IP
• manufacture and supply the products for 
clinical evaluations
• finalize the products for registration and 
commercial supply 
Each of PATH’s private sector partners in 
this project already controlled key IP for the 
technologies included in its respective diagnos-
tic test. This eliminated the need to broker IP 
for reagents from multiple parties. However, 
the two partnerships are more complex when 
it comes to creating PATH’s backup IP rights 
if either industry partner were to decide not to 
go forward. In one agreement, PATH obtained, 
under certain backup conditions, a long-term 
supply agreement to the partner’s key reagent, as 
well as the ability to sublicense others to produce 
a final diagnostic test incorporating this reagent. 
In the other agreement, the industry partner 
agreed to appoint a third party to manufacture 
and supply the diagnostic test if it does not want 
to continue commercialization. The latter part-
ner would never be comfortable allowing its core 
background IP to move out of its direct con-
trol, so rather than asking the company to grant 
PATH rights to background IP, PATH focused 
on ensuring continued supply. Both agreements 
set pricing targets that are significantly lower 
than anything currently available.
Following the successful completion of re-
search, development, and validation, PATH’s 
industry partners will be responsible for obtain-
ing the necessary regulatory approvals and for 
manufacturing and selling the test at an afford-
able price in India, China, and other developing 
countries. By the end of 2008, two easy-to-use, 
inexpensive, and appropriately designed diagnos-
tic products to detect cervical precancer and can-
cer should be available in developing countries.
2.1.3		 Key	insights
All projects come with their own unique chal-
lenges, particularly when multiple partnerships 
are involved. In the case of the START project, 
PATH was able to avoid some common pitfalls 
by carefully selecting its partners. For example, 
because PATH came forward with links to 
clinical researchers and policy-makers, and be-
cause it had a solid understanding of the speci-
fications that any new cervical-cancer-screening 
test would need, PATH was able to attract two 
top-tier industry partners that had the expertise 
and capacity to move product development for-
ward. These partners were attractive to PATH 
because they owned proprietary control of the 
key reagents needed for their specific technolo-
gies. This allowed the project to avoid the even 
more uncertain, complex, and lengthy negotia-
tions necessary to bring multiple IP holders into 
a workable product development project. 
PATH also provided access to well-character-
ized, highly sought-after clinical specimens from 
countries outside the industry partner’s normal 
research networks. In addition, PATH offered 
the opportunity for major field-based clinical 
assessments of final products, assessments that 
would be sufficient for product registration in 
those countries. As a result, the two industry 
partners realized that working with PATH would 
provide a unique opportunity to reengineer their 
product (in the case of one partner) or develop 
a new product (in the case of the other partner) 
to address lower-price market segments, thus 
gaining valuable inroads into the challenging but 
attractive markets of India and China. Without 
BROOKE, HARNER-JAY, LASHER & JACOBY
1760 | HANDBOOK OF BEST PRACTICES
the PATH program incentives, it is unlikely that 
either company would have undertaken these 
major efforts to adapt and develop their tech-
nologies for use in developing countries. 
2.2	 Meningitis	vaccine:	a	new	model		
for	vaccine	development
Meningitis, also referred to as spinal meningitis, 
is an infection in the fluid that surrounds the 
brain and spinal cord. When caused by a bacte-
rial infection, the disease can be quite severe and 
may result in brain damage, hearing loss, learning 
disabilities, and death. Epidemic meningitis has 
been present on the African continent for about 
100 years. 
Over the last 20 years, countries located in 
Africa’s “meningitis belt,” roughly located be-
tween Senegal and Ethiopia, have depended on 
a disease control strategy involving surveillance 
and, once outbreaks are detected, reactive mass 
immunization campaigns using meningococcal 
polysaccharide vaccines. These interventions are 
massive, expensive, and disruptive, and they de-
flect scarce resources from public health efforts to 
control other diseases. Moreover, recent studies 
have shown that after an epidemic has begun, fol-
low-up mass vaccinations are ineffective at pre-
venting meningitis. 
Unfortunately, while the public health need 
for a meningitis vaccine in Africa is great, no 
manufacturers have been willing to develop an 
affordable, effective group A meningococcal vac-
cine. In the 1990s, when more than 100,000 
people died in Africa from a group A meningi-
tis outbreak, there was also a group C meningitis 
outbreak in the United Kingdom, which resulted 
in 1,000 deaths. By 2001, three vaccine manu-
facturers had developed group C meningococcal 
vaccine for the United Kingdom. No vaccine for 
group A, however, had been developed.2
2.2.1 	 How	the	public	and	private	sectors	
came	together
The disease-specific components for a highly ef-
fective group A meningococcal conjugate vac-
cine existed before the PATH/World Health 
Organization (WHO) Meningitis Vaccine 
Project began. The conjugation technology also 
existed, which was a key production process 
step—it chemically links the two components, 
which makes the vaccine highly immunogenic 
and effective in young children, provides long-
lasting protection, and decreases carriage and 
transmission rates. Yet no one was bringing these 
components together to develop and produce a 
meningococcal A vaccine. The challenge was to 
develop a program capable of motivating a vac-
cine producer to take a risk on an indigent mar-
ket unable to pay high prices for the meningo-
coccal A vaccine. 
To address this challenge, in 2000 WHO com-
missioned an independent assessment of existing 
IP on conjugation technology and of the costs for 
project development and production for a group 
A or group A/C meningococcal conjugate vac-
cine intended for Africa.3 The assessment showed 
that development was feasible and that a vaccine 
costing around US$0.40 per dose was possible—a 
price that health managers in sub-Saharan African 
countries were willing to pay. Soon after, the Bill 
& Melinda Gates Foundation awarded PATH a 
ten-year grant to establish, in partnership with 
WHO, the Meningitis Vaccine Project, which will 
advance the development, production scale-up, 
testing, licensure, and introduction of conjugate 
meningococcal A vaccines for Africa. 
2.2.2	 PATH’s	management	of	IP
The Meningitis Vaccine Project brought three crit-
ical partners to the table: SynCo Bio Partners B.V., 
which supplied meningococcal polysaccharide A 
(one of the two main components of the vaccine); 
the Serum Institute of India Limited (SIIL) to sup-
ply tetanus toxoid (the second main component 
of the vaccine) and to scale-up the manufactur-
ing processes for the final vaccine; and the U.S. 
Food and Drug Administration’s (FDA) Center 
for Biologics Evaluation and Research to transfer 
their conjugation technology. This consortium was 
a new model for vaccine development: a key raw 
material came from one source, the technology 
from another, and the final scale-up for produc-
tion from another. Moreover, it included a north-
to-south transfer of technology and capacity.
PATH first negotiated a nonexclusive li-
cense for the FDA conjugation technology from 
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the U.S. National Institutes of Health Office of 
Technology Transfer (on behalf of the FDA), 
which PATH then sublicensed to SIIL. To pro-
tect the charitable mission of the project, PATH 
and SIIL agreed that if SIIL were to cease de-
veloping or producing the vaccine, SIIL would 
transfer to PATH the manufacturing know-
how developed during their collaboration to 
enable another manufacturer to make the vaccine. 
SIIL also granted back to PATH a nonexclusive, 
sublicensable license to SIIL-owned technology 
necessary to make the vaccine. In addition, the 
PATH-SIIL agreement set out an explicit initial 
pricing of US$0.40 per dose for sales to the public 
sector. PATH’s agreement with SIIL also includes 
explicit procedures and remedies should SIIL not 
meet public sector demand or charge the public 
sector more for the vaccine than the maximum 
agreed-upon price. 
2.2.3 	 Key	insights
It is somewhat unusual for vaccine manufacturers 
to accept a nonexclusive sublicense for a key pro-
duction process such as a conjugation technol-
ogy. However, the PPP and technology transfer 
gave SIIL incentive to accept this. First, since no 
manufacturer had been willing to make this vac-
cine, SIIL considered the risk that a competing 
manufacturer would step forward to use nonex-
clusively available FDA technology for a group A 
meningococcal conjugate vaccine was very small. 
Second, although SIIL is one of the world’s lead-
ing vaccine manufacturers and had prior research 
experience working with conjugation technology, 
both SIIL and PATH knew they would be facing 
complex development challenges and an aggres-
sive timetable. To help address these challenges 
and make the project more attractive to SIIL, 
PATH formed a technical team composed of 
the FDA inventors and other industry and gov-
ernment experts, who creatively and efficiently 
helped the Meningitis Vaccine Project surmount 
the inevitable technology scale-up and standard-
ization hurdles. Third, the U.S. National Institutes 
of Health Office of Technology Transfer (NIH 
OTT) would have likely required higher up front 
fees, milestone payments, and higher royalty rates 
if PATH and/or SIIL had demanded an exclusive 
license to the conjugation technology. By nonex-
clusively in-licensing the conjugation technology 
under lower-cost terms and bundling it with fur-
ther technology transfer support, pharmaceutical 
development, and clinical trials funding, PATH 
provided a package that would allow SIIL to keep 
the finished vaccine price at the targeted US$0.40 
per dose, even after paying royalties to the NIH 
OTT. At this price, the new vaccine would cost 
less than current expenditures in hyperendemic 
areas, even before adding lost livelihood income 
and disability savings. 
2.3		 Creativity	and	flexibility	accelerate	vaccine	
stabilization	technologies	
The global health community is trying to make 
vaccines available to all the world’s children, but 
this commitment is stressing an already fragile 
cold chain: the distribution network of equip-
ment and procedures used to maintain vaccine 
quality from the vaccine manufacturer to the 
recipient. While strengthening and expanding 
existing cold-chain capacity is one option for 
reducing these stresses, improving vaccine ther-
mostability—the inherent ability for vaccines 
to withstand extreme temperatures—is likely to 
be the more effective and sustainable approach. 
In recent years, stabilization technology has ad-
vanced so far that it could reduce the reliance 
of vaccines on the cold chain and facilitate ex-
panded delivery options. These products could 
reduce the logistical burden of vaccine delivery, 




Vaccine producers typically seek to obtain suffi-
cient product stability to meet the standards of 
developed countries. This means that vaccines 
typically require storage at frozen (−20º C) or 
refrigerated (2–8º C) temperatures. Some heat-
sensitive vaccines (such as measles, BCG, and yel-
low fever vaccines) must be lyophilized (freeze-
dried) in order to achieve this level of stability. 
Vaccine producers have been reluctant to further 
improve thermostability to reduce reliance on 
the cold chain for two main reasons. First, there 
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is no perceived need for such products in devel-
oped countries where cold chain breaks are infre-
quent. This means that vaccine producers would 
rely solely on developing country sales to recoup 
their development investment. Second, the com-
mitment of vaccine purchasers to buy stabilized 
vaccines for use in the developing world is uncer-
tain—especially at higher prices. 
In the absence of a market for thermostable 
vaccine products, PATH initially investigated 
the feasibility of stabilizing vaccines with fund-
ing from the U.S. Agency for International 
Development (USAID) under a program called 
HealthTech: Technologies for Health. In 2003, 
PATH received funding from the Bill & Melinda 
Gates Foundation to investigate the technical, 
programmatic, and market feasibility of stabiliza-
tion technologies. PATH is pursuing a portfolio 
approach to the project, working with a range of 
private sector companies and universities to ac-
celerate the development of different stabilization 
technologies that could be applied to a variety of 
vaccines. PATH has also developed its own pro-
prietary technology to protect vaccines against 
freeze damage (U.S. and Patent Cooperation 
Treaty [PCT] patent applications are pending). 
As certain technologies show themselves to be 
more promising than others in terms of avail-
ability, accessibility, and affordability, the portfo-
lio will be narrowed. When the technologies are 
mature enough to transfer, vaccine producers will 
need to help validate and scale up the technolo-
gies for commercial production.
2.3.2	 PATH’s	management	of	IP
The primary focus of PATH’s IP management 
strategy for the vaccine stabilization project has 
been to keep options open by holding some own-
ership of the new IP generated with partners. This 
makes it possible to move forward with the tech-
nology if the partner is unwilling and to improve 
the efficiency of research within the portfolio 
(that is, use the project IP with other partners). 
Since the landscape of patents in the stabilization 
field is fairly crowded, the strategy also involves 
creating partnerships with those that hold foun-
dational IP to which others may eventually need 
access. 
In practice, this strategy requires a great deal 
of creativity and flexibility. In many cases, for ex-
ample, PATH and its partner jointly own proj-
ect IP. Moreover, in certain circumstances, access 
to background IP is negotiated at the start. This 
is ideal because it gives PATH control without 
jeopardizing the partner’s access. However, two 
specific partnerships illustrate the extremes of 
managing IP. On one end of the spectrum is a 
technology that PATH created in-house and is 
developing in collaboration with a partner. Since 
PATH owned the technology, it was able to ne-
gotiate full ownership of all improvements, even 
those to which the partner may contribute. On 
the other end of the spectrum, a private sector 
partner maintained very tight control over its 
proprietary IP. Rather than accept funding from 
PATH, the company tested its technology against 
the applications of interest to PATH, assuming 
the entire R&D burden in order to fully control 
the IP. In this case, PATH was able to obtain an 
opportunity to negotiate access to their IP in the 
future. Although not ideal structurally, this col-
laboration allowed PATH to build a relationship 
with a partner whose technology may be impor-
tant to other technologies in the portfolio. This 
may allow PATH to avoid a potential roadblock 
to access in the future.
In addition to IP management, the project’s 
global access strategy makes concerted efforts to 
align partners along the vision of how the end 
products might be made available in developing 
countries. For such purposes, PATH developed a 
Preferential Technology Access Program, which is 
written into each partner’s agreement. For exam-
ple, partners must agree to license their technol-
ogy on nonexclusive terms to vaccine manufac-
turers in order to maximize access, place a royalty 
cap on those licensing arrangements, and restrict 
licensing and milestone fees. The exact terms vary 
with each partnership. The goal is to enable access 
to these technologies as they move downstream in 
the development pipeline.
2.3.3	 Conclusions
When it comes to upstream research projects, 
we know very little about which technologies 
will emerge as promising, which may need to be 
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eventually combined, and which may prove foun-
dational for others. PATH’s strategy has been to 
invest in a wide variety of promising approaches, 
promising to maximize the chances for success 
and integration and to negotiate some degree of 
access. PATH can thereby prevent those technol-
ogies that are emerging from the portfolio—and 
even technologies that already exist—from lim-
iting the widespread adoption of stabilization 
technologies by vaccine manufacturers serving 
the developing world. This requires a constant 
reexamination of product scenarios and players. 
PATH uses as much flexibility and creativity as 
possible to move forward a market that in its ab-
sence would stall. ■
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ABSTRACT
For smallholder farmers in Africa, yields of major staple 
crops (maize, sorghum, millet, cassava, cowpea, bananas/
plantains) have remained stagnant or even declined in the 
past 40 years. Numerous biotic and abiotic stresses have 
contributed to this dire trend. Local research efforts to 
overcome these stresses have been hampered by declining 
support for agricultural research, limited access to elite 
genetic material and other technologies protected by IP 
rights, and the absence of commercial interest in these 
crops from private owners of agricultural technologies. 
The African Agricultural Technology Foundation (AATF) 
is a new initiative addressing the challenge of reversing 
the negative trend in agriculture by negotiating access to 
proprietary technologies and facilitating their delivery to 
smallholder farmers in Sub-Saharan Africa.
This chapter addresses the IP issues and partnership ar-
rangements associated with the access, development, and 
deployment of agricultural technologies in Sub-Saharan 
Africa by AATF. The chapter explores the model developed 
by AATF, which incorporates the acquisition, develop-
ment, and deployment of new technologies from private 
sector partners, to try to address the agricultural needs of 
resource-poor smallholder farmers in Sub-Saharan Africa.
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selection and adaptation of crop landraces. More 
recently, progress has been accelerated through 
the development of new varieties of crops, mainly 
through crossing and selecting parent crops with 
desirable characteristics. In Africa, smallholder 
farmers constitute approximately 70% of the 
general population and 90% of the agricultural 
workforce. According to Omanya and colleagues,1 
despite the availability of agricultural technolo-
gies (such as improved seeds and farm inputs), 
crop productivity in Africa has remained low or 
stagnant. This is true mostly because improved 
crop varieties that are resistant to biotic and abi-
otic constraints are not being planted. High costs 
and the unavailability of technologies in times of 
need have made drought-tolerant or disease- and 
pest-resistant seeds inaccessible, particularly to 
smallholder farmers in developing countries. The 
problem is compounded by the complexities as-
sociated with the protection of IP rights. Patents 
and plant breeders’ rights attempt to strike a bal-
ance between protecting the rights of an inven-
tion and providing a benefit to the society as a 
whole, but such protected materials also often 
raise the cost of accessing new plant varieties.
The decline in agricultural productivity and 
the rise of IP rights has created a new challenge: 
How can the development community stimu-
late the development of innovative technologies 
while providing mechanisms that support the 
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1.	 InTRoduCTIon
The agricultural sector in developing countries 
is the key source of food, incomes, employ-
ment, and often, foreign exchange. Put another 
way, agriculture is crucial for sustaining liveli-
hoods and stimulating overall economic growth. 
Traditionally, agricultural progress has been de-
pendent on on-farm experimentation and the 
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smallholder farmers’ access to these technolo-
gies? A balance must be achieved in order to 
reach the goal of improving the economic pro-
ductivity, and therefore, the lives, of these farm-
ers. Delmer and colleagues2 have described sev-
eral initiatives designed to meet this challenge. 
Besides AATF, two other groups are working 
toward these initiatives: 
• the Public Intellectual Property Resource 
for Agriculture (PIPRA), a U.S.-based ini-
tiative with global reach that seeks  to pool 
publicly owned and patented technologies 
for use by research institutions in develop-
ing countries
• the Centre for the Application of Molecular 
Biology to International Agriculture 
(CAMBIA), an Australia-based initiative, 
which aims to provide technical solutions 
that empower local innovators to develop 
new agricultural innovations
AATF focuses specifically on negotiating 
access to proprietary technologies and facilitat-
ing delivery of the technologies to smallholder 
farmers in Sub-Saharan Africa. The next section 
describes AATF in more detail and discusses in-
depth AATF’s policy on IP management. Finally, 




Improving agricultural productivity in Africa is key 
to expanding the economy and reducing poverty. 
Since the 1970s, significant investment and new 
technologies have caused agricultural productiv-
ity to rise dramatically in Asia and Latin America. 
But investment and innovation have been limited 
in Africa and agricultural productivity suffered. 
Sub-Saharan Africa has the highest hunger and 
malnutrition rates and the least productive ag-
riculture in the world: approximately one-third 
of the population lacks food security (defined by 
the Food and Agriculture Organization [FAO] as 
having enough food to lead healthy and produc-
tive lives), and one-half lives on less than US$1 
per day. According to World Bank figures, the 
25 countries with the highest death rates are in 
Africa, and 24 of the 25 countries with the lowest 
life expectancy are in Sub-Saharan Africa. Most 
of the region’s population depends for their liveli-
hood on agriculture, which accounts for only 30% 
of the region’s gross domestic product (GDP). 
Farmers make up about 90% of those individuals 
earning less than US$1 per day. Between 1980 
and 1995, Sub-Saharan Africa was the only re-
gion of the world where crop production actually 
decreased: yields fell by 8% compared to increases 
of 27% in Asia and 12% in Latin America. 
Developments in agricultural science and 
technology, however, hold out hope for signifi-
cant improvements in food security and poverty 
reduction in Sub-Saharan Africa. African Poverty 
Reduction Strategy Papers, documents from 
the New Partnership for Africa Development 
(NEPAD), and multilateral policies and plans all 
emphasize the need for Africa to access new, bet-
ter agricultural technology from the internation-
al community. Some of these technologies can 
be readily adapted to the region’s conditions and 
can be provided immediately to poor farmers. 
The private and public sectors hold the key to 
accessing these technologies—but neither alone 
can exploit this potential. Private sector compa-
nies have significant technological resources but 
currently no commercial incentive to invest in 
the specific technologies, varieties, and traits suit-
able for the unique agricultural conditions of the 
relatively small Sub-Saharan Africa market. On 
the other hand, public sector organizations have 
vast experience working on regionally important 
crops but need improved access to the proprietary 
technologies held by the private sector and other 
public sector institutions. Further, the region’s 
public sector research institutions could benefit 
from assistance in adapting technologies to the 
needs of resource-poor farmers in Sub-Saharan 
Africa. But issues related to the availability, com-
plexity, high transaction costs, licensing, test-
ing, safety, and potential liability associated with 
these agricultural technologies bar access to these 
technologies by the region’s researchers, devel-
opment specialists, and resource-poor farmers. 
To address these issues, we need new, innovative 
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approaches based on the support and collabora-
tion of both the public and private sectors.
The fundamental rationale for the creation 
of AATF was to establish links between private 
sector and public sector institutions (that own 
technological innovations) in developed nations 
and African stakeholders in agricultural develop-
ment, such as the National Agricultural Research 
and Development Organizations, farmers’ as-
sociations, nongovernmental organizations, and 
national, private sector agribusinesses. The goal of 
AATF is to facilitate access to advanced scientific 
and technological resources and to promote their 
adaptation for use in specific projects intended to 
increase the productivity of smallholder farmers 
in Sub-Saharan Africa. AATF is an Africa-based, 
Africa-led entity, registered as a charity under the 
laws of England and Wales, with the specific ob-
jective of relieving poverty in Africa by facilitat-
ing public/private partnerships for the transfer 
and use of innovative agricultural technologies by 
smallholder farmers, particularly resource-poor 
farmers. AATF thus contributes to increased 
productivity, higher farm output, increased food 
security, and higher incomes. Headquartered in 
Nairobi, Kenya, AATF was officially launched 
there in June 2004.
2.2	 Operating	principles	and	strategy
AATF’s strategy for achieving its objectives is to 
act as the principal and “responsible party” in fa-
cilitating, on a case-by-case basis, public/private 
partnerships. AATF works closely with other 
African institutions, responding on a project-by-
project basis to the expressed needs of African 
farmers. The foundation endeavors to assemble 
all the necessary components for each project, 
balancing concerns for expense, simplicity, and 
effectiveness. More specifically, AATF:
• consults with African stakeholders to iden-
tify priority crops and key constraints for 
resource-poor farmers
• consults with potential technology provid-
ers, in both the private and public sectors, 
to identify technologies that can address 
those constraints
• negotiates with potential partners to devel-
op a project business plan that specifies the 
role of each partner institution and deter-
mines how and where the technology will 
be used
• enters into licensing agreements to access 
and hold proprietary technologies within 
paying royalties and to ensure freedom to 
operate (FTO) for all the components of the 
technologies
• sublicenses partner institutions:
- to carry out research, as needed, to adapt 
the technologies to smallholder farming 
conditions
- to test adapted technologies for regula-
tory compliance
- to produce and distribute the 
technologies
• monitors compliance with the require-
ments of sublicenses to minimize the risk 
of technology failure
• facilitates the work of appropriate partner 
institutions to ensure that links in the value 
chain are connected, are effective, result in 
technology products that reach farmers, 
and allow farmers’ surplus harvests to reach 
markets.
• creates partnerships within African coun-
tries and with external stakeholders to de-
velop necessary indigenous capacities over 
time
As implied above and further illustrated in 
Figure 1, AATF operates along the entire product 
value chain, from the transfer and adaptation of 
technology to farmers’ access to output markets, 
with each implementation step undertaken with 
the relevant partner organizations. The nature of 
AATF’s involvement varies from project to proj-
ect, depending on the specific requirements and 
issues that need addressing.
Depending on the needs of African farm-
ers, AATF promotes the development and 
transfer of all types of technology. The choice 
of technologies reflects African priorities, is 
demand driven, and is guided by the potential 
to improve food security and reduce poverty. 
AATF gives preference to technologies that are 
simple, cost effective, and provide sustainable 
value to the farmer. So far, eight broad areas 
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have been identified as priorities for interven-
tion by AATF:
• Striga control in cereals (Striga is a parasitic 
weed)
• improvement of cowpea productivity and 
utilization
• bananas/plantain productivity 
• nutritional quality enhancement in maize 
and rice 
• drought tolerance in cereals
• reduction/elimination of mycotoxins in 
food grains
• cassava productivity improvement
• insect resistance in maize
AATF’s policy is based on the belief that 
developing countries in Sub-Saharan Africa 
must make their own decisions about whether 
or not to adapt and adopt particular agricultur-
al technologies, including genetically modified 
(GM) organisms. AATF expects that these de-
cisions will be based on appropriate national or 
regional assessments of the costs, benefits, and 
social acceptability of each technology. In the 
case of food biotechnologies, AATF will always 
require countries that license technologies to 
have the capacity to manage their safe develop-
ment and use through appropriate, operational 
national biosafety regulations and other neces-
sary instruments.
2.3 Liability	and	other	concerns
A major concern of AATF’s project collaborators, 
whether they are public entities or multinational 
companies, is liability exposure once propri-
etary technologies have been licensed to AATF 
and subsequently sublicensed to other parties 
for use in Sub-Saharan Africa.4 A related con-
cern is the possible misuse of the technology 
and associated confidential information. AATF 
has devised the following product stewardship 
mechanisms to address these concerns. For each 
project, AATF: 
• develops a business plan, which outlines 
the specific uses of the technology, together 
with management and oversight protocols 
that will govern and monitor such use
• conducts risk analyses to aid in formulating 
and implementing risk mitigation plans 
Liability issues can arise due to damage 
caused by the use of agricultural technologies to 
persons, property, or the environment, for exam-
ple, damage that may result from the contamina-
tion of seed and organic crop purity. Due to the 
close proximity in Sub-Saharan Africa of small-
holder farmers to one another, pollen from one 
holding can move easily to neighbouring hold-
ings, contaminating seedlings, produce, and air. 
Complaints of allergies and health-related prob-
lems arising from pollen flow and food consump-
tion have led to liability suits in some countries 
outside Africa. While this issue is yet to be tested 
in Sub-Saharan Africa, farmers and biotechnol-
ogy companies have the responsibility to take 
steps to ensure, in so far as practicable, that tech-
niques are developed and used to prevent such 
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role, helps farmers and companies carry out this 
responsibility. 
AATF is proactive in its role of product stew-
ardship. It ensures that smallholder farmers and 
research partners comply with all relevant licens-
ing conditions, standards, guidelines, regulatory 
requirements, and any instructions regarding the 
use of GM crops. Scientific and technical safe-
guards are developed for all projects, and stake-
holders are advised on the appropriate use of 
technologies and products. 
AATF further protects technology donors 
from liability through indemnification provi-
sions and warranty disclaimers in agreements 
and by conducting a comprehensive risk analysis 
for each project. Most not-for-profit organiza-
tions are typically averse to providing indemni-
fication in the agreements they sign, but AATF 
is not a typical not-for-profit organization. On 
a case-by-case basis, AATF indemnifies technol-
ogy donors. AATF also uses warranty disclaim-
ers, allowing donors to disclaim guarantees that 
would otherwise arise by law. AATF’s risk analy-
sis procedures identify risks early and allow for 
the development of risk-mitigation strategies for 




AATF firmly believes that effective and responsi-
ble management of IP starts with the formulation 
of an IP policy that: 
• sets clear objectives and principles of con-
duct in obtaining access to and use of IP 
and protected technologies
• establishes guidelines as to how and when 
IP protection will be sought and exercised
• promotes basic principles concerning the 
use of IP and protected material by re-
cipients to ensure that this use is consistent 
with furthering AATF’s mission
	  
AATF is formulating a policy to guide the 
management of IP by both AATF and its project 
collaborators. The policy seeks to ensure that any 
knowledge and products that result from AATF 
projects will be used for the maximum public 
benefit of resource-poor smallholder farmers in 
Sub-Saharan Africa. 
Through a series of collaborative projects and 
technology transfers, activities coordinated by 
AATF are expected to contribute to the develop-
ment of improved technologies used by resource-
poor smallholder farmers. Partners in projects 
coordinated by AATF are required to commit to 
facilitating a sharing and transfer of technology 
and research products for both research and com-
mercial use that will benefit resource-poor small-
holder farmers. 
Further, AATF’s IP policy stresses the re-
sponsible, respectful use of other’s IP rights. 
Additionally, in the acquisition and management 
of IP, AATF complies with all relevant interna-
tional laws and treaties as well as the national laws 
of the countries in which it operates. 
Finally, AATF is guided by its core values 
of accessibility, accountability, credibility, dedi-
cation, transparency, and trustworthiness. Our 
approach to IP management is best illustrated 







As a responsible party, AATF ensures that propri-
etary technology is properly acquired and used 
by AATF and its project collaborators in order 
to achieve the results needed to further AATF’s 
mission. AATF and its partners always endeavor 
to develop and deploy products that are free and 
clear of restrictions imposed by third-party IP 
rights. AATF makes genuine efforts to disclose 
any outstanding restrictions that might apply to 
such technologies and, where possible, obtains 
any required permissions. 
The Cowpea Improvement Project currently 
under development best illustrates this commit-
ment (see also Box 1 for further details). AATF 
has negotiated with Monsanto and obtained a 
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royalty-free, nonexclusive license to Monsanto 
technology, a Bacillus thuringiensis (Bt) gene (cry-
1Ab) for use in the development and deployment 
within Africa of cowpea (Vigna unguiculata) va-
rieties with resistance to the cowpea pod borer 
(Maruca vitrata), in order to provide a sustainable 
crop for resource-poor farmers of Africa to grow 
for consumption and sale. 
AATF coordinated a comprehensive technol-
ogy due diligence, whose primary objective was to 
inform on FTO, vis-à-vis research, to produce im-
proved cowpea cultivation, harvesting, and stor-
age processes, and to improve use and consump-
tion of the final product. Achieving this objective 
required taking an inventory of all technologies 
to be used in the project, completing a search 
and analysis of patent databases for filed or issued 
patents, and preparing a report analyzing the po-
tential strengths, weaknesses, opportunities, and 
threats related to the project. 
The FTO assessment helped to determine 
the ownership rights in the gene and other com-
ponent technologies that promoters needed to 
develop the improved cowpea variety. In the fu-
ture the assessment will serve as a guide to AATF 
and its project collaborators to ensure that the 
technologies used do not infringe the IP rights of 
the owners. Further, the assessment will serve as a 
basis for seeking all required permissions from the 
owners of the technologies, thus removing, or at 
least reducing, the potential for IP infringement 
should a product be exported from Sub-Saharan 
Box	1:	The	Cowpea	Improvement	project
“Cowpea	 is	 the	most	 important	 food	grain	 legume	 in	 the	dry	 savannas	of	 tropical	Africa.	The	
legume	is	consumed	by	nearly	200	million	Africans,	provides	cash	income	to	smallholder	farmers,	
serves	 as	 nutritional	 fodder	 for	 livestock,	 and	 provides	 an	 ideal	 way	 to	 complement	 protein-
deficient	diets.”	
The	overall	goal	of	 the	AATF	cowpea	project	 is	 to	 facilitate	 the	development,	distribution	and	
adoption	of	appropriate	 technologies	 that	will	 substantially	 increase	cowpea	productivity	and	


















•		 Commonwealth	 Scientific	 and	 Industrial	 Research	 Organization	 (CSIRO),	 Plant	 Industries,	
Australia.	
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Africa into a territory where third-party IP rights 
are in place. 
In line with good IP management practice, 
AATF will keep the FTO up-to-date by utilizing 
existing “Watch Lists” to track applicable patent 
and litigation trends. 
3.2.2 Preserving	the	confidentiality	of	IP	and	
related	project	information
AATF considers it good IP management practice 
to preserve the integrity of confidential informa-
tion contained in third-party IP, IP resulting from 
AATF-coordinated projects, and general project 
information. Therefore, AATF includes a confi-
dentiality clause in all employment contracts and 
stresses compliance with this clause as a condi-
tion of continued employment for AATF per-
sonnel. Further, AATF advocates that its project 
collaborators require personnel involved in any 
AATF-coordinated project to sign confidential-
ity agreements. Finally, AATF routinely enters 
into nondisclosure agreements with its collabora-
tors to facilitate the free exchange of information 
and materials, including IP, and to preserve the 
integrity of confidential information at the insti-
tutional level. 
3.2.3	 Defining	ownership	rights
Good IP management requires that all owner-
ship rights are defined at the start of any engage-
ment, taking into consideration any attendant 
responsibilities, including liability and risk 
management. The rights of AATF employees 
are defined in an employment contract, which 
stipulates that any rights (intellectual or tangi-
ble property) in research products, publications, 
and other works created or contributed to by 
AATF personnel in the course of their normal 
and assigned professional duties will be vested 
in AATF. 
The ownership rights of AATF and technol-
ogy providers are negotiated and determined on 
a project-by-project basis. For instance, in the 
Cowpea Improvement Project, Monsanto will 
retain its existing IP rights, while AATF will 
own all right, title, and interest associated with 
any improvement realized through the use of 
Monsanto’s technology under the terms of the li-
cense agreement.
The ownership rights of AATF and of proj-
ect collaborators are negotiated on a project-by-
project basis with the goal of equitably sharing 
such rights. The goal is achieved by taking into 
consideration the following principal factors: 
• the intellectual contribution of each partner 
to the particular project (foreground IP) 
• the contribution of IP, materials, research 
effort, and preparatory work of each partner 
brought to the project (background IP) 
• the facilities provided by each partner
• the financial contribution of each partner
• other considerations determined by the 
partners to be relevant
Any rights (intellectual or tangible property) 
in research products, publications, and other 
works commissioned by AATF will be assigned 
and vested in AATF. Any rights (intellectual or 
tangible property) in research products, publica-
tions, and other works jointly commissioned by 
AATF and the project collaborators will be as-
signed to and vested in AATF and the project 
collaborators as joint right holders. 
3.2.4 Execution	of	agreements
AATF believes it is essential and indeed good IP 
management practice to finalize all contractual 
terms, set them out in writing, and have an agree-
ment duly signed by the authorized representa-
tives of the parties before commencement of any 
engagement. Therefore, AATF ensures that all ar-
rangements with third parties associated with the 
access to or the creation, use, or exploitation of IP 
protected materials are appropriately document-
ed. Documentation for the Cowpea Improvement 
Project, for example, will, in the end, involve sev-
eral agreements between AATF and its collaborat-
ing partners. First, AATF obtained a license from 
Monsanto, and thereafter sublicensed the licensed 
Bt gene to CSIRO and IITA in order to introduce 
the Bt gene into the cowpea genome. The AATF, 
potentially, will sublicense the resulting successful 
transgenic events to African agricultural research 
institutions, which will introgress the Bt gene in 
cultivated cowpea varieties. These varieties would 
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then be licensed to commercial, nongovernment, 
humanitarian, or public institutions charged with 
disseminating the improved cowpea varieties in 
Africa. 
3.2.5 	 Identification	of	IP	assets
Maintaining IP asset inventories or a register 
of IP assets is essential for effectively managing 
those assets. AATF and its collaborating part-
ners encourage the adoption of procedures and 
practices—such as DNA fingerprinting, the 
keeping of appropriate laboratory notebooks, 
and controls over the release of information—
to properly identify, record, safeguard, and 
manage IP generated under projects coordi-
nated by AATF. 
3.2.6 Publication	of	project	research	results
AATF anticipates facilitating access to and use 
of improved germplasm and research products 
for the public benefit through publication and 
public disclosure. Therefore, to the extent deter-
mined appropriate and feasible by AATF and its 
project collaborators, research outputs and prod-
ucts from AATF projects will be placed in the 
public domain. 
3.2.7  Statutory	protection	of	IP
In certain cases, statutory IP protection may be 
necessary to ensure the continued availability 
of germplasm, inventions, publications, and 
databases to AATF and its partners. Such pro-
tection may also be needed to provide AATF 
with the necessary leverage to negotiate access 
to other proprietary rights and technologies re-
quired for product development. Therefore, in 
appropriate cases, AATF may seek IP protec-
tion for products (termed improvements) gen-
erated from projects for which the foundation 
has obtained ownership rights. For instance, 
as noted earlier, AATF will own all right to, 
title to, and interest in any improved cowpea 
varieties or other improvements developed us-
ing Monsanto’s technology. In consultation 
with the project collaborators, AATF may seek 
to protect these improvements by obtaining 
IP protection through patents, plant breeders’ 
rights, copyrights, trademarks, statutory inven-
tion registrations or their equivalent, and/or 
trade secrets.
In seeking IP rights,5 AATF will be guided 
by its commitment to serve African resource-
poor smallholder farmers—not by opportunities 
to obtain revenues. To the extent that IP licens-
ing generates financial returns, they will be used 
by AATF and the project collaborators to achieve 
AATF’s charitable objectives. AATF will ensure 
that all third-party licenses to the improvements 
make provisions for: 
• ready access by others for humanitarian 
use 
• avoidance of possible restrictions arising 
from “blocking” patents and ensuring the 
project collaborators’ ability to pursue re-
search without undue hindrance
• the transfer of technology, research prod-
ucts, and other benefits to African resource-
poor smallholder farmers through public 
channels and, where appropriate, through 
the commercialization or utilization of re-
search products.
With regard to the protection of cells, genes, 
molecular constructs, plants, varieties, and traits, 
AATF and its project collaborators will, to the 
extent permitted by applicable law, consider the 
effects that protection has on the distribution of, 
use of, and access to the protected product be-
fore proceeding with an application for statutory 
protection. 
AATF and its project collaborators may allow 
third parties to take IP rights on research prod-
ucts or material derived from research products 
if it is determined that doing so would best serve 
the public good. In such cases, AATF and its col-
laborators will ensure that agreements granted 
to recipients to protect intellectual property do 
not in any way waive the rights of AATF and the 
collaborators to challenge excessive protection 
through administrative and/or court proceedings. 
AATF and its collaborators may also reserve the 
right to retain research products for use by AATF 
and its collaborators, and they may also enter into 
agreements to deploy research products in a tar-
geted manner to certain partners and/or in certain 
markets. 
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AATF encourages the wide dissemination of pub-
lications (printed and electronic), including da-
tabases, reports, training materials, public aware-
ness material, artwork, and audio-visual material 
to be used for maximum public benefit. For in-
stance, AATF and its project collaborators have 
issued publicity materials, including press releas-
es in English and three Kenyan local languages 
(Kiswahili, Dholuo and Luhya), to help publicize 
the deployment of Imidazolinone Resistant (IR) 
maize technology in the western part of Kenya. 
Named Ua Kayongo (“kill Striga” in English), it 
will help to control the parasitic weed Striga. 
In creating such publicity materials, AATF and 
its project collaborators seek to use the copyright 
material of others only within “fair use” limitations, 
or with the consent of the copyright owner, and to 
properly attribute the source of the material. 
AATF and the project collaborator publica-
tions (printed and electronic) will normally carry 
standard copyright notices that indicate AATF 
and/or project collaborators as the copyright 
owner(s) of the compilation (for the specific edi-
tion and year of publication). 
AATF and the project collaborators will gen-
erally incorporate standard copyright notification 
statements in their publications: 
• permitting, especially in the case of the 
National Agricultural Research Systems 
(NARS), the making of a reasonable num-
ber of copies of such copyrighted material 
for noncommercial purposes 
• requiring attribution where such copy-
right material is reproduced in other 
publications
• prohibiting interference or tampering with 
the material without the express consent of 
AATF and/or the project collaborators
• addressing any other issues relevant to the 
best use being made of the material, such as 
procedures for the dissemination and recall 
of material subject to updating 
AATF and its project collaborators may, to 
the extent available in national laws, enforce the 
copyrights in such publications (printed and elec-
tronic) and protect them from unfair competition 
in order to: 
• respond to a breach of the above terms 
• prevent misappropriation of such material 
for commercial purposes
• protect the integrity of such material 
To the extent practicable, AATF will develop 
databases that assist the resource-poor and will 
make best efforts to keep these databases in the 
public domain. 
3.2.9 Trademarks	
AATF and the project collaborators may register 
as trademarks all distinctive marks associated with 
their initiatives, in order to protect the goodwill 
and reputation associated with the use of these 
marks by AATF and its collaborators. 
4.	 ConCluSIonS
Conventional methods for technology develop-
ment and transfer have not always sufficiently 
supported sustainable food security and con-
tributed to the alleviation of rural poverty in 
Sub-Saharan Africa. Although there have been 
numerous attempts in the past to promote pub-
lic/private partnerships in the region, most have 
had little tangible or lasting effect. It has become 
increasingly obvious that new approaches are 
needed to mobilize new science for new appli-
cations in Africa. It is also increasingly obvious 
that developing these approaches will require the 
potential complementarities of public and private 
sector research and development efforts. 
AATF represents an innovative approach 
based on forging collaborations between these 
sectors to identify and transfer proprietary tech-
nologies that would otherwise be unavailable for 
trying to address the problems of resource-poor 
smallholder farmers. AATF is surely not the only 
possible answer or a “silver bullet.” And it may 
not be the only or even the best means to achieve 
the goal of easing access to important technolo-
gies for humanitarian purposes. But its African 
focus, leadership, and operational location prom-
ise a more comprehensive, realistic appreciation 
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of the constraints to technology transfer in Africa, 
which will allow for the design of more feasible 
solutions and closer follow-up and continuity 
in implementation. A wide range of stakehold-
ers in the private and public sectors and in civil 
society have already pledged their commitment 
to making the AATF concept work, and AATF 
seeks to retain the confidence of these stakehold-
ers through effective leadership and responsible 
IP management. ■
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ABSTRACT
The mission of the Drugs for Neglected Diseases initiative 
(DNDi) is to develop safe, effective, and affordable new 
drugs for patients suffering from neglected diseases and 
to ensure equitable access to these drugs. DNDi believes 
that intellectual property (IP) rights should not pose a 
barrier to access to these medicines. Hence, a balanced 
approach to IP management is critical for effective im-
plementation of DNDi’s mission. The organization has 
written an IP policy that both encapsulates and articu-
lates DNDi’s approach to IP based on core principles and 
beliefs. The policy reflects the DNDi philosophy, vision, 
and mission, ensuring that its products are accessible and 
affordable to patients who need them most. DNDi rec-
ognizes the reality of IP and seeks to implement its hu-
manitarian mission using best, pragmatic practices for IP 
management. Indeed, DNDi has already demonstrated 
that this is feasible, having successfully negotiated with 
both private and public sector institutions in order to ac-
tualize its principled mission.
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consequence of the need to recoup the suppos-
edly high costs of researching and developing the 
drugs and the need for pharmaceutical compa-
nies to make a profit. These drugs were, and are, 
not only out of reach for individual patients but 
also for governments of disease-endemic coun-
tries. Intellectual property (IP) rights are among 
the factors driving these high prices, leaving pa-
tients in the developing world to their own lim-
ited resources and, ultimately, to undesirable 
outcomes with disability and death as the worst 
consequences.
The statistics show that hundreds and thou-
sands of disadvantaged people in developing 
countries are suffering their diseases in silence. 
These patients are unable to afford even the 
(largely inadequate) existing treatments, most of 
which have toxic side-effects, are ineffective, and 
need to be delivered in hospital conditions. These 
patients, though they urgently need new, safe, and 
field-adapted medicines, do not constitute lucra-
tive markets that the current drug R&D model 
targets, hence the plight of these patients remains 
unanswered (Figure 1). Of the 1,556 new drugs 
that came to the market from 1975 to 2004, only 
21 (1.3%), were for tropical diseases such as hu-
man African trypanosomiasis, Chagas’ disease, 
leishmaniasis, helminthic infections, schistoso-
miasis, onchocerciasis, malaria and tuberculosis 
– diseases that account for 12% of the global 
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1. InTRoduCTIon
In 1999, a need was identified for an alterna-
tive method to research and develop new drugs 
for infectious, tropical diseases. The doctors of 
Médecins Sans Frontières (MSF) gave testimony 
to the fact that the handful of drugs (to treat such 
diseases) that did exist was inaccessible to patients 
suffering from the diseases. Most of the drugs still 
have to be delivered in hospital situations, which 
is difficult where health care is rudimentary. In 
addition, the medicines are unaffordable, as a 
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agement in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). 
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. J Banerji and B Pecoul. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
noncommercial purposes is permitted and encouraged.
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disease burden. Ten of the 21, including four of 
the five developed since 1999, were marketed for 
malaria and tuberculosis.1 This fatal imbalance is 
responsible for the deaths of more than 35,000 
people a day.
The Drugs for Neglected Diseases initiative 
(DNDi) firmly believes that drug research can be 
an activity in the public domain that leads to the 
advancement of health, and recognizes that pat-
ented products do not always benefit those who 
need them most. DNDi considers its products as 
public goods. It does not wish to profit from its 
new products and wants to share the knowledge 
it creates by transferring technology to other re-
searchers and manufacturers when required. The 
R&D process requires access to knowledge from 
both private and public research organizations 
so that DNDi can use the best available science 
to research and develop new drugs for neglected 
diseases. Based on its core principles and beliefs, 
DNDi has crafted an IP policy that pragmatically 
captures the organization’s philosophy, vision and 
mission, and, thereby, ensures that products of-
fered by DNDi are made accessible and affordable 
to patients who need them most (see Box 1 at the 
end of this chapter).
2. dndi’S	vISIon	And	mISSIon
DNDi was set up to address the imbalance in 
access to critically needed medicines, by giving 
patients in developing countries the opportunity 
to be the direct beneficiaries of new products of 
drug R&D for diseases that do not represent a 
viable drug market. DNDi’s mission is to develop 
safe, effective, and affordable new drugs for pa-
tients suffering from neglected diseases (Figure 1) 
and to ensure equitable access to these. By 2014, 
it aims to develop and make available six to eight 
such field-relevant treatments. 
This, of course, is easier said than done, pri-
marily because to most scientists, pharmaceutical 
companies, and institutions with whom DNDi 
collaborates, the idea of placing a potentially com-
mercial product, such as a drug, into the public 
domain is both novel and bizarre. DNDi’s “no 
profit, no patents” stance calls for, and is commit-
ted to, a significant amount of long and sensitive 
figure	1:	The	global	pharmaceutical	market	and	neglected	diseases
neglected	diseases	lie	outside	the	world	market
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negotiation, to ensure that it becomes more ac-
ceptable and widely supported. 
Furthermore, whereas the response to calls, 
from numerous civil society groups and non-
governmental organizations (NGOs), to dis-
pense with patents for essential health tools has 
been met in some spheres with scorn and disre-
gard, certain organisations are slowly beginning 
to agree that patents often hinder R&D. For ex-
ample, the recent 2006 report from the World 
Health Organization (WHO) Commission on 
Intellectual Property, Innovation, and Public 
Health (CIPIH) explicitly stated, “There is no 
evidence that the implementation of the TRIPS 
[Trade Related Aspects of Intellectual Property] 
Agreement 2 in developing countries will signifi-
cantly boost R&D in pharmaceuticals on Type 
II and particularly Type III [neglected] diseases.3 
Insufficient market incentives are the decisive 
factor.” 
This assertion is echoed loud and clear in 
the preamble of the recently adopted (27 May 
2006) World Health Assembly resolution (WHA 
59.24) titled Public Health, Innovation, Essential 
Health Research, and Intellectual Property 
Rights: Towards a Global Strategy and Plan of 
Action which notes, “… that intellectual property 
rights are an important incentive for the develop-
ment of new health-care products; … however … 
this incentive alone does not meet the need for 
the development of new products to fight diseases 
where the potential paying market is small or un-
certain… .”
Nevertheless, DNDi’s approach to IP, al-
though highly principled, is quite pragmatic (as 
articulated in its IP policy), and will, therefore, 
contribute to encouraging further innovations 
and, even more importantly, to ensuring that 
patients have access to new products. At the 
heart of DNDi’s IP policy lies the belief that 
the lives of neglected patients are more impor-
tant than the profit motive. However, convinc-
ing industrial and academic partners that this 
belief should influence their investment deci-
sions continues to be a challenge. Decisions 
regarding the possible acquisition of patents, 
ownership, and licensing terms will be made on 
a case-by-case basis.
3. negoTIATIng	wITh	InduSTRy
DNDi’s first opportunity to put into action its 
vision of IP came in October 2003 when it es-
tablished preliminary contact with the French 
pharmaceutical giant sanofi-aventis regarding 
artesunate-amodiaquine, a fixed-dose artesunate-
based combination therapy (FACT) for chloro-
quine-resistant malaria. Artesunate-combination 
therapies are considered an important addition 
to the arsenal of treatments for chloroquine-re-
sistant malaria, especially in Africa, where more 
than a million children die each year from the 
disease. FACT was one of DNDi’s earliest proj-
ects operating under a grant from the European 
Commission’s International Cooperation and 
Development (EC-INCO DEV) programme. 
The terms of its contract with INCO-DEV de-
scribed collaboration with an industrial partner 
(sanofi-aventis) for industrial validation, produc-
tion, and distribution. 
In keeping with these terms, DNDi estab-
lished preliminary contact with sanofi-aventis, 
offering them the stable artesunate/amodiaquine 
fixed-dose combination (AS/AQ) for completion 
of development and industrial scale-up and to 
make the registered medicine available to malaria 
patients. At the time, the drug company already 
had a combination AS/AQ on the market but it 
was not a fixed-dose combination (two drugs in 
one tablet), as was the one DNDi had been able 
to develop. 
Negotiations led, finally, to a contract agree-
able to both parties that was signed in December 
2004, and DNDi transferred its AS/AQ dossier to 
sanofi-aventis. The agreement was an innovative 
breakthrough. Both parties wished to make this 
easier-to-use combination available to the poorest 
patients, at an affordable price and manufactured 
to highest international quality standards. At its 
own cost, sanofi-aventis took full responsibility 
for the drug registration, as well as for the consti-
tution of a WHO pre-qualification file. 
DNDi was able to convince sanofi-aventis to 
agree to exclusivity of AS/AQ until first registra-
tion in a ‘reference state’4 or prequalification by 
WHO,5 after which the drug would be non-exclu-
sive and available for production by any generic 
manufacturer without paying either sanofi-aventis 
BANERJI & PECOUL
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or DNDi for the right to do so. The agreement also 
stated that sanofi-aventis would supply the drug at 
cost (as a generic) to the public sector, NGOs (for 
example, MSF), and international organizations, 
such as WHO and the United Nations Children’s 
Fund (UNICEF). Under the terms of the agree-
ment, sanofi-aventis could market the product 
under a trade name in all territories—includ-
ing disease-endemic countries where the generic 
product would be available—in the private sector 
(pharmacies) at a commercial price. For the infor-
mation and the data made available to the private 
sector by DNDi, sanofi-aventis would pay DNDi 
a fee, amounting to 3% of net sales, for seven years 
after launch of the product. DNDi has decided to 
use this amount to further reduce the price of AS/
AQ to the public sector.
This was DNDi’s first success. Each negotia-
tion that followed for other projects was an equal-
ly uphill task as illustrated in the following exam-
ple of a research agreement with the University of 
California, San Francisco.
4. negoTIATIng	wITh	ACAdemIA
Following the biotechnology boom during the 
last couple of decades, most universities see con-
siderable financial potential in much of their 
medical research. University research depart-
ments now ensure that if this research is to be 
licensed to outside partners, then proceeds from 
any commercialization flow back to the university 
and the inventors. Protection of IP by the univer-
sity is central to this, together with ensuring that 
the best commercial license is negotiated with the 
partner if a marketed product is the likely out-
come of the research.
When DNDi first approached the University 
of California, San Francisco (UCSF), it sought 
to support research that might lead to new treat-
ments for human African sleeping sickness. Both 
parties found ready agreement in the use of IP for 
research purposes. However the goal of DNDi 
was to commercialize the product of the research 
in a way that makes it accessible to patients, and 
its marketing strategy is somewhat contrary to 
normally accepted practice in the United States. 
DNDi aims to manufacture and sell its products 
for the lowest price possible. It would have 
been difficult for UCSF to find a less attractive 
partner!
At the start, major issues of contention were 
the requests by DNDi for: 
• a royalty-free license to develop drugs aris-
ing from the research for commercializa-
tion in all disease-endemic countries
• freedom to manufacture the drugs in any 
country
• freedom from the requirement to patent 
the research outcomes for commercializa-
tion in any of the disease-endemic coun-
tries (Patents can add several million dol-
lars to the cost of a drug.) UCSF retains the 
right to patent for other uses but not in a 
manner that will restrict DNDi’s use of the 
research.
Throughout the protracted negotiations, staff 
at the university’s business development depart-
ment were supportive of DNDi’s IP policy and 
commercial goals. The main obstacle was simply 
the difficulty faced by the legal representatives 
when asked to step away from the standard pro 
forma protocol and negotiate an agreement that 
flew in the face of their obligation to negotiate the 
best return on IP. Fortunately, at the end, a com-
promise was reached that favoured DNDi very 
strongly, and all its requests were met. Equally 
gratifying was the comment from the staff of the 
UCSF commercialization departments that they 
gained tremendous personal satisfaction from the 
terms of the contract and from being involved in 
making new treatments available for the seriously 
neglected disease.
DNDi has learned some lessons from this ex-
perience. In many instances, legal opinions were 
drafted by third parties who were not familiar with 
the mission of DNDi, which slowed the pace of 
negotiations. Furthermore, the people with whom 
DNDi held negotiation talks agreed with the or-
ganization’s goals but often did not convey them 
effectively to outside legal representatives and oth-
er decision makers. During the final negotiations, 
however, DNDi interacted with all decision mak-
ers directly—their strong support of DNDi’s goals 
is reflected in the final draft of the agreement.
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4. ConCluSIonS
As clearly articulated in its IP Policy statement, 
DNDi is committed to managing IP in a man-
ner that pragmatically and effectively advances its 
mission of providing the most vulnerable popula-
tions in developing countries with equitable ac-
cess to critically needed medicines. Perhaps this is 
most clearly stated in the preamble of the DNDi 
IP policy statement:
The DNDi IP approach will be pragmatic, and 
decisions regarding the possible acquisition of pat-
ents, ownership, and licensing terms will be made 
on a case-by-case basis. DNDi will put the needs of 
neglected patients first and will negotiate to obtain 
the best possible conditions for them. The DNDi’s 
decisions regarding IP will contribute to ensuring 
access and encouraging further innovations.
By taking this realistic, yet creative, view of IP, 
DNDi seeks to advance best practices in IP man-
agement that will directly address global public 
interest. More importantly, by engaging in sophis-
ticated, successful negotiations with both the pub-
lic and private sectors to fulfil its dynamic vision, 
DNDi has demonstrated that this mission and 
policy is not simply an academic exercise. These 
negotiations skills, based on the foundation of the 
DNDi IP Policy statement, will ultimately ensure 
the implementation of DNDi’s mission with long-
term benefits accruing to those who most need, 
yet can least afford, essential medicines. ■
jaYa BanerjI, Communications Manager, DNDi, 1 
Place St. Gervais, 1201 Geneva, Switzerland. Currently: 
Medicines for Malaria Venture, 20, route de Pré-Bois, 1215 
Geneva 15, Switzerland. banerjij@mmv.org
Bernard peCoul, Executive Director, DNDi, 1 Place St. 
Gervais, 1201 Geneva, Switzerland. bpecoul@dndi.org 
1 Chirac P and E Torreele. 2006. Global Framework on Es-
sential Health R&D. The Lancet 367 (9522):1560–61.
2 The TRIPs Agreement of the World Trade Organization 
(WTO) is an agreement that addresses intellectual 
property concerns. It provides a set of minimum 
standards for intellectual property protection to which 
all but the poorest member countries of the WTO must 
conform.
3 Type II diseases are incident in both rich and poor 
countries, but with a substantial proportion of 
cases in the poor countries, for example, HIV/AIDS 
and tuberculosis. Type III diseases are those that 
are overwhelmingly or exclusively incident in the 
developing countries such as sleeping sickness or 
African river blindness. Type II diseases are often 
termed neglected diseases and Type III, very neglected 
diseases.
4 Countries that have stringent regulatory requirements 
are considered “reference states.” Registration of a 
drug in a reference state facilitates its approval in other 
countries that do not have the regulatory infrastructure 
to fully assess a new registration dossier.
5 Prequalification is a rigorous process of review and 
approval of the quality, safety, and efficacy of drug 
products conducted by the World Health Organization 
at the request of the manufacturer. It was originally 
intended to give United Nations procurement agencies 
a guarantee of quality and now extends to other bulk 
purchasers, including countries and NGOs.
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Box	1:	dndi’s	Ip	policy
DNDi hereby adopts the following intellectual property (IP) policy:
I.	preamble	
The mission of DNDi is to develop safe, effective, and affordable new treatments, for patients 
suffering from neglected diseases, and to ensure equitable access to these.
The DNDi IP policy will be guided by the following principles as laid down in the business plan:
1. The need to ensure that drugs are affordable to and access is equitable for patients who need 
them
2. The desire to develop drugs as public goods when possible
The DNDi IP approach will be pragmatic, and decisions regarding the possible acquisition of 
patents, ownership, and licensing terms will be made on a case by case basis. DNDi will put the 
needs of neglected patients first, and will negotiate to obtain the best possible conditions for 
them. The DNDi’s decisions regarding IP will contribute to ensuring access and encouraging 
further innovations. DNDi regards drug research as a public good that should primarily lead to 
the advancement of health.
In addition to a pragmatic day-to-day approach on IP, the DNDi is committed to contributing 
to the thinking and development of IP approaches in health R&D that are aimed at serving the 
public good.
II.	definitions
For the purpose of this policy, the term “intellectual property” includes, but is not limited to, 




In implementing the IP strategy, DNDi will adhere to the following basic principles: 
1. DNDi will ensure that the results of the work carried out under its auspices are disseminated 
as widely as possible and its products made readily available and affordable in developing 
countries.
  Where the acquisition of IP is not necessary to promote its mission and goals, DNDi will make 
all possible efforts to ensure that the results of its work are placed and remain in the public 
domain. However, it is possible that promoting DNDi’s mission and goals will sometimes require 
outputs to be protected by IP (see Sections IV and V). Given the costs involved, patenting is 
likely to be the exception rather than the rule. Other nonpatent types of IP such as confidential 
information (“trade secrets”) and copyrights will also need to be considered.
2. To make the results of its work useful and encourage the research community to engage in 
additional or follow-on research in the field of neglected diseases, DNDi will seek—whenever 
possible, and without undermining its rationale for acquiring IP—to disseminate its research 
through publications, presentations, the Internet (emulating the Human Genome Project) and 
other appropriate channels.
3. DNDi does not seek to finance its research and operations through IP rent revenues. Although 
they will constitute an exception rather than the rule, patents might be sought to strengthen 
DNDi’s ability to ensure control of the development process and to negotiate with partners.
(Continued	on	next	page)
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4. IP is generated through DNDi-sponsored research projects, it should be used to achieve DNDi’s 
mission. To this end, DNDi will pursue creative and innovative strategies to make the fruits of 
research projects readily available to patients affected by neglected diseases. This will require 
avoiding prohibitively costly approaches, restrictive IP strategies, or other issues that may 
inhibit or delay the rapid adoption of the invention to the benefit of developing countries.
Iv.	Rationale	for	Acquiring	or	otherwise	dealing	with	Intellectual	property
DNDi recognizes that in pursuing its mission it may find it necessary to acquire or otherwise 
manage and enforce IP. In this regard, DNDi acknowledges that it will have to deal with IP to:
1. conclude contracts and undertake research with its research partners, contractors, collaborators 
and founders;
2. obtain rights to work on and develop molecules, including facilitating DNDi’s or its partners’ 
access to proprietary research materials;
3. ensure equitable access to, and affordability of, the end products of its research for patients.
v.	Acquisition,	management,	and	enforcement	of	Intellectual	property
Where it is considered necessary to acquire or otherwise manage IP, DNDi will put in place 
measures to ensure the timely acquisition of IP by itself or its project partners, collaborators or 
founders for and on behalf of DNDi. When necessary to achieve DNDi’s objectives, enforcement 
may include legal actions to protect the DNDi IP.
DNDi will ensure that IP, however acquired, allows the initiative full freedom to operate, including 
retaining the right to use the inventions on which IP is obtained for DNDi’s further research, 
including with other partners. To this end, DNDi will use various mechanisms such as assignment 
of the IP to DNDi, exclusive licenses and licenses of right. It will negotiate terms with partners 
to ensure that they will not use the acquired and/or held IP in a manner that impedes equitable 
and affordable access to the products of the research, or that impedes additional or follow-on 
research by DNDi, its partners and other researchers, especially those undertaking research on 
neglected diseases.
DNDi will not accept projects in which IP is obviously going to be an insurmountable barrier to 
follow-up research on behalf of DNDi and/or equitable and affordable access. Either at the onset 
of a project or when problems arise, it will be important that negotiations with the public and/or 
private sector are backed with advocacy support.
vI.	Transfer	and	licensing	of	Intellectual	property
DNDi seeks to enhance R&D activities for neglected disease therapeutics and may wish to in-
license technologies developed by others that would help bring such products to the public. To 
ensure the availability and affordability of neglected disease therapeutics, it will transfer or out-
license its technologies to facilitate manufacturing and distribution of its products. As a general 
policy:
1. DNDi will ensure that the terms of each transfer or licensing agreement take into consideration 
the impact of the technology on research in medicine, and more broadly, public health; the 
level of support provided by DNDi; the stage of scientific and clinical development of the 
technology; DNDi’s portfolio and drug pipeline requirements; and timing and other business 
and economic considerations;
2. DNDi will ensure that the terms and conditions of any licensing or transfer agreement 
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3. DNDi will ensure that technologies developed under DNDi sponsorship are brought to practical 
application in a timely manner and made affordable and accessible to the public;
4. DNDi will negotiate and award licenses which may be exclusive, for specific indications, fields 
of use, or geographic areas, and other terms as circumstances allow;
5. DNDi will monitor the performance of licensees and ensure that licensed technology is fully 
developed;
6. DNDi will develop and use model agreements, where appropriate, to enable alternative forms 
of dispute resolution and therefore avoid litigation.
vII.	Communities’	Involvement	in	dndi’s	Research	and	Benefit	Sharing
When DNDi will consider patenting an invention resulting from work with communities on 
traditional medicine or on community genetics, that community will be assured of receiving all 
eventual benefits from this work.
vIII.	Amendments	and	Changes	to	the	policy
DNDi retains the right to review, revise and/or amend this policy or any of its terms at its discretion, 
at any time. When warranted and in agreement with the Chair of the Board, the Executive Director 
will recommend the review, revision or amendment of this policy for further approval of the DNDi 
Board of Directors.
Ix.	Administration	and	Implementation	of	the	policy
The Executive Director will ensure the full implementation of this policy and put in place, subject 
to Board approval, administrative, financial, technical, and other mechanisms and procedures to 
ensure its full implementation.
Box	1	(continued)
ABSTRACT
This brief case study describes how the International 
Centre of Insect Physiology and Ecology (ICIPE) helped 
African growers maintain access to foreign markets and 
improve livelihoods by being able to achieve standards 
certification for agricultural export commodities. The 
process involved a characterization of the problem and 
a conceptualization and execution of a solution. The so-
lution included creating a regional certification body in 
East Africa capable of providing globally recognized cer-
tification at costs that were locally affordable. The level 
of technical know-how needed by the certification body 
in order to be effective was significant, so the expertise of 
ICIPE was instrumental in creating the local certification 
body. Ongoing certification services provided by the cer-
tification body are highly market oriented, and because 
of this orientation the group was spun off as a private 
company, as Africert Limited.
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issues in agricultural production methods, north-
south market chains, and the environmental sus-
tainability of commercial agricultural production.
Although, the global trend has been toward 
freer markets with fewer economic trade barriers, 
emerging trade standards (both legislated standards 
and private standards) have the potential to act as 
nontariff barriers to trade, between African growers 
and European markets, for agricultural products.
From the late 1990s, both large- and small-
scale producers of export products in Africa found 
themselves faced with new consumer standards 
alongside the established ones. These standards all 
required separate verification (certification of con-
formity) from independent entities. However, these 
requirements invariably involved high costs related 
to implementation of the standards (both in terms 
of capacity and structures) and to their indepen-
dent certification. Most farmers, particularly in the 
horticultural sector, found themselves faced with a 
possibility of being locked out of the very markets 




To address this problem, in 2001 the German 




For a long time, smallholder farmers in develop-
ing countries, including Kenya, have experienced 
difficulty in accessing international markets for 
goods produced on their farms. Whereas most 
of the factors involved have been attributed to 
archaic production and processing systems that 
invariably increase costs of production, other fac-
tors have recently been implicated. They involve 
new legal and private (consumer and market) re-
quirements (or industry standards) for food safety, 
traceability, maximum residue limits (MRLs) for 
pesticide levels in food products, ethical and social 
Munyi P and R Nyagah. 2007. From Science to Market: Transferring Standards Certification Know-How from ICIPE to Africert 
Ltd. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, 
RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007.  P Munyi and R Nyagah. Sharing the Art of IP Management: Photocopying and distribution through the Internet for 
noncommercial purposes is permitted and encouraged.
From Science to Market: Transferring Standards 
Certification Know-How from ICIPE to Africert Ltd.
peter munYI, Chief Legal Officer, International Centre of Insect Physiology and Ecology (ICIPE), Kenya
ruth nYaGah, Chief Executive Officer, Africert Limited, Kenya
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through its German acronym GTZ [Deutsche 
Gesellschaft für Technische Zusammenarbeit 
GmbH]) developed the concept of facilitating 
the creation of a “local certification body for prod-
ucts from organic agriculture in East Africa.” The 
mandate to develop and implement this concept 
was given to the International Centre of Insect 
Physiology and Ecology (ICIPE)1 with a view 
to ultimately establishing a regional certification 
body for organic products in Africa, able to offer 
internationally recognized certification services 
to small-scale producers at locally competitive 
costs. The terms of reference under the project 
included: 
•	 identifying stakeholders in Kenya, Tanzania, 
and Uganda 
•	 identifying possible business partners 
•	 elaborating and modifying regional stan-
dards for organic agriculture 
•	 elaborating and implementing a quality 
management system according to ISO 652 
and EN 450113 
•	 establishing and publicizing the regional 
certification body among possible clients 
within the region
•	 monitoring and evaluating the local proj-
ects’ progress.
Execution of the terms of reference entailed 
several key aspects, one of which was identifica-
tion and training of personnel who would be able 
to undertake the duties of the certification body. 
Around the same time (from January 2004), 
EurepGAP4 was seeking to extend its standards 
to the horticulture and floriculture industries of 
East Africa, particularly Kenya. This was seen as 
an opportunity through which the intended ac-
tivities could actually be carried out. As a result, 
training small-scale farmers in the horticulture 
and floriculture industries formed a key platform 
activity from which it was then possible to initiate 
the launch of a certification body. 
2.2	 The	creation	of	Africert
Upon successful completion of the EurepGAP 
training, the next step involved formation of an 
independent company to carry out the certifica-
tion process. Africert Ltd. was thus incorporated, 
in November 2003, with its main objectives being 
to carry on, either alone or with others in Kenya 
and elsewhere, in providing certification services 
and operating certification systems and processes, 
as well as quality assurance services; to carry on, 
in any part of the world, the activities of a cer-
tification company, testing products and suppli-
ers’ quality systems and surveillance, and testing 
product samples, with a view to ensuring that the 
products tested, or certified, meet national or in-
ternational standards, specifications, or technical 
regulations.
A key condition for the formation of Africert 
Ltd. was to ensure impartiality in offering its ser-
vices. Thus, a strict impartiality condition was in-
cluded in the so-called memorandum of the com-
pany. This statement of Africert’s mission reads:
To be impartial, responsible for decisions relat-
ing to its granting, maintaining, extending, suspend-
ing and withdrawing certification, to identify the 
management (committee, group or person) which 
shall have overall responsibility for the performance 
of testing, inspection, evaluation and certification, 
the formulation of policy matters relating to its oper-
ation, the decisions on certification, the supervision 
of the implementation of its policies, the supervision 
of its finances, the delegation of authority to com-
mittees or individuals as required to undertake the 
objectives as listed in this Memorandum, and for the 
technical basis for granting certification.
On the question of ownership and gover-
nance, local ownership was emphasized. Thus, 
initial shares in the company were granted to 
ICIPE, holding its shares in trust, and an individ-
ual with the technical and managerial qualifica-
tions to guide the company toward achieving its 
objectives. Subsequently, as of mid-2006, ICIPE 
completely divested its shares in the company fol-
lowing identification of a qualified local institu-
tion to purchase the shares.
Africert thereafter embarked upon the pro-
cess of setting up its business infrastructure as well 
as undertaking activities geared toward achieving 
accreditation under ISO 65 and EN 45011, in 
order to be able to certify agricultural products 
against various standards, beginning with the 
EurepGAP standards for fruits and vegetables. 
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Africert has added other standards to its list of 
certification services. It has completely spun off 
from ICIPE physically, occupying its own of-
fices outside the ICIPE campus, and employing 
its own staff. And, ICIPE senior management no 
longer sits on Africert’s board of directors.
2.3	 Current	activities	of	Africert
Africert Ltd. is currently carrying out certifica-
tion and inspection services throughout eastern 
Africa, including Ethiopia, Rwanda, and Zambia 
for the following standards.
• EurepGAP fruits and vegetables.
• Utz kapeh. Utz kapeh means “good cof-
fee.” Coffee farms and cooperatives use utz 
kapeh certification to prove that they grow 
their coffee professionally and with care for 
their local communities and the environ-
ment. Utz Kapeh empowers growers with 
knowledge of good agricultural practices 
and the global coffee market. Certification 
gives growers a stronger position in the 
market due to buyers’ specific demand for 
certified coffee.
• British Retail Consortium (BRC) Food 
Technical Standard. This standard is used 
to evaluate processors of fresh produce for 
compliance with major European Union 
retailers’ requirements for food safety and 
quality. 
• Starbucks C.A.F.E. (Coffee and Farmer 
Equity) Practices. C.A.F.E. is a verification 
program based on social and environmental 
good practice in coffee growing, processing, 
and marketing.
• Ethical Trade Partnership in the tea sector. 
The fundamental principles of the ETP 
standard are those of the Ethical Trading 
Initiative (ETI) base code, which is based 
on local laws and collective bargaining 
agreements that are relevant to workers’ 
welfare. The code is used to support, clarify, 
and enrich the standard and ensure that it 
is appropriate to the country in which the 
standard is to be applied.
• MPS GAP/SQ in cut flowers. MPS GAP/
SQ is a body of standards that looks into 
issues of social and environmental manage-
ment of resources within the cut flower in-
dustry. Africert works under a subcontract-
ing agreement with MPS-Holland.
• Organic agriculture.
3.	 ConCluSIonS
The creation of a regional certification body in 
East Africa and the evolution of Africert Ltd. serves 
to illustrate two issues. First, that publicly funded 
research and development institutions in the de-
veloping countries have opportunities to employ 
their areas of expertise to improve livelihoods and 
incomes whether by facilitating access to markets 
or otherwise. Whereas in the case of Africert, the 
length of the project was short, the impact of re-
sults was directly felt both at the production level 
and in the markets. 
Secondly, transfer of know-how as an aspect 
of technology transfer is easier to achieve than 
other complex technology transfer aspects that 
require heavy capital equipment and other in-
frastructure. However, this may be a function of 
the fact that transfer of know-how may be more 
appropriate in service industries than in other in-
dustries, such as engineering and biotechnology. 
Most importantly, technology transfer can facili-
tate access to markets and improves incomes. ■
peter munYI, Chief Legal Officer, International Centre 
of Insect Physiology and Ecology (ICIPE), PO Box 30772-
00100, Nairobi, Kenya. pmunyi@icipe.org 
ruth nYaGah, Chief Executive Officer, Africert Limited 
PO BOX 74696-00200, Nairobi, Kenya. rnyagah@afric-
ert.co.ke 
1 ICIPE is an international organization, based in Nairobi, 
with a mandate to help alleviate poverty, improve gen-
eral food security and nutrition, and promote better hu-
man health for peoples of the tropics through research 
and development of environmentally friendly manage-
ment strategies for arthropod pests and disease vectors.
2 ISO 65 is one of the many standards developed by the 
International Standard Organization, which maintains 
standards for state-of-the-art products, services, 
processes, materials and systems, and for good 
conformity assessment, managerial and organizational 
practice in agriculture.
3 EN 45011 is the recognized European Standard for 
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product certification.  The objective of the standard is 
to promote confidence in the way product certification 
is carried out, giving assurance to the consumer that 
products meet identifiable and consistent quality 
levels. The standard requires inspection, testing, and 
surveillance to ensure that quality standards are met. 
When products meet standards, the products earn a 
certificate and carry a mark of conformity. More and 
more often retailers and global food-service chains 
are requiring that products be independently (by 
a third party) inspected and accredited against a 
recognized standard. Accreditation to EN 45011 meets 
this requirement. Accreditation of quality assurance 
schemes to the EN 45011 standard is a detailed 
process.
4 EurepGAP, founded in 1997, is a private organization 
that sets voluntary standards for the certification of 
agricultural products around the globe. EurepGAP 
started out primarily as an initiative undertaken 
by retailers belonging to the Euro-Retailer Produce 
Working Group (EUREP) along with British retailers, 
in conjunction with supermarkets that were the 
driving forces, in continental Europe. The organization 
observed consumers’ growing concerns with product 
safety, and environmental and labour standards and 
it decided to take greater responsibility for what 
happened in the supply chain. The development of 
common certification standards were also in the 
interest of many producers. Those with contractual 
relations to several retailers complained that each 
year they had to undergo multiple audits of different 
quality criteria. Against this background EUREP started 
to work on harmonizing standards and procedures to 
serve the development of good agricultural practices 





Putting Intellectual Property to Work: 
Experiences from Around the World
FOCUS ON SOLUTIONS:  
ACCELERATING PRODUCT DEVELOPMENT AND DELIVERY

ABSTRACT
This chapter shares the results of a project that analyzed the 
potential for consolidating patents in the malaria vaccine 
field. Goals include streamlining access to critical patents, 
advancing the development of products, and providing 
equitable access to the innovations. The study assessed 
the current status of the relevant patents and surveyed 
the holders of key patents to determine the availability 
for licensing. Other key activities included prioritizing 
patents with respect to a vaccine’s potential for success, 
identifying potential patent roadblocks by discussing the 
issue with patent holders, and proposing a mechanism 
for accessing key patents in the field of malaria vaccines. 
The potential role for some form of patent consolidation 
or technology trust, including pooling patents and tech-
nology, was explored. This chapter does not recommend 
developing a broad-based technology trust for existing 
malaria-antigen patents. Instead, several other steps are 
recommended to consolidate available rights and improve 
access for future patent families.
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For many reasons, including costs as well as the 
challenge of managing potential environmental 
and health effects of chemical parasite removal, 
these approaches have not been as effective in 
developing countries. Alarmingly, various factors 
are now spreading malaria into areas previously 
free of infection. New approaches to prevention 
and treatment are sorely needed.
No safe, effective vaccine for malaria exists. 
Developing a vaccine is a priority because of one 
especially exacerbating problem: the malaria par-
asite and the insects that carry it are becoming 
resistant to existing drug treatments and thera-
peutic-control measures. A malaria vaccine could 
greatly reduce the effects of the disease in terms 
of suffering and lives lost. It also could prevent 
the spread of malaria more cost effectively than 
any existing treatment. Vaccine use would reduce 
the need for expensive, often unaffordable medi-
cines and remediate the problem of drug-resistant 
parasites. Moreover, vaccine use would reduce the 
need for chemical treatment to control mosquito 
populations, thus minimizing negative environ-
mental effects. 
Developing a malaria vaccine, however, 
presents big challenges. Above all, there is an 
economic challenge. Developing a vaccine for 
which there is a great medical need but no profit-
able market requires a clear, sustained source of 
funding. Fortunately, a variety of public, private, 
CHAPTER 17.21
1. InTRoduCTIon
Malaria is one of the most widespread and deadly 
tropical diseases. There are more than 300 million 
cases and more than one million deaths each year. 
Ninety percent of the cases occur among children 
in Sub-Saharan Africa. Developed countries have 
largely eradicated the disease through hygiene, 
effective drugs, and the reduction of mosquito 
breeding grounds via wetlands clearing, chemical 
treatment to control mosquito populations (early 
on, with DDT), and water-system management. 
Shotwell SL. 2007. Patent Consolidation and Equitable Access: PATH’s Malaria Vaccines. In Intellectual Property Manage-
ment in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). 
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. SL Shotwell. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
Patent Consolidation and Equitable Access: 
PATH’s Malaria Vaccines
SANDRA L. SHOTwELL, Managing Partner, Alta Biomedical Group LLC, U.S.A.
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and philanthropic efforts are targeting the prob-
lem. In particular, the Bill & Melinda Gates 
Foundation is providing philanthropic fund-
ing to product-development partnerships. The 
Malaria Vaccine Initiative (MVI) is the main 
recipient of funding and the catalyzing force for 
malaria vaccine development. MVI seeks to ac-
celerate vaccine development through multiple 
approaches including partnering and the fund-
ing of promising projects. Addressing challenges 
simultaneously on multiple fronts, MVI has 





Developing an effective malaria vaccine presents 
significant technical challenges:
• Malaria is caused by different parasite spe-
cies in different countries and has variants 
within those species. The main species in 
terms of global health are Plasmodium 
vivax, found mainly in Asia and South 
America, and P. falciparum, found mainly 
in Sub-Saharan Africa. 
• Malarial parasites have several different 
stages in their life cycle, some of which are 
short in duration or occur within the host’s 
cells, making the parasites difficult to target 
with a vaccine.
• During each stage of the malaria parasite’s 
life cycle, it produces a number of differ-
ent antigens (substances that can evoke 
an immune response in humans), some of 
which may be useful in developing a vac-
cine. There may be several thousand po-
tential target antigens, only a few dozen 
of which have been studied for use, either 
separately or in combination, as potential 
vaccines.
Because of these technical challenges, ma-
laria-vaccine research has continued for decades. 
Only very recently has a vaccine been shown to 
be effective in Phase 2 clinical trials1 in adults and 
then in children in Africa.2 
2.2 Commercialization	challenges
Given the encouraging results of the Phase 2 
clinical studies, there is a strong possibility 
that a malaria vaccine may be ready for regu-
latory approval in five to ten years. The pros-
pect of manufacturing, delivering, and paying 
for a vaccine, however, now raises commercial 
challenges:
• Different populations need very different 
vaccine products. For example, a vaccine 
for children in endemic areas is not likely 
to be suitable as a traveler’s vaccine.
• Funding mechanisms are needed. Without 
clear definitions and estimates of the vari-
ous markets, it is difficult for companies 
to justify the expense associated both with 
speculative vaccine development and with 
more straightforward manufacture and 
marketing costs. To help provide certainty 
for the various markets, MVI is working 
on a model that takes a variety of vaccine 
products and market needs into account. 
Current market projections make it clear 
that even after development costs have 
been handled and an approved vaccine 
is ready for manufacture and marketing, 
continued public and philanthropic fund-
ing will be required in many markets in 
developing countries. 
• Delivery channels are needed to get vac-
cines to the areas where they are needed.
2.3  IP	challenges
The possibility of commercializing an effec-
tive malaria vaccine raises significant IP chal-
lenges. Many patents, some with overlapping 
claims, cover malaria antigens that may be 
needed for vaccine development. Such a “pat-
ent thicket” is daunting because it is likely 
that more than one antigen will be needed for 
an effective vaccine. Unfortunately, accessing 
many patents one at a time via traditional li-
censing or partnering could tie up resources 
needed to develop and deliver the vaccines. 
Moreover, the negotiations required to access 
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key patents could delay the delivery of the vac-
cine. Indeed, access to key patents might not 
even be available, which would affect invest-
ment decisions upstream in the development 
pipeline about vaccine candidates. Because 
of this, it may not be possible to pursue the 
most powerful vaccine candidates if compa-
nies holding valuable malaria-vaccine IP are 
unwilling to license to others even if they are 
not developing a malaria vaccine themselves. 
Assessing the availability of access to key pat-
ents becomes a priority. 
3. pATenT	AvAIlABIlITy
3.1 The	antigen	patent	landscape
Ten malaria antigens were selected for review 
based on their use in the most-advanced vaccine 
development projects—clinical trials or late-stage 
preclinical studies. The antigens come from sev-
eral key malaria parasites, most significantly P. 
falciparum and P. vivax, and from multiple phases 
of the parasite life cycle. Public patent databases 
were used to collect and organize patents and 
patent applications with claims covering these 
ten antigens. The patent landscape contained 
167 patent families filed by 75 different organi-
zations (sometimes in combination with other 
organizations).
Alta Biomedical worked with key MVI busi-
ness and scientific staff and Falco Archer to review 
and prioritize the 167 patent families. A total of 
39 out of 167 patent families (23%) were ranked 
as moderate to high priority based on the patent 
status (pending, issued, lapsed, or expired), length 
of estimated patent life, territory, and overlap be-
tween claims and vaccine-candidate attributes. 
The 39 patents were held by 21 organizations. 
Alta Biomedical met in person or by telephone 
with 16 of these organizations. Four of the re-
maining organizations were in direct contact with 
MVI; the fifth was not approached.
In early 2005, information from direct inter-
views and from MVI contacts led to grouping the 
39 patent families into four categories (Figure 1). 
Some of the priority patents covered only one an-
tigen; some covered multiple antigens. The distri-
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3.2 Ensuring	equitable	access
Before this study, almost half of the priority pat-
ents were removed from access by public patent 
holders (not private companies). Significantly, 
69% (27) of the moderate- to high-priority cases 
originally were filed by a public entity. Five of 
those were filed jointly with a company. By the 
time of the study, only 21% (8) remained avail-
able for licensing from the public entity. Thus, al-
most half of the priority cases were removed from 
access due to actions taken by the patent holder.
To ensure that in the future public entities 
provide ongoing access, MVI is working with 
multiple groups of stakeholders to develop rec-
ommended practices. This work has involved 
active participation in meetings with licensing 
practitioners through the Licensing Executives 
Society (LES)3 and the Association of University 
Technology Managers (AUTM)4, including 
the latter’s special interest group Technology 
Managers for Global Health (TMGH).5 In addi-
tion, MVI and Alta Biomedical have participated 
in smaller group discussions on equitable-access 
approaches, and in global health IP meetings 
such as those organized by the Centre for the 
Management of Intellectual Property in Health 
Research and Development (MIHR).6
3.3 Patent	pooling
To speed the delivery of vaccines to market, it 
would help to simplify licensing transactions 
for the malaria-antigen patents needed for po-
tential vaccine products. One possible approach 
to simplifying licensing transactions would be 
to consolidate the necessary patents in a patent 
pool that could be accessed by any party with 
one license on reasonable terms. To understand 
this approach and assess its usefulness in the ma-
laria-antigen area, one must consider information 
about past patent pools, about how patent pools 
are being used today, and about how patent pools 
are contemplated for use in health care. 
In the past, patent pools sometimes have 
been used for anticompetitive purposes, such 
as collusion and price fixing. To prevent this, 
the U.S. Department of Justice (DOJ) and the 
Federal Trade Commission have set up guidelines 
to ensure that patent pools are “procompetitive.” 
The guidelines include the following:7
• Patents in a pool should cover complemen-
tary technologies that can be used together 
as the basis for products. 
• Patents should not cover competing tech-
nologies that could be used separately to 
address the same market need.
• Under the best of circumstances, an inde-
pendent standard-setting body would estab-
lish criteria, or standards, in the field to set 
guidelines for what technology can be in-
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• An independent expert should determine 
which patents fit the guidelines for inclu-
sion in the pool.
• The pooled patents should be available on a 
nonexclusive basis.
• The pooled patents should be available sep-
arately from the individual patent holders on 
a nonexclusive basis so potential licensees 
are not forced to license the entire pool.
• The pooled patents should be available to 
all parties on nondiscriminatory terms.
It is unclear how these guidelines would ap-
ply to the malaria-antigen patents. While the last 
four points can be addressed, whether patents for 
multiple malaria antigens can meet the require-
ments of complementary versus competitiveness 
is uncertain, and what would be considered an 
independent standard-setting body is unclear.
As far as complementary versus competitive 
technologies, individual antigens may well be 
viewed as both. Arguably, they could be used to-
gether or separately to develop distinct vaccines. 
In particular, Richard Johnson of Arnold & Porter 
has raised a general concern that, based upon 
analysis of DOJ guidelines, universities may have 
difficulties creating a pool that includes “a large 
fraction of the potential research and development in 
an innovation market.”8 This may be viewed as an 
antitrust concern. Given the modest number of 
key patents for any single antigen, the large num-
ber of target antigens, and the inclusion of more 
than one antigen in many vaccine product candi-
dates, efforts that consolidate patents for only one 
antigen do not seem of broad value to the field. 
As far as standards in the field, it is possible that 
an organization such as the National Institutes of 
Health or the World Health Organization might 
develop a consensus or set standards that require 
a vaccine to include antigens from more than one 
stage of the parasite life cycle, although even then 
there are multiple candidate antigens from each 
stage that could be used separately.
Also, a licensee may not need access to, for 
example, all of the ten most-advanced antigen 
candidates to develop its planned vaccine. In that 
situation, it seems possible that the DOJ might 
view the separate antigens as requiring separate 
pools.
Two other areas have been proposed for for-
mal patent pools in the health care field: the Severe 
Acute Respiratory Syndrome (SARS) genome 
(proposed by holders of SARS genome patents)9 
and the Acquired Immune Deficiency Syndrome 
(AIDS) essential patents (proposed by Essential 
Inventions, Inc.).10 Both suffer from some of the 
same issues: many patent holders, the lack of an 
independent standard-setting body, and (perhaps 
most critically) the inclusion of potentially com-
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1). The proposed SARS pool may have the advan-
tage of being early in the product-development 
life cycle, with patent holders and others aware 
that resolving patent access may be essential to 
stimulating investment in product development.
3.4 Business	issues	with	patent	pools
Several business issues could make a formal malar-
ia-antigen patent pool challenging. For companies 
currently developing vaccines covered by patents, 
the patents are likely part of a core business strategy 
for which a patent pool may be an anathema. Their 
participation in such a pool may be unlikely. 
Moreover, setting up a patent pool can be 
expensive, with large up front costs for develop-
ing the pool’s legal framework, taking the pool 
through regulatory review, and performing a le-
gal review of the patents considered for inclusion 
in the pool. In the electronics industry, a large-
company member of the pool typically contrib-
utes much of the up-front funding. That option, 
however, seems unlikely in the case of malaria an-
tigens. While a small portion of the pool’s licens-
ing income typically covers the expense of a com-
mercially successful pool, it seems unrealistic to 
seek significant licensing income from a malaria 
vaccine for some of the world’s poorest nations. 
Furthermore, such a goal would run counter to 
the mission of developing a vaccine that is broad-
ly affordable and available. 
A final concern about a potential malaria-an-
tigen patent pool is a simple business issue—very 
few entities would be interested in accessing any 
particular antigen patent. For example, if a com-
pany was developing a vaccine using two antigens, 
it would not need access to patents that cover oth-
ers. An antigen used in one vaccine candidate may 
be included in a second vaccine candidate, but in 
combination with a different antigen or antigens. 
One can easily imagine a scenario where companies 
would not need access to a broad set of patents, but 
would prefer to pick and choose. This suggests that 
an individual access, or clearinghouse, approach 
might be preferable to a patent pool.
3.5 Patent	pool	alternatives
A pragmatic course would be to obtain access to 
the key patents that are available through license 
or assignment. Access by MVI or another orga-
nization on behalf of the field could ensure that 
these patents do not present a potential roadblock. 
In addition, MVI has developed constructive 
partnerships with key corporate holders of malaria 
patent rights and can continue to develop these 
partnerships as needed.
This strategy could lead to a clearinghouse 
approach, with IP rights accessible on a pick-and-
choose basis by multiple potential partners or li-
censees, thus avoiding the DOJ approval issues. 
The approach also could simplify the licensing 
transaction by setting up, in advance, arrange-
ments that provide assured access at a known cost 
(similar to setting up a patent pool in advance). 
But a clearinghouse does not resolve the concern 
that key patents could remain outside the clearing-
house. Ideally, a clearinghouse would include all 
the necessary patents for each antigen. Obtaining 
access to all the necessary patents would require 
working with companies to include their patents 
in the clearinghouse, which is not an impossible 
task but one that puts the transaction burden up 
front on the party trying to set up the clearing-
house. It seems more reasonable to work directly 
with companies when it becomes clear that access 
will be needed to a specific company technology. 
The relationship may involve not just straight 
licensing but, among other things, co-develop-
ment, manufacturing contracts, partnering, and 
marketing. It might make sense to wait to devel-
op such a relationship until the needs are clearer. 
4. ConCluSIonS
The results of the MVI study suggest that devel-
oping a broad-based technology trust for exist-
ing malaria antigen patents is not a good idea 
for several reasons. As the findings above should 
make clear, with few exceptions the patents held 
by public and academic institutions have been as-
signed or exclusively licensed to private compa-
nies. The patents are not currently available for 
licensing from the original public-institution pat-
ent holders. While it may be possible to sublicense 
the patents from the current private holders, do-
ing so is likely to be difficult and costly; engaging 
patent holders in contributing to a patent pool or 
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 HANDBOOK OF BEST PRACTICES  | 1795 
clearinghouse also could be difficult. While the 
concept of a technology trust or patent pool may 
still be useful for patents to be filed in the fu-
ture, even some of those would be under option 
for license by the private companies holding the 
existing patents. In addition, the number of high-
priority cases for any malaria antigen is small, as is 
the number of entities likely to seek access to any 
given patent family. This makes the expense of a 
patent pool even less justifiable.
Other than a broad-based technology trust, 
there are several effective ways to consolidate avail-
able rights and improve access for future patent 
families in the malaria vaccine field, including:
• Taking assignment to or licensing the lim-
ited number of high- or moderate-priority 
patent families to ensure access. Holding 
these patents could be useful for developing 
products or for cross-licensing with private 
patent holders. 
• Developing policy and public statements 
about why these priority patents are be-
ing held on behalf of the field, including a 
statement regarding the intention to allow 
access by others.
• Continuing to develop constructive part-
nerships with the corporate holders of the 
remaining key patents, as needed.
• Reviewing the geographic limitations of 
existing patents held by private companies, 
and considering approaches to vaccine de-
velopment that do not infringe on these pat-
ents, for example, considering production by 
firms capable of high-quality, less-expensive 
production and manufacture in middle-in-
come countries not covered by patents.
• Negotiating with patent holders for access 
to their know-how for development outside 
the patent coverage area.
• Educating public and academic patent 
holders about malaria-vaccine development 
issues in patenting and licensing as well as 
about balanced approaches that can meet 
institutional goals and accelerate the de-
velopment of patents into useful vaccines. 
This would help to ensure that future ac-
tions by public research institutions do not 
create ongoing access problems. 
• Working to develop consensus about when 
patenting makes sense, as well as the ben-
efits of pooling for future inventions not 
yet patented or licensed.
• Gathering and developing model language 
to use in patent strategies and licenses cov-
ering malaria-vaccine technology that can 
ensure the development of appropriate, af-
fordable products for markets in develop-
ing countries. 
• Working with national and international 
leaders to encourage broad usage and a 
common approach for the field. Possible 
partners in this endeavor include MVI, The 
Rockefeller Foundation, MIHR, AUTM, 
LES, U.S. federal laboratories, and leading 
U.S. and international universities. ■ 
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1 Phase II trials are conducted on population groups of 
around 20–300 and are designed to determine dosing 
levels and assess clinical efficacy of a vaccine. Phase 
II builds on the initial safety studies of the vaccine 
(Phase I) and forms the basis for Phase III studies (typi-
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The Cohen-Boyer licensing program, by any variety 
of metrics, was widely successful. Recombinant DNA 
(rDNA) products provided a new technology platform 
for a range of industries, resulting in over US$35 bil-
lion in sales for an estimated 2,442 new products. Over 
the duration of the life of the patents (they expired in 
December 1997), the technology was licensed to 468 
companies, many of them fledgling biotech companies 
who used the licenses to establish their legitimacy. Over 
the 25 years of the licensing program, Stanford and the 
University of California system accrued US$255 million 
in licensing revenues (to the end of 2001), much of which 
was subsequently invested in research and research infra-
structure. In many ways, Stanford’s management of the 
Cohen-Boyer patents has become the gold standard for 
university technology licensing. Stanford made pragmatic 
decisions and was flexible, adapting its licensing strategies 
as circumstances changed.
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that time.  The first patent issued on December 
2, 1980, after 6 years under review at the U.S. 
Patent and Trademark Office: the original appli-
cation was filed in November 1974.  This date was 
two weeks before the effective date of the Bayh-
Dole Act, which assigned intellectual property 
(IP) rights over faculty discoveries from federally 
funded research to universities and emphasized 
the university’s responsibility for commercializa-
tion.1 The intention was to provide a means for 
economic growth, technological change, and en-
hanced U.S. competitiveness. 
The Cohen and Boyer’s discovery provided 
tools for genetic engineering and was the subject of 
controversy that led to a lively public debate dur-
ing the decade of the 1970s.  Sally Smith Hughes 
documents Cohen and Boyer’s scientific discovery, 
Stanford’s decision to pursue patents, and the pub-
lic controversies surrounding recombinant DNA.2 
The debate was symbolically resolved with the June 
1980 U.S. Supreme Court ruling on Diamond v 
Chakrabarty, a landmark 5–4 decision, which 
made the patenting of life forms possible with the 
Court’s oft-quoted clause, “anything under the sun, 
that is made by man.” This decision cleared the way 
for the Cohen-Boyer application, which covered a 
fundamental technique, with the potential to be-
come a platform technology that essentially led to 
a new paradigm in biotech research. 
CHAPTER 17.22
1.  InTRoduCTIon
The licensing of the Cohen-Boyer patents by 
Stanford University represents one of the most 
successful university technology licenses. The 
discovery covers the technique of recombinant 
DNA and allows for the useful manipulation of 
genetic material.  Examining Stanford’s licensing 
of the intellectual property is best understood 
in context and as part of the university’s larger 
strategy.  Moreover, designing and setting up the 
licensing program involved uncharted territory at 
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Of course, once the patent was granted, 
Stanford University, as the assignee, was required 
to design a licensing program that would be con-
sistent with the public-service mission of the 
university and provide sufficient incentives for 
private industry to invest the requisite resources 
to bring products to market while producing rev-
enue for the university. Feldman, Colaianni and 
Liu3 detail the history of Stanford’s licensing pro-
gram, focusing on the process and the logic that 
guided the commercialization regime. Given the 
early controversy surrounding the Cohen-Boyer 
patent, the eventual success required a great deal 
of creativity, strategy, and persistence. Certainly, 
the professionals involved all contributed to the 
success, from Donald Kennedy, then president of 
Stanford, Robert Rosenzweig, then vice president 
for public affairs, Nils Reimer, founding director 
of the Stanford Office of Technology Licensing 
(OTL) to Katherine Ku, then licensing associate 
and current director of the OTL. 
The purpose of this chapter is to summa-
rize lessons learned from Stanford’s design and 
implementation of the Cohen-Boyer licensing 
program. Many universities attempt to emulate 
Stanford University’s success at technology trans-
fer; however, there is a limited appreciation for 
the high degree of creativity and adaptability of 
the Stanford Office of Technology and Licensing 
(OTL) in setting up its licensing program and 
making the myriad decisions that guided the 
ultimate outcome. In spite of many obstacles, 
Stanford University pursued the recombinant 
DNA patents and designed a strategy that met the 
public-service goals of the university by broadly 
licensing the technology; provided incentives for 
private companies to commercialize derivative 
products; and contributed to the creation of an 
innovation system that benefited Silicon Valley 




Despite the economic success of the licensing 
program, profit was not the primary motive. 
Stanford University had four goals that guided 
the development of the Cohen-Boyer license: 
• to be consistent with the public-service ide-
als of the university 
• to provide the appropriate incentives in 
order that genetic engineering technology 
could be commercialized for public benefit 
in an adequate and timely manner 
• to manage the technology in order to mini-
mize the potential for biohazard 
• to provide income for educational and re-
search purposes
Robert Rosenzweig, vice president for public 
affairs at Stanford, in a 1976 open letter addressed 
to “Those Interested in Recombinant DNA,” wrote 
“It is a fact that the financing of private universi-
ties is more difficult now than at any time in re-
cent memory and that the most likely prediction for 
the future is that a hard struggle will be required to 
maintain their quality.” As a result of these finan-
cial concerns, he concluded, “we cannot lightly 
discard the possibility of significant income that is 
derived from activity that is legal, ethical, and not 
destructive of the values of the institution.” 
The balance of financial objectives against 
other goals is further demonstrated when Stanford 
decided not to pursue extending the patent life. 
The original 1974 patent application had claimed 
both the process of making recombinant DNA 
and any products that resulted from using that 
method. These applications were subsequently di-
vided into the process patent and two divisional 
product applications: one claimed recombinant 
DNA products produced in prokaryotic cells 
and the other claimed the products in eukaryotic 
cells. Stanford filed a terminal disclaimer, which 
meant that all subsequent applications claiming 
recombinant DNA, regardless of how long the 
patent prosecution process took, would expire 
on December 2, 1997—the same date as the 
original 1980 patent.4 In effect, Stanford agreed 
to give up royalty rights on the life of the sub-
sequent patents (issued in 1984 and 1988) that 
would have extended past the original patent’s 
expiration date. This limited Stanford’s collection 
of royalties because of the time delay inherent in 
commercialization, especially of pharmaceutical 
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products. Stanford honored its obligation to the 
licensees with the realization that, as Kathy Ku 
wrote at the time “...it would not be good public 
policy or public relations if we were to ask for or even 
get such an extension.” 
Stanford did not require other nonprofit re-
search institutions to take a license in order to use 
the technology. Niels Reimers and Kathy Ku re-
port that the thought of licensing the technology 
out to other nonprofit research institutions had 
never entered into discussions about the licens-
ing program. This licensing practice established a 
research exemption, or research-use exemption, 
which is consistent with the norms of open sci-
ence,5 and stands in contrast to recent develop-
ments in research-use exemption policies, such as 
Duke v. Madey and the WARF stem-cell licens-
ing program.6 
To summarize, engaging in commercial ac-
tivity encourages higher education institutions to 
act like for-profit entities. Intellectual property 
has no value unless it is defended. Stanford set up 
a litigation reserve fund that provides a credible 
threat of enforcement of the license. Despite sev-
eral attempts to withhold payments from a variety 
of large and small companies plus one attorney 
who made challenges to the patents a “hobby,” 
Stanford was able to settle these disputes infor-
mally and without formal litigation. This stands 
in contrast to the recent upswing in litigation by 
U.S. universities, including a recent law suit filed 
by the University of Alabama to prevent an artist 
from using the universities athletic colors.   
2.2  Consult	widely	to	build	consensus	
While intellectual property typically involves 
limited disclosure, Stanford University engaged 
in a pattern of consulting widely across various 
stakeholders to achieve consensus and to ensure 
that its actions were supported. For example, 
Rosenzweig worked to achieve consensus with 
both the faculty and the National Institutes of 
Health (NIH) as the sponsoring agency. In a 1976 
open letter, he asked the faculty to comment on 
whether the university should proceed with the 
patent process. Rosenzweig also sent a letter to 
Donald Fredrickson, NIH director, asking his 
opinion on patenting the Cohen-Boyer discovery 
and enclosed a copy of the memorandum sent to 
faculty. Fredrickson responded by sending a mass 
mailing to “a broad range of individuals and insti-
tutions,” asking them for their comments on the 
patent question. 7 Fredrickson’s letter laid out five 
possible alternatives that NIH could take regard-
ing recombinant DNA patenting and subsequent 
licensing: In response, Fredrickson received ap-
proximately 50 letters. 
A compromise consensus emerged from 
among a list that Frederickson generated that 
Stanford should be able to patent recombinant 
DNA research but with nonexclusive licensing. 
A nonexclusive license ran counter to economic 
logic, contrary to the subsequent preferences ar-
ticulated in the Bayh-Dole, Act and ignored peti-
tions from Genentech and Cetus who stood to 
gain from exclusive licenses. The logic was that 
rDNA was a platform technology and that any 
one company could not exploit all the possible 
applications. Broad nonexclusive licensing not 
only contributed to the economic success of the 
patents but also created a population of compa-
nies who drove the technology forward. 
There are other instances when Stanford 
sought transparency that was consistent with the 
actions of a university. While applicants generally 
keep patent applications secret from the date they 
are filed until they are granted and therefore pro-
tected, Stanford opened the patent prosecution 
file to the public. This was an unusual move that 
was consistent with reducing subsequent ques-
tions about the technology and was also consis-
tent with the public mission of the university. 
Stanford engaged in an open process that at-
tempted to build consensus across a wide range 
of stakeholders. While the university did stand to 
profit from the licensing program, their actions 
were consistent with the university’s larger and 
more traditional societal goals.
2.3 Don’t	behave	opportunistically	
The most successful university technology trans-
fer involves relationships that develop over time. 
Signing a licensing agreement represents a trans-
action that is a first step in a relationship that re-
quires maintenance and oversight. Each licensee 
received an annual letter from the Stanford OTL. 
FELDMAN, COLAIANNI & LIU
1800 | HANDBOOK OF BEST PRACTICES
That went a long way in establishing long-term 
relationships and encouraging dialogue. 
When Stanford initiated its licensing pro-
gram, no precedent existed for specific licensing 
terms of the IP. Keeping with its practice of con-
sulting widely and building consensus, Stanford 
interviewed a variety of companies representing 
different markets when the license terms, particu-
larly the royalty rates on end products, were be-
ing formulated. Through this effort, licenses were 
pre-sold and unrealistic terms were avoided. To 
make the licensing process easier, the OTL took 
great pains to categorize the different potential 
recombinant DNA products and to offer appro-
priate royalty rates. In the end, the OTL settled 
on four different product categories: basic genetic 
products, bulk products, end products, and pro-
cess improvement products. By scaling the rates 
to reflect the visibility of the licensee’s product 
and the expected revenue from each license, the 
OTL encouraged compliance. A graduated royal-
ty system ensured that smaller companies weren’t 
penalized with low sales volume. 
Stanford made pragmatic decisions about 
pricing its intellectual property and kept the an-
nual fees and royalty rates reasonable. While this 
might have reflected a strategy to deal with some 
of the weaknesses with the patent, the university 
could have been greedy and pursued higher rates. 
Nils Reimers recalled at least one alumnus writ-
ing, “You’ve got a patent; you can dominate every-
thing here. Why are you charging such a low royalty? 
You know Stanford could use the money. Charge a 
higher royalty.”8 This advice was not taken. The 
rates that were chosen were selected after con-
sultation with industry about accepted practices 
and did not exploit the university’s monopoly 
position. 
Furthermore, Stanford created special provi-
sions for lower licensing fees and royalty rates for 
small firms in 1989. At this time, 209 fledging 
biotech firms, most of them in the San Francisco 
Bay Area, signed licensing agreements.  
2.4 Be	flexible	and	experiment	
Over the 17 years of the licensing program 
Stanford experimented with five versions of 
the standard license agreements and provided 
three special licensing agreements. A total of 
468 companies licensed the Cohen-Boyer tech-
nology. Licensing the patents was very much a 
learning process that balanced the capabilities of 
companies, especially in the embryonic biotech 
industry, with the economic potential of the 
technology. Ku later noted, “Stanford was try-
ing to license an invention for which products had 
never been sold and which would apply to many 
diverse, established industries, in addition to the 
newly emerging biotechnology industry.”9 Table 1 
summarizes the various licensing regimes and 
the number of companies that signed up under 
each version. Certainly the economic impact 
would have been less without this flexibility and 
adjustments. 
The first version of the license provided two 
incentives to encourage companies to sign up. 
Remember that the technology was already in the 
public domain through publication and that the 
open patent files and companies were already us-
ing rDNA. It was not clear that companies would 
comply with the terms. The first incentive for 
companies to take a license in 1981 was a credit 
toward future royalties over the first five years, 
up to a total of US$300,000. The second incen-
tive came when companies were advised that 
the licensing terms would change and encour-
aged them to sign up early. In response to this 
news, 82 companies signed up. The largest share 
of earned royalties from product sales accrued to 
these firms.10
The first license’s terms were a US$10,000 
up-front fee with a minimum annual advance 
(MAA) of US$10,000. Earned royalty rates on 
products were provided on a graduated basis for 
bulk products, end product sales, and process im-
provements on existing products based on pro-
duction cost savings. Under the licensing agree-
ments, Stanford received unprecedented royalties 
on downstream drug sales in a stipulation known 
as reach-through licensing: Stanford received end- 
product royalties based on a percentage of final 
product sales. The Cohen-Boyer IP rights ex-
tended to all products developed using the tech-
nology. If companies did not sign a license agree-
ment, any end products they developed that used 
rDNA could potentially be contested. 
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The second standard licensing agreement 
dropped the royalty-credit incentive and an ad-
ditional 15 companies signed the agreement. In 
August 1985, the OTL issued its third standard 
version of the license agreement, which allowed 
for negotiation by providing a space to write 
in agreed-upon rates. In practice, though, the 
earned-royalty rates were almost always at the 
same graduated rates that were used in the sec-
ond version. This fact may be attributed to the 
sharing of information among potential licensees 
about prevailing terms and what terms might be 
expected. Another ten firms signed up under this 
licensing agreement. Another adjustment was 
made in November 1986, with the fourth stan-
dard licensing agreement. Instead of a graduated-
royalty rate, a flat rate of 1% on end products 
and 3% on bulk products was used. These were 
the highest rates under the prior version and re-
flected the realization that the patents could earn 
higher rates. In response, perhaps motivated by 
the possibility of further increases in the future, 
21 more firms signed licensing agreements. The 
fifth version of the Cohen-Boyer standard licens-
ing agreement, adopted in September 1989, dem-
onstrated further strategic changes. In order to 
encourage licensing by small start-up companies, 
consideration of company size was introduced. 
For companies with fewer than 125 employees, 
the sign-up fee and MAA fee remained the same, 
at US$10,000 each. The strategy worked—209 
small biotech firms became licensees under this 
version, along with 12 large companies. 
In addition to the standard agreements, there 
were three nonstandard licensing agreements that 
provided alternative agreements, making sure 
that Stanford could collect as much revenue as 
possible without being unfair to companies with 
special circumstances. The first was an alternative 
license for small distributors or resellers of recom-
binant DNA products. Fifty companies signed on 
under this alternative agreement, accounting for 
17.5% of the total 275 licensees signed after 1991 
and providing US$462,000 in licensing revenue. 
At the end of 1994, a research and development 
license agreement, with greatly reduced rates, was 
developed to encourage start-ups that would not 
realize product sales within the patent lifetime. 
Another 39 companies signed the research and 
development license agreements, and, although 
these licenses did not yield much licensing 
revenue, they were important to the legitimacy of 
the small companies. A third nonstandard licens-
ing agreement was offered in the final year to tie 
up a few loose ends. 
In total, the Cohen-Boyer licenses generated 
US$254 million in revenue during its 17-year 
term. The initial sign-up and annual fees generated 
US$26 million, which was 10% of the total licens-
ing income. The licensing program certainly would 
have been less successful without these revisions 
and accommodations. A whopping 90% of the 
total revenue (US$228 million) was from royalty 
income from product sales. This mirrors the com-
mercial success of recombinant DNA products.
2.5 Technology	transfer	is	all		
about	skewed	distributions	
While others have noted that the distribution of 
technology transfer revenues are highly skewed, 
with a few blockbusters accounting for most rev-
enues, our examination of the companies that 
licensed the recombinant DNA technology and 
their products demonstrates that even within a 
single license, highly skewed outcomes account 
for the high revenues. Commercial products de-
veloped by the licensees generated over US$35 
billion dollars in sales of recombinant DNA 
products over the life of the patent. Stanford 
reported 2,442 products based on recombinant 
DNA by the time the Cohen-Boyer patent ex-
pired in December 1997, reflecting a range of ap-
plications in a variety of industries.11 Starting in 
1991, 400 new products, on average, were being 
brought to the market every year. Recombinant 
DNA product sales reached US$500 million 
dollars in 1987 and then doubled from 1988 to 
1990. Sales doubled again from 1991 to 1994 
and yet again from 1994 to 1998. 
The revenue received from each of the Cohen-
Boyer licensees ranged from US$4.24 million to 
US$54.78 million dollars. Of the 468 licensees 
of Cohen-Boyer technology, ten companies alone 
provided 77% (US$197 million) of the total li-
censing income. One company, Amgen, account-
ed for over one-fifth of the total revenues received 
FELDMAN, COLAIANNI & LIU
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under the licensing program. Figure 1 provides a 
breakdown of the royalty share provided by dif-
ferent companies. 
Table 2 lists these ten companies and the 
products developed under the license. Many of 
the products were developed under strategic al-
liances between start-up biotech firms and large 
pharmaceutical firms, or between biotech firms. 
All of the top-ten companies, except Merck 
(which signed the agreement in 1984) signed the 
first standard agreement in December 1980. The 
next 10 companies accounted for another 10%, 
while the remaining companies generated less 
than 13% of total royalty revenue. 
3.  ConCluSIonS
In the 1970s, universities became more entrepre-
neurial, looking for different streams of revenue 
that supported the university’s mission. As a re-
sult, a new system of technology transfer emerged. 
Certainly the Cohen-Boyer patents and Stanford 
University’s licensing program were at the heart 
of the debate and central to the evolving system. 
It would be a mistake to look back at 
Stanford’s success with the Cohen-Boyer licenses 
and think that its success was inevitable or that 
the licensing process was easy. An examination 
of history reveals many episodes where Stanford 
University could have behaved opportunistical-
ly or taken a wrong turn. The mistaken notion 
that Stanford and the University of California 
system were pursuing revenue as a primary goal 
ignores the controversies that faced Stanford at 
that time and the creativity and discipline that 
Stanford had to employ to surmount them. 
Stanford’s licensing program is a good example, 
not just in terms of its monetary success, but 
in terms of the lessons it affords to others who 
work in the area of licensing and technology 
transfer. While many universities have now in-
stituted licensing programs and are aggressively 
pursuing intellectual property rights, our study 
demonstrates that this process is not at all easy 
or straightforward. In retrospect, Stanford’s li-
censing venture might have failed at several 
turns and Stanford was forced to be innova-
tive to accommodate the great uncertainties 
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Schering $17,960,351 Intron A f FY 1986–1987
Johnson & Johnson $13,418,280 Procrit g FY 1992–1993
Merck $10,085,657 Recombivax HB h FY 1986–1987
Abbott $9,804,444 Various in vitro HIV 
diagnostics 
FY1987–1988
Novo-Nordisk $8,669,119 Novolin FY 1990–1991
Genetic Institute $5,946,978 Recombinate FY 1993–1994
Chiron $5,099,071 Proleukin
Betaseron i FY 1987–1988
a. Partnered with Ortho and Johnson and Johnson.
b. Partnered with Genentech.
c. Partnered with Centocor.
d. Partnered with Lilly.
e. Partnered with Roche.
f. Partnered with Biogen.
g. Partnered with Amgen and Ortho.
h. Partnered with Biogen.
i. Partnered with Berliex.
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California taken only financial considerations 
into account, it is likely that they would have 
opted for much higher royalty rates or a more 
lucrative limited-use exclusive license. Stanford 
made very pragmatic decisions about pricing 
its intellectual property. In addition, it might 
have had to aggressively litigate instead of play-
ing a defensive litigation strategy. Moreover, the 
process was not finished once the first licensing 
agreement was formulated; Stanford made prag-
matic decisions and proved flexible, adapting its 
licensing strategies as circumstances changed. 
Had it not been for Stanford’s enlightened 
licensing practices, the Cohen-Boyer technology 
might have been placed in the public domain 
where the technology could have remained un-
developed or in the laboratories of large estab-
lished pharmaceutical companies. Or it might 
have been licensed exclusively and the rise of a 
biotechnology industry might have been delayed 
for years or decades. Small companies gained le-
gitimacy through licensing the Cohen-Boyer pat-
ents, making it easy for the companies to attract 
funding and strategic alliances. Hundreds of small 
biotech firms were founded on the recombinant 
DNA technology, some of which have grown 
into large and successful firms. In total, 2,442 
known products were developed from the recom-
binant DNA technology, among them drugs to 
mitigate the effects of heart disease, lung disease, 
anemia, HIV-AIDS, cancer, diabetes, and numer-
ous other diseases and disorders. Stanford and 
the University of California received a quarter of 
a billion dollars that was used to fund internal 
research and provide infrastructure. It would be 
interesting to trace how those funds were actually 
used and what additional benefits may thus have 
been generated. 
Stanford University’s licensing program still 
provides a reference point for the future prac-
tices of university technology transfer.  While 
the amount of licensing revenue received and 
the value of the commercial product generated 
are awe inspiring, it should be remembered that 
this process was neither easy nor straightforward. 
The Stanford OTL was very creative and adaptive 
in designing their licensing program. They never 
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ABSTRACT
The public sector is making substantially increased invest-
ments in health technology innovation through public/
private partnerships to bring improved health technolo-
gies to underserved people in developing countries. These 
product-development partnerships, however, face a com-
mon problem: how to manage intellectual property (IP). 
Such management involves many issues. In relation to 
a case study, presented in this chapter, of plant-derived 
hepatitis B virus vaccine, the challenges involve obtaining 
freedom to operate, securing new intellectual property, 
and deploying intellectual property to developing coun-
tries. We conclude that while challenges abound, the IP 
issues are fairly clear and can be addressed with straight-
forward IP management approaches. The cost of manag-
ing the intellectual property is expected to be minimal on 
the price of the finished vaccine. In the medium term, 
an IP protection strategy might offset costs and generate 
modest income. Most important for the partnerships is 
to develop a clear, transparent IP policy, with emphasis 
on the licensing principles, so that products can be made 
available to developing countries at affordable prices.
 HANDBOOK OF BEST PRACTICES  | 1809 
clinical evaluation including human serum pro-
teins (epidermal growth factor), monoclonal anti-
bodies, such as antigenic peptides for rabies virus, 
tuberculosis and HIV, antibodies to treat cancer, 
cardiovascular diseases, gastric lipase in the fight 
against cystic fibrosis, and hepatitis B antibodies, 
and a range of vaccines.1 Recombinant protein 
drugs are one of the fastest growing segments of 
the pharmaceutical industry, currently generat-
ing over US$20 billion in annual revenues. They 
are the so-called third generation of recombinant 
plant products.2
From a global perspective, plant-derived vac-
cines represent an attractive mode of production 
to address diseases of the poor and to stimulate 
manufacturing in developing countries.3 Over 
the last decade, the concept of plant-derived vac-
cines has grown more sophisticated and many re-
search partnerships have emerged that involve ad-
vanced research centers in developing countries. 
Several potential characteristics of plant-derived 
vaccines could make them particularly attractive 
for controlling infectious diseases in developing 
countries. 
• The vaccines would be orally active, thus 
eliminating the need for injection and the 
associated cost and safety concerns. 
• Oral activity is associated with the ability 
of plant-derived vaccines to evoke mucosal 
immunity, which is valuable for a number 
CHAPTER 17.23
1.	 InTRoduCTIon
The goal of molecular pharming is to develop 
valuable new drugs and vaccines for significant 
diseases in developed and developing countries. 
A number of substances have already been pro-
duced in plants and include flavors, nutraceu-
ticals, biodegradable plastics, and metabolites. 
From a health perspective, plants have been 
engineered to produce therapeutic proteins for 
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of infections that are transmitted through 
the mucosa. 
• Plant-derived oral vaccines should be heat 
stable, thus largely eliminating the need for 
a cold chain for these vaccines. 
• It might be possible to make multi-antigen 
vaccines either by multiple gene splicing or 
by mixing various plant-derived vaccines. 
• A very important potential aspect of plant-
derived vaccines is that developing countries 
could launch and carry forward their devel-
opment and ultimately their production.
• Plant-derived vaccines could be produced 
on a very large scale and at very low cost, 
perhaps as little as a few cents per dose.
 
Indeed, a multi-disciplinary team led by 
Charles Arntzen4 recently carried out detailed 
calculations of the comparative costs of the 
production of vaccines by traditional methods and 
by plants. The chapter here is an extension of that 
report. In that study (as indeed in this chapter), 
hepatitis B vaccine (HBV) was used as a model. 
The cost-of-production study computed the costs 
for facilities in the United States, Korea, and India 
capable of producing 75 million doses per year. 
The “effective cost” was also computed (in other 
words, the cost per dose to deliver in a developing 
country immunization program and the percent 
savings that could be enjoyed over the effective 
cost using plant-derived vaccines). The results are 
summarized in Table 1. It shows that the potential 
economic benefits of plant-derived vaccines justify 
the establishment of a comprehensive program to 
bring one or more products to the market soon. 
It is not surprising therefore that govern-
ment- and foundation-funded molecular pharm-
ing represents a new generation of public sector 
initiatives that seek to rectify a widely acknowl-
edged imbalance: a lack of investment in R&D 
for health technologies for the poor. Since the 
private sector is, by definition, profit driven, it 
cannot, on its own, address this imbalance be-
cause of the need to make a competitive return on 
investment, which the market for the poor does 
not provide. 
The public sector is now making substan-
tially increased investments in health technology 
innovation through public/private partnerships. 
These product-development partnerships face a 
common problem: how to manage intellectual 
property (IP). This is no small challenge. IP man-
agement is a complex field in which learning, un-
derstanding, and using best practices is essential. 
Table	1.	Comparison	of	production	and	effective	Cost	
for	Three	Countries	and	Two	presentations































Cost $0.27 $0.15 $0.06 $0.09 $0.04 $0.075 $0.03
Effective Cost $0.42 $0.16 $0.08 $0.10 $0.05 $0.08 $0.04





for effective cost 
62% 81% 76% 88% 81% 90%
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IP management involves many issues, includ-
ing patenting, the protection of confidential 
information, and the formation of cooperative 
R&D programs. For any area where many orga-
nizational actors converge, there are three primary 
challenges to IP management: 
1. Securing new intellectual property. New 
research initiatives will naturally develop 
new intellectual property. It is essential 
to public sector goals that this intellectual 
property be identified and secured, either 
by filing the appropriate patent applica-
tions or by obtaining licenses from patent 
holders. If, for example, one group devel-
ops a method for promoting the synthesis 
of an antigen, and another group develops 
a technique for purifying the antigen from 
plant material, it is essential to be able to 
bring together both intellectual proper-
ties for developing the final product. This 
IP challenge can be largely overcome by 
undertaking an inventory of the existing 
intellectual property of key groups. To ac-
complish this work there must be access to 
technical experts who can identify the spe-
cific ways the intellectual property can be 
useful for product development.
2. Freedom to operate (FTO). If a molecular 
pharming initiative is to achieve its goals, 
the partnership will need to undertake a 
thorough Freedom-to-Operate review to 
provide a clear picture about which pat-
ents do, may, and do not stand in the way 
of developing products. These assessments 
are always associated with a high level of 
uncertainty, for a number of reasons, in-
cluding the large number of patents that 
may exist, the numerous jurisdictions 
(countries) in which the patents have been 
or have not been filed, and the varying 
practices of patent offices. A blocking pat-
ent may exist and might be voided in key 
markets only through long and costly legal 
battles. The value of an FTO assessment is 
that it provides a good sense of the IP is-
sues relevant for any development project, 
which helps minimize costly, unforeseen 
problems.
3. Deploying intellectual property. Public 
sector groups are often dedicated to achiev-
ing social goals, such as developing safe 
and effective health technologies to address 
disease. Further, these groups would like to 
see these products made widely available 
at affordable prices to all levels of society. 
To accomplish these ends, public sector 
groups should use humanitarian licensing 
practices. For example, if a group helps 
to develop a new monoclonal antibody 
against the rabies virus, it could license the 
technology to companies in Europe and 
the U.S., but the group could also reserve 
the right to license companies in develop-
ing countries under different terms. These 
countries may enjoy some advantages, such 
as lower costs of production. Licensing to 
companies in developing countries could 
also help to make the product available to 






As with most biotechnology products, the IP 
situation in plant-derived vaccines is complex. 
Managing IP and tangible property presents add-
ed challenges and expense because plant-derived 
vaccines build on many distinct areas of innova-
tion, including:
• Engineering of proteins and specific anti-
gens (including immunogens and specific 
genes encoding antigenic proteins). Many 
patents in this area are the same as those 
that apply to vaccine production through 
conventional means.
• Antigen production and accumulation in 
plants (including the expression of foreign 
genes and the optimization of genes). The 
technologies associated specifically with 
the expression of antigenic determinants 
in plants are the subject of several issued 
patents.
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• Genetic transformation of plants (includ-
ing vectors for use in plant transforma-
tion, transformation protocols, molecular 
toolkits, and various equipment). Basic 
plant transformation technologies have 
been under development for more than 
20 years. The procedures commonly in 
use today are covered by a range of issued 
and pending patents. Virtually all of the 
groups that have been involved in plant-
derived vaccine activities have utilized the 
agrobacterium-mediated approach to plant 
transformation. 
• Selectable marker systems (that allow for 
the identification of plant cells that have 
successfully taken up the DNA, and com-
prising the gene expression systems), such 
as kanamycin (nptII), mannose-phosphate-
6-isomerase, among others. 
• Transcription regulatory elements (to en-
sure that the introduced genes are expressed 
in plants), including promoters (constitui-
tive and/or tissue specific), and transcrip-
tion terminators (terminator nucleotide 
sequences), which are quite often NOS or 
rubisco E9 terminator sequences. 
• Sub-cellular targeting systems (used to 
“guide” the transcribed products into spe-
cific cellular organs), such as rubisco sub-
units and plastid signal sequences 
• Related technologies (such as adjuvants, 
and product formulation and immuno-
modulatory technologies). 
• Bioprocess engineering for extraction and 
processing.
An additional complication is that most 
plant-derived vaccine projects are developed 
through the collaborative efforts of a range of re-
search institutions, including private companies 
and academic institutions. Materials often change 
hands periodically during the development pro-
gram, possibly in conformity with material trans-
fer agreements that stipulate certain restrictions. 
Research agreements must be developed for all of 
these collaborative efforts. The agreements must 
address what will happen if such inventions are 
developed jointly. Further, nasal administration 
of vaccines may require access to a number of pat-
ents, which may be difficult to obtain. 
Despite the complexity, the task is manage-
able. Corporations typically manage their intel-
lectual property in a strategic manner. This entails, 
among others, significant in- and out-licensing 
activities to obtain FTO as part of an integral 
element in their product development strategy.
In contrast, public institutions are generally less 
experienced with FTO procedures. A better un-
derstanding of IP management will allow these 
institutions to take advantage of the flexibilities 
in IP systems. In the United States, for example, 
groups can undertake research without a license 
on patented technologies if the goal is to generate 
data for the regulatory requirements of the U.S. 
Food and Drug Administration (FDA).
While a patent thicket exists for plant-derived 
vaccines in industrialized countries, very few of 
these patents have been filed in developing coun-
tries. The absence of many patents in developing 
countries simplifies matters significantly with 
respect to humanitarian use and also facilitates 
commercial applications in developing countries. 
It does not, however, reduce the overall need for 
IP management in order to obtain FTO. 
There are several models of humanitarian-
use licensing where patent rights are effectively 
pooled. One example is the approach used by 
the developers of the biotech rice containing pro-
Vitamin A, called “Golden Rice.” The developers 
of Golden Rice encountered many of the FTO 
issues that face developers of plant-derived vac-
cines. An FTO assessment revealed that Golden 
Rice was related to over 70 patent applications 
and issued patents, most notably in the United 
States and Europe, and that patent applications 
were owned by over a dozen institutions. Few 
patents were applied for or issued in developing 
countries. However, because the material was 
developed in Europe, it could not be transferred 
for use in developing countries without proper 
licenses. There were a few reasons for this, not 
the least of which was that several material trans-
fer agreements were limited to research use only. 
Thanks to the publicity surrounding Golden Rice 
and the seriousness of vitamin A deficiency in de-
veloping countries, these patent constraints were 
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resolved in only a few months. The public and 
private organizations that held relevant patents 
made them available at no cost to the inventor, 
who, in turn, granted one single license for all 
the necessary intellectual property to develop-
ing country institutions. Golden Rice serves as a 
useful model of how to approach the owners or 
assignees of proprietary technologies for royalty-
free access for humanitarian uses. 
One important difference between nutrition-
ally enhanced rice and plant-derived vaccines is 
that the vectors and gene-expression components 
used to produce Golden Rice were assembled 
without advance consideration of intellectual 
property and FTO. Thus, the way forward with 
plant-derived vaccines should proceed more 
smoothly than it did with Golden Rice with re-
spect to IP issues. Preliminary analysis and con-
tinued review of the IP landscape, however, are 
essential elements in the development of plant-
derived vaccines. While it is relatively easy to put 
the different pieces into place, managing the pro-
cess, in tandem with scientific advancements and 
the development of the product, remains a major 
challenge. 
Based on a preliminary review of a specific 
plant-derived vaccine against hepatitis B virus, 
it was concluded that (1) the IP issues are fairly 
clear, although additional FTO analysis will be 
required to address specific cases, (2) the issues 
can be addressed with straightforward IP man-
agement approaches, and (3) the impact on the 
cost of finished vaccine is expected to be mini-
mal. If a great deal of the work is conducted in 
developing countries, the IP management issues 
will be significantly simplified, since a number 
of the relevant patents may not have been filed 
in developing countries and thus the need for li-
censes would be reduced significantly (unless the 





Increasingly, IP rights influence every stage of vac-
cine development. In this section, the specific as-
pects of IP management are considered as tools to 
(1) achieve freedom to operate, (2) capitalize on 
new inventions, and (3) achieve the highest possi-
ble level of accessibility and affordability in devel-
oping countries. The relevant IP includes patents, 
trademarks, know-how/trade secrets, plant variety 
protection (PVP), and tangible property (such as 
research materials obtained through agreements). 
For practical purposes, we consider IP manage-
ment at three different levels:
• incoming third-party intellectual property 
• newly generated intellectual property, and 
• outlicensed intellectual property
2.2.1  Third-party	intellectual	property
Third-party intellectual property considerations 
relate to tangible and intangible property and the 
relevant contractual obligations.
Tangible property. The components of tan-
gible property typically comprise plants, genes, 
vectors, and the conditions under which such 
material property was obtained. In most cases, 
public germplasm or varieties are available (in-
cluding corn, tomatoes, and tobacco). Whereas 
scientists in public research institutions typically 
prefer to obtain such materials from colleagues, 
the resulting material transfer restrictions should 
not be underestimated. In the private sector, it 
would be more typical to have genes synthesized, 
which avoids the material transfer restrictions on 
the genes. 
Other tangible property issues involve the 
machinery required for bioprocesses. 
Intangible property. The intangible property 
aspects are often more complex. Among the rea-
sons for this complexity is that intangible prop-
erty takes many forms, including utility patents, 
trademarks, trade secrets/know-how, plant va-
riety protection/plant breeders’ rights and plant 
patents (including utility patents on plants).
• Utility patents. Much of the third-party 
intellectual property will be in the form of 
utility patents. A detailed FTO opinion will 
be based on the specific antigen, process, 
and market in which the products are to 
be sold. In countries where certain patents 
are not issued, licenses will not be required 
either for the production or the sale of such 
vaccines.
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• Plant variety protection/plant breeders’ 
rights, plant patents (United States only) 
and utility patents on plants (mainly United 
States). Depending on which crop is being 
used, different types of intellectual prop-
erty may apply. For example, it is becom-
ing increasingly common for companies 
and universities alike to seek utility patents 
on inbreds and hybrids of corn, and for va-
rieties of soybeans, cotton, fruit trees, and 
ornamental plants. If such protected ma-
terial were used, a license may need to be 
obtained to use the plant or export it for 
production in other countries. Similarly, 
with the advent of new PVP regulations 
(under the 1991 UPOV [International 
Union for the Protection of New Varieties 
of Plants] treaty), a variety with PVP could 
not be used to produce plant-derived vac-
cines within the duration of the certificate’s 
validity, because inserting one gene or a set 
of genes would make it an “essentially de-
rived” or protected line.6 
  However, many of the IP problems de-
scribed here can be avoided if appropriate 
strategies are pursued from the outset. This 
could, for example, entail the use of public 
germplasm instead of proprietary varieties. 
Such a step may not be a feasible nor cost 
effective since some newer varieties might 
be the highest yielding or provide the high-
est regeneration efficiency during genetic 
modification work.
• Trade secrets/know-how. Some of the critical 
steps of bioprocesses lie in the know-how 
or trade secrets. Know-how refers to the 
knowledge of how something is produced, 
and not the specific components that con-
stitute a product. Know-how can be li-
censed through appropriate confidentiality 
or secrecy agreements. Requirements for li-
censing, however, vary widely from country 
to country and certain information may not 
be legally protected in many jurisdictions.
Cost implications. Traditionally, in-licensed 
intellectual property has considerable impact on 
the cost and pricing of vaccines. Estimates of the 
licensing fees vary widely—from as high as 20% 
of sales prices for newly introduced vaccines, to 
as low of 2% for haemophilius influenzae type B. 
However, this comparison of royalty rates does not 
help much when it comes to plant-derived vac-
cines, since the total royalties of all in-licensed IP 
will depend on the type of product, the number 
of patents, and type of market. Manufacturing 
costs per vaccine can be reduced by economies of 
scale/increased production, but, in such cases, roy-
alty fees are unlikely to be affected since they are 
generally fixed percentages of the sale price of each 
dose. 
In terms of possible royalty rates for the hepa-
titis B model that has been mentioned in this chap-
ter, it is perhaps premature to speculate on royalty 
ranges and licensing terms, since such speculation 
may influence the type of deal that could be ob-
tained. Nevertheless, it seems that reasonable roy-
alty rates in aggregate would add no more than 1% 
to 5% to the estimated total production costs. 
Finally, in addition to the costs related to in-
licensed IP, IP-management-related expenditures 
will be incurred during the R&D phase. These in-
clude expenditures for FTO opinions, which will 
need to be commissioned well ahead of produc-
tion. Typical FTOs cost $20,000 to $100,000, 




Since the decision of the Supreme Court of the 
United States on Merck v. Integra Life Sciences in 
2005,7 analysts contend that, with the broadened 
definition by the Supreme Court of the Hatch-
Waxman Act8 as it relates to data exclusivity, 
research in preparation of FDA approval is ex-
empt from the requirement for research licenses. 
Although this broad conclusion has not been 
tested within specific circumstances in the lower 
courts, it is reasonable to assume for hepatitis B 
that there are no IP constraints during the re-
search phase, until clinical trials are complete and, 
possibly, the submission of an investigational new 
drug (IND) application to the FDA.
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Many of the existing patents related to HBV are 
unlikely to be relevant for a number of reasons. 
First, several surface antigens are either in the 
public domain or their patents are limited to 
parenteral9 administration, rather than oral de-
livery, or the claims do not cover their produc-
tion in plants. In addition, the patent issued in 
1989 to Merck & Co, and the 1986 Chiron pat-
ent for the first recombinant vaccine (hepatitis 
B), will have expired by the time a plant-derived 
vaccine reaches the market. Furthermore, these 
patents seem to be limited to the production 
of virus-like particles in yeast only. A full FTO 
assessment will nevertheless be required to pro-
vide clearer answers and reveal other intellectual 




A preferred method of production for the HBV 
is through stable lines produced through agrobac-
terium-mediated transformation. The IP thicket 
related to agrobacterium is relatively complex and 
still evolving; at least one of the interference pro-
ceedings of agrobacterium-related patents filed 
prior to March 1995 is still ongoing, and no de-
tails on possible claims have been made public.10 
However, based on counterpart patents issued in 
Eurpoe, it is fair to assume that at least one li-
cense could be required from either Monsanto or 
Syngenta (since they, or companies they acquired, 
are presumed to have filed patents for agrobac-
terium-mediated transformation prior to March 
1995).
The currently used plasmid is a derivative 
of the antigen pBin19 and may be covered by 
Monsanto patents. The promoter that drives the 
gene expression (CaMV 35S) and the selectable 
marker that allows for the selection of transformed 
cells (nptII) are both covered by Monsanto pat-
ents. Other patents may also cover the applica-
tions; these will be identified during an FTO. 
However, broad patents are not known to these 
authors that cover all transgenic corn, tomato, or 
tobacco. There might be some differences in agro-
bacterium-related patents depending on whether 
a monocotyledoneous or dicotyledoneous plant 
is used. These differences, however, will not ma-




Three of the most often cited patents related to 
plant-made pharmaceuticals for oral administra-
tion are the Curtiss-Cardineau patents (U.S. pat-
ents No. 5,654,184, 5,679,880 and 5,686,079), 
assigned to Washington University in St. Louis, 
but now owned by Dow. However, all claims of 
the three patents are limited to oral administration 
of “transgenic plants” or of “transgenic plant tis-
sue.” It is unclear whether the Curtiss-Cardineau 
patent would cover the oral administration of an-
tigens “extracted” from plant tissue. 
3.2.4 Bioprocess	facility
Many aspects of a bioprocess facility (which is 
required for the extraction, purification and pro-
cessing of the vaccine) are covered by the very 
broad U.S. patent No. 6,617,435 B2 and U.S. 
application No. 2004/0166026 A1 and, possibly, 
patents that are continuations, divisionals, for-
eign counterparts, reissues, reexaminations, and 
continuations-in-part of known patents. The for-
mer is assigned to the now-defunct Large Scale 
Biology (LSB) Corp. in Vacaville, California; the 
latter, if issued, also would be assigned to the suc-
cessors of LSB Corp.11 Since much of this bio-
process facility design would draw on the trade 
secrets and know-how of LSB Corp., a license 
from LSB Corp. or its successor would be highly 
desirable.
3.2.5		 Cost	implications
Production of plant-derived hepatitis B vaccines 
through plant transformation and antigen pro-
duction in plants is expected to require a num-
ber of licenses.  These should be obtainable, es-
pecially because the proof of concept has already 
been demonstrated and confidence built into 
the technology. In aggregate, licenses for HBV 
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technology, plant transformation and broad 
molecular pharming patents, the total royalties 
should not add more than 1% to 3% to the cost 
of production. This estimate is based on common 
industry licensing practices. 
Bioprocess patents are in a different catego-
ry because know-how is important for the con-
struction and operations of bioprocess facilities. 
Nevertheless, favorable terms for a license that 
would not exceed 1% to 3% of the cost of pro-
duction could likely be obtained.
3.3	 New	intellectual	property
3.3.1		 Utility	patents	
During the development of plant-derived vac-
cines, certain new inventions will emerge that 
might be patentable. Aside from the typical in-
ventions related to antigens, plant transforma-
tion systems, and related technologies, innovative 
business models and production processes might 
also be developed. Care should be taken in mak-
ing decisions about whether or not the inventions 
should be patented, kept as trade secrets, or made 
public and consideration given especially to the 
best ways to make the plant-derived vaccine avail-
able at affordable prices to the neediest countries 
in the developing world. This goal is more likely 
to be achieved if a certain level of control over the 
vaccine is retained.
3.3.2 	 Trade	secrets/know-how
Many critical aspects of the operations of biopro-
cessing facilities are valuable knowledge. In some 
jurisdictions, this knowledge can be protected 
under trade secret law. It is customary for any 
pharmaceutical production plant to keep its stan-
dard operating procedures as trade secrets, given 
the considerable time and resources involved in 
fine tuning operations. By extension, employees 
of such plants will need to be informed of pro-
cedures for keeping information confidential and 
should have related clauses in their employment 
contracts.
3.3.3	 Trademarks
One expense that might be worth considering is 
the creation of a quality seal for all plant-derived 
vaccines that are made using the processes out-
lined in this chapter. Such trademarks could be 
valuable and would afford a level of quality assur-
ance and control not otherwise available. 
3.3.4	 Cost	implications
Obtaining IP protection through utility patents, 
and trademarks incurrs legal and government 
filing fees (especially if trademarks are pursued in 
multiple countries). (Trade secret protection, on 
the other hand, costs nothing.) There will also be 
expenses related to ongoing licensing negotiations. 
Nonetheless, the added cost for the protection of 
new intellectual property will undoubtedly be 
small compared to overall production costs. The 
expenses would likely add no more than US$10-
100,000 per year to the cost of production. In 
time these costs can be recovered, and the IP may 
even lead to a modest royalty stream if licensed. 
4.	 ConCluSIonS	
The chapter’s survey of intellectual and material 
property issues was based on a cursory FTO re-
view. We attempted to highlight key issues and es-
timated the possible costs associated with the res-
olution of these. As the current research emphasis 
evolves into a product development program with 
more downstream considerations, a detailed FTO 
will be required leading to in- and out-licensing 
of intellectual property. To successfully move the 
candidate vaccine through the various stages from 
research to commercialization will also require the 
development of a global access strategy to reach 
developing country markets.12 For this, various 
components will need to be integrated, includ-
ing regulatory aspects, manufacturing, access to 
markets/distribution, and trade. IP management 
then essentially becomes nothing but a useful tool 
for reinforcing the vaccine development and de-
ployment/marketing strategy. ■
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Plant breeders and research managers need to understand 
how intellectual property (IP) restrictions on germplasm 
and traits affect freedom to operate for a breeding pro-
gram. Access to patented germplasm and traits is restrict-
ed and can only be used under some form of material 
transfer agreement or similar contract. Patented materials 
have to be maintained under strict provisions of the con-
tract. This adds to the cost of breeding, parent seed, and 
production programs. Moreover, maintaining separate 
versions and precise records of patented materials increas-
es the number of seed lots that a program must maintain. 
For example, different versions of inbred lines of maize 
must be maintained for each patented trait. Otherwise, 
stacking two or more traits produces lines with each trait 
and also lines with every combination of those traits.
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• tips to enable you to avoid costly er-
rors in managing licensed biotechnology 
applications
Initially, you may wonder why it is essential 
that breeders and research managers learn how to 
manage proprietary biotechnology efficiently in 
any breeding program. The reasons are actually 
quite simple.
For breeders, a working understanding of the 
extra workload, costs, constraints, and potential 
benefits of using proprietary biotechnology is 
necessary to establish priorities for developing 
transgenic inbreds and hybrids. A breeder’s lack 
of basic information about the licensing of pro-
prietary biotechnology could be a costly waste of 
time, opportunity, and money. Ignoring issues as-
sociated with managing proprietary biotechnol-
ogy will not make them go away. Indeed, the fail-
ure to make informed decisions about what traits 
to adopt and how to handle them will result in de 
facto decisions that may be neither desirable nor 
reversible.
For research managers, a working understand-
ing of intellectual property (IP) in biotechnology 
is necessary to obtain freedom-to-operate (FTO) 
and to commercialize traits. Managers must un-
derstand the real costs of obtaining, backcrossing, 
increasing, and testing multiple biotech traits in 
order to properly allocate resources to breeding, 
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1.	InTRoduCTIon
As the manager of research and development 
at a major seed company for several years dur-
ing the 1980s and 1990s, I saw firsthand how 
proprietary biotechnology transformed our busi-
ness. Drawing on my experience, this chapter 
describes:
• the complexities of managing proprietary 
transgenic inbred lines, hybrids, and genes 
through the breeding, testing, parent seed, 
and hybrid production processes
• licensing and contracts relevant to the use 
of proprietary biotechnology in breeding 
programs
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parent seed, and production programs. Finally, 
to make decisions about product development 
and release, managers must understand contrac-
tual obligations related to product quality and 
efficacy. 
While I use corn as the example throughout 
this chapter, most of the principles discussed here 
are equally applicable to the breeding of almost 
any crop. So, as you read through this module, 




Traditional corn breeding programs in the de-
veloped world breed hybrid varieties for farmers’ 
use. Hybrids in the United States today are most-
ly crosses between two inbred lines. New inbred 
lines are developed by selfing plants from a source 
population. Source populations could include 
open pollinated varieties, synthetics, or crosses 
between two or more inbred lines. 
Successful commercial corn breeding pro-
grams today often start with source populations 
created by crossing two relatively elite inbred lines 
that both combine well with another line (tester) 
to produce hybrids exhibiting high levels of heter-
osis. The source population is then self-pollinated 
for seven to eight generations, with several hun-
dred selfed families being selected and advanced 
during each selfed generation. After one to three 
selfed generations, the selfed families are crossed 
onto an inbred of a complementary heterotic 
group (tester) and the hybrid progeny are evalu-
ated in replicated trials for yield and desirable ag-
ronomic traits. Lines from the selfed families that 
produce the best tester hybrids are advanced to 
further selfing generations and recrossed onto ad-
ditional testers to produce new hybrids to evalu-
ate. As the families are selfed, each generation 
becomes more and more homozygous, or inbred, 
eventually giving rise to new inbred lines. New 
inbred lines that produce new hybrids 5%–10% 
better than the best current hybrids are advanced. 
New hybrids are evaluated over several hundred 
locations over two to three years before a selected 
few are released as new commercial hybrids. 
The above process requires eight to ten gen-
erations of selfing and three to five concurrently 
run years of hybrid testing. Each year of testing is 
called a stage, so that hybrids advance from stage 
one to stage five of testing. Each successive stage 
is marked by fewer hybrids grown at more loca-
tions. The first three stages typically are composed 
of two replicated plots of each hybrid, approxi-
mately 1/1000th acre in size, grown at ten to 100 
locations. The last two stages are usually produced 
on strips of ten to 20 rows of each hybrid, planted 
under farm conditions. Historically, the develop-
ment of new inbred lines has taken eight to ten 
years. Advances in data collection and analysis 
technology, and the use of off-season nurseries to 
grow additional generations per year, can cut the 
development time for new inbred lines to five or 
six years. With concurrent testing of new hybrids, 
the entire process can be shortened to six or eight 
years. 
The development of transgenic corn con-
taining proprietary insect resistant (Bt genes) 
and herbicide tolerant (Roundup Ready® and 
LibertyLink®) genes creates additional expense 
and workload for corn breeding programs. Each 
new gene or combination of genes must be in-
corporated into existing and newly developed 
elite inbred lines, requiring multiple generations 
of backcrossing. In addition, new versions of 
hybrids carrying each proprietary gene need to 
be generated and tested in replicated trials over 
many locations for several years. Since the propri-
etary genes are legally protected, usually by utility 
patents, corn breeders must obtain FTO for use 
of the new genes. This requires licenses and con-




Commercial corn breeding programs are fast 
paced and very competitive. Competitive breed-
ing programs rapidly adopt new information 
technologies and biotechnologies. Developing 
new corn inbred parents and competitive new 
hybrids historically took ten years or longer. The 
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basic process can require eight to ten generations 
to obtain new homozygous inbred lines to use as 
parents, and four to five years of testing combina-
tions to select new hybrids for commercial release. 
If done in sequence, this would require 12 to 15 
years to develop a new hybrid. If breeders initiate 
hybrid trials during the years when new inbred 
lines are being self-pollinated, they can effectively 
cut the time required to ten years or less. A fast-
track breeding protocol using off-season breeding 
nurseries (to provide two, and sometimes three, 
generations of self-pollinating lines per year) can 
decrease the time required to develop new homo-
zygous inbred lines and hybrids to seven or eight 
years (Figure 1). To produce an additional one or 
two generations per year, it is essential that breed-
ing programs utilize new technologies to harvest 
trials of experimental hybrids and to select lines 
to advance in off-season nurseries.
3.2 Super-fast-track	conversion	programs
Starting in the 1990s, breeders developed, 
through plant transformation, corn lines into 
which proprietary genes from organisms un-
year	1
Winter-1 Cross inbred 1 and inbred 2
Winter-2 F1 Self
Summer S1 Self and cross onto tester
year	2
Winter 1 S2 Self
Summer S3 Self and evaluate early generation tests
year	3
Winter 1 S4 Self and cross onto more testers
Summer S5
Self, evaluate stage 1 hybrids, cross new lines onto (such as cytoplasmic 
male sterility [cms], insect resistance [Bt], or Roundup Ready® [rr])
year	4
Winter S6 Self
Summer S7 Self and evaluate stage 2 hybrids
year	5
Summer Evaluate stage 3 hybrids
year	6
Summer Evaluate stage four hybrids “on farm”
year	7
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related to corn were inserted into the corn ge-
nome. Important traits, such as insect resistance 
(Bt) and tolerance to herbicides (Roundup 
Ready® and LibertyLink®), were developed and 
made available to the seed corn industry. These 
traits were rapidly accepted by the industry 
worldwide, dramatically changing traditional 
corn breeding.
The genes for insect resistance and tolerance 
to herbicides provided traits that were advanta-
geous for corn farmers; however, the first sources 
of these genes were in corn lines that were not 
very competitive. In order to be commercially 
useful, the genes had to be incorporated into 
elite inbred lines that produced competitive hy-
brids. The process of incorporating a new gene 
into a corn inbred line usually requires between 
seven and eight backcross generations, during 
which a source of the new gene is crossed to an 
elite inbred line. After this, selected progeny are 
back crossed onto the elite inbred line for seven 
or eight generations (Figure 2). Even if you used 
two or three backcross generations per year by 
employing off-season nurseries, you would still 
need three years to recover a version of an elite 
line that was essentially identical to the origi-
nal inbred line but also expressed the new gene. 
Unfortunately, because every year new hybrids 
are developed that out-perform older hybrids 
by 5%–10%, the half-life of many corn hybrids 
today is three to five years. This means that by 
the time you could convert the parents of a com-
mercial hybrid to a new gene through tradition-
al backcross procedures, the sales of the hybrid 
would likely be in decline.
year	1
Winter Cross elite inbred Source of a new gene F1
Summer Elite inbred F1 BC1
year	2
Winter Elite inbred BC1 BC2
Summer Elite inbred BC2 BC3
year	3
Winter Elite inbred BC3 BC4
Summer Elite inbred BC4 BC5
year	4
Winter Elite inbred BC5 BC6
Summer Elite inbred BC6 BC7
year	5
Winter Elite inbred BC7 BC8
Summer
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Thanks to new technologies involving mo-
lecular markers, however, it is possible to back-
cross a new gene into an elite inbred in three 
to four total generations, rather than seven to 
eight.1 This means that a breeding company 
can utilize a super-fast-track conversion pro-
gram to backcross proprietary genes into elite 
inbred parents before the hybrids produced be-
come obsolete (Figure 3). Seed companies are 
therefore able to acquire new genes and trans-
fer them very rapidly into elite inbred lines. Of 
course, super-fast-track conversion programs 
are not cheap. The use of off-season nurseries 
and molecular markers to obtain the rapid con-
versions adds considerable labor and expense to 
the process of commercial corn breeding. Also, 
breeding companies must obtain regulatory ap-
proval for the gene construct being converted. 
Obtaining regulatory approval in countries 
normally used for off-season nurseries, such as 
Mexico, Chile, and Argentina, is difficult and 
time consuming. This means that off-season 
nursery conversion must be done on U.S. soil, 
basically in Hawaii, Florida, and Puerto Rico, 
creating additional expense. 
4.	 CRITICAl	BReedIng	deCISIonS	
4.1 Which	lines	and	how	many	to	convert?
A typical corn-breeding company sells a number 
of specific hybrids of different maturities and geo-
graphical adaptation. The major seed corn com-
panies usually have ten to 20 elite inbred lines in 
commercial use, plus several hundred new lines 
nearing inbred status in the developmental pipe-
line. The decision about which, and how many, 
inbreds to enter into a fast-track conversion pro-
gram requires a lot of thought and often some 
bold decisions. Since financial resources dedi-
cated to research and development are limited, 
directing funds to fast-track conversion often 
requires redirecting resources away from use in 
conventional breeding. Critical decisions about 
how much fast-track conversion you can afford 
are often difficult to make.
4.2 Which	genes	and	how	many	to	convert?
A number of transgenes that are available from 
biotech companies have been inserted into 
corn. Each of these genes has different uses in 
different genetic backgrounds. The usefulness 
year	1
Winter Elite inbred Source of a new gene F1
Summer Elite inbred F1 BC1 




Selected Progeny at @ 
BC4 generation
BC5
BC5 progeny selected 
with PCR markers
Summer Elite inbred





BC9 Selfed as new 
version of elite inbred
figure	3:	Super	fast-Track	Conversion	protocol
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of each gene must be monitored during the 
conversion process, since each gene may offer 
a trait desired by at least one segment of the 
population of farmers a seed company serves. 
Additionally, contractual restrictions often de-
termine how and where genes can be deployed. 
Breeders must test lines undergoing conversion 
to measure the level of gene expression and to 
demonstrate that all plants undergoing con-
version carry the gene in an active form. It is 
expensive to incorporate each gene into elite 
and newly developing inbred lines. It is even 
more expensive to do all the testing required 
by licensing agreements. In addition, each con-
verted line must be tested in hybrid combina-
tions that contain each gene, as compared to 
the same hybrids without the genes, to dem-
onstrate that genetically modified, or GM, hy-
brids perform as well as non-GM counterparts. 
Of course, if different genes provide traits that 
are desirable individually, then the combination 
of two or more genes in the same hybrid offers 
an even more desirable product. Unfortunately, 
each gene needs to be transferred individually 





As new lines reach the second or third selfed gen-
eration, they are crossed onto one or several tester 
lines to generate hundreds of hybrids for evalua-
tion. In stage one of hybrid testing, hybrids are 
evaluated at three to four locations in replicated, 
paired row plots (Figure 4). In stage two of test-
ing, the best 10% of these hybrids are remade 
and tested in paired-row plots at ten to 20 loca-
tions. Subsequently, in stage three, the best 10% 
of stage two hybrids are advanced to paired-row 
plots at 50 to 100+ locations. The best of these, 
presuming that they have significant performance 
advantage over currently grown hybrids, are pro-
duced in quantities to allow testing at 100 to sev-
eral hundred locations. For a period of two years, 
the hybrids are planted in paired-row plots and 
in strip plots (roughly one-tenth of an acre) and 
harvested using current farming practices; this 
comprises stages four and five of testing. After 
five years of small-plot and strip-plot testing at 
several hundred locations per year, the best-per-
forming hybrids are approved for sale.
STAGE 1
Hundreds of new hybrids, tested in paired-row plots, 1/1000th of an acre each in 
replicated trials, at three to five locations
STAGE 2
The best at 10% of stage one hybrids, tested in paired-row plots in replicated 
trials, at ten to 50 locations
STAGE 3
The best at 10% of stage two hybrids, tested in paired-row plots in replicated 
trials, at 30 to 100 locations
STAGE 4
The best ten to 15 hybrids from stage three, tested again in paired-row plots, 
replicated at 30 to 100 locations, and also tested in one-tenth-acre strip plots on 
farms at 100 to 200 locations
STAGE 5
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5.2 GM	hybrid	test	process
GM hybrids are hybrids that contain propri-
etary biotech traits introduced into corn from 
other species through plant transformation. 
These GM hybrids present several challenges 
to the hybrid release process. First, with new 
gene constructs, hybrid evaluation trials must 
be done under an experimental use permit. This 
imposes restrictions on the number of hybrids 
and testing locations, which means that fewer 
hybrids can be evaluated and more years are 
needed to obtain data sufficient to justify com-
mercial release.
Second, licensing agreements often impose, 
for each hybrid, stringent requirements for degree 
of expression of proprietary genes. This requires 
expensive, time-consuming tests to be run on all 
hybrids being evaluated.
Finally, the number of hybrids that must be 
tested increases with every new proprietary gene 
or combination of genes used. Even if only three 
new genes are used, the number of hybrids to 
be tested in early generations goes from several 
hundred to nearly one thousand. If combina-
tions of each of the three genes are developed, 
you can approach two thousand hybrids to test 
in early generations. Even at the later stages of 
testing, strip tests at several hundred locations 
per year can increase from eight to ten new hy-
brids, in conventional programs, to 40 to 50, if 
three genes with some two-way combinations are 
tested. Consequently, the number of genes and 
hybrids must be carefully selected or the costs and 
logistics become prohibitive.
Fortunately, breeders can use a fast-track hy-
brid release process to speed the release of new 
GM hybrids. If there are no detrimental effects 
from the proprietary genes being incorporated, 
and the backcross conversion process is carefully 
monitored to get converted lines that differ from 
the elite line by only one to a few genes, then per-
formance of hybrids involving the converted lines 
will be very similar to the performance of hybrids 
involving the elite, nonconverted lines. Therefore, 
it is possible to decrease the five-stage, five-year 
testing process to three years. Usually, the con-
verted versions of hybrids are tested only at stages 
three, four, and five. This means that once elite 
inbreds are fully converted to a proprietary gene, 





Traditionally, new inbreds are advanced from re-
search programs to parent seed programs when 
the inbred performs successfully in one or more 
hybrid combinations in stage three of research 
testing, usually the third year of multilocation 
testing across a wide geographic area. Once ad-
vanced, the parent seed department starts in-
creasing seed of the new inbreds and producing 
seed of the new hybrid combinations to build up 
quantities needed for commercial release. Often, 
three generations of seed increase are needed to 
produce enough inbred seed of a new female 
parent to allow for seed sufficient for commer-
cial release.
Normally, only one of three or four new in-
breds that make it to stage three of testing actual-
ly makes it to commercial release. During testing 
stages four and five (strip tests on farms at many 
locations for two or more years), many hybrids 
containing new inbreds are dropped. The seed 




Each biotech trait added to an inbred produces 
another version of the inbred that must be in-
creased prior to potential commercial release. 
So, rather than increasing one version of a new 
inbred, you have to increase two, three, or even 
more versions, many of which are never sold in 
any hybrids. This greatly increases the costs asso-
ciated with producing hybrid and inbred seed.
7.		 lICenSIng	And	ConTRACTuAl		
ISSueS	WITh	gm	TRAITS
Proprietary GM traits and converted varieties are 
usually protected by some form of intellectual 
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property (IP) protection, which defines ownership 
of the traits, plants, or technologies. This protec-
tion may be in the form of utility patents, plant 
variety protection certificates, or trade secrets. 
Most transgenic plants embody numerous com-
ponents and processes, each of which may have 
IP protection. You must make sure that anyone 
that supplies you with proprietary traits has legal 
access to all proprietary components and process-
es used in developing the genetically modified, or 
GM, traits. Suppliers of proprietary traits should 
be willing to include appropriate warranty clauses 
into any agreement you execute that protects you 
from any IP protection infringement that may 
arise from commercializing the traits.2
Several types of legal agreements are avail-
able for gaining access to proprietary traits and 
technologies. These may be as simple as material 
transfer agreements (MTAs), or as complex as 
commercial licensing agreements. Often, you can 
gain early access to proprietary genes and technol-
ogy under research agreements. These allow you 
to obtain and incorporate proprietary genes into 
your germplasm, evaluate performance, and then 
choose only those genes that meet your commer-
cial objectives before having to negotiate terms 
of commercialization. Proprietary genes and 
technology that you choose not to commercial-
ize must be returned and plants containing those 
genes destroyed. This allows you to test a wide 
range of genes/technologies without having to 
pay royalties or fees. However, you should ensure 
that such research agreements contain a mecha-
nism that allows you to commercialize those 
genes/technologies that you do select. Often, 
commercial agreements require an up-front pay-
ment to access the genes, and afterwards royalty 
payments based on volume and the price of prod-
ucts sold containing the proprietary genes. If you 
do not reach an agreement with the gene sup-
plier regarding terms of commercialization before 
starting your research, you ought to at least agree 
that you will be offered terms comparable to the 
seed industry standard.
The contracts or licenses required to get ac-
cess to proprietary genes often contain strict limi-
tations on what you can and cannot do with the 
genes. It is important that all personnel who have 
access to the proprietary genes understand these 
requirements. Also, these contracts often contain 
specific tests or measurements that you must con-
duct to verify the purity and efficacy of the genes 
after you have crossed them into your germplasm. 
These tests take time and money to perform and 
sometimes require breeders to learn new skills.
Newly developed proprietary traits also must 
be approved by governmental regulatory agen-
cies. Until approval is obtained, the traits must 
be grown under experimental use permits. These 
restrict the size and number of test plots that 
you can plant and require a lot of supervision 
and documentation. Experimental use permits 
also restrict your use of off-season nurseries. You 
cannot grow a GM trait in any country that has 
not approved the trait. This prevents the use of 
Mexico, Chile, or Argentina for off-season nurs-
eries, which forces you to use Hawaii, Florida, or 
Puerto Rico. This raises costs and limits the flex-
ible use of off-season nurseries.
8.	 ConCluSIon
Since this chapter was originally written, several 
proprietary biotech traits have been commercial-
ized on large acreages throughout the world. As 
traits like the Bt gene have become commonplace 
in breeding programs, new source populations 
have been established in which both parents 
contain the Bt gene. This eliminates the need 
for fast-track or super-fast-track conversions and 
reduces the complexity of producing hybrids 
with that trait. However, as Bt and Roundup 
Ready® became commonplace, new transgenic 
traits have appeared. Thus, as companies reduce 
the workload and expense associated with the 
first generation of transgenic traits, new traits 
are increasing the complexity again. Also, trans-
genic traits for such crops as soybeans, cotton, 
and canola have been developed, extending the 
complexity to other crop breeding programs. This 
cycle of managing trait complexity will continue 
until the traits are no longer competitive, or until 
the patents expire. Many of the patents on first 
generation traits, and on the first patented inbred 
lines and hybrids, were issued in the last half of 
the 1980s, which means that both the traits and 
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patented inbreds became public property starting 
in 2006. This could have a large and positive im-
pact on plant breeding programs, since programs 
will be able to access and utilize these off patent 
materials without restrictions. Several inbreds 
from Pioneer Hi-Bred International Inc. (now a 
DuPont Company) and DeKalb Genetics (now 
owned by Monsanto) were applied for in 1986 
and subsequent years. The patents are valid for 
20 years after the application date. That means 
that the first inbreds patented came off patent in 
2006. Each year additional inbreds will come off 
patent. Even though 20 years old, some of these 
inbreds represent significant sources of elite gene 
combinations representing some unique heterotic 
groups that could upgrade public plant breeding 
germplasm in the temperate world. As I under-
stand it, seed of the patented inbreds is supposed 
to be maintained by the American Type Culture 
Collection and made available upon request from 
the U.S. Patent Office for the purpose of dem-
onstrating the validity of the material patented. 
Presumably, seed will not be maintained after the 
patents expire. ■
VERNON gRACEN, Professor, Department of Plant Breeding 
and Genetics, 520 Bradfield Hall, Cornell University, 
Ithaca, NY, 14853, U.S.A. vg45@cornell.edu 
1 See the section Plant Breeding 2 in citnews.unl.edu/
hscroptechnology/lessonFrames.html for a review of 
marker assisted back crossing.
2 Kowalski SP, RV Ebora, RD Kryder and RH Potter.. 2002. 
Transgenic crops, biotechnology and ownership rights: 




This chapter looks at the results of a unique public–private 
partnership instituted to provide resource-constrained 
farmers in the developing world with access to propri-
etary agri-biotechnologies. Eggplant, a widely consumed 
vegetable crop in the tropics, is commonly infested by the 
eggplant fruit and shoot borer (EFSB), which devastates 
both plants in the field during development and eggplant 
fruits after harvesting. The chapter considers the applica-
tion of insect-resistance technology (based on the Cry1Ac 
protein from Bacillus thuringiensis) in eggplant, focusing 
on its sublicensing from a private company to a partner-
ship of public institutes and agricultural universities in 
Bangladesh, India, and the Philippines.
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these species, the eggplant fruit and shoot 
borer (Leucinodes orbonalis), or EFSB, is the 
most widespread and devastating in South and 
Southeast Asia, with infestation inflicting about 
a 70% crop loss.1 EFSB larvae feed inside the 
eggplant shoot and fruits, retarding the vegeta-
tive growth of the plant and decreasing the mar-
ketability and edibility of the fruit.
Many attempts to crossbreed eggplant va-
rieties with EFSB-resistant wild varieties have 
been unsuccessful. So farmers have had to rely 
heavily on chemical pesticides to control EFSB. 
According to a study conducted on pest control 
for eggplant in South Asia, farmers spend about 
US$400 per hectare on pesticides, two-thirds of 
which are used to control ESFB.2 In addition, 
EFSB populations have gradually become resis-
tant to certain chemicals, so farmers have resorted 
to using other chemicals, some of which are more 
hazardous to human health and to the environ-
ment, as well as illegal, to control the insect.
2. The	TeChnology
MAHYCO, a private Indian company, was the first 
in India to develop a hybrid eggplant containing 
a gene that provides resistance to EFSB. The gene 
it used (cry1Ac which produces the corresponding 
protein called Cry1Ac3) is obtained from Bacillus 
CHAPTER 17.25
1. InTRoduCTIon
Eggplant (Solanum melanogena) is an important 
vegetable crop widely cultivated and consumed 
in the subtropical and tropical regions of Asia and 
Africa. It grows in a wide range of climatic con-
ditions and is a staple of human consumption. 
About 510,000 hectares of arable land in India 
and 20,000 hectares in the Philippines are devot-
ed to cultivating eggplant.
A long-duration crop, eggplant is grown 
using either hybrid varieties or open-pollinated 
varieties (OPVs, for which seeds can be saved 
and used later). Although much preventive care 
is taken, eggplant is commonly attacked by 
more than a dozen insect-pest species. Among 
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thuringiensis (Bt). Bt is a spore-forming bacterium 
that produces crystal proteins (called Cry proteins) 
that are toxic to many species of insects, including 
EFSB. Bt action is very specific. To become lethal, 
the Bt protein has to be ingested; the Bt toxin is 
activated in the high pH environment of the in-
sect gut. The activated protein perforates the lin-
ing of the gut, which causes the death of the insect 
within a of couple days. 
A main advantage of this technology is that it 
reduces the use of chemical pest control, thereby 
making the technology environmentally harmless. 
Through its safety tests, the U.S. Environmental 
Protection Agency has found no human health 
hazards related to Bt use. The agency has ex-
empted Bt from its standards for food-residue 
tolerances and groundwater concentration, from 
endangered species labeling, and from special 
review requirements, indicating that cultivation 
of crops using Bt is safe for resource-constrained 
farmers in the developing world. 
3. The	lICenSIng	ARRAngemenT
MAHYCO is the first Indian company to have 
received the rights under license for the use of the 
Bt cry1Ac gene technology for insect-pest man-
agement from Monsanto Company. This licensed 
cry-gene technology was used by MAHYCO to 
develop and generate hybrid eggplant events. 
Under the aegis of the Agricultural Biotechnology 
Support Project II (ABSP II), funded by the U.S. 
Agency for International Development, Sathguru 
Management Consultants Pvt. Ltd. partnered 
with MAHYCO. The cry-gene technology was 
licensed then to several public institutes in South 
and Southeast Asia that were participating in a 
public–private consortium created to develop 
EFSB-resistant OPV eggplant that would im-
prove the conditions of resource-constrained 
farmers in developing countries. The ABSP II 
played a pivotal role in this venture by funding all 
the consortium partners for their R&D roles in 
developing the EFSB-resistant eggplant. 
The technology was sublicensed by 
MAHYCO on a royalty-free basis to public re-
search institutes in India (the Indian Institute 
of Vegetable Research, Tamil Nadu Agricultural 
University, and the University of Agricultural 
Sciences, Dharwad), in Bangladesh (the 
Bangladesh Agricultural Research Institute), and 
in the Philippines (the University of Philippines, 
Los Banos). MAHYCO also sublicensed this tech-
nology to East West Seeds, a private corporation 
in Bangladesh, on commercial royalty-bearing 
terms. To safeguard the licensor’s interests, specif-
ic strategies for the stewardship and monitoring 
of the technology by the licensees were addressed 
and formulated early in the sublicensing process.
4.  TRAnSgenIC	eggplAnT
Most eggplant farmers in India grow OPVs. The 
area planted with hybrid varieties is less than 
30% of the total area. Growers that plant these 
hybrid varieties also tend to use more purchased 
inputs and have higher yields compared to grow-
ers who plant OPVs.4 The main reason that the 
cultivation of OPVs is more widespread is that 
OPV seeds can be saved and replanted in future 
growing seasons. As a result, OPV seeds are much 
more available and affordable. The market price 
of hybrid seeds is five to ten times the market 
price of OPV seeds.
The first transgenic Bt hybrids developed 
by MAHYCO are slated to be commercially 
released in India by the end of the 2006–2007 
season,5 after the fulfillment of all regulatory re-
quirements. The transgenic Bt OPVs under de-
velopment by the public–private partnership are 
expected to be commercialized about six months 
later. Because of the existing price differential be-
tween conventional OPVs and hybrids, and be-
cause of the zero premium being charged for the 
Bt trait in the OPVs, it is still expected that most 
of the existing growers of hybrid eggplant will 
adopt the Bt hybrids rather than the Bt OPV, 
even though the Bt OPVs would be priced much 
lower than the Bt hybrids. This is primarily due 
to production and yield differences between the 
two systems. Farmers growing OPV eggplant are 
most likely to adopt the Bt OPV because of the 
cost factor. Growers of both types of eggplant 
can be expected to shift to the corresponding Bt 
versions because of the expected savings in pesti-
cide expenses.6
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The public–private partnership also addresses 
distribution issues: the participating public insti-
tutions will be able to deliver high-quality Bt egg-
plant seeds that are resistant to EFSB through their 
own public distribution systems on a cost basis (in 
other words, without adding profit margins). 
Most resource-constrained farmers in the 
developing world cultivate OPVs because of the 
lower costs involved. By recognizing these agricul-
tural practices, and by providing the public sector 
with access to Bt technology for use in OPVs, via 
a unique public–private partnership, MAHYCO 
both commercializes its Bt hybrid eggplant (sold 
on a for-profit basis) and through its donation ad-
dresses the need to improve crops of vital impor-
tance to poor farmers. ■
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ABSTRACT
The strawberry improvement program located at the 
University of California, Davis focuses on breeding cul-
tivars for the strawberry industry in California, yet today 
it supports the majority of production of fresh-market 
strawberries globally. Around the world, UPOV-compli-
ant Plant Breeders’ Rights (PBR) are the most common 
form of IP protections sought by University of California 
(UC) to protect its strawberry cultivars. Inside the U.S. 
and Canada, cultivars are licensed on a nonexclusive basis 
directly to nurseries. Outside of the U.S. and Canada, UC 
relies on business partners, referred to as “master licens-
ees,” as intermediaries. A master licensee is provided with 
exclusive rights within a defined territory that includes 
the right to issue nonexclusive sublicenses to nurseries 
within that territory. Overall, a three-tier royalty structure 
is utilized, with growers inside California paying the least, 
growers in the U.S. outside of California and in Canada 
pay slightly more, and all other growers pay even more, 
a percentage of which is shared with the master licensee. 
The ultimate future of the UC strawberry breeding pro-
gram is tied to the continued development of competitive 
cultivars, but the team is highly skilled and, partly due to 
the licensing program, funding is stable.
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fresh-market strawberry industry. UC cultivars 
represent 75%–80% of the production of the 
US$1.3 billion California strawberry industry and 
represent 50%–60% of worldwide production. 
The UC strawberry licensing program is active 
in the United States, Europe, Asia, Africa, South 
America, and Australia and generates an annual 
licensing revenue stream of US$4.5 million. This 
case study summarizes patent portfolio develop-
ment, licensing strategy, and income trends for 
this successful university licensing endeavor.
2.	 Ip	poRTfolIo	developmenT
Newly developed UC strawberry cultivars are 
protected in the United States under U.S. plant 
patents administered by the U.S. Patent and 
Trademark Office (PTO). A U.S. plant patent is 
available for asexually propagated plant species 
while plant variety protection certificates, admin-
istered by the U.S. Department of Agriculture 
(USDA), are reserved for the protection of sexual-
ly propagated species. Outside counsel is utilized 
by UC to secure U.S. plant patents for strawberry 
cultivars. 
In ex-U.S. jurisdictions, U.S.-based patent 
counsel directs the prosecution of intellectual 
property in cooperation with ex-U.S. counsel. 
Counsel outside of the United States is often 
identified by the licensee in the respective terri-
CHAPTER 17.26
1.	 InTRoduCTIon	
The strawberry improvement program located 
at University of California, Davis1 focuses on 
breeding cultivars for the California strawberry 
industry. University of California (UC) straw-
berry cultivars are developed for the cool coastal 
Mediterranean and arid subtropical regions of 
California and have become the basis of a global 
Bennett AB and M Carriere. 2007. The University of California’s Strawberry Licensing Program. In Intellectual Property Man-
agement in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). 
MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
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tory. Worldwide, the process of obtaining IP for 
plant cultivars is a specialized area of IP prosecu-
tion and this reduces the pool of capable attorneys 
in a given territory. Additionally, plant-based IP 
is a new legal construct in some territories where 
UC seeks protection for strawberry cultivars. 
These factors complicate the process of identify-
ing competent, cost-effective representation and 
emphasize the importance of in-country licensees 
in selecting legal representation. Ex-U.S. licensees 
are ultimately responsible for bearing the cost of 
IP prosecution in their territory. Since their busi-
ness models depend on strong IP, they are moti-
vated to aid in the search for capable legal repre-
sentation. In some territories outside the United 
States, UC has identified non-attorney plant IP 
specialists, but in most cases it relies on the ser-
vices of registered patent attorneys that also spe-
cialize in plant-based IP.
UPOV-compliant Plant Breeders’ Rights 
(PBR) is the most common form of IP sought 
for UC strawberry cultivars. (The Union for the 
Protection of New Varieties of Plants [UPOV] 
has set forth standards for licensing new plant 
varieties.) Although UC and its licensing part-
ners worldwide seek UPOV-compliant PBR 
for UC strawberry cultivars, such protection is 
unavailable in some territories. As a result, the 
UC licensing program and its master licensees 
are active in expanding the scope of protection 
for plants in some countries worldwide. A suc-
cessful approach has been to build grassroots 
support for plant IP by coupling access to cul-
tivars with availability of IP for those cultivars. 
For example, in China a strawberry industry 
organization successfully lobbied governmental 
authorities to add strawberry to the list of pro-
tectable species. This action was encouraged by 
UC’s licensee for China. With PBR now avail-
able for UC strawberry cultivars in China, the 
Chinese strawberry industry gains access to UC 
cultivars, which leads to rural economic develop-
ment in China, and UC licensing expands into 
the Chinese market. In Egypt, UC strawberry 
cultivars represent Egypt Plant Patent Nos. 1, 2, 
and 3, as a result of aggressively pursuing access 
to the nascent Egyptian plant patent system. In 
Brazil, UC strawberry cultivars are among the 
first protected strawberries under the new system 
of protection.
The decision to file or to engage in expanding 
the scope of IP for a given territory is made joint-
ly between UC and the respective master licensee. 
The primary criterion is the expected value of the 
future licensing revenue stream. UC rarely files 
its strawberry cultivars “at-risk” (that is, without 
a licensee already identified in that jurisdiction). 
Master licensees are required to pay the cost of 




In the United States and Canada, cultivars are li-
censed on a nonexclusive basis directly to plant 
nurseries. Nurseries are licensed the right to prop-
agate plants and to sell the propagated daughter 
plants to fruit growers. Strawberry growers annu-
ally replant fruiting fields, so a royalty is collected 
annually. Royalties are assessed on a per-1,000 
plants (purchased) basis rather than on the basis 
of sales.
Outside of the United States and Canada, the 
UC relies on business partners as an intermediary 
in support of the strawberry licensing program. 
These partners, referred to as master licensees, 
are provided with exclusive rights within a de-
fined territory. The master licensee is granted the 
right to issue nonexclusive sublicense agreements 
to nurseries within the territory. In exchange for 
this exclusive right, the master licensee supports 
IP development and provides enforcement of IP 
rights including access to the local court system, 
as required. Critical responsibilities of the master 
licensee are market development, technical sup-
port, and the transfer of production know-how. 
In addition to being the local eyes and ears of 
UC’s licensing function, the master licensee fa-
cilitates testing and evaluation of promising new 
cultivars. In exchange for the services provided by 
the master licensee, UC agrees to share a percent-
age of collected royalties.
A three-tier royalty structure is utilized. 
Growers of UC cultivars in California currently 
pay, in royalties, US$3.00/1000 plants. Growers 
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in the United States outside of California and 
in Canada pay US$4.50/1000 plants. Outside 
of the United States and Canada growers pay 
US$10.50/1000, a percentage of which is shared 
with the master licensee. In addition to the roy-
alty component described above, a research fee is 
collected to directly support new cultivar develop-
ment. The research fee of US$1.00/1000 plants 
entitles the licensee to a lower royalty rate (rates 
stated above). The licensee receives a US$1.50 re-
duction in royalties for the US$1.00 research fee 
contribution.
The structure of the strawberry licensing pro-
gram is driven in part by UC’s presence as a public 
institution in the state of California. Nurseries and 
fruit growers in California are given preferential 
treatment, in addition to the reduced royalty rates 
for California. California-based nurseries (licens-
ees) are the only nurseries in the worldwide licens-
ing program that have access to all licensed markets. 
The sales territories of non-California nurseries are 
limited to a defined region. After the initial release 
of a new UC strawberry cultivar, its use is restricted 
to California for the first two years. This policy is 
designed to benefit fruit growers in the state who 
are concerned about competition in their own 
markets from UC cultivars grown abroad.
UC strawberry plants are shipped worldwide 
from California nurseries. To facilitate monitor-
ing of worldwide strawberry plant shipments, an 
electronic, Web-based system is currently being 
developed with the goal of providing real-time 
shipping information for UC and its master li-
censees worldwide. Licensed nurseries will elec-
tronically declare sales before shipment. This pre-
shipping electronic notification enables master 
licensees to accept or reject a proposed sale based 
on the intended use of the plant material and 
the licensing status of the recipient. The system 
is expected to reduce the occurrence of out-of-
compliance shipments and provide the supply-
ing nursery with assurance that its shipments are 
consistent with UC licensing policy worldwide.
4.	 InCome	TRendS
For the latest fiscal year, gross annual income for 
the strawberry licensing program was US$4.7 
million. Gross income increased from US$3.4 
million in 2000 due to the combination of a 
rate increase in 2000 and market expansion 
in Europe, North Africa, South America, and 
Mexico. Approximately 45 percent of annual in-
come is generated by California sales. Five percent 
derives from sales in the United States outside of 
California and in Canada. The remaining 50% 
of licensing income is derived from sales outside 
the United States and Canada. The largest non-
U.S. markets, by country, are Spain, Mexico, 
Morocco, and Australia (from largest to small-
est, within this group). In addition to royalty 
income, total research fee collection now totals 
US$650,000 annually and represents the lion’s 
share of funding for the strawberry breeding pro-
gram at UC Davis. This amount contrasts with 
the US$350,000 support from the California 
Strawberry Commission, the second largest con-
tributor to the breeding program.
After 2007, income is expected to increase 
based on a 2006 rate increase and further mar-
ket expansion. Over the next five years, market 
expansion is anticipated in Brazil, Northern 
Europe, China, and Turkey. Additionally, new 
licensing strategies are expected to boost income 
from established markets as master licensees will 
be given the opportunity to price-to-market in the 
high-value territories of the European Union and 
elsewhere. 
The ultimate future of the program is tied to 
the continued development of competitive cul-
tivars. The UC breeding team is highly skilled, 
and funding for the endeavor is stable. As a result, 
the UC breeding and licensing programs are posi-
tioned for success for at least the next 10 years.
5.	 ConCluSIonS
The strawberry licensing program of the University 
of California provides a clear example of how 
intellectual property protection by a public sec-
tor institution enables the global dissemination 
of innovative results by providing an economic 
stimulus to those who adopt the technology. It 
also allows those who benefit most directly from 
the technology to help sustain financially the pro-
gram that serves them.
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welcome.html.
ABSTRACT
In the late 1990s, a consortium of public sector organiza-
tions commercialized the first and still-major food bio-
technology product developed by public sector organiza-
tions. The author represented the Papaya Administrative 
Committee, an organization of papaya growers in Hawaii, 
in obtaining patent licenses necessary for the commercial 
introduction of a disease-resistant transgenic papaya. This 
chapter describes the approach taken in deciding what 
patents needed to be licensed, how the licenses were ob-
tained, and how they were administered.
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required to identify which patent rights needed to 
be licensed, to negotiate and obtain licenses, and 
to help PAC administer the licenses that were ob-
tained. This paper describes how I assisted PAC 
with these tasks and brings to light some practi-
cal considerations relating to the patenting and 
licensing of transgenic plant technology. 
2.		 IdenTIfICATIon	of	pATenT	RIghTS	
ThAT	needed	To	Be	lICenSed
Under 35 U.S.C. § 271, a U.S. patent gives its 
owner the right to prevent others from making, 
using, selling, or offering to sell the subject matter 
of the patent in the United States. The recipient 
of a license of such patent rights has the ability to 
engage in at least some of these activities without 
risking an injunction and/or being held liable for 
damages. PAC wanted to be able to go forward 
quickly with the transgenic papaya without fear 
of such risks. Therefore, my first task was to de-
termine which patent rights needed to be licensed 
by PAC.
The task involved determining which pat-
ents would be infringed by the transgenic pa-
paya technology in the absence of a license. In 
order to proceed, it was first necessary to identify 
which technology was used in making the trans-
genic papaya. Based on the findings, a group of 
patents was identified that potentially needed to 
CHAPTER 17.27
1.		 InTRoduCTIon
In the fall of 1995, I was retained by papaya 
growers in Hawaii to provide legal assistance on 
patent and licensing issues related to a transgenic, 
disease-resistant papaya that had been developed 
for use in Hawaii. Although this technology was 
developed by Dennis Gonsalves while at Cornell 
University along with researchers in Hawaii, my 
client was actually the Papaya Administrative 
Committee (PAC) in Hilo, Hawaii. PAC had been 
created many years earlier under a federal market-
ing order by the U.S. Department of Agriculture 
(USDA) to assist the Hawaiian papaya industry 
in marketing papaya. 
As a result of the devastating effect of papaya 
ringspot virus (PRSV) on the industry, PAC un-
dertook to obtain the patent licenses necessary for 
commercial introduction of the transgenic, dis-
ease-resistant papaya. As PAC’s legal advisor, I was 
Goldman M. 2007. The IP Management of the PRSV-Resistant Papayas Developed by Cornell University and the University 
of Hawaii and Commercialized in Hawaii. In Intellectual Property Management in Health and Agricultural Innovation: A 
Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Avail-
able online at www.ipHandbook.org.
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be licensed. Such identification of candidate pat-
ents often requires conducting an infringement 
search on computer databases and in the U.S. 
Patent and Trademark Office (PTO). In the case 
of transgenic papaya, we also had some guidance 
from industry sources. Once a group of candi-
date patents was identified, I proceeded with the 
legal analysis to determine which of those patents 
would actually be infringed. 
The exclusionary rights afforded by a U.S. 
patent are defined by the claims. Therefore, in an-
alyzing a patent for infringement, it is first neces-
sary to interpret the scope of the patent (in other 
words, the claims of the patent). This involves ex-
amining the literal language of the claims, review-
ing the specification (or the body) of the patent, 
and studying the prosecution history of the cor-
responding patent application (in other words, 
the correspondence to and from the PTO dur-
ing the patent application process). Through this 
analysis, the meaning of the terms in the patent 
claims and, accordingly, the scope of the claims 
as a whole is determined. With this information, 
it can then be decided whether the claims are in-
fringed by the subject technology. A U.S. patent 
can be directly infringed in two ways:
•	 by literal infringement
•	 under the doctrine of equivalents
 
Literal infringement occurs if the language 
of the claims covers, literally, the subject tech-
nology. The absence of literal infringement does 
not, however, mean that infringement is avoided. 
Infringement can occur under the doctrine of 
equivalents if the differences between the subject 
technology and the claimed invention are insub-
stantial. One approach to determining whether 
infringement has occurred under the doctrine 
of equivalents is to analyze whether the subject 
technology and the patented invention do sub-
stantially the same thing in substantially the same 
way to achieve substantially the same results. The 
scope of the doctrine of equivalents is limited 
by what the prior art teaches and by what the 
patentee surrendered during prosecution of the 
patent.
In the context of a patent covering a trans-
genic plant, infringement can occur if a party 
makes, uses, or sells that plant. These actions 
constitute direct infringement (see Figure 1). 
Even if there have been no acts of direct infringe-
ment by a particular party, liability can ensue if 
that party induces or contributes to another’s acts 
of direct infringement.
“Inducing infringement” occurs when one 
party aids and abets the direct infringing acts of 
another. Such liability can occur in the context of 
patents covering a method of making transgenic 
plants disease resistant (Figure 2). Researchers 
who are making such transgenic plants using a 
particular vector would be directly infringing 
such a patent. However, the supplier of this vec-
tor would not be directly infringing but could be 
liable for inducing infringement if the vector is 
provided with instructions to use it in order to 
produce disease-resistant transgenic plants.
“Contributory infringement” occurs when a 
party sells a nonstaple article of commerce which 
has no substantial noninfringing use. In the con-
text of a patent covering a method of making a 
transgenic plant that is disease resistant, a party 
planting seeds for such transgenic plants would 
be a direct infringer. However, a party selling 
seeds for such plants, though not liable for direct 
infringement, would have contributory infringe-
ment liability (Figure 3).
The technology used by Dennis Gonsalves 
and colleagues to develop a transgenic papaya, 
in brief, consisted of the preparation of a vector 
and the introduction of it into papaya by biolistic 
transformation.1 The vector, a map of which is 
shown in Figure 4 was an Agrobacterium-binary 
vector which included the 35S promoter, the 
5’ untranslated leader sequence, the PRSV coat 
protein encoding gene, and the β-glucoronidase 
(GUS) gene. Thus, we needed to consider licens-
ing patent rights relating to various DNA com-
ponents, plant transformation procedures, modes 
of plant disease-resistance mediation, and trans-
genic plants.
With the assistance of Dennis Gonsalves, I 
analyzed the technology utilized in developing 
the transgenic, disease-resistant papaya and deter-
mined which of the candidate patents needed to 
be licensed. It was determined that licenses were 
needed from Company Y for patent rights 
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figure	4:	Agrobacterium	Binary	vector	pgA482gg/cppRv-4
Organization and proteolytic protein products of the 10, 326 base monocistonic PRSV genome. 
(A) Shown in detail, the N-terminal sequence of the coat, the protein (PRSV-CP). Box arrows 
represent the proteolytic sites producing the mature coat protein (CP).(B) Map of the functional 
genes of the Agrobacterium transformation vector pGA482GG/cpPRV-4 used for PRSV-resistant 
papaya. The coat protein gene cassette consists of the coat protein structural gene of PRSV HA 
5-1 translationally fused to the N-terminal end of the cucumber mosaic virus coat protein (CMV-
CP), including the translation initiation codon, the CMV 5’ untranslated sequence (5’ UTR), and 
the Cauliflower Mosaic Virus 35S promoter. The PRSV-CP gene cassette is flanked by selectable 
and visible marker genes, neo (encoding NPTII) and gus, respectively. BR and BL are the left and 
right borders of the transformation vector T-DNA sequence. 
Source: Courtesy Dennis Gonsalves (November 2006).
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relating to various components of the vector 
and the general mode of plant disease resistance. 
From Massachusetts Institute of Technology 
(M.I.T.), PAC decided to license rights to the 5' 
untranslated leader sequence. Company X had 
rights to technology to impart resistance to PRSV 
by use of a gene from the virus. We wanted to 
license that technology. We also wanted rights 
to the GUS gene from Cambia Biosystems LLC 
(Canberra, Australia). For various reasons, we 
decided that licenses were not needed for other 
candidate patents. 
3.		 lICenSe	negoTIATIonS
After identifying which patent rights PAC should 
license, the next job was to obtain the necessary 
licenses. This proved to be a very difficult task be-
cause the parties had different strategic objectives. 
PAC wanted to be able to distribute trans-
genic papaya seed without charging recipients 
and without having to maintain the accounting 
records normally needed for licenses involving a 
royalty on net sales. Therefore, we sought licenses 
involving a one-time, up-front payment. With 
this approach, PAC also wanted to be assured 
that it would receive licenses under any patents 
infringed by the transgenic papaya that issued af-
ter the license agreement was signed. Otherwise, 
PAC would be at risk of having to negotiate a 
new license and making further payments to a 
party that had already granted a license to PAC. 
Another issue was PAC’s financial resources. Since 
PAC’s licensing activities were financed by public 
funds and contributions from its members, many 
of whom were farmers in Hawaii, the licensing 
fees needed to be manageable. While PAC needed 
a substantial level of accommodation from licen-
sors on financial issues, its demands on the scope 
of any grant under a license agreement were mod-
est. In particular, PAC needed to obtain the right 
to grow transgenic papaya plants in Hawaii and 
to sell the resulting fruit worldwide. Finally, since 
PAC did not itself grow or sell papaya, it needed 
to be able to sublicense its rights to constituents, 
including growers. 
All of the licensors were sympathetic to the 
need to introduce a transgenic, disease-resistant 
papaya in Hawaii. However, each had its own 
strategic interests, which needed to be protected. 
Some licensors did not, at that time, have a policy 
of or experience with licensing out, and they were 
reluctant to proceed with setting a corporate-wide 
strategy based on a license for a very small crop. 
Undoubtedly, there was concern over having any 
deal with PAC dictate which terms would have to 
be offered for future licenses on strategically im-
portant crops. Many of the individuals working 
on business development for the licensors were 
very busy and did not have much time to focus 
efforts on a deal for a very small crop with poten-
tially little economic return. Some licensors had 
a tremendous commitment to developing a plant 
biotechnology business and wanted to ensure that 
any licensees of its rights did not jeopardize the 
industry as a whole. Lastly, the licensors needed 
to know that the financial terms of any license 
were fair. Given the relatively low strategic inter-
est a transgenic papaya license had to the licen-
sors, PAC had to engage in an extensive effort to 
educate them about the Hawaiian papaya indus-
try, the impact of PRSV in Hawaii, and the ben-
efit of the transgenic papaya to papaya growers in 
Hawaii. In particular, we tried to gain sympathy 
from the licensors by explaining that the virus had 
devastated the Hawaiian papaya industry and that 
the transgenic papaya needed to be introduced in 
Hawaii to ensure that farmers could maintain 
their livelihood. Our promotional efforts often 
led to questions about PAC’s purpose and mem-
bership. When the licensors saw that large, well-
known fruit packing companies were members of 
PAC, there were usually questions from the licen-
sors about who was being aided by the licenses. 
However, we were able to explain that the true 
beneficiaries of the licenses were growers whose 
farms were being severely hurt by PRSV.
In some cases, sympathy for the plight of 
growers was not sufficient and the licensors need-
ed to be further motivated. The USDA was help-
ful in several instances. Because it is an impor-
tant regulatory agency in the plant biotechnology 
industry, the licensors wanted to remain in the 
USDA’s good graces in order to avoid jeopardiz-
ing regulatory approvals for their own projects. 
Since the USDA created PAC, was already 
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actively involved in the Hawaiian papaya indus-
try, and wanted to see the transgenic, disease-re-
sistant papaya introduced in Hawaii, the agency 
was very willing to help PAC. Without that help, 
a number of the licenses may never have been 
obtained. 
Once we had communicated with the licen-
sors, we were generally able to persuade them to 
prepare a draft license agreement from which li-
cense negotiations could proceed. Although we 
usually prefer to generate the first draft of a li-
cense agreement, doing so tends to be more cost-
ly, and we were trying to limit PAC’s costs for 
the project. In any event, once the initial draft li-
cense agreement was received, we proceeded with 
license negotiations and ultimately were able to 
enter into license agreements with all of the tar-
geted licensees. 
Company X was anxious to put the transgen-
ic papaya on the market as a philanthropic effort 
and was PAC’s first licensor.
Cambia Biosystems LLC is a technology li-
censing company without any particular interest 
in exploiting the GUS gene technology in the 
plant biotechnology industry. They were inter-
ested in helping the Hawaiian papaya industry, 
as long Cambia could be assured of a fair deal, 
from an economic standpoint. Cambia was our 
next licensee.
Company Y was sympathetic to the plight of 
the Hawaiian papaya industry, but as a result of 
the company’s extensive involvement in the trans-
genic plant industry, its strategic interests were the 
most difficult to harmonize. Once the company 
was able to resolve its objectives, it moved enthu-
siastically forward with license negotiations. It re-
garded the license to be negotiated with PAC as a 
prototype for future deals involving outlicensing 
of Company Y technology. Company Y became 
PAC’s third licensor. 
The last license was obtained from M.I.T., 
which had no particular strategic concerns 
about licensing in the plant biotechnology 
industry but was concerned about whether a 
paid-up license provided fair compensation. 
We ultimately were able to develop an arrange-
ment by which M.I.T. could be assured of an 
economically fair deal.
As a result, PAC had obtained the licenses 
it needed to begin growing transgenic papaya in 
Hawaii. Shortly after the last license agreement 
was executed, PAC began distribution of trans-
genic papaya seed to growers. The commercial 
use of this product of biotechnology has had a 
substantial beneficial economic impact on the 
Hawaiian papaya industry.
4.	leSSonS	leARned
There are a number of lessons to be learned from 
the transgenic-papaya licensing effort. These les-
sons, relating to both patent and licensing is-
sues, can benefit researchers, technology trans-
fer professionals, business people, and lawyers. 
Researchers in the transgenic biotechnology area 
should recognize that there are patents covering 
many commonly used genetic components and 
plant transformation procedures. The manufac-
ture, use, sale of, or offer to sell such patented 
materials by researchers without a research license 
is an act of direct patent infringement. Engaging 
in any of these activities would put the research-
ers’ employers at risk of being sued and having to 
pay the patentees’ damages, as well as attorneys’ 
fees. If the researcher were employed at an aca-
demic institution, the prospect of incurring such 
expenses would be daunting. Even if a research 
license were obtained, it would not allow intro-
duction of the product of research into a com-
mercial product. Any effort to do so would be 
an act of patent infringement. In the case of an 
academic institution working with commercial 
entities, the licensing out of technology utilizing 
the patent rights of others, or the transfer of ma-
terials incorporating patented subject matter, also 
raises issues of patent infringement. In particu-
lar, the institution can be deemed to be inducing 
infringement (aiding and abetting the infringing 
acts of another) or engaging in contributory in-
fringement (selling or offering to sell a material 
having no substantial use other than in conjunc-
tion with a patented process). To avoid these is-
sues, researchers should use unpatented or easily 
licensed technology wherever possible.
On the other hand, developers of technol-
ogy wishing to enhance their licensing royalties 
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and their leverage over competitors may wish to 
make their technology freely available once the 
necessary patent applications have been filed. 
The widespread use of such technology can lead 
to its adoption as an industry standard for which 
substantial licensing revenue can be derived. 
Moreover, the use of a company’s patented tech-
nology in the commercial product of a competi-
tor can give the company significant leverage over 
the competitor in accessing technology owned by 
the competitor, in maximizing royalty payments 
from the competitor, and in preventing the com-
petitor from introducing an important commer-
cial product. 
In licensing patent rights from others, it is 
important to examine what the various patents 
you are considering would actually cover. In the 
transgenic plant industry, there is a great deal of 
“street talk” about patents and what they purport 
to cover. Reliance on “scuttlebutt” could result in 
the procurement of and payment for licenses on 
patent rights that are not needed. On the other 
hand, failure to obtain all the necessary licenses 
raises the threat of an injunction, of liability for 
damages, and of the costs of litigation. A careful 
analysis of the patent landscape is well worth the 
expense. Entities licensing technology on behalf 
of others need to properly control how it makes 
the technology available. In the case of PAC, 
it has made transgenic papaya seed available to 
growers only after they attend an educational 
program and sign a material transfer/sublicense 
agreement with PAC. Likewise, researchers wish-
ing to obtain transgenic papaya seed from PAC 
are required to sign a material transfer/research 
sublicense agreement with PAC. These measures 
were undertaken to ensure that growers and re-
searchers understood the obligations pursuant to 
the license agreements and complied with those 
obligations.
5.		 ConCluSIon
The above events may not be of great economic 
significance to global agriculture. However, as 
one of the first efforts to develop a transgenic 
fruit crop, procure the necessary licenses, and in-
troduce a product into commerce, Hawaii’s trans-
genic papaya story is certainly an important event 
for the plant biotechnology industry. The success-
ful results achieved by PAC may well serve as a 
model for future transgenic plant technology. ■
mIChael l. Goldman, Partner, Nixon Peabody LLP. 
Corner of Clinton Ave. and Broad Street, PO Box 
31051, Clinton Square, Rochester, NY, 14603, U.S.A., 
mgoldman@nixonpeabody.com 
  1 See Ling K, S Namba, C Gonsalves, JL Slightom and 
D Gonsalves. 1991. Protection Against Detrimental 
Effects of Potyvirus Infection in Transgenic Tobacco 
Plants Expressing the Papaya Ringspot Virus Coat 
Protein Gene. Bio/Technology 9:752–758. See also Fitch 
M, RM Manshardt, D Gonsalves, JL Slightom and JC 
Sanford. 1992. Virus Resistant Papaya Plants Derived 
from Tissues Bombarded with the Coat Protein Gene of 
Papaya Ringspot Virus. Bio/Technology 10:1466–1472.
ABSTRACT
Fundación Chile is a private, non-profit organization ac-
tive in developing applications of biotechnology that can 
improve productivity and add value to existing agricul-
tural and natural resource products of Chile. Fundación 
Chile seeks to create technology-based companies that 
would have significant economic and social impact in 
Chile. This case study details Fundación Chile’s initiative 
in grape biotechnology: globally assessing the availability 
and priority of different technological components and 
initiating efforts to access, license, and transfer those key 
technologies for the initiative.
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Fundación Chile is unusual in that it is a 
non-profit institution with active participation 
in the creation of innovative private companies 
and involvement in a wide range of activities rel-
evant to different stages in the development of 
new businesses. These activities include technol-
ogy services, R&D, creation and incubation of 
companies, seed capital, scale-up, and financial 
innovation. 
Fundación Chile’s activities are focused on 
increasing the volume and value derived from 
Chilean production of products that can be ex-
ported or can replace imports, but possibilities are 
also considered for production in other countries.
1.1	 Fundación	Chile	and	biotechnology
Since 1997 Fundación Chile has been active in de-
veloping applications of biotechnology that can 
improve productivity, add value to existing prod-
ucts, and promote introduction of new products 
in its business areas. Biotechnology activities are 
mainly focused in forestry, fruit, and aquaculture, 
with an increasing emphasis on quality and uti-
lization. Biotechnologies used include recombi-
nant proteins, tissue culture, molecular genetics, 
functional genomics, and genetic engineering.
Strategic alliances in biotechnology in the 
private sector include 




Fundación Chile1 is a private non-profit orga-
nization. Its mission is to add economic value 
to Chile’s products and services by promoting 
innovation and technology transfer focused on 
Chile’s natural resources and productive capac-
ity. Fundación Chile’s primary strategy is to de-
velop new technology-based companies in Chile 
that can have a significant economic and social 
impact. These new companies are generally joint 
ventures with strategic partners, although other 
models, such as licensing, are used.
The main activities are focused in the ar-
eas of Agribusiness, Marine Resources, Forestry 
and Forest Products, Environment, Information 
Technology, Education and Human Resources, 
and Tourism. 
Fernandez C. 2007. Fundación Chile: Technology Transfer for Somatic Embryogenesis of Grapes. In Intellectual Property 
Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et 
al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
© 2007. C Fernandez. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
Fundación Chile: Technology Transfer 
for Somatic Embryogenesis of Grapes
Carlos fernandeZ, Director, Strategic Studies, Foundation for Agriculture Innovation (FIA),Chile
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•	 a JV in grape biotechnology with Interlink 
Associates LLC (Princeton, USA)
•	 an R&D collaboration in stone fruit bio-
technology with Okanagan Biotechnology 
Inc. (Summerland, Canada) 
•	 a strategic alliance in forestry biotechnol-
ogy with CellFor Inc. (Canada)
Fundación Chile seeks to establish strong 
Intellectual Property (IP) positions through the 
licensing of key existing IP and the development 
of new IP in areas of specific strategic importance 
in Chile in which it participates in R&D 
Fundación Chile’s biotechnology activities 
involve an extensive network of Chilean and 
foreign research centers and universities, as well 
as participation in key international consortia. 
Collaborators in biotechnology R&D in Chile 
include 
• Fundación Ciencias para la Vida
•	 the Chilean National Institute for 
Agricultural Research
•	 the University of Chile
•	 the University of Concepción
•	 the University of Santiago
•	 the University of Talca
•	 University Federico Santa Maria
•	 Andres Bello University
•	 Austral University
Alliances with foreign research centers and 
universities include 
•	 the University of California
•	 Cornell University
•	 the University of Florida
•	 the United States Department of Agriculture
•	 New Zealand HortResearch
•	 New Zealand Forest Research 
Fundación Chile is a member of PIPRA 
(Public Intellectual Property Resource for 
Agriculture) and the California Institute of Food 
and Agricultural Research, and it is a participant 
in the ALCUE-Food Specific Support Action 
funded by the 6th European Framework.
By establishing these networks, Fundación 
Chile has been able to participate in the develop-
ment of new product candidates over a relatively 
short time frame. A recombinant protein vac-
cine for salmon developed in a collaboration of 
Fundación Chile and Fundacion Ciencias para 
la Vida has been licensed to Syngenta and is be-
ing introduced into the market. Elite clones of 
radiata pine developed through somatic embryo-
genesis in collaboration with CellFor are in ad-
vanced stages of testing and are being scaled up 
for market introduction by a Fundación Chile 
company, GenFor. Other biotechnology pro-
grams of Fundación Chile, including the genetic 
engineering of grape varieties, peaches, and pine 





Agricultural biotechnology R&D programs are 
long-term, expensive and controversial; it is es-
sential that the institution is committed to the 
process. In the late 1990s Fundación Chile made 
a strategic decision to invest in development of 
biotechnology applications in strategic sectors of 
the Chilean economy: forestry, agriculture, and 
aquaculture. Genetic engineering was clearly a 
key technology with a large potential impact, as 
demonstrated by the rapid adoption of geneti-
cally engineered varieties of maize, soybeans, and 
cotton in some parts of the world. However, these 
crops play a relatively minor role in Chile. Little 
effort was being expended anywhere in the world 
in perennial crop species, such table grapes, which 
make up an important part of Chilean exports, 




Typically, three different types of technological 
components are needed for development of a ge-
netically engineered plant product:
•	 Germplasm that provides a competitive ge-
netic background
•	 Specific genes that confer new traits of 
interest
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•	 Enabling tools such as genetic markers, 
promoters, tissue culture and regeneration 
systems, and transformation methods
In addition, human resources, laboratory 
infrastructure, and financing are needed to carry 
out the R&D to adapt and combine these com-
ponents to produce a product.
Laboratory infrastructure existed in Chile, 
but improvements were needed. There were ca-
pable researchers in Chile, but a limited number. 
Research efforts were spread over many different 
objectives, and sustained support for a specific 
program was rare.
In the case of grapes, the foundational tech-
nologies were not available in the local R&D in-
stitutions at the start of the program, except, to a 
limited degree, germplasm. A global search led to 
the identification of sources of technologies and 
expertise. The availability of different components 
and priority for access were assessed, and efforts 
were initiated to access, license, and transfer key 
components.
2.3	 IP	and	freedom	to	operate
The IP and freedom-to-operate issues were com-
plex, due to the need to address the situations 
both in Chile and in major export markets, the 
long and uncertain time frames for development 
and commercialization of genetically engineered 
perennial fruit crops, and the concentration of 
rights to core technologies in companies with 
little or no interest in “orphan crops.” A complete 
solution was not possible in the short term with 
the resources available. However, it was possible 
to establish a position in key technologies that 
maximized the likelihood of being competitive in 
a specific niche.
Based on our experience, a critical aspect was 
the active involvement of personnel with experi-
ence in commercial R&D programs and major 
agribiotech research centers in other countries, 
and experience in licensing agricultural biotech-
nologies. Practices vary from country to country 
and institution to institution within a country. At 
the time of the initiation of the program there 
was little experience in Chile with patenting 
and licensing of technology developed in public 
research institutions. The ability of partners with 
international experience to provide appropriate 
examples drawn from a variety of sources played 
an important role in bridging gaps in experience 
and expectations.
The description of our experiences below 
will, we hope, assist others in similar situations 
to make significant progress towards obtaining 
components needed to develop a biotechnol-
ogy program appropriate for the development of 





At the time the program was initiated there were 
only a few published reports of transformation of 
Vitis vinifera. In order to be able to obtain R&D 
funding from public and private sources, and to 
be considered seriously as a potential licensee by 
technology providers, it was considered critical to 
demonstrate the ability to reproducibly transform 
the target species. 
For many transformation systems, an impor-
tant factor is the availability of a robust tissue cul-
ture system that makes it possible to regenerate 
plants efficiently. In our experience, tissue culture 
systems involve considerable art and are often 
difficult to reproduce in other laboratories. Thus, 
establishment of a strong position in grape tissue 
culture was selected as the highest initial priority. 
The process and progress in this area are discussed 
below. 
The second priority was access to specific 
gene candidates for engineering a trait of com-
mercial interest in the Chilean market. This was 
carried out in parallel in order to ensure that the 
tissue culture and transformation platform devel-
oped could be applied to production of proto-




The search used different and complementary 
channels, including reviews of research publica-
tions, project databases, conference proceedings, 
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patents and patent applications, news items, and 
personal contacts. All of them are relevant and 
provide useful information. 
Access to many of these sources has been fa-
cilitated by the rapid improvement of the Internet, 
in terms of content and ease of access. Even for 
people without good Internet access, the avail-
ability of high-quality documents in electronic 
form has greatly reduced the cost of access.
Open sites such as PubMed (www.ncbi.nlm.
nih.gov) and HighWire Press (highwire.stanford.
edu) provide convenient access not only to bib-
liographic information, but to many full papers. 
An increasing number of full papers are available 
at no charge, and most others can be downloaded 
for a fee from sites of journal publishers or spe-
cialized clearing houses. 
Online databases such as those at the the 
World Intellectual Property Office (www.wipo.int/
ipdl), the European Patent Office (www.espacenet.
com), the United States Patent and Trademark 
Office (www.uspto.gov), and many other national 
patent offices provide increasingly convenient ac-
cess to issued patents and published applications.
Less widely appreciated, but valuable due to 
their more specialized content, are online data-
bases of research projects. These often include 
information that is otherwise difficult or impos-
sible to find. Examples include the European 
Union Community Research & Development 
Information Service (cordis.europa.eu), the 
Current Research Information System of the 
USDA (cris.csrees.usda.gov), the FAO-BioDeC 
database of biotechnology projects in develop-
ing countries (www.fao.org/BIOTECH), and the 
RedBio (Red de Cooperación Técnica en Biotecnología 
Vegetal para America Latina y el Caribe) database 
of biotechnology activities by member country 
(www.redbio.org). In Chile the web sites of the 
major funding agencies for R&D—CONICYT 
(www.conicyt.cl), CORFO (www.corfo.cl), and 
FIA (www.fia.cl)—include databases of projects. 
Many research institutions provide databases of 
internal research activities and funded projects, 
which may be useful once specific institutions of 
interest have been identified.
Advanced Internet search sites such as 
Google™ have changed the way that most people 
think about Internet searching. Today it is often 
an easy way to get started. It is important to re-
member that searches conducted on such sites 
generally do not access information stored in spe-
cialized databases such as those described above.
All of the above are useful in the identifica-
tion of potential technology providers, collabo-
rators and competitors. However, direct contacts 
are critical early in the process to validate the in-
formation and to establish a foundation for future 
relationships. It is important to establish contacts 
both at the level of the researcher/inventor and at 
the level of the institution.
2.6	 Negotiation	of	a	research	and	
option	agreement
Once the identification of the laboratory or in-
stitution has been made, documents are typically 
exchanged via electronic mail. Most large private 
companies and universities have standard forms 
that are adapted to the specific needs of a given 
project. Typical research agreements include the 
following information: 
•	 Date and identification of the parties
•	 Definitions of terms
•	 Reports and conferences for proper follow- 
up of activities
•	 Costs, payments and other support 
•	 Publications
•	 Intellectual property
•	 Grant of rights
•	 Confidentiality and publicity
•	 Term and termination
•	 Insurance and indemnification




•	 Counterparts and headings
It is important to emphasize that this stan-
dard approach was designed for the United States. 
Intellectual property laws vary among countries, 
so it is important that the contents of any agree-
ment are reviewed by a local attorney knowledge-
able in intellectual property matters. 
Most universities in the United States, and 
many other public research institutions, will 
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require that the public institution be able to con-
tinue to use the technology for research and edu-
cation purposes even if exclusive rights for com-
mercial use are granted.
Our general approach has been to negotiate 
agreements that provide rights to use technologies 
for R&D and an option for a commercial license. 
We want to avoid a situation where resources 
are invested in research if the results cannot be 
commercialized. Due to the high degree of un-
certainty in development and commercialization 
of agribiotech products, we also want to avoid 
paying for rights that in the end will not be used. 
In agreements for access to technology we have 
generally tried to structure compensation in ways 
that reduces the up-front cost in favor of shar-
ing of benefits realized from commercialization of 
products. This is important for making effective 
use of the resources available, but more impor-
tantly, helps to align the interests of the technol-
ogy provider with our interests. The agreements 
typically contain modest up-front payments, 
milestone payments based on successful transfer 
of the technology, additional milestone payments 
if a commercial license is entered into and a prod-
uct is introduced into the market, and royalties 
based on revenue derived from commercializa-
tion of products produced using the technology.
In the case of grape tissue culture, the in-
stitution in which the technology had been de-
veloped already had agreements with a private 
company. Thus, we initially had to negotiate an 
agreement with the third party. Changes in the 
scope of activities of the company later led to a 
return of rights to the university and additional 
negotiations with the university. Similar events 
have affected other agreements related to the 
project. Thus, it is important to recognize that 
management of these agreements is a dynamic 
process.
2.7	 Material	Transfer	Agreements	(MTA)
In addition to intellectual property, the transfer 
of technology in agricultural biotechnology often 
requires or is facilitated by the transfer of ma-
terials. Terms for the use of the materials, their 
disposal, etc., are generally covered by a material 
transfer agreement (MTA). 
In countries with limited innovation, lawyers 
have not been exposed or do not have enough ex-
perience on matters related to MTAs. If this is 
the case, the practical approach was to use as a 
reference form prepared by the technology trans-
fer offices of universities in the United States and 
other countries with experience on these matters. 
Some of these offices have sample forms posted 
on their Web site.2
An MTA typically includes the following 
information: 
•	 Date 
•	 Identification of the provider and recipient
•	 Definition of the material 
•	 Agreement to be bound by the laws of a 
specific, legal district
•	 Recipients agreement to the defined uses 
and conditions, such as compliance with 
local laws and regulations regarding the use 
of the material, limits on individuals with 
access to the material, limits on import/ex-
port of the material
•	 Conditions of ownership in case of 
derivatives
•	 Conditions of exclusivity or non-exclusiv-
ity, commercial or non-commercial use, 
and disposal of the material
•	 Experimental nature of the material, and 
no warranty expressed
•	 Terms if borrower intends commercializa-
tion of the material or derivatives
•	 Terms if borrower intends to publish results 
or deliver a presentation
•	 Reporting of observations and results and 
conditions of use of such information
•	 Material physical integrity and 
recordkeeping
•	 Conditions for termination
•	 Signatures and agreement to execute the 
agreement
The MTA should be carefully reviewed. In 
the past, investigators have sometimes accepted 
terms that have had critical effects on the value 
of the R&D they conducted, particularly terms 
regarding reporting requirements and right of the 
provider to use information generated by the re-
cipient. It is also critical to consider whether the 
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material provided incorporates material or tech-
nology owned by third parties. If so, it is advis-
able to request clarification of any restrictions 
that may be “inherited” with the material.
2.8	 Importation	of	materials	
Each country has its own regulations regarding 
the importation of biological materials. In Chile, 
there are forms and procedures that must be fol-
lowed. Samples of tissue cultures of grapes were 
imported following these procedures without 
major obstacles, although significant time and 
resources were required. 
2.9	 Exchange	of	professionals	
between	laboratories
Good communication between the parties is es-
sential for a successful outcome. For transfer of 
some technologies, the exchange of written infor-
mation and materials, supplemented by commu-
nication via phone calls and e-mail may be suffi-
cient. However, in many cases, successful transfer 
is greatly facilitated by the active participation of 
investigators from the provider and recipient lab-
oratories in activities in both laboratories. In the 
case of the grape tissue culture system, a Chilean 
investigator first spent time in the laboratory of 
the inventor to get hands-on experience with 
the procedures, and then returned to set up the 
system locally. Several months later, the inventor 
came to Chile and spent a full week working side 
by side with the local investigators, reinforcing 
the training and providing an opportunity to re-
solve issues that had arisen during the implemen-
tation. Some time later, the project leader visited 
the inventor’s laboratory to observe procedures 
there, with the accumulated experiences in Chile 
providing a foundation for increased “receptiv-
ity.” At the end of each exchange, written reports 
were prepared, disseminated, and discussed.
3.	 ConCluSIonS
Currently the lab in Chile has been able to master 
grape embryogenic tissue culture and regenera-
tion techniques and apply them to genetic engi-
neering. Transformation of these tissue cultures 
has allowed the production of thousands of trans-
formed grape lines, from which promising lines 
have been advanced to the field for additional 
testing. ■
Carlos fernandeZ, Director, Strategic Studies, Foundation 
for Agriculture Innovation (FIA), Loreley 1582, La Reina, 
Santiago, Chile. carlos.fernandez@fia.gob.cl 
1 See, also in this Handbook, Chapter 17.2 by C Fernandez 
and MR Moynihan.
2 See, for example, F. H. Erbisch. 2005. Basic Workbook 
in Intellectual Property Management. Michigan State 
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MIHR/PIPRA. 2007. Sample Agreements. In Intellectual Property Management in Health and Agricultural Innovation: A 
Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Avail-
able online at www.ipHandbook.org.
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APPENDIX
This section shares several sample agreements for illustration:
1. Co-Development Agreement ............................................................................1855
2. Public Sector Technology License ......................................................................1865
3. Public Sector Patent License (Medical Research Center of South Africa) ...........1877
4. Plant Variety and Trademark License .................................................................1893
5. Intellectual Property and Trademark License (Stanford University, U.S.A.) .......1903
6. Distributorship Agreement................................................................................1921
We selected the above for illustration because they expand on or complement those that have been 
discussed or provided in the Handbook chapters, or because they explain in greater depth certain types 
of clauses and provisions (for example, due diligence provisions in the MRC sample license no. 3), or 
because they contain clauses and provisions that might help to illustrate the various licensing principles 
discussed in the chapters (for example, licensing terms related to field of use). 
The agreements given here are also available on the online version of the Handbook (www.ipH-
andbook.org) together with sample agreements from different institutions from countries around the 
world. They are downloadable in Microsoft® Word or Adobe® PDF formats. Among others, the online 
version’s agreements include confidentiality, material transfer (for germplasm, biological resources, ma-
terials for testing, research tools, and experimental animals), IP licenses for copyright, software, trade-
marks, trade secrets, and various forms of exclusive, co-exclusive, and nonexclusive licenses. Documents 
such as the Model Provisions for an Equitable Access and Neglected Disease License (developed by a 
working group at Yale University and convened by Universities Allied for Essential Medicines) are also 
included online. Other chapters in this Handbook contain sample agreements of nonasserts, invention 
disclosures, licensing checklists, and more. Please refer to the index at the back of this Handbook for a 
list of agreements.
Editor’s Note
None of these template or sample agreements should be considered as a “correct” agreement. 
They are provided solely as a reference resource intended for illustrative and educational pur-
poses only. They may be used as a starting point for discussions, but any organization will benefit 
from developing its own template agreements, since these place the regularly required major ele-
ments within the institution’s context and needs. In any case, the institution’s counsel should always 








(To be used in circumstances where PSRC and a party, ABC, are agreeing 
to a research program primarily to be carried out in the laboratories of ABC)
1.0	 Introduction
This Co-development Agreement (“Agreement”) between ABC Company (“ABC”) and the Public 
Sector Research Centre (“PSRC”) will be effective when signed by all Parties. The research and 
development activities that will be undertaken by each of the Parties in the course of this 
Agreement are detailed in the Research Plan (“RP”), which is included as Appendix A. The funding 
and staffing commitments of the Parties are set forth in Appendix B. Any exceptions or changes 
to the Agreement are set forth in Appendix C.
2.0	 definitions
As	used	in	this	Agreement,	the	following	terms	shall	have	the	meanings	provided	hearein:
2.1 Invention means any invention or discovery that is or may be patentable.
2.2 Principal	Investigator(s) or PIs	means the person(s) designated respectively by the Parties to 
this Agreement that will be responsible for the scientific and technical conduct of the RP.
2.3 Proprietary/Confidential	 Information means confidential scientific, business, or financial 
information provided that such information does not include:
2.3.1 information that is publicly known or available from other sources that are not under a 
confidentiality obligation to the source of the information
2.3.2 information that has been made available by its owners to others without a confidentiality 
obligation 
2.3.3 information that is already known by or available to the receiving Party without a 
confidentiality obligation
2.3.4 information that relates to potential hazards or cautionary warnings associated with the 
production, handling, or use of the subject matter of the Research Plan of this Agreement
2.4 Research	License shall mean a nontransferable, nonexclusive license under any Intellectual 
Property (IP) license to make and use a licensed invention for purposes of research and not 
for purposes of commercial manufacture or distribution or in lieu of purchase. 
2.5 Research	Materials means all tangible materials other than Subject Data first produced in 
the performance of this Agreement.
2.6 Research	Plan or RP means the statement in Appendix A of the respective research and 
development commitments of the Parties to this Agreement.
Source: Mahoney RT (ed.). 2004. Handbook of Best Practices for Management of Intellectual Property in 
Health Research and Development. MIHR: Oxford, U.K. Reproduced with permission.
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2.7 Subject	Invention means any Invention of the Parties, conceived or first actually reduced to 
practice in the performance of the Research Plan of this Agreement. 
2.8 Subject	Data means all recorded information first produced in the performance of this 
Agreement by the Parties.
3.0	 Cooperative	Research
3.1 principal	Investigators. ABC research work under this Agreement will be performed by the 
ABC laboratory identified in the RP, and the ABC PI designated in the RP will be responsible 
for the scientific and technical conduct of this project on behalf of ABC. Also designated in 
the RP is the PSRC PI who will be responsible for the scientific and technical conduct of this 
project on behalf of the PSRC.
3.2 Research	plan	Change. The RP may be modified by mutual written consent of the Principal 
Investigators. Substantial changes in the scope of the RP will be treated as amendments 
under Article 13.5.
4.0	 Reports
4.1 Interim	Reports. The Parties shall exchange formal written interim progress reports on a 
schedule agreed to by the PIs, but at least within twelve (12) months after this Agreement 
becomes effective and at least within every twelve (12) months thereafter. Such reports 
shall set forth the technical progress made, identifying such problems as may have 
been encountered and establishing goals and objectives requiring further effort, any 
modifications to the Research Plan pursuant to Article 3.2, and all Agreement-related 
patent applications filed.
4.2 final	Reports. The Parties shall exchange final reports of their results within four (4) months 
after completing the projects described in the RP or after the expiration or termination of 
this Agreement.
5.0	 financial	and	Staffing	obligations
5.1 ABC	and	pSRC	Contributions. The contributions of the Parties, including payment schedules, 
if applicable, are set forth in Appendix B. ABC shall not be obligated to perform any of 
the research specified herein or to take any other action required by this Agreement, if 
the funding is not provided as set forth in Appendix B. ABC shall return excess funds to 
PSRC when it sends its final fiscal report pursuant to Article 5.2, except for staffing support 
pursuant to Article 10.3. 
5.2 Accounting	Records. ABC shall maintain separate and distinct current accounts, records, 
and other evidence supporting all its obligations under this Agreement, and shall provide 
the PSRC a final fiscal report pursuant to Article 4.2.
5.3 Capital	equipment. Equipment purchased by ABC with funds provided by the PSRC shall be 
the property of ABC. All capital equipment provided under this Agreement by one party for 
the use of another Party remains the property of the providing Party unless other disposition 
is mutually agreed upon in writing by the Parties. If title to this equipment remains with 
the providing Party, that Party is responsible for maintenance of the equipment and the 
costs of its transportation to and from the site where it will be used.
Co-development	Agreement
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6.0	 Intellectual	property	Rights	and	patent	Applications
6.1 Reporting. The Parties shall promptly report to each other in writing each Subject Invention 
resulting from the research conducted under this Agreement that is reported to them by 
their respective employees. Each Party shall report all Subject Inventions to the other Party 
in sufficient detail to determine inventorship. Such reports shall be treated as Proprietary/
Confidential Information in accordance with Article 8.4.
6.2 pSRC	employee	Inventions. If the PSRC does not elect to retain its IP rights, PSRC shall offer 
to assign these IP rights to the Subject Invention to ABC pursuant to Article 6.5. If ABC 
declines such assignment, the PSRC may release its IP rights as it may determine.
6.3 ABC	 employee	 Inventions. ABC may elect to retain IP rights to each Subject Invention 
made solely by ABC employees. If ABC does not elect to retain IP rights, ABC shall offer to 
assign these IP rights to such Subject Invention to PSRC pursuant to Article 6.5. 
6.4 joint	Inventions. Each Subject Invention made jointly by ABC and PSRC employees shall 
be jointly owned by ABC and PSRC. PSRC may elect to file the joint patent or other IP 
application(s) thereon and shall notify ABC promptly upon making this election. If PSRC 
decides to file such applications, it shall do so in a timely manner and at its own expense. 
If PSRC does not elect to file such application(s), ABC shall have the right to file the joint 
application(s) in a timely manner and at its own expense. If either Party decides not to 
retain its IP rights to a jointly owned Subject Invention, it shall offer to assign such rights 
to the other Party pursuant to Article 6.5. If the other Party declines such assignment, the 
offering Party may release its IP rights as provided in Articles 6.2 and 6.3.
6.5 filing	of	patent	Applications. With respect to Subject Inventions made by PSRC as described 
in Article 6.2, or by ABC as described in Article 6.3, a Party exercising its right to elect to 
retain IP rights to a Subject Invention agrees to file patent or other IP applications in a 
timely manner and at its own expense and after consultation with the other Party. The 
Party may elect not to file a patent or other IP application thereon in any particular country 
or countries provided it so advises the other Party ninety (90) days prior to the expiration 
of any applicable filing deadline, priority period or statutory bar date, and hereby agrees to 
assign its IP right, title, and interest, in such country or countries, to the Subject Invention 
to the other Party and to cooperate in the preparation and filing of a patent or other IP 
applications. In any countries in which title to patent or other IP rights is transferred to 
PSRC, PSRC agrees that ABC inventors will share in any royalty distribution that PSRC pays 
to its own inventors.
6.6 patent	expenses. The expenses attendant to the filing of patent or other IP applications 
generally shall be paid by the Party filing such application. If an exclusive license to any 
Subject Invention is granted to PSRC, PSRC shall be responsible for all past and future out-of-
pocket expenses in connection with the preparation, filing, prosecution and maintenance 
of any applications claiming such exclusively licensed inventions and any patents or 
other IP grants that may issue on such applications. PSRC may waive its exclusive license 
rights on any application, patent or other IP grant, at any time, and incur no subsequent 
compensation obligation for that application, patent, or IP grant.
6.7 prosecution	of	 Intellectual	property	Applications. Within one month of receipt or filing, 
each Party shall provide the other Party with copies of the applications and all documents 
received from or filed with the relevant patent or other IP office in connection with the 
prosecution of such applications. Each Party shall also provide the other Party with the 
power to inspect and make copies of all documents retained in the patent or other IP 
APPENDIX
1858 | HANDBOOK OF BEST PRACTICES
application files by the applicable patent or other IP office. Where licensing is contemplated 
by PSRC, the Parties agree to consult with each other with respect to the prosecution of 
applications for ABC Subject Inventions described in Article 6.3 and joint Subject Inventions 
described in Article 6.4. If PSRC elects to file and prosecute IP applications on joint Subject 
Inventions pursuant to Article 6.4, ABC will be granted an associate power of attorney (or 
its equivalent) on such IP applications.
7.0	 licensing
7.1 option	 for	 Commercialization	 license. With respect to ABC’s IP rights to any Subject 
Invention not made solely by the PSRC’s employees for which a patent or other IP application 
is filed, ABC hereby grants to the PSRC an option to elect an exclusive or nonexclusive 
commercialization license. The terms of the license will fairly reflect the nature of the 
invention, the relative contributions of the Parties to the invention and the Agreement, the 
risks incurred by the PSRC, and the costs of subsequent research and development needed 
to bring the invention to the marketplace.
7.2 exercise	of	license	option. The option of Article 7.1 must be exercised by written notice 
mailed within three (3) months after PSRC receives written notice that the patent or other 
IP application is filed. Exercise of this option by the PSRC initiates a negotiation period 
that expires nine (9) months after the patent or other IP application filing date. If the last 
proposal by the PSRC has not been responded to in writing by ABC within this nine-month 
(9) period, the negotiation period shall be extended to expire one (1) month after ABC so 
responds, during which month the PSRC may accept in writing the final license proposal of 
ABC. In the absence of such acceptance, ABC will be free to license such IP rights to others. 
In the event that the PSRC elects the option for an exclusive license, but no such license is 
executed during the negotiation period, ABC agrees not to make an offer for an exclusive 
license on more favorable terms to a third party for a period of six (6) months without first 
offering PSRC those more favorable terms.
7.3 joint	Inventions	not	exclusively	licensed. In the event that the PSRC does not acquire an 
exclusive commercialization license to IP rights in all fields in joint Subject Inventions 
described in Article 6.4, then each Party shall have the right to use the joint Subject 
Invention and to license its use to others in all fields not exclusively licensed to PSRC. The 
Parties may agree to a joint licensing approach for such IP rights.
8.0	 proprietary	Rights	and	publication
8.1 Right	of	Access. ABC and PSRC agree to exchange all Subject Data produced in the course 
of research under this Agreement, whether developed solely by ABC or jointly with 
PSRC. Research Materials will be shared equally by the Parties to the Agreement unless 
other disposition is agreed to by the Parties. All Parties to this Agreement will be free to 
utilize Subject Data and Research Materials for their own purposes, consistent with their 
obligations under this Agreement.
8.2 ownership	of	Subject	data	and	Research	materials. Subject to the sharing requirements of 
Paragraph 8.1 and the regulatory filing requirements of Paragraph 8.3, the producing Party 
will retain ownership of and title to all Subject Inventions, all Subject Data and all Research 
Materials produced solely by their investigators. Jointly developed Subject Inventions, 
Subject Data and Research Materials will be jointly owned. 
Co-development	Agreement
APPENDIX 
 HANDBOOK OF BEST PRACTICES  | 1859 
Co-development	Agreement
8.3 dissemination	of	Subject	data	and	Research	materials. To the extent allowed under law, 
PSRC and ABC agree to use reasonable efforts to keep Subject Data and Research Materials 
confidential until published or until corresponding patent applications are filed. Any 
information that would identify human subjects of research or patients will always be 
maintained confidentially. PSRC shall have the exclusive right to use any and all Agreement 
Subject Data in and for any regulatory filing by or on behalf of PSRC, except that ABC shall 
have the exclusive right to use Subject Data for that purpose, and authorize others to do 
so, if the Agreement is terminated or if PSRC abandons its commercialization efforts.
8.4 proprietary/Confidential	Information. Each Party agrees to limit its disclosure of Proprietary/
Confidential Information to the amount necessary to carry out the Research Plan of this 
Agreement, and shall place a confidentiality notice on all such information. Confidential 
oral communications shall be reduced to writing within 30 days by the disclosing Party. 
Each Party receiving Proprietary/Confidential Information agrees that any information so 
designated shall be used by it only for the purposes described in the attached Research 
Plan. Any Party may object to the designation of information as Proprietary/Confidential 
Information by another Party and may decline to accept such information. Subject Data 
and Research Materials developed solely by PSRC may be designated as Proprietary/
Confidential Information when they are wholly separable from the Subject Data and 
Research Materials developed jointly with ABC investigators and advance designation of 
such data and material categories is set forth in the RP. The exchange of other confidential 
information, for example, patient-identifying data, should be similarly limited and treated. 
Jointly developed Subject Data and Research Material derived from the Research Plan may 
be disclosed by PSRC to a third party under a confidentiality agreement for the purpose of 
possible sublicensing pursuant to the Licensing Agreement and subject to Article 8.7.
8.5 protection	of	proprietary/Confidential	Information. Proprietary/Confidential Information 
shall not be disclosed, copied, reproduced, or otherwise made available to any other person 
or entity without the consent of the owning Party. Each Party agrees to use its best efforts 
to maintain the confidentiality of Proprietary/Confidential Information.
8.6 duration	 of	 Confidentiality	 obligation. The obligation to maintain the confidentiality 
of Proprietary/Confidential Information shall expire at the earlier of the date when the 
information is no longer Proprietary Information as defined in Article 2.3 or three (3) years 
after the expiration or termination date of this Agreement. PSRC may request an extension 
to this term when necessary to protect Proprietary/Confidential Information relating to 
products not yet commercialized.
8.7 publication. The Parties are encouraged to make publicly available the results of their 
research. Before either Party submits a paper or abstract for publication or otherwise 
intends to publicly disclose information about a Subject Invention, Subject Data, or 
Research Materials, the other Party shall be provided thirty (30) days to review the proposed 
publication or disclosure to ensure that Proprietary/Confidential Information is protected. 
The publication or other disclosure shall be delayed for up to thirty (30) additional days 
upon written request by any Party as necessary to preserve patent or other IP rights.
9.0	 Representations	and	warranties
9.1 Representations	and	warranties	of	ABC. ABC hereby represents and warrants to PSRC that 
the official signing this Agreement has authority to do so.
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9.2 Representations	and	warranties	of	pSRC. 
(a) PSRC hereby represents and warrants to ABC that PSRC has the requisite power and 
authority to enter into this Agreement and to perform according to its terms, and that 
PSRC’s official signing this Agreement has authority to do so. PSRC further represents that 
it is financially able to satisfy any funding commitments made in Appendix B.
(b) PSRC certifies that the statements herein are true, complete, and accurate to the best of 
its knowledge. PSRC is aware that any false, fictitious, or fraudulent statements or claims 
may subject it to criminal, civil, or administrative penalties.
10.0	 Termination
10.1 Termination	by	mutual	Consent. ABC and PSRC may terminate this Agreement, or portions 
thereof, at any time by mutual written consent. In such event the Parties shall specify the 
disposition of all property, inventions, patent, or other IP applications, and other results of 
work accomplished or in progress, arising from or performed under this Agreement, all in 
accordance with the rights granted to the Parties under the terms of this Agreement.
10.2 unilateral	 Termination. Either ABC or PSRC may unilaterally terminate this entire 
Agreement at any time by giving written notice at least thirty (30) days prior to the desired 
termination date, and any rights accrued in property, patents, or other IP rights shall be 
disposed of as provided in paragraph 10.1.
10.3 Staffing. If this Agreement is mutually or unilaterally terminated prior to its expiration, 
funds will nevertheless remain available to ABC for continuing any staffing commitment 
made by PSRC pursuant to Article 5.1 above and Appendix B, if applicable, for a period of 
six (6) months after such termination. If there are insufficient funds to cover this expense, 
PSRC agrees to pay the difference.
10.4 new	Commitments. No Party shall make new commitments related to this Agreement 
after a mutual termination or notice of a unilateral termination and shall, to the extent 
feasible, cancel all outstanding commitments and contracts by the termination date. 
10.5 Termination	Costs. Concurrently with the exchange of final reports pursuant to Articles 4.2 
and 5.2, ABC shall submit to PSRC for payment a statement of all costs incurred prior to the 
date of termination and for all reasonable termination costs including the cost of returning 
PSRC property or removal of abandoned property, for which PSRC shall be responsible.
11.0	 disputes
11.1 governing	law. This Agreement shall be governed by the law of ___________.
11.2 Settlement. Any dispute, controversy, or claim arising under, out of, or in connection 
with this agreement, including, without limitation, its formation, validity, binding effect, 
interpretation, performance, breach, or termination, as well as noncontractual claims, that 
is not disposed of by agreement of the Principal Investigators, shall be submitted jointly 
to the signatories of this Agreement to reach an amicable settlement. If an amicable 
settlement cannot be reached within 30 days for any reason, the dispute shall be referred 
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to and finally settled by arbitration in accordance with the UNCITRAL Arbitration Rules 
then obtaining. The appointing authority shall be the Secretary-General of the Permanent 
Court of Arbitration, the number of arbitrators shall be three, and the language to be used 
in the arbitral proceedings shall be English. The place of arbitration shall be determined by 
mutual agreement, but if agreement cannot be reached the proceedings shall take place 
in ______________.
 Either party to this agreement may request any judicial authority to order any interim 
measures of protection for the preservation of its rights and interests to the extent permitted 
by law, including, without limitation, injunctions and measures for the conservation of such 
property and information that form part of the subject matter in dispute. Such requests 
shall not be deemed incompatible with, or as a waiver of, this agreement to arbitrate. 
In respect of any requests for interim measures of protection, and without limitation to 
proceeding in any other forum, the parties hereby consent to the exercise of jurisdiction by 
the judicial authorities of _________________.
 In the event a party fails to proceed with arbitration, unsuccessfully challenges the 
arbitrator’s award, fails to comply with the arbitrator’s award, or fails to comply with any 
interim measure of protection issued by any competent authority, the other party shall 
be entitled to costs of suit, including reasonable attorney’s fees, for having to compel 
arbitration or defend or enforce the award or interim measure.
11.3 Continuation	 of	work. Pending the resolution of any dispute or claim pursuant to this 
Article, the Parties agree that performance of all obligations shall be pursued diligently in 
accordance with the direction of the ABC signatory. 
12.0	 liability
12.1 no	warranties. Except as specifically stated in Article 9, the parties make no express or 
implied warranty as to any matter whatsoever, including the conditions of the research or 
any invention or product, whether tangible or intangible, made, or developed under this 
agreement, or the ownership, merchantability, or fitness for a particular purpose of the 
research or any invention or product.
12.2 Indemnification. PSRC agrees to hold the ABC harmless and to indemnify ABC for all 
liabilities, demands, damages, expenses, and losses arising out of the use by PSRC for any 
purpose of the Subject Data, Research Materials, and/or Subject Inventions produced in 
whole or part by ABC employees under this Agreement, unless due to the negligence or 
willful misconduct of ABC, its employees, or agents. PSRC shall be liable for any claims or 
damages it incurs in connection with this Agreement. ABC will hold PSRC harmless for 
liabilities, demands, damages, expenses and losses caused by the negligence or willful 
misconduct of ABC, its employees or agents. 
12.3 force	 majeure. Neither Party shall be liable for any unforeseeable event beyond its 
reasonable control, not caused by the fault or negligence of such Party, that causes such 
Party to be unable to perform its obligations under this Agreement, and that it has been 
unable to overcome by the exercise of due diligence. In the event of the occurrence of such 
a force majeure event, the Party unable to perform shall promptly notify the other Party. 
It shall further use its best efforts to resume performance as quickly as possible and shall 
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13.0	 miscellaneous
13.1 entire	Agreement. This Agreement constitutes the entire agreement between the Parties 
concerning the subject matter of this Agreement and supersedes any prior understanding 
or written or oral agreement. 
13.2 headings. Titles and headings of the articles and subarticles of this Agreement are for 
convenient reference only, do not form a part of this Agreement, and shall in no way affect 
its interpretation. 
13.3 waivers. None of the provisions of this Agreement shall be considered waived by any Party 
unless such waiver is given in writing to the other Party. The failure of a Party to insist upon 
strict performance of any of the terms and conditions hereof, or failure or delay to exercise 
any rights provided herein or by law, shall not be deemed a waiver of any rights of any 
Party.
13.4 Severability. The illegality or invalidity of any provisions of this Agreement shall not impair, 
affect, or invalidate the other provisions of this Agreement.
13.5 Amendments. If either Party desires a modification to this Agreement, the Parties shall, 
upon reasonable notice of the proposed modification or extension by the Party desiring 
the change, confer in good faith to determine the desirability of such modification or 
extension. Such modification shall not be effective until a written amendment is signed 
by the signatories to this Agreement or by their representatives duly authorized to execute 
such amendment. 
13.6 Assignment. Neither this Agreement nor any rights or obligations of any Party hereunder 
shall be assigned or otherwise transferred by either Party without the prior written consent 
of the other Party.
13.7 notices. All notices pertaining to or required by this Agreement shall be in writing and 
shall be signed by an authorized representative and shall be delivered by hand or sent by 
certified mail, return receipt requested, with postage prepaid, to the addresses indicated 
on the signature page for each Party. Any Party may change such address by notice given to 
the other Party in the manner set forth above.
13.8 Independent	 Contractors. The relationship of the Parties to this Agreement is that of 
independent contractors and not as agents of each other or as joint venturers or partners. 
Each Party shall maintain sole and exclusive control over its personnel and operations. PSRC 
employees who will be working at ABC facilities may be asked to sign a Guest Researcher 
or Special Volunteer Agreement appropriately modified in view of the terms of this 
Agreement.
13.9 use	of	name	or	endorsements. By entering into this Agreement, ABC does not directly or 
indirectly endorse any product or service provided, or to be provided, whether directly or 
indirectly related to either this Agreement or to any patent or other IP license or agreement 
that implements this Agreement by its successors, assignees, or licensees. PSRC shall not 
in any way state or imply that this Agreement is an endorsement of any such product 
or service by the ABC or any of its organizational units or employees. PSRC issued press 
releases that reference or rely upon the work of ABC under this Agreement shall be made 
available to ABC at least seven (7) days prior to publication for review and comment.
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13.10 exceptions	to	this	Agreement. Any exceptions or modifications to this Agreement that are 
agreed to by the Parties prior to their execution of this Agreement are set forth in Appendix 
C.
13.11 Reasonable	 Consent. Whenever a Party’s consent or permission is required under this 
Agreement, such consent or permission shall not be unreasonably withheld.
14.0	 duration	of	Agreement
14.1 duration. It is mutually recognized that the duration of this project cannot be rigidly defined 
in advance, and that the contemplated time periods for various phases of the RP are only 
good-faith guidelines subject to adjustment by mutual agreement to fit circumstances 
as the RP proceeds. In no case will the term of this Agreement extend beyond the term 
indicated in the RP unless it is revised in accordance with Article 13.5.
14.2 Survivability. The provisions of articles 4.2, 5–8, 10.3–10.5, 11.1, 12.2–12.4, 13.1, 13.10, and 14.2 
shall survive the termination of this Agreement.
Agreement	SIgnATuRe	pAge
FOR ABC:        Date
Mailing Address for Notices:
FOR PSRC:      Date
Mailing Address for Notices:
[Include additional signature and address blocks as necessary for all Parties to this Agreement.]
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Title of Agreement: _________________________________________________________________ 
ABC Principal Investigator: ___________________________________________________________
His/Her Laboratory:_________________________________________________________________
PSRC PRINCIPAL INVESTIGATOR: ______________________________________________________
Term of Agreement: __________ ( ____ ) years.
The Research Plan that follows should be concise but of sufficient detail to permit reviewers 
of this Agreement to evaluate the scientific merit of the proposed collaboration. The RP should 
explain the scientific importance of the collaboration and the research goals of ABC and PSRC. 
The respective contributions in terms of expertise and/or research materials of ABC and PSRC 
should be summarized. Initial and subsequent projects contemplated under the RP, and the 
time periods estimated for their completion, should be described and pertinent methodological 
considerations summarized. Pertinent literature references may be cited and additional relevant 
information included. Include additional pages to identify the Principal Investigators of all other 
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public	Sector	Technology	license
THIS AGREEMENT is effective this ______ day of ______, 20__ (“Effective Date”), by and between 
the Public Sector Research Centre (“PSRC”), an International Organization established according 
to the procedures of the Vienna Convention on the Law of Treaties, and ______________________, 
a corporation organized under the laws of [COUNTRY] (“COMPANY”). 
wITneSSeTh
WHEREAS PSRC has the rights to a newly developed technology for [USE OF TECHNOLOGY] 
 ________________________based on such core technology;
WHEREAS the core technology was developed in collaboration with [NAMES OF COLLABORATORS] 
________________________, who have certain rights to the technology;
WHEREAS PSRC has the right to make, use, and sell and to sublicense others to make, use, and sell 
products arising from the technology;
WHEREAS COMPANY is engaged in [MAKING, USING, OR SELLING]______________ products such 
as [TYPE OF PRODUCTS] ____________________________________and
WHEREAS COMPANY desires to obtain a license to make, use, and sell [PRODUCTS] 
________________________based on the core technology.
NOW, THEREFORE, the parties intending to be legally bound agree as follows:
Article	I:	defInITIonS
 1.1  “Technology” means the technology for [DETAILED DEFINITION OF USE OF TECHNOLOGY] 
_____________________________________________________________________________
_______.
 1.2  “Licensed Product” means a product that uses the Technology.
 1.3  “Exclusive Territory” means [COUNTRIES] ____________________________.
 1.4  “Non-exclusive Territory” means [COUNTRIES]____________________________.
Article	II:	gRAnT	of	lICenSe
2.1  Subject to [ANY RESTRICTIONS THAT MAY EXIST FOR PSRC IN LICENSING THE TECHNOLOGY] 
____________________________, PSRC grants to COMPANY on the terms and conditions 
herein stated:
a. An exclusive license, except as hereinabove provided, to make, use, and sell the Licensed 
Product in the Exclusive Territory for the purpose of [LIST OF SPECIFIC USES TO WHICH THE 
PRODUCT CAN BE PUT] __________________________________________; and
b. A nonexclusive license to sell Licensed Product in the Nonexclusive Territory,
Source: Mahoney RT (ed.). 2004. Handbook of Best Practices for Management of Intellectual Property in 
Health Research and Development. MIHR: Oxford, U.K. Reproduced with permission.
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 2.2  If at any time during the period of this Agreement COMPANY desires to license the 
Technology in countries not heretofore included in the Agreement, PSRC agrees to negotiate 
with COMPANY in good faith for such extension, provided that (a) the license rights in 
such additional countries have not previously been licensed to others; (b) COMPANY has 
existing distribution capability in each of such additional countries; (c) COMPANY has 
manufacturing capacity to serve such additional markets; (d) COMPANY is successfully 
marketing the Licensed Product in the Territory; and (e) COMPANY is not in default or 
breach of any covenant or any obligation of this Agreement.
Article	III:	Know-how
PSRC agrees to provide COMPANY with all know-how owned or controlled by PSRC that is 
reasonably required for the transmission of the Technology in accordance with the schedule 
and conditions specified in this Article III. Such material shall include a manual outlining the 
Technology; identifying all materials used; and indicating a supply source, the specifications for 
each material and product, and the required quality control procedures. In addition, PSRC will 
arrange:
(a) one (1) or more visits to the facilities of COMPANY by one (1) or more technicians 
knowledgeable in the Technology for a total period to be determined by PSRC; and
(b) up to three (3) visits by COMPANY’s staff to suitable training sites chosen by PSRC by up 
to two (2) COMPANY technicians fluent in English and experienced and qualified in the 
technology to be transferred for a total period of up to forty (40) days.
Article	Iv:	TeChnICIAn	vISITS
4.1  COMPANY will pay the fully allocated cost of PSRC’s or, at PSRC’s option, a designated agent’s 
technicians during the visits specified in Article III, paragraph (a). COMPANY shall reimburse 
PSRC for the out-of-pocket expenditures incurred by the technicians and for materials used 
during the visits specified in Article III, paragraph (a). PSRC, through a designated agent, 
will use its best efforts at keeping costs to a minimum level throughout the technology 
transfer without sacrificing quality.
 4.2  COMPANY will pay the costs of its technicians and/or staff during the visits specified in 
Article III, paragraphs (a) and (b) and all costs for materials and equipment used pursuant 
to Article III, paragraph (a).
Article	v:	ImpRovemenTS
Should COMPANY or PSRC develop or obtain rights to additional know-how or improvements in 
the manufacture or composition of any of the items comprising the Technology, such know-how 
and/or improvements shall be licensed to the other party royalty free with the right to sublicense 
said improvements to others subject to:
(a) the terms and conditions of any agreements by which PSRC or COMPANY, as the case may 
be, obtained rights to such licensed improvements or know-how; and
(b) any sublicense granted under this Article shall incorporate terms that require the 
sublicensee to respect this Agreement.
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 6.1  COMPANY shall pay PSRC a technology transfer fee of ___________ U.S. dollars ($_____) to 
help offset PSRC’s costs and expenses. This fee shall be paid within thirty (30) days of the 
Effective Date.
6.2  COMPANY shall pay for the costs incurred in training COMPANY staff. Periodic expense 
estimates will be submitted by PSRC to COMPANY, and COMPANY shall pay PSRC seventy-
five percent (75%) of the estimated amounts within ten (10) days thereof in U.S. dollars to 
PSRC. The balance shall be invoiced by PSRC periodically and shall be paid to PSRC under 
the payment terms and conditions stated above. If, at the conclusion of each stage, the 
amounts paid by COMPANY up to that point exceed the amount due, PSRC shall repay the 
excess within ten (10) days.
 6.3  COMPANY shall pay PSRC a royalty of ____ percent (_%) on net sales of Licensed Products. 
Net sales means the gross amounts of bona fide sales to others not owned or controlled 
by COMPANY less cash discounts and rebates actually given, in addition to duties, returns, 
and free replacements. No royalties shall be payable with respect to any sale of Licensed 
Products that takes place between COMPANY and any company owned or controlled by 
COMPANY, but such royalty shall accrue upon the resale of the Licensed Products to a third 
party. Whenever a company owned or controlled by COMPANY itself uses the Licensed 
Products, royalty shall accrue on such Licensed Products. Said royalty shall be calculated 
by using, as a sales price, the average price at which COMPANY sold Licensed Products to 
third parties during the calendar quarter within which the Licensed Products were used 
by the company owned or controlled by COMPANY.
 6.4  Royalties shall be payable each calendar quarter on the last business day of the month 
following the calendar quarter for the royalties covering the preceding calendar quarter. 
Royalties are to be paid in U.S. dollars and sent by wire transfer on or before the date due 
to an account specified by PSRC unless otherwise agreed in writing. 
 6.5  On the due date of each royalty payment, COMPANY shall furnish to PSRC a full accounting 
showing separately the total sales of Licensed Products to the Public Sector, the total sales 
of Licensed Products to the Private Sector, a calculation of the royalties payable in respect 
thereof, production quantities, and sales prices.
 6.6  COMPANY shall maintain sufficiently detailed records and books of accounts to enable 
PSRC to verify the payments made to PSRC by COMPANY and the reports filed therewith. 
COMPANY shall permit an independent accountant, appointed by PSRC and to whom 
COMPANY has no reasonable objection, to inspect, at reasonable times and upon 
reasonable notice at the principal place of business of COMPANY, the books and records of 
COMPANY relating to the manufacture, use, and sale of Licensed Products. The accountant 
shall report to PSRC only whether the amounts reported and paid to PSRC by COMPANY 
are accurate and, if not, what the correct figures should be. A copy of the report shall 
also be supplied to COMPANY. In no event shall an examination of COMPANY’s books and 
records be made for a period prior to three (3) years from the date such audit is requested 
by PSRC. In the event the accountant reports that COMPANY has underpaid the amounts 
due to PSRC, then COMPANY shall bear the costs of such audit.
public	Sector	Technology	license
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 7.1  COMPANY agrees to use its best efforts to promote diligently the sale and distribution of 
Licensed Products throughout the Exclusive Territory in accordance with the milestones 
established in Exhibit A.
 7.2  COMPANY will use its best efforts to promptly establish a validated manufacturing process 
for Licensed Products.
 7.3  Governmental Approvals
(a) The cost of obtaining governmental approval and/or registration to make, use, and sell 
Licensed Products in the Territory shall be borne by COMPANY. COMPANY agrees to use its 
best efforts to obtain such governmental approval and/or registration and shall use due 
diligence therein;
(b) COMPANY agrees that PSRC shall have full access to any application for governmental 
approval or registration and the data contained therein together with the right to use such 
application, data, and any subsequent approval to obtain the approval of any government 
of any country outside of the Territory to make, use, and/or sell Licensed Products in such 
country, provided that PSRC shall require that any company licensed by PSRC shall respect 
this Agreement; and
(c) If this Agreement is terminated under Article 11.1, COMPANY agrees, to the extent permitted 
by local law and/or government regulation, to assign to PSRC or to PSRC’s designee and 
without cost to PSRC or PSRC’s designee all governmental approvals and/or registrations 
owned or controlled by COMPANY for the manufacture, use, and/or sale of Licensed 
Products.
 7.4  COMPANY agrees that it will not knowingly sell or allow the sale of any Licensed Product 
that it produces which sale would be outside the terms of this Agreement except with the 
written approval of PSRC.
 7.5  COMPANY agrees to obtain the prior written approval of PSRC for any labels, containers, 
packaging, package inserts, or any product associated or sold with the Licensed Products. 
If PSRC has not responded within thirty (30) days after receipt of a request for approval, 
the materials shall be deemed to be approved. Upon written request by PSRC and with 
reasonable notice, COMPANY further agrees to print on the packaging of the Licensed 
Products a legend crediting PSRC and/or the Collaborators with providing the technology 
on which the Licensed Products are based, provided that COMPANY has no reasonable 
objection to the language used.
7.6  COMPANY agrees to only use, promote, or knowingly sell Licensed Products for uses 
consistent with the guidelines for uses of such products as published by [REGULATORY 
AGENCY, WHO, OR OTHERS]. A summary of these guidelines is attached hereto as Exhibit B. 
PSRC may update these guidelines from time to time as agencies update their guidelines. 
PSRC will allow COMPANY ninety (90) days from issuance of any updated guidelines to 
correct any of COMPANY’s promotional materials or selling practices not consistent 
with the updated guidelines. COMPANY agrees that, if requested by PSRC, COMPANY will 
communicate these guidelines to its existing and potential purchasers of the Licensed 
Products in a form mutually agreeable to COMPANY and PSRC.
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Article	vIII:	good	mAnufACTuRIng	pRACTICeS	And	quAlITy	ASSuRAnCe
8.1  COMPANY agrees that all Licensed Products manufactured by COMPANY shall be produced 
in accordance with GMP prescribed under ISO 9002 and subsequent revisions. COMPANY 
shall comply with the additional manufacturing requirements outlined in Exhibit C herein 
and subsequent written directives from PSRC.
8.2  During the term of the license, COMPANY agrees to periodic quality control (“QC”) testing 
by PSRC and/or a third party selected by PSRC and to whom COMPANY has no reasonable 
objection. COMPANY shall reimburse PSRC for the cost of said third-party testing. It is 
anticipated that QC testing will be performed on not fewer than the first three (3) batches 
produced and, thereafter, not fewer than one (1) batch per year. All QC testing under this 
paragraph 8.2 is in addition to testing required under paragraph 8.1 and/or the applicable 
laws and regulations of each country in the Territory where COMPANY manufactures and/
or sells the Licensed Product.
8.3  COMPANY shall permit a duly authorized representative of PSRC, upon reasonable notice, 
to inspect the premises of COMPANY from time to time to ascertain that the provisions of 
this Article are being complied with by COMPANY.
8.4  COMPANY agrees to mark Licensed Products’ packaging in accordance with the applicable 
laws of each country in the Territory where COMPANY manufactures and/or sells the 
Licensed Product.
8.5  In the event that COMPANY, at any time, fails to meet GMP and QC standards as provided 
for in this Article, COMPANY shall immediately, at the direction of PSRC or the government 
of any country in which COMPANY manufactures and/or sells a Licensed Product, recall all 
such Licensed Products not yet sold and cease further sales until such standards are met.
Article	Ix:	ConfIdenTIAlITy
9.1  COMPANY shall keep confidential and refrain from using, except under the terms of this 
Agreement, all know-how disclosed to it by PSRC, its employees, and its agents under this 
Agreement. The obligation of confidence shall not apply to:
(a) know-how that, at the time of disclosure, COMPANY can demonstrate was in the public 
domain;
(b) know-how that, after disclosure, becomes part of the public domain other than by 
COMPANY;
(c) know-how that COMPANY can show was in COMPANY’s possession at the time of disclosure 
and was not acquired directly or indirectly from PSRC; or
(d) know-how that has been, is now, or is hereinafter furnished or made known to COMPANY 
by a third party as a matter of right and who did not derive the information from PSRC.
public	Sector	Technology	license
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9.2  Confidential information shall not be deemed to fall within the exceptions of Article 9.1 if (1) 
the confidential information is specific and is merely embraced by more general information 
in the public domain or in COMPANY’s possession or (2) the confidential information is a 
combination that can be pieced together or reconstructed from multiple sources, none of 
which shows the whole combination, its principle of operation, and method of use.
9.3  Nothing contained in this Article shall be construed as restricting COMPANY from disclosing 
the know-how to others as a necessary adjunct to the manufacture, use, and sale of the 
Licensed Products in accordance with this Agreement.
9.4  COMPANY further agrees to take all reasonable precautions to prevent any of its personnel 
from divulging to any other party, except as is otherwise provided herein, any know-how 
furnished to COMPANY by PSRC under this Agreement.
9.5  The provisions of this Article shall survive the term of this Agreement.
Article	x:	hold	hARmleSS
10.1  Except for willful misconduct by PSRC, its employees, and its agents, COMPANY agrees to 
hold harmless and indemnify PSRC, its employees, and its agents from the following:
(a) all product liability claims arising from the manufacture, use, or sale of the Licensed 
Products made by COMPANY; 
(b) all medical malpractice claims in the use of Licensed Products manufactured, distributed, 
or sold by COMPANY; and
(c) all claims against COMPANY or PSRC for infringement arising from the manufacture, use, 
or sale by COMPANY of Licensed Products.
10.2  COMPANY shall, at its sole expense, assume the defense of such suit or claim. PSRC shall 
promptly notify COMPANY of any suit or claim against PSRC, its employees, or its agents of 
which PSRC is aware. COMPANY may elect to cease to manufacture, distribute, or sell the 
Licensed Product or obtain a license for the Licensed Product rather than defend a patent 
infringement suit, provided that COMPANY shall continue to be responsible with respect to 
any claim of infringement arising from any action of COMPANY occurring before the date 
of ceasing manufacture, distribution, or sale or before the date of any license.
10.3  Insofar as COMPANY has liability insurance, COMPANY agrees to instruct its insurance 
carrier to name PSRC as an additional insured; to issue PSRC a certificate of coverage; and 
to give PSRC notice of any cancellation, renewal, or changes in coverage.
10.4  The provisions of this Article shall survive the term of this Agreement, whether or not such 
cause of action or claim had accrued at the time of termination.
APPENDIX 
 HANDBOOK OF BEST PRACTICES  | 1871 
public	Sector	Technology	license
Article	xI:	TeRm
11.1  This Agreement shall commence on the Effective Date and may be terminated under the 
following circumstances and on the following terms and conditions: 
(a) If COMPANY has not successfully manufactured pilot-scale batches of at least one (1) 
Licensed Product in its facility within one (1) year from the Effective Date, PSRC may 
terminate by giving COMPANY thirty (30) days’ written notice; 
(b) If COMPANY has not obtained permission, if such permission is required under [COUNTRY] 
law, from the Government of [COUNTRY] to sell at least one (1) Licensed Product in 
[COUNTRY] within _______ (__) months from the Effective Date, PSRC may terminate this 
Agreement by giving COMPANY thirty (30) days’ written notice;
(c) If COMPANY has not successfully completed the milestones established in Exhibit A, PSRC 
may terminate by giving COMPANY sixty (60) days’ written notice;
(d) COMPANY may terminate at any time by giving PSRC ninety (90) days’ written notice;
(e) If either party should at any time default or commit any breach of any covenant or any 
obligation of the license and should fail to remedy any default or breach within thirty 
(30) days after written notice thereof by the other party, the injured party may, at its sole 
option, terminate this license by notice in writing to such effect; 
(f) If an order be made or an effective resolution be passed for the winding up of COMPANY; 
if there is a failure, distress, execution, or other legal process levied or enforced upon 
or against a substantial portion of the chattels or property of COMPANY; if a receiver is 
appointed for the undertaking of the property and assets of COMPANY or a substantial 
portion thereof; or if COMPANY shall make any assignment or composition for the benefit 
of its creditors or shall cease to carry on business, then PSRC may terminate by giving 
COMPANY thirty (30) days’ written notice; 
(g) If COMPANY has not obtained permission to sell a Licensed Product from the government 
of any country requiring such permission within two (2) years from the date a grant 
was first made by PSRC to COMPANY for sales anywhere in the world for such Licensed 
Product, PSRC may terminate that portion of the grant giving COMPANY permission to 
sell said Licensed Product in those countries for which a complete application for said 
government permission has not been filed. This partial termination shall occur by PSRC 
giving COMPANY thirty (30) days’ written notice; and
(h) By mutual agreement of the parties.
11.2		 UPON TERMINATION OF THIS AGREEMENT:
(a) All rights and licenses created by this Agreement shall expire, except that any sums due 
as royalty shall remain payable and Articles X and XI shall remain in effect. COMPANY shall 
return to PSRC all technical documents given to COMPANY pursuant to this Agreement, 
shall destroy any copies of the technical documentation supplied, shall refrain from 
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further manufacture or distribution of the Licensed Products anywhere in the world, and 
shall assign and transfer to PSRC or to PSRC’s designee all governmental approvals and/
or registrations to make, use, and/or sell Licensed Products that are owned or controlled 
by COMPANY to the extent permitted by local law and/or government regulation. Within 
thirty (30) days after termination, COMPANY shall return to PSRC all know-how; and
(b) The relationships of PSRC and COMPANY to any third parties thereafter shall be determined 
by mutual agreement and both parties agree to cooperate in executing and delivering 
such instruments of assignment or other instruments or documents as may be required to 
effectuate such assignments.
11.3  Unless terminated sooner, this Agreement shall remain in force and effect for _______ (__) 
years from the Effective Date. Thereafter, COMPANY shall retain the right to make, use, and 
sell Licensed Products without further obligation to PSRC hereunder except as provided 
under Articles IX and X.
Article	xII:	ThIRd	pARTy	lICenSeS
COMPANY agrees to cooperate fully with PSRC in assisting other companies or organizations 
selected by PSRC, and to whom COMPANY has no reasonable objection, to manufacture the 
Licensed Products in a country outside of the Territory and to obtain any requisite governmental 
approval for the manufacture, use, and sale of the Licensed Products in such country, provided 
that such other company or organization covenants not to manufacture, use, and/or sell Licensed 
Products in the Territory. In providing manufacturing and registration assistance hereunder, 
COMPANY shall be reimbursed its expenses, including employee time, plus ten percent (10%).
Article	xIII:	noTICe
Any notice required or provided for by the terms of this Agreement shall be in writing, and all 
notices, reports, and payments (other than royalties) provided for hereunder shall be sent by 
registered mail, prepaid, or facsimile to the business address of the party to be served therewith. 
It is agreed that the business addresses of the parties shall be as follows:
If to COMPANY: 
Facsimile: 




If to PSRC:  Facsimile: 




or such other addresses as either party shall have notified the other party. Any such notice, royalty, 
or payment shall be deemed to have been given or made on the date such letter was registered or 
delivered for transmission to the sender’s facsimile operator, but any assumption of actual notice 
or payment shall be subject to rebuttal to show that it has not actually been received.
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Article	xIv:	ASSIgnABIlITy
This Agreement shall not be assignable or transferable by COMPANY without the written consent 
of PSRC, but may be assigned or transferred by PSRC without the consent of COMPANY. COMPANY 
may, however, assign this Agreement to any wholly owned subsidiary of COMPANY, but COMPANY 
assumes full responsibility to PSRC for the fulfillment of all the terms of this Agreement by the 
assignee.
Article	xv:	enTIRe	AgReemenT
This Agreement contains the entire agreement and understanding between the parties with 
respect to the subject matter herein and supersedes all prior discussions and other writings, 
except for those specifically referred to herein. This Agreement shall not be modified except in 
writing.
Article	xvI:	ARBITRATIon
This Agreement shall be governed by the law of ___________. The parties hereto undertake to 
settle any dispute, controversy, or claim arising under, out of, or in connection with this Agreement, 
including, without limitation, its formation, validity, binding effect, interpretation, performance, 
breach, or termination, as well as noncontractual claims, in an amicable manner. If an amicable 
settlement cannot be reached within 30 days for any reason, the dispute shall be referred to and 
finally settled by arbitration in accordance with the UNCITRAL Arbitration Rules then obtaining. 
The appointing authority shall be the Secretary-General of the Permanent Court of Arbitration, the 
number of arbitrators shall be three, and the language to be used in the arbitral proceedings shall 
be English. The place of arbitration shall be determined by mutual agreement, but if agreement 
cannot be reached the proceedings shall take place in ______________.
Either party to this Agreement may request any judicial authority to order any interim measures 
of protection for the preservation of its rights and interests to the extent permitted by law, 
including, without limitation, injunctions and measures for the conservation of such property and 
information that form part of the subject matter in dispute. Such requests shall not be deemed 
incompatible with, or as a waiver of, this agreement to arbitrate. In respect of any requests for 
interim measures of protection, and without limitation to proceeding in any other forum, the 
parties hereby consent to the exercise of jurisdiction by the judicial authorities of ___________
______.
In the event a party fails to proceed with arbitration, unsuccessfully challenges the arbitrator’s 
award, fails to comply with the arbitrator’s award, or fails to comply with any interim measure of 
protection issued by any competent authority, the other party shall be entitled to costs of suit, 
including reasonable attorney’s fees, for having to compel arbitration or defend or enforce the 
award or interim measure.
Article	xvII:	wAIveR
No waiver by either party of any provision hereof shall be deemed a waiver of any other provision 
hereof or of any subsequent breach by either party of the same or any other provision. None of 
the terms of this Agreement will be held to have been waived or altered unless such waiver or 
alteration is in writing and signed by both the parties hereto.
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Article	xvIII:	wARRAnTy
PSRC warrants that the Technology and the know-how associated therewith were developed by 
PSRC; that the Technology and know-how are owned by PSRC; and that, subject to [LIST HERE 
ANY RESTRICTIONS], PSRC has a worldwide, exclusive license for such Technology and know-
how together with the right to sublicense others thereunder to make, use, and sell Licensed 
Products anywhere in the world. Nothing in this Agreement will be construed as a warranty 
or representation that anything made, used, sold, or otherwise disposed of under any license 
granted in this Agreement is or will be free from infringement of patents of third parties. Except 
as specifically set forth herein, PSRC makes no representations or warranties, either express 
or implied, arising by law or otherwise, including, but not limited to, implied warranties of 
merchantability or fitness for a particular purpose. In no event will PSRC, its employees, and its 
agents have any obligation or liability arising from tort or for loss of revenue or profit or for 
incidental or consequential damages.
It is the sole responsibility of COMPANY to undertake a thorough search for third party patents 
before selling any Licensed Product in any national market, and COMPANY agrees that PSRC, 
its employees, and its agents shall not have any liability for infringement of any patent as a 
consequence of the manufacture, use, or sale of any Licensed Product or by reason of any other 
use of the Technology by COMPANY.
IN WITNESS WHEREOF the parties hereto have caused these presents to be executed in duplicate 
by their respective duly authorized officers.
For PSRC:     For COMPANY:
  
By:____________________________     By:____________________________
       
     
Date:__________________________    Date:__________________________
  
exhibit	A
Milestones     Target Date 
(in months from signing agreement)
 1. Establish a validated assembly or manufacturing process  
 2. Conduct clinical trials of product produced in [COUNTRY] 
 3. etc.  
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The following items must be completed or in place before products are released for general use:
[The Institute may specify a number of conditions depending on local considerations. Examples 
are listed here:
1. Review and approval by PSRC of package inserts and packaging materials 
2. Inspection of manufacturing and control procedures, facilities, records, inventories, and 
reference samples by an PSRC consultant 
3. Establishment of a system of post-market surveillance that [specify requirements] ______
_____________________________________
4. Establishment of an introduction program to product users
5. Notification/discussion with PSRC of any change in manufacturing procedure. Pilot 
batches using new manufacturing procedures must pass stability testing before going 
into industrial production. The first two industrial batches using new manufacturing 
procedures must go into ongoing stability testing at room temperature (manufacturer’s 
warehouse). No less than one batch per year must be placed in the same program. Results 
are to be used to support registration and/or modify information about shelf life. 
6. PSRC reserves the right to audit the manufacturer’s installations, process, and inventory, 
and to retain samples on a yearly basis. At any point in the distribution system, product 
may be tested by PSRC as part of this audit.]
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This License Agreement (the “Agreement”) is made by and between ________________________, 
a___________________________, duly established under the Companies Act having an address 
at ______________________ (“LICENSEE”) and the South African Medical Research Council, a non-
profit organization having an address at Fransie van Zijl Drive, Parowvallei, Cape Town (“MRC”). 
This Agreement is effective on the date of the last signature (“Effective Date”)
the _____ day of _____________ 20_____. 
wITneSSeTh
ReCITAlS
WHEREAS the MRC is the sole owner of the Technology titled ______________________, which is 
covered by Patent Rights as defined below;
WHEREAS the MRC warrants that it possesses the right to license the Technology; 
WHEREAS the MRC is desirous that the Technology be developed and utilized to the fullest 
possible extent to produce commercially marketable Products so that its benefits can be enjoyed 
by the general public;
WHEREAS LICENSEE entered into a Confidential Disclosure Agreement with the MRC, effective 
______, for the purpose of evaluating the Invention; 
WHEREAS LICENSEE entered into a Letter of Intent with the MRC, effective _________, for the 
purpose of negotiating this Agreement; 
WHEREAS LICENSEE desires to acquire an exclusive (or non-exclusive) license, under the terms 
and conditions hereinafter set forth, in the Territory for commercial development, use, and sale 
of the Invention.




Source: MRC Innovation Centre, PO Box 19070, Tygerberg, 7505, Cape Town, South Africa. Reproduced with 
permission. Visit innovation.mrc.ac.za to download many additional template and sample agreements.
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NOW THEREFORE, For these and other valuable considerations, the receipt of which is hereby 
acknowledged, the parties agree as follows:
1.	 defInITIonS
The terms, as defined herein, shall have the same meanings in both their singular and plural 
forms. 
1.1  “Affiliate” shall mean any corporation or other business entity controlled by, controlling 
or under common control with LICENSEE. For this purpose, “control” shall mean direct or 
indirect beneficial ownership of at least a fifty percent (50%) of the voting stock of, or at 
least a fifty percent (50%) interest in the income of such corporation or other business 
entity, or such other relationship as in fact, constitutes actual control.
1.2  “Combination Product” means any product which is a Licensed Product and contains other 
products(s) or product component(s) that 
(i) does not use Invention, Technology or Patent Rights; 
(ii) the sale, use or import by itself does not contribute to the infringement of Patent Rights; 
(iii) can be sold separately by LICENSEE, its Sublicensee or an Affiliate; and 
(iv) enhances the market price of the final product(s) sold used or imported by LICENSEE, its 
Sublicensee, or an Affiliate.
1.3  “Field of use” means ………………………… [specific	field	of	use	for	the	license]. 
1.4  “Know-How” means the ideas, methods, characterization and techniques developed by the 
MRC before the Effective Date, which are necessary for practicing the Patent Rights.
1.5  “Licensed Method” means any method that uses Technology or any part thereof, or is 
covered by Patent Rights the use of which would constitute, but for the license granted to 
LICENSEE under this Agreement, an infringement of any pending or issued and unexpired 
claim within Patent Rights.
1.6  “Licensed Product” shall mean any composition or product or part thereof which:
(i)  is covered in whole or in part by an issued, unexpired claim or a pending claim contained 
in the Patent Rights in the country in which any Licensed Product is made, used or sold;
(ii)  is manufactured by the Licensed Method or using a process which is covered in whole or 
in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in 
the country in which any Licensed Process is used or in which such product or part thereof 
is used or sold. 
1.7  “Net Sales” means the total of the gross invoice prices of Licensed Products sold by LICENSEE, 
its Sublicensee, an Affiliate, or any combination thereof, less the sum of the following 
actual and customary deductions where applicable and separately listed: cash, trade, or 
quantity discounts; sales, use, tariff, import/export duties or other excise taxes imposed 
on particular sales (except for value-added and income taxes imposed on the sales of 
Product in foreign countries); transportation or shipping charges to purchasers; or credits 
to LICENSEE because of rejections, allowances or returns. For purposes of calculating Net 
Sales, transfers to a Sublicensee or an Affiliate of Licensed Product under this Agreement 
for 
(i) end use (but not resale) by the Sublicensee or Affiliate shall be treated by LICENSEE at list 
price of LICENSEE, or 
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1.8  “Patent Costs” means all out-of-pocket expenses for the preparation, filing, prosecution, 
and maintenance of all South African and foreign patents included in Patent Rights. 
Patent Costs shall also include reasonable out-of-pocket expenses for patentability 
opinions, inventorship determination, preparation and prosecution of patent application, 
re-examination, re-issue, interference, and opposition activities related to patents or 
applications in Patent Rights. 
1.9  “Patent Rights” shall mean all of the following MRC intellectual property: 
(i)  SA Patent Application Number ______________, 
(ii) PCT Patent Application Number _____________, 
 and any new claim, reissues, reexaminations, improvements or extensions, continuations, 
divisionals, and the foreign counterpart patents, patent applications and patents issuing 
therefrom relating to the product. The MRC shall be the assignee and owner of all such 
Patents and Patent Applications.
1.10  “Process” shall mean any process which is covered in whole or in part by an issued, unexpired 
claim or pending claim contained in the Patent Rights.
           
1.11  “Sponsor Rights” means all the applicable provisions of any license to the South African 
Government executed by the MRC and the overriding obligations to the Government and 
the overriding obligations to ……. under the sponsorship agreement with the same.
1.12  “Sublicensee” as used in this Agreement shall mean any third party to whom LICENSEE has 
granted a license to make, have made, use and/or sell the Product under the Patent Rights, 
provided said third party has agreed in writing with LICENSEE to accept the conditions and 
restrictions agreed to by LICENSEE in this Agreement.
1.13  “Technology” means the following MRC intellectual property:
(i) Patent Rights, as defined in 1.8 above.
(ii) Any and all copyrights, mask works, trademarks, service marks, trade dress, trade secrets, 
confidential information, proprietary information or know-how pertaining to Invention.
1.14  “Term” means the period of time beginning on the Effective Date and ending on the later 
of 
(i) the expiration date of the longest-lived Patent Rights; or 
(ii) the twenty-first (21st) anniversary of Effective Date.
1.15  “Territory” means ………………………… [areas in which the license is valid].
2.	 gRAnTS
2.1  license. In consideration for payment of royalties and subject to the limitations set forth 
in this Agreement and Sponsor’s Rights, the MRC hereby grants to LICENSEE, and LICENSEE 
hereby accepts, a license under Patent Rights to make, have made for its own use and sale, 
use, sell, offer for sale, and import Licensed Products and to practice Licensed Methods and 
to use Technology, in the Field within the Territory and during the Term.
 The license granted herein is exclusive and the MRC shall not grant to third parties a 
further license under Patent Rights or to use Technology in the Field, within the Territory 
and during the Term. (or The license granted herein is non-exclusive and the MRC may 
grant to third parties further licenses under Patent Rights or to use Technology in the Field, 
within the Territory and during the Term.)  
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 The MRC grants to the LICENSEE the authority to make application for Patents, in the 
name of the MRC; all expenses of obtaining and maintaining said patents shall be paid by 
LICENSEE.
 LICENSEE agrees that the Technology constitutes a trade secret. LICENSEE agrees to include 
a clause in any and all agreements for sale or transfer to third parties that use of Technology 
or Products derived therefrom shall be for non-commercial research and development 
purposes only.
 LICENSEE agrees that if commercially useful derivatives or developments from the 
Technology are made by LICENSEE or sublicensees, such derivatives or developments shall 
belong to the MRC. The MRC shall negotiate with LICENSEE or sublicensees for appropriate 
compensation which will be reasonable and customary in the field of the developments.
2.2  Sublicense.	
(i) The license granted in Paragraph 2.1 includes the right of LICENSEE to grant sublicenses to 
third parties during the Term but only for as long the license is exclusive. 
(ii) With respect to sublicense granted pursuant to Paragraph 2.2(a), LICENSEE shall: 
(1) not receive, or agree to receive, anything of value in lieu of cash as considerations from 
a third party under a sublicense granted pursuant to Paragraph 2.2(a) without the 
express written consent of the MRC; 
(2) to the extent applicable, include all of the rights of and obligations due to the MRC 
(and, if applicable, the Sponsor’s Rights) and contained in this Agreement; 
(3) promptly provide the MRC with a copy of each sublicense issued; and 
(4) collect and guarantee payment of all payments due, directly or indirectly, to the MRC 
from Sublicensees and summarize and deliver all reports due, directly or indirectly, to 
the MRC from Sublicensees. 
(iii) Upon termination of this Agreement for any reason, the MRC, at its sole discretion, shall 
determine whether LICENSEE shall cancel or assign to the MRC any and all sublicenses. 
2.3  Reservation	of	Rights. The MRC reserves the right to: 
(i) practice the Invention, Technology and Patent Rights for its own use
(ii) use the Invention, Technology and Patent Rights for educational and research purposes; 
(iii) publish or otherwise disseminate any information about the Invention and Technology at 
any time; 
(iv) allow other nonprofit institutions to use Invention, Technology and Patent Rights for 
educational and non-commercial research purposes in their facilities; and 
(v) require LICENSEE to sublicense to a third party the Invention, Technology and Patent Rights 
in any field of no commercial interest to LICENSEE. 
3.	 ConSIdeRATIonS
3.1  fees	 and	 Royalties. The parties hereto understand that the fees and royalties payable 
by LICENSEE to the MRC under this Agreement are partial considerations for the license 
granted herein to LICENSEE under Technology, and Patent Rights. LICENSEE shall pay the 
MRC: 
(i) a license	issue	fee of ___ Rands (R_______) upon execution of this    
Agreement; or
(i)  a license	issue	fee of ___ Rands (R_______), within thirty (30) days after    
the Effective Date; or 
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(i)  in recognition of LICENSEE being a startup business and partially in lieu of cash, a license	
issue	fee in the form of ___ % [or ___ shares] of the LICENSEE’S common stock authorized in 
the Shareholder’s Agreement of the LICENSEE (or authorized in the Article of Incorporation 
of the LICENSEE) dated ________, and a copy of which is attached to this Agreement as 
Exhibit A; or 
(i)  partially in lieu of cash, a license	issue	fee in the form of an option granted to the MRC 
to purchase for one Rand (R1.00) ___ % [or ___ shares] of the LICENSEE’S common stock 
authorized in the Shareholder’s Agreement of the LICENSEE (or authorized in the Article 
of Incorporation of the LICENSEE) dated _________, and a copy of which is attached to 
this Agreement as Exhibit A. The option period commences on Effective Date and shall 
terminate _____ years thereafter. This option, in whole or in part, can be exercised by the 
MRC or transferred by the MRC to the inventors any time during the option period. 
(ii)  license	 maintenance	 fees of ___ Rand (R_______) per year and payable on the first 
anniversary of the Effective Date and annually thereafter on each anniversary; provided 
however, that LICENSEE’s obligation to pay this fee shall end on the date when LICENSEE is 
commercially selling a Licensed Product; 
(iii)  milestone	payments in the amounts payable according to the     
following schedule or events: 
  Amount Date or Event 
  (1) …………………
  (2) …………………
(iv)  an earned	Royalty of ___ percent (___%) on Net Sales of Licensed    
Products by LICENSEE and/or its Affiliate(s); or
(iv)  an earned	Royalty	
(1)  of ___ percent (___%) on Net Sales of Licensed Products     
 for diagnostic uses by LICENSEE and/or its Affiliate(s);     
 and 
(2)  of ___ percent (___%) on Net Sales of Licensed Products for therapeutic uses by 
LICENSEE and/or its Affiliate(s); provided, however, that the earned royalty due on Net 
Sales of Combination Product by LICENSEE and/or its Affiliate(s) shall be calculated as 
below: 
 Earned Royalties due the MRC = A/(A+B+C . . .) x Royalty Rate on Net Sales of the 
Licensed Products applicable in (i) or (ii) x Net Sales of Combination Product, where: 
A is the separately listed sale price of the Licensed Product or Licensed Product 
components; and B and C . . . are the separately listed sale prices of the individual 
products or product components. If LICENSEE does not separately sell any of the B, C . 
. . products or product components used in Combination Product, the purchase price 
paid by LICENSEE in the procurement of said products or product components shall be 
used.
(v)  fifty percent (50%) of all sublicense	fees received by LICENSEE from its Sublicensees that 
are not earned royalties; 
(vi)  on each and every sublicense	royalty payment received by LICENSEE from its Sublicensees 
on sales of Licensed Product by Sublicensee, the higher of 
(1) fifty percent (50%) of the royalties received by  LICENSEE; or 
(2) royalties based on the royalty rate in Paragraph 3.1(iv) as  applied to Net Sales 
of Sublicensee; 
(vii) beginning the calendar year of commercial sales of the first License Product by LICENSEE, 
its Sublicensee, or an Affiliate and if the total earned royalties paid by LICENSEE under 
Paragraphs 3.1(iv) and (vi) to the MRC in any such year cumulatively amounts to less than 
_______ Rand (R_______) (“minimum	Annual	Royalty”), LICENSEE shall pay to the MRC 
a Minimum Annual Royalty on or before February 28 following the last quarter of such 
year the difference between amount noted above and the total earned royalty paid by 
LICENSEE for such year under Paragraphs 3.1(iv) and (vi); provided, however, that for the 
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year of commercial sales of the first Licensed Product, the amount of Minimum Annual 
Royalty payable shall be pro-rated for the number of months remaining in that calendar 
year; or
(vii) beginning the calendar year of commercial sales of the first License Product by LICENSEE, 
its Sublicensee, or an Affiliate, LICENSEE will pay _______ Rand (R_______) (“minimum	
Annual	Royalty”). Such Minimum Annual Royalties will be considered as a credit toward 
earned royalties due for the applicable calendar year and the royalty reports shall reflect 
the use of such credit.
a)  The provisions for Minimum Annual Royalties shall be construed as an annual 
minimum payment requirement and none of the Minimum Annual Royalty payments 
are refundable or applicable to succeeding years. 
b)  If the aggregate earned royalties for any given calendar year for which a minimum 
annual royalty is payable do not exceed the Minimum Annual Royalty, LICENSEE may 
pay the MRC, with its payment for the last calendar year quarter, a balancing payment 
in an amount equal to the difference between the minimum annual royalty and the 
earned royalties for that calendar year. 
c)  If LICENSEE does not make the balancing payment described in Section 5.3.b, the MRC 
shall have the option on sixty (60) days notice to LICENSEE to convert this Agreement 
from an Exclusive License into a non-exclusive license, in which event, LICENSEE shall 
not have any further Minimum Annual Royalty obligation and LICENSEE will also be 
granted any more favorable term or terms granted by the MRC to another licensee. 
3.2  All fees and royalty payments specified in Paragraphs 3.1(i) through 3.1(vii) above shall be 
paid by LICENSEE pursuant to Paragraph 4.3 and shall be delivered by LICENSEE to the MRC 
as noted in Paragraph 10.1. Earned Royalties will be reduced by ____ % upon expiration of 
Patent Rights.
3.3  patent	Costs. LICENSEE shall reimburse the MRC all past (prior to the Effective Date) and 
future (on or after the Effective Date) Patent Costs plus a fifteen percent (15%) patent 
service fee within thirty (30) days following receipt by LICENSEE of an itemized invoice 
from the MRC. Past Patent Costs are _______ (R_______) 
3.4  due	diligence.	
(a)  LICENSEE shall: 
(1) adhere to the following milestones: (a) 1st milestone within ____ (_) years from the 
Effective Date of this Agreement; (b) 2nd milestone within ____ (_) years from the 
Effective Date; 
(2) use its best efforts to develop, manufacture, market and sell the Products in the 
Territory and will exert its best efforts to create a demand for the Licensed Products; 
(3) maintain satisfactory standards in respect to the nature of the Product manufactured 
and/or sold by LICENSEE. LICENSEE, agrees that all Product manufactured and/or sold 
by it shall be of a quality which is appropriate to products of the type here involved. 
LICENSEE agrees that similar provisions shall be included by sublicenses of all tiers;
(4) annually spend not less than _______ Rand (R_______) for the development of Licensed 
Products during the first __ years of this Agreement. LICENSEE may, at its sole option, 
fund the research of any one of the Inventors and credit the amount of such funding 
actually paid to the MRC against its obligation under this paragraph; or
(3) annually spend not less than _______ Rand (R_______) for the development of Licensed 
Products during the first __ years of this Agreement. LICENSEE recognizes the expertise 
of the Inventors in Invention and is committed to contract the Inventors to further 
develop Invention at the MRC at R__ a year for a total of ___ years. LICENSEE may credit 
the amount actually paid to the MRC under such contract against its obligation under 
this paragraph; 
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(4) market Licensed Products in South Africa within six (6) months of receiving regulatory 
approval to market such Licensed Products; 
(5) reasonably fill the market demand for Licensed Products following commencement of 
marketing at any time during the term of this Agreement; and 
(6) obtain all necessary governmental approvals for the manufacture, use and sale of 
Licensed Products. 
(b)  If LICENSEE fails to perform any of its obligations specified in Paragraphs 3.4(a)(1)-(6), then 
the MRC shall have the right and option upon thirty (30) days written notice to either 
terminate this Agreement or change LICENSEE’s exclusive license to a nonexclusive license 
unless LICENSEE begins to diligently cure any breach and such breach is cured within thirty 
(30) days of receipt of the notice. This right, if exercised by the MRC, supersedes the rights 
granted in Article 2. 
4.	 RepoRTS,	ReCoRdS	And	pAymenTS
4.1  Reports. 
(a)  progress	Reports. 
(1) Beginning _____ 200_ and ending on the date of first commercial sale of a Licensed 
Product in South Africa, LICENSEE shall submit to the MRC semi-annual progress 
reports covering LICENSEE’s (and Affiliate’s and Sublicensee’s) activities to develop and 
test all Licensed Products and obtain governmental approvals necessary for marketing 
the same. Such reports shall include a summary of work completed; summary of work 
in progress; current schedule of anticipated events or milestones; market plans for 
introduction of Licensed Products; and summary of resources (Rand value) spent in 
the reporting period. 
(2) LICENSEE shall also report to the MRC, in its immediately subsequent progress report, 
the date of first commercial sale of a Licensed Product in each country.
 
(b)  Royalty	Reports. After the first commercial sale of a Licensed Product anywhere in the 
world, LICENSEE shall submit to the MRC quarterly royalty reports on or before each 
February 28, May 31, August 31 and November 30 of each year. Each royalty report shall 
cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar 
quarter and shall show: 
(1) the gross sales, deductions and Net Sales during the most recently completed calendar 
quarter and the royalties, in Rands, payable with respect thereto; 
(2) the number of each type of Licensed Product sold; 
(3) sublicense fees and royalties received during the most recently completed calendar 
quarter in Rands, payable with respect thereto; 
(4) the method used to calculate the royalties; and 
(5) the exchange rates used. 
If no sales of Licensed Products have been made and no sublicense revenues have been received 
by LICENSEE during any reporting period, LICENSEE shall so report. 
4.2  Records	&	Audits. 
(a)  LICENSEE shall keep, and shall require its Affiliates and Sublicensees to keep, accurate and 
correct records of all Licensed Products manufactured, used, and sold, and sublicense fees 
received under this Agreement. Such records shall be retained by LICENSEE for at least five 
(5) years following a given reporting period. 
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(b)  All records shall be available during normal business hours for inspection at the expense 
of the MRC by the MRC’s Internal Audit Department or by a Certified Public Accountant 
selected by the MRC and in compliance with the other terms of this Agreement for the 
sole purpose of verifying reports and payments. Such inspector shall not disclose to the 
MRC any information other than information relating to the accuracy of reports and 
payments made under this Agreement or other compliance issues. In the event that any 
such inspection shows an under reporting and underpayment in excess of five percent 
(5%) for any twelve (12) month period, then LICENSEE shall pay the cost of the audit as 
well as any additional sum that would have been payable to the MRC had the LICENSEE 
reported correctly, plus an interest charge at a rate of ten percent (10%) per year. Such 
interest shall be calculated from the date the correct payment was due to the MRC up 
to the date when such payment is actually made by LICENSEE. For underpayment not 
in excess of five percent (5%) for any twelve (12) month period, LICENSEE shall pay the 
difference within thirty (30) days without interest charge or inspection cost. 
4.3  payments. 
(a)  All fees and royalties due the MRC shall be paid in Rands and all cheques shall be made 
payable to the MRC. When Licensed Products are sold in currencies other than Rands, 
LICENSEE shall first determine the earned royalty in the currency of the country in which 
Licensed Products were sold and then convert the amount into equivalent Rands, using 
the exchange rate quoted in the Wall Street Journal, or the exchange rate fixed for such 
date by the appropriate South African governmental agency, on the last business day of 
the applicable reporting period. 
(b)  Royalty	payments. 
(1) Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when 
delivered to a third party or Affiliate.
(2) LICENSEE shall pay earned royalties quarterly on or before February 28, May 31, August 
31 and November 30 of each calendar year. Each such payment shall be for earned 
royalties accrued within LICENSEE’s most recently completed calendar quarter. 
(3) Royalties earned on sales occurring or under sublicense granted pursuant to this 
Agreement in any country outside South Africa shall not be reduced by LICENSEE for 
any taxes, fees, or other charges imposed by the government of such country on the 
payment of royalty income, except that all payments made by LICENSEE in fulfillment 
of the MRC tax liability in any particular country may be credited against earned 
royalties or fees due the MRC for that country. LICENSEE shall pay all bank charges 
resulting from the transfer of such royalty payments. 
(4) If at any time legal restrictions prevent the prompt remittance of part or all royalties by 
LICENSEE with respect to any country where a Licensed Product is sold or a sublicense 
is granted pursuant to this Agreement, LICENSEE shall convert the amount owed to 
the MRC into Rands and shall pay the MRC directly from its SA sources of fund for as 
long as the legal restrictions apply. 
(5) LICENSEE shall not collect royalties from, or cause to be paid on Licensed Products 
sold to the account of the SA Government or any agency thereof as provided for in the 
license to the SA Government. 
(6) In the event that any patent or patent claim within Patent Rights is held invalid in a 
final decision by a patent office from which no appeal or additional patent prosecution 
has been or can be taken, or by a court of competent jurisdiction and last resort and 
from which no appeal has or can be taken, all obligation to pay royalties based solely 
on that patent or claim or any claim patentably indistinct therefrom shall cease as of 
the date of such final decision. LICENSEE shall not, however, be relieved from paying 
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any royalties that accrued before the date of such final decision, that are based on 
another patent or claim not involved in such final decision, or that are based on the 
use of Technology. 
(c)  late	payments.	In the event royalty, reimbursement and/or fee payments are not received 
by the MRC when due, LICENSEE shall pay to the MRC interest charges at a rate of ten 
percent (10%) per year on the amount due. Such interest shall be calculated from the date 
payment was due until actually received by the MRC. 
5.	 pATenT	mATTeRS
5.1  patent	prosecution	and	maintenance. 
(a)  Provided that LICENSEE has reimbursed the MRC for Patent Costs pursuant to Paragraph 
3.2, the MRC shall diligently prosecute and maintain the South African and, if available, 
foreign patents, and applications in Patent Rights using counsel of its choice. the MRC 
shall provide LICENSEE with copies of all relevant documentation relating to such 
prosecution and LICENSEE shall keep this documentation confidential. The counsel shall 
take instructions only from the MRC, and all patents and patent applications in Patent 
Rights shall be assigned solely to the MRC. 
(b)  The MRC shall consider amending any patent application in Patent Rights to include 
claims reasonably requested by LICENSEE to protect the products contemplated to be sold 
by LICENSEE under this Agreement at LICENSEE’S cost. 
(c)  LICENSEE shall apply for an extension of the term of any patent in Patent Rights if 
appropriate. LICENSEE shall prepare all documents for such application, and the MRC shall 
execute such documents and take any other additional action as LICENSEE reasonably 
requests in connection therewith. 
d)  LICENSEE may elect to terminate its reimbursement obligations with respect to any patent 
application or patent in Patent Rights upon three (3) months’ written notice to the MRC. 
The MRC shall use reasonable efforts to curtail further Patent Costs for such application 
or patent when such notice of termination is received from LICENSEE. The MRC, in its sole 
discretion and at its sole expense, may continue prosecution and maintenance of said 
application or patent, and LICENSEE shall then have no further license with respect thereto. 
Non-payment of any portion of Patent Costs with respect to any application or patent 
may be deemed by the MRC as an election by LICENSEE to terminate its reimbursement 
obligations with respect to such application or patent. The failure of LICENSEE to pay 
any such fee or costs within thirty (30) days of receipt of an invoice for same shall cause 
LICENSEE to automatically, without further action by the MRC, lose all rights in the 
jurisdiction for which fees or costs were due.
5.2  patent	Infringement.	
(a)  If LICENSEE learns of any substantial infringement of Patent Rights, LICENSEE shall so 
inform the MRC and provide the MRC with reasonable evidence of the infringement. 
Neither party shall notify a third party of the infringement of Patent Rights without the 
consent of the other party. Both parties shall use reasonable efforts and cooperation to 
terminate infringement without litigation. 
(b)  LICENSEE may request the MRC to take legal action against such third party for the 
infringement of Patent Rights. Such request shall be made in writing and shall include 
reasonable evidence of such infringement and damages to LICENSEE. If the infringing 
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activity has not abated ninety (90) days following LICENSEE’s request, the MRC shall elect 
to or not to commence suit on its own account. The MRC shall give notice of its election in 
writing to LICENSEE by the end of the one-hundredth (100th) day after receiving notice of 
such request from LICENSEE. LICENSEE may thereafter bring suit for patent infringement at 
its own expense, if and only if the MRC elects not to commence suit and the infringement 
occurred in a jurisdiction where LICENSEE has an exclusive license under this Agreement. 
If LICENSEE elects to bring suit, the MRC may join that suit at its own expense. 
(c)  Recoveries from actions brought pursuant to Paragraph 5.2(b) shall belong to the party 
bringing suit. Legal actions brought jointly by the MRC and LICENSEE and fully participated 
in by both shall be at the joint expense of the parties and all recoveries shall be shared 
jointly by them in proportion to the share of expense paid by each party. 
(d)  Each party shall cooperate with the other in litigation proceedings at the expense of the 
party bringing suit. Litigation shall be controlled by the party bringing the suit, except that 
the MRC may be represented by counsel of its choice in any suit brought by LICENSEE. 
5.3  patent	marking. LICENSEE shall mark all Licensed Products made, used or sold under the 
terms of this Agreement, or their containers, in accordance with the applicable patent 
marking laws. 
6.	 goveRnmenTAl	mATTeRS
6.1  governmental	Approval	or	Registration. If this Agreement or any associated transaction is 
required by the law of any nation to be either approved or registered with any governmental 
agency, LICENSEE shall assume all legal obligations to do so. LICENSEE shall notify the 
MRC if it becomes aware that this Agreement is subject to a South African or foreign 
government reporting or approval requirement. LICENSEE shall make all necessary filings 
and pay all costs including fees, penalties, and all other out-of-pocket costs associated with 
such reporting or approval process. 
6.2  export	Control	laws. LICENSEE shall observe all applicable South African and foreign laws 
with respect to the transfer of Licensed Products and related technical data to foreign 
countries, including, without limitation, the International Traffic in Arms Regulations and 
the Export Administration Regulations. 
6.3  preference	for	South	African	Industry. If LICENSEE sells a Licensed Product or Combination 
Product in SA, LICENSEE shall manufacture said product substantially in SA. 
6.4  Rights	of	SA	government. If the technology was developed with funds provided by South 
Africa, this agreement is subject to all applicable laws, regulations, and the terms of any 
agreements under which funds were provided. This includes any rights of South Africa to 
use the Technology for governmental purposes, any limits on the place of manufacture 
of products using the Technology, and any obligations to make products based on the 
technology available with in a reasonable time. 
7.	 TeRmInATIon	of	The	AgReemenT
7.1  Termination	by	the	mRC. If LICENSEE fails to perform or violates any term of this Agreement, 
then the MRC may give written notice of default (“Notice of Default”) to LICENSEE. If 
LICENSEE fails to cure the default within thirty (30) days of the Notice of Default, the MRC 
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may terminate this Agreement and the license granted herein by a second written notice 
(“Notice of Termination”) to LICENSEE. If a Notice of Termination is sent to LICENSEE, this 
Agreement shall automatically terminate on the effective date of that notice. Termination 
shall not relieve LICENSEE of its obligation to pay any fees owed at the time of termination 
and shall not impair any accrued right of the MRC. 
7.2  Termination	by	licensee. 
(a)  LICENSEE shall have the right at any time and for any reason to terminate this Agreement 
upon a ninety (90) day written notice to the MRC. Said notice shall state LICENSEE’s reason 
for terminating this Agreement. 
(b)  Any termination under Paragraph 7.2(a) shall not relieve LICENSEE of any obligation 
or liability accrued under this Agreement prior to termination or rescind any payment 
made to the MRC or action by LICENSEE prior to the time termination becomes effective. 
Termination shall not affect in any manner any rights of the MRC arising under this 
Agreement prior to termination. 
7.3  Survival	on	Termination. The following Paragraphs and Articles shall survive the termination 
of this Agreement: 
(a)  Article 4 (REPORTS, RECORDS AND PAYMENTS);
 
(b)  Paragraph 7.4 (Disposition of Licensed Products on Hand); 
(c)  Paragraph 8.2 (Indemnification); 
(d)  Article 9 (USE OF NAMES AND TRADEMARKS); 
(e)  Paragraph 10.2 hereof (Secrecy); and 
(f)  Paragraph 10.5 (Failure to Perform). 
7.4  disposition	of	licensed	products	on	hand. Upon termination of this Agreement, LICENSEE 
may dispose of all previously made or partially made Licensed Product within a period of 
one hundred and twenty (120) days of the effective date of such termination provided that 
the sale of such Licensed Product by LICENSEE, its Sublicensees, or Affiliates shall be subject 
to the terms of this Agreement, including but not limited to the rendering of reports and 
payment of royalties required under this Agreement. 
8.	 lImITed	wARRAnTy	And	IndemnIfICATIon
8.1  limited	warranty.	
(a)  The MRC warrants that it has the lawful right to grant this license. 
(b)  The license granted herein and the associated Technology are provided “AS IS WITH ALL 
FAULTS”, AND THE ENTIRE RISK AS TO SATISFACTORY QUALITY, PERFORMANCE, ACCURACY, 
AND EFFORT IS WITH THE LICENSEE. THE MRC MAKES NO WARRANTIES, EXPRESS 
OR IMPLIED, AND HEREBY DISCLAIMS ALL SUCH WARRANTIES, AS TO ANY MATTER 
WHATSOEVER, INCLUDING, WITHOUT LIMITATION, THE CONDITION, INCLUDING PURITY, 
OF ANY INVENTION(S), TECHNOLOGY OR PRODUCT, WHETHER TANGIBLE OR INTANGIBLE, 
LICENSED UNDER THIS AGREEMENT; OR OF MERCHANTABILITY, OR FITNESS FOR A 
PARTICULAR PURPOSE OF THE INVENTION, TECHNOLOGY OR PRODUCT; OR OWNERSHIP; 
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OR THAT THE USE OF THE LICENSED TECHNOLOGY OR PRODUCT WILL NOT INFRINGE ANY 
PATENT, COPYRIGHTS, TRADEMARKS, OR OTHER RIGHTS. LICENSOR SHALL NOT BE LIABLE 
FOR ANY DIRECT, CONSEQUENTIAL, OR OTHER DAMAGES SUFFERED BY ANY LICENSEE 
OR ANY THIRD PARTIES RESULTING FROM THE USE, PRODUCTION, MANUFACTURE, SALE, 
LEASE, CONSUMPTION, OR ADVERTISEMENT OF THE TECHNOLOGY OR PRODUCT. 
(c)  In no event shall the MRC be liable for any consequential, special, exemplary, punitive 
or incidental damages even if it has been advised of the possibility of such damages 
resulting from this Agreement or the exercise of the license granted herein or the use of 
the Invention, Licensed Product, Licensed Method or Technology. 
(d)  Nothing in this Agreement shall be construed as: 
(1) a warranty or representation by the MRC as to the validity or scope of any Patent 
Rights; 
(2) a warranty or representation that anything made, used, sold or otherwise disposed of 
under any license granted in this Agreement is or shall be free from infringement of 
patents of third parties; 
(3) an obligation to bring or prosecute actions or suits against third parties for patent 
infringement except as provided in Paragraph 5.2 hereof; 
(4) conferring by implication, estoppel or otherwise any license or rights under any 
patents of the MRC other than Patent Rights as defined in this Agreement, regardless 
of whether those patents are dominant or subordinate to Patent Rights; 
(5) an obligation to furnish any know-how not provided in Patent Rights and Technology; 
or 
(6) an obligation to update Technology. 
(e)  LICENSEE agrees that the MRC’s liability in connection with the Invention, Technology and 
Patent Rights, whether arising in contract, negligence, strict liability, tort or otherwise 
shall not exceed the lesser of (i) the amount paid by LICENSEE to the MRC for the license, 
or (ii) R_____.
(f)  LICENSEE understands and agrees that the MRC is not engaged, and does not purport 
to be engaged, in LICENSEE’S business and LICENSEE assumes all responsibilities and 
obligations with respect to any decision LICENSEE makes or action LICENSEE may take as 
a result of LICENSEE’S use of the Invention, Technology and Patent Rights. The limitations 
of warranties, liabilities, and remedies under this Agreement are a reflection of the risks 
assumed by the parties in order to obtain the Invention, Technology or Patent Rights at the 
specified license fee. LICENSEE agrees to assume the risk for: (i) all liabilities disclaimed by 
the MRC contained herein, and (ii) all alleged damages in excess of the amount, if any, of 
the remedy provided hereunder.
8.2  Indemnification. 
(a)  LICENSEE shall indemnify, hold harmless and defend the MRC, its officers, employees, and 
agents; the sponsors of the research that led to the Invention; and the Inventors of the 
patents and patent applications in Patent Rights and their employers against any and 
all claims, suits, losses, damage, costs, fees, and expenses resulting from or arising out 
of exercise of this license or any sublicense or which may be brought against LICENSOR, 
its Trustees, officers, faculty, employees or students as a result of or arising out of any 
negligent act or omission of LICENSEE, its agents, or employees, or arising out of use, 
production, manufacture, sale, lease, consumption or advertisement by LICENSEE or any 
third party of any licensed Product, Invention or Technology licensed under this Agreement. 
This indemnification shall include, but not be limited to, any product liability.
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(b)  LICENSEE, at its sole cost and expense, shall insure its activities in connection with the work 
under this Agreement and obtain, keep in force and maintain insurance or an equivalent 
program of self insurance as follows: 
(1) comprehensive or commercial general liability insurance (contractual liability included) 
with limits of at least: (i) each occurrence, R1,000,000; (ii) products/completed 
operations aggregate, R5,000,000; (iii) personal and advertising injury, R1,000,000; 
and (iv) general aggregate (commercial form only), R5,000,000; and 
(2) the coverage and limits referred to above shall not in any way limit the liability of 
LICENSEE. 
(c)  LICENSEE shall furnish the MRC with certificates of insurance showing compliance with 
all requirements. Such certificates shall: (i) provide for thirty (30) day advance written 
notice to the MRC of any modification; (ii) indicate that the MRC has been endorsed as an 
additional insured under the coverage referred to above; and (iii) include a provision that 
the coverage shall be primary and shall not participate with nor shall be excess over any 
valid and collectable insurance or program of self-insurance carried or maintained by the 
MRC. 
(d)  The MRC shall notify LICENSEE in writing of any claim or suit brought against the MRC in 
respect of which the MRC intends to invoke the provisions of this Article. LICENSEE shall 
keep the MRC informed on a current basis of its defense of any claims under this Article. 
9.	 uSe	of	nAmeS	And	TRAdemARKS
9.1  Nothing contained in this Agreement confers any right to use in advertising, publicity, 
or other promotional activities any name, trade name, trademark, or other designation 
of either party hereto (including contraction, abbreviation or simulation of any of the 
foregoing). Unless required by law, the use by LICENSEE of the name, Medical Research 
Council is prohibited, without the express written consent of the MRC. 
9.2  The MRC may disclose to the Inventors the terms and conditions of this Agreement upon 
their request. If such disclosure is made, the MRC shall request the Inventors not disclose 
such terms and conditions to others. 
9.3  The MRC may acknowledge the existence of this Agreement and the extent of the grant 
in Article 2 to third parties, but the MRC shall not disclose the financial terms of this 
Agreement to third parties, except where the MRC is required by law to do so. 
10.	 mISCellAneouS	pRovISIonS
10.1  Correspondence. Any notice or payment required to be given to either party under this 
Agreement shall be deemed to have been properly given and effective: 
(a)  on the date of delivery if delivered in person, or 
(b)  five (5) days after mailing if mailed by first-class or certified mail, postage   
paid, to the respective addresses given below, or to such other address as    
is designated by written notice given to the other party. 
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If sent to LICENSEE: 
[Name and address of licensee] 
Attention: __________________ 
If sent to the MRC: 
MRC Innovation Centre
Fransie van Zijl Drive, Parowvallei 
Cape Town 
Attention: Prof Bunn 
10.2  Secrecy. 
(a)  “Confidential Information” shall mean information, including Technology, relating to the 
Invention and disclosed by the MRC to LICENSEE during the term of this Agreement, which 
if disclosed in writing shall be marked “Confidential”, or if first disclosed otherwise, shall 
within thirty (30) days of such disclosure be reduced to writing by the MRC and sent to 
LICENSEE: 
(b)  Licensee shall: 
(1) use the Confidential Information for the sole purpose of performing under the terms 
of this Agreement; 
(2) safeguard Confidential Information against disclosure to others with the same degree 
of care as it exercises with its own data of a similar nature; 
(3) not disclose Confidential Information to others (except to its employees, agents 
or consultants who are bound to LICENSEE by a like obligation of confidentiality) 
without the express written permission of the MRC, except that LICENSEE shall not be 
prevented from using or disclosing any of the Confidential Information that: 
(i) LICENSEE can demonstrate by written records was previously known to it; 
(ii) is now, or becomes in the future, public knowledge other than through acts or 
omissions of LICENSEE; or 
(iii) is lawfully obtained by LICENSEE from sources independent of the MRC; and 
(c)  The secrecy obligations of LICENSEE with respect to Confidential Information shall 
continue for a period ending five (5) years from the termination date of this Agreement. 
10.3  Assignability. This Agreement may be assigned by the MRC. This Agreement may not be 
assigned by LICENSEE except in connection with the sale or other transfer of LICENSEE’s 
entire business or that part of LICENSEE’s business to which the license granted hereby 
relates. LICENSEE shall give the MRC thirty (30) days’ prior notice of such assignment 
or transfer. Any other assignment of this License Agreement without the prior written 
consent of the MRC shall be void. Such written consent shall not be unreasonably withheld 
or delayed. 
10.4  no	waiver. No waiver by either party of any breach or default of any covenant or agreement 
set forth in this Agreement shall be deemed a waiver as to any subsequent and/or similar 
breach or default. 
10.5  failure	to	perform. In the event of a failure of performance due under this Agreement and 
if it becomes necessary for either party to undertake legal action against the other on 
account thereof, then the prevailing party shall be entitled to reasonable attorney’s fees in 
addition to costs and necessary disbursements. 
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10.6  governing	 laws. THIS AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN 
ACCORDANCE WITH THE LAWS OF THE REPUBLIC OF SOUTH AFRICA, but the scope and 
validity of any patent or patent application shall be governed by the applicable laws of the 
country of the patent or patent application. Any action in connection with this Agreement 
shall be commenced and maintained only in the South African Court and LICENSEE consent 
to personal jurisdiction and venue in any such court.
10.7  force	majeure. A party to this Agreement may be excused from any performance required 
herein if such performance is rendered impossible or unfeasible due to any catastrophe or 
other major event beyond its reasonable control, including, without limitation, war, riot, 
and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or 
other serious labor disputes; and floods, fires, explosions, or other natural disasters. When 
such events have abated, the non-performing party’s obligations herein shall resume. 
10.8  headings. The headings of the several sections are inserted for convenience of reference 
only and are not intended to be a part of or to affect the meaning or interpretation of this 
Agreement. 
10.9  entire	Agreement.	This Agreement embodies the entire understanding of the parties and 
supersedes all previous communications, representations or understandings, either oral or 
written, between the parties relating to the subject matter hereof. 
10.10  Amendments. No amendment or modification of this Agreement shall be valid or binding 
on the parties unless made in writing and signed on behalf of each party. 
10.11  Severability. In the event that any of the provisions contained in this Agreement is held to be 
invalid, illegal, or unenforceable in any respect, such invalidity, illegality or unenforceability 
shall not affect any other provisions of this Agreement, and this Agreement shall be 
construed as if the invalid, illegal, or unenforceable provisions had never been contained in 
it. 
10.12  Time	limitation	on	Initiation	of	actions.	No action, regardless of form, arising out of the 
subject matter of this Agreement may be brought by LICENSEE more than one (1) year after 
the cause of action has arisen.
IN WITNESS WHEREOF, both the MRC and LICENSEE have executed this Agreement, in duplicate 
originals, by their respective and duly authorized officers on the day and year written. 
[lICenSee]:		 	 	 	 						The	mRC: 
By:            By:      
                                        (Signature)                                                   (Signature) 
Name:            Name:     
Title:            Title:       
Date:            Date:     
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WITNESS:      WITNESS: 
By:             By:      
                                        (Signature)                              (Signature) 
Name:             Name:     
Title:             Title:       
Date:             Date:     
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by and between
BeTTeR	 Seed	 CompAny, a company organised and existing under the laws of ___________ 
[country] in the name of BETTER SEED CO Ltd and having its registered office in ____________ 
[address] (hereinafter called “BETTER SEED CO.”)
and
golden	hyBRIdS,	a company organised and existing under the laws of ___________ [country] in the 
name of Golden Hybrids S.A. and having its registered office in ____________ [address] (hereinafter 
called “GOLDEN HYBRIDS”).
InTRoduCTIon
GOLDEN HYBRIDS is a company breeding, trialling, producing, marketing and selling new varieties 
of various agricultural species. 
BETTER SEED CO. is a breeder of corn and other species and the owner of the varieties provided 
under this agreement, or has the right to organize for introduction and marketing of varieties in 
certain territories. 
Under this agreement, GOLDEN HYBRIDS will trial certain varieties owned or represented by 
BETTER SEED CO., with the intention of becoming an exclusive distributor and exclusive producer 
of the varieties in Southeast Asia.
1.	 defInITIonS
GROSS SALES means income at invoice values received for LICENSED PRODUCTS over a given 
period of time.
INTELLECTUAL PROPERTY means the patents, copyrights, trademarks, design rights, data protection 
rights, PVP and any other statutory rights for inventions, improvements, designs, and any other 
intellectual property rights.
INVENTION means the invention, which is the subject matter of PATENTS, PLANT VARIETY 
PROTECTION or any other form of INTELLECTUAL PROPERTY protection and licensed hereunder 
to GOLDEN HYBRIDS.
LICENSED MATERIAL means all forms of living and non-living biological material including 
without limitation strains, clones, plants, parts of plants, cultivars, germplasm, and genetic 
material provided by BETTER SEED CO. to GOLDEN HYBRIDS under this agreement.
LICENSED PRODUCTS means the crop or crops or any parts of the VARIETIES or TRIAL VARIETIES 
listed in Schedule 1 and 2.
Sample	Agreement	4:		
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Source:	Based on an actual agreement. The names of the parties are purely fictional and have been 
inserted for illustration purposes only. Certain terms of the license have been modified or left blank.
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NET SALES means GROSS SALES reduced by customer discounts, returns, freight out, and 
allowances.
PVP means Plant Variety Protection; the protection of varieties as a form of exclusive ownership 
and use rights determined based on distinctness, uniformity and stability of the Plant Material.
RIGHTS shall mean plant variety rights to the Varieties in the Territory.
SUBSIDIARY of BETTER SEED CO. means any corporation over 50% of the voting stock of which is 
directly or indirectly owned or controlled by such GOLDEN HYBRIDS. 
TERRITORY shall mean Country X and any such countries listed in Schedule 4 as amended from 
time to time by mutual written agreement.
TRIAL VARIETIES shall mean all the varieties of corn listed in Schedule 1, as amended from time 
to time.




2.1 BETTER SEED CO. grants to GOLDEN HYBRIDS and its SUBSIDIARIES the exclusive right to 
grow the Trial Varieties in the Territory for a period of 7 (seven) growing seasons in order to 
evaluate the material.
2.2 GOLDEN HYBRIDS shall at its own expense in relation to each of the Trial Varieties carry out 
the necessary trials to determine whether they are suitable for use in the Territory. GOLDEN 
HYBRIDS shall keep full and accurate records and provide BETTER SEED CO. with the results 
of the trials in the form provided. GOLDEN HYBRIDS shall notify BETTER SEED CO. of the 
location of the trials. GOLDEN HYBRIDS shall allow BETTER SEED CO. and its agents access 
to the trials on reasonable notice.
2.3 BETTER SEED CO. shall at GOLDEN HYBRIDS’s expense provide GOLDEN HYBRIDS with 
sufficient seed to carry out trials, and supply such technical and other relevant information 
in its possession as will assist GOLDEN HYBRIDS effectively to evaluate the Trial Varieties.
2.4 BETTER SEED CO. shall supply GOLDEN HYBRIDS with up to 20 (twenty) new Trial Varieties 
per year, if available.
2.5 At any time before and for 6 (six) months after the end of the trials of a variety, GOLDEN 
HYBRIDS may request that the Trial Variety becomes one of the Varieties, and on consent 
from BETTER SEED CO. it becomes one of the Varieties. If a variety is not selected for 
commercialisation, the Agreement shall terminate with regard to that variety.
3.	 gRAnT	of	RIghTS
3.1 GOLDEN HYBRIDS is granted the exclusive right to produce Varieties.
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3.2 GOLDEN HYBRIDS is granted the exclusive right to authorise third parties to exercise Rights 
for the marketing and sale in the Territory of seed of the Varieties.
3.3 BETTER SEED CO. undertakes not to produce or market seed of the Licensed Products in the 
Territory.
3.4 GOLDEN HYBRIDS agrees to permit BETTER SEED CO. or its representatives to inspect the 
facilities where Licensed Products are being produced and packaged.
4.	 duRATIon
4.1	 Notwithstanding clause 10 below, this agreement shall become effective upon signature 
by both parties hereto and will remain in force for 5 (five) years (EXPIRATION). 
4.2	 Unless terminated with at least 6 months notice and 6 months prior to Expiration, this 
agreement shall automatically be renewed for periods of 2 (two) years.
5.	 golden	hyBRIdS’S	oBlIgATIonS
5.1 GOLDEN HYBRIDS shall at its own expense ensure (so far as possible) that the Varieties are 
entered on the National Plant Variety List in the Territory and shall maintain the Varieties 
on the National Plant Variety List and the Rights for the Varieties in the Territory and shall 
not allow such entry or Rights to lapse unless the variety is withdrawn from the market.
5.2 GOLDEN HYBRIDS shall at its own expense apply for Rights on the single-cross hybrids in 
the Territory. If a variety is not granted Rights by the authorities within a reasonable time 
frame in the Territory, the Agreement shall terminate with regard to that variety.
5.3 Before selling LICENSED PRODUCTS, GOLDEN HYBRIDS shall submit to BETTER SEED CO., 
at no cost to BETTER SEED CO. and for approval as to quality, at least one complete set of 
all promotional and advertising material associated therewith. Failure of BETTER SEED CO. 
to approve such samples within 10 (ten) working days after receipt hereof will be deemed 
approval. If BETTER SEED CO. should disapprove any such sample, it shall provide specific 
reasons for such disapproval. Once such samples have been approved by BETTER SEED CO., 
GOLDEN HYBRIDS shall not materially depart therefrom without BETTER SEED CO.’s prior 
express written consent, which shall not be unreasonably withheld.
5.4 GOLDEN HYBRIDS shall advise BETTER SEED CO. annually of its marketing plans for the 
subsequent year for the Varieties.
5.5 GOLDEN HYBRIDS shall purchase all inbreds for the production of the Varieties from BETTER 
SEED CO. unless BETTER SEED CO. licenses to GOLDEN HYBRIDS the right to produce inbreds. 
Such license, if agreed, shall be granted through an amendment to this Agreement.
5.6 GOLDEN HYBRIDS shall maintain clear records of all amounts of hybrids and varieties 
produced and inform BETTER SEED CO. on a yearly basis of such quantities produced, sold, 
distributed as promotional materials, and stock levels.
5.7 GOLDEN HYBRIDS shall use in its promotion of the Varieties BETTER SEED CO. trademarks, 
logos and distinctive BETTER SEED CO. business marks (Schedule 3).
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5.8 On all advertising and technical material GOLDEN HYBRIDS shall refer to BETTER SEED CO. 
as breeder of the Varieties.
5.9 GOLDEN HYBRIDS shall maintain ISO 9001 quality standards. If ISO 9001 standard 
certification were revoked or suspended, GOLDEN HYBRIDS shall notify BETTER SEED CO. 
immediately and GOLDEN HYBRIDS shall use its best efforts to restore such a quality in 
a timely manner. In the event that GOLDEN HYBRIDS has not taken appropriate steps to 
restore such a quality within 24 months after notification by BETTER SEED CO., BETTER 
SEED CO. has the right to terminate this Agreement.
6.	 BeTTeR	Seed	Co.’s	oBlIgATIonS
6.1 Subject to the receipt of reasonable notice from GOLDEN HYBRIDS BETTER SEED CO. shall 
sell to GOLDEN HYBRIDS such quantities of pre-basic and basic seed of the parental lines 
as GOLDEN HYBRIDS may from time to time request. Seed shall meet the standard of 
certification required in the Territory. The prices for such seed shall be agreed in writing 
prior to delivery and may be reviewed from time to time.
6.2 BETTER SEED CO. shall provide all the supporting information reasonably required by 
GOLDEN HYBRIDS for the purposes of any application, entry or maintenance.
6.3 BETTER SEED CO. shall notify GOLDEN HYBRIDS should it become aware of any changes 
that materially affect the execution of this Agreement.
6.4 BETTER SEED CO. agrees to supply GOLDEN HYBRIDS, at BETTER SEED CO. expense, at least 
5kg (five kg) per F1 hybrid seed per growing season (where 1 calendar year has 2-3 seasons) 
for the exclusive purpose of GOLDEN HYBRIDS registering the hybrid in national field trials. 
Such national field trials require 3 (three) growing seasons.
6.5 BETTER SEED CO. agrees to supply GOLDEN HYBRIDS, at BETTER SEED CO. expense, at least 
50kg (fifty kg) per F1 hybrid seed per growing season (where 1 calendar year has 2-3 seasons) 
for the exclusive purpose of GOLDEN HYBRIDS conducting demonstration trials prior to 
commercialization. Such demonstration trials require 3 (three) growing seasons.
6.6 At the request of GOLDEN HYBRIDS, BETTER SEED CO. shall provide adequate samples of 
all certification lots of seed of the Varieties in order that GOLDEN HYBRIDS can use such 
samples for check plots.
7.	 RoyAlTIeS
7.1 BETTER SEED CO. shall, at its own discretion, supply GOLDEN HYBRIDS with inbreds for 
the production of hybrids. If such inbreds are supplied, BETTER SEED CO. shall sell them to 
GOLDEN HYBRIDSS at a price not to exceed $10/kg per inbred line.
7.2 All seed of the Varieties, whether certified or not (and sold) as seed within the Territory 
under the licence granted under Clause 3 above shall be subject to the payment of a 
royalty.
7.3 The royalty shall be on a sliding scale basis where royalties are due on the sale price on net 
volume sold, for each calendar year, for each hybrid:
 -  first 100 metric tons of seed sold:  calculated at 6.5 % royalties 
-  101-250 metric tons of seed sold:  calculated at 5.5 % royalties 
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-  251-500 metric tons of seed sold:  calculated at 4.5 % royalties 
-  501+ metric tons of seed sold:  calculated at 4.0 % royalties
7.4 GOLDEN HYBRIDS shall keep accurate accounts and records of all Gross and Net sales of 
seed of the Varieties upon which royalties are payable. BETTER SEED CO. or an independent 
accountant authorised by BETTER SEED CO. shall be permitted to inspect such accounts 
and records at least once in each year solely for the purpose of verifying the volume and 
type of sales upon which royalties are payable. 
7.5 If on investigation GOLDEN HYBRIDS has underpaid royalties by more than 2.5% of the 
amount due, the costs of the investigation shall be paid by GOLDEN HYBRIDS.
7.6 GOLDEN HYBRIDS agrees to negotiate in good faith with BETTER SEED CO. on minimum 
aggregate inbred and royalty payments. Such negotiations shall commence as soon as field 
trial data and sales projections permit, but must be concluded prior to the first commercial 
sales. Such clause shall be incorporated in Schedule 5 and duly signed.
8.	 pAymenT	of	RoyAlTIeS
8.1 Not later than 15 January in each year GOLDEN HYBRIDS shall send a report to BETTER SEED 
CO. giving details of seed sales of the Varieties upon which royalty is payable in respect of 
the period of 12 months ended the previous year. GOLDEN HYBRIDS shall pay to BETTER 
SEED CO. by bank transfer on or around 1 February of every year.
8.2 Royalty shall be paid in US Dollars converted at the exchange rate in effect with BANK on 
the close of business on the business day before the due date for payment. In the event 
such bank rates differ, the average of the two shall be applied.
8.3 BETTER SEED CO. shall deduct the mandatory 10% taxes (effective deduction of 11.11%) on 
royalty payments prior to making the transfer. Such tax shall not be applied to payments 
for the supply of inbred seed. GOLDEN HYBRIDS shall notify BETTER SEED CO. immediately 
if and when the mandatory tax rate changes.
 
9.	 BReACh	of	RIghTS
9.1 If GOLDEN HYBRIDS becomes aware of any third party breach of rights in the Varieties it shall 
promptly notify BETTER SEED CO., which shall take such steps as it considers appropriate to 
remedy the breach and take such steps as are necessary to enforce the Rights.
10.	 TeRmInATIon
10.1 Notwithstanding Clause 4 above either party may terminate this Agreement at any time 
without incurring any liability thereby and without prejudice to any other remedies it may 
have if:
i) the other commits a breach of this Agreement and if capable of remedy that other fails to 
remedy the breach within one month having been required to do so by written notice; or 
ii) the other enters into liquidation whether compulsorily or voluntarily (except for the 
purposes of reconstruction or amalgamation) or if a receiver or administrative receiver 
is appointed over the assets of the other of the equivalent of any of these events in the 
Territory.
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iii) If by reason of any circumstances as described in Clause 18 the performance of this 
Agreement becomes impossible for more than 12 (twelve) consecutive months either 
party shall be entitled to terminate this Agreement.
iv) GOLDEN HYBRIDS shall, notwithstanding termination of this Agreement, remain 
permanently as non-exclusive license of each of the Varieties under the terms of this 
Agreement where Rights have been applied for and granted or seed has been marketed 
for more than 3 (three) growing seasons by GOLDEN HYBRIDS. 
v) Sales and invoicing of seeds remaining at the termination of this Agreement have to 
be made as “certified seed”. BETTER SEED CO. has the right to take over seed of higher 
qualities from GOLDEN HYBRIDS at cost price.
11.	 SuRRendeR
GOLDEN HYBRIDS may surrender its rights to any of the Trial Varieties or Varieties at any time, on 
giving notice to BETTER SEED CO.. Surrender will not affect the obligations of GOLDEN HYBRIDS 
under Clauses 5, 6 and 7 above.
12.	 ASSIgnmenT
12.1 This Agreement is personal to the parties and may not be assigned by either party without 
the prior written consent of the other, although each party may perform the obligations 
undertaken by it and exercise the rights granted to it under this Agreement either itself or 
through any one or more of its subsidies or associated companies.
13.	 ConfIdenTIAlITy
The parties shall not disclose during the validity of this Agreement or thereafter to any third party 
any commercial, technical or other information of a confidential nature received of obtained by 
either party from the other except information provided as a marketing aid.
14.	 dISpuTe	ReSoluTIon
14.1 In event of dispute shall arise between the PARTIES to this Agreement, the PARTIES agree 
to participate in at least 4 (four) hours mediation in accordance with the mediation rules 
of F.I.S. Arbitration procedures for the International Seed Trade.
14.2 In case the PARTIES are unable to resolve the dispute in mediation they agree to submit 
the dispute to final and binding arbitration under the arbitration rules of F.I.S. Arbitration 
procedures for the International Seed Trade, and the judgment upon the award rendered 
by the Arbitrator(s) may be entered into any court having judgment thereof. 
14.3 The PARTIES agree to share equally the costs of mediation and arbitration.
15.	 goodwIll
In the event of termination of the Agreement, neither party shall be entitled under law or 
otherwise to receive any payment from the other for actual, consequential, indirect, special or 
incidental damages, costs or expenses, whether foreseeable or unforeseeable (including but 
not limited to labour claims and loss of profits, investments or goodwill), any right to which the 
parties hereby waive and disclaim to the fullest extent permitted by law.
APPENDIX 
 HANDBOOK OF BEST PRACTICES  | 1899 
plant	variety	and	Trademark	license
16.	 ImpRovemenTS	And	dISCoveRIeS
16.1 If during the term of this Agreement GOLDEN HYBRIDS generates any improvement or 
discovery which improves the Licensed Material, it shall notify BETTER SEED CO. immediately 
and the Parties shall meet to discuss the ownership and intellectual property protection 
of such improvement or discovery , and if appropriate, the Territory and Countries in which 
such intellectual property protection should be sought. 
16.2 Should such improvement or discovery be protectable under intellectual property statutes, 
BETTER SEED CO. will be granted a royalty-free, worldwide, non-exclusive commercial license 
thereunder including the right to sublicense for all applications and an exclusive first 
option for a period of 12 months from the date the BETTER SEED CO. received notification of 
such improvement or discovery to negotiate worldwide exclusive access or all uses. 
16.3 In any event, GOLDEN HYBRIDS shall retain royalty bearing non-exclusive licenses for use 
in Territory. The terms of any license to be granted under this section shall be negotiated 
between the PARTIES and reduced to writing.
17.	 wARRAnTy	And	lIABIlITy
17.1 Except as expressly provided herein, BETTER SEED CO. makes no representation and extends 
no warranties. BETTER SEED CO. disclaims any responsibility with respect to performance, 
merchantability, fitness for a particular purpose or freedom from infringement of third 
party patent rights (other than as of the date of the execution of this Agreement BETTER 
SEED CO. is not aware of any such infringement).
17.2 BETTER SEED CO. shall in no event be liable for damages, whether direct or otherwise, 
arising out of the use by GOLDEN HYBRIDS or any third party of information or materials 
supplied hereunder. 
17.3 In no event shall BETTER SEED CO. be liable for lost or prospective profits or special or 
consequential damages, whether or not BETTER SEED CO. has been advised of the possibility 
of the damages, nor for any claim by a third party against GOLDEN HYBRIDS. 
17.4 BETTER SEED CO. warrants that it is the sole owner of the LICENSED INTELLECTUAL PROPERTY 
and Materials and that it has the right to grant licenses. 
18.	 dISClAImeR
18.1 The seed supplied under this Agreement is from a conventional breeding program in which 
genetically modified material has never been deliberately introduced. The methods used 
in the breeding, development and production of these plant progenies, lines and varieties 
include procedures aimed at minimizing the adventitious presence of Genetically Modified 
Organisms (“GMO”).
18.2 BETTER SEED CO. shall not be liable, in any circumstances or for any reason, for incidental or 
consequential losses or special or punitive damages or any losses or damages of a similar 
nature. As a condition of liability, BETTER SEED CO. must receive notice by Registered Post 
within 30 (thirty) days after any defect becomes apparent.
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19.	 foRCe	mAjeuRe
Neither party shall be in default hereunder by reason of its delay in performance of, or failure to 
perform, any of its obligations hereunder, if such delay or failure is caused by strikes or other labour 
disturbance, acts of God, acts of the public enemy, riots or other civil disturbances, fire, flood, 
interference by civil or military authorities, compliance with government laws, rules or regulations, 
delays in transportation, failure of suppliers, inability to secure necessary governmental priorities 
for materials, or any other circumstances beyond its control and without its fault or negligence.
20.	 goveRnmenT	And	RegulAToRy	AppRovAlS
GOLDEN HYBRIDS shall be responsible for adhering to all laws and regulations and for obtaining 
and complying with all government and regulatory approvals, licenses, clearances and consents 
pertinent to or required to cover its activities under this Agreement.
21.	 mISCellAneouS
21.1 If any part of this Agreement is declared illegal or invalid then it shall be severed from the 
Agreement without affecting the remainder.
21.2 Each PARTY is acting as an independent entity. Nothing in this Agreement shall be construed 
so as to constitute a partnership or joint venture of any kind between BETTER SEED CO. and 
GOLDEN HYBRIDS.
21.3 Any notices given by either party to the other shall be made in writing by International 
Courier and addressed to them at their addresses set out above.
21.4 This Agreement shall be construed and interpreted according to the laws of Lucerne, 
Switzerland.
In witness whereof, the duly authorised representatives for and on behalf of the parties hereto 
have executed this Agreement in duplicate, each party taking 1 (one) copy, as of the day and year 
written below.
Date    
[BETTER SEED CO.]     [GOLDEN HYBRIDS]
By:            By:      
Title:            Title:       
SChedule	1
TRIAL VARIETIES
[description and listing of varieties]
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Schedule amended on [Date]                          
By:             By:      
                                     (Signature)                                               (Signature)




[description and listing of varieties]
Schedule amended on [Date]                          
By:             By:      
                                     (Signature)                                               (Signature)
By signature of this amended Schedule, all earlier Schedules 




Schedule amended on [Date]                           
                        
By:             By:      
                                     (Signature)                                               (Signature)
By signature of this amended Schedule, all earlier Schedules 
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Schedule amended on [Date]                          
By:             By:      
                                     (Signature)                                               (Signature)




In case the royalties paid for a given variety do not aggregate a minimum of _________ US dollars 
for the year ending December 31, ______, increasing by ____% annually for _____ succeeding 
calendar years, and continuing at such level ______ subsequently, BETTER SEED CO. shall be 
entitled to revert to a non-exclusive license for each such variety for which payments do not 
meet the minimum payment.
Schedule amended on [Date]	                         
By:             By:      
                                     (Signature)                                               (Signature)
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Source: Office of Technology Licensing, Stanford University, 1705 El Camino Real, Palo Alto, CA, 
94306, U.S.A. Reproduced with permission. Visit http://otl.stanford.edu and www.stanford.edu/
group/ICO/ to download many additional template and sample agreements.
The	CollegIATe	lICenSIng	CompAny
STAndARd	ReTAIl	pRoduCT	lICenSe	AgReemenT
This is an Agreement between ___________________, a _____________ organized under the laws 
of the state of _________, having a principal place of business at ___________________________
__________________ (“Licensee”), and the Collegiate Licensing Company, a Georgia corporation, 
having a principal place of business at 290 Interstate North, Suite 200, Atlanta, Georgia 30339 
(“CLC”), as agent on behalf of the Collegiate Institutions (as defined below). 
WHEREAS, the individual Collegiate Institutions have authorized CLC as agent to administer their 
respective trademark licensing programs; and 
WHEREAS, certain Collegiate Institutions have authorized CLC to enter into this Agreement on 
their behalf to license the use of certain Licensed Indicia (as defined below); and 
WHEREAS, Licensee desires to manufacture, advertise, distribute and sell certain Licensed Articles 
(as defined below) containing the Licensed Indicia, and certain Collegiate Institutions, through 
CLC, are willing, subject to certain conditions, to grant this license. 
NOW, THEREFORE, in consideration of the parties’ mutual covenants and undertakings, and other 
good and valuable consideration the receipt and sufficiency of which are acknowledged, the 
parties agree as follows:
1.	 defInITIonS
In addition to the terms defined elsewhere in this Agreement, as used in this Agreement, the 
following terms shall have the following respective meanings:
(a) “Collegiate Institutions” means the individual colleges, universities and other institutions 
represented by CLC, including any additions or deletions that may be made from time-to-
time by CLC.
(b) “Licensed Indicia” means the names and identifying indicia of the Collegiate Institutions 
including, without limitation, the trademarks, service marks, trade dress, team names, 
nicknames, abbreviations, city/state names in the appropriate context, slogans, designs, 
colors, uniform and helmet designs, distinctive landmarks, logographics, mascots, seals 
and other symbols associated with or referring to the respective Collegiate Institutions. 
Licensed Indicia includes those shown in Appendix B, modifications of the Licensed Indicia 
approved for use by the Collegiate Institutions, and any other names or identifying indicia 
adopted and approved for use by the Collegiate Institutions.
(c) “Licensed Articles” means the products listed in Appendix C which contain Licensed 
Indicia. 
(d) “Authorized Brands” means any additional brand names or labels Licensee may use in 
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association with the Licensed Articles. Authorized Brands are listed in Appendix D.
(e) “Distribution Channels” means the channels of trade in which Licensee may advertise, 
distribute and sell the Licensed Articles in the Territory. The Distribution Channels 
authorized herein are indicated in Appendix D, which may also identify Distribution 
Channels that are not authorized in this Agreement. Licensee shall not advertise, distribute 
or sell Licensed Articles to any third party that Licensee knows or should reasonably 
know intends or is likely to advertise, redistribute or resell Licensed Articles outside the 
authorized Distribution Channels.  
(f) “Territory” means the United States of America, its territories and possessions, and United 
States military bases abroad. Licensee shall not advertise, distribute or sell Licensed Articles 
outside the Territory, or to any person or entity that Licensee knows or should reasonably 
know intends or is likely to advertise, redistribute or resell Licensed Articles outside the 
Territory. 
(g) “Net Sales” means the total gross sales of all Licensed Articles distributed or sold at 
the greater of Licensee’s invoiced selling price or Licensee’s regular domestic wholesale 
warehouse price, including the royalty amount, less lawful quantity trade discounts actually 
allowed and taken as such by customers and shown on the invoice, less any credits for 
returns actually made as supported by credit memoranda issued to customers, less sales 
taxes, and less prepaid transportation charges on Licensed Articles shipped by Licensee 
from its facilities to the purchaser. There shall be no other deductions allowed including, 
without limitation, deductions for direct or indirect costs incurred in the manufacturing, 
distributing, selling, importing or advertising (including cooperative and other advertising 
and promotional allowances) of the Licensed Articles, nor shall any deductions be allowed 
for non-collected or uncollectable accounts, commissions, cash or early payment discounts, 
close-out sales, distress sales, sales to employees, or any other costs.
(h) “Premiums” means any products, including Licensed Articles, bearing any Licensed Indicia 
featured alone or in combination with the indicia of any third party, that Licensee sells or 
gives away for the purposes of (i) promoting, publicizing or increasing the sale of its own 
products or services; or (ii) promoting, publicizing or increasing the sale of the products 
or services of any third party. Premiums include, without limitation, combination sales, 
incentives for sales force, and trade or consumer promotions such as sweepstakes.
2.	 gRAnT	of	lICenSe
(a) Grant: Upon execution of this Agreement, and subject to its terms and conditions, the 
Collegiate Institutions listed in Appendix A, through CLC, grant Licensee the nonexclusive, 
revocable, nontransferable rights to manufacture, advertise, distribute and sell the Licensed 
Articles listed in Appendix C, containing the Licensed Indicia shown in Appendix B, under 
the applicable Authorized Brands and in the Distribution Channels indicated in Appendix 
D, in the Territory, during the Term. Licensee shall exercise such rights in accordance with all 
CLC and Collegiate Institution guidelines, policies and requirements provided to Licensee, 
which shall be deemed part of the Agreement. 
(b) Rights Reserved: Nothing in this Agreement shall be construed to prevent CLC or any 
Collegiate Institution from granting any other licenses or rights for use of the Licensed 
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(c) Term: This Agreement shall begin effective as of last date of signature below and shall 
expire __________________, unless terminated sooner or renewed in the manner provided 
in this Agreement. 
(d) Renewal: Upon expiration, if Licensee has complied with all terms and conditions of this 
Agreement during the preceding Term or renewal period, Licensee shall be considered 
for renewal of this Agreement. Renewal is at the discretion of the individual Collegiate 
Institutions in consultation with CLC. Licensee recognizes and agrees that CLC and the 
Collegiate Institutions have no express or implied obligation to renew the Agreement. CLC 
and the Collegiate Institutions will have no liability to Licensee for any expenses incurred 
by Licensee in anticipation of any renewal of the Agreement.
(e) Limitations on License: This license is subject to the following limitations and obligations, 
as well as other limitations and obligations set forth in the Agreement:
(1) Licensee shall not use the Licensed Indicia for any purpose other than as authorized in 
this Agreement. Any proposed additions to the Licensed Articles and/or new designs 
shall be submitted in writing or via iCLC to CLC and samples shall be submitted to 
CLC for prior approval, as provided in Section 10. Licensee shall, upon notice by CLC, 
immediately recall any unauthorized products or designs from the marketplace, and 
destroy them or submit them to CLC, at CLC’s option and at Licensee’s expense.
(2) Licensee shall not use any brand names other than Authorized Brands in connection 
with the manufacture, advertising, distribution and sale of the Licensed Articles. CLC 
and the Collegiate Institutions shall have the right to remove or change any of the 
Authorized Brands during the Term. 
(3) Licensee shall advertise, distribute and sell Licensed Articles only in the authorized 
Distribution Channels. CLC and the Collegiate Institutions shall have the right to 
determine whether a particular retail account falls within a particular Distribution 
Channel. Unless specified in Appendix D, Licensee shall have no right to advertise, 
distribute or sell Licensed Articles directly to consumers.
(4) Licensee must receive CLC’s prior written authorization to use any Distributor of 
any Licensed Article. A “Distributor” shall mean any party whose business includes 
purchasing manufactured products from any other third party and shipping such 
products to retailers without changing such products. Licensee will remain primarily 
obligated to CLC and the Collegiate Institutions under this Agreement notwithstanding 
CLC’s approval of a Distributor and Licensee shall ensure that any approved Distributor 
complies with all applicable terms and conditions of the Agreement including, without 
limitation, providing such Distributor with instructions relating to the distribution 
of the Licensed Articles and the Distribution Channels for the Licensed Articles. If an 
approved Distributor engages in conduct that would be a default under the Agreement 
if Licensee engaged in such conduct, Licensee shall be deemed in default and shall 
fully cooperate with CLC to ensure that such conduct ceases promptly. 
(5) Licensee shall not provide any method of application of Licensed Indicia for any third 
party unless CLC authorizes Licensee to provide said application under the terms of an 
authorized manufacturer’s or supplier’s agreement. 
(6) Licensee shall not contract with any domestic or foreign third party for the production 
of Licensed Articles or application of Licensed Indicia by that party (“Manufacturer”) 
without CLC’s prior written authorization. In the event that Licensee desires to have 
a Manufacturer produce one or more Licensed Article, or any component thereof, 
Licensee shall provide CLC with the name, address, telephone number and principal 
contact of the proposed Manufacturer. CLC must approve any Manufacturer, and the 
Manufacturer must execute an authorized manufacturer’s or supplier’s agreement 
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provided by CLC prior to use of the Licensed Indicia. In addition, Licensee shall take 
the steps necessary to ensure the following: Manufacturer shall produce the Licensed 
Articles only as and when directed by Licensee, which remains fully responsible for 
ensuring that the Licensed Articles are manufactured in accordance with the terms 
herein including approval, labor code requirements and royalty payment; Manufacturer 
shall not advertise, distribute or sell Licensed Articles to any person or entity other 
than Licensee; and Manufacturer shall not delegate in any manner whatsoever its 
obligations with respect to the Licensed Articles. Licensee’s failure to comply with this 
Section may result in termination of this Agreement and/or confiscation and seizure 
of Licensed Articles. CLC and the individual Collegiate Institutions hereby reserve the 
right to terminate the engagement of any Manufacturer at any time. 
(7) Licensee shall comply, and ensure that all Manufacturers comply, with labor code and 
monitoring requirements as established by the respective Collegiate Institutions and 
as set forth in The Collegiate Licensing Company Special Agreement Regarding Labor 
Codes of Conduct, which is incorporated herein by reference. CLC shall give Licensee 
reasonable written notice of any changes in labor code requirements. Licensee, 
upon receipt of the notice, is responsible for complying with the new labor code 
requirements. 
(8) Any Licensed Articles manufactured at a location outside of the United States shall 
be taken into the possession of Licensee prior to being distributed or sold in the 
Territory.
(9) Licensee shall have no right to delegate any responsibility to any Sublicensee of any 
Licensed Article without the prior written approval of CLC. A “Sublicensee” shall mean 
any third party that manufactures any Licensed Article, ships such product to retailers, 
and invoices retailers directly. 
(10) Licensee shall not use any of the Licensed Articles as Premiums unless Licensee 
receives prior written authorization through CLC pursuant to a separate agreement 
with CLC. Licensee shall not provide Licensed Articles as Premiums to any third party 
whom Licensee knows or should reasonably know intends to use the Licensed Articles 
as Premiums. 
(11)  Licensee is not permitted, without the applicable Collegiate Institution’s prior written 
authorization, to promote or market a Licensed Article by means of a direct mailing or 
any other direct solicitation to a list of alumni, students, parents, athletic contributors, 
faculty or staff, or other group associated with the Collegiate Institution, regardless of 
how Licensee acquires such list. 
(12) The National Collegiate Athletic Association (NCAA) rules prohibit the use of the name 
or likeness of any person who has current or remaining collegiate athletic eligibility on 
or in connection with the sale or promotion of any commercial product or service. In 
conducting activity under this Agreement, Licensee shall not encourage or participate 
in any activity that would cause an athlete or a Collegiate Institution to violate any such 
rule of the NCAA or other governing body of any intercollegiate athletic conference.
3.		 mARKeTIng	effoRTS	/	peRfoRmAnCe
(a)  Marketing Efforts: Licensee recognizes that marketing efforts for Licensed Articles are 
important to the success of this program and Licensee, if requested, will assist CLC 
with such efforts by its participation.
 
(b)  Performance: With respect to each of the Collegiate Institutions listed in Appendix 
A, Licensee shall manufacture, distribute, sell and maintain inventory of sufficient 
quantities of Licensed Articles to meet the reasonable market demand in the 
Distribution Channels.
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4.		 SeleCTIon	of	CollegIATe	InSTITuTIonS	
Prior to execution of this Agreement, Licensee requested a license for certain Collegiate 
Institutions. Appendix A lists those Collegiate Institutions that have approved Licensee’s request 
for a license. Licensee may from time-to-time request the addition of Collegiate Institutions to 
this Agreement, as provided in Section 5(d).
5.		 modIfICATIon	of	AppendICeS
(a)  The Collegiate Institutions and their royalty charges listed in Appendix A, the Licensed 
Indicia shown in Appendix B, the Collegiate Institution policies including those in Appendix 
B-1, the Licensed Articles listed in Appendix C, the Authorized Brands and Distribution 
Channels indicated in Appendix D, and labor code requirements may be changed by CLC 
when and if such changes are directed by CLC and the Collegiate Institutions. 
(b)  Through periodic advisory bulletins or notices, including, without limitation, notification 
through online publications (e.g., iCLC) or via email, CLC will give Licensee written 
reasonable notice of any changes to appendices or policies. Licensee, upon receipt of 
the bulletins or notices, is responsible for distributing them promptly to the appropriate 
party(s) and complying with the modified appendices and policies.
(c)  Licensee recognizes and agrees that certain changes to Appendices A, B, B-1, C, or D may 
affect Licensee’s rights regarding certain Collegiate Institutions, Licensed Indicia, Licensed 
Articles, Authorized Brands or Distribution Channels. Licensee agrees that such rights shall 
cease on the effective date of the notice of such changes, in accordance with the terms 
of the notice. In such event, those provisions of Section 17 regarding disposal of inventory 
shall become effective for the affected Collegiate Institutions, Licensed Indicia, Licensed 
Articles, Authorized Brands or Distribution Channels unless Licensee obtains written 
permission from the affected Collegiate Institutions concerned to continue to use the 
Licensed Indicia, or to manufacture, advertise, distribute or sell the Licensed Articles.
(d)  Upon notification by CLC of the addition of a Collegiate Institution to the CLC program, 
or at any other time, Licensee may request in writing or through iCLC the addition of 
Collegiate Institutions to the Agreement. Any such addition will require an addendum 
to Appendix A. Such addendum will be fully executed only upon Licensee’s completion of 
product and design approval requirements, as provided in Section 10.
6.		 pAymenTS	
(a)  Rate: Licensee agrees that it shall pay to CLC the applicable royalty charges set forth 
adjacent to the respective Collegiate Institutions listed in Appendix A. Unless otherwise 
specified, the royalties paid (“Royalty Payments”) shall be based upon Net Sales, as defined 
in Section 1(g), of all Licensed Articles sold during the Term and any renewal, and during 
any period allowed pursuant to Section 17. 
(b)  For purposes of determining the Royalty Payments, sales shall be deemed to have been 
made when Licensed Articles are billed, invoiced, shipped, or paid for, whichever occurs 
first.
(c)  Advance Payments: Upon execution of this Agreement by Licensee, and upon any renewal, 
Licensee shall pay CLC, as a nonrefundable payment, the Advance Payments set forth in 
Appendix A. Upon renewal, the Advance Payments will be prorated, where applicable, 
as per CLC’s written instructions. Licensee may apply the Advance Payments as credits 
against Royalty Payments and Minimum Guarantee payments (if applicable) due for the 
APPENDIX
1908 | HANDBOOK OF BEST PRACTICES
Intellectual Property and Trademark License
specific Collegiate Institutions, which credits shall expire no later than twenty (20) days 
after the expiration of the Term and any renewal period.
(d) Minimum Guarantee: Licensee shall pay CLC the Minimum Guarantee amounts (if 
applicable) set forth in Appendix A by no later than twenty (20) days after the end of the 
Term and any renewal period, unless specified otherwise in Appendix A.
(e)  Administrative Fee: Upon execution of this Agreement by Licensee, and upon any renewal, 
Licensee shall pay CLC, as a non-refundable payment, the Administrative Fee set forth in 
Appendix A.
(f)  Royalty Payments shall be paid by Licensee to CLC on all Licensed Articles (including, 
without limitation, any seconds, irregulars, etc. permitted pursuant to the provisions of 
Section 10(b) of this Agreement) distributed or sold by Licensee or any of its affiliated or 
subsidiary companies even if not billed or billed at less than the regular Net Sales price 
for such Licensed Articles, and payment shall be computed based upon the regular Net 
Sales price for such Licensed Articles distributed or sold to the trade by Licensee or, if such 
regular Net Sales pricing is not available, as determined by CLC’s evaluation of comparable 
prices charged the trade for similar products.
(g)  Distribution: In the event Licensee distributes or sells Licensed Articles at a special price 
directly or indirectly to itself, including without limitation, any affiliate or subsidiary of 
Licensee, to any other person, firm or corporation related in any manner to Licensee or 
its officers, directors or major stockholders, or through a Distributor (such distribution 
arrangements being subject to prior written approval by CLC), Licensee shall pay royalties 
with respect to such distribution or sales based upon the regular Net Sales price for such 
Licensed Articles distributed or sold to the trade by Licensee or, if such regular Net Sales 
pricing is not available, as determined by CLC’s evaluation of comparable prices charged 
the trade for similar products.
(h) FOB Sales: If a customer of Licensee purchases Licensed Articles FOB the manufacturing 
source or participates in other arrangements which result in such customer paying less 
for the Licensed Articles than Licensee’s regular selling price to the trade (such FOB Sales 
or other arrangements being subject to prior written approval by CLC), Licensee shall pay 
royalties with respect to such distribution or sales based upon the regular Net Sales price 
for such Licensed Articles distributed or sold to the trade by Licensee or, if such regular 
Net Sales pricing is not available, as determined by CLC’s evaluation of comparable prices 
charged the trade for similar products. 
(i)  Multiple Royalties: CLC recognizes that Licensee may be a party to other license agreements 
which, together with this Agreement, would subject certain Licensed Articles to one 
or more additional royalty payments above and beyond the Royalty Payments. Royalty 
Payments required to be paid to CLC for Licensed Articles may be reduced only by mutually 
agreed upon amounts set forth in writing. 
( j) Exempt Area: On or around certain Collegiate Institution campuses, certain accounts or 
areas may be exempt from the obligation to pay Royalty Payments for sales made and 
delivered by Licensee to customers located within the exempt area. If, however, Licensee 
charges royalties for such sales, then Royalty Payments are due and payable on such sales. 
Appendix B-1 lists those exemptions. CLC and the Collegiate Institutions reserve the right 
to add to or delete from Appendix B-1, and will notify Licensee of these changes in writing 
as provided in Section 5(b). Licensee shall be responsible for obtaining and documenting 
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confirmation from CLC or a Collegiate Institution licensing official that a particular account 
is exempt. 
7.		 RoyAlTy	STATemenT	And	penAlTIeS
(a)  On or before the twentieth (20th) day of each month, Licensee shall submit to CLC, in 
a format provided or approved by CLC, a full and complete statement, certified by an 
officer of the Licensee to be true and accurate, showing the quantity, description, and 
Net Sales (including itemization of any permitted deductions and/or exemptions) of 
the Licensed Articles distributed and/or sold during the preceding month, listed (i) by 
Collegiate Institution, (ii) by Licensed Article, (iii) by applicable Authorized Brand, and (iv) 
by Distribution Channel. Such report shall include any additional information kept in the 
normal course of business by the Licensee which is appropriate to enable an independent 
determination of the amount due hereunder with respect to each Collegiate Institution. 
All Royalty Payments then due CLC shall be made simultaneously with the submission of 
the statements. If no sales or use of the Licensed Articles were made during any reporting 
period for one or more Collegiate Institutions, Licensee shall provide CLC a written 
statement to that effect as part of the report.
(b)  Licensee shall pay CLC an additional charge of one and one-half percent (1.5%) per month, 
compounded on a monthly basis, or the maximum rate allowed by law, if lower, on any 
payment due under the Agreement that remains unpaid after such payment becomes 
due.
(c)  CLC’s receipt or acceptance of any statements or Royalty Payments, or the cashing of any 
royalty checks, shall not preclude CLC from questioning the correctness thereof at any 
time. Upon discovery of any verifiable inconsistency or mistake in such statements or 
payments, Licensee shall immediately rectify such inconsistency or mistake. 
(d)  Licensee shall, unless otherwise directed in writing by CLC, send all payments and 
statements to CLC at the address set forth in the heading of this Agreement, or transmit 
the same via electronic format approved by CLC. 
8.		 owneRShIp	of	lICenSed	IndICIA	And	pRoTeCTIon	of	RIghTS
(a)  Licensee acknowledges and agrees that the respective Collegiate Institutions own each of 
their respective Licensed Indicia, modifications of the Licensed Indicia, as well as any other 
Licensed Indicia adopted for use by the Collegiate Institutions, that each of the Licensed 
Indicia is valid, and that each Collegiate Institution has the exclusive right to use each 
of its Licensed Indicia subject only to limited permission granted to Licensee to use the 
Licensed Indicia pursuant to this Agreement. Licensee acknowledges the validity of the 
state and federal registrations each Collegiate Institution owns, obtains or acquires for 
its Licensed Indicia. Licensee shall not, at any time, file any trademark application with 
the United States Patent and Trademark Office, or with any other governmental entity 
for the Licensed Indicia, regardless of whether such Licensed Indicia is shown in Appendix 
B. Licensee shall not use any of the Licensed Indicia or any similar mark as, or as part 
of, a trademark, service mark, trade name, fictitious name, company or corporate name 
anywhere in the world. Any trademark or service mark registration obtained or applied for 
that contains the Licensed Indicia or any similar mark shall be immediately transferred to 
the applicable Collegiate Institution without compensation. 
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(b)  Licensee shall not oppose or seek to cancel or challenge, in any forum, including, but not 
limited to, the United States Patent and Trademark Office, any application or registration 
of the Licensed Indicia of any Collegiate Institution. Licensee shall not object to, or file any 
action or lawsuit because of, any use by the Collegiate Institutions of their Licensed Indicia 
for any goods or services, whether such use is by the Collegiate Institutions directly or 
through licensees or authorized users. 
(c)  Licensee recognizes the great value of the good will associated with the Licensed Indicia 
and acknowledges that such good will belongs to the Collegiate Institutions, and that 
such Licensed Indicia have inherent and/or acquired distinctiveness. Licensee shall not, 
during the term of this Agreement or thereafter, dispute or contest the property rights 
of the Collegiate Institutions, dispute or contest the validity of this Agreement, or use the 
Licensed Indicia or any similar mark in any manner other than as licensed hereunder.
(d)  Licensee agrees to assist CLC in the protection of the rights of the Collegiate Institutions in 
and to the Licensed Indicia and shall provide, at reasonable cost to be borne by CLC and/or 
the Collegiate Institutions, any evidence, documents, and testimony concerning the use by 
Licensee of the Licensed Indicia, which CLC may request for use in obtaining, defending, 
or enforcing rights in any Licensed Indicia or related application or registration. Licensee 
shall notify CLC in writing of any infringements by others of the Licensed Indicia of which 
it is aware. CLC and the applicable Collegiate Institution shall have the right to determine 
whether any action shall be taken on account of any such alleged infringements. Licensee 
shall not institute any suit or take any action on account of any such alleged infringements 
without first obtaining the written authorization of CLC and the Collegiate Institutions. 
Licensee agrees that it is not entitled to share in any proceeds received by CLC or any 
Collegiate Institution (by settlement or otherwise) in connection with any formal or 
informal action brought by CLC, Collegiate Institutions or other entity. 
(e)  Nothing in this Agreement gives Licensee any right, title, or interest in the Licensed Indicia 
except the right to use the Licensed Indicia in accordance with the terms of this Agreement. 
Licensee’s use of the Licensed Indicia shall inure to the benefit of the respective Collegiate 
Institutions. 
(f-1) Acknowledgment: Licensee acknowledges that any original designs, artwork or other 
compilations (“Works”) created by it pursuant to this Agreement that contain the 
Licensed Indicia are “compilations” or “supplementary works” as those terms are used in 
Section 101 of the Copyright Act, and that the Works will be, and will be treated as having 
been, specially ordered or commissioned for use as a compilation or supplementary work 
rendered for, at the instigation and under the overall direction of the Collegiate Institutions; 
and therefore that all the work on and contributions to the Works by Licensee, as well as 
the Works themselves, are and at all times shall be regarded as “work made for hire” by the 
Licensee for the Collegiate Institutions. Without limiting the foregoing acknowledgment 
or subsequent assignment, Licensee further acknowledges that any rights that Licensee 
might have under this Agreement do not in any way dilute or affect the interests of 
the Collegiate Institutions in the Licensed Indicia or any derivatives thereof; nor permit 
Licensee to copy or use the Works or the Licensed Indicia, except as expressly permitted 
under this Agreement; nor to affix a copyright or trademark notice to any product bearing 
the Works or the Licensed Indicia, except as expressly permitted under this Agreement. 
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(f-2) Assignment: Without curtailing or limiting the foregoing acknowledgment, Licensee 
assigns, grants and delivers (and agrees further to assign, grant and deliver) exclusively 
to the respective Collegiate Institutions, all rights, titles and interests of every kind and 
nature whatsoever in and to the Works, and all copies and versions, including all copyrights 
and all renewals. Licensee further agrees to execute and deliver to CLC and the Collegiate 
Institutions such other and further instruments and documents as CLC or the particular 
Collegiate Institutions from time-to-time reasonably may request for the purpose of 
establishing, evidencing and enforcing or defending the complete, exclusive, perpetual 
and worldwide ownership by such respective Collegiate Institutions of all rights, titles 
and interests of every kind and nature whatsoever, including all copyrights, in and to 
the Works, and Licensee appoints CLC as agent and attorney-in-fact, with full power of 
substitution, to execute and deliver such documents or instruments as Licensee may fail 
or refuse promptly to execute and deliver, this power and agency being coupled with an 
interest and being irrevocable. 
 
(g)  Licensee acknowledges that its breach or threatened breach of this Agreement will result 
in immediate and irremediable damage to CLC and/or the Collegiate Institutions and that 
money damages alone would be inadequate to compensate CLC and/or the Collegiate 
Institutions. Therefore, in the event of a breach or threatened breach of this Agreement 
by Licensee, CLC and/or the Collegiate Institutions may, in addition to other remedies, 
immediately obtain and enforce injunctive relief prohibiting the breach or threatened 
breach or compelling specific performance. In the event of any breach or threatened breach 
of this Agreement by Licensee or infringement of any rights of the Collegiate Institutions, if 
CLC and/or the Collegiate Institutions employ attorneys or incur other expenses, Licensee 
shall reimburse CLC and/or the Collegiate Institutions for their reasonable attorney’s fees 
and other expenses. 
9.		 dISplAy	And	AppRovAl	of	lICenSed	IndICIA
(a)  Licensee shall use the Licensed Indicia properly on all Licensed Articles, as well as labels, 
containers, packages, tags and displays (collectively “Packaging”), and in all print and 
online advertisements and promotional literature, and television and radio commercials 
promoting Licensed Articles (collectively “Advertising Materials”). On all visible Packaging 
and Advertising Materials, the Licensed Indicia shall be emphasized in relation to 
surrounding material by using a distinctive typeface, color, underlining, or other technique 
approved by CLC and the Collegiate Institutions. Any use of any Licensed Indicia shall 
conform to the requirements as specified in Appendix B. Wherever appropriate, the 
Licensed Indicia shall be used as a proper adjective, and the common noun for the product 
shall be used in conjunction with the Licensed Indicia. The proper symbol to identify the 
Licensed Indicia as a trademark (i.e., the ® symbol if the Licensed Indicia is registered in the 
United States Patent and Trademark Office or the ™ symbol if not so registered) and/or 
copyright legend (i.e., © [Date][Collegiate Institution]) shall be placed adjacent to each 
Licensed Indicia. Except when otherwise expressly authorized in writing by CLC, Licensee 
shall not use on any one Licensed Article or its Packaging the Licensed Indicia of more than 
one Collegiate Institution.
(b)  CLC will provide to Licensee guidance on the proper use of the Licensed Indicia. A true 
representation or example of any proposed use by Licensee of any of the Licensed Indicia 
listed, in any visible or audible medium, and all proposed Licensed Articles, Packaging and 
Advertising Materials containing or referring to any Licensed Indicia, shall be submitted at 
Licensee’s expense to CLC for written approval prior to such use, as provided in Section 10. 
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Licensee shall not use any Licensed Indicia in any form or in any material disapproved or 
not approved by CLC.
(c)  Licensee shall display on each Licensed Article or its Packaging and Advertising Materials 
the trademark and license notices required by CLC’s written instructions in effect as of the 
date of manufacture.
10.		 pRoCeduRe	foR	AppRovAl
(a)  Licensee understands and agrees that it is an essential condition of this Agreement to 
protect the standards and good reputations of the Collegiate Institutions, and agrees 
that the Licensed Articles, Packaging, Advertising Materials and/or designs containing 
the Licensed Indicia shall be of high and consistent quality, subject to the prior written 
approval and continuing supervision and control of CLC and the Collegiate Institutions. 
Licensee shall submit all Licensed Articles, Packaging, Advertising Materials and/or 
designs containing the Licensed Indicia to CLC in a timely fashion to ensure that CLC and 
the Collegiate Institutions have adequate time to review such materials prior to the date 
of their proposed use by Licensee, and Licensee must receive prior written quality control 
approval by CLC as provided herein.
 
(b)  Prior to the manufacture, use, distribution or sale of any Licensed Article, Packaging, 
Advertising Materials and/or designs containing the Licensed Indicia, Licensee shall 
submit to CLC for approval, at Licensee’s expense and in the format required by CLC, at 
least one sample of each proposed Licensed Article, Packaging, Advertising Materials 
and/or design for each Collegiate Institution and one sample for CLC as the same would 
be manufactured, used, distributed or sold. If CLC approves in writing or via iCLC the 
proposed Licensed Article, Packaging, Advertising Materials and/or design, the same 
shall be accepted to serve as an example of quality for that Licensed Article, Packaging, 
Advertising Materials and/or design, and production quantities may be manufactured 
by Licensee in strict conformity with the approved sample. All approvals provided herein 
are effective only for the Term or renewal period in which Licensee has submitted and 
CLC has approved the Licensed Articles, Packaging, Advertising Materials and/or designs, 
unless Licensee is otherwise notified in writing by CLC. Licensee shall not depart from the 
approved quality standards in any material respect without the prior written approval of 
CLC. Licensed Articles, Packaging, Advertising Materials and/or designs not meeting those 
standards, including seconds, irregulars, etc., shall not be distributed or sold under any 
circumstances without CLC’s prior written authorization. 
 
(c)  Licensee may only use the Licensed Indicia as shown in Appendix B and approved in 
the manner set forth herein. Licensee may not modify the Licensed Indicia without the 
prior written approval of CLC as provided in Section 10(b) above. The use of the Licensed 
Indicia in conjunction with original artwork supplied by the Licensee requires the express 
approval of CLC as provided in Section 10(b) above. Licensee may submit sketches of 
proposed artwork for preliminary approval before submitting finished samples.
(d)  The descriptions of the Licensed Articles are set out in Appendix C. Licensee agrees to 
adhere strictly to the description of each Licensed Article.
(e)  At time of renewal, or upon request by CLC at any other time, in addition to any other 
requirement, Licensee shall submit to CLC such number of each Licensed Article, Packaging, 
Advertising Materials and/or design manufactured, used, distributed or sold under the 
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Licensed Indicia as may be necessary for CLC to examine and test to assure compliance 
with the quality and standards for Licensed Articles, Packaging, Advertising Materials and/
or designs approved herein. Each item shall be shipped in its usual container or wrapper, 
together with all labels, tags, and other materials usually accompanying the item. Licensee 
shall bear the expense of manufacturing and shipping the required number of Licensed 
Articles, Packaging, Advertising Materials and/or designs to the destination(s) designated 
by CLC.
(f)  If CLC notifies Licensee of any defect in any Licensed Article, Packaging, Advertising 
Materials and/or designs or of any deviation from the approved use of any of the Licensed 
Indicia, Licensee shall have fifteen (15) days from the date of notification from CLC to 
correct every noted defect or deviation. Defective Licensed Articles, Packaging, Advertising 
Materials and/or designs in Licensee’s inventory shall not be used, distributed or sold and 
shall, upon request by CLC, be immediately recalled from the marketplace and destroyed 
or submitted to CLC, at CLC’s option and at Licensee’s expense. However, if it is possible to 
correct all defects in the Licensed Articles, Packaging, Advertising Materials and/or designs 
in Licensee’s inventory, said items may be distributed or sold after all defects are corrected 
to the satisfaction of CLC, which shall be indicated in writing. CLC and/or its authorized 
representatives shall have the right at reasonable times without notice to inspect 
Licensee’s plants, warehouses, storage facilities and operations related to the production 
of Licensed Articles.
(g) Licensee shall comply with all applicable laws, regulations, standards and procedures 
relating or pertaining to the manufacture, use, advertising, distribution or sale of the 
Licensed Articles. Licensee shall comply with the requirements, including reporting 
requirements, of any regulatory agencies (including, without limitation, the United 
States Consumer Product Safety Commission, Federal Trade Commission, or Food and 
Drug Administration) which shall have jurisdiction over the Licensed Articles. Both before 
and after Licensed Articles are put on the market, Licensee shall follow reasonable and 
proper procedures for testing Licensed Articles for compliance with laws, regulations, 
standards and procedures, and shall permit CLC and/or its authorized representatives, 
upon reasonable notice, to inspect its and its Manufacturer’s testing, manufacturing and 
quality control records, procedures and facilities and to test or sample Licensed Articles for 
compliance with this Section. Licensed Articles found by CLC at any time not to comply 
with applicable laws, regulations, standards and procedures shall be deemed disapproved, 
even if previously approved by CLC, and shall not be shipped and/or shall be subject to 
recall unless and until Licensee can demonstrate to CLC’s satisfaction that such Licensed 
Articles have been brought into full compliance. 
(h)  Licensee shall inform CLC in writing of any complaint regarding the Licensed Articles 
promptly upon Licensee’s receipt of such complaint.
(i)  Any unauthorized or unapproved use by Licensee of any Licensed Indicia of any Collegiate 
Institution shall constitute grounds for immediate termination of this Agreement and 
also may result in action against Licensee for trademark infringement and/or unfair 
competition, other applicable claims, and collection of monetary damages.
11.		 dISplAy	of	offICIAl	lABel
(a)  Licensee shall, prior to advertising, distribution or sale of any Licensed Article, affix to each 
Licensed Article, its Packaging and Advertising Materials an “Officially Licensed Collegiate 
Products” tag or label in the form prescribed by CLC (“Official Label”). In addition, Licensee 
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shall affix Licensee’s Authorized Brand(s) to each Licensed Article, its Packaging and 
Advertising Materials. It is acceptable for Licensee’s Authorized Brand(s) to appear on the 
Official Label subject to prior written approval by CLC. Licensee shall obtain Official Labels 
from the supplier(s) authorized by CLC to provide those labels. 
(b)  Licensee is responsible for affixing the Official Label to each Licensed Article, its Packaging 
and Advertising Materials. Licensee shall not provide Official Labels to any third party for 
any purpose whatsoever, without prior written approval by CLC.
(c)  Licensee agrees to defend, indemnify and hold harmless CLC, the Collegiate Institutions, 
and those Indemnified Parties set forth in Section 14(a) from all liability claims, costs or 
damages, including but not limited to any liability for the conversion or seizure of any 
of the Licensed Articles not containing the Official Label and/or Licensee’s Authorized 
Brand(s) as required by this Section. This provision is in addition to and in no way limits 
Section 14.
(d) Licensee’s purchase and use of the Official Label is contingent upon the Licensee 
maintaining its rights under this Agreement. Upon termination or expiration of this 
Agreement, subject to those provisions of Section 17 regarding disposal of inventory, 
Licensee must return all Official Labels to CLC for destruction. Licensee agrees that there 
will be no financial reimbursement to the Licensee by CLC, its agents, employees, or 
business partners for any unused Official Labels.
12.		 no	joInT	venTuRe	oR	endoRSemenT	of	lICenSee
Nothing in this Agreement shall be construed to place the parties in the relationship of partners, 
joint venturers or agents, and Licensee shall have no power to obligate or bind CLC or any Collegiate 
Institution in any manner whatsoever. Neither CLC nor any Collegiate Institution is in any way a 
guarantor of the quality of any product produced by Licensee. Licensee shall neither state nor 
imply, directly or indirectly, that the Licensee or its activities, other than under this license, are 
supported, endorsed or sponsored by CLC or by any Collegiate Institution and, upon the direction 
of CLC, shall issue express disclaimers to that effect.
13.		 RepReSenTATIonS
Licensee represents, warrants and agrees that the Licensed Articles, Packaging, Advertising 
Materials and/or designs shall (i) be of good quality in design, material and workmanship and 
suitable for their intended purpose, (ii) not cause harm when used with ordinary care, and (iii) not 
infringe or violate the rights of any third party. Licensee further represents, warrants and agrees 
that all work on and contribution to the Works shall be by bona fide “employees” of Licensee 
working “within the scope of employment” as those terms are used in 17 U.S.C. § 101, et. seq. Each 
party represents and warrants that it has the right and authority to enter into and perform under 
this Agreement.
14.		 IndemnIfICATIon	And	InSuRAnCe
(a)  Licensee is solely responsible for, and will defend, indemnify and hold harmless CLC, the 
Collegiate Institutions, and their respective officers, agents, and employees (collectively 
“Indemnified Parties”) from any claims, demands, causes of action or damages, including 
reasonable attorney’s fees, arising out of (i) any unauthorized use of or infringement of 
any patent, copyright, trademark or other proprietary right of a third party by Licensee in 
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connection with the Licensed Articles, Packaging, Advertising Materials and/or designs 
covered by this Agreement, (ii) defects or alleged defects or deficiencies in said Licensed 
Articles, Packaging, Advertising Materials and/or designs or the use thereof, (iii) false 
advertising, fraud, misrepresentation or other claims related to the Licensed Articles, 
Packaging, Advertising Materials and/or designs not involving a claim of right to the 
Licensed Indicia, (iv) the unauthorized use of the Licensed Indicia or any breach or alleged 
breach by Licensee of any of its representations, warranties, covenants or obligations 
contained in this Agreement, (v) libel or slander against, or invasion of the right of privacy, 
publicity or property of, or violation or misappropriation of any other right of any third 
party, and/or (vi) agreements or alleged agreements made or entered into by Licensee to 
effectuate the terms of this Agreement. The indemnifications hereunder shall survive the 
expiration or termination of this Agreement. 
(b)  Prior to the first sale or distribution of any Licensed Article, or use of the Licensed Indicia, 
Licensee shall obtain from an insurance carrier having a rating of at least A-7 by the A.M. 
Best & Co. or other rating satisfactory to CLC, and thereafter maintain, Commercial General 
Liability insurance, including product, advertising and contractual liability insurance. 
Licensee’s insurance coverage shall provide adequate protection for the Indemnified 
Parties as additional insured parties on Licensee’s policy against any claims, demands, or 
causes of action and damages, including reasonable attorney’s fees, arising out of any 
of the circumstances described in Section 14(a) above. Such insurance policy shall not be 
canceled or materially changed in form without at least thirty (30) days written notice 
to CLC. Prior to the first sale or distribution of any Licensed Article, or use of the Licensed 
Indicia, Licensee shall furnish CLC a certificate of such insurance and endorsements in 
the form prescribed by CLC. Licensee agrees that such insurance policy or policies shall 
provide coverage of one million dollars ($1,000,000) for personal and advertising injury, 
bodily injury and property damage arising out of each occurrence, or Licensee’s standard 
insurance policy limits, whichever is greater. However, recognizing that the aforesaid 
amounts may be inappropriate with regard to specific classes of goods, it is contemplated 
that CLC may require reasonable adjustment to the foregoing amounts. Any adjustment 
must be confirmed in writing by CLC.
 
15.		 ReCoRdS	And	RIghT	To	AudIT
(a)  Licensee shall keep, maintain and preserve at its principal place of business during 
the Term, any renewal periods and at least three (3) years following termination or 
expiration, complete and accurate books, accounts, records and other materials covering 
all transactions related to this Agreement in a manner such that the information 
contained in the statements referred to in Section 7 can be readily determined including, 
without limitation, customer records, invoices, correspondence and banking, financial 
and other records in Licensee’s possession or under its control. CLC and/or its authorized 
representatives shall have the right to inspect and audit all materials related to this 
Agreement regarding any Collegiate Institution represented by CLC, which right to inspect 
and audit shall include the conduct of normal audit tests of additional Licensee records 
including those covering “non-licensed” sales to verify that they are not sales covered by 
this Agreement. In addition to the materials required by normal accounting practices, 
Licensee must retain detail of Licensed Article sales to the invoice number level for 
audit purposes, and invoices must indicate the Collegiate Institution name beside each 
Licensed Article. Licensee will provide CLC and/or its authorized representatives the above-
referenced invoice detail information in an Excel CD-ROM or disk format.
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(b)  Such materials shall be available for inspection and audit (including photocopying) 
at any time during the Term, any renewal periods and at least three (3) years following 
termination or expiration during reasonable business hours and upon at least five (5) 
days notice by CLC and/or its representatives. Licensee will cooperate and will not cause 
or permit any interference with CLC and/or its representatives in the performance of their 
duties of inspection and audit. CLC and/or its representatives shall have free and full access 
to said materials for inspection and audit purposes. Licensee shall pay CLC the amount of 
any additional costs beyond the cost of the originally scheduled audit incurred by CLC (i) 
due to a change in a scheduled audit date, which change is made at Licensee’s request and 
approved by CLC, or (ii) if Licensee’s books and records are not organized and/or available 
for audit.
(c)  Following the conduct of the audit, Licensee shall take immediate steps to timely resolve 
all issues raised therein, including payment of any monies owing and due. Should an audit 
indicate either (i) an underpayment of five percent (5%) or more, or (ii) an underpayment 
of $5,000 or more, of the monies due CLC, the cost of the audit shall be paid by Licensee. 
Payment of any audit costs is in addition to the full amount of any underpayment including 
late payment charges as provided in Section 7(b). Without prejudice to the rights set forth 
in Section 16 below, Licensee must cure any contract breaches discovered during the 
audit, provide amended reports if required, and submit the amount of any underpayment 
including late payment charges and, if applicable, the cost of the audit and/or cancellation 
fees within fifteen (15) days from the date Licensee is notified of the audit result.
16.		 defAulT;	CoRReCTIve	ACTIonS;	TeRmInATIon
(a) Licensee’s failure to fully comply with each provision of the Agreement, including but not 
limited to Licensee’s failure to perform as required or breach of any provision, shall be 
deemed a default under the Agreement. Upon default, CLC and the individual Collegiate 
Institutions may require the Licensee to take action to correct such default for such 
Collegiate Institutions. In the event that Licensee is required to take corrective action, CLC 
and the Collegiate Institutions shall determine the corrective action that Licensee will 
be required to take for such failure to perform or breach commensurate with the scope 
and history of Licensee’s past performance. Such action may include, without limitation, 
requiring Licensee to adopt remedial accounting and reporting measures; requiring 
Licensee to conduct an internal audit; requiring Licensee to train its personnel or permitting 
CLC to assist therein at Licensee’s expense; and requiring Licensee to discontinue the 
manufacture, advertising, distribution and sale of certain products bearing the Licensed 
Indicia. Additionally, in the event any default by Licensee results in damages to CLC or the 
Collegiate Institutions in an amount that would be difficult or impossible to ascertain 
(including, without limitation, sales of products bearing the Licensed Indicia that have 
not been approved pursuant to Section 10, sales of Licensed Articles without labeling as 
required in Section 11, etc.), then CLC and the Collegiate Institutions shall be entitled to 
receive compensation for damages in an amount to be determined by CLC in consultation 
with the Collegiate Institutions. The amount of such compensation payable pursuant to 
this provision shall not be less than an amount equivalent to the greater of the Advance 
Payment or $100, per occurrence, for each affected Collegiate Institution; provided, however, 
that nothing contained herein shall limit CLC’s or the Collegiate Institutions’ rights under 
this Agreement, in law, in equity or otherwise, including, without limitation, the amount 
of damages CLC or the Collegiate Institutions may be entitled to. If damages are assessed 
against the Licensee pursuant to this provision, then Licensee’s ability to continue to 
operate under this Agreement shall be contingent upon payment of such damages in the 
time allowed by CLC and the Collegiate Institutions.
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(b)  In addition to the right to require corrective action for default as set forth in Section 
16(a), CLC and the individual Collegiate Institutions shall have the right to terminate this 
Agreement without prejudice to any other rights under this Agreement, in law, in equity 
or otherwise, upon written notice to Licensee at any time should any of the following 
occur, which shall also be deemed defaults under the Agreement: 
(1) Licensee has not begun the bona fide manufacture, distribution, and sale of Licensed 
Articles within one (1) month of the date of approval of the samples of Licensed 
Articles.
(2)  Licensee fails to continue the bona fide manufacture, distribution, and sale of Licensed 
Articles during the Term. If, during any calendar quarter of the Term, Licensee fails to 
sell any of the Licensed Articles or fails to sell any Licensed Articles for a particular 
Collegiate Institution, CLC may terminate this Agreement with respect to said Licensed 
Article or Collegiate Institution.  
(3)  Licensee fails to make any payment due or fails to deliver any required statement. 
(4) The amounts stated in the periodic statements furnished pursuant to Section 7 are 
significantly or consistently understated. 
(5) Licensee fails to generate royalties during the Term or any renewal period that meet 
or exceed the amount of the Advance Payments and Minimum Guarantee amounts as 
provided in Section 6 and Appendix A. 
(6)  Licensee fails to make available its premises, records or other business information for 
any audit or to resolve any issue raised in connection with any audit, as required in 
Section 15. 
(7)  Licensee fails to pay its liabilities when due, or makes any assignment for the benefit 
of creditors, or files any petition under any federal or state bankruptcy statute, or is 
adjudicated bankrupt or insolvent, or if any receiver is appointed for its business or 
property, or if any trustee in bankruptcy shall be appointed under the laws of the 
United States government or the several states.
(8) Licensee attempts to grant or grants a sublicense or attempts to assign or assigns any 
right or duty under this Agreement to any person or entity without the prior written 
authorization of CLC.  
(9) Licensee distributes or sells any Licensed Articles outside the authorized Distribution 
Channels for such Licensed Articles, or distributes or sells any Licensed Articles to any 
third party that Licensee knows or should reasonably know intends to distribute or sell 
such Licensed Articles outside the authorized Distribution Channels for such Licensed 
Articles.
(10) Licensee distributes or sells any Licensed Articles outside the Territory or distributes or 
sells any Licensed Articles to a third party that Licensee knows or should reasonably 
know intends to distribute or sell such Licensed Articles outside the Territory. 
(11) If an entity acquires in a single transaction or through a series of transactions more 
than fifty percent (50%) ownership or controlling interest in Licensee.
(12) Licensee or any related entity manufactures, distributes or sells any product infringing 
or diluting the trademark, property or any other right of any Collegiate Institution or 
any other party.
(13) Licensee fails to deliver to CLC and maintain in full force and effect the insurance 
referred to in Section 14(b). 
(14) CLC, a Collegiate Institution, or any governmental agency or court of competent 
jurisdiction finds that the Licensed Articles are defective in any way, manner or form.
(15) Any monitoring agency authorized by a Collegiate Institution determines that Licensee 
is in violation of the labor code adopted by that Collegiate Institution, and Licensee 
fails to effectively remediate said violation for that Collegiate Institution within a time 
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period that is reasonable with respect to the nature and extent of the violation.
(16) Licensee commits any act or omission that damages or reflects unfavorably, embarrasses 
or otherwise detracts from the good reputation of any Collegiate Institution.
(17)  Licensee manufactures, distributes or sells Licensed Articles of quality lower than 
the samples approved, or manufactures, distributes, sells or uses Licensed Articles or 
Licensed Indicia in a manner not approved or disapproved by CLC. 
(18) Licensee fails to affix to each Licensed Article, its Packaging and Advertising Materials 
an Official Label and Authorized Brand in the manner provided in Section 11. 
(19) Licensee commits a default under any other provision of this Agreement, and fails to 
cure such default within fifteen (15) days of written notice from CLC. 
(c) CLC shall have the right to terminate this Agreement upon written notice to Licensee 
without cause with respect to a particular Collegiate Institution in the event that said 
Collegiate Institution directs CLC to terminate this Agreement. This termination shall be 
without prejudice to any other rights CLC may have, whether under the provisions of this 
Agreement, in law, in equity or otherwise.
(d)  The entire unpaid balance of all Royalty Payments and other amounts owing and due 
under this Agreement shall immediately become due and payable upon termination. 
17.		 effeCT	of	expIRATIon	oR	TeRmInATIon;	dISpoSAl	of	InvenToRy
(a)  Effect of Expiration or Termination: After expiration or termination of this Agreement 
for any reason, Licensee shall immediately discontinue the manufacture, advertising, 
use, distribution and sale of all Licensed Articles, Packaging and Advertising Materials, 
the use of all Licensed Indicia, and all similar marks, except as provided in Section 17(b), 
or unless expressly authorized in writing by CLC or the applicable Collegiate Institution. 
Until payment to CLC of any monies due it, CLC shall have a lien on any units of Licensed 
Articles not then disposed of by Licensee and on any monies due Licensee from any jobber, 
wholesaler, distributor, or other third parties with respect to sales of Licensed Articles.
(b)  Disposal of Inventory: After expiration or termination of this Agreement for any reason, 
Licensee shall have no further right to manufacture, advertise, use, distribute or sell 
Licensed Articles, Packaging or Advertising Materials utilizing the Licensed Indicia, but 
may continue to distribute its remaining inventory of Licensed Articles in existence at 
the time of expiration or termination for a period of sixty (60) days; provided, however, 
that Licensee has delivered all statements (including Final Statement) and payments then 
due, that during the disposal period Licensee shall deliver all statements and payments 
due in accordance with Section 7, that Licensed Articles are sold at Licensee’s regular Net 
Sales price and within the Distribution Channels, and that Licensee shall comply with all 
other terms and conditions of this Agreement. Notwithstanding the foregoing, Licensee 
shall not manufacture, advertise, use, distribute or sell any Licensed Articles, Packaging or 
Advertising Materials after the expiration or termination of this Agreement because of: (i) 
departure of Licensee from the quality and style approved by CLC under this Agreement, 
(ii) failure of Licensee to obtain product or design approval, or (iii) a default under Section 
16. 
18.		 fInAl	STATemenT
Upon expiration or termination of this Agreement for any reason, or at any other time upon 
request by CLC or the Collegiate Institutions, Licensee shall furnish to CLC a statement showing 
the number and description of Licensed Articles on hand or in process. Following such expiration 
APPENDIX
 HANDBOOK OF BEST PRACTICES  | 1919 
Intellectual Property and Trademark License
or termination, including inventory disposal period, if allowed, CLC may request Licensee to either 
(i) surrender unsold Licensed Articles, Packaging and Advertising Materials, as well as dies, molds 
and screens used to manufacture such Licensed Articles and Packaging, or (ii) destroy all such 
remaining unsold materials, certifying their destruction to CLC and specifying the number of 
each destroyed. CLC and/or its authorized representatives reserve the right to conduct physical 
inventories to ascertain or verify Licensee’s compliance with the foregoing.
19.		 SuRvIvAl	of	RIghTS
The terms and conditions of this Agreement necessary to protect the rights and interests of 
CLC and the Collegiate Institutions, including, without limitation, Licensee’s obligations under 
Sections 8, 13, 14 and 15, shall survive the termination or expiration of this Agreement. The terms 
and conditions of this Agreement providing for any other activity following the effective date 
of termination or expiration of this Agreement shall survive until such time as those terms and 
conditions have been fulfilled or satisfied.
20.		 noTICeS
All notices and statements to be given and all payments to be made, shall be given or made 
to the parties at their respective addresses set forth herein, unless notification of a change of 
address is given in writing. Unless otherwise provided in the Agreement, all notices shall be 
sent by certified mail, return receipt requested; facsimile, the receipt of which is confirmed by 
confirmation document; email, confirmed by email receipt confirmation notice; or nationally 
recognized overnight delivery service that provides evidence of delivery, and shall be deemed to 
have been given at the time they are sent.
21.		 ConfoRmITy	To	lAw	And	polICy
(a)  Licensee shall comply with such guidelines, policies, and requirements as CLC may give 
written notice from time-to-time including, without limitation, guidelines, policies and/or 
requirements contained in periodic CLC bulletins or notices. 
(b)  Licensee undertakes and agrees to obtain and maintain all applicable permits and licenses 
at Licensee’s expense.
(c)  Licensee shall pay all federal, state and local taxes due on or by reason of the manufacture, 
distribution or sale of the Licensed Articles.
22.		 SeveRABIlITy
The determination that any provision of this Agreement is invalid or unenforceable shall not 
invalidate this Agreement, and the remainder of this Agreement shall be valid and enforceable to 
the fullest extent permitted by law.
23.		 non-ASSIgnABIlITy
This Agreement is personal to Licensee. Neither this Agreement nor any of Licensee’s rights shall 
be sold, transferred or assigned by Licensee without CLC’s prior written approval, and no rights 
shall devolve by operation of law or otherwise upon any assignee, receiver, liquidator, trustee or 
other party. Subject to the foregoing, this Agreement shall be binding upon any approved assignee 
or successor of Licensee and shall inure to the benefit of CLC, its successors and assigns. 
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24.		 enTIRe	AgReemenT	/	no	wAIveR
Unless otherwise specified herein, this Agreement or any renewal, including appendices, 
constitutes the entire agreement and understanding between the parties and cancels, terminates, 
and supersedes any prior agreement or understanding, written or oral, relating to the subject 
matter hereof between Licensee, CLC and the Collegiate Institutions. There are no representations, 
promises, agreements, warranties, covenants or understandings other than those contained 
herein. None of the provisions of this Agreement may be waived or modified, except expressly in 
writing signed by both parties. However, failure of either party to require the performance of any 
term in this Agreement or the waiver by either party of any breach shall not prevent subsequent 
enforcement of such term nor be deemed a waiver of any subsequent breach. 
25.	 CollegIATe	InSTITuTIon	RIghT	To	enfoRCe
Each Collegiate Institution is entitled to enforce its rights in the Licensed Indicia and the terms of 
this Agreement directly against the Licensee; and each Collegiate Institution is entitled to all the 
rights and remedies available under this Agreement.
26.		 mISCellAneouS
When necessary for appropriate meaning, a plural shall be deemed to be the singular and 
singular shall be deemed to be the plural. The attached appendices are an integral part of this 
Agreement. Section headings are for convenience only and shall not add to or detract from any 
of the terms or provisions of this Agreement. This Agreement shall be governed by and construed 
in accordance with the laws of the state of Georgia, which shall be the sole jurisdiction for any 
disputes. This Agreement shall not be binding on CLC until signed by CLC as agent on behalf of 
the Collegiate Institutions.
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed effective as 
of the last date of signature below.
LICENSEE:
By: __________________________________________ [Seal]
                  (Signature of officer, partner, or person duly authorized to sign)
Title: ___________________________________________
Date: ___________________________________________
THE COLLEGIATE LICENSING COMPANY, as agent on behalf of the Collegiate Institutions
By: __________________________________________
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A Public Sector Research Center intends neither to be a manufacturer or distributor. This sample 
agreement would be used in circumstances where the public sector institution is assisting a 
manufacturer to obtain one or more distributors or vice versa.
This Agreement is effective this ________ day of ____________, 20__ (“Effective Date”), by and 
between [MANUFACTURER], a corporation organized and existing under the laws of [COUNTRY] 
(“Manufacturer”), and [DISTRIBUTOR], a corporation organized and existing under the laws of 
[COUNTRY] (“Distributor”).
WITNESSETH
WHEREAS the intellectual property related to product (as hereafter defined), including Trademarks, 
is owned or controlled by [TMOWNER] (“Trademark Owner”);
WHEREAS Trademark Owner has granted to Manufacturer the right to use and sell the Product in 
[COUNTRY] under the Trademarks using the Distributor; and
WHEREAS Manufacturer wishes to appoint Distributor to sell the Product in [COUNTRY], 
and Distributor is willing and able to import, promote, distribute, and sell Product under the 
Trademarks in [COUNTRY].
NOW, THEREFORE, the parties intending to be legally bound agree as follows:
ARTICle	I:	defInITIonS
Wherever used in this Agreement, the following terms have the following meanings:
1.1  Product means [PRODUCT DEFINITION/COMPOSITION]
1.2  Public Sector [CURRENT DEFINITION]
1.3  Private Sector means all markets not defined as Public Sector.
 
1.4  Trademark means all trademarks, service marks, logotypes, commercial symbols, insignias, 
and designs pertaining thereto, including, but not limited to, the trademark [TM] _____ 
and the logotype associated therewith, now owned by Trademark Owner and licensed to 
Manufacturer, as the same may be amended, modified, revised, or improved hereafter that 
are associated and identified with the manufacture and sale of the Product.
ARTICle	II:	AppoInTmenT	of	dISTRIBuToR
2.1  Subject to the terms and conditions of this Agreement, Manufacturer appoints Distributor 
as its nonexclusive agent for the importation, promotion, distribution, and sale of Product 
under the Trademarks in [COUNTRY].
Source: Mahoney RT (ed.). 2004. Handbook of Best Practices for Management of Intellectual Property 
in Health Research and Development. MIHR: Oxford, U.K. Reproduced with permission.
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2.2  This Agreement grants the Distributor the right to package the Product but does not grant 
the Distributor the right to manufacture the Product or to have it manufactured by a third 
party.
ARTICle	III:	uSe	of	TRAdemARK
3.1  Distributor recognizes the substantial value of the goodwill associated with the Trademark 
and acknowledges that the Trademark and all rights therein and the goodwill pertaining 
thereto belong exclusively to Trademark Owner. Distributor agrees not to commit any act 
or omission adverse or injurious to said rights.
3.2   Distributor agrees that every use of the Trademark by Distributor shall inure to the benefit 
of Trademark Owner, and that Distributor shall not at any time acquire any rights in the 
Trademark by virtue of any use Distributor may make of the Trademark.
3.3  Distributor agrees to cooperate fully and in good faith with Trademark Owner for the 
purpose of securing, preserving, and protecting Trademark Owner’s rights in and to the 
Trademarks, including executing a trademark license with Trademark Owner and/or with 
the Manufacturer which license may be registered with the Patent and Trademark Office 
(or its equivalent) in [COUNTRY].
3.4  Distributor acknowledges that Distributor’s failure to cease the use of the Trademark on 
the termination or expiration of this Agreement will result in immediate and irreparable 
damage to Trademark Owner and to the rights of any subsequent licensee. Distributor 
acknowledges and admits that there is no adequate remedy at law for such failure and 
agrees that, in the event of such failure, Trademark Owner shall be entitled to equitable 
relief by way of temporary and permanent injunctions and such other and further relief as 
any court with jurisdiction may deem just and proper.
3.5 Distributor shall report to Trademark Owner and Manufacturer, in writing, any infringement 
or imitation of the Trademarks of which Distributor becomes aware. Trademark Owner shall 
have the sole right to determine whether to institute litigation upon such infringements 
as well as the selection of counsel. Trademark Owner may commence or prosecute any 
claims or suits for infringement of the Trademarks in its own name or in the name of 
Manufacturer or the Distributor or may join Distributor and/or Manufacturer as a party 
thereto. If Trademark Owner brings an action against any infringer of the Trademark, 
Distributor and Manufacturer shall cooperate with Trademark Owner and lend whatever 
assistance is necessary in the prosecution of such litigation. If Trademark Owner decides 
not to institute such litigation, it may authorize, within its sole discretion, in writing, 
Distributor or Manufacturer to institute such litigation.
3.6  Distributor shall not contest or deny the validity or enforceability of the Trademark or 
oppose or seek to cancel any registration thereof by Trademark Owner, or aid or abet others 
in doing so, either during the term of this Agreement or at any time thereafter.
3.7  Distributor acknowledges that any use of the Trademark in violation of the provisions of 
this Article will cause irreparable damage to Trademark Owner and its licensees, constitutes 
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ARTICle	Iv:	RegISTRATIon	of	pRoduCT
4.1  Distributor shall register the Product with the regulatory authorities of [COUNTRY].
4.2  Manufacturer will provide a technical dossier for registration and assist in responding to 
specific questions that may arise during registration. Registration documents supplied to 
Distributor shall be in English. Any translation of the registration documents shall be the 
responsibility of Distributor.
4.3  If the law and/or regulations of [COUNTRY] require that Distributor be named as sole 
or joint owner of the subject registration, Distributor agrees that upon termination or 
expiration of this Agreement, Distributor will promptly assign to Trademark Owner all 
right, title, and interest that the Distributor may have in the subject registration and will 
terminate Distributor’s own interest therein.
4.4  The technical dossier provided hereunder contains technical and proprietary information 
supplied by the Manufacturer and shall be deemed to have been provided in confidence for 
the sole purpose herein set forth. Distributor undertakes not to use any of the information 
for any purpose other than the registration in [COUNTRY] of the Product manufactured by 
Manufacturer and not to disclose any information to any third party, other than government 
regulatory authorities, without the written consent of Manufacturer.
4.5  Distributor will use all possible care and diligence to obtain the prompt issuance of the 
registration for the Product.
4.6  All expenses incurred relating to the registration of Product, including but not limited to 
taxes, official fees, and clinical trials that might be required by the government authorities 
of [COUNTRY], shall be borne by the Distributor.
ARTICle	v:	Supply	TeRmS
5.1  Distributor agrees that Manufacturer shall be Distributor’s sole supplier of Product and 
agrees that it will distribute only Product purchased from manufacturer except that 
Distributor may receive and distribute in the Public Sector, Product supplied to Distributor 
by international donor agencies for such distribution regardless of where the donor agency 
obtained such Product. All Product sold to Distributor hereunder shall be manufactured by 
Manufacturer in accordance with Good Manufacturing Practices.
5.2  Since Manufacturer has made, or is making, distribution arrangements for Product with 
representatives in other countries, Distributor agrees that it shall not knowingly allow 
Product to be distributed for use in countries outside of [COUNTRY] without prior approval 
from Manufacturer.
5.3  All orders submitted by Distributor to Manufacturer are subject to acceptance by 
Manufacturer, to government restrictions and approval, and to allocations that may be 
necessary due to production capacity restrictions.
5.4  To assure a constant supply of the Product, Distributor shall stock a sufficient quantity 
of the Product to satisfy without delay the demands for it, and Distributor undertakes to 
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keep at all times _____-months’ (__) stock of the Product for the Private and Public Sectors 
in [COUNTRY]. However, Distributor is not required to carry a stock of Product in the 
expectation of sales to entities of the Public Sector who purchase through public bidding. 
To this end, Distributor shall place with Manufacturer timely and sufficient orders for the 
Product, taking into account the market demand, shipping time, and filling of the order by 
Manufacturer. Manufacturer shall supply and ship to Distributor as quickly as possible and 
always within ninety (90) days of receiving its purchase order with the amount of Product 
specified therein.
5.5  Distributor shall at all times remain in close contact with those entities of the Public Sector 
that purchase through public bidding and with those of their officers whose responsibilities 
have a bearing on these purchases; assure that it is immediately advised whenever a tender 
for [PRODUCT TYPE] is being solicited; and whenever such is the case, relay the information 
to the Manufacturer within forty-eight (48) hours.
5.6  Distributor shall clear the Products from the airport or other port of entry at its own expense 
within fifteen (15) days after their arrival in [COUNTRY]. Distributor shall be responsible for 
the clearance of customs of Product and local transport to its facilities.
5.7  Distributor agrees to inspect the Product immediately upon delivery and to give notice 
by fax to the manufacturer within fifteen (15) days of such delivery of any matter of thing 
by reason whereof it alleges that the Product is not in good condition. If no such notice 
is served by the Distributor upon the Manufacturer, the Product shall be deemed to be 
in accordance with this Agreement in all respects and the Distributor shall be deemed 
to have accepted the Product. If Distributor, having served notice on the Manufacturer, 
demonstrates that the Product is not in good condition, Manufacturer shall at its option 
either replace the defective goods with Product complying with this Agreement or refund 
to the Distributor the price paid for defective Product.
5.8  Distributor agrees to inform Manufacturer in writing three (3) months before the end of 
each calendar year of its estimated requirements of the Product for the following year.
5.9  Manufacturer shall be free to accept or not the return of expired Product.
ARTICle	vI:	pRICIng	And	pAymenTS
6.1  Prices charged to Distributor will, unless otherwise negotiated, be in accord with the 
Manufacturer’s prices for Public Sector and Private Sector distribution prevailing at the 
time of shipment. After the initial order, two (2) months’ notice will be given for any price 
increase. Manufacturer will endeavor to keep Distributor supplied with current information 
regarding pricing. The price for the Public Sector shall be preferential and set at the lowest 
possible reasonable level permitting a commercially reasonable return; however, nothing 
herein shall be interpreted as requiring the sale of Product below fully allocable costs plus 
a mark up of _______ percent (__%). Price shall be FOB [PLACE].
6.2  Distributor guarantees payment of all orders placed or approved by Distributor. Orders will 
provide for payment terms of thirty (30) days from date of order in [CURRENCY], except 
that in the event of unsatisfactory payment history, Manufacturer reserves the right to 
provide Product to Distributor on a COD basis.
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ARTICle	vII:	pACKAgIng
7.1  Distributor shall package the Product under the supervision of its own technicians, in its 
own factory or in another qualified factory, and shall oversee the process with all necessary 
care, strictly following good pharmaceutical manufacturing practices.
7.2  Should Distributor need to have the Product packaged by a third party, said party must 
first have been approved by the Manufacturer and must commit itself in writing to comply 
with the articles of this Agreement relevant to the Product.
7.3  Distributor agrees to mark all packaging for Product in accordance with the applicable 
laws in [COUNTRY]. Said packaging shall be submitted to Manufacturer for approval before 
it is made up or printed.
7.4  All packaging costs and expenses shall be borne entirely by the Distributor.
ARTICle	vIII:	AdveRTISIng	And	pRomoTIon
8.1  Distributor undertakes at its own expense to actively promote the Product in [COUNTRY] 
by the best legal and appropriate means and to retain a trained sales force of [TYPE] 
representatives and detailers to assure an effective promotion of the Product with the 
[TYPE] community and with other professional [TYPE] personnel. Distributor shall further 
place, at its own expense, promotional advertisement and writings on the Product in [TYPE] 
and other suitable publications covering [COUNTRY].
8.2 Each year by September 30, Distributor shall submit to Manufacturer for approval 
Distributor’s promotional plan for the following year detailing promotional visits to health 
professionals and to others, distribution of samples of the Products and promotional 
materials and to whom, advertisements and writings of the Product to be placed in 
publications in [COUNTRY], and planned participation and contributions to [TYPE] reunions 
and function. Said promotional plan to be reviewed jointly by the Distributor and the 
Manufacturer each six (6) months for the eventual modifications by mutual agreement. 
Special educational or promotional activities not included in the promotional plan require 
the approval of the Manufacturer, and the apportionment of their cost, if there be any, will 
be decided by mutual consent of the parties.
8.3  Distributor shall submit to Manufacturer quarterly marketing reports listing the 
promotional activities carried out during each month of the last period.
8.4  Manufacturer shall provide to Distributor free of charge, save customs duties, a certain 
quantity of free samples of the Product and dummies of the scientific, technical, 
commercial, and training materials required to carry out promotional programs for the 
Product. Should the laws of [COUNTRY] not recognize the distribution of free samples, 
in no event shall Distributor be allowed to claim any discount on the price of Product. 
Distributor shall provide, at its own cost, to the Public Sector agencies that use or may use 
Product, the needed scientific, technical, educative, and training material for this purpose 
and previously approved by the Manufacturer.
8.5  In promoting the Product, Distributor shall refrain from making any claims regarding 
its therapeutic action or effectiveness different or greater than those specified by the 
Manufacturer and by the Sanitary Authorities of [COUNTRY].
distributorship	Agreement
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8.6 All advertisements and promotional materials, including text and graphics, used by 
Distributor shall be subject to prior written approval of Manufacturer, which approval shall 
not be unreasonably withheld.
ARTICle	Ix:	RepoRTIng
9.1  Distributor will provide to Manufacturer monthly sales reports containing such information 
retarding sales of Product as Manufacturer shall specify, and including nonbinding, good-
faith forecasts of its anticipated requirements and shipping dates for the three (3) month 
periods following such reports.
9.2  On or before February 1 of each year, Distributor shall supply Manufacturer with a report 
for the preceding calendar year or part thereof showing separately the quantity of 
Product purchased from Manufacturer and sold to the Private Sector and Public Sector 
in [COUNTRY], the average selling price of the Product purchased from Manufacturer, the 
quantity of Product supplied to Distributor by international donor agencies, and the selling 
price, if any, of the Product supplied by the international donor agencies. Manufacturer 
shall promptly provide a copy of the report to Trademark Owner.
9.3  Distributor shall, upon request by Manufacturer or Trademark Owner provide supporting 
documentation adequately justifying the pricing structure for the Public Sector. The rights 
created by this paragraph are directly enforceable by Manufacturer on behalf of any Public 
Sector agency wishing to purchase Product. To the extent possible under [COUNTRY] law, 
the rights created by this paragraph are directly enforceable by any Public-Sector agency 
on its own behalf. In addition to any other rights possessed by Manufacturer, a breach 
of any of the provisions of this paragraph shall be sufficient basis for termination of this 
Agreement by Manufacturer upon thirty (30) days’ written notice.
ARTICle	x:	CovenAnTS	And	RepReSenTATIonS	of	dISTRIBuToR
10.1  Distributor is a corporation duly formed, validly existing, and in good standing under the 
laws of [COUNTRY] and is duly qualified to transact business.
10.2  Distributor agrees that it shall not use or distribute Product in any manner inconsistent 
with the terms and intent of this Agreement.
10.3  Distributor agrees to use its best efforts to successfully market and distribute Product 
from Manufacturer in [COUNTRY] on a continuing basis during the term of this Agreement 
and to comply with good business practices and all laws and regulations relevant to this 
Agreement or the subject matter hereof.
10.4  Distributor agrees to keep Manufacturer informed as to any problems encountered with the 
Products and any resolutions arrived at for those problems and to communicate promptly 
to Manufacturer any and all suggested modifications, design changes or improvements 
of the Products. Manufacturer agrees to promptly pass this information on to Trademark 
Owner. Distributor and Manufacturer further agree that Trademark Owner shall have 
all right, title, and interest in and to any such suggested modifications, design changes, 
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ARTICle	xI:	ConfIdenTIAlITy
All technical, corporate, business, and other proprietary information furnished by Trademark 
Owner of Manufacturer hereunder, or which results from the joint efforts of Trademark Owner 
and/or Manufacturer’s and Distributor’s personnel, shall be deemed to have been furnished to 
Distributor in confidence for the sole purposes herein set forth, and Distributor undertakes not 
to use any of this information for any purpose not connected with the orders accepted under 
this Agreement. Distributor shall also take all reasonable precautions to prevent communication, 
without the written consent of Trademark Owner or Manufacturer, of any such technical or other 
proprietary information to any third party, except as may be necessary to carry out the purposes 
of this Agreement.
ARTICle	xII:	TeRm	And	TeRmInATIon
12.1  This Agreement is effective as of the Effective Date and will expire ________(__) years 
thereafter, provided the following minimum volumes have been purchased by Distributor:
 Year   Amount
The above minimum volume for [YEAR] assumes approval for product registration by the 
government in [COUNTRY] by [DATE], and will be reduced or expanded pro rata using the quantity 
specified for [YEAR] in case of delayed or expedited approval. If Distributor does not purchase the 
minimum volume specified for any year, Manufacturer may terminate this Agreement by giving 
thirty (30) days’ written notice, provided that if Distributor during the thirty (30)-day period orders 
sufficient Product for immediate delivery to make up the deficiency, the notice will be revoked.
12.2  This Agreement may also be terminated in the event Manufacturer determines that a 
change in management or effective financial control of Distributor has or will adversely 
affect the distribution of Product in accordance with this Agreement.
12.3  Distributor may terminate this Agreement any time by giving six (6) months’ written 
notice to Manufacturer. During this six (6)-month period, Distributor will continue to use 
its best efforts to promote the sale and use of Product.
12.4  Extensions and renewals of this Agreement will be subject to agreement between the 
parties made at least six (6) months prior to its expiration.
ARTICle	xIII:	RIghTS	And	oBlIgATIonS	on	TeRmInATIon
Upon termination or expiration of this Agreement, Distributor shall return unused inventory 
to Manufacturer. Distributor shall dispose of all advertising material relating to the Product or 
the Trademark and shall discontinue immediately any use of the Trademark. Distributor shall 
maintain as confidential all proprietary information supplied to Distributor hereunder.
ARTICle	xIv:	RelATIonShIp	of	pARTIeS
The parties hereto expressly understand and agree that Distributor is an independent contractor 
in the performance of each and every part of this Agreement and is solely responsible for the 
actions of all of its employees and agents. Neither Trademark Owner nor Manufacturer shall be 
obligated by any agreements, representations, or warranties made by Distributor, its employees, 
or its agents nor with respect to any other action of Distributor, its employees, or its agents, nor 
distributorship	Agreement
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shall Trademark Owner or Manufacturer be obligated for any claims, liabilities, damages, debts, 
settlements, costs, expenses, and liabilities that my arise on account of Distributor’s activities, or 
those of its employees or its agents.
ARTICle	xv:	hold	hARmleSS
15.1  Distributor agrees to use its best efforts to ensure that Product is transported, stored, and 
distributed in accordance with handling instructions provided by Manufacturer. Distributor 
further agrees to use its best efforts to ensure that Product is provided to customers in 
a manner which facilitates its safe and proper use. Manufacturer shall have the right to 
enter and inspect any premises or facilities used by Distributor for or in connection with 
the preparation, promotion, marketing, and distribution of the Product, at any time during 
normal business hours and shall further have the right to take a reasonable number of 
samples of the Product at no charge in order to determine Distributor’s compliance with 
the terms and condition of this Agreement.
 The Distributor shall sell the Product on its own account and in no event shall the 
Manufacturer be deemed liable for credits the Distributor may grant or for any other 
obligations the Distributor may have to fulfill for its sales or other types of transaction 
in [COUNTRY]. It is understood and agreed that the Distributor has no right or authority 
whatsoever to accept any financial obligation on the Manufacturer’s name or account 
without the Manufacturer’s prior written approval.
15.2  Distributor shall, in respect of Product distributed by it, indemnify and hold harmless 
Trademark Owner, and its employees and agents against any and all claims that might 
arise, and liabilities and related fees and expenses that might be incurred, on account of 
any injury, illness, suffering, disease, or death to any person or unborn offspring of any such 
person by reason of the distribution, sale, or use of the Product distributed by Distributor.
ARTICle	xvI:	noTICeS
Any report, accounting, objection, notice, or consent required or provided for by the terms of this 
Agreement shall be in writing, and all accounting, obligations, notices, consents, and reports 
provided for hereunder shall be sent by registered mail, prepaid, or by facsimile to the business 
address of the party to be served therewith. It is agreed that the business addresses of the parties 
shall be as follows:
 If to Manufacturer: ________________________________________________________
 If to Distributor: __________________________________________________________
ARTICle	xvII:	pRohIBITIon	AgAInST	ASSIgnmenT
This Agreement is entered into in reliance upon and in consideration of the experience, knowledge, 
skills, and qualifications of and trust and confidence placed in Distributor by Manufacturer. 
Therefore, neither Distributor’s interest in this Agreement nor any of its rights or privileges 
hereunder shall be assigned, transferred, shared, or divided voluntarily or involuntarily, by 
operation of law or otherwise, in any manner, without the prior written consent of Manufacturer 
and Trademark Owner. In the event of any change in management or effective financial control of 
Distributor, Distributor shall inform Manufacturer immediately. If, in the opinion of Manufacturer, 
this change adversely affects the management of Distributor or the business or general best 
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interest of either party, Manufacturer may, within sixty (60) days of Distributor’s notice, terminate 
this Agreement and cancel any or all pending orders by giving Distributor ninety (90) days’ 




No failure or omission by any party in the performance of any obligation of this Agreement shall 
be deemed a breach of this Agreement nor create any liability if the same shall arise from any 
cause or causes beyond the control of such party, including, but not restricted to, the following, 
which for the purposes of this Agreement shall be regarded as beyond the control of the party 
concerned:
Government regulations, acts of God, strikes or other acts of workers, fire, storm, explosions, riots, 
war, rebellion, transportation embargoes, or failures or delays in transportation.
ARTICle	xIv:	AmendmenTS
No amendment or other modification of this Agreement shall be valid or binding on any party 
hereto unless reduced to writing and executed by the parties hereto.
ARTICle	xx:	wAIveR
No waiver by any party of any provision hereof shall be deemed a waiver of any other provision 
hereof or of any subsequent breach by any party of the same or any other provision. None of 
the terms of this Agreement will be held to have been waived or altered unless such waiver or 
alteration is in writing and signed by all of the parties hereto.
ARTICle	xxI:	goveRnIng	lAw	And	ARBITRATIon
21.1  This Agreement shall be governed by the law of ________________.
21.2  The parties hereto undertake to settle any dispute, controversy, or claim arising under, 
out of, or in connection with this Agreement, including, without limitation, its formation, 
validity, binding effect, interpretation, performance, breach, or termination, as well as 
noncontractual claims, in an amicable manner. If an amicable settlement cannot be 
reached within 30 days for any reason, the dispute shall be referred to and finally settled 
by arbitration in accordance with the UNCITRAL Arbitration Rules then obtaining. The 
appointing authority shall be the Secretary-General of the Permanent Court of Arbitration, 
the number of arbitrators shall be three, and the language to be used in the arbitral 
proceedings shall be English. The place of arbitration shall be determined by mutual 
agreement, but if agreement cannot be reached the proceedings shall take place in _____
_________.
21.3  Either party to this Agreement may request any judicial authority to order any interim 
measures of protection for the preservation of its rights and interests to the extent permitted 
by law, including, without limitation, injunctions and measures for the conservation of such 
property and information that form part of the subject matter in dispute. Such requests 
shall not be deemed incompatible with, or as a waiver of, this agreement to arbitrate. 
In respect of any requests for interim measures of protection, and without limitation to 
proceeding in any other forum, the parties hereby consent to the exercise of jurisdiction by 
the judicial authorities of _________________.
21.4  In the event a party fails to proceed with arbitration, unsuccessfully challenges the 
arbitrator’s award, fails to comply with the arbitrator’s award, or fails to comply with any 
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interim measure of protection issued by any competent authority, the other party shall 
be entitled to costs of suit, including reasonable attorney’s fees, for having to compel 
arbitration or defend or enforce the award or interim measure.
IN WITNESS WHEREOF the parties hereto have caused these presents to be executed in triplicate 
by their duly authorized officers.
For Manufacturer:           For Distributor:
By:             By:      
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U.S. Patent Office, and has published in the area of 
intellectual property concerning biodiversity access. In 
2003, she was a nominee in the T Sector Magazine and 
BIOCOM BioFUSION award for the “Life Sciences 
In-House Legal Counsel of the Year.” Currently she is 
the President of Capia IP, which provides business-based 
IP advice and services to the life-sciences industry, and 
co-owner of BioAtla, a U.S.-based biotechnology com-
pany with operations in China, which offers protein en-
gineering and evolution services.
ANDERSON, Mark
Mark Anderson is a U.K.-qualified solicitor who spe-
cializes in intellectual property and commercial trans-
actions. He founded Anderson & Company, the 
Technology Law Practice™, in 1994, after having spent 
seven years with Bristows, a specialist IP law firm in 
London. He works from offices overlooking the River 
Thames in the Oxfordshire countryside. Most of his 
clients are biotech and IT companies and universities 
in the U.K. and continental Europe. He is a member 
of the U.K. Intellectual Property Lawyers Association 
and a member of the IP Working Party of the Law 
Society of England and Wales. He has written and co-
authored several books on IP-related subjects, includ-
ing Technology Transfer: Law, Practice and Precedents, 2nd 
ed. (Haywards Heath: Tottel, 2003) and Modern Law of 
Patents: Butterworths, 2005).
BALLANTyNE, Zoë
Zoë Ballantyne is currently responsible for the prepara-
tion and negotiation of legal agreements and IP advice 
for the technology transfer division of the Wellcome 
Trust and the Wellcome Trust Sanger Institute. Her work 
covers a broad spectrum of corporate, commercial, and 
intellectual property law, as well as intellectual property 
policy. Ms. Ballantyne graduated from the University of 
Cambridge with a degree in natural sciences, special-
izing in genetics. She obtained a post-graduate diplo-
ma in law and completed the Legal Practice Course at 
Nottingham Law School. She subsequently obtained a 
diploma in intellectual property law from the University 
of Bristol. Ms. Ballantyne qualified as a solicitor in 2001 
and practiced in the IP department and the life-sciences 
group of the international law firm Ashurst before join-
ing the Wellcome Trust in 2004. 
AMMANN, Klaus
Klaus is Emeritus Professor of Biodiversity at the 
University of Bern, Switzerland. He has worked in veg-
etation and glacial history, vegetation ecology, urban 
ecology, lichen chemistry, biomonitoring air pollution 
and plant taxonomy. He also served as director of the 
Botanical Garden at the University of Bern. He has been 
the leader of numerous research projects supported by 
the Swiss Government and the E.U. on research in eco-
logical monitoring in Bulgaria, biomonitoring air pol-
lution, European plant conservation, risk assessment of 
gene flow of transgenic crops, and communication strat-
egies. He is a member of numerous scientific committees 
and organizations, such as chair of the section of biodi-
versity of the European Federation of Biotechnology, 
and the Swiss committee on biosafety. He is member 
of the board of directors of Africa Harvest and involved 
in biosafety research on sorghum in Africa. He also is 
active in the field of philosophy and methodology of 
science communication, together with his wife Dr. 
Biljana Papazov Ammann. Presently he is guest profes-
sor at the Delft University of Technology, Department 
of Biotechnology, Holland.
ANDERSON, Carolyn
Ms. Anderson was a member of the founding manage-
ment team of Diversa Corp. where she served as Vice 
President of Intellectual Property and Licensing. Ms. 
Anderson led the company’s IP group from inception 
in 1994 to her departure in 2005. In 2000, the Diversa 
management team achieved the most successful biotech-
nology IPO at that time, raising over $200 million in 
gross proceeds. In addition, during her tenure as the head 
of intellectual property, Ms. Anderson was the IP lead in 
business negotiations that raised $300 million in com-
mitted funding from corporate partners. Diversa’s patents 
were cited by MIT Magazine as being in the top 10 in the 
world both in 2003 and 2004 across all industries based 
on citation frequency. Before joining Diversa Corp., Ms. 
Anderson served in multiple roles at Stratagene Cloning 
Systems, a molecular biology company based in La Jolla, 
California, including in sales, marketing, product man-
agement, and business development. 
Ms. Anderson earned her undergraduate degree at 
the University of California, San Diego, in Biochemistry 
and Cell Biology, is a registered patent agent with the 
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BANERJI, Jaya
Jaya Banerji has spent over 15 years in communications. 
She has worked in India, the Middle East, Switzerland, 
and the U.K. She acquired her expertise in writing, ed-
iting, scripting, publishing, and advocacy from both 
the not-for-profit and commercial sectors. Ms. Banerji 
has been a freelance writer, editor, and reviewer for 
the print media and a number of publishing houses. 
She has worked at Kali for Women, Delhi, Asia’s first 
feminist publishing house, McKinsey & Company 
India, Médecins Sans Frontières’ Campaign for Access 
to Essential Medicines, and the Drugs for Neglected 
Diseases Initiative. She has recently joined the Medicines 
for Malaria venture. Throughout her career, Ms. Banerji 
has retained her strong belief in the rights of the most 
vulnerable and impoverished, especially women and 
children. She continues to do what she loves best—writ-
ing, editing, and scripting communications that she 
hopes will contribute in some small way to making the 
world a more just and equitable place.
BARBOuR, Eric
Eric Barbour joined Syngenta in November of 2005. He 
currently heads a team of licensing managers support-
ing biotech and seeds organizations. In this capacity, he 
manages a range of activities, from licensing university 
technologies to making deals with major competitors. 
Eric’s background is in IP licensing and valuation. He 
also has a strong research background in the area of 
insect control and herbicide tolerance traits and gene 
expression. Eric has worked in both the public and pri-
vate sectors, with ten years management experience in 
licensing and intellectual property in the agricultural 
seed business.
Prior to joining Syngenta, Eric was employed by 
Pioneer Hi-Bred International Inc. in the Intellectual 
Property Licensing and Management group. Before 
Pioneer, he worked as a research scientist at Allelix Crop 
Technologies, working on transgenic traits in canola 
and other crops. 
Eric is an active member of the Licensing Executive 
Society, the Biotechnology Industry Organization and, 
until recently, an affiliate member of the Association of 
University Technology Managers. He graduated with a 
BS.c. and M.Sc. degrees from the University of Guelph, 
Canada, and has an M.B.A. from Drake University. 
BATES, Tony
Tony Bates joined the National Health Service (NHS) 
in England in 1992, when the NHS R&D initiative 
began. He was a member of the team in the Department 
of Health that introduced management of R&D into the 
NHS. Dr. Bates was the Intellectual Property Adviser to 
the National Health Service in England beginning in 
1998. His main responsibility was to advise NHS Trusts 
and Primary Care Trusts on how NHS policy should be 
implemented in order to have the greatest benefit for the 
NHS and its patients. He helped develop policies and 
produced the Department of Health Framework and 
Guidance (for the management of intellectual proper-
ty), which was published in 2002. He was instrumental 
in changing the law to allow NHS bodies to take share-
holdings in spinout companies. He also created the IP 
management network of NHS Innovations Hubs.
He is a physicist by training and was in the 
Department of Physics at the University of Cardiff 
for about 18 years, where he was a researcher in solid-
state physics. During that time, two of his inventions 
reached the marketplace. He moved from academia into 
IP management. After ten more years’ experience in 
Cardiff University, he became Director of Planning and 
Marketing and was responsible for research and intel-
lectual property.
Dr. Bates retired in 2004 but continues to work as a 
consultant in intellectual property.
BEAChy, Roger 
Roger Beachy is president of the Donald Danforth Plant 
Science Center in St. Louis, Missouri. He previously 
held academic positions at Washington University, 
St. Louis, and the Scripps Research Institute, La Jolla, 
California. His research includes projects to reduce vi-
rus infection in plants via biotechnology, and in studies 
of the control of gene expression in plants. Beachy is a 
member of the U.S. National Academy of Sciences and a 
Fellow of the Academy of Microbiology; he has received 
several awards for his work, including the Wolf Prize 
in Agriculture. The Danforth Center has committed 
significant efforts to research in developing countries, 
including through private-public partnerships, and 
Beachy is involved in a variety of efforts with regard to 
rationalizing regulations that control commercialization 
of agricultural biotechnology. 
Beachy is President of the International Association 
of Plant Biotechnology. He belongs to numerous institu-
tional boards, including the PNAS Editorial Board, the 
NRC Governing Board, the Board on Agriculture and 
Natural Resources (National Research Council of the 
National Academy of Sciences), Malaysia’s International 
Advisory Panel, and the Governing Board of Directors 
of the International Crops Research Institute for the 
Semi-Arid Tropics (ICRISAT), and the Burrill and 
Company Board of Advisors.
BENNETT, Alan B.
Alan Bennett currently serves as the Associate Vice 
Chancellor for Research at U.C. Davis. He is responsi-
ble for technology transfer, strengthening research-based 
alliances with industry, and supporting technology-
based economic development in the Sacramento/Davis 
region. He is the founding Executive Director of the 
Public Intellectual Property Resource for Agriculture 
(PIPRA), an organization consisting of 37 universities 
in nine countries that is dedicated to the collective man-
agement of intellectual property and supports broad 
commercial innovation and humanitarian uses of tech-
nology in agriculture. From 2000 to 2004, Dr. Bennett 
served as the Executive Director of the University of 
California Systemwide Office of Technology Transfer 
and Research Administration, where he was respon-
sible for IP management and research policy for the 
University of California system; this task involved man-
aging a portfolio of more than 5,000 cases, 700 active 
licenses, and revenue in excess of US$350 million for 
the four-year period. He earned B.S. and Ph.D. degrees 
in Plant Biology at U.C. Davis and Cornell University, 
respectively. He joined the U.C. Davis faculty in 1983. 
His research in plant molecular genetics has focused 
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on cell-wall disassembly and fruit development. Dr. 
Bennett has published over 130 research papers in lead-
ing scientific journals, holds several utility patents re-
lated to crop quality traits, and is a regular speaker at 
universities, international symposia, and private compa-
nies. He is a Fellow of the American Association for the 
Advancement of Science (AAAS) and of the California 
Council for Science and Technology (CCST).
BICh, T. Q.
Mr. Truong Quang Bich is Director of the Cuc Phuong 
National Park, Nho Quan, Ninh Binh, Vietnam. He is 
a forestry specialist with special expertise in forest man-
agement and biodiversity conservation. His research 
has focused on natural regeneration of forest following 
shifting cultivation, especially in some areas within Cuc 
Phuong National Park formerly settled by ethnic com-
munities, before the establishment of this national park 
in 1962. More recently, he has been Project Director of 
community-based environmental education and visitor 
interpretation of the Cuc Phuong National Park, and, 
since 1998, he has served as a Co-Project Leader of an 
ICBG program with responsibility of implementing 
biotic survey and biodiversity conservation at the Cuc 
Phuong National Park.
BINh, Le Tran
A doctoral graduate from the University of Greifswald, 
Germany, Professor Le Tan Binh is a plant biotechnolo-
gist with expertise in plant tissue culture. His research 
for the past 25 years has focused on the use of molecu-
lar biology techniques for the improvement of crop 
plants, especially rice, and for improved utilization of 
Vietnam’s biological resources. He has served as Principal 
Investigator of numerous projects, and since 1999 he 
has served as the Secretary General of the Vietnamese 
Association of Biotechnologists. He has also been the 
focal person in the Subcommittee for Biotechnology for 
the Vietnamese Biotechnology Committee of Science 
and Technology. He is the Director of Institute of 
Biotechnology, Vietnamese Academy of Science and 
Technology, Hanoi. 
BJöRK, Lars
Lars Björk studied biotechnology and chemistry at the 
Royal Institute of Technology in Stockholm, where he 
received a M.Sc. in 1965 for research on the produc-
tion of secondary metabolites and a Licenciate degree 
in 1970 for research on secondary metabolite accumu-
lation in plant tissue cultures. From 1984 to 1986, he 
was director of a Nordic project for introduction of 
this art in Sweden, Norway, Denmark, and Finland. 
During this time, he became an advisor to pharmaceu-
tical and food companies, advising them on the usage 
of raw materials and the development of new prod-
ucts. He became Associate Professor of Pharmacognosy 
at Uppsala University in 1986. He received a Ph.D. 
in Pharmaceutical Sciences in 1990 with a thesis on 
techniques to improve secondary metabolism in plant 
tissues. He was responsible for the creation of a new 
unit within the Swedish University of Agriculture, the 
Phytochemical Centre, Balsgård. From 1991 to 2001, 
he was the research director of the Centre and inves-
tigated the selection of plant species and the domes-
tication of wild species. From 1995 to 2005, he was 
a member of the board of the European Federation of 
Medicinal Plant Producers and contributed to the cre-
ation of new rules for Good Agricultural Practices for 
the production of raw materials to be used in the man-
ufacture of pharmaceuticals; these rules were later ad-
opted by the European Drug Administration (EMEA). 
In 2001, he became Senior Research Officer at Lund 
University, directing projects that determine the bio-
logical activity of natural products, a post he still holds. 
His institute is involved in bioprospecting in Bolivia, 
Morocco, Egypt, India, and other countries. He insti-
tuted Ethnobotany as an academic subject at Uppsala 
University in the spring of 2005. His current research 
concentrates on Laos but also includes other countries 
in Southeast Asia, as well as Morocco. He works on bio-
prospecting projects with Ph.D. students at both Lund 
and Uppsala. As a member of the Swedish Scientific 
Council for Biological Diversity (an advisory commit-
tee to the Swedish government on questions concern-
ing the Convention on Biological Diversity), he has 
been especially involved in questions concerning access 
and benefit sharing. 
BLAKENEy, Michael
Michael Blakeney is Herchel Smith Professor of 
Intellectual Property Law at Queen Mary, University of 
London and Director of the Queen Mary Intellectual 
Property Research Institute. He has held academic 
positions at a number of universities in Australia and 
the U.K. and worked in the Asia Pacific Bureau of the 
World Intellectual Property Organization. He is an 
arbitrator for the International Court of Arbitration. 
Professor Blakeney has acted as an intellectual property 
management advisor for the Asian Development Bank, 
the Consulting Group for International Agricultural 
Research, the European Commission (EC), the 
European Patent Office, the Food and Agricultural 
Organization, the World Intellectual Property 
Organization, and a number of universities and public 
research institutes.
He has directed E.C. projects to create intellec-
tual property infrastructures in a number of new E.U. 
Member States and E.U. Applicant States. He has writ-
ten and edited a number of books in the fields of intellec-
tual property, media, and competition law. His most re-
cent publications are: Trade Related Aspects of Intellectual 
Property Rights. A Concise Guide to the TRIPS Agreement 
(London: Sweet & Maxwell, 1996); Intellectual Property 
Aspects of Ethnobiology (Editor) (London: Sweet & 
Maxwell, 1999); Border Control of Intellectual Property 
Rights (Editor) (London: Sweet & Maxwell, 2001); IP 
in Biodiversity and Agriculture: Regulating the Biosphere 
(Editor with P. Drahos) (London: Sweet & Maxwell, 
2001); Enforcement Handbook (Brussels: EC, 2003), 
and International Encyclopaedia of Intellectual Property 
Treaties (with A. Ilardi) (Oxford: Oxford University 
Press, 2004).
BLAyA ALgARRA, Alicia
Alicia Blaya earned the title Magister Lvcentinvs in 
Intellectual Property and Information Society Law 
from Universidad de Alicante, Spain. She earned an 
LLM in International Commercial Law, University of 
Westminster, London, U.K., in 2000 and a law degree 
from the Universidad de Alicante in 1996.
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Since 1997, Blaya has been a registered member 
of the Professional Association of Lawyers of Alicante 
(Spain), where she was born. During her early years of 
working for a law firm, she provided legal assistance 
and trial work on civil, administrative and commercial 
cases.
She became Legal Advisor of the IPR-Helpdesk 
Project in 2002 and Senior Legal Advisor in 2003. Since 
2005 she has served as Coordinator of the legal team 
and has been responsible for the research and techno-
logical development content and training actions of the 
project. She has worked inside the IP field, especially in 
the area of the IP-related aspects relevant for E.U.-fund-
ed research projects. She has contributed to several pub-
lications in various fields of IP and has taught courses 
on innovation in Spain, both to postgraduate students 
and Latin American professionals. Blaya has given many 
seminars in a wide range of IP-related issues relevant for 
research projects as well as in IP law and innovation, 
both in European countries and other countries, such as 
Cuba, Ukraine, Russia, and Egypt.
BOADI, Richard y.
Richard Boadi is a national of Ghana and a member 
of the bars of the State of New York and the Republic 
of Ghana. He is currently legal counsel to the African 
Agricultural Technology Foundation (AATF). In this 
capacity, he advises the Board, management, and staff 
about current technology transfer policy and legal devel-
opments at national, regional, and international levels; 
he drafts, reviews, and negotiates agreements to which 
AATF is a party; he creates and fosters networks with 
licensees; and he handles other in-house legal needs 
of AATF. Before joining AATF, Mr. Boadi worked in 
the following capacities: as a senior attorney with the 
New York State Office for Technology; a contracts and 
commercial lawyer with the New York City Human 
Resources Administration; a Teaching Assistant for the 
Faculty of Law at the University of Ghana; a Junior 
Barrister with Reindorf Chambers in Accra, Ghana; and 
an Assistant Legal Officer with the Ghana Copyright 
Office. He is a graduate of Cornell University (LL.M.), 
the Ghana School of Law (B.L.), and the University of 
Ghana (LL.B.). 
BOBROWICZ, Donna
Donna Bobrowicz has a B.S. in Medical Laboratory 
Sciences, an M.B.A., and a J.D. She is a U.S. patent at-
torney with over 20 years of experience, specializing in 
chemical and biochemical technologies in both human 
health and agriculture. She has been the in-house coun-
sel in licensing matters for the technology acquisition 
group of the seed producer Pioneer Hi-Bred Inc. She 
has also been counsel for licensing and patents at the 
human diagnostics divisions at Abbott Laboratories and 
Akzo Pharma and for the cellulose and plastic casings 
manufacturer Viskase Companies, Inc. She has been 
affiliated with SWIFTT, the Strategic World Initiative 
for Technology Transfer at Cornell University, and has 
been part of an IP audit team at agricultural institutes 
in Kenya and Colombia. Currently, she is setting up 
technology transfer processes at the Stritch School of 
Medicine, Loyola University Chicago. She has her own 
IP practice in the metropolitan Chicago area. 
BOETTIgER, Sara
Sara Boettiger is an agricultural economist with a back-
ground in intellectual property (IP) law. She works as 
Director of Strategic Planning and Development at The 
Public Intellectual Property Resource for Agriculture 
(PIPRA) and is a consultant for the Bill & Melinda 
Gates Foundation. She publishes in the field of IP law 
and policy and is a member of the Board of Directors 
for the Institute of Forest Biotechnology. Her profes-
sional interests are the design and implementation of 
practical services that support innovation and improve 
livelihoods in developing countries. Her research inter-
ests are the legal and economic ramifications of IP rights 
and developing countries, collaborative innovation sys-
tems, open source in copyright and patents, university 
technology transfer systems, and the strategic use of pat-
ents in developed countries. 
Dr. Boettiger holds a B.A. from the University of 
Arizona, an M.S. from the University of California, 
Berkeley, and a Ph.D. in Agricultural and Resource 
Economics from the University of California, 
Berkeley. 
BOKANgA, Mpoko
Mpoko Bokanga is a food scientist with a Master’s degree 
from the Massachusetts Institute of Technology and a 
doctorate from Cornell University. He has been involved 
in agricultural research and development in Africa for 
the past 17 years. Before becoming the first Executive 
Director of AATF, Dr. Bokanga worked as an Industrial 
Development Officer of Agro-industries with the 
United Nations Industrial Development Organization 
(UNIDO) in Abuja, Nigeria. From 1989 to 2002, he 
was a Research Scientist with the International Institute 
of Tropical Agriculture (IITA). He has also been a 
Visiting Professor of Food Science at Alabama A & M 
University and a Research Associate for Westreco Inc., 
a Nestlé Research Company. At Westreco, Dr. Bokanga 
developed processes based on immobilized microbial and 
enzyme systems; and at IITA, he developed technologies 
for processing cassava and yams into new products that 
were subsequently introduced into more than a dozen 
African countries. He has co-authored or edited three 
books and published several papers on the biochemis-
try and health implications of cyanogenesis in cassava 
and on the processing of root and tuber crops. He is the 
coordinator of the Working Group on Cassava Safety 
(WOCAS), a subcommittee of the International Society 
for Tropical Root Crops (ISTRC), whose main function 
is to monitor the progress of and encourage research on 
cyanogenesis in cassava and its implications for food 
safety. Dr. Bokanga is the current chair of ISTRC-AB, 
the African branch of the ISTRC, and holds a visiting 
professorship at the University of Greenwich in England 
(2005-2008).
BORLAug, Norman E.
In 1970, Norman Borlaug won the Nobel Peace Prize 
for his lifelong work to feed a hungry world. His work, 
more than that of any other person, is credited with sav-
ing lives.
In 1944, Dr. Borlaug joined the Rockefeller 
Foundation’s pioneering technical-assistance program 
in Mexico, at which he was a research scientist in charge 
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of wheat improvement. For the next two decades, he 
worked to solve a series of wheat production problems 
in Mexico and to train a generation of young scientists. 
With the establishment of the International Maize 
and Wheat Improvement Center (CIMMYT) in 
Mexico in 1966, Borlaug assumed leadership of the 
wheat program; he continues to serve as a consultant for 
it. The high-yielding, disease-resistant wheat cultivars he 
developed, along with improved management practices, 
transformed agricultural production in Mexico during 
the 1950s and in Asia and Latin America in the 1960s 
and 1970s. This transformation has come to be known 
as the Green Revolution. 
In 1984, Dr. Borlaug joined Texas A&M University 
and was named Distinguished Professor of International 
Agriculture. Since 1986, he has also served as presi-
dent of the Sasakawa Africa Association and leader of 
the Sasakawa-Global 2000 agricultural program in 
Sub-Saharan Africa, in partnership with former U.S. 
President Jimmy Carter and Yohei Sasakawa.
Borlaug has been awarded 58 honorary doctorate 
degrees, and is a member or fellow of the academies 
of science in 12 nations. The U.S. National Academies 
of Science awarded him the National Service Medal 
in 2002 and in 2004 President Bush bestowed upon 
Borlaug the U.S. National Medal of Science. He was 
the driving force behind the establishment of the World 
Food Prize in 1985 and serves as Chairman of its 
Council of Advisors. 
BREMER, howard 
Howard Bremer holds degrees in Chemical Engineering 
and Law from the University of Wisconsin-Madison. He 
has been admitted to membership in the bars of the U.S. 
Supreme Court, the Court of Appeals for the Federal 
Circuit, the District Court for the Southern District of 
Ohio, and the State of Wisconsin, and has practiced be-
fore the Patent and Trademark Office. He has twice been 
Chairman of the Patent Law Section of the State Bar 
of Wisconsin, President and Trustee of the Association 
of University Technology Managers (AUTM), and 
President of the Wisconsin Intellectual Property Law 
Association. He has been active in the American Bar 
Association Section on Intellectual Property Law and 
the American Intellectual Property Law Association. He 
recently was awarded the Jefferson Medal by the New 
Jersey Intellectual Property Law Association. He has en-
gaged in legislative activities involving questions of in-
tellectual property, and served on the National Advisory 
Commission on Patent Law Reform. He was employed 
by the Procter and Gamble Company for 12 years and 
was Patent Counsel for the Wisconsin Alumni Research 
Foundation for 28 years.
BREWSTER, Amanda L.
Amanda Brewster serves as a Policy Officer for the 
Wellcome Trust in London. Previously, she worked 
as a Program Associate of the Science and Intellectual 
Property in the Public Interest project of the American 
Association for the Advancement of Science (AAAS) 
in Washington, D.C. She has also worked on science 
policy for the National Council for Science and the 
Environment. Although she has conducted field research 
on the vector ecology of Lyme disease and on insect pol-
lination, in recent years she has used her training as a 
biologist to study the intersections of scientific research, 
innovation, human health, and the environment. She 
holds a master’s degree in international health policy 
from the London School of Economics and Political 
Science and a bachelor’s degree in molecular, cellular, 
and developmental biology from Yale University.
BROOKE, Steve
Steve Brooke, an advisor for commercialization and 
corporate partnerships in PATH’s Technology Solutions 
Strategic Program, plays a lead role in public-private 
product development collaboration, product commer-
cialization strategy, and intellectual property manage-
ment. Mr. Brooke conceptualizes, develops, negotiates, 
and implements complex collaborations and strategies, 
and negotiates co-development, licensing issues, and 
agreements. He also provides guidance and advice to 
staff working in these areas and manages projects that 
have a high degree of commercialization and/or private 
partner focus. Prior to receiving a master of business 
administration degree in marketing and finance from 
Northwestern University, he served as marketing man-
ager for a medical products company. Mr. Brooke has 
lived in both Europe and Asia.
BROWN, Alfred (Buz)
Alfred Brown has served as the President of BCM 
Technologies (BCMT) since 2003. He is its chief vi-
sionary and was responsible for transforming BCM 
Technologies into BCM Ventures. He has over 30 
years of experience in biotechnology commercializa-
tion and venture creation, including large pharma-
ceutical, biotech, academic and venture capital roles, 
with particular expertise in the areas of cancer, im-
munology, regenerative medicine, molecular diagnos-
tics, and predictive medicine. Before joining BCMT, 
Dr. Brown was Director of the Office of Cooperative 
Research at the Yale School of Medicine, where he 
co-developed the “Yale Model” of academic ven-
ture creation with Drs. Gardiner, Soderstrom, and 
Swartley. The Yale Model is now recognized as one 
of the leading academic technology commercializa-
tion and venture creation programs. Dr. Brown has 
helped to create many companies, including Achillion 
Pharmaceuticals (in registration), Applied Spine 
Technologies, HistoRx, Kemia, RibX Pharmaceuticals, 
and VaxInnate. Before working at Yale, Dr. Brown 
served as founder and CEO of Penn Technology 
Group, Knowledge Express Data System and Ontyx, 
Inc. (now Apelon, Inc.). He started his professional 
career at SmithKline & French Labs in immunology 
and cancer drug research and later assumed responsi-
bility for strategic planning and biotechnology busi-
ness development. Dr. Brown has a B.A. in biology 
from Colby College, a Ph.D. in pharmacology and 
toxicology from the University of Rochester School of 
Medicine; in addition, he has completed a post-doc-
toral fellowship in the Pharmacology Department at 
the Yale School of Medicine. He serves on the boards 
of Oncovance Technologies, Molecular LogiX, Kardia 
Therapeutics, Progression Therapeutics, and EnVivo 
Pharmaceuticals (observer). Dr. Brown will serve as 
the managing director of BCMV and focus his efforts 
on investments in the areas of therapeutics, diagnos-
tics, and devices.
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BuBELA, Tania
Tania Bubela (B.Sc. Ph.D. LL.B.) is an Assistant 
Professor in the Department of Marketing, Business 
Economics and Law in the School of Business at the 
University of Alberta. She is also a Research Associate at 
the Health Law Institute at the University of Alberta and 
a Member of the Centre for Intellectual Property Policy 
in the Faculty of Law at McGill University. Her doctoral 
research was in the biological sciences; she taught biol-
ogy and genetics as a faculty member at the University 
of Toronto at Mississauga. After gaining a law degree in 
2003, Dr. Bubela clerked for The Honourable Louise 
Arbour at the Supreme Court of Canada. Dr. Bubela’s 
research focuses on intellectual property systems in bio-
technology, as well as questions of health law, ethics, and 
policy as they relate to emerging technologies such as 
functional genomics and stem cell research.
BuRDON, Jeremy
Dr. Burdon is currently Director of IP Assets at Arizona 
Technology Enterprises, LLC (AzTE) in Tempe, 
Arizona, with responsibility for the Health Sciences 
portfolio. Prior to moving to AzTE, Dr. Burdon was 
with Medtronic, Inc. There he was responsible for man-
aging the Intellectual Property portfolio and patent 
liaison activities for implantable medical device tech-
nologies, in both research and advanced development 
environments. 
Dr. Burdon spent more than nine years at Motorola, 
Inc., initially with its Component Products Division 
in New Mexico, researching polymer thin-film tech-
nologies and oxide semiconductor thin-films for RF/
Microwave applications, where he moved several tech-
nologies into the advanced development stage. Dr. 
Burdon then worked at Motorola Corporate Research 
in Tempe, Arizona, developing material technologies for 
micro-devices, and on advanced development of micro 
fluidic devices for analytical and on-chip bio-analysis. 
Dr. Burdon holds a B.Sc. in chemistry and a Ph.D. 
in Polymer Science from the University Of Sussex, U.K., 
where his research focused on oxidative degradation of 
organic/polymer materials and the polymerization be-
havior of bisphenol-A epoxy systems for graphite-based 
composites using chemiluminescence and ion-recom 
luminescence techniques. Dr. Burdon holds 14 issued 
patents in the areas of materials, micro-devices, micro-
fluidic systems and implantable medical devices.
CAhOON, Richard S.
Richard Cahoon received his undergraduate degrees 
in biology and political science from the University 
of Utah. His Master’s degree is from Montana State 
University in the field of bioprocess engineering. He 
founded and was president of a biotechnology device 
company and was later a managing partner of a biopro-
cess engineering consulting firm.
In 1990, Dr. Cahoon joined the Cornell Center 
for Technology, Enterprise & Commercialization 
as Assistant Director for Technology Marketing. 
Previously, he was Associate Director of the Center for 
Biofilm Engineering, an NSF Engineering Research 
Center at Montana State University. In 1992, he was 
appointed Cornell’s Associate Director for Patents and 
Technology Marketing; a year later, he was promoted 
to Vice President of the Cornell Research Foundation 
(CRF), Cornell’s intellectual property subsidiary. In 
January 2003, Richard became Senior Vice President of 
CRF; he has been serving as Acting Executive Director 
of the Cornell Center for Technology, Enterprise, and 
Commercialization since 2002.
Dr. Cahoon has more than 25 years of experience 
in various aspects of technology commercialization, 
including R&D management, inventing, project en-
gineering, product development, marketing and sales, 
process engineering, entrepreneurship, collaboration 
management, intellectual property, and licensing. He 
also holds a patent for a bioprocess system. His Ph.D. 
is from Cornell in Natural Resource Policy with a dis-
sertation that focused on the relationship between in-
tellectual property and biological resource conservation 
law and policy.
CAMPBELL, Alison F.
Alison Campbell is Director of KCL Enterprises Ltd., 
the commercialization and research support company 
of King’s College, London. KCLE manages all aspects 
of the College’s external partnering activities, from 
business development to IP management, licensing, 
start-up company formation, and the administra-
tion and negotiation of research grants and contracts. 
KCLE also supports training in enterprise within 
the College. Dr. Campbell has worked in technol-
ogy transfer and business development for 15 years. 
Before joining KCLE, she was Acting CEO of MRC 
Technology. She has experience in the biotechnology 
industry and worked for a number of years at Celltech 
Ltd. A biochemist, Dr. Campbell is a graduate of 
University College London and earned a Ph.D. in 
chemical biology from Imperial College. She currently 
serves as a nonexecutive director on the boards of a 
number of spinout companies and two London enter-
prise initiatives (Simfonec and the London Technology 
Network). She is a nonexecutive director of the uni-
versity seed fund, Kinetique. She is a member of the 
UNICO committee (the U.K. university commercial-
ization organization), and is Chair of Praxis (the U.K. 
Technology Transfer Training Programme).
CARRIERE, Michael
Michael D. Carriere, manager of the strawberry licensing 
program at the University of California, Davis, received 
his B.S. degree in Agricultural Science and Management 
from the University of California, Davis in 1988 and his 
Ph.D. degree in Plant Biology also from the University 
of California, Davis in 2000. His Ph.D. work focused 
on functional genomics and the physiology of submer-
gence tolerance in rice. Prior to graduate school, Dr. 
Carriere spent four years in a private sector rice cultivar 
improvement program. In his current role he is charged 
with building the global licensing presence of UC Davis 
strawberry cultivars within the public sector framework 
of a land-grant institution. Dr. Carriere has given in-
vited presentations at conferences and universities on 
the topic of university plant licensing. He lives in Davis, 
California with his wife and two children.
CARVALhO, Sergio M. Paulino de 
Sergio M. Paulino de Carvalho is General Coordinator 
of Institutional Partnership and Regional Diffusion of 
the Brazilian National Institute of Industrial Property. 
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He is also Researcher at the Agricultural Research 
Enterprise of the State of Rio de Janeiro (PESAGRO-
RIO) and Associate Researcher with the Study Group on 
the Organization of Research and Innovation (GEOPI), 
State University of Campinas (UNICAMP), Campinas, 
São Paulo, Brazil.
He is an economist from the Federal Fluminense 
University (UFF), with a Master’s and Ph.D. Degree 
in Scientific and Technological Policy at the State 
University of Campinas (UNICAMP). He is author of 
several publications and articles on intellectual property 
policies and the organization of research.
ChAMAS, Claudia Inês
Claudia Chamas is a researcher at the Oswaldo Cruz 
Institute (FIOCRUZ, Ministry of Health, Ministry of 
Health). She works on intellectual property issues and is 
the author of several journal articles on the topic that fo-
cus on biotechnology and pharmaceuticals. She received a 
bachelor’s degree in Chemical Engineering and a MSc and 
DSc in Production Engineering at the Federal University 
of Rio de Janeiro. In the years 2000 and 2002, she was vis-
iting researcher at the Max-Planck-Institut für Geistiges 
Eigentum, Wettbewerbs- und Steuerrecht in Munich. She 
has organised seminars and coordinated research projects 
that were funded by Brazilian funding agencies (CNPq, 
Faperj, etc). She is a regular guest speaker at various uni-
versities and is a member of the Brazilian Association of 
Intellectual Property, the Brazilian Ministry of Health’s 
Intellectual Property Committee, and the Brazilian 
Association of Fine Chemicals, Biotechnology, and 
Specialties Industries’ Industrial Property Committee.
ChAPMAN, Audrey R.
Audrey Chapman holds the Healey Endowed Chair in 
Medical Humanities, Law, and Ethics at the University 
of Connecticut Health Center. She formerly served as 
the Director of the Science and Human Rights Program 
at the American Association for the Advancement of 
Science (AAAS) and as the Co-Director of the AAAS 
initiative on Science and Intellectual Property in the 
Public Interest. She is the author, coauthor, or editor of 
sixteen books and numerous articles and reports deal-
ing with ethical, human rights, and intellectual property 
issues related to health, pharmaceuticals, and genetic 
developments. She received a Ph.D. in public law and 
government from Columbia University and graduate de-
grees in theology and ethics from New York Theological 
Seminary and Union Theological Seminary. She has 
worked closely with the United Nations Committee 
on Economic, Social and Cultural Rights and the UN 
Special Rapporteur on the Right to Health. She is 
currently a member of the University of Connecticut 
Embryonic Stem Cell Oversight Committee, the 
John Dempsey Hospital Ethics Committee, and the 
Expert Genomics Advisory Panel of the Connecticut 
Department of Public Health.
She has worked on a wide range of ethical, human 
rights, and intellectual property issues related to health 
and pharmaceuticals. 
ChAPMAN, Junko
Junko has been a Research Associate at MIHR (Centre 
for the Management of Intellectual Property in Health 
Research and Development) since April 2005. Before 
MIHR, she spent ten years at RIKEN (The Institute for 
Physical and Chemical Research), a semi-governmental 
research institute in Japan. At RIKEN, Junko’s responsi-
bilities included conclusion of MTAs (Material Transfer 
Agreements) and collaborative research agreements and 
management of RIKEN’s intellectual property portfolio. 
Junko was also heavily involved in establishing a system 
for disseminating RIKEN’s key inventions internation-
ally. These inventions included RIKEN’s mouse cDNA 
clones, which have since become globally recognized 
and widely used. 
Junko graduated from SPRU (Science and 
Technology Policy Research), University of Sussex, in 
2001, where she received her M.Sc. in Science and 
Technology Policy, during which time she focused, in 
part, on the impact of harmonization of patent systems. 
Junko is also a graduate of GRIPS (National Graduate 
Institute for Policy Studies, Japan), where she received a 
Master in International Development Studies in 2005.
ChEN, Zhang Liang 
Zhang Liang Chen was born on February 3, 1961, in 
Fujian, China. He received his Ph.D. in 1987 from 
Washington University for his research in the Division 
of Biology and Biomedical Sciences in the field of plant 
molecular biology and his work in early transgenic 
plant research. He then returned to China as an asso-
ciate professor. Two years later, he was a full professor 
at Beijing University. He has continued his research in 
transgenic plants and biosafety. He served as director of 
National Key Laboratory of Protein Engineering and 
Plant Genetic Engineering. In 1995, he became vice-
president of research at Peking University. In 2002, he 
became the president of China Agricultural University. 
He and his research group have published over 190 in-
ternational papers and seven book, and hold over eight 
patents.
Dr. Chen is also Chair of the Plant Biotech Committee 
of UNESCO, Consultant for the International Society 
for Plant Molecular Biology (ISPMB), and mem-
ber of the Sino-Euro Administration Committee for 
Biotechnology Cooperation. He also serves as a member 
and Vice-Chairman of the Council of Scientific Advisers 
to the International Center for Genetic Engineering and 
Biotechnology (ICGEB) in Italy and India.
ChI-hAM, Cecilia
Cecilia Chi-Ham, a native of Honduras, earned a B.S. 
degree in Chemistry and Environmental Sciences at the 
University of the Ozarks and a Ph.D. in Chemistry and 
Biochemistry at the University of Southern Mississippi. 
In 2004, upon completing her post-doctoral work at 
Michigan State University in the field of plant biology, 
Dr. Chi-Ham joined the Public Intellectual Property 
Resource for Agriculture (PIPRA). Dr. Chi-Ham is 
a plant biologist interested in facilitating agricultural 
innovations, particularly in developing countries, and 
leads PIPRA’s Biotechnology Resources Program. The 
Biotechnology Resources Program’s activities include 
the following: developing research tools with maxi-
mum freedom-to-operate that can support a wide 
array of agricultural applications for humanitarian and 
commercial purposes; facilitating technology transfer; 
building new partnerships and research collaborations; 
and providing legal information on biotechnology 
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tools. The program’s multi-disciplinary activities strad-
dle the delicate junction between the scientific, legal, 
business development, and regulatory affairs that are 
an integral part of research and development of new 
agricultural innovations in developed and developing 
countries. 
ChRISTOFFERSEN, Leif
Leif Christoffersen is a Founder at the E.O. Wilson 
Biodiversity Foundation, a nonprofit environmental or-
ganization focused on linking businesses to sustainable 
resources and conservation efforts, as well as educating 
them about the importance of biodiversity. From 2000 
to 2005, Mr. Christoffersen served as the Biodiversity 
Manager at the Diversa Corporation and managed 
biodiversity collaborations and bioprospecting efforts 
in Alaska, Antarctica, Australia, Bermuda, Costa Rica, 
Ghana, Hawaii, Indonesia, Kenya, Puerto Rico, Russia, 
and South Africa; he also managed Diversa’s biodiver-
sity collaboration with the Center for Reproduction of 
Endangered Species (CRES). From 1995 to 2000, he 
served as the Vice President for the World Foundation 
for Environment and Development (WFED), working 
with Yellowstone National Park and the National Park 
Service; he also worked with the National Institute for 
Biodiversity in Costa Rica and the Center for Ecological 
Research and BioResources Development in Russia, de-
veloping bioprospecting programs and facilitating nego-
tiations for benefit-sharing arrangements with biotech 
companies. While at WFED, Mr. Christoffersen also 
served as a Climate Change consultant to the United 
Nations Environment Programme. Previously, Mr. 
Christoffersen had worked for CARE International in 
marketing, public relations, and environmental moni-
toring and evaluation in Costa Rica, Kenya, and Norway. 
Mr. Christoffersen received his B.A. in Economics from 
Hobart College in Geneva, New York, where he won 
the Elizabeth and Ruth Young Peace Prize. He is sched-
uled to graduate with an M.B.A. from the Rady School 
of Management at the University of California, San 
Diego, in August 2007.
CLIFT, Charles
Charles Clift has had a great deal of experience in the 
U.K. Department for International Development 
(DFID), where he works principally as an economist 
on all aspects of DFID’s work. He began his career as 
an agricultural economist, advising DFID on its agri-
cultural research priorities. He has lived and worked in 
Africa, the Caribbean, and India. He has also been re-
sponsible for the management of DFID’s economic and 
social research, and the coordination of all of DFID’s 
research programmes, including those concerned with 
health and agriculture. From 2001 to 2002, he acted 
as Head of the Secretariat of the U.K. Commission 
on Intellectual Property Rights (www.iprcommission.
org). From 2004 to 2006, he was employed in a simi-
lar capacity by the WHO Commission on Intellectual 
Property Rights, Innovation and Public Health (www.
who.int/intellectualproperty).
COLAIANNI, Alessandra
Alessandra Colaianni is a member of the undergraduate 
class of 2007 at Duke University, where she is double-
majoring in Biology and Philosophy. While at Duke, 
she has worked as a research assistant to Dr. Robert 
Cook-Deegan, director of the Center for Genome 
Ethics, Law, and Policy, which is a part of the Institute 
for Genome Sciences and Policy at Duke. Her research 
there has focused mainly on compiling histories of the 
Cohen-Boyer patents, which she has written about with 
Dr. Maryann Feldman, and the Axel patents. After she 
graduates in May, she will continue to work with Dr. 
Cook-Deegan for a year while applying to law school.
CONWAy, gordon
Gordon Conway took up his appointment as Chief 
Scientific Adviser for the Department of International 
Development (DFID) in January 2005. He was edu-
cated at the University of Wales, Bangor, the University 
of Cambridge, the University of Trinidad, and the 
University of California, Davis. His discipline is ag-
ricultural ecology. In the early 1960’s, he worked in 
Sabah, North Borneo, and became one of the pioneers 
of sustainable agriculture. From 1970 to 1986, he was 
Professor of Environmental Technology at the Imperial 
College of Science and Technology in London. During 
this period, he lived and worked in many countries in 
Asia and the Middle East. He then directed the sustain-
able agriculture program of the International Institute 
for Environment and Development in London. From 
1988 to 1992, he was Representative of the Ford 
Foundation in New Delhi; from 1992 to 1998, he 
was Vice-Chancellor of the University of Sussex and 
Chair of the Institute for Development Studies. He was 
President of The Rockefeller Foundation from 1998 to 
2004. He has honorary degrees from the Universities 
of Sussex, Brighton, Wales, and the West Indies; he is 
an honorary fellow of the Institute of Biology, and a 
fellow of Imperial College, the American Academy of 
Arts and Sciences, and the Royal Society. He authored 
Unwelcome Harvest: Agriculture and Pollution (London: 
Earthscan), The Doubly Green Revolution: Food for All in 
the 21st Century (London: Penguin; Ithaca, New York: 
Cornell University Press), and Islamophobia: A Challenge 
for Us All (London: The Runnymede Trust).
COOK, Tim
After being awarded a doctorate in cryogenic engineer-
ing at Oxford, Tim Cook joined the Oxford Instruments 
Group (a spinout company from the University of 
Oxford) in 1975. During his 12 years with them, the 
Group’s turnover grew from £1million to £100 million. 
In 1983, Dr. Cook was appointed Managing Director of 
the Group’s subsidiary, Oxford Analytical Instruments. 
After two more appointments as Managing Director, 
Dr. Cook became a private investor in 1990 and the 
founding Managing Director of Oxford Semiconductor 
and Oxford Asymmetry (a spinout from the University 
of Oxford, floated in 1998 and recently sold for over 
£300 million).
In 1997, Dr. Cook was appointed Managing 
Director of Isis Innovation, the technology transfer 
company of the University of Oxford. Since then, Isis 
has recruited 37 staff members and negotiated over 100 
option and licence agreements. In the last nine years, 
Isis has established 54 new spinout companies from the 
University, which have collectively raised over £300 mil-
lion in investment capital. In January 2006, Dr. Cook 
became Visiting Professor in Science Entrepreneurship; 
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he became Deputy Chairman of Isis Innovation in April 
of that year.
Is addition to his work in Oxford, Dr. Cook is also 
working on technology transfer with other universities. 
He has given invited lectures in many countries and vis-
ited University Technology Transfer Organizations in 
the U.S., Australia, Europe, and Japan. 
COOK, Trevor
Trevor Cook joined Bird & Bird in 1974 with a de-
gree in chemistry from Southampton University. He 
was admitted as a Solicitor in 1977 and then joined the 
Intellectual Property Department of Bird & Bird, where 
since 1981 he has been a partner. He specializes in in-
tellectual property and regulatory law. He is Treasurer 
of the U.K. Group of The International Association for 
the Protection of Industrial Property (AIPPI), Secretary 
to the British Copyright Council Standing Committee 
on Copyright and Technology, and a member of the 
Council of the Intellectual Property Institute. In re-
cent years, he has acted in many of the leading patent 
infringement cases that have come before the English 
courts, most of which have concerned pharmaceuticals 
and biotechnology, and also in many of the leading cas-
es regarding the protection of regulatory data that have 
come before the European Court of Justice. 
CORREA, Carlos M.
Carlos M. Correa is Director of the Center for 
Interdisciplinary Studies of Industrial Property Law and 
Economics at the University of Buenos Aires, as well 
as Director of the Post-graduate Courses on Intellectual 
Property at the same University. He has been a Visiting 
Professor and taught post-graduate courses at several 
universities. He has also been a consultant in differ-
ent areas of law and economics (including investment, 
science and technology, and intellectual property) to 
UNCTAD, UNIDO, UNDP, WHO, FAO, the Inter-
American Development Bank, INTAL, the World 
Bank, SELA, ECLA, UNDP, and other regional and 
international organizations, as well as several govern-
ments. He was a member of the U.K. International 
Commission on Intellectual Property, which was estab-
lished in 2001, and of the Commission on Intellectual 
Property, Innovation, and Public Health, which was es-
tablished by the World Health Assembly in 2004. He 
is the author of several books and numerous articles on 
law and economics, particularly on the topics of invest-
ment, technology, and intellectual property. 
COSTANZA, Charles
Charles (Chuck) Costanza is a consultant to the bio-
technology industry. Since 2002, he has consulted for 
Diversa Corporation, a San Diego-based corporation 
that has pioneered the development of high-perfor-
mance specialty enzymes. Mr. Costanza advises the 
company on business development in emerging mar-
kets, and specializes in biodiversity access agreements. 
He has presented papers around the world and to 
many different audiences (business, NGO, academic, 
and government) on the subject of biodiversity access 
agreements. Prior to working with Diversa, Chuck 
worked in the financial and technology industries, 
managing projects, consulting, and developing business 
across the U.S., Europe, the former Soviet Union, and 
Asia. He worked for ICF Consulting, Inc. as a project 
manager, and developed and oversaw projects for clients 
such as The World Bank, British Petroleum, and the 
U.S. Environmental Protection Agency. Prior to work-
ing for ICF, Mr. Costanza worked as a project manager 
for the International Finance Corporation; in this ca-
pacity, he led a multinational team of 70 economists 
and lawyers who helped to privatize collective farms in 
Ukraine in 1996, the first privatizations of their kind. 
Fluent in Russian and German, Mr. Costanza received 
a Bachelor’s Degree from the College of the Holy Cross 
and a Master’s Degree from Harvard University.
CROW, Michael
Michael Crow—educator, knowledge enterprise archi-
tect, and science and technology policy scholar—be-
came president of Arizona State University on July 1, 
2002. He is currently helping to transform ASU into 
one of the nation’s leading public metropolitan research 
universities. Under his direction, the university’s faculty 
pursue teaching, research, and creative work that is fo-
cused on the major challenges and questions of our time 
and, especially, the challenges related to Arizona’s envi-
ronment and economy. He has committed the univer-
sity to global engagement and to setting a new standard 
for public service. During his tenure, ASU has marked 
a number of important milestones: the establishment 
of major global interdisciplinary research initiatives 
such as the Biodesign Institute, the Global Institute 
for Sustainability, and the Flexible Display Center; an 
unprecedented expansion of research infrastructure that 
added more than one million square feet of new research 
space; a dramatic increase in federal research awards; 
and the four largest gifts in the history of the university. 
Prior to joining ASU, Dr. Crow was Professor of Public 
and International Affairs and Executive Vice Provost 
of Columbia University. He is the author of books and 
articles on the analysis of knowledge organizations, 
knowledge transfer, science and technology policy, and 
the practice and theory of public policy. 
CROWELL, W. Mark
W. Mark Crowell is Associate Vice Chancellor for 
Economic Development and Technology Transfer 
at the University of North Carolina at Chapel Hill 
(UNC). Prior to joining UNC, he held similar posi-
tions at North Carolina State University and at Duke 
University. He has extensive experience in technology 
transfer, new company development, seed capital for-
mation, and research park development and marketing. 
Mr. Crowell also leads UNC’s efforts to connect its re-
search enterprises with economic and business devel-
opment opportunities in the region, state, nation, and 
world. Mr. Crowell, as a representative of UNC, sits on 
the boards of major statewide and regional economic 
development and entrepreneurial support agencies in 
North Carolina. 
Mr. Crowell is Past President (2005) of the Association 
of University Technology Managers (AUTM). AUTM is 
the pre-eminent international organization in the field 
of academic technology transfer. AUTM has a member-
ship of nearly 3,500 professionals, almost 12% of whom 
are from outside of North America. AUTM’s mission is 
to promote and enhance the global technology transfer 
profession through education, training, networking, and 
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advocacy, and through the identification and dissemina-
tion of best practices in academic technology transfer. 
Mr. Crowell’s speaking and consulting experience in 
the past two years includes keynote addresses at inter-
national conferences in at least 15 countries outside the 
U.S., as well as advisory roles with many major national 
and international organizations, including the AAAS 
and the National Academies of Sciences. He has exten-
sive management experience in organizations and ini-
tiatives related to technology transfer and innovation-
based economic development.
CRuZ, Richard L.
Richard L. Cruz focuses his practice on securing, licens-
ing, and enforcing intellectual property rights, primar-
ily in the electrical, electro-mechanical, and electronic 
arts. His practice includes domestic and foreign patent 
prosecution, patent validity and infringement analysis, 
state-of-the-art and patentability opinions, licensing, 
due diligence, copyrights, and trademarks, and the liti-
gation circuits, software, and electronics fields. 
Mr. Cruz earned his law degree, with honors, from 
Widener University School of Law. While at Widener, 
Mr. Cruz was a member of the Moot Court and Trial 
Advocacy Honor Societies. Mr. Cruz also earned a 
Certificate in Trial Advocacy, with honors, while in law 
school. He is a member of the Pennsylvania bar and is ad-
mitted to practice before the U.S. Patent and Trademark 
Office and the Eastern District of Pennsylvania. Prior 
to attending law school, Mr. Cruz earned a degree in 
Engineering from the University of Pittsburgh. 
CuNNINghAM, Sean
Sean Cunningham is a partner at the firm of DLA Piper 
U.S. L.L.P. in San Diego, California. Mr. Cunningham 
is a trial lawyer who specializes in patent litigation, with 
an emphasis on litigation in the International Trade 
Commission, multi-jurisdictional litigation, and liti-
gation involving conduct in standard-setting organiza-
tions. He received his law degree from the University of 
Kansas School of Law, where he was Order of the Coif 
and Editor of the Kansas Law Review. Sean has spent 
his entire legal career with DLA Piper (formerly known 
as Gray Cary Ware & Freidenrich). He is a member 
of the Federal Circuit Bar Association, the American 
Intellectual Property Law Association, and the Intellectual 
Property Section of the California Bar Association. Mr. 
Cunningham frequently works with companies such as 
Hewlett-Packard, Agilent Technologies, and Qualcomm 
Incorporated. His full biography can be found at www.
dlapiper.com/sean_cunningham/.
DI gIORgIO, Rosana Ceron
Rosana Di Giorgio currently serves as Intellectual 
Property & Partnership Development Director of Inova 
Unicamp, the Technology Licensing Office of the State 
University of Campinas, Brazil (Unicamp). She is re-
sponsible for business development between the univer-
sity and the marketplace. In the three years since she 
joined Unicamp, she has signed 150 technology transfer 
agreements involving IP development and licensing be-
tween the university and the commercial sector, a new 
record for both Brazil and Latin America; as a result, 
Unicamp is the biggest licensor in the country. Some 
of these technology transfer agreements have already 
resulted in commercialized products, such as BiPhor 
and Aglicon-Soy. She is also responsible for defining 
policies, practices, legal affairs, team building, and man-
agement of the university’s IP portfolio, which, since 
1999, has been considered the country’s largest.
In the past three years, she has been invited to speak 
at about 40 national and international conferences, 
symposia, and workshops on the subject of transferring 
academic technology to the commercial sector. These 
talks have attracted investors, industry representatives, 
and academics. Some of her publications include: arti-
cles for business magazines, such as Líderes Empresariais 
and Les Novelles, and business newspapers, such as 
Gazeta Mercantil; books like Propriedade Intelectual: 
O Caminho para o Desenvolvimento, chapter 7, a book 
sponsored and launched by Microsoft; television in-
terviews for such channels as Globo News, EPTV, and 
TV Bandeirantes; radio interviews for such channels as 
CBN and Eldorado; and electronic reports, such as a 
WIPO report on best practices.
Her previous experience includes eight years man-
aging people, projects, accounts, and business develop-
ment in Brazil and abroad; creating innovative solutions 
for several market sectors (financial, energy, IT, and 
pharmaceutical); strategic planning; market research; 
and business plan and business viability analysis. She 
previously served as Executive Director of facTI, a pri-
vate foundation concerned with IT; under her guidance, 
the foundation became financially viable in one year. 
She was also Corporate Business Development Manager 
and Semiconductor Division Manager at CPqD, the 
biggest research and development center in Brazil for 
telecommunications and IT.
DI SANTE, Anne C.
Anne C. Di Sante (University of Michigan M.B.A., 
Marketing; University of Michigan M.S., Microbiology/
Immunology; University of Michigan B.S., Medical 
Technology) is the Director of the Technology Transfer 
Office at Wayne State University. She is responsible for 
the daily operations related to traditional invention 
management activities undertaken by the TTO staff, 
including resource allocation, commercialization strat-
egy development and implementation, and agreement 
negotiation and maintenance. Prior to joining WSU in 
1998, she held various positions within the Technology 
Management Office (now the Office of Technology 
Transfer) at the University of Michigan, ranging from 
student intern to Acting Director. She is experienced 
in managing inventions from all scientific disciplines; 
however, she specializes in medical, pharmaceutical, and 
biotechnology inventions. She has had the pleasure of 
managing several key biomedical inventions, including 
the cystic fibrosis gene, several gene therapy technologies, 
anti-viral compounds, anti-cancer compounds, methods 
for antibiotic development, a nasal vaccine for the pre-
vention of influenza, and several immunotherapy tech-
nologies. Currently, she is a member of the Intellectual 
Property Commercialization Committee, the governing 
body for the Michigan Universities Commercialization 
Initiative, a $9.0 million project funded by the State of 
Michigan; she is also a member of the MUCI Finance 
Committee. Ms. Di Sante is also an active member of 
the Association of University Technology Managers, 
currently serving as editor of the AUTM Newsletter. 
AUTHOR BIOS
 HANDBOOK OF BEST PRACTICES  | 1941 
She has also served on AUTM’s Board of Trustees as 
Vice President of the Central Region and as an Executive 
Committee participant. She participated in the develop-
ment of the BioMed Expo (now the MichBio Expo), 
serving on the planning committee for four years. She is 
a member of the Licensing Executives Society.
DODDS, John
John Dodds was born in the U.K. but has lived and 
worked in the Middle East, Latin America, and the 
United States. He became a U.S. citizen in the 1980s. 
Originally trained as a biochemist, he earned both 
a Bachelor’s and Doctoral degree at the University of 
London. Dr. Dodds also earned a law degree in the 
U.S. and founded the law firm Dodds and Associates 
in 1999. His early research career focused on plant bio-
chemistry and plant tissue culture. In the early 1980s, 
Dr. Dodds co-authored a standard and well-used text-
book on techniques for culturing plant tissue. His work 
focused on plant genetic conservation in vitro and plant 
transformation systems. He then moved into the area of 
agricultural development and has worked in, and trav-
eled to, more than 100 countries. Dr. Dodds has also 
been a teacher in many capacities, from a professor in 
both the U.S. and the U.K. to the coordinator of regular 
IP training programs that have been offered through his 
law firm in several countries. In his few hours of spare 
time, Dr. Dodds also writes novels and assists his wife in 
restoring historic buildings.
DuNN, Martha
Dr. Dunn joined Ciba-Geigy in 1994 as a Research 
Scientist, working in the areas of protein structure/func-
tion and molecular recombination for the discovery of 
novel traits, in support of the agribusiness sector of 
Ciba-Geigy. 
Martha joined the Licensing Department in 1998, 
where she helped negotiate agreements to support 
R&D and commercialization activities for Syngenta 
Biotechnology and its affiliated companies. 
Prior to this, Martha worked at Genetics Institute in 
Cambridge, Massachusetts, as a research scientist in the 
Immunology Department and was responsible for assay 
development for GI’s ongoing projects.
Dr. Dunn is a registered as a Patent Agent with the 
U.S. Patent and Trademark Office, an active member 
of the Licensing Executive Society, the Biotechnology 
Industry Organization and an affiliate member of the 
Association of University Technology Managers. 
Martha graduated with a B.S. from Boston College 
and has received her Ph.D. in Biochemistry and 
Biophysics from the University of North Carolina at 
Chapel Hill. 
EDWARDS, Mark g. 
Mark G. Edwards is the Managing Director of 
Recombinant Capital, Inc. (Recap), a consulting firm 
based in Walnut Creek, California. More than 500 bio-
technology, pharmaceutical, and service companies sub-
scribe to Recap’s databases (Recap.com & rDNA.com) 
or retain Recap to advise them on biotech alliances and 
valuations.
Mr. Edwards has been invited to speak to many 
trade and industry groups about structuring alliances 
and other business relationships that are related to the 
development and commercialization of new technolo-
gies, compounds, or products. These groups include the 
Institute of Medicine, the Licensing Executives Society, 
the Association of University Technology Managers, 
Sigma Xi (the Scientific Research Society of the National 
Academy of Sciences), and the Biotechnology Industry 
Organization. He has also provided expert testimony at 
deposition or trial in lawsuits dealing with either rea-
sonable royalties or normal custom and practice in the 
biotechnology and pharmaceutical industries. 
Mr. Edwards is on the Board of Directors of Allos 
Therapeutics, Inc. Prior to founding Recap in 1988, 
Mr. Edwards was Manager of Business Development at 
Chiron Corporation. He received his B.A. and M.B.A. 
degrees from Stanford University.
EISS, Robert
Robert Eiss presently serves as the CEO of MIHR. 
He has held senior management positions at the U.S. 
National Institutes of Health (NIH) and the White 
House Office of National Drug Control Policy. He has 
more than twenty years of experience in the planning 
and management of NIH-supported global health pro-
grams. He helped initiate the Multilateral Initiative on 
Malaria, a consortium of international investors that 
supports research for improved control and prevention 
of malaria in Sub-Saharan Africa. He has also helped 
start a cooperative venture between NIH-supported in-
stitutions and the World Bank’s Global Development 
Network, whose goal is to assess the effects of health on 
economic productivity. He also conceived of the “Global 
Forum on Bioethics,” an informal partnership among 
multiple organizations that addresses issues of equity 
and social justice in North-South research enterprises, 
including allocation of intellectual property rights. 
He has been responsible for the analysis and im-
plementation of policies related to IP allocation in 
cooperative programs involving NIH and its interna-
tional counterparts. As a representative of NIH to the 
White House Committee on International Science, 
Engineering and Technology, he was lead author on 
reports that established policy frameworks for coopera-
tive programs between the U.S. and both the European 
Union and Russia. He also served as Associate Director 
of the White House Office of National Drug Control 
Policy, where he helped institute a national initiative to 
improve access to treatment in the public and criminal 
justice settings through block and discretionary grants. 
A native of Washington, D.C., Mr. Eiss graduated 
from the University of Maryland at College Park and 
received his M.A. from Oxford University. 
FAThALLA, Mahmoud F. 
Dr. Fathalla is a professor of Obstetrics and Gynecology 
and former Dean of the Medical School at Assiut 
University in Egypt and is currently the chairman of the 
World Health Organization (WHO) Global Advisory 
Committee on Health Research. He has served as the 
Director of the UNDP, UNFPA, World Bank, WHO 
Special Programme of Research, Development and 
Research Training in Human Reproduction and has 
served as a consultant to various international bodies 
such as the WHO, UNPF, IPPF, Population Council, 
and the Ford and Rockefeller foundations. He is the au-
thor of more than 150 scientific publications. Professor 
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Fathalla has been an international campaigner for Safe 
Motherhood and a founder of the Safer Motherhood 
Initiative. His scientific interests include women’s 
health, safe motherhood, reproductive health, eth-
ics and human rights, and contraceptive research and 
development.
FEINDT, hans h. 
Hans Feindt currently supervises the Monitoring and 
Enforcement Branch of the Division of Technology 
Development and Transfer in the NIH Office of 
Technology Transfer (OTT). He has been with OTT 
since November 2002. Before joining NIH, he worked 
in various roles as a scientist, project leader, and research 
director in the medical diagnostics industry at a number 
of large and small U.S. companies. During his 20-year 
industry career, he was employed by Bethesda Research 
Laboratories, Becton Dickinson & Co., Quidel 
Corporation, and OraSure Technologies. He contribut-
ed to the development and commercialization of rapid, 
antibody-based tests for a variety of important infec-
tious disease agents. Some of these tests are still in com-
mercial use. In addition to developing new products, he 
also transferred and established new technologies that 
were obtained through licensing or acquisition deals by 
the companies where he was employed. He is listed as 
a co-inventor on numerous patents and a co-author on 
a number of scientific publications. Dr. Feindt earned a 
Ph.D. in biochemistry from Brandeis University and a 
B.S. in chemistry from the University of Delaware. He 
and his family currently reside in Baltimore, Maryland.
FELDMAN, Maryann P.
Maryann P. Feldman is the inaugural Zell Miller 
Distinguished Professor of Higher Education at the 
Institute of Higher Education of The University of 
Georgia. Previously, she was Professor of Business 
Economics at the University of Toronto, where she also 
held the Jeffrey S. Skoll Chair in Technical Innovation 
and Entrepreneurship at the Rotman School of 
Management. Dr. Feldman’s work focuses on the ways 
in which universities transfer technology and the im-
plications of those transfers for economic develop-
ment. She explores the means by which geographic 
clusters produce economic growth and has special ex-
pertise in university-generated technologies and the 
commercialization of academic research. Prior to her 
appointment at Toronto, Dr. Feldman was at Johns 
Hopkins University, where she was a faculty member 
at the Institute for Policy Studies. At Johns Hopkins, 
Dr. Feldman was the founding policy director at the 
Information Security Institute (JHUISI) at the Whiting 
School of Engineering. Her most recent book, co-edited 
with P. Braunerhjelm, is Cluster Genesis: the Origins and 
Emergence of Technology-Based Economic Development 
(Oxford: Oxford University Press, 2006).
FENTON, gillian M.
Gillian M. Fenton is a patent and intellectual property 
attorney who specializes in the fields of biotechnology 
and pharmaceutical patents and licensing. She has over 
fourteen years’ experience as an attorney and is a member 
of the bar in Massachusetts, Maryland, and the District 
of Columbia and is also registered to practice before the 
U.S. Patent and Trademark Office. Ms. Fenton currently 
is Chief Intellectual Property Counsel at Emergent 
BioSolutions Inc., where she is responsible for all patent 
matters and licensing-related intellectual property mat-
ters. She previously served as in-house counsel at Biogen, 
Inc. and at several Boston-based law firms, including 
Foley Hoag LLP. Ms. Fenton is a 1992 graduate of Suffolk 
University Law School in Boston. Before she entered the 
field of law, she was a scientist in the immunology labo-
ratory at Genetics Institute, Inc. She is a 1984 graduate 
of Trinity College in Hartford, Connecticut, where she 
received a bachelor’s degree in biochemistry.
FERNáNDEZ, Carlos
Carlos Fernández studied agronomy at Universidad 
de Chile. After working as an Assistant Professor at 
the Agronomy Faculty of the same university, he re-
ceived a Ph.D. in Plant Physiology at the University 
of California, Davis. Upon graduation, he joined 
Monsanto Company, where he held various manage-
ment positions that gave him responsibilities in sev-
eral countries. He led the development of agricultural 
technologies in Latin American countries, first from the 
company headquarters in St. Louis and later from Sao 
Paulo, Brazil. Among other things, he contributed to 
the development of new applications for Roundup, the 
most successful herbicide in the world, and the develop-
ment of nontillage systems for various crops. In Europe, 
he developed new products and actively participated 
in the design of the Roundup post-patent policy for 
Europe and Africa.
While working for Monsanto in California, he evalu-
ated and contributed to the development and introduc-
tion of transgenic crops to the market. During his stay in 
California, he returned to the University of California, 
Davis, and earned an M.B.A. In 1999, he returned to 
Santiago, Chile, and began working at Fundación Chile, 
where he coordinated programs related to technology 
transfer, intellectual property, regulatory matters, and 
the development of transgenic crops. He contributed to 
the Cooperative Agreement between the University of 
California, Davis and Fundación Chile. In addition to his 
work at Fundación Chile, he serves as a consultant to the 
Food and Agricultural Organization of the UN and the 
Chilean Ministry of Economy. Some of his latest contri-
butions as a consultant include two studies sponsored by 
the Ministry of Economy of Chile: “Comparative Analysis 
of Biotechnology Policies in N. Zealand, Canada, United 
States, Australia, Japan, China, Argentina, Brazil, Spain 
and Chile” and “Formulation of a Model for a Technology 
Transfer Office for Chile.” He also contributed to a recent 
study, sponsored by UNDP, titled “Commercialization 
Impact on Agricultural Export Products Caused by the 
Introduction of GMO in Chile.”
As of July 2006, Dr. Fernández is the Head of 
Strategic Studies and the technology transfer unit of the 
Foundation for Agriculture Innovation.
FERNANDEZ, Dennis S.
Dennis Fernandez has over 20 years’ experience in Silicon 
Valley and high-tech industry as a patent prosecutor 
and intellectual property litigator, a venture capital-
ist, and an engineering manager. He specializes in de-
veloping offensive and defensive patent strategies for 
start-up electronics, software, and biotech companies 
and their investors. Mr. Fernandez serves as strategic 
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advisor to leading venture capital firms, including Sevin 
Rosen, Venrock, Charles River Ventures, and Walden 
International. Some of his clients include Marvell 
Technology, SiRF Technology, Ayala Corporation, 
Stanford University, and Northwestern University, as 
well as various start-up companies acquired by Cisco, 
Broadcom, Ciena, and Cadence Design Systems. He 
also serves on the Editorial Board of the Nanotechnology 
Law & Business Journal, the Board of Directors of the 
Association of Patent Law Firms, and the Science and 
Technology Advisory Council. Previously, Dennis served 
on a consultancy with the United Nations Development 
Programme on Asian economic development.
Mr. Fernandez also holds several U.S. and interna-
tional patents in the areas of digital television, sensor 
networks, and bioinformatics. He has an electrical en-
gineering degree from Northwestern University, a law 
degree from Suffolk University Law School, and is a 
Registered U.S. Patent Attorney.
FINSTON, Susan K.
Susan K. Finston has more than 20 years of experience 
in the management of international legal and public pol-
icy issues. In June 2005, Ms. Finston founded Finston 
Consulting, LLC. Her company provides a range of ser-
vices to the biotechnology industry, including business 
development, strategic marketing, technology transfer, 
policy analysis and advocacy, ally development, and 
education and awareness programs for start-ups and 
multinational companies.
Ms. Finston is a board member of BayhDole25, a 
technology transfer NGO that was established in 2005 
to study the social and economic impact of the Bayh-
Dole Act of 1980 and related international technology 
transfer legislation. She also serves as Executive Director 
of the American BioIndustry Alliance (ABIA), an ad-
vocacy organization that seeks enabling conditions for 
biotechnology through sustainable, mutually beneficial 
Access and Benefit Sharing (ABS) policies. She was re-
cently elected to the Alumni Board of the Ford School of 
Public Policy at the University of Michigan, where she 
received a Joint JD/MPP degree in 1986. She also served 
on the Board of Governors of the Washington Foreign 
Law Society and was a member of the National Advisory 
Board of the International Society of Environmental 
Biotechnology. For publications, presentations, and up-
coming events, see www.finstonconsulting.com. 
FONg, h. h. S. 
Professor Harry Fong is a Professor Emeritus of 
Pharmacognosy and Associate Director, WHO 
Collaborating Centre on Traditional Medicine at 
the College of Pharmacy, the University of Illinois 
at Chicago, as well as Adjunct Professor at RMIT 
University in Melbourne, Australia. He is an inter-
nationally known pharmacognosist/natural products 
chemist with more than 48 years of experience center-
ing on the search for anti-tumor, cancer chemopreven-
tive, antimalarial, anti-HIV, and anti-TB agents from 
plants and on quality-control standardization and 
clinical evaluation of herbal medicine/botanical-dietary 
supplements. His research has resulted in more than 
255 research papers, a number of books, book chapters, 
and review articles. He was an Associate Editor of the 
Journal of Natural Products and was a primary writer of 
the WHO Monographs on Selected Medicinal Plants Vol. 
1-4 and the WHO Guidelines on GACP. His work and 
services led to many honors. He served as President of 
the American Society of Pharmacognosy from 1978 to 
1979, President of the Society for Economic Botany 
from 1981 to 1982, Visiting Professor at Guangzhou 
University of Traditional Chinese Medicine University, 
and Honorary Member of the American Society of 
Pharmacognosy beginning in 2004. He is a recipient of 
the Jack L. Beal Post-Baccalaureate Alumnae Award, the 
College of Pharmacy, Ohio State University; Member, 
WHO Traditional Medicine Expert Panel (1997 to 
present); and Member, International Advisory Board on 
Hong Kong Chinese Materia Medica Standards (2002 
to present).
FRASER, John A.
John A. Fraser has been the Executive Director of the 
Office of IP Development and Commercialization 
at Florida State University, Tallahassee, since 1996. 
Previously, he was Director of the University/Industry 
Liaison Office at Simon Fraser University, Vancouver. 
Mr. Fraser has substantial corporate and university 
experience. He has also held the following positions: 
Executive Vice President and co-founder of UTC, Inc., 
a venture-capital-backed, North Carolina-based univer-
sity licensing/technology transfer firm; President and 
CEO of UTI, a University of Calgary-based for-profit 
technology transfer company; Vice President of TDC, 
Inc., a Toronto and Vancouver-based venture capital 
firm; and President of Burnside Development, a tech-
nology commercialization consulting firm. He has co-
founded three companies and assisted in the launching 
of another 12 technology-based firms. 
In 2006, he became President of AUTM, the glob-
al, academic professional technology transfer associa-
tion, and served a two-year term as VP Membership 
(2001–2003). He is a Founding Board Director of 
TalTech Alliance, the technology association of the 
Tallahassee region, and its Executive Committee. He is 
also a Founding Board member of the Florida Research 
Consortium and its Executive Committee; he was ap-
pointed by the governor to increase university/company 
interactions to better the Florida economy. Through the 
Johns Hopkins University technology transfer program, 
he has helped scientists and engineers create business 
plans for new start-up companies. In 2006, he joined 
the Board of BioFlorida, the statewide biotechnology 
trade association. 
Mr. Fraser holds a Master’s Degree in Biochemistry 
from the University of California, Berkeley. 
FREEMAN, John W. 
John Freeman is a Principal in the law firm of Fish & 
Richardson P.C., with 35 years of experience. He has a 
diverse practice emphasizing patent licensing and patent 
opinions. He specializes in biotechnology, chemistry, 
bioinformatics and biology. He has extensive experience 
in academic-industry collaborations, diligence involving 
intellectual property, and all aspects of patent counseling 
and prosecution. He also has experience in pharmaceu-
tical patent counselling, including pre-suit investigation 
and strategic issues under Hatch-Waxman provisions.
Prior to joining Fish & Richardson, Mr. Freeman 
served in the office of general counsel at the Civil 
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Aeronautics Board, where he was responsible for lit-
igated cases involving administrative law. He also 
served as a law clerk to Justice Robert N.C. Nix of the 
Pennsylvania Supreme Court. He received a B.A. from 
Williams College in organic chemistry and a J.D. from 
the University of Pennsylvania Law School.
FREIRE, Maria
Dr. Maria C. Freire is CEO and President of The Global 
Alliance for TB Drug Development, a position she has 
held since 2001. During her service, the Alliance has 
built the largest pipeline of TB drugs in the world, ad-
vanced compounds into clinical testing, and pioneered 
precedent-setting agreements with industry. 
From 1995 to 2001, Dr. Freire directed the Office 
of Technology Transfer at the NIH, where she was re-
sponsible of technology transfer policies and procedures 
for the Department of Health and Human Services and 
for patenting and licensing activities at the NIH and 
the FDA.
Dr. Freire is an internationally recognized expert 
in technology commercialization. She is a member 
of the NIH Advisory Board for Clinical Research, a 
Governor of the New York Academy of Sciences, and 
the Chair of the Working Group for New TB Drugs for 
the global Stop TB Partnership. Dr. Freire was select-
ed as one of ten Commissioners of the World Health 
Organization’s Commission on Intellectual Property 
Rights, Innovation and Public Health (CIPIH) and a 
member of Time magazine’s Global Health Summit 
Board of Advisors. 
Born in Lima, Peru, Dr. Freire trained at the 
Universidad Peruana Cayetano Heredia. She holds a 
Ph.D. in biophysics and completed post-graduate stud-
ies in immunology and virology at the University of 
Virginia and the University of Tennessee, respectively, 
and at the John F. Kennedy School of Government at 
Harvard University. She has received numerous na-
tional and international awards, including the Arthur 
S. Flemming Award, DHHS Secretary’s Award for 
Distinguished Service, and the Bayh-Dole Award.
gACEL, Rafael A.
Rafael A. Gacel is an Associate Director of Technology 
Transfer Services at the University of California, Davis. 
Since joining U.C. Davis in January 2000, he has also 
served as an intellectual property officer and a material 
transfer analyst; he has worked on thousands of MTAs, 
confidentiality agreements, research agreements, and 
licenses; and he has given presentations and classes on 
MTA-related topics. From 1998 to 2000, he was an 
administrative analyst at UC Berkeley; from 1996 to 
1998, he was a deputy director of financial manage-
ment with the U.S. Senate (assigned to the U.S. Capital 
Police); from 1976 to 1996, he was a financial man-
agement officer, an information systems officer, a com-
manding officer, and an engineer equipment operator 
in the U. S. Marine Corps. Mr. Gacel earned a B.S. in 
Civil Engineering from the University of Washington 
in 1983, an M.B.A from National University in 1986, 
and an M.S. in Information Systems from the Naval 
Postgraduate School in 1991. He immigrated to the 
United States of America as a Cuban refugee in 1964, 
and has been living in Davis, California, since 1998. 
Mr. Gacel has also lived in the Dominican Republic, 
Guatemala, and Okinawa. He has three children: 
Enrique, Maria, and Emmanuel.
gAO, Wangsheng
Wangsheng Gao is the Director of the Regional 
Agricultural Development Center at China Agriculture 
University (CAU). He is also a Professor of Farming 
Systems and Ecology at the College of Agronomy and 
Biotechnology at CAU and Chairman of the China 
Farming-system Research Society. From 1979 to 1983, he 
was an undergraduate in the Department of Agronomy of 
Gansu Agriculture University (GAU), where he earned his 
B.A. From 1984 to 1990, he worked at GAU and earned 
his M.S. degree there in 1989. From 1991 to 1994, he re-
turned to CAU and earned a Ph.D. there. Since 1995, he 
has taught at CAU. Between 1995 and 2006, he finished 
more than 10 research programs supported by national 
science & technology project. His areas of research inter-
est are farming systems and regional rural development, 
conservation tillage and sustainable agriculture, agro-eco-
system eco-economical analyses, and agricultural high-
technology assessment and developmental policy. 
gARNER, Cathy
Cathy Garner is currently Chief Executive of Manches-
ter: Knowledge Capital. Dr. Garner has a background 
in university-business links and technology transfer, as 
well as extensive experience in the fields of urban re-
generation, education, and knowledge-based business 
development.
She is a Trustee of the U.K. registered charity MIHR 
and was its founding CEO until 2004. Dr. Garner es-
tablished and ran the Research and Enterprise Office 
at the University of Glasgow in Scotland. She helped 
establish the Scottish Institute for Enterprise and was 
a founder-director of the Scottish North American 
Business Council. She is a member of the Association 
of University Technology Managers (AUTM) in the 
U.S. and has served as their inaugural Vice President for 
International Relations.
Her career includes eight years of policy and research 
management in the public sector and ten years of aca-
demic research in education and urban regeneration. 
She has acted as an intellectual property advisor to the 
U.K., Canada, Japan, and South Africa and served as a 
Non-Executive Director on numerous Boards. She is a 
Fellow of the Royal Statistical Society.
ghAFELE, Roya
Roya Ghafele works as an economist with the World 
Intellectual Property Organization. She concentrates on 
questions related to value creation and intellectual prop-
erty in the area of life sciences. Dr. Ghafele has published 
widely in the field of IP management in the life sciences 
and has advised the governments of several developing 
countries on how to better align intellectual property 
with overall innovation and health policies. Previously, 
Dr. Ghafele worked with the OECD Trade Directorate, 
McKinsey & Company, and as a professional bal-
let dancer. Dr. Ghafele was trained at Johns Hopkins 
University, the Sorbonne, and Vienna University. Her 
doctoral dissertation, “Globalization, Francophone 
Africa and the WTO – a Historical Discourse Analysis” 
was awarded the Theodor Körner Research Prize by the 
president of Austria. 
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gOLD, E. Richard
Richard Gold is the Director of the Centre for 
Intellectual Property Policy. He teaches courses on intel-
lectual property and innovation at McGill University’s 
Faculty of Law. His research centers on the nexus be-
tween innovation and development, particularly with 
respect to biotechnology in the international context. 
He is the Principal Investigator of the Intellectual 
Property Modelling Group, a transdisciplinary research 
team investigating intellectual property regimes and 
their links to innovation, financing, public opinion, and 
development. Dr. Gold has consulted with the World 
Intellectual Property Organization, the Organization for 
Economic Cooperation and Development, the World 
Health Organization, and various Canadian federal and 
provincial governments and institutions. Dr. Gold holds 
an S.J.D. and LL.M. from the University of Michigan, 
a LL.B. (Honors) from the University of Toronto and a 
B.Sc. from McGill University. 
gOLDMAN, Michael L.
Michael L. Goldman practices law at Nixon Peabody 
LLP. He has extensive experience in patent licensing 
and intellectual property agreements, particularly with 
sponsored research agreements and license agreements. 
He deals regularly with pharmaceutical, genomics, and 
biotechnology companies, as well as universities, agri-
cultural cooperatives, and international entities. His 
work has focused on serving large and small companies, 
universities, and other institutions in the biotechnology 
and chemical fields. He served as a law clerk for Hon. 
Jack R. Miller, Circuit Judge, U.S. Court of Appeals for 
the Federal Circuit in Washington, D.C., and served as 
a patent examiner for the U.S. Patent and Trademark 
Office. He is a chemical engineer and was previously 
employed by the Gulf Oil Corporation and the Bendix 
Corporation. Mr. Goldman has authored articles and 
given presentations on various licensing projects around 
the world. He is admitted to practice in the District of 
Columbia Court of Appeals, the New York Court of 
Appeals, and the U.S. Court of Appeals for the Federal 
Circuit. Mr. Goldman is a registered attorney in the 
U.S. Patent and Trademark Office and a member of the 
American Intellectual Property Law Association, the 
American Bar Association, the District of Columbia Bar 
Association, the New York State Bar Association, and 
the Federal Circuit Bar Association.
gRACEN, Vernon
Vernon Gracen is currently a Visiting Professor in the 
department of Plant Breeding and Genetics at Cornell 
University. He teaches an introductory course in Plant 
Breeding and manages curriculum development for 
the Cornell Transnational Learning Program. Raised in 
Savannah, Georgia, he now lives in Ithaca, New York. 
He earned a B.S. in Education from Georgia Southern 
College and a Ph.D. in Agronomy from the University 
of Florida. He joined Cornell University as an Assistant 
Professor in Plant Breeding and Biometry in 1970 and 
moved through the ranks of Associate and Full Professor. 
His research interests were in the areas of breeding for 
disease and insect resistance in maize and cassava. He 
joined Cargill Hybrid Seed in 1987 as Vice President, 
Director of Research and Development for the North 
American Seed Division. He became Director of 
Research for Cargill’s Worldwide Seed Business in 1992. 
He returned to Cornell as a Visiting Professor in 2001. 
gRAFF, gregory D.
Gregory D. Graff is an applied economist with expertise 
in the economics of innovation, entrepreneurship, intel-
lectual property, and technology transfer, especially as 
they apply to the agricultural life sciences and biotech-
nology. He applies microeconomic and econometric 
tools to scientific, patent, regulatory, and commercial 
data, building uniquely thorough industry-level datas-
ets to analyze the impacts of innovation and technology 
transactions on markets, industrial organization, and 
the political economy of science policy. 
Dr. Graff currently manages research projects for 
the Public Sector Intellectual Property Resource for 
Agriculture (PIPRA), a consortium of 37 agricultural 
research universities and institutes that is hosted by 
the University of California. PIPRA uses an innova-
tive model of collaborative intellectual property man-
agement to mobilize its members’ technologies for the 
purpose of genetically improving “orphan” crops. Dr. 
Graff has taught as a university lecturer at both U.C. 
Berkeley and U.C. Davis and has recently published 
articles in The Review of Economics and Statistics, World 
Development, California Management Review, and Nature 
Biotechnology as well as chapters in several books. Dr. 
Graff has a Ph.D. in agricultural and resource econom-
ics from U.C. Berkeley (2002), an M.A. in economics 
from Ohio State University (1995), and a B.S. in biol-
ogy from Cornell University (1992).
guO, hua
Hua Guo focuses her practice on patent prosecution, 
opinions, and agreements dealing with biotechnology, 
pharmaceuticals, chemicals, and medical devices. 
Prior to joining Jones Day, Dr. Guo worked as an 
intern in the Corporation Sponsored Research and 
Licensing Office of Massachusetts General Hospital, 
where she was actively involved in technology licens-
ing, marketing, prior art searches, and patent prosecu-
tion before the USPTO. Previously, she was an associate 
at King & Wood, PRC Lawyers, where she prepared, 
filed, and prosecuted domestic and foreign patent appli-
cations pertaining to biotechnology, pharmaceuticals, 
chemicals, and medical devices. She also consulted with 
clients on invention patentability and patent validity.
Dr. Guo got her Master’s degree in Intellectual 
Property at Franklin Pierce Law Center. Before attending 
law school, she earned an M.D. and a Ph.D. in molecular 
pathology. She is a member of Association of Attorneys 
specializing in the practice of Intellectual Property 
Law (AIPLA), the All China Patent Agent Association 
(ACPAA), and the Chinese Bar Association. 
guRRy, Francis
Francis Gurry, a national of Australia, is Deputy 
Director General of the World Intellectual Property 
Organization (WIPO) in Geneva. He is responsible for 
WIPO’s activities in the area of patents, which include 
patent policy questions and the administration of the 
Patent Cooperation Treaty (PCT), under which some 
145,000 international patent applications were filed in 
2006, biotechnology and genetic resource policy ques-
tions, traditional knowledge, and the WIPO Arbitration 
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and Mediation Center, which has administered over 
26,000 disputes over Internet domain names since 
2000. 
Dr. Gurry holds law degrees from the University 
of Melbourne and a Doctor of Philosophy from the 
University of Cambridge in the United Kingdom. He 
is a Professorial Fellow of the Faculty of Law of the 
University of Melbourne.
He is the author of a textbook on the law of trade 
secrets and confidential information, entitled Breach of 
Confidence, published by Oxford University Press in the 
United Kingdom in 1984, and co-author, with Frederick 
Abbott and Thomas Cottier, of The International 
Intellectual Property System: Commentary and Materials, 
published by Kluwer in July 1999.
gyLLENhAAL, C. 
Dr. Gyllenhaal is an ethnobotanist by training. She 
is a Research Assistant Professor at the University of 
Illinois at Chicago and Research Program Manager 
at the Block Center for Integrative Cancer Treatment 
located in Evanston, Illinois. She has been active in a 
variety of research projects that includes herbal supple-
ments and, especially, cancer therapy, traditional medi-
cines, biological activities of natural products, and IP 
issues related to indigenous traditional medicinal plant 
knowledge. Her involvement with a project led by D. 
D. Soejarto (funded through the NIH/FIC ICBG) has 
given Gyllenhaal substantial experience in administer-
ing and subcontracting for international collaborative 
projects. She has been an Associate Editor of Economic 
Botany and Taxonomy and Editor of Journal of Natural 
Products. Since 2001, she has served as Associate Editor 
of Integrative Cancer Therapies.
hAEuSSLER, h. Walter 
H. Walter Haeussler is a member of the Board of 
Directors at HemoBioTech. He has served as the 
Director of Technology Transfer at Texas Tech University, 
as General Counsel to Advisys Inc., an animal biotech-
nology company, and as the former President of the 
Cornell Research Foundation at Cornell University. 
Before that, he was with Jones, Tullar & Cooper P.C., 
Arlington, Virginia, rising to the position of manag-
ing partner. From 1963 to 1972, he was an intellec-
tual property attorney with PPG Industries, Pittsburgh. 
Haeussler earned a B.S. in chemistry from Bowling 
Green University, Bowling Green, Ohio, and a J.D. 
from Duquesne University School of Law, Pittsburgh.
hAMZAOuI, Amina 
Dr. Amina Hamzaoui is the Associate Director of 
Intellectual Property at the Whitehead Institute of 
Biomedical Research in Cambridge, Massachusetts, 
U.S.A. She manages and oversees activities related to the 
intellectual property that is produced from research and 
other work conducted at the Institute. Prior to joining 
the Whitehead Institute in April 2005, Dr. Hamzaoui 
was an Assistant Professor at St. Thomas University, in 
Miami, Florida. During her tenure at St. Thomas, she 
served as the Chairperson of the Institutional Review 
Board/Research Ethics Committee for research with hu-
man participants. She did her postdoctoral fellowship in 
1998 at the University of Miami School of Medicine. 
She has over seven years of comprehensive research 
experience in analysis, theory development, and practi-
cal application in the area of cardiovascular disease and 
in the development and improvement of the biosynthet-
ic materials used in arterial and vascular reconstructive 
surgery. Dr. Hamzaoui received her Ph.D. in Chemistry 
of Materials & Polymer Science in 1997 from Université 
des Sciences Montpellier II – Montpellier, France, her 
Master of Science in Biomedical Engineering in 1993 
from Université Paris XIII/Galileo Institute, Paris, 
France and a Bachelor of Science in Biochemistry from 
Université des Sciences Montpellier II – Montpellier, 
France.
hANDLER, Philana S. 
Philana S. Handler is an associate at the firm of 
Whitham, Curtis, Christofferson & Cook. Ms. Handler 
has worked in the field of intellectual property for near-
ly a decade since joining the firm of Whitham, Curtis, 
Whitham & McGinn in 1997. She received the degree 
of Bachelor of Science in Psychology from the George 
Mason University in 2000. While an undergraduate, 
Ms. Handler was a member of the Honor Committee, 
as well as president of the Judicial Board of the George 
Mason University. Ms. Handler received her law degree, 
with honors, from the David A. Clarke School of Law 
in 2004. During law school, Ms. Handler assisted in the 
development of small businesses and nonprofit organi-
zations; her duties included filing government forms, 
preparing contracts, and trademark work. In addition, 
during law school, Ms. Handler advocated on behalf of 
children in need of special education services.
Currently, Ms. Handler primarily handles trade-
mark, copyright, and unfair competition matters, as 
well as litigation matters. She also heads up the firm’s 
patent annuity program. Ms. Handler is involved in a 
supporting role in patent matters concerning mechani-
cal and biological technologies and also works on vari-
ous contract and licensing matters. 
hANNA, Kathi E.
Kathi E. Hanna has over 25 years of experience in sci-
ence and health policy as an analyst, writer, and edi-
tor specializing in biomedical research policy and bio-
ethics. She served as Research Director and Editorial 
Consultant to President Clinton’s National Bioethics 
Advisory Commission (NBAC) and directed the 
completion of NBAC’s reports. In the mid-1990s, Dr. 
Hanna was Senior Advisor on Reproductive Health 
to the Advisory Committee on Gulf War Veterans 
Illnesses. More recently, she served as the lead author 
and editor of President Bush’s Task Force to Improve 
Health Care Delivery for Our Nation’s Veterans. In the 
1980s and 1990s, Dr. Hanna was a Senior Analyst at the 
congressional Office of Technology Assessment, where 
she contributed to numerous science policy studies re-
quested by congressional committees on science educa-
tion, research funding, biotechnology, women’s health, 
human genetics, bioethics, and reproductive tech-
nologies. In the past two decades, she has served as an 
analyst and editorial consultant to the Howard Hughes 
Medical Institute, the National Institutes of Health, the 
U.S. National Academies, the U.S. Office for Human 
Research Protections, and various charitable founda-
tions, voluntary health organizations, and biotechnolo-
gy companies. Before moving to the Washington, D.C., 
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area, she was the Genetics Coordinator at Children’s 
Memorial Hospital in Chicago, where she directed 
clinical counseling and coordinated an international 
research program in prenatal diagnosis. Dr. Hanna re-
ceived an A.B. in Biology from Lafayette College, an 
M.S. in Human Genetics from Sarah Lawrence College, 
and a doctorate from George Washington University. 
She is currently Senior Vice President at Styllus, LLC, 
a medical and scientific writing company based in the 
Boston and Washington, D.C., areas.
hANSEN, Stephen A.
Stephen A. Hansen is Project Director with the Science 
& Human Rights Program. His work currently focuses 
on projects that relate to the effects of intellectual prop-
erty rights on science, particularly those that relate to 
traditional knowledge and human rights. He serves as 
the Project Manager for an AAAS project: Science & 
Intellectual Property in the Public Interest (SIPPI). He 
is co-author of the handbook Traditional Knowledge and 
Intellectual Property. He also designed the Traditional 
Ecological Knowledge Prior Art Database (T.E.K.*P.
A.D), an online digital archive of traditional practices 
from local communities throughout the world that 
are already in the public domain. Mr. Hansen’s other 
main area of work is in economic, social, and cultural 
rights (ESCR); he has worked with the United Nations 
Committee on Economic, Social and Cultural Rights 
and UNESCO in this capacity. He is the author of a 
chapter on cultural rights in the AAAS publication Core 
Obligations: Building a Framework for Economic, Social 
and Cultural Rights. He has also been involved in viola-
tions monitoring and documentation and has authored 
The Thesaurus of Economic, Social and Cultural Rights. 
He has directed projects with the National Commission 
for Human Rights in Honduras, as well as the Centro 
de Estudios Legales y Sociales (Center for Legal and 
Social Research, CELS) in Buenos Aires, Argentina. Mr. 
Hansen holds a Bachelor’s degree in Anthropology from 
Oberlin College and an M.A. in Anthropology from The 
George Washington University in Washington, D.C.
hARNER-JAy, Claudia
Claudia Harner-Jay is a program officer with PATH’s 
Technology Solutions Strategic Program. Her major re-
sponsibilities include creating and implementing com-
mercialization strategies for health technologies; man-
aging intellectual property issues; identifying potential 
partners and performing due diligence; and negotiat-
ing collaboration agreements. She also serves as team 
leader or project manager for select health technology 
initiatives. While at PATH, Ms. Harner-Jay has man-
aged numerous market research studies to help refine 
product development activities, identify potential part-
ners, and inform introduction strategies. Before joining 
PATH, Ms. Harner-Jay was a business development 
manager at Monsanto Life Sciences Company and 
helped develop the market for agricultural products 
produced by small farmers in low-resource settings in 
Latin America. In addition, she has worked with cof-
fee farmers in Central America, where her findings and 
recommendations led to a US$50 million World Bank 
loan for the coffee industry in El Salvador. Ms. Harner-
Jay also worked for UBS in Zurich, where she earned a 
Swiss Banking Diploma. She holds an M.B.A. and an 
M.S. in environmental policy from the University of 
Michigan and a B.A. in international affairs from the 
University of Puget Sound. She is fluent in both Spanish 
and German.
hARNEy, Dennis J.
Dennis J. Harney is an attorney at Sonnenschein Nath & 
Rosenthal LLP, where he is a member of the Intellectual 
Property and Technology Practice Group. His practice 
encompasses all areas of intellectual property law, in-
cluding preparation and prosecution of patent appli-
cations in the United States and foreign countries. Dr. 
Harney’s work focuses primarily on biotechnology and 
biochemical patent preparation and prosecution, in-
cluding patents for transgenic plants and bacteria; novel 
DNA and protein sequences; and biological, chemical, 
and pharmaceutical therapeutics. Dr. Harney’s practice 
also encompasses validity/invalidity and infringement 
opinions and counseling related to patentability and 
freedom to operate. 
In 2003, Dr. Harney earned a J.D. from University 
of Dayton School of Law, where he graduated first in 
his class; in 2003, he earned a Ph.D. in Botany from 
Miami University, where he specialized in plant stress 
physiology; and in 1996, he earned an M.S. in Botany 
from Miami University, where he studied plant second-
ary product chemistry. 
Dr. Harney is a member of the American Intellectual 
Property Law Association (AIPLA); the Intellectual 
Property Owner’s Association (IPO); the Missouri 
Bar Association; and the American Society of Plant 
Biologists. Dr. Harney has served on the AIPLA 
Biotechnology Committee and currently serves on the 
IPO Committee for Genetic Resources and Traditional 
Knowledge. Dr. Harney is also an adjunct professor at 
Saint Louis University School of Law, where he teaches 
a course titled “Biotechnology and the Law.”
hEhER, Anthony D.
Anthony D. Heher has a longstanding interest in re-
search and innovation and the contribution that they 
can make to economic and social development. His 
experience includes 12 years at South Africa’s Council 
for Scientific and Industrial Research (CSIR); 16 years 
as founder and CEO of a high-tech spinout company 
based on his doctoral research; and ten years working 
in economic development, including two years at the 
South African Department of Trade & Industry, where 
he was Chief Director for Industrial Promotion in 
1997 and head of the national economic cluster pro-
gram. From 2000 to 2005, he was Director of UCT 
Innovation at the University of Cape Town. In 2006, he 
rejoined AfED, an economic and business consultancy 
that he founded in 1998. He is actively involved in a 
projects ranging from entrepreneurship development to 
economic development through public-private partner-
ships. He was instrumental in the establishment of the 
Southern African Research & Innovation Management 
Association (SARIMA) in 2001 and was its founding 
President. SARIMA is focused on capacity building and 
linking the various players in the research and innova-
tion spectrum so that they can cooperate more effective-
ly. He has a Ph.D. in engineering. He has had a varied 
academic career: he is a graduate of the Universities of 
Natal, Pretoria, and California in Physics, Mathematics, 
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Electrical Engineering, Mechanical Engineering and 
Computer Science; he also holds an executive M.B.A. 
from Wits Business School. He has remained an active 
researcher his whole working life, although his research 
output has taken rather varied forms!
hENNESSEy, William O.
William Hennessey is Professor of Law at the Franklin 
Pierce Law Center. He directed Pierce Law’s graduate 
programs in intellectual property and summer from 1986 
until 2003. A noted IP expert, author, and lecturer, he re-
cently directed the fourth annual Pierce Law Intellectual 
Property Summer Institute at Tsinghua University 
School of Law in Beijing, China. He co-authored a legal 
casebook on international IP law and policy. 
Professor Hennessey has served as a legal advi-
sor to the governments of Indonesia and the People’s 
Republic of China and has served as a consultant to 
the World Bank, Asian Development Bank, United 
Nations Development Programme, U.S. Agency for 
International Development, U.S. Department of State, 
and the U.S. Patent and Trademark Office. He has also 
served as consultant for the World Intellectual Property 
Organization in many countries on various issues con-
cerning IP protection and economic development.
hERSEy, Karen
Karen Hersey is Visiting Professor of Law at the Franklin 
Pierce Law Center in Concord, New Hampshire. 
Professor Hersey recently retired as Senior Counsel 
for intellectual property at Massachusetts Institute 
of Technology where she represented M.I.T.’s inter-
ests on intellectual property matters with a variety of 
constituencies including industrial research partners 
and both U.S. and foreign governments. In 1992, she 
served as the academic community’s representative to 
a Congressionally mandated Department of Defense 
Government-Industry Advisory Committee on Rights 
in Technical Data and Computer Software to study 
and recommend changes in the Department of Defense 
Procurement Regulations in the areas of technical data 
and computer software. She publishes widely in the area 
of intellectual property law as it impacts institutions of 
higher education. Professor Hersey is a past President 
of the Association of University Technology Managers 
(AUTM). In addition to offering courses dealing with 
technology transfer for nonprofit organizations and in-
tellectual property management in universities, she also 
teaches U.S. Copyright Law. She received her B.A. from 
Goucher College and her LL.B. from Boston University 
School of Law.
hIEP, N. T.
A doctoral graduate from Komarov Botanical Institue of 
the Russian Academy of Sciences, St. Petersburg, Russia, 
Dr. Nguyen Tien Hiep’s expertise is in plant taxonomy, 
evolutionary biology, and ecology, specializing on the 
studies of the flora of Vietnam. As a senior scientist at 
the Institute of Ecology and Biological Resources of 
the Vietnamese Academy of Science and Technology, 
Hanoi, he is best known for his research output in 
the study of the cycads and other gymnosperms of 
Vietnam. He has served as coordinator of many interna-
tional collaborative projects, especially projects between 
the Institute of Ecology and Biological Resources and 
Museum National D’Histoire Naturelle, Paris, France, 
and the Missouri Botanical Garden, St. Louis, USA. 
Since 1998, he has served as a Project Co-Leader of an 
ICBG Program, with responsibility in biotic survey of 
the Cuc Phuong National Park.
hINES, Sally
Sally Hines is the Administrative Services Manager of 
the Office of Technology Licensing (OTL) at Stanford 
University. She has been with the Stanford OTL since 
its beginning in 1970 and was instrumental in setting 
up many office procedures that are still in use. The 
Stanford OTL has increased its staff from two people 
in 1970 to approximately 30 people today. Ms. Hines 
handles office management, facilities management, 
equity management, human resources, and the $4M 
operating budget for the office. She has also been in-
volved with the Association of University Technology 
Managers (AUTM) since its inception and has served 
on its Board. She currently serves as Chairperson of the 
AUTM TOOLS course for administrative staff. 
hOPE, Janet
Janet Hope is a qualified biochemist and molecular bi-
ologist, as well as a former practicing lawyer. She has 
published in the fields of constitutional, criminal, ad-
ministrative, environmental, human rights, and intel-
lectual property law.
In January 2003, she published the first substantial 
treatise on open-source biotechnology (available at rsss.
anu.edu.au/~janeth). Under the supervision of Professor 
Peter Drahos, she completed her doctoral dissertation on 
Open Source Biotechnology at the Australian National 
University in 2004.
Together with colleagues Dianne Nicol and John 
Braithwaite, Dr. Hope is the recipient of an Australian 
Research Council grant to investigate a range of collabor-
ative intellectual property mechanisms in the Australian 
biotechnology industry. Her book Bio Bazaar: The Open 
Source Revolution and Biotechnology will be published by 
Harvard University Press in late 2007.
hSu, Justin
Justin Hsu is currently a third year undergraduate 
Industrial Engineering and Operations Research stu-
dent at the University of California, Berkeley. Prior to 
his summer tenure at Fernandez & Associates L.L.P., 
he was a mechanical engineering intern at Lawrence 
Berkeley National Laboratory, where he worked on 
magnetic measurement systems at the Advanced Light 
Source, a synchrotron radiation facility. His professional 
and academic interests include intellectual property law, 
venture capital, stochastic processes, and optimization 
with applications in finance and operations research. In 
his spare time, he enjoys football and playing the gui-
tar, among other things. Upon graduation, Justin hopes 
to attend graduate school and work several years in the 
Silicon Valley high-tech industry before taking the U.S. 
patent bar examination.
huIE, James T.
James T. Huie earned his bachelor of arts degree in 
Molecular and Cell Biology, with an emphasis in 
Biochemistry, at the University of California, Berkeley. 
Subsequently, Mr. Huie obtained his law degree at Santa 
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Clara University School of Law. During and after law 
school, Mr. Huie developed skills in patent prosecu-
tion at Fernandez & Associates, LLP. After some time 
in the patent field, Mr. Huie changed his focus to cor-
porate practice within the venture capital industry. He 
has practiced in the Silicon Valley at such law firms as 
Greenberg Traurig, LLP and Wilson, Sonsini, Goodrich 
& Rosati, PC. Currently an associate at Wilson, Sonsini, 
Goodrich & Rosati, PC. he represents early-stage and 
public medical device companies, as well as institu-
tional and venture capital investors, in transactions that 
involve equity and debt financings, mergers and acquisi-
tions, public offerings, and public filings.
huNg, N. V.
Dr. Nguyen Van Hung is Deputy Director of the Insti-
tute of Chemistry and Director of Bioorganic Division, 
Vietnamese Academy of Science and Technology, Hanoi, 
Vietnam. He is a phytochemist with special expertise in 
the isolation, structure elucidation, and synthesis of me-
dicinally important compounds, such as the antimalarial 
drug artemisinin. Early in 2006, he and his chemistry 
team at the Institute of Chemistry successfully isolated 
shikimic acid from the starting raw material Chinese star 
anise fruit, Illicium verum Hook. f. (Illiciaceae), and using 
this molecule as a precursor, they successfully synthesized 
the drug oseltamivir (Tamiflu). Since 1998, he has served 
as a Co-Project Leader in chemistry of an International 
Cooperative Biodiversity Groups (ICBG) program with 
responsibility in the isolation and structure elucidation 
of biologically active compounds.
IDRIS, Kamil
Dr. Kamil Idris has been Director General of the World 
Intellectual Property Organization (WIPO) since 
November 1997. He is head of the International Union 
for the Protection of New Varieties of Plants (UPOV). 
He was formally re-appointed to a second six-year term as 
Director General of WIPO on May 27, 2003. His man-
date will end on November 30, 2009. Formerly, Kamil 
Idris was a member of the International Law Commission 
from 1992 to 1996 and from 2000 to 2001. 
Kamil Idris holds a Bachelor of Law (LL.B.) from 
Khartoum University, Sudan; a Bachelor of Arts in 
Philosophy, Political Science and Economic Theories 
from Cairo University, Egypt; a master’s in International 
Law and International Affairs from Ohio University, 
United States; and a Doctorate in International Law 
from the Graduate Institute of International Studies, 
University of Geneva, Switzerland. 
JACOBy, Erica
Erica Jacoby, a senior commercialization associate in 
PATH’s Technology Solutions Strategic Program, serves 
as a resource in the general areas of business planning, 
market development, and commercialization activities. 
Her primary responsibilities include identifying, con-
ducting due diligence, and selecting partners; conduct-
ing market assessments; developing commercialization 
strategies; and writing and negotiating legal agreements. 
In these capacities, she is involved with several different 
technology development projects at PATH, including 
needle-free injections, vitamin-fortified rice, neonatal 
resuscitators, and HIV/STI prevention technologies 
such as the female condom. Prior to joining PATH, 
Ms. Jacoby worked in marketing and research at sev-
eral organizations, including a diagnostic test manufac-
turer, the Institute of the Americas, and the Graduate 
School of International Relations/Pacific Studies at 
the University of California, San Diego (UCSD). Her 
overseas experience includes work and study in Mexico, 
Slovakia, Spain, and Venezuela. She holds a Master’s de-
gree in Pacific international affairs, with a concentration 
in international management, from the University of 
California, San Diego.
JAhN, Molly
Molly Jahn holds degrees from Swarthmore College, 
M.I.T., and Cornell University, and pursued postdoc-
toral work at U.C. Berkeley. At Cornell, Molly focused 
her research on plant breeding, genetics, genomics and 
molecular biology and on the development of improved 
crop germplasm. Her group at Cornell has produced a 
number of globally successful crop varieties currently 
grown commercially on six continents. Molly has worked 
extensively internationally in Latin America, Asia and 
Africa to link crop breeding objectives to outcomes 
that improve human welfare, such as nutritional status 
and income. Molly was recently named a Fellow of the 
AAAS and was elected to the Board of Directors of The 
World Vegetable Center, the international research cen-
ter for vegetables. On August 1, 2006, she was named 
the twelfth dean of the College of Agricultural and Life 
Sciences at the University of Wisconsin - Madison.
JONES, Keith J.
Keith J. Jones is the Director of the Office of 
Intellectual Property Administration and the Executive 
Director of the Washington State University Research 
Foundation. 
Dr. Jones, assisted by a staff of seven, is responsible 
for the evaluation, patenting, marketing, and licens-
ing of the approximately 70 invention disclosures per 
year submitted to the Office of Intellectual Property 
at WSU. WSU is a large research university that pro-
duces intellectual property ranging from medical ap-
plications to new wheat varieties. WSU intellectual 
property results in about 15 licenses per year, and last 
year produced an income of over US$2 million. Dr. 
Jones is also responsible for initiating and managing 
other university technology commercialization ac-
tivities, including the WSU Research and Technology 
Park, the Cougar Gap Fund, and the Venture Partner 
Program. Dr. Jones is frequently invited to speak na-
tionally and internationally on university technology 
commercialization.
Previously, Dr. Jones was Director of 
Commercialization-Life Sciences at Virginia Tech for 
six years. He has experience in international business 
development at a San Diego Ag-Biotechnology com-
pany, Mycogen Corp., where he developed new markets 
for biotech products in the Middle and Far East. He 
worked for two years as a scientific advisor at one of 
the most prestigious intellectual property litigation law 
firms in the U.S. He was a USAID contractor for two 
years, during which time he was involved with univer-
sity development based in Sumatra, Indonesia. 
He has a Ph.D. from North Carolina State University 
in Plant Pathology and holds three issued patents and 
one pending patent. 
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JORDA, Karl F.
Karl F. Jorda is the David Rines Professor of Intellectual 
Property Law as well as the Director of the Germeshausen 
Center for the Law of Innovation and Entrepreneurship 
at Franklin Pierce Law Center, where he primar-
ily teaches Technology Licensing and IP Management. 
From 1995 to 2003, he also taught International IP 
Law as Adjunct Professor at the Fletcher School of Law 
and Diplomacy, Tufts University. Before joining Pierce 
Law in 1989, he was Chief IP Counsel for 26 years at 
CIBA-GEIGY Corporation (now Novartis, Syngenta, 
and Ciba Speciality Chemicals). 
Dr. Jorda was President of the Pacific Intellectual 
Property Association (PIPA) and the New York 
Intellectual Property Law Association. He served on 
the Boards of Directors of AIPLA, ABA-IPL Section, 
INTA, IPO, ACPC and AIPPI-American Group. Dr. 
Jorda is also the recipient of several rewards: the 1996 
Jefferson Medal of the NJIPLA, “the United States’ 
highest honor in intellectual property,” for “extraor-
dinary contributions to the U.S. intellectual property 
law system”; the 1989 PIPA medal for “Outstanding 
Contributions to International Cooperation in the 
Intellectual Property Field”; and the 1998 Distinguished 
Alumni Award of the University of Great Falls. In 1990 
and 1991, he served as a consultant to the Indonesian 
and Bulgarian IP offices. From 1999 to 2005, he was the 
U.S. Representative to the Confidentiality Commission 
of the Organization for the Prohibition of Chemical 
Weapons in The Hague, Netherlands.
Dr. Jorda received his undergraduate degree (sum-
ma cum laude) from the University of Great Falls, and 
an M.A. and a J.D. from Notre Dame University. He 
is admitted to the bars of Illinois, Indiana, and New 
York as well as to practice before the U.S. Supreme 
Court, the Court of Appeals for Federal Circuit, and 
the U.S. and Canadian Patent and Trademark Offices. 
He is a frequent speaker in IP programs in foreign 
countries under the auspices of WIPO, USAID, 
USIA, IESC, etc. He has lectured in 41 countries, 27 
of them developing countries, including Madagascar 
and Mongolia. 
KAMPF, Roger 
Roger Kampf is from Hamburg, Germany. He joined 
the World Trade Organization in May 2004 and works 
as Counsellor in the Intellectual Property Division. 
He is responsible for the Secretariat’s work in the area 
of TRIPS and public health and enforcement, as well 
as for providing technical assistance in relation to in-
tellectual property. Mr. Kampf previously worked for 
the European Commission, both at its headquarters 
in Brussels and at its permanent representation in 
Geneva; from 1998 to 2004, he was responsible for 
intellectual property issues in WTO and WIPO, as 
well as for government procurement. Previously, he 
was involved in negotiating financial services under the 
GATS Agreement (the General Agreement on Trade 
in Services), and also worked as an assistant in public 
law and European Communities law at the University 
of Hamburg. Mr. Kampf holds a law degree from the 
University of Hamburg and a degree in public admin-
istration from the Ecole Nationale d’Administration in 
Paris. He has published on various aspects of EC and 
WTO law.
KARJALA, Dennis S.
Dennis S. Karjala was an engineering/physics major 
at Princeton University and holds a Ph.D. in electri-
cal engineering from the University of Illinois (1965). 
He received his J.D. from the University of California, 
Berkeley, in 1972, where he was editor-in-chief of the 
California Law Review and Order of the Coif. After five 
years of private practice in San Francisco, Dr. Karjala 
joined the College of Law at Arizona State University 
in January 1978 as Associate Professor. He has been a 
Professor of Law since the fall of 1981 and currently 
holds the Jack E. Brown Chair. His teaching and re-
search are primarily in the area of intellectual property 
law, especially copyright and the application of intel-
lectual property law to digital technologies. He has also 
taught and written on the subjects of corporate and 
securities law and federal income taxation. Dr. Karjala 
has also done some comparative work on Japanese copy-
right and corporate law. Dr. Karjala was active in the 
opposition to the 1998 Sonny Bono Copyright Term 
Extension Act and in the Eldred case, which unsuccess-
fully challenged the constitutionality of the Copyright 
Term Extension Act. 
KEEVEy-KhOTARI, Simon
Simon Keevey-Khotari is an English-qualified barrister 
who specializes in intellectual property and commer-
cial transactions. He spent more than five years with 
Anderson & Company, most of which was spent on 
a long-term secondment with Imperial Innovations 
Limited, the technology transfer company of Imperial 
College, London. He has also co-authored a book 
with Mark Anderson titled Drafting Confidentiality 
Agreements, 2nd ed. (The Law Society of England and 
Wales 2004).
KEILLER, Todd S.
Todd S. Keiller has more than 30 years of licensing, busi-
ness development, and marketing experience. He has 
worked for 16 years in the industrial sector in a vari-
ety of sales, marketing, and business development roles, 
ten of which were in the Science and Medical Products 
Divisions of Corning Glass Works. He has over 16 
years of academic licensing experience and is the former 
Vice President, Ventures of the Brigham and Women’s 
Hospital in Boston. In 1998, Todd joined the University 
of Vermont and assisted the College of Medicine in tech-
nology affairs. In 1999, he was appointed Director of 
Technology Transfer for the entire University. He also 
handles technology transfer for Maine Medical Center, 
Caritas St. Elizabeth’s Medical Center of Boston, and 
Boston Biomedical Research Institute. Mr. Keiller has 
contributed to the foundation of seven companies, the 
most recent of which are Nephromics (a company focused 
on the diagnosis of preeclampsia), Vascular Genetics, Inc. 
(a gene therapy company, now traded publicly under the 
name of CorAutus), and Tolerance Pharmaceuticals (a 
diagnostic and therapeutic company devoted to trans-
plantation, which was purchased by Roche). Mr. Keiller 
holds an A.B. from Dartmouth College and an M.B.A. 
from the Tuck School of Business Administration. 
KESAN, Jay P.
Jay P. Kesan is Professor and Director of the Program 
in Intellectual Property and Technology Law at the 
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University of Illinois at Urbana-Champaign. His aca-
demic interests and writings are in the area of patent 
law, cyberlaw, and law and technology. Some of his 
recent scholarly work is focused on computer software 
and agricultural biotechnology. He is a registered patent 
attorney and received his J.D. summa cum laude from 
Georgetown University. He also has a Ph.D. in Electrical 
and Computer Engineering from the University of Texas 
at Austin and worked for several years as a research sci-
entist at the IBM T.J. Watson Research Center in New 
York. For a more complete biography, please see www.
jaykesan.com.
KEuSCh, gerald T.
Professor Jerry Keusch is Associate Provost and Associate 
Dean for Global Health at Boston University and 
Director of the university’s Global Health Initiative. 
He is a physician-scientist, whose career has focused on 
the study of infectious diseases of developing countries 
at the laboratory and field levels. He has received all 
three of the major recognition awards of the Infectious 
Diseases Society of America for this work, includ-
ing the Squibb, Finland and Bristol Awards. Professor 
Keusch is a member of Institute of Medicine at the U.S. 
National Academies, where he serves on its Board on 
Global Health. He is also a member of the Roundtable 
on Science and Technology for Sustainability at the 
National Research Council and its Task Force on Linking 
Knowledge with Action for Sustainable Development, 
both at the U.S. National Academies.
Prior to joining Boston University Professor 
Keusch was the Associate Director for International 
Research and Director of the Fogarty International 
Center at the U.S. National Institutes of Health. 
During his tenure funding for global health research 
and capacity building dramatically increased. Among 
the innovations he initiated were explorations into 
the creative use of intellectual property rights deemed 
to NIH grantees to insure that developing coun-
tries could benefit from discovery funded by public 
resources. His work in this area, together with the 
Rockefeller Foundation, led to the formation of the 
Center for the Management of Intellectual Property 
in Health Research (MIHR). He served on the 
Founding Board of MIHR and has subsequently been 
Vice-Chair of the MIHR Board. 
KhuSh, gurdev Singh
Dr. Khush was born in a small village in Punjab. After 
receiving his education at the Punjab Agricultural 
University and the University of California, Davis, Dr. 
Khush, in 1967, joined the International Rice Research 
Institute in the Philippines where he served as the Head 
of Plant Breeding, Genetics, and Biochemistry Division 
until 2002. As a result of wide-scale adoption of his 
high-yielding varieties, rice production increased 135% 
between 1967 and 2000, to feed an estimated one bil-
lion additional consumers. His contributions to rice 
genetics and biotechnology are equally well recognized. 
He has written three books, more than 80 book chapters 
and 160 research papers. 
Dr. Khush has served as consultant to rice breed-
ing programs of 15 countries as well as The Rockefeller 
Foundation, the Third World Academy of Sciences, 
Italy, and the International Science Foundation, 
Sweden. He is now serving as a member of Scientific 
Advisory Committee (overseas) to the Department of 
Biotechnology, Government of India and member of 
Science Council, an advisory body to Chinese Academy 
of Agricultural Sciences, Beijing.
For his monumental contributions to the World 
Food Security, Dr. Khush has been honored with 
numerous awards and honors such as the Japan 
Prize (1987), World Food Prize (1996), Rank Prize 
(1998), Wolf Prize (2000), International Scientific 
and Technological Cooperation Award from the 
Government of China (2001), and Padma Shriaward 
from the president of India. He is one of five Indian sci-
entists who have been elected to membership of Royal 
Society (FRS) as well as the U.S. National Academy 
of Sciences. Dr Khush has received Doctor of Science, 
honoris causa, degrees from nine universities including 
from University of Cambridge in England and Ohio 
State University.
Commenting on his life work, Dr. Cantrell, Director 
of the International Rice Research Institute said, “While 
Dr. Khush’s name may have passed the lips of many, 
his life’s work has passed the lips of almost half of 
humanity.”
KOWALSKI, Stanley P.
Stanley P. Kowalski was born and grew up in a working-
class neighborhood in Pittsburgh, Pennsylvania, where 
he attended Catholic primary and public high school. 
He matriculated at the Pennsylvania State University, 
and later at the University of Pittsburgh, earning B.S. 
degrees in horticulture and biology, with emphases in 
genetics and biochemistry. Later, he earned a Ph.D. in 
plant breeding from Cornell University. Dr. Kowalski’s 
experience as a research scientist has included studies 
of plant nutrition at the Pennsylvania State University, 
wheat breeding at the University of Nebraska, purifica-
tion and characterization of DNA polymerases at the 
University of Rochester, biochemical characterization of 
insect resistance in potatoes at Cornell University, lipid-
mediated signal transduction at the National University 
of Singapore, plant genome mapping at Texas A&M 
University, glycolipid biosynthesis at Cornell University, 
and a study of the biochemical/genetic basis of plant/in-
sect interactions at the U.S.D.A. Beltsville Agricultural 
Research Center. He has been long interested in inter-
national development, due both to his exposure to the 
dynamic international programs at Cornell and the in-
fluence of Professor Norman Borlaug, whose office was 
located directly across the hall from Dr. Kowalski’s labo-
ratory at Texas A&M University.
The second phase of Dr. Kowalski’s career has been 
defined by a transition from research to internation-
al work. He received a foreign language area studies 
scholarship and completed Cornell’s one-year inten-
sive Chinese-language program (Chinese FALCON). 
Subsequently, he worked for the International Service 
for the Acquisition of Agri-Biotech Applications 
(ISAAA) in the intellectual property/technology trans-
fer initiative, during which time he conducted the 
preliminary freedom-to-operate analysis of GoldenRice. 
After working at ISAAA, he earned a J.D. with an em-
phasis in intellectual property at the Franklin Pierce 
Law center. He has published numerous research and 
legal articles. 
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KRATTIgER, Anatole
Anatole Krattiger, a Swiss citizen, began his career as 
a farmer, lived in many parts of the world, and is cur-
rently a research professor at the Biodesign Institute at 
Arizona State University (ASU). As adjunct professor 
at the Sandra Day O’Connor College of Law at ASU, 
he co-teaches a course on innovation management and 
controversies in health and agri-biotechnology. He is 
an Adjunct Professor at Cornell University where he 
co-teaches a course on IP management in the life sci-
ences. He founded, and serves as Chairman of, bioDe-
velopments-International Institute, a nonprofit orga-
nization that brings people together to jointly develop 
solutions to problems that extend beyond geographic 
and cultural frontiers. He recently served as Executive 
to the Humanitarian Board for GoldenRice, a position 
that required him to work on licensing, technology 
transfer, and regulatory issues; he also served as Director 
of Research at MIHR in the U.K. during its formative 
years. In the early 1990s, he contributed to the inter-
national establishment of ISAAA, a global agri-biotech-
nology broker developing public-private partnerships 
in agriculture; he served as executive director of ISAAA 
until 2000. He also briefly worked on biodiversity-policy 
issues at the International Academy of the Environment 
in Geneva, Switzerland, and as a scientist in biotechnol-
ogy at CIMMYT in Mexico. 
Dr. Krattiger is a member of the Advisory Council 
on Intellectual Property of the Franklin Pierce Law 
Center in Concord, New Hampshire, and a member of 
the board of the Black Sea Biotechnology Association. 
He is editor-in-chief of Innovation Strategy Today and 
a member of the editorial boards of the International 
Journal of Biotechnology and the International Journal 
of Technology Transfer and Commercialization. He 
was a Distinguished Advisor to the Council for 
Biotechnology Information in Washington, D.C., un-
til the Council merged with BIO. He holds a diploma 
in farming, a bachelor’s degree in agronomy from the 
Swiss Agricultural College, a master’s degree in plant 
breeding, and a Ph.D. in biochemistry and genetics 
from the University of Cambridge, U.K.
LAShER, heidi
Heidi Lasher is a freelance writer and communications 
consultant. Her work spans a range of health topics 
from immunization and vaccines to HIV/AIDS, repro-
ductive health, and financial sustainability. Formerly 
a communications officer for the Children’s Vaccine 
Program at PATH, Ms. Lasher worked extensively in 
Andhra Pradesh, India on an immunization-strengthen-
ing and hepatitis B vaccine introduction project. Before 
working at PATH, Ms. Lasher was a project manager 
for a Seattle-based strategic communications consult-
ing firm. Ms. Lasher now provides freelance services 
to various international public health organizations in 
training, facilitation, writing and editing, media rela-
tions, and advocacy. Ms. Lasher and her family live in 
Bozeman, Montana.
LESSER, William h.
William Lesser has been in the Department of Applied 
Economics and Management at Cornell University 
since receiving his Ph.D. in agricultural economics, 
with a specialization in marketing, from the University 
of Wisconsin in 1978. Early on at Cornell he was an in-
novator in the application of PCs to food distribution, 
writing some of the earliest specialized software. Much 
of the time has, however, been focused on the farm and 
consumer level effects of biotechnology on agriculture. 
A particular specialization is the ramifications of pat-
ents and Plant Breeders Rights. In a related area, he has 
examined ownership of and access to genetic resources. 
Work has involved advising the governments of Brazil, 
Bangladesh, Switzerland and Indonesia, among others. 
He has written three books and numerous articles and 
chapters on the subject of agricultural biotechnology. 
His teaching has included export marketing, interna-
tional marketing, and futures and options. In 2003, he 
was appointed as Chair of the Department of Applied 
Economics and Management at Cornell.
LIu, Connie Kang
Connie Liu has a B.Eng. in biomedical engineering from 
the Huazhong University of Science and Technology in 
China and a Master’s degree in biotechnology from the 
University of Toronto. She was a bioprocess engineer at 
a large biotech company in China before joining the 
academic research community as a researcher at Hong 
Kong Polytechnic University. She has industrial expe-
rience in project management and technology transfer 
from academia to industry. She has also received train-
ing in Chinese and Canadian intellectual property law, 
including intellectual property policy and strategies. 
Her interests revolve around innovation and intellectual 
property in the biotech and pharmaceutical industries; 
she has special interest in the commercialization of aca-
demic research, licensing technologies, firms’ research 
strategies, and intellectual property management. She 
was a Research Associate to Dr. Maryann Feldman 
from 2004 to 2006. Currently, Ms Liu is an M.B.A. 
candidate at the Rotman School of Management at the 
University of Toronto.
LIVNE, Oren
Oren Livne is currently the Associate Director for 
Licensing at the University of California, Santa Barbara 
(UCSB). He is a founding member of UCSB’s first 
on-campus technology transfer office, the Office of 
Technology and Industry Alliances. He oversees the 
patenting and licensing of all inventions developed 
at UCSB. He has the pleasure of directly managing a 
significant number of inventions, including those pro-
duced by UCSB’s world-renowned Solid State Lighting 
& Display Center. Prior to joining UCSB, he was based 
at the University of California’s Office of The President. 
He serves as a mentor to UCSB’s chapter of Engineers 
Without Borders, whose mission is to improve quality 
of life through environmentally and economically sus-
tainable engineering projects. He is also an advisor to 
students in UCSB’s Technology Management Program, 
which aims to educate the next generation of technol-
ogy-based entrepreneurs. He is a registered patent agent 
with several pending and issued patents of his own.
LuND, Brett
Brett Lund has represented and counselled dozens of 
life science and technology companies in the areas of 
technology transfer, company formation, venture capi-
tal financings, licensing, mergers and acquisitions, and 
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initial public offerings. Mr. Lund served as a corporate 
attorney specializing in emerging growth companies at 
the San Diego office of the law firm Cooley Godward 
LLP, where he represented a wide range of companies 
including Maxim Pharmaceuticals, Qualcomm, Acadia 
Pharmaceuticals, Vertex Pharmaceuticals, AMCC, and 
the Titan Corporation. Mr. Lund left Cooley Godward 
to become the Associate General Counsel for Ford 
Motor Company’s telematics division. At Ford, he 
helped to develop a nationwide wireless voice/data net-
work, in-vehicle hardware, and associated services. 
Mr. Lund has also worked in Marketing and Product 
Development for Johnson & Johnson’s diabetes group, 
and served as Business Development Manager for Incyte 
Genomics. He is currently the Licensing Manager for 
Syngenta Biotechnology and is primarily responsible 
for developing alliances in their BioFuels business. Mr. 
Lund holds a Masters in Business Administration from 
the Fuqua School of Business at Duke University, a Juris 
Doctorate from Duke Law School, and a Bachelors 
degree in political science from the University of 
California, San Diego. He is a member of the California 
Bar Association, North Carolina Bar Association, 
Association of University Technology Managers, and 
the Licensing Executives Society.
MACWRIghT, Robert S. 
Robert S. MacWright is Executive Director and CEO 
of the University of Virginia Patent Foundation, 
which evaluates, protects, and licenses inventions that 
originate from research performed at the University 
of Virginia (UVA). In addition, Dr. MacWright is the 
founder and President of Spinner Technologies, Inc., 
a UVA Patent Foundation subsidiary that encourages 
and assists faculty entrepreneurs and their start-up 
companies. Dr. MacWright also led Spinner’s efforts 
to create the Jefferson Corner Group, an angel invest-
ment fund focused on UVA start-ups. He has been 
Executive Director of the UVA Patent Foundation 
since 1997.
Dr. MacWright joined the university licensing profes-
sion in 1985, when he became Assistant Director of the 
Rutgers University Office of Corporate and Industrial 
Research Services. He initiated the first independent 
patent and licensing program at Rutgers, and served as 
Director of the Rutgers Office of Corporate Liaison and 
Technology Transfer from 1988 to 1992.
Dr. MacWright holds a Ph.D. in biochemistry from 
Rutgers University and the University of Medicine and 
Dentistry of New Jersey, and has carried out postdoctor-
al and industrial research in molecular genetics and pro-
tein chemistry. He also holds a law degree from Rutgers 
Law-Newark. He is a Registered U .S. Patent Attorney, 
and is admitted to practice in New York, New Jersey, 
and Virginia. He formerly practiced law in the New 
York City IP firm of Kenyon & Kenyon, and also in 
the intellectual property department of Skadden, Arps, 
Slate, Meagher & Flom, LLP, a well-known New York 
mergers and acquisitions firm. 
MAhONEy, Richard T.
Richard T. Mahoney is Director, Vaccine Access, for 
the Pediatric Dengue Vaccine Initiative, a program 
of the International Vaccine Institute (IVI) in Korea. 
Previously, he was Research Professor in the School of 
Life Sciences and in the Biodesign Institute of Arizona 
State University. As a consultant to the Rockefeller 
Foundation, he played a lead role in the consultative 
process that led to the formation of MIHR. Previously, 
he was responsible for institutional development in 
the establishment and launching of the IVI in Seoul, 
Korea. In this role, he was responsible for cultivating 
relations with vaccine manufacturers and managing in-
tellectual property, among other things. Dr. Mahoney 
has had a long career in public health and is known for 
his work with the International Task Force on Hepatitis 
B Immunization, accomplished while he was with 
the Program for Appropriate Technology in Health 
(PATH). Before co-founding and joining PATH, he 
was a Program Officer in Population with the Ford 
Foundation. He oversaw the development and imple-
mentation of IP management policies for the Ford 
Foundation, PATH, and IVI. Prof. Mahoney continues 
to write on policy and economic research. 
MANgENA, Mosibudi
Mosibudi Mangena is the Minister of Science and 
Technology in South Africa and President of the 
Azanian People’s Organisation (AZAPO). He was born 
in Tzaneen, matriculated from Hebron Training College 
in 1969, and received an M.Sc. degree in Applied 
Mathematics from the University of South Africa (called 
the University of Azania on the AZAPO website). He 
joined the South African Students’ Organisation (SASO) 
and was elected to the Student’s Representative Council 
at the University of Zululand in 1971. Moving back to 
Pretoria, he became chairperson of the SASO Pretoria 
branch in 1972. He chaired the Botswana region of the 
Black Consciousness Movement of Azania (BCMA) 
in 1981 and the BCMA central committee from 1982 
to 1994. He returned from exile in 1994 and became 
leader of Azapo. He was appointed Deputy Minister 
of Education in South Africa by Nelson Mandela in 
2001, and became Minister of Science and Technology 
in 2004.
MARChANT, gary
Gary Marchant is the Lincoln Professor Emerging 
Technologies, Law and Ethics at the Sandra Day 
O’Connor College of Law at Arizona State University. 
He is also a Professor of Life Sciences at ASU and 
Executive Director of the ASU Center for the Study 
of Law, Science and Technology. Professor Marchant 
has a Ph.D. in Genetics from the University of British 
Columbia, a Masters of Public Policy degree from the 
Kennedy School of Government, and a law degree from 
Harvard. Prior to joining the ASU faculty in 1999, he 
was a partner in a Washington, D.C. law firm, where his 
practice focused on environmental and administrative 
law. Professor Marchant teaches and researches in the 
subject areas of environmental law, risk assessment and 
risk management, genetics and the law, biotechnology 
law, food and drug law, legal aspects of nanotechnology, 
and law, science, and technology.
MAShELKAR, R.A.
Dr. R.A. Mashelkar is presently the President of the 
Indian National Science Academy (INSA) and President 
of Global Research Alliance (GRA), a network of pub-
licly funded R&D institutes from five continents with 
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over 60,000 scientists. Prior to this, for over eleven 
years Dr. Mashelkar served as the Director General of 
Council of Scientific and Industrial Research (CSIR), 
an organization with thirty-eight laboratories and about 
20,000 employees. His leadership transformed CSIR 
into a user-focused, performance-driven organization, 
a process of transformation that has been recently her-
alded as one of the ten most significant achievements of 
Indian Science and Technology in the 20th century.
Dr. Mashelkar is only the third Indian engineer to 
have been elected as a Fellow to the Royal Society (FRS), 
London, in the 20th century. He was elected Foreign 
Associate of the National Academy of Science (U.S.) 
in 2005, and was only the eighth Indian since 1863 
to be elected. He was elected a Foreign Fellow of the 
U.S. National Academy of Engineering (2003), Fellow 
of the Royal Academy of Engineering (U.K.) in 1996, 
and Fellow of the World Academy of Art & Science 
(U.S.) in 2000. Twenty-six universities have honored 
him with honorary doctorates, including the universi-
ties of London, Salford, Pretoria, Wisconsin, and Delhi. 
He is currently the President of the Materials Research 
Society of India.
In post-liberalized India, Dr. Mashelkar has played 
a critical role in shaping the country’s S&T policies. 
He was a member of the Scientific Advisory Council to 
the Prime Minister and also of the Scientific Advisory 
Committee to the Cabinet set up by successive 
governments. 
Dr. Mashelkar has won more than 50 awards and 
medals, including the S.S. Bhatnagar Prize (1982), the 
Pandit Jawaharlal Nehru Technology Award (1991), 
the G.D. Birla Scientific Research Award (1993), the 
Material Scientist of Year Award (2000), the IMC Juran 
Quality Medal (2002), the HRD Excellence Award 
(2002), the Lal Bahadur Shastri National Award for 
Excellence in Public Administration and Management 
Sciences (2002), the World Federation of Engineering 
Organizations (WFEO) Medal of Engineering 
Excellence by WFEO, Paris (2003), the Lifetime 
Achievement Award by the Indian Science Congress 
(2004), the Science Medal by the Academy of Science 
for the Developing World (2005), and the Ashutosh 
Mookherjee Memorial Award by the Indian Science 
Congress (2005), among others.
The President of India honored Dr. Mashelkar with 
the Padmashri (1991) and with the Padmabhushan 
(2000), which are two of the highest civilian honors 
in India, in recognition of his contribution to nation 
building.
MATThEWS, Duncan
Duncan Matthews is Senior Lecturer in Intellectual 
Property Law. He has acted as a consultant to the 
Directorate General Trade of the European Commission, 
the ECAP II EC-ASEAN Intellectual Property Rights Co-
operation Programme, and the Science and Intellectual 
Property in the Public Interest Program (SIPPI) of the 
American Association for the Advancement of Science 
(AAAS). He holds an Economic and Social Research 
Council (ESRC) research grant on NGOs, Intellectual 
Property Rights, and Multilateral Institutions. He is the 
author of the following publications: “From the August 
30, 2003 WTO Decision to the December 6, 2005 
Agreemement on an Amendment to TRIPS: Improving 
Access to Medicines in Developing Countries?” [2006] 
10 Intellectual Property Quarterly 91-130, ISSN: 1364-
906X; “TRIPS Flexibilities and Access to Medicines 
in Developing Countries: The Problem with Technical 
Assistance and Free Trade Agreements” [2005] 27 
European Intellectual Property Review 420-427, ISSN: 
0142-0461; “Is History Repeating Itself? The Outcome 
of Negotiations on Access to Medicines, the HIV/AIDS 
Pandemic and Intellectual Property Rights in the World 
Trade Organisation” [2004] 1 Law, Social Justice and 
Global Development Journal (LGD), ISSN: 1467-0437; 
“The WTO Decision on Implementation of Paragraph 
6 of the Doha Declaration on the TRIPs Agreement 
and Public Health: A Solution to the Access to Essential 
Medicines Problem?” [2004] 7(1) Journal of International 
Economic Law 73-107, ISSN: 1369-3034; “A Strategic 
Approach to Managing Intellectual Property” (Co-au-
thor with J. Pickering and J. Kirkland) in R. Blackburn 
(Editor), Intellectual Property and Innovation Management 
in Small Firms, London: Routledge, 2003, 35-54, ISBN: 
0415228840; Globalising Intellectual Property Rights: 
The TRIPs Agreement, London: Routledge, 2002 ISBN: 
041522327X.
MCBRIDE, Timothy B.
Timothy B. McBride is an attorney for the intellectual 
property law firm of Senniger Powers. Mr. McBride’s 
practice includes all areas of intellectual property law, 
including the preparation and prosecution of patent ap-
plications in the United States and abroad. His work is 
focused in the following areas: preparation and prosecu-
tion of patents in the fields of biotechnology, molecular 
biology, immunology, and animal science, including 
patents for transgenic plants and bacteria, novel DNA 
and protein sequences, vaccines, gene therapeutics, and 
diagnostics; validity/invalidity and infringement opin-
ions; and counseling related to patentability and free-
dom to operate.
Mr. McBride received his Bachelor of Science degree 
in Neurobiology and Animal Physiology from Purdue 
University in 1996. He received his Bachelor of Arts 
degree in Psychology from Purdue University in 1997 
and his Juris Doctorate from Indiana University School 
of Law-Indianapolis in 2001. Mr. McBride is also an 
adjunct professor in the School of Engineering and 
Applied Science at Washington University, where he 
teaches a course on intellectual property for engineers 
and scientists.
MCCALLA, Alex F.
Alex is Professor of Agricultural and Resource 
Economics, Emeritus, at the University of California, 
Davis. He was born in Alberta, Canada, and received his 
first two degrees from the University of Alberta before 
moving on to the University of Minnesota where he re-
ceived his doctorate in Agricultural Economics in 1966. 
Throughout his academic career he was associated with 
the University of California-Davis where he served as 
Dean of the College of Agricultural and Environmental 
Sciences and Associate Director of the California 
Agricultural Experiment Station (1970–1975) and 
Founding Dean, Graduate School of Management 
(1979–1981).
Dr. McCalla is best known for his research in in-
ternational trade where he has published extensively. 
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The quality of his research and communication skills 
has been recognized by the American Agricultural 
Economics Association, which presented him with its 
Quality of Communication Award in 1979 and its 
Quality of Research Discovery Award in 1982. He was 
elected Fellow of the American Agricultural Economics 
Association in 1988, Fellow of the Canadian Agricultural 
Economics Society in 2000, and a Distinguished Scholar 
of the Western Agricultural Economics Association 
in 2004. He was a founding member and co-conve-
ner of the International Agricultural Trade Research 
Consortium. He served as the Chair of the Technical 
Advisory Committee (TAC) of the Consultative Group 
on International Agricultural Research (CGIAR) from 
1988 to 1994.
He elected early retirement from the University of 
California in June 1994 and was appointed Director 
of the Agriculture and Natural Resources Department 
of the World Bank in Washington, D.C., effective 
September 12, 1994. During his tenure he led a ma-
jor effort to revitalize the World Bank’s commitment 
to Rural Development. He was appointed Director of 
Rural Development in July 1997, following a Bank reor-
ganization. He retired from the World Bank December 
31, 1999.
In June 1998 he was awarded the Degree of Doctor 
of Science, honoris causa, by McGill University in 
Montreal, Canada. On December 28, 1999, he was 
awarded the Doctor’s Degree of Honor by the Georgian 
State Agrarian University. In September of 2004 he 
received the Distinguished Alumni Award from the 
University of Alberta.
He served as Chair of the Board of Trustees of 
CIMMYT, the International Maize and Wheat 
Improvement Center with Headquarters in Mexico, 
(2001–2005) and is a member of the Board of Directors 
of the Danforth Plant Science Center in St. Louis.
MCCRACKIN, Ann M.
Ann M. McCrackin is a registered patent attorney and 
a shareholder of Schwegman, Lundberg, Woessner & 
Kluth. Her practice focuses on computer architec-
ture, software, and business methods. She also spe-
cializes in reexamination practice and international 
patent protection. Ms. McCrackin holds a Bachelor’s 
degree from Iowa State University, with a major in 
speech communication and minors in computer sci-
ence and English (B.S., 1992). She also completed 
graduate coursework in computer engineering at 
Iowa State University. Ms McCrackin received her 
J.D. from Franklin Pierce Law Center in Concord, 
New Hampshire, in 1997. At Franklin Pierce, she 
was a senior editor of IDEA: The Journal of Law and 
Technology. Her legal curriculum concentrated on in-
tellectual property law. Prior to attending law school, 
she worked for the Center for Advanced Technology 
Development (CATD) at Iowa State University. At 
CATD, she analyzed the suitability of commercial-
ization software and negotiated and prepared license 
agreements for scientific software. Ms. McCrackin is 
frequently invited to speak on various patent pros-
ecution topics and is a co-editor of Electronic and 
Software Patents: Law and Practice, a treatise pub-
lished by BNA Books. 
MCgEE, David R.
David R. McGee joined the University of California, 
Davis in January 2004. He is the Executive Director for 
Technology and Industry Alliances (TIA), an organiza-
tion within the Office of Research at U.C. Davis. TIA 
provides patent and copyright protection and licensing 
services for the University’s intellectual property, and 
helps faculty and industry collaborate on research proj-
ects and spinout companies.
Prior to joining U.C. Davis, Dr. McGee was a con-
sultant in biotechnology and intellectual property strat-
egy. In 1987, Dr. McGee founded Large Scale Biology 
Corporation (LSBC), a biotechnology healthcare firm 
that develops new biopharmaceuticals, including pa-
tient-specific vaccines in plants using viral vectors. He 
served as the corporate Executive Vice President and 
the President of the Biomanufacturing Business Unit 
at LSBC until June 2003. From 1982 to 1987, Dr. 
McGee was a founding member and Vice President 
of Operations at Sungene Technologies Corporation, 
a plant biotechnology company that improved major 
commercial crop species using genetic engineering and 
tissue culture. Dr. McGee received his Ph.D. in genetics 
from Louisiana State University and served as a faculty 
instructor of zoology and genetics. Dr. McGee currently 
serves on the boards of a number of private and non-
profit companies.
MEDAKKER, Akshat
Akshat Medakker is a technology manager at Sathguru 
Management consultants, where he focuses on a variety 
of projects relating to intellectual property and technol-
ogy transfer. Currently, he assists clients in the Indian 
government as well as the private sector in both India 
and the U.S. in matters of patenting, negotiation for 
licensing, and drafting of licensing and other IP agree-
ments. Prior to joining Sathguru, Mr. Medakker over-
saw strategic business development for a biotech com-
pany in India. He graduated from the University of 
Sydney with a degree in Molecular Biotechnology and 
has research experience as a molecular biologist in both 
Australia and India.
Mr. Medakker is also actively involved in the Society 
for Technology Management. He coordinates the ac-
tivities of the association, including course design 
and the delivery of intensive training for technology 
managers and researchers in IP rights and technology 
management.
MIN, Eun-Joo 
Eun-Joo Min is Senior Legal Officer at the Arbitration 
and Mediation Center of the World Intellectual Property 
Organization (WIPO). She holds a Ph.D. in law from 
Yonsei University in Seoul, Republic of Korea, a cer-
tificate degree in international law from the Graduate 
Institute of International Affairs in Geneva, Switzerland, 
and was a Fulbright Scholar at the University of Michigan 
Law School. Prior to joining WIPO in February 2000, 
Dr. Min taught international law and international eco-
nomic law at the International Division and College of 
Law at Yonsei University.
At the WIPO Arbitration and Mediation Center, Dr. 
Min manages arbitration and mediation cases, develops 
and implements new alternative dispute resolution 
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(ADR) procedures, develops educational programs on 
ADR, collaborates in the development of new infor-
mation technology applications in support of WIPO 
case administration, and manages relations between the 
Center and other organizations and users of the WIPO 
Arbitration and Mediation Center’s services. Dr. Min is 
the co-editor of Collection of WIPO Domain Name Panel 
Decisions (The Hague: Kluwer Law International, 2003) 
and has written and spoken extensively on ADR and 
intellectual property.
MONgEON, Marcel D. 
Marcel Mongeon is an Intellectual Property Coach who 
assists companies and institutions in devising and imple-
menting strategies to help them profit from their intan-
gible assets. He is an experienced international speaker 
and seminar leader in many fields, including business 
strategy, understanding legal issues (such as intellectual 
property management), and negotiations.
Mr. Mongeon is a lawyer qualified to practice in the 
Canadian provinces of Ontario and Québec as well as 
in New York. He is a Canadian Registered Patent and 
Trade-mark Agent. He holds business, law, and sci-
ence degrees from McGill University (B.Com., LL.B., 
B.C.L.), McMaster University (M.B.A.), and Swinburne 
University (M.Sc.). He is a Fellow of the Intellectual 
Property Institute of Canada. He oversaw all sponsored 
research, patenting, and commercialization activities of 
the technology transfer office at McMaster University 
from 1997 to 2006. He has also had experience in the 
manufacturing, hospitality, and information technol-
ogy industries. He has practiced law with major firms in 
Montréal and Toronto.
Mr. Mongeon is an active Rotarian and has served 
on the boards of his local chamber of commerce, the 
Canadian Council of Better Business Bureaus, the 
international Association of University Technology 
Managers, and the Canadian University Intellectual 
Property Group, among others.
MOREL, Carlos
Dr. Carlos M. Morel is currently the Director of the 
Centre for Technological Development in Health 
(CDTS), a new unit being implemented at the Oswaldo 
Cruz Foundation (FIOCRUZ, Rio de Janeiro, Brazil) to 
stimulate health product innovation. 
A molecular biologist and medical doctor by train-
ing, Dr. Morel received his M.D. from the Medical 
Faculty of the Federal University of Pernambuco. 
He completed his graduate studies at the Biophysics 
Institute of the Federal University of Rio de Janeiro 
and at the Molecular Biology Department of the Swiss 
Cancer Institute in Lausanne (ISREC), Switzerland. His 
research has been in the field of molecular parasitology, 
and he has collaborated with various international orga-
nizations and research programs working on neglected 
diseases and capacity building. 
Dr. Morel was previously a Professor at Brasilia 
University (UnB, Brasilia, Brazil) and President of 
FIOCRU. He was also Director of the UNICEF/
UNDP/World Bank/WHO Special Programme for 
Research and Training in Tropical Diseases (TDR) at 
the World Health Organization in Geneva, where he 
established close working relationships with product-
development public private partnerships and global 
ventures committed to public health. He participated 
actively in the establishment of the Medicines for 
Malaria Venture (MMV), the Global Alliance for TB 
Drug Development (GATB), the Drugs for Neglected 
Diseases Initiative (DNDi), and the Foundation for 
Innovative New Diagnostics (FIND). 
A member of the Brazilian Academy of Sciences and 
an Honorary Fellow of the Royal Society of Tropical 
Medicine and Hygiene in London, Dr. Morel holds 
the National Order of Scientific Merit (Brazil) and 
Doctor Honoris Causa from the Federal University of 
Pernambuco (Brazil). He has been a member of the 
MIHR Board of Trustees since its founding. 
MOyNIhAN, Michael R.
Michael R. Moynihan has more than 20 years’ experi-
ence in plant biotechnology. For the past ten years, he 
has primarily been involved in technology transfer and 
the development of public-private research networks in 
his capacities as a Senior Project Director at InterLink 
Biotechnologies LLC and Director of Biotechnology 
Development at Fundación Chile. Dr. Moynihan 
earned an Sc.B. in Biology from Brown University in 
1974 and M.A. and Ph.D. degrees in Biology from 
Harvard University in 1979 and 1982. He was a 
Visiting Research Fellow at the Institute for Molecular 
and Cellular Biology at Osaka University, a Postdoctoral 
Associate in the Section of Plant Biology at Cornell 
University, a Postdoctoral Associate at the Center for 
Agricultural Molecular Biology at Rutgers University, 
and a Principal Scientist in the plant biotechnology 
laboratory of EniChem Americas.
MuNOZ TELLEZ, Viviana
Viviana Munoz is a Programme Officer at the South 
Centre, an intergovernmental organization of devel-
oping countries based in Geneva, Switzerland. Ms. 
Munoz assists the research, policy analysis, policy 
advice, capacity building, and training activities of 
the Centre’s Innovation and Access to Knowledge 
Programme. Her efforts support the development, 
coordinated use, and improvement of the capacities 
of developing countries and their institutions. The 
Centre aims to integrate the development dimension 
into their policies on innovation, access to knowledge, 
and intellectual property.
Previously, Ms. Munoz worked at Queen Mary 
Intellectual Property Research Institute, University of 
London, as Research Assistant for an Economic and 
Social Research Council (ESRC) project (www.ipngos.
org/). The project examined the role that nongovern-
mental organizations (NGOs) play in supporting the 
positions of countries on intellectual property, public 
health, and biodiversity at multilateral institutions. She 
has also worked as an independent consultant. Some of 
her recent works include: Munoz V. (with Matthews D.), 
Bilateral technical assistance and the TRIPS agreement: the 
United States, Japan and the European Communities in 
comparative perspective, Journal of World Intellectual 
Property, Vol. 9, No. 6. (November 2006), pp. 629-
653, and Munoz V. (with Waitara C.), An Analysis of 
the Impact of the Treaty on the Protection of Broadcasting 
Organisations and Cablecasting Organisations on 
Developing Countries, Research Paper 9, South Centre, 
(December 2006). 
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Ms. Munoz holds a B.A. in International Relations 
from the U. Rosario, Colombia, and an M.Sc. in 
Development Management from the London School of 
Economics. 
MuNyI, Peter
Peter Munyi is the Chief Legal Officer of the 
International Centre of Insect Physiology and Ecology 
(ICIPE). He offers in-house legal advice to ICIPE in 
many areas; intellectual property law is his speciality. 
Through SEAPRI, an ICIPE initiative, Mr. Munyi also 
offers legal and policy advice on agriculture, genetic re-
sources, and environmental issues to the governments 
of developing countries, international organizations, 
and nongovernmental organizations. He has published 
widely on many topics, including intellectual prop-
erty-related issues, genetic resources, and biodiversity. 
He holds a Master’s degree in European Intellectual 
Property Law from Stockholm University, Sweden, and 
a Bachelor’s Degree in Law from Moi University, Kenya. 
Prior to joining ICIPE, Mr. Munyi was a commercial 
lawyer in a private practice based in Nairobi.
MuTSChLER, Martha
Martha Mutschler is a professor in the Department 
of Plant Breeding, College of Agriculture and Life 
Sciences, Cornell University. She directs a research pro-
gram in tomato and onion breeding and genetics. Her 
work deals with plant genetics and breeding projects 
concerning the genetic control of novel traits derived 
from wild species, the genetic control/physiological 
mechanisms underlying these traits, and the use of these 
mechanisms in vegetable improvement. This work has 
resulted in several U.S. patents, as well as the release 
of elite breeding lines with novel forms of disease re-
sistance or insect resistance, or modified production 
traits such as extended shelf life or early maturity. Dr. 
Mutschler has served on the board of directors for the 
Cornell Research Foundation (the patent and licens-
ing unit for Cornell University) for over a decade. This 
service led to her interest in plant intellectual property, 
a subject on which she has published. It also led her 
to develop a computer-assisted instruction module for 
training undergraduate and graduate students in IP 
issues. 
NEAgLEy, Clinton h.
Clinton H. Neagley is Associate Director of Technology 
Transfer Services at the University of California, Davis. 
His responsibilities include patenting and licensing 
inventions in the fields of agriculture, biotechnol-
ogy, chemistry, and physical science, as well as assist-
ing academic researchers on intellectual property mat-
ters. Before joining U.C. Davis, Dr. Neagley was Chief 
Patent Counsel and Director of Licensing for DNA 
Plant Technology Corporation (DNAP), where he was 
responsible for intellectual property and technology 
contracts, managing the patent portfolio, and licensing 
and freedom-to-operate assessment. Prior to his position 
at DNAP, Dr. Neagley spent ten years with the New 
York City intellectual property law firm of Davis Hoxie 
Faithfull & Hapgood, where he worked on litigation, 
licensing, and patent prosecution. As a partner at Davis 
Hoxie, he played a lead role in the biotechnology group, 
representing clients from large established companies, 
start-up companies, and universities. He has lectured 
and published on many topics of patent law. He is a 
member of the California and New York Bars and is a 
registered Patent Attorney. Dr. Neagley has a J.D. from 
Cornell Law School and a Ph.D. in Chemistry from the 
University of California, Davis. 
NEEDLE, William h. 
William H. Needle is the founder of Needle & 
Rosenberg, P.C., one of the largest intellectual property 
law firms in the Southeast. He has exclusively practiced 
patent, trademark, copyright, and trade secret law over 
his entire 36-year career. Mr. Needle is an adjunct pro-
fessor of Licensing Law at Emory University School of 
Law and adjunct professor of Patent Law at Georgia 
State University College of Law. He serves as a mediator 
or arbitrator in complex disputes involving intellectual 
property issues and has been an expert witness in pat-
ent, trademark, and copyright infringement actions. On 
several occasions, he has been appointed to serve as a 
Special Master by U.S. District Court Judges in patent 
infringement cases wherein his recommendations on 
validity, infringement, and damages in two actions were 
affirmed by the Federal Circuit Court of Appeals. 
Mr. Needle has served as a Special Assistant Attorney 
General for the State of Georgia for intellectual prop-
erty law issues for over 30 years and is a Fellow of the 
Lawyers Foundation of the State Bar of Georgia. He is 
a member of several organizations: the Advisory Board 
of The Technological Innovation: Generating Economic 
Results (TI: GER) program, a collaboration between 
Georgia Tech and Emory Law School that prepares stu-
dents to commercialize new technologies; the Advisory 
Board of the School of Biomedical Engineering at the 
University of Alabama at Birmingham; and the Advisory 
Board of Georgia Tech’s College of Sciences. In addi-
tion, he served on the committee that was tasked with 
formulating Local Rules regarding patent litigation for 
the U.S. District Court, Northern District of Georgia.
Mr. Needle’s peers in the legal community voted him 
one of Georgia Trend magazine’s “Legal Elite” every year 
from 2003 to 2007 and named him one of the “Top 
100 Georgia Super Lawyers” every year from 2004 to 
2007. He has also been listed as one of the best intellec-
tual property lawyers in Atlanta for over ten years in The 
Best Lawyers in America®. Additionally, he is a certified 
“Memphis in May” barbecue judge.
Mr. Needle graduated with a B.S. in Chemistry from 
the Georgia Institute of Technology in 1967. He received 
his J.D. from the Emory University School of Law in 
1970. 
NELKI, Daniel
Daniel Nelki is Head of Legal and Operations in Tech-
nology Transfer at the Wellcome Trust. Dr. Nelki ob-
tained his Ph.D. in 1987 from the University of London 
and went on to conduct postdoctoral research in mouse 
molecular genetics at King’s College, London. He ob-
tained a Diploma in Law in 1991 and, following com-
pletion of his professional solicitor’s qualifications, prac-
ticed with the international law firm Baker & McKenzie, 
eventually specializing as an intellectual property law-
yer. He joined the Wellcome Trust in 1995 and played 
a key role in planning and structuring the Technology 
Transfer group, thanks to his uniquely multi-faceted 
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perspectives. He is particularly knowledgeable on the 
topics of intellectual property and charity law, as well 
as the commercial exploitation of fundamental research. 
He has earned a Master’s in Law (LLM) for his thesis on 
the ownership of human genes and tissue.
NELSEN, Lita
Lita Nelsen is the Director of the Technology Licensing 
Office at the Massachusetts Institute of Technology, 
where she has been since 1986. Every year, the of-
fice manages over 400 new inventions originating 
from M.I.T., the Whitehead Institute, and Lincoln 
Laboratory. Typically, the office negotiates over 100 
licenses and starts up over 20 new companies each 
year. Ms. Nelsen earned her B.S. and M.S. degrees in 
Chemical Engineering from M.I.T., as well as an M.S. 
in Management from M.I.T. as a Sloan Fellow. Prior 
to joining the M.I.T. Technology Licensing Office, 
Ms. Nelsen spent 20 years in industry, primarily in 
the fields of membrane separations, medical devices, 
and biotechnology; she worked at such companies as 
Amicon, Millipore, Arthur D. Little, Inc., and Applied 
Biotechnology. Ms. Nelsen was the 1992 President of 
the Association of University Technology Managers. She 
serves on the board of the Mount Auburn Hospital and 
the Scientific Advisory Board of the Children’s Hospital 
Oakland Research Foundation. She also serves as the 
intellectual property advisor to the International AIDS 
Vaccine Initiative and is a founding and current board 
member of MIHR. Ms. Nelsen is widely published in 
the fields of technology transfer and university/indus-
try collaborations. She was a CMI Fellow at Cambridge 
MIT Institute (at the University of Cambridge), where 
she studied the role of university/industry/government 
partnerships in technology transfer and local economic 
development. She is a co-founder of Praxis, the U.K. 
University Technology Transfer Training Programme.
NEWMAN, Pauline
Pauline Newman is a judge of the U.S. Court of 
Appeals for the Federal Circuit. She received a B.A. 
from Vassar College, an M.A. in Pure Science from 
Columbia University, a Ph.D. in Chemistry from Yale 
University, and an LL.B. from New York University 
School of Law. Before her appointment as circuit judge 
in 1984, she was Director of Patents and Licensing 
at FMC Corporation in Philadelphia. She worked as 
Science Policy Specialist at UNESCO, Paris, and as a 
research chemist at American Cyanamid Company. She 
has served as adviser to various governmental programs, 
and has been an officer and director of several bar and 
scientific associations. She has been awarded the Wilbur 
Cross Medal by Yale University, the Vanderbilt Medal 
by New York University School of Law, the Jefferson 
Medal by the New Jersey Patent Law Association, 
and the Award for Outstanding Contributions to 
International Cooperation by the Pacific Industrial 
Property Association. She is a distinguished Professor of 
Law at George Mason University School of Law and the 
author of articles in the fields of innovation and science 
and the law.
NILSSON, Malin
Malin Nilsson graduated in 2001 from the Swedish 
University of Agricultural Sciences, where she received 
her M.Sc. in Horticulture. She studied crop produc-
tion, plant protection, and developmental studies, 
but finally got hooked on plant breeding and genet-
ics; it was an interest that brought her to the Research 
Institute Geisenheim, Germany, where she spent part 
of her time as a student. Ms. Nilsson has worked in 
the International Division of the Swedish plant breed-
ing company Svalöf Weibull since 2001. Initially, her 
responsibilities were mainly within the field of plant 
variety licensing, ranging from establishing agreements 
to practical follow-up of the obligations and rights un-
der such agreements. During this period, she became 
interested in intellectual property rights, an interest that 
was further developed when she moved on to work with 
the complete product portfolio as Product Manager in 
Oilcrops. In 2006, after a short period spent sharpen-
ing her skills in the role of Sales Manager Sweden, she 
took the position of Marketing Manager in Cereals and 
Oilseeds. Ms. Nilsson’s current position allows her to 
use and further develop her competence in the field of 
intellectual property, especially in plant variety rights, 
throughout the value chain. 
NOTTENBuRg, Carol 
Carol Nottenburg is a patent lawyer specializing in 
biotechnology. She migrated to law after a career in 
science. Her career path took her from undergradu-
ate days at Caltech (B.S. Biology) to graduate work at 
Stanford University (Ph.D. Genetics), to a postdoc-
toral fellowship at the University of California, San 
Francisco, where she worked in the laboratory of Dr. 
Harold Varmus, Nobel Laureate, and ultimately to the 
Fred Hutchinson Cancer Research Center (FHCRC) 
in Seattle, Washington, where she joined the faculty 
of the Clinical Division. For five years, her laboratory 
studied the causes of poor immune system development 
in patients who have had bone marrow transplants. Dr. 
Nottenburg then turned to the pursuit of a career in 
patent law. After graduating magna cum laude from the 
University of Puget Sound Law School (now Seattle 
University Law School), she joined the law firm of Seed 
and Berry in Seattle, Washington. She took primary 
responsibility for a number of small biotech company 
clients, and her practice focused on integrating patent 
strategies with business strategies. A move to CAMBIA, 
a nonprofit, private research institute in Australia, al-
lowed her to become involved in policy issues sur-
rounding intellectual property. At the same time that 
she was responsible for intellectual property matters 
at CAMBIA, she spearheaded the development of the 
internet-based Patent Lens Resource (www.patentlens.
net). Now returned to private practice, Dr. Nottenburg 
assists clients with integrating patent and business strat-
egies and with strengthening the clients’ capacity to deal 
with both ordinary and more esoteric patent matters. 
NugENT, Rachel
Rachel is a senior associate in CGD’s Global Health 
Programs. She provides economic and policy expertise 
to support HPRN Working Groups, manages CGD 
programs on Population and Economic Development, 
and conducts research on other global health topics. She 
has 25 years of experience as a development economist, 
managing and carrying out research and policy analysis 
in the fields of health, agriculture, and the environment. 
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Prior to joining CGD, Rachel worked at the Population 
Reference Bureau, the Fogarty International Center of 
the U.S. National Institutes of Health, and the United 
Nations Food and Agriculture Organization. 
She received her Ph.D. in Economics from George 
Washington University, and served as associate professor 
and chair of the economics department at Pacific Lutheran 
University in Tacoma, Washington. Rachel’s publications 
include a range of topics, from the cost-effectiveness of 
noncommunicable disease interventions and health im-
pacts of fiscal policies, to impacts of microcredit on the 
environment in developing countries and the economic 
impacts of transboundary diseases and pests.
NyAgAh, Ruth Ruguru 
Ruth is a Kenyan citizen and has been working in the 
horticultural industry for the last 12 years, in work 
ranging from managing export farms to quality con-
trol. She currently works as an auditor technical and 
social auditor for various consumer standards, including 
EUREPGAP, ETP, HACCP, and BRC. She is also the 
managing director of Africert Ltd, the first local certifi-
cation company to be accredited to ISO 65/EN45011 
in East and Central Africa, which she set up through 
funding from GTZ in 2004. Africert’s entry in the 
certification arena in East and Central Africa provides 
producers, who would have otherwise been marginal-
ized in accessing the lucrative export markets due to the 
high costs of importing certification services, with an 
internationally accredited certification company, right 
within their region.
Ruth is a member of the EUREPGAP Certification 
body Committee and is a private consultant for both 
UNCTAD and FAO on issues related to the uptake of 
private standards and their effect on smallholder farmers 
in export horticulture in Kenya.
Ruth holds a Bachelor of Science degree in General 
Agriculture from the University of Eastern Africa, 
Baraton (Kenya), and a Master of Science in Post Harvest 
Horticulture from the University of Greenwich, Natural 
Resources Institute (NRI), U.K.
OEhLER, Joachim
Joachim Oehler is CEO of Concept Foundation, an 
internationally operating, independent not-for-profit 
organization that is active in IP management for health 
products; its goal is to create the best public sector ben-
efits through the out-licensing of intellectual property. 
Dr. Oehler initiated and established the value-based 
approach of Concept Foundation to the out-licensing 
model of its products, and developed an authoritative 
framework for the performance orientation of license 
agreements through detailed milestones that maxi-
mize public sector benefits. Before joining Concept 
Foundation, he managed a fully integrated pharmaceu-
tical company out of Tokyo, Japan. His company’s ca-
pacities spanned the entire spectrum of pharmaceutical 
business: product development, application laboratories, 
clinical research, local manufacturing, drug regulatory 
affairs and registration, clinical market development, 
marketing, and sales, as well as administration, logistics 
management, warehousing, and so on. Previously, Dr. 
Oehler had held several senior divisional management 
positions in Japanese subsidiaries of multinational phar-
maceutical companies. Before working with Japanese 
companies, he held several marketing positions in the 
pharmaceutical industry in Europe and North America. 
Dr. Oehler continues to advise a select group of com-
panies and organizations on cross-cultural management 
issues.
OLSON, Arne M.
A native of the Chicago area, Arne M. Olson has prac-
ticed intellectual property law for over 25 years. He has 
handled complex litigation involving patent, trademark, 
copyright, trade secret, Internet domain name protec-
tion, cybersquatting, and licensing matters. Mr. Olson 
advises clients on licensing, intellectual property protec-
tion, and litigation involving a wide range of technolo-
gies. His clients include several universities and research 
institutions, as well as publicly traded companies.
Mr. Olson has a bachelor’s degree in physics from 
the University of Chicago and a J.D. with honors from 
the DePaul University School of Law. He is admitted 
to practice in Illinois before the U. S. Court of Appeals 
for the Seventh Circuit and the U. S. Court of Appeals 
for the Federal Circuit. He is also a member of the Trial 
Bar of the U. S. District Court for the Northern District 
of Illinois and the U.S. District Court for the Western 
District of Michigan. He is registered to practice before 
the U.S. Patent and Trademark Office. 
His professional memberships include the 
International Trademark Association, the American 
Bar Association, the American Intellectual Property 
Law Association, and the American Association for the 
Advancement of Science. He was designated a “Super 
Lawyer” by Law & Politics magazine in 2005, 2006, 
and 2007, and was selected as a Leading Lawyer in in-
tellectual property law by the Illinois Leading Lawyers 
Network, Law Bulletin Publishing Company.
PAgE, Nigel 
Nigel is the Finance Editor of IAM magazine (www.
iam-magazine.com). He has worked for more than 15 
years as a journalist and editor in print media. After 
qualifying as a barrister in the U.K., Nigel switched ca-
reers to work in journalism and helped to launch various 
legal and business publications, including Legal Business 
magazine, the U.K.’s leading monthly magazine for 
the legal market. He continues to contribute to vari-
ous newspapers and magazines, including the Financial 
Times, Euromoney, and Financial News. He was one of 
the founders of IAM magazine in 2004 and became its 
Finance Editor in 2005.
PARDEE, William
William Pardee received his PhD from Cornell 
University, and has been professor of Agronomy and 
Plant Breeding at Cornell since 1966. Earlier, he served 
as assistant, then associate professor of Agronomy, at the 
University of Illinois and as visiting professor at Oregon 
State University. Professor Pardee’s research focuses on 
seed production, seed policies, and crop varietal improve-
ment. He has participated in numerous national commit-
tees and symposia, and in international seed programs. 
He has been elected as fellow in the American Society of 
Agronomy, the Crop Science Society of America, and the 
American Society of the Advancement of Science. From 
1978 to 1987, he served as Chairman of the Department 
of Plant Breeding and Biometry at Cornell. 
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His extension goal is to help farmers and seed grow-
ers improve their competitive positions and income 
through the use of improved seeds of superior varieties. 
To achieve this, he works closely with seed growers and 
dealers to encourage the production and distribution of 
high quality seed, and writes and speaks regularly for 
grower, dealer, and farmer audiences, providing infor-
mation designed to help them in their choice of seed. 
He has participated in policy decisions related to seed at 
state and national levels, seeking to maintain practical 
yet effective seed policies and regulations. 
PÉCOuL, Bernard
Bernard Pécoul has been Executive Officer of the 
Geneva-based Drugs for Neglected Diseases Initiative 
(DNDi) since its inception in 2003.
Dr. Pécoul earned a medical degree from the French 
University of Clermont Ferrand, France, and a Master’s 
of Public Health from Tulane University in the U.S. He 
joined Médecins Sans Frontières (MSF) as a volunteer 
physician in 1983; in Honduras, he provided healthcare 
to refugees from El Salvador, Nicaragua, and Guatemala. 
In 1985, still with MSF, he moved to Thailand and 
Malaysia, managing public health projects for refugees 
from Vietnam, Burma, and Laos. He was a co-founder 
and director of research and training from 1988-1991 at 
Epicentre, an epidemiological research organization in 
Paris, France. Then, from 1991-1998, he was the Executive 
Director of the French section of MSF, where he oversaw 
100 field projects in 40 countries. From 1998 to 2003, 
Dr. Pécoul was Executive Director of Médecins Sans 
Frontières’ Campaign for Access to Essential Medicines, 
whose goal is to increase access to essential medicines in 
developing countries by advocating for a combination 
of policies: lower drug prices on a sustainable basis, in-
creased research on neglected diseases, and production of 
unprofitable but medically necessary drugs. 
While at MSF, Dr. Pécoul had been active in the 
creation of the Drugs for Neglected Diseases Initiative 
(DNDi), which was finally launched as a foundation in 
July 2003. In October 2003, he was selected as Executive 
Director of the fledgling Initiative. DNDi is a not-for-
profit organization that seeks to develop and make avail-
able drugs that treat neglected diseases (such as sleeping 
sickness, leishmaniasis, and Chagas disease) that afflict 
the poor in developing countries. As executive director, 
Bernard is coordinating the entire research and develop-
ment initiative and managing a team of project manag-
ers and scientists who are located in various parts of the 
world, particularly in Asia, Africa, and Latin America.
PEFILE, Sibongile
Prior to her appointment as Council of Scientific and 
Industrial Research (CSIR) Group Manager for R&D 
Outcomes, Sibongile Pefile was the CSIR Intellectual 
Property and Innovation Manager. With an academic 
background in pharmacy, which includes an M.Sc. in 
Pharmaceutics and a Ph.D. in Pharmacology, Dr. Pefile 
moved into the field of intellectual property when she 
became Programme Director at the Centre for the 
Management of Intellectual Property in Health Research 
and Development (MIHR). In this capacity, she was re-
sponsible for the strategic planning, implementation, 
and coordination of MIHR capacity development pro-
grams in intellectual property management. 
Her work as a consultant for the Rockefeller 
Foundation led to the formation of MIHR. Prior to 
consulting for the Rockefeller Foundation, she spent 
several years working for the Technology and Business 
Development Directorate at the Medical Research 
Council, where she was responsible for establishing the 
Indigenous Knowledge systems office. The office ad-
dressed policy, ethical, and intellectual property issues 
relating to health research and indigenous knowledge 
systems and technologies. She is a member of several 
international bodies concerned with intellectual prop-
erty and its management, and has published and pre-
sented numerous papers on this topic. In 2006, she 
attended the Mastering Technology Enterprises pro-
gramme, IMD, and completed the UNISA/WIPO IP 
Law Specialization course. 
PEZZuTO, J. M. 
A biochemist with research interests in the areas of bi-
ology-driven natural-product drug discovery and char-
acterization, in particular cancer chemotherapy, cancer 
chemoprevention, malaria, and AIDS, Professor John 
Pezzuto is Dean of the College of Pharmacy, University 
of Hawaii. He has also served as Dean of the College 
of Pharmacy, Nursing, and Health Sciences at Purdue 
University in West Lafayette, Indiana. Previously, he 
held the rank of Full Professor in both the College of 
Pharmacy and the College of Medicine of the University 
of Illinois at Chicago, where he was a Distinguished 
University Professor. Since 1977, he has continuously 
received support from the U.S. National Institutes of 
Health and currently serves as the Principal Investigator 
of a program project grant in cancer chemopreven-
tion, while also a Co-Investigator for an International 
Collaborative Biodiversity Group. He wrote and co-
authored 400 publications and co-invented several pat-
ented technologies. He has edited three books, serves on 
the editorial boards of 11 international journals. He is 
the former editor-in-chief of the International Journal 
of Pharmacognosy, and of Combinatorial Chemistry and 
High Throughput Screening. He is the current editor-in-
chief of Pharmaceutical Biology.
PhILLIPS, Peter W. B.
Peter W.B. Phillips is a professor in the department 
of Political Studies at the University of Saskatchewan. 
He holds concurrent faculty appointments in both 
Agricultural Economics and Management at the U. 
of S. and is a Professor-at-Large in the Institute of 
Advanced Studies at the University of Western Australia. 
Dr. Phillips’ research concentrates on issues related to 
governing transformative innovations, a topic that in-
volves examining intellectual property rights for agricul-
tural biotechnology, the economics and management 
of innovation and trade, and marketing issues related 
to new technologies. He has done theoretical, empiri-
cal, institutional, and policy analysis of technological 
change, has published a variety of books and journal 
articles on governing innovation, and has consulted on 
innovation policy with industry and governments in 
Canada, the U.S., the E.U., and Australia, as well as 
with the Organization for Economic Co-operation and 
Development (OECD). He is either a principal inves-
tigator or investigator of seven internationally peer-re-
viewed research programs that have a combined budget 
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of CAD$52 million. He is currently a member of the 
Canadian Biotechnology Advisory Committee, a senior 
research associate with the Estey Centre for Law and 
Economics in International Trade, a member of the 
editorial boards of AgBioForum and IP Strategy, a fel-
low at The Centre for Innovation Studies (THECIS), 
and a member of the Canadian Association of Business 
Economists. 
PITKEThLy, Robert
Robert Pitkethly is a university lecturer in manage-
ment studies (intellectual property) at the Said Business 
School, University of Oxford. In addition, he is a fel-
low and tutor in management at St. Peter’s College, 
where he is also a senior research associate of the Oxford 
Intellectual Property Research Centre. His teaching and 
research interests are centered on strategic management 
and the management of intellectual property. He has 
worked as a management consultant in connection with 
a wide variety of technology-based and general manage-
ment issues and has also worked as a qualified U.K. and 
European Patent Attorney in both private practice and 
industry. 
He holds degrees in chemistry, business admin-
istration, and Japanese studies. Prior to moving to 
Oxford, he was a Research Fellow at the Judge Institute 
at Cambridge University. He has also been a Visiting 
Research Fellow at the Institute of Intellectual Property 
and the National Institute of Science and Technology 
in Tokyo.
POTRyKuS, Ingo
Ingo Potrykus is the engine behind the GoldenRice 
Project and the Humanitarian Board. Together 
with Peter Beyer, he was one of the inventors of the 
GoldenRice technology. Since his retirement as a pro-
fessor in 1999, far from settling down, he has devoted 
enormous efforts to bringing biofortified GoldenRice to 
those who need it. 
Prof. Potrykus was born in 1933 in Hirschberg, 
Silesia, Germany. He has been married since 1960, 
and has three children and eight grandchildren. In 
1968, he earned a Ph.D. in Plant Genetics at the Max-
Planck-Institute for Plant Breeding Research, Cologne, 
Germany. 
He conducted research in botany at the University 
of Basel, Switzerland, and was an Assistant Professor at 
the Institute of Plant Physiology, Stuttgart-Hohenheim 
from 1970 to 1974. From 1974 to 1976, he was 
Research Group Leader at the Max-Planck-Institute for 
Genetics, Ladenburg-Heidelberg, and then, until 1986, 
at the Friedrich Miescher-Institute, Basel, Switzerland. 
From 1986 until his academic retirement in 1999, he 
was Full Professor in Plant Sciences at the Swiss Federal 
Institute of Technology (ETH), Zurich. 
Since 1974, his research has focused on plant-sci-
ence-based contributions to food security in developing 
countries, where he was involved in the development 
and application of genetic engineering technology for 
“food security” crops such as rice (Oryza sativa), wheat 
(Triticum aestivum), sorghum (Sorghum bicolor), and 
cassava (Manihot esculenta). Focusing on problems in 
the areas of disease and pest resistance that were difficult 
to solve with traditional techniques, he worked to im-
prove food quality and yield, improved exploitation of 
natural resources, and improved biosafety. This work was 
performed by an international team of 60 coworkers, on 
average, that was financed from competitive grants and 
core funding. The GoldenRice project, initiated in 1991 
as Ph.D. project, was possible only because of that core 
funding. Details of the GoldenRice project can be found 
in approximately 340 publications in refereed journals 
and 30 international patents. 
Professor Potrykus’s teaching activities have included 
lectures and courses in basic and advanced plant biol-
ogy and plant biotechnology in Biology, Agronomy, 
Pharmacy, Forestry, and Environmental Sciences de-
partments, as well as International Training Courses 
such as EMBO. His numerous awards include: the 
KUMHO (ISPMB) Science International Award in 
Plant Molecular Biology and Biotechnology in 2000, 
the American Society of Plant Biologists (ASPB) 
Leadership in Science Public Service Award in 2001, the 
Crop Science of America (CSSA) Klepper Endowment 
Lectureship in 2001, the CSSA President’s Award in 
2002, and the European Culture Award in Science in 
2002. He received an Honorary Doctorate from the 
Swedish University of Agricultural Sciences in 2002. 
He is a member of Academia Europaea, the World 
Technology Network, the Swiss Academy of Technical 
Sciences, and the Hungarian Academy of Sciences.
POTTER, Robert h.
As a Senior Associate at AGBIOS, Robert H. Potter 
provides biotechnology regulatory, intellectual property 
rights, and risk assessment expertise to a variety of ca-
pacity-building and commercial projects. Before join-
ing AGBIOS in 2005, Dr. Potter was the Technology 
Coordinator for the U.S. Agency for International 
Development (USAID) Agricultural Biotechnology 
Support Project II at Cornell University, where he was 
responsible for technology evaluation and product deliv-
ery planning. Dr. Potter was previously employed as an 
intellectual property specialist for Cornell University’s 
Strategic World Initiative for Technology Transfer pro-
gram. He has extensive experience in the preparation 
and presentation of workshops on intellectual property 
issues related to agricultural biotechnology and plant 
genomics. Dr. Potter’s scientific training is in plant 
molecular biology. He holds a Ph.D. from Rothamsted 
Experimental Station in the U.K., and has postdoctoral 
experience at the Agricultural University of Norway 
and Murdoch University, West Australia. His research 
has included gene expression studies in the developing 
barley grain, investigations of the molecular basis of 
host plant response to attack by root-knot nematodes 
(Meloidogyne spp.), and the use of molecular markers in 
wheat and barley breeding.
RAZgAITIS, Richard
Dr. Richard Razgaitis has 40 years of experience work-
ing with development, commercialization, and tech-
nology management. He began his professional ca-
reer as a “rocket scientist” on the Saturn/Apollo lunar 
launch team, and worked on every launch from Apollo 
1 through the first lunar landing. He was a faculty 
member for 10 years and taught more than 20 differ-
ent undergraduate and graduate level courses. He was 
also a research scientist and inventor at a billion-dol-
lar private institute. For 10 years, he was vice president 
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of commercial development/licensing at two different 
billion-dollar companies. Since 1998, he has been a 
consultant in IP/technology management, opportunity 
discovery, valuation, and dealmaking. 
He is the author of three books on valuation and deal-
making: Early-Stage Technologies: Valuation and Pricing; 
Valuation and Pricing of Technology-Based Intellectual 
Property; Dealmaking Using Real Options and Monte 
Carlo Analysis (all published by John Wiley). He has also 
authored two book chapters: “Technology Valuation,” 
published in The LESI Guide to Licensing Best Practices 
(Wiley, 2002), and “Pricing the Intellectual Property 
Rights to Early-Stage Technologies: A Primer of Basic 
Tools,” AUTM Technology Transfer Practice Manual 
(2003). For more than 10 years, he taught technology 
valuation and pricing courses for AUTM to more than 
2,000 students.
For more than 10 years he held a variety of senior 
positions in the Licensing Executives Society, including 
VP and Treasurer. Since 2000, he has been on the Board 
of the Licensing Foundation, the past three years as its 
President. He has served on the Board of the National 
Inventors Hall of Fame Foundation.
He has B.Sc., M.Sc., and Ph.D. degrees in engineer-
ing, and an M.B.A. Dr. Razgaitis has been a registered 
Professional Engineer in Texas, Oregon and Ohio, and 
is an inventor on four patents. He and his wife have 
been married 40 years and have five children.
RILEy, M. C. 
Mary Riley received her doctorate in cultural anthro-
pology from Tulane University and her law degree from 
Northern Illinois University. She is a co-investigator with 
the UIC-based International Cooperative Biodiversity 
Group (ICBG) and is a visiting senior research special-
ist at the University of Illinois at Chicago, Program 
for Collaborative Research in the Pharmaceutical 
Sciences (PCRPS). In addition, she is an attorney with 
Merritt, Flebotte, Wilson, Webb & Caruso, PLLC, 
in Columbia, South Carolina. She edited the volume 
Indigenous Intellectual Property Rights: Legal Obstacles 
and Innovative Solutions (Altamira Press). 
RITTER, John F. 
John F. Ritter is the Director of the Office of Technology 
Licensing and Intellectual Property at Princeton 
University. Mr. Ritter is a Registered Patent Attorney 
and has been at Princeton University since September 
1996. Prior to joining Princeton, Mr. Ritter was a senior 
member of the technology licensing team at Rutgers 
University and held several marketing positions in in-
dustry. Mr. Ritter has a B.S. in Engineering and an 
M.B.A. in Marketing, in addition to a law degree. He is 
a member of the New Jersey and Pennsylvania bars. 
RODIN, Judith
Judith Rodin has served as president of the Rockefeller 
Foundation since March 2005. Trained as a research 
psychologist, Dr. Rodin was previously the president of 
the University of Pennsylvania, and earlier the provost 
of Yale University. The Rockefeller Foundation was es-
tablished in 1913 by John D. Rockefeller, Sr. to “pro-
mote the well-being” of humanity by addressing the 
root causes of serious problems. The Foundation works 
globally to expand opportunities for poor and vulner-
able people and to help ensure that the benefits of glo-
balization are shared more equitably. 
Judith Rodin was born and raised in Philadelphia, 
Pennsylvania. She graduated from the University of 
Pennsylvania, and received her Ph.D. from Columbia 
University. A pioneer in the behavioral medicine move-
ment, she taught at New York University before em-
barking on 22 years on the faculty at Yale, where she 
ultimately held appointments in both the School of Arts 
and Sciences and the School of Medicine. Named presi-
dent at Penn in 1994, she was the first woman to serve 
as president of an Ivy League institution. 
Dr. Rodin serves on a number of leading nonprofit 
boards, as well as on the boards of AMR Corporation, 
Citigroup, and Comcast Corporation. She is the au-
thor of more than 200 academic articles and chapters 
and has written or co-written 11 books. She served on 
President Clinton’s Committee of Advisors on Science 
and Technology. A member of a number of leading aca-
demic societies, including the Institute of Medicine of 
the National Academy of Sciences, she has received nine 
honorary doctorate degrees. 
ROhRBAugh, Mark L.
Mark L. Rohrbaugh, Ph.D., J.D., has served since 
1991 as the Director of the Office of Technology 
Transfer (OTT), National Institutes of Health (NIH), 
Department of Health and Human Services (HHS). 
OTT manages the patenting and commercial licens-
ing of a large portfolio of NIH and FDA intramural 
inventions and contributes to the HHS’s intramural 
and extramural technology transfer policy. OTT li-
censees have brought to market well over 100 prod-
ucts, 25 of which are FDA-approved; in 2005, the 
licensee sales generated by these products approached 
US$5 billion. OTT also advises NIH on the terms and 
conditions of funding agreements with respect to in-
tellectual property, material transfer, and data rights. 
Dr. Rohrbaugh serves as Vice-Chair of the Public 
Health Service Technology Transfer Policy Board 
and represents the HHS on the National Science and 
Technology Council Technology Committee. He has 
represented the HHS at meetings of the World Health 
Organization (WHO), the Organisation for Economic 
Co-operation and Development (OECD), and the 
United Nations Industrial Development Organization 
(UNIDO).
Dr. Rohrbaugh previously served as Director of the 
Office of Technology Development at the National 
Institute of Allergy and Infectious Diseases (NIAID), 
where he managed a staff that was responsible for the 
negotiation of technology transfer agreements between 
industry and academic institutions for the conduct of 
NIAID intramural basic and clinical research and extra-
mural cooperative networks. 
Prior to joining the NIH, Dr. Rohrbaugh conducted 
molecular and cell biology research in academic and 
industrial laboratories. He received his Ph.D. in bio-
chemistry from The Pennsylvania State University and a 
degree in law with honors from The George Washington 
University Law School, where he served as an Articles 
Editor for American Intellectual Property Law Association 
Quarterly. 
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ROSS, gavin S.
Gavin Ross is Vice President of Business Development 
for HortResearch (USA), a U.S. subsidiary of 
HortResearch, a New Zealand fruit research company. 
He has held a number of positions within HortResearch. 
In the 1990s, he established a laboratory that focused on 
the genes and enzymes involved in apple fruit ripening. 
In 1997, he took over the leadership of the postharvest 
science group of HortResearch, which was one of the 
largest research groups in this area in the world. Three 
years later, he was part of the team that raised the funds 
to launch HortResearch’s fruit genomics program, and 
he led the program in its early phases. In recent years, he 
has made the transition from science to business devel-
opment. His experience includes several years working 
at a publicly listed New Zealand biotechnology com-
pany. In his current role, he represents HortResearch in 
the U.S. market and is building a genuine presence for 
the company in North America. He is actively involved 
in product development and support, as well as technol-
ogy licensing. 
RyAN, Camille D.
A self-professed “late bloomer,” Camille D. Ryan began 
her academic career after working for several years in 
the local agricultural biotechnology industry. She first 
worked with a small plant biotechnology company 
that specialized in developing proprietary technologies 
and cloned plant varieties for mine reclamation work 
and site remediation. Subsequently, she moved into a 
position with the biotechnology department of a large 
multinational corporation that specializes in crop pro-
duction, and worked on cross-functional team efforts 
to bring the first genetically modified canola varieties 
to the market. 
Throughout her academic career, Ms. Ryan has been 
involved in a number of research projects, including 
the Innovation Systems Research Network’s “Cluster 
Initiative,” which examines intellectual property struc-
tures and innovation in the Saskatoon agricultural 
biotechnology cluster. Her links with local industry 
have been a natural segué for her collaborations with 
the National Research Council’s Plant Biotechnology 
Institute (NRC-PBI) and the Industrial Research 
Assistance Program (IRAP), as well as with the Canadian 
Light Source Synchrotron (CLS). Currently, Ms. Ryan 
works as a research assistant for Genome Canada’s 
GE3LS project. She conducts theoretical, empirical, and 
policy analysis that explores the management of intellec-
tual property in genomics-based research projects. She 
is currently in the process of finalizing her Ph.D. dis-
sertation in Interdisciplinary Studies at the University 
of Saskatchewan. 
RygNESTAD, hild
Hild Rygnestad provides consulting services in the area 
of project controls, as well as economic and financial 
analyses, to a range of private and public sector cli-
ents with operations in the international marketplace. 
In particular, she focuses on cost controls, contract 
management, and risk analysis. Before becoming an 
independent consultant, Dr. Rygnestad worked as a 
Program Associate with the Strategic World Initiative for 
Technology Transfer (SWIFTT) at Cornell University, 
where she was responsible for the development, design, 
and maintenance of a contract management database 
and a Web-based course in intellectual property man-
agement. Previously, Dr. Rygnestad had worked as a 
researcher with the Danish Research Institute of Food 
Economics, where she conducted research in the area of 
agricultural economics, especially analyses of environ-
mental economics and policy. Dr. Rygnestad’s scientific 
education is in agricultural economics. She holds a B.Sc. 
from the Agricultural University of Norway and a Ph.D. 
from the University of Western Australia.
SALICRuP, Luis A.
Luis A. Salicrup serves as Senior Advisor for International 
Technology Transfer Activities at the Office of Technology 
Transfer (OTT) in the Office of the Director of the 
National Institutes of Health (NIH). He leads OTT’s 
efforts to transfer public health service technologies 
from NIH and the Food & Drug Administration (FDA) 
to institutions in developing countries in order to solve 
global health problems. Dr. Salicrup also developed and 
implemented The International Training Program for 
NIH OTT. The goal of this program is to provide prac-
tical experience in relevant areas of global health to staff 
from public and private institutions located in develop-
ing countries. Dr. Salicrup is also responsible for teach-
ing the courses “Technology Transfer,” “Biomedical 
Business Development and International Strategic 
Partnering,” and “Biotechnology Business Leadership” 
at NIH’s Foundation for Advanced Studies.
Before joining OTT, Dr. Salicrup was International 
Health Research Scientist/Program Director at NIH’s 
Fogarty International Center. Before working at NIH, 
Dr. Salicrup was CEO and President of Techno-Sur 
and Associates, a consulting firm that provides interna-
tional health, technology management, and university-
industry alliances services to international and regional 
organizations, as well as to government agencies and 
universities worldwide. Dr. Salicrup received his Ph.D. 
in microbiology and molecular genetics from Rutgers 
University. He also holds a Master’s in Technology 
Management. After completing postdoctoral training at 
Princeton University and NIH, he served as Manager of 
the Divisions of Quality Control and Technical Support 
at Baxter Diagnostics International Inc. and was 
Associate Professor of Microbiology and Immunology 
at the Inter American University and the University 
of Puerto Rico. Dr. Salicrup is a member of numerous 
professional organizations and has published in several 
scientific journals. 
SALIM, Emil
Emil Salim is on the faculty of economics at the 
University of Indonesia. Previously, he was the State 
Minister for Population and Environment from 1978 
to 1993. He currently serves as a member of many inter-
national and national committees, including the United 
Nations High Level Advisory Board on Sustainable 
Development. He serves as Chairman of the National 
Economic Board, an economic expert team to President 
Abdurachman Wahid. He was a member of the eco-
nomic expert team to President Suharto on debt and 
development issues of the nonaligned countries, and a 
member of the Indonesian Peoples’ Assembly. In addi-
tion, he was Co-chairman of the World Commission on 
Forestry and Sustainable Development. 
AUTHOR BIOS
1964 | HANDBOOK OF BEST PRACTICES
Dr. Salim also serves as Chairman of the Board of 
Trustees for a number of leading Indonesian envi-
ronmental organizations, including the Indonesian 
Biodiversity Foundation, the Foundation for Sustainable 
Development, and the Indonesian Ecolabelling Institute. 
He received his master’s degree and his doctorate in eco-
nomics from the University of California, Berkeley, in 
the United States.
SALLES-FILhO, Sergio
Sergio Salles-Filho is a full professor at the Department 
of Science and Technology Policy at the State University 
of Campinas, SP, Brazil. He earned a B.S. in Agronomic 
Engineering at the Rural Federal University of Rio de 
Janeiro in 1980. He earned his Master’s degree at the 
State University of São Paulo in 1985 in the biological 
treatment of agro-industrial wastes. Since then, he has 
dedicated himself to studies of the social ramifications 
of science, technology, and innovation. His first studies 
were technological assessments, with a specialization in 
the impact of modern biotechnology on less developed 
countries. 
In 1995, he founded, with a group of colleagues, 
the Study Group on Organization of Research and 
Innovation (GEOPI), which is dedicated to the de-
velopment of theoretical and empirical studies of the 
management of technology and innovation. Nowadays, 
his main areas of research are the organization of areas 
and institutions of ST&I, technological assessment and 
institutional evaluation, technological prospective, and 
intellectual property and financing in ST&I.
SANDELIN, Jon
Jon Sandelin graduated from the University of 
Washington with a degree in Chemistry in 1962, served 
four years as a Naval Officer on the U.S. submarine 
Ronquil, and then earned an M.B.A. from Stanford 
University in 1968. He returned to Stanford University 
in 1970 as the Financial Officer of the Stanford 
Computer Center; he later became the Associate 
Director of the Center. He joined Stanford’s Office of 
Technology Licensing (OTL) in 1984. At the OTL, he 
was responsible for licensing all forms of intellectual 
property, including inventions, computer software, 
and university trademarks. Mr. Sandelin has served as 
a consultant for the licensing of research-related inven-
tions to other universities, nonprofit research organiza-
tions, and governments. He is the author of many arti-
cles on technology transfer through licensing, and has 
given numerous workshops and presentations on this 
topic in the United States and overseas. Mr. Sandelin 
served two terms as a vice president of the Association 
of University Technology Managers (AUTM), where 
he was responsible for developing AUTM’s overseas re-
lationships. He is also past president of the Association 
of Collegiate Licensing Administrators (ACLA). On 
July 1, 2002, he was selected to serve a three-year term 
on the Public Advisory Committee for the U.S. Patent 
and Trademark Office (USPTO). This Committee 
prepares an annual report for the U.S. President and 
Congress on the operations of the USPTO. He was 
granted emeritus status in March 2003, and now de-
votes most of his time to consulting projects, primarily 
for overseas clients.
SASSON, Albert 
Professor Albert Sasson, a Moroccan, is a world-re-
nowned international consultant in biotechnology. He 
has authored more than 200 publications concerning his 
research and popularization activities in soil microbiol-
ogy, algology, and agrobiology. He has published books 
and contributed to publications on biology teaching, 
environment and development issues, biotechnologies, 
and food and nutrition. Biotechnologies in Developing 
Countries is one of his outstanding publications. 
Professor Sasson is a prolific speaker, with invalu-
able information and insight in the areas of cloning, 
genetically modified foods, the use of biotechnology in 
agriculture and its possible impact on man and the envi-
ronment, and ethical and legal issues related to biotech-
nology. He has expert knowledge of how biotechnology 
can reduce poverty and the successes and failures of its 
application worldwide. 
After a career as a university dean, he joined UNESCO 
in 1974, where he served as Special Advisor to the UN 
for over 27 years. Since January 2000, Prof. Sasson has 
been senior consultant to UNESCO, Moroccan institu-
tions, and the company Publicis Dialog (Paris). He pro-
vides special advice to governments worldwide on the 
development of national policies on biotechnology, and 
is an advocate for the adaptation of technologies by the 
third world for their social and economic development. 
Professor Albert Sasson is a man with a passion for 
science, especially for discoveries in the life sciences. 
He is truly fascinated with the application of science to 
food, agriculture, medicine, pharmaceuticals, energy, 
the environment, and bio-remediation.
SATyANARAyANA, Kanikaram 
Kanikaram Satyanarayana holds a doctorate degree in 
biosciences. After a brief postdoctoral stint, he joined 
the Council of Scientific and Industrial Research in 
New Delhi. In 1980, he moved to the Indian Council 
of Medical Research (ICMR). He is involved in science 
and technology policy and evaluation, and is Chief of 
the Intellectual Property Rights Unit. For over twenty 
years, he has worked extensively in the areas of science 
and technology evaluation and science policy issues; he 
was instrumental in the formulation of Indian national 
policies in these areas.
In 1996, Dr. Satyanarayana published the first guide-
lines for promoting industry-academia partnerships in 
medical research in Contract Research, Consultancy and 
Technology Transfer policy of the ICMR. These guidelines 
are currently being revised to be in agreement with the 
new WTO and IPR regimes. He has organized several 
training workshops on WTO and IP rights issues for the 
benefit of scientists at ICMR institutes, medical colleges, 
and other institutes. Some of these training workshops 
were conducted with international funding (WHO). 
He set up the Intellectual Property Rights Unit at the 
ICMR in 1999 and brought out the Intellectual Property 
Rights Policy of ICMR in 2002. He is a member of sever-
al national committees on intellectual property and has 
participated in several national and international con-
ferences on such topics as globalization, the impact of 
TRIPS on public health, access to health care in devel-
oping countries, and so on. An active researcher, he has 
obtained competitive grants from various agencies in 
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India and the World Health Organization. He has also 
published several papers in national and international 
journals. He is closely associated with the U.K.-based 
Centre for the Management of intellectual property 
in Health R&D (MIHR) and has contributed to their 
Manual for Technology Transfer Managers. Currently, he 
is the only member of the International Editorial Board 
of the second edition of this Handbook who is from a 
developing country. He is a founder and Secretary of 
the Society for Technology Management, India, and is 
currently a Senior Deputy Director-General and Chief 
of the Intellectual Property Rights Unit at the ICMR.
SChNEIDERMAN, Anne M.
Anne M. Schneiderman is an intellectual property law-
yer in private practice in Ithaca, New York. A scientist 
and registered patent attorney, Dr. Schneiderman coun-
sels clients in a wide range of high-technology indus-
tries, including biotechnology, pharmaceuticals, medical 
devices, agroscience, and mechanical and electrical en-
gineering. Her law practice is involved in the following 
activities: worldwide patent procurement; conducting 
due diligence reviews for financings, collaborations, and 
partnering deals; the preparation of patentability, free-
dom-to-operate, noninfringement, and validity opin-
ions; and the analysis, development, and establishment 
of intellectual property portfolios.
Before establishing her law offices, Dr. Schneiderman 
served as in-house counsel and director of intellectual 
property for a high-technology start-up company. She 
then practiced for six years with Pennie & Edmonds 
LLP, a leading U.S. intellectual property law firm (now 
dissolved) in their Palo Alto and Manhattan offices. 
Dr. Schneiderman is a graduate of Stanford 
University, with degrees in biological sciences (B.S. with 
distinction) and law (J.D.). She also holds a Ph.D. in 
neurobiology from Harvard University. Before becom-
ing a lawyer, she was a neurobiologist with academic 
appointments at Cornell and Yale Universities. Dr. 
Schneiderman’s training in both science and law has 
allowed her to assist scientists, inventors, and manage-
ment teams in transforming their ideas into patentable 
inventions. 
SChuBERT, Karel R. 
Dr. Karel R. Schubert is internationally recognized for 
his academic and industrial work on plant and micro-
bial biochemistry, molecular biotechnology, metabolic 
engineering, and for his discovery of natural products 
and genes to control pests, pathogens, and parasites. 
Dr. Schubert received his B.S. degree in chemistry 
(Magna Cum Laude), from West Virginia University in 
1971, and M. S. and Ph.D. degrees in biochemistry from 
the University of Illinois, Urbana-Champaign, in 1973 
and 1975. After completing his doctoral degree, Dr. 
Schubert was a Research Fellow in the Department of 
Botany and Plant Pathology at Oregon State University. 
He received additional postgraduate training in nema-
tology at the University of California, Davis. He was 
an Assistant and Associate Professor of Biochemistry at 
Michigan State University, a Research Manager with 
Monsanto, Assistant Director of the Center for Plant 
Science and Biotechnology at Washington University, 
and Director of the Plant Genetic Resources Center at 
the Missouri Botanical Garden. 
From 1990 to 2000, Dr. Schubert held The 
George Lynn Cross Endowed Chair of Botany and 
Microbiology and OCAST Most Eminent Scholar at 
the University of Oklahoma. While in Oklahoma, Dr. 
Schubert also founded ProTech, Inc., an Oklahoma-
based start-up company, and served as Chief Executive 
Officer and Director of Research. In August 2000, Dr. 
Schubert joined the scientific and administrative staff of 
the Donald Danforth Plant Science Center, as the Vice 
President for Technology Management and Science 
Administration. As VP for Technology Management 
and Science Administration, Dr. Schubert has been in-
volved in technology transfer activities, patenting, and 
licensing within the agricultural and healthcare sectors. 
In addition to his administrative responsibilities, Dr. 
Schubert has focused on humanitarian projects, includ-
ing the nutritional biofortification of cereal and root 
crops. Dr. Schubert has been involved in the formation 
of PIPRA and served as the Chairman of its Executive 
Committee.
SEKI, Akinori
Akinori Seki is president of the Sasakawa Peace 
Foundation (SPF), an organization committed to fos-
tering international understanding, exchange, and co-
operation. Seki studied at the Gakushuuin University 
of Economics and received his Ph.D. from the London 
School of Business.
He worked for many years for the Marubeni 
Corporation, where he became General Manager 
(Strategies and Coordination) and Deputy Executive 
Officer (Corporate Strategies Department). He also 
lived in Africa briefly as President of Gambia Fisheries’ 
Co. Ltd. He joined the SPF in 1999, initially as Program 
Director, before becoming Chief Operating Officer, 
then Executive Director, and now President.
He has served as an advisor to many organizations, 
including the Myanmar Economic and Management 
Institute, the United Nations Industrial Development 
Organization (UNIDO), and the University of 
Cambodia, and he was a committee member of 
KEIDANREN and of the study group for Indo-China. 
He serves on the Board of Directors of the Bellagio 
Forum and is Member of the Advisory Committee, 
UNIDO (Tokyo Office). He is an Honorary Professor 
of Tafaccur University, in the Republic of Azerbaijan.
SERAgELDIN, Ismail
Ismail Serageldin is Director of the Library of Alexandria 
and also chairs the Boards of Directors for each of the 
Biblioteca Alexandria’s affiliated research institutes 
and museums. He is also a Distinguished Professor at 
Wageningen University in the Netherlands. He serves as 
Chair and Member of a number of advisory committees 
for academic, research, scientific and international in-
stitutions and civil society efforts, including the Institut 
d’Egypte (Egyptian Academy of Science), TWAS (Third 
World Academy of Sciences), the Indian National 
Academy of Agricultural Sciences, and the European 
Academy of Sciences and Arts. He is former Chairman 
of the Consultative Group on International Agricultural 
Research (CGIAR, 1994-2000), Founder and former 
Chairman of the Global Water Partnership (GWP, 
1996-2000) and the Consultative Group to Assist the 
Poorest (CGAP), a microfinance program (1995-2000). 
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Serageldin has also served in a number of capacities 
at the World Bank, including as Vice President for 
Environmentally and Socially Sustainable Development 
(1992-1998), and for Special Programs (1998-2000). 
He has published over 50 books and monographs 
and over 200 papers on a variety of topics, including 
biotechnology, rural development, sustainability, and 
the value of science to society. He holds a Bachelor of 
Science degree in engineering from Cairo University 
and a Master’s and Ph.D. from Harvard University. He 
has received 19 honorary doctorates. 
ShEVELuKhA, Victor S. 
Victor Shevelukha was born in 1929, currently lives in 
Moscow, and is head of the Agricultural Biotechnology 
Department, Russian State Agrarian University, Moscow. 
He is a member of the V.I. Lenin All-Union Academy 
of Agricultural Sciences (VASKhNIL), the Russian 
academy of Agricultural Sciences, the International 
Academy of Agrarian Education, the Slavonic Academy, 
the Agrarian Academy of the Belarus Republic, the 
International Academy of Informational Sciences, and 
the Academy of Natural Sciences, among other public 
academies.
Victor has authored more than 400 scientific works, 
including 10 monographs and manuals on plant pro-
duction, plant breeding, seed production, agricultural 
biotechnology, plant physiology, and agricultural eco-
nomic policy. He has advised 45 Ph.D. students and 
12 doctors of sciences and is currently Chairman of the 
Scientific Council in RSAU-MAAS, which confers doc-
torate degrees in the fields of genetics, biotechnology, 
plant breeding, and seed production.
He worked as a senior agronomist at MAAT’s train-
ing farm, Druzhba, in the Yaroslavl region (1955-
1957); as a secretary of the Ryazantcev CPSU district 
committee, Yaroslavl region (1957-1959); as the head 
of agricultural department, Yaroslavl CPSU regional 
committee; as the first vice-chairman of Yaroslavl re-
gional executive committee (1959-1964); as senior 
lecturer, associate professor, professor, and head of 
Crop Science Department at the Belarus Agricultural 
Academy (1964-1973); the director of Belarus Research 
Institute for Arable Farming (1973-1974); a secretary 
of the Central Committee, Belarussia Communist Party 
(1974-1979); a Deputy Minister of Agriculture of the 
USSR; a member of Collegium in the USSR Ministry 
of Agriculture (1979-1983); academic-secretary of Plant 
Production and Breeding Department, V.I. Lenin All-
Union Academy of Agricultural Sciences and Russian 
Academy of Agricultural Sciences (1983-1994); a depu-
ty of the State Duma, Federal Assembly of the Russian 
Federation; and vice-chairman of the Committee for 
Education & Science, the State Duma (1994-2000).
Prof. Shevelukha is also a member of both the Russian 
Federation Union of Writers and the Russian Federation 
Union of journalists. He has written and published 10 
volumes of fiction and sociopolitical journalism. 
Finally, Victor has been awarded the K.A. Timiryazev 
and V.I. Vernadsky gold medals, orders and medals of the 
USSR, Russia, and foreign countries, and honorary deeds 
and titles from the State Duma (Russian Parliament), 
the Federal Assembly of the Russian Federation, the 
Ministry of Agriculture, and the Ministry of Education 
and Science.
ShORT, Jay M.
Jay M. Short is the Founder, President, and Chairman 
of the E.O. Wilson Biodiversity Foundation. He has 
more than 20 years’ experience working in biotechnol-
ogy-based businesses, environmentally compatible devel-
opment, and the commercialization of products derived 
from biodiversity. He is a Founder of Diversa and has 
also served as its CEO, President, and CTO. During his 
tenure, the company established the first agreement ever 
negotiated with a National Park to access biodiversity for 
commercial development. Under Dr. Short’s steward-
ship, Diversa established similar pioneering agreements 
with Russia, Ghana, Kenya, Mexico, Bermuda, and 
Indonesia. These agreements were in alignment with and 
even exceeded the recommendations of the Convention 
on Biological Diversity. The company was also the first 
to generate biodiversity access royalties for Costa Rica.
Dr. Short led the company’s highly successful initial 
public offering (IPO), which raised over $200 million 
in gross proceeds; at the time, it was the largest biotech-
nology IPO ever completed. His team also raised $300 
million in committed funding from corporate partners, 
including Novartis, Syngenta, Dow, Merck, Dupont, 
Danisco, Givaudan, and Cargill. Dr. Short invented key 
genomic technologies for the discovery and optimiza-
tion of products from microbial genes and gene path-
ways; these technologies are used in industrial, chemical, 
agricultural, and pharmaceutical applications. Under 
his leadership, Diversa was one of Deloitte and Touche’s 
“Technology Fast 50” for every year following the com-
pany’s IPO. Dr. Short also directed industry-leading ef-
forts in bioethics through Diversa’s pioneering practice 
of establishing equitable benefit-sharing relationships 
with countries that provided genetic materials.
Before joining Diversa, Dr. Short served as President 
of Stratacyte and V.P. of R&D and Operations at 
Stratagene. Dr. Short earned his B.A. in chemistry at 
Taylor University and his Ph.D. in biochemistry at 
CWRU. He is the author of more than 100 publica-
tions and is named as inventor on more than 100 is-
sued patents. His patents were cited by MIT Magazine as 
among the top 10 in the world both in 2003 and 2004 
across all industries. He received San Diego’s 2001 E&Y 
Entrepreneur of the Year Award and was the recipient of 
two first-place awards granted by the UCSD-Connect 
Program, which recognizes innovation in biotechnology. 
In 2003, he received the ABL Innovations in HealthCare 
Gold Award; in 2004, he received the Henry F. Whalen, 
Jr. Award for Business Development from the ACS. 
Dr. Short has served on the National Research Council 
(NRC) panel for the National Institute of Standards and 
Technology (NIST) and numerous other governmen-
tal committees. He currently serves as a Director for 
Invitrogen, Senomyx, and Anaptys. He is Entrepreneur-
in-Residence for UCSD-Connect. In addition, he is an 
advisor for City National Bank, a fellow of the Explorer’s 
Club, and is founder and co-owner of Capia IP.
ShOTWELL, Sandra L.
Sandra L. Shotwell is a Founder and Managing Partner 
of Alta Biomedical Group, a consulting firm specializing 
in technology commercialization. Her current clients at 
Alta Biomedical Group include both early-stage and es-
tablished companies, as well as research institutions and 
nonprofit organizations. 
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Dr. Shotwell has over 20 years’ experience in man-
aging technologies on behalf of U.S. and international 
research organizations and corporations. She has ex-
tensive experience in license negotiation, the develop-
ment of business strategies, and the management of 
research administration. Her technology management 
experience includes positions at Stanford University 
and the European Union’s Joint Research Center. She 
established the National Institutes of Health (NIH) 
Technology Licensing Branch, where she directed li-
censing for the NIH, the Centers for Disease Control, 
and the Food and Drug Administration. She served as 
Director of Technology and Research Collaborations 
at Oregon Health Sciences University (OHSU), where 
she was responsible for technology licensing, company 
spinouts, research grants and contracts, and company-
sponsored research. While at OHSU, she assisted in the 
creation of six new spinout companies. 
Dr. Shotwell currently serves on the Board of 
Directors of the Oregon Bioscience Association and the 
International Sustainable Development Foundation. She 
has previously served on the Boards of Virogenomics, 
Inc., the Stanford OTL Gap Fund, and the Association 
of University Technology Managers. She is active in the 
Licensing Executives Society and the Association of 
University Technology Managers. Dr. Shotwell did her un-
dergraduate work at Princeton University, earned a Ph.D. 
in Biology from the California Institute of Technology, 
and did postdoctoral research in Neurobiology at 
Stanford University School of Medicine.
SLATE, Peter J.
Peter J. Slate is the founding Chief Executive Officer of 
Arizona Technology Enterprises, the technology licens-
ing and venturing arm of Arizona State University. Mr. 
Slate has extensive experience as an entrepreneur and 
advisor to emerging and start-up venture companies. He 
has also held senior business development and strategy 
positions with public and private companies, including 
Baxter International, where he was Director of Corporate 
Strategy and the founder of Baxter’s Global Technology 
Outlicensing Group, and Zenith Electronics, where he 
played a key role in the company’s operational and fi-
nancial restructuring. Prior to joining Zenith, Mr. Slate 
was the Vice President and Associate General Counsel 
of Primecare International, Inc., a leading physician 
practice management company, where he oversaw ac-
quisitions and financing transactions. Mr. Slate began 
his career as a corporate attorney with the law firm of 
Katten, Muchin, and Zavis in Chicago, specializing in 
mergers and acquisitions, securities, private equity, and 
technology development transactions. 
Mr. Slate has a B.A. from the University of 
Michigan, a Juris Doctorate from George Washington 
University, and a Master’s in Business Administration 
from the Kellogg Graduate School of Management at 
Northwestern University. He has served on a number 
of corporate and philanthropic Boards of Directors 
and is a past Chairman of the Chicago Chapter of the 
Licensing Executives Society (LES). Mr. Slate lectures 
regularly on the subjects of technology and investment 
due diligence, venture capital, strategic alliances, and 
licensing.
SLOMAN, Robert g.
In May 1992, Robert G. Sloman acquired exclu-
sive rights to develop and license technology transfer 
management software from his former employer, 
Washington Research Foundation. The software was 
originally designed by Mr. Sloman and his WRF team. 
In October 1992, he founded Inteum Co. and began to 
develop and license the software. Inteum Co. has grown 
to be the leader in its field, with software installations 
across North America and around the world. The head 
office of Inteum is in Kirkland, Washington, and there 
is a branch office in Akron, Ohio. Inteum has long-term 
business relationships with several companies that con-
tribute to its services and products. In 2000, the origi-
nally licensed software was superseded by a completely 
new system, designed in-house and called Inteum C/S. 
Mr. Sloman has hired and trained a highly successful 
team of individuals with diverse backgrounds and estab-
lished Inteum Co. LLC as an internationally recognized, 
vital, and successful organization. The team members 
are also company shareholders. 
Mr. Sloman had prior professional experience with 
Flow Systems, Inc. in Kent, Washington and Monsanto 
Australia Ltd. in Melbourne, Australia. He has devel-
oped an effective management style and a structured, 
managed approach to growth, focusing on managing 
talented people effectively and providing a rigorous in-
frastructure to support them. 
SODERSTROM, Jon
Jon Soderstrom is currently the Managing Director of the 
Office of Cooperative Research at Yale University. The 
Office manages the intellectual assets created at Yale in 
order to achieve the maximum benefit for the public and 
provide a financial return that will support the university’s 
research efforts. He is responsible for (1) developing and 
managing the intellectual property portfolio, (2) defining 
and executing commercialization strategies, including the 
negotiation of licenses and corporate-sponsored research 
agreements, and (3) developing and marketing business 
concepts for new spin-off ventures to the investment com-
munity. Since joining the Office in 1996, he has partici-
pated in the formation of more than 25 new ventures, 
including polyGenomics, Molecular Staging (acquired 
by Qiagen), Agilix, Asilas Genomic Systems, Achillion 
Pharmaceuticals (NASQ: ACHN), PhytoCeutica, 
Protometrix (acquired by Invitrogen), Iconic Therapeutics, 
Applied Spine Technologies, HistoRx, and VaxInnate. 
Collectively, these companies have raised over $350 mil-
lion in professional venture capital.
Prior to holding this position, Dr. Soderstrom was the 
Director of Program Development for Oak Ridge National 
Laboratory (ORNL); previously, he had served for ten 
years as Director of Technology Licensing for Martin 
Marietta Energy Systems. In the Office of Technology 
Transfer, he directed a group of ten professionals responsi-
ble for negotiating licenses and Cooperative Research and 
Development Agreements (CRADAs). Dr. Soderstrom 
was a founding board member and past president of the 
Association of Federal Technology Transfer Executives. 
He is also a member of the Licensing Executive Society 
and the Association of University Technology Managers 
(AUTM). He is the President-Elect of AUTM, has served 
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as Vice President for Public Policy, and is a member of 
the Board of Directors and Executive Committee. He is 
frequently asked to lecture and teach seminars on various 
aspects of the technology transfer process and economic 
development both within the United States and abroad. 
He has testified before Congress on technology transfer 
issues and served as an expert witness in patent infringe-
ment litigation.
In addition to his professional accomplishments, Dr. 
Soderstrom was honored as the 87th “Point of Light” by 
President George H. W. Bush in March of 1990 for his 
volunteer work in constructing and rehabilitating low-
income housing in East Tennessee. Dr. Soderstrom re-
ceived his Ph.D. from Northwestern University in 1980 
and his A.B. from Hope College in 1976.
SOEJARTO, D. D. 
A plant taxonomist and economic botanist by train-
ing, Professor Soejarto is best known for his more than 
40 years of plant exploration work, which covers more 
than 20 countries. He has established three Herbarium 
Research Institutions (in Colombia, the Philippines, 
and Vietnam). He was honored as Founder of the 
Herbarium of the University of Antioquia (Medellin, 
Colombia), during a 2004 national conference on 
medicinal plants that celebrated the founding of the 
herbarium and the deposit of its 100,000th specimen. 
During his exploration program in Southeast Asia un-
der the U.S. National Cancer Institute’s funding (1986-
2004), the anti-HIV calanolides were discovered from a 
species of Calophyllum trees of Malaysia. 
He is a co-author, together with the NCI scientists, 
of the calanolides patent, and was elected University of 
Illinois Senior University Scholar, 1996-1999. He devel-
oped an expertise in pharmacognosy and IP issues as a 
result of a long period of association with chemist and bi-
ologist colleagues, as well as with the Office of Intellectual 
Property/Technology Management at the University of 
Illinois, Chicago. He has served as Editor of Journal of 
Ethnopharmacology (1988-2004), and is currently a mem-
ber of the editorial board of five scientific journals. He has 
been a recipient of an NIH/FIC ICBG grant as Principal 
Investigator for two cycles (1998-2003; 2003-2008), and 
is author and co-author of more than 200 scientific pa-
pers and book chapters, and three books.
SOMERSALO, Susanne
Susanne Somersalo has her Ph.D. in Plant Physiology 
from the University of Turku, Finland. After an academ-
ic career at the University of Turku and University of 
Helsinki, Dr. Somersalo served several years in Helsinki 
University’s licensing office as project manager and re-
search evaluator. She then earned a master’s degree in 
Intellectual Property Law at Franklin Pierce Law Center, 
New Hampshire, U.S.A. She is a registered patent agent 
with the U.S. Patent and Trademark Office and current-
ly works as an IP specialist in the Washington, D.C.- 
based law firm Dodds and Associates. 
SOuThAVONg, B. h.
Professor Bounhong Southavong is a pharmacist and 
pharmacognosist with special expertise in the study of 
Lao Traditional Medicines, especially medicinal plants. 
Since 1997, he has been Director of the Traditional 
Medicine Research Center, Ministry of Health of Laos, 
Vientiane, Lao P.D.R. He is also President of the Council 
of Medical Sciences, and has been Vice President of the 
National Ethic Committee on Medical Sciences Research, 
and of the Council of Medical Care Professionals of the 
Ministry of Health of Laos. The Project Leader of an 
ICBG program since 1998, he has the responsibility of 
implementing research on the studies of medicinal plants 
of Laos. One outcome of this ICBG program is the Lao 
Biodiversity Fund (LBF), established in 2004, for which 
he serves as Vice President. The mission of LBF is to pro-
mote the sustainable utilization of Lao plant resources, 
the conservation of biodiversity (in particular, medicinal 
plants), community development, and the protection of 
Lao Traditional Medicines.
STEINBOCK, Martha Bair
Martha Bair Steinbock serves as the Deputy Assistant 
Administrator, Office of Technology Transfer, Agricultural 
Research Service (ARS), U.S. Department of Agriculture 
(USDA), in Beltsville, Maryland. In this capacity, she 
helps oversee the national technology transfer efforts of 
the USDA, including the development of cooperative re-
search agreements. She also serves as the U.S. Executive 
Secretary for the US-EC Task Force on Biotechnology 
Research. Prior to becoming Deputy Assistant 
Administrator, Ms. Steinbock was the Technology 
Transfer Coordinator for the Pacific West Area of ARS. 
She has also worked as an international affairs special-
ist for the USDA Office of Agricultural Biotechnology 
and the USDA Foreign Agricultural Service. Prior to 
joining USDA, she worked as a consulting econo-
mist for the Food and Agriculture Organization of the 
United Nations in Rome, Italy. Ms. Steinbock received 
a Masters degree in International Affairs from the Johns 
Hopkins University, School of Advanced International 
Studies, and did her undergraduate studies at Portland 
State University and Reed College, in Portland, Oregon. 
Ms. Steinbock is a native of northern California, where 
she was raised on a family farm.
STEVENS, Ashley J.
Dr. Stevens has been Director of the Office of Technology 
Transfer at Boston University since 1995 and is also 
Director for Research Programs in the Institute for 
Technology Entrepreneurship and Commercialization 
in the School of Management, where he teaches a 
graduate level, inter-disciplinary course on Technology 
Commercialization. Before joining Boston University, 
he was Director of the Office of Technology Transfer at 
the Dana-Farber Cancer Institute, a teaching affiliate of 
the Harvard Medical School. 
Prior to entering the technology transfer profession, 
Dr. Stevens worked in the biotechnology industry for 
nearly ten years. He was a co-founder of Kytogenics, 
Inc., where he is still a Director. He was also co-found-
er and General Manager of Genmap, Inc., and Vice 
President of Business Development for BioTechnica 
International. He started his career with The Procter & 
Gamble Company, where he held a number of positions 
in sales, marketing, strategic planning, and acquisitions. 
Dr. Stevens is very active with the Association of 
University Technology Managers, most recently as Vice 
President, Annual Meeting and Surveys, and publishes 
and lectures frequently on many aspects of technology 
transfer, including the Bayh-Dole Act, the economic 
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impact of technology transfer and its role in economic 
development, and the role of technology transfer in 
global health and technology valuation. AUTM pre-
sented him with the Bayh-Dole Award for 2007. Dr. 
Stevens holds a Bachelor of Arts in Natural Sciences, 
and a Master of Arts and a Doctor of Philosophy in 
Physical Chemistry from Oxford University. 
STREITZ, Wendy D.
Wendy D. Streitz is the Director of Policy, Analysis, 
and Campus Services (PACS) in the University of 
California’s central Office of Technology Transfer. The 
PACS unit coordinates the system-wide technology 
transfer program and has wide-ranging responsibilities, 
including developing and implementing policies, pro-
viding guidance for campuses and external entities re-
garding the University’s policies and practices, training, 
and legislative analysis.
Prior to joining the University of California, Ms. 
Streitz was Associate Director of Intellectual Property 
and Technology Transfer at Auburn University in 
Alabama, where she was directly involved in the broad 
spectrum of technology transfer. Her caseload included 
technologies from both the physical and life sciences. 
Previously, she had spent twelve years as an electrical 
engineer and engineering manager at Westinghouse 
Electric Corporation, holding leadership positions in 
radar signal processing.
Ms. Streitz received a BS in Engineering from Harvey 
Mudd College and an MSEE from Johns Hopkins 
University.
SWAMINAThAN, M. S.
Professor M. S. Swaminathan has been acclaimed by 
TIME magazine as one of the twenty most influen-
tial Asians of the 20th century, one of the only three 
from India, the other two being Mahatma Gandhi and 
Rabindranath Tagore. He has been described by the 
United Nations Environment Programme as “the Father 
of Economic Ecology,” and by Javier Perez de Cuellar, 
Secretary General of the United Nations, as “a living 
legend who will go into the annals of history as a world 
scientist of rare distinction.” He was Chairman of the 
UN Science Advisory Committee, set up in 1980 to 
take follow-up action on the Vienna Plan of Action. He 
has also served as Independent Chairman of the FAO 
Council and President of the International Union for 
the Conservation of Nature and Natural Resources. He 
is the current President of the Pugwash Conferences on 
Science and World Affairs. 
A plant geneticist by training, Professor 
Swaminathan’s contributions to the agricultural renais-
sance of India have led to his being widely referred to as 
the scientific leader of the green revolution movement. 
His advocacy of sustainable agriculture leading to an 
“evergreen revolution” has made him an acknowledged 
world leader in the field of sustainable food security. The 
International Association of Women and Development 
conferred on him their first international award for his 
significant contributions to promoting the knowledge, 
skill, and technological empowerment of women in ag-
riculture, and for his pioneering role in mainstreaming 
gender considerations in agriculture and rural develop-
ment. Professor Swaminathan was awarded the Ramon 
Magsaysay Award for Community Leadership in 1971, 
the Albert Einstein World Science Award in 1986, and 
the first World Food Prize in 1987. 
Professor Swaminathan is a Fellow of many of the 
leading scientific academies of India and the world, 
including the Royal Society of London and the U.S. 
National Academy of Sciences. He has received 55 
honorary doctorate degrees from universities around 
the world. He currently holds the UNESCO Chair 
in Ecotechnology at the M. S. Swaminathan Research 
Foundation in Chennai (Madras), India, and was 
Chairman of the National Commission on Agriculture, 
Food, and Nutrition Security of India until October 
2006.
SyDARA, K.
Associate Professor Kongmany Sydara is a natural prod-
uct chemist with special expertise in the isolation of bio-
logically active compounds from Lao plants and in the 
standardization of Lao Traditional Medicines. He is the 
Deputy Director of the Traditional Medicine Research 
Center, Ministry of Health, Vientiane, Lao P.D.R. Since 
1998, he has served as a Co-Project Leader of an ICBG 
program, with responsibility for implementing the stud-
ies of medicinal plants of Laos. He is co-author of more 
than 10 scientific papers and books.
TARZIAN SORENSEN, J. A. 
Dr. Jill Tarzian Sorensen is Associate Provost and 
Director of the Office of Licensing and Technology 
Development at Johns Hopkins University. She is an IP 
lawyer with nearly 20 years of law and business experi-
ence. She has spent 18 of those years at the University 
of Illinois at Chicago, where she served as Assistant 
University Counsel and then Associate University 
Counsel beginning in 1987. In 1998, she became 
Director of Technology Management and Assistant Vice 
Chancellor for Research, reorganizing the office accord-
ing to a decentralized model responsive to the needs of 
the university’s schools and faculty. In five years, her of-
fice nearly doubled the university’s invention disclosures 
and the number of licenses it executed. The office also 
promoted new models of technology transfer, including 
leveraging intellectual property, particularly in global 
health, for sustainable economic development in devel-
oping countries. Last year, she assumed a new position 
as Director of Health Initiatives, building international 
partnerships focused on global health. 
TAuBMAN, Antony
Antony Taubman is currently Acting Director and 
Head of the Global Intellectual Property Issues Division 
(including the Traditional Knowledge Division and Life 
Sciences Program) of WIPO, a position he assumed 
in May 2002, with responsibility for programs on 
intellectual property and genetic resources, traditional 
knowledge and folklore, the life sciences, and related 
global issues. After a diplomatic career, he left the 
Australian Department of Foreign Affairs and Trade 
(DFAT) in 2001 to join the newly formed Australian 
Centre for Intellectual Property in Agriculture, at the 
Australian National University, teaching and researching 
on international IP law. From 1998 to 2001, he was 
Director of the International Intellectual Property 
Section of DFAT, and in that capacity was engaged in 
multilateral and bilateral negotiations on intellectual 
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property issues, domestic policy development, regional 
cooperation, and TRIPS dispute settlement. He has taken 
part in many training and capacity building programs 
on intellectual property law and TRIPS in Australia and 
a number of Asian countries. He has authored a training 
handbook on intellectual property and biotechnology, 
a comprehensive study on the implementation of the 
TRIPS Agreement, and a range of academic and general 
publications on international intellectual property 
law and policy. He has held a teaching appointment 
at the School of Law at the University of Melbourne, 
delivering a specialist postgraduate course on TRIPS 
Law and Practice.
He joined DFAT in 1988 as a career diplomat, and 
his service included disarmament policy and partici-
pation in the negotiations on the Chemical Weapons 
Convention, a posting in the Australian Embassy in 
Tehran as Deputy Head of Mission, and a posting to the 
Hague as Alternate Representative to the Preparatory 
Commission for the Organisation for the Prohibition of 
Chemical Weapons and Chair of the Expert Group on 
Confidentiality. He previously worked for WIPO from 
1995 to 1998; his duties then included development 
cooperation in Asia and the Pacific, the development 
of the revised WIPO program and budget, and associ-
ated policy development. A registered patent attorney, 
he worked in private practice in the law of patents, 
trademarks, and designs in Melbourne in the 1980s. 
His tertiary education has included computer science, 
mathematics, engineering, classical languages, philoso-
phy, international relations and law, and he has taught 
ancient Greek philosophy at Melbourne University.
TERNOuTh, Philip 
Philip Ternouth is the Associate Director for R&D and 
Knowledge Transfer at the Council for Industry and 
Higher Education (CIHE). He is also a Regional Advisor 
for Knowledge Transfer Partnerships, a U.K. govern-
ment-sponsored program that employs graduates who 
are supervised by researchers and work with companies 
on business transformation projects. He originally read 
Natural Sciences at Sidney Sussex College at Cambridge 
University. He then spent the next 11 years in research, ur-
ban regeneration projects, and management in the public 
sector. In 1985, he went into the IT industry, specializing 
in pre-sales consultancy. He then moved into marketing. 
In 1995, after five years of board-level appointments in 
small companies and management and marketing con-
sultancies, he joined Vuman Limited, the technology 
exploitation company of the University of Manchester, 
where he became Business Development Director. 
Since 2000, he has been active in a number of 
knowledge transfer activities, including researching 
and writing “Knowledge Transfer, Towards a Strategic 
Framework” and “The Business of Knowledge Transfer” 
for the Council for Industry and Higher Education. He 
has chaired the board of a start-up company, Manchester 
Geomatics Limited. Recently, he researched and co-
authored “International Competitiveness: Businesses 
Working with U.K. Universities.” He is currently en-
gaged in editing for publication a set of case studies that 
illustrate the support of entrepreneurship in and around 
Oxford. 
Mr. Ternouth is an active member of national 
and international organizations that provide mutual 
support and professional development in the trans-
fer of university technology to commercial applica-
tion. He has presented numerous papers on aspects of 
technology and knowledge transfer at conferences in 
the U.K., U.S., and Europe. He has also undertaken 
a number of consultancy assignments in the U.K. and 
overseas for research institutions and governments, 
assisting them in developing their knowledge trans-
fer agendas. He holds professional and postgraduate 
qualifications in marketing and is a member of the 
Institute of Directors.
ThANgARAJ, harry 
Harry Thangaraj is Director of Research at MIHR. He 
began his career as a doctor after graduating from the 
Christian Medical College, Vellore, India. After com-
pleting a Ph.D. in Microbial Genetics in London in 
1991, he worked until 2004 on various research projects 
involving pathogenic mycobacteria; he has several pub-
lications on this topic.
In 2005, Dr. Thangaraj completed a Master’s degree 
in Intellectual Property Management at Queen Mary 
University, London (QMUL), during which he was 
awarded a prize by Glaxo Smith Kline for highest scores 
in the Patent Law examinations. He worked as an in-
tern both at the Enterprise and Innovation Office of St. 
George’s University London and at Bristows, one of the 
U.K.’s largest and oldest firms specializing in IP law. In 
2006, he obtained a Certificate in Intellectual Property 
Law from QMUL, a foundational exam (part-qualifica-
tion) for U.K. Patent Attorneys. He is currently involved 
with “Global Access Strategies” and the creative uses of 
IP management for the Pharma-Planta Consortium, 
an E.U.-funded initiative to develop plant-derived bio-
pharmaceuticals for the treatment and diagnosis of dis-
eases that disproportionately affect poorer populations 
of the world.
ThOMSON, Jennifer A.
Jennifer Ann Thomson is Professor of Microbiology 
in the Department of Molecular and Cell Biology at 
the University of Cape Town, South Africa (UCT). 
Previously, she had held the positions of Head of the 
Department of Microbiology at UCT, the Director 
of the Laboratory for Molecular and Cell Biology at 
the Council for Scientific and Industrial Research, and 
Associate Professor in the Department of Genetics at the 
University of the Witwatersrand in Johannesburg. Her 
research involves the development of genetically modi-
fied maize that is resistant to the Maize streak virus (en-
demic to Africa) and tolerant to drought. She received 
an honorary doctorate from the Sorbonne University, 
Paris in 2005, and the UNESCO/L’Oreal award for 
Women in Science in 2004. She is Chair of the Board 
of the African Agricultural Technology Foundation, 
based in Nairobi, Kenya. She is a Director of the South 
African Pebble Bed Modular Reactor (Pty) Ltd. She has 
published a book, Genes for Africa: Genetically Modified 
Crops in the Developing World.
ThORNSTRöM, Carl-gustaf 
Carl-Gustaf Thornström is Associate Professor in social 
and economic geography. His teaching and research 
emphasize agricultural issues, natural resources mana-
gement, and geopolitics. He is also a guest researcher in 
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genetic policies at the Swedish Biodiversity Centre, an 
adviser to the Swedish University of Agricultural Sciences 
(Sida), and a referee to the Swedish Government office 
regarding genetic policy issues. For more than 20 years, 
Dr. Thornström has worked with policy issues related 
to international agricultural research at SAREC, a de-
partment for research cooperation within Sida (Swedish 
International Development Cooperation Agency). Dr. 
Thornström’s research focuses mainly on policy: genetic 
resources, intellectual property rights, and coherence is-
sues that affect international agreements and processes; 
specific topics include life patents, GMOs, protection of 
traditional knowledge, enclosure of the biological/gene-
tic commons, access to genetic resources, and proprie-
tary science. Dr. Thornström was born June 18, 1946. 
He is married, with two children.
TuCKER, William T.
William T. Tucker was born in the U.K. and educated 
in Australia. He holds a B.Sc. (Hons) and a Ph.D. in 
Microbiology from the University of Queensland. Dr. 
Tucker has held postdoctoral research fellowships at 
Stanford University (with Professor Stanley Cohen) 
and at the Research School of Biological Sciences at the 
Australian National University in Canberra, Australia. 
He also holds an M.B.A. degree from St. Mary’s College 
in Moraga, California.
Dr. Tucker’s career has focused on agricultur-
al biotechnology. During his ten-year tenure with 
Advanced Genetic Sciences, and later its successor 
organization, DNA Plant Technology, he worked first 
as a research scientist, and later in technology man-
agement and business development. He then joined 
Applera Corporation (Applied Biosystems in Foster 
City, California), where he was part of the team that 
licensed PCR technology for commercial applications. 
Dr. Tucker then joined the business development team 
at the agricultural genomics unit of Celera Genomics, 
where he sought out agricultural applications of mo-
lecular marker technology, high throughput sequenc-
ing, and related genomics platforms. He continued 
this work when Paradigm Genetics (based in North 
Carolina) acquired the plant-related part of Celera’s 
agricultural genomics business.
In 2003, Dr. Tucker joined the Office of Technology 
Transfer at the University of California, Office of the 
President (UCOP), in Oakland, California, where he 
focused on the licensing of plant varieties developed by 
scientists at U.C. Davis and U.C. Riverside. Since 2004, 
Dr. Tucker has been the Executive Director of Research 
Administration and Technology Transfer at UCOP.
VAN FLEET, Justin W. 
Justin W. van Fleet is the Founder and Principal edu-
cational consultant for The Advance Associates, an 
international education and development consulting 
company based in Washington, D.C. He specializes 
in the development of online and offline curricula, ca-
pacity-building and training programs, and evaluation 
methodologies for a variety of audiences. His most re-
cent intellectual property and indigenous knowledge 
project involved the development and facilitation of a 
training program for South African small-scale farmers 
on intellectual property rights to promote and protect 
indigenous knowledge and resources. 
Previously, he has held staff positions in educational 
capacities for NetAid (New York City), the Harvard 
University François-Xavier Bagnoud Center for Health 
and Human Rights (Boston), and the American 
Association for the Advance of Science’s Science and 
Human Rights program (Washington, DC). He holds 
a Master of Education from the Harvard University 
Graduate School of Education and is currently pursu-
ing his Ph.D. in International Education Policy at the 
University of Maryland.
VAN MONTAgu, Baron Marc
Baron Marc Van Montagu is an Emeritus Professor at 
Ghent University, and founder and Chairman of the 
Board of IPBO, the Institute for Plant Biotechnology 
for Developing Countries. He received a Ph.D. in or-
ganic chemistry/biochemistry from Ghent University 
in 1965, and served as the Director of the Department 
of Genetics at the Flanders Interuniversity Institute 
for Biotechnology, before joining the faculty at Ghent 
University in 1999. 
Dr. Van Montagu has made pioneering contribu-
tions to plant gene discovery, including the discovery 
of the gene transfer mechanism between Agrobacterium 
and plants, which was central to the development of 
transgenic plants. His work at the Lab of Genetics, 
Ghent University, produced two spin-off biotech com-
panies, Plant Genetic Systems (PGS) and Crop Design. 
His research at PGS led to the construction of the first 
herbicide tolerant plants, as well as the construction of 
the first plants producing the Bt (Bacillus thuringensis) 
insecticide. His was listed among the top 100 living 
contributors to biotechnology by The Scientist magazine 
and, until 2004, was the most cited scientist in the field 
of Plant and Animal Science. 
He is currently the President of the European 
Federation of Biotechnology (EFB) and the Chairman 
of the Public Research and Regulation Initiative 
(PRRI), and is a member of several other scientific advi-
sory committees. He has been granted numerous prizes 
and awards in recognition of his pioneering research, 
including the Japan Prize and the Theodor Bucher med-
al. In 1990, he was granted the title of Baron by King 
Baudouin of the Belgians.
VIJAyARAghAVAN, K.
K. Vijayaraghavan (Vijay) is a Certified Management 
Consultant (CMC) and a Fellow of the International 
Council of Management Consulting Institutes (ICMCI). 
He holds a Master’s degree and Fellowship in public ac-
counting and management consulting, with a focus on 
strategic and technology management consulting. He is 
the Chief Executive of Sathguru Management Consultants 
Pvt Ltd, a large consulting firm based in Hyderabad, 
India. Sathguru advises government organizations, mul-
tilateral and bilateral development institutions, private 
enterprises, and NGOs in several countries across the 
Asian region. Mr. Vijay is engaged in shaping a number 
of Indian policy initiatives in the life sciences, and is a 
member of selected national committees constituted for 
this purpose. Sathguru is also an Associate of the program 
Cornell-in-India. Mr. Vijay co-directs Cornell’s program 
in India, which also extends to several other countries in 
Asia. He is a Regional Coordinator for ABSPII South 
Asian activities (in India and Bangladesh). 
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VIKSNINS, Ann S.
Ann S. Viksnins is an acknowledged expert in PCT law. 
She prepares and prosecutes patent applications in the 
biological arts, including molecular biology, immunol-
ogy, plant sciences, and cellular biology. Ms. Viksnins 
graduated cum laude from St. Olaf College with a 
double major in biology and religion. At the University 
of Minnesota Law School, Ms. Viksnins earned a Juris 
Doctor degree cum laude and was an Editor of the 
Minnesota Law Review. Ms. Viksnins is also a graduate 
of the College of Biological Sciences at the University 
of Minnesota, where she earned a Master of Science 
degree in genetics. Ms. Viksnins has been practicing 
intellectual property law since 1992. She is a frequent 
writer and speaker on patent law issues, and has served 
in leadership roles in various professional organizations 
at the national level. Ms. Viksnins is a member of the 
Minnesota bar, a registered U.S. patent attorney, regis-
tered to practice before the U.S. Court of Appeals for 
the Federal Circuit, and the managing partner of the 
law firm of Viksnins Harris & Padys PLLP.
VILJAMAA, Kimmo
Kimmo Viljamaa is consultant at Advansis Ltd, Finland. 
He also works as a part-time researcher at the Research 
Unit for Urban and Regional Development Studies 
at the University of Tampere. His current work deals 
with various domestic and international development 
projects related to national and regional innovation 
policies. Recently, he has worked actively with these is-
sues, particularly in several Eastern European countries. 
Before taking his current positions, he worked for seven 
years at the University of Tampere on various research 
projects related to regional innovation policy and re-
gional development, including the Local Innovation 
Systems (LIS) project coordinated by the Industrial 
Performance Center at MIT. His recent research focus-
es on the dynamics of regional innovation systems, the 
interplay of technological development and regional 
development policy, regional industrial clustering, the 
role of universities in regional innovation systems, and 
the role of knowledge management in regional innova-
tion policy.
Vu, Bui Minh
Professor Bui Minh Vu is an economist with special ex-
pertise in forest economics. He is Director of the Institute 
for International Business Management and Training, 
Vietnam, and Chairman of the Forest Economics 
branch, Vietnamese Forestry Science Association. He 
is best known for his research on Agro-forestry eco-
nomics. His work has been honored by the Vietnamese 
Agriculture and Rural Development Ministry, which 
presented him with its Hung King Award in 1981, 
and an Award of Science and Technology in 1986. He 
also received the Award for Forestry Development of 
Vietnam. Throughout his academic career, Professor 
Bui Minh Vu was associated with Hanoi University 
of Economics, Hanoi University of Agriculture, and 
the Institute for Agricultural Science Research, Hanoi 
University of Forestry. At the moment, he is a special 
expert in community development through a micro-
loan program. 
WATAL, Jayashree
Jayashree Watal has been a Counsellor in the Intellectual 
Property Division of the WTO since February 2001. 
Ms. Watal has more than 22 years of experience working 
in the Indian government; for ten of those years, she was 
devoted to policy, diplomacy, research, and administra-
tion on intellectual property rights. She worked in the 
Indian Ministry of Commerce as Director of the Trade 
Policy Division in New Delhi from 1995 to 1998, rep-
resenting India at a crucial stage in the Uruguay Round 
TRIPS negotiations in 1989-90.
She has researched and published articles on issues 
related to intellectual property rights, including a book, 
Intellectual Property Rights in the WTO and Developing 
Countries (Oxford University Press, India and Kluwer 
Law International, 2001). She was a Visiting Scholar at 
the Center for International Development at Harvard 
University (2000), the Institute for International 
Economics, Washington, D.C. (Oct. 1998-August 
2000), and the George Washington University Law 
School, Washington, D.C. (1997- 2000). 
WATANABE, Kazuo N.
Kazuo N. Watanabe is a research professor who studies 
plant genetic resources, IP rights issues, biosafety, and 
bioethics research at the Gene Research Center of the 
University of Tsukuba, Japan (2001–present). He has 
a part-time service to the International Plant Genetics 
Resource Institute (IPGRI) for providing his scientific 
expertise on plant genetics and biotechnology, including 
biosafety and IP rights aspects for developing countries. 
After receiving his Ph.D. in plant breeding and plant 
genetics from the University of Wisconsin-Madison, 
Dr. Watanabe worked from 1988 to 1996 on the 
germplasm enhancement of tuber-bearing Solanum 
species for the Centro Internacional de la Papa (CIP) 
in Lima, Peru. CIP gives scientific and technical sup-
port regarding potato production and breeding to de-
veloping countries. From the end of 1991 to 1996, he 
was seconded to the Department of Plant Breeding at 
Cornell University as an adjunct assistant professor as 
part of a shuttle research program on Solanaceae mo-
lecular genetics. He was also an advisor to ISAAA for 
issues of biotechnology transfer in developing countries. 
Dr. Watanabe returned to Japan and was an associate 
professor at the Institute of Biology-oriented Science 
and Technology at Kinki University from 1996-2001. 
His work dealt with transgenic crops and biosafety is-
sues associated with environmental risks to plant genetic 
diversity. Since his return to Japan, Dr. Watanabe has 
been serving the Japanese government in negotiation 
sessions at the Cartagena Protocol on Biosafety for the 
Convention on Biological Diversity (CBD). He also 
serves developing countries on plant genetic resources 
associated with issues related to the CBD and FAO-IT. 
Dr. Watanabe has served as a technical expert for proj-
ects involving plant genetic resources in several develop-
ing countries, as well as the global PGR program that 
has been run by the Japan International Cooperation 
Agency since 1996. Currently, he serves as a research re-
view board member for the National Genebank Project, 
the Rice Genome Project, and the STAFF research insti-
tute of the Japan Bioindustry Association. Dr. Watanabe 
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is also an adjunct professor at Cornell University and 
the Institute of Advanced Studies at the United Nations 
University. He teaches courses on multi-disciplinary re-
search activities that use plant genetic resources to build 
capacity and create policies in developing countries.
WEIDEMIER, B. Jean 
B. Jean Weidemier is the principal of Cambridge 
Licensing Law, LLC. Ms. Weidemier’s legal practice 
concentrates on technology transfer, and she has ex-
tensive experience in the following areas: patent and 
software licensing in life sciences and high-technology 
industries, university and nonprofit technology trans-
fer, strategic collaboration agreements, research and de-
velopment contracts, and related agreements. Prior to 
founding her own firm in 2005, Ms. Weidemier was 
employed in the following capacities: at Testa, Hurwitz 
& Thibeault as Counsel in the Licensing Group; at the 
Massachusetts Institute of Technology as Counsel and 
Technology Licensing Officer; and at Hershey Foods 
Corporation as Counsel. Ms. Weidemier is a gradu-
ate of Dickinson College (B.A., Psychology) and the 
University of Richmond School of Law.
WhIThAM, Michael E.
Michael E. Whitham is a principal in the law firm of 
Whitham, Curtis, Christofferson & Cook. He has 
worked in the field of intellectual property law for over 
20 years and has been frequently invited to lecture on 
topics such as inventorship, licensing, technology audits, 
and patent practice. His law firm is focused on intel-
lectual property law. It handles the following issues: in-
tellectual property licenses; litigation; contractual mat-
ters, including employee/consulting agreements, joint 
development agreements, material transfer agreements, 
supply agreements, and so on; counseling, including 
technology audits, patent evaluations, strategic acquisi-
tions, patent development strategies, trademark brand-
ing strategies, and copyrighted material acquisition 
and distribution; patent preparation and prosecution; 
trademark and copyright registration; and antitrust. Mr. 
Whitham represents large and small companies, as well 
as several nonprofit research organizations and univer-
sities throughout the world (particularly in the U.S., 
Germany, Japan, Korea, and Brazil). Mr. Whitham is 
a licensed attorney and holds degrees in biochemistry, 
chemistry, and law. Mr. Whitham also serves on the 
Board of the Albert B. Sabin Vaccine Institute, a non-
profit organization dedicated to the development, sup-
ply, and use of vaccines by people throughout the world, 
particularly those in most need.
WOLSON, Rosemary
Rosemary Wolson is Intellectual Property Manager 
at the Council for Scientific and Industrial Research 
(CSIR) in Pretoria, South Africa. She has a B.Sc. (Hons) 
degree in Microbiology and an LL.B., both from the 
University of Cape Town. In her previous position as 
Intellectual Property Manager at the University of Cape 
Town (UCT), she participated in establishing UCT 
Innovation, the division responsible for UCT’s technol-
ogy transfer and research contract management func-
tions. Her experience as an early technology transfer 
practitioner in a developing country sparked her interest 
in broader policy issues related to the roles of innovation 
and intellectual property rights in promoting develop-
ment; she takes on selected applied-research projects 
in these areas from time to time. She is also involved 
in various capacity-building and information-sharing 
initiatives in South Africa, other countries in Africa, 
and other parts of the world. She is a member of the 
International Advisory Committee of Public Interest 
Intellectual Property Advisors (PIIPA) and sits on the 
Executive Board of the Southern African Research and 
Innovation Management Association (SARIMA), a re-
gional network of stakeholders.
WySE, Roger E.
Roger E. Wyse is Managing Director and General 
Partner of Burrill & Company, a life sciences merchant 
bank and leading life sciences venture capital firm locat-
ed in San Francisco, California. Dr. Wyse joined Burrill 
& Company in 1998 and has overseen venture capital 
investing, partnering, and the spinout of technology 
from large companies in the agricultural, nutraceutical, 
health and wellness, and industrial biotechnology fields. 
The firm has over $850 million under management.
Dr. Wyse chairs or serves on the boards of 11 pri-
vate companies. He is Co-Chairman of the newly 
formed $150 million Malaysian Life Capital Fund. He 
is also a member of the International Advisory Panel 
for Biotechnology (BioIAP) for the Prime Minister of 
Malaysia. He was founder and Chairman of the Alliance 
for Animal Genome Research.
He has over 27 years of experience as an interna-
tionally recognized scientist and as a dean at two ma-
jor research universities, Rutgers and the University of 
Wisconsin-Madison. Before joining Burrill & Company, 
Dr. Wyse served for five years as Dean of the College 
of Agricultural and Life Sciences at the University of 
Wisconsin-Madison. From 1986 to 1992, he was Dean 
of Research at Rutgers University.
Dr. Wyse earned international recognition for his 
basic studies in plant biochemistry. He has published 
over 150 scientific papers. In 1982, he received the pres-
tigious Arthur Flemming Award for the Outstanding 
Young Scientist in the U.S. Federal Service. He was 
elected a Fellow of both the Crop Science Society of 
America and The American Society of Agronomy. He 
has also served as a consultant to numerous Fortune 500 
companies. 
Xu, Ji 
Ji XU, graduated from China Agricultural University, 
received post-graduate education in the United States 
(University of Maryland and California State University), 
and on-the-job training by United Nations Specialized 
Organizations in Italy/Rome, Thailand/Bangkok, and 
the Philippines/Cebu. He served the Chinese Ministry 
of Agriculture as a government officer and was then ap-
pointed by the Central Government as the Alternate 
Permanent Representative of P. R. China to the United 
Nations Agencies on Food and Agriculture in Rome. He 
has also served the Food and Agriculture Organization 
of the United Nations and was assigned by FAO as the 
Assistant FAO Representative in China. Currently, he 
is a Professor and Advisor of International Relations in 
China Agricultural University.
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XuAN, L. T. 
A plant physiologist, biochemist, and biotechnologist by 
training, Dr. Le Thi Xuan has dedicated more than 20 
years of her research to plant tissue culture technology. 
She has been a major contributor in the establishment of 
plant biotechnology facilities and training in many re-
search institutes throughout Vietnam, from 1975 to the 
present. From 1994 through 1999, she led a MacArthur 
Foundation-funded project as its Principal Investigator 
on the discovery of bioactive compounds in plants 
from the Cuc Phuong National Park, Vietnam. Since 
1998, she has been Project Leader of an International 
Cooperative Biodiversity Groups (ICBG) program, re-
sponsible for implementing the bio-conservation of bio-
active and threatened plants of Cuc Phuong National 
Park.
XuAN, Vo-Tong
Dr. Vo-Tong Xuan is a distinguished agricultural scien-
tist, an outstanding educator, a low-profile institution 
builder, and a national and international leader in agri-
cultural development. 
As a scientist, he is widely recognized for his expertise 
in the management of saline and acid-sulphate soils and 
other problem soils in Vietnam. He is an expert in rice 
production and in rice-based farming systems, as well as 
in agricultural diversification in the Mekong Delta. His 
technical expertise and strong farmer-focused leadership 
in the Mekong Delta greatly increased rice productiv-
ity and contributed to the emergence of Vietnam as the 
third-largest rice exporting country in the world. Xuan 
has authored and co-authored six books and more than 
100 technical papers about agricultural, rural develop-
ment, and sustainable food security.
As an educator, he emphasized scientific as well as 
down-to-earth hands-on-training in the University 
of Cantho, at which he served as Chairman of the 
Departments of Bio-Agronomy and Agronomy, and 
Assistant Dean of Agriculture. He rose to the rank of 
Vice Rector of the University of Cantho and, in 2000, 
was elected President of Angiang University, a position 
he still holds. 
As an institution builder, Xuan developed and strength-
ened the Mekong Delta Farming Systems Research 
and Development Institute and served as its Director 
from 1983 to 2001. He also served as FAO Project 
Coordinator for the establishment of Agricultural 
Service Centers for Small Farmers. He organized the 
Vietnam Farming Systems R & D Network and has 
been serving as its Coordinator since 1991. 
As a national leader in agriculture, Dr. Xuan was ap-
pointed member of the National Council on Science 
and Technology, the National Council on Education, 
the National Council on Professorial Titles Advisory 
Council of the Vietnam Chamber of Commerce and 
Industry, the Steering Committee of the Vietnam-
Holland Research Program on Rural Development, and 
the Consultants’ Group to the Prime Minister.
As an international leader in agriculture, he is widely 
recognized for his integrated approaches to agricultural 
development and deep concern for efficient and effec-
tive use of natural resources, sustainability, and envi-
ronmental issues, as well as, for food security problems 
of developing countries. He is a strong advocate of the 
farming system approach in agricultural development. 
He has served in key positions in the following inter-
national organizations: Member, Board of Governors, 
Asian Institute of Management in Manila; Member, 
Board of Trustees of IRRI; Member, Board of Trustees 
of The Rockefeller Foundation; Member, Board of 
Trustees of the International Potato Center at Lima, 
Peru; Member, FAO’s Advisory Committee on Farmer-
Centered Agricultural Resource Management Program; 
Member, Technical Advisory Committee of the CGIAR; 
Member, Policy Advisory Council, Australian Centre for 
International Agricultural Research; Member, Advisory 
Council of the Asian Development Research Forum.
Dr. Xuan served as international consultant, lecturer of 
IFAD, FAO, DANIDA, SIDA, and IDRC-Singapore 
since the 1980’s. 
He received from the Prime Minister of Canada a 
certificate of recognition for his “dedication and con-
tribution to the world of sciences.” The Ministry of 
Agriculture, Fisheries and Forestry of the Republic 
of France, awarded him the “Chevalier de l’Ordre du 
Merite Agricole Medal.” He was elected the 2002 Nikkei 
Asia Prize for Regional Growth; Most Distinguished 
Alumnus of the University of the Philippines College 
of Agriculture Alumni Association; Ramon Magsaysay 
Award for Government Service; and the 2005 ASTD 
Derek Tribe Award. Other awards include: the People’s 
Teacher Award, Vietnam Farmers’ Federation Medal 
“For the Cause of the Farmers’ State Award as “Hero of 
the Working Class,” Outstanding Scientific Achievement 
Award from the Prime Minister, Most Distinguished 
Alumnus Award from the University of the Philippines 
at Los Banos.
yIN, Ronald
Ronald Yin is a partner with DLA Piper US LLP. He spe-
cializes in patent law and has over 30 years of experience 
in this field. He received a B.S. in Physics from M.I.T., 
an M.S. in Applied Physics from Cornell University, and 
a J.D. from Georgetown University. He began practic-
ing patent law at RCA Corporation in Princeton, New 
Jersey. He later moved to California, where he joined a 
small, multi-national company, Measurex Corp., where 
he was the sole in-house counsel. At Measurex, he had 
responsibility for general matters, as well as patent mat-
ters. After Measurex, he practiced for 20 years with 
the firm of Limbach, Limbach & Sutton, headquartered 
in the historic Ferry Building in San Francisco. After the 
firm dissolved, he joined the firm of Gray Cary Ware 
& Freidenrich, which merged with Piper Rudnick and 
DLA in 2004 and subsequently became DLA Piper. 
He is a member of the bar of the states of California 
and New Jersey, and is registered to practice before the 
U.S. Patent and Trademark Office. He is also a former 
member of the Executive Committee of the Intellectual 
Property Section of the State Bar of California.
yOuNg, Terry A.
Terry A. Young has more than 20 years experience in IP 
rights, innovation management, and technology com-
mercialization. He was Assistant Vice Chancellor for 
Technology Transfer for The Texas A&M University 
System and Executive Director of its Technology 
Licensing Office. He currently serves as the Director 
of Research Development at the University of South 
Dakota. 
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He has started three technology transfer offices 
(TTOs) from scratch and led each office to success. He 
has also started two companies, one of them a univer-
sity spinout that licensed university technology. From 
2001-2002, he served as President of the International 
Association of University Technology Transfer 
Managers, which has nearly 4,000 members. He has 
made more than 55 trips abroad in the capacity of an 
expert consultant on IP rights and technology transfer 
issues. He has authored more than ten book chapters 
or journal articles on IP rights and technology com-
mercialization, including a chapter entitled National 
Innovation Systems to be published in Innovation and 
Business Partnering in Japan, Europe and the United 
States, (London: Rutledge, September 2006). In 2002, 
he was appointed a member of the National Academy 
of Engineering of the Czech Republic, in recognition 
of his work establishing an intellectual property and in-
novation commercialization regime in that country. In 
2004, he was recognized by Nigerian academicians as 
the country’s intellectual property Man of the Year. In 
2005, he received a U.S. National Service Award for his 
contributions to economic growth in Eurasia. Also in 
2005, he was appointed by U.S. President George W. 
Bush as one of only five members of the U.S.-Russian 
Innovation Council on High Technologies, whose goal 
was to improve scientific cooperation between the two 
countries.
ZABLOCKI, Edward M. 
Mr. Edward M. Zablocki, M.S., C.I.P. has worked for 
24 years in the area of research administration at the 
State University of New York at Buffalo. He graduated 
from Williams College magna cum laude with induc-
tion into the Phi Beta Kappa national honor society. 
Mr. Zablocki has a master’s degree from the University 
at Buffalo, with a concentration in the area of public 
administration. He has been involved in a range of 
research administration activities, including develop-
ing a technology incubator, fostering university/indus-
try relations, creating research centers, promoting the 
University’s contribution to local economic develop-
ment, and promoting research compliance. He is pres-
ently the Research Subjects Protection Administrator, 
overseeing compliance with the ethical imperatives and 
regulatory mandates that apply to research involving 
humans and animals. Mr. Zablocki is a Certified IRB 
Professional (C.I.P.), which demonstrates his knowledge 
in the field of human research subject protection.
ZuCKER, howard A.
Dr. Howard Zucker, M.D., J.D., is the Assistant 
Director General of the WHO for Health Technology 
and Pharmaceuticals and also the Representative of 
the WPO Director General for Intellectual Property, 
Innovation, and Public Health. He received his B.S. de-
gree from McGill University and his M.D. from George 
Washington University School of Medicine. He trained 
in pediatrics at Johns Hopkins Hospital, anaesthesiol-
ogy at The Hospital of the University of Pennsylvania, 
pediatric critical care medicine and paediatric anaesthe-
siology at The Children’s Hospital of Philadelphia, and 
pediatric cardiology at Children’s Hospital Boston at 
Harvard Medical School. He was an Assistant Professor 
at Yale University School of Medicine, an Associate 
Professor at Columbia University College of Physicians 
and Surgeons, Adjunct Associate Professor at Cornell 
University Medical School, research affiliate at M.I.T. 
and on the faculty at the National Institutes of Health. 
He received his J.D. from Fordham University School 
of Law and his Masters in Law from Columbia Law 
School. Dr Zucker served as a White House Fellow and 
most recently was Deputy Assistant Secretary of Health 
at the U.S. Department of Health and Human Services. 
He completed the National Preparedness Leadership 
Initiative Executive Education program at the Kennedy 
School of Government/Harvard School of Public 
Health and is admitted to the Bar of the Supreme Court 
of the United States. Dr Zucker is also a member of the 
Council on Foreign Relations and listed in Best Doctors 
in America and Who’s Who in the World.
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•  World Intellectual Property Organization: 
www.wipo.int/tk/en/glossary/index.html.
•  U.S. Patent and Trademark Office: 
www.uspto.gov/main/glossary/index.html.




A transfer of intellectual property (IP) rights. An assign-
ment of a patent, for example, is a transfer of sufficient 
rights so that the recipient has title to the patent. An 
assignment can be a transfer of all rights of exclusivity 
in the patent, a transfer of an undivided portion (for 
example, a 50 percent interest), or a transfer of all rights 
within a specified location (for example, a certain area 
of the United States). Anything less is considered to be a 
license transfer, rather than a patent transfer.
Bayh-Dole Act of 1980
The U.S. Bayh-Dole Act (P.L. 96-517, 94 Stat. 3015, 
codified at 35 U.S.C. §§ 200–211) allows universities, 
not-for-profit organizations, and small businesses to re-
tain certain IP rights related to inventions made via fed-
erally supported R&D. Serving as the statutory founda-
tion facilitating federally supported R&D technology 
transfer, the Act was designed to promote commercial-
ization of innovations arising from such R&D through 
cooperation between the research community, industry, 
and state and local governments.
In order to develop a coherent system for best 
practices in intellectual property management, the 
various terms of art commonly used must be clear-
ly and unambiguously defined, such that they are 
standardized and universally understood to have 
the same meaning. In this glossary we have at-
tempted to present precise, accurate definitions for 
important, commonly used terms in the fields of 
technology transfer and IP management. We hope 
that providing such definitions will make possible 
clear, transparent communication and thereby 
lead to increased mutual understanding between 
technology transfer professionals, IP managers, re-
searchers, investors, and entrepreneurs involved in 
the business of promoting innovation. Clear com-
munication that promotes increased understand-
ing will be particularly important in international 
contexts. For the use of specific definitions in 
agreements, readers should also consult their in-
stitution’s legal advisors. While some areas of law 
are fairly uniform throughout the world, language 
differs significantly from country to country, and 
even within countries, for some areas of law. 
The definitions contained in the glossary 
are derived, in part, from McCarthy’s Desk 
Encyclopedia of Intellectual Property.1 In addition 
to this glossary, the reader is encouraged to refer, 
for expanded definitions and additional terms, to 
online intellectual property glossaries, including 
those found on the following Web sites:
MIHR/PIPRA. 2007. Glossary. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of 
Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at 
www.ipHandbook.org.
© 2007. MIHR/PIPRA. Sharing the Art of IP Management: Photocopying and distribution through the Internet for noncom-
mercial purposes is permitted and encouraged.
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Berne Convention
A major multinational copyright treaty, with nearly 
150 members. There are five main points to the Berne 
Convention: (1) national treatment, that is, nondiscrim-
ination with respect to foreign authors and copyright 
owners; (2) no formalities, that is, copyright is auto-
matically granted and is not conditioned on formalities 
such as registration or notice; (3) minimum duration of 
copyright; (4) moral rights provided to authors under 
the national laws of member nations; and (5) copyright 
protection independent of whether such protection ex-
ists in the country of origin.
best mode
A condition for the grant of a patent, found in the pat-
ent specification. An inventor must describe and dis-
close the best method he or she knows for carrying out 
the invention.
biotechnology
The use of biological methods (often genetic engineering 
and related advanced-molecular-biology applications) 
to produce products, processes, and related services. 
Generally, these are patentable under U.S. patent law.
claims
The section of the patent that defines an invention (the 
technology that is the exclusive property of the patentee 
for the duration of the patent) and is legally enforce-
able; that is, the claims set the metes and bounds of the 
patent rights. The patent specification must conclude 
with a claim, particularly pointing out and distinctly 
claiming the subject matter that the applicant regards as 
the invention or discovery. The claim or claims are in-
terpreted as set forth in the specification: the terms and 
phrases used in the claims must be sufficiently described 
in the specification, that is, patent claims must read in 
the light of the specification. The specification discloses 
and the claims define the invention.
commercialization
The process of taking an invention or discovery to the 
marketplace. It involves working the idea into a busi-
ness plan, consideration of protection options, and 
determining how to market and distribute the finished 
product.
compulsory license
A license granted by the state upon request to a third 
party that, through the license, is permitted to exploit 
a patented invention after the owner of the patent has 
refused to provide a voluntary license under acceptable 
conditions.
confidential disclosure agreement 
See confidentiality agreement.
confidentiality agreement (nondisclosure agreement, 
confidential disclosure agreement)
A legal document through which intellectual property 
can be disclosed by one party to another wherein the lat-
ter party is permitted to use the information for certain 
purposes, and only those purposes, that are stated in the 
agreement and agrees not to disclose the information 
to others.
continuation
A second patent application containing a disclosure 
identical to one in a previous (parent or grandparent) 
application filed by the same applicant as the original 
application, while the original application is still pend-
ing, and that is entitled to the filing (priority) date of the 
original application.
continuation-in-part
A second patent application containing a disclosure 
identical to one in a previous (parent or grandparent) 
application filed by the same applicant as the original 
application, but, in contrast to the continuation ap-
plication, also contains new matter not found in the 
original application. Hence, whereas claims that rely 
on matter in the parent application are entitled to the 
original filing date priority, claims that rely on any new 
matter are entitled only to the later continuation-in-part 
application filing date.
contributory infringement
An indirect infringement of IP rights in which people, 
or organizations, contribute to a direct act of infringe-
ment by another (in order to aid or abet the act of in-
fringement), for example, knowingly selling an article 
that is used solely to practice a patented process or to 
manufacture a patented product.
copyright
An exclusive right conferred by the government on the 
creator of a work to bar others from reproducing, adapt-
ing, distributing to the public, performing in public, or 
publicly displaying said work. Copyright does not pro-
tect an abstract idea; it protects only the concrete ex-
pression of an idea. In order to obtain copyright protec-
tion, a work must have originality and some modicum 
of creativity.
Convention on Biological Diversity
An international agreement articulated at the 1992 Earth 
Summit in Rio de Janeiro, the Convention seeks to es-
tablish a comprehensive strategy for sustainable devel-
opment, setting out commitments for maintaining the 
world’s ecological underpinnings in light of increasing 
business and economic development. The Convention 
established three main goals: the conservation of bio-
logical diversity, the sustainable use of its components, 
and the fair and equitable sharing of the benefits from 
the use of genetic resources.
GLOSSARY
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cross licensing
A legal agreement in which two or more parties that have 
potentially conflicting patent claims, or other conflict-
ing IP rights, reach an agreement to share the IP rights 
in question through a reciprocal licensing arrangement.
dependent claim
A claim in a patent that refers back to a previous claim 
and defines an invention that is narrower in scope than 
that in the previous claim. A dependent claim is written 
in such a way as to be more restricting than the technol-
ogy defined in the previous claim (often an independent 
claim).
descriptive mark
A word, picture, or other symbol that describes some 
quality or trait of a product or service, such as the pur-
pose, size, color, class of users, or end effect on users. 
A descriptive term is not considered to be inherently 
distinctive; to establish validity of a descriptive mark for 
registration or protection in court, proof of acquired 
distinctiveness of the mark is needed. This acquired dis-
tinctiveness confers secondary meaning. For example, 
“Kentucky Fried Chicken” a mark that originally was 
descriptive, subsequently acquired secondary meaning 
as a trademark for a distinctive type of commercial food 
product.
design patent
A government grant of exclusive rights in a novel, non-
obvious, and ornamental industrial design. A design 
patent confers the right to exclude others from mak-
ing, using, or selling designs that closely resemble the 
patented design. A design patent covers the ornamental 
aspects of a design; its functional aspects are covered by 
a utility patent. A design patent and a utility patent can 
cover different aspects of the same article.
differential pricing (tiered pricing)
The practice of setting different prices for different mar-
kets—typically higher prices in richer markets and lower 
prices in poorer markets.
disclosure of origin
A requirement imposed on patent applicants to disclose 
in patent applications the geographic origin of biologi-
cal material on which the invention (subject of the pat-
ent application) is based.
divisional patent application
A patent application that is carved out of a parent appli-
cation, such that the parent application is divided into 
one or more divisional patent applications. Divisional 
applications are entitled to the original filing-date prior-
ity of the parent application.
due diligence
Investigations undertaken to assess the ownership and 
scope of one or more IP rights that are being sold, li-
censed or used as collateral in a transaction. This is done 
in order to identify business and legal risks associated 
with the IP rights being analyzed.
duration 
The term, or length of time that an IP right lasts. A 
U.S. utility patent on an invention, for example, has a 
duration of 20 years from the date on which the pat-
ent application was filed, as does a plant patent. The 
duration of a U.S. copyright is usually the life of the 
author plus 70 years (for works created after January 1, 
1978). Protection of information as a trade secret lasts 
as long as the information remains secret. Duration of 
a trademark continues as long as it is used (as a source 
indicator) and properly maintained/protected.
examination. See patent examination.
exclusive license agreement
A legal document licensing intellectual property to an-
other party for its exclusive use. Exclusively licensed pat-
ent rights cannot, within the scope or field of the exclu-
sive license, be subsequently or simultaneously licensed 
to any other party.
field-of-use restriction
A provision in an IP license that restricts use of the li-
censed intellectual property by the licensee to only in a 
defined product or service market.
first to file
A rule under which patent priority is determined. The 
rule gives priority to the party that first files a patent 
application for an invention, rather than to the party 
that is first to invent. First to file is followed by almost 
every nation in the world except the United States. For 
trademarks, priority between conflicting applications to 
register a trademark is handled by publishing the ap-
plication with the earliest filing date for possible oppo-
sition by the applicant with a later filing date. In the 
United States, ownership of a trademark is determined 
by who was first to use it, not by who was first to file an 
application for registration. However, under the intent-
to-use system, an application for registration can be filed 
prior to actual use of a mark.
first to invent
A rule under which patent priority is determined by 
which inventor was the first to actually invent, rather 
than by who was the first to file a patent application. 
This is the rule followed in the United States. Compare 
to first to file.
GLOSSARY
1980 | HANDBOOK OF BEST PRACTICES
freedom to operate
The ability to undertake research and/or commercial 
development of a product without infringing the unli-
censed intellectual or tangible property rights of others.
functionality
That aspect of design that makes a product work better 
for its intended purpose, as opposed to making the prod-
uct look better or to identify its commercial source.
Indigenous Cultural and IP Rights
Indigenous Cultural and IP Rights refers to the rights 
to a heritage, that its, to the objects, sites, knowledge, 
and methods of transmission of communities that have 
traditionally been defined by the social ownership of 
knowledge. This right privileges customary law over 
modern law. Heritage includes all aspects of culture 
(art, music, dance, literature, and so on), indigenous 
knowledge (medicinal, nutritional), and land manage-
ment practices. There are numerous attempts today 
to give legal substance and scientific validity to indig-
enous knowledge. Article 29 of the Draft Declaration 
of the Rights of World Indigenous People states that 
“[i]ndigenous people are entitled to the recognition of full 
ownership, control and protection of their cultural and in-
tellectual property.”
industrial property
Industrial property is a subset of intellectual property, 
referring to those types of intellectual property that 
have an industrial application. Specifically, it refers to 
patents, trademarks, designs, mask works, and plant 
breeders’ rights.
infringement
An invasion of an exclusive right of intellectual prop-
erty. Infringement of a utility patent includes making, 
using, or selling a patented product or process without 
permission. Infringement of a design patent involves 
fabrication of a design that, to the ordinary observer, is 
substantially the same as an existing design, where the 
resemblance is intended to induce the observer to pur-
chase one thing supposing it to be another. Infringement 
of a trademark consists of the unauthorized use or imi-
tation of a mark that is the property of another in order 
to deceive, confuse, or mislead others. Infringement of a 
copyright involves reproducing, adapting, distributing, 
performing in public, or displaying in public the copy-
righted work of someone else.
intellectual property (IP)
Creative ideas and expressions of the human mind that 
have commercial value and are entitled to the legal pro-
tection of a property right. The major legal mechanisms 
for protecting intellectual property are copyrights, pat-
ents, and trademarks. IP rights enable owners to select 
who may access and use their intellectual property and 
to protect it from unauthorized use.
international patent application 
Refer to Patent Cooperation Treaty (PCT).
intellectual property management
The means by which an institutionally owned IP port-
folio is managed with regard to marketing, patenting, 
licensing, and administration.
invention
The creation of a new technical idea and of the physi-
cal embodiment of the idea or the means to accomplish 
it. To be patentable, an invention must be novel, must 
have utility, and would not have been obvious to those 
possessing ordinary skill in the particular art of the 
invention.
inventive step (nonobviousness)
A condition for patentability, which means that the in-
vention would not be obvious to someone with knowl-
edge and experience in the technological field of the in-
vention. According to the European Patent Convention, 
“An invention shall be considered as involving an inventive 
step if, having regard to the state of the art, it is not obvious 
to a person skilled in the art.” 
joint inventors
Two or more inventors of a single invention who work 
together during the inventive process.
know-how
Information that enables a person to accomplish a par-
ticular task or to operate a particular device or process. 
Refer to trade secret.
license
A grant of permission to use an IP right within a defined 
time, context, market line, or territory. There are impor-
tant distinctions between exclusive licenses and nonex-
clusive licenses. An exclusive license is “exclusive” as to a 
defined scope, that is, the license might not be the only 
license granted for a particular IP asset, as there might 
be many possible fields and scopes of use that can also be 
subject to exclusive licensing. In giving an exclusive li-
cense, the licensor promises that he or she will not grant 
other licenses of the same rights within the same scope 
or field covered by the exclusive license. The owner of 
IP rights may also grant any number of nonexclusive 
licenses covering rights within a defined scope. A patent 
license is a transfer of rights that does not amount to an 
assignment of the patent. A trademark or service mark 
can be validly licensed only if the licensor controls the 
nature and quality of the goods or services sold by the 
licensee under the licensed mark. Under copyright law, 
an exclusive licensee is the owner of a particular right 
of copyright, and he or she may sue for infringement 
of the licensed right. There is never more than a single 
copyright in a work regardless of the owner’s exclusive 
license of various rights to different persons.
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licensee
A party obtaining rights under a license agreement.
licensor
A party granting rights under a license agreement.
license out
The process by which one person, company, or institu-
tion extends to another person, company, or institution 
permission to use the former’s intellectual property.
license in
The process by which a person, company, or institu-
tion obtains permission to use the intellectual property 
owned by someone else.
material transfer agreement (MTA)
A contract between the owner of a tangible material and 
a party seeking the right to use the material for research 
or other assessment purposes. The material may be either 
patented or unpatented. Material transfer agreements 
tend to be shorter than license agreements. The purpose 
of an MTA is to document the transfer the material and 
outline the terms of use, including identification of the 
research or assessment project, terms of confidentiality, 
publication, and liability.
maintenance fees
Fees for maintaining in force a patent. The fees typically 
have to be paid at irregular intervals, depending on the 
jurisdiction, and significantly increase over time.
notice
A formal sign or notification attached to items that em-
body or reproduce an intellectual property assset—for 
example, the presence of the word patent or its ab-
breviation, pat., together with the patent number, on 
a patented article made by a patent holder or his/her 
licensees. The formal statutory notice of U.S. trade-
mark registration is the letter R inside a circle: ®, Reg. 
U.S. Pat. & Tm. Off., or Registered in U.S. Patent and 
Trademark Office. Many firms use informal trademark 
notices, such as Brand, TM, Trademark, SM, or Service 
Mark, adjacent to words or other symbols considered 
to be protectable marks. Notice of copyright consists of 
the letter C in a circle symbol: © or the word Copr. or 
Copyright, the copyright owner’s name, and the year of 
first publication.
nonassignable
A condition whereby a licensing agreement and/or 
the rights, obligations, and terms thereof may not be 





A license under which rights are granted to the licensee 
but not exclusively to that licensee; the licensor reserves 
the right to give the same or similar rights to use the 
licensed materials to other parties.
nonobviousness 
One of three conditions an invention must meet to be 
patentable. See also inventive step.
nontransferable
The licensing agreement and/or the rights, obligations, 
and terms thereof that may not be sold, given, assigned, 
or otherwise conveyed to any party who is not a signa-
tory to the agreement.
novelty
One of three conditions an invention must meet to be 
patentable.
obviousness
A condition of an invention that makes it ineligible to 
receive a valid patent; the condition of an invention 
whereby a person with ordinary skill in a field of tech-
nology can readily deduce it from publicly available in-
formation (prior art). See also ordinary skill in the art.
ordinary skill in the art
The level of technical knowledge, experience, and exper-
tise possessed by the ordinary engineer, scientist, or de-
signer in a technology that is relevant to an invention.
Paris Convention
The main international treaty governing patents, 
trademarks, and unfair competition. The Convention 
is administered by the World Intellectual Property 
Organization (WIPO) and has four principal provi-
sions: (1) national treatment for all seeking protection 
of IP rights, whether foreign or nationals; (2) minimum 
level of protection; (3) Convention priority, with a 
specified time (12 months for patents, six months for 
trademarks) for applications to be filed in other member 
nations; and (4) administrative framework within the 
Paris Union.
patent (U.S.)
A grant by the federal government to an inventor of the 
right to exclude others from making, using, or selling 
his or her invention. There are three kinds of patents in 
the United States: a standard utility patent on the func-
tional aspects of products and processes; a design patent 
on the ornamental design of useful objects; and a plant 
patent on a new variety of a living plant. Patents do not 
protect ideas, only structures and methods that apply 
technological concepts. Each type of patent confers the 
right to exclude others from a precisely defined scope of 
technology, industrial design, or plant variety. In return 
for the right to exclude, an inventor must fully disclose 
GLOSSARY
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the details of the invention to the public so that others 
can understand it and use it to further develop the tech-
nology. Once the patent expires, the public is entitled to 
make and use the invention and is entitled to a full and 
complete disclosure of how to do so.
patent application
A technical document that describes in detail an inven-
tion for which a patent is sought.
patent examination
A process of review of a patent application, undertaken 
by a patent examiner, to determine whether the ap-
plication complies with all statutory requirements for 
patentability. The examination process reviews prior art 
to ensure novelty, along with determining compliance 
with other statutory requirements, rules, and matters of 
procedure and form.
Patent Cooperation Treaty (PCT)
An international treaty that provides a mechanism 
through which an applicant can file a single application 
that, when certain requirements have been fulfilled, may 
then be pursued as a regular national filing in any of the 
PCT member nations. There are currently more than 
120 PCT member nations.
patent pooling
A patent pool is an agreement between two or more pat-
ent owners to license one or more of their patents to one 
another or to third parties. A patent pool allows inter-
ested parties to gather all the necessary tools to practice 
a certain technology.
patent searching
A process carried out by the patent examiner for check-
ing the novelty of a patent application. The subsequent 
patent research report lists published items comprising 
both patent and nonpatent literature relevant to the 
subject of the invention.
plant breeders’ rights
Plant breeder’s rights are used to protect new varieties of 
plants by giving exclusive commercial rights to market a 
new variety or its reproductive material.
plant patent
In the United States, the Plant Patent Act of 1930 pro-
vides a grant of exclusive IP rights to applicants who 
have invented or discovered a new asexually propagated 
variety of plant. Tuberous plants are not covered by 
plant patents.
plant variety protection (PVP)
A form of patent-like protection for sexually propagated 
plants, as well as hybrids, tubers, and harvested plant 
parts. The Plant Variety Protection Act of 1970 is ad-
ministered by the U.S. Department of Agriculture and 
not the U.S. Patent and Trademark Office (which does 
issue plant patents).
prior art
The existing body of technological information against 
which an invention is judged in order to determine 
whether it is novel and nonobvious and can thus be 
patented.
prior informed consent
The consent given by a party with respect to an activity af-
ter being fully informed of all material facts relating to that 
activity. The Convention for Biological Diversity requires 
that access to genetic resources shall be subject to the prior 
informed consent of the country providing the resources.
priority date
The date of the first filing of a patent application that 
describes an invention in detail. Priority date, as well as 
patentability, with respect to novelty of invention, is de-
termined in light of any relevant prior art existing at the 
time of filing. In other words, depending on the specific 
jurisdiction, if the invention was known or published 
previous to the priority date, the applicant will be un-
able to obtain a patent.
provisional application
A provisional application is a document in patent ac-
tions that serves to establish an early priority date of an 
invention. A provisional application will not mature 
into a regular application, and does not form the basis 
of a grant of a patent. It is a document that precedes the 
complete application upon which the grant is based. A 
provisional application establishes a priority date for dis-
closure of the details of an invention and allows a period 
of up to 12 months for development and refinement of 
the invention before the patent claims take their final 
form in a complete, regular patent application.
process claim
A claim of a patent that covers the method by which an 
invention is performed by defining the steps to be fol-
lowed. This differs from a product claim or an apparatus 
claim, which covers the structure of a product.
product-by-process claim
A patent claim through which a product is claimed by 
defining the process by which it is made. The product-
by-process form of claim is most often used to define 
new chemical compounds, since many new chemicals, 
drugs, and pharmaceuticals can practicably be defined 
only by describing the process of making them.
public domain
The status of an invention, creative work, commercial 
symbol, or any other creation that is not protected by 
some form of IP right. Items that have been determined 
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to be in the public domain are available for copying and 
use by anyone.
reduction to practice
The physical part of the inventive process that completes 
and ends the process of invention by demonstrating that 
the invention has a practical application. Reduction to 
practice can be carried out either by the actual construc-
tion of an apparatus, by performing the steps in a pro-
cess, or by formally filing a patent application (construc-
tive reduction to practice).
research tools
The term research tool includes the full range of tools 
that scientists may use in the laboratory, including cell 
lines, monoclonal antibodies, reagents, animal models, 
growth factors, combinatorial chemistry and DNA li-
braries, clones and cloning tools (such as PCR), meth-
ods, and laboratory equipment and machines.2 There 
is concern about the patenting of research tools, be-
cause such patents may inhibit the free undertaking of 
research.
royalty





(1) A word, slogan, design, picture, or other symbol 
used to identify and distinguish goods. (2) Any iden-
tifying symbol, including a word, design, or shape of a 
product or container, that qualifies for legal status as a 
trademark, service mark, collective mark, certification 
mark, trade name, or trade dress. Trademarks identify 
one seller’s goods and distinguish them from goods sold 
by others. They signify that all goods bearing the mark 
come from, or are controlled by, a single source and are 
of an equal level of quality. And they advertise, promote, 
and generally assist in selling goods. A trademark is in-
fringed by another if the second use causes confusion of 
source, affiliation, connection, or sponsorship.
trade secret
Business information that is the subject of reasonable 
efforts to preserve confidentiality and has value because 
it is not generally known in the corresponding trade. 
Such confidential information is protected against those 
who gain access to it through improper methods or by a 
breach of confidence. Misappropriation of a trade secret 
is a type of unfair competition.
traditional knowledge
Tradition-based creations, innovations, literary, artistic 
or scientific works, performances and designs originating 
from or associated with a particular people or territory.
Trade-Related Aspects of Intellectual Property Rights 
(TRIPS)
An international agreement that was initiated under the 
forerunner of the World Trade Organization (WTO), 
the General Agreement on Tariffs and Trade (GATT), 
under the Uruguay round of trade negotiations. The 
TRIPS Agreement is the most comprehensive multilat-
eral agreement on Intellectual Property covering all IP 
instruments. It was the first IP rights accord to legiti-
mize the patenting of living organisms. TRIPS provides 
the guidelines for the harmonization of IP rights laws 
under the WTO. All WTO member countries have sub-
stantive TRIPS obligations.
unfair competition
Commercial conduct that the law views as unjust, 
providing a civil claim against a person who has been 
injured by the conduct. Trademark infringement has 
long been considered to be unfair competition. Other 
recognized legal categories of unfair competition are 
false advertising, trade libel, misappropriation of a 
trade secret, infringement of the right of publicity, and 
misappropriation.
UPOV (the Convention of the International Union for 
the Protection of New Varieties of Plants) 
An international treaty that guarantees to plant breed-
ers in member nations national treatment and a right 
of priority. National plant variety protection statutes of 
member nations are brought into harmonization with 
the various UPOV provisions, for example, the require-
ments of distinctness, uniformity, stability, and novelty 
for new crop varieties.
utility
The usefulness of a patented invention. To be patentable 
an invention must operate and be capable of use, and it 
must perform some “useful” function for society. ■
1 McCarthy JT, RE Schechter and DJ Franklyn. 1995 and 
2004. McCarthy’s Desk Encyclopedia of Intellectual 
Property, 2nd and 3rd editions. The Bureau of National 
Affairs: Washington, DC.
2 From NIH Research Tools Guidelines. ott.od.nih.gov/
policy/rt_guide.html.
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crops of commercial interest, 1222
Green Revolution, 1548–1549 
intrinsic integrity of organisms, 1545–1548
agricultural biotechnology, business partnerships, 
1221–1226
American Association for the Advancement of Science 
(AAAS)
Science and Intellectual Property in the Public 
Interest (SIPPI), 58
ANDA. See Abbreviated New Drug Application.
anticommons, 35, 79
Argentina, 172–173
Arizona State University, 1661–1672
Association of University Technology Managers 
(AUTM), 19–20, 25, 617–623
Better World Project, 20
professional networking, 617–618, 620–621
attorney, 635–639. 
policy development, role of, 635–639, 637, 
1405–1414
strategy development, role in, 636
See also patent counsel.
attorney-client privilege, 1377, 1382, 1414
attorney-client relationship, 635
Australia
IP management and technology transfer, insti-
tutional capacities, 549
licensing income, universities, 210
author, definition of, 426
AUTM. See Association of University Technology 
Managers (AUTM) 
B
bacille Calmette-Guerin (BCG) vaccine, 68
bag-tag license, 1334–1335
Bailment Law, 697, 699, 761, 1334.
See also material transfer agreement (MTA).
Bayer Healthcare A.G.
Global Alliance for TB Drug Development, 
and, 101–102
Bayer Healthcare A.G. v. Housey Pharmaceuticals, 1004
A
AAAS. See American Association for the Advancement 
of Science (AAAS)
Science and Intellectual Property in the Public 
Interest (SIPPI).
AATF. See African Agricultural Technology Foundation 
(AATF).
Abbreviated New Drug Application (ANDA), 90
access and benefit sharing, 1469–1493
biodiversity access agreements (BAA), 1495
biological materials, seeds, or new crop variet-
ies, 1461–1467
confidentiality agreements, 1475
finding access and benefit-sharing information, 
1475
inventions and new technology, 316
letter of intent, 1471
medicines, 256
mutually agreed terms, 1473–1475
obtaining research permits, 1464
preparing your research permit application, 
1464–1465, 1471
prior informed consent, 31–33, 1471–1473, 
1498
scenarios, 1470–1471
African Agricultural Technology Foundation (AATF), 
1391, 1765–1774
operating principles and strategy, 1767–1769
IP management, 1769–1773
IP policy, 1769
Aeras Global TB Vaccine Foundation (Aeras), 67–69, 
1249
Vanderbilt University, and, 101




the developed world, in, 92
the developing world, in, 92–93
See also HIV.
agreements. See contracts and agreements.
agricultural biotechnology
Index
Readers are encouraged to consult the online version of this Handbook (www.iphandbook.org) for fuller 
indexing, a robust search engine, and a “Web log” presentation of key content areas with comments.
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Bayh-Dole Act (Patent and Trademark Amendment 
Act of 1980 [35 U.S.C. §§ 200–211]), 19, 80, 
156–158, 159, 266, 748–749, 795, 880, 1730
criticisms of, 159–160
limitation on assignment of rights, 701
march-in provisions for government use. See 
march-in rights or provisions.
benefit sharing, 33–35, 1461-1467
See also traditional knowledge (TK).
Bern Convention, 1563
BIO Ventures for Global Health (BVGH), 72–73
biodiversity




biodiversity access agreements, 1495, 1499 (BAA)
benefit sharing, 1502





sharing financial benefits, 1502
sharing nonfinancial benefits, 1502, 1505
biodiversity, public-private collaboration, 1497
Biological Innovation for an Open Society (BiOS), 
135, 887
biopiracy, 1437–1438, 1495
IP and tangible property, 1438–1439
patents, and, 1438–1443
bioprospecting, 1495–1510, 1495
INBio, in Costa Rica, 874–876
screening, payment for, 870–871
valuation, 861–876
BiOS. See Biological Innovation for an Open Society 
(BiOS).
biotechnology industry, 281–282, 295–296. 
See also clusters or clustering.
biotechnology patent, 351–360, 991–1008
enforcements and provisions, 997–998
biotechnology R&D, 299–300
Bonn Guidelines on Mutually Agreed Terms, 1474
Brand. See trademark.




government incentives for innovation, 1750
IP management, 174–175, 1563–1575
IP and agriculture, 1566
IP and health, 1568–1571
national innovation system, 1563
patenting activities, 1748





BRCA1 and BRCA2 breast-cancer genes, 35, 36
Brulotte v. Thys Co., 1003
BVGH. See BIO Ventures for Global Health.
bundling technologies, 162.
business incubator, 1305–1314.










Canada, 224, 228 288-292
Cartagena Protocol on Biosafety, 1386–1387, 1463, 
1540
CBD. See Convention on Biological Diversity (CBD).
CDC. See Centers for Disease Control and Prevention 
(CDC).
Central American Free Trade Agreement (CAFTA), 
435
Centers for Disease Control and Prevention (CDC), 
32, 71, 92, 101
C.F.R. See Code of Federal Regulations (CFR).
CGIAR. See Consultative Group on International 
Agricultural Research (CGIAR).
C.M. Rick Tomato Genetics Resource Center 
(TGRC), 709 
Chile, 175, 1577–1583
Fundación Chile, 567, 1579, 1845–1850
genetic engineering of grapes, 1580–1582
IP management, 175, 567–570
proposal for national system of TTOs in, 
570–573
radiata pine biotechnology program, 1582
regulatory issues, 1578
technology and IP issues, 1577–1578
China, 175–176, 1585–1592, 1673–1682
agriculture and IP protection, 1588–1591
copyright law, 1674–1675
IP laws, 175, 1673–1674
IP management and technology transfer, insti-
tutional capacities, 176, 550
IP management at Tsinghua University, 
1679–1680
IP ownership, 175–176 
IP rights protection, 1585–1588
ownership of IP created with government fund-
ing, 1675–1676
patent law, 1674
technology transfer and economic develop-
ment, 1680–1681
CIMMYT. See International Maize and Wheat 
Improvement Center (CIMMYT), IP policy.
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claims. See patent claims.
Clayton Act (15 U.S.C. §§12–29 and 29 U.S.C. §52), 
266, 267
clinical trials or clinical research
in developing countries, 162, 201
clusters or clustering, 281, 295–305, 317
analysis, 320–321, 322
biotechnology clusters in Canada, 288–289
companies, large, role of, 299, 325–326
examples of, 288–289
formation and development, 283, 299, 
314–316, 319, 329
life science, selected, 287
Massachusetts biotechnology cluster, 314–315
models of, 285
technology transfer, 328
types of, 323, 324, 327
university, role of, 299, 300, 304, 311, 314, 
325–326, 328
Code of Federal Regulations (C.F.R.)
37 C.F.R., 265, 266, 779
co-development agreements, 677, 1128–1129, 1855
See also contracts and agreements.
Cohen-Boyer. See Stanford University.
collaborative research agreements, 677, 717–724, 
734–738
See also contracts and agreements.
collaborative research agreements, terms and provisions 
of amendments, 723
confidentiality, 721, 730–732, 735–736
IP rights and obligations, 721–722, 737
list of materials, 724
payment, 736
publications, 720–721 
statement of objectives, 718
statement of work, 719–720
termination, 723
See also contracts and agreements, terms and 
provisions of.
collective work, definition of, 426
commons, the, 882
monopolizing, 1447–1448
Computer Generated Contract Template System 
(CoGenCo), 1029–1042
compulsory licensing, 10–11, 149, 249–250, 256–
257, 273–277
freedom to operate and, 1324
plant variety protection and, 396
remuneration, 276–277
research, 275
confidential information. See undisclosed information 
and data, protection of.
confidentiality agreements, 671, 689–695, 753, 
1128–1129
collaboration, in the context of, 999
exceptions and limitations, 692–694
representation, 694–695
template, 691–692
See also contracts and agreements.
conflict of commitment. See institutional policies, con-
flict of interest and conflict of commitment.
conflict of interest. See institutional policies, conflict of 
interest and conflict of commitment.
consent process, 478
Consultative Group on International Agricultural 
Research (CGIAR), 1318
germplasm accessions, 414–415, 1466–1470
material transfer agreement (MTA) for germ-
plasm, 526
research tools and, 85
contracts and agreements, 120, 675–687, 728–729
civil code jurisdictions, and, 725–728
co-development agreements, 677, 1128–1129, 
1855
common law jurisdictions, and, 725, 727–728
contract law and, 726–728
distributorship agreements, 678, 1921
drafting, 726–728
invention assignment agreements, 504–506, 
783–784
life span of, 651–652, 652
patent license, 1865,1877
template agreements, use and limitations of, 
639, 675–676
trademark license, 1903
variety (plant) license, 1029, 1893
See also collaborative research agreements.
See also confidentiality agreements. 
See also licenses. 
See also licensing. 
See also material transfer agreement (MTA). 
See also licensing, options to commercialize 
agreement.
contracts and agreements, management systems, 
652–657
data accessibility, 653–654





contracts and agreements, negotiation of, 1155–1163
protecting the interests of the public sector, 
1160–1162
skills needed, 1156–1158
tactics for negotiating a license agreement, 
1158–1160
See also licenses, negotiation of.
contracts and agreements, terms and provisions of
adjudication 426, 774
arbitration provisions, 681, 1130, 1417
confidentiality clause, 679, 996–997
definitions, 678
dispute resolution, 1415–1427
enforcements and provisions, 997–998
fees and royalties, 995–996
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recitals, preamble, and whereas clause, 678
signatories, 682
statement of completeness, 682
subject law, 682
term and termination provisions, 681, 998, 
1218
warranties and notices, 681, 1390
See also collaborative research agreements, terms 
and provisions of.
See also confidentiality agreements.
See also licenses, terms and provisions of.
Convention on Biological Diversity (CBD), 34, 383, 
393, 1461–1462, 1469–1470, 1539
biodiversity defined, 1495
biodiversity rights and IP audits, 524
copyright, 339, 391–392, 759–760, 917
categories of works, 343
copyright marking, 348
copyright ownership, 421
databases, 344, 422, 521–522
definition, 426
Digital Millennium Copyright Act of 1998, 
759
duration, 343
fair use, 345, 420










university use of, 636
video, 522
copyright assignment, definition of, 426
copyright protection and plant protection, 378–379
Cooperative Research and Development 
Agreements (CRADAs) [35 U.S.C. s 3710a], 
160, 163, 269
Cooperative Research and Technology Enhancement 
Act (CREATE Act), 269
corn, 1819–1827
Cornell University, 1014–1016
Court of Appeals for the Federal Circuit. See U.S. 
Court of Appeals for the Federal Circuit.
courts, role of, 147–152
CRADA. See Cooperative Research and Development 
Agreements (CRADAs).
CREATE Act. See Cooperative Research and 
Technology Enhancement Act (CREATE Act).




data exclusivity. See undisclosed information and data, 
protection of.
defensive publishing, 879–895
definitions. See contracts and agreements, terms and 
provisions of.
Diamond v. Chakrabarty, 80, 880, 1443
directive on patenting of biotechnology inventions, 
European Union, 32–33
disclosure and enablement requirements, 254
distributorship agreement, 678. 
DNDi. See Drugs for Neglected Diseases initiative 
(DNDi).
documentation of inventions, 750, 763–771
laboratory notebooks, and, 773–777
laboratory notebook policy, 768–771
laboratory notebook, storage of and archival 
of, 767
Doha Declaration on the TRIPS Agreement and Public 
Health, 255–258, 262, 412, 1452, 1540
access to medicines, 256
compulsory licenses, 149, 256–257, 274
parallel imports, 256
parallel trade, 1429–1434
waivers for the production and export and 
import of needed pharmaceutical products, 
257
domain name, Internet, 363
Donald Danforth Plant Science Center, 1683–1696
Drugs for Neglected Diseases initiative (DNDi), 




EAR. See export administration regulations (EAR) (15 
C.F.R. §§ 730–774).
early-stage technology, marketing of, 1165–1171
Eastman Kodak Co. v. Goodyear Tire & Rubber Co., 
1003
eggplant, 1829–1831
licensing insect resistance, 1830–1831
EMBRAPA. See Empresa Brasileira de Pesquisa 
Agropecuária.
employee agreement, 347
Empresa Brasileira de Pesquisa Agropecuária, 174–175, 
1564–1568, 1748
entrepreneurship, 315–316, 326
government encouragement of, 1285–1287
universities, at, 313
EPC. See European Patent Convention (EPC).
EPO. See European Patent Office (EPO).
equitable access license, 58
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equitable estoppel, 1409–1410
nonassertion covenants, 739–743
ethics of patenting, 29–36
deontological opposition to patenting living 
organisms, 30
gene-related patents and, 1446–1449
patentability of life-forms, prior consent and 
patenting of biological materials, 31–33, 
410–411
traditional knowledge, appropriating or patent-
ing, 31
Ethiopia, 176
European Patent Convention (EPC), 383
European Patent Office (EPO), 953, 954
European Union 1593–1604
Directive on Patenting of Biotechnology 
Innovations, 32–33
framework programs and transnational coop-
eration, 1594–1596
Group of Advisers on the Ethical Implications 
of Biotechnology, 32
IP rights, issues in FP6, 1596–1603
Sixth Framework Program (FP6), 1594–1603
exclusions for ordre public, 254
exclusions for methods of treatment, 254
experimental use exemption. See patent law.
export administration regulations (EAR) (15 C.F.R. §§ 
730–774), 268
f
fair use, 345, 420, 759, 1367, 1773
Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 
149




Finnish Funding Agency of Technology and 
Innovation (TEKES), 301–302
FTO. See freedom to operate (FTO).
freedom to operate (FTO), 751–752, 1213, 1317–
1327, 1329–1343, 1363–1384, 1847
analysis, 1330–1331
copyright information, 1359, 1367
corporate identity, 1367





international treaty information, 1359
interviewing researchers and, 1336–1337
options and, 1317–1327
patents and trade secrets, 1366
patent counsel and, 1331–1332
patent databases and, 1339
patent ownership and status searches, 1375
patent searching, 1345–1361, 1373
plant breeders’ rights, 1367–1368
research tools, 1336–1337
questions and 1337
risk and, 1317–1327, 1379
scientific databases and 1337–1339
scope, 1370–1373
strategy and, 1317–1327, 1378–1379
trademark searches, 1359
when to conduct, 1368–1370




legal liability and, 1385–1392
geographic information systems, 419–429
remote sensing (RS), 419
software issues, 429
geographical indications, 255, 343, 916–917
Article 23, 260
multilateral register, 260–261
plant protection and, 378–379
germplasm, 389–399
genebank management, 395
global access, 1–10, 63–78, 89–105
equitable access license, 98–99
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